PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Aoki, K; Ishida, N; Kawakita, M				Aoki, K; Ishida, N; Kawakita, M			Substrate recognition by nucleotide sugar transporters - Further characterization of substrate recognition regions by analyses of UDP-galactose/CMP-sialic acid transporter chimeras and biochemical analysis of the substrate specificity of parental and chimeric transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE TRANSPORTER; YEAST SACCHAROMYCES-CEREVISIAE; N-ACETYLNEURAMINIC ACID; GOLGI VESICLE MEMBRANES; ADHESION DEFICIENCY-II; OVARY CELL MUTANT; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; MOLECULAR CHARACTERIZATION; FUCOSE TRANSPORTER	Human UDP-Gal transporter 1 ( hUGT1) and the human CMP-Sia transporter (hCST) are similar in structure, with amino acid sequences that are 43% identical, but they have quite distinct transport substrates. To define their substrate recognition regions, we constructed various chimeras between the two transporters and demonstrated that distinct submolecular regions of the transporter molecules are involved in the specific recognition of UDP-Gal and CMP-Sia (Aoki, K., Ishida, N., and Kawakita, M. ( 2001) J. Biol. Chem. 276, 21555-21561). In a further attempt to define the minimum submolecular regions required for the recognition of specific substrates, we found that substitution of helix 7 of hCST into the corresponding part of hUGT1 was necessary and sufficient for a chimera to show CST activity. Additional replacement of helix 2 or 3 of hUGT1 with the corresponding hCST sequence markedly increased the efficiency of CMP-Sia transport. For UGT activity, helices 1 and 8 of hUGT1 were necessary ( but not sufficient), and helices 9 and 10 or helices 2, 3, and 7 derived from hUGT1 were also required to render the chimera competent for UDP-Gal transport. The in vitro analyses of a chimera with dual specificity indicated that it transported both UMP and CMP and mediated exchange reactions between these nucleotides and nucleotide sugars that are recognized specifically by either of the parental transporters.	Kogakuin Univ, Dept Appl Chem, Shinjuku Ku, Tokyo 1638677, Japan; Tokyo Metropolitan Inst Med Sci, Dept Immunol, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan	Kogakuin University; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Kawakita, M (corresponding author), Kogakuin Univ, Dept Appl Chem, Shinjuku Ku, 1-24-2 Nishi Shinjuku, Tokyo 1638677, Japan.	bt13004@ns.kogakuin.ac.jp						Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; Aoki K, 2001, J BIOL CHEM, V276, P21555, DOI 10.1074/jbc.M101462200; Aoki K, 1999, J BIOCHEM, V126, P940, DOI 10.1093/oxfordjournals.jbchem.a022538; Baldwin TC, 2001, PLANT CELL, V13, P2283, DOI 10.1105/tpc.13.10.2283; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CAREY DJ, 1980, CELL, V19, P597, DOI 10.1016/S0092-8674(80)80036-5; Chiaramonte M, 2001, BIOCHEMISTRY-US, V40, P14260, DOI 10.1021/bi011262w; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2001, J BIOL CHEM, V276, P4424, DOI 10.1074/jbc.M009114200; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 1999, J BIOCHEM, V126, P1107, DOI 10.1093/oxfordjournals.jbchem.a022556; Ishida N, 1998, J BIOCHEM, V124, P171, DOI 10.1093/oxfordjournals.jbchem.a022076; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kawakita M, 1998, J BIOCHEM, V123, P777; Kumamoto K, 2001, CANCER RES, V61, P4620; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MILLA ME, 1992, J BIOL CHEM, V267, P103; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Sun-Wada GH, 1998, J BIOCHEM, V123, P912; Tiralongo J, 2000, ANAL BIOCHEM, V285, P21, DOI 10.1006/abio.2000.4705; Tomiya N, 2001, ANAL BIOCHEM, V293, P129, DOI 10.1006/abio.2001.5091; Yoshioka S, 1997, J BIOCHEM, V122, P691	41	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22887	22893		10.1074/jbc.M302620200	http://dx.doi.org/10.1074/jbc.M302620200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682060	hybrid			2022-12-25	WOS:000183503900094
J	Wang, J; Al-Lamki, RS; Zhang, H; Kirkiles-Smith, N; Gaeta, ML; Thiru, S; Pober, JS; Bradley, JR				Wang, J; Al-Lamki, RS; Zhang, H; Kirkiles-Smith, N; Gaeta, ML; Thiru, S; Pober, JS; Bradley, JR			Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; LEUKOCYTE ADHESION MOLECULE-1; PHORBOL-MYRISTATE ACETATE; ACTIVATED PROTEIN-KINASE; ALPHA CONVERTING-ENZYME; MAST-CELLS; PRECURSOR; EXPRESSION; METALLOPROTEINASE; TRANSDUCTION	Tumor necrosis factor (TNF) activates pro-inflammatory functions of vascular endothelial cells (EC) through binding to receptor type 1 (TNFR1) molecules expressed on the cell surface. The majority of TNFR1 molecules are localized to the Golgi apparatus. Soluble forms of TNFR1 (as well as of TNFR2) can be shed from the EC surface and inhibit TNF actions. The relationships among cell surface, Golgi-associated, and shed forms of TNFR1 are unclear. Here we report that histamine causes transient loss of surface TNFR1, TNFR1 shedding, and mobilization of TNFR1 molecules from the Golgi in cultured human EC. The Golgi pool of TNFR1 serves both to replenish cell surface receptors and as a source of shed receptor. Histamine-induced shedding is blocked by TNF-alpha protease inhibitor, an inhibitor of TNF-alpha-converting enzyme, and through the H1 receptor via a MEK-1/p42 and p44 mitogen-activated protein kinase pathway. Cultured EC with histamine-induced surface receptor loss become transiently refractory to TNF. Histamine injection into human skin engrafted on immunodeficient mice similarly caused shedding of TNFR1 and diminished TNF-mediated induction of endothelial adhesion molecules. These results both clarify relationships among TNFR1 populations and reveal a novel anti-inflammatory activity of histamine.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Pathol, Cambridge CB2 2QQ, England; Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06511 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Yale University	Bradley, JR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Box 157,Level 5,Hills Rd, Cambridge CB2 2QQ, England.			Bradley, John/0000-0002-7774-8805; Wang, Jun/0000-0003-3667-3760				Aksentijevich I, 2001, AM J HUM GENET, V69, P301, DOI 10.1086/321976; Al-Lamki RS, 2001, LAB INVEST, V81, P1503, DOI 10.1038/labinvest.3780364; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bolz SS, 1997, CARDIOVASC RES, V36, P437, DOI 10.1016/S0008-6363(97)00197-1; BRADLEY JR, 1995, AM J PATHOL, V146, P27; BRADLEY JR, 1995, AM J PATHOL, V147, P627; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Furuta GT, 1997, GASTROENTEROLOGY, V113, P1560, DOI 10.1053/gast.1997.v113.pm9352858; Gaeta ML, 2000, LAB INVEST, V80, P1185, DOI 10.1038/labinvest.3780126; Galon J, 2000, CURR OPIN IMMUNOL, V12, P479, DOI 10.1016/S0952-7915(00)00124-2; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HWANG CD, 1993, J IMMUNOL, V151, P5631; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Jones SJ, 1999, J IMMUNOL, V162, P1042; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Krauss S, 2000, FASEB J, V14, P2581, DOI 10.1096/fj.00-0064com; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; Li Y, 2001, MICROVASC RES, V61, P253, DOI 10.1006/mvre.2001.2304; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; Miki I, 1996, CELL IMMUNOL, V171, P285; Mills J, 1997, J NEUROSCI, V17, P9415; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURRAY AG, 1994, P NATL ACAD SCI USA, V91, P9146, DOI 10.1073/pnas.91.19.9146; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Robinson AJ, 2001, BRIT J PHARMACOL, V133, P1378, DOI 10.1038/sj.bjp.0704200; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; van Mourik JA, 2002, HISTOCHEM CELL BIOL, V117, P113, DOI 10.1007/s00418-001-0368-9; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; ZAVOICO GB, 1989, J IMMUNOL, V142, P3993; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200; Zhang ZL, 2001, FASEB J, V15, P303	50	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21751	21760		10.1074/jbc.M212662200	http://dx.doi.org/10.1074/jbc.M212662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12646554	hybrid			2022-12-25	WOS:000183354200056
J	Lee, N; Chen, J; Sun, L; Wu, SJ; Gray, KR; Rich, A; Huang, MX; Lin, JH; Feder, JN; Janovitz, EB; Levesque, PC; Blanar, MA				Lee, N; Chen, J; Sun, L; Wu, SJ; Gray, KR; Rich, A; Huang, MX; Lin, JH; Feder, JN; Janovitz, EB; Levesque, PC; Blanar, MA			Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOMAGNESEMIA; SECONDARY HYPOCALCEMIA; CA2+ CHANNEL; TRP CHANNELS; GENOMIC DNA; GENE FAMILY; PROTEIN; HOMOLOGY; LTRPC2; IDENTIFICATION	Transient receptor potential (TRP) cation-selective channels are an emerging class of proteins that are involved in a variety of important biological functions including pain transduction, thermosensation, mechanoregulation, and vasorelaxation. Utilizing a bioinformatics approach, we have identified the full-length human TRPM3 (hTRPM3) as a member of the TRP family. The hTRPM3 gene is comprised of 24 exons and maps to human chromosome 9q-21.12. hTRPM3 is composed of 1555 amino acids and possesses the characteristic six-transmembrane domain of the TRP family. hTRPM3 is expressed primarily in kidney and, at lesser levels, in brain, testis, and spinal cord as demonstrated by quantitative RT-PCR and Northern blotting. In situ hybridization in human kidney demonstrated that hTRPM3 mRNA expression is predominantly found in the collecting tubular epithelium. Heterologous expression of hTRPM3 in human embryonic kidney cells (HEK 293) showed that hTRPM3 is localized to the cell membrane. hTRPM3-expressing cells exhibited Ca2+ concentration-dependent Ca2+ entry. Depletion of intracellular Ca2+ stores by lowering extracellular Ca2+ concentration and treatment with the Ca2+-ATPase inhibitor thapsigargin or the muscarinic receptor agonist carbachol further augmented hTRPM3-mediated Ca2+ entry. The nonselective Ca2+ channel blocker, lanthanide gadolinium (Gd3+), partially inhibited hTRPM3-mediated Ca2+ entry. These results are consistent with the hypothesis that hTRPM3 mediates a Ca2+ entry pathway that apparently is distinct from the endogenous Ca2+ entry pathways present in HEK 293 cells.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Metab & Cardiovasc Dis Drug Discovery, Princeton, NJ 08543 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Appl Genom, Princeton, NJ 08543 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Discovery Toxicol, Princeton, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Lee, N (corresponding author), 311 Pennington Rocky Hill Rd, Pennington, NJ 08534 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Dambach DM, 2002, HEPATOLOGY, V35, P1093, DOI 10.1053/jhep.2002.33162; Duncan LM, 1998, CANCER RES, V58, P1515; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Nagase T, 2000, DNA RES, V7, P273; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Tsavaler L, 2001, CANCER RES, V61, P3760; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Walder RY, 1997, HUM MOL GENET, V6, P1491, DOI 10.1093/hmg/6.9.1491; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	32	143	157	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20890	20897		10.1074/jbc.M211232200	http://dx.doi.org/10.1074/jbc.M211232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12672827	hybrid			2022-12-25	WOS:000183230500059
J	Liu, Y; Shi, ZQ; Silveira, A; Liu, JZ; Sawadogo, M; Yang, HM; Feng, X				Liu, Y; Shi, ZQ; Silveira, A; Liu, JZ; Sawadogo, M; Yang, HM; Feng, X			Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; BONE-RESORPTION; FUNCTIONAL DOMAINS; TERMINAL KINASE; MULTIPLE FORMS; FACTOR USF; T-CELLS; LIGAND; ACTIVATION	Tartrate-resistant acid phosphatase ( TRAP) plays an important role in bone resorption. TRAP expression in osteoclasts is regulated by receptor activator of NF-kappaB ( RANKL), a potent activator of osteoclast differentiation. However, the molecular mechanism underlying the RANKL-induced TRAP expression remains unknown. Here we show that two regions in the mouse TRAP promoter (one at - 1858 to - 1239 and the other at - 1239 to - 1039, relative to the translation start site) are implicated in RANKL- induced TRAP transcription in RAW264.7 cells. A detailed characterization of the region at - 1239 to - 1039 identifies a 12-bp sequence, AGC-CACGTGGTG, that specifically binds nuclear proteins from RAW264.7 cells and primary bone marrow macrophages (BMMs) in an electrophoretic mobility shift assay ( EMSA). Moreover, the binding is significantly enhanced in EMSA with nuclear extracts from RANKL-treated RAW264.7 cells and BMMs, suggesting that the 12-bp sequence may be involved in RANKL- induced TRAP transcription. Various assays reveal that nuclear proteins binding to the 12-bp sequence are upstream stimulatory factors (USF) 1 and 2. Importantly, mutation of the USF-binding site partially blocks RANKL-induced TRAP transcription in RAW264.7 cells, confirming that USF1 and USF2 are functionally involved in RANKL- induced TRAP transcription. In summary, our data show that USF1 and USF2 play a functional role in RANKL- dependent TRAP expression during osteoclast differentiation.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Alabama System; University of Alabama Birmingham; University of Texas System; UTMD Anderson Cancer Center	Feng, X (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.							Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103; BAKER RE, 1989, J BIOL CHEM, V264, P10843; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763; BERBEN G, 1990, YEAST, V6, P451, DOI 10.1002/yea.320060510; Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521-1878(199810)20:10<837::AID-BIES9>3.0.CO;2-D; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CASSADY AI, 1993, GENE, V130, P201, DOI 10.1016/0378-1119(93)90420-8; CLARK SA, 1989, J BONE MINER RES, V4, P399; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Daumer KM, 2002, J BONE MINER RES, V17, P1701, DOI 10.1359/jbmr.2002.17.9.1701; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JOHNSON DR, 1990, BONE MINER, V8, P109, DOI 10.1016/0169-6009(90)90114-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Luo X, 1996, MOL CELL BIOL, V16, P1367; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756-3282(00)00368-9; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; REDDY SV, 1995, J BONE MINER RES, V10, P601; REDDY SV, 1993, J BONE MINER RES, V8, P1263; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Schwartz CJE, 2001, EMBO J, V20, P510, DOI 10.1093/emboj/20.3.510; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Vaananen HK, 2000, J CELL SCI, V113, P377; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YAZIJI H, 1995, AM J CLIN PATHOL, V104, P397; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V159, P68, DOI 10.1016/0006-291X(89)92405-4	53	29	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20603	20611		10.1074/jbc.M212093200	http://dx.doi.org/10.1074/jbc.M212093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663664	hybrid			2022-12-25	WOS:000183230500021
J	Su, Y; Zhou, AW; Al-Lamki, RS; Karet, FE				Su, Y; Zhou, AW; Al-Lamki, RS; Karet, FE			The a-subunit of the V-type H+-ATPase interacts with phosphofructokinase-1 in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLE; TURTLE URINARY-BLADDER; AMINO-TERMINAL DOMAIN; VACUOLAR PROTON PUMP; TRANSLOCATING ATPASE; GENE ENCODES; BINDING; VPH1P; EXPRESSION; TRANSPORT	V-type or H+-ATPases are a family of ATP-dependent proton pumps that move protons across the plasma membrane at specialized sites such as kidney epithelial cells and osteoclasts as well as acidifying intracellular compartments. The 100-kDa polytopic a-subunit of this group of ATPases is suggested to play an important role in coupling the two functions of the pump, ATP hydrolysis and proton transport. In man, different a-subunit isoforms are encoded by four genes. ATP6V0A4 encodes a4, which is expressed apically in alpha-intercalated cells in both human and mouse kidney. We sought binding partners for the C terminus of a4 in order to address its potential role in the H+-ATPase complex. Random peptide phage display analysis revealed a consensus motif (WLELRP) with almost complete homology to part of the enzyme phosphofructokinase 1 (PFK-1). Activity of this enzyme is the rate-limiting step in glycolysis. Specificity of a4 binding to this peptide was confirmed by enzyme-linked immunosorbent assay. Protein-protein interaction was further demonstrated by co-immunoprecipitation of a4 with PFK-1 from solubilized human kidney membrane proteins. An in vitro bead-bound PFK-1 pull-down assay showed that this interaction was also true for the ubiquitously expressed a1 subunit. Finally, PFK-1 co-immunolocalized with a4 in alpha-intercalated cells in the collecting ducts of human kidney. These findings indicate a direct link between V-type H+-ATPases and glycolysis via the C-terminal region of the a-subunit of the pump and suggest a novel regulatory mechanism between H+-ATPase function and energy supply. This interaction between the a-subunit and PFK-1 also provides new evidence that the C terminus of this subunit lies cytoplasmically in vivo.	Univ Cambridge, Dept Med Genet, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Div Nephrol, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Karet, FE (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Box 139, Cambridge CB2 2XY, England.			Karet, Fiona/0000-0002-2457-2869; ZHOU, Aiwu/0000-0002-2555-5091				BEAUWENS R, 1976, J GEN PHYSIOL, V68, P421, DOI 10.1085/jgp.68.4.421; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Brown D, 1996, J EXP BIOL, V199, P2345; Clarke M, 2002, J CELL SCI, V115, P2893; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; ELSON A, 1990, GENOMICS, V7, P47, DOI 10.1016/0888-7543(90)90517-X; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 2000, J EXP BIOL, V203, P71; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; KEMP RG, 1987, BIOCHEMISTRY-US, V26, P3443, DOI 10.1021/bi00386a029; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YL, 1999, BIOCHEMISTRY-US, V38, P16407, DOI 10.1021/bi991761l; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; NAKAJIMA H, 1990, BIOCHEM BIOPH RES CO, V173, P1317, DOI 10.1016/S0006-291X(05)80931-3; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; STEINMETZ PR, 1981, J MEMBRANE BIOL, V59, P27, DOI 10.1007/BF01870818; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VIK SB, 1994, J BIOL CHEM, V269, P30364; VORA S, 1982, ISOZYMES-CURR T BIOL, V6, P119; Weber J, 1997, FEBS LETT, V412, P169, DOI 10.1016/S0014-5793(97)00773-4; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHENG RL, 1994, J BIOL CHEM, V269, P18475	46	94	97	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20013	20018		10.1074/jbc.M210077200	http://dx.doi.org/10.1074/jbc.M210077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649290	hybrid			2022-12-25	WOS:000183078000058
J	Ojuka, EO; Jones, TE; Han, DH; Chen, M; Holloszy, JO				Ojuka, EO; Jones, TE; Han, DH; Chen, M; Holloszy, JO			Raising Ca2+ in L6 myotubes mimics effects of exercise on mitochondrial biogenesis in muscle	FASEB JOURNAL			English	Article						PPAR gamma coactivator 1; mitochondrial transcription factor A; NRF-1; NRF-2	ACTIVATED PROTEIN-KINASE; TRANSCRIPTIONAL COACTIVATOR PGC-1; RAT SKELETAL-MUSCLE; GENE-EXPRESSION; BIOCHEMICAL ADAPTATION; SARCOPLASMIC-RETICULUM; EPITROCHLEARIS MUSCLE; ENERGY-METABOLISM; NUCLEAR; CELLS	Skeletal muscle adapts to endurance exercise with an increase in mitochondria. Muscle contractions generate numerous potential signals. To determine which of these stimulates mitochondrial biogenesis, we are using L6 myotubes. Using this model we have found that raising cytosolic Ca2+ induces an increase in mitochondria. In this study, we tested the hypothesis that raising cytosolic Ca2+ in L6 myotubes induces increased expression of PGC-1, NRF-1, NRF-2, and mtTFA, factors that have been implicated in mitochondrial biogenesis and in the adaptation of muscle to exercise. Raising cytosolic Ca2+ by exposing L6 myotubes to caffeine for 5 h induced significant increases in PGC-1 and mtTFA protein expression and in NRF-1 and NRF-2 binding to DNA. These adaptations were prevented by dantrolene, which blocks Ca2+ release from the SR. Exposure of L6 myotubes to caffeine for 5 h per day for 5 days induced significant increases in mitochondrial marker enzyme proteins. Our results show that the adaptive response of L6 myotubes to an increase in cytosolic Ca2+ mimics the stimulation of mitochondrial biogenesis by exercise. They support the hypothesis that an increase in cytosolic Ca2+ is one of the signals that mediate increased mitochondrial biogenesis in muscle.	Washington Univ, Sch Med, Dept Med, Sect Appl Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Sect Appl Physiol, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu			NIA NIH HHS [AG00425, AG00078] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG000425, R01AG000425, R56AG000425] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; BIANCHI CP, 1961, J GEN PHYSIOL, V44, P845, DOI 10.1085/jgp.44.5.845; BOOTH FW, 1977, J BIOL CHEM, V252, P416; BOOTH FW, 1997, HDB PHYSL 12, P1075; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; DAVIES KJA, 1981, ARCH BIOCHEM BIOPHYS, V209, P539, DOI 10.1016/0003-9861(81)90312-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; LAWRENCE JC, 1983, AM J PHYSIOL, V244, pC348, DOI 10.1152/ajpcell.1983.244.5.C348; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; OHIRA Y, 1987, AM J PHYSIOL, V253, pC639, DOI 10.1152/ajpcell.1987.253.5.C639; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V283, pE1040, DOI 10.1152/ajpendo.00242.2002; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; PALADE P, 1987, J BIOL CHEM, V262, P6142; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Terada S, 2001, J APPL PHYSIOL, V90, P2019, DOI 10.1152/jappl.2001.90.6.2019; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	43	161	177	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					675	681		10.1096/fj.02-0951com	http://dx.doi.org/10.1096/fj.02-0951com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665481				2022-12-25	WOS:000182580100013
J	Huang, WC; Chen, JJ; Chen, CC				Huang, WC; Chen, JJ; Chen, CC			c-Src-dependent tyrosine phosphorylation of IKK beta is involved in tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; HUMAN-ENDOTHELIAL-CELLS; EPITHELIAL ICAM-1 EXPRESSION; DIFFERENTIAL REGULATION; MONOCYTE ADHESION; ACTIVATION; PATHWAY; COMPLEX; LFA-1	The signaling pathway involved in tumor necrosis factor-alpha (TNF-alpha)-induced intercellular adhesion molecule-1 (ICAM-1) expression was further studied in human A549 epithelial cells. TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ICAM-1 promoter activity was inhibited by a protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or an Src-specific tyrosine kinase inhibitor (PP2). TNF-alpha- or TPA-induced IkappaB kinase (IKK) activation was also blocked by these inhibitors, which slightly reversed TNF-alpha-induced but completely reversed TPA-induced IkappaBalpha degradation. c-Src and Lyn, two members of the Src kinase family, were abundantly expressed in A549 cells, and their activation by TNF-alpha or TPA was inhibited by the same inhibitors. Furthermore, the dominant-negative c-Sre (KM) mutant inhibited induction of ICAM-1 promoter activity by TNF-alpha or TPA. Overexpression of the constitutively active PKCalpha or wild-type c-Src plasmids induced ICAM-1 promoter activity, this effect being inhibited by the dominant-negative c-Src (KAI) or IKKbeta (KM) mutant but not by the nuclear factor-kappaB-inducing kinase (NIK) (KA) mutant. The c-Src (KM) mutant failed to block induction of ICAM-1 promoter activity caused by overexpression of wild-type NIK. In co-immunoprecipitation and immunoblot experiments, IKKbeta was found to be associated with c-Src and to be phosphorylated on tyrosine residues after TNF-alpha or TPA treatment. Two tyrosine residues, Tyr(188) and Tyr(199), near the activation loop of IKKbeta, were identified as being important for NF-kappaB activation. Substitution of these residues with phenylalanines abolished ICAM-1 promoter activity and c-Src-dependent phosphorylation of IKKbeta induced by TNF-alpha or TPA. These data suggest that, in addition to activating NIK, TNF-alpha also activates PKC-dependent c-Sre. These two pathways converge at IKKbeta and go on to activate NF-kappaB, via serine phosphorylation and degradation of IkappaB-alpha, and, finally, to initiate ICAM-1 expression.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10018, Taiwan	National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1,Jen Ai Rd,1st Sect, Taipei 10018, Taiwan.		Chen, Jun-Jie/E-1894-2012; Huang, Wei-Chien/H-3126-2019; CHEN, JUNJIE/HHM-8428-2022; Huang, Wei-Chien/D-1740-2012	Huang, Wei-Chien/0000-0001-6467-8716; Huang, Wei-Chien/0000-0001-6467-8716; CHEN, CHING-CHOW/0000-0002-7810-0939				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; CARLOS T, 1991, BLOOD, V77, P2266; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen CC, 2000, MOL PHARMACOL, V58, P1479, DOI 10.1124/mol.58.6.1479; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; POBER JS, 1986, J IMMUNOL, V137, P1893; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Ten RM, 1999, J IMMUNOL, V163, P3851; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	45	116	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9944	9952		10.1074/jbc.M208521200	http://dx.doi.org/10.1074/jbc.M208521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645577	hybrid			2022-12-25	WOS:000181524000142
J	Takahashi, K; Saishin, Y; Saishin, Y; Silva, RL; Oshima, Y; Oshima, S; Melia, M; Paszkiet, B; Zerby, D; Kadan, MJ; Liau, G; Kaleko, M; Connelly, S; Luo, TC; Campochiaro, PA				Takahashi, K; Saishin, Y; Saishin, Y; Silva, RL; Oshima, Y; Oshima, S; Melia, M; Paszkiet, B; Zerby, D; Kadan, MJ; Liau, G; Kaleko, M; Connelly, S; Luo, TC; Campochiaro, PA			Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment	FASEB JOURNAL			English	Article						blood-retinal barrier; diabetic retinopathy; macular edema; ocular neovascularization; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MEDIATED GENE-TRANSFER; ADENOVIRAL VECTORS; TUMOR-GROWTH; ANGIOGENESIS; INHIBITION; MICE; ANGIOSTATIN; METASTASES	Endostatin, a proteolytic fragment of collagen XVIII, is an endogenous inhibitor of tumor angiogenesis that also inhibits choroidal neovascularization. In this study, we assessed the effects of increased intraocular expression of endostatin on vascular endothelial growth factor (VEGF)induced changes in the retina. After subretinal injection of a pair of gutless adenoviral vectors (AGV) designed to provide tamoxifen-inducible expression of endostatin, diffuse endostatin immunoreactivity was induced thoroughout the retina by administration of tamoxifen. Induction of endostatin in double transgenic mice with doxycycline-induced expression of VEGF in the retina resulted in significant suppression of leakage of intravascular [H-3]mannitol into the retina. The ability of endostatin to reduce VEGF-induced retinal vascular permeability was confirmed by using [H-3]mannitol leakage and two other parameters, fluorescein leakage and retinal thickness, after subretinal injection of a bovine immunodeficiency lentiviral vector coding for endostatin (BIV-vectored endostatin, or BIVendostatin). Subretinal injection of BIVendostatin resulted in more discrete, less intense staining for endostatin in the retina than that seen with the inducible AGV system, which suggested lower levels and allowed visualization of sites where endostatin was concentrated. Endostatin staining outlined retinal blood vessels, which suggested endostatin binding to a component of vessel walls. More prolonged or higher level expression of VEGF in the retina resulted in neovascularization and retinal detachment, both of which were also significantly reduced by BIVendostatin. These data suggest that endostatin may be an endogenous inhibitor of vasopermeability as well as neovascularization. In patients with diabetic retinopathy, endostatin gene transfer may provide a way to decrease the risk of three causes of visual loss: macular edema, neovascularization, and retinal detachment.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Adv Vis Therapies Inc, Rockville, MD 20854 USA	Johns Hopkins University; Johns Hopkins University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu						Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; AGRESTI A, 1990, J AM STAT ASSOC, V85, P453, DOI 10.2307/2289783; Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083; BLANKS JC, 1986, J COMP NEUROL, V254, P543, DOI 10.1002/cne.902540407; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Chang MA, 2000, INVEST OPHTH VIS SCI, V41, P4281; Chen QR, 1999, CANCER RES, V59, P3308; Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Derevjanik NL, 2002, INVEST OPHTH VIS SCI, V43, P2462; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Feldman AL, 2000, CANCER RES, V60, P1503; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200; Kim YM, 2000, CANCER RES, V60, P5410; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matukonis M, 2002, HUM GENE THER, V13, P1293, DOI 10.1089/104303402760128522; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Polito A, 2002, AM J OPHTHALMOL, V134, P240, DOI 10.1016/S0002-9394(02)01528-3; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Reddy PS, 2002, MOL THER, V5, P63, DOI 10.1006/mthe.2001.0510; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Takahashi K, 2002, HUM GENE THER, V13, P1305, DOI 10.1089/104303402760128531; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Toietta G, 2002, MOL THER, V5, P204, DOI 10.1006/mthe.2002.0532; Urbich C, 2002, FASEB J, V16, P706, DOI 10.1096/fj.01-0637fje; Xu L, 2001, MOL THER, V3, P262, DOI 10.1006/mthe.2000.0254; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87; Yin GY, 2002, MOL THER, V5, P547, DOI 10.1006/mthe.2002.0590; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	55	108	119	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					896	+		10.1096/fj.02-0824fje	http://dx.doi.org/10.1096/fj.02-0824fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670875				2022-12-25	WOS:000181892600007
J	Tsuchida, A; Okajima, T; Furukawa, K; Ando, T; Ishida, H; Yoshida, A; Nakamura, Y; Kannagi, R; Kiso, M; Furukawa, K				Tsuchida, A; Okajima, T; Furukawa, K; Ando, T; Ishida, H; Yoshida, A; Nakamura, Y; Kannagi, R; Kiso, M; Furukawa, K			Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION CLONING; GENOMIC ANALYSIS; TYPE-1 CHAIN; ANTIGENS; BETA-1,3-GALACTOSYLTRANSFERASE; GLYCOSPHINGOLIPIDS; DETERMINES; ADHESION; SIALYL	Biosynthesis of disialyl Lewis a (Le(a)) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides. Among lactotetraosylceramide (Lc4), neolactotetraosylceramide, and their sialyl forms, only sialyl Lc4 was sialylated with ST6GalNAc V and ST6GalNAc VI. The products were confirmed to be disialyl Lea in TLC-immunostaining. Compared with the original substrate GM1b, the synthetic rates of disialyl Le(a) were 22 and 38% with ST6GalNAc V and ST6GalNAc VI, respectively. Since sialyl Lea could not be converted to disialyl Lea, disialyl Lea was produced only from disialyl Lc4. Therefore, it appears that ST6GalNAc V/VI and fucosyltransferase III (FUT-3) compete for sialyl Lc4, their common substrate. The results of either one transfection or co-transfection of two genes into COS1 cells revealed that both ST6GalNAc VI and FUT-3 contributed in the synthesis of disialyl Le(a) but partly compete with each other. Many colon cancer cell lines expressed the ST6GalNAc VI gene more or less, and some of them actually expressed disialyl Le(a). None of them expressed ST6GalNAc V. These results suggested the novel substrate specificity of ST6GalNAc VI, which is responsible for the synthesis of disialyl Le(a) but not for alpha-series gangliosides in human colon tissues.	Nagoya Univ, Dept Biochem 2, Sch Med, Showa Ku, Nagoya, Aichi 4660065, Japan; Gifu Univ, Dept Appl Bioorgan Chem, Gifu 5011193, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Aichi Canc Ctr, Program Mol Pathol, Res Inst, Nagoya, Aichi 4648681, Japan	Nagoya University; Gifu University; Kirin Brewery Company Limited; Aichi Cancer Center	Furukawa, K (corresponding author), Nagoya Univ, Dept Biochem 2, Sch Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.		Okajima, Tetsuya/I-7332-2014; Kannagi, Reiji/Q-6459-2018	Okajima, Tetsuya/0000-0002-3677-648X; Kannagi, Reiji/0000-0003-4202-2921				BARA J, 1986, AM J CLIN PATHOL, V85, P152, DOI 10.1093/ajcp/85.2.152; FUKUYA S, 1994, J BIOL CHEM, V269, P32418; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; ITZKOWITZ SH, 1988, CANCER RES, V48, P3834; KANNAGI R, 1988, CANCER RES, V48, P3856; KOPROWSKI H, 1981, SCIENCE, V212, P53, DOI 10.1126/science.6163212; Kudo T, 1998, LAB INVEST, V78, P797; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; Kurosawa N, 2000, J BIOCHEM-TOKYO, V127, P845, DOI 10.1093/oxfordjournals.jbchem.a022678; KUSUNOKI S, 1993, BRAIN RES, V623, P83, DOI 10.1016/0006-8993(93)90013-D; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NUDELMAN E, 1986, J BIOL CHEM, V261, P5487; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; REUTTER W, 1981, SIALIC ACIDS CHEM ME, P263; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; TAKADA A, 1993, CANCER RES, V53, P354; TSUJI S, 1996, GLYCOBIOLOGY, V6, P5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	25	59	61	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22787	22794		10.1074/jbc.M211034200	http://dx.doi.org/10.1074/jbc.M211034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668675	hybrid			2022-12-25	WOS:000183503900082
J	Park, S; Caffrey, MS; Johnson, ME; Fung, LWM				Park, S; Caffrey, MS; Johnson, ME; Fung, LWM			Solution structural studies on human erythrocyte alpha-spectrin tetramerization site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; NUCLEAR-MAGNETIC-RESONANCE; BETA-SPECTRIN; SELF-ASSOCIATION; COILED-COIL; PROTEIN STRUCTURES; NMR; DOMAIN; DATABASE; SEQUENCE	We have determined the solution NMR structure of a recombinant peptide that consists of the first 156 residues of erythroid alpha-spectrin. The first 20 residues preceding the first helix (helix C') are in a disordered conformation. The subsequent three helices ( helices A(1), B-1, and C-1) form a triple helical bundle structural domain that is similar, but not identical, to previously published structures for spectrin from Drosophila and chicken brain. Paramagnetic spin label-induced NMR resonance broadening shows that helix C', the partial domain involved in alpha- and beta-spectrin association, exhibits little interaction with the structural domain. Surprisingly, helix C' is connected to helix A(1) of the structural domain by a segment of 7 residues ( the junction region) that exhibits a flexible disordered conformation, in contrast to the predicted rigid helical structure. We suggest that the flexibility of this particular junction region may play an important role in modulating the association affinity of alpha- and beta-spectrin at the tetramerization site of different isoforms, such as erythroid spectrin and brain spectrin. These findings may provide insight for explaining various physiological and pathological conditions that are a consequence of varying alpha- and beta-subunit self-association affinities in their formation of the various spectrin tetramers.	Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Loyola Univ, Dept Chem, Chicago, IL 60626 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago	Fung, LWM (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, 900 S Ashland, Chicago, IL 60607 USA.		Johnson, Michael E/F-5141-2013	Johnson, Michael E/0000-0002-8246-4081	NCRR NIH HHS [RR 08438, RR 02301, RR 02781] Funding Source: Medline; NHLBI NIH HHS [HL 57604] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301, S10RR008438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057604] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battiste JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/bi000060h; Begg GE, 1997, BIOCHEMISTRY-US, V36, P6977, DOI 10.1021/bi970186n; Begg GE, 2000, J BIOL CHEM, V275, P3279, DOI 10.1074/jbc.275.5.3279; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chao HM, 1996, BIOCHEMISTRY-US, V35, P12175, DOI 10.1021/bi9530604; Cherry L, 1999, J BIOL CHEM, V274, P2077, DOI 10.1074/jbc.274.4.2077; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; Gascard P, 2000, CURR OPIN HEMATOL, V7, P123, DOI 10.1097/00062752-200003000-00009; Giorgi M, 2001, EXP MOL PATHOL, V70, P215, DOI 10.1006/exmp.2001.2377; Goodman SR, 1999, BRAIN RES BULL, V50, P345, DOI 10.1016/S0361-9230(99)00098-2; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guilhaudis L, 2002, EUR J BIOCHEM, V269, P4860, DOI 10.1046/j.1432-1033.2002.03187.x; Hayes NVL, 2000, J CELL SCI, V113, P2023; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Luo BH, 2002, EUR J HAEMATOL, V68, P73, DOI 10.1034/j.1600-0609.2002.01569.x; LUSITANI DM, 1994, J BIOL CHEM, V269, P25955; McKeown C, 1998, DEVELOPMENT, V125, P2087; Mehboob S, 2001, BIOCHEMISTRY-US, V40, P12457, DOI 10.1021/bi010984k; Morshauser RC, 1999, J MAGN RESON, V139, P232, DOI 10.1006/jmre.1999.1802; Park S, 2000, FEBS LETT, V485, P81, DOI 10.1016/S0014-5793(00)02186-4; Park S, 2002, BLOOD, V100, P283, DOI 10.1182/blood.V100.1.283; Park S, 2001, CELL MOL BIOL LETT, V6, P571; Park S, 1999, J BIOMOL NMR, V15, P345, DOI 10.1023/A:1008339507922; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; PERROTTA S, 1995, BRIT J HAEMATOL, V89, P933; SPEICHER DW, 1983, J BIOL CHEM, V258, P4938; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1982, J CELL BIOCHEM, V18, P479, DOI 10.1002/jcb.1982.240180409; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	48	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21837	21844		10.1074/jbc.M300617200	http://dx.doi.org/10.1074/jbc.M300617200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672815	hybrid			2022-12-25	WOS:000183354200067
J	Singha, NC; Vlamis-Gardikas, A; Holmgren, A				Singha, NC; Vlamis-Gardikas, A; Holmgren, A			Real-time kinetics of the interaction between the two subunits, Escherichia coli thioredoxin and gene 5 protein of phage T7 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CONFERS PROCESSIVITY; MONOCLONAL-ANTIBODY; MUTANT THIOREDOXINS; REDUCED FORM; BINDING; BACTERIOPHAGE-T7; RESOLUTION; ACID	T7 phage DNA polymerase is a tight 1: 1 complex of the gene 5 protein ( g5p) ( 80 kDa) of phage T7 and thioredoxin ( 12 kDa) from the Escherichia coli host. The holoenzyme is essential for the replication of the phage. We estimated the real- time kinetics and thermodynamics of the interaction of g5p with thioredoxin ( wild type and mutants) using surface plasmon resonance. Thioredoxin was immobilized on a CM5 sensor chip through a six- carbon spacer ( 6- amino- n- hexanoic acid) using standard amine coupling. Reduced thioredoxin bound g5p but oxidized thioredoxin did not. The association and dissociation phases of the complex fit a two- exponential model with an apparent equilibrium dissociation constant ( K-D) of 2.2 nM for thioredoxin with 4.7 x 10(4).M-1 . s(-1) and 10.5 x 10(-5) . s(-1) as the corresponding association ( k(a)) and dissociation ( k(d)) rate constants. The strong binding of g5p to thioredoxin is therefore due to fast association and very slow dissociation, a situation similar to antigen- antibody interactions. Thioredoxin mutants P34S, D26A, K57M, D26A/ K57M, W31F, W31Y, K36A, K36E, and Y49F had KD values in the range of 1 to 8 nM, whereas mutant W28A had a K-D of 12.5 nM. No detectable interaction was observed for mutants P40G, W31H, W31A, and C35A. The effect of temperature on K-D and the changes in enthalpy (-DeltaH = 20.2 kcal .M-1) and entropy (TDeltaS = -8.4 kcal . M-1) upon formation of the complex suggested that the interaction is driven by an increase in enthalpy and opposed by a decrease in entropy.	Karolinska Inst, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459				ALDER S, 1983, J BIOL CHEM, V258, P6956; [Anonymous], 1990, CURRENT RES PROTEIN, P449; BARISAS BG, 1971, BIOCHEMISTRY-US, V10, P2816; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; CHAMBERLIN M, 1974, J VIROL, V14, P509, DOI 10.1128/JVI.14.3.509-516.1974; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; England P, 1997, BIOCHEMISTRY-US, V36, P164, DOI 10.1021/bi961419y; Gleason F.K., 1988, FEMS MICROBIOL REV, V4, P271; GLEASON FK, 1990, BIOCHEMISTRY-US, V29, P3701, DOI 10.1021/bi00467a016; Hanin V, 1997, MOL IMMUNOL, V34, P829, DOI 10.1016/S0161-5890(97)00119-3; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1981, J BIOL CHEM, V256, P3118; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JANIN J, 1990, J BIOL CHEM, V265, P16027; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JOHNSTON MF, 1974, BIOCHEMISTRY-US, V13, P390, DOI 10.1021/bi00699a026; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LUNN CA, 1984, J BIOL CHEM, V259, P469; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; NAVARRO JA, 1991, BIOCHEMISTRY-US, V30, P2192, DOI 10.1021/bi00222a024; NIKKOLA M, 1993, BIOCHEMISTRY-US, V32, P5093, DOI 10.1021/bi00070a017; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; REUTIMANN H, 1985, P NATL ACAD SCI USA, V82, P6783, DOI 10.1073/pnas.82.20.6783; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; Slaby I, 1996, J BIOL CHEM, V271, P3091, DOI 10.1074/jbc.271.6.3091; Slaby I, 1991, Protein Expr Purif, V2, P270, DOI 10.1016/1046-5928(91)90083-U; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STONE MJ, 1993, BIOCHEMISTRY-US, V32, P426, DOI 10.1021/bi00053a007; TABOR S, 1987, J BIOL CHEM, V262, P16212; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712	53	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21421	21428		10.1074/jbc.M302310200	http://dx.doi.org/10.1074/jbc.M302310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670954	hybrid			2022-12-25	WOS:000183354200016
J	Ahn, W; Lee, MG; Kim, KH; Muallem, S				Ahn, W; Lee, MG; Kim, KH; Muallem, S			Multiple effects of SERCA2b mutations associated with Darier's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CALCIUM-PUMP PROTEIN; OLIGOMERIC STRUCTURE; CELL-ADHESION; CA2+ PUMP; CADHERINS; MORPHOGENESIS; INACTIVATION; ATP2A2; DISSOCIATION	Darier's disease (DD) is an autosomal dominant disorder caused by mutations in the ATP2A2 gene, encoding sarco/endoplasmic reticulum Ca2+-ATPase pump type 2b isoform (SERCA2b). Although >100 mutations in the ATP2A2 gene were identified, no apparent relation between genotype/phenotype emerged. In this work, we analyzed 12 DD-associated mutations from all of the regions of SERCA2b to study the underlying pathologic mechanism of DD and to elucidate the role of dimerization in SERCA2b activity. Most mutations markedly affected protein expression, partially because of enhanced proteasome-mediated degradation. All of the mutants showed lower activity than the wild type pump. Notably, several mutants that cause relatively severe phenotype of DD inhibited the activity of the endogenous and the co-expressed wild type SERCA2b. Importantly, these effects were not attributed to changes in passive Ca2+ leak, inositol 1,4,5-trisphosphate receptor activity, or sensitivity to inositol 1,4,5-trisphosphate. Rather, co-immunoprecipitation experiments showed that SERCA2b monomers interact to influence the activity of each other. These findings reveal multiple molecular mechanisms to account for the plethora of pathologic states observed in DD and provide the first evidence for the importance of SERCA2b dimerization in pump function in vivo.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Yonsei Univ, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yonsei University; Yonsei University	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Shmuel.Muallem@UTSouthwestern.edu	Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE13902] Funding Source: Medline; NIDDK NIH HHS [DK 38939] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038939] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baba-Aissa F, 1998, MOL CHEM NEUROPATHOL, V33, P199, DOI 10.1007/BF02815182; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Bruses JL, 2000, CURR OPIN CELL BIOL, V12, P593, DOI 10.1016/S0955-0674(00)00137-X; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Carvalho-Alves PC, 2000, BBA-BIOMEMBRANES, V1467, P73, DOI 10.1016/S0005-2736(00)00206-6; CASTELLANI L, 1989, J CELL BIOL, V108, P511, DOI 10.1083/jcb.108.2.511; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P1997; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hakuno M, 2000, BRIT J DERMATOL, V142, P702, DOI 10.1046/j.1365-2133.2000.03415.x; HYMEL L, 1984, J BIOL CHEM, V259, P4890; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; NAPOLITANO CA, 1983, BIOPHYS J, V42, P119, DOI 10.1016/S0006-3495(83)84377-X; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Palm T, 2001, BIOL CHEM, V382, P417, DOI 10.1515/BC.2001.051; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; Ranscht B, 2000, INT J DEV NEUROSCI, V18, P643, DOI 10.1016/S0736-5748(00)00030-7; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tavadia S, 2001, CLIN EXP DERMATOL, V26, P696, DOI 10.1046/j.1365-2230.2001.00921.x; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Zhao XS, 2001, EMBO J, V20, P2680, DOI 10.1093/emboj/20.11.2680	38	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20795	20801		10.1074/jbc.M301638200	http://dx.doi.org/10.1074/jbc.M301638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670936	hybrid			2022-12-25	WOS:000183230500047
J	Shirley, AM; Chapple, C				Shirley, AM; Chapple, C			Biochemical characterization of sinapoylglucose : choline sinapoyltransferase, a serine carboxypeptidase-like protein that functions as an acyltransferase in plant secondary metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPHANUS-SATIVUS L; YEAST CARBOXYPEPTIDASE; SINAPINE SYNTHASE; ARABIDOPSIS; WHEAT; PURIFICATION; SEEDS; 1-SINAPOYLGLUCOSE; TRANSACYLATION; BIOSYNTHESIS	Recently, serine carboxypeptidase-like (SCPL) proteins that catalyze transacylation reactions in plant secondary metabolism have been identified from wild tomato and Arabidopsis. These include sinapoylglucose: choline sinapoyltransferase (SCT), an enzyme that functions in Arabidopsis sinapate ester synthesis. SCT and the other known SCPL acyltransferases all share the conserved serine, aspartic acid, and histidine residues employed for catalysis by classical serine carboxypeptidases, although the importance of these residues and the mechanism by which this class of SCPL proteins catalyze acyltransferase reactions is unknown. To characterize further SCT and its catalytic mechanism, we have employed the Saccharomyces cerevisiae vacuolar protein localization 1 mutant, which secretes the serine carboxypeptidase, carboxypeptidase Y, and other proteins normally targeted to the vacuole. When expressed in this strain, SCT is similarly secreted. SCT has been purified from the yeast medium and used for kinetic characterization of the protein. Immunological analysis of SCT has revealed that the expected 50-kDa mature protein is proteolytically processed in yeast and in planta, most likely resulting in the production of a heterodimer derived from a 30- and 17-kDa polypeptide.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chapple, C (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.		Chapple, Clint CS/Q-5456-2017	Chapple, Clint CS/0000-0002-5195-562X				BAMFORTH CW, 1979, J I BREWING, V85, P334, DOI 10.1002/j.2050-0416.1979.tb03937.x; BECH LM, 1989, J BIOL CHEM, V262, P13726; Booij-James IS, 2000, PLANT PHYSIOL, V124, P1275, DOI 10.1104/pp.124.3.1275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P297, DOI 10.1007/BF02907172; CHAPPLE CCS, 1992, PLANT CELL, V16, P735; CLAUSEN S, 1982, PHYTOCHEMISTRY, V21, P917, DOI 10.1016/0031-9422(82)80093-9; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P148; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; GHANGAS GS, 1993, P NATL ACAD SCI USA, V90, P9911, DOI 10.1073/pnas.90.21.9911; GHANGAS GS, 1995, ARCH BIOCHEM BIOPHYS, V316, P370, DOI 10.1006/abbi.1995.1049; GMELIN R, 1970, PHYTOCHEMISTRY, V9, P667, DOI 10.1016/S0031-9422(00)85712-X; GRAWE W, 1986, Z NATURFORSCH C, V41, P28; HAMMERTON RW, 1986, PLANT PHYSIOL, V80, P692, DOI 10.1104/pp.80.3.692; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; Hause B, 2002, PLANTA, V215, P26, DOI 10.1007/s00425-001-0716-y; HAYASHI R, 1975, J BIOL CHEM, V250, P5221; HAYASHI R, 1973, J BIOL CHEM, V248, P8366; HOBSONFROHOCK A, 1977, BRIT POULTRY SCI, V18, P539, DOI 10.1080/00071667708416400; JOHNSTON JR, 1994, MOL GENETICS YEAST P, P121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; Lehfeldt C, 2000, PLANT CELL, V12, P1295, DOI 10.1105/tpc.12.8.1295; Li AX, 1999, PLANT PHYSIOL, V121, P453, DOI 10.1104/pp.121.2.453; Li AX, 2000, P NATL ACAD SCI USA, V97, P6902, DOI 10.1073/pnas.110154197; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Lorenzen M, 1996, PLANT PHYSIOL, V112, P1625, DOI 10.1104/pp.112.4.1625; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MIKOLA L, 1986, PLANT PHYSIOL, V81, P823, DOI 10.1104/pp.81.3.823; NIELSEN TL, 1990, APPL MICROBIOL BIOT, V33, P307, DOI 10.1007/BF00164527; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PETERSON LM, 1982, ANAL BIOCHEM, V125, P420, DOI 10.1016/0003-2697(82)90024-0; Sambrook J., 2002, MOL CLONING LAB MANU; SHARMA V, 1985, PLANTA, V163, P563, DOI 10.1007/BF00392714; Shirley AM, 2001, PLANT J, V28, P83, DOI 10.1046/j.1365-313X.2001.01123.x; STRACK D, 1983, Z NATURFORSCH C, V38, P21; STRACK D, 1981, Z NATURFORSCH C, V36, P215; UMETSU H, 1983, PHYTOCHEMISTRY, V22, P591, DOI 10.1016/0031-9422(83)83054-4; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; VOGT T, 1993, ARCH BIOCHEM BIOPHYS, V300, P622, DOI 10.1006/abbi.1993.1086; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758	45	56	60	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19870	19877		10.1074/jbc.M302362200	http://dx.doi.org/10.1074/jbc.M302362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657648	hybrid			2022-12-25	WOS:000183078000039
J	Pace, A; Garcia-Marin, LJ; Tapia, JA; Bragado, MJ; Jensen, RT				Pace, A; Garcia-Marin, LJ; Tapia, JA; Bragado, MJ; Jensen, RT			Phosphospecific site tyrosine phosphorylation of p125(FAK) and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR; LOOP PHOSPHORYLATION; TERMINAL DOMAIN; DIFFERENT MODES; PKC-DELTA; ANG-II; PROTEIN; PYK2; RAT	The focal adhesion kinases, p125(FAK) and proline-rich kinase 2 (PYK2), are involved in numerous processes as adhesion, cytoskeletal changes, and growth. These kinases have 45% homology and share three tyrosine phosphorylation (TyrP) sites. Little information exists on the ability of stimulants to cause TyrP of each kinase site and the cellular mechanism involved. We explored the ability of the neurotransmitter/hormone, CCK, to stimulate TyrP at each site. In rat pancreatic acini, CCK stimulated TyrP at each site in both kinases. TyrP was rapid except for pY397FAK. The magnitude of TyrP differed with the different FAK and PYK2 sites. The CCK dose-response curve for TyrP for sites in each kinase was similar. CCK-JMV, an agonist of the high affinity receptor state and antagonist of the low affinity receptor state, was less efficacious than CCK at each FAK/PYK2 site and inhibited CCK maximal stimulation. Thapsigargin decreased CCK-stimulated TyrP of pY402PYK2 and pY925FAK but not the other sites. GF109203X reduced TyrP of only the PYK2 sites, pY402 and pY580. GF109203X with thapsigargin decreased TyrP of pY402PYK2 and the three FAK sites more than either inhibitor alone. Basal TyrP of pY397FAK was greater than other sites. These results demonstrate that CCK stimulates tyrosine phosphorylation of each of the three homologous phosphorylation sites in FAK and PYK2. However, CCK-stimulated TyrP at these sites differs in kinetics, magnitude, and participation of the high/low affinity receptor states and by protein kinase C and [Ca2+](i). These results show that phosphorylation of these different sites is differentially regulated and involves different intracellular mechanisms in the same cell.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Extremadura, Dept Fisiol, Caceres 10071, Spain; Univ Extremadura, Dept Bioquim Biol Mol & Genet, Caceres 10071, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universidad de Extremadura; Universidad de Extremadura	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov	Garcia-Marin, Luis J/L-4680-2014; Tapia, Jose A./C-5181-2008; Bragado, M Julia/L-6988-2014	Garcia-Marin, Luis J/0000-0002-1795-7381; Tapia, Jose A./0000-0002-3614-6867; Bragado, M Julia/0000-0001-7770-0775				Andreev J, 1999, MOL CELL BIOL, V19, P2338; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dikic Ivan, 1999, Cell Biochemistry and Biophysics, V30, P369, DOI 10.1007/BF02738120; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Garcia LJ, 1999, ADV MOL CELL ENDOCR, V3, P119; Garcia LJ, 1997, BBA-MOL CELL RES, V1358, P189, DOI 10.1016/S0167-4889(97)00056-6; Garcia LJ, 1997, BIOCHEM J, V327, P461; Gardner Jerry D., 1993, P151; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HUANG S, 1994, J BIOL CHEM, V269, P26121; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; Jensen Robert T., 1994, P1377; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; Jeon SH, 2001, BIOCHEM BIOPH RES CO, V282, P1026, DOI 10.1006/bbrc.2001.4686; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V290, P1470, DOI 10.1006/bbrc.2002.6350; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG613, DOI 10.1152/ajpgi.1994.266.4.G613; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; Lev S, 1999, MOL CELL BIOL, V19, P2278; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liddle RA., 1994, GUT PEPTIDES BIOCH P; Lobo M, 2000, BIOCHEM BIOPH RES CO, V276, P1068, DOI 10.1006/bbrc.2000.3547; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; Maulik G, 2002, CLIN CANCER RES, V8, P620; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PEIKIN SR, 1978, AM J PHYSIOL, V235, pE743, DOI 10.1152/ajpendo.1978.235.6.E743; POLLO DA, 1994, BBA-MOL CELL RES, V1224, P127, DOI 10.1016/0167-4889(94)90120-1; Raja S, 1997, J BIOL CHEM, V272, P10941; RAMBAUD JC, 1988, GUT, V29, P537, DOI 10.1136/gut.29.4.537; RELOU IA, 2003, BIOCHEM J, V15, P407; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Rosado JA, 1998, BBA-MOL CELL RES, V1404, P412, DOI 10.1016/S0167-4889(98)00072-X; ROZENGURT E, 1995, CANCER SURV, V24, P81; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Tapia JA, 2002, BBA-MOL CELL RES, V1593, P99, DOI 10.1016/S0167-4889(02)00346-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Wang JG, 2001, BIOCHEM BIOPH RES CO, V288, P356, DOI 10.1006/bbrc.2001.5775; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Wrenn RW, 2001, BIOCHEM BIOPH RES CO, V282, P882, DOI 10.1006/bbrc.2001.4657; Wu SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1432, DOI 10.1152/ajpcell.00323.2001; Yule David I., 1994, P1447; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	75	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19008	19016		10.1074/jbc.M300832200	http://dx.doi.org/10.1074/jbc.M300832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12651850	hybrid			2022-12-25	WOS:000182932200038
J	Petrovas, C; Jeay, S; Lewis, RE; Sonenshein, GE				Petrovas, C; Jeay, S; Lewis, RE; Sonenshein, GE			B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain	ONCOGENE			English	Article						B-myb oncogene; gene repression; cyclin A; type V collagen; smooth muscle cells	SMOOTH-MUSCLE CELLS; GENE-PRODUCT; DNA-BINDING; A-MYB; TRANSCRIPTION; TRANSACTIVATION; EXPRESSION; PROTEIN; PROMOTER; PROLIFERATION	B-Myb is a widely expressed member of the myh oncogene family that has been shown to act as either an activator or repressor of gene transcription in a cell-type-specific fashion. For example, in aortic smooth muscle cells B-Myb represses transcription of the alpha2(V) collagen gene. Recently, phosphorylation of B-Myb by cyclin A was shown to enhance greatly its ability to transactivate. Here, we have tested the effects of cyclin A on the ability of B-Myb to repress. We report that coexpression of cyclin A abolished repression of the alpha2(V) collagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by ectopic and endogenous B-Myb protein. Mutation of 10 of 22 putative cyclin A sites, which greatly reduces the effects of cyclin A on transactivation by B-Myb, had no effect on the ability of cyclin A to alleviate B-Myb-mediated repression of alpha2(V) collagen promoter activity. Furthermore, the stability of the mutant B-Myb protein was largely unaffected by cyclin A, although ectopic expression of cyclin A enhanced the rate of decay of wild-type B-Myb protein. Thus, the mechanisms of repression and activation appear distinct, for example, mediated by different critical phosphorylation sites or protein-protein interactions. B-Myb mutants with either deletion of aa 374-581 (B-Myb-Mut3) or C-terminal truncation beyond aa 491 (B-Myb-491) positively regulated alpha2(V) collagen promoter activity, and were not affected by cyclin A. Thus, our findings indicate that the ability of B-Myb to function as a repressor of matrix promoter activity is abolished by cyclin A, and maps the sites mediating negative regulation by B-Myb to the region between aa 491 and 582.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	Boston University; University of Nebraska System; University of Nebraska Medical Center	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.		Lewis, Robert E./H-3404-2019	JEAY, SEBASTIEN/0000-0001-7476-3340	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 P01 HL13262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bruno MD, 1999, J BIOL CHEM, V274, P27523, DOI 10.1074/jbc.274.39.27523; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; Grassilli E, 1999, CANCER RES, V59, P2451; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Iwai N, 2001, ONCOGENE, V20, P1425, DOI 10.1038/sj.onc.1204236; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; Kypreos KE, 1998, CELL GROWTH DIFFER, V9, P723; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Piccinini G, 1999, J INVEST DERMATOL, V112, P191, DOI 10.1046/j.1523-1747.1999.00485.x; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; TASHIRO S, 1995, ONCOGENE, V10, P1699; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	39	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2011	2020		10.1038/sj.onc.1206231	http://dx.doi.org/10.1038/sj.onc.1206231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673206				2022-12-25	WOS:000181967700011
J	Yang, L; Ross, K; Qwarnstrom, EE				Yang, L; Ross, K; Qwarnstrom, EE			RelA control of I kappa B alpha phosphorylation - A positive feedback loop for high affinity NF-kappa B complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; GREEN FLUORESCENT PROTEIN; SIGNAL-INDUCED DEGRADATION; REGULATES DNA-BINDING; NUCLEAR EXPORT SIGNAL; LIVING CELLS; TRANSCRIPTIONAL ACTIVATION; IKK-ALPHA; LOCALIZATION; BETA	NF-kappaB-IkappaB complex formation regulates the level and specificity of NF-kappaB activity. Quantitative analyses showed that RelA-NF-kappaB-induced IkappaBalpha binding is regulated through inhibitor retention and phosphorylation. RelA caused an increase in IkappaBalpha phosphorylation and in degradation, which was enhanced monotonically with inhibitor concentration. In vivo analysis demonstrated the RelA-induced IkappaBalpha/RelA interactions to be specific, saturable, and phosphorylation-dependent. In addition, it showed that phosphorylation regulates both the level and affinity of the complexes and demonstrated an increased average affinity to coincide with reduction in the level of complexes during cytokine-induced pathway activation. The data show that RelA regulation of NF-kappaB-IkappaBalpha complex formation is IkappaBalpha phosphorylation-dependent and that IkappaBalpha/NF-kappaB binding is dynamic and determined by concentration of the subunits. In addition, they suggest that regulation of both complex levels and affinities through phosphorylation, with effects on the system steady state, participate in selective activation of the NF-kappaB pathway.	Univ Sheffield, Sch Med, Div Genom Med, Cell Biol Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Qwarnstrom, EE (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Cell Biol Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			Qwarnstrom, Eva/0000-0003-4417-8663				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XQ, 1999, J BIOL CHEM, V274, P21244, DOI 10.1074/jbc.274.30.21244; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Schooley K, 2003, BIOCHEM J, V369, P331, DOI 10.1042/BJ20020253; Szollosi J, 1998, CYTOMETRY, V34, P159; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yang L, 2001, BIOCHEM BIOPH RES CO, V285, P603, DOI 10.1006/bbrc.2001.5205; Zaccolo M, 2000, IUBMB LIFE, V49, P375; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	49	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30881	30888		10.1074/jbc.M212216200	http://dx.doi.org/10.1074/jbc.M212216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12663663	hybrid			2022-12-25	WOS:000184658800060
J	Han, WK; Sapirstein, A; Hung, CC; Alessandrini, A; Bonventre, JV				Han, WK; Sapirstein, A; Hung, CC; Alessandrini, A; Bonventre, JV			Cross-talk between cytosolic phospholipase A(2)alpha (cPLA(2 alpha)) and secretory phospholipase A(2) (sPLA(2)) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells - sPLA(2) regulates cPLA(2)alpha activity that is responsible for arachidonic acid release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE-CELLS; P38 MAP KINASE; P388D(1) MACROPHAGES; INDEPENDENT PATHWAYS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; MAST-CELLS; TYROSINE PHOSPHORYLATION; PROSTAGLANDIN PRODUCTION	Oxidant stress and phospholipase A(2) (PLA(2)) activation have been implicated in numerous proinflammatory responses of the mesangial cell (MC). We investigated the cross-talk between group IValpha cytosolic PLA(2) (cPLA(2)alpha) and secretory PLA(2)s (sPLA(2)s) during H2O2-induced arachidonic acid (AA) release using two types of murine MC: (i) MC+/+, which lack group IIa and V PLA(2)s, and (ii) MC-/-, which lack groups IIa, V, and IValpha PLA(2)s. H2O2-induced AA release was greater in MC+/+ compared with MC-/-. It has been argued that cPLA(2)alpha plays a regulatory role enhancing the activity of sPLA(2)s, which act on phospholipids to release fatty acid. Group IIa, V, or IValpha PLA(2)s were expressed in MC-/- or MC+/+ using recombinant adenovirus vectors. Expression of cPLA(2)alpha in H2O2-treated MC-/- increased AA release to a level approaching that of H2O2-treated MC+/+. Expression of either group IIa PLA(2) or V PLA(2) enhanced AA release in MC+/+ but had no effect on AA release in MC-/-. When sPLA(2) and cPLA(2)alpha are both present, the effect of H2O2 is manifested by preferential release of AA compared with oleic acid. Inhibition of the ERK and protein kinase C signaling pathways with the MEK-1 inhibitor, U0126, and protein kinase C inhibitor, GF 1092030x, respectively, and chelating intracellular free calcium with 1,2-bis(2-aminophenoyl)ethane-N,N,N',N'-tetraacetic acid-AM, which also reduced ERK1/2 activation, significantly reduced H2O2-induced AA release in MC+/+ expressing either group IIa or V PLA(2)s. By contrast, H2O2-induced AA release was not enhanced when ERK1/2 was activated by infection of MC+/+ with constitutively active MEK1-DD. We conclude that the effect of group IIa and V PLA(2)s on H2O2-induced AA release is dependent upon the presence of cPLA(2)alpha and the activation of PKC and ERK1/2. Group IIa and V PLA(2)s are regulatory and cPLA(2)alpha is responsible for AA release.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med & Anesthesia,Med Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med & Anesthesia,Anesthesia Serv, Charlestown, MA 02129 USA; Harvard MIT Div Hlth Sci & Technol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Bonventre, JV (corresponding author), Brigham & Womens Hosp, MRB4,75 Francis St, Boston, MA 02115 USA.	joseph_bonventre@hms.harvard.edu			NIDDK NIH HHS [DK38452, DK10036, DK39773] Funding Source: Medline; NINDS NIH HHS [NS10828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010036, R37DK039773, R01DK039773, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; Bonventre JV, 1999, J AM SOC NEPHROL, V10, P404; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BOYER CS, 1995, BIOCHEM PHARMACOL, V50, P753, DOI 10.1016/0006-2952(95)00195-6; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; Catherwood MA, 2002, KIDNEY INT, V61, P599, DOI 10.1046/j.1523-1755.2002.00168.x; CHEUNG JY, 1986, AM J PHYSIOL, V251, pF690, DOI 10.1152/ajprenal.1986.251.4.F690; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Geijsen N, 2000, FEBS LETT, V471, P83, DOI 10.1016/S0014-5793(00)01373-9; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hayama M, 2002, AM J PHYSIOL-RENAL, V282, pF485, DOI 10.1152/ajprenal.00210.2001; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; HOMANMULLER JWT, 1975, J LAB CLIN MED, V85, P198; Husain S, 1998, BBA-LIPID LIPID MET, V1392, P127, DOI 10.1016/S0005-2760(98)00011-3; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lianos EA, 1999, J LAB CLIN MED, V134, P478, DOI 10.1016/S0022-2143(99)90169-5; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mahadevan P, 1996, DIABETES, V45, P44, DOI 10.2337/diabetes.45.1.44; Melien O, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-5; Meyer TN, 1996, KIDNEY INT, V49, P388, DOI 10.1038/ki.1996.57; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NEGRI M, 1991, CLIN CHIM ACTA, V199, P305, DOI 10.1016/0009-8981(91)90124-U; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Roberts ML, 1998, BIOCHEM BIOPH RES CO, V251, P166, DOI 10.1006/bbrc.1998.9434; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; van der Helm HA, 2000, BBA-MOL CELL BIOL L, V1484, P215, DOI 10.1016/S1388-1981(00)00021-4; Weigel G, 1997, THROMB RES, V87, P363, DOI 10.1016/S0049-3848(97)00140-0; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Xu JF, 2002, J NEUROCHEM, V83, P259, DOI 10.1046/j.1471-4159.2002.01145.x; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053	89	130	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24153	24163		10.1074/jbc.M300424200	http://dx.doi.org/10.1074/jbc.M300424200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12676927	hybrid			2022-12-25	WOS:000183638600121
J	Considine, MJ; Goodman, M; Echtay, KS; Laloi, M; Whelan, J; Brand, MD; Sweetlove, LJ				Considine, MJ; Goodman, M; Echtay, KS; Laloi, M; Whelan, J; Brand, MD; Sweetlove, LJ			Superoxide stimulates a proton leak in potato mitochondria that is related to the activity of uncoupling protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID CYCLING MECHANISM; FREE FATTY-ACIDS; ALTERNATIVE OXIDASE; PLANT-MITOCHONDRIA; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; HOMOLOGS; WHEAT	The ability of plant mitochondrial uncoupling proteins to catalyze a significant proton conductance in situ is controversial. We have re-examined conditions that lead to uncoupling of mitochondria isolated from the tubers of potato ( Solanum tuberosum). Specifically, we have investigated the effect of superoxide. In the absence of superoxide, linoleic acid stimulated a proton leak in mitochondria respiring NADH that was insensitive to GTP. However, when exogenous superoxide was generated by the addition of xanthine and xanthine oxidase, there was an additional linoleic acid-stimulated proton leak that was specifically inhibited by GTP. Under these conditions of assay ( NADH as a respiratory substrate, in the presence of linoleic acid and xanthine/ xanthine oxidase) there was a higher rate of proton conductance in mitochondria from transgenic potato tubers overexpressing the StUCP gene than those from wild type. The increased proton leak in the transgenic mitochondria was completely abolished by the addition of GTP. This suggests that superoxide and linoleic acid stimulate a proton leak in potato mitochondria that is related to the activity of uncoupling protein. Furthermore, it demonstrates that changes in the amount of StUCP can alter the rate of proton conductance of potato mitochondria.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Western Australia, Sch Biomed & Life Sci, Crawley, WA 6009, Australia	University of Oxford; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Western Australia	Sweetlove, LJ (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.		Considine, Michael/A-9978-2011; Brand, Martin D/A-9423-2012; Whelan, James/F-6402-2011	Considine, Michael/0000-0002-4468-6820; Brand, Martin D/0000-0003-4418-6153; Whelan, James/0000-0001-5754-025X	Biotechnology and Biological Sciences Research Council [JF16984] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Borecky J, 2001, FEBS LETT, V505, P240, DOI 10.1016/S0014-5793(01)02835-6; Brand M. D., 1995, BIOENERGETICS, V154, P62; Considine MJ, 2001, PLANT PHYSIOL, V126, P1619, DOI 10.1104/pp.126.4.1619; Desikan R, 2001, PLANT PHYSIOL, V127, P159, DOI 10.1104/pp.127.1.159; DOUCE R, 1989, ANNU REV PLANT PHYS, V40, P371, DOI 10.1146/annurev.pp.40.060189.002103; Douce R., 1985, MITOCHONDRIA HIGHER; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; FRANCK A, 1980, CELL, V21, P285, DOI 10.1016/0092-8674(80)90136-1; GIELEN J, 1984, EMBO J, V3, P835, DOI 10.1002/j.1460-2075.1984.tb01894.x; Hanak P, 2001, FEBS LETT, V495, P137, DOI 10.1016/S0014-5793(01)02338-9; Hourton-Cabassa C, 2002, J BIOL CHEM, V277, P41533, DOI 10.1074/jbc.M202805200; Ito K, 1999, PLANT SCI, V149, P167, DOI 10.1016/S0168-9452(99)00159-4; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P34882, DOI 10.1074/jbc.273.52.34882; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Maia IG, 1998, FEBS LETT, V429, P403, DOI 10.1016/S0014-5793(98)00634-6; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; Murayama S, 2000, MOL GEN GENET, V264, P112, DOI 10.1007/s004380000289; Pastore D, 2000, FEBS LETT, V470, P88, DOI 10.1016/S0014-5793(00)01292-8; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; Sluse FE, 1998, FEBS LETT, V433, P237, DOI 10.1016/S0014-5793(98)00922-3; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Watanabe A, 2002, PLANTA, V215, P90, DOI 10.1007/s00425-001-0714-0; Watanabe A, 1999, PLANT CELL PHYSIOL, V40, P1160, DOI 10.1093/oxfordjournals.pcp.a029501	37	105	112	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22298	22302		10.1074/jbc.M301075200	http://dx.doi.org/10.1074/jbc.M301075200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672801	hybrid			2022-12-25	WOS:000183503900018
J	Alefantis, T; Barmak, K; Harhaj, EW; Grant, C; Wigdahl, B				Alefantis, T; Barmak, K; Harhaj, EW; Grant, C; Wigdahl, B			Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NUCLEOTIDE-SEQUENCE ANALYSIS; CREB BINDING-PROTEIN; LEPTOMYCIN-B; CRM1; LYMPHOCYTES; EXPRESSION; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Human T cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T cell leukemia and HTLV-I-associated myelopathy/ tropical spastic paraparesis. The HTLV-I transactivator protein Tax plays an integral role in the etiology of adult T cell leukemia, as expression of Tax in T lymphocytes has been shown to result in immortalization. In addition, Tax is known to interface with numerous transcription factor families, including activating transcription factor/cAMP response element-binding protein and nuclear factor-kappaB, requiring Tax to localize to both the nucleus and cytoplasm. In this report, the nucleocytoplasmic localization of Tax was examined in Jurkat, HeLa, and U-87 MG cells. The results reported herein indicate that Tax contains a leucine-rich nuclear export signal (NES) that, when fused to green fluorescent protein (GFP), can direct nuclear export via the CRM-1 pathway, as determined by leptomycin B inhibition of nuclear export. However, cytoplasmic localization of full-length Tax was not altered by treatment with leptomycin B, suggesting that native Tax utilizes another nuclear export pathway. Additional support for the presence of a functional NES has also been shown because the NES mutant Tax(L200A)-GFP localized to the nuclear membrane in the majority of U-87 MG cells. Evidence has also been provided suggesting that the Tax NES likely exists as a conditionally masked signal because the truncation mutant TaxDelta214-GFP localized constitutively to the cytoplasm. These results suggest that Tax localization may be directed by specific changes in Tax conformation or by specific interactions with cellular proteins leading to changes in the availability of the Tax NES and nuclear localization signal.	Penn State Univ, Coll Med, Dept Microbiol & Immunol H107, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Wigdahl, B (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol H107, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.		Barmak, Katayun/AFU-8454-2022	Barmak, Katayun/0000-0003-0070-158X	NATIONAL CANCER INSTITUTE [R01CA054559] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akaoka H, 1996, J VIROL, V70, P8727, DOI 10.1128/JVI.70.12.8727-8736.1996; Akaoka H, 2001, VIRUS RES, V78, P57, DOI 10.1016/S0168-1702(01)00284-2; Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; Berg P, 2001, J BIOL CHEM, V276, P43231, DOI 10.1074/jbc.M105261200; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1999, J VIROL, V73, P738, DOI 10.1128/JVI.73.1.738-745.1999; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MAJOR M, 1995, AIDS RES HUM RETROV, V11, P415, DOI 10.1089/aid.1995.11.415; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; MUKHOPADHYAYA R, 1993, AIDS RES HUM RETROV, V9, P109, DOI 10.1089/aid.1993.9.109; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAINE E, 1991, VIROLOGY, V182, P111, DOI 10.1016/0042-6822(91)90654-T; RATNER L, 1991, AIDS RES HUM RETROV, V7, P923, DOI 10.1089/aid.1991.7.923; RENJIFO B, 1995, J VIROL, V69, P2611, DOI 10.1128/JVI.69.4.2611-2616.1995; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Szymocha R, 2000, J NEUROVIROL, V6, P350, DOI 10.3109/13550280009030761; Szymocha R, 2000, AIDS RES HUM RETROV, V16, P1723, DOI 10.1089/08892220050193218; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WESSNER R, 1995, J NEUROVIROL, V1, P62, DOI 10.3109/13550289509111011; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yao Y, 2000, LEUKEMIA, V14, P535; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	53	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21814	21822		10.1074/jbc.M211576200	http://dx.doi.org/10.1074/jbc.M211576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670929	hybrid			2022-12-25	WOS:000183354200064
J	Canals, S; Casarejos, MJ; de Bernardo, S; Rodriguez-Martin, E; Mena, MA				Canals, S; Casarejos, MJ; de Bernardo, S; Rodriguez-Martin, E; Mena, MA			Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX I; ARACHIDONIC-ACID; SUBSTANTIA-NIGRA; CELL-DEATH; BUTHIONINE SULFOXIMINE; PARKINSONS-DISEASE; GLIAL-CELLS; NEURONS; BRAIN; LIPOXYGENASE	Glutathione (GSH) depletion is the earliest biochemical alteration shown to date in brains of Parkinson's disease patients. However, data from animal models show that GSH depletion by itself is not sufficient to induce nigral degeneration. We have previously shown that non-toxic inhibition of GSH synthesis with L-buthionine-(S, R)sulfoximine in primary midbrain cultures transforms a nitric oxide ( NO) neurotrophic effect, selective for dopamine neurons, into a toxic effect with participation of guanylate cyclase ( GC) and cGMP-dependent protein kinase (PKG) ( Canals, S., Casarejos, M. J., de Bernardo, S., Rodriguez-Martin, E., and Mena, M. A. (2001) J. Neurochem. 79, 1183 - 1195). Here we demonstrate that arachidonic acid ( AA) metabolism through the 12-lipoxygenase (12-LOX) pathway is also central for this GSH-NO interaction. LOX inhibitors ( nordihydroguaiaretic acid and baicalein), but not cyclooxygenase ( indomethacin) or epoxygenase ( clotrimazole) ones, prevent cell death in the culture, even when added 10 h after NO treatment. Furthermore, the addition of AA to GSH-depleted cultures precipitates a cell death process that is indistinguishable from that initiated by NO in its morphology, time course, and 12-LOX, GC, and PKG dependence. The first AA metabolite through the 12-LOX enzyme, 12-hydroperoxyeicosatetraenoic acid, induces cell death in the culture, and its toxicity is greatly enhanced by GSH depletion. In addition we show that if GSH synthesis inhibition persists for up to 4 days without any additional treatment, it will induce a cell death process that also depends on 12-LOX, GC, and PKG activation. In this study, therefore, we show that the signaling pathway AA/12-LOX/12-HPETE/GC/ PKG may be important in several pathologies in which GSH decrease has been documented, such as Parkinson's disease. The potentiating effect of NO over such a signaling pathway may be of relevance as part of the cascade of events leading to and sustaining nerve cell death.	Hosp Ramon & Cajal, Dept Invest, Serv Neurobiol, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Mena, MA (corresponding author), Hosp Ramon & Cajal, Dept Invest, Serv Neurobiol, Ctra Colmenar,Km 8, E-28034 Madrid, Spain.	maria.a.mena@hrc.es	Casarejos, María jose/AAA-9629-2019; Canals, Santiago/N-5838-2014	Casarejos, María jose/0000-0003-1288-1717; Canals, Santiago/0000-0003-2175-8139				BRUNE B, 1991, MOL PHARMACOL, V39, P671; Canals S, 2001, J NEUROCHEM, V79, P1183, DOI 10.1046/j.1471-4159.2001.00635.x; Canals S, 2001, J NEUROCHEM, V76, P56, DOI 10.1046/j.1471-4159.2001.00010.x; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Di Monte DA, 2001, CLIN NEUROSCI RES, V1, P419, DOI 10.1016/S1566-2772(01)00020-2; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; GrasbonFrodl EM, 1996, J NEUROCHEM, V67, P1653; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; Guidarelli A, 2000, BRIT J PHARMACOL, V129, P1539, DOI 10.1038/sj.bjp.0703275; HAGMANN W, 1993, PROSTAGLANDINS, V46, P471, DOI 10.1016/0090-6980(93)90066-G; HILWIG I, 1975, EXP CELL RES, V91, P457, DOI 10.1016/0014-4827(75)90128-7; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; Hunot S, 2001, CLIN NEUROSCI RES, V1, P434, DOI 10.1016/S1566-2772(01)00022-6; Hurst JS, 1997, J OCUL PHARMACOL TH, V13, P415, DOI 10.1089/jop.1997.13.415; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; Klivenyi P, 2000, J NEUROSCI, V20, P1; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; Liberatore GT, 1999, NAT MED, V5, P1403; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; Marshall KA, 1999, FREE RADICAL BIO MED, V27, P515, DOI 10.1016/S0891-5849(99)00094-5; MENA MA, 1993, NEUROREPORT, V4, P438, DOI 10.1097/00001756-199304000-00025; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Mytilineou C, 1999, J NEUROCHEM, V73, P112, DOI 10.1046/j.1471-4159.1999.0730112.x; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; Nakamura K, 1997, J NEUROCHEM, V69, P1850; Nakamura K, 2000, J NEUROCHEM, V74, P2305, DOI 10.1046/j.1471-4159.2000.0742305.x; OURESHI GA, 1995, NEUROREPORT, V6, P1642, DOI 10.1097/00001756-199508000-00013; Pardo B, 1997, BRAIN RES PROTOC, V1, P127, DOI 10.1016/S1385-299X(96)00020-7; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; PILEBLAD E, 1989, J NEUROCHEM, V52, P978, DOI 10.1111/j.1471-4159.1989.tb02550.x; PIOMELLI D, 1990, TRENDS PHARMACOL SCI, V11, P367, DOI 10.1016/0165-6147(90)90182-8; PRETUS HA, 1985, PROSTAGLANDINS, V30, P591, DOI 10.1016/0090-6980(85)90023-1; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RAFF MC, 1979, BRAIN RES, V174, P283, DOI 10.1016/0006-8993(79)90851-5; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Rodriguez-Martin E, 2002, NEUROPHARMACOLOGY, V43, P877, DOI 10.1016/S0028-3908(02)00150-8; Samochocki M, 1996, MOL CHEM NEUROPATHOL, V29, P79, DOI 10.1007/BF02815195; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Shergill JK, 1996, BIOCHEM BIOPH RES CO, V228, P298, DOI 10.1006/bbrc.1996.1656; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHORNICK LP, 1993, J BIOL CHEM, V268, P371; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Tariq M, 2001, BRAIN RES BULL, V54, P77, DOI 10.1016/S0361-9230(00)00427-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Toffa S, 1997, J NEURAL TRANSM, V104, P67, DOI 10.1007/BF01271295; Weber GF, 1999, NEUROSCI BIOBEHAV R, V23, P1079, DOI 10.1016/S0149-7634(99)00041-X; Wullner U, 1996, NEUROREPORT, V7, P921; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	65	82	84	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21542	21549		10.1074/jbc.M213174200	http://dx.doi.org/10.1074/jbc.M213174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12679339	hybrid			2022-12-25	WOS:000183354200030
J	El Alami, M; Dubois, E; Oudjama, Y; Tricot, C; Wouters, J; Stalon, V; Messenguy, F				El Alami, M; Dubois, E; Oudjama, Y; Tricot, C; Wouters, J; Stalon, V; Messenguy, F			Yeast epiarginase regulation, an enzyme-enzyme activity control - Identification of residues of ornithine carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; PROTEIN-PROTEIN; LIGAND-BINDING; RESOLUTION; COMPLEX; ORNITHINETRANSCARBAMYLASE; TRANSCARBAMOYLASE; LOCALIZATION	In the presence of ornithine and arginine, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active. The mechanism by which these nonallosteric enzymes form a stable complex triggered by the binding of their respective substrates raises the question of how such a cooperative association is induced. Analyses of mutations in both enzymes identify residues that are required for their association, some of them being important for catalysis. In arginase, two cysteines at the C terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure. In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase. The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Inst Rech Microbiol, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Messenguy, F (corresponding author), Free Univ Brussels, Microbiol Lab, Ave Emile Gryzon 1, B-1070 Brussels, Belgium.	fanarg@ulb.ac.be		Wouters, Johan/0000-0002-4920-6857				Archibald RM, 1944, J BIOL CHEM, V156, P121; BECHET J, 1965, BIOCHEM BIOPH RES CO, V21, P226, DOI 10.1016/0006-291X(65)90276-7; Bewley MC, 1999, STRUCT FOLD DES, V7, P435, DOI 10.1016/S0969-2126(99)80056-2; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; de Montiguy J, 2000, FEBS LETT, V487, P87, DOI 10.1016/S0014-5793(00)02286-9; Dubois E, 1997, MOL GEN GENET, V253, P568, DOI 10.1007/s004380050359; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENSTEIN E, 1986, J BIOL CHEM, V261, P6192; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GREEN SM, 1991, J BIOL CHEM, V266, P21474; Ha Y, 1997, P NATL ACAD SCI USA, V94, P9550, DOI 10.1073/pnas.94.18.9550; HENSLEY P, 1988, CURR TOP CELL REGUL, V29, P35; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; ISSALY IM, 1974, EUR J BIOCHEM, V49, P485, DOI 10.1111/j.1432-1033.1974.tb03853.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jin L, 1997, NAT STRUCT BIOL, V4, P622, DOI 10.1038/nsb0897-622; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Louvet O, 1997, BIOTECHNIQUES, V23, P816, DOI 10.2144/97235bm11; MESSENGUY F, 1976, J BACTERIOL, V128, P49, DOI 10.1128/JB.128.1.49-55.1976; MESSENGUY F, 1971, EUR J BIOCHEM, V22, P277, DOI 10.1111/j.1432-1033.1971.tb01542.x; MESSENGUY F, 1969, FEBS LETT, V3, P47, DOI 10.1016/0014-5793(69)80093-1; Messenguy F, 2000, FOOD TECHNOL BIOTECH, V38, P277; PENNINCKX M, 1975, EUR J BIOCHEM, V58, P533, DOI 10.1111/j.1432-1033.1975.tb02402.x; PENNINCKX M, 1974, EUR J BIOCHEM, V49, P429, DOI 10.1111/j.1432-1033.1974.tb03848.x; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; SALI A, 1997, MODELLER PROTEIN STR; Shi DS, 1998, J BIOL CHEM, V273, P34247, DOI 10.1074/jbc.273.51.34247; SIMON JP, 1977, EUR J BIOCHEM, V75, P571, DOI 10.1111/j.1432-1033.1977.tb11557.x; URRESTARAZU LA, 1977, EUR J BIOCHEM, V79, P473, DOI 10.1111/j.1432-1033.1977.tb11830.x; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P10762, DOI 10.1073/pnas.92.23.10762; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; VISSERS S, 1982, J GEN MICROBIOL, V128, P1235; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WIPF B, 1979, J BACTERIOL, V140, P874, DOI 10.1128/JB.140.3.874-880.1979	41	2	3	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21550	21558		10.1074/jbc.M300383200	http://dx.doi.org/10.1074/jbc.M300383200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12679340	hybrid			2022-12-25	WOS:000183354200031
J	Pospisil, CH; Stafford, AR; Fredenburgh, JC; Weitz, JI				Pospisil, CH; Stafford, AR; Fredenburgh, JC; Weitz, JI			Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; BOUND THROMBIN; PROTHROMBIN FRAGMENT-2; PLASMINOGEN-ACTIVATOR; ALLOSTERIC LINKAGE; TERNARY COMPLEX; FACTOR XA; BINDING; ANTITHROMBIN; INHIBITION	Exosite 1 on thrombin mediates low affinity binding to sites on the NH2 termini of the alpha- and beta-chains of fibrin. A subpopulation of fibrin molecules (gamma(A)/gamma'-fibrin) has an alternate COOH terminus of the normal gamma-chain (gamma(A)/gamma(A)-fibrin) that binds thrombin with high affinity. To determine the roles of exosites 1 and 2 in the high affinity interaction of thrombin with gamma(A)/gamma'-fibrin, binding studies were done with thrombin variants and exosite 1- or 2-directed ligands. alpha-Thrombin bound gamma(A)/gamma'-fibrin via high and low affinity binding sites. A peptide analog of the COOH terminus of the gamma'-chain that binds alpha-thrombin via exosite 2 blocked the high affinity binding of alpha-thrombin to gamma(A)/gamma'-fibrin, suggesting that the interaction of alpha-thrombin with the gamma'-chain is exosite 2-mediated. In support of this concept, (a) gamma-thrombin, which lacks a functional exosite 1, bound to gamma(A)/gamma'-fibrin, but not to gamma(A)/gamma(A)-fibrin; ( b) thrombin R93A/R97A/R101A, an exosite 2-defective variant, bound only to gamma(A)/gamma'-fibrin via low affinity sites; and ( c) exosite 2-directed ligands reduced alpha-thrombin binding to gamma(A)/gamma'-fibrin. However, several lines of evidence indicate that exosite 1 contributes to the high affinity interaction of thrombin with gamma(A)/gamma-fibrin. First, the affinity of gamma-thrombin for gamma(A)/gamma'-fibrin was lower than that of alpha-thrombin. Second, removal of a low affinity binding site on the beta-chain of gamma(A)/gamma'-fibrin reduced its affinity for alpha-thrombin. Third, exosite 1- directed ligands reduced alpha-thrombin binding to gamma(A)/gamma'-fibrin. Taken together, these data suggest that, although exosite 2 mediates the interaction of thrombin with the gamma'-chain of gamma(A)/gamma'-fibrin, simultaneous ligation of exosite 1 by low affinity binding sites is essential for the high affinity interaction of thrombin with gamma(A)/gamma'-fibrin.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University	Weitz, JI (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BADIMON L, 1994, HAEMOSTASIS, V24, P69; Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Bock SC, 2001, HEMOSTASIS THROMBOSI, V4th, P321; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; Brufatto N, 2001, J BIOL CHEM, V276, P17663, DOI 10.1074/jbc.M011586200; Colman RWCA, 2001, HEMOSTASIS THROMBOSI, P3; DELLENBACK RJ, 1970, P SOC EXP BIOL MED, V134, P353; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FRANCIS CW, 1980, BLOOD, V56, P456; Fredenburgh JC, 2001, J BIOL CHEM, V276, P44828, DOI 10.1074/jbc.M108710200; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; HOFSTEENGE J, 1990, EUR J BIOCHEM, V188, P55, DOI 10.1111/j.1432-1033.1990.tb15370.x; HOGG PJ, 1990, J BIOL CHEM, V265, P248; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; Hogg PJ, 1997, THROMB HAEMOSTASIS, V77, P424; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; LIU LW, 1991, J BIOL CHEM, V266, P23632; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; Lovely RS, 2003, J THROMB HAEMOST, V1, P124, DOI 10.1046/j.1538-7836.2003.00027.x; Lovely RS, 2002, THROMB HAEMOSTASIS, V88, P26; Meh DA, 2001, THROMB HAEMOSTASIS, V85, P470; Meh DA, 2001, THROMB RES, V103, P63, DOI 10.1016/S0049-3848(01)00273-0; Meh DA, 1996, J BIOL CHEM, V271, P23121, DOI 10.1074/jbc.271.38.23121; Mosesson MW, 1998, P NATL ACAD SCI USA, V95, P10511, DOI 10.1073/pnas.95.18.10511; Mutch NJ, 2001, THROMB HAEMOSTASIS, V86, P1028; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PRAGER NA, 1995, CIRCULATION, V92, P962, DOI 10.1161/01.CIR.92.4.962; Rezaie AR, 2001, BLOOD, V97, P2308, DOI 10.1182/blood.V97.8.2308; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; Stewart RJ, 2000, J BIOL CHEM, V275, P10112, DOI 10.1074/jbc.275.14.10112; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; Yang Z, 2000, P NATL ACAD SCI USA, V97, P14156, DOI 10.1073/pnas.97.26.14156; YE J, 1993, J BIOL CHEM, V268, P2373; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	46	61	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21584	21591		10.1074/jbc.M300545200	http://dx.doi.org/10.1074/jbc.M300545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682049	hybrid			2022-12-25	WOS:000183354200035
J	Price, PA; Nguyen, TMT; Williamson, MK				Price, PA; Nguyen, TMT; Williamson, MK			Biochemical characterization of the serum fetuin-mineral complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; HUMAN ALPHA-2-HS GLYCOPROTEIN; BONE-REMODELING COMPARTMENT; PHOSPHORYLATED GLYCOPROTEIN; MOLECULAR-CLONING; CORTICAL BONE; RAT; IDENTIFICATION; CALCIFICATION; CALCIUM	The present study was carried out to characterize the fetuin-mineral complex (FMC), a high molecular mass complex of calcium phosphate mineral and the proteins fetuin and matrix Gla protein (MGP) that was initially discovered in serum of rats treated with etidronate and appears to play a critical role in inhibiting calcification in vivo. Fetuin purified from the FMC contains 3.3 mol of protein-bound phosphate. There is 1.3 mg of FMC/ml of serum 6 h after etidronate injection, and the FMC is 46% fetuin and 53% mineral by mass. Formation of the FMC in the first 6 h after etidronate injection does not increase serum fetuin despite the fact that 50% of serum fetuin is associated with the FMC, and clearance of the FMC in the 9-24-h interval lowers total serum fetuin by 50%. These observations suggest that the fetuin component of the FMC is derived from fetuin initially in serum and that clearance of the FMC removes the associated fetuin from circulation. One additional protein was consistently present in all preparations of the FMC, spp24 (secreted phosphoprotein 24). This 24-kDa protein is similar in domain structure to fetuin and, like fetuin and MGP, contains several residues of phosphoserine and accumulates in bone. Exogenous spp24 associated strongly with the FMC when added to serum containing it. These observations suggest that spp24 may, like fetuin and MGP, play a role in inhibiting calcification.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Price, PA (corresponding author), Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA.				NIAMS NIH HHS [AR 25921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHTON BA, 1976, CALC TISS RES, V22, P27; ASHTON BA, 1974, EUR J BIOCHEM, V45, P525, DOI 10.1111/j.1432-1033.1974.tb03577.x; Brandt E, 2000, J LEUKOCYTE BIOL, V67, P471, DOI 10.1002/jlb.67.4.471; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Haglund AC, 2001, BIOCHEM J, V357, P437, DOI 10.1042/0264-6021:3570437; HALE JE, 1988, J BIOL CHEM, V263, P5820; Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575; HU B, 1995, J BIOL CHEM, V270, P431, DOI 10.1074/jbc.270.1.431; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Kazi JA, 1998, J BIOCHEM-TOKYO, V124, P179, DOI 10.1093/oxfordjournals.jbchem.a022077; LECAM A, 1985, J BIOL CHEM, V260, P5965; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MEGGIO F, 1988, EUR J BIOCHEM, V177, P281, DOI 10.1111/j.1432-1033.1988.tb14374.x; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; OHNISHI T, 1993, J BONE MINER RES, V8, P367; OTAWARA Y, 1986, J BIOL CHEM, V261, P828; Parfitt AM, 2001, J BONE MINER RES, V16, P1583, DOI 10.1359/jbmr.2001.16.9.1583; Price PA, 2003, J BIOL CHEM, V278, P22144, DOI 10.1074/jbc.M300744200; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; PRICE PA, 1994, PROTEIN SCI, V3, P822; Price PA, 2002, J BONE MINER RES, V17, P1171, DOI 10.1359/jbmr.2002.17.7.1171; PRICE PA, 1985, J BIOL CHEM, V260, P4971; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; QUELCH KJ, 1984, CALCIFIED TISSUE INT, V36, P545, DOI 10.1007/BF02405363; RAVANAT C, 1994, EUR J BIOCHEM, V223, P203, DOI 10.1111/j.1432-1033.1994.tb18984.x; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; WENDEL M, 1993, MATRIX, V13, P331, DOI 10.1016/S0934-8832(11)80029-6	29	103	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22153	22160		10.1074/jbc.M300739200	http://dx.doi.org/10.1074/jbc.M300739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676928	hybrid			2022-12-25	WOS:000183354200104
J	Toyomura, T; Murata, Y; Yamamoto, A; Oka, T; Sun-Wada, GH; Wada, Y; Futai, M				Toyomura, T; Murata, Y; Yamamoto, A; Oka, T; Sun-Wada, GH; Wada, Y; Futai, M			From lysosomes to the plasma membrane - Localization of vacuolar type H+-ATPase with the a3 isoform during osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; NF-KAPPA-B; CAENORHABDITIS-ELEGANS; V-ATPASE; MOLECULAR-CLONING; PREFERENTIAL EXPRESSION; RECEPTOR ACTIVATOR; BONE-RESORPTION; MOUSE HOMOLOG; SUBUNIT-A	Osteoclasts generate a massive acid flux to mobilize bone calcium. Local extracellular acidification is carried out by vacuolar type H+-ATPase (V-ATPase) localized in the plasma membrane. We have shown that a3, one of the four subunit a isoforms (a1, a2, a3, and a4), is a component of the plasma membrane V-ATPase (Toyomura, T., Oka, T., Yamaguchi, C., Wada, Y., and Futai, M. ( 2000) J. Biol. Chem. 275, 8760-8765). To establish the unique localization of V-ATPase, we have used a murine macrophage cell line, RAW 264.7, that can differentiate into multinuclear osteoclast-like cells on stimulation with RANKL ( receptor activator of nuclear factor kappaB ligand). The V-ATPase with the a3 isoform was localized to late endosomes and lysosomes, whereas those with the a1 and a2 isoforms were localized to organelles other than lysosomes. After stimulation, the V-ATPase with the a3 isoform was immunochemically colocalized with lysosome marker lamp2 and was detected in acidic organelles. These organelles were also colocalized with microtubules, and the signals of lamp2 and a3 were dispersed by nocodazole, a microtubule depolymerizer. In RAW-derived osteoclasts cultured on mouse skull pieces, the a3 isoform was transported to the plasma membrane facing the bone and accumulated inside podosome rings. These findings indicate that V-ATPases with the a3 isoform localized in late endosomes/lysosomes are transported to the cell periphery during differentiation and finally assembled into the plasma membrane of mature osteoclasts.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Osaka University; Japan Science & Technology Agency (JST); Kansai Medical University	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248; ALDRIDGE DC, 1969, J ANTIBIOT, V22, P170, DOI 10.7164/antibiotics.22.170; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; DEBRABANDER M, 1977, CELL BIOL INT REP, V1, P177, DOI 10.1016/0309-1651(77)90038-8; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 1998, J BIOCHEM-TOKYO, V124, P259, DOI 10.1093/oxfordjournals.jbchem.a022105; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002-9440(10)64942-5; Imai-Senga Y, 2002, GENE, V289, P7, DOI 10.1016/S0378-1119(02)00542-5; James IE, 1999, J BONE MINER RES, V14, P1562, DOI 10.1359/jbmr.1999.14.9.1562; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Murata Y, 2002, J BIOL CHEM, V277, P36296, DOI 10.1074/jbc.M200586200; NAKAMURA H, 1994, ARCH HISTOL CYTOL, V57, P535, DOI 10.1679/aohc.57.535; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Sun-Wada GH, 2001, GENE, V274, P93, DOI 10.1016/S0378-1119(01)00603-5; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; YAMASHITA T, 1990, J CELL PHYSIOL, V145, P587, DOI 10.1002/jcp.1041450327	57	221	225	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22023	22030		10.1074/jbc.M302436200	http://dx.doi.org/10.1074/jbc.M302436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672822	hybrid			2022-12-25	WOS:000183354200089
J	Le, HT; Schaldach, CM; Firestone, GL; Bjeldanes, LF				Le, HT; Schaldach, CM; Firestone, GL; Bjeldanes, LF			Plant-derived 3,3 '-diindolylmethane is a strong androgen antagonist in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE ARREST; BRASSICA VEGETABLES; BINDING DOMAIN; RECEPTOR; ANTIGEN; BREAST; INDOLE-3-CARBINOL; APOPTOSIS; GENE; ACTIVATION	3,3'-Diindolylmethane ( DIM) is a major digestive product of indole-3-carbinol, a potential anticancer component of cruciferous vegetables. Our results indicate that DIM exhibits potent antiproliferative and antiandrogenic properties in androgen-dependent human prostate cancer cells. DIM suppresses cell proliferation of LNCaP cells and inhibits dihydrotestosterone (DHT) stimulation of DNA synthesis. These activities were not produced in androgen-independent PC-3 cells. Moreover, DIM inhibited endogenous PSA transcription and reduced intracellular and secreted PSA protein levels induced by DHT in LNCaP cells. Also, DIM inhibited, in a concentration-dependent manner, the DHT-induced expression of a prostate-specific antigen promoter-regulated reporter gene construct in transiently transfected LNCaP cells. Similar effects of DIM were observed in PC-3 cells only when these cells were cotransfected with a wild-type androgen receptor expression plasmid. Using fluorescence imaging with green fluorescent protein androgen receptor and Western blot analysis, we demonstrated that DIM inhibited androgen-induced androgen receptor (AR) translocation into the nucleus. Results of receptor binding assays indicated further that DIM is a strong competitive inhibitor of DHT binding to the AR. Results of structural modeling studies showed that DIM is remarkably similar in conformational geometry and surface charge distribution to an established synthetic AR antagonist, although the atomic compositions of the two substances are quite different. Taken together with our published reports of the estrogen agonist activities of DIM, the present results establish DIM as a unique bifunctional hormone disrupter. To our knowledge, DIM is the first example of a pure androgen receptor antagonist from plants.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Bjeldanes, LF (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.	lfb@nature.berkeley.edu			NIEHS NIH HHS [P30-ES01896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRADFIELD CA, 1987, J TOXICOL ENV HEALTH, V21, P311, DOI 10.1080/15287398709531021; BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; Chinni SR, 2002, CLIN CANCER RES, V8, P1228; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Denis L, 1999, EUR UROL, V35, P377, DOI 10.1159/000019912; Dixon SC, 2001, PHARMACOL REV, V53, P73; Duffy MJ, 1996, ANN CLIN BIOCHEM, V33, P511, DOI 10.1177/000456329603300604; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; Ge XK, 1999, ANTICANCER RES, V19, P3199; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Kristal AR, 2002, NUTR CANCER, V42, P1, DOI 10.1207/S15327914NC421_1; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; LINDZEY J, 1994, VITAM HORM, V49, P383; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Riby JE, 2000, BIOCHEMISTRY-US, V39, P910, DOI 10.1021/bi9919706; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; Roy AK, 2001, ANN NY ACAD SCI, V949, P44; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; Small EJ, 1998, DRUG AGING, V13, P71, DOI 10.2165/00002512-199813010-00007; Terry P, 2002, NUTR CANCER, V42, P25, DOI 10.1207/S15327914NC421_4; Terry P, 2001, JAMA-J AM MED ASSOC, V285, P2975, DOI 10.1001/jama.285.23.2975; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VERNON SE, 1983, J UROLOGY, V130, P95, DOI 10.1016/S0022-5347(17)50977-5; Voorrips LE, 2000, AM J EPIDEMIOL, V152, P1081, DOI 10.1093/aje/152.11.1081; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; WARRIAR N, 1994, PROSTATE, V24, P176, DOI 10.1002/pros.2990240403; WATTENBERG LW, 1978, CANCER RES, V38, P1410; WATTENBERG LW, 1980, J ENVIRON PATHOL TOX, V3, P35; Webber MM, 1995, CLIN CANCER RES, V1, P1089; Webber MM, 1997, PROSTATE, V30, P58; Wilson WD, 1997, CHEM PHYS LETT, V267, P431, DOI 10.1016/S0009-2614(97)00135-8; Wingo PA, 1997, CA-CANCER J CLIN, V47, P239, DOI 10.3322/canjclin.47.4.239	51	156	171	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21136	21145		10.1074/jbc.M300588200	http://dx.doi.org/10.1074/jbc.M300588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665522	hybrid			2022-12-25	WOS:000183230500090
J	Snyder, JT; Singer, AU; Wing, MR; Harden, TK; Sondek, J				Snyder, JT; Singer, AU; Wing, MR; Harden, TK; Sondek, J			The pleckstrin homology domain of phospholipase C-beta(2) as an effector site for Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-BINDING DOMAIN; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; RHO GTPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INOSITOL TRISPHOSPHATE; CRYSTAL-STRUCTURE; HIGH-AFFINITY; PH DOMAINS; C-EPSILON	Increasing evidence links the activation of Rho family GTPases to the stimulation of lipid hydrolysis catalyzed by phospholipase C ( PLC)-beta isozymes. To better define this relationship, members of a library of recombinant Rho GTPases were screened for their capacity to directly engage various purified PLC-beta isozymes. Of the 17 tested members of the Rho family, only the active isoforms of Rac (Rac1, Rac2, and Rac3) both stimulate PLC-beta activity in vivo and bind PLC-beta(2) and PLC-beta(3), but not PLC-beta(1), in vitro. Furthermore, the recognition site for Rac GTPases was localized to the pleckstrin homology (PH) domain of PLC-beta(2), and this PH domain is fully sufficient to selectively interact with the active versions of the Rac GTPases, but not with other similar Rho GTPases. Together, these findings present a quantitative evaluation of the direct interactions between Rac GTPases and PLC-beta isozymes and define a novel role for the PH domain of PLC-beta(2) as a putative effector site for Rac GTPases.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Neurobiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Harden, TK (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.	tkh@med.unc.edu	, Proteomics Core UNC/AFQ-7201-2022	Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536, P01GM065533, R01GM062299, R01GM057391] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57391, GM29536, GM62299, GM65533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abrams CS, 1996, BBA-MOL CELL RES, V1314, P233, DOI 10.1016/S0167-4889(96)00109-7; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN HA, 1991, MOL PHARMACOL, V40, P648; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Day YSN, 2002, PROTEIN SCI, V11, P1017, DOI 10.1110/ps.4330102; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Illenberger D, 1997, EUR J BIOCHEM, V246, P71, DOI 10.1111/j.1432-1033.1997.t01-1-00071.x; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Philip F, 2002, FEBS LETT, V531, P28, DOI 10.1016/S0014-5793(02)03411-7; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Sawai T, 1999, BIOL PHARM BULL, V22, P229; Scarlata S, 2002, BIOCHEMISTRY-US, V41, P7092, DOI 10.1021/bi025625j; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Xu NZ, 1996, CELL MOL NEUROBIOL, V16, P51, DOI 10.1007/BF02578386	57	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21099	21104		10.1074/jbc.M301418200	http://dx.doi.org/10.1074/jbc.M301418200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657629	hybrid			2022-12-25	WOS:000183230500085
J	Spicer, AP; Joo, A; Bowling, RA				Spicer, AP; Joo, A; Bowling, RA			A hyaluronan binding link protein gene family whose members are physically linked adjacent to chrondroitin sulfate proteoglycan core protein genes - The missing links	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BRAIN-DEVELOPMENT; CELL-ADHESION; DOMAIN; NEUROCAN; GENOME; MODULE; BRAL1; IDENTIFICATION; CARBOHYDRATE	We describe a vertebrate hyaluronan and proteoglycan binding link protein gene family (HAPLN), consisting of four members including cartilage link protein. The encoded proteins share 45 - 52% overall amino acid identity. In contrast to the average sequence identity between family members, the sequence conservation between vertebrate species was very high. Human and mouse link proteins share 81 - 96% amino acid sequence identity. Two of the four link protein genes (HAPLN2 and HAPLN4) were restricted in expression to the brain/central nervous system, while one of the four genes (HAPLN3) was widely expressed. Genomic structures revealed that all four HAPLN genes were similar in exon-intron organization and were also similar in genomic organization to the 5' exons for the CSPG core protein genes. Strikingly, all four HAPLN genes were located immediately adjacent to the four CSPG core protein genes creating four pairs of CSPG- HAPLN genes within the mammalian genome. Furthermore, the two brain-specific HAPLN genes ( HAPLN2 and HAPLN4) were physically linked to the brain-specific CSPG genes encoding brevican and neurocan, respectively. The tight physical association of the HAPLN and CSPG genes supports a hypothesis that the first HAPLN gene arose as a partial gene duplication event from an ancestral CSPG gene. There is some degree of coordinated expression of each gene pair. Collectively, the four HAPLN genes are expressed by most tissue types, reflecting the fundamental importance of the hyaluronan-dependent extracellular matrix to tissue architecture and function in vertebrate species. Comparison of the genomic structures for the HAPLN, CSPG genes and other members of the link module superfamily provide strong support for a common evolutionary origin from an ancestral gene containing one link module encoding exon.	Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Spicer, AP (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.	aspicer@ibt.tamu.edu						Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; FALTZ LL, 1979, J BIOL CHEM; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Friedman R, 2001, GENOME RES, V11, P1842, DOI 10.1101/gr.200601; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kobayashi H, 1999, ENDOCRINOLOGY, V140, P3835, DOI 10.1210/en.140.8.3835; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nomoto H, 2002, ACTA MED OKAYAMA, V56, P25; OHNO S, 1993, CURR OPIN GENET DEV, V3, P911, DOI 10.1016/0959-437X(93)90013-F; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Oohashi T, 2002, MOL CELL NEUROSCI, V19, P43, DOI 10.1006/mcne.2001.1061; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Rauch U, 2001, CELL MOL LIFE SCI, V58, P1842, DOI 10.1007/PL00000822; Tsifrina E, 1999, AM J PATHOL, V155, P1625, DOI 10.1016/S0002-9440(10)65478-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhou XH, 2001, MOL CELL BIOL, V21, P5970, DOI 10.1128/MCB.21.17.5970-5978.2001	34	127	136	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21083	21091		10.1074/jbc.M213100200	http://dx.doi.org/10.1074/jbc.M213100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663660	hybrid			2022-12-25	WOS:000183230500083
J	Witherow, DS; Tovey, SC; Wang, Q; Willars, GB; Slepak, VZ				Witherow, DS; Tovey, SC; Wang, Q; Willars, GB; Slepak, VZ			G beta 5 center dot RGS7 inhibits G alpha q-mediated signaling via a direct protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RGS PROTEINS; FLUORESCENT PROTEIN; GAMMA-SUBUNIT; IN-VITRO; MEMBRANE; BINDING; DOMAIN; BETA; TRANSDUCIN	A subfamily of regulators of G protein signaling (RGS) proteins consisting of RGS6, -7, -9, and -11 is characterized by the presence of a unique Ggamma-like domain through which they form obligatory dimers with the G protein subunit Gbeta5 in vivo. In Caenorhabditis elegans, orthologs of Gbeta5.RGS dimers are implicated in regulating both Galpha(i) and Galpha(q) signaling, and in cell-based assays these dimers regulate Galpha(i/o)- and Galpha(q/11)-mediated pathways. However, initial studies with purified Gbeta5.RGS6 or Gbeta5.RGS7 showed that they only serve as GTPase activating proteins for Galpha(o). Pull-down assays and coimmunoprecipitation with these dimers failed to detect their binding to either Galpha(o) or Galpha(q), indicating that the interaction might require additional factors present in vivo. Here, we asked if the RGS7.Gbeta5 complex binds to Galpha(q) using fluorescence resonance energy transfer (FRET) in transiently transfected mammalian cells. RGS7, Gbeta5, and Galpha subunits were tagged with yellow variants of green fluorescent protein. First we confirmed the functional activity of the fusion proteins by co-immunoprecipitation and also their effect on signaling. Second, we again demonstrate the interaction between RGS7 and Gbeta5 using FRET. Finally, using both FRET spectroscopy on cell suspensions and microscopy of individual cells, we showed FRET between the yellow fluorescence protein-tagged RGS7.Gbeta5 complex and cyan fluorescence protein-tagged Galpha(q), indicating a direct interaction between these molecules.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33136 USA; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Miami; University of Miami; University of Leicester	Slepak, VZ (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.			Witherow, D. Scott/0000-0002-7344-1574	NATIONAL EYE INSTITUTE [R01EY012982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12982] Funding Source: Medline; NIGMS NIH HHS [R01 GM060019, R01 GM060019-03S1, R01 GM060019-02, R01 GM060019-02S1, R01 GM 600019, R01 GM060019-01, R01 GM060019-03] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benzing T, 2000, J BIOL CHEM, V275, P28167; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Hausmann ON, 2002, EUR J NEUROSCI, V15, P602, DOI 10.1046/j.1460-9568.2002.01916.x; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Simonds W F, 2000, Pharm Acta Helv, V74, P333, DOI 10.1016/S0031-6865(99)00043-6; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wieland T, 1997, J BIOL CHEM, V272, P8853; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	36	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21307	21313		10.1074/jbc.M212884200	http://dx.doi.org/10.1074/jbc.M212884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670932	hybrid			2022-12-25	WOS:000183230500109
J	Bosch, L; Ramon, E; del Valle, LJ; Garriga, P				Bosch, L; Ramon, E; del Valle, LJ; Garriga, P			Structural and functional role of helices I and II in rhodopsin - A novel interplay evidenced by mutations at Gly-51 and Gly-89 in the transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOMINANT RETINITIS-PIGMENTOSA; AMINO-ACID SUBSTITUTION; INTRADISCAL DOMAIN; CONSTITUTIVE ACTIVATION; MONOCLONAL-ANTIBODIES; POINT MUTANTS; GENE; EXPRESSION; BOVINE	The naturally occurring mutations G51A and G51V in transmembrane helix I and G89D in the transmembrane helix II of rhodopsin are associated with the retinal degenerative disease autosomal dominant retinitis pigmentosa. To probe the orientation and packing of helices I and II a number of replacements at positions 51 and 89 were prepared by using site-directed mutagenesis, and the corresponding proteins expressed in COS-1 cells were characterized. Mutations at position 51 ( G51V and G51L) bound retinal like wild-type rhodopsin but had thermally destabilized structures in the dark, altered photobleaching behavior, destabilized metarhodopsin II active conformations, and were severely defective in signal transduction. The effects observed can be correlated with the size of the mutated side chains that would interfere with specific interhelical interaction with Val-300 in helix VII. Mutations at position 89 had sensitivity to charge, as in G89K and G89D mutants, which showed reduced transducin activation. G89K showed a second absorbing species in the UV region at 350 nm, suggesting a charge effect of the introduced lysine. Increased formation of non-active forms of rhodopsin, like metarhodopsin III, may have some influence in the molecular defect underlying retinitis pigmentosa in the mutants studied. At the structural level, the effect of the mutations analyzed can be rationalized assuming a very specific set of tertiary interactions in the interhelical packing of the transmembrane segments of rhodopsin.	Univ Politecn Cataluna, Ctr Mol Biotechnol, Dept Engn Quim, Terrassa 08222, Catalonia, Spain	Universitat Politecnica de Catalunya	Garriga, P (corresponding author), Univ Politecn Cataluna, Ctr Mol Biotechnol, Dept Engn Quim, Colom 1, Terrassa 08222, Catalonia, Spain.	pere.garriga@upc.es	Del Valle, Luis J./I-1342-2015; Garriga, Pere/C-1949-2017; Bosch-Presegué, Laia/Z-1351-2019	Del Valle, Luis J./0000-0001-9916-1741; Garriga, Pere/0000-0003-4234-8382; Bosch-Presegué, Laia/0000-0001-8025-2416				ALKORTA I, 1994, PROTEIN ENG, V7, P1231, DOI 10.1093/protein/7.10.1231; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Berson EL, 2002, INVEST OPHTH VIS SCI, V43, P3027; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Farrar GJ, 2002, EMBO J, V21, P857, DOI 10.1093/emboj/21.5.857; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; FRYXELL KJ, 1987, EMBO J, V6, P443, DOI 10.1002/j.1460-2075.1987.tb04774.x; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Garriga P, 2002, FEBS LETT, V528, P17, DOI 10.1016/S0014-5793(02)03241-6; Garriga P, 1996, P NATL ACAD SCI USA, V93, P4560, DOI 10.1073/pnas.93.10.4560; GARTNER W, 1995, PHOTOCHEM PHOTOBIOL, V62, P1, DOI 10.1111/j.1751-1097.1995.tb05231.x; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Gripentrog JM, 2000, BIOCHEM J, V352, P399, DOI 10.1042/0264-6021:3520399; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; MACKE JP, 1993, AM J HUM GENET, V53, P80; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Ramon E, 2003, J BIOL CHEM, V278, P6427, DOI 10.1074/jbc.M210929200; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; TING TD, 1993, METH NEUROSCI, V15, P180; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	61	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20203	20209		10.1074/jbc.M301319200	http://dx.doi.org/10.1074/jbc.M301319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660238	hybrid			2022-12-25	WOS:000183078000081
J	Paul, S; Planque, S; Zhou, YX; Taguchi, H; Bhatia, G; Karle, S; Hanson, C; Nishiyama, Y				Paul, S; Planque, S; Zhou, YX; Taguchi, H; Bhatia, G; Karle, S; Hanson, C; Nishiyama, Y			Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODIES; LIGHT-CHAIN; PROTEOLYTIC ANTIBODIES; SITE; MECHANISM; BINDING; NEUTRALIZATION; HYDROLYSIS; RECEPTOR; DOMAIN	We report the results of efforts to strengthen and direct the natural nucleophilic activity of antibodies (Abs) for the purpose of specific cleavage of the human immunodeficiency virus-1 coat protein gp120. Phosphonate diester groups previously reported to form a covalent bond with the active site nucleophile of serine proteases ( Paul, S., Tramontano, A., Gololobov, G., Zhou, Y. X., Taguchi, H., Karle, S., Nishiyama, Y., Planque, S., and George, S. ( 2001) J. Biol. Chem. 276, 28314 - 28320) were placed on Lys side chains of gp120. Seven monoclonal Abs raised by immunization with the covalently reactive analog of gp120 displayed irreversible binding to this compound ( binding resistant to dissociation with the denaturant SDS). Catalytic cleavage of biotinylated gp120 by three monoclonal antibodies was observed. No cleavage of albumin and the extracellular domain of the epidermal growth factor receptor was detected. Cleavage of model peptide substrates occurred on the C- terminal side of basic amino acids, and K-m for this reaction was similar to200-fold greater than that for gp120 cleavage, indicating Ab specialization for the gp120 substrate. A hapten phosphonate diester devoid of gp120 inhibited the catalytic activity with exceptional potency, confirming that the reaction proceeds via a serine protease mechanism. Irreversible binding of the hapten phosphonate diester by polyclonal IgG from mice immunized with gp120 covalently reactive analog was increased compared with similar preparations from animals immunized with control gp120, indicating induction of Ab nucleophilicity. These findings suggest the feasibility of raising antigen-specific proteolytic antibodies on demand by covalent immunization.	Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, Houston, TX 77030 USA; Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Richmond, CA 94804 USA	University of Texas System; California Department of Health Care Services	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, MSB 2-250,6431 Fannin, Houston, TX 77030 USA.				NIAID NIH HHS [AI31268, AI46029] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R01AI031268, R21AI031268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; BRADEN BC, 1995, FASEB J, V1, P9; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; GREEN NM, 1965, BIOCHEM J, V94, P23; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; KALAGA R, 1995, J IMMUNOL, V155, P2695; Karle S, 2003, VACCINE, V21, P1213, DOI 10.1016/S0264-410X(02)00504-2; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Lefevre S, 2001, FEBS LETT, V489, P25, DOI 10.1016/S0014-5793(01)02075-0; Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; NODA Y, 1994, BIOPOLYMERS, V34, P217, DOI 10.1002/bip.360340208; Nossal GJV, 2002, IMMUNOL REV, V185, P15, DOI 10.1034/j.1600-065X.2002.18503.x; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Paul S, 1996, MOL BIOTECHNOL, V5, P197, DOI 10.1007/BF02900358; PAUL S, 1990, J BIOL CHEM, V265, P11910; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RAO G, 1991, J PROTEIN CHEM, V10, P117, DOI 10.1007/BF01024661; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Sun JL, 2001, J IMMUNOL, V167, P5775, DOI 10.4049/jimmunol.167.10.5775; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Taguchi H, 2002, BIOORG MED CHEM LETT, V12, P3167, DOI 10.1016/S0960-894X(02)00640-6; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	36	55	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20429	20435		10.1074/jbc.M300870200	http://dx.doi.org/10.1074/jbc.M300870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665517	hybrid			2022-12-25	WOS:000183078000109
J	Rahman, MM; Miyamoto, H; Takatera, H; Yeh, SY; Altuwaijri, S; Chang, CS				Rahman, MM; Miyamoto, H; Takatera, H; Yeh, SY; Altuwaijri, S; Chang, CS			Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COACTIVATOR; HORMONE; BLOCKADE; CLONING; LIGAND; GENE; TRANSACTIVATION; CASTRATION; INDUCTION; CARCINOMA	Although the progression of prostate cancer initially is dependent on androgens, tumor progression to an androgen-independent growth eventually occurs in most of patients treated with androgen ablation and/or antiandrogen therapy. After the initial response, antiandrogens lose their efficacy and eventually act as agonists to promote androgen receptor (AR)-mediated growth of prostate cancer cells. An aberrant regulation of AR activity, presumably by AR coregulators, may contribute to this acquired agonist activity of antiandrogens. Using an in vitro mutagenesis and a double-negative selection in yeast two-hybrid screening, we have identified a dominant-negative AR coregulator ARA70 (dARA70N), which can inhibit AR transcriptional activity by inactivating the normal function of ARA70 in the LNCaP cells. Whereas ARA70 in oligomeric form interacts with AR and enhances its transcriptional activity, dARA70N lacks AR interaction and might retain the ability to form a non-functional heteromer with ARA70 and interrupt AR transcriptional activity without a change in AR protein itself. The addition of dARA70N reduces the agonist activity and rescues the normal function of antiandrogens in prostate cancer cells. RNA-interference-mediated silencing of ARA70 gene further confirms these observations. Taken together, these findings indicate that ARA70 may contribute to the acquired agonist activity of antiandrogens and plays an important role in making prostate cancer cells resistant to androgen ablation and/or antiandrogen therapy. ARA70 may, thus, be a critical target for developing therapeutic agents against AR-mediated progression of prostate cancer.	Univ Rochester, Med Ctr, Dept Biochem, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Biochem, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	Chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516; Miyamoto, Hiroshi/0000-0001-7610-7769	NCI NIH HHS [CA-71570] Funding Source: Medline; NIDDK NIH HHS [DK-60905] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOULNIK I, 2000, KEYST S NUCL REC STE, P116; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Dalesio O, 2000, LANCET, V355, P1491; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; DOPALBHAI K, 2003, J BIOL CHEM, V278, P8118; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gao TS, 1999, MOL ENDOCRINOL, V13, P1645, DOI 10.1210/me.13.10.1645; Goktas S, 1999, SEMIN ONCOL, V26, P162; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haapala K, 2001, LAB INVEST, V81, P1647, DOI 10.1038/labinvest.3780378; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; Hecker A, 2003, FEBS LETT, V535, P49, DOI 10.1016/S0014-5793(02)03856-5; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kelly WK, 1998, EUR UROL, V34, P18, DOI 10.1159/000052292; KELLY WK, 1993, J CLIN ONCOL, V11, P607, DOI 10.1200/JCO.1993.11.4.607; LABRIE F, 1993, CLIN INVEST MED, V16, P475; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; Miyamoto H, 2002, J BIOL CHEM, V277, P4609, DOI 10.1074/jbc.M108312200; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Miyamoto H, 2000, INT J UROL, V7, P32; Palmberg C, 1999, EUR UROL, V36, P191, DOI 10.1159/000067996; Schellhammer PF, 1996, UROLOGY, V47, P622, DOI 10.1016/S0090-4295(96)00002-7; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Truica CI, 2000, CANCER RES, V60, P4709; WESTIN P, 1995, AM J PATHOL, V146, P1368; YEH S, 1999, LANCET, V349, P852; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	39	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19619	19626		10.1074/jbc.M210941200	http://dx.doi.org/10.1074/jbc.M210941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649293	hybrid			2022-12-25	WOS:000183078000009
J	Young, JI; Sedivy, JM; Smith, JR				Young, JI; Sedivy, JM; Smith, JR			Telomerase expression in normal human fibroblasts stabilizes DNA 5-methylcytosine transferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLTRANSFERASE INHIBITION; CELL-CYCLE; TRANSFORMATION; METHYLATION; SENESCENCE; IMMORTALIZATION; TUMORIGENESIS; MAINTENANCE; ANTISENSE; GENE	The finite proliferative potential of normal human fibroblasts can be overcome, a process commonly called immortalization, by the introduction of the catalytic subunit of human telomerase. In contrast to malignant transformation, the pattern of gene expression remains largely unmodified in telomerase-induced immortalization. Here we show evidence that suggests that the maintenance of a "young" pattern of gene expression by telomerization is mediated, at least in part, by a novel function of human telomerase that involves regulation of DNA methyltransferase I gene expression.	Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Brown University	Young, JI (corresponding author), Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA.				NIA NIH HHS [AG13663] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG013663] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS RLP, 1979, BIOCHIM BIOPHYS ACTA, V561, P345, DOI 10.1016/0005-2787(79)90143-6; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOALVANHELDEN EG, 1989, MUTAT RES, V219, P263, DOI 10.1016/0921-8734(89)90027-1; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HOLLIDAY R, 2001, STEM CELL BIOL; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; Wei S, 1999, CANCER RES, V59, P1539; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	29	55	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19904	19908		10.1074/jbc.M301685200	http://dx.doi.org/10.1074/jbc.M301685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665523	hybrid			2022-12-25	WOS:000183078000044
J	Jiang, ZH; Tang, H; Havlioglu, N; Zhang, XC; Stamm, S; Yan, RQ; Wu, JY				Jiang, ZH; Tang, H; Havlioglu, N; Zhang, XC; Stamm, S; Yan, RQ; Wu, JY			Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FAMILIAL FRONTOTEMPORAL DEMENTIA; MULTIPLE SYSTEM TAUOPATHY; SR PROTEINS; MICROTUBULE-BINDING; ALZHEIMERS-DISEASE; PRESENILE-DEMENTIA; PICKS-DISEASE; 5'-SPLICE-SITE SELECTION; MISSENSE MUTATION	Mutations in the human tau gene leading to aberrant splicing have been identified in FTDP-17, an autosomal dominant hereditary neurodegenerative disorder. Molecular mechanisms by which such mutations cause tau aberrant splicing were not understood. We characterized two mutations in exon 10 of the tau gene, N279K and Del280K. Our results revealed an exonic splicing enhancer element located in exon 10. The activity of this AG-rich splicing enhancer was altered by N279K and Del280K mutations. This exonic enhancer element interacts with human Tra2beta protein. The interaction between Tra2beta and the exonic splicing enhancer correlates with the activity of this enhancer element in stimulating splicing. Biochemical studies including in vitro splicing and RNA interference experiments in transfected cells support a role for Tra2beta protein in regulating alternative splicing of human tau gene. Our results implicate the human tau gene as a target gene for the alternative splicing regulator Tra2beta, suggesting that Tra2beta may play a role in aberrant tau exon 10 alternative splicing and in the pathogenesis of tauopathies.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany; Pharmacia Corp, Dept Cell & Mol Biol, Kalamazoo, MI 49007 USA	Washington University (WUSTL); Washington University (WUSTL); University of Erlangen Nuremberg; Pfizer	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	jwu@molecool.wustl.edu	Tang, Hao/G-9841-2011	Yan, Riqiang/0000-0001-7195-7617	NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967, R01GM053945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017518] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197, R01 CA114197-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIA NIH HHS [R01 AG017518] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM070967-02, R01 GM53945/AG17518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Baker M, 1997, ANN NEUROL, V42, P794, DOI 10.1002/ana.410420516; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; BLACK DL, 1995, RNA, V1, P763; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Bugiani O, 1999, J NEUROPATH EXP NEUR, V58, P667, DOI 10.1097/00005072-199906000-00011; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Daoud R, 2002, J NEUROSCI, V22, P5889; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Hoffman BE, 2000, MOL CELL BIOL, V20, P181, DOI 10.1128/MCB.20.1.181-186.2000; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iijima M, 1999, NEUROREPORT, V10, P497, DOI 10.1097/00001756-199902250-00010; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; Lapham J, 1997, RNA, V3, P950; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lippa CF, 2000, ANN NEUROL, V48, P850, DOI 10.1002/1531-8249(200012)48:6<850::AID-ANA5>3.3.CO;2-M; Mandelkow E, 1999, NATURE, V402, P588, DOI 10.1038/45095; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Neumann M, 2001, ANN NEUROL, V50, P503, DOI 10.1002/ana.1223; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Pastor P, 2001, ANN NEUROL, V49, P263, DOI 10.1002/1531-8249(20010201)49:2<263::AID-ANA50>3.0.CO;2-K; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Preuss U, 1997, J CELL SCI, V110, P789; Rizzini C, 2000, J NEUROPATH EXP NEUR, V59, P990, DOI 10.1093/jnen/59.11.990; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Rosso SM, 2002, ANN NEUROL, V51, P373, DOI 10.1002/ana.10140; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 2000, ANN NEUROL, V48, P939; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Tolnay M, 2000, NEUROPATH APPL NEURO, V26, P368, DOI 10.1046/j.1365-2990.2000.00109.x; Varani L, 2000, NUCLEIC ACIDS RES, V28, P710, DOI 10.1093/nar/28.3.710; WANG J, 1995, RNA, V1, P335; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yasuda M, 2000, ANN NEUROL, V47, P422, DOI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G; Yu YT, 1999, METHODS, V18, P13, DOI 10.1006/meth.1999.0752; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	80	89	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18997	19007		10.1074/jbc.M301800200	http://dx.doi.org/10.1074/jbc.M301800200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649279	Green Accepted, hybrid			2022-12-25	WOS:000182932200037
J	Stolz, J; Vielreicher, M				Stolz, J; Vielreicher, M			Tpn1p, the plasma membrane vitamin B-6 transporter of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE-CYTOSINE PERMEASE; GENE FAMILIES; YEAST; BIOSYNTHESIS; PYRIDOXINE; PROTEIN; SEQUENCE; RESISTANCE; EXPRESSION; GENOME	Pyridoxine (PN) is a metabolic precursor of pyridoxal phosphate that functions as a cofactor of many enzymes in amino acid metabolism. PN, pyridoxal, and pyridoxamine are collectively referred to as vitamin B-6, and mammalian organisms depend on its uptake from the diet. In addition to the ability to use extracellular vitamin B-6, most unicellular organisms are also capable of synthesizing PN to generate pyridoxal phosphate. Here, we report the isolation of Saccharomyces cerevisiae mutants that have lost the ability to transport PN across the plasma membrane. We used these mutants to isolate TPN1, the first known gene encoding a transport protein for vitamin B-6. Tpn1p is a member of the purine-cytosine permease family within the major facilitator superfamily. The protein functions as a proton symporter, localizes to the plasma membrane, and has high affinity for PN. TPN1 mutants lost the ability to utilize extracellular PN, pyridoxal, and pyridoxamine, showing that there is no other transporter for vitamin B-6 encoded in the genome. Amino acid substitutions that led to a loss of Tpn1p function localized to transmembrane domain 4 within the 12-transmembrane domain protein. Moreover, expression of TPN1 was regulated and increased with decreasing concentrations of vitamin B-6 in the medium. We also provide evidence that of the highly conserved SNZ and SNO genes in S. cerevisiae, only the protein encoded by SNZ1 is required for vitamin B-6 biosynthesis.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Stolz, J (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ St 31, D-93040 Regensburg, Germany.	juergen.stolz@biologie.uni-regensburg.de	Vielreicher, Martin/L-1768-2013	Vielreicher, Martin/0000-0002-7515-1431				ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ball Maria M., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P347; Bean LE, 2001, GENETICS, V157, P1067; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; BOWMAN BB, 1990, ANN NY ACAD SCI, V585, P106, DOI 10.1111/j.1749-6632.1990.tb28046.x; Braun EL, 1996, J BACTERIOL, V178, P6865, DOI 10.1128/jb.178.23.6865-6872.1996; BRETHES D, 1992, EUR J BIOCHEM, V210, P785, DOI 10.1111/j.1432-1033.1992.tb17481.x; Casaregola S, 2001, INT J SYST EVOL MICR, V51, P1607, DOI 10.1099/00207713-51-4-1607; CHEVALLIER MR, 1975, J BACTERIOL, V122, P629, DOI 10.1128/JB.122.2.629-641.1975; DEMPSEY WB, 1987, ESCHERICHIA COLI SAL, V1, P539; Drewke C, 2001, VITAM HORM, V61, P121; Eddy AA, 1996, MICROBIOL-UK, V142, P449, DOI 10.1099/13500872-142-3-449; Ehrenshaft M, 1998, MOL CELL, V1, P603, DOI 10.1016/S1097-2765(00)80060-X; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; Kucharczyk R, 1998, FEBS LETT, V424, P127, DOI 10.1016/S0014-5793(98)00153-7; MIDDLETON HM, 1977, J NUTR, V107, P126, DOI 10.1093/jn/107.1.126; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; POLAK A, 1973, EUR J BIOCHEM, V32, P276, DOI 10.1111/j.1432-1033.1973.tb02608.x; REICHERT U, 1974, BIOCHIM BIOPHYS ACTA, V356, P108, DOI 10.1016/0005-2736(74)90298-3; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; Said HM, 2002, AM J PHYSIOL-RENAL, V282, pF465, DOI 10.1152/ajprenal.00267.2001; SHANE B, 1976, J BIOL CHEM, V251, P1042; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; Yagi T, 1996, BIOSCI BIOTECH BIOCH, V60, P893, DOI 10.1271/bbb.60.893	43	59	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18990	18996		10.1074/jbc.M300949200	http://dx.doi.org/10.1074/jbc.M300949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649274	hybrid			2022-12-25	WOS:000182932200036
J	Seong, HA; Kim, KT; Ha, H				Seong, HA; Kim, KT; Ha, H			Enhancement of B-MYB transcriptional activity by ZPR9, a novel zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; NECROSIS-FACTOR RECEPTOR; RETINOIC ACID RECEPTOR; C-MYB; A-MYB; CYTOPLASMIC DOMAIN; LEUCINE-ZIPPER; FACTOR FAMILY; GENE-PRODUCT; TRANSACTIVATION	By using the yeast two-hybrid system, the zinc finger protein ZPR9 was identified as one of the B-MYB interacting proteins that associates with the carboxyl-terminal conserved region of B-MYB. ZPR9 was found to form in vivo complexes with B-MYB, as demonstrated by in vivo binding assay and coimmunoprecipitation experiments of the endogenously and exogenously expressed proteins. Deletion analysis revealed that this binding was mediated by all three functional domains, an amino-terminal DNA-binding domain, a transactivation domain, and a carboxyl-terminal conserved region of B-MYB. We show that the interaction of ZPR9 with B-MYB is functional because cotransfection of ZPR9 significantly up-regulates B-MYB transcriptional activity in a dose-dependent manner. In addition, coexpression of ZPR9 with B-MYB caused the accumulation of B-MYB, as well as ZPR9, in the nucleus. Furthermore, constitutive expression of ZPR9 in human neuroblastoma cells induces apoptosis in the presence of retinoic acid. These results strongly suggest that ZPR9 plays an important role in modulation of the transactivation by B-MYB and cellular growth of neuroblastoma cells.	Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Chungbuk National University; Pohang University of Science & Technology (POSTECH)	Ha, H (corresponding author), Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea.	hyunha@cbucc.chungbuk.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; FAVIER D, 1994, ONCOGENE, V9, P305; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Gil M, 1998, IMMUNOL LETT, V64, P79, DOI 10.1016/S0165-2478(98)00081-9; GOLAY J, 1991, BLOOD, V77, P149; Gonda TJ, 1996, CURR TOP MICROBIOL, V211, P99; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Heyer BS, 1999, DEV DYNAM, V215, P344; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Seong HA, 2002, BIOCHEM J, V361, P597, DOI 10.1042/0264-6021:3610597; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; WU RY, 1994, J BIOL CHEM, V269, P25085; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9655	9662		10.1074/jbc.M207478200	http://dx.doi.org/10.1074/jbc.M207478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645566	hybrid			2022-12-25	WOS:000181524000103
J	Vitadello, M; Penzo, D; Petronilli, V; Michieli, G; Gomirato, S; Menabo, R; Di Lisa, F; Gorza, L				Vitadello, M; Penzo, D; Petronilli, V; Michieli, G; Gomirato, S; Menabo, R; Di Lisa, F; Gorza, L			Overexpression of the stress-protein Grp94 reduces cardiomyocyte necrosis due to calcium overload and simulated ischemia	FASEB JOURNAL			English	Article						endoplasmic reticulum proteins; cell resistance to injury; myocyte death; gene transfer	GLUCOSE-REGULATED PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM CHAPERONES; HEAT-SHOCK PROTEINS; CELL-DEATH; MOLECULAR CHAPERONES; CLINICAL-APPLICATIONS; ATRIAL-FIBRILLATION; EPITHELIAL-CELLS; CA2+	Increase in free intracellular calcium [Ca2+](i) plays a crucial role in cardiomyocyte ischemic injury. Here we demonstrate that overexpression of the sarcoplasmic-reticulum stress-protein Grp94 reduces myocyte necrosis due to calcium overload or simulated ischemia. Selective three-to eightfold Grp94 increase, with no change in Grp78 or calreticulin amount, was achieved by stable transfection of skeletal C2C12 and cardiac H9c2 muscle cells. After exposure to the calcium ionophore A23187, LDH release from five different Grp94-overexpressing clones of either C2C12 and H9c2 origin was significantly lower than that of control ones and [Ca2+](i) increase was significantly delayed. The number of necrotic cells, evaluated by propidium iodide uptake, was reduced when cells from the Grp94-overexpressing H9c2 clone were exposed to conditions simulating ischemia. Experiments performed in neonatal rat cardiomyocytes cotransfected with grp94 and the green fluorescent protein (GFP) cDNAs validated the protective effect of Grp94 overexpression. A lower percentage of propidium-iodide positive/GFP-fluorescent myocytes co-expressing exogenous Grp94, with respect to myocytes expressing GFP alone, was observed after exposure to either A23187 (6.6% vs. 14.0%, respectively) or simulated ischemia (8.5% vs. 17.7%, respectively). In conclusion, the selective increase in Grp94 protects cardiomyocytes from both ischemia and calcium overload counteracting [Ca2+](i) elevations.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Padua	Gorza, L (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	lgorza@bio.unipd.it	Petronilli, Valeria/C-3558-2015	Petronilli, Valeria/0000-0003-4026-6404; GORZA, LUISA/0000-0003-4897-400X; Di Lisa, Fabio/0000-0001-9757-8818				Ausma J, 2000, J MOL CELL CARDIOL, V32, P355, DOI 10.1006/jmcc.1999.1090; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; Bush KT, 1999, AM J PHYSIOL-RENAL, V277, pF211, DOI 10.1152/ajprenal.1999.277.2.F211; CARROZZA JP, 1992, CIRC RES, V71, P1334, DOI 10.1161/01.RES.71.6.1334; Cornelussen RN, 1996, AM J PHYSIOL-HEART C, V271, pH1938, DOI 10.1152/ajpheart.1996.271.5.H1938; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; Gorza L, 2000, FASEB J, V14, P461, DOI 10.1096/fasebj.14.3.461; Gorza L, 1996, CIRCULATION, V93, P1896, DOI 10.1161/01.CIR.93.10.1896; KANG HS, 1991, J BIOL CHEM, V266, P5643; KOCH G, 1986, J CELL SCI, V86, P217; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MARBAN E, 1990, CIRC RES, V66, P1255, DOI 10.1161/01.RES.66.5.1255; MARBER MS, 1993, J MOL CELL CARDIOL, V25, P1119, DOI 10.1006/jmcc.1993.1124; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; McDonough JL, 1999, CIRC RES, V84, P9; MIYATA H, 1992, CIRC RES, V71, P605, DOI 10.1161/01.RES.71.3.605; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; Vitadello M, 1998, BIOCHEM J, V332, P351, DOI 10.1042/bj3320351; Vitadello M, 2001, CIRCULATION, V103, P2201; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072	38	100	103	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					923	+		10.1096/fj.02-0644fje	http://dx.doi.org/10.1096/fj.02-0644fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670879				2022-12-25	WOS:000181892600010
J	Spitzenberger, F; Pietropaolo, S; Verkade, P; Habermann, B; Lacas-Gervais, S; Mziaut, H; Pietropaolo, M; Solimena, M				Spitzenberger, F; Pietropaolo, S; Verkade, P; Habermann, B; Lacas-Gervais, S; Mziaut, H; Pietropaolo, M; Solimena, M			Islet cell autoantigen of 69 kDa is an arfaptin-related protein associated with the Golgi complex of insulinoma INS-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE SECRETORY GRANULES; ADP-RIBOSYLATION FACTOR; PANCREATIC BETA-CELLS; INTEGRAL MEMBRANE-PROTEIN; TERMINAL-SPECIFIC PHOSPHOPROTEIN; MULTIPLE SEQUENCE ALIGNMENT; GLUTAMIC-ACID DECARBOXYLASE; COPI-COATED VESICLES; BREFELDIN-A; SYNAPSIN-I	Islet cell autoantigen of 69 kDa (ICA69) is a cytosolic protein of still unknown function. Involvement of ICA69 in neurosecretion has been suggested by the impairment of acetylcholine release at neuromuscular junctions upon mutation of its homologue gene ric-19 in C. elegans. In this study, we have further investigated the localization of ICA69 in neurons and insulinoma INS-1 cells. ICA69 was enriched in the perinuclear region, whereas it did not co-localize with markers of synaptic vesicles/synaptic-like microvesicles. Confocal microscopy and subcellular fractionation in INS-1 cells showed co-localization of ICA69 with markers of the Golgi complex and, to a minor extent, with immature insulin-containing secretory granules. The association of ICA69 with these organelles was confirmed by immunoelectron microscopy. Virtually no ICA69 immunogold labeling was observed on secretory granules near the plasma membrane, suggesting that ICA69 dissociates from secretory granule membranes during their maturation. In silico sequence and structural analyses revealed that the N-terminal region of ICA69 is similar to the region of arfaptins that interacts with ARF1, a small GTPase involved in vesicle budding at the Golgi complex and immature secretory granules. ICA69 is therefore a novel arfaptin-related protein that is likely to play a role in membrane trafficking at the Golgi complex and immature secretory granules in neurosecretory cells.	Dresden Univ Technol, Carl Gustav Carus Med Sch, D-01307 Dresden, Germany; Dresden Univ Technol, Dept Internal Med 3, Carl Gustav Carus Med Sch, D-01307 Dresden, Germany; Univ Pittsburgh, Sch Med, Div Immunogenet, Inst Diabet, Pittsburgh, PA 15213 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Scion GmbH, D-01307 Dresden, Germany	Technische Universitat Dresden; Technische Universitat Dresden; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Max Planck Society	Solimena, M (corresponding author), Dresden Univ Technol, Carl Gustav Carus Med Sch, Fetscherstr 74, D-01307 Dresden, Germany.		Solimena, Michele/GVS-5990-2022; Solimena, Michele/E-1275-2011; Habermann, Bianca/N-4886-2016; Verkade, Paul/N-7240-2014	Habermann, Bianca/0000-0002-2457-7504; Verkade, Paul/0000-0002-2497-1026				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Austin C, 2000, J BIOL CHEM, V275, P21862, DOI 10.1074/jbc.M908875199; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Cherfils J, 2001, FEBS LETT, V507, P280, DOI 10.1016/S0014-5793(01)02970-2; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DECAMILLI P, 1988, J NEUROSCI, V8, P1625; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; Friday RP, 2003, J BIOL CHEM, V278, P853, DOI 10.1074/jbc.M210175200; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Jackson C L, 2000, Subcell Biochem, V34, P233; Jean C, 1999, EUR J CELL BIOL, V78, P549, DOI 10.1016/S0171-9335(99)80020-X; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Karges W, 1996, DIABETES, V45, P513, DOI 10.2337/diabetes.45.4.513; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Nickel W, 1998, J CELL SCI, V111, P3081; Nozawa K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar422; ORCI L, 1984, P NATL ACAD SCI-BIOL, V81, P6743, DOI 10.1073/pnas.81.21.6743; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Ort T, 2000, EUR J CELL BIOL, V79, P621, DOI 10.1078/0171-9335-00095; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; Pilon M, 2000, MOL BIOL CELL, V11, P3277, DOI 10.1091/mbc.11.10.3277; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Solimena M, 1998, DIABETES METAB REV, V14, P227, DOI 10.1002/(SICI)1099-0895(1998090)14:3<227::AID-DMR215>3.0.CO;2-E; SOLIMENA M, 1994, J CELL BIOL, V126, P331, DOI 10.1083/jcb.126.2.331; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOOZE SA, 1994, BIOCHIMIE, V76, P271, DOI 10.1016/0300-9084(94)90157-0; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Tsai SC, 1998, J BIOL CHEM, V273, P20697, DOI 10.1074/jbc.273.33.20697; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; Wendler F, 2001, MOL BIOL CELL, V12, P1699, DOI 10.1091/mbc.12.6.1699; Williger BT, 1999, FEBS LETT, V454, P85, DOI 10.1016/S0014-5793(99)00771-1; Winer S, 2002, J IMMUNOL, V168, P475, DOI 10.4049/jimmunol.168.1.475; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	76	24	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26166	26173		10.1074/jbc.M213222200	http://dx.doi.org/10.1074/jbc.M213222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12682071	hybrid			2022-12-25	WOS:000183920200115
J	Young, ET; Dombek, KM; Tachibana, C; Ideker, T				Young, ET; Dombek, KM; Tachibana, C; Ideker, T			Multiple pathways are co-regulated by the protein kinase Snf1 and the transcription factors Adr1 and Cat8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE ALCOHOL-DEHYDROGENASE; YEAST SACCHAROMYCES-CEREVISIAE; ENCODING PEROXISOMAL PROTEINS; GENE-EXPRESSION; REGULATE TRANSCRIPTION; GLUCONEOGENIC ENZYMES; FUNCTIONAL-ANALYSIS; GLYCEROL KINASE; ACTIVATOR CAT8P; DNA-BINDING	ADR1 and CAT8 encode carbon source-responsive transcriptional regulators that cooperatively control expression of genes involved in ethanol utilization. These transcription factors are active only after the diauxic transition, when glucose is depleted and energy-generating metabolism has shifted to the aerobic oxidation of non-fermentable carbon sources. The Snf1 protein kinase complex is required for activation of their downstream target genes described previously. Using DNA microarrays, we determined the extent to which these three factors collaborate in regulating the expression of the yeast genome after glucose depletion. The expression of 108 genes is significantly decreased in the absence of ADR1. The importance of ADR1 during the diauxic transition is illustrated by the observation that expression of almost one-half of the 40 most highly glucose-repressed genes is ADR1-dependent. ADR1-dependent genes fall into a variety of functional classes with carbon metabolism containing the largest number of members. Most of the genes in this class are involved in the oxidation of different non-fermentable carbon sources. These microarray data show that ADR1 coordinates the biochemical pathways that generate acetylCoA and NADH from non-fermentable substrates. Only a small number of ADR1-dependent genes are also CAT8-dependent. However, nearly one-half of the ADR1-dependent genes are also dependent on the Snf1 protein kinase for derepression. Many more genes are SNF1-dependent than are either ADR1- or CAT8-dependent suggesting that SNF1 plays a broader role in gene expression than either ADR1 or CAT8. The largest class of SNF1-dependent genes encodes regulatory proteins that could extend SNF1 dependence to additional pathways.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Young, ET (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	ety@u.washington.edu	Califano, Andrea/F-7239-2012	Ideker, Trey/0000-0002-1708-8454	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Blank L, 2002, MICROBIOL-SGM, V148, P133, DOI 10.1099/00221287-148-1-133; Bramer CO, 2001, MICROBIOL-SGM, V147, P2203, DOI 10.1099/00221287-147-8-2203; Buhler J., 2000, U WASHINGTON CSE TEC, P1; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DOMBEK KM, 1993, MOL CELL BIOL, V13, P4391, DOI 10.1128/MCB.13.7.4391; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; FRAENKEL DG, 1992, ANNU REV GENET, V26, P159; Grauslund M, 1999, NUCLEIC ACIDS RES, V27, P4391, DOI 10.1093/nar/27.22.4391; Grauslund M, 2000, CAN J MICROBIOL, V46, P1096, DOI 10.1139/cjm-46-12-1096; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Gurvitz Aner, 2000, Molecular Cell Biology Research Communications, V4, P81, DOI 10.1006/mcbr.2000.0261; HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; Hiesinger M, 2001, CURR GENET, V39, P68, DOI 10.1007/s002940000182; Ideker T, 2000, J COMPUT BIOL, V7, P805, DOI 10.1089/10665270050514945; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; KNIGHT SAB, 1994, MOL CELL BIOL, V14, P7792, DOI 10.1128/MCB.14.12.7792; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; KUNAU WH, 1992, ANTON LEEUW INT J G, V62, P63, DOI 10.1007/BF00584463; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Luttik MAH, 2000, J BACTERIOL, V182, P7007, DOI 10.1128/JB.182.24.7007-7013.2000; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Overkamp KM, 2002, YEAST, V19, P509, DOI 10.1002/yea.856; PAVLIK P, 1993, CURR GENET, V24, P21, DOI 10.1007/BF00324660; PRONK JT, 1994, MICROBIOL-UK, V140, P717, DOI 10.1099/00221287-140-4-717; Qian OY, 1999, GENETICS, V152, P89; Ramil E, 2000, MOL MICROBIOL, V37, P1116, DOI 10.1046/j.1365-2958.2000.02065.x; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; Rempola B, 2000, MOL GEN GENET, V262, P1081, DOI 10.1007/PL00008651; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sagee S, 1998, MOL CELL BIOL, V18, P1985, DOI 10.1128/MCB.18.4.1985; Shani N, 1996, P NATL ACAD SCI USA, V93, P11901, DOI 10.1073/pnas.93.21.11901; Shirra MK, 1999, GENETICS, V152, P73; Shirra MK, 2001, MOL CELL BIOL, V21, P5710, DOI 10.1128/MCB.21.17.5710-5722.2001; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; Sloan JS, 1999, J BIOL CHEM, V274, P37575, DOI 10.1074/jbc.274.53.37575; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; Trotter PJ, 2001, ANNU REV NUTR, V21, P97, DOI 10.1146/annurev.nutr.21.1.97; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Verdone L, 2002, EMBO J, V21, P1101, DOI 10.1093/emboj/21.5.1101; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Vyas VK, 2001, GENETICS, V158, P563; Walther K, 2001, MICROBIOL-SGM, V147, P2037, DOI 10.1099/00221287-147-8-2037; Williams-Hart T, 2002, GENETICS, V160, P1423; Young ET, 2002, J BIOL CHEM, V277, P38095, DOI 10.1074/jbc.M206158200; Young ET, 1998, J BIOL CHEM, V273, P32080, DOI 10.1074/jbc.273.48.32080; YU J, 1989, MOL CELL BIOL, V9, P34, DOI 10.1128/MCB.9.1.34	66	221	225	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26146	26158		10.1074/jbc.M301981200	http://dx.doi.org/10.1074/jbc.M301981200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12676948	hybrid			2022-12-25	WOS:000183920200113
J	Del Toro, R; Levitsky, KL; Lopez-Barneo, J; Chiara, MD				Del Toro, R; Levitsky, KL; Lopez-Barneo, J; Chiara, MD			Induction of T-type calcium channel gene expression by chronic hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; SMOOTH-MUSCLE-CELLS; NERVE GROWTH-FACTOR; GATED ION CHANNELS; CA2+ CHANNELS; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; FUNCTIONAL-CHARACTERIZATION; LACTATE-DEHYDROGENASE; ERYTHROPOIETIN GENE	Cellular responses to hypoxia can be acute or chronic. Acute responses mainly depend on oxygen-sensitive ion channels, whereas chronic responses rely on the hypoxia-inducible transcription factors ( HIFs), which upregulate the expression of enzymes, transporters, and growth factors. It is unknown whether the expression of genes coding for ion channels is also influenced by hypoxia. We report here that the alpha(1H) gene of T-type voltage-gated calcium channels is highly induced by lowering oxygen tension in PC12 cells. Accumulation of alpha(1H) mRNA in response to hypoxia is time- and dose-dependent and paralleled by an increase in the density of T-type calcium channel current recorded in patch clamped cells. HIF appears to be involved in the response to hypoxia, since cobalt chloride, desferrioxamine, and dimethyloxalylglycine, compounds that mimic HIF-regulated gene expression, replicate the hypoxic effect. Moreover, functional inhibition of HIF-2alpha protein accumulation using antisense HIF-2alpha oligonucleotides reverses the effect of hypoxia on T-type Ca2+ channel expression. Importantly, regulation by oxygen tension is specific for T-type calcium channels, since it is not observed with the L-, N-, and P/Q-channel types. These findings show for the first time that hypoxia induces an ion channel gene via a HIF-dependent mechanism and define a new role for the T-type calcium channels as regulators of cellular excitability and calcium influx under chronic hypoxia.	Univ Sevilla, Hosp Univ Virgen Rocio, Edificio Labs, Lab Invest Biomed, E-41013 Seville, Spain; Univ Sevilla, Dept Fisiol, Lab Invest Biomed, E-41013 Seville, Spain	University of Sevilla; Virgen del Rocio University Hospital; University of Sevilla	Lopez-Barneo, J (corresponding author), Univ Sevilla, Hosp Univ Virgen Rocio, Edificio Labs, Lab Invest Biomed, 2A Planta,Ave Manuel Siurot S-N, E-41013 Seville, Spain.		del Toro, Raquel/H-4788-2014; IBIS, NEUROBIOLOGIA/O-9922-2015; Chiara, María Dolores/AAG-5765-2019	del Toro, Raquel/0000-0002-1379-7990; Chiara, María Dolores/0000-0002-1112-1583				Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Bournaud R, 2001, J PHYSIOL-LONDON, V537, P35, DOI 10.1111/j.1469-7793.2001.0035k.x; Brussaard AB, 1997, J NEUROSCI METH, V71, P55, DOI 10.1016/S0165-0270(96)00126-4; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CASTELLANO A, 1991, J GEN PHYSIOL, V97, P303, DOI 10.1085/jgp.97.2.303; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Chemin J, 2000, FEBS LETT, V478, P166, DOI 10.1016/S0014-5793(00)01832-9; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; Conrad PW, 2001, COMP BIOCHEM PHYS B, V128, P187, DOI 10.1016/S1096-4959(00)00326-2; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Fearon IM, 2000, PFLUG ARCH EUR J PHY, V441, P181, DOI 10.1007/s004240000424; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; GARBER SS, 1989, J NEUROSCI, V9, P3976; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Green KN, 2002, J PHYSIOL-LONDON, V541, P1013, DOI 10.1113/jphysiol.2002.017582; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kuga T, 1996, CIRC RES, V79, P14, DOI 10.1161/01.RES.79.1.14; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592, DOI 10.1152/ajpcell.1998.274.6.C1592; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lee JH, 1999, J NEUROSCI, V19, P1912; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liu HY, 1996, J NEUROSCI, V16, P7557; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MCCOBB DP, 1989, NEURON, V2, P1633, DOI 10.1016/0896-6273(89)90052-4; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; Millhorn DE, 2000, ADV EXP MED BIOL, V475, P131; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; NUSS HB, 1993, CIRC RES, V73, P777, DOI 10.1161/01.RES.73.4.777; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; RATCLIFFE PJ, 1998, OXYGEN REGULATION IO, P67; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SCHMITT R, 1995, ARTERIOSCL THROM VAS, V15, P1161, DOI 10.1161/01.ATV.15.8.1161; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEN L, 1994, CIRC RES, V75, P149, DOI 10.1161/01.RES.75.1.149; SWANDULLA D, 1988, J GEN PHYSIOL, V92, P197, DOI 10.1085/jgp.92.2.197; Taylor SC, 1999, J PHYSIOL-LONDON, V514, P483, DOI 10.1111/j.1469-7793.1999.483ae.x; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; WANG GL, 1993, BLOOD, V82, P3610; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wenger RH, 1997, BIOL CHEM, V378, P609; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	59	99	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22316	22324		10.1074/jbc.M212576200	http://dx.doi.org/10.1074/jbc.M212576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12679337				2022-12-25	WOS:000183503900021
J	Zeng, Q; Tran, TTH; Tan, HX; Hong, WJ				Zeng, Q; Tran, TTH; Tan, HX; Hong, WJ			The cytoplasmic domain of Vamp4 and Vamp5 is responsible for their correct subcellular targeting - The N-terminal extension of Vamp4 contains a dominant autonomous targeting signal for the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE-ASSOCIATED MEMBRANE-PROTEIN-4; PLASMA-MEMBRANE; SECRETORY PATHWAY; PROTEIN-TRANSPORT; YEAST ENDOSOMES; SNARE COMPLEXES; VHS DOMAIN; R-SNARE; FUSION; CELLS	SNAREs represent a superfamily of proteins responsible for the last stage of docking and subsequent fusion in diverse intracellular membrane transport events. The Vamp subfamily of SNAREs contains 7 members (Vamp1, Vamp2, Vamp3/cellubrevin, Vamp4, Vamp5, Vamp7/Ti-Vamp, and Vamp8/endobrevin) that are distributed in various post-Golgi structures. Vamp4 and Vamp5 are distributed predominantly in the trans-Golgi network (TGN) and the plasma membrane, respectively. When C-terminally tagged with enhanced green fluorescent protein, the majority of Vamp4 and Vamp5 is correctly targeted to the TGN and plasma membrane, respectively. Swapping the N-terminal cytoplasmic region and the C-terminal membrane anchor domain between Vamp4 and Vamp5 demonstrates that the N-terminal cytoplasmic region of these two SNAREs contains the correct subcellular targeting information. As compared with Vamp5, Vamp4 contains an N-terminal extension of 51 residues. Appending this 51-residue N-terminal extension onto the N terminus of Vamp5 results in targeting of the chimeric protein to the TGN, suggesting that this N-terminal extension of Vamp4 contains a dominant and autonomous targeting signal for the TGN. Analysis of deletion mutants of this N-terminal region suggests that this TGN-targeting signal is encompassed within a smaller region consisting of a di-Leu motif followed by two acidic clusters. The essential role of the di-Leu motif and the second acidic cluster was then established by site-directed mutagenesis.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010; ZENG, Qi/E-9812-2010					Antonin W, 2000, MOL BIOL CELL, V11, P3289, DOI 10.1091/mbc.11.10.3289; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; Hao JC, 1997, J NEUROSCI, V17, P1596; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hettema EH, 2003, EMBO J, V22, P548, DOI 10.1093/emboj/cdg062; Hong WJ, 1998, J CELL SCI, V111, P2831; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kato Y, 2002, NAT STRUCT BIOL, V9, P532, DOI 10.1038/nsb807; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LOW SH, 1991, J BIOL CHEM, V266, P13391; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Peden AA, 2001, J BIOL CHEM, V276, P49183, DOI 10.1074/jbc.M106646200; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sampo B, 2003, NEURON, V37, P611, DOI 10.1016/S0896-6273(03)00058-8; Scales SJ, 2002, J BIOL CHEM, V277, P28271, DOI 10.1074/jbc.M204929200; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Steegmaier M, 2000, TRAFFIC, V1, P553, DOI 10.1034/j.1600-0854.2000.010705.x; Stephens DJ, 2001, J CELL SCI, V114, P1053; Storey H, 2002, BIOCHEM J, V366, P15, DOI 10.1042/BJ20020048; Subramaniam VN, 2000, J CELL SCI, V113, P997; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Whyte JRC, 2002, J CELL SCI, V115, P2627; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; Xu Y, 2002, MOL BIOL CELL, V13, P3493, DOI 10.1091/mbc.E02-01-0004; Zeng Q, 1998, MOL BIOL CELL, V9, P2423, DOI 10.1091/mbc.9.9.2423; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	51	38	38	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23046	23054		10.1074/jbc.M303214200	http://dx.doi.org/10.1074/jbc.M303214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682051	hybrid			2022-12-25	WOS:000183503900112
J	Loder, MK; Melikian, HE				Loder, MK; Melikian, HE			The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; BIOGENIC-AMINE TRANSPORTERS; PLASMA-MEMBRANE; NEUROTRANSMITTER TRANSPORTERS; FUNCTIONAL REGULATION; TRANSFERRIN RECEPTOR; SYNTAXIN 1A; PARKINSONS-DISEASE; COUPLED RECEPTORS	The dopamine transporter (DAT) removes dopamine from the extracellular milieu and is potently inhibited by number of psychoactive drugs, including cocaine, amphetamines, and methylphenidate ( Ritalin). Multiple lines of evidence demonstrate that protein kinase C (PKC) down-regulates dopamine transport, primarily by redistributing DAT from the plasma membrane to endosomal compartments, although the mechanisms facilitating transporter sequestration are not defined. Here, we demonstrate that DAT constitutively internalizes and recycles in rat pheochromocytoma (PC12) cells. Temperature blockades demonstrated basal internalization and reliance on recycling to maintain DAT cell surface levels. In contrast, recycling blockade with bafilomycin A(1) significantly decreased transferrin receptor (TfR) surface expression but had no effect on DAT surface levels, suggesting that DAT and TfR traffic via distinct endosomal mechanisms. Kinetic analyses reveal robust constitutive DAT cycling to and from the plasma membrane, independent of transporter expression levels. In contrast, phorbol ester-mediated PKC activation accelerated DAT endocytosis and attenuated transporter recycling in a manner sensitive to DAT expression levels. These data demonstrate constitutive DAT trafficking and that PKC-mediated DAT sequestration is achieved by a combination of accelerated internalization and reduced recycling. Additionally, the differential sensitivity to expression level exhibited by constitutive and regulated DAT trafficking suggests that these two processes are mediated by independent cellular mechanisms.	Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, Worcester, MA 01604 USA; Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01604 USA; Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01604 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Melikian, HE (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, 303 Belmont St, Worcester, MA 01604 USA.	haley.melikian@umassmed.edu	Melikian, Haley/S-8301-2016	Melikian, Haley/0000-0002-9694-5556	NIDA NIH HHS [R01 DA015169, R01 DA015169-03, R01 DA 15169-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015169] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Amara SG, 1998, DRUG ALCOHOL DEPEN, V51, P87, DOI 10.1016/S0376-8716(98)00068-4; Apparsundaram S, 2001, J PHARMACOL EXP THER, V299, P666; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bernard V, 1999, J NEUROSCI, V19, P10237; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Brech A, 1998, BBA-BIOMEMBRANES, V1373, P195, DOI 10.1016/S0005-2736(98)00104-7; Brooks DJ, 2001, J NEURAL TRANSM, V108, P1283, DOI 10.1007/s007020100005; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Chinni SR, 1999, BIOCHEM J, V339, P599, DOI 10.1042/0264-6021:3390599; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; Cohen J, 2002, CURR OPIN NEUROBIOL, V12, P223, DOI 10.1016/S0959-4388(02)00314-8; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; GROSSHANS DR, 2001, NAT NEUROSCI, V10, P10; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Huff RA, 1997, J NEUROCHEM, V68, P225; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Jones SR, 1998, J NEUROSCI, V18, P1979; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Marullo S, 1999, RECEPTOR CHANNEL, V6, P255; Melikian HE, 1999, J NEUROSCI, V19, P7699; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Nelson N, 1998, J NEUROCHEM, V71, P1785; Olanow CW, 2002, NEUROLOGY, V58, pS33, DOI 10.1212/WNL.58.suppl_1.S33; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sung U, 2003, J NEUROSCI, V23, P1697; Szaszi K, 2002, J BIOL CHEM, V277, P42623, DOI 10.1074/jbc.M206629200; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; Tintner R, 2002, CURR OPIN NEUROL, V15, P467, DOI 10.1097/00019052-200208000-00011; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Uhl GR, 2002, MOL PSYCHIATR, V7, P21, DOI 10.1038/sj/mp/4000964; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; Weinberger DR, 2001, BIOL PSYCHIAT, V50, P825, DOI 10.1016/S0006-3223(01)01252-5; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	73	195	198	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22168	22174		10.1074/jbc.M301845200	http://dx.doi.org/10.1074/jbc.M301845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682063	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000183354200106
J	Phillips, C; Gunderson, S				Phillips, C; Gunderson, S			Sequences adjacent to the 5 ' splice site control U1A binding upstream of the IgM heavy chain secretory poly(A) site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; TERMINAL RNP DOMAIN; MESSENGER-RNA; PREMESSENGER RNA; HALF-LIFE; STEM-LOOP; PROTEIN; POLYADENYLATION; SPECIFICITY; COMPLEX	We have recently shown that the stability of the alternatively expressed immunoglobulin M heavy chain secretory mRNA is developmentally regulated by U1A. U1A binds novel non-consensus sites upstream of the secretory poly(A) site and inhibits poly(A) tail addition in undifferentiated cells. U1A's dependence for binding and function upon a stem-loop structure has been extensively characterized for the consensus sites. We therefore probed the structure surrounding the novel U1A binding sites. We show that two of the three novel binding sites represent the major single-stranded regions upstream of the secretory poly(A) site, consistent with a major role at this site. The strength of binding and ability of U1A to inhibit poly(A) polymerase correlate with the accessibility of the novel sites. However, long range interactions are responsible for maintaining them in an open configuration. Mutation of an RNase V1-sensitive site 102 nucleotides upstream, directly adjacent to the competing 5' splice site, changes the structure of one the U1A binding sites and thus abolishes the binding of the second U1A molecule and the ability of U1A ability to inhibit poly(A) polymerase activity at this site. These sites bind U1A via its N-terminal domain but with a 10-fold lower affinity than U1 small nuclear RNA. This lower binding affinity is more conducive to U1A's regulation of poly(A) tail addition to heterologous mRNA.	Rutgers State Univ, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Phillips, C (corresponding author), Rutgers State Univ, Nelson Labs, Rm 322,604 Allison Rd, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Beck DL, 1998, RNA, V4, P331; BERBERICH I, 1990, EUR J IMMUNOL, V20, P445, DOI 10.1002/eji.1830200233; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; COX A, 1989, NUCLEIC ACIDS RES, V17, P10439, DOI 10.1093/nar/17.24.10439; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Gubser CC, 1996, BIOCHEMISTRY-US, V35, P2253, DOI 10.1021/bi952319f; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Gunnewiek JMTK, 2000, MOL CELL BIOL, V20, P2209, DOI 10.1128/MCB.20.6.2209-2217.2000; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; Huttenhofer A, 1996, RNA, V2, P354; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; MASON JO, 1988, GENE DEV, V2, P1003, DOI 10.1101/gad.2.8.1003; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; Phillips C, 1999, NUCLEIC ACIDS RES, V27, P429, DOI 10.1093/nar/27.2.429; Phillips C, 1997, NUCLEIC ACIDS RES, V25, P2344, DOI 10.1093/nar/25.12.2344; Phillips C, 2001, EMBO J, V20, P6443, DOI 10.1093/emboj/20.22.6443; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; Rimmele ME, 1998, RNA, V4, P1386, DOI 10.1017/S1355838298981171; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; STUMP WT, 1995, RNA, V1, P55; Teunissen SWM, 1997, BIOCHEMISTRY-US, V36, P1782, DOI 10.1021/bi9623237; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Varani L, 2000, NAT STRUCT BIOL, V7, P329; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	39	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22102	22111		10.1074/jbc.M301349200	http://dx.doi.org/10.1074/jbc.M301349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670951	hybrid			2022-12-25	WOS:000183354200098
J	Zhang, WY; Crocker, E; McLaughlin, S; Smith, SO				Zhang, WY; Crocker, E; McLaughlin, S; Smith, SO			Binding of peptides with basic and aromatic residues to bilayer membranes - Phenylalanine in the myristoylated alanine-rich C kinase substrate effector domain penetrates into the hydrophobic core of the bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; OVERHAUSER ENHANCEMENT SPECTROSCOPY; SPINNING NMR-SPECTROSCOPY; CROSS-RELAXATION RATES; SOLID-STATE NMR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPID-VESICLES; ETHANOL DISTRIBUTION; LIPID BILAYERS; FATTY-ACIDS	Electrostatic interactions with positively charged regions of membrane- associated proteins such as myristoylated alanine- rich C kinase substrate ( MARCKS) may have a role in regulating the level of free phosphatidylinositol 4,5- bisphosphate ( PI( 4,5) P-2) in plasma membranes. Both the MARCKS protein and a peptide corresponding to the effector domain ( an unstructured region that contains 13 basic residues and 5 phenylalanines), MARCKS-( 151 - 175), laterally sequester the polyvalent lipid PI( 4,5) P2 in the plane of a bilayer membrane with high affinity. We used high resolution magic angle spinning NMR to establish the location of MARCKS( 151 - 175) in membrane bilayers, which is necessary to understand the sequestration mechanism. Measurements of cross- relaxation rates in two- dimensional nuclear Overhauser enhancement spectroscopy NMR experiments show that the five Phe rings of MARCKS( 151 - 175) penetrate into the acyl chain region of phosphatidylcholine bilayers containing phosphatidylglycerol or PI( 4,5) P-2. Specifically, we observed strong crosspeaks between the aromatic protons of the Phe rings and the acyl chain protons of the lipids, even for very short ( 50 ms) mixing times. The position of the Phe rings implies that the adjacent positively charged amino acids in the peptide are close to the level of the negatively charged lipid phosphates. The deep location of the MARCKS peptide in the polar head group region should enhance its electrostatic sequestration of PI( 4,5) P2 by an " image charge" mechanism. Moreover, this location has interesting implications for membrane curvature and local surface pressure effects and may be relevant to a wide variety of other proteins with basic- aromatic clusters, such as phospholipase D, GAP43, SCAMP2, and the N- methyl- D- aspartate receptor.	SUNY Stony Brook, Dept Biochem & Cell Biol, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Phys & Astron, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Smith, SO (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Ctr Struct Biol, 450 Life Sci Bldg,Z-5115, Stony Brook, NY 11794 USA.	steven.o.smith@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046732, R01GM024971, R55GM046732, R37GM024971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46732, GM 24971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Baldus M, 2002, PROG NUCL MAG RES SP, V41, P1, DOI 10.1016/S0079-6565(02)00007-9; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bouchard M, 1995, BIOPHYS J, V69, P1933, DOI 10.1016/S0006-3495(95)80063-9; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Chou JJ, 2002, J AM CHEM SOC, V124, P2450, DOI 10.1021/ja017875d; Contreras LM, 2001, BIOPHYS J, V80, P2273, DOI 10.1016/S0006-3495(01)76199-1; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Davis JH, 1995, BIOPHYS J, V69, P1917, DOI 10.1016/S0006-3495(95)80062-7; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; ELLENA JF, 1985, J AM CHEM SOC, V107, P1530, DOI 10.1021/ja00292a013; Feller SE, 1999, J AM CHEM SOC, V121, P8963, DOI 10.1021/ja991456n; Feller SE, 2002, BIOPHYS J, V82, P1396, DOI 10.1016/S0006-3495(02)75494-5; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gambhir A, 2003, BIOPHYS J, V84, p131A; Gawrisch K, 2002, CHEM PHYS LIPIDS, V116, P135, DOI 10.1016/S0009-3084(02)00024-5; HILGEMANN DW, 2001, SCI STKE; Holte LL, 1997, BIOCHEMISTRY-US, V36, P4669, DOI 10.1021/bi9626416; Hurley JH, 2002, CELL, V111, P143, DOI 10.1016/S0092-8674(02)01044-9; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Huster D, 1999, J PHYS CHEM B, V103, P243, DOI 10.1021/jp983428h; Huster D, 1999, J AM CHEM SOC, V121, P1992, DOI 10.1021/ja9838413; Huster D, 2002, J AM CHEM SOC, V124, P874, DOI 10.1021/ja017001r; Huster D, 2001, ANGEW CHEM INT EDIT, V40, P1056, DOI 10.1002/1521-3773(20010316)40:6<1056::AID-ANIE10560>3.0.CO;2-7; Irvine R, 2000, SCI STKE, pre1; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kumashiro KK, 1998, J AM CHEM SOC, V120, P5043, DOI 10.1021/ja972655e; Levitt M. H., 2001, SPIN DYNAMICS; London E, 2002, CURR TOP MEMBR, V52, P89; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MIYAZAKI J, 1992, BIOCHIM BIOPHYS ACTA, V1103, P62, DOI 10.1016/0005-2736(92)90057-S; OLDFIELD E, 1987, BIOCHEMISTRY-US, V26, P6919, DOI 10.1021/bi00396a009; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; ROUX M, 1988, EUR BIOPHYS J BIOPHY, V16, P267, DOI 10.1007/BF00254062; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; Segrest JP, 2002, CURR TOP MEMBR, V52, P397; SIMON SA, 1982, J PHYS CHEM-US, V86, P1449, DOI 10.1021/j100397a048; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Smith SO, 1996, Q REV BIOPHYS, V29, P395, DOI 10.1017/S0033583500005898; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; Victor K, 1999, BIOCHEMISTRY-US, V38, P12527, DOI 10.1021/bi990847b; Victor KG, 2001, BIOPHYS J, V81, P2241, DOI 10.1016/S0006-3495(01)75871-7; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; XU ZC, 1986, BIOPHYS J, V49, P779, DOI 10.1016/S0006-3495(86)83705-5; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; YOUNG LRD, 1988, BIOCHEMISTRY-US, V27, P5281	60	104	107	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21459	21466		10.1074/jbc.M301652200	http://dx.doi.org/10.1074/jbc.M301652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670959	hybrid			2022-12-25	WOS:000183354200020
J	Smith, BD; Soellner, MB; Raines, RT				Smith, BD; Soellner, MB; Raines, RT			Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHOGLUCONATE DEHYDROGENASE; CRYPTOCOCCUS-NEOFORMANS; SALT CONCENTRATION; CRYSTAL-STRUCTURE; ENZYMES; INACTIVATION; SUBSTRATE; MECHANISM; COMPLEX; ORIGIN	Ribonuclease A (RNase A) can make multiple contacts with an RNA substrate. In particular, the enzymatic active site and adjacent subsites bind sequential phosphoryl groups in the RNA backbone through Coulombic interactions. Here, oligomers of vinylsulfonic acid (OVS) are shown to be potent inhibitors of RNase A that exploit these interactions. Inhibition is competitive with substrate and has K-i = 11 pM in assays at low salt concentration. The effect of salt concentration on inhibition indicates that nearly eight favorable Coulombic interactions occur in the RNase A.OVS complex. The phosphonic acid and sulfuric acid analogs of OVS are also potent inhibitors although slightly less effective. OVS is also shown to be a contaminant of MES and other buffers that contain sulfonylethyl groups. Oligomers greater than nine units in length can be isolated from commercial MES buffer. Inhibition by contaminating OVS is responsible for the apparent decrease in catalytic activity that has been observed in assays of RNase A at low salt concentration. Thus, OVS is both a useful inhibitor of RNase A and a potential bane to chemists and biochemists who use ethanesulfonic acid buffers.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719				ALTHAUS IW, 1992, EXPERIENTIA, V48, P1127, DOI 10.1007/BF01948005; BACH MK, 1964, BIOCHIM BIOPHYS ACTA, V91, P619, DOI 10.1016/0926-6550(64)90010-6; BRESLOW DS, 1954, J AM CHEM SOC, V76, P6399, DOI 10.1021/ja01653a045; CHAMBON P, 1967, BIOCHIM BIOPHYS ACTA, V149, P584, DOI 10.1016/0005-2787(67)90186-4; CHENG TC, 1974, J BIOL CHEM, V249, P1781; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DELROSAR.EJ, 1969, BIOCHEMISTRY-US, V8, P1884, DOI 10.1021/bi00833a017; EDELHOCH H, 1956, J BIOL CHEM, V219, P351; FELLIG J, 1959, ARCH BIOCHEM BIOPHYS, V85, P313, DOI 10.1016/0003-9861(59)90496-5; Fisher BM, 1998, J BIOL CHEM, V273, P34134, DOI 10.1074/jbc.273.51.34134; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HEYMANN H, 1958, ARCH BIOCHEM BIOPHYS, V73, P366, DOI 10.1016/0003-9861(58)90282-0; IRIE M, 1965, J BIOCHEM-TOKYO, V57, P355, DOI 10.1093/oxfordjournals.jbchem.a128089; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; Kim BM, 1999, PROTEIN SCI, V8, P430; KIM JS, 1993, J BIOL CHEM, V268, P17392; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LIBONATI M, 1992, MOL CELL BIOCHEM, V117, P139; LITTAUER UZ, 1962, BIOCHIM BIOPHYS ACTA, V61, P609, DOI 10.1016/0926-6550(62)90114-7; MACH B, 1968, P NATL ACAD SCI USA, V59, P445, DOI 10.1073/pnas.59.2.445; NELSON CA, 1961, J BIOL CHEM, V236, P3173; Niehaus WG, 1995, ARCH BIOCHEM BIOPHYS, V324, P325, DOI 10.1006/abbi.1995.0045; NIEHAUS WG, 1993, MYCOPATHOLOGIA, V123, P155, DOI 10.1007/BF01111266; Park C, 2000, FEBS LETT, V468, P199, DOI 10.1016/S0014-5793(00)01227-8; Park C, 2003, BIOCHEMISTRY-US, V42, P3509, DOI 10.1021/bi026076k; Park C, 2001, J AM CHEM SOC, V123, P11472, DOI 10.1021/ja0164834; Park C, 2001, METHOD ENZYMOL, V341, P81, DOI 10.1016/S0076-6879(01)41146-3; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHARDS FM, 1971, ENZYMES, V4, P647; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Russo A, 2001, METHOD ENZYMOL, V341, P629, DOI 10.1016/S0076-6879(01)41181-5; Russo N, 1999, J BIOL CHEM, V274, P14902, DOI 10.1074/jbc.274.21.14902; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; SELA M, 1962, J BIOL CHEM, V237, P418; STOWELL JK, 1995, J ORG CHEM, V60, P6930, DOI 10.1021/jo00126a051; UI N, 1971, BIOCHIM BIOPHYS ACTA, V229, P567; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; YAKOVLEV GI, 1992, EUR J BIOCHEM, V204, P187, DOI 10.1111/j.1432-1033.1992.tb16622.x; ZOLLNER N, 1953, AM J PHYSIOL, V173, P223, DOI 10.1152/ajplegacy.1953.173.2.223	46	62	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20934	20938		10.1074/jbc.M301852200	http://dx.doi.org/10.1074/jbc.M301852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649287	hybrid			2022-12-25	WOS:000183230500064
J	Valgardsdottir, R; Prydz, H				Valgardsdottir, R; Prydz, H			Transport signals and transcription-dependent nuclear localization of the putative DEAD-box helicase MDDX28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EXPORT SIGNALS; GENE ENCODES; PROTEIN; MITOCHONDRIAL; TRANSLOCATION; SEQUENCE; DOMAINS; CRM1; INHIBITOR	The human protein MDDX28 is a putative RNA helicase and a nucleocytoplasmic shuttling protein also localized to the mitochondria. Its localization is novel among RNA helicases. We have studied its intracellular targeting signals and show that the first 20 amino acids of MDDX28 are necessary and sufficient for both mitochondrial import and nuclear export of the protein. Mutation of the five leucines in the sequence to alanines abolished the mitochondrial targeting signal as well as greatly reducing the nuclear export signal, indicating that these signal sequences are highly overlapping. Two short stretches of basic amino acids separated by 44 residues were both necessary and sufficient for full nuclear localization. However, they were not absolutely essential, because the protein was present in 7% of the nuclei when both signals were mutated. This indicates that MDDX28 contains another unidentified weak nuclear localization signal(s). Three basic domains in the N-terminal half of the protein and its RNA binding ability were essential for nucleolar localization as well as transcription-inhibition-dependent localization to nuclear subcompartments. Two of these basic domains were the same as those constituting the nuclear localization signal, suggesting that they are responsible for bringing the protein into the nucleus to the sites of RNA binding. Our results indicate that MDDX28 nucleo-cytoplasmic shuttling is dependent on the availability of nascent RNA.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Gaustadalleen 21, N-0349 Oslo, Norway.	hans.prydz@biotek.uio.no						Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Askjaer P, 2000, J BIOL CHEM, V275, P11561, DOI 10.1074/jbc.275.16.11561; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Chiodi I, 2000, J CELL SCI, V113, P4043; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Husberg C, 2001, J BIOL CHEM, V276, P17641, DOI 10.1074/jbc.M007951200; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; Le Panse S, 1999, J CELL SCI, V112, P2145; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Mohr S, 2002, CELL, V109, P769, DOI 10.1016/S0092-8674(02)00771-7; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Shibata K, 2000, GENOME RES, V10, P1757, DOI 10.1101/gr.152600; SHUNU C, 2002, FEBS LETT, V484, P22; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; STUURMAN N, 1992, J CELL SCI, V101, P773; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Valgardsdottir R, 2001, J BIOL CHEM, V276, P32056, DOI 10.1074/jbc.M011629200; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Weil R, 1999, MOL CELL BIOL, V19, P6345; Willer M, 1999, CURR BIOL, V9, P1085, DOI 10.1016/S0960-9822(99)80477-1; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	40	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21146	21154		10.1074/jbc.M300888200	http://dx.doi.org/10.1074/jbc.M300888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663657	hybrid			2022-12-25	WOS:000183230500091
J	Ceci, P; Ilari, A; Falvo, E; Chiancone, E				Ceci, P; Ilari, A; Falvo, E; Chiancone, E			The Dps protein of Agrobacterium tumefaciens does not bind to DNA but protects it toward oxidative cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROTEIN; ESCHERICHIA-COLI; LISTERIA-INNOCUA; STREPTOCOCCUS-MUTANS; HELICOBACTER-PYLORI; IRON; FERRITIN; STRESS; MOLSCRIPT; HOMOLOG	Agrobacterium tumefaciens Dps ( DNA-binding proteins from starved cells), encoded by the dps gene located on the circular chromosome of this plant pathogen, was cloned, and its structural and functional properties were determined in vitro. In Escherichia coli Dps, the family prototype, the DNA binding properties are thought to be associated with the presence of the lysine-containing N-terminal tail that extends from the protein surface into the solvent. The x-ray crystal structure of A. tumefaciens Dps shows that the positively charged N-terminal tail, which is 11 amino acids shorter than in the E. coli protein, is blocked onto the protein surface. This feature accounts for the lack of interaction with DNA. The intersubunit ferroxidase center characteristic of Dps proteins is conserved and confers to the A. tumefaciens protein a ferritin-like activity that manifests itself in the capacity to oxidize and incorporate iron in the internal cavity and to release it after reduction. In turn, sequestration of Fe( II) correlates with the capacity of A. tumefaciens Dps to reduce the production of hydroxyl radicals from H2O2 through Fenton chemistry. These data demonstrate conclusively that DNA protection from oxidative damage in vitro does not require formation of a Dps-DNA complex. In vivo, the hydroxyl radical scavenging activity of A. tumefaciens Dps may be envisaged to act in concert with catalase A to counteract the toxic effect of H2O2, the major component of the plant defense system when challenged by the bacterium.	Univ Roma La Sapienza, Consiglio Nazl, Ric Inst Mol Biol & Pathol, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Chiancone, E (corresponding author), Univ Roma La Sapienza, Consiglio Nazl, Ric Inst Mol Biol & Pathol, Dept Biochem Sci A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Ilari, Andrea/T-5501-2017	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Falvo, Elisabetta/0000-0001-9584-8669; Ceci, Pierpaolo/0000-0001-7712-8430				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; BOTWELL TH, 1955, BIOCHEM J, V59, P599; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Gupta S, 2002, PROTEIN ENG, V15, P503, DOI 10.1093/protein/15.6.503; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; Ishikawa T, 2003, J BACTERIOL, V185, P1010, DOI 10.1128/JB.185.3.1010-1017.2003; KLEE H, 1987, ANNU REV PLANT PHYS, V38, P467, DOI 10.1146/annurev.pp.38.060187.002343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Suzuki K, 2001, DNA RES, V8, P141, DOI 10.1093/dnares/8.4.141; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Xu XQ, 2001, MOL MICROBIOL, V42, P645, DOI 10.1046/j.1365-2958.2001.02653.x; Yamamoto Y, 2000, J BACTERIOL, V182, P3740, DOI 10.1128/JB.182.13.3740-3747.2000; Yamamoto Y, 2002, J BACTERIOL, V184, P2931, DOI 10.1128/JB.184.11.2931-2939.2002; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200; Zupan J, 1997, CRIT REV PLANT SCI, V16, P279, DOI 10.1080/713608150	35	113	119	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20319	20326		10.1074/jbc.M302114200	http://dx.doi.org/10.1074/jbc.M302114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660233	hybrid			2022-12-25	WOS:000183078000095
J	Fujimoto, Z; Kaneko, S; Momma, M; Kobayashi, H; Mizuno, H				Fujimoto, Z; Kaneko, S; Momma, M; Kobayashi, H; Mizuno, H			Crystal structure of rice alpha-galactosidase complexed with D-galactose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORTIERELLA-VINACEA; CATALYTIC NUCLEOPHILE; SUBSTRATE-SPECIFICITY; GLYCOSIDE HYDROLASES; PURIFICATION; SEQUENCE; CRYSTALLIZATION; CDNA; GALACTOMANNAN; PURPUROGENUM	alpha-Galactosidases catalyze the hydrolysis of alpha-1,6-linked galactosyl residues from galacto-oligosaccharides and polymeric galacto-(gluco) mannans. The crystal structure of rice alpha-galactosidase has been determined at 1.5Angstrom resolution using the multiple isomorphous replacement method. The structure consisted of a catalytic domain and a C-terminal domain and was essentially the same as that of alpha-N-acetylgalactosaminidase, which is the same member of glycosyl hydrolase family 27. The catalytic domain had a (beta/alpha)(8)-barrel structure, and the C-terminal domain was made up of eight beta-strands containing a Greek key motif. The structure was solved as a complex with D-galactose, providing a mode of substrate binding in detail. The D-galactose molecule was found bound in the active site pocket on the C-terminal side of the central beta-barrel of the catalytic domain. The D-galactose molecule consisted of a mixture of two anomers present in a ratio equal to their natural abundance. Structural comparisons of rice alpha-galactosidase with chicken alpha-N-acetylgalactosaminidase provided further understanding of the substrate recognition mechanism in these enzymes.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Natl Food Res Inst, Biol Funct Div, Tsukuba, Ibaraki 3058642, Japan	National Institute of Agrobiological Sciences - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Mizuno, H (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.			Fujimoto, Zui/0000-0002-3551-6854				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Courtois J.E., 1966, METHODS ENZYMOLOGY, P565; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEY PM, 1993, BIOTECHNOL APPL BIOC, V17, P361; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Fujimoto Z, 2002, ACTA CRYSTALLOGR D, V58, P1374, DOI 10.1107/S0907444902010168; Garman SC, 2002, STRUCTURE, V10, P425, DOI 10.1016/S0969-2126(02)00726-8; GOLUBEV AM, 1993, J MOL BIOL, V231, P933, DOI 10.1006/jmbi.1993.1340; Hart DO, 2000, BIOCHEMISTRY-US, V39, P9826, DOI 10.1021/bi0008074; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Ishiguro M, 2001, APPL ENVIRON MICROB, V67, P1601, DOI 10.1128/AEM.67.4.1601-1616.2001; KANEKO R, 1990, AGR BIOL CHEM TOKYO, V54, P237, DOI 10.1080/00021369.1990.10869898; KANEKO R, 1991, AGR BIOL CHEM TOKYO, V55, P109, DOI 10.1080/00021369.1991.10870536; Kim WD, 2002, PHYTOCHEMISTRY, V61, P621, DOI 10.1016/S0031-9422(02)00368-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Ly HD, 2000, CARBOHYD RES, V329, P539, DOI 10.1016/S0008-6215(00)00214-7; MCCLEARY BV, 1983, PHYTOCHEMISTRY, V22, P649, DOI 10.1016/S0031-9422(00)86956-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURALI R, 1994, J MOL BIOL, V239, P578, DOI 10.1006/jmbi.1994.1397; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REID JS, 1985, BIOCH STORAGE CARBOH, P205; REID JSG, 1992, BIOCHEM SOC T, V20, P23, DOI 10.1042/bst0200023; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Shibuya H, 1995, BIOSCI BIOTECH BIOCH, V59, P2333, DOI 10.1271/bbb.59.2333; Shibuya H, 1999, BIOSCI BIOTECH BIOCH, V63, P1096, DOI 10.1271/bbb.63.1096; Shibuya H, 1998, APPL ENVIRON MICROB, V64, P4489; Shibuya H, 1997, BIOSCI BIOTECH BIOCH, V61, P592, DOI 10.1271/bbb.61.592; SHIBUYA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1345, DOI 10.1271/bbb.59.1345; YAMANE T, 1971, SUCR BELGE, V90, P345; Yoshida S, 1997, BIOSCI BIOTECH BIOCH, V61, P359, DOI 10.1271/bbb.61.359	40	93	98	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20313	20318		10.1074/jbc.M302292200	http://dx.doi.org/10.1074/jbc.M302292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657636	hybrid			2022-12-25	WOS:000183078000094
J	Hartgroves, LC; Lin, J; Langen, H; Zech, T; Weiss, A; Harder, T				Hartgroves, LC; Lin, J; Langen, H; Zech, T; Weiss, A; Harder, T			Synergistic assembly of linker for activation of T cells signaling protein complexes in T cell plasma membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA-1; MEDIATED ACTIVATION; TYROSINE RESIDUES; RECEPTOR; LAT; TRANSDUCTION; IDENTIFICATION; ACCUMULATION; PLC-GAMMA-1	Transmembrane adaptor molecule LAT ( linker for activation of T cells) forms a central scaffold for signaling protein complexes that accumulate in the vicinity of activated T cell antigen receptors (TCR). Here we used biochemical analysis of immunoisolated plasma membrane domains and fluorescence imaging of green fluorescence protein-tagged signaling proteins to investigate the contributions of different tyrosine-based signaling protein docking sites of LAT to the formation of LAT signaling protein assemblies in TCR membrane domains. We found that the phospholipase C gamma docking site of LAT and different Grb2/Gads docking sites function in an interdependent fashion and synergize to accumulate LAT, Grb2, and phospholipase C gamma in TCR signaling assemblies. Two-dimensional gels showed that Grb2 is a predominant cytoplasmic adaptor in the isolated LAT signaling complexes, whereas Gads, Crk-1, and Grap are present in lower amounts. Taken together our data suggest a synergistic assembly of multimolecular TCR . LAT signal transduction complexes in T cell plasma membrane domains.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	University of Oxford; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Roche Holding	Harder, T (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	thomas.harder@path.ox.ac.uk		Zech, Tobias/0000-0001-8394-088X				Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Celis JE, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P375; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HARDER T, 2001, SCI STKE; Leo A, 2002, J CLIN INVEST, V109, P301; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SCHATTEN G, 1986, EXP CELL RES, V166, P191, DOI 10.1016/0014-4827(86)90519-7; Tanimura N, 2003, J CELL BIOL, V160, P125, DOI 10.1083/jcb.200207096; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	25	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20389	20394		10.1074/jbc.M301212200	http://dx.doi.org/10.1074/jbc.M301212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646565	hybrid			2022-12-25	WOS:000183078000104
J	Helfenbein, KG; Ellis, TP; Dieckmann, CL; Tzagoloff, A				Helfenbein, KG; Ellis, TP; Dieckmann, CL; Tzagoloff, A			ATP22, a nuclear gene required for expression of the F-0 sector of mitochondrial ATPase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SYSTEM; ESCHERICHIA-COLI; ROTARY MOTOR; YEAST; SYNTHASE; IDENTIFICATION; COMPLEX; SUBUNIT; PROTEINS; MUTANTS	Expression of the mitochondrial proton-translocating ATPase of Saccharomyces cerevisiae has been shown to depend on chaperones that target the F-1 and F-0 sectors of this inner membrane complex. Here we report a new gene, designated ATP22 ( reading frame YDR350C on chromosome IV), that provides an essential function in the assembly of F0. ATP22 was cloned by transformation of C208/L2, a strain previously assigned to complementation group G99 of a collection of respiration-defective nuclear pet mutants. C208/L2 and the other atp22 mutants have oligomycin-insensitive F-1-ATPase, suggesting that the lesion is confined to F-0. This is supported by the sedimentation properties of the mutant ATPase and results of immunochemical analysis of F-0 subunit polypeptides. Northern analysis of ATPase transcripts and in vivo pulse labeling of the mitochondrial translation products in the mutant indicate normal expression of subunits 6, 8, and 9, the three mitochondrial gene products of F-0. Atp22p therefore functions at a posttranslational stage in assembly of F-0. Localization studies indicate Atp22p to be a component of the mitochondrial inner membrane. Protease protection experiments further indicate that Atp22p faces the matrix side of the membrane where most of the ATPase proteins are located and assembled.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	Columbia University; University of Arizona	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet.bio.columbia.edu			NHLBI NIH HHS [HL2274, R01 HL022174] Funding Source: Medline; NIGMS NIH HHS [GM34893] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1991, FEBS LETT, V278, P234, DOI 10.1016/0014-5793(91)80124-L; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BEILHARZ MW, 1982, FEBS LETT, V147, P235, DOI 10.1016/0014-5793(82)81049-1; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAMOUGRAND N, 1995, J MOL BIOL, V247, P588, DOI 10.1006/jmbi.1995.0165; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fillingame RH, 2000, J EXP BIOL, V203, P9; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KAGAWA Y, 1966, J BIOL CHEM, V241, P2461; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACREADIE IG, 1983, NUCLEIC ACIDS RES, V11, P4435, DOI 10.1093/nar/11.13.4435; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXAM AM, 1980, METHOD ENZYMOL, V65, P49; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paul MF, 2000, J BIOL CHEM, V275, P29238, DOI 10.1074/jbc.M004546200; PAYNE MJ, 1991, CURR GENET, V19, P343, DOI 10.1007/BF00309594; PELISSIER P, 1995, CURR GENET, V27, P409, DOI 10.1007/BF00311209; PENEFSKY HS, 1965, J BIOL CHEM, V240, P4694; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHATZ G, 1968, J BIOL CHEM, V243, P2192; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1971, J BIOL CHEM, V246, P7328; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; WALLENFELS K, 1962, METHOD ENZYMOL, V5, P212, DOI 10.1016/S0076-6879(62)05207-6; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	50	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19751	19756		10.1074/jbc.M301679200	http://dx.doi.org/10.1074/jbc.M301679200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646576	hybrid			2022-12-25	WOS:000183078000025
J	Ley, R; Balmanno, K; Hadfield, K; Weston, C; Cook, SJ				Ley, R; Balmanno, K; Hadfield, K; Weston, C; Cook, SJ			Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY MEMBER; CELL-CYCLE ARREST; MOLECULAR-CLONING; APOPTOSIS; SURVIVAL; KINASES; IDENTIFICATION; EXPRESSION; ERK5/BMK1; ISOFORMS	Both the ERK and phosphatidylinositol 3'-kinase (PI3K) signaling pathways can protect cells from apoptosis following withdrawal of survival factors. We have previously shown that the ERK1/2 pathway acts independently of PI3K to block expression of the BH3-only protein, Bim(EL), and prevent serum withdrawal-induced cell death, although the precise mechanism by which ERK reduced Bim(EL) levels was unclear. By comparing Bim mRNA and Bim protein, expression we now show that the rapid expression of Bim(EL) following serum withdrawal cannot be accounted for simply by increases in mRNA following inhibition of PI3K. In cells maintained in serum Bim(EL) is a phosphoprotein. We show that activation of the ERK1/2 pathway is both necessary and sufficient to promote Bim(EL) phosphorylation and that this leads to a substantial increase in turnover of the Bim(EL) protein. ERK1/2-dependent degradation of Bim(EL) proceeds via the proteasome pathway because it is blocked by proteasome inhibitors and is defective at the restrictive temperature in cells with a temperature-sensitive mutation in the E1 component of the ubiquitin-conjugating system. Finally, co-transfection of Bim(EL) and FLAG-ubiquitin causes the accumulation of polyubiquitinated forms of Bim, and this requires the ERK1/2 pathway. Our findings provide new insights into the regulation of Bim and the role of the ERK pathway in cell survival.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England.			Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H457] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	30	495	503	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18811	18816		10.1074/jbc.M301010200	http://dx.doi.org/10.1074/jbc.M301010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646560	hybrid			2022-12-25	WOS:000182932200015
J	Settle, M; Gordon, MD; Nadella, M; Dankort, D; Muller, W; Jacobs, JR				Settle, M; Gordon, MD; Nadella, M; Dankort, D; Muller, W; Jacobs, JR			Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model	ONCOGENE			English	Article						apoptosis; DEgft; Grb-2; Neu; SHC	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE C-GAMMA; EGF RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; SH3 DOMAINS; PTB DOMAIN; MAMMARY TUMORIGENESIS	The ErbB-2/Neu receptor tyrosine kinase plays a causal role in tumorigenesis in mammals. Neu's carboxyl terminus contains five phosphorylated tyrosines that mediate transformation through interaction with cytoplasmic SH2 or PTB containing adaptor proteins. We show that Drosophild adaptors signal from individual phosphotyrosine sites of rat Neu. Activated Neu expression in the midline glia suppressed apoptosis, similar to that seen with activated Drosophild EGF-R expression. Expression in eye and wing tissues generated graded phenotypes suitable for dos F-sensitive modifier genetics. Suppression of ErbB-2/Neu-induced phenotypes in tissues haplosufficient for genes encoding adaptor protein or second messengers suggests that pTyr 1227(YD) signals require Shc, and that pTyr 1253 (YE) signalling does not employ Ras, but does require Raf function. Signalling from pTyr (YB) was affected by a haplosufficiency in drk (Grb-2), and in genes thought to function downstream of Grb-2: dab, sos, csw (Shp-2), and dos (Gab-1). These data demonstrate the power of Drosophila genetics to unmask the molecules that signal from oncogenic ErbB-2/Neu.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	McMaster University	Jacobs, JR (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	jacobsr@mcmaster.ca	Gordon, Michael D/H-9586-2012	Gordon, Michael D/0000-0002-5440-986X; jacobs, j roger/0000-0002-5878-5416; Dankort, David/0000-0002-5862-6829				BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BAUMANN P, 1993, DEVELOPMENT, P65; Bhandari P, 2001, ONCOGENE, V20, P6871, DOI 10.1038/sj.onc.1204849; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Dong R, 1997, DEV BIOL, V190, P165, DOI 10.1006/dbio.1997.8688; Dougall WC, 1996, DNA CELL BIOL, V15, P31, DOI 10.1089/dna.1996.15.31; Firth L, 2000, GENETICS, V156, P733; Gayko U, 1999, P NATL ACAD SCI USA, V96, P523, DOI 10.1073/pnas.96.2.523; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; Hamlet MRJ, 2001, GENETICS, V159, P1073; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jacobs JR, 2000, PROG NEUROBIOL, V62, P475, DOI 10.1016/S0301-0082(00)00016-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lanoue BR, 2000, GENOME, V43, P564, DOI 10.1139/gen-43-3-564; Lanoue BR, 1999, DEV GENET, V25, P321, DOI 10.1002/(SICI)1520-6408(1999)25:4<321::AID-DVG6>3.0.CO;2-Y; Le N, 1998, MOL CELL BIOL, V18, P4844, DOI 10.1128/MCB.18.8.4844; Lee T, 1996, DEVELOPMENT, V122, P409; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Lesokhin AM, 1999, DEV BIOL, V205, P129, DOI 10.1006/dbio.1998.9121; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; Maixner A, 1998, DEV GENET, V23, P347, DOI 10.1002/(SICI)1520-6408(1998)23:4<347::AID-DVG9>3.0.CO;2-C; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RICCI A, 1995, ONCOGENE, V11, P1519; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Stewart BA, 2001, DEV BIOL, V234, P13, DOI 10.1006/dbio.2001.0228; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1916	1926		10.1038/sj.onc.1206240	http://dx.doi.org/10.1038/sj.onc.1206240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673197				2022-12-25	WOS:000181967700002
J	Vukovic, B; Park, PC; Al-Maghrabi, J; Beheshti, B; Sweet, J; Evans, A; Trachtenberg, J; Squire, J				Vukovic, B; Park, PC; Al-Maghrabi, J; Beheshti, B; Sweet, J; Evans, A; Trachtenberg, J; Squire, J			Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma	ONCOGENE			English	Article						prostate; telomere; heterogeneity	IN-SITU HYBRIDIZATION; ATYPICAL ADENOMATOUS HYPERPLASIA; NUMERICAL CHROMOSOMAL CHANGES; INDEPENDENT ORIGIN; TUMOR PROGRESSION; ALLELIC LOSS; INSTABILITY; CANCER; IMMUNOHISTOCHEMISTRY; EPIDEMIOLOGY	Mechanisms underlying prostate cancer (CaP) initiation and progression are poorly understood. A chromosomal instability mechanism leading to the generation of numerical and structural chromosomal changes has been implicated in the preneoplastic and neoplastic stages of CaP. Telomere dysfunction is one potential mechanism associated with the onset of such instability. To determine whether there was alteration in telomere length and chromosome number, 15 paraffin-embedded prostatectomy specimens were investigated using quantitative peptide nucleic acid (PNA) FISH analysis of representative foci of carcinoma, putative precancerous lesions (high-grade prostatic intraepithelial neoplasia, HPIN) and nondysplastic prostate epithelium. A significant decrease in telomere length was shown in both HPIN and CaP in comparison with normal epithelium. In addition, elevated rates of aneusomy suggested that increased levels of chromosomal aberrations were associated with decreased telomere length. Moreover, multiple foci of HPIN were shown to have a heterogeneous overall reduction of telomere length. This reduction was more evident in the histologic regions of the prostate containing CaP. Such observations lend support to the hypothesis that telomere erosion may be a consistent feature of CaP oncogenesis and may also be associated with the generation of chromosomal instability that characterizes this malignancy.	Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Dept Med Biophys, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Lab Med & Pathobiol, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Div Pathol, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Div Urol, Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Squire, J (corresponding author), Univ Toronto, Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jeremy.squire@utoronto.ca	Al-Maghrabi, Jaudah/L-4367-2013; Squire, Jeremy A/A-9352-2012	Al-Maghrabi, Jaudah/0000-0002-0812-9592; Squire, Jeremy A/0000-0002-9863-468X; Sweet, Joan/0000-0002-6791-4929				Al-Maghrabi J, 2002, ARCH PATHOL LAB MED, V126, P165; Al-Maghrabi J, 2001, MODERN PATHOL, V14, P1252, DOI 10.1038/modpathol.3880471; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BASTACKY SI, 1995, J UROLOGY, V153, P987, DOI 10.1016/S0022-5347(01)67619-5; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bohr V, 1998, TOXICOL LETT, V103, P47; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; COLEMAN WB, 1995, CLIN CHEM, V41, P644; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; Cunningham JM, 1996, CANCER RES, V56, P4475; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Erbersdobler A, 1996, PATHOL RES PRACT, V192, P418, DOI 10.1016/S0344-0338(96)80003-3; Erbersdobler A, 1999, PROSTATE, V38, P92, DOI 10.1002/(SICI)1097-0045(19990201)38:2<92::AID-PROS2>3.0.CO;2-6; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; GIARETTI W, 1990, INT J CANCER, V45, P597, DOI 10.1002/ijc.2910450404; Goyns MH, 2000, MECH AGEING DEV, V114, P69, DOI 10.1016/S0047-6374(00)00095-6; GRAHAM SD, 1992, CANCER, V70, P359, DOI 10.1002/1097-0142(19920701)70:1+<359::AID-CNCR2820701329>3.0.CO;2-B; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Haas GP, 1997, CA-CANCER J CLIN, V47, P273, DOI 10.3322/canjclin.47.5.273; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Harding MA, 2000, UROL ONCOL, V5, P258, DOI 10.1016/S1078-1439(00)00073-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hixon ML, 2000, FRONT BIOSCI, V5, pD50, DOI 10.2741/Hixon; ISAACS WB, 1994, SEMIN ONCOL, V21, P514; Kallakury BVS, 1997, DIAGN MOL PATHOL, V6, P192, DOI 10.1097/00019606-199708000-00003; Koeneman KS, 1998, J UROLOGY, V160, P1533, DOI 10.1016/S0022-5347(01)62608-9; Lin Y, 1997, J UROLOGY, V157, P1161, DOI 10.1016/S0022-5347(01)65160-7; MACOSKA JA, 1994, CANCER RES, V54, P3824; McClintock B, 1941, GENETICS, V26, P234; MCNEAL J, 1986, HUM PATHOL, V17; Meeker AK, 2002, AM J PATHOL, V160, P1259, DOI 10.1016/S0002-9440(10)62553-9; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; MUIR CS, 1991, ACTA ONCOL, V30, P133, DOI 10.3109/02841869109092336; MULLER HJ, 1938, COLLECTING NET, V13, P183; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Qian JQ, 1999, EUR UROL, V35, P479, DOI 10.1159/000019883; QIAN JQ, 1995, UROLOGY, V46, P837, DOI 10.1016/S0090-4295(99)80354-9; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Sakr WA, 1998, ANAL QUANT CYTOL, V20, P417; Sakr WA, 1996, EUR UROL, V30, P138; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; Sakr WA, 2001, UROLOGY, V57, P115, DOI 10.1016/S0090-4295(00)00953-5; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; Scates DK, 1997, BRIT J UROL, V80, P263, DOI 10.1046/j.1464-410X.1997.00248.x; Shackney SE, 1995, CYTOMETRY, V22, P307, DOI 10.1002/cyto.990220407; Takahashi C, 1997, EUR UROL, V32, P494, DOI 10.1159/000480814; Takahashi S, 1996, CLIN CANCER RES, V2, P137; van der Kwast TH, 1999, EUR UROL, V35, P508, DOI 10.1159/000019889; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wullich B, 1999, J UROLOGY, V161, P1997, DOI 10.1016/S0022-5347(05)68872-6; Zhang WB, 1998, CANCER RES, V58, P619	59	65	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1978	1987		10.1038/sj.onc.1206227	http://dx.doi.org/10.1038/sj.onc.1206227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673203				2022-12-25	WOS:000181967700008
J	Hooper, JD; Zijlstra, A; Aimes, RT; Liang, HY; Claassen, GF; Tarin, D; Testa, JE; Quigley, JP				Hooper, JD; Zijlstra, A; Aimes, RT; Liang, HY; Claassen, GF; Tarin, D; Testa, JE; Quigley, JP			Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen	ONCOGENE			English	Article						subtractive immunization; metastasis; SIMA135/CDCP1; proteomics; colon cancer; CUB	MONOCLONAL-ANTIBODIES; SERINE PROTEASES; PROTEINS; BINDING; ACTIVATION; EXPRESSION; PHENOTYPE; DOMAINS; CANCER; GROWTH	We have previously used a subtractive immunization (SI) approach to generate monoclonal antibodies (mAbs) against proteins preferentially expressed by the highly metastatic human epidermoid carcinoma cell line, M(+)HEp3. Here we report the immunopurification, identification and characterization of SIMA135/CDCP1 (subtractive immunization M(+)HEp3 associated 135kDa protein/CUB domain containing protein 1) using one of these mAbs designated 41-2. Protein expression levels of SIMA135/CDCP1 correlated with the metastatic ability of variant HEp3 cell lines. Protein sequence analysis predicted a cell surface location and type I orientation of SIMA135/CDCP1, which was confirmed directly by immunocytochemistry. Analysis of deglycosylated cell lysates indicated that up to 40 kDa of the apparent molecular weight of SIMA135/CDCP1 is because of N-glycosylation. Western blot analysis using a antiphosphotyrosine antibody demonstrated that SIMA135/CDCP1 from HEp3 cells is tyrosine phosphorylated. Selective inhibitor studies indicated that an Src kinase family member is involved in the tyrosine phosphorylation of the protein. In addition to high expression in M(+)HEp3 cells, the SIMA135/CDCP1 protein is expressed to varying levels in 13 other human tumor cell lines, manifesting only a weak correlation with the reported metastatic ability of these tumor cell lines. The protein is not detected in normal human fibroblasts and endothelial cells. Northern blot analysis indicated that SIMA135/CDCP1 mRNA has a restricted expression pattern in normal human tissues with highest levels of expression in skeletal muscle and colon. Immunohistochemical analysis indicated apical and basal plasma membrane expression of SIMA135/CDCP1 in epithelial cells in normal colon. in colon tumor, SIMA135/CDCP1 expression appeared dysregulated showing extensive cell surface as well as cytoplasmic expression. Consistent with in vitro shedding experiments on HEp3 cells, SIMA135/CDCP1 was also detected within the lumen of normal and cancerous colon crypts, suggesting that protein shedding may occur in vivo. Thus, specific immunodetection followed by proteomic analysis allows for the identification and partial characterization of a heretofore uncharacterized human cell surface antigen.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jquigley@scripps.edu	Hooper, John/B-4153-2011; zijlstra, andries/G-4564-2013; Hooper, John/C-1481-2016	zijlstra, andries/0000-0001-8460-8803; Hooper, John/0000-0003-1054-8486	NATIONAL CANCER INSTITUTE [R01CA065660] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007695, T32HL007195, P01HL031950] Funding Source: NIH RePORTER; NCI NIH HHS [CA65660] Funding Source: Medline; NHLBI NIH HHS [HL31950, T32 HL07695, T32 HL07195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADHAM IM, 1990, HUM GENET, V84, P125; Bajorath J, 2000, PROTEINS, V39, P103, DOI 10.1002/(SICI)1097-0134(20000501)39:2<103::AID-PROT1>3.3.CO;2-7; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Goebeler M, 1996, J CELL SCI, V109, P1957; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; Grogan MJ, 2002, ANNU REV BIOCHEM, V71, P593, DOI 10.1146/annurev.biochem.71.110601.135334; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hansen SG, 1999, VIROLOGY, V254, P124, DOI 10.1006/viro.1998.9543; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; KING SW, 1988, BIOTECHNIQUES, V6, P856; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Maruo Y, 2002, INT J CANCER, V100, P486, DOI 10.1002/ijc.10514; MATTHEW WD, 1983, COLD SPRING HARB SYM, V48, P625, DOI 10.1101/SQB.1983.048.01.066; Mayer BJ, 2001, J CELL SCI, V114, P1253; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NIELSENPREISS SM, 1993, J CELL BIOCHEM, V51, P219, DOI 10.1002/jcb.240510214; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Riggott MJ, 1996, J NEUROSCI METH, V68, P235; Rye PD, 2001, TUMOR BIOL, V22, P269, DOI 10.1159/000050626; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Sleister HM, 2002, J IMMUNOL METHODS, V261, P213, DOI 10.1016/S0022-1759(01)00567-1; Soos G, 1997, ANTICANCER RES, V17, P4253; Stocker J W, 1976, Contemp Top Immunobiol, V5, P191; TESTA JE, 1992, CANCER RES, V52, P5597; Testa JE, 1999, CANCER RES, V59, P3812; Wajih N, 2002, CIRC RES, V90, P46, DOI 10.1161/hh0102.102756; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Yammani RR, 2001, J BIOL CHEM, V276, P44777, DOI 10.1074/jbc.M106419200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	106	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1783	1794		10.1038/sj.onc.1206220	http://dx.doi.org/10.1038/sj.onc.1206220			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660814				2022-12-25	WOS:000181678200005
J	Rossman, TG; Visalli, MA; Komissarova, EV				Rossman, TG; Visalli, MA; Komissarova, EV			fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence	ONCOGENE			English	Article						transformation; fau; ubiquitin-like protein; arsenic; hygromycin; ribosomal protein	PROTEIN; ARSENITE; INDUCTION; FUSION; CDNA; GENE; PATHWAYS; SEQUENCE; HOMOLOG; CLONING	Arsenite is the most likely carcinogenic form of arsenic in the environment. Previously, expression cloning for cDNAs whose overexpression confers arsenite-resistance in Chinese hamster V79 cells identified two genes:fau and a novel gene, asr2. The fau gene encodes a ubiquitin-like protein (here called FUBI) fused to the ribosomal S30 protein. Since the expression of the fox sequence (antisense to fau) increased the tumorigenicity of a mouse sarcoma virus, it was proposed that fau might be a tumor suppressor gene. We intended to test its ability to block arsenite-induced transformation of human osteogenic sarcoma (HOS) cells to anchorage-independence. Instead, we found that overexpressing fau itself was able to transform HOS cells. When the two domains were expressed separately, only FUBI was transforming and only the S30 domain conferred arsenite resistance. An incidental finding was the transforming activity of the selectable marker, hyg. FUBI belongs to the ubiquitin-like protein group that is capable of forming conjugates to other proteins, although none have so far been identified. Alternatively, FUBI may act as a substitute or inhibitor of ubiquitin, to which it is most closely related, or to close ubiquitin-like relatives UCRP, FAT10, and/or Nedd8.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; NYU, Sch Med, Inst Canc, Tuxedo Pk, NY 10987 USA	New York University; New York University	Rossman, TG (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	rossman@env.med.nyu.edu		Komissarova, Elena V./0000-0001-6848-0635	NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010344, P30ES000260, R01ES009252] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIEHS NIH HHS [P42 ES10344, R01 ES09252, ES00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; Finkel M P, 1976, Recent Results Cancer Res, P92; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Huang CS, 2001, MOL CELL BIOCHEM, V222, P29, DOI 10.1023/A:1017974131948; Huang SC, 1998, CARCINOGENESIS, V19, P889, DOI 10.1093/carcin/19.5.889; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; MICHIELS L, 1993, ONCOGENE, V8, P2537; Miller AC, 1998, ENVIRON HEALTH PERSP, V106, P465, DOI 10.1289/ehp.98106465; Nakamura M, 1999, J BIOL CHEM, V274, P18026, DOI 10.1074/jbc.274.25.18026; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 1996, J IMMUNOL, V156, P533; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Ramirez P, 1997, MUTAT RES-REV MUTAT, V386, P291, DOI 10.1016/S1383-5742(97)00018-5; RANI AS, 1992, CARCINOGENESIS, V13, P2021, DOI 10.1093/carcin/13.11.2021; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; REDMAN KL, 1996, BIOCHEM J, V315, P21; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; Rossman TG, 2001, ARSENIC EXPOSURE AND HEALTH EFFECTS IV, P285; Sambrook J, 1989, MOL CLONING; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; VOGT B, 2001, MUTAT RES, V478, P59; WANG ZL, 1994, BIOTECHNIQUES, V16, P460; WONG JM, 1993, CANCER RES, V53, P1916; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	48	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1817	1821		10.1038/sj.onc.1206283	http://dx.doi.org/10.1038/sj.onc.1206283			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660817				2022-12-25	WOS:000181678200008
J	Tanuma, N; Shima, H; Shimada, S; Kikuchi, K				Tanuma, N; Shima, H; Shimada, S; Kikuchi, K			Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTP epsilon C	ONCOGENE			English	Article						PTP; PTP epsilon; tumorigenicity; M1	MACROPHAGE DIFFERENTIATION; MICE; M1; TRANSFORMATION; TRANSMEMBRANE; SUPPRESSES; FAMILY	Recently, we reported that a cytosolic isoform of protein-tyrosine phosphatase epsilon (PTPepsilonC), when overexpressed, inhibits terminal differentiation and apoptosis of murine M1 myeloblastic leukemia cells induced by interleukin-6. To determine whether these observed effects in vitro correspond to a tumorigenicity of PTPepsilonC-expresser (M1-epsilonC) cells in vivo, parent M1 and M1-epsilonC cells were intravenously inoculated into scid or nude mice, and survival of mice receiving these cell lines was monitored. Unexpectedly, both scid and nude mice inoculated with M1-epsilonC cells showed significantly prolonged survival time than those receiving parent M1 cells. While parent M1 cells inoculated by intravenous injection formed metastatic tumors in the spleen, expression of PTPepsilonC suppressed tumor development in the spleen. The results suggest a suppressive role of PTPepsilonC in tumorigenesis.	Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Inst Med Genet, Div Immunobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University; Hokkaido University	Kikuchi, K (corresponding author), Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0600815, Japan.	kikuchi@imm.hokudai.ac.jp	Tanuma, Naoyuki/V-7911-2019					Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; McArdle L, 2001, J INVEST DERMATOL, V117, P1255, DOI 10.1046/j.0022-202x.2001.01534.x; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Qiao S, 2001, J BIOL CHEM, V276, P9460, DOI 10.1074/jbc.M008744200; Smith SI, 2000, CANCER RES, V60, P808; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tanuma N, 2001, BLOOD, V98, P3030, DOI 10.1182/blood.V98.10.3030; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Urushibara N, 1998, INT J ONCOL, V12, P603; Warabi M, 2000, EXP MOL PATHOL, V68, P187, DOI 10.1006/exmp.2000.2303; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	25	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1758	1762		10.1038/sj.onc.1206267	http://dx.doi.org/10.1038/sj.onc.1206267			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660811				2022-12-25	WOS:000181678200002
J	Huang, XL; Pawliczak, R; Yao, XL; Cowan, MJ; Gladwin, MT; Walter, MJ; Holtzman, MJ; Madara, P; Logun, C; Shelhamer, JH				Huang, XL; Pawliczak, R; Yao, XL; Cowan, MJ; Gladwin, MT; Walter, MJ; Holtzman, MJ; Madara, P; Logun, C; Shelhamer, JH			Interferon-gamma induces p11 gene and protein expression in human epithelial cells through interferon-gamma-activated sequences in the p11 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ANNEXIN-II TETRAMER; INTERCELLULAR-ADHESION MOLECULE-1; HUMAN EPIDERMAL-KERATINOCYTES; CYTOKINE-INDUCED EXPRESSION; CALCIUM-BINDING PROTEINS; GROWTH-FACTOR-ALPHA; IFN-GAMMA; PROSTAGLANDIN GENERATION; PLASMINOGEN ACTIVATION	The effect of interferon (IFN)-gamma on p11 expression was studied in two human epithelial cell lines (BEAS-2B and HeLa). Treatment with IFN-gamma resulted in increased steady-state levels of p11 mRNA and protein expression, with a time-dependent and dose-dependent effect. Transient transfection experiments of a reporter gene construct containing -1498 bp of the 5'-flanking region of the p11 promoter demonstrated that IFN-gamma induced p11 gene expression at the transcriptional level. These effects were inhibited at the promoter and protein levels by a specific JAK-2 kinase inhibitor, AG-490. Functional analysis of the p11 promoter indicates that two T-activated sequence elements (GAS) located at positions - 1219 and - 1090 are important for the induction of the p11 promoter by IFN-gamma. Transfection of mutated reporter constructs demonstrated that the mutation at the GAS-2 site (-1090) inhibited the p11 promoter activity, with a reduction of about similar to73% and mutation at the GAS-3 site (- 1219) eliminated about 26% of the p11 promoter activity. A STAT1 dominant negative mutant vector at Tyr-701 (JAK kinase phosphorylation site) blocked the effect of IFN-gamma on the p11 promoter activity. IFN-gamma induced a rapid tyrosine phosphorylation and nuclear translocation of STAT1 protein, which is involved in the binding to the GAS-2 site in the p11 promoter by EMSA analysis. These data suggest that IFN-gamma-induced p11 expression is mediated through the binding of STAT1 to GAS sites in the p11 promoter. Inhibition of p11 expression by inhibitory antisense RNAs (iRNA) treatment resulted in enhanced IFN-gamma and calcium ionophor-stimulated arachidonic acid release suggesting that at least in part IFN-gamma-stimulated p11 expression may serve a counterregulatory role.	NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Med Univ Lodz, Dept Clin Immunol & Allergy, PL-92213 Lodz, Poland	National Institutes of Health (NIH) - USA; Washington University (WUSTL); Medical University Lodz	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bldg 10,Rm 7D43,10 Ctr Dr,MSC1662, Bethesda, MD 20892 USA.		Pawliczak, Rafa/S-2021-2019; Pawliczak, Rafal Tomasz/S-9649-2016	Pawliczak, Rafa/0000-0001-6784-453X; 	CLINICAL CENTER [ZIACL000182, Z01CL000182, Z01CL001160] Funding Source: NIH RePORTER	CLINICAL CENTER		Akiba S, 2000, BRIT J PHARMACOL, V131, P1004, DOI 10.1038/sj.bjp.0703637; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; BENNION SD, 1995, J INVEST DERMATOL, V105, pS71, DOI 10.1111/1523-1747.ep12316107; Bovolenta C, 1999, J IMMUNOL, V162, P323; Chun SY, 2001, ENDOCRINOLOGY, V142, P2311, DOI 10.1210/en.142.6.2311; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dolan-O'Keefe M, 2000, AM J PHYSIOL-LUNG C, V278, pL649, DOI 10.1152/ajplung.2000.278.4.L649; Dong YS, 1999, J IMMUNOL, V162, P4731; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gladwin MT, 2000, AM J PHYSIOL-LUNG C, V279, pL1103, DOI 10.1152/ajplung.2000.279.6.L1103; HARDER T, 1992, GENE, V113, P269, DOI 10.1016/0378-1119(92)90406-F; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Lee YJ, 1996, J IMMUNOL, V157, P1559; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MASIAKOWSKI P, 1990, J NEUROSCI RES, V27, P264, DOI 10.1002/jnr.490270304; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; PONZONI M, 1992, FEBS LETT, V310, P17, DOI 10.1016/0014-5793(92)81136-A; PONZONI M, 1993, BIOCHEM J, V294, P893, DOI 10.1042/bj2940893; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	44	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9298	9308		10.1074/jbc.M212704200	http://dx.doi.org/10.1074/jbc.M212704200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645529	hybrid			2022-12-25	WOS:000181524000055
J	Mutalik, VK; Shah, P; Venkatesh, KV				Mutalik, VK; Shah, P; Venkatesh, KV			Allosteric interactions and bifunctionality make the response of glutamine synthetase cascade system of Escherichia coli robust and ultrasensitive	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCONVERTIBLE ENZYME CASCADES; PROTEIN-KINASE CASCADE; SIGNAL-TRANSDUCTION; COVALENT MODIFICATION; METABOLIC-REGULATION; BIOCHEMICAL SYSTEMS; ZERO-ORDER; SENSITIVITY; ADENYLYLATION; STATE	Glutamine synthetase (GS) regulation in Escherichia coli by reversible covalent modification cycles is a prototype of signal transduction by enzyme cascades. Such enzyme cascades are known to exhibit ultrasensitive response to primary stimuli and act as signal integration systems. Here, we have quantified GS bicyclic cascade based on steady state analysis by evaluating Hill coefficient. We demonstrate that adenylylation of GS with glutamine as input is insensitive to total enzyme concentrations of GS, uridylyltransferase/uridylyl-removing enzyme, regulatory protein PII, and adenylyltransferase/adenylyl-removing enzyme. This robust response of GS adenylylation is also observed for change in system parameters. From numerical analyses, we show that the robust ultrasensitive response of bicyclic cascade is because of allosteric interactions of glutamine and 2-ketoglutarate, bifunctionality of converter enzymes, and closed loop bicyclic cascade structure. By system level quantification of the GS bicyclic cascade, we conclude that such a robust response may help the cell in adapting to different carbon and nitrogen status.	Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India; Indian Inst Technol, Dept Chem Engn, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Venkatesh, KV (corresponding author), Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India.	venks@che.iitb.ac.in	Mutalik, Vivek/AAB-6827-2021; Shah, Parag/ABE-5518-2020	Mutalik, Vivek/0000-0001-7934-0400; Shah, Parag/0000-0002-5839-1687				Aon MA, 2001, CELL BIOL INT, V25, P1091, DOI 10.1006/cbir.2001.0804; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; Batchelor E, 2003, P NATL ACAD SCI USA, V100, P691, DOI 10.1073/pnas.0234782100; Berg OG, 2000, BIOPHYS J, V79, P1228, DOI 10.1016/S0006-3495(00)76377-6; CARDENAS ML, 1989, BIOCHEM J, V257, P339, DOI 10.1042/bj2570339; Cardenas ML, 2000, NATO ASI 3 HIGH TECH, V74, P289; CARDENAS ML, 1997, NEW BEER OLD BATTLE, P159; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CHOCK PB, 1990, NATO ADV SCI I A-LIF, V190, P183; CHOCK PB, 1977, P NATL ACAD SCI USA, V74, P2766, DOI 10.1073/pnas.74.7.2766; Cohen, 1983, CONTROL ENZYME ACTIV; Detwiler PB, 2000, BIOPHYS J, V79, P2801, DOI 10.1016/S0006-3495(00)76519-2; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; GOLDBETER A, 1984, J BIOL CHEM, V259, P14441; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KAMBEROV ES, 1995, J BIOL CHEM, V270, P17797, DOI 10.1074/jbc.270.30.17797; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kitano Hiroaki, 2001, P1; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LAPORTE DC, 1983, NATURE, V305, P286, DOI 10.1038/305286a0; Lauffenburger DA, 2000, P NATL ACAD SCI USA, V97, P5031, DOI 10.1073/pnas.97.10.5031; Morohashi M, 2002, J THEOR BIOL, V216, P19, DOI 10.1006/jtbi.2002.2537; MURA U, 1981, J BIOL CHEM, V256, P3022; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; Ortega F, 2002, P NATL ACAD SCI USA, V99, P1170, DOI 10.1073/pnas.022267399; Ortega F, 2002, MOL BIOL REP, V29, P211, DOI 10.1023/A:1020334014497; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; RHEE SG, 1985, CURR TOP CELL REGUL, V27, P221; RHEE SG, 1978, P NATL ACAD SCI USA, V75, P3138, DOI 10.1073/pnas.75.7.3138; SEGAL A, 1974, ARCH BIOCHEM BIOPHYS, V161, P319, DOI 10.1016/0003-9861(74)90267-7; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; SMALL JR, 1990, EUR J BIOCHEM, V191, P405, DOI 10.1111/j.1432-1033.1990.tb19136.x; STADTMAN ER, 1977, P NATL ACAD SCI USA, V74, P2761, DOI 10.1073/pnas.74.7.2761; Stadtman ER, 2001, J BIOL CHEM, V276, P44357, DOI 10.1074/jbc.R100055200; Thattai M, 2002, BIOPHYS J, V82, P2943, DOI 10.1016/S0006-3495(02)75635-X; van Heeswijk WC, 2000, P NATL ACAD SCI USA, V97, P3942, DOI 10.1073/pnas.97.8.3942; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; VANHEESWIJK WC, 1998, THESIS U AMSTERDAM A	47	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26327	26332		10.1074/jbc.M300129200	http://dx.doi.org/10.1074/jbc.M300129200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12676964	hybrid			2022-12-25	WOS:000184155700007
J	Wiley, DJ; Marcus, S; D'Urso, G; Verde, F				Wiley, DJ; Marcus, S; D'Urso, G; Verde, F			Control of cell polarity in fission yeast by association of Orb6p kinase with the highly conserved protein methyltransferase Skb1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; CYCLE; ENCODES; MORPHOGENESIS; INTERACTS; BINDING; GROWTH	In the fission yeast Schizosaccharomyces pombe, proper establishment and maintenance of cell polarity require Orb6p, a highly conserved serine/threonine kinase involved in regulating both cell morphogenesis and cell cycle control. Orb6p localizes to the cell tips during interphase and to the cell septum during mitosis. To investigate the mechanisms involved in Orb6p function, we conducted a two-hybrid screen to identify proteins that interact with Orb6p. Using this approach, we identified Skb1p, a highly conserved protein methyltransferase that has been implicated previously in cell cycle control, in the coordination of cell cycle progression with morphological changes, and in hyperosmotic stress response. We found that Skb1p associates with Orb6p in S. pombe cells and that the two proteins interact directly in vitro. Loss of Skb1p exacerbates the phenotype of orb6 mutants, suggesting that Skb1p and Orb6p functionally interact in S. pombe cells. Our results suggest that Skb1p affects the intracellular localization of Orb6p and that loss of Skb1p leads to a redistribution of the Orb6p kinase away from the cell tips. Furthermore, we found that Orb6p kinase activity is strongly increased following exposure to salt shock, suggesting that Orb6p has a role in cell response to hyperosmotic stress. Previous studies have shown that Skb1p interacts with the fission yeast p21-activated kinase homologue Pak1p/Shk1p to regulate cell polarity and cell cycle progression. Our findings identify Orb6p as an additional target for Skb1p and suggest a novel function for Skb1p in the control of cell polarity by regulating the subcellular localization of Orb6p.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Miami; University of Texas System; UTMD Anderson Cancer Center	Verde, F (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	fverde@miami.edu			NIGMS NIH HHS [R01GM53239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao SL, 2001, J BIOL CHEM, V276, P14549, DOI 10.1074/jbc.C100096200; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DRUBIN DG, 2000, CELL POLARITY; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lew DJ, 2000, CURR OPIN GENET DEV, V10, P47, DOI 10.1016/S0959-437X(99)00051-9; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; MA KJ, 1996, GENE DEV, V10, P1327; Ma XJ, 2000, TRENDS BIOCHEM SCI, V25, P11, DOI 10.1016/S0968-0004(99)01509-1; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; STREIBLOVA E, 1972, Z ALLG MIKROBIOL, V12, P673, DOI 10.1002/jobm.3630120808; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25256	25263		10.1074/jbc.M209703200	http://dx.doi.org/10.1074/jbc.M209703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12646585	hybrid			2022-12-25	WOS:000183824800120
J	Hirata, T; Iwamoto-Kihara, A; Sun-Wada, GH; Okajima, T; Wada, Y; Futai, M				Hirata, T; Iwamoto-Kihara, A; Sun-Wada, GH; Okajima, T; Wada, Y; Futai, M			Subunit rotation of vacuolar-type proton pumping ATPase - Relative rotation of the G and c subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; CROSS-LINKING; MUTATIONAL ANALYSIS; TORQUE GENERATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; GAMMA-SUBUNIT; A3 ISOFORM; V-ATPASE; SYNTHASE	Vacuolar-type ATPases V1V0 (V-ATPases) are found ubiquitously in the endomembrane organelles of eukaryotic cells. In this study, we genetically introduced a His tag and a biotin tag onto the c and G subunits, respectively, of Saccharomyces cerevisiae V-ATPase. Using this engineered enzyme, we observed directly the continuous counter-clockwise rotation of an actin filament attached to the G subunit when the enzyme was immobilized on a glass surface through the c subunit. V-ATPase generated essentially the same torque as the F-ATPase (ATP synthase). The rotation was inhibited by concanamycin and nitrate but not by azide. These results demonstrated that the V- and F-ATPase carry out a common rotational catalysis.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan; Osaka Univ, Inst Sci & Ind Res, Nanosci & Nanotechnol Ctr, Osaka 5670047, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); University of Tokyo	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp		Okajima, Toshihide/0000-0003-1733-9580				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Futai M, 2000, J EXP BIOL, V203, P107; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; HOLLIDAY LS, 2003, CALCIFIED TISSUE INT, V15, P15; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; IHARA K, 1992, J EXP BIOL, V172, P475; Iko Y, 2001, J BIOL CHEM, V276, P47508, DOI 10.1074/jbc.M108803200; Imai-Senga Y, 2002, GENE, V289, P7, DOI 10.1016/S0378-1119(02)00542-5; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; KANE PM, 1989, J BIOL CHEM, V264, P19236; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Murata Y, 2002, J BIOL CHEM, V277, P36296, DOI 10.1074/jbc.M200586200; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Sze H, 2002, TRENDS PLANT SCI, V7, P157, DOI 10.1016/S1360-1385(02)02240-9; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Turina P, 2003, EMBO J, V22, P418, DOI 10.1093/emboj/cdg073; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	58	138	147	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23714	23719		10.1074/jbc.M302756200	http://dx.doi.org/10.1074/jbc.M302756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12670943	hybrid			2022-12-25	WOS:000183638600065
J	Chesneau, V; Becherer, JD; Zheng, YF; Erdjument-Bromage, H; Tempst, P; Blobel, CP				Chesneau, V; Becherer, JD; Zheng, YF; Erdjument-Bromage, H; Tempst, P; Blobel, CP			Catalytic properties of ADAM19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-CONVERTING-ENZYME; METALLOPROTEASE-DISINTEGRIN MDC9; AMYLOID PRECURSOR PROTEIN; OSTEOCLAST DIFFERENTIATION; INTRACELLULAR MATURATION; SECRETASE CLEAVAGE; SURFACE PROTEIN; T-CELLS; MEMBRANE	ADAMs are membrane-anchored glycoproteins with functions in fertilization, heart development, neurogenesis, and protein ectodomain shedding. Here we report an evaluation of the catalytic activity of recombinantly expressed soluble forms of ADAM19, a protein that is essential for cardiovascular morphogenesis. Proteolytic activity of soluble forms of ADAM19 was first demonstrated by their autocatalytic removal of a purification tag (Myc-His) and their ability to cleave myelin basic protein and the insulin B chain. The metalloprotease activity of ADAM19 is sensitive to the hydroxamic acid-type metalloprotease inhibitor BB94 (batimastat) but not to tissue inhibitors of metalloproteases (TIMPs) 1-3. Moreover, ADAM19 cleaves peptides corresponding to the known cleavage sites of tumor necrosis factor-alpha (TNF-alpha), TNF-related activation-induced cytokine (TRANCE, also referred to as osteoprotegerin ligand), and kit ligand-1 (KL-1) in vitro. Although ADAM19 is not required for shedding of TNFalpha and TRANCE in mouse embryonic fibroblasts, its overexpression in COS-7 cells results in strongly increased TRANCE shedding. This suggests a potential role for ADAM19 in shedding TRANCE in cells where both molecules are highly expressed, such as in osteoblasts. Interestingly, our results also indicate that ADAM19 can function as a negative regulator of KL-1 shedding in both COS-7 cells and mouse embryonic fibroblasts, instead of acting directly on KL-1. The identification of potential in vitro substrates offers the basis for further functional studies of ADAM19 in cells and in mice.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; GlaxoSmithKline, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Physiol Biophys & Mol Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; GlaxoSmithKline; Cornell University	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Zheng, Yufang/F-1091-2011	Zheng, Yufang/0000-0002-0488-2624; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; Alfandari D, 2001, CURR BIOL, V11, P918, DOI 10.1016/S0960-9822(01)00263-9; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BLUNDELL TL, 1994, NAT STRUCT BIOL, V1, P73, DOI 10.1038/nsb0294-73; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; Clarke HRG, 1998, PROTEIN EXPRES PURIF, V13, P104, DOI 10.1006/prep.1998.0861; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Faveeuw C, 2001, BLOOD, V98, P688, DOI 10.1182/blood.V98.3.688; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fritsche J, 2000, BLOOD, V96, P732; Gunn TM, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-2; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kaup M, 2002, J BIOL CHEM, V277, P38494, DOI 10.1074/jbc.M203461200; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nath D, 2001, J CELL SCI, V114, P1213; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Sotillos S, 1997, DEVELOPMENT, V124, P4769; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wei P, 2001, BIOCHEM BIOPH RES CO, V280, P744, DOI 10.1006/bbrc.2000.4200; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	78	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22331	22340		10.1074/jbc.M302781200	http://dx.doi.org/10.1074/jbc.M302781200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682046	hybrid			2022-12-25	WOS:000183503900023
J	Gao, F; Bren, N; Little, A; Wang, HL; Hansen, SB; Talley, TT; Taylor, P; Sine, SM				Gao, F; Bren, N; Little, A; Wang, HL; Hansen, SB; Talley, TT; Taylor, P; Sine, SM			Curariform antagonists bind in different orientations to acetylcholine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; NICOTINIC RECEPTORS; MOLECULAR-DYNAMICS; CONFER SELECTIVITY; AUTOMATED DOCKING; SUBUNIT INTERFACE; GAMMA-SUBUNIT; RESIDUES; REVEALS; DOMAIN	Acetylcholine-binding protein (AChBP) recently emerged as a prototype for relating structure to function of the ligand binding domain of nicotinic acetylcholine receptors (AChRs). To understand interactions of competitive antagonists at the atomic structural level, we studied binding of the curare derivatives d-tubocurarine (d-TC) and metocurine to AChBP using computational methods, mutagenesis, and ligand binding measurements. To account for protein flexibility, we used a 2-ns molecular dynamics simulation of AChBP to generate multiple snapshots of the equilibrated dynamic structure to which optimal docking orientations were determined. Our results predict a predominant docking orientation for both d-TC and metocurine, but unexpectedly, the bound orientations differ fundamentally for each ligand. At one subunit interface of AChBP, the side chain of Tyr-89 closely approaches a positively charged nitrogen in d-TC but is farther away from the equivalent nitrogen in metocurine, whereas, at the opposing interface, side chains of Trp-53 and Gln-55 closely approach the metocurine scaffold but not that of d-TC. The different orientations correspond to similar to170degrees rotation and similar to30degrees degree tilt of the curare scaffold within the binding pocket. Mutagenesis of binding site residues in AChBP, combined with measurements of ligand binding, confirms the different docking orientations. Thus structurally similar ligands can adopt distinct orientations at receptor binding sites, posing challenges for interpreting structure-activity relationships for many drugs.	Mayo Clin, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA; Mayo Grad Sch, Biomed Engn Program, Rochester, MN 55905 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Mayo Clinic; Mayo Clinic; University of California System; University of California San Diego	Sine, SM (corresponding author), Mayo Clin, Dept Physiol & Biophys, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	sine@mayo.edu	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947; Little, Alicia/0000-0003-0066-9372	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744, F32NS043063] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744, R37 NS031744, R01 NS031744, F32 NS043063] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Carlson HA, 2000, MOL PHARMACOL, V57, P213; CODDING PW, 1973, ACTA CRYSTALLOGR B, VB 29, P935, DOI 10.1107/S0567740873003663; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FRAENKEL Y, 1994, BIOCHEMISTRY-US, V33, P644, DOI 10.1021/bi00169a004; FU DX, 1994, J BIOL CHEM, V269, P26152; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kua J, 2002, J AM CHEM SOC, V124, P8260, DOI 10.1021/ja020429l; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; LEE BS, 1991, J BIOL CHEM, V266, P11448; Lin JH, 2002, J AM CHEM SOC, V124, P5632, DOI 10.1021/ja0260162; Molles BE, 2002, BIOCHEMISTRY-US, V41, P7895, DOI 10.1021/bi025732d; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; Osterberg F, 2002, PROTEINS, V46, P34, DOI 10.1002/prot.10028; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; SINE SM, 1981, J BIOL CHEM, V256, P6692; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SOBELL HM, 1972, P NATL ACAD SCI USA, V69, P2212, DOI 10.1073/pnas.69.8.2212; Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+; Winget P, 2002, J PHYS CHEM A, V106, P5160, DOI 10.1021/jp020277g	30	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23020	23026		10.1074/jbc.M301151200	http://dx.doi.org/10.1074/jbc.M301151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682067	Green Accepted, hybrid			2022-12-25	WOS:000183503900109
J	Hegde, SS; Blanchard, JS				Hegde, SS; Blanchard, JS			Kinetic and mechanistic characterization of recombinant Lactobacillus viridescens FemX (UDP-N-acetylmuramoyl pentapeptide-lysine N-6-alanyltransferase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CELL WALLS; TRANSFER RIBONUCLEIC ACID; BETA-LACTAM RESISTANCE; STAPHYLOCOCCUS-AUREUS; STREPTOCOCCUS-PNEUMONIAE; INTERPEPTIDE BRIDGES; PEPTIDOGLYCAN; BIOSYNTHESIS; SPECIFICITY; GLYCINE	The FemABX family encodes enzymes that incorporate L-amino acids into the interchain peptide bridge of Gram-positive cell wall peptidoglycan and are novel nonribosomal peptidyl transferases that use aminoacyl-tRNA as the amino acid donor. We previously reported the identification of the femX gene from Lactobacillus viridescens and recombinant expression of active FemX (LvFemX) that catalyzes the transfer of L-Ala from Ala-tRNA(Ala) to the epsilon-amino group of L-lysine of UDP-MurNAc pentapeptide (Hegde, S. S., and Shrader, T. E. (2001) J. Biol. Chem. 276, 6998-7003). Recombinant LvFemX exhibits K-m values of 42 and 15 muM for UDP-MurNAc pentapeptide and Escherichia coli Ala-tRNA(Ala), respectively, and exhibited a k(cat) value of 660 min(-1). Initial velocity and inhibition kinetic studies support an ordered sequential mechanism for the enzyme, and we propose that catalysis proceeds via a ternary complex. The pH dependence of the activity was bell-shaped, depending on the ionization state of two groups exhibiting apparent pK(a) values of 5.5 and 9.3. Chemical modification of the enzyme and the kinetics of inactivation, and protection by substrate, indicated the involvement of carboxyl groups in the catalytic function of the enzyme. Site-directed mutagenesis identified Asp(109) as a candidate for the catalytic base and Glu(320) plays an additional important role in the catalytic function of the enzyme.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Blanchard, JS (corresponding author), Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asahara H, 2002, P NATL ACAD SCI USA, V99, P3499, DOI 10.1073/pnas.052028599; Benson TE, 2002, STRUCTURE, V10, P1107, DOI 10.1016/S0969-2126(02)00807-9; BERGERBACHI B, 1989, MOL GEN GENET, V219, P263; Bouhss A, 2001, J BACTERIOL, V183, P5122, DOI 10.1128/JB.183.17.5122-5127.2001; BOUHSS A, 2002, J BIOL CHEM, V277; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; dePouplana LR, 1997, BIOCHEMISTRY-US, V36, P15041, DOI 10.1021/bi971788+; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; FRACKLYN C, 1989, NATURE, V337, P478; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; Hegde SS, 2001, J BIOL CHEM, V276, P6998, DOI 10.1074/jbc.M008591200; LUNDBLAD RL, 1995, TECHNIQUES PROTEIN M, P233; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PETIT JF, 1968, J BIOL CHEM, V243, P757; PHO DB, 1977, BIOCHEMISTRY-US, V16, P4533; PLAPP R, 1970, J BIOL CHEM, V245, P3667; PLAPP R, 1970, J BIOL CHEM, V245, P3675; ROBERTS WSL, 1968, J BIOL CHEM, V243, P768; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; STRANDEN AM, 1997, J BACTERIOL, V79, P9; Vetting MW, 2002, NAT STRUCT BIOL, V9, P653, DOI 10.1038/nsb830; Weber B, 2000, FEMS MICROBIOL LETT, V188, P81, DOI 10.1016/S0378-1097(00)00214-7	26	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22861	22867		10.1074/jbc.M301565200	http://dx.doi.org/10.1074/jbc.M301565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12679335	hybrid			2022-12-25	WOS:000183503900091
J	Cerosaletti, KM; Concannon, P				Cerosaletti, KM; Concannon, P			Nibrin forkhead-associated domain and breast cancer C-terminal domain are both required for nuclear focus formation and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; S-PHASE CHECKPOINT; DNA-DAMAGE; FHA DOMAIN; MRE11 COMPLEX; BRCT DOMAINS; NBS1 GENE; REPAIR; PROTEIN; KINASE	The Mre11.Rad50.nibrin protein complex plays an essential role in the mammalian cellular response to DNA double-strand breaks. The disorder Nijmegen breakage syndrome (NBS) results from mutations in the NBS1 gene that encodes nibrin, and NBS cells are radiosensitive and defective in S-phase checkpoint activation following irradiation. In response to radiation, nibrin is phosphorylated by Atm, and the Mre11.Rad50.nibrin complex relocalizes to form punctate nuclear foci. The N terminus of nibrin contains a forkhead-associated (FHA) domain and a breast cancer C-terminal (BRCT) domain, the functions of which are unclear. To determine the role of the FHA and BRCT domains in nibrin function, we have performed site-directed mutagenesis of conserved residues in these motifs. Mutations in the nibrin FHA and BRCT domains did not affect interaction with Mre11.Rad50 or nuclear localization of the complex. However, mutation of conserved residues in either domain disrupted nuclear focus formation and blocked nibrin phosphorylation after irradiation, suggesting that these events may be functionally interdependent. Despite an effect on nibrin phosphorylation, expression of the FHA or BRCT mutants in NBS cells restored the downstream phosphorylation of Chk2 and Smc1, necessary for S-phase checkpoint activation. None of the mutations revealed separate functions for the FHA or BRCT domains, suggesting they do not function independently.	Virginia Mason Res Ctr, Mol Genet Program, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98101 USA	Virginia Mason Medical Center; University of Washington; University of Washington Seattle	Concannon, P (corresponding author), Virginia Mason Res Ctr, Mol Genet Program, 1201 9th Ave, Seattle, WA 98101 USA.			Concannon, Patrick/0000-0002-5801-1859	NCI NIH HHS [CA 57569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2000, MUTAGENESIS, V15, P281, DOI 10.1093/mutage/15.3.281; Cerosaletti KM, 2002, GENE CHROMOSOME CANC, V35, P282, DOI 10.1002/gcc.10114; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lombard DB, 2000, CANCER RES, V60, P2331; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Resnick IB, 2002, J PEDIATR-US, V140, P355, DOI 10.1067/mpd.2002.122724; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Y, 2000, GENE DEV, V14, P927; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	39	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21944	21951		10.1074/jbc.M211689200	http://dx.doi.org/10.1074/jbc.M211689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12679336	hybrid			2022-12-25	WOS:000183354200080
J	Grimm, C; Kraft, R; Sauerbruch, S; Schultz, G; Harteneck, C				Grimm, C; Kraft, R; Sauerbruch, S; Schultz, G; Harteneck, C			Molecular and functional characterization of the melastatin-related cation channel TRPM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL; SECONDARY HYPOCALCEMIA; RECEPTOR; PROTEIN; FAMILY; LTRPC2; CELLS; IDENTIFICATION; HYPOMAGNESEMIA; MELANOMA	Proteins of the mammalian TRP ( transient receptor potential) family form a heterogenous group of cation channels important for cellular Ca2+ signaling and homeostasis. Here we present the full- length sequence of TRPM3, a member of the melastatin- like subfamily ( TRPM) of TRP channels. TRPM3 expression was found in human kidney and brain. HEK293 cells transiently transfected with TRPM3 showed a constitutive Ca2+ and Mn2+ entry. Whole- cell patch clamp experiments confirmed the spontaneous activity of TRPM3 and revealed permeability ratios P-Ca/P-Na of 1.57 and P-Na/P-Cs of 0.75. In cell- attached patches, spontaneous inward and outward currents were observed. At negative membrane potentials and in the presence of either 140 mM Cs+, 140 mM Na+, or 100 mM Ca2+ in the pipette solution, the single channel conductance levels were 133, 83, and 65 pS, respectively. The Ca2+ entry in TRPM3- expressing HEK293 cells increased during treatment with hypotonic extracellular solution. The reduction of extracellular osmolarity was accompanied by cell swelling, suggesting volume- regulated activity of TRPM3. From its function and expression in human kidney, we propose a role of TRPM3 in renal Ca2+ homeostasis.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Free Univ Berlin, Fachbereich Biol Chem Pharm, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Harteneck, C (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.		Kraft, Robert/E-9199-2011; Grimm, Christian/ABF-9121-2020	Kraft, Robert/0000-0002-5774-6001; Grimm, Christian/0000-0002-0177-5559				Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Duncan LM, 1998, CANCER RES, V58, P1515; Duncan LM, 2001, J CLIN ONCOL, V19, P568, DOI 10.1200/JCO.2001.19.2.568; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198	30	246	264	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21493	21501		10.1074/jbc.M300945200	http://dx.doi.org/10.1074/jbc.M300945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672799	hybrid			2022-12-25	WOS:000183354200024
J	Hatta, T; Mukerjee-Dhar, G; Damborsky, J; Kiyohara, H; Kimbara, K				Hatta, T; Mukerjee-Dhar, G; Damborsky, J; Kiyohara, H; Kimbara, K			Characterization of a novel thermostable Mn(II)-dependent 2,3-dihydroxybiphenyl 1,2-dioxygenase from a polychlorinated biphenyl- and naphthalene-degrading Bacillus sp JF8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; ACTIVE-SITE; CATECHOL 2,3-DIOXYGENASE; 3,4-DIHYDROXYPHENYLACETATE 2,3-DIOXYGENASE; PSEUDOMONAS-PSEUDOALCALIGENES; EVOLUTIONARY RELATIONSHIPS; CHLORINE SUBSTITUTION; EXTRADIOL DIOXYGENASE; CRYSTAL-STRUCTURE; KEY ROLE	A novel thermostable Mn( II)- dependent 2,3- dihydroxybiphenyl-1,2- dioxygenase ( BphC_ JF8) catalyzing the meta-cleavage of the hydroxylated biphenyl ring was purified from the thermophilic biphenyl and naphthalene degrader, Bacillus sp. JF8, and the gene was cloned. The native and recombinant BphC enzyme was purified to homogeneity. The enzyme has a molecular mass of 125 +/- 10 kDa and was composed of four identical subunits ( 35 kDa). BphC_ JF8 has a temperature optimum of 85 degreesC and a pH optimum of 7.5. It exhibited a half- life of 30 min at 80degreesC and 81 min at 75degreesC, making it the most thermostable extradiol dioxygenase studied. Inductively coupled plasma mass spectrometry analysis confirmed the presence of 4.0 - 4.8 manganese atoms per enzyme molecule. The EPR spectrum of BphC_ JF8 exhibited g = 2.02 and g = 4.06 signals having the 6- fold hyperfine splitting characteristic of Mn( II). The enzyme can oxidize a wide range of substrates, and the substrate preference was in the order 2,3- dihydroxybiphenyl > 3- methylcatechol > catechol > 4- methylcatechol > 4- chlorocatechol. The enzyme is resistant to denaturation by various chelators and inhibitors ( EDTA, 1,10- phenanthroline, H2O2, 3- chlorocatechol) and did not exhibit substrate inhibition even at 3 mM 2,3- dihydroxybiphenyl. A decrease in Km accompanied an increase in temperature, and the K-m value of 0.095 muM for 2,3- dihydroxybiphenyl ( at 60degreesC) is among the lowest reported. The kinetic properties and thermal stability of the native and recombinant enzyme were identical. The primary structure of BphC_ JF8 exhibits less than 25% sequence identity to other 2,3- dihydroxybiphenyl 1,2- dioxygenases. The metal ligands and active site residues of extradiol dioxygenases are conserved, although several amino acid residues found exclusively in enzymes that preferentially cleave bicyclic substrates are missing in BphC_ JF8. A three- dimensional homology model of BphC_ JF8 provided a basis for understanding the substrate specificity, quaternary structure, and stability of the enzyme.	Okayama Univ Sci, Res Inst Technol, Okayama 7038232, Japan; Railway Tech Res Inst, Environm Biotechnol Lab, Tokyo 1858540, Japan; Masaryk Univ, Natl Ctr Biomol Res, CS-61137 Brno, Czech Republic	Okayama University of Science; Masaryk University Brno	Hatta, T (corresponding author), Okayama Univ Sci, Res Inst Technol, 401-1 Seki, Okayama 7038232, Japan.	thatta@po.harenet.ne.jp	Damborsky, Jiri/H-3799-2012	Damborsky, Jiri/0000-0002-7848-8216				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARENSDORF JJ, 1994, APPL ENVIRON MICROB, V60, P2884, DOI 10.1128/AEM.60.8.2884-2889.1994; Arnott MA, 2000, J MOL BIOL, V304, P657, DOI 10.1006/jmbi.2000.4240; ASTURIAS JA, 1993, J BACTERIOL, V175, P4631, DOI 10.1128/JB.175.15.4631-4640.1993; ASTURIAS JA, 1994, J BIOL CHEM, V269, P7807; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; Bergdoll M, 1998, PROTEIN SCI, V7, P1661, DOI 10.1002/pro.5560070801; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; BOLIN JT, 2001, HDB METALLOPROTEINS, P632; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDIDUS S, 1994, MICROBIOL-SGM, V140, P321, DOI 10.1099/13500872-140-2-321; CERDAN P, 1994, J BACTERIOL, V176, P6074, DOI 10.1128/jb.176.19.6074-6081.1994; CHEN CI, 1995, BIOTECHNOL BIOENG, V48, P614, DOI 10.1002/bit.260480609; Choo DW, 1998, APPL ENVIRON MICROB, V64, P486; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DONG FM, 1992, APPL ENVIRON MICROB, V58, P2531, DOI 10.1128/AEM.58.8.2531-2535.1992; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; Eltis LD, 1996, J BACTERIOL, V178, P5930, DOI 10.1128/jb.178.20.5930-5937.1996; ELTIS LD, 1993, J BIOL CHEM, V268, P2727; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; FURUKAWA K, 1979, APPL ENVIRON MICROB, V38, P301, DOI 10.1128/AEM.38.2.301-310.1979; FURUKAWA K, 1987, J BACTERIOL, V169, P924, DOI 10.1128/jb.169.2.924-927.1987; GIBELLO A, 1994, BIOCHEM J, V301, P145, DOI 10.1042/bj3010145; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GURUJEYALAKSHMI G, 1989, APPL ENVIRON MICROB, V55, P500, DOI 10.1128/AEM.55.2.500-502.1989; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HARAYAMA S, 1989, J BIOL CHEM, V264, P15328; HE ZQ, 1995, CHIN J BIOCH, V11, P114; HEISS G, 1995, J BACTERIOL, V177, P5865, DOI 10.1128/jb.177.20.5865-5871.1995; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; Hsieh YS, 1998, BIOCHEMISTRY-US, V37, P4731, DOI 10.1021/bi972395d; JOHNSON JL, 1994, SIMILARITY ANAL DNAS; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Khan AA, 1996, APPL ENVIRON MICROB, V62, P1825, DOI 10.1128/AEM.62.5.1825-1830.1996; Kita A, 1999, STRUCTURE, V7, P25, DOI 10.1016/S0969-2126(99)80006-9; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maliekal J, 2002, J AM CHEM SOC, V124, P15064, DOI 10.1021/ja027319z; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079, DOI 10.1128/AEM.61.6.2079-2085.1995; Milo RE, 1999, EXTREMOPHILES, V3, P185, DOI 10.1007/s007920050115; Mukerjee-Dhar G, 1998, ARCH MICROBIOL, V169, P61; Mutzel A, 1996, APPL MICROBIOL BIOT, V46, P593, DOI 10.1007/s002530050866; Natarajan M. R., 1994, Biodegradation, V5, P77, DOI 10.1007/BF00700632; Ogata K, 1997, PROTEIN ENG, V10, P353, DOI 10.1093/protein/10.4.353; QUE L, 1981, J BIOL CHEM, V256, P941; REED GH, 1971, BIOCHEMISTRY-US, V10, P3190, DOI 10.1021/bi00793a005; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; Rost B, 1996, METHOD ENZYMOL, V266, P525; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santos R, 1999, J BACTERIOL, V181, P4509, DOI 10.1128/JB.181.15.4509-4516.1999; SEEGER M, 1995, APPL ENVIRON MICROB, V61, P2654, DOI 10.1128/AEM.61.7.2654-2658.1995; Senda T, 1996, J MOL BIOL, V255, P735, DOI 10.1006/jmbi.1996.0060; Shimura M, 1999, FEMS MICROBIOL LETT, V178, P87, DOI 10.1111/j.1574-6968.1999.tb13763.x; SONDOSSI M, 1992, APPL ENVIRON MICROB, V58, P485, DOI 10.1128/AEM.58.2.485-495.1992; STELLWAG.E, 1973, BIOCHEMISTRY-US, V12, P1552, DOI 10.1021/bi00732a014; SUZUKI Y, 1989, P JPN ACAD B-PHYS, V65, P146, DOI 10.2183/pjab.65.146; SUZUKI Y, 1987, APPL MICROBIOL BIOT, V26, P546, DOI 10.1007/BF00253030; TAIRA K, 1992, J BIOL CHEM, V267, P4844; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaillancourt FH, 1998, J BIOL CHEM, V273, P34887, DOI 10.1074/jbc.273.52.34887; Vaillancourt FH, 2002, J BIOL CHEM, V277, P2019, DOI 10.1074/jbc.M106890200; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Vieille C, 1996, Biotechnol Annu Rev, V2, P1, DOI 10.1016/S1387-2656(08)70006-1; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Xie J, 2002, J AM CHEM SOC, V124, P3769, DOI 10.1021/ja016254h; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	77	50	56	5	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21483	21492		10.1074/jbc.M210240200	http://dx.doi.org/10.1074/jbc.M210240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672826	hybrid			2022-12-25	WOS:000183354200023
J	Miller, WE; Houtz, DA; Nelson, CD; Kolattukudy, PE; Lefkowitz, RJ				Miller, WE; Houtz, DA; Nelson, CD; Kolattukudy, PE; Lefkowitz, RJ			G-protein-coupled receptor (GPCR) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; CHEMOKINE RECEPTOR; KAPOSIS-SARCOMA; MURINE CYTOMEGALOVIRUS; SELECTIVE REGULATION; CC-CHEMOKINES; DESENSITIZATION; ENDOCYTOSIS; IDENTIFICATION; EXPRESSION	Phosphorylation of G- protein- coupled receptors ( GPCRs) by GRKs and subsequent recruitment of beta- arrestins to agonist- occupied receptors serves to terminate or attenuate signaling by blocking G- proteins from further interaction with the receptors. Human cytomegalovirus encodes a GPCR termed US28 that is homologous to the human chemokine family of GPCRs but differs from the cellular receptors in that it maintains high constitutive activity in the absence of agonist. Although US28 is constitutively active, mechanisms that regulate this activity are unknown. We provide evidence that US28 is constitutively phosphorylated by GRKs in cells and that in consequence, beta- arrestin 2 is localized to the plasma membrane. Deletion of the carboxyl terminal 40 amino acids in US28 generates a receptor that is severely impaired in its ability to become phosphorylated and recruit beta- arrestin and accordingly demonstrates increased inositol phosphate signaling. This result indicates that the carboxyl terminus of US28 contains an important signaling regulatory region and mutational analysis deleting carboxyl terminal serines identified serine 323 as a critical residue within this region. In addition, overexpression of wild type GRK5 leads to hyperphosphorylation of US28 that results in a decrease of inositol phosphate accumulation. These results are consistent with the hypothesis that GRK phosphorylation and recruitment of beta- arrestin to the US28 viral GPCR attenuates signaling to the traditional Galpha(q)- stimulated inositol phosphate pathway. Finally, in contrast to the results with inositol phosphate signaling, we provide evidence that the US28 carboxyl- terminal phosphorylation sites and beta- arrestin- interacting domain are required for maximal activation of the p38 mitogen-activated protein kinase. Taken together, these results indicate that US28 interacts with these important regulatory proteins to control multiple aspects of signal transmission. Understanding the regulation of viral GPCRs by GRKs and beta- arrestins will provide important new insights into not only aspects of viral pathogenesis but also basic mechanisms of receptor signaling.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; University of Cincinnati; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University	Miller, WE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		kolattukudy, pappachan e/A-1350-2012; Lefkowitz, Robert/AAW-2649-2021	Miller, William/0000-0001-6900-4884	NHLBI NIH HHS [HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 1998, J VIROL, V72, P2352, DOI 10.1128/JVI.72.3.2352-2363.1998; Beisser PS, 2002, CURR TOP MICROBIOL, V269, P203; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Davis-Poynter NJ, 1999, INTERVIROLOGY, V42, P331, DOI 10.1159/000053969; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; GAO JL, 1994, J BIOL CHEM, V269, P28539; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Randolph-Habecker J, 2002, CYTOKINE, V19, P37, DOI 10.1006/cyto.2002.0874; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Sallese M, 2001, TRENDS PHARMACOL SCI, V22, P168, DOI 10.1016/S0165-6147(00)01641-2; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002	59	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21663	21671		10.1074/jbc.M303219200	http://dx.doi.org/10.1074/jbc.M303219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668664	hybrid			2022-12-25	WOS:000183354200045
J	Rylott, EL; Rogers, CA; Gilday, AD; Edgell, T; Larson, TR; Graham, IA				Rylott, EL; Rogers, CA; Gilday, AD; Edgell, T; Larson, TR; Graham, IA			Arabidopsis mutants in short- and medium-chain acyl-CoA oxidase activities accumulate acyl-CoAs and reveal that fatty acid beta-oxidation is essential for embryo development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL PROTEINS; LIPID MOBILIZATION; PLANTS; PATHWAYS; GENES; TRIACYLGLYCEROL; GERMINATION; METABOLISM; NUMBER; ALPHA	The short- chain acyl- CoA oxidase ( ACX4) is one of a family of ACX genes that together catalyze the first step of peroxisomal fatty acid beta- oxidation during early, post-germinative growth in oilseed species. Here we have isolated and characterized an Arabidopsis thaliana mutant containing a T- DNA insert in ACX4. In acx4 seedlings, short- chain acyl- CoA oxidase activity was reduced by greater than 98%, whereas medium- chain activity was unchanged from wild type levels. Despite the almost complete loss of short- chain activity, lipid catabolism and seedling growth and establishment were unaltered in the acx4 mutant. However, the acx4 seedlings accumulated high levels ( 31 mol %) of short- chain acyl- CoAs and showed resistance to 2,4- dichlorophenoxybutyric acid, which is converted to the herbicide and auxin analogue 2,4- dichlorophenoxyacetic acid by beta- oxidation. A mutant in medium- chain length acyl- CoA activity ( acx3) ( 1) shows a similar phenotype to acx4, and we show here that acx3 seedlings accumulate medium- chain length acyl- CoAs ( 16.4 mol %). The acx3 and acx4 mutants were crossed together, and remarkably, the acx3acx4 double mutants aborted during the first phase of embryo development. We propose that acx3acx4 double mutants are nonviable because they have a complete block in short-chain acyl- CoA oxidase activity. This is the first demonstration of the effects of eliminating ( short- chain) beta- oxidation capacity in plants and shows that a functional beta- oxidation cycle is essential in the early stages of embryo development.	Univ York, Dept Biol, CNAP, York YO10 5YW, N Yorkshire, England	University of York - UK	Graham, IA (corresponding author), Univ York, Dept Biol, CNAP, POB 373, York YO10 5YW, N Yorkshire, England.	iag1@york.ac.uk	Larson, Tony/AAI-4782-2020; Rylott, Elizabeth L/A-6059-2012	Larson, Tony/0000-0003-1337-3482; Rylott, Elizabeth L/0000-0002-1609-414X				Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Chang CC, 1999, J CELL SCI, V112, P1579; CHU CH, 1994, BIOCHEM J, V302, P23, DOI 10.1042/bj3020023; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; DIEUAIDE M, 1992, PLANT PHYSIOL, V99, P595, DOI 10.1104/pp.99.2.595; Eastmond PJ, 2000, BIOCHEM SOC T, V28, P95, DOI 10.1042/bst0280095; Eastmond PJ, 2000, J BIOL CHEM, V275, P34375, DOI 10.1074/jbc.M004945200; Eastmond PJ, 2000, BIOCHEM SOC T, V28, P755, DOI 10.1042/BST0280755; Eccleston VS, 1998, PLANT CELL, V10, P613, DOI 10.1105/tpc.10.4.613; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; Footitt S, 2002, EMBO J, V21, P2912, DOI 10.1093/emboj/cdf300; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; Froman BE, 2000, PLANT PHYSIOL, V123, P733, DOI 10.1104/pp.123.2.733; Germain V, 2001, PLANT J, V28, P1, DOI 10.1046/j.1365-313X.2001.01095.x; Graham IA, 2002, BIOCHEM SOC T, V30, P1095, DOI 10.1042/BST0301095; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Hayashi H, 1999, J BIOL CHEM, V274, P12715, DOI 10.1074/jbc.274.18.12715; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Hayashi M, 2002, PLANT CELL PHYSIOL, V43, P1, DOI 10.1093/pcp/pcf023; HOLTMAN WL, 1994, PLANT SCI, V99, P43, DOI 10.1016/0168-9452(94)90119-8; Hooks MA, 1999, PLANT J, V20, P1, DOI 10.1046/j.1365-313X.1999.00559.x; HOOKS MA, 1995, PHYTOCHEMISTRY, V40, P657, DOI 10.1016/0031-9422(95)98169-H; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JURGENS G, 1994, ARABIDOPSIS EMBRYOS; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; KINDL H, 1987, BIOCH PLANTS, V9, P31; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; LANGE PR, 1998, ADV PLANT LIPID RES, P343; Larson TR, 2002, PLANT J, V32, P519, DOI 10.1046/j.1365-313X.2002.01440.x; Larson TR, 2001, PLANT J, V25, P115, DOI 10.1046/j.1365-313x.2001.00929.x; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; Logemann E, 2000, P NATL ACAD SCI USA, V97, P1903, DOI 10.1073/pnas.97.4.1903; Logemann E, 2002, P NATL ACAD SCI USA, V99, P2428, DOI 10.1073/pnas.042692199; Miersch O, 2000, BIOL CHEM, V381, P715, DOI 10.1515/BC.2000.092; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Olesen C, 1997, FEBS LETT, V412, P138, DOI 10.1016/S0014-5793(97)00766-7; Richmond TA, 1999, PLANT CELL, V11, P1911, DOI 10.1105/tpc.11.10.1911; Rylott EL, 2001, BIOCHEM SOC T, V29, P283, DOI 10.1042/BST0290283; Smith JJ, 2000, J BIOL CHEM, V275, P20168, DOI 10.1074/jbc.M909285199; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wolf G, 1998, NUTR REV, V56, P61, DOI 10.1111/j.1753-4887.1998.tb01693.x	48	85	89	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21370	21377		10.1074/jbc.M300826200	http://dx.doi.org/10.1074/jbc.M300826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682048	hybrid			2022-12-25	WOS:000183354200010
J	Sharma, GD; He, JC; Bazan, HEP				Sharma, GD; He, JC; Bazan, HEP			p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing - Evidence of cross-talk activation between MAP kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATINOCYTE GROWTH-FACTOR; PROTEIN-KINASE; IN-VITRO; PATHWAY; CELLS; EXPRESSION; HGF; KGF; INHIBITION; APOPTOSIS	One important action of growth factors is their participation in tissue repair; however, the signaling pathways involved are poorly understood. In a model of corneal wound healing, we found that two paracrine growth factors, hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF), induced rapid and marked activation and prompt nuclear accumulation of phospho-p38 (p-p38) and -ERK1/2 (p-ERK1/2), but not of JNK (p-JNK1/2), in corneal epithelial cells. Interruption of p38 and ERK1/2 signaling pathways by pretreatment with inhibitors SB203580 and PD98059 and subsequent stimulation with HGF or KGF abolished the activation and nuclear localization. Inhibition of either one of these mitogen-activated protein kinases, p38 or ERK1/2, induced a robust cross-activation of the other. In immunofluorescence studies of wounded cornea, p-p38, unlike p-ERK1/2, was immediately detectable in epithelium after injury. Inhibition of p38 by SB203580 blocked migration of epithelial cells almost completely. In contrast, PD98059 seemed to slightly increase the migration, through concomitant activation of p38. Unlike ERK1/2, p38 did not significantly contribute to proliferation of epithelial cells. Inhibition of either the ERK1/2 or p38 pathway resulted in delayed corneal epithelial wound healing. Interruption of both signaling cascades additively inhibited the wound-healing process. These findings demonstrate that both p38 and ERK1/2 coordinate the dynamics of wound healing: while growth factor-stimulated p38 induces epithelial migration, ERK1/2 activation induces proliferation. The cross-talk between these two signal cascades and the selective action of p38 in migration appear to be important to corneal wound healing, and possibly wound healing in general, and may offer novel drug targets for tissue repair.	Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Bazan, HEP (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.				NATIONAL EYE INSTITUTE [P30EY002377, R01EY006635] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 06635, P30 EY 02377] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BRAZZELL RK, 1991, INVEST OPHTH VIS SCI, V32, P336; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Chandrasekher G, 2002, INVEST OPHTH VIS SCI, V43, P1422; Chandrasekher G, 2001, EXP EYE RES, V73, P191, DOI 10.1006/exer.2001.1026; Chandrasekher G, 1999, CURR EYE RES, V18, P168, DOI 10.1076/ceyr.18.3.168.5372; Chung EH, 1999, INVEST OPHTH VIS SCI, V40, P1952; Edin ML, 2001, EXP CELL RES, V270, P214, DOI 10.1006/excr.2001.5345; Foreman DM, 1996, EXP EYE RES, V62, P555, DOI 10.1006/exer.1996.0065; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hurst J, 1999, INVEST OPHTH VIS SCI, V40, P790; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Imanishi J, 2000, PROG RETIN EYE RES, V19, P113, DOI 10.1016/S1350-9462(99)00007-5; Joyce NC, 1996, INVEST OPHTH VIS SCI, V37, P645; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Rieck PW, 2001, EXP EYE RES, V73, P639, DOI 10.1006/exer.2001.1067; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schilling-Schon A, 2000, EXP EYE RES, V71, P583, DOI 10.1006/exer.2000.0918; SOTOZONO C, 1995, INVEST OPHTH VIS SCI, V36, P1524; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Tangkijvanich P, 2002, J CELL PHYSIOL, V191, P351, DOI 10.1002/jcp.10112; Wilson SE, 1999, EXP EYE RES, V68, P377, DOI 10.1006/exer.1998.0603; WILSON SE, 1994, EXP EYE RES, V59, P665, DOI 10.1006/exer.1994.1152; WILSON SE, 1993, INVEST OPHTH VIS SCI, V34, P2544; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X	30	280	290	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21989	21997		10.1074/jbc.M302650200	http://dx.doi.org/10.1074/jbc.M302650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663671	hybrid			2022-12-25	WOS:000183354200085
J	Ashby, MC; Camello-Almaraz, C; Gerasimenko, OV; Petersen, OH; Tepikin, AV				Ashby, MC; Camello-Almaraz, C; Gerasimenko, OV; Petersen, OH; Tepikin, AV			Long distance communication between muscarinic receptors and Ca2+ release channels revealed by carbachol uncaging in cell-attached patch pipette	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; POLARIZED EXPRESSION; RYANODINE RECEPTORS; EXOCRINE PANCREAS; CALCIUM; OSCILLATIONS; MITOCHONDRIA; SIGNALS	We have investigated the characteristics of cytosolic Ca2+ signals induced by muscarinic receptor activation of pancreatic acinar cells that reside within intact pancreatic tissue. We show that these cells exhibit global Ca2+ waves and local apical Ca2+ spikes. This is the first evidence for local Ca2+ signaling in undissociated pancreatic tissue. The mechanism of formation of localized Ca2+ signals was examined using a novel approach involving photolysis of caged carbachol inside a patch pipette attached to the basal surface of an acinar unit. This local activation of basal muscarinic receptors elicited local cytosolic Ca2+ spikes in the apical pole more than 15 mum away from the site of stimulation. In some experiments, local basal receptor activation elicited a Ca2+ wave that started in the apical pole and then spread toward the base. Currently, there are two competing hypotheses for preferential apical Ca2+ signaling. One invokes the need for structural proximity of the cholinergic receptors and the Ca2+ release channels in the apical pole, whereas the other postulates long distance communication between basal receptors and the channels. Our intrapipette uncaging experiments provide definitive evidence for long distance communication between basal muscarinic receptors and apical Ca2+ release channels.	Univ Liverpool, MRC, Secretory Control Res Grp, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Ashby, MC (corresponding author), Univ Bristol, Sch Med, Dept Anat, Ctr Synapt Plastic, Univ Walk, Bristol BS8 1TD, Avon, England.		Petersen, Ole H/E-8708-2010; Gerasimenko, Oleg/A-6622-2010; Camello, Cristina/K-8238-2014	Gerasimenko, Oleg/0000-0003-2573-8258; Camello, Cristina/0000-0003-0882-8497; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513; Ashby, Michael/0000-0002-8593-8473				Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; Ashby MC, 2002, J CELL BIOL, V158, P283, DOI 10.1083/jcb.200112025; Bootman MD, 2001, J CELL SCI, V114, P2213; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Meldolesi J, 2001, PROG NEUROBIOL, V65, P309, DOI 10.1016/S0301-0082(01)00004-1; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Motta PM, 1997, MICROSC RES TECHNIQ, V37, P384, DOI 10.1002/(SICI)1097-0029(19970601)37:5/6<384::AID-JEMT3>3.3.CO;2-L; NIELSEN SP, 1972, J PHYSIOL-LONDON, V223, P685, DOI 10.1113/jphysiol.1972.sp009869; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Thomason PA, 2002, CURR BIOL, V12, pR399, DOI 10.1016/S0960-9822(02)00885-0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9	31	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20860	20864		10.1074/jbc.M302599200	http://dx.doi.org/10.1074/jbc.M302599200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657637	hybrid			2022-12-25	WOS:000183230500055
J	Fasolini, M; Wu, XQ; Flocco, M; Trosset, JY; Oppermann, U; Knapp, S				Fasolini, M; Wu, XQ; Flocco, M; Trosset, JY; Oppermann, U; Knapp, S			Hot spots in Tcf4 for the interaction with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; PROTEIN INTERFACES; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; COMPLEX; BINDING; THERMODYNAMICS; CADHERIN; EFFECTOR; ICAT	The interaction of beta-catenin with T-cell factor (Tcf) 4 plays a central role in the Wnt signaling pathway and has been discussed as a possible site of intervention for the development of anti-cancer drugs. In this study, we performed Ala-scanning mutagenesis of all Tcf4 residues in the Tcf-beta-catenin interface and studied the binding energetics of these mutants using isothermal titration calorimetry. Binding of Tcf4 was found to be highly cooperative. Single site mutations of most Tcf4 residues resulted in a significant reduction in binding enthalpies but in similar binding constants as compared with wild type Tcf4. Interestingly, this was also true for residues that are disordered in the reported crystal structures. The mutation D16A caused the largest reduction in binding constant (50-fold) accompanied by a large unfavorable enthalpy change (DeltaDeltaH(obs)) of +8 kcal/mol at 25 degreesC. In contrast, the mutation of the Tcf residues Glu(24) and Glu(28), which have been proposed as an interaction hot spot due to their location in a field of strong positive electrostatic potential on the beta-catenin surface ( charge button), resulted only in a significant reduction of binding enthalpies, which were largely compensated for by unfavorable entropic contributions to the binding. Other mutations that significantly reduced Tcf binding constants were D11A and alanine mutations of the hydrophobic residues Leu(41), Val(44), and Leu(48). The measured thermodynamic data are discussed with the available structural information of Tcf-beta-catenin crystal structures and allow us to propose possible sites for development of Tcf antagonists.	Pharmacia Corp, Discovery Res Oncol, Dept Chem, I-20014 Nerviano, Italy; Karolinska Inst, S-17177 Stockholm, Sweden	Pfizer; Karolinska Institutet	Knapp, S (corresponding author), Pharmacia Corp, Discovery Res Oncol, Dept Chem, Viale Pasteur 10, I-20014 Nerviano, Italy.		Knapp, Stefan/AAG-2347-2019	Knapp, Stefan/0000-0001-5995-6494				Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Berglund H, 1995, J AM CHEM SOC, V117, P12883, DOI 10.1021/ja00156a036; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; CARLSON M, 1991, J APPL CRYSTALLOGR, V24, P958; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; Frisch C, 1997, J MOL BIOL, V267, P696, DOI 10.1006/jmbi.1997.0892; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; Lundback T, 1998, J MOL BIOL, V276, P775, DOI 10.1006/jmbi.1997.1558; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sheinerman FB, 2002, J MOL BIOL, V318, P161, DOI 10.1016/S0022-2836(02)00030-X; Shih IM, 2000, CANCER RES, V60, P1671; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	32	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21092	21098		10.1074/jbc.M301781200	http://dx.doi.org/10.1074/jbc.M301781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657632	hybrid			2022-12-25	WOS:000183230500084
J	Kubota, H; Obata, T; Ota, K; Sasaki, T; Ito, T				Kubota, H; Obata, T; Ota, K; Sasaki, T; Ito, T			Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha kinase GCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 2-ALPHA KINASE; GI DOMAIN; INITIATION; TOR; PHOSPHORYLATION; YEAST; EXPRESSION; STARVATION; BINDING	When starved for amino acids, Saccharomyces cerevisiae accumulates uncharged tRNAs to activate its sole eukaryotic initiation factor (eIF) 2alpha kinase GCN2. Subsequent phosphorylation of eIF2alpha impedes general translation, but translationally derepresses the transcription factor GCN4, which induces expression of various biosynthetic genes to elicit general amino acid control response. By contrast, when supplied with enough nutrients, the yeast activates the target of rapamycin signaling pathway to stimulate translation initiation by facilitating the assembly of eIF4F. A cross-talk was suggested between the two pathways by rapamycin-induced translation of GCN4 mRNA. Here we show that rapamycin causes an increase in phosphorylated eIF2alpha to translationally derepress GCN4. This increment is not observed in the cells expressing mammalian non-GCN2 eIF2alpha kinases in place of GCN2. It is thus suggested that rapamycin does not inhibit dephosphorylation of eIF2alpha but rather activates the kinase GCN2. This activation seems to require an interaction between the kinase and uncharged tRNAs, because rapamycin, similar to amino acid starvation, fails to induce eIF2alpha phosphorylation in the cells with GCN2 defective in tRNA binding. However, in contrast with amino acid starvation, rapamycin activates GCN2 without increasing the amount of uncharged tRNAs, but presumably by modifying the tRNA binding affinity of GCN2.	Kanazawa Univ, Div Genome Biol, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Div Expt Therapeut, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Ctr Dev Mol Target Drugs, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; JST, BIRD, Chiyoda Ku, Tokyo 1020081, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Japan Science & Technology Agency (JST)	Ito, T (corresponding author), Kanazawa Univ, Div Genome Biol, Inst Canc Res, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	titolab@kenroku.kanazawa-u.ac.jp		Ito, Takashi/0000-0001-6097-2803; OBATA, TOHRU/0000-0002-7376-0110				Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Ashe MP, 2001, EMBO J, V20, P6464, DOI 10.1093/emboj/20.22.6464; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Garcia-Barrio M, 2002, J BIOL CHEM, V277, P30675, DOI 10.1074/jbc.M203187200; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Kimball SR, 2001, BIOCHEM BIOPH RES CO, V280, P293, DOI 10.1006/bbrc.2000.4103; Kubota H, 2001, J BIOL CHEM, V276, P17591, DOI 10.1074/jbc.M011793200; Kubota H, 2000, J BIOL CHEM, V275, P20243, DOI 10.1074/jbc.C000262200; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Marbach I, 2001, J BIOL CHEM, V276, P16944, DOI 10.1074/jbc.M100383200; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; Miura F, 2001, FEBS LETT, V505, P103, DOI 10.1016/S0014-5793(01)02792-2; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; SARKAR S, 1999, P NATL ACAD SCI USA, V99, P190; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Tavernarakis N, 1996, GENE, V179, P271, DOI 10.1016/S0378-1119(96)00379-4; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; Valenzuela L, 2001, J BACTERIOL, V183, P2331, DOI 10.1128/JB.183.7.2331-2334.2001; WEK SA, 1995, MOL CELL BIOL, V15, P4497	26	77	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20457	20460		10.1074/jbc.C300133200	http://dx.doi.org/10.1074/jbc.C300133200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12676950	hybrid			2022-12-25	WOS:000183230500004
J	Maurer, JA; Dougherty, DA				Maurer, JA; Dougherty, DA			Generation and evaluation of a large mutational library from the Escherichia coli mechanosensitive channel of large conductance, MscL - Implications for channel gating and evolutionary design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; ION-CHANNEL; MYCOBACTERIUM-TUBERCULOSIS; STRETCH-INACTIVATION; POTASSIUM CHANNEL; SINGLE RESIDUE; K+ CHANNEL; MECHANISM; ACTIVATION	Random mutagenesis of the mechanosensitive channel of large conductance ( MscL) from Escherichia coli coupled with a high-throughput functional screen has provided new insights into channel structure and function. Complementary interactions of conserved residues proposed in a computational model for gating have been evaluated, and important functional regions of the channel have been identified. Mutational analysis shows that the proposed S1 helix, despite having several highly conserved residues, can be heavily mutated without significantly altering channel function. The pattern of mutations that make MscL more difficult to gate suggests that MscL senses tension with residues located near the lipid headgroups of the bilayer. The range of phenotypical changes seen has implications for a proposed model for the evolutionary origin of mechanosensitive channels.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Dougherty, DA (corresponding author), CALTECH, Div Chem & Chem Engn, 1200 E Calif Blvd,Mail Code 164-30 Cr, Pasadena, CA 91125 USA.			Maurer, Joshua/0000-0002-6663-0721	NIGMS NIH HHS [GM-08501, GM-62532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062532] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajouz B, 2000, J BIOL CHEM, V275, P1015, DOI 10.1074/jbc.275.2.1015; BETANZOS M, 2002, NAT STRUCT BIOL, V9; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; BRIGHTGAERTNER E, 1972, BIOCHIM BIOPHYS ACTA, V270, P40, DOI 10.1016/0005-2760(72)90175-0; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Elmore DE, 2002, BIOPHYS J, V82, p628A; Elmore DE, 2001, BIOPHYS J, V81, P1345, DOI 10.1016/S0006-3495(01)75791-8; Gu CX, 2001, BIOPHYS J, V80, P2678, DOI 10.1016/S0006-3495(01)76237-6; Gu LQ, 1998, BIOPHYS J, V74, P2889, DOI 10.1016/S0006-3495(98)77995-0; Gullingsrud J, 2001, BIOPHYS J, V80, P2074, DOI 10.1016/S0006-3495(01)76181-4; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jones SE, 2000, BIOCHEM BIOPH RES CO, V279, P208, DOI 10.1006/bbrc.2000.3921; Kloda A, 2001, CELL BIOCHEM BIOPHYS, V34, P349, DOI 10.1385/CBB:34:3:349; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; LUGTENBERG EJJ, 1976, BIOCHIM BIOPHYS ACTA, V441, P38, DOI 10.1016/0005-2760(76)90279-4; Martinac B, 2002, P NATL ACAD SCI USA, V99, P4308, DOI 10.1073/pnas.072632899; Martinac B, 2001, CELL PHYSIOL BIOCHEM, V11, P61, DOI 10.1159/000047793; Maurer JA, 2000, J BIOL CHEM, V275, P22238, DOI 10.1074/jbc.M003056200; Maurer JA, 2001, BBA-BIOMEMBRANES, V1514, P165, DOI 10.1016/S0005-2736(01)00390-X; Okada K, 2002, J BIOL CHEM, V277, P27682, DOI 10.1074/jbc.M202497200; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; RAO JKM, 1987, INT J PEPT PROT RES, V29, P276; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUUTARI M, 1994, CRIT REV MICROBIOL, V20, P285, DOI 10.3109/10408419409113560; SUUTARI M, 1993, ARCH MICROBIOL, V159, P119, DOI 10.1007/BF00250270; Tabarean IV, 2002, BIOPHYS J, V82, P2982, DOI 10.1016/S0006-3495(02)75639-7; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21076	21082		10.1074/jbc.M302892200	http://dx.doi.org/10.1074/jbc.M302892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670944	hybrid, Green Accepted			2022-12-25	WOS:000183230500082
J	Morohashi, K; Minami, M; Takase, H; Hotta, Y; Hiratsuka, K				Morohashi, K; Minami, M; Takase, H; Hotta, Y; Hiratsuka, K			Isolation and characterization of a novel GRAS gene that regulates meiosis-associated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCARECROW GENE; GIBBERELLIN RESPONSES; SIGNAL-TRANSDUCTION; NUCLEAR RECEPTOR; ARABIDOPSIS; FAMILY; ENCODES; PATHWAY; PROTEIN; TRANSCRIPTION	GRAS protein is a family of plant-specific proteins that plays a role in various developmental processes. Here we report a novel GRAS protein from lily, designated LlSCL (Lilium longiflorum Scarecrow-like), dominantly expressed at the premeiotic phase within anthers. The LlSCL protein has two highly basic regions, and transient expression analyses of dissected GFP-LlSCL fusion proteins showed that both basic regions are important for the nuclear localization. A series of transcriptional activation experiments of truncated LlSCL proteins fused to the yeast GAL4 DNA-binding domain clearly demonstrated that the amino terminus of the LlSCL protein has a strong activity of transcriptional activation in the yeast as well as in the plant cell. Further investigation on the effect of the LlSCL protein on the transcriptional activity of the meiosis-associated promoter revealed that in pollen mother cells of the lily, the activity of the meiosis-associated promoter is specifically enhanced by LlSCL protein co-expression. These results suggest that LlSCL is involved in transcriptional regulation during microsporogenesis within the lily anther.	Yokohama Natl Univ, Div Plant Biotechnol, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan; Niigata Univ Hlth & Welf, Dept Hlth & Nutr, Niigata 9503198, Japan	Yokohama National University; Nara Institute of Science & Technology; Niigata University	Hiratsuka, K (corresponding author), Yokohama Natl Univ, Div Plant Biotechnol, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan.		Morohashi, Kengo/AAV-2545-2021; Morohashi, Kengo/C-5511-2014					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bolle C, 2000, GENE DEV, V14, P1269; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Couteau F, 1999, PLANT CELL, V11, P1623, DOI 10.1105/tpc.11.9.1623; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; ERICKSON RO, 1948, AM J BOT, V35, P729, DOI 10.2307/2438154; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOTTA Y, 1985, CELL, V40, P785, DOI 10.1016/0092-8674(85)90338-1; Ikeda A, 2001, PLANT CELL, V13, P999, DOI 10.1105/tpc.13.5.999; Itoh H, 2002, PLANT CELL, V14, P57, DOI 10.1105/tpc.010319; Kobayashi T, 1994, DNA Res, V1, P15, DOI 10.1093/dnares/1.1.15; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lim J, 2000, PLANT CELL, V12, P1307, DOI 10.1105/tpc.12.8.1307; Liu LS, 1999, EUR J BIOCHEM, V262, P247, DOI 10.1046/j.1432-1327.1999.00349.x; Minami M, 2001, PLANT BIOTECHNOL-NAR, V18, P71; MOROHASHI K, 2000, PLANT BIOTECHNOL, V17, P131, DOI DOI 10.5511/PLANTBIOTECHNOLOGY.17.131; Mousavi A, 1999, PLANT CELL PHYSIOL, V40, P406, DOI 10.1093/oxfordjournals.pcp.a029556; Ogawa M, 2000, GENE, V245, P21, DOI 10.1016/S0378-1119(00)00018-4; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Richards DE, 2000, BIOESSAYS, V22, P573, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;573::AID-BIES10&gt;3.0.CO;2-H; Sassa N, 2001, PLANT CELL PHYSIOL, V42, P385, DOI 10.1093/pcp/pce048; Schumacher K, 1999, P NATL ACAD SCI USA, V96, P290, DOI 10.1073/pnas.96.1.290; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; UEFUJI H, 2001, PLANT BIOTECHNOL, V18, P151; Wen CK, 2002, PLANT CELL, V14, P87, DOI 10.1105/tpc.010325	31	105	117	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20865	20873		10.1074/jbc.M301712200	http://dx.doi.org/10.1074/jbc.M301712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657631	hybrid			2022-12-25	WOS:000183230500056
J	Park, TS; O'Brien, DJ; Carman, GM				Park, TS; O'Brien, DJ; Carman, GM			Phosphorylation of CTP synthetase on Ser(36), Ser(330), Ser(354), and Ser(454) regulates the levels of CTP and phosphatidylcholine synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; POLYACRYLAMIDE GEL-ELECTROPHORESIS; CYTIDINE TRIPHOSPHATE SYNTHETASE; CYTOSINE INDUCES APOPTOSIS; LEUKEMIC CELL-LINE; PHOSPHOLIPID BIOSYNTHESIS; HIERARCHICAL PHOSPHORYLATION; LYMPHOBLASTIC-LEUKEMIA; MOLECULAR-CLONING; GENE-PRODUCT	The Saccharomyces cerevisiae URA7-encoded CTP synthetase is phosphorylated and stimulated by protein kinase C. We examined the hypothesis that Ser(36), Ser(330), Ser(354), and Ser(454), contained in a protein kinase C sequence motif in CTP synthetase, were target sites for the kinase. Synthetic peptides containing a phosphorylation motif at these serine residues served as substrates for protein kinase C in vitro. Ser-->Ala (S36A, S330A, S354A, and S454A) mutations in CTP synthetase were constructed by site-directed mutagenesis and expressed normally in a ura7 ura8 double mutant that lacks CTP synthetase activity. The CTP synthetase activity in extracts from cells bearing the S36A, S354A, and S454A mutant enzymes was reduced when compared with cells bearing the wild type enzyme. Kinetic analysis of purified mutant enzymes showed that the S36A and S354A mutations caused a decrease in the V-max of the reaction. This regulation could be attributed in part by the effects phosphorylation has on the nucleotide-dependent oligomerization of CTP synthetase. In contrast, CTP synthetase activity in cells bearing the S330A mutant enzyme was elevated, and kinetic analysis of purified enzyme showed that the S330A mutation caused an elevation in the V-max of the reaction. In vitro data indicated that phosphorylation of CTP synthetase at Ser(330) affected the phosphorylation of the enzyme at another site. The phosphorylation of CTP synthetase at Ser(36), Ser(330), Ser(354), and Ser(454) residues was physiologically relevant. Cells bearing the S36A, S354A, and S454A mutations had reduced CTP levels, whereas cells with the S330A mutation had elevated CTP levels. The alterations in CTP levels correlated with the regulatory effects CTP has on the pathways responsible for the synthesis of the membrane phospholipid phosphatidylcholine.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bearne SL, 2001, BIOCHEM J, V356, P223, DOI 10.1042/0264-6021:3560223; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Bischoff KM, 1998, ANAL BIOCHEM, V260, P1, DOI 10.1006/abio.1998.2680; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CULBERTSON MR, 1975, GENETICS, V80, P23; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; ESKO JD, 1980, J BIOL CHEM, V255, P4474; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; Hendriks EF, 1998, BBA-GENE STRUCT EXPR, V1399, P213, DOI 10.1016/S0167-4781(98)00108-0; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mahony TJ, 1998, FEMS MICROBIOL LETT, V165, P153; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Pappas A, 1999, BIOCHEMISTRY-US, V38, P16671, DOI 10.1021/bi9920127; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P257; van Kuilenburg ABP, 2000, BBA-GENE STRUCT EXPR, V1492, P548, DOI 10.1016/S0167-4781(00)00141-X; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; VANDENBERG AA, 1995, EUR J CANCER, V31A, P108, DOI 10.1016/0959-8049(94)00442-8; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VANNE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; Verschuur AC, 1998, ADV EXP MED BIOL, V431, P667; Verschuur AC, 2000, ADV EXP MED BIOL, V486, P319; Verschuur AC, 2001, LEUKEMIA RES, V25, P891, DOI 10.1016/S0145-2126(01)00047-9; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	93	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20785	20794		10.1074/jbc.M301394200	http://dx.doi.org/10.1074/jbc.M301394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670958	hybrid			2022-12-25	WOS:000183230500046
J	Shi, XP; Tugusheva, K; Bruce, JE; Lucka, A; Wu, GX; Chen-Dodson, E; Price, E; Li, YM; Xu, M; Huang, Q; Sardana, MK; Hazuda, DJ				Shi, XP; Tugusheva, K; Bruce, JE; Lucka, A; Wu, GX; Chen-Dodson, E; Price, E; Li, YM; Xu, M; Huang, Q; Sardana, MK; Hazuda, DJ			beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; PRESENILIN-1; INHIBITOR; BACE1; GENERATION; COMPARTMENT; DOMAIN; SITE	The amyloid beta peptides (Abeta) are the major components of the senile plaques characteristic of Alzheimer's disease. Abeta peptides are generated from the cleavage of amyloid precursor protein (APP) by beta- and gamma-secretases. beta-Secretase ( BACE), a type-I transmembrane aspartyl protease, cleaves APP first to generate a 99-amino acid membrane-associated fragment (CT99) containing the N terminus of Abeta peptides. gamma-Secretase, a multi-protein complex, then cleaves within the transmembrane region of CT99 to generate the C termini of Abeta peptides. The production of Abeta peptides is, therefore, dependent on the activities of both BACE and gamma-secretase. The cleavage of APP by BACE is believed to be a prerequisite for gamma-secretase-mediated processing. In the present study, we provide evidence both in vitro and in cells that BACE-mediated cleavage between amino acid residues 34 and 35 ( Abeta-34 site) in the Abeta region is dependent on gamma-secretase activity. In vitro, the Abeta-34 site is processed specifically by BACE1 and BACE2, but not by cathepsin D, a closely related aspartyl protease. Moreover, the cleavage of the Abeta-34 site by BACE1 or BACE2 occurred only when Abeta 1-40 peptide, a gamma-secretase cleavage product, was used as substrate, not the non-cleaved CT99. In cells, overexpression of BACE1 or BACE2 dramatically increased the production of the Abeta 1-34 species. More importantly, the cellular production of Abeta 1 - 34 species induced by overexpression of BACE1 or BACE2 was blocked by a number of known gamma-secretase inhibitors in a concentration-dependent manner. These gamma-secretase inhibitors had no effect on enzymatic activity of BACE1 or BACE2 in vitro. Our data thus suggest that gamma-secretase cleavage of CT99 is a prerequisite for BACE-mediated processing at Abeta- 34 site. Therefore, BACE and gamma-secretase activity can be mutually dependent.	Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA	Merck & Company	Shi, XP (corresponding author), Merck Res Labs, Dept Biol Chem, WP16-205, West Point, PA 19486 USA.	xiao-ping_shi@merck.com						Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2003, J BIOL CHEM, V278, P5531, DOI 10.1074/jbc.M211485200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shi XP, 2002, NEUROBIOL AGING, V23, pS180; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	31	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21286	21294		10.1074/jbc.M209859200	http://dx.doi.org/10.1074/jbc.M209859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665519	hybrid			2022-12-25	WOS:000183230500107
J	Young, RM; Holowka, D; Baird, B				Young, RM; Holowka, D; Baird, B			A lipid raft environment enhances Lyn kinase activity by protecting the active site tyrosine from dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; AFFINITY IGE RECEPTOR; RBL-2H3 MAST-CELLS; SRC FAMILY KINASES; MEMBRANE DOMAINS; BIOLOGICAL-MEMBRANES; ANCHORED PROTEINS; PLASMA-MEMBRANES; BETA-SUBUNIT; PHOSPHORYLATION	The plasma membrane contains ordered lipid domains, commonly called lipid rafts, enriched in cholesterol, sphingolipids, and certain signaling proteins. Lipid rafts play a structural role in signal initiation by the high affinity receptor for IgE. Cross-linking of IgE-receptor complexes by antigen causes their coalescence with lipid rafts, where they are phosphorylated by the Src family tyrosine kinase, Lyn. To understand how lipid rafts participate in functional coupling between Lyn and FcepsilonRI, we investigated whether the lipid raft environment influences the specific activity of Lyn. We used differential detergent solubility and sucrose gradient fractionation to isolate Lyn from raft and nonraft regions of the plasma membrane in the presence or absence of tyrosine phosphatase inhibitors. We show that Lyn recovered from lipid rafts has a substantially higher specific activity than Lyn from nonraft environments. Furthermore, this higher specific activity correlates with increased tyrosine phosphorylation at the active site loop of the kinase domain. Based on these results, we propose that lipid rafts exclude a phosphatase that negatively regulates Lyn kinase activity by constitutive dephosphorylation of the kinase domain tyrosine residue of Lyn. In this model, cross-linking of FcepsilonRI promotes its proximity to active Lyn in a lipid raft environment.	Cornell Univ, Dept Chem & Biol Chem, Baker Lab, Ithaca, NY 14850 USA	Cornell University	Baird, B (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Baker Lab, Ithaca, NY 14850 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007273] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI22449] Funding Source: Medline; NIGMS NIH HHS [T32-GM07273] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER G, 1991, J BIOL CHEM, V266, P22613; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Gidwani A, 2001, BIOCHEMISTRY-US, V40, P12422, DOI 10.1021/bi010496c; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; Hibbs ML, 1997, INT J BIOCHEM CELL B, V29, P397, DOI 10.1016/S1357-2725(96)00104-5; Holowka D, 2000, J CELL SCI, V113, P1009; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; Honda ZI, 2000, MOL CELL BIOL, V20, P1759, DOI 10.1128/MCB.20.5.1759-1771.2000; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kovarova M, 2001, MOL CELL BIOL, V21, P8318, DOI 10.1128/MCB.21.24.8318-8328.2001; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Mao SY, 1997, J BIOL CHEM, V272, P14067, DOI 10.1074/jbc.272.22.14067; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MENON AK, 1986, J CELL BIOL, V102, P541, DOI 10.1083/jcb.102.2.541; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Peirce M, 2000, J BIOL CHEM, V275, P34976, DOI 10.1074/jbc.M005819200; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; SWIETER M, 1995, J IMMUNOL, V155, P5330; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torigoe C, 2001, BIOCHEMISTRY-US, V40, P4016, DOI 10.1021/bi0027534; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Vonakis BM, 2001, J BIOL CHEM, V276, P1041, DOI 10.1074/jbc.M003397200; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487	45	141	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20746	20752		10.1074/jbc.M211402200	http://dx.doi.org/10.1074/jbc.M211402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670955	hybrid			2022-12-25	WOS:000183230500041
J	Sellers, JA; Hou, L; Athar, H; Hussain, MM; Shelness, GS				Sellers, JA; Hou, L; Athar, H; Hussain, MM; Shelness, GS			A Drosophila microsomal triglyceride transfer protein homolog promotes the assembly and secretion of human apolipoprotein B - Implications for human and insect lipid transport and metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ABETALIPOPROTEINEMIA GENE; GENOME SEQUENCE; EXPRESSION; VITELLOGENIN; BINDING; CELLS; MODEL; LIPOPHORIN; IDENTIFICATION	The assembly and secretion of triglyceride-rich lipoproteins in vertebrates requires apolipoprotein B ( apoB) and the endoplasmic reticulum-localized cofactor, microsomal triglyceride transfer protein (MTP). Invertebrates, particularly insects, transport the majority of their neutral and polar lipids in lipophorins; however, the assembly of lipophorin precursor particles was presumed to be MTP-independent. A Drosophila melanogaster expressed gene sequence (CG9342), displaying 23% identity with human MTP, was recently identified. When coexpressed in COS cells, CG9342 promoted the assembly and secretion of apoB34 and apoB41 (N-terminal 34 and 41% of human apoB). The apoB34-containing particles assembled by human MTP and CG9342 displayed similar peak densities of similar to1.169 g/ml and similar lipid compositions. However, CG9342 displayed differential sensitivities to two inhibitors of human MTP and low vesicle-based lipid transfer activity, in vitro. In addition, important predicted structural distinctions exist between the human and Drosophila proteins suggesting overlapping but not identical functional roles. We conclude that CG9342 and human MTP are orthologs that share only a subset of functions, consistent with known differences in intracellular and extracellular aspects of vertebrate and invertebrate lipid transport and metabolism.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Suny Downstate Med Ctr, Dept Anat & Cell Biol & Pediat, Brooklyn, NY 11203 USA	Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Shelness, GS (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu			NHLBI NIH HHS [HL07867, HL49373, HL64272] Funding Source: Medline; NIDDK NIH HHS [DK46900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046900, R01DK046900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; BAKER ME, 1988, BIOCHEM J, V255, P1057, DOI 10.1042/bj2551057; Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Chang G, 2002, CURR OPIN DRUG DISC, V5, P562; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; ESSER V, 1988, J BIOL CHEM, V263, P13282; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Hamilton RL, 1998, J LIPID RES, V39, P1543; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hui TY, 2002, J LIPID RES, V43, P785; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KANNEL WB, 1992, CORONARY HEART DIS E, P67; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Kutty RK, 1996, J BIOL CHEM, V271, P20641, DOI 10.1074/jbc.271.34.20641; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OHLENDORF DH, 1977, J BIOL CHEM, V252, P7992; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pennington JE, 1996, J LIPID RES, V37, P1144; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Robl JA, 2001, J MED CHEM, V44, P851, DOI 10.1021/jm000494a; RYAN RO, 1986, J BIOL CHEM, V261, P563; Segrest JP, 1999, J LIPID RES, V40, P1401; Sellers JA, 2001, J LIPID RES, V42, P1897; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Stapleton M, 2002, GENOME RES, V12, P1294, DOI 10.1101/gr.269102; SWIFT LL, 1995, J LIPID RES, V36, P395; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WEERS PMM, 1993, J BIOL CHEM, V268, P4300; WEERS PMM, 1992, J LIPID RES, V33, P485; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1991, J BIOL CHEM, V266, P3300	58	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20367	20373		10.1074/jbc.M300271200	http://dx.doi.org/10.1074/jbc.M300271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657646	hybrid			2022-12-25	WOS:000183078000101
J	Taylor, ER; Hurrell, F; Shannon, RJ; Lin, TK; Hirst, J; Murphy, MP				Taylor, ER; Hurrell, F; Shannon, RJ; Lin, TK; Hirst, J; Murphy, MP			Reversible glutathionylation of complex I increases mitochondrial superoxide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; NITRIC-OXIDE; PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; UBIQUINONE OXIDOREDUCTASE; RADICAL GENERATION; HYDROGEN-PEROXIDE; OXYGEN RADICALS	Increased production of reactive oxygen species (ROS) by mitochondria is involved in oxidative damage to the organelle and in committing cells to apoptosis or senescence, but the mechanisms of this increase are unknown. Here we show that ROS production by mitochondrial complex I increases in response to oxidation of the mitochondrial glutathione pool. This correlates with thiols on the 51- and 75-kDa subunits of complex I forming mixed disulfides with glutathione. Glutathionylation of complex I increases superoxide production by the complex, and when the mixed disulfides are reduced, superoxide production returns to basal levels. Within intact mitochondria oxidation of the glutathione pool to glutathione disulfide also leads to glutathionylation of complex I, which correlates with increased superoxide formation. In this case, most of this superoxide is converted to hydrogen peroxide, which can then diffuse into the cytoplasm. This mechanism of reversible mitochondrial ROS production suggests how mitochondria might regulate redox signaling and shows how oxidation of the mitochondrial glutathione pool could contribute to the pathological changes that occur to mitochondria during oxidative stress.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Murphy, Michael P/C-2120-2009; Hirst, Judy/F-4803-2011	Murphy, Michael P/0000-0003-1115-9618; Hirst, Judy/0000-0001-8667-6797				Balijepalli S, 1999, NEUROPHARMACOLOGY, V38, P567, DOI 10.1016/S0028-3908(98)00215-9; Balijepalli S, 1999, NEUROSCI LETT, V272, P203, DOI 10.1016/S0304-3940(99)00593-5; Barja G, 1999, METHODS AGING RES, P533; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; Borutaite V, 2000, FEBS LETT, V467, P155, DOI 10.1016/S0014-5793(00)01140-6; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BURCH HB, 1957, METHOD ENZYMOL, V3, P960, DOI 10.1016/S0076-6879(57)03485-0; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; COOPER JM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P198, DOI 10.1016/S0005-2728(05)80019-2; DAVEY GP, 1992, BIOCHEM J, V288, P439, DOI 10.1042/bj2880439; DIMONTE DA, 1992, ANN NEUROL, V32, pS111, DOI 10.1002/ana.410320719; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jenner P, 1993, ACTA NEUROL SCAND  S, V146, P6; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Tyler D. D., 1967, METHOD ENZYMOL, V10, P75, DOI DOI 10.1016/0076-6879(67)10014-1; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Werhahn W, 2002, ELECTROPHORESIS, V23, P640, DOI 10.1002/1522-2683(200202)23:4&lt;640::AID-ELPS640&gt;3.0.CO;2-F	57	328	342	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19603	19610		10.1074/jbc.M209359200	http://dx.doi.org/10.1074/jbc.M209359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649289	hybrid			2022-12-25	WOS:000183078000007
J	Hohl, M; Thorel, F; Clarkson, SG; Scharer, OD				Hohl, M; Thorel, F; Clarkson, SG; Scharer, OD			Structural determinants for substrate binding and catalysis by the structure-specific endonuclease XPG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; RNA-POLYMERASE; OPEN COMPLEX; PROTEIN; RAD2; TRANSCRIPTION; REPLICATION; EXONUCLEASE; NUCLEASES	XPG belongs to the Fen1 family of structure-specific nucleases and is responsible for the 3' endonucleolytic incision during mammalian nucleotide excision repair. In addition, it has ill-defined roles in the transcription-coupled repair of oxidative DNA damage and likely also in transcription that are independent of its nuclease activity. We have used DNA binding and footprinting assays with various substrates to gain insight into how XPG interacts with DNA. Ethylation interference footprinting revealed that XPG binds to its substrates through interaction with the phosphate backbone on one face of the helix, mainly to the double-stranded DNA. By comparing DNA binding and cleavage activity using single-/double-stranded DNA junction substrates differing in the length of the single-stranded regions, we have found that the 3' but not the 5' single-stranded arm was necessary for DNA binding and incision activity. Furthermore, we show that although a 5' overhang is not required for XPG activity, an overhang containing double-stranded DNA near the junction inhibits the nuclease but not substrate binding activity. Apparently, junction accessibility or flexibility is important for catalysis but not binding of XPG. These results show that XPG has distinct requirements for binding and cleaving DNA substrates.	Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland; Ctr Med Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	University of Zurich; University of Geneva	Scharer, OD (corresponding author), Univ Zurich, Inst Mol Canc Res, August Forel Str 7, CH-8008 Zurich, Switzerland.	scharer@imr.unizh.ch	Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715				Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dervan JJ, 2002, P NATL ACAD SCI USA, V99, P8542, DOI 10.1073/pnas.082241699; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; LARSON CJV, 1996, NUCL ACIDS, P324; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Park MS, 1997, J BIOL CHEM, V272, P27823, DOI 10.1074/jbc.272.44.27823; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Shiomi N, 2001, MUTAT RES-DNA REPAIR, V487, P127, DOI 10.1016/S0921-8777(01)00111-2; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; Stary A, 2002, BIOCHIMIE, V84, P49, DOI 10.1016/S0300-9084(01)01358-X; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Suck D, 1997, BIOPOLYMERS, V44, P405, DOI 10.1002/(SICI)1097-0282(1997)44:4<405::AID-BIP5>3.0.CO;2-L; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Xu Y, 2001, J BIOL CHEM, V276, P30167, DOI 10.1074/jbc.M100985200	49	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19500	19508		10.1074/jbc.M213155200	http://dx.doi.org/10.1074/jbc.M213155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644470	Green Published, hybrid			2022-12-25	WOS:000182932200100
J	Jeffrey, JL; Feng, JY; Qi, CCR; Anderson, KS; Furman, PA				Jeffrey, JL; Feng, JY; Qi, CCR; Anderson, KS; Furman, PA			Dioxolane guanosine 5 '-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase - Steady state and pre-steady state kinetic analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; DRUG-RESISTANCE; ANTIRETROVIRAL DRUGS; NUCLEOSIDE ANALOG; MUTATIONS K65R; DNA-SYNTHESIS; MECHANISM; SENSITIVITY; VARIANTS	The frequency of human immunodeficiency virus, type 1 (HIV-1) mutations in response to antiviral therapy and resulting drug resistance is of major concern. Amdoxovir ((-)-beta-D-2,6-diaminopurine dioxolane), the prodrug of dioxolane guanosine (DXG), is currently in phase I/II clinical development for the treatment of HIV-1 infection. In vitro, HIV-1 mutants resistant to 3'-azido-3'-deoxythymidine (M41L/D67N/K70R/T215Y/K219Q) and (-)beta-L-2',3'-dideoxy-3'-thiacytidine (3TC) (M184V) remain sensitive to DXG. HIV-1 with the reverse transcriptase mutations K65R, L74V, and/or Q151M were less sensitive to DXG, whereas the mutation K103N re-sensitized the virus to the inhibitory effect of DXG. In order to understand these observations at the enzyme level, we investigated the inhibition of the HIV-1 reverse transcriptase-catalyzed viral DNA synthesis by dioxolane guanosine 5'-triphosphate (DXG-TP), 3'-azido-3'-deoxythymidine-TP, and 3TC-TP by using steady state kinetic analysis and the incorporation of DXG-5'-monophosphate by using pre-steady state kinetic analysis. This mechanistic study provided detailed information on the amdoxovir-related drug resistance at a molecular level. Overall, the enzymatic data correlated well with the antiviral data obtained from cell culture experiments and further supported the use of amdoxovir for the treatment of nucleoside reverse transcriptase inhibitor-experienced patients.	Gilead Sci Inc, Triangle Pharmaceut Inc, Durham, NC 27717 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Gilead Sciences; Yale University	Feng, JY (corresponding author), Gilead Sci Inc, Triangle Pharmaceut Inc, Durham, NC 27717 USA.	joy.feng@gilead.com			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064; Bazmi HZ, 2000, ANTIMICROB AGENTS CH, V44, P1783, DOI 10.1128/AAC.44.7.1783-1788.2000; Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775, DOI 10.1128/AAC.42.11.2775; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Dunne AL, 2001, AIDS, V15, P1471, DOI 10.1097/00002030-200108170-00003; FARAJ A, 1994, ANTIMICROB AGENTS CH, V38, P2300, DOI 10.1128/AAC.38.10.2300; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; Furman PA, 2001, ANTIMICROB AGENTS CH, V45, P158, DOI 10.1128/AAC.45.1.158-165.2001; Gu ZX, 1999, ANTIMICROB AGENTS CH, V43, P2376, DOI 10.1128/AAC.43.10.2376; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x; Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 1997, BIOCHEMISTRY-US, V36, P14430, DOI 10.1021/bi970645k; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; KIM HO, 1993, J MED CHEM, V36, P519, DOI 10.1021/jm00057a001; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LAETHEM KV, 2001, AIDS, V15, P553; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MELLORS JW, 1996, P 5 INT WORKSH HIV D; MEWSHAW JP, 2002, AIDS, V29, P11; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Naeger LK, 2001, ANTIVIR THER, V6, P115; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; *NAT DAT CORP, 2002, HLTH RET AUD; Rousseau MN, 2001, J ACQ IMMUN DEF SYND, V26, P36, DOI 10.1097/00126334-200101010-00005; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; SELMI B, 2002, DART FRONTIERS DRUG; Shahs FS, 2000, J BIOL CHEM, V275, P27037; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Smith RH, 1998, THEOCHEM-J MOL STRUC, V423, P67, DOI 10.1016/S0166-1280(97)00071-7; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; White KL, 2002, ANTIMICROB AGENTS CH, V46, P3437, DOI 10.1128/AAC.46.11.3437-3446.2002; Wilson JE, 1996, METHOD ENZYMOL, V275, P398	46	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18971	18979		10.1074/jbc.M210113200	http://dx.doi.org/10.1074/jbc.M210113200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12651859	hybrid			2022-12-25	WOS:000182932200034
J	Won, J; Kim, DY; La, M; Kim, D; Meadows, GG; Joe, CO				Won, J; Kim, DY; La, M; Kim, D; Meadows, GG; Joe, CO			Cleavage of 14-3-3 protein by caspase-3 facilitates bad interaction with Bcl-x(L) during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; CYTOCHROME-C; SIGNALING PROTEINS; MITOCHONDRIA; KINASE; DEATH; PHOSPHORYLATION; BINDING; RELEASE; COMPLEXES	The 14-3-3epsilon protein was identified as one of the caspase-3 substrates by the modified yeast two-hybrid system. The cellular 14-3-3epsilon protein was also cleaved in response to the treatment of apoptosis inducers in cultured mammalian cells. Asp(238) of the 14-3-3epsilon protein was determined as the site of cleavage by caspase-3. The affinity of the cleaved 14-3-3 mutant protein (D238) to Bad, a death-promoting Bcl-2 family protein, was lower than that of wild type or the uncleavable mutant 14-3-3epsilon protein (D238A). However, Bad associated with the cellular Bcl-x(L) more effectively in human 293T cells coexpressing Bad with the truncated form of the 14-3-3epsilon protein ( D238) than in control cells co-expressing Bad with wild type or the uncleavable mutant 14-3-3epsilon protein ( D238A). The present study suggests that the cleavage of 14-3-3 protein during apoptosis promotes cell death by releasing the associated Bad from the 14-3-3 protein and facilitates Bad translocation to the mitochondria and its interaction with Bcl-x(L).	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Washington State Univ, Canc Prevent & Res Ctr, Dept Pharmaceut Sci, Pullman, WA 99164 USA	Korea Advanced Institute of Science & Technology (KAIST); Washington State University	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.							AGUAN K, 1990, NUCLEIC ACIDS RES, V18, P1071, DOI 10.1093/nar/18.4.1071; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim JW, 2000, J CELL SCI, V113, P955; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	34	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19347	19351		10.1074/jbc.M213098200	http://dx.doi.org/10.1074/jbc.M213098200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12657644	hybrid			2022-12-25	WOS:000182932200082
J	Sonderegger, CK; Narisawa-Saito, M; Vogt, PK				Sonderegger, CK; Narisawa-Saito, M; Vogt, PK			The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression	ONCOGENE			English	Article						FoxG1; oncogenic transformation; chicken embryo fibroblasts; oligomerization; transcriptional repression	DNA-RECOGNITION; ACUTE LEUKEMIAS; MLL GENE; PROTEIN; BF-1; CLONING; EXPRESSION; MEMBER; PAX3; CONVERSION	Expression of the oncoprotein Qin induces tumors in chickens and oncogenic transformation of chicken embryo fibroblasts in culture. We performed a detailed deletion analysis of the C-terminal region of Qin (amino acids 246-451, extending from the winged helix domain to the C-terminus) and identified amino acids 246-379 as important for transformation. The same region mediates homo-oligomerization of Qin as documented in vitro by GST pulldowns and in vivo by coimmunoprecipitation. A 60 amino-acid region within the oligomerization domain is necessary and sufficient for transcriptional repression induced by Qin.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/gcc.2870030611; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Lu XY, 2000, P NATL ACAD SCI USA, V97, P1988, DOI 10.1073/pnas.040573197; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; RAO A, 2001, SCI STKE, pE1; Rodriguez C, 2001, J BIOL CHEM, V276, P30224, DOI 10.1074/jbc.M102759200; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SONDEREGGER CK, 2003, IN PRESS ONCOGENE; SONDEREGGER CK, 2001, UNPUB; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WHANGPENG J, 1992, GENE CHROMOSOME CANC, V5, P299, DOI 10.1002/gcc.2870050405; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	38	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1908	1915		10.1038/sj.onc.1206307	http://dx.doi.org/10.1038/sj.onc.1206307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673196				2022-12-25	WOS:000181967700001
J	Zhou, A; Scoggin, S; Gaynor, RB; Williams, NS				Zhou, A; Scoggin, S; Gaynor, RB; Williams, NS			Identification of NF-kappa B-regulated genes induced by TNF alpha utilizing expression profiling and RNA interference	ONCOGENE			English	Article						TNF alpha; NF-kappa B; cDNA microarrays; RNA interference; gene expression profiles; apoptosis	TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CULTURED-MAMMALIAN-CELLS; PROSTAGLANDIN-E SYNTHASE; ZINC FINGER PROTEIN; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; ENDOTHELIAL-CELLS; EGR-1 PROMOTER	Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine with important roles in regulating inflammatory responses as well as cell cycle proliferation and apoptosis. Although TNFalpha stimulates apoptosis, it also activates the transcription factor NF-kappaB, and studies have shown that inhibition of NF-kappaB potentiates the cytotoxicity of TNFalpha. Since several chemotherapy agents act like TNFalpha to both promote apoptosis and activate NF-kappaB, understanding the role of NF-kappaB in suppressing apoptosis may have significant clinical applications. To understand the effects of stimulation with TNFalpha and the role of NF-kappaB in regulating this response, a 23k human cDNA microarray was used to screen TNFalpha-inducible genes in HeLa cells. Real-time PCR verified expression changes in 16 of these genes and revealed three distinct temporal patterns of expression after TNFalpha stimulation. Using RNA interference to disrupt expression of the p65 subunit of NF-kappaB, all but two of the genes were shown to depend on this transcription factor for their expression, which correlated well with the existence of NF-kappaB binding sites in most of their promoters. Inflammatory, proapoptotic, and antiapoptotic genes were all shown to be regulated by NF-kappaB, demonstrating the wide variety of targets activated by NF-kappaB signaling and the necessity of differentiating among these genes for therapeutic purposes.	Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, NS (corresponding author), Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Scoggin, Shane/0000-0003-2510-2823	NCI NIH HHS [CA74128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Berman KS, 2002, CLIN CANCER RES, V8, P354; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chaudhary LR, 1996, MOL CELL BIOCHEM, V156, P69; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; COFFER P, 1995, ONCOGENE, V10, P985; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dong G, 1999, CANCER RES, V59, P3495; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Finch JS, 2001, GENE, V267, P135, DOI 10.1016/S0378-1119(01)00398-5; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; Grimbacher B, 1998, RHEUMATOL INT, V17, P185, DOI 10.1007/s002960050032; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Harborth J, 2001, J CELL SCI, V114, P4557; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; KAKIZAKI Y, 1995, KIDNEY INT, V48, P1866, DOI 10.1038/ki.1995.485; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; Manos EJ, 2001, CANCER RES, V61, P433; Murakami T, 2000, J Atheroscler Thromb, V7, P39; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SARMA V, 1992, J IMMUNOL, V148, P3302; Schageman JJ, 2002, BIOTECHNIQUES, V32, P338, DOI 10.2144/02322st07; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tsai JC, 2000, FASEB J, V14, P1870; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VAN AD, 1996, SCIENCE, V274, P787; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	59	152	165	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2054	2064		10.1038/sj.onc.1206262	http://dx.doi.org/10.1038/sj.onc.1206262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673210				2022-12-25	WOS:000181967700015
J	Tuo, JS; Jaruga, P; Rodriguez, H; Bohr, VA; Dizdaroglu, M				Tuo, JS; Jaruga, P; Rodriguez, H; Bohr, VA; Dizdaroglu, M			Primary fibroblasts of Cockayne syndrome patients are defective in cellular repair of 8-hydroxyguanine and 8-hydroxyadenine resulting from oxidative stress	FASEB JOURNAL			English	Article						GS; fibroblast cell line; gamma irradiation	TRANSCRIPTION-COUPLED REPAIR; B GENE-PRODUCT; EXCISION-REPAIR; DNA-DAMAGE; XERODERMA-PIGMENTOSUM; MAMMALIAN-CELLS; PREFERENTIAL REPAIR; IONIZING-RADIATION; ESCHERICHIA-COLI; ACTIVE GENES	Cockayne syndrome (CS) is a genetic human disease with clinical symptoms that include neurodegeneration and premature aging. The disease is caused by the disruption of CSA, CSB, or some types of xeroderma pigmentosum genes. It is known that the CSB protein coded by the CS group B gene plays a role in the repair of 8-hydroxyguanine (8-OH-Gua) in transcription-coupled and non-strand discriminating modes. Recently we reported a defect of CSB mutant cells in the repair of another oxidatively modified lesion 8-hydroxyadenine (8-OHAde). We show here that primary fibroblasts from CS patients lack the ability to efficiently repair these particular types of oxidatively induced DNA damages. Primary fibroblasts of 11 CS patients and 6 control individuals were exposed to 2 Gy of ionizing radiation to induce oxidative DNA damage and allowed to repair the damage. DNA from cells was analyzed using liquid chromatography/isotope dilution mass spectrometry to measure the biologically important lesions 8-OH-Gua and 8-OHAde. After irradiation, no significant change in background levels of 8-OH-Gua and 8-OH Ade was observed in control human cells, indicating their complete cellular repair. In contrast, cells from CS patients accumulated significant amounts of these lesions, providing evidence for a lack of DNA repair. This was supported by the observation that incision of 8-OH-Gua- or 8-OHAde-containing oligodeoxynucleotides by whole cell extracts of fibroblasts from CS patients was deficient compared to control individuals. This study suggests that the cells from CS patients accumulate oxidatively induced specific DNA base lesions, especially after oxidative stress. A deficiency in cellular repair of oxidative DNA damage might contribute to developmental defects in CS patients.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Dizdaroglu, M (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	miral@nist.gov	Jaruga, Pawel/M-4378-2015; Bohr, Vilhelm/AAP-5931-2020	Jaruga, Pawel/0000-0001-9192-6084	NATIONAL INSTITUTE ON AGING [Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P42; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hayashi M, 2001, J NEUROPATH EXP NEUR, V60, P350, DOI 10.1093/jnen/60.4.350; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; KLEIN JC, 1992, NUCLEIC ACIDS RES, V20, P4437, DOI 10.1093/nar/20.17.4437; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686; MAYNE LV, 1982, CANCER RES, V42, P1473; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Rapin I, 2000, NEUROLOGY, V55, P1442, DOI 10.1212/WNL.55.10.1442; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; SOFFER D, 1979, ANN NEUROL, V6, P340, DOI 10.1002/ana.410060407; Tan XZ, 1999, CARCINOGENESIS, V20, P2287, DOI 10.1093/carcin/20.12.2287; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; Tuo J, 2000, FREE RADICAL BIO MED, V29, P147, DOI 10.1016/S0891-5849(00)00324-5; Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200; Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	47	122	122	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					668	674		10.1096/fj.02-0851com	http://dx.doi.org/10.1096/fj.02-0851com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665480				2022-12-25	WOS:000182580100012
J	Pourtier-Manzanedo, A; Vercamer, C; Van Belle, E; Mattot, V; Mouquet, F; Vandenbunder, B				Pourtier-Manzanedo, A; Vercamer, C; Van Belle, E; Mattot, V; Mouquet, F; Vandenbunder, B			Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model	ONCOGENE			English	Article						in vivo model; growth factors; tumor; angiogenesis; inhibition; Ets-1	TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; MAST-CELLS; GROWTH; GENE; PROMOTER; FAMILY; INHIBITOR; TNP-470	We and others have shown that members of the Ets family of transcription factors are involved in morphogenic properties of endothelial cells in vitro. To investigate the role of these factors in the transcriptional regulation of angiogenesis in vivo, we set up a nontramnatic model that allows daily macroscopic examination of both growth factor- and tumor-induced angiogenesis in mouse ears. In the same animal, we were thus able to record variations in the patterns of neovessels induced and cell populations recruited by the angiogenic factors FGF-2 and VEGF. In this model, inhibition of FGF-2-induced angiogenesis by the pharmacological compound TNP-470 was readily observed, demonstrating that the mouse ear model is also useful in the evaluation of antiangiogenic strategies. Our functional analysis of Ets transcription factors activity utilized a competitor protein, Ets1-DB, a dominant negative Ets1 mutant lacking the transactivation domain. Retrovirus-mediated expression of Ets1-DB inhibited FGF-2-induced angiogenesis, while the expression of Ets1-DB in cancerous and stromal cells disturbed tumor-induced angiogenesis. These results illustrate the value of the ear model and highlight the role of Ets family members in the transcriptional regulation of tumor angiogenesis.	Univ Lille 2, CNRS, Inst Biol Lille,FRE 2353, Inst Pasteur, F-59021 Lille, France; Univ Lille 2, CNRS, Inst Biol Lille,UMR 8526, Inst Pasteur, F-59021 Lille, France; Univ Lille 2, Hop Cardiol, Serv Cardiol & Hemodynam B, F-59037 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Vandenbunder, B (corresponding author), Univ Lille 2, CNRS, Inst Biol Lille,IPL, FRE 2527, 1 Rue Calmette,BP 447, F-59021 Lille, France.	bernard.vandenbunder@ibl.fr	POURTIER, ALBIN/G-7401-2012; Mouquet, Frederic/P-6899-2019	POURTIER, ALBIN/0000-0002-1576-3946; VAN BELLE, ERIC/0000-0001-6509-443X				Anderson MK, 1999, DEVELOPMENT, V126, P3131; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2001, INT J MOL MED, V8, P149; Bolon I, 1996, LAB INVEST, V75, P1; BOLON I, 1995, AM J PATHOL, V147, P1298; Bond SJ, 2000, J SURG RES, V92, P18, DOI 10.1006/jsre.2000.5854; COURDENT AD, 1996, INT J DEV BIOL, V40, P1097; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dellian M, 1996, AM J PATHOL, V149, P59; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Edel MJ, 1998, ANTICANCER RES, V18, P4505; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Ito M, 1998, BIOCHEM BIOPH RES CO, V246, P123, DOI 10.1006/bbrc.1998.8585; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Konerding MA, 1998, AM J PATHOL, V152, P1607; Kria L, 1998, CURR EYE RES, V17, P986, DOI 10.1076/ceyr.17.10.986.5245; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Lichtenberg J, 1997, PHARMACOL TOXICOL, V81, P280; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; Maier JAM, 1997, ANTI-CANCER DRUG, V8, P238, DOI 10.1097/00001813-199703000-00004; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; Sapi E, 1998, CANCER RES, V58, P1027; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	43	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1795	1806		10.1038/sj.onc.1206215	http://dx.doi.org/10.1038/sj.onc.1206215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660815				2022-12-25	WOS:000181678200006
J	Schagdarsurengin, U; Wilkens, L; Steinemann, D; Flemming, P; Kreipe, HH; Pfeifer, GP; Schlegelberger, B; Dammann, R				Schagdarsurengin, U; Wilkens, L; Steinemann, D; Flemming, P; Kreipe, HH; Pfeifer, GP; Schlegelberger, B; Dammann, R			Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatocellular adenoma; methylation; RASSF1; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-CHROMOSOME 3P21.3; CPG ISLAND; DNA METHYLATION; LUNG-CANCER; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; BREAST CANCERS; CIRRHOSIS	Aberrant promoter methylation is a fundamental mechanism of inactivation of tumor suppressor genes in cancer. The Ras association domain family 1A gene (RASSF1A) is frequently epigenetically silenced in several types of human solid tumors. In this study, we have investigated the expression and methylation status of the RASSF1A gene in hepatocellular carcinoma (HCC). In two HCC cell tines (HepG2 and Hep3B) RASSF1A was inactivated and treatment of these cell lines with a DNA methylation inhibitor reactivated the transcription of RASSF1A. The methylation status of the RASSF1A promoter region was analysed in 26 primary liver tissues including HCC, hepatocellular adenoma (HCA), liver fibrosis, hepatocirrhosis. Out of 15, 14 (93%) HCC were methylated at the RASSF1A CpG island and hypermethylation was independent of hepatitis virus infection. RASSF1A was also methylated in two out of two fibrosis and in three (75%) out of four cirrhosis; the latter carries an increased risk of developing HCC. Additionally, we analysed the methylation status of p16(INK4A), and other cancer-related genes in the same liver tumors. Aberrant methylation in the HCC samples was detected in 71% of samples for p16, 25% for TIMP3, 17% for PTEN, 13% for CDH1, and 7% for RARbeta2. In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic background. Therefore, this study gives additional evidence against a progression of adenoma to carcinoma in the liver. Thus, RASSF1A hypermethylation could be useful as a marker of malignancy and to distinguish between the distinct forms of highly differentiated liver neoplasm.	Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet Med Fak, D-06097 Halle Saale, Germany; Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Zell & Mol Pathol, D-30625 Hannover, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	Martin Luther University Halle Wittenberg; Hannover Medical School; Hannover Medical School; City of Hope; Beckman Research Institute of City of Hope	Dammann, R (corresponding author), Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet Med Fak, Magdeburger Str 2, D-06097 Halle Saale, Germany.	reinhard.dammann@medizin.uni-halle.de	Schagdarsurengin, Undraga/AAH-4312-2020; Schagdarsurengin, Undraga/AAH-4346-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938; 	NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER; NCI NIH HHS [CA88873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Bachman KE, 1999, CANCER RES, V59, P798; Boige V, 1997, CANCER RES, V57, P1986; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Flemming P, 2001, PATHOLOGE, V22, P184, DOI 10.1007/s002920100456; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Roncalli M, 2000, HEPATOLOGY, V31, P846, DOI 10.1053/he.2000.5790; Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyooka S, 2001, CANCER RES, V61, P5727; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; Wistuba II, 2000, CANCER RES, V60, P1949; Wong IHN, 1999, CANCER RES, V59, P71; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zhong S, 2002, CLIN CANCER RES, V8, P1087	44	143	159	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1866	1871		10.1038/sj.onc.1206338	http://dx.doi.org/10.1038/sj.onc.1206338			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660822				2022-12-25	WOS:000181678200013
J	Dib, K; Melander, F; Axelsson, L; Dagher, MC; Aspenstrom, P; Andersson, T				Dib, K; Melander, F; Axelsson, L; Dagher, MC; Aspenstrom, P; Andersson, T			Down-regulation of Rac activity during beta(2) integrin-mediated adhesion of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENT HUMAN NEUTROPHILS; NADPH OXIDASE ACTIVATION; ACTIN POLYMERIZATION; LEUKOCYTE ADHESION; PLASMA-MEMBRANE; SMALL GTPASES; RHO GTPASES; PROTEIN; FAMILY; CDC42	In human neutrophils, beta(2) integrin engagement mediated a decrease in GTP-bound Rac1 and Rac2. Pretreatment of neutrophils with LY294002 or PP1 (inhibiting phosphatidylinositol 3-kinase (PI 3-kinase) and Src kinases, respectively) partly reversed the beta(2) integrin-induced down-regulation of Rac activities. In contrast, beta(2) integrins induced stimulation of Cdc42 that was independent of Src family members. The PI 3-kinase dependence of the beta(2) integrin-mediated decrease in GTP-bound Rac could be explained by an enhanced Rac-GAP activity, since this activity was blocked by LY204002, whereas PP1 only had a minor effect. The fact that only Rac1 but not Rac2 (the dominating Rac) redistributed to the detergent-insoluble fraction and that it was independent of GTP loading excludes the possibility that down-regulation of Rac activities was due to depletion of GTP-bound Rac from the detergent-soluble fraction. The beta(2) integrin-triggered relocalization of Rac1 to the cytoskeleton was enabled by a PI 3-kinase-induced dissociation of Rac1 from LyGDI. The dissociations of Rac1 and Rac2 from LyGDI also explained the PI 3-kinase-dependent translocations of Rac GTPases to the plasma membrane. However, these accumulations of Rac in the membrane, as well as that of p47(phox) and p67(phox), were also regulated by Src tyrosine kinases. Inasmuch as Rac GTPases are part of the NADPH oxidase and the respiratory burst is elicited in neutrophils adherent by beta(2) integrins, our results indicate that activation of the NADPH oxidase does not depend on the levels of Rac-GTP but instead requires a beta(2) integrin-induced targeting of the Rac GTPases as well as p47(phox) and p67(phox) to the plasma membrane.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden; CEA, CNRS,UMR 5092, Dept Reponse & Dynam Cellulaires, Lab Biochim & Biophys Syst Integres, F-38054 Grenoble, France; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Skane University Hospital; CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Ludwig Institute for Cancer Research	Dib, K (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Entrance 78, SE-20502 Malmo, Sweden.			Melander, Fredrik/0000-0002-3670-6633; DAGHER, Marie-Claire/0000-0001-6878-3169				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; ARNAOUT MA, 1990, BLOOD, V75, P1037; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Azim AC, 2000, METHOD ENZYMOL, V325, P257; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BAEHNER RL, 1968, NEW ENGL J MED, V278, P971, DOI 10.1056/NEJM196805022781801; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Berton G, 1996, INT J CLIN LAB RES, V26, P160, DOI 10.1007/BF02592978; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Boukharov AA, 1998, BIOCHEM J, V330, P1391, DOI 10.1042/bj3301391; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Dib K, 2001, J IMMUNOL, V166, P6311, DOI 10.4049/jimmunol.166.10.6311; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Geiszt M, 2001, BIOCHEM J, V355, P851, DOI 10.1042/bj3550851; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hellberg C, 1996, BIOCHEM J, V317, P403, DOI 10.1042/bj3170403; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; KLEMPNER MS, 1980, J CELL BIOL, V86, P21, DOI 10.1083/jcb.86.1.21; LAUDANNA C, 1993, BIOCHEM BIOPH RES CO, V190, P935, DOI 10.1006/bbrc.1993.1139; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; QUINN MT, 1993, J BIOL CHEM, V268, P20983; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; Yan SR, 1999, INFLAMMATION, V23, P167, DOI 10.1023/A:1020245129632; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	53	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24181	24188		10.1074/jbc.M302300200	http://dx.doi.org/10.1074/jbc.M302300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12676940	hybrid			2022-12-25	WOS:000183638600124
J	Lam, BJ; Bakshi, A; Ekinci, FY; Webb, J; Graveley, BR; Hertel, KJ				Lam, BJ; Bakshi, A; Ekinci, FY; Webb, J; Graveley, BR; Hertel, KJ			Enhancer-dependent 5 '-splice site control of fruitless pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DROSOPHILA DOUBLESEX GENE; SR PROTEINS; SEXUAL-DIFFERENTIATION; 5-SPLICE-SITE RECOGNITION; REGULATORY ELEMENTS; ALTERNATIVE EXON; TRANSFORMER; SELECTION; DIVERSITY	The Drosophila fruitless ( fru) gene encodes a transcription factor that essentially regulates all aspects of male courtship behavior. The use of alternative 5 '- splice sites generates fru isoforms that determine gender- appropriate sexual behaviors. Alternative splicing of fru is regulated by TRA and TRA2 and depends on an exonic splicing enhancer ( fruRE) consisting of three 13- nucleotide repeat elements, nearly identical to those that regulate alternative sex- specific 3 '- splice site choice in the doublesex ( dsx) gene. dsx has provided a useful model system to investigate the mechanisms of enhancer- dependent 3 '- splice site choice. However, little is known about enhancer- dependent regulation of alternative 5 '-splice sites. The mechanisms of this process were investigated using an in vitro system in which recombinant TRA/ TRA2 could activate the female- specific 5 '- splice site of fru. Mutational analysis demonstrated that one 13- nucleotide repeat element within the fruRE is required and sufficient to activate the regulated female-specific splice site. As was established for dsx, the fruRE can be replaced by a short element encompassing tandem 13- nucleotide repeat elements, by heterologous splicing enhancers, and by artificially tethering a splicing activator to the pre- mRNA. Complementation experiments showed that Ser/ Arg- rich proteins facilitate enhancer- dependent 5 '- splice site activation. We conclude that splicing enhancers function similarly in activating regulated 5 '- and 3 '- splice sites. These results suggest that exonic splicing enhancers recruit multiple spliceosomal components required for the initial recognition of 5 '- and 3 '- splice sites.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of California System; University of California Irvine; University of Connecticut	Hertel, KJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	khertel@uci.edu	Graveley, Brenton R/C-3108-2013	Hertel, Klemens/0000-0002-7560-9529; Graveley, Brenton/0000-0001-5777-5892	NIGMS NIH HHS [R01 GM062287, R01 GM062516, R01 GM062516-02, GM62287, GM62516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062516, R01GM062287] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BLACK DL, 1995, RNA, V1, P763; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Burge CB, 1999, RNA WORLD, P525; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; Expert-Bezancon A, 2002, J BIOL CHEM, V277, P16614, DOI 10.1074/jbc.M201083200; Fujii S, 2002, EMBO J, V21, P5353, DOI 10.1093/emboj/cdf556; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Li XL, 2000, RNA, V6, P1847, DOI 10.1017/S1355838200000674; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Lund M, 2002, RNA, V8, P166, DOI 10.1017/S1355838202010786; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; Modafferi EF, 1999, RNA, V5, P687, DOI 10.1017/S1355838299990155; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1997, EUKARYOTIC MRNA PROC, P103; Rio Donald C., 1992, Gene Expression, V2, P1; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22740	22747		10.1074/jbc.M301036200	http://dx.doi.org/10.1074/jbc.M301036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12646561	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000183503900076
J	Kim, GS; Hong, JS; Kim, SW; Koh, JM; An, CS; Choi, JY; Cheng, SL				Kim, GS; Hong, JS; Kim, SW; Koh, JM; An, CS; Choi, JY; Cheng, SL			Leptin induces apoptosis via ERK/cPLA2/cytochrome C pathway in human bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); HUMAN POLY(ADP-RIBOSE) POLYMERASE; CYTOCHROME-C; OB/OB MICE; DNA-REPAIR; LONG FORM; OB-R; RECEPTOR; EXPRESSION; DIFFERENTIATION	Leptin, the Ob gene product, has emerged recently as a key regulator of bone mass. However, the mechanism mediating leptin effect remains controversial. Because the action of leptin is dependent on its receptors, we analyzed their expression in osteoblast-lineage primary human bone marrow stromal cells (hBMSC). Both the short and long forms of leptin receptors were detected in hBMSC. Leptin significantly decreased the viability of hBMSC. This cytotoxic effect was prevented by Z-ValAla-Asp-fluoromethylketone, a pan-caspase inhibitor, implicating that leptin-induced hBMSC death was caspase-dependent. Further investigation demonstrated that leptin activated caspase-3 and caspase-9, but not caspase-8, and increased the cleavage of poly-(ADP- ribose) polymerase and cytochrome c release into cytosol. Leptin activated ERK, but not p38 and JNK, and up-regulated cPLA2 activity; the latter was abolished by pre-treatment of cells with the MEK inhibitor (PD98059 or U0126) or cPLA2 inhibitor (AACOCF3). PD98059, U0126, and AACOCF3 also diminished the leptin-induced cytochrome c release into cytosol, cell death, and caspase-3 activation. These data indicated that leptin induced hBMSC apoptosis via ERK/cPLA2/cytochrome c pathway with activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase. To our knowledge, this is the first study demonstrating the direct detrimental effect of leptin on bone cells.	Univ Ulsan, Coll Med, Div Endocrinol & Metab, Asan Med Ctr, Seoul 138736, South Korea; Asan Inst Life Sci, Seoul 138736, South Korea; Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci, Seoul 151742, South Korea; Kyungpook Natl Univ, Dept Biochem, Taegu 700721, South Korea; Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	University of Ulsan; Seoul National University (SNU); Kyungpook National University; Washington University (WUSTL)	Kim, GS (corresponding author), Univ Ulsan, Coll Med, Div Endocrinol & Metab, Asan Med Ctr, 388-1 Poongnap Dong, Seoul 138736, South Korea.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Artwohl M, 2002, INT J OBESITY, V26, P577, DOI 10.1038/sj.ijo.0801947; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; BOULIKAS T, 1991, ANTICANCER RES, V11, P489; Caprio M, 2001, TRENDS ENDOCRIN MET, V12, P65, DOI 10.1016/S1043-2760(00)00352-0; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Cohen B, 2001, J BIOL CHEM, V276, P7697, DOI 10.1074/jbc.C000634200; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Gimble JM, 1998, CRIT REV EUKAR GENE, V8, P141, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.30; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200; Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim CH, 1997, ENDOCR RES, V23, P181, DOI 10.3109/07435809709031852; Kim TD, 2000, COMPOS STRUCT, V49, P21, DOI 10.1016/S0263-8223(99)00122-1; Konopleva M, 1999, BLOOD, V93, P1668, DOI 10.1182/blood.V93.5.1668.405a15_1668_1676; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014-5793(02)02889-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin J, 2000, DOMEST ANIM ENDOCRIN, V19, P53, DOI 10.1016/S0739-7240(00)00064-3; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Park KS, 1997, DIABETES, V46, P1230, DOI 10.2337/diabetes.46.7.1230; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PUZAS JE, 1985, ENDOCRINOLOGY, V116, P2463, DOI 10.1210/endo-116-6-2463; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P9558, DOI 10.1073/pnas.95.16.9558; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; Soldatenkov VA, 1996, INT J ONCOL, V9, P547; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; SURYAWAN A, 1993, COMP BIOCHEM PHYS A, V105, P485, DOI 10.1016/0300-9629(93)90424-3; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	65	102	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21920	21929		10.1074/jbc.M204598200	http://dx.doi.org/10.1074/jbc.M204598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12665505	hybrid			2022-12-25	WOS:000183354200077
J	Larrivee, B; Lane, DR; Pollet, I; Olive, PL; Humphries, RK; Karsan, A				Larrivee, B; Lane, DR; Pollet, I; Olive, PL; Humphries, RK; Karsan, A			Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELLS; C-KIT; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING PATHWAYS; SELF-RENEWAL; APOPTOSIS; PROLIFERATION; ACTIVATION; DIFFERENTIATION; VASCULOGENESIS	Vascular endothelial growth factor ( VEGF) and its receptors play an essential role in the formation and maintenance of the hematopoietic and vascular compartments. The VEGF receptor-2 (VEGFR-2) is expressed on a population of hematopoietic cells, although its role in hematopoiesis is still unclear. In this report, we have utilized a strategy to selectively activate VEGFR-2 and study its effects in primary bone marrow cells. We found that VEGFR-2 can maintain the hematopoietic progenitor population in mouse bone marrow cultured in the absence of exogenous cytokines. Maintenance of the hematopoietic progenitor population is due to increased cell survival with minimal effect on proliferation. Progenitor survival is mainly mediated by activation of the phosphatidylinositol 3'-kinase/Akt pathway. Although VEGFR-2 also activated Erk1/2 mitogen-activated protein kinase, it did not induce cell proliferation, and blockade of this pathway only partially decreased VEGFR-2-mediated survival of hematopoietic progenitors. Thus, the role of VEGFR-2 in hematopoiesis is likely to maintain survival of hematopoietic progenitors through the activation of antiapoptotic pathways.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z4, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1L3, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada; British Columbia Canc Agcy, Terry Fox Labs, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency	Karsan, A (corresponding author), British Columbia Canc Res Ctr, Dept Med Biophys, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Pollet, Ingrid Louise/O-5031-2019; Karsan, Aly/K-2067-2015	Pollet, Ingrid Louise/0000-0001-7207-8294; Humphries, Richard/0000-0003-0540-7005; Larrivee, Bruno/0000-0003-1388-3108				Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Blau C A, 1999, Prog Exp Tumor Res, V36, P162; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Choi K, 1998, DEVELOPMENT, V125, P725; Choi K, 2002, J HEMATOTH STEM CELL, V11, P91, DOI 10.1089/152581602753448568; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gehling UM, 2000, BLOOD, V95, P3106; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hidaka M, 1999, P NATL ACAD SCI USA, V96, P7370, DOI 10.1073/pnas.96.13.7370; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Larrivee B, 2000, INT J MOL MED, V5, P447; Liu Q, 1997, J IMMUNOL, V159, P829; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; Otto KG, 2001, BLOOD, V98, P2077, DOI 10.1182/blood.V98.7.2077; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Richard RE, 2000, BLOOD, V95, P430, DOI 10.1182/blood.V95.2.430; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Schuh AC, 1999, P NATL ACAD SCI USA, V96, P2159, DOI 10.1073/pnas.96.5.2159; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sui XW, 2000, BRIT J HAEMATOL, V110, P63, DOI 10.1046/j.1365-2141.2000.02145.x; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Traver D, 2002, CELL, V108, P731, DOI 10.1016/S0092-8674(02)00686-4; Whitney ML, 2001, J BIOL CHEM, V276, P41191, DOI 10.1074/jbc.M103191200; Xaus J, 2001, IMMUNOBIOLOGY, V204, P543, DOI 10.1078/0171-2985-00091; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng H, 2001, BLOOD, V98, P328, DOI 10.1182/blood.V98.2.328; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	52	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22006	22013		10.1074/jbc.M212158200	http://dx.doi.org/10.1074/jbc.M212158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668684	hybrid			2022-12-25	WOS:000183354200087
J	Tremblay, JJ; Viger, RS				Tremblay, JJ; Viger, RS			Transcription factor GATA-4 is activated by phosphorylation of serine 261 via the cAMP/protein kinase A signaling pathway in gonadal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE GENE-TRANSCRIPTION; NUCLEAR RECEPTOR SF-1; BINDING-PROTEIN-BETA; CYCLIC-AMP; SERTOLI CELLS; MOUSE TESTIS; LEYDIG-CELLS; STAR GENE; EXPRESSION; ENDOTHELIN-1	Gonadal gene expression is regulated by pituitary hormones acting through the cAMP/protein kinase A (PKA) signal transduction pathway. The downstream molecular effectors of these signals, however, have yet to be fully understood. We have recently shown that cAMP stimulation of gonadal cells leads to phosphorylation of the transcription factor GATA-4, a key regulator of gonadal gene expression, thus suggesting that this factor might be a novel target for the cAMP/PKA signaling pathway. We now show that the rapid phosphorylation of GATA-4 induced by cAMP in vivo can be blocked by a PKA-specific inhibitor but not by mitogen-activated protein kinase inhibitors, indicating that GATA-4 is predominantly phosphorylated by PKA in response to cAMP in gonadal cells. In addition, using in vitro kinase assays, we show that PKA phosphorylation of GATA-4 occurs predominantly on an evolutionarily conserved serine residue located at position 261. Phosphorylation of GATA-4 Ser(261) by PKA enhances its transcriptional activity on different gonadal promoters, an effect that was markedly reduced with a S261A mutant. Moreover, the S261A mutant blunted cAMP-induced promoter activity in gonadal cells. Finally, PKA-dependent phosphorylation of GATA-4 also led to enhanced recruitment of the CREB-binding protein coactivator. This recruitment and transcriptional cooperation were dramatically impaired with the S261A mutant. Thus, our results identify GATA-4 as a novel downstream effector of cAMP/PKA signaling in gonadal cells, where phosphorylation of Ser261 and recruitment of CREB-binding protein likely represent a key mechanism for conveying the cAMP responsiveness of gonadal genes that lack classical cAMP regulatory elements.	CHU Laval, Ctr Rech, Ontogeny & Reproduct Res Unit, St Foy, PQ G1V 4G2, Canada; Univ Laval, Ctr Rech Biol Reprod, Dept Obstet & Gynecol, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Viger, RS (corresponding author), CHU Laval, Ctr Rech, Ontogeny & Reproduct Res Unit, Rm T1-49,2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		Tremblay, Jacques J./AAO-2491-2021	Tremblay, Jacques J./0000-0002-4738-6284				ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Hales DB, 2001, ENDOCRINOLOGY, V142, P974, DOI 10.1210/en.142.3.974; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hautala N, 2001, CIRCULATION, V103, P730; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KEENEY DS, 1995, MOL ENDOCRINOL, V9, P1091, DOI 10.1210/me.9.8.1091; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; Ketola I, 1999, ENDOCRINOLOGY, V140, P1470, DOI 10.1210/en.140.3.1470; Kiiveri S, 2002, ENDOCRINOLOGY, V143, P3136, DOI 10.1210/endo.143.8.8939; Kiiveri S, 2002, ENDOCR RES, V28, P647, DOI 10.1081/ERC-120016980; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCoard SA, 2001, BIOL REPROD, V65, P366, DOI 10.1095/biolreprod65.2.366; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Patel MV, 2001, J INVEST DERMATOL, V117, P1559, DOI 10.1046/j.0022-202x.2001.01587.x; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Robert NM, 2002, ENDOCRINOLOGY, V143, P3963, DOI 10.1210/en.2002-220280; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; Siggers P, 2002, MECH DEVELOP, V111, P159, DOI 10.1016/S0925-4773(01)00602-5; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Song KH, 2001, ENDOCRINOLOGY, V142, P5116, DOI 10.1210/en.142.12.5116; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Tremblay AJ, 2001, BIOL REPROD, V64, P1191, DOI 10.1095/biolreprod64.4.1191; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Tremblay JJ, 2001, ENDOCRINOLOGY, V142, P977, DOI 10.1210/en.142.3.977; Tremblay JJ, 2002, ENDOCRINOLOGY, V143, P3935, DOI 10.1210/en.2002-220413; Tremblay JJ, 2001, MOL ENDOCRINOL, V15, P1636, DOI 10.1210/me.15.9.1636; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wooton-Kee CR, 2000, ENDOCRINOLOGY, V141, P1345, DOI 10.1210/en.141.4.1345; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147; Zhang ZF, 2002, ENDOCRINOLOGY, V143, P829, DOI 10.1210/en.143.3.829	52	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22128	22135		10.1074/jbc.M213149200	http://dx.doi.org/10.1074/jbc.M213149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670947	hybrid			2022-12-25	WOS:000183354200101
J	Ciszak, EM; Korotchkina, LG; Dominiak, PM; Sidhu, S; Patel, MS				Ciszak, EM; Korotchkina, LG; Dominiak, PM; Sidhu, S; Patel, MS			Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BENZOYLFORMATE DECARBOXYLASE; MULTIENZYME COMPLEXES; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; DIPHOSPHATE; MOTIF; SITES; TRANSKETOLASE; INTERMEDIATE	The derivative of vitamin B1, thiamin pyrophosphate, is a cofactor of enzymes performing catalysis in pathways of energy production. In alpha(2)beta(2)-heterotetrameric human pyruvate dehydrogenase, this cofactor is used to cleave the C-alpha-C(=O) bond of pyruvate followed by reductive acetyl transfer to lipoyl-dihydrolipoamide acetyltransferase. The dynamic nonequivalence of two, otherwise chemically equivalent, catalytic sites has not yet been understood. To understand the mechanism of action of this enzyme, we determined the crystal structure of the holo-form of human pyruvate dehydrogenase at 1.95-Angstrom resolution. We propose a model for the flip-flop action of this enzyme through a concerted similar to2-Angstrom shuttle-like motion of its heterodimers. Similarity of thiamin pyrophosphate binding in human pyruvate dehydrogenase with functionally related enzymes suggests that this newly defined shuttle-like motion of domains is common to the family of thiamin pyrophosphate-dependent enzymes.	NASA, Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA; Univ Space Res Assoc, Huntsville, AL 35812 USA; SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Universities Space Research Association (USRA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ciszak, EM (corresponding author), NASA, Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA.	Ewa.M.Ciszak@nasa.gov	Dominiak, Paulina Maria/K-7882-2019; Dominiak, Paulina M/U-5181-2018	Dominiak, Paulina M/0000-0002-1466-1243	NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chabriere E, 2001, SCIENCE, V294, P2559, DOI 10.1126/science.1066198; Ciszak E, 2001, ACTA CRYSTALLOGR D, V57, P465, DOI 10.1107/S0907444901000427; DELANO WL, 2002, PHYMOL MOL GRAPHICS; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; Khailova L, 1990, BIOCH PHYSL TDP ENZY, P251; KHAILOVA LS, 1985, BIOCHEM INT, V11, P509; Kleiger G, 2001, BIOCHEMISTRY-US, V40, P14484, DOI 10.1021/bi011016k; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; Kovina MV, 1998, FEBS LETT, V440, P81, DOI 10.1016/S0014-5793(98)01423-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lobell M, 1996, J AM CHEM SOC, V118, P1867, DOI 10.1021/ja951830t; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan K, 1998, BIOCHEMISTRY-US, V37, P1357, DOI 10.1021/bi971835y; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; PERHAM RN, 1996, ALPHA KETO ACID DEHY, P1; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sergienko EA, 2000, BIOCHEMISTRY-US, V39, P13862, DOI 10.1021/bi001214w; Sergienko EA, 2002, BIOCHEMISTRY-US, V41, P3952, DOI 10.1021/bi011860a; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	33	111	122	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21240	21246		10.1074/jbc.M300339200	http://dx.doi.org/10.1074/jbc.M300339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651851	hybrid, Green Submitted			2022-12-25	WOS:000183230500102
J	Fringer, J; Grinnell, F				Fringer, J; Grinnell, F			Fibroblast quiescence in floating collagen matrices - Decrease in serum activation of MEK and RAF but not Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; CELL-PROLIFERATION; CONTRACTION; MYOFIBROBLASTS; INTEGRINS; APOPTOSIS; MEMBRANE	Fibroblasts synthesize, organize, and maintain connective tissues during development and in response to injury and fibrotic disease. Studies on cells in three-dimensional collagen matrices have shown that fibroblasts switch between proliferative and quiescence phenotypes, depending upon whether matrices are attached or floating during matrix remodeling. Previous work showed that cell signaling through the ERK pathway was decreased in fibroblasts in floating matrices. In the current research, we extend the previous findings to show that serum stimulation of fibroblasts in floating matrices does not result in ERK translocation to the nucleus. In addition, there was decreased serum activation of upstream members of the ERK signaling pathway, MEK and Raf, even though Ras became GTP loaded. The findings suggest that quiescence of fibroblasts in floating collagen matrices may result from a defect in Ras coupling to its downstream effectors.	Univ Texas, Dept Cell Biol, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, Dept Cell Biol, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu			NIGMS NIH HHS [GM31321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031321, R01GM031321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fringer J, 2001, J BIOL CHEM, V276, P31047, DOI 10.1074/jbc.M101898200; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graf R, 2002, APOPTOSIS, V7, P493, DOI 10.1023/A:1020634924760; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Grinnell F, 1999, CURR TOPICS PATHOL, V93, P61; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HE YJ, 1994, J CELL BIOL, V126, P457, DOI 10.1083/jcb.126.2.457; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lorena D, 2002, WOUND REPAIR REGEN, V10, P86, DOI 10.1046/j.1524-475X.2002.00201.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mio T, 1996, IN VITRO CELL DEV-AN, V32, P427; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NISHIYAMA T, 1989, MATRIX, V9, P193, DOI 10.1016/S0934-8832(89)80050-2; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pozzi M, 1998, J CELL BIOL, V142, P587; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHOR SL, 1980, J CELL SCI, V41, P159; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SETH A, 1992, J BIOL CHEM, V267, P24796; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Tamariz E, 2002, MOL BIOL CELL, V13, P3915, DOI 10.1091/mbc.E02-05-0291; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; YOSHIZATO K, 1984, ANN PLAS SURG, V13, P9, DOI 10.1097/00000637-198407000-00002; Zhu YK, 2001, IN VITRO CELL DEV-AN, V37, P10; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	54	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20612	20617		10.1074/jbc.M212365200	http://dx.doi.org/10.1074/jbc.M212365200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663662	hybrid			2022-12-25	WOS:000183230500022
J	Kreiling, JL; Byrd, JC; Deisz, RJ; Mizukami, IF; Todd, RF; MacDonald, RG				Kreiling, JL; Byrd, JC; Deisz, RJ; Mizukami, IF; Todd, RF; MacDonald, RG			Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor - Contrasting interactions of full-length and soluble forms of uPAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II/MANNOSE 6-PHOSPHATE RECEPTOR; IGF-II; LIGAND-BINDING; MANNOSE-6-PHOSPHATE RECEPTOR; PERINATAL LETHALITY; MISSENSE MUTATIONS; BETA-GALACTOSIDASE; CELLULAR RECEPTOR; CANCER CELLS; IN-VIVO	Urokinase-type plasminogen activator receptor ( uPAR) binding by the mannose 6-phosphate/insulinlike growth factor II receptor ( Man-6-P/IGF2R) is considered important to Man-6-P/IGF2R tumor suppressor function via regulation of cell surface proteolytic activity. Our goal was to map the uPAR binding site of the Man-6-P/IGF2R by analyzing the uPAR binding characteristics of a panel of minireceptors containing different regions of the Man-6-P/IGF2R extracytoplasmic domain. Coimmunoprecipitation assays revealed that soluble recombinant uPAR ( suPAR) bound the Man-6-P/IGF2R at two distinct sites, one localized to the amino-terminal end of the Man-6-P/IGF2R extracytoplasmic domain ( repeats 1 - 3) and the other to the more carboxyl-terminal end ( repeats 7 - 9). These sites correspond with the positions of the two Man-6-P binding domains of Man-6-P/ IGF2R. Indeed, the suPAR-Man-6-P/IGF2R interaction was inhibited by Man-6-P, and binding-competent suPAR species represented a minor percentage ( 8 - 30%) of the suPAR present. In contrast, Man-6-P/ IGF2R binding of endogenous, full-length uPAR solubilized from plasma membranes of the prostate cancer cell line, PC-3, was not inhibited by Man-6-P. Further studies showed that very little (< 5%) endogenous uPAR was Man-6-P/ IGF2R binding-competent. We conclude that, contrary to previous reports, the interaction between uPAR and Man-6-P/ IGF2R is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/ IGF2R by different mechanisms.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	MacDonald, RG (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.		Todd, Robert/GWM-4486-2022		NCI NIH HHS [5R01CA91885] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHBAROU A, 1994, CANCER RES, V54, P2372; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DeLeon DD, 1996, ENDOCRINOLOGY, V137, P1851, DOI 10.1210/en.137.5.1851; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, ONCOGENE, V10, P1725; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; Devi GR, 1999, CANCER RES, V59, P4314; ELLIS V, 1989, J BIOL CHEM, V264, P2185; FILSON AJ, 1993, DEVELOPMENT, V118, P731; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hankins GR, 1996, ONCOGENE, V12, P2003; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KIESS W, 1989, J BIOL CHEM, V264, P4710; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; MIZUKAMI IF, 1994, CLIN IMMUNOL IMMUNOP, V71, P96, DOI 10.1006/clin.1994.1057; Mohan PM, 1999, CANCER RES, V59, P3369; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Gorman DB, 1999, CANCER RES, V59, P5692; O'Gorman DB, 2002, ENDOCRINOLOGY, V143, P4287, DOI 10.1210/en.2002-220548; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Xing RH, 1997, CANCER RES, V57, P3585	55	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20628	20637		10.1074/jbc.M302249200	http://dx.doi.org/10.1074/jbc.M302249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665524	hybrid			2022-12-25	WOS:000183230500025
J	Schmierer, B; Schuster, MK; Shkumatava, A; Kuchler, K				Schmierer, B; Schuster, MK; Shkumatava, A; Kuchler, K			Activin A signaling induces Smad2, but not Smad3, requiring protein kinase A activity in granulosa cells from the avian ovary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PORCINE FOLLICULAR-FLUID; FUNCTIONAL-CHARACTERIZATION; STRUCTURAL BASIS; DOMESTIC-FOWL; RAT OVARY; INHIBIN-A; RECEPTOR; ACTIVATION; EXPRESSION	Activin A signaling is an important regulator of ovarian granulosa cell function. The cytosolic signal transducer Smad2 is most highly expressed in chicken granulosa cells (cGC) of preovulatory follicles. Moreover, Smad2 shows predominant nuclear localization in freshly isolated cGC, indicating active Smad signaling in vivo. Primary cGC cultured in vitro require activin A to sustain high Smad2 levels, which otherwise drop dramatically in the absence of activin A. This activin A-dependent Smad2 expression is abrogated by protein kinase A (PKA) inhibitors, suggesting a role for PKA in activin signaling. In the absence of activin A, strong PKA activators such as follicle-stimulating hormone (FSH) and 8-bromo-cyclic AMP fail to elicit Smad2 induction. However, FSH and 8-bromo-cyclic AMP boost activin A-dependent Smad2 up-regulation, giving rise to Smad2 levels similar to expression in vivo levels. Interestingly, the effect is specific for Smad2, since expression of the structurally and functionally closely related Smad3 remains entirely unaffected. Hence, activin A induces Smad2, but not Smad3, to high levels requiring PKA activation. Since Smad2 and Smad3 target distinct yet overlapping sets of TGF-beta/activin-responsive genes, the selective Smad2 induction by FSH/activin A could allow FSH to efficiently modulate the transcriptional readout of activin A signaling in avian granulosa cells.	Univ & BioCenter Vienna, Inst Med Biochem, Dept Mol Genet, A-1030 Vienna, Austria	University of Vienna	Kuchler, K (corresponding author), Univ & BioCenter Vienna, Inst Med Biochem, Dept Mol Genet, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	kaku@mol.univie.ac.at	Schmierer, Bernhard/P-4208-2019; kuchler, karl/AAL-6937-2020; Schmierer, Bernhard/C-1416-2009	Schmierer, Bernhard/0000-0002-9082-7022; kuchler, karl/0000-0003-2719-5955; Schmierer, Bernhard/0000-0002-9082-7022				Amsterdam A, 2002, MOL CELL ENDOCRINOL, V187, P69, DOI 10.1016/S0303-7207(01)00701-8; Babu PS, 2000, J BIOL CHEM, V275, P27615; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BURGER HG, 1988, ENDOCRINOLOGY, V122, P1701; CAMERON VA, 1994, ENDOCRINOLOGY, V134, P799, DOI 10.1210/en.134.2.799; Crepieux P, 2001, ONCOGENE, V20, P4696, DOI 10.1038/sj.onc.1204632; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Drummond AE, 2002, ENDOCRINOLOGY, V143, P1423, DOI 10.1210/en.143.4.1423; El-Hefnawy T, 2001, ENDOCRINOLOGY, V142, P4357, DOI 10.1210/en.142.10.4357; ERICKSON GF, 1978, ENDOCRINOLOGY, V103, P1960, DOI 10.1210/endo-103-5-1960; Findlay JK, 1999, TRENDS ENDOCRIN MET, V10, P183, DOI 10.1016/S1043-2760(98)00144-1; FINDLAY JK, 1993, BIOL REPROD, V48, P15, DOI 10.1095/biolreprod48.1.15; Findlay JK, 2001, MOL CELL ENDOCRINOL, V180, P139, DOI 10.1016/S0303-7207(01)00521-4; FINDLAY JK, 1993, OVARY, P413; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Joore J, 1998, MECH DEVELOP, V79, P5, DOI 10.1016/S0925-4773(98)00152-X; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; Mulheron G.W., 1993, OVARY, P337; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PERRY MM, 1978, J ANAT, V125, P481; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; RIVIER J, 1985, BIOCHEM BIOPH RES CO, V133, P120, DOI 10.1016/0006-291X(85)91849-2; ROBERTSON DM, 1985, BIOCHEM BIOPH RES CO, V126, P220, DOI 10.1016/0006-291X(85)90594-7; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Schmierer B, 2003, BIOL REPROD, V68, P620, DOI 10.1095/biolreprod.102.008714; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WOODRUFF TK, 1993, ENDOCRINOLOGY, V132, P725, DOI 10.1210/en.132.2.725; WOODRUFF TK, 1993, ENDOCRINOLOGY, V133, P2998, DOI 10.1210/en.133.6.2998; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yakmovych I, 2001, FASEB J, V15, P553; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	23	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21197	21203		10.1074/jbc.M212425200	http://dx.doi.org/10.1074/jbc.M212425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665510	hybrid			2022-12-25	WOS:000183230500097
J	Spafford, JD; Chen, LN; Feng, ZP; Smit, AB; Zamponi, GW				Spafford, JD; Chen, LN; Feng, ZP; Smit, AB; Zamponi, GW			Expression and modulation of an invertebrate presynaptic calcium channel alpha(1) subunit homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM-CHANNELS; G-PROTEIN INHIBITION; N-TYPE; MOLECULAR DETERMINANTS; STRUCTURAL DETERMINANTS; CA2+ CHANNELS; SYNAPTIC-TRANSMISSION; NEUROPEPTIDE FMRFA; FAST INACTIVATION; BETA-GAMMA	Here we report the first assessment of the expression and modulation of an invertebrate alpha(1) subunit homolog of mammalian presynaptic Ca(v)2 calcium channels ( N-type and P/Q-type) in mammalian cells. Our data show that molluscan channel (LCa(v)2a) isolated from Lymnaea stagnalis is effectively membrane-targeted and electrophysiologically recordable in tsA-201 cells only when the first 44 amino acids of LCav2a are substituted for the corresponding region of rat Ca(v)2.1. When coexpressed with rat accessory subunits, the biophysical properties of LCa(v)2a-5'rbA resemble those of mammalian N-type calcium channels with respect to activation and inactivation, lack of pronounced calcium dependent inactivation, preferential permeation of barium ions, and cadmium block. Consistent with reports of native Lymnaea calcium currents, the LCa(v)2a-5'rbA channel is insensitive to micromolar concentrations of omega-conotoxin GVIA and is not affected by nifedipine, thus confirming that it is not of the L-type. Interestingly, the LCa(v)2a-5'rbA channel is almost completely and irreversibly inhibited by guanosine 5'-3-O-(thio) triphosphate but not regulated by syntaxin1, suggesting that invertebrate presynaptic calcium channels are differently modulated from their vertebrate counterparts.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Neurosci Res Inst, NL-1081 HV Amsterdam, Netherlands	University of Calgary; Vrije Universiteit Amsterdam	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca	Smit, August B/E-8410-2011	Zamponi, Gerald W./0000-0002-0644-9066				Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Barrett CF, 2000, J GEN PHYSIOL, V115, P277, DOI 10.1085/jgp.115.3.277; Berjukow S, 2001, J BIOL CHEM, V276, P17076, DOI 10.1074/jbc.M010491200; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bourinet E, 1996, J NEUROSCI, V16, P4983; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; BREZINA V, 1987, J PHYSIOL-LONDON, V388, P565, DOI 10.1113/jphysiol.1987.sp016632; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Currie KPM, 1997, J NEUROSCI, V17, P4570; Degtiar VE, 2000, J NEUROSCI, V20, P4355, DOI 10.1523/JNEUROSCI.20-12-04355.2000; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dreijer AMC, 1995, INVERTEBR NEUROSCI, V1, P75, DOI 10.1007/BF02331834; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Feng ZP, 2002, J PHYSIOL-LONDON, V539, P53, DOI 10.1113/jphysiol.2001.013125; Feng ZP, 2001, J BIOL CHEM, V276, P15728, DOI 10.1074/jbc.M100406200; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Huber I, 2000, BIOCHEM J, V347, P829, DOI 10.1042/0264-6021:3470829; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2002, J BIOL CHEM, V277, P44399, DOI 10.1074/jbc.M206902200; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Jeziorski MC, 2000, J EXP BIOL, V203, P841; Kaneko S, 2002, J NEUROSCI, V22, P82, DOI 10.1523/JNEUROSCI.22-01-00082.2002; Kawasaki F, 2002, J NEUROSCI, V22, P5856; Kawasaki F, 2000, J NEUROSCI, V20, P4885; Kimura T, 2002, NEUROREPORT, V13, P2389, DOI 10.1097/00001756-200212200-00003; Kits KS, 1996, INVERTEBR NEUROSCI, V2, P9, DOI 10.1007/BF02336657; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Kohn AB, 2001, PARASITOLOGY, V123, P489, DOI 10.1017/S0031182001008691; Kumar PP, 2002, MOL PHARMACOL, V61, P649, DOI 10.1124/mol.61.3.649; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; MANSONHING H, 1989, NATURE, V341, P237, DOI 10.1038/341237a0; MANSONHING H, 1992, NEUROSCI LETT, V137, P133, DOI 10.1016/0304-3940(92)90315-X; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Roullet JB, 1999, J BIOL CHEM, V274, P25439, DOI 10.1074/jbc.274.36.25439; Sather WA, 2003, ANNU REV PHYSIOL, V65, P133, DOI 10.1146/annurev.physiol.65.092101.142345; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200; Staras K, 2002, EUR J NEUROSCI, V15, P109, DOI 10.1046/j.0953-816x.2001.01845.x; Stotz SC, 2001, J BIOL CHEM, V276, P33001, DOI 10.1074/jbc.M104387200; Stotz SC, 2001, TRENDS NEUROSCI, V24, P176, DOI 10.1016/S0166-2236(00)01738-0; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Timmermann DB, 2002, J NEUROSCI RES, V67, P48, DOI 10.1002/jnr.10074; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Wappl E, 2001, J BIOL CHEM, V276, P12730, DOI 10.1074/jbc.M010164200; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; YAKEL JL, 1991, J NEUROPHYSIOL, V65, P1517, DOI 10.1152/jn.1991.65.6.1517; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1996, PFLUG ARCH EUR J PHY, V431, P470; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	66	29	30	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21178	21187		10.1074/jbc.M302212200	http://dx.doi.org/10.1074/jbc.M302212200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12672808	hybrid, Green Published			2022-12-25	WOS:000183230500095
J	Verma, R; Wharram, B; Kovari, I; Kunkel, R; Nihalani, D; Wary, KK; Wiggins, RC; Killen, P; Holzman, LB				Verma, R; Wharram, B; Kovari, I; Kunkel, R; Nihalani, D; Wary, KK; Wiggins, RC; Killen, P; Holzman, LB			Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; ZIPPER-BEARING KINASE; SIGNAL-TRANSDUCTION; LIPID RAFTS; GLOMERULAR PROTEIN; PODOCYTE STRUCTURE; TYROSINE KINASES; FINNISH TYPE; MICE; GENE	Recent investigations have focused on characterizing the molecular components of the podocyte intercellular junction, because several of these components, including Nephrin, are functionally necessary for development of normal podocyte structure and filter integrity. Accumulating evidence suggests that the Nephrin-associated protein complex is a signaling nexus. As such, Nephrin-dependent signaling might be mediated in part through Nephrin phosphorylation. Described are biochemical and mouse genetics experiments demonstrating that membrane-associated Nephrin is tyrosine-phosphorylated by the Src family kinase Fyn. Nephrin fractionated in detergent-resistant glomerular membrane fractions with Fyn and Yes. Fyn directly bound Nephrin via its SH3 domain, and Fyn directly phosphorylated Nephrin. Glomeruli in which Fyn, Yes, or Fyn and Yes were genetically deleted in mice were characterized to explore the relationship between these kinases and Nephrin. Fyn deletion resulted in coarsening of podocyte foot processes and marked attenuation of Nephrin phosphorylation in isolated glomerular detergent-resistant membrane fractions. Yes deletion had no identifiable effect on podocyte morphology but dramatically increased Nephrin phosphorylating activity. Similar to Fyn deletion, simultaneous deletion of Fyn and Yes reduced Nephrin phosphorylating activity. These results demonstrate that endogenous Fyn catalyzes Nephrin phosphorylation in podocyte detergent-resistant membrane fractions. Although Yes appears to effect the regulation of Nephrin phosphorylation, the mechanism by which this occurs requires investigation.	Univ Michigan, Sch Med, Div Nephrol, Dept Internal Med, Ann Arbor, MI 48109 USA; Dept Vet Affairs, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Texas Med Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Div Nephrol, Dept Internal Med, 1560 MSRB 2, Ann Arbor, MI 48109 USA.		nihalani, deepak/AAK-9453-2020	Holzman, Lawrence/0000-0002-8961-234X; Wary, Kishore/0000-0001-8851-8565; Wiggins, Roger/0000-0002-1166-2849				Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; LAINE J, 1993, KIDNEY INT, V44, P867, DOI 10.1038/ki.1993.324; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Moeller MJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015614.68893.0B; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Oved S, 2002, NATURE, V416, P133, DOI 10.1038/416133a; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8; Smoyer WE, 1998, J MOL MED, V76, P172, DOI 10.1007/s001090050206; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Werlen G, 2002, CURR OPIN IMMUNOL, V14, P299, DOI 10.1016/S0952-7915(02)00339-4; Wharram BL, 2000, J CLIN INVEST, V106, P1281, DOI 10.1172/JCI7236; Yu CCK, 2001, CURR BIOL, V11, P34, DOI 10.1016/S0960-9822(00)00024-5	31	186	195	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20716	20723		10.1074/jbc.M301689200	http://dx.doi.org/10.1074/jbc.M301689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668668	hybrid			2022-12-25	WOS:000183230500037
J	Zhang, HB; Nohr, J; Jensen, CH; Petersen, RK; Bachmann, E; Teisner, B; Larsen, LK; Mandrup, S; Kristiansen, K				Zhang, HB; Nohr, J; Jensen, CH; Petersen, RK; Bachmann, E; Teisner, B; Larsen, LK; Mandrup, S; Kristiansen, K			Insulin-like growth factor-1/insulin bypasses Pref-1/FA1-mediated inhibition of adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 PREADIPOCYTE DIFFERENTIATION; CIRCULATING GENE-PRODUCT; ACTIVATED PROTEIN-KINASE; FETAL ANTIGEN-1 MFA1; FACTOR-I; ADIPOSE CONVERSION; TRANSCRIPTIONAL REGULATION; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; S6 KINASE	Pref-1 is a highly glycosylated Delta-like transmembrane protein containing six epidermal growth factor-like repeats in the extracellular domain. Pref-1 is abundantly expressed in preadipocytes, but expression is down-regulated during adipocyte differentiation. Forced expression of Pref-1 in 3T3-L1 cells was reported to inhibit adipocyte differentiation. Here we show that efficient and regulated processing of Pref-1 occurs in 3T3-L1 preadipocytes releasing most of the extracellular domain as a 50-kDa heterogeneous protein, previously isolated and characterized as FA1. Unexpectedly, we found that forced expression of the soluble form, FA1, or full-length Pref-1 did not inhibit adipocyte differentiation of 3T3-L1 cells when differentiation was induced by standard treatment with methylisobutylxanthine, dexamethasone, and high concentrations of insulin. However, forced expression of either form of Pref-1/FA1 in 3T3-L1 or 3T3-F442A cells inhibited adipocyte differentiation when insulin or insulin-like growth factor-1 (IGF-1) was omitted from the differentiation mixture. We demonstrate that the level of the mature form of the IGF-1 receptor is reduced and that IGF-1-dependent activation of p42/p44 mitogen-activated protein kinases (MAPKs) is compromised in preadipocytes with forced expression of Pref-1. This is accompanied by suppression of clonal expansion and terminal differentiation. Accordingly, supplementation with insulin or IGF-1 rescued p42/p44 MAPK activation, clonal expansion, and adipocyte differentiation in a dose-dependent manner.	Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Univ So Denmark, Dept Immunol & Microbiol, DK-5000 Odense C, Denmark; Rheoscience, DK-2610 Rodovre, Denmark	University of Southern Denmark; University of Southern Denmark	Kristiansen, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.	kak@bmb.sdu.dk	Mandrup, Susanne/B-6693-2008; Jensen, Charlotte Harken/AAZ-1738-2020; Kristiansen, Karsten/J-5148-2014; Jensen, Charlotte Harken/P-4612-2014	Jensen, Charlotte Harken/0000-0001-9683-8761; Kristiansen, Karsten/0000-0002-6024-0917; Jensen, Charlotte Harken/0000-0001-9683-8761; Mandrup, Susanne/0000-0002-0961-5787				Bachmann E, 1996, J REPROD FERTIL, V107, P279; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; BIRGITTE U, 1999, J BIOL CHEM, V43, P30864; BONEY CM, 1994, ENDOCRINOLOGY, V135, P1863, DOI 10.1210/en.135.5.1863; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Carlsson C, 1997, ENDOCRINOLOGY, V138, P3940, DOI 10.1210/en.138.9.3940; DEDORA JF, 1997, MOL CELL BIOL, V17, P6068; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; FAY TN, 1988, EUR J OBSTET GYN R B, V29, P73, DOI 10.1016/0028-2243(88)90167-0; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hansen JB, 2002, J BIOL CHEM, V277, P26335, DOI 10.1074/jbc.M203870200; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; JENSEN CH, 1993, HUM REPROD, V8, P635, DOI 10.1093/oxfordjournals.humrep.a138110; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; KELLER DC, 1993, BLOOD, V82, P1428; Krogh TN, 1997, EUR J BIOCHEM, V244, P334, DOI 10.1111/j.1432-1033.1997.00334.x; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Liu KN, 2002, MOL CELL ENDOCRINOL, V194, P51, DOI 10.1016/S0303-7207(02)00188-0; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; OHSUMI J, 1991, FEBS LETT, V288, P13, DOI 10.1016/0014-5793(91)80991-B; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Rosen ED, 2000, GENE DEV, V14, P1293; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Ruiz-Hidalgo MJ, 2002, EXP CELL RES, V274, P178, DOI 10.1006/excr.2001.5464; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; Smas CM, 1998, J BIOL CHEM, V273, P31751, DOI 10.1074/jbc.273.48.31751; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Sorisky A, 1999, CRIT REV CL LAB SCI, V36, P1, DOI 10.1080/10408369991239169; STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; YIN TG, 1992, J BIOL CHEM, V267, P8347	63	41	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20906	20914		10.1074/jbc.M300022200	http://dx.doi.org/10.1074/jbc.M300022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651852	hybrid			2022-12-25	WOS:000183230500061
J	Nagy, T; Nurizzo, D; Davies, GJ; Biely, P; Lakey, JH; Bolam, DN; Gilbert, HJ				Nagy, T; Nurizzo, D; Davies, GJ; Biely, P; Lakey, JH; Bolam, DN; Gilbert, HJ			The alpha-glucuronidase, GlcA67A, of Cellvibrio japonicus utilizes the carboxylate and methyl groups of aldobiouronic acid as important substrate recognition determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLASE FAMILY 10; CELLULOSA XYLANASE; TRICHODERMA-REESEI; ACTIVE-SITE; BINDING; XYLOOLIGOSACCHARIDES; SPECIFICITY; REFINEMENT; RESIDUES; ENZYMES	alpha-Glucuronidases are key components of the ensemble of enzymes that degrade the plant cell wall. They hydrolyze the alpha1,2-glycosidic bond between 4-O-methyl-D-glucuronic acid (4-O-MeGlcA) and the xylan or xylooligosaccharide backbone. Here we report the crystal structure of an inactive mutant (E292A) of the alpha-glucuronidase, GlcA67A, from Cellvibrio japonicus in complex with its substrate. The data show that the 4-O-methyl group of the substrate is accommodated within a hydrophobic sheath flanked by Val-210 and Trp-160, whereas the carboxylate moiety is located within a positively charged region of the substrate-binding pocket. The carboxylate side chains of Glu-393 and Asp-365, on the "beta-face" of 4-O-MeGlcA, form hydrogen bonds with a water molecule that is perfectly positioned to mount a nucleophilic attack at the anomeric carbon of the target glycosidic bond, providing further support for the view that, singly or together, these amino acids function as the catalytic base. The capacity of reaction products and product analogues to inhibit GlcA67A shows that the 4-O-methyl group, the carboxylate, and the xylose sugar of aldobiouronic acid all play an important role in substrate binding. Site-directed mutagenesis informed by the crystal structure of enzyme-ligand complexes was used to probe the importance of highly conserved residues at the active site of GlcA67A. The biochemical properties of K288A, R325A, and K360A show that a constellation of three basic amino acids ( Lys-288, Arg-325, and Lys-360) plays a critical role in binding the carboxylate moiety of 4-O-MeGlcA. Disruption of the apolar nature of the pocket created by Val-210 (V210N and V210S) has a detrimental effect on substrate binding, although the reduction in affinity is not reflected by an inability to accommodate the 4-O-methyl group. Replacing the two tryptophan residues that stack against the sugar rings of the substrate with alanine (W160A and W543A) greatly reduced activity.	Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Slovak Acad Sci, Inst Chem, Bratislava 84238, Slovakia	Newcastle University - UK; University of York - UK; Slovak Academy of Sciences	Gilbert, HJ (corresponding author), Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Biely, Peter/ABF-3465-2020; Davies, Gideon J/A-9042-2011	Biely, Peter/0000-0002-9915-7707; Davies, Gideon J/0000-0002-7343-776X; Bolam, David/0000-0003-0314-3122				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; Biely P, 2000, BBA-GEN SUBJECTS, V1474, P360, DOI 10.1016/S0304-4165(00)00029-5; Biely P, 2000, ANAL BIOCHEM, V286, P289, DOI 10.1006/abio.2000.4810; BRETT CT, 1996, PHYSL BIOCH PLANT CE, V1, P16; BRONNENMEIER K, 1995, MICROBIOL-SGM, V141, P2033, DOI 10.1099/13500872-141-9-2033; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; COUGHLAN MP, 1993, BIOTECHNOL APPL BIOC, V17, P259; Coutinho PM, 1999, ROY SOC CH, P3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Sinnott ML, 1998, BIOCHEM SOC T, V26, P160, DOI 10.1042/bst0260160; STRYER L, 2002, BIOCHEMISTRY-US, P50; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; UCHIDA H, 1992, BIOSCI BIOTECH BIOCH, V56, P1608, DOI 10.1271/bbb.56.1608; WIGLEY DB, 1987, BIOCHEM BIOPH RES CO, V149, P927, DOI 10.1016/0006-291X(87)90497-9; Zaide G, 2001, EUR J BIOCHEM, V268, P3006, DOI 10.1046/j.1432-1327.2001.02193.x	25	25	26	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20286	20292		10.1074/jbc.M302205200	http://dx.doi.org/10.1074/jbc.M302205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654910	hybrid			2022-12-25	WOS:000183078000091
J	Nakagawa, T; Hirano, Y; Inomata, A; Yokota, S; Miyachi, K; Kaneda, M; Umeda, M; Furukawa, K; Omata, S; Horigome, T				Nakagawa, T; Hirano, Y; Inomata, A; Yokota, S; Miyachi, K; Kaneda, M; Umeda, M; Furukawa, K; Omata, S; Horigome, T			Participation of a fusogenic protein, glyceraldehyde-3-phosphate dehydrogenase, in nuclear membrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; LAMIN-B RECEPTOR; CELL-FREE SYSTEM; FORMATION INVITRO; PORE COMPLEXES; GTP HYDROLYSIS; EGG EXTRACTS; RAN GTPASE; ENVELOPE; FUSION	We found an autoimmune serum, K199, that strongly suppresses nuclear membrane assembly in a cell-free system involving a Xenopus egg extract. Four different antibodies that suppress nuclear assembly were affinity-purified from the serum using Xenopus egg cytosol proteins. Three proteins recognized by these antibodies were identified by partial amino acid sequencing to be glyceraldehyde-3-phosphate dehydrogenase (GAPDH), fructose-1,6-bisphosphate aldolase, and the regulator of chromatin condensation 1. GAPDH is known to be a fusogenic protein. To verify the participation of GAPDH in nuclear membrane fusion, authentic antibodies against human and rat GAPDH were applied, and strong suppression of nuclear assembly at the nuclear membrane fusion step was observed. The nuclear assembly activity suppressed by antibodies was recovered on the addition of purified chicken GAPDH. A peptide with the sequence of amino acid residues 70-94 of GAPDH, which inhibits GAPDH-induced phospholipid vesicle fusion, inhibited nuclear assembly at the nuclear membrane fusion step. We propose that GAPDH plays a crucial role in the membrane fusion step in nuclear assembly in a Xenopus egg extract cell-free system.	Niigata Univ, Fac Sci, Dept Biochem, Niigata 9502181, Japan; Niigata Univ, Grad Sch Sci & Technol, Course Funct Biol, Niigata 9502181, Japan; Yamanashi Med Univ, Biol Lab, Tamaho, Yamanashi 4093898, Japan; Hlth Sci Res Inst, Keigu Med Clin, Kanagawa 2300023, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 1130021, Japan; Niigata Univ, Ctr Instrumental Anal, Niigata 9502181, Japan	Niigata University; Niigata University; University of Yamanashi; Tokyo Metropolitan Institute of Medical Science; Niigata University	Horigome, T (corresponding author), Niigata Univ, Fac Sci, Dept Biochem, Igarashi 2, Niigata 9502181, Japan.	thori@chem.sc.niigata-u.ac.jp	Hirano, Yasuhiro/AAN-4617-2021	Hirano, Yasuhiro/0000-0001-7339-4053				ARCARI P, 1989, BIOCHEM GENET, V27, P439, DOI 10.1007/BF02399673; BENAVENTE R, 1989, CHROMOSOMA, V98, P233, DOI 10.1007/BF00327308; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; Bodoor K, 1999, J CELL SCI, V112, P2253; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; de Arcuri BF, 1999, BIOCHEM BIOPH RES CO, V262, P586, DOI 10.1006/bbrc.1999.1243; Drummond S, 1999, J CELL BIOL, V144, P225, DOI 10.1083/jcb.144.2.225; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Han XL, 1998, BBA-BIOMEMBRANES, V1414, P95, DOI 10.1016/S0005-2736(98)00154-0; Haraguchi T, 2000, J CELL SCI, V113, P779; Hessler RJ, 1998, J LEUKOCYTE BIOL, V63, P331, DOI 10.1002/jlb.63.3.331; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Imai N, 1997, J BIOCHEM-TOKYO, V122, P1024; Kaneda M, 1997, J BIOCHEM-TOKYO, V122, P1233; Kawahire S, 1997, J BIOCHEM-TOKYO, V121, P881, DOI 10.1093/oxfordjournals.jbchem.a021669; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KONSTANTINOV K, 1995, CLIN IMMUNOL IMMUNOP, V74, P89, DOI 10.1006/clin.1995.1013; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Miyachi K, 1996, MOL BIOL REP, V23, P227, DOI 10.1007/BF00351173; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; NICKELLS RW, 1988, J CELL BIOL, V107, P1901, DOI 10.1083/jcb.107.5.1901; NICKOWITZ RE, 1994, GASTROENTEROLOGY, V106, P193, DOI 10.1016/S0016-5085(94)95333-3; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PIECHACZYK M, 1984, NATURE, V312, P469, DOI 10.1038/312469a0; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sasagawa S, 1999, EUR J CELL BIOL, V78, P593, DOI 10.1016/S0171-9335(99)80025-9; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Takano M, 2002, EUR J BIOCHEM, V269, P943, DOI 10.1046/j.0014-2956.2001.02730.x; Ukaji F, 1999, ANN RHEUM DIS, V58, P169, DOI 10.1136/ard.58.3.169; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 2001, CURR BIOL, V11, P208, DOI 10.1016/S0960-9822(01)00053-7	54	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20395	20404		10.1074/jbc.M210824200	http://dx.doi.org/10.1074/jbc.M210824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651855	hybrid			2022-12-25	WOS:000183078000105
J	Nagai, K; Arai, H; Yanagita, M; Matsubara, T; Kanamori, H; Nakano, T; Iehara, N; Fukatsu, A; Kita, T; Doi, T				Nagai, K; Arai, H; Yanagita, M; Matsubara, T; Kanamori, H; Nakano, T; Iehara, N; Fukatsu, A; Kita, T; Doi, T			Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESANGIAL CELL-PROLIFERATION; EXTRACELLULAR-MATRIX; GAS6; WARFARIN; MICE; GLOMERULONEPHRITIS; INHIBITION; THROMBOSIS; ANTAGONIST; MECHANISM	Nephropathy is one of the most common complications of diabetes mellitus. Glomerular hypertrophy is a hallmark in the early phase of the nephropathy. The mechanism of glomerular hypertrophy, however, remains incompletely understood. We have reported that Gas6 (growth arrest-specific gene 6) and its receptor, Axl, play a key role in the development of glomerulonephritis. Here we show the important role of Gas6/Axl in the pathogenesis of diabetic glomerular hypertrophy. In streptozotocin (STZ)-induced diabetic rats, mesangial and glomerular hypertrophy and an increase in the glomerular filtration rate (GFR) and albuminuria were observed after 12 weeks of STZ injection. The glomerular expression of Gas6 and Axl was increased in those rats. Administration of warfarin inhibited mesangial and glomerular hypertrophy and the increase in GFR and albuminuria in STZ rats. Moreover, we found less mesangial hypertrophy in STZ-treated Gas6 knockout mice than control mice. In vitro we found that stimulation of mesangial cells with Gas6 resulted in mesangial cell hypertrophy. Thus we have found a novel mechanism of glomerular hypertrophy through the Gas6/Axl-mediated pathway in the development of diabetic nephropathy. Inhibition of the Gas6/Axl pathway in diabetic patients might be beneficial to slow down the progression of diabetic nephropathy.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Artificial Kidneys, Kyoto 6068507, Japan; Shionogi & Co Ltd, Discovery Res Lab, Osaka 5530002, Japan; Univ Tokushima, Dept Clin Biol & Med, Tokushima 7708503, Japan	Kyoto University; Kyoto University; Kyoto University; Shionogi & Company Limited; Tokushima University	Nagai, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.		Arai, Hidenori/P-9816-2017; FUKATSU, ATSUSHI/R-7941-2019	Arai, Hidenori/0000-0002-9000-6849; Yanagita, Motoko/0000-0002-0339-9008				Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; Booth SL, 2000, NUTR REV, V58, P20, DOI 10.1111/j.1753-4887.2000.tb01820.x; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Gallus AS, 2000, MED J AUSTRALIA, V172, P600, DOI 10.5694/j.1326-5377.2000.tb124127.x; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P2132, DOI 10.1093/ndt/17.12.2132; HOLFORD NHG, 1986, CLIN PHARMACOKINET, V11, P483, DOI 10.2165/00003088-198611060-00005; Hostetter TH, 2001, J CLIN INVEST, V107, P161, DOI 10.1172/JCI12066; Kaizu Kazo, 1991, Journal of Diabetic Complications, V5, P92, DOI 10.1016/0891-6632(91)90030-S; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Krolewski M, 1996, KIDNEY INT, V50, P2041, DOI 10.1038/ki.1996.527; Lehmann R, 2000, CLIN CHIM ACTA, V297, P135, DOI 10.1016/S0009-8981(00)00240-0; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MAKINO H, 1992, VIRCHOWS ARCH B, V62, P19, DOI 10.1007/BF02899661; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604; Stockelman MG, 1998, AM J PHYSIOL-RENAL, V275, pF154, DOI 10.1152/ajprenal.1998.275.1.F154; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yanagita M, 2002, J CLIN INVEST, V110, P239, DOI 10.1172/JCI200214861; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Yanagita M, 1999, J AM SOC NEPHROL, V10, P2503; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; Ziswiler R, 1998, J AM SOC NEPHROL, V9, P2055; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9	36	85	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18229	18234		10.1074/jbc.M213266200	http://dx.doi.org/10.1074/jbc.M213266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644472	Green Submitted, hybrid			2022-12-25	WOS:000182838300084
J	Ancey, C; Kuster, A; Haan, S; Herrmann, A; Heinrich, PC; Muller-Newen, G				Ancey, C; Kuster, A; Haan, S; Herrmann, A; Heinrich, PC; Muller-Newen, G			A fusion protein of the gp130 and interleukin-6R alpha ligand-binding domains acts as a potent interleukin-6 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; SOLUBLE IL-6 RECEPTOR; MONOCLONAL-ANTIBODY; NONPEPTIDE ANTAGONIST; RHEUMATOID-ARTHRITIS; ACTIVATION; ASSOCIATION; EXPRESSION; COMPLEX; IDENTIFICATION	Interleukin (IL)-6 is involved in the maintenance and progression of several diseases such as multiple myeloma, rheumatoid arthritis, or osteoporosis. The present work aims at the development of an IL-6 inhibitor for the use in anti-cytokine therapies. The IL-6 receptor is composed of two different subunits, an alpha-subunit (IL-6Ralpha) that binds IL-6 with low affinity and a beta-subunit (gp130) that binds the IL-6.IL-6Ralpha complex with high affinity and as a result triggers intracellular signaling. In its soluble form, gp130 is a natural antagonist that neutralizes IL-6.soluble IL-6Ralpha complexes. It was our strategy to appropriately fuse the two receptor subunit fragments involved in IL-6 receptor complex formation to bind IL-6 with high affinity and to antagonize its effects. The ligand-binding domains of gp130 (D1-D2-D3) and IL-6Ralpha (D2-D3) were connected using three different linkers. The resulting constructs were expressed in stably transfected insect cells and tested for their ability to inhibit IL-6 activity in several in vitro systems. All fusion proteins were strong inhibitors of IL-6 signaling and abrogated IL-6-induced phosphorylation of STAT3, proliferation of transfected Ba/F3 cells, and induction of acute-phase protein synthesis. As intended, the fused receptors were much more effective than the separately expressed soluble receptor proteins. The fusion protein strategy presented here can also be applied to other cytokines that signal via receptors composed of two different subunits to design new potent inhibitors for anticytokine therapies.	Univ Klinikum RWTH Aachen, Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Heinrich, PC (corresponding author), Univ Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.							AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Ciapponi L, 1997, NAT BIOTECHNOL, V15, P997, DOI 10.1038/nbt1097-997; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; EHLERS M, 1994, J IMMUNOL, V153, P1744; Goldenberg MM, 1999, CLIN THER, V21, P75, DOI 10.1016/S0149-2918(00)88269-7; Hayashi M, 2002, P NATL ACAD SCI USA, V99, P14728, DOI 10.1073/pnas.232562799; Hayashi M, 2002, J PHARMACOL EXP THER, V303, P104, DOI 10.1124/jpet.102.036137; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HONDA M, 1992, J IMMUNOL, V148, P2175; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Kurth I, 1999, J IMMUNOL, V162, P1480; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Moritz RL, 1999, GROWTH FACTORS, V16, P265, DOI 10.3109/08977199909069145; Muller-Newen G, 1998, J IMMUNOL, V161, P6347; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Pflanz S, 2000, J IMMUNOL, V165, P7042, DOI 10.4049/jimmunol.165.12.7042; RACADOT E, 1995, CYTOKINES MOL THER, V1, P133; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WENDLING D, 1993, J RHEUMATOL, V20, P259; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	33	29	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16968	16972		10.1074/jbc.C300081200	http://dx.doi.org/10.1074/jbc.C300081200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12646580	hybrid			2022-12-25	WOS:000182818600071
J	Ban, T; Hamada, D; Hasegawa, K; Naiki, H; Goto, Y				Ban, T; Hamada, D; Hasegawa, K; Naiki, H; Goto, Y			Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-MICROGLOBULIN	Real-time monitoring of fibril growth is essential to clarify the mechanism of amyloid fibril formation. Thioflavin T (ThT) is a reagent known to become strongly fluorescent upon binding to amyloid fibrils. Here, we show that, by monitoring ThT fluorescence with total internal reflection fluorescence microscopy (TIRFM), amyloid fibrils of beta2-microgobulin (beta2-m) can be visualized without requiring covalent fluorescence labeling. One of the advantages of TIRFM would be that we selectively monitor fibrils lying along the slide glass, so that we can obtain the exact length of fibrils. This method was used to follow the kinetics of seed-dependent beta2-m fibril extension. The extension was unidirectional with various rates, suggesting the heterogeneity of the amyloid structures. Since ThT binding is common to all amyloid fibrils, the present method will have general applicability for the analysis of amyloid fibrils. We confirmed this with the octapeptide corresponding to the C terminus derived from human medin and the Alzheimer's amyloid beta-peptide.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan; Fukui Med Univ, Dept Pathol, Fukui 9101193, Japan; Japan Sci & Technol Corp, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Hamada, Daizo/F-3307-2011; Naiki, Hironobu/G-5599-2014; Hamada, Daizo/N-1118-2016	Hamada, Daizo/0000-0002-1799-5476				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Grimbergen RFP, 1999, ACTA CRYSTALLOGR A, V55, P84, DOI 10.1107/S0108767398008897; Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; Hamada D, 2002, PROTEIN SCI, V11, P2417, DOI 10.1110/ps.0217702; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Inoue Y, 2001, J BIOL CHEM, V276, P35227, DOI 10.1074/jbc.C100304200; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Yamasaki R, 1999, J MOL BIOL, V292, P965, DOI 10.1006/jmbi.1999.3129	24	285	291	3	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16462	16465		10.1074/jbc.C300049200	http://dx.doi.org/10.1074/jbc.C300049200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12646572	hybrid, Green Published			2022-12-25	WOS:000182818600002
J	Iwamoto, T; Okumura, S; Iwatsubo, K; Kawabe, JI; Ohtsu, K; Sakai, I; Hashimoto, Y; Izumitani, A; Sango, K; Ajiki, K; Toya, Y; Umemura, S; Goshima, Y; Arai, N; Vatner, SF; Ishikawa, Y				Iwamoto, T; Okumura, S; Iwatsubo, K; Kawabe, JI; Ohtsu, K; Sakai, I; Hashimoto, Y; Izumitani, A; Sango, K; Ajiki, K; Toya, Y; Umemura, S; Goshima, Y; Arai, N; Vatner, SF; Ishikawa, Y			Motor dysfunction in type 5 adenylyl cyclase-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-RECEPTORS; GENE-EXPRESSION; D1; STRIATUM	Various neurotransmitters, such as dopamine, stimulate adenylyl cyclase to produce cAMP, which regulates neuronal functions. Genetic disruption of the type 5 adenylyl cyclase isoform led to a major loss of adenylyl cyclase activity in a striatum-specific manner with a small increase in the expression of a few other adenylyl cyclase isoforms. D1 dopaminergic agonist-stimulated adenylyl cyclase activity was attenuated, and this was accompanied by a decrease in the expression of the D1 dopaminergic receptor and G(s)alpha. D2 dopaminergic agonist-mediated inhibition of adenylyl cyclase activity was also blunted. Type 5 adenylyl cyclase-null mice exhibited Parkinsonian-like motor dysfunction, i.e. abnormal coordination and bradykinesia detected by Rotarod and pole test, respectively, and to a lesser extent locomotor impairment was detected by open field tests. Selective D1 or D2 dopaminergic stimulation improved some of these disorders in this mouse model, suggesting the partial compensation of each dopaminergic receptor signal through the stimulation of remnant adenylyl cyclase isoforms. These findings extend our knowledge of the role of an effector enzyme isoform in regulating receptor signaling and neuronal functions and imply that this isoform provides a site of convergence of both D1 and D2 dopaminergic signals and balances various motor functions.	Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Neuropharmacol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Med, Yokohama, Kanagawa 2360004, Japan; Tokyo Metropolitan Inst Neurosci, Dept Clin Neuropathol, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Dept Anat & Embryol, Tokyo 1838526, Japan; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Yokohama City University; Yokohama City University; Yokohama City University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ishikawa, Y (corresponding author), Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan.	ishikayo@umdnj.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL059729, P01HL059139] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Brandon EP, 1998, J NEUROSCI, V18, P3639; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Gerfen CR, 2002, J NEUROSCI, V22, P5042, DOI 10.1523/JNEUROSCI.22-12-05042.2002; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HARDMAN JG, 2001, GOODMAN GILMANS PHAR, P447; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HESS EJ, 1986, EUR J PHARMACOL, V121, P31, DOI 10.1016/0014-2999(86)90389-4; HESS EJ, 1987, MOL PHARMACOL, V31, P50; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Lee KW, 2002, J NEUROSCI, V22, P7931; MARSHALL JF, 1989, BRAIN RES, V493, P247, DOI 10.1016/0006-8993(89)91160-8; Matsuura K, 1997, J NEUROSCI METH, V73, P45, DOI 10.1016/S0165-0270(96)02211-X; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; Mons N, 1998, LIFE SCI, V62, P1647, DOI 10.1016/S0024-3205(98)00122-2; Onda T, 2001, J BIOL CHEM, V276, P47785, DOI 10.1074/jbc.M107233200; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Smith DE, 2000, PEDIATR NEUROL, V23, P33, DOI 10.1016/S0887-8994(00)00134-X; Surmeier D J, 1998, Adv Pharmacol, V42, P1020; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; XIE GX, 1994, P NATL ACAD SCI USA, V91, P3779, DOI 10.1073/pnas.91.9.3779; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	26	86	91	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16936	16940		10.1074/jbc.C300075200	http://dx.doi.org/10.1074/jbc.C300075200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12665504	hybrid			2022-12-25	WOS:000182818600067
J	Sonderegger, CK; Vogt, PK				Sonderegger, CK; Vogt, PK			Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts	ONCOGENE			English	Article						corepressor; TLE1; FoxG1; oncogenic transformation; chicken embryo fibroblasts	TRANSCRIPTIONAL REPRESSION; ONCOGENIC TRANSFORMATION; GROUCHO; PROTEIN; EXPRESSION; AML1; OLIGOMERIZATION; IDENTIFICATION; INTERACTS; HOMOLOGS	The oncoprotein Qin is a member of the winged helix family of transcriptional regulators. The region C-terminal to its winged helix DNA-binding domain is required for transformation of chicken embryo fibroblasts. We isolated the corepressor TLE1 as a binding partner for Qin in a yeast two-hybrid screen and localized the TLE1-binding region to a 60 amino-acid stretch directly C-terminal of the winged helix domain of Qin. We show in vivo interaction of full-length Qin and TLE1 in a mammalian two-hybrid system. Coexpression of TLE1-binding Qin and TLE1 induces phosphorylation of TLEI. The DNA-binding activity of Qin is not required for this function. Binding of Qin to TLE1 correlates with Qin-induced transformation. Addition of the TLE1-binding motif WRPW to the C-terminus of a transformation-defective Qin deletion mutant restores binding to TLE1 and significantly enhances transformation. Expression of TLE1 in CEF by the retroviral vector RCAS enhances cell growth and induces formation of agar colonies.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; AOKI M, 2002, COMMUNICATION; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chang HW, 1996, ONCOGENE, V13, P441; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; NISHIZAWA M, 2002, UNPUB; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; SONDEREGGER CK, 2003, IN PRESS ONCOGENE; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	33	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1749	1757		10.1038/sj.onc.1206308	http://dx.doi.org/10.1038/sj.onc.1206308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660810				2022-12-25	WOS:000181678200001
J	Fischer, L; Szellas, D; Radmark, O; Steinhilber, D; Werz, O				Fischer, L; Szellas, D; Radmark, O; Steinhilber, D; Werz, O			Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors	FASEB JOURNAL			English	Article						leukotriene; polymorphonuclear leukocytes; inflammation; MAPK; calcium	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-NEUTROPHILS; PRODUCT FORMATION; MONO-MAC-6 CELLS; IN-VITRO; LEUKOTRIENES; CALCIUM; TRANSLOCATION; STIMULATION; PEROXIDASE	Nonredox-type 5-lipoxygenase (5-LO) inhibitors such as ZM230487 or L-739.010 potently suppress leukotriene biosynthesis at low cellular peroxide tone. Here, we show that inhibition of 5-LO product formation by nonredox-type 5-LO inhibitors in human isolated polymorphonuclear leukocytes (PMNL) depends on the activation pathway of 5-LO. Thus, compared with 5-LO product synthesis induced by the Ca2+-mobilizing agent ionophore A23187, cell stress-induced 5-LO product formation involving 5-LO kinase pathways required similar to10- to 100-fold higher concentrations of ZM230487 or L-739.010 for comparable 5-LO inhibition. No such differences were observed for the iron ligand-type 5-LO inhibitor BWA4C or the novel-type 5-LO inhibitors hyperforin and 3-O-acetyl-11-keto-boswellic acid. Experiments using purified 5-LO revealed that Ca2+ is no prerequisite for potent enzyme inhibition by ZM230487, and exposure of PMNL to the combination of ionophore and cell stress did not restore potent 5-LO suppression. Intriguingly, a significant difference in the potency of nonredox-type inhibitors (but not of BWA4C) was determined between wild-type 5-LO and the mutant S271A/S663A-5-LO (lacking phosphorylation sites for ERK1/2 and MAPKAPK-2) in HeLa cells. Collectively, our data suggest that compared with Ca2+-mediated 5-LO product formation, enzyme activation involving 5-LO phosphorylation events specifically and strongly alters the susceptibility of 5-LO toward nonredox-type inhibitors in intact cells.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					Alanko J, 1998, BIOCHEM PHARMACOL, V55, P101, DOI 10.1016/S0006-2952(97)00398-5; Albert D, 2002, BIOCHEM PHARMACOL, V64, P1767, DOI 10.1016/S0006-2952(02)01387-4; Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; Burkert E, 2003, J LEUKOCYTE BIOL, V73, P191, DOI 10.1189/jlb.0702354; Burkert E, 2002, J LEUKOCYTE BIOL, V71, P477; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; CLAESSON HE, 1981, BIOCHEM BIOPH RES CO, V99, P1230, DOI 10.1016/0006-291X(81)90751-8; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; CRAWLEY GC, 1992, J MED CHEM, V35, P2600, DOI 10.1021/jm00092a010; Ding XZ, 1999, BIOCHEM BIOPH RES CO, V261, P218, DOI 10.1006/bbrc.1999.1012; Garcia C, 1996, J BONE MINER RES, V11, P1619; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; MCMILLAN RM, 1992, TRENDS PHARMACOL SCI, V13, P323, DOI 10.1016/0165-6147(92)90100-K; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; NASSER SMS, 1994, THORAX, V49, P743, DOI 10.1136/thx.49.8.743; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; POUBELLE PE, 1987, BIOCHEM BIOPH RES CO, V149, P649, DOI 10.1016/0006-291X(87)90417-7; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; SAFAYHI H, 1992, J PHARMACOL EXP THER, V261, P1143; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SERHAN CN, 1984, PROSTAG OTH LIPID M, V27, P563, DOI 10.1016/0090-6980(84)90092-3; Smith WG, 1995, J PHARMACOL EXP THER, V275, P1332; Steinhilber D, 1999, CURR MED CHEM, V6, P71; Turner CR, 1996, INFLAMM RES, V45, P42, DOI 10.1007/BF02263504; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1997, N-S ARCH PHARMACOL, V356, P441, DOI 10.1007/PL00005074; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 1998, MOL PHARMACOL, V54, P445, DOI 10.1124/mol.54.2.445	48	114	118	3	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					949	+		10.1096/fj.02-0815fje	http://dx.doi.org/10.1096/fj.02-0815fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670876				2022-12-25	WOS:000181892600011
J	Hammarton, TC; Clark, J; Douglas, F; Boshart, M; Mottram, JC				Hammarton, TC; Clark, J; Douglas, F; Boshart, M; Mottram, JC			Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE EXPRESSION; PROTEIN-KINASE; CYTOKINESIS; SEGREGATION; YEAST; DIVISION; DIFFERENTIATION; REPLICATION; DEFICIENT; HOMOLOG	African trypanosomes have a tightly coordinated cell cycle to effect efficient segregation of their single organelles, the nucleus, flagellum, and kinetoplast. To investigate cell cycle control in trypanosomes, a mitotic cyclin gene (CYC6) has been identified in Trypanosoma brucei. We show that CYC6 forms an active kinase complex with CRK3, the trypanosome CDK1 homologue, in vivo. Using RNA interference, we demonstrate that absence of CYC6 mRNA results in a mitotic block and growth arrest in both the insect procyclic and mammalian bloodstream forms. In the procyclic form, CYC6 RNA interference generates anucleate cells with a single kinetoplast, whereas in bloodstream form trypanosomes, cells with one nucleus and multiple kinetoplasts are observed. Fluorescence-activated cell sorting analysis shows that bloodstream but not procyclic trypanosomes are able to reinitiate nuclear S phase in the absence of mitosis. Taken together, these data show that procyclic trypanosomes can undergo cytokinesis without completion of mitosis, whereas a mitotic block in bloodstream form trypanosomes inhibits cytokinesis but not kinetoplast replication and segregation nor an additional round of nuclear DNA synthesis. This indicates that there are fundamental differences in cell cycle controls between life cycle forms of T. brucei and that key cell cycle checkpoints present in higher eukaryotes are absent from trypanosomes.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Glasgow; University of Munich	Mottram, JC (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	j.mottram@udcf.gla.ac.uk	Hammarton, Tansy/A-5632-2011; Boshart, Michael/A-2700-2011	Hammarton, Tansy/0000-0002-0799-6600; Boshart, Michael/0000-0002-5070-2663; Mottram, Jeremy/0000-0001-5574-3766				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; DAS A, 1994, J CELL SCI, V107, P3477; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Grellier P, 1999, CELL MOTIL CYTOSKEL, V42, P36, DOI 10.1002/(SICI)1097-0169(1999)42:1&lt;36::AID-CM4&gt;3.0.CO;2-G; Gull K, 1998, TRENDS MICROBIOL, V6, P319, DOI 10.1016/S0966-842X(98)01314-6; Hammarton Tansy C, 2003, Prog Cell Cycle Res, V5, P91; Hassan P, 2001, MOL BIOCHEM PARASIT, V113, P189, DOI 10.1016/S0166-6851(01)00220-1; HATA S, 1991, EMBO J, V10, P2681, DOI 10.1002/j.1460-2075.1991.tb07811.x; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MATTHEWS KR, 1994, PARASITOL TODAY, V10, P473, DOI 10.1016/0169-4758(94)90159-7; Mottram JC, 1996, BIOCHEM J, V316, P833, DOI 10.1042/bj3160833; MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Ploubidou A, 1999, J CELL SCI, V112, P4641; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; Vassella E, 2001, MOL MICROBIOL, V41, P33, DOI 10.1046/j.1365-2958.2001.02471.x; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5	33	133	134	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22877	22886		10.1074/jbc.M300813200	http://dx.doi.org/10.1074/jbc.M300813200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682070	hybrid			2022-12-25	WOS:000183503900093
J	McGill, MA; McGlade, CJ				McGill, MA; McGlade, CJ			Mammalian numb proteins promote notch1 receptor ubiquitination and degradation of the notch1 intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; MOUSE CORTICAL NEUROGENESIS; CELL FATE; ASYMMETRIC LOCALIZATION; SIGNALING PATHWAY; PLASMA-MEMBRANE; ORGAN LINEAGE; IN-VIVO; DROSOPHILA; DIVISION	The cell fate determinant Numb influences developmental decisions by antagonizing the Notch signaling pathway. However, the underlying molecular mechanism of this inhibition is poorly understood. Here we report that the mammalian Numb protein promotes the ubiquitination of membrane-bound Notch1 receptor. Furthermore, Numb expression resulted in the degradation of the Notch intracellular domain following activation, which correlated with a loss of Notch-dependent transcriptional activation of the Hes1 promoter as measured by a Hes1 luciferase reporter assay. The phospho-tyrosine-binding (PTB) domain of Numb was required for both Notch1 ubiquitination and down-regulation of Notch1 nuclear activity. Numb-mediated ubiquitination of Notch1 was not dependent on the PEST region, which was previously shown to mediate Sel10-dependent ubiquitination of Notch in the nucleus, suggesting a distinct E3 ubiquitin ligase is involved. In agreement we demonstrate that Numb interacts with the cytosolic HECT domain-containing E3 ligase Itch and that Numb and Itch act cooperatively to promote ubiquitination of membrane-tethered Notch1. These results suggest that Numb recruits components of the ubiquitination machinery to the Notch receptor thereby facilitating Notch1 ubiquitination at the membrane, which in turn promotes degradation of the intracellular domain circumventing its nuclear translocation and downstream activation of Notch1 target genes.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jmcglade@sickkids.on.ca						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; Cornell M, 1999, GENETICS, V152, P567; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844; Zilian O, 2001, CURR BIOL, V11, P494, DOI 10.1016/S0960-9822(01)00149-X	53	342	352	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23196	23203		10.1074/jbc.M302827200	http://dx.doi.org/10.1074/jbc.M302827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682059	hybrid			2022-12-25	WOS:000183503900128
J	Ximenes, HM; Kamagate, A; Van Eylen, F; Carpinelli, A; Herchuelz, A				Ximenes, HM; Kamagate, A; Van Eylen, F; Carpinelli, A; Herchuelz, A			Opposite effects of glucose on plasma membrane Ca2+-ATPase and Na/Ca exchanger transcription, expression, and activity in rat pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; ENDOPLASMIC-RETICULUM; CA2+ CONCENTRATION; ISLET CELLS; INSULIN SECRETAGOGUES; SECRETION; GENES; IDENTIFICATION; OSCILLATIONS; LANGERHANS	When stimulated by glucose the pancreatic beta-cell displays large oscillations of the intracellular free Ca2+ concentration, resulting from intermittent Ca2+ entry from the outside and outflow from the inside, the latter process being mediated by the plasma membrane Ca2+-ATPase (PMCA) and the Na+/Ca2+ exchanger (NCX). To understand the respective role of these two mechanisms, we studied the effect of glucose on PMCA and NCX transcription, expression, and activity in rat pancreatic islet cells. Glucose (11.1 and 22.2 mM) induced a parallel decrease in PMCA transcription, expression, and activity. In contrast the sugar induced a parallel increase in NCX transcription, expression, and activity. The effects of the sugar were mimicked by the metabolizable insulin secretagogue alpha-ketoisocaproate and persisted in the presence of the Ca2+-channel blocker nifedipine. The above results are compatible with the view that, when stimulated, the beta-cell switches from a low efficiency Ca2+-extruding mechanism, the PMCA, to a high capacity system, the Na/Ca exchanger, to better face the increase in Ca2+ inflow. These effects of glucose do not result from a direct effect of the sugar itself and are not mediated by the increase in intracellular free Ca2+ concentration induced by the sugar.	Free Univ Brussels, Pharmacol Lab, Sch Med, B-1070 Brussels, Belgium; Univ Sao Paulo, Dept Human Physiol & Biophys, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universidade de Sao Paulo	Herchuelz, A (corresponding author), Free Univ Brussels, Pharmacol Lab, Sch Med, Bat GE,808 Route Lennik, B-1070 Brussels, Belgium.	herchu@ulb.ac.be	Ximenes, Helena H.M.A./N-8661-2013; Carpinelli, Angelo R/G-8566-2011	Ximenes, Helena H.M.A./0000-0001-8073-4888; Carpinelli, Angelo R/0000-0002-0781-4934				Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; Best L, 2002, J MEMBRANE BIOL, V185, P193, DOI 10.1007/s00232-001-0114-1; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Camby I, 2002, J NEUROPATH EXP NEUR, V61, P585, DOI 10.1093/jnen/61.7.585; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1988, METHOD ENZYMOL, V157, P3; Choufani G, 1999, CANCER-AM CANCER SOC, V86, P2353, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2353::AID-CNCR25>3.0.CO;2-A; Dyachok O, 2001, J CELL SCI, V114, P2179; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; GAGLIARDINO JJ, 1994, DIABETES METAB REV, V10, P1, DOI 10.1002/dmr.5610100102; Gilon P, 1999, J BIOL CHEM, V274, P20197, DOI 10.1074/jbc.274.29.20197; GOBBE P, 1989, RES COMMUN CHEM PATH, V63, P231; Goldschmidt D, 1996, LAB INVEST, V75, P295; GREEB J, 1989, J BIOL CHEM, V264, P18569; GRONDA CM, 1988, BIOCHIM BIOPHYS ACTA, V943, P183, DOI 10.1016/0005-2736(88)90550-0; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HERCHUELZ A, 1992, ANN NY ACAD SCI, V639, P642; HOENIG M, 1990, BIOCHIM BIOPHYS ACTA, V1022, P333, DOI 10.1016/0005-2736(90)90282-S; Kamagate A, 2000, CELL CALCIUM, V27, P231, DOI 10.1054/ceca.2000.0116; KOTAGAL N, 1985, ARCH BIOCHEM BIOPHYS, V238, P161, DOI 10.1016/0003-9861(85)90152-3; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; LEVIN SR, 1978, J CLIN INVEST, V62, P692, DOI 10.1172/JCI109177; Nagy N, 2001, LAB INVEST, V81, P599, DOI 10.1038/labinvest.3780269; PENNISTON JT, 1994, CELL PHYSIOL BIOCHEM, V4, P148, DOI 10.1159/000154718; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pilette C, 2001, AM J RESP CRIT CARE, V163, P185, DOI 10.1164/ajrccm.163.1.9912137; PLASMAN PO, 1990, AM J PHYSIOL, V259, pE844, DOI 10.1152/ajpendo.1990.259.6.E844; Saussez S, 1998, CANCER, V82, P252, DOI 10.1002/(SICI)1097-0142(19980115)82:2<252::AID-CNCR2>3.3.CO;2-1; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Van Eylen F, 1998, DIABETES, V47, P1873, DOI 10.2337/diabetes.47.12.1873; Van Eylen F, 2002, DIABETES, V51, P366, DOI 10.2337/diabetes.51.2.366; VanEylen F, 1997, CELL CALCIUM, V21, P185, DOI 10.1016/S0143-4160(97)90043-9; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597	38	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22956	22963		10.1074/jbc.M212339200	http://dx.doi.org/10.1074/jbc.M212339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682074	hybrid			2022-12-25	WOS:000183503900102
J	Jackson, LK; Goldsmith, EJ; Phillips, MA				Jackson, LK; Goldsmith, EJ; Phillips, MA			X-ray structure determination of Trypanosoma brucei ornithine decarboxylase bound to D-ornithine and to G418 - Insights into substrate binding and ODC conformational flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION SPECIFICITY; ANGSTROM RESOLUTION; POLYAMINES; ANALOGS; DIFLUOROMETHYLORNITHINE; INHIBITION; MECHANISM; CATALYSIS; ANTIZYME; TARGET	Ornithine decarboxylase (ODC) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the rate-determining step in the biosynthesis of polyamines. ODC is a proven drug target to treat African sleeping sickness. The x-ray crystal structure of Trypanosoma brucei ODC in complex with D-ornithine (D-Orn), a substrate analog, and G418 (Geneticin), a weak non-competitive inhibitor, was determined to 2.5-Angstrom resolution. D-Orn forms a Schiff base with PLP, and the side chain is in a similar position to that observed for putrescine and alpha-difluoromethylornithine in previous T. brucei ODC structures. The D-Orn carboxylate is positioned on the solvent-exposed side of the active site (si face of PLP), and Gly-199, Gly-362, and His-197 are the only residues within 4.2 Angstrom of this moiety. This structure confirms predictions that the carboxylate of D-Orn binds on the si face of PLP, and it supports a model in which the carboxyl group of the substrate L-Orn would be buried on the re face of the cofactor in a pocket that includes Phe-397, Tyr-389, Lys-69 ( methylene carbons), and Asp-361. Electron density for G418 was observed at the boundary between the two domains within each ODC monomer. A ten-amino acid loop region (392-401) near the 2-fold axis of the dimer interface, which contributes several residues that form the active site, is disordered in this structure. The disordering of residues in the active site provides a potential mechanism for inhibition by G418 and suggests that allosteric inhibition from this site is feasible.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	margaret.phillips@UTSouthwestern.edu			NIAID NIH HHS [R01 AI 34432] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; BITONTI AJ, 1985, BIOCHEM PHARMACOL, V34, P1773, DOI 10.1016/0006-2952(85)90648-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; DANZIN C, 1981, J MED CHEM, V24, P16, DOI 10.1021/jm00133a005; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fairlamb Alan H., 1997, P149; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Grishin NV, 1996, PROTEINS, V24, P272, DOI 10.1002/(SICI)1097-0134(199602)24:2<272::AID-PROT17>3.0.CO;2-K; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jackson LK, 2003, BIOCHEMISTRY-US, V42, P2933, DOI 10.1021/bi026795z; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZOE FAS, 1993, ACTA TROP, V54, P153, DOI 10.1016/0001-706X(93)90089-T; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; Osterman AL, 1999, BIOCHEMISTRY-US, V38, P11814, DOI 10.1021/bi9906221; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1995, J CELL BIOCHEM, P132; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; POULIN R, 1992, J BIOL CHEM, V267, P150; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521	38	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22037	22043		10.1074/jbc.M300188200	http://dx.doi.org/10.1074/jbc.M300188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672797	hybrid			2022-12-25	WOS:000183354200091
J	Murata, H; Hresko, RC; Mueckler, M				Murata, H; Hresko, RC; Mueckler, M			Reconstitution of phosphoinositide 3-kinase-dependent insulin signaling in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; TYROSINE PHOSPHATASES; RECEPTOR SUBSTRATE-1; GLUT4 TRANSLOCATION; GLUCOSE TRANSPORTER; RAT ADIPOCYTES; MEMBRANE; DIFFERENTIATION	Early insulin signaling events were examined in a novel cell-free assay utilizing subcellular fractions derived from 3T3-L1 adipocytes. The following cellular processes were observed in vitro in a manner dependent on insulin, time of incubation, and exogenous ATP: 1) autophosphorylation and activation of the insulin receptor; 2) tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1); 3) association of tyrosine-phosphorylated IRS-1 with phosphoinositide 3-kinase; 4) activation of the kinase Akt via its phosphorylation on Thr-308 and Ser-473; and 5) phosphorylation of glycogen synthase kinase-3 by activated Akt. The activation of Akt in vitro was abolished in the presence of the phosphoinositide 3-kinase inhibitor, wortmannin, thus recapitulating the most notable regulatory feature of Akt observed in vivo. Evidence is presented indicating that the critical spatial compartmentalization of signaling molecules necessary for efficient signal transduction is likely to be preserved in the cell-free system. Additionally, data are provided demonstrating that full Akt activation in this system is dependent on plasma membrane-associated IRS-1, cannot be mediated by robust cytosol-specific tyrosine phosphorylation of IRS-1, and occurs in the complete absence of detectable IRS-2 phosphorylation in the cytosol and plasma membrane.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Inoue G, 1999, P NATL ACAD SCI USA, V96, P14919, DOI 10.1073/pnas.96.26.14919; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Jarett L, 1974, Methods Enzymol, V31, P60; KELLY KL, 1993, J BIOL CHEM, V268, P4391; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEBWOHL DE, 1991, J BIOL CHEM, V266, P386; MCDONALD JM, 1976, P NATL ACAD SCI USA, V73, P1542, DOI 10.1073/pnas.73.5.1542; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; RICE KM, 1992, J BIOL CHEM, V267, P10163; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SEALS JR, 1979, J BIOL CHEM, V254, P6991; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	43	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21607	21614		10.1074/jbc.M302934200	http://dx.doi.org/10.1074/jbc.M302934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682058	hybrid			2022-12-25	WOS:000183354200038
J	Ogihara, T; Watada, H; Kanno, R; Ikeda, F; Nomiyama, T; Tanaka, Y; Nakao, A; German, MS; Kojima, I; Kawamori, R				Ogihara, T; Watada, H; Kanno, R; Ikeda, F; Nomiyama, T; Tanaka, Y; Nakao, A; German, MS; Kojima, I; Kawamori, R			P38 MAPK is involved in activin A- and hepatocyte growth factor-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; SCATTER FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; PANCREAS; DIFFERENTIATION; IDENTIFICATION; KINASE; PATHWAY; RHOA	Neurogenin3 ( ngn3) is a transcription factor that is essential for the differentiation of pancreatic endocrine cells. To investigate the signaling pathway that regulates ngn3 expression, we used AR42J- B13 cells as a model of the differentiation of pancreatic islets. In these cells, treatment with activin A and hepatocyte growth factor ( HGF) induced the expression of ngn3. Reporter gene analysis using human ngn3 gene ( NEUROG3) promoter fragments of various lengths identified the region between - 402 and - 327 bp of NEUROG3 as an activin A- and HGF- responsive DNA sequence. This DNA sequence normally functions as a repressor in AR42J- B13 cells, but treatment with activin A and HGF negates the repressor activity. Interestingly, function of the activin A- and HGF- responsive sequence was not influenced by the overexpression of the Smad inhibitory factor, Smad7. Instead, activin A and HGF activation was inhibited by overexpression of a dominant- negative mutant of transforming growth factor- beta- activated kinase 1 ( TAK1), or mitogen- activated protein kinase kinase 3 ( MKK3), or by treatment with a p38 MAPK- specific inhibitor, SB203580. Activin A and HGF function through the TAK1- MKK3- p38 MAPK pathway to relieve transcription repressors located between - 402 and - 326 bp on the NEUROG3 promoter, and consequently activate ngn3 expression and endocrine differentiation of AR42J- B13 cells.	Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Atopy Res Ctr Sch Med, Bunkyo Ku, Tokyo 1138421, Japan; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol & Mol Med, Maebashi, Gumma 3718512, Japan	Juntendo University; Juntendo University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Gunma University	Watada, H (corresponding author), Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.			Watada, Hirotaka/0000-0001-5961-1816				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edlund H, 1999, CURR OPIN CELL BIOL, V11, P663, DOI 10.1016/S0955-0674(99)00033-2; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Kim SK, 2000, GENE DEV, V14, P1866; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shiozaki S, 1999, BBA-MOL CELL RES, V1450, P1, DOI 10.1016/S0167-4889(99)00022-1; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaoka T, 1998, J CLIN INVEST, V102, P294, DOI 10.1172/JCI2769; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang YQ, 1999, DIABETOLOGIA, V42, P719, DOI 10.1007/s001250051220; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10	43	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21693	21700		10.1074/jbc.M302684200	http://dx.doi.org/10.1074/jbc.M302684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670941	hybrid			2022-12-25	WOS:000183354200049
J	Zhang, XL; Zhang, DY; Michel, FJ; Blum, JL; Simmen, FA; Simmen, RCM				Zhang, XL; Zhang, DY; Michel, FJ; Blum, JL; Simmen, FA; Simmen, RCM			Selective interactions of Kruppel-like factor 9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; REPRODUCTIVE FUNCTIONS; REGULATORY PROTEINS; DOWN-REGULATION; PR-A; EXPRESSION; PROMOTER; ESTROGEN; GROWTH; SEQUENCE	The Sp/ KLF transcription factor basic transcription element-binding protein ( BTEB1) regulates gene transcription by binding to GC- rich sequence motifs present in the promoters of numerous tissue- specific as well as housekeeping genes. Similar to other members of this family, BTEB1 can act as a transactivator or transrepressor depending on cell and promoter context, although the molecular mechanism underlying these distinct activities remains unclear. Here we report that BTEB1 can mediate signaling pathways involving the nuclear receptor for the steroid hormone progesterone in endometrial epithelial cells by its selective interaction with the progesterone receptor ( PR) isoforms, PR- A and PR- B. Functional interaction with ligand- activated PR- B resulted in superactivation of PR- B transactivity, facilitated the recruitment of the transcriptional integrator CREB- binding protein within the PR- dimer, and was dependent on the structure of the ligand bound by PR- B. By contrast, BTEB1 did not influence agonist- bound PR- A transactivity, although it augmented PR- A inhibition of PR- B- mediated transactivation as well as potentiated ligand- independent PR- A transcriptional activity in the presence of CREB- binding protein. We also demonstrate similar positive modulatory actions of BTEB1- related family members Kruppel- like family ( KLF) 13/ FKLF2/ BTEB3 and Sp1 on PR- B transactivity. Further, we provide support for the potential significance of the selective functional interactions of PR isoforms with BTEB1 in the peri- implantation uterus using mouse and pig models and in the breast cancer cell lines MCF- 7 and T47D. Our results suggest a novel mechanism for the divergent physiological consequences of PR- A and PR- B on progesterone- dependent gene transcription in the uterus involving select KLF members.	Univ Florida, Interdisciplinary Concentrat Anim Mol & Cell Biol, Gainesville, FL 32611 USA; Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA	State University System of Florida; University of Florida; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Simmen, RCM (corresponding author), Univ Florida, Interdisciplinary Concentrat Anim Mol & Cell Biol, Gainesville, FL 32611 USA.	simmenrosalia@uams.edu	Blum, Jason L./O-5023-2019; Simmen, Frank A/J-9464-2012	Blum, Jason/0000-0003-1381-6802; Simmen, Frank/0000-0001-6842-7754	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021961, R29HD021961] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD021961, HD 21961] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arnett-Mansfield RL, 2001, CANCER RES, V61, P4576; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Boonyaratanakornkit V, 1999, J BIOL CHEM, V274, P26431, DOI 10.1074/jbc.274.37.26431; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; Cheng KW, 2001, MOL ENDOCRINOL, V15, P2078, DOI 10.1210/me.15.12.2078; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339; Dai D, 2002, CANCER RES, V62, P881; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; GADSBY JE, 1980, J REPROD FERTIL, V60, P409, DOI 10.1530/jrf.0.0600409; Gao JG, 2000, MOL ENDOCRINOL, V14, P1954, DOI 10.1210/me.14.12.1954; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Gowri PM, 2003, MOL CELL BIOL, V23, P815, DOI 10.1128/MCB.23.3.815-825.2003; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; Hsiang CH, 2002, ONCOGENE, V21, P2212, DOI 10.1038/sj.onc.1205293; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; Jacobsen BM, 2002, J BIOL CHEM, V277, P27793, DOI 10.1074/jbc.M202584200; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Kumar NS, 1998, CANCER RES, V58, P1860; LAMIAN V, 1993, J STEROID BIOCHEM, V46, P439, DOI 10.1016/0960-0760(93)90098-H; Leonhardt SA, 1998, MOL ENDOCRINOL, V12, P1914, DOI 10.1210/me.12.12.1914; Leonhardt SA, 2002, EXP BIOL MED, V227, P969, DOI 10.1177/153537020222701104; Leslie KK, 1997, ANN NY ACAD SCI, V828, P17, DOI 10.1111/j.1749-6632.1997.tb48520.x; Liu SF, 1997, BRIT J PHARMACOL, V121, P1241; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; Lydon JP, 1999, CANCER RES, V59, P4276; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; McGowan EM, 1999, MOL ENDOCRINOL, V13, P1657, DOI 10.1210/me.13.10.1657; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Milde-Langosch K, 2001, J CANCER RES CLIN, V127, P537, DOI 10.1007/s004320100256; Morita M, 2003, MOL CELL BIOL, V23, P2489, DOI 10.1128/MCB.23.7.2489-2500.2003; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; *SAS I, 1999, SAS SYST WIND VERS 8; Sasaki M, 2001, CANCER RES, V61, P97; SCHOTT DR, 1991, BIOCHEMISTRY-US, V30, P7014, DOI 10.1021/bi00242a029; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; SIMMEN FA, 1991, BIOL REPROD, V44, P1, DOI 10.1095/biolreprod44.1.1; Simmen RCM, 1999, ENDOCRINOLOGY, V140, P2517, DOI 10.1210/en.140.6.2517; Simmen RCM, 2000, MOL CELL ENDOCRINOL, V159, P159, DOI 10.1016/S0303-7207(99)00191-4; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Tan J, 1999, ENDOCRINOLOGY, V140, P5310, DOI 10.1210/en.140.11.5310; Thuneke I, 2000, BREAST CANCER RES TR, V63, P243, DOI 10.1023/A:1006432600478; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Wang Y, 1997, BIOL REPROD, V57, P707, DOI 10.1095/biolreprod57.4.707; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Zhang DY, 2002, ENDOCRINOLOGY, V143, P62, DOI 10.1210/en.143.1.62; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang XL, 2001, MOL CELL ENDOCRINOL, V181, P81, DOI 10.1016/S0303-7207(01)00536-6	65	79	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21474	21482		10.1074/jbc.M212098200	http://dx.doi.org/10.1074/jbc.M212098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672823	hybrid			2022-12-25	WOS:000183354200022
J	Bagyinka, C; Osz, J; Szaraz, S				Bagyinka, C; Osz, J; Szaraz, S			Autocatalytic oscillations in the early phase of the photoreduced methyl viologen-initiated fast kinetic reaction of hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-GIGAS; THIOCAPSA-ROSEOPERSICINA; CHROMATIUM-VINOSUM; ACTIVATION; STATES; FORMS	The kinetic characteristics of the hydrogen uptake reaction of hydrogenase, obtained by conventional activity measurements, led to the proposal of an autocatalytic reaction step in the hydrogenase cycle or during the activation process. The autocatalytic behavior of an enzyme reaction may result in oscillating concentrations of enzyme intermediates and/or products contributing to the autocatalytic step. This behavior has been investigated in the early phase of the hydrogenase-methyl viologen reaction. To measure fast hydrogenase kinetics, flash-reduced methyl viologen has been used as a light-induced trigger in transient kinetic phenomena associated with intermolecular electron transfer to hydrogenase. Here we report fast kinetic measurements of the hydrogenase-methyl viologen reaction by use of the excimer laser flash-reduced redox dye. The results are evaluated on the assumption of an autocatalytic reaction in the hydrogenase kinetic cycle. The kinetic constants of the autocatalytic reaction, i.e. the methyl viologen binding to and release from hydrogenase, were determined, and limits of the kinetic constants relating to the intramolecular (intraenzyme) reactions were set.	Hungarian Acad Sci, Inst Biophys, Biol Res Ctr, H-6701 Szeged, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center	Bagyinka, C (corresponding author), Temesvari Krt 62,POB 521, H-6701 Szeged, Hungary.		Bagyinka, Csaba/D-1600-2012					ANAND SR, 1965, BIOCHEMISTRY-US, V4, P2747, DOI 10.1021/bi00888a027; BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAGYINKA C, 1982, BIOCHEM J, V202, P255, DOI 10.1042/bj2020255; CAMMACK R, 1986, BIOCHIMIE, V68, P85, DOI 10.1016/S0300-9084(86)81072-0; CZEGE J, 1989, PHOTOCHEM PHOTOBIOL, V50, P697, DOI 10.1111/j.1751-1097.1989.tb04329.x; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; DER A, 1985, ANAL BIOCHEM, V150, P481, DOI 10.1016/0003-2697(85)90538-X; FERNANDEZ VM, 1984, BIOCHIM BIOPHYS ACTA, V790, P1, DOI 10.1016/0167-4838(84)90324-8; FERNANDEZ VM, 1985, BIOCHIM BIOPHYS ACTA, V832, P69, DOI 10.1016/0167-4838(85)90175-X; FISHER HF, 1954, J BIOL CHEM, V209, P569; KOVACS KL, 1990, FEMS MICROBIOL LETT, V87, P407, DOI 10.1016/0378-1097(90)90487-B; KOVACS KL, 1991, J BIOL CHEM, V266, P947; KRASNA AI, 1954, J AM CHEM SOC, V76, P3015, DOI 10.1021/ja01640a045; Lotka AJ, 1910, J PHYS CHEM-US, V14, P271, DOI 10.1021/j150111a004; Pershad HR, 1999, BIOCHEMISTRY-US, V38, P8992, DOI 10.1021/bi990108v; ROMANOVSKII JM, 1970, IS MATH BIOPHYSICS, P82; SHERMAN MB, 1991, J BACTERIOL, V173, P2576, DOI 10.1128/jb.173.8.2576-2580.1991; TIGYI G, 1986, BIOCHIMIE, V68, P69, DOI 10.1016/S0300-9084(86)81070-7; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; YAGI T, 1973, J BIOCHEM-TOKYO, V73, P1069, DOI 10.1093/oxfordjournals.jbchem.a130161	21	11	11	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20624	20627		10.1074/jbc.M300623200	http://dx.doi.org/10.1074/jbc.M300623200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663658	hybrid			2022-12-25	WOS:000183230500024
J	Denisov, AY; Madiraju, MSR; Chen, G; Khadir, A; Beauparlant, P; Attardo, G; Shore, GC; Gehring, K				Denisov, AY; Madiraju, MSR; Chen, G; Khadir, A; Beauparlant, P; Attardo, G; Shore, GC; Gehring, K			Solution structure of human BCL-w - Modulation of ligand binding by the C-terminal helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIAPOPTOTIC PROTEIN BCL-2; PROGRAMMED CELL-DEATH; PEPTIDE COMPLEX; FAMILY PROTEINS; APOPTOSIS; NMR; SURVIVAL; EXPRESSION; BCL-X(L); SPERMATOGENESIS	The structure of human BCL-w, an anti-apoptotic member of the BCL-2 family, was determined by triple-resonance NMR spectroscopy and molecular modeling. Introduction of a single amino acid substitution (P117V) significantly improved the quality of the NMR spectra obtained. The cytosolic domain of BCL-w consists of 8 alpha-helices, which adopt a fold similar to that of BCL-x(L), BCL-2, and BAX proteins. Pairwise root meant square deviation values were less than 3 Angstrom for backbone atoms of structurally equivalent regions. Interestingly, the C-terminal helix alpha8 of BCL-w folds into the BH3-binding hydrophobic cleft of the protein, in a fashion similar to the C-terminal transmembrane helix of BAX. A peptide corresponding to the BH3 region of the pro-apoptotic protein, BID, could displace helix alpha8 from the BCL-w cleft, resulting in helix unfolding. Deletion of helix alpha8 increased binding affinities of BCL-w for BAK and BID BH3-peptides, indicating that this helix competes for peptide binding to the hydrophobic cleft. These results suggest that although the cytosolic domain of BCL-w exhibits an overall structure similar to that of BCL-x(L) and BCL-2, the unique organization of its C-terminal helix may modulate BCL-w interactions with pro-apoptotic binding partners.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada; GemminX Biotechnol Inc, Montreal, PQ H2X 4A5, Canada	McGill University; McGill University	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.		Gehring, Kalle/N-2945-2019; Gehring, Kalle/I-4403-2013	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				Bairey O, 1999, CLIN CANCER RES, V5, P2860; Billeter M, 1995, J BIOMOL NMR, V5, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gibson L, 1996, ONCOGENE, V13, P665; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Meehan T, 2001, CELL DEATH DIFFER, V8, P225, DOI 10.1038/sj.cdd.4400799; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesleh MF, 2002, J AM CHEM SOC, V124, P4206, DOI 10.1021/ja0178665; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; PENG JW, 1994, METHOD ENZYMOL, V239, P563; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Rutledge SE, 2002, CURR OPIN CHEM BIOL, V6, P479, DOI 10.1016/S1367-5931(02)00352-6; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Troy CM, 2002, J NEUROSCI RES, V69, P145, DOI 10.1002/jnr.10294; Voutsadakis IA, 2000, ACTA ONCOL, V39, P151, DOI 10.1080/028418600430707; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Wilson JW, 2000, BRIT J CANCER, V82, P178, DOI 10.1054/bjoc.1999.0897; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	45	100	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21124	21128		10.1074/jbc.M301798200	http://dx.doi.org/10.1074/jbc.M301798200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651847	hybrid			2022-12-25	WOS:000183230500088
J	Kawai, Y; Saito, A; Shibata, N; Kobayashi, M; Yamada, S; Osawa, T; Uchida, K				Kawai, Y; Saito, A; Shibata, N; Kobayashi, M; Yamada, S; Osawa, T; Uchida, K			Covalent binding of oxidized cholesteryl esters to protein - Implications for oxidative modification of low density lipoprotein and atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; MASS-SPECTROMETRY; SCAVENGER RECEPTOR; BOUND ALDEHYDES; IN-VIVO; MACROPHAGES; LDL; PHOSPHOLIPIDS; MALONDIALDEHYDE; CHROMATOGRAPHY	It has been proposed that plasma low density lipoproteins (LDL) undergo oxidative modification before they can produce foam cells in atherosclerosis. The oxidation of LDL generates a variety of reactive aldehydic products, which covalently bind to the LDL apolipoprotein B-100 (apoB). In the present study, to investigate the mechanisms contributing to the modification of LDL, we analyzed oxidized cholesteryl esters generated during the autoxidation of LDL and characterized their covalent binding to the lysine residues of LDL apoB. In addition, we raised a monoclonal antibody specific to a lysine-bound oxidized cholesteryl ester and determined its production in human atherosclerotic lesions. The peroxidation of LDL with Cu2+ produced 9-oxononanoylcholesterol (9-ONC) and 5-oxovaleroylcholesterol as the major oxidized cholesteryl esters. We observed that the levels of 9-ONC and 5-oxovaleroylcholesterol peaked at 12 h and significantly decreased thereafter. The reduction of the core aldehyde levels was accompanied by (i) the formation of free 7-ketocholesterol and 7-ketocholesteryl ester core aldehydes and (ii) an increase in the amounts of apoB-bound cholesterol and 7-ketocholesterol, suggesting that the cholesteryl ester core aldehydes were further converted to their 7-ketocholesterol- and apoB-bound derivatives. To detect the protein-bound 9-ONC, we raised the monoclonal antibody 2A81, directed against 9-ONC-modified protein, and found that it extensively recognized protein-bound cholesteryl ester core aldehydes. Agarose gel electrophoresis followed by immunoblot analysis of the oxidized LDL clearly demonstrated the formation of antigenic structures. Furthermore, immunohistochemical analysis of the atherosclerotic lesions from the human aorta showed that immunoreactive materials with mAb 2A81 were indeed present in the lesions, in which the intense immunoreactivity was mainly located in the macrophage-derived foam cells and the thickening neointima of the arterial walls. The results of this study suggest that the binding of cholesteryl ester core aldehydes to LDL might represent the process common to the oxidative modification of lipoproteins.	Nagoya Univ, Lab Food & Biodynam, Grad Sch Biogr Sci, Nagoya, Aichi 4648601, Japan; Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan; NOF Co, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan	Nagoya University; Tokyo Women's Medical University	Uchida, K (corresponding author), Nagoya Univ, Lab Food & Biodynam, Grad Sch Biogr Sci, Nagoya, Aichi 4648601, Japan.		Kawai, Yoshichika/G-3231-2011	Uchida, Koji/0000-0003-3894-5299				BALL RY, 1987, BRIT J EXP PATHOL, V68, P427; Bolgar MS, 1996, J BIOL CHEM, V271, P27999, DOI 10.1074/jbc.271.45.27999; Bruenner BA, 1996, ANAL BIOCHEM, V241, P212, DOI 10.1006/abio.1996.0402; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gillotte KL, 2000, J LIPID RES, V41, P824; Girotti AW, 1998, J LIPID RES, V39, P1529; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; Hoppe G, 1997, J LIPID RES, V38, P1347; Itabe H, 1998, PROG LIPID RES, V37, P181, DOI 10.1016/S0163-7827(98)00009-5; ITABE H, 1994, J BIOL CHEM, V269, P15274; KAMIDO H, 1992, LIPIDS, V27, P645, DOI 10.1007/BF02536126; KAMIDO H, 1992, FEBS LETT, V304, P269, DOI 10.1016/0014-5793(92)80635-T; Karten B, 1998, J LIPID RES, V39, P1508; Li W, 1998, ARTERIOSCL THROM VAS, V18, P177, DOI 10.1161/01.ATV.18.2.177; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; MANDER EL, 1994, BBA-LIPID LIPID MET, V1212, P80, DOI 10.1016/0005-2760(94)90192-9; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ravandi A, 1997, LIPIDS, V32, P989, DOI 10.1007/s11745-997-0129-6; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; TERAO J, 1990, MEMBRANE LIPID OXIDA, V1, P219; TERTOV VV, 1995, BIOCHEM BIOPH RES CO, V214, P608, DOI 10.1006/bbrc.1995.2329; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Uchida K, 1997, ARCH BIOCHEM BIOPHYS, V346, P45, DOI 10.1006/abbi.1997.0266; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; WANG CJ, 1990, CHEM PHYS LIPIDS, V55, P265, DOI 10.1016/0009-3084(90)90164-M; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; Yamada S, 2001, J LIPID RES, V42, P1187; Yancey PG, 1998, J LIPID RES, V39, P1349	37	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21040	21049		10.1074/jbc.M212426200	http://dx.doi.org/10.1074/jbc.M212426200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663661	hybrid			2022-12-25	WOS:000183230500078
J	Tokuda, H; Harada, A; Hirade, K; Matsuno, H; Ito, H; Kato, K; Oiso, Y; Kozawa, O				Tokuda, H; Harada, A; Hirade, K; Matsuno, H; Ito, H; Kato, K; Oiso, Y; Kozawa, O			Incadronate amplifies prostaglandin F-2 alpha-induced vascular endothelial growth factor synthesis in osteoblasts - Enhancement of MAPK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE HYDROLYSIS; GENE-EXPRESSION; PHOSPHOLIPASE-D; CELL-LINE; ACTIVATION; DIFFERENTIATION; BISPHOSPHONATES; POTENT; BONE	We have previously reported that prostaglandin F-2alpha (PGF(2alpha)) activates p44/p42 mitogen-activated protein kinase (MAPK) through protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the mechanism of vascular endothelial growth factor (VEGF) synthesis induced by PGF(2alpha) and the effect of incadronate on the VEGF synthesis in these cells. PGF(2alpha) significantly stimulated the VEGF synthesis in a dose-dependent manner between 1 pM and 10 muM. Cycloheximide reduced the PGF(2alpha) effect. PGF(2alpha) increased the levels of mRNA for VEGF. Cloprostenol, a PGF(2alpha)-sensitive receptor agonist, potently induced the VEGF synthesis. Indomethacin, an inhibitor of cyclooxygenase, significantly reduced the PGF(2alpha)-induced VEGF synthesis. Bisindolylmaleimide, an inhibitor of PKC, reduced the PGF(2alpha)-induced VEGF synthesis. The VEGF synthesis induced by PGF(2alpha) was significantly attenuated in the PKC down-regulated cells. PGF(2alpha) elicited the translocation of PKCbetaI from cytosol to membrane fraction. PD98059 or U0126, inhibitors of MEK, suppressed the VEGF synthesis induced by PGF(2alpha). Farnesyltransferase inhibitor failed to affect the PGF(2alpha)-induced VEGF synthesis. Incadronate enhanced the synthesis of VEGF induced by PGF(2alpha). NaF-induced VEGF synthesis was also amplified by incadronate. PD98059 suppressed the enhancement by incadronate of PGF(2alpha)-induced VEGF synthesis. Incadronate markedly enhanced the phosphorylation of Raf-1, MEK1/2, and p44/p42 MAPK induced by PGF(2alpha) or 12-O-tetradecanoylphorbol-13-acetate, a PKC activator. Incadronate significantly enhanced the cloprostenol-increased level of VEGF concentration in mouse plasma in vivo. These results strongly suggest that PGF(2alpha) stimulates VEGF synthesis through the PKC-dependent activation of p44/p42 MAPK in osteoblasts and that the incadronate enhances the VEGF synthesis at the point between PKC and Raf-1.	Gifu Univ, Dept Pharmacol, Sch Med, Gifu 5008705, Japan; Chubu Natl Hosp, Dept Internal Med, Natl Inst Longev Sci, Aichi 4748511, Japan; Chubu Natl Hosp, Dept Orthopaed, Natl Inst Longev Sci, Aichi 4748511, Japan; Aichi Human Serv Ctr, Dept Biochem, Inst Dev Res, Aichi 4800391, Japan; Nagoya Univ, Dept Internal Med 1, Sch Med, Nagoya, Aichi 4668550, Japan	Gifu University; Nagoya University	Kozawa, O (corresponding author), Gifu Univ, Dept Pharmacol, Sch Med, Gifu 5008705, Japan.			Hirade, Kouseki/0000-0001-8367-602X; Ito, Hidenori/0000-0002-6527-477X				ALESSI DR, 1995, J BIOL CHEM, V270, P27484; DUKES M, 1974, NATURE, V250, P330, DOI 10.1038/250330a0; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fleisch H, 2002, PRINCIPLES BONE BIOL, V2nd, P1361; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; Hamilton A., 1995, DRUG NEWS PERSPECT, V8, P138; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Hatakeyama D, 2002, J CELL BIOCHEM, V85, P621, DOI 10.1002/jcb.10166; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kozawa O, 1997, AM J PHYSIOL-ENDOC M, V272, pE208, DOI 10.1152/ajpendo.1997.272.2.E208; KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014-4827(92)90158-5; KOZAWA O, 1994, J CELL BIOCHEM, V55, P373, DOI 10.1002/jcb.240550315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679; Miao LY, 2002, AM J PHYSIOL-HEART C, V283, pH983, DOI 10.1152/ajpheart.00141.2002; MIWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1229, DOI 10.1016/0006-291X(90)90817-7; NII A, 1994, TOXICOL PATHOL, V22, P536, DOI 10.1177/019262339402200509; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Pilbeam Carol C., 1996, P715; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Reinholz GG, 2000, CANCER RES, V60, P6001; Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382; SAKAI T, 1992, CELL CALCIUM, V13, P329, DOI 10.1016/0143-4160(92)90068-4; SCHALAEPPI JM, 1997, ENDOCR RES, V23, P213; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tokuda H, 1999, CELL SIGNAL, V11, P325, DOI 10.1016/S0898-6568(98)00048-5; Tokuda H, 2001, J ENDOCRINOL, V170, P629, DOI 10.1677/joe.0.1700629; TOKUDA H, 1992, J CELL BIOCHEM, V48, P262, DOI 10.1002/jcb.240480306; Tokuda H, 2000, J BONE MINER RES, V15, P2371, DOI 10.1359/jbmr.2000.15.12.2371; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324; Wang DS, 1996, J BONE MINER RES, V11, P472; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	45	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18930	18937		10.1074/jbc.M209159200	http://dx.doi.org/10.1074/jbc.M209159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646577	hybrid			2022-12-25	WOS:000182932200029
J	Wang, WM; Lee, S; Steiglitz, BM; Scott, IC; Lebares, CC; Allen, ML; Brenner, MC; Takahara, K; Greenspan, DS				Wang, WM; Lee, S; Steiglitz, BM; Scott, IC; Lebares, CC; Allen, ML; Brenner, MC; Takahara, K; Greenspan, DS			Transforming growth factor-beta induces secretion of activated ADAMTS-2 - A procollagen IIIN-proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; CHICK-EMBRYO TENDONS; EHLERS-DANLOS SYNDROME; SMOOTH-MUSCLE CELLS; I N-PROTEINASE; C-PROTEINASE; PARTIAL-PURIFICATION; BOVINE DERMATOSPARAXIS; PROPROTEIN CONVERTASES; FIBROBLAST-CULTURES	The metalloproteinase ADAMTS-2 has procollagen I N-proteinase activity capable of cleaving procollagens I and II N-propeptides in vitro, whereas mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin. Yet despite its important role in the regulation of collagen deposition, information regarding regulation and substrate specificity of ADAMTS-2 has remained sparse. Here we demonstrate that ADAMTS-2 can, like the procollagen C-proteinases, be regulated by transforming growth factor-beta1 (TGF-beta1), with implications for mechanisms whereby this growth factor effects net increases in formation of extracellular matrix. TGF-beta1 induced ADAMTS-2 mRNA similar to8-fold in MG-63 osteosarcoma cells in a dose- and time-dependent, cycloheximide-inhibitable manner, which appeared to operate at the transcriptional level. Secreted AD-AMTS-2 protein induced by TGF-beta1 was 132 kDa and was identical in size to the fully processed, active form of the protease. Biosynthetic processing of ADAMTS-2 to yield the 132-kDa form is shown to be a two-step process involving sequential cleavage by furin-like convertases at two sites. Surprisingly, purified recombinant AD-AMTS-2 is shown to cleave procollagen III N-propeptides as effectively as those of procollagens I and II, whereas processing of procollagen III is shown to be decreased in Ehlers-Danlos VIIC. Thus, the dogma that procollagen I and procollagen III N-proteinase activities are provided by separate enzymes appears to be false, whereas the phenotypes of dermatosparaxis and Ehlers-Danlos VIIC may arise from defects in both type I and type III collagen biosynthesis.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; FibroGen Inc, San Francisco, CA 94080 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; FibroGen	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.		Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215, GM63471] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215, R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BATEMAN JF, 1986, J BIOL CHEM, V261, P4198; Bernstein EF, 1996, J AM ACAD DERMATOL, V34, P209, DOI 10.1016/S0190-9622(96)80114-9; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; HALILA R, 1986, BIOCHEM J, V239, P47, DOI 10.1042/bj2390047; HALILA R, 1984, BIOCHEMISTRY-US, V23, P1251, DOI 10.1021/bi00301a036; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1994, J BIOL CHEM, V269, P11381; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NUSGENS BV, 1980, BIOCHEM J, V191, P699, DOI 10.1042/bj1910699; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SMITH LT, 1992, AM J HUM GENET, V51, P235; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; TUDERMAN L, 1982, EUR J BIOCHEM, V125, P545, DOI 10.1111/j.1432-1033.1982.tb06716.x; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349	56	81	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19549	19557		10.1074/jbc.M300767200	http://dx.doi.org/10.1074/jbc.M300767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646579	hybrid			2022-12-25	WOS:000182932200106
J	Schonhoff, CM; Gaston, B; Mannick, JB				Schonhoff, CM; Gaston, B; Mannick, JB			Nitrosylation of cytochrome c during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX DISC; FAS-INDUCED APOPTOSIS; NITRIC-OXIDE; MONOCLONAL-ANTIBODY; PHOSPHOLIPID-VESICLES; PROTEASE CASCADE; RESONANCE RAMAN; S-NITROSYLATION; IONIC-STRENGTH; DEATH DOMAIN	Cytochrome c released from mitochondria into the cytoplasm plays a critical role in many forms of apoptosis by stimulating apoptosome formation and subsequent caspase activation. However, the mechanisms regulating cytochrome c apoptotic activity are not understood. Here we demonstrate that cytochrome c is nitrosylated on its heme iron during apoptosis. Nitrosylated cytochrome c is found predominantly in the cytoplasm in control cells. In contrast, when cytochrome c release from mitochondria is inhibited by overexpression of the anti-apoptotic proteins B cell lymphoma/leukemia (Bcl)-2 or Bcl-X-L, nitrosylated cytochrome c is found in the mitochondria. These data suggest that during apoptosis, cytochrome c is nitrosylated in mitochondria and then rapidly released into the cytoplasm in the absence of Bcl-2 or Bcl-X-L overexpression. In vitro nitrosylation of cytochrome c increases caspase-3 activation in cell lysates. Moreover, the inhibition of intracellular cytochrome c nitrosylation is associated with a decrease in apoptosis, suggesting that cytochrome c nitrosylation is a proapoptotic modification. We conclude that nitrosylation of the heme iron of cytochrome c may be a novel mechanism of apoptosis regulation.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Virginia	Mannick, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.							ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; ASCENZI P, 1994, J INORG BIOCHEM, V53, P273, DOI 10.1016/0162-0134(94)85114-X; Beltran B, 2002, P NATL ACAD SCI USA, V99, P8892, DOI 10.1073/pnas.092259799; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; CORTESE JD, 1992, BIOCHIM BIOPHYS ACTA, V1100, P189; DHEIN J, 1992, J IMMUNOL, V149, P3166; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025; HILDEBRANDT P, 1990, EUR BIOPHYS J, V18, P193, DOI 10.1007/BF02427378; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; Marshall WL, 1999, VIROLOGY, V256, P1, DOI 10.1006/viro.1999.9599; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orii Y, 1978, J Biochem, V84, P1542; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3880, DOI 10.1021/bi00230a011; SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu TN, 2001, J BIOL CHEM, V276, P13034, DOI 10.1074/jbc.M009773200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	97	104	4	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18265	18270		10.1074/jbc.M212459200	http://dx.doi.org/10.1074/jbc.M212459200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646553	hybrid			2022-12-25	WOS:000182838300089
J	Allen, DA; Harwood, SM; Varagunam, M; Raftery, MJ; Yaqoob, MM				Allen, DA; Harwood, SM; Varagunam, M; Raftery, MJ; Yaqoob, MM			High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases	FASEB JOURNAL			English	Article						diabetic nephropathy; peroxynitrite; cell death; ebselen	HUMAN ENDOTHELIAL-CELLS; PEROXYNITRITE-INDUCED APOPTOSIS; NITRIC-OXIDE; DIABETES-MELLITUS; NITROTYROSINE FORMATION; TGF-BETA; ACTIVATION; PROTEIN; HYPERGLYCEMIA; PROLIFERATION	Diabetic nephropathy is the leading cause of end-stage renal disease in the Western world. Poor glycemic control contributes to the development of diabetic nephropathy, but the mechanisms underlying high glucose-induced tissue injury are not fully understood. In the present study, the effect of high glucose on a proximal tubular epithelial cell (PTEC) line was investigated. Reactive oxygen species (ROS) were detected using the fluorescent probes dichlorofluorescein diacetate, dihydrorhodamine 123, and 2,3-diaminonapthalene. Peroxynitrite (ONOO-) generation and nitrite concentrations were increased after 24 h of high glucose treatment (P<0.05). LLC-PK1 cells exposed to high D-glucose (25 mM) for up to 48 h had increased DNA fragmentation (P<0.01), caspase-3 activity (P<0.001), and annexin-V staining (P<0.05) as well as decreased expression of XIAP when compared with controls (5 mM D-glucose). The ONOO- scavenger ebselen reduced DNA fragmentation and caspase-3 activity as well as the high glucose-induced nitrite production and DCF fluorescence. High glucose-induced DNA fragmentation was completely prevented by an inhibitor of caspase-3 (P<0.01) and a pan-caspase inhibitor (P<0.001). Caspase inhibition did not affect ROS generation. This study, in a PTEC line, demonstrates that high glucose causes the generation of ONOO-, leading to caspase-mediated apoptosis. Ebselen and a caspase-3 inhibitor provided significant protection against high glucose-mediated apoptosis, implicating ONOO- as a proapoptotic ROS in early diabetic nephropathy.	Univ London, Dept Expt Med & Nephrol, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, London EC1A 7BE, England	University of London; Queen Mary University London	Allen, DA (corresponding author), Univ London, Dept Expt Med & Nephrol, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, Suite 22,Domin House,59 Bartholomews Close, London EC1A 7BE, England.	d.a.allen@qmul.ac.uk						Adrie C, 2000, AM J PHYSIOL-CELL PH, V279, pC452, DOI 10.1152/ajpcell.2000.279.2.C452; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bestwick CS, 2001, BBA-GEN SUBJECTS, V1528, P49, DOI 10.1016/S0304-4165(01)00167-2; Bian K, 1999, AM J PHYSIOL-RENAL, V277, pF33, DOI 10.1152/ajprenal.1999.277.1.F33; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CATALANO C, 1992, NEPHROL DIAL TRANSPL, V7, P181, DOI 10.1093/oxfordjournals.ndt.a092103; CATALANO C, 1993, CLIN SCI, V84, P461, DOI 10.1042/cs0840461; Ceriello A, 2001, DIABETOLOGIA, V44, P834; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; DECKERT T, 1981, ACTA ENDOCRINOL-COP, V97, P14; Du XL, 1999, FREE RADICAL BIO MED, V27, P752, DOI 10.1016/S0891-5849(99)00079-9; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Ha H, 1999, DIABETES RES CLIN PR, V45, P147, DOI 10.1016/S0168-8227(99)00044-3; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; IKENAGA H, 1993, CLIN SCI, V84, P469, DOI 10.1042/cs0840469; Ishii N, 2001, J AM SOC NEPHROL, V12, P1630, DOI 10.1681/ASN.V1281630; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Jones SC, 1999, DIABETIC MED, V16, P932, DOI 10.1046/j.1464-5491.1999.00174.x; Kikkawa R, 1997, KIDNEY INT, V52, pS39; Kim MS, 2001, BIOCHEM PHARMACOL, V61, P779, DOI 10.1016/S0006-2952(01)00541-X; Montero A, 2000, KIDNEY INT, V58, P1963, DOI 10.1111/j.1523-1755.2000.00368.x; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; Noiri E, 2001, AM J PHYSIOL-RENAL, V281, pF948, DOI 10.1152/ajprenal.0071.2001; Park SH, 2001, KIDNEY INT, V59, P1695, DOI 10.1046/j.1523-1755.2001.0590051695.x; Posthuma N, 2001, PERITON DIALYSIS INT, V21, P43; Powell LA, 2001, FREE RADICAL BIO MED, V31, P1149, DOI 10.1016/S0891-5849(01)00648-7; Prabhakar SS, 2001, AM J PHYSIOL-RENAL, V281, pF179, DOI 10.1152/ajprenal.2001.281.1.F179; Priyadarsini KI, 2001, CHEM RES TOXICOL, V14, P567, DOI 10.1021/tx000239t; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith SC, 1999, PLACENTA, V20, P309, DOI 10.1053/plac.1998.0383; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Suarez-Pinzon WL, 2001, J AUTOIMMUN, V16, P449, DOI 10.1006/jaut.2001.0507; SuarezPinzon WL, 1997, DIABETES, V46, P907, DOI 10.2337/diabetes.46.5.907; Supinski G, 1999, J APPL PHYSIOL, V87, P783, DOI 10.1152/jappl.1999.87.2.783; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Tannous M, 1999, DIABETOLOGIA, V42, P539, DOI 10.1007/s001250051192; Thuraisingham RC, 2000, KIDNEY INT, V57, P1968, DOI 10.1046/j.1523-1755.2000.00046.x; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; Uemura S, 2001, CIRC RES, V88, P1291, DOI 10.1161/hh1201.092042; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Zanetti M, 2001, ARTERIOSCL THROM VAS, V21, P195, DOI 10.1161/01.ATV.21.2.195; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341	55	193	201	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					908	+		10.1096/fj.02-0130fje	http://dx.doi.org/10.1096/fj.02-0130fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670885				2022-12-25	WOS:000181892600006
J	Bachschmid, M; Thurau, S; Zou, MH; Ullrich, V				Bachschmid, M; Thurau, S; Zou, MH; Ullrich, V			Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation	FASEB JOURNAL			English	Article						nitric oxide; 6-ketoprostaglandin F1-alpha; peroxynitrous acid; lipopolysaccharides; prostaglandin endoperoxides	SMOOTH-MUSCLE CELLS; BOVINE CORONARY-ARTERIES; NITRIC-OXIDE RELEASE; TYROSINE NITRATION; PROSTAGLANDIN-I2 SYNTHASE; SIMULTANEOUS GENERATION; VASCULAR ENDOTHELIUM; XANTHINE-OXIDASE; NAD(P)H OXIDASE; IN-VIVO	In bovine coronary artery segments, peroxynitrite inhibits prostacyclin (PGI(2)) synthase by tyrosine nitration. Using this pharmacological model, we show that a 1 h exposure of bovine coronary artery segments to endotoxin (lipopolysaccharide [LPS]) inhibits the relaxation phase following angiotensin II (Ang II) stimulation and causes a vasospasm that can be suppressed by a thromboxane A(2) (TxA(2)) receptor blocker. In parallel, PGI(2) synthesis decreases in favor of prostaglandin E-2 formation. Immunoprecipitation and costaining with an anti-nitrotyrosine antibody identified PGI(2) synthase as the main nitrated protein in the endothelium. All effects of LPS could be prevented in the presence of the nitric oxide (NO) synthase inhibitor N-omega-monomethyl-L-arginine and polyethylene-glycolated Cu/Zn- superoxide dismutase. Thus, the early phase of endothelial cell activation in bovine coronary arteries by inflammatory agents proceeds by a protein synthesis-independent priming process for a source of superoxide that we tentatively attribute to xanthine oxidase. Upon receptor activation, Ang II stimulates NO and superoxide production, resulting in a peroxynitrite-mediated nitration and inhibition of PGI(2) synthase. The remaining 15-hydroxy-prostaglandin 9,11-endoperoxide (PGH(2)) first activates the TxA(2)/PGH(2) receptor and then is converted to prostaglandin E-2 (PGE(2)) by smooth muscle cells. PGE(2) together with a lack of NO and PGI(2) is known to promote the adhesion of white blood cells and their immigration to the inflammatory locus.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Fach X910, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de		Bachschmid, Markus Michael/0000-0002-0748-5528				BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Bhagat K, 1996, CARDIOVASC RES, V32, P822; Bhagat K, 1997, CIRCULATION, V96, P3042, DOI 10.1161/01.CIR.96.9.3042; Brandes RP, 1999, HYPERTENSION, V33, P1243, DOI 10.1161/01.HYP.33.5.1243; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Cines DB, 1998, BLOOD, V91, P3527; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Daiber A, 2002, J BIOL CHEM, V277, P11882, DOI 10.1074/jbc.M111988200; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DEWITT DL, 1983, J CLIN INVEST, V72, P1882, DOI 10.1172/JCI111151; Dogne JM, 2000, CURR MED CHEM, V7, P609, DOI 10.2174/0929867003374868; Goligorsky MS, 2000, ACTA PHYSIOL SCAND, V168, P33; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Hailer NP, 2000, TRANSPLANTATION, V70, P236; HAROLD JG, 1985, PROSTAGLANDINS, V29, P19, DOI 10.1016/0090-6980(85)90147-9; Harrison R, 1997, BIOCHEM SOC T, V25, P786, DOI 10.1042/bst0250786; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; Hunt BJ, 1997, LANCET, V350, P293, DOI 10.1016/S0140-6736(05)62261-1; Klein T, 1998, MOL PHARMACOL, V53, P385, DOI 10.1124/mol.53.3.385; Kromer BM, 1999, BRIT J PHARMACOL, V126, P1171, DOI 10.1038/sj.bjp.0702433; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Minetti M, 2000, BIOCHEMISTRY-US, V39, P6689, DOI 10.1021/bi9927991; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; POBER JS, 1988, AM J PATHOL, V133, P426; Prescott SM, 2001, J INVEST MED, V49, P104, DOI 10.2310/6650.2001.34106; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; RAND MJ, 1993, CLIN EXP PHARMACOL P, V20, P141, DOI 10.1111/j.1440-1681.1993.tb01661.x; RHODEN KJ, 1989, BRIT J PHARMACOL, V98, P325, DOI 10.1111/j.1476-5381.1989.tb16898.x; Ryan Matthew G., 1997, Biochemical Society Transactions, V25, p530S; SAUSSY DL, 1986, J BIOL CHEM, V261, P3025; SCHMIDT P, IN PRESS J BIOL CHEM; Scott GS, 2001, MED HYPOTHESES, V56, P95, DOI 10.1054/mehy.2000.1118; SHIMIZU S, 1994, RES COMMUN CHEM PATH, V84, P301; SMITH WL, 1983, J BIOL CHEM, V258, P5922; Sohn HY, 2000, BRIT J PHARMACOL, V131, P667, DOI 10.1038/sj.bjp.0703566; Soler M, 2000, CIRC RES, V87, P504; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419; Thorup C, 1998, PFLUG ARCH EUR J PHY, V435, P432, DOI 10.1007/s004240050535; Ullrich V, 2000, BIOCHEM BIOPH RES CO, V278, P1, DOI 10.1006/bbrc.2000.3733; VANE JR, 1990, NEW ENGL J MED, V323, P27; Vanhoutte PM, 2002, EUR HEART J SUPPL, V4, pA8, DOI 10.1016/S1520-765X(02)90068-4; Yura T, 1999, KIDNEY INT, V56, P471, DOI 10.1046/j.1523-1755.1999.00596.x; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2; Zou MH, 1999, J EXP MED, V190, P135, DOI 10.1084/jem.190.1.135; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	52	76	81	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					914	+		10.1096/fj.02-0530fje	http://dx.doi.org/10.1096/fj.02-0530fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670882				2022-12-25	WOS:000181892600012
J	Six, DA; Dennis, EA				Six, DA; Dennis, EA			Essential Ca2+-independent role of the Group IVA cytosolic phospholipase A(2) C2 domain for interfacial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; ARACHIDONIC-ACID RELEASE; INFECTED INSECT CELLS; LIPID-BINDING DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEMBRANE-DOCKING; HIGH-AFFINITY; HYDROLYZING PHOSPHOLIPASE-A2; LYSOPHOSPHOLIPASE ACTIVITY; ANIONIC PHOSPHOLIPIDS	The cytosolic Group IVA phospholipase A(2) (GIVAPLA(2)) translocates to intracellular membranes to catalyze the release of lysophospholipids and arachidonic acid. GIVAPLA(2) translocation and subsequent activity is regulated by its Ca2+-dependent phospholipid binding C2 domain. Phosphatidylinositol 4,5-bisphosphate (PI-4,5-P2) also binds with high affinity and specificity to GIVAPLA(2), facilitating membrane binding and activity. Herein, we demonstrate that GIVAPLA(2) possessed full activity in the absence of Ca2+ when PI-4,5-P-2 or phosphatidylinositol 3,4,5-trisphosphate were present. A point mutant, D43N, that is unable to bind Ca2+ also had full activity in the presence of PI-4,5-P-2. However, when GIVAPLA(2) was expressed without its Ca2+-binding C2 domain (DeltaC2), there was no interfacial activity. GIVAPLA(2) and DeltaC2 both had activity on monomeric lysophospholipids. DeltaC2, but not the C2 domain alone, binds to phosphoinositides (PIP(n)s) in the same manner as the full-length GIVAPLA(2), confirming the location of the PIPn binding site as the GIVAPLA(2) catalytic domain. Moreover, proposed PIPn-binding residues in the catalytic domain (Lys(488), Lys(541), Lys(543), and Lys(544)) were confirmed to be essential for PI-4,5-P-2-dependent activity increases. Exploiting the effects of PI-4,5-P-2, we have discovered that the C2 domain plays a critical role in the interfacial activity of GIVAPLA(2) above and beyond its Ca2+-dependent phospholipid binding.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Dennis, Edward A./M-5554-2019; Six, David A/D-6523-2011	Dennis, Edward A./0000-0003-3738-3140; Six, David A/0000-0002-9013-1711	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07202] Funding Source: Medline; NIGMS NIH HHS [GM07240] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEGADZIE BY, 1993, GENE, V128, P307, DOI 10.1016/0378-1119(93)90580-V; Balboa MA, 2000, BIOCHEM BIOPH RES CO, V267, P145, DOI 10.1006/bbrc.1999.1964; Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; Deems RA, 2000, ANAL BIOCHEM, V287, P1, DOI 10.1006/abio.2000.4766; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Huwiler A, 2001, FASEB J, V15, P7; Killermann K, 2000, FASEB J, V14, pA1462; Kokotos G, 2002, J MED CHEM, V45, P2891, DOI 10.1021/jm025538p; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lefkowitz LJ, 1999, BIOCHEMISTRY-US, V38, P14174, DOI 10.1021/bi991432t; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Loo RW, 1997, J BIOL CHEM, V272, P19214, DOI 10.1074/jbc.272.31.19214; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Sheridan AM, 2001, J BIOL CHEM, V276, P29899, DOI 10.1074/jbc.M103758200; Siddhanta A, 2003, J BIOL CHEM, V278, P1957, DOI 10.1074/jbc.M209137200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; TAMIYAKOIZUMI K, 1989, BIOCHIM BIOPHYS ACTA, V1002, P182, DOI 10.1016/0005-2760(89)90285-3; Thomas CL, 1999, BIOCHEM SOC T, V27, P648, DOI 10.1042/bst0270648; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Verger R, 1980, Methods Enzymol, V64, P340; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; ZHANG YY, 1991, METHOD ENZYMOL, V197, P456; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	68	62	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23842	23850		10.1074/jbc.M301386200	http://dx.doi.org/10.1074/jbc.M301386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12672805	hybrid			2022-12-25	WOS:000183638600080
J	Glinkowska, M; Majka, J; Messer, W; Wegrzyn, G				Glinkowska, M; Majka, J; Messer, W; Wegrzyn, G			The mechanism of regulation of bacteriophage lambda p(R) promoter activity by Escherichia coli DnaA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; REPLICATION; INITIATOR; PLASMIDS; EXPRESSION; ORIGIN; SWITCH	Apart from its function as an initiator of DNA replication, the Escherichia coli DnaA protein is also a specific transcription factor. It activates and represses a number of promoters. However, mechanisms of transcription stimulation by DnaA remained unknown. Bacteriophage lambdap(R) promoter is one of the promoters activated by DnaA. It was reported previously that DnaA binds downstream of the p(R) promoter and perhaps interacts with the RNA polymerase beta subunit. Here we demonstrate that DnaA positively regulates transcription from pR by stimulation of two steps in transcription initiation: RNA polymerase binding to the promoter region and promoter escape. For this transcription activation, two weak DnaA boxes located downstream of pR are necessary and sufficient. Such a mechanism of transcription activation and location of the activator-binding sites relative to the transcription start point are unusual in prokaryotes. Changes in the distance between the transcription start point and the first DnaA box by 5 and 10 bp and alterations in the orientation of these boxes did not abolish the stimulation of transcription by DnaA, but the efficiency of the promoter activation was different for various mutations. It seems plausible that formation of higher order nucleoprotein structures, involving DNA looping, is necessary for effective stimulation of the pR promoter. At high concentrations, DnaA is a repressor of pR rather than an activator. This repression was found to be because of inhibition of RNA polymerase binding to the promoter region.	Univ Gdansk, Dept Mol Biol, PL-80822 Gdansk, Poland; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Polish Acad Sci, Inst Oceanol, PL-81347 Gdynia, Poland	Fahrenheit Universities; University of Gdansk; Max Planck Society; Polish Academy of Sciences; Institute of Oceanology of the Polish Academy of Sciences	Wegrzyn, G (corresponding author), Univ Gdansk, Dept Mol Biol, Kladki 24, PL-80822 Gdansk, Poland.	wegrzyn@biotech.univ.gda.pl	Wegrzyn, Grzegorz/AAL-1179-2020; Wegrzyn, Grzegorz/ABD-6699-2020	Wegrzyn, Grzegorz/0000-0003-4042-7466	FOGARTY INTERNATIONAL CENTER [R03TW001244] Funding Source: NIH RePORTER; FIC NIH HHS [TW01244] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Baranska S, 2002, NUCLEIC ACIDS RES, V30, P1176, DOI 10.1093/nar/30.5.1176; Baranska S, 2001, MICROBIOL-UK, V147, P535, DOI 10.1099/00221287-147-3-535; Bolivar F, 1979, Methods Enzymol, V68, P245; Chamberlin Michael J., 1996, P7; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; Glinkowska M, 2001, MICROBIOL-SGM, V147, P1923, DOI 10.1099/00221287-147-7-1923; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Konopa G, 1999, FEMS MICROBIOL LETT, V174, P25, DOI 10.1016/S0378-1097(99)00116-0; KUR J, 1987, J MOL BIOL, V198, P203, DOI 10.1016/0022-2836(87)90306-8; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; LEARN B, 1993, COLD SPRING HARB SYM, V58, P389, DOI 10.1101/SQB.1993.058.01.046; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Messer W, 2001, BIOCHIMIE, V83, P5, DOI 10.1016/S0300-9084(00)01216-5; Quinones A, 1997, MOL MICROBIOL, V23, P1193, DOI 10.1046/j.1365-2958.1997.2961658.x; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Sambrook J, 1989, MOL CLONING; SCHAEFER C, 1988, GENE, V73, P347, DOI 10.1016/0378-1119(88)90499-4; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; Szalewska-Palasz A, 1998, MOL GEN GENET, V259, P679, DOI 10.1007/s004380050863; Szalewska-Palasz A, 1998, P NATL ACAD SCI USA, V95, P4241, DOI 10.1073/pnas.95.8.4241; TAYLOR K, 1995, FEMS MICROBIOL REV, V17, P109; TAYLOR K, 1998, MOL MICROBIOL, P81; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wegrzyn G, 1996, MOL GEN GENET, V252, P580; WEGRZYN G, 1995, GENE, V154, P47, DOI 10.1016/0378-1119(94)00849-N	28	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22250	22256		10.1074/jbc.M212492200	http://dx.doi.org/10.1074/jbc.M212492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12654908	hybrid			2022-12-25	WOS:000183503900011
J	Tan, WB; Rouen, S; Barkus, KM; Dremina, YS; Hui, DW; Christianson, JA; Wright, DE; Yoon, SO; Dobrowsky, RT				Tan, WB; Rouen, S; Barkus, KM; Dremina, YS; Hui, DW; Christianson, JA; Wright, DE; Yoon, SO; Dobrowsky, RT			Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL DIABETIC-NEUROPATHY; OXIDATIVE STRESS; IN-VIVO; MACROPHAGE INFILTRATION; GENE-TRANSCRIPTION; PERIPHERAL-NERVE; TYROSINE KINASE; O-GLCNAC; C-JUN; DEATH	Altered neurotrophism in diabetic peripheral neuropathy (DPN) is associated in part with substantial degenerative changes in Schwann cells (SCs) and an increased expression of the p75 neurotrophin receptor (p75(NTR)). Caveolin-1 (Cav-1) is highly expressed in adult SCs, and changes in its expression can regulate signaling through Erb B2, a co-receptor that mediates the effects of neuregulins in promoting SC growth and differentiation. We examined the hypothesis that hyperglycemia-induced changes in Cav-1 expression and p75NTR signaling may contribute to altered neurotrophism in DPN by modulating SC responses to neuregulins. In an animal model of type 1 diabetes, hyperglycemia induced a progressive decrease of Cav-1 in SCs of sciatic nerve that was reversed by insulin therapy. Treatment of primary neonatal SCs with 20-30 mM D-glucose, but not L-glucose, was sufficient to inhibit transcription from the Cav-1 promoter and decrease Cav-1 mRNA and protein expression. Hyperglycemia prolonged the kinetics of Erb B2 phosphorylation and significantly enhanced the mitogenic response of SCs to neuregulin1-beta1, and this effect was mimicked by the forced down-regulation of Cav-1. Intriguingly, nerve growth factor antagonized the enhanced mitogenic response of SCs to neuregulin1-beta1 and inhibited the glucose-induced down-regulation of Cav-1 transcription, mRNA, and protein expression through p75(NTR)-dependent activation of JNK. Our data suggest that Cav-1 down-regulation may contribute to altered neurotrophism in DPN by enhancing the response of SCs to neuregulins and that p75(NTR)-mediated JNK activation may provide a mechanism for the neurotrophic modulation of hyperglycemic stress.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Ohio State Univ, Neurobiotech Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University of Kansas; University of Kansas; University of Kansas Medical Center; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Dobrowsky, RT (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 5064 Malott Hall,1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	dobrowsky@ku.edu	Yoon, Sung Ok/C-5992-2012; Tan, Wenbin/AAF-2037-2020	Tan, Wenbin/0000-0002-2334-8988; Christianson, Julie/0000-0003-4117-5192	NIDDK NIH HHS [DK59749] Funding Source: Medline; NINDS NIH HHS [R01 NS043314, NS38154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK059749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043314, R01NS038154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Apfel SC, 1999, DIABETES OBES METAB, V1, P3, DOI 10.1046/j.1463-1326.1999.00006.x; APFEL SC, 1994, BRAIN RES, V634, P7, DOI 10.1016/0006-8993(94)90252-6; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Bentley CA, 2000, J NEUROSCI, V20, P7706; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Cameron NE, 1997, DIABETES, V46, pS31, DOI 10.2337/diab.46.2.S31; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Clarkson MR, 2002, J BIOL CHEM, V277, P9707, DOI 10.1074/jbc.M109172200; Conti G, 1997, EXP NEUROL, V146, P206, DOI 10.1006/exnr.1997.6521; Conti G, 2002, J NEUROL SCI, V195, P35, DOI 10.1016/S0022-510X(01)00684-0; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dobrowsky RT, 2000, J NEUROSCI RES, V61, P237, DOI 10.1002/1097-4547(20000801)61:3<237::AID-JNR1>3.0.CO;2-M; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Fu Q, 1998, J NEUROCHEM, V71, P549; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Garratt AN, 2000, J CELL BIOL, V148, P1035, DOI 10.1083/jcb.148.5.1035; Greene D. A., 1997, DIABETES MELLITUS, P1009; Grinspan JB, 1996, J NEUROSCI, V16, P6107; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Hounsom L, 1997, CLIN NEUROSCI, V4, P380; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Lemke G, 2001, ANNU REV NEUROSCI, V24, P87, DOI 10.1146/annurev.neuro.24.1.87; Li GB, 2003, J NEUROCHEM, V84, P347, DOI 10.1046/j.1471-4159.2003.01526.x; Mikol DD, 1999, GLIA, V27, P39; Mikol DD, 2002, GLIA, V38, P191, DOI 10.1002/glia.10063; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; Peterson TE, 1999, CIRC RES, V85, P29; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Scarpini E, 1996, J NEUROL SCI, V135, P55, DOI 10.1016/0022-510X(95)00260-9; Sprott KM, 2002, BIOCHEM J, V365, P181, DOI 10.1042/BJ20020215; Sugimoto K, 2000, DIABETES-METAB RES, V16, P408; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; Tikoo R, 2000, J NEUROSCI, V20, P4627, DOI 10.1523/JNEUROSCI.20-12-04627.2000; Vincent AM, 2002, ANN NY ACAD SCI, V959, P368, DOI 10.1111/j.1749-6632.2002.tb02108.x; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zanazzi G, 2001, J CELL BIOL, V152, P1289, DOI 10.1083/jcb.152.6.1289	58	31	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23151	23162		10.1074/jbc.M212986200	http://dx.doi.org/10.1074/jbc.M212986200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12679365	hybrid			2022-12-25	WOS:000183503900123
J	Benharouga, M; Sharma, M; So, J; Haardt, M; Drzymala, L; Popov, M; Schwapach, B; Grinstein, S; Du, K; Lukacs, GL				Benharouga, M; Sharma, M; So, J; Haardt, M; Drzymala, L; Popov, M; Schwapach, B; Grinstein, S; Du, K; Lukacs, GL			The role of the C terminus and Na+/H+ exchanger regulatory factor in the functional expression of cystic fibrosis transmembrane conductance regulator in nonpolarized cells and epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-INTERACTING DOMAIN; PROTEIN-KINASE-A; DEPENDENT REGULATION; PLASMA-MEMBRANE; FACTOR-I; CFTR; RECEPTOR; BINDING; EZRIN; LOCALIZATION	The conserved C-terminal peptide motif ((DTRL)-D-1476) of the cystic fibrosis transmembrane conductance regulator (CFTR) ensures high affinity binding to different PSD-95/Disc-large/zonula occludens-1 (PDZ) domain-containing molecules, including the Na+/H+ exchanger regulatory factor (NHERF)/ezrin-radixin- moesin-binding phosphoprotein of 50 kDa. The physiological relevance of NHERF binding to CFTR is not fully understood. Individuals with mutations resulting in premature termination of CFTR (S1455X or Delta26 CFTR) have moderately elevated sweat Cl- concentration, without an obvious lung and pancreatic phenotype, implying that the CFTR function is largely preserved. Surprisingly, when expressed heterologously, the Delta26 mutation was reported to abrogate channel activity by destabilizing the protein at the apical domain and inducing its accumulation at the basolateral membrane (Moyer, B., Denton, J., Karlson, K., Reynolds, D., Wang, S., Mickle, J., Milewski, M., Cutting, G., Guggino, W., Li, M., and Stanton, B. (1999) J. Clin. Invest. 104, 1353 - 1361). The goals of this study were to resolve the contrasting clinical and cellular phenotype of the Delta26 CFTR mutation and evaluate the role of NHERF in the functional expression of CFTR at the plasma membrane. Complex formation between CFTR and NHERF was disrupted by C-terminal deletions, C-terminal epitope tag attachments, or overexpression of a dominant negative NHERF mutant. These perturbations did not alter CFTR expression, metabolic stability, or function in nonpolarized cells. Likewise, inhibition of NHERF binding had no discernible effect on the apical localization of CFTR in polarized tracheal, pancreatic, intestinal, and kidney epithelia and did not influence the metabolic stability or the cAMP-dependent protein kinase-activated chloride channel conductance in polarized pancreatic epithelia. On the other hand, electrophysiological studies demonstrated that NHERF is able to stimulate the cAMP-dependent protein kinase-phosphorylated CFTR channel activity in intact cells. These results help to reconcile the discordant genotype-phenotype relationship in individuals with C-terminal truncations and indicate that apical localization of CFTR involves sorting signals other than the C-terminal 26 amino acid residues and the PDZ-binding motif in differentiated epithelia.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; ZMBH, INF 282, D-69120 Heidelberg, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ruprecht Karls University Heidelberg	Lukacs, GL (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	glukacs@sickkids.ca	Haardt, Martin/B-5857-2011	Haardt, Martin/0000-0001-7810-975X; Lukacs, Gergely/0000-0003-0900-0675				Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Citi S, 1998, BBA-MOL CELL RES, V1448, P1, DOI 10.1016/S0167-4889(98)00125-6; de Beauregard MAC, 2000, EUR J CELL BIOL, V79, P795, DOI 10.1078/0171-9335-00116; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gentzsch M, 2002, BIOCHEM J, V366, P541, DOI 10.1042/BJ20020511; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Gustafson CE, 1998, HISTOCHEM CELL BIOL, V110, P377, DOI 10.1007/s004180050298; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris BZ, 2001, J CELL SCI, V114, P3219; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; Hollande E, 1998, EUR J CELL BIOL, V76, P220, DOI 10.1016/S0171-9335(98)80037-X; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kartner N, 1998, METHOD ENZYMOL, V292, P629; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MADDEN ME, 1988, PANCREAS, V3, P512, DOI 10.1097/00006676-198810000-00003; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Mickle JE, 2000, MED CLIN N AM, V84, P597, DOI 10.1016/S0025-7125(05)70243-1; Milewski MI, 2001, J CELL SCI, V114, P719; Mohamed A, 1997, BIOCHEM J, V322, P259, DOI 10.1042/bj3220259; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; OSTEDGAARD L, 2002, PED PULM S, V24, P184; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramalho AS, 2002, AM J RESP CELL MOL, V27, P619, DOI 10.1165/rcmb.2001-0004OC; RaveHarel N, 1997, AM J HUM GENET, V60, P87; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RIORDAN JR, 1989, SCIENCE, V245, P1066; Salvatore F, 2002, AM J MED GENET, V111, P88, DOI 10.1002/ajmg.10461; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; TROJAN J, 1994, P NATL ACAD SCI USA, V91, P6088, DOI 10.1073/pnas.91.13.6088; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Zielenski J, 2000, RESPIRATION, V67, P117, DOI 10.1159/000029497	66	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22079	22089		10.1074/jbc.M301030200	http://dx.doi.org/10.1074/jbc.M301030200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12651858	hybrid			2022-12-25	WOS:000183354200096
J	Munz, C; Psichari, E; Mandilis, D; Lavigne, AC; Spiliotaki, M; Oehler, T; Davidson, I; Tora, L; Angel, P; Pintzas, A				Munz, C; Psichari, E; Mandilis, D; Lavigne, AC; Spiliotaki, M; Oehler, T; Davidson, I; Tora, L; Angel, P; Pintzas, A			TAF7 (TAF(II)55) plays a role in the transcription activation by c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; POLYMERASE-II TRANSCRIPTION; DNA-BINDING; IN-VITRO; PROTEIN-KINASES; RETINOIC ACID; TFIID COMPLEX; CROSS-TALK; AP-1; DOMAIN	c-Jun is a member of the AP- 1 family of transcription factors regulating expression of specific target genes in a variety of cellular processes including proliferation, stress response, and tumorigenicity. In the present study we have analyzed the mechanism of c- Jun function as a transactivator with respect to members of the basal transcription machinery, TATA- binding protein-associated factors ( TAFs). We show that one member of the family, human TAF7 ( formerly TAF(II)55), physically interacts with c- Jun through two independent interaction domains, within the N- and C- terminal part of c-Jun. Interaction in vitro correlates with enhanced transactivation function of c- Jun in HEK293 and COS cells in the presence of increasing amounts of TAF7. TAF7 interacts preferentially with DNA- bound phosphorylated c- Jun, suggesting that TAF7 represents a novel c- Jun co- activator mediating activation of AP- 1 target genes in response to extracellular signals.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, GR-11635 Athens, Greece; CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Helmholtz Association; German Cancer Research Center (DKFZ); National Hellenic Research Foundation; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, B-0800,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Münz, Christian/W-4881-2017; Lavigne, Anne-Claire/O-8805-2015; Piris, Miguel A/AAP-1445-2020; Tora, Laszlo/E-9999-2018	Piris, Miguel A/0000-0001-5839-3634; Tora, Laszlo/0000-0001-7398-2250; Davidson, Irwin/0000-0001-5533-1171				Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Jung DJ, 2002, MOL CELL BIOL, V22, P5203, DOI 10.1128/MCB.22.14.5203-5211.2002; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; Martin J, 1999, MOL CELL BIOL, V19, P5548; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; OEHLER T, 1993, ONCOGENE, V8, P1141; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PAPAVASSILIOU AG, 1992, P NATL ACAD SCI USA, V89, P11562, DOI 10.1073/pnas.89.23.11562; Pham AD, 1999, MECH DEVELOP, V84, P3, DOI 10.1016/S0925-4773(99)00051-9; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	60	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21510	21516		10.1074/jbc.M212764200	http://dx.doi.org/10.1074/jbc.M212764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676957	Green Published, hybrid			2022-12-25	WOS:000183354200026
J	Price, PA; Lim, JE				Price, PA; Lim, JE			The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; ACID-CONTAINING PROTEIN; CORTICAL BONE; RAT; CALCIFICATION; GLYCOPROTEIN; SERUM; ARTERIES; GENE	The present studies show that the previously reported ability of fetuin to inhibit the precipitation of hydroxyapatite from supersaturated solutions of calcium and phosphate in vitro is accompanied by the formation of the fetuin-mineral complex, a high molecular mass complex of calcium phosphate mineral and the proteins fetuin and matrix Gla protein that was initially discovered in the serum of rats treated with etidronate and that appears to play a critical role in inhibiting calcification in vivo. Rat serum potently inhibited the precipitation of calcium phosphate mineral when the concentration of calcium and phosphate were increased by 10 mM each, and the modified serum was incubated at 37degreesC for 9 days; in the absence of serum, precipitation occurred in seconds. Large amounts of the fetuin-mineral complex were generated in the first 3 h of this incubation and remained throughout the 9-day incubation. Purified bovine fetuin inhibited the precipitation of mineral for over 14 days in a solution containing 5 mM calcium and phosphate at pH 7.4 at 22degreesC, whereas precipitation occurred in minutes without fetuin. There was a biphasic drop in ionic calcium in the fetuin solution, however, from 5 to 3 mM in the first hour and from 3 to 0.9 mM between 20 and 24 h; these changes in ionic calcium are due to the formation of complexes of calcium, phosphate, and fetuin. The complex found at 24 h to 14 days is identical to the fetuin-mineral complex found in the serum of etidronate-treated rats, whereas the complex found between 1 and 20 h is less stable.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Price, PA (corresponding author), Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA.				NIAMS NIH HHS [AR 25921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHTON BA, 1976, CALC TISS RES, V22, P27; ASHTON BA, 1974, EUR J BIOCHEM, V45, P525, DOI 10.1111/j.1432-1033.1974.tb03577.x; BROWN WM, 1992, BIOESSAYS, V14, P749, DOI 10.1002/bies.950141105; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; OTAWARA Y, 1986, J BIOL CHEM, V261, P828; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; Price PA, 2002, J BONE MINER RES, V17, P1171, DOI 10.1359/jbmr.2002.17.7.1171; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; QUELCH KJ, 1984, CALCIFIED TISSUE INT, V36, P545, DOI 10.1007/BF02405363; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SUZUKI M, 1994, J EXP ZOOL, V270, P501, DOI 10.1002/jez.1402700603; WENDEL M, 1993, MATRIX, V13, P331, DOI 10.1016/S0934-8832(11)80029-6	20	170	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22144	22152		10.1074/jbc.M300744200	http://dx.doi.org/10.1074/jbc.M300744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676929	hybrid			2022-12-25	WOS:000183354200103
J	Lara, P; Onate-Sanchez, L; Abraham, Z; Ferrandiz, C; Diaz, I; Carbonero, P; Vicente-Carbajosa, J				Lara, P; Onate-Sanchez, L; Abraham, Z; Ferrandiz, C; Diaz, I; Carbonero, P; Vicente-Carbajosa, J			Synergistic activation of seed storage protein gene expression in Arabidopsis by ABI3 and two bZIPs related to OPAQUE2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSPERM-SPECIFIC EXPRESSION; TRANSCRIPTIONAL ACTIVATOR; GCN4-LIKE MOTIF; B3 DOMAIN; PROMOTER; INTERACTS; ELEMENTS; RECOGNIZES; TARGET; BOX	The expression of many seed storage protein genes in cereals relies on transcription factors of the bZIP class, belonging to the maize OPAQUE2 family. Here, we describe a survey of such factors in the genome of Arabidopsis thaliana, and the characterization of two of them, AtbZIP10 and AtbZIP25. Expression analysis by in situ hybridization shows that the occurrence of their mRNAs in the seed starts from early stages of development, peaks at maturation, and declines later in seed development, matching temporally and spatially those of the seed storage protein genes encoding 2S albumins and cruciferins. Gel mobility shift assays showed that AtbZIP10 and AtbZIP25 bind the ACGT boxes present in At2S and CRU3 promoters. Moreover, using the yeast two-hybrid system we show that AtbZIP10 and AtbZIP25 can interact in vivo with ABI3, an important regulator of gene expression in the seed of Arabidopsis. Transient expression analyses of a reporter gene under the control of the At2S1 promoter in transgenic plants overexpressing ectopically AtbZIP10, AtbZIP25, and ABI3 reveal that none of these factors could activate significantly the reporter gene when expressed individually. However, co-expression of AtbZIP10/25 with ABI3 resulted in a remarkable increase in the activation capacity over the At2S1 promoter, suggesting that they are part of a regulatory complex involved in seed-specific expression. This study shows a common mechanism of ABI3 in regulating different seed-specific genes through combinatorial interactions with particular bZIP proteins and a conserved role of O2-like bZIPs in monocot and dicot species.	ETS Ingn Agron, Lab Bioquim & Biol Mol, Dept Biotecnol UPM, Madrid 28040, Spain		Vicente-Carbajosa, J (corresponding author), ETS Ingn Agron, Lab Bioquim & Biol Mol, Dept Biotecnol UPM, Madrid 28040, Spain.	jvicente@bit.etsia.upm.es	Ferrandiz, Cristina/E-6280-2015; Oñate-Sánchez, Luis J/C-6274-2017; Diaz, Isabel/I-8840-2014; Vicente-Carbajosa, Jesus/A-9368-2008	Ferrandiz, Cristina/0000-0002-2460-1068; Oñate-Sánchez, Luis J/0000-0001-7047-5739; Diaz, Isabel/0000-0001-9865-902X; Vicente-Carbajosa, Jesus/0000-0002-6332-1712				Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Bensmihen S, 2002, PLANT CELL, V14, P1391, DOI 10.1105/tpc.000869; Carbonero P, 2000, SEED BIOLOGY: ADVANCES AND APPLICATIONS, P27, DOI 10.1079/9780851994048.0027; Chang JF, 1999, J MOL BIOL, V288, P941, DOI 10.1006/jmbi.1999.2711; Choi HI, 2000, J BIOL CHEM, V275, P1723, DOI 10.1074/jbc.275.3.1723; dePater S, 1996, PLANT MOL BIOL, V32, P515, DOI 10.1007/BF00019103; Diaz I, 2002, PLANT J, V29, P453, DOI 10.1046/j.0960-7412.2001.01230.x; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Ellerstrom M, 1996, PLANT MOL BIOL, V32, P1019, DOI 10.1007/BF00041385; Ezcurra I, 1999, PLANT MOL BIOL, V40, P699, DOI 10.1023/A:1006206124512; Ezcurra I, 2000, PLANT J, V24, P57, DOI 10.1046/j.1365-313x.2000.00857.x; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Hill A, 1996, J BIOL CHEM, V271, P3366, DOI 10.1074/jbc.271.7.3366; Hobo T, 1999, P NATL ACAD SCI USA, V96, P15348, DOI 10.1073/pnas.96.26.15348; Hoekstra FA, 2001, TRENDS PLANT SCI, V6, P431, DOI 10.1016/S1360-1385(01)02052-0; HUGHES DW, 1989, GENE DEV, V3, P358, DOI 10.1101/gad.3.3.358; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Luerssen K, 1998, PLANT J, V15, P755, DOI 10.1046/j.1365-313X.1998.00259.x; MATZKE AJM, 1990, PLANT MOL BIOL, V14, P323, DOI 10.1007/BF00028769; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; Nakamura S, 2001, PLANT J, V26, P627, DOI 10.1046/j.1365-313x.2001.01069.x; Nesi N, 2001, PLANT CELL, V13, P2099, DOI 10.1105/tpc.13.9.2099; Onate L, 1999, J BIOL CHEM, V274, P9175, DOI 10.1074/jbc.274.14.9175; Onodera Y, 2001, J BIOL CHEM, V276, P14139, DOI 10.1074/jbc.M007405200; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PIROVANO L, 1994, PLANT MOL BIOL, V24, P515, DOI 10.1007/BF00024119; Reidt W, 2000, PLANT J, V21, P401, DOI 10.1046/j.1365-313x.2000.00686.x; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V74, P5463; Schwechheimer C, 1998, TRENDS PLANT SCI, V3, P378, DOI 10.1016/S1360-1385(98)01302-8; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; Stone SL, 2001, P NATL ACAD SCI USA, V98, P11806, DOI 10.1073/pnas.201413498; Suzuki A, 1998, PLANT CELL PHYSIOL, V39, P555, DOI 10.1093/oxfordjournals.pcp.a029404; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; TAKAIWA F, 1991, PLANT MOL BIOL, V16, P49, DOI 10.1007/BF00017916; Takaiwa F, 1996, PLANT MOL BIOL, V30, P1207, DOI 10.1007/BF00019553; vanderGeest AHM, 1996, PLANT MOL BIOL, V32, P579, DOI 10.1007/BF00020199; Vettore AL, 1998, PLANT MOL BIOL, V36, P249, DOI 10.1023/A:1005995806897; Vicente-Carbajosa J, 1998, PLANT J, V13, P629, DOI 10.1111/j.1365-313X.1998.00068.x; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; Vincentz M, 1997, PLANT MOL BIOL, V34, P879, DOI 10.1023/A:1005874404706; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Wobus U, 1999, CURR OPIN PLANT BIOL, V2, P33, DOI 10.1016/S1369-5266(99)80007-7; YUNES JA, 1994, PLANT CELL, V6, P237, DOI 10.1105/tpc.6.2.237	52	125	154	3	40	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21003	21011		10.1074/jbc.M210538200	http://dx.doi.org/10.1074/jbc.M210538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657652	hybrid, Green Accepted			2022-12-25	WOS:000183230500073
J	Cheema, SK; Mishra, SK; Rangnekar, VM; Tari, AM; Kumar, R; Lopez-Berestein, G				Cheema, SK; Mishra, SK; Rangnekar, VM; Tari, AM; Kumar, R; Lopez-Berestein, G			Par-4 transcriptionally regulates bcl-2 through a WT1-binding site on the bcl-2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROSTATE-CANCER; TUMOR-SUPPRESSOR WT1; T(14-18) LYMPHOMAS; PROTEIN PAR-4; CREB PROTEINS; RETINOIC ACID; B-CELLS; APOPTOSIS; GENE; EXPRESSION	Elevated expression levels of the bcl-2 proto-oncogene have been extensively correlated with the appearance of androgen independence in prostate cancer. Although bcl-2 was first cloned as the t(14:18) translocation breakpoint from human follicular B cell lymphoma, the mechanism of overexpression of bcl-2 is largely undefined for advanced prostate cancer because there are no gross alterations in the gene structure. We investigated the role of the product of the prostate apoptosis response gene-4 (Par-4) and the product of the Wilms' tumor 1 gene (WT1) in the regulation of Bcl-2 expression in prostate cancer cell lines. We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. The decrease in the Bcl-2 protein and transcript following all-trans-retinoic acid treatment was accompanied by changes in localization of Par-4 and an induction in the expression of WT1 protein. In stable clones expressing ectopic Par-4 and in ATRA-treated cells, we observed decreased Bcl-2 protein and transcript. This was accompanied by an induction in WT1 expression. The involvement of WT1 in the Par-4-mediated down-modulation of Bcl-2 was further defined by blocking endogenous WT1 expression, which resulted in an increase in Bcl-2 expression. Finally, we detected Par-4 and WT1 proteins binding to a previously identified WT1-binding site on the bcl-2 promoter both in vitro and in vivo leading to a decrease in transcription from the bcl-2 promoter. We conclude that Par-4 regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. These data also identify Par-4 nuclear localization as a novel mechanism for ATRA-mediated bcl-2 regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carrier, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Kentucky	Lopez-Berestein, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carrier, Box 422,1515 Holcombe Blvd, Houston, TX 77030 USA.			Mishra, Sandip/0000-0002-0776-6581				Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Boehrer S, 2001, Hematol J, V2, P103, DOI 10.1038/sj.thj.6200089; Boehrer S, 2002, CANCER RES, V62, P1768; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DE LUCA LM, 1991, FASEB J, V5, P2924; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Hall AK, 1996, ANTI-CANCER DRUG, V7, P312, DOI 10.1097/00001813-199605000-00012; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HEWITT SM, 1995, CANCER RES, V55, P5386; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kallakury BVS, 1996, MODERN PATHOL, V9, P41; Kyprianou N, 2000, HISTOL HISTOPATHOL, V15, P1211, DOI 10.14670/HH-15.1211; Lara PN, 1999, CANCER INVEST, V17, P137; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Miyake H, 1999, CANCER RES, V59, P4030; Oh WK, 1999, J CLIN ONCOL, V17, P3664, DOI 10.1200/JCO.1999.17.11.3664; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Pasquali D, 1996, J CLIN ENDOCR METAB, V81, P2186, DOI 10.1210/jc.81.6.2186; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; RAFFO AJ, 1995, CANCER RES, V55, P4438; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REED JC, 1991, CANCER RES, V51, P6529; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; Sundaresan A, 1997, CELL GROWTH DIFFER, V8, P1071; Tari AM, 2000, METHOD ENZYMOL, V313, P372; Trump DL, 1997, CANCER CHEMOTH PHARM, V39, P349, DOI 10.1007/s002800050582; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WERNER H, 1994, J BIOL CHEM, V269, P12577; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	49	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19995	20005		10.1074/jbc.M205865200	http://dx.doi.org/10.1074/jbc.M205865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644474	hybrid			2022-12-25	WOS:000183078000056
J	Sawhney, RS; Sharma, B; Humphrey, LE; Brattain, MG				Sawhney, RS; Sharma, B; Humphrey, LE; Brattain, MG			Integrin alpha(2) and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha-driven colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; ANIMAL-MODEL; REAL-TIME; EXPRESSION; CARCINOMA; RECEPTOR; CASCADE	Recently, we have shown that autocrine transforming growth factor-alpha (TGF-alpha) controls the expression of integrin alpha(2), cell adhesion to collagen IV and motility in highly progressed HCT116 colon cancer cells (Sawhney, R. S., Zhou, G-H. K., Humphrey, L. E., Ghosh, P., Kreisberg, J. I., and Brattain, M. G. (2002) J. Biol. Chem. 277, 75-86). We now report that expression of basal integrin alpha(2) and its biological effects are controlled by constitutive activation of the extracellular signal-regulated/mitogen-activated protein kinase (ERK/MAPK) pathway. Treatment of cells with selective mitogen-activated protein kinase kinase (MEK) inhibitors PD098059 and U0126 showed that integrin alpha(2) expression, cell adhesion, and activation of ERK are inhibited in a parallel concentration-dependent fashion. Moreover, autocrine TGF-alpha-mediated epidermal growth factor receptor activation was shown to control the constitutive activation of the ERK/MAPK pathway, since neutralizing antibody to the epidermal growth factor receptor was able to block basal ERK activity. TGF-alpha antisense-transfected cells also showed attenuated activation of ERK. Using a real time electric cell impedance sensing technique, it was shown that ERK-dependent integrin alpha(2)-mediated cell micromotion signaling is controlled by autocrine TGF-alpha. Thus, this study implicates ERK/MAPK signaling activated by endogenous TGF-alpha as one of the mechanistic features controlling metastatic spread.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	michael.brattain@roswellpark.org		Sharma, Bhavya/0000-0003-4388-5702	NCI NIH HHS [CA 54807] Funding Source: Medline; PHS HHS [50457, 34432] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BRATTAIN MG, 1981, CANCER RES, V41, P1751; BRESALIER RS, 1987, INT J CANCER, V39, P625, DOI 10.1002/ijc.2910390514; BRESALIER RS, 1987, CANCER RES, V47, P1398; CARMICHAEL J, 1987, CANCER RES, V47, P936; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GIAEVER I, 1989, PHYSICA D, V38, P128, DOI 10.1016/0167-2789(89)90182-6; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Ho WC, 1997, MOL BIOL CELL, V8, P1863, DOI 10.1091/mbc.8.10.1863; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; LEE DC, 1995, PHARMACOL REV, V47, P51; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Reddy L, 1998, EXP CELL RES, V245, P360, DOI 10.1006/excr.1998.4273; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rigot V, 1998, J CELL SCI, V111, P3119; Sawhney RS, 2002, J BIOL CHEM, V277, P75, DOI 10.1074/jbc.M103268200; SCHLAEPFER DD, 1994, NATURE, V372, P786; SUN LZ, 1994, BIOCH MOL ASPECTS SE, V2, P495; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919; Wells A, 2000, ADV CANCER RES, V78, P31; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19861	19869		10.1074/jbc.M213162200	http://dx.doi.org/10.1074/jbc.M213162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657625	hybrid			2022-12-25	WOS:000183078000038
J	Shim, M; Smart, RC				Shim, M; Smart, RC			Lithium stabilizes the CCAAT/enhancer-binding protein alpha (C/EBP alpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; GRANULOCYTIC DIFFERENTIATION; ADIPOCYTE DIFFERENTIATION; MYELOID-LEUKEMIA; IN-VIVO; EXPRESSION; TRANSCRIPTION; FAMILY; BETA; MICE	CCAAT/enhancer-binding protein alpha (C/EBPalpha), a basic leucine zipper transcription factor, is involved in mitotic growth arrest and differentiation. Given that numerous proteins involved in cell cycle regulation are degraded via the ubiquitin-proteasome system, we examined whether the C/EBPalpha protein is degraded via a proteasomal mechanism. In cycloheximide-treated BALB/MK2 keratinocytes we found that C/EBPalpha is a short-lived protein with a half-life of similar to1 h. Treatment with proteasome inhibitors, MG-132 or lactacystin, blocked the degradation of the C/EBPalpha protein. Higher molecular weight species of ubiquitinated C/EBPalpha were detected in BALB/MK2, and in vitro studies confirmed that C/EBPalpha is degraded by the proteasome in an ATP- and ubiquitin-dependent manner. GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation. However, a mutant C/EBPalpha containing T to A mutations in the GSK3 phosphorylation sites (T222A and T226A) retained its response to LiCl, and additional pharmacological inhibitors of GSK3 did not alter C/EBPalpha levels indicating the effects of LiCl on C/EBPalpha are GSK3-independent. LiCl treatment of BALB/ MK2 cells inhibited C/EBPalpha degradation and produced a 6-fold increase in the half-life of C/EBPalpha protein. In vitro studies revealed that LiCl inhibited proteasome activity and the ensuing degradation of C/EBPalpha. These results demonstrate C/EBPalpha is degraded via a ubiquitin-dependent proteasomal pathway, and LiCl stabilizes C/EBPalpha through a GSK3-independent pathway involving direct inhibition of proteasome activity.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.			Smart, Robert/0000-0002-6767-6756	NCI NIH HHS [CA 46637] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046637, R29CA046637] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Maki CG, 1996, CANCER RES, V56, P2649; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rice AM, 2001, J BIOL CHEM, V276, P42722, DOI 10.1074/jbc.M106583200; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	42	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19674	19681		10.1074/jbc.M301356200	http://dx.doi.org/10.1074/jbc.M301356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12668682	hybrid			2022-12-25	WOS:000183078000016
J	Jang, IH; Lee, S; Park, JB; Kim, JH; Lee, CS; Hur, EM; Kim, IS; Kim, KT; Yagisawa, H; Suh, PG; Ryu, SH				Jang, IH; Lee, S; Park, JB; Kim, JH; Lee, CS; Hur, EM; Kim, IS; Kim, KT; Yagisawa, H; Suh, PG; Ryu, SH			The direct interaction of phospholipase C-gamma 1 with phospholipase D2 is important for epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR TYROSINE KINASE; SRC HOMOLOGY DOMAINS; PHOSPHATIDIC-ACID; SH3 DOMAIN; MEMBRANE DOMAINS; PLASMA-MEMBRANE; EGF RECEPTOR; PX DOMAINS; D ISOZYMES	The epidermal growth factor (EGF) receptor has an important role in cellular proliferation, and the enzymatic activity of phospholipase C (PLC)-gamma1 is regarded to be critical for EGF-induced mitogenesis. In this study, we report for the first time a phospholipase complex composed of PLC-gamma1 and phospholipase D2 (PLD2). PLC-gamma1 is co-immunoprecipitated with PLD2 in COS-7 cells. The results of in vitro binding analysis and co-immunoprecipitation analysis in COS-7 cells show that the Src homology (SH) 3 domain of PLC-gamma1 binds to the proline-rich motif within the Phox homology (PX) domain of PLD2. The interaction between PLC-gamma1 and PLD2 is EGF stimulation-dependent and potentiates EGF-induced inositol 1,4,5-trisphosphate (IP3) formation and Ca2+ increase. Mutating Pro-145 and Pro-148 within the PX domain of PLD2 to leucines disrupts the interaction between PLC-gamma1 and PLD2 and fails to potentiate EGF-induced IP3 formation and Ca2+ increase. However, neither PLD2 wild type nor PLD2 mutant affects the EGF-induced tyrosine phosphorylation of PLC-gamma1. These findings suggest that, upon EGF stimulation, PLC-gamma1 directly interacts with PLD2 and this interaction is important for PLC-gamma1 activity.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); University of Hyogo	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010; Hur, Eun Mi/AAU-4906-2021; Yagisawa, Hitoshi/C-9305-2012	Yagisawa, Hitoshi/0000-0002-5365-4513; Jang, Il Ho/0000-0002-0820-3035; Ryu, Sung Ho/0000-0003-0913-3048; KIM, KYONG-TAI/0000-0001-7292-2627				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; Bae SS, 1998, J NEUROCHEM, V71, P178; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Chang JS, 1997, CANCER RES, V57, P5465; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; DANNIEL LW, 1999, BIOCHIM BIOPHYS ACTA, V1439, P265; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GERGEL JR, 1994, BIOCHEMISTRY-US, V33, P14671, DOI 10.1021/bi00253a004; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hess JA, 1998, J BIOL CHEM, V273, P20517, DOI 10.1074/jbc.273.32.20517; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim JH, 1999, J IMMUNOL, V163, P5462; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; KIM UH, 1990, FEBS LETT, V270, P33, DOI 10.1016/0014-5793(90)81228-G; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee S, 2002, J BIOL CHEM, V277, P6542, DOI 10.1074/jbc.M108047200; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; Pei ZD, 1998, FEBS LETT, V423, P53, DOI 10.1016/S0014-5793(98)00063-5; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Suh BC, 1999, BRIT J PHARMACOL, V126, P399, DOI 10.1038/sj.bjp.0702248; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	70	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18184	18190		10.1074/jbc.M208438200	http://dx.doi.org/10.1074/jbc.M208438200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646582	hybrid, Green Published			2022-12-25	WOS:000182838300078
J	Gianni, D; Zambrano, N; Bimonte, M; Minopoli, G; Mercken, L; Talamo, F; Scaloni, A; Russo, T				Gianni, D; Zambrano, N; Bimonte, M; Minopoli, G; Mercken, L; Talamo, F; Scaloni, A; Russo, T			Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; C-SRC; TYROSINE KINASE; INTRACELLULAR DOMAIN; MEMBRANE COMPARTMENT; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; RHO GTPASES; FE65; ACTIVATION	The beta-amyloid peptide (Abeta) present in the senile plaques of Alzheimer's disease derives from the cleavage of a membrane protein, named APP, driven by two enzymes, known as beta- and gamma-secretases. The mechanisms regulating this cleavage are not understood. We have developed an experimental system to identify possible extracellular signals able to trigger the cleavage of an APP-GaI4 fusion protein, which is detected by measuring the expression of the CAT gene transcribed under the control of the Gal4 transcription factor, which is released from the membrane upon the cleavage of APP-Gal4. By using this assay, we purified a protein contained in the C6 cell-conditioned medium, which activates the cleavage of APP-Gal4 and which we demonstrated to be PDGF-BB. The APP-Gal4 processing induced by PDGF is dependent on the gamma-secretase activity, being abolished by an inhibitor of this enzyme, and is the consequence of the activation of a pathway downstream of the PDGF-receptor, which includes the non-receptor tyrosine kinase Src and the small G-protein Rac1. These findings are confirmed by the observation that a constitutively active form of Src increases AP generation and that, in cells stably expressing APP, the generation of Abeta is strongly decreased by the Src tyrosine kinase inhibitor PP2.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; CNR, ISPAAM, Prote & Mass Spectrometry Lab, I-80147 Naples, Italy; Aventis Pharma, Neurodegenerat Dis Grp, F-94400 Vitry Sur Seine, France; CEINGE Biotecnol Avanzate, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR); Sanofi-Aventis; Sanofi France; CEINGE Biotecnologie Avanzate	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	russot@dbbm.unina.it	Zambrano, Nicola/B-9352-2014; RUSSO, Tommaso/K-1331-2016	Zambrano, Nicola/0000-0001-9395-3481; RUSSO, Tommaso/0000-0003-4426-0106; Scaloni, Andrea/0000-0001-9362-8515				Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Bruni P, 2002, J BIOL CHEM, V277, P35481, DOI 10.1074/jbc.M205227200; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG B, 1995, J NEUROSCI, V15, P7095; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; FURTOSS O, 2002, EMBO J, V21, P514; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; Howell BW, 1999, MOL CELL BIOL, V19, P5179; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; Matsuda S, 2001, J NEUROSCI, V21, P6597; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Oumesmar BN, 1997, J NEUROSCI, V17, P125, DOI 10.1523/JNEUROSCI.17-01-00125.1997; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; Suter DM, 2001, J CELL BIOL, V155, P427, DOI 10.1083/jcb.200107063; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WESTERMANN R, 1988, J NEUROCHEM, V50, P1747, DOI 10.1111/j.1471-4159.1988.tb02474.x; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	64	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9290	9297		10.1074/jbc.M211899200	http://dx.doi.org/10.1074/jbc.M211899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645527	hybrid			2022-12-25	WOS:000181524000054
J	Weigel, JA; Raymond, RC; McGary, C; Singh, A; Weigel, PH				Weigel, JA; Raymond, RC; McGary, C; Singh, A; Weigel, PH			A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits hyaluronan clearance by perfused liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; RAT-LIVER; BINDING PROTEINS; ACID; SULFATE; DISEASE; DEGRADATION; SERUM; OLIGOSACCHARIDES; MORPHOGENESIS	Hyaluronan (HA) and chondroitin sulfate clearance from lymph and blood is mediated by the hyaluronan receptor for endocytosis (HARE). The purification and molecular cloning (Zhou, B., Weigel, J. A., Saxena, A., and Weigel, P. H. (2002) Mol. Biol. Cell 13, 2853-2868) of this cell surface receptor were finally achieved after we developed monoclonal antibodies (mAbs) against HARE. There are actually two independent isoreceptors for HA, which in rat are designated the 175-kDa HARE and 300-kDa HARE. Only one mAb (number 174) effectively and completely blocked the specific uptake of I-125-HA at 37 degreesC by rat liver sinusoidal endothelial cells. I-125-HA binding to both the 175-kDa and 300-kDa HARE proteins in a ligand blot assay was almost completely inhibited by <1 mug/ml mAb-174, whereas mouse IgG had little or no effect. MAb-174 also performed very well in Western analysis, indirect fluorescence microscopy, and a variety of immuno-procedures. Immunohistochemistry using mAb-174 localized HARE to the sinusoidal cells of rat liver, spleen, and lymph node. Western analysis using mAb-174 revealed that the sizes of both HARE glycoproteins were the same in these three tissues. I-125-HA was taken up and degraded by excised rat livers that were continuously perfused ex vivo with a recirculating medium. This HA clearance and metabolism by liver, which is a physiological function of HARE, was very effectively blocked by mAb-174 but not by mouse IgG. The results indicate that mAb-174 will be a useful tool to study the functions of HARE and the physiological significance of RA clearance.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA; Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14642 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Rochester	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD DAR, 1991, BRIT J PLAST SURG, V44, P579, DOI 10.1016/0007-1226(91)90093-Y; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cantor JO, 1998, P SOC EXP BIOL MED, V217, P471; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; Csoka TB, 1997, INVAS METAST, V17, P297; DEACIUC IV, 1993, HEPATOLOGY, V17, P266, DOI 10.1002/hep.1840170217; DEACIUC IV, 1993, BIOCHEM PHARMACOL, V46, P671, DOI 10.1016/0006-2952(93)90553-9; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; Gakunga P, 1997, DEVELOPMENT, V124, P3987; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; ITASAKA H, 1995, J SURG RES, V59, P589, DOI 10.1006/jsre.1995.1209; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LUNDIN A, 1985, BRIT J DERMATOL, V112, P663, DOI 10.1111/j.1365-2133.1985.tb02334.x; Manek NJ, 2000, AM FAM PHYSICIAN, V61, P1795; Manicourt DH, 1999, ARTHRITIS RHEUM, V42, P1861, DOI 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meyer K, 1934, J BIOL CHEM, V107, P629; Panay N, 1999, CURR OPIN OBSTET GYN, V11, P379, DOI 10.1097/00001703-199908000-00004; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Rao PN, 1996, LIVER, V16, P48; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SMEDSROD B, 1985, CELL TISSUE RES, V241, P639; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1992, CANCER METAST REV, V11, P1, DOI 10.1007/BF00047598; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; WEIGEL PH, 1992, MECH CONTROL GLYCOCO, P421; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200; ZHOU B, 2003, IN PRESS GLYCOBIOLOG	53	63	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9808	9812		10.1074/jbc.M211462200	http://dx.doi.org/10.1074/jbc.M211462200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645574	hybrid			2022-12-25	WOS:000181524000124
J	Morris, CA; Wells, AL; Yang, ZH; Chen, LQ; Baldacchino, CV; Sweeney, HL				Morris, CA; Wells, AL; Yang, ZH; Chen, LQ; Baldacchino, CV; Sweeney, HL			Calcium functionally uncouples the heads of myosin VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; MOTOR FUNCTION; STEP-SIZE; LEVER ARM; ACTIN; BINDING; PHOSPHORYLATION; LOCALIZATION; MECHANISM; MOVEMENT	This study examines the steady state activity and in vitro motility of single-headed (S1) and double-headed (HMM) myosin VI constructs within the context of two putative modes of regulation. Phosphorylation of threonine 406 does not alter either the rate of actin filament sliding or the maximal actin-activated ATPase rate of S1 or HMM constructs. Thus, we do not observe any regulation of myosin VI by phosphorylation within the motor domain. Interestingly, in the absence of calcium, the myosin VI HMM construct moves in an in vitro motility assay at a velocity that is twice that of S1 constructs, which may be indicative of movement that is not based on a "lever arm" mechanism. Increasing calcium above 10 muM slows both the rate of ADP release from S1 and HMM actomyosin VI and the rates of in vitro motility. Furthermore, high calcium concentrations appear to uncouple the two heads of myosin VI. Thus, phosphorylation and calcium are not on/off switches for myosin VI enzymatic activity, although calcium may alter the degree of processive movement for myosin VI-mediated cargo transport. Lastly, calmodulin mutants reveal that the calcium effect is dependent on calcium binding to the N-terminal lobe of calmodulin.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, A700 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	lsweeney@mail.med.upenn.edu	Sweeney, H Lee/F-1862-2010		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048931, R01AR035661] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-35661, AR-048931] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Mammano F, 1999, J NEUROSCI, V19, P6918, DOI 10.1523/JNEUROSCI.19-16-06918.1999; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	30	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23324	23330		10.1074/jbc.M208957200	http://dx.doi.org/10.1074/jbc.M208957200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12682054	hybrid			2022-12-25	WOS:000183638600016
J	Wang, ZQ; Malone, MH; He, HL; McColl, KS; Distelhorst, CW				Wang, ZQ; Malone, MH; He, HL; McColl, KS; Distelhorst, CW			Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; ACUTE CHILDHOOD LEUKEMIA; FAMILY MEMBER BIM; CELL-DEATH; BCL-2 FAMILY; DOWN-REGULATION; DNA-BINDING; T-CELLS; IN-VIVO	Despite being one of the earliest recognized and most clinically relevant forms of apoptosis, little is known about the transcriptional events that mediate glucocorticoid-induced apoptosis. Therefore, we used oligonucleotide microarrays to identify the pattern of dexamethasone-induced changes in gene expression in two well characterized models of glucocorticoid-induced apoptosis, the murine lymphoma cell lines S49.A2 and WEHI7.2. Dexamethasone treatment induced a diverse set of gene changes that evolved over a 24-h period preceding the onset of cell death. These include previously reported changes in the expression of genes regulating prosurvival signals mediated by c-Myc and NFkappaB. Unexpectedly, we discovered that glucocorticoid treatment increases expression of the gene encoding Bim, a BH3-only member of the Bcl-2 family that is capable of directly activating the apoptotic cascade. Induction of Bim was confirmed by immunoblotting not only in S49.A2 and WEHI7.2 cells but also in the human leukemia cell line CEM-C7 and in primary murine thymocytes. All three prototypical isoforms of Bim (Bim(EL), Bim(L), and Bim(S)) were induced by dexamethasone. Because elevated expression of Bim initiates the execution phase of cell death, this report that Bim is induced by dexamethasone provides novel insight into the mechanism through which glucocorticoid-mediated changes in gene expression induce apoptosis in lymphoid cells.	Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Dept Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA042755, P30CA043703, T32CA059366] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA059366-10, P30 CA43703, R01 CA42755-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; *AFF INC, 2002, GEN EXPR AN TECHN MA; ALEXANIAN R, 1992, BLOOD, V80, P887; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Catts VS, 2001, LEUKEMIA, V15, P929, DOI 10.1038/sj.leu.2402128; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; COHEN JJ, 1984, J IMMUNOL, V132, P38; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deroo BJ, 2001, ONCOGENE, V20, P3039, DOI 10.1038/sj.onc.1204328; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; Geley S, 1996, CANCER RES, V56, P5033; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Medh RD, 2001, ONCOGENE, V20, P4629, DOI 10.1038/sj.onc.1204680; MIYASHITA T, 1992, CANCER RES, V52, P5407; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ramdas J, 1998, ENDOCRINOLOGY, V139, P3813, DOI 10.1210/en.139.9.3813; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Smets LA, 1999, ADV EXP MED BIOL, V457, P607; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tao YX, 2001, J BIOL CHEM, V276, P2329, DOI 10.1074/jbc.C000526200; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; VIETTI TJ, 1965, J PEDIATR-US, V66, P18, DOI 10.1016/S0022-3476(65)80334-1; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WOLFF JA, 1967, J PEDIATR-US, V70, P626, DOI 10.1016/S0022-3476(67)80052-0; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	47	180	188	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23861	23867		10.1074/jbc.M301843200	http://dx.doi.org/10.1074/jbc.M301843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12676946	hybrid			2022-12-25	WOS:000183638600082
J	Malovrh, P; Viero, G; Dalla Serra, M; Podlesek, Z; Lakey, JH; Macek, P; Menestrina, G; Anderluh, G				Malovrh, P; Viero, G; Dalla Serra, M; Podlesek, Z; Lakey, JH; Macek, P; Menestrina, G; Anderluh, G			A novel mechanism of pore formation - Membrane penetration by the N-terminal amphipathic region of equinatoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-ANEMONE; FORMING TOXIN; STICHOLYSIN-I; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; BETA-BARREL; X-RAY; PROTEIN; MODEL; CYTOLYSIN	Equinatoxin II is a representative of actinoporins, eukaryotic pore-forming toxins from sea anemones. It creates pores in natural and artificial lipid membranes by an association of three or four monomers. Cysteine-scanning mutagenesis was used to study the structure of the N terminus, which is proposed to be crucial in transmembrane pore formation. We provide data for two steps of pore formation: a lipid-bound monomeric intermediate state and a final oligomeric pore. Results show that residues 10-28 are organized as an alpha-helix in both steps. In the first step, the whole region is transferred to a lipid-water interface, laying flat on the membrane. In the pore-forming state, the hydrophilic side of the amphipathic helix lines the pore lumen. The pore has a restriction around Asp-10, according to the permeabilization ratio of ions flowing through pores formed by chemically modified mutants. A general model was introduced to derive the tilt angle of the helix from the ion current data. This study reveals that actinoporins use a unique single helix insertion mechanism for pore formation.	Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana 1000, Slovenia; CNR, ITC, Ist Biofis, Sez Trento, I-38050 Povo, TN, Italy; Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Ljubljana; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Istituto per le Tecnologie della Costruzione (ITC-CNR); Newcastle University - UK	Anderluh, G (corresponding author), Univ Ljubljana, Biotech Fac, Dept Biol, Vecna Pot 111, Ljubljana 1000, Slovenia.	gregor.anderluh@uni-lj.si	Anderluh, Gregor/C-6905-2014; Serra, Mauro Dalla/A-6218-2010; Maček, Peter/Y-9877-2019; Serra, Mauro Dalla/AAK-9299-2021; Viero, Gabriella/G-2096-2012; Maček, Peter/U-4662-2017	Anderluh, Gregor/0000-0002-9916-8465; Serra, Mauro Dalla/0000-0003-1048-2739; Maček, Peter/0000-0001-6470-7759; Serra, Mauro Dalla/0000-0003-1048-2739; Viero, Gabriella/0000-0002-6755-285X; Maček, Peter/0000-0001-6470-7759; Lakey, Jeremy/0000-0003-4646-9085				Anderluh G, 1997, PROTEIN ENG, V10, P751, DOI 10.1093/protein/10.7.751; Anderluh G, 2003, PROTEIN EXPRES PURIF, V28, P173, DOI 10.1016/S1046-5928(02)00681-2; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 1996, BIOCHEM BIOPH RES CO, V220, P437, DOI 10.1006/bbrc.1996.0391; Anderluh G, 2000, J MEMBRANE BIOL, V173, P47, DOI 10.1007/s002320001006; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; BELMONTE G, 1994, BBA-BIOMEMBRANES, V1192, P197, DOI 10.1016/0005-2736(94)90119-8; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Bockris J.OM., 1970, MODERN ELECTROCHEMIS, P1, DOI DOI 10.1007/B114168; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GAZIT E, 1994, BIOCHEM J, V304, P895, DOI 10.1042/bj3040895; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; Heuck AP, 2002, CELL BIOCHEM BIOPHYS, V36, P89, DOI 10.1385/CBB:36:1:89; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; Oren Z, 1998, BIOPOLYMERS, V47, P451; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Schultz S. G., 1980, BASIC PRINCIPLES MEM; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Tejuca M, 2001, J MEMBRANE BIOL, V183, P125, DOI 10.1007/s00232-001-0060-y; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; Valeva A, 1997, P NATL ACAD SCI USA, V94, P11607, DOI 10.1073/pnas.94.21.11607; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X	44	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22678	22685		10.1074/jbc.M300622200	http://dx.doi.org/10.1074/jbc.M300622200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676945	hybrid			2022-12-25	WOS:000183503900068
J	Ohshima, N; Takahashi, M; Hirose, F				Ohshima, N; Takahashi, M; Hirose, F			Identification of a human homologue of the DREF transcription factor with a potential role in regulation of the histone H1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-RELATED ELEMENT; CELL NUCLEAR ANTIGEN; CHROMATIN-REMODELING FACTOR; EYE IMAGINAL DISC; DNA-REPLICATION; S-PHASE; DROSOPHILA-MELANOGASTER; BINDING-FACTOR; BOUNDARY-ELEMENT; CYCLE REGULATION	A human homologue (hDREF/KIAA0785) of Drosophila DREF, a transcriptional regulatory factor required for expression of genes involved in DNA replication and cell proliferation, was identified by BLAST search. Amino acid sequences corresponding to three regions highly conserved between two Drosophila species also proved to be very similar in the hDREF/KIAA0785 polypeptide. A consensus binding sequence (5'-TGTCG(C/T)GA(C/T)A) for hDREF/KIAA0785, determined by the CASTing method, overlapped with that for the Drosophila DREF (5'-TGTCGATA). We found hDREF/KIAA0785 binding sequences in the promoter regions of human genes related to cell proliferation. Analyses using a specific antibody revealed that an hDREF/KIAA0785 binds to the promoter region of the histone H1 gene. Co-transfection experiments with an hDREF/KIAA0785-expressing plasmid and a histone H1 promoter-directed luciferase reporter plasmid in HeLa cells revealed possible activation of the histone H1 promoter. Immunohistochemical analysis demonstrated that hDREF/KIAA0785 is localized in the nuclei. Although the expression level of the factor was found to be low in serum-deprived human normal fibroblasts, the amount was increased by adding serum to cultures and reached a maximum during S phase. RNA interference experiments targeting hDREF/KIAA0785 resulted in inhibition of S phase entry and reduction of histone H1 mRNA in HeLa cells. These results suggest that expression of hDREF/KIAA0785 may have a role in regulation of human genes related to cell proliferation.	Aichi Canc Ctr, Div Biochem, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Grad Sch Med, Dept Pathol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Nagoya University	Hirose, F (corresponding author), Aichi Canc Ctr, Div Biochem, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Hirose, Fumiko/0000-0003-4586-4892				Albig W, 1997, GENE, V184, P141, DOI 10.1016/S0378-1119(96)00582-3; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Bergman Y, 1998, BIOL CHEM, V379, P401; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COLLART DG, 1988, J BIOL CHEM, V263, P15860; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DALTON S, 1988, MOL CELL BIOL, V8, P4576, DOI 10.1128/MCB.8.10.4576; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elfring LK, 1998, GENETICS, V148, P251; Esposito T, 1999, HUM MOL GENET, V8, P61, DOI 10.1093/hmg/8.1.61; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1997, J BIOL CHEM, V272, P10928; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; HALTINER MM, 1986, MOL CELL BIOL, V6, P277; Hart CM, 1997, MOL CELL BIOL, V17, P999, DOI 10.1128/MCB.17.2.999; Hart CM, 1999, CHROMOSOMA, V108, P375, DOI 10.1007/s004120050389; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HIROSE F, 1994, J BIOL CHEM, V269, P2937; Hirose F, 1996, J BIOL CHEM, V271, P3930; Hirose F, 2001, MOL CELL BIOL, V21, P7231, DOI 10.1128/MCB.21.21.7231-7242.2001; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hirose F, 1999, MOL CELL BIOL, V19, P6020; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JORDANO J, 1988, ONCOGENE, V2, P359; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Matsukage A, 1995, GENE, V166, P233, DOI 10.1016/0378-1119(95)00586-2; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; NAGASE T, 1998, DNA RES, V5, P169; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PLUMB M, 1984, P NATL ACAD SCI-BIOL, V81, P434, DOI 10.1073/pnas.81.2.434; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Takahashi Y, 1999, NUCLEIC ACIDS RES, V27, P510, DOI 10.1093/nar/27.2.510; VANWIJNEN AJ, 1988, NUCLEIC ACIDS RES, V16, P571, DOI 10.1093/nar/16.2.571; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x	59	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22928	22938		10.1074/jbc.M303109200	http://dx.doi.org/10.1074/jbc.M303109200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12663651	hybrid			2022-12-25	WOS:000183503900099
J	Drisaldi, B; Stewart, RS; Adles, C; Stewart, LR; Quaglio, E; Biasini, E; Fioriti, L; Chiesa, R; Harris, DA				Drisaldi, B; Stewart, RS; Adles, C; Stewart, LR; Quaglio, E; Biasini, E; Fioriti, L; Chiesa, R; Harris, DA			Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CULTURED-CELLS; INTRACELLULAR-TRANSPORT; BIOCHEMICAL-PROPERTIES; INSERTIONAL MUTATION; PROTEIN; DISEASES; METABOLISM; EXPRESSION; APOPTOSIS	The cellular mechanisms by which prions cause neurological dysfunction are poorly understood. To address this issue, we have been using cultured cells to analyze the localization, biosynthesis, and metabolism of PrP molecules carrying mutations associated with familial prion diseases. We report here that mutant PrP molecules are delayed in their maturation to an endoglycosidase H- resistant form after biosynthetic labeling, suggesting that they are impaired in their exit from the endoplasmic reticulum ( ER). However, we find that proteasome inhibitors have no effect on the maturation or turnover of either mutant or wild- type PrP molecules. Thus, in contrast to recent studies from other laboratories, our work indicates that PrP is not subject to retrotranslocation from the ER into the cytoplasm prior to degradation by the proteasome. We find that in transfected cells, but not in cultured neurons, proteasome inhibitors cause accumulation of an unglycosylated, signal peptide- bearing form of PrP on the cytoplasmic face of the ER membrane. Thus, under conditions of elevated expression, a small fraction of PrP chains is not translocated into the ER lumen during synthesis, and is rapidly degraded in the cytoplasm by the proteasome. Finally, we report a previously unappreciated artifact caused by treatment of cells with proteasome inhibitors: an increase in PrP mRNA level and synthetic rate when the protein is expressed from a vector containing a viral promoter. We suggest that this phenomenon may explain some of the dramatic effects of proteasome inhibitors observed in other studies. Our results clarify the role of the proteasome in the cell biology of PrP, and suggest reasonable hypotheses for the molecular pathology of inherited prion diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Mario Negri Inst Pharmacol Res, DTI, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20157 Milan, Italy	Washington University (WUSTL); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Chiesa, Roberto/G-1561-2017; Fioriti, Luana/AAN-7207-2021; Biasini, Emiliano/A-3147-2011	Chiesa, Roberto/0000-0002-3842-3733; Biasini, Emiliano/0000-0002-3927-6341; fioriti, luana/0000-0003-2429-8967; Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS 35496] Funding Source: Medline; Telethon [139/B] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 2000, SCIENCE, V287, P816, DOI 10.1126/science.287.5454.816; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Lehmann S, 2000, J BIOL CHEM, V275, P1520; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Miller TM, 1996, J NEUROSCI, V16, P7487; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; O'Hare T, 1999, J IMMUNOL, V163, P11; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Porcile C, 2002, ANN NY ACAD SCI, V973, P402, DOI 10.1111/j.1749-6632.2002.tb04673.x; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wu HM, 2002, AM J RESP CELL MOL, V27, P234, DOI 10.1165/ajrcmb.27.2.4792; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Young Katherine, 1999, P139; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	48	169	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21732	21743		10.1074/jbc.M213247200	http://dx.doi.org/10.1074/jbc.M213247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663673	hybrid			2022-12-25	WOS:000183354200054
J	Liu, CY; Birk, DE; Hassell, JR; Kane, B; Kao, WWY				Liu, CY; Birk, DE; Hassell, JR; Kane, B; Kao, WWY			Keratocan-deficient mice display alterations in corneal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN; LUMICAN; DECORIN; EXPRESSION	Keratocan ( Kera) is a cornea- specific keratan sulfate proteoglycan ( KSPG) in the adult vertebrate eye. It belongs to the small leucine- rich proteoglycan ( SLRP) gene family and is one of the major components of extracellular KSPG in the vertebrate corneal stroma. The Kera gene is expressed in ocular surface tissues including cornea and eyelids during morphogenesis. Corneal KSPGs play a pivotal role in matrix assembly, which is accountable for corneal transparency. In humans, mutations of the KERA gene are associated with cornea plana ( CNA2) that manifests decreases in vision acuity due to the flattened forward convex curvature of cornea. To investigate the biological role of the Kera gene and to establish an animal model for corneal plana, we generated Kera knockout mice via gene targeting. Northern and Western blotting and immunohistochemical analysis showed that no Kera mRNA or keratocan protein was detected in the Kera (-/-) cornea. The expression levels of other SLRP members including lumican, decorin, and fibromodulin were not altered in the Kera (-/-) cornea as compared with that of the wild- type littermates. Mice lacking keratocan have normal corneal transparency at the age of 12 months. However, they have a thinner corneal stroma and a narrower cornea-iris angle of the anterior segment in comparison to the wild- type littermates. As demonstrated by transmission electron microscopy, Kera (-/-) mice have larger stromal fibril diameters and less organized packing of collagen fibrils in stroma than those of wild type. Taken together, our results showed that ablation of the Kera gene resulted in subtle structural alterations of collagenous matrix and did not perturb the expression of other SLRPs in cornea. Keratocan thus plays a unique role in maintaining the appropriate corneal shape to ensure normal vision.	Univ Miami, Sch Med,Dept Ophthalmol, Bascom Palmer Eye Inst, McKnight Vis Res Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Cell Biol & Anat, Miami, FL 33136 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ S Florida, Shriners Hosp Children Tampa, Coll Med, Tampa, FL 33612 USA; Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA	Bascom Palmer Eye Institute; University of Miami; Bascom Palmer Eye Institute; University of Miami; Bascom Palmer Eye Institute; University of Miami; Jefferson University; State University System of Florida; University of South Florida; University System of Ohio; University of Cincinnati	Liu, CY (corresponding author), Univ Miami, Sch Med,Dept Ophthalmol, Bascom Palmer Eye Inst, McKnight Vis Res Ctr, 1638 NW 10th Ave,Rm 621, Miami, FL 33136 USA.	cliu2@med.miami.edu	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088; Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY012486, R01EY011845, R01EY008104, R01EY005129, R37EY008104] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BETTELHEIM FA, 1975, BIOCHIM BIOPHYS ACTA, V381, P203, DOI 10.1016/0304-4165(75)90202-0; CHAKRAVARTI S, 2000, INVESTIG OPHTHALMOL, V11, P3365; CHARKRAVARTI S, 1998, J CELL BIOL, V112, P987; DOANE KJ, 1992, EXP CELL RES, V202, P113, DOI 10.1016/0014-4827(92)90410-A; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; HAHN RA, 1992, DEVELOPMENT, V115, P383; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KAO WWY, 1983, J BIOL CHEM, V258, P7779; LEHMANN OJ, 2000, INVESTIG OPHTHALMOL, V42, P3118; LINSENMAYER TF, 1990, ANN NY ACAD SCI, V580, P143, DOI 10.1111/j.1749-6632.1990.tb17926.x; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Pellegata NS, 2000, NAT GENET, V25, P91, DOI 10.1038/75664; Pressman CL, 2000, GENESIS, V26, P15, DOI 10.1002/(SICI)1526-968X(200001)26:1<15::AID-GENE5>3.0.CO;2-V; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RAWE IM, 1992, HISTOCHEM J, V24, P311, DOI 10.1007/BF01046162; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SMITH RS, 2002, SYSTEMATIC EVALUATIO, P285; Tasheva ES, 2002, MOL VIS, V8, P407; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	23	142	150	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21672	21677		10.1074/jbc.M301169200	http://dx.doi.org/10.1074/jbc.M301169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12665512	hybrid			2022-12-25	WOS:000183354200046
J	Zhang, JJ; Zhang, YL; Inouye, M				Zhang, JJ; Zhang, YL; Inouye, M			Thermotoga maritima MazG protein has both nucleoside triphosphate pyrophosphohydrolase and pyrophosphatase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTT; STREPTOCOCCUS-PNEUMONIAE; METHANOCOCCUS-JANNASCHII; MUTAGENIC SUBSTRATE; CATALYTIC DOMAIN; DNA-SYNTHESIS; CLONING; GENE; FAMILY; CDNA	MazG proteins form a widely conserved family among bacteria, but their cellular function is still unknown. Here we report that Thermotoga maritima MazG protein ( Tm- MazG), the product of the TM0913 gene, has both nucleoside triphosphate pyrophosphohydrolase ( NTPase) and pyrophosphatase activities. Tm- MazG catalyzes the hydrolysis of all eight canonical ribo- and deoxyribonucleoside triphosphates to their corresponding nucleoside monophosphates and PPi and subsequently hydrolyzes the resultant PPi to P-i. The NTPase activity with deoxyribonucleoside triphosphates as substrate is higher than corresponding ribonucleoside triphosphates. dGTP is the best substrate among the deoxyribonucleoside triphosphates, and GTP is the best among the ribonucleoside triphosphates. Both NTPase and pyrophosphatase activities were enhanced at higher temperatures and blocked by the alpha,beta-methyleneadenosine triphosphate, which cannot be hydrolyzed by Tm- MazG. Furthermore, PPi is an inhibitor for the Tm- MazG NTPase activity. Significant decreases in the NTPase activity and concomitant increases in the pyrophosphatase activity were observed when mutations were introduced at the highly conserved amino acid residues in Tm- MazG N- terminal region ( E41Q/ E42Q, E45Q, E61Q, R97A/ R98A, and K118A). These results demonstrated that Tm- MazG has dual enzymatic functions, NTPase and pyrophosphatase, and that these two enzymatic activities are coordinated.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.			Zhang, Junjie/0000-0001-8809-1485				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Chung JH, 2001, NUCLEIC ACIDS RES, V29, P3099, DOI 10.1093/nar/29.14.3099; COX EC, 1973, GENETICS, V73, P67; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Harris TK, 2000, BIOCHEMISTRY-US, V39, P1655, DOI 10.1021/bi9918745; Hwang KY, 1999, NAT STRUCT BIOL, V6, P691; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; Lin SR, 2001, J BIOL CHEM, V276, P18695, DOI 10.1074/jbc.M011084200; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Satoh T, 1999, BIOCHEMISTRY-US, V38, P1531, DOI 10.1021/bi981445r; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; VANDERHEIDEN BS, 1970, BIOCHIM BIOPHYS ACTA, V215, P555, DOI 10.1016/0304-4165(70)90109-1; Zhang JJ, 2002, J BACTERIOL, V184, P5323, DOI 10.1128/JB.184.19.5323-5329.2002	26	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21408	21414		10.1074/jbc.M213294200	http://dx.doi.org/10.1074/jbc.M213294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12657645	hybrid			2022-12-25	WOS:000183354200014
J	O'Neill, RJ; Vorob'eva, OV; Shahbakhti, H; Zmuda, E; Bhagwat, AS; Baldwin, GS				O'Neill, RJ; Vorob'eva, OV; Shahbakhti, H; Zmuda, E; Bhagwat, AS; Baldwin, GS			Mismatch uracil glycosylase from Escherichia coli - A general mismatch or a specific DNA glycosylase?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; SHORT-PATCH REPAIR; CRYSTAL-STRUCTURE; PRIMARY SUBSTRATE; ENDONUCLEASE; MUG; 3,N-4-ETHENOCYTOSINE; RECOGNITION; STIMULATION; TURNOVER	The gene for the mismatch-specific uracil glycosylase ( MUG) was identified in the Escherichia coli genome as a sequence homolog of the mammalian thymine DNA glycosylase, with activity against uracil in U . G mismatches. Subsequently, 3,N-4-ethenocytosine (epsilonC), thymine, 5-hydroxymethyluracil, and 8-(hydroxymethyl)3, N-4-ethenocytosine have been proposed as possible substrates for this enzyme. The evaluation of various DNA adducts as substrates is complicated by the biphasic nature of the kinetics of this enzyme. Our results demonstrate that product release by the enzyme is very slow and hence comparing the "steady-state" parameters of the enzyme for different substrates is of limited use. Consequently, the ability of the enzyme to excise a variety of damage products of purines and pyrimidines was studied under single turnover conditions. Although the enzyme excised both epsilonC and U from DNA, the former adduct was significantly better as a substrate in terms of binding and hydrolysis. Some products of oxidative and alkylation damage are also moderately good substrates for the enzyme, but thymine is a poor substrate. This comparison of different substrates under single turnover conditions provides a rational basis for comparing substrates of MUG and we relate these conclusions to the known crystal structures of the enzyme and its catalytic mechanism.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Trevigen, Gaithersburg, MD 20877 USA	Imperial College London; Wayne State University	Baldwin, GS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Sir Alexander Flemming Bldg, London SW7 2AZ, England.		Kisil, Olga V/G-6580-2017; Bhagwat, Ashok/AAU-4186-2021; Bhagwat, Ashok/ABA-3861-2020	Kisil, Olga V/0000-0003-4799-1318; Bhagwat, Ashok/0000-0003-1188-0579; Baldwin, Geoffrey/0000-0003-4800-023X				Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bartsch H, 2000, TOXICOLOGY, V153, P105, DOI 10.1016/S0300-483X(00)00307-3; Bhagwat AS, 2002, MOL MICROBIOL, V44, P1421, DOI 10.1046/j.1365-2958.2002.02989.x; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; Jiang YL, 2002, J BIOL CHEM, V277, P15385, DOI 10.1074/jbc.M200634200; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Mokkapati SK, 2001, MOL MICROBIOL, V41, P1101, DOI 10.1046/j.1365-2958.2001.02559.x; Pope MA, 2002, J BIOL CHEM, V277, P22605, DOI 10.1074/jbc.M203037200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P1806, DOI 10.1021/bi00833a004; SHAPIRO R, 1972, BIOCHEMISTRY-US, V11, P23, DOI 10.1021/bi00751a005; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; ZHANG WF, 1995, CHEM RES TOXICOL, V8, P148, DOI 10.1021/tx00043a020	29	49	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20526	20532		10.1074/jbc.M210860200	http://dx.doi.org/10.1074/jbc.M210860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668677	hybrid			2022-12-25	WOS:000183230500012
J	Sreenivas, A; Carman, GM				Sreenivas, A; Carman, GM			Phosphorylation of the yeast phospholipid synthesis regulatory protein Opi1p by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; TRANSCRIPTIONAL ACTIVATOR INO2; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE SYNTHESIS; NEGATIVE REGULATOR; SHUTTLE VECTORS; CTP SYNTHETASE; FACTOR PHO4; BIOSYNTHESIS; GENES	The Opi1p transcription factor plays a negative regulatory role in the expression of UAS(INO)-containing genes involved in phospholipid synthesis in the yeast Saccharomyces cerevisiae. The phosphorylation of Opi1p by protein kinase A (cAMP-dependent protein kinase) was examined in this work. Using a maltose-binding protein-Opi1p fusion protein as a substrate, protein kinase A activity was time- and dose-dependent and dependent on the concentrations of Opi1p and ATP. Protein kinase A phosphorylated Opi1p on multiple serine residues. The synthetic peptides SCRQKSQPSE and SQVRESLLNL containing the protein kinase A motif for Ser(31) and Ser(251), respectively, within Opi1p were substrates for protein kinase A. Phosphorylation of S31A and S251A mutant maltose-binding protein-Opi1p fusion proteins by protein kinase A was reduced when compared with the wild type protein, and phosphopeptides present in wild type Opi1p were absent from the S31A and S251A mutant proteins. In vivo labeling experiments showed that the extent of phosphorylation of the S31A and S251A mutant proteins was reduced when compared with the wild type protein. The physiological consequence of the phosphorylation of Opi1p at Ser(31) and Ser(251) was examined by measuring the effects of the S31A and S251A mutations on the expression of the UAS(INO)-containing gene INO1. The beta-galactosidase activity driven by an INO1-CYC-lacZ reporter gene in opi1Delta mutant cells expressing the S31A and S251A mutant Opi1p proteins was elevated 42 and 35%, respectively, in the absence of inositol and 55 and 52%, respectively, in the presence of inositol when compared with cells expressing wild type Opi1p. These data supported the conclusion that phosphorylation of Opi1p at Ser(31) and Ser(251) mediated the stimulation of the negative regulatory function of Opi1p on the expression of the INO1 gene.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Elkhaimi M, 2000, NUCLEIC ACIDS RES, V28, P3160, DOI 10.1093/nar/28.16.3160; Graves JA, 2000, GENETICS, V154, P1485; GRAVES JA, 1996, THESIS CARNEGIE MELL; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; HUDAK KA, 1994, GENETICS, V136, P475; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu C, 2000, J BIOL CHEM, V275, P31972, DOI 10.1074/jbc.M003055200; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SIKORSKI RS, 1989, GENETICS, V122, P19; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yu Y, 2002, J BIOL CHEM, V277, P34978, DOI 10.1074/jbc.M205316200; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	69	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20673	20680		10.1074/jbc.M300132200	http://dx.doi.org/10.1074/jbc.M300132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668681	Green Published, hybrid			2022-12-25	WOS:000183230500031
J	Zackova, M; Skobisova, E; Urbankova, E; Jezek, P				Zackova, M; Skobisova, E; Urbankova, E; Jezek, P			Activating omega-6 polyunsaturated fatty acids and inhibitory purine nucleotides are high affinity Ligands for novel mitochondrial uncoupling proteins UCP2 and UCP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSPORT; SKELETAL-MUSCLE; GENE-EXPRESSION; UP-REGULATION; H+ TRANSPORT; COENZYME-Q; FLIP-FLOP; BINDING; MECHANISM; OBESITY	Human UCP2 and UCP3, expressed in yeast, were studied to establish their high affinity regulatory ligands. UCPn were reconstituted into liposomes and assayed for fatty acid (FA)-induced H+ efflux. All natural long chain FAs activated UCP2- and UCP3-mediated H+ translocation. Coenzyme Q(10) had no further significant activating effect. Evaluated parameters of FA activation (FA cycling) kinetics revealed the highest apparent affinity to UCP2 ( the lowest K-m values: 20 and 29 muM, respectively) for omega-6 polyunsaturated FAs (PUFAs), all-cis-8,11,14-eicosatrienoic and all-cis-6,9,12-octadecatrienoic acids, which are also the most potent agonists of the nuclear PPARbeta receptor in the activation of UCP2 transcription. omega-3 PUFA, cis-5,8,11,14,17-eicosapentaenoic acid had lower affinity (K-m, 50 muM), although as an omega-6 PUFA, arachidonic acid exhibited the same low affinity as lauric acid (K-m, similar to200 muM). These findings suggest a possible dual role of some PUFAs in activating both UCPn expression and uncoupling activity. UCP2 (UCP3)-dependent H+ translocation activated by all tested FAs was inhibited by purine nucleotides with apparent affinity to UCP2 (reciprocal K-i) decreasing in order: ADP>ATPsimilar toGTP>GDPmuch greater thanAMP. Also [H-3] GTP ([H-3] ATP) binding to isolated Escherichia coli (K-d, similar to5 muM) or yeast-expressed UCP2 (K-d, similar to1.5 muM) or UCP3 exhibited high affinity, similar to UCP1. The estimated number of [H-3] GTP high affinity (K-d, <0.4 mu M) binding sites was (in pmol/mg of protein) 182 in lung mitochondria, 74 in kidney, 28 in skeletal muscle, and similar to 20 in liver mitochondria. We conclude that purine nucleotides must be the physiological inhibitors of UCPn-mediated uncoupling in vivo.	Acad Sci Czech Republ, Dept 75, Inst Physiol, Prague 14220 4, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Jezek, P (corresponding author), Acad Sci Czech Republ, Dept 75, Inst Physiol, Videnska 1083, Prague 14220 4, Czech Republic.	jezek@biomed.cas.cz	Jezek, Petr/B-9264-2012	Jezek, Petr/0000-0002-2720-9395; Zackova, Marketa/0000-0002-5504-9851				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; Chevillotte E, 2001, J BIOL CHEM, V276, P10853, DOI 10.1074/jbc.M008010200; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; Deiana M, 2001, TOXICOL LETT, V123, P125, DOI 10.1016/S0378-4274(01)00372-1; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Engstova H, 2001, J BIOL CHEM, V276, P4683, DOI 10.1074/jbc.M009409200; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; FEIL S, 1994, EUR J BIOCHEM, V219, P681, DOI 10.1111/j.1432-1033.1994.tb19984.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Hagen T, 2000, BIOCHEM BIOPH RES CO, V276, P642, DOI 10.1006/bbrc.2000.3535; Hagen T, 2000, BIOCHEMISTRY-US, V39, P5845, DOI 10.1021/bi992980+; Hagen T, 1999, FEBS LETT, V454, P201, DOI 10.1016/S0014-5793(99)00811-X; Hanak P, 2001, FEBS LETT, V495, P137, DOI 10.1016/S0014-5793(01)02338-9; Heidkaemper D, 2000, FEBS LETT, V480, P265, DOI 10.1016/S0014-5793(00)01949-9; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Huang SG, 1998, J BIOL CHEM, V273, P859, DOI 10.1074/jbc.273.2.859; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jekabsons MB, 2002, BIOCHEM J, V366, P565, DOI 10.1042/BJ20020469; JEZEK P, 1988, J BIOENERG BIOMEMBR, V20, P603, DOI 10.1007/BF00768922; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1999, FEBS LETT, V455, P79, DOI 10.1016/S0014-5793(99)00853-4; Jezek P, 1999, J BIOENERG BIOMEMBR, V31, P457, DOI 10.1023/A:1005496306893; Johnson MM, 1997, J NUTR, V127, P1435, DOI 10.1093/jn/127.8.1435; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; Nagase I, 2001, FEBS LETT, V494, P175, DOI 10.1016/S0014-5793(01)02341-9; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	57	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20761	20769		10.1074/jbc.M212850200	http://dx.doi.org/10.1074/jbc.M212850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670931	hybrid			2022-12-25	WOS:000183230500043
J	Anisfeld, AM; Kast-Woelbern, HR; Meyer, ME; Jones, SA; Zhang, YQ; Williams, KJ; Willson, T; Edwards, PA				Anisfeld, AM; Kast-Woelbern, HR; Meyer, ME; Jones, SA; Zhang, YQ; Williams, KJ; Willson, T; Edwards, PA			Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; LOW-DENSITY-LIPOPROTEIN; ORPHAN NUCLEAR RECEPTOR; ACTIVATED RECEPTOR; BILE-ACID; REMNANT LIPOPROTEINS; LIPID HOMEOSTASIS; LIGAND CATABOLISM; APOLIPOPROTEIN-E; CULTURED-CELLS	Syndecan-1 (SDC1), a transmembrane heparan sulfate proteoglycan that participates in the binding and internalization of extracellular ligands, was identified in a screen designed to isolate genes that are regulated by the farnesoid X-receptor (FXR, NR1H4). Treatment of human hepatocytes with either naturally occurring ( chenodeoxycholic acid) or synthetic (GW4064) FXR ligands resulted in both induction of SDC1 mRNA and enhanced binding, internalization, and degradation of low density lipoprotein. Transient transfection assays, using wild-type and mutant SDC1 promoter-luciferase genes, led to the identification of a nuclear hormone receptor-binding hexad arranged as a direct repeat separated by one nucleotide (DR-1) in the proximal promoter that was necessary and sufficient for activation by FXR. The wild-type, but not a mutated DR-1 element, conferred FXR responsiveness to a heterologous thymidine kinase promoter-reporter gene. Four murine FXR isoforms have been identified recently that differ either at their amino terminus and/or by the presence or absence of four amino acids in the hinge region. Interestingly, the activities of the human SDC1 promoter-reporter constructs were highly induced by the two FXR isoforms that do not contain the four-amino acid insert and were unresponsive to the isoforms containing the four amino acids. Thus, current studies demonstrate that hepatic SDC1 is induced in an FXR isoform-specific manner. Increased expression of SDC1 may account in part for the hypotriglyceridemic effect that can result from the administration of chenodeoxycholic acid to humans.	Univ Calif Los Angeles, Dept Med & Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA; Thomas Jefferson Univ, Dept Med, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; GlaxoSmithKline; Jefferson University	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		feinstein, doug/M-9414-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL068445, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL56984, HL30568, HL68445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BELL GD, 1973, BMJ-BRIT MED J, V3, P520, DOI 10.1136/bmj.3.5879.520; Carey DJ, 1997, BIOCHEM J, V327, P1; Edwards PA, 2002, J LIPID RES, V43, P2; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 1999, J LIPID RES, V40, P1; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Williams K J, 2001, Methods Mol Biol, V171, P457; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WU GY, 1984, HEPATOLOGY, V4, P1190, DOI 10.1002/hep.1840040615; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	38	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20420	20428		10.1074/jbc.M302505200	http://dx.doi.org/10.1074/jbc.M302505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660231	hybrid			2022-12-25	WOS:000183078000108
J	Mulherkar, R; Kirtane, BM; Ranichandani, A; Mansukhani, NP; Kannan, S; Naresh, KN				Mulherkar, R; Kirtane, BM; Ranichandani, A; Mansukhani, NP; Kannan, S; Naresh, KN			Expression of enhancing factor/phospholipase A(2) in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis	ONCOGENE			English	Article						enhancing factor; secretory phospholipase A(2); transgenic mice; epidermal growth factor; squamous cell carcinoma; hair follicle	MOUSE SMALL-INTESTINES; GROWTH-FACTOR RECEPTOR; TRANSGENIC MICE; PHOSPHOLIPASE A(2); HAIR-FOLLICLES; KERATIN GENE; STEM-CELLS; DIFFERENTIATION; LOCALIZATION; PROTEIN	Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group 11 phospholipase A(2). EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and scanty hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.	Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, ACTREC, Genet Engn Lab,Canc Res Inst, Kharghar 410208, Navi Mumbai, India; Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India	Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital	Mulherkar, R (corresponding author), Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, ACTREC, Genet Engn Lab,Canc Res Inst, Kharghar 410208, Navi Mumbai, India.			Naresh, Kikkeri N/0000-0003-3807-3638				COHEN S, 1963, J INVEST DERMATOL, V40, P1; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DEO MG, 1983, INDIAN J BIOCHEM BIO, V20, P228; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; JIANG CK, 1991, J INVEST DERMATOL, V96, P162, DOI 10.1111/1523-1747.ep12460939; Kadam S, 1999, BIOCHEM J, V340, P237, DOI 10.1042/0264-6021:3400237; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; LAVKER RM, 1993, J INVEST DERMATOL, V101, P16; MORRIS RJ, 1986, CANCER RES, V46, P3061; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1986, J CELL PHYSIOL, V127, P183, DOI 10.1002/jcp.1041270122; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; ROOP DR, 1988, CANCER RES, V48, P3245; Shibata MA, 1997, MOL CARCINOGEN, V18, P160, DOI 10.1002/(SICI)1098-2744(199703)18:3<160::AID-MC5>3.0.CO;2-J; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WAGLE A, 1989, CELL BIOL INT REP, V13, P309, DOI 10.1016/0309-1651(89)90154-9; Xie W, 1998, CELL GROWTH DIFFER, V9, P313	27	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1936	1944		10.1038/sj.onc.1206229	http://dx.doi.org/10.1038/sj.onc.1206229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673199				2022-12-25	WOS:000181967700004
J	Jazayeri, M; Andreyev, A; Will, Y; Ward, M; Anderson, CM; Clevenger, W				Jazayeri, M; Andreyev, A; Will, Y; Ward, M; Anderson, CM; Clevenger, W			Inducible expression of a dominant negative DNA polymerase-gamma depletes mitochondrial DNA and produces a rho(0) phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL LINE; FUNCTIONAL-ANALYSIS; MYOCLONIC EPILEPSY; INSULIN-SECRETION; MUTATION; MTDNA; DISEASES; REPLICATION; DEFICIENCY; CREATION	We report the inducible, stable expression of a dominant negative form of mitochondria-specific DNA polymerase-gamma to eliminate mitochondrial DNA (mtDNA) from human cells in culture. HEK293 cells were transfected with a plasmid encoding inactive DNA polymerase-gamma harboring a D1135A substitution (POLGdn). The cells rapidly lost mtDNA (t(1/2) = 2-3 days) when expression of the transgene was induced. Concurrent reduction of mitochondrial encoded mRNA and protein, decreased cellular growth rate, and compromised respiration and mitochondrial membrane potential were observed. mtDNA depletion was reversible, as demonstrated by restoration of mtDNA copy number to normal within 10 days when the expression of POLGdn was suppressed following a 3-day induction period. Long term (20 days) expression of POLGdn completely eliminated mtDNA from the cells, resulting in p(0) cells that were respiration-deficient, lacked electron transport complex activities, and were auxotrophic for pyruvate and uridine. Fusion of the p(0) cells with human platelets yielded clonal cybrid cell lines that were populated exclusively with donor-derived mtDNA. Respiratory function, mitochondrial membrane potential, and electron transport activities were restored to normal in the cybrid cells. Inducible expression of a dominant negative DNA polymerase-gamma can yield mtDNA-deficient cell lines, which can be used to study the impact of specific mtDNA mutations on cellular physiology, and to investigate mitochondrial genome function and regulation.	MitoKor Inc, San Diego, CA 92121 USA		Anderson, CM (corresponding author), 11494 Sorrento Valley Rd, San Diego, CA 92121 USA.	andersonc@mitokor.com		Ward, Manus/0000-0002-7085-9668; Andreyev, Alexander Y./0000-0002-9246-9943				Anderson CM, 1999, DRUG DEVELOP RES, V46, P67, DOI 10.1002/(SICI)1098-2299(199901)46:1<67::AID-DDR10>3.0.CO;2-V; BEREITERHAHN J, 1978, J CELL SCI, V30, P99; Birch-Machin MA, 1993, METHODS TOXICOL, V2, P51; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; BOULET L, 1992, AM J HUM GENET, V51, P1187; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Clayton D A, 2000, Hum Reprod, V15 Suppl 2, P11; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; Errede B, 1978, Methods Enzymol, V53, P40; Fiskum G, 2000, METHOD ENZYMOL, V322, P222; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; JUKES TH, 1990, EXPERIENTIA, V46, P1117, DOI 10.1007/BF01936921; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819; Miller SW, 1996, J NEUROCHEM, V67, P1897; PHAM NA, 2001, 5 EUR M MIT PATH SEP; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Rothman SM, 1999, BIOCHEM SOC SYMP, V66, P111, DOI 10.1042/bss0660111; SAIKUMAR P, 1985, BIOCHIM BIOPHYS ACTA, V840, P127, DOI 10.1016/0304-4165(85)90169-2; Schapira AHV, 2000, CURR OPIN NEUROL, V13, P527, DOI 10.1097/00019052-200010000-00004; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379; TIRANTI V, 1995, HUM MOL GENET, V4, P2017, DOI 10.1093/hmg/4.11.2017; Trounce I, 1996, SOMAT CELL MOLEC GEN, V22, P81, DOI 10.1007/BF02374379; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541	41	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9823	9830		10.1074/jbc.M211730200	http://dx.doi.org/10.1074/jbc.M211730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645575	hybrid			2022-12-25	WOS:000181524000126
J	Cedrola, S; Guzzi, G; Ferrari, D; Gritti, A; Vescovi, AL; Pendergrass, JC; La Porta, CAM				Cedrola, S; Guzzi, G; Ferrari, D; Gritti, A; Vescovi, AL; Pendergrass, JC; La Porta, CAM			Inorganic mercury changes the fate of murine CNS stem cells	FASEB JOURNAL			English	Article						neuronal stem cell; inorganic mercury; HSP-70	AMYOTROPHIC-LATERAL-SCLEROSIS; ADULT MAMMALIAN BRAIN; DENTAL AMALGAM FILLINGS; CENTRAL-NERVOUS-SYSTEM; APAF-1 APOPTOSOME; CHLORIDE HGCL2; GRANULE CELLS; BETA-TUBULIN; MOUSE BRAIN; HUMAN FETAL	Stem cells isolated from the central nervous system of both embryonic and adult mice can generate neurons and glia through the activation of different patterns of differentiation in dependence of exposure to appropriate epigenetic signals. On the other hand, environmental conditions might affect the proliferation, migration, and differentiation of these cells. We report here, for the first time, that inorganic mercury affects the proliferative and differentiative capacity of adult neuronal stem cells (ANSCs). Actually, inorganic mercury increases apoptosis in ASNC. Furthermore, in stem cell-derived astrocytes, high levels of the 70 kDa heat shock protein (HSP-70) occur, while the levels of GTP-beta-tubulin activity dramatically decrease. Interestingly, when induced to differentiate, inorganic mercury modifies morphological proprieties of astrocytes, while the neuron population is reduced. These results demonstrate that inorganic mercury produces toxicity in the ANSC-derived neuronal population and affects the biological properties of the glial-derived population.	Dept Gen Physiol & Biochem, Sect Gen Pathol, I-20133 Milan, Italy; Italian Assoc Met & Biocompatibil Res, Milan, Italy; San Raffaele Hosp, Inst Stem Cell Res, Dept Biotechnol, Milan, Italy; Tox Exposure Study Trust Fdn ALT, Lexington, KY USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	La Porta, CAM (corresponding author), Dept Gen Physiol & Biochem, Sect Gen Pathol, Celoria 26, I-20133 Milan, Italy.	Caterina.LaPorta@unimi.it	Gritti, Angela/K-2729-2016; Vescovi, Angelo Luigi/A-4919-2015; Ferrari, Daniela/AHE-7647-2022; la porta, caterina/K-7345-2013	Gritti, Angela/0000-0002-9845-0370; Vescovi, Angelo Luigi/0000-0002-1742-4112; Ferrari, Daniela/0000-0001-7251-9854; Guzzi, Gianpaolo/0000-0002-7171-4460; la porta, caterina/0000-0002-3010-8966				ADAMS CR, 1983, JAMA-J AM MED ASSOC, V250, P642; ALBERS JW, 1982, NEUROLOGY, V32, P1168, DOI 10.1212/WNL.32.10.1168; ALBERS JW, 1988, ANN NEUROL, V24, P651, DOI 10.1002/ana.410240510; ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; ARMSTRONG R D, 1963, Am Ind Hyg Assoc J, V24, P366, DOI 10.1080/00028896309343231; ARVIDSON B, 1992, MUSCLE NERVE, V15, P1089, DOI 10.1002/mus.880151006; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; Bucio L, 1999, MUTAT RES-FUND MOL M, V423, P65, DOI 10.1016/S0027-5107(98)00226-7; CHAPMAN LJ, 1990, BRIT J IND MED, V47, P838; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111; CLARKSON TW, 1988, BIOL MONITORING TOXI, P199; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1997, J NEUROSCI, V17, P5046; Dougherty CA, 2001, BIOCHEMISTRY-US, V40, P15725, DOI 10.1021/bi010070y; DRASCH G, 1994, EUR J PEDIATR, V153, P607, DOI 10.1007/s004310050200; DUHR EF, 1993, TOXICOL APPL PHARM, V122, P273, DOI 10.1006/taap.1993.1196; Fonfria E, 2001, NEUROPHARMACOLOGY, V41, P819, DOI 10.1016/S0028-3908(01)00130-7; GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Gritti A, 2002, J PHYSIOL-PARIS, V96, P81, DOI 10.1016/S0928-4257(01)00083-3; GUENEAU G, 1982, DEV NEUROSCI-BASEL, V5, P345, DOI 10.1159/000112694; JULIAN FT, 1991, SPECTROMETRY ACTA RE, V14, P169; KAPLAN MS, 1981, J COMP NEUROL, V195, P323, DOI 10.1002/cne.901950211; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KISHI R, 1978, TOXICOL APPL PHARM, V46, P555, DOI 10.1016/0041-008X(78)90303-4; KOSTA L, 1975, NATURE, V254, P238, DOI 10.1038/254238a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leong CCW, 2001, NEUROREPORT, V12, P733, DOI 10.1097/00001756-200103260-00024; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LORSCHEIDER FL, 1995, TOXICOLOGY, V97, P19, DOI 10.1016/0300-483X(94)02964-V; LORSCHEIDER FL, 1990, LANCET, V336, P1578, DOI 10.1016/0140-6736(90)93353-Q; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEY RI, 1984, AM J PHYSIOL, V246, P195; MITCHELL JD, 1987, NEUROL CLIN, V5, P43, DOI 10.1016/S0733-8619(18)30934-4; MOLLERMADSEN B, 1986, ENVIRON RES, V41, P29, DOI 10.1016/S0013-9351(86)80165-7; MOLLERMADSEN B, 1990, TOXICOL APPL PHARM, V103, P303, DOI 10.1016/0041-008X(90)90232-J; MORIWAKA F, 1993, J NEUROL SCI, V118, P38, DOI 10.1016/0022-510X(93)90243-R; NYLANDER M, 1987, SWED DENT J, V11, P179; Pamphlett R, 1996, J NEUROL SCI, V135, P63, DOI 10.1016/0022-510X(95)00258-4; Pendergrass AC, 1997, NEUROTOXICOLOGY, V18, P315; Ratcliffe HE, 1996, J TOXICOL ENV HEALTH, V49, P221, DOI 10.1080/009841096160817; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sallsten G, 1996, J DENT RES, V75, P594, DOI 10.1177/00220345960750011301; SCHIONNING JD, 1993, TOXICOL APPL PHARM, V121, P43, DOI 10.1006/taap.1993.1127; SHAPIRO IM, 1982, LANCET, V1, P1147; Shenker BJ, 2000, ENVIRON RES, V84, P89, DOI 10.1006/enrs.2000.4078; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Tiffany-Castiglioni E, 2001, NEUROTOXICOLOGY, V22, P577, DOI 10.1016/S0161-813X(01)00050-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3	62	19	20	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					869	+		10.1096/fj.02-0491fje	http://dx.doi.org/10.1096/fj.02-0491fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670884				2022-12-25	WOS:000181892600009
J	Ma, XY; Wang, H; Ding, B; Zhong, HH; Ghosh, S; Lengyel, P				Ma, XY; Wang, H; Ding, B; Zhong, HH; Ghosh, S; Lengyel, P			The interferon-inducible p202a protein modulates NF-kappa B activity by inhibiting the binding to DNA of p50/p65 heterodimers and p65 homodimers while enhancing the binding of p50 homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; MYOBLAST DIFFERENTIATION; TRANSCRIPTIONAL ACTIVITY; CELL-SURVIVAL; RETINOBLASTOMA PROTEIN; MUSCLE DIFFERENTIATION; NEGATIVE REGULATOR; IMMUNE-RESPONSES; C-MYC	p202a is a member of the interferon-inducible murine p200 family of proteins. These proteins share 1 or 2 partially conserved 200 amino acid segments of the a or the b type. The known biological activities of p202a include among others the regulation of muscle differentiation, cell proliferation, and apoptosis. These biological activities of p202a can be correlated with the inhibition of the activity of several transcription factors. Thus, the binding of p202a results in the inhibition of the sequence-specific binding to DNA of the c-Fos, c-Jun, E2F1, E2F4, MyoD, myogenin, and c-Myc transcription factors. This study concerns the mechanisms by which p202a inhibits the activity of NF-kappaB, a transcription factor involved among others in host defense, inflammation, immunity, and the apoptotic response. NF-kappaB consists of p50 and p65 subunits. We demonstrate that p202a can inhibit in vitro and in vivo the binding to DNA of p65 homodimers and p50/65 heterodimers, whereas it increases the binding of p50 homodimers. Thus p202a can impair NF-kappaB activity both by inhibiting the binding to DNA of the transcriptionally active p65 homodimers and p50/p65 heterodimers and by boosting the binding of the repressive p50 homodimers. p202a can bind p50 and p65 in vitro and in vivo, and p202a can be part of the p50 homodimer complex bound to DNA. p50 binds in p202a to the a type segment, whereas p65 binds to the b type segment. Transfected ectopic p202a increases the apoptotic effect of tumor necrosis factor ( at least in part) by inhibiting NF-kappaB and its antiapoptotic activity.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Immunol Sect, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Lengyel, P (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.			Ma, Xian-Yong/0000-0001-5203-0429; Wang, Hong/0000-0003-4130-8741				Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BORN J, 1986, CELL DIFFER DEV, V19, P97, DOI 10.1016/0045-6039(86)90066-7; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cha-Molstad H, 2000, J IMMUNOL, V165, P4592, DOI 10.4049/jimmunol.165.8.4592; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; GETZ MJ, 1976, CELL, V7, P255, DOI 10.1016/0092-8674(76)90025-8; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Hertel L, 1999, VIROLOGY, V262, P1, DOI 10.1006/viro.1999.9885; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawasaki H, 2002, NAT BIOTECHNOL, V20, P376, DOI 10.1038/nbt0402-376; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Min W, 1996, MOL CELL BIOL, V16, P359; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Muller KM, 1998, ANAL BIOCHEM, V259, P54, DOI 10.1006/abio.1998.2606; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rozzo SJ, 2001, IMMUNITY, V15, P435, DOI 10.1016/S1074-7613(01)00196-0; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang H, 2000, J BIOL CHEM, V275, P27377; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Wang H, 2002, J INTERF CYTOK RES, V22, P729, DOI 10.1089/10799900260100231; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; Wen Y, 2000, CANCER RES, V60, P42; Xin H, 2003, J CELL BIOCHEM, V88, P191, DOI 10.1002/jcb.10372; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	75	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23008	23019		10.1074/jbc.M302105200	http://dx.doi.org/10.1074/jbc.M302105200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676938	hybrid			2022-12-25	WOS:000183503900108
J	Jiang, N; Benard, CY; Kebir, H; Shoubridge, EA; Hekimi, S				Jiang, N; Benard, CY; Kebir, H; Shoubridge, EA; Hekimi, S			Human CLK2 links cell cycle progression, apoptosis, and telomere length regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; GENE-TRANSFER; PROTEIN; DNA; EXPRESSION	Mutations in the clk- 2 gene of the nematode Caenorhabditis elegans affect organismal features such as development, behavior, reproduction, and aging as well as cellular features such as the cell cycle, apoptosis, the DNA replication checkpoint, and telomere length. clk- 2 encodes a novel protein ( CLK- 2) with a unique homologue in each of the sequenced eukaryotic genomes. We have studied the human homologue of CLK- 2 ( hCLK2) to determine whether it affects the same set of cellular features as CLK- 2. We find that overexpression of hCLK2 decreases cell cycle length and that inhibition of hCLK2 expression arrests the cell cycle reversibly. Overexpression of hCLK2, however, renders the cell hypersensitive to apoptosis triggered by oxidative stress or DNA replication block and gradually increases telomere length. The evolutionary conservation of the pattern of cellular functions affected by CLK- 2 suggests that the function of hCLK2 in humans might also affect the same organismal features as in worms, including life span. Surprisingly, we find that hCLK2 is present in all cellular compartments and exists as a membrane- associated as well as a soluble form.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 1B1, Canada	McGill University; McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.		Benard, Claire/I-7526-2015	Kebir, Hania/0000-0001-6174-8846				Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Benard C, 2002, MECH AGEING DEV, V123, P869, DOI 10.1016/S0047-6374(02)00024-6; Benard C, 2001, DEVELOPMENT, V128, P4045; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; DESJARDINS LM, 1995, EXP CELL RES, V216, P380, DOI 10.1006/excr.1995.1048; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; HEKIMI S, 1995, GENETICS, V141, P1351; Hekimi S, 2001, TRENDS GENET, V17, P712, DOI 10.1016/S0168-9525(01)02523-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; Kota RS, 1998, NUCLEIC ACIDS RES, V26, P1528, DOI 10.1093/nar/26.6.1528; Kota RS, 1999, CHROMOSOMA, V108, P278, DOI 10.1007/s004120050379; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Perls T, 2000, RES PRO CEL, V29, P1; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Runge KW, 1996, MOL CELL BIOL, V16, P3094; SANO M, 1994, J TOXICOL ENV HEALTH, V43, P339, DOI 10.1080/15287399409531925; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	29	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21678	21684		10.1074/jbc.M300286200	http://dx.doi.org/10.1074/jbc.M300286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670948	hybrid			2022-12-25	WOS:000183354200047
J	Kremer, L; Dover, LG; Morbidoni, HR; Vilcheze, C; Maughan, WN; Baulard, A; Tu, SC; Honore, N; Deretic, V; Sacchettini, JC; Locht, C; Jacobs, WR; Besra, GS				Kremer, L; Dover, LG; Morbidoni, HR; Vilcheze, C; Maughan, WN; Baulard, A; Tu, SC; Honore, N; Deretic, V; Sacchettini, JC; Locht, C; Jacobs, WR; Besra, GS			Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; CATALASE-PEROXIDASE GENE; KETOACYL-ACP SYNTHASE; ISONIAZID RESISTANCE; ENZYMATIC CHARACTERIZATION; ESCHERICHIA-COLI; ENOYL REDUCTASE; BIOCHEMICAL-CHARACTERIZATION; DRUG ETHIONAMIDE; TUBERCULOSIS	Isoniazid (INH) remains one of the key drugs used to control tuberculosis, with the enoyl-AcpM reductase InhA being the primary target. However, based on the observation that INH-treated Mycobacterium tuberculosis overproduces KasA, an enzyme involved in the biosynthesis of mycolic acids, and induces the formation of a covalent complex consisting of AcpM, KasA, and INH, it has been proposed that KasA represents the primary target of INH. However, the relevance of this complex to INH action remains obscure. This study was aimed at clarifying the role of InhA and KasA in relation to INH activity. By using anti-KasA antibodies we detected the KasA-containing complex in INH-treated Mycobacterium smegmatis. In addition, INH-treated cells also produced constant levels of KasA that were not sequestered in the complex and presumably were sufficient to ensure mycolic acid biosynthesis. Interestingly, a furA-lacking strain induced the complex at lower concentrations of INH compared with the control strain, whereas higher INH concentrations were necessary to induce the complex in a strain that lacks katG, suggesting that INH needs to be activated by KatG to induce the KasA-containing complex. The InhA inhibitors ethionamide and diazaborine also induced the complex; thus, its formation was not specifically relevant to INH action but was because of InhA inhibition. In addition, in vitro assays using purified InhA and KasA demonstrated that KatG-activated INH, triclosan, and diazaborine inhibited InhA but not KasA activity. Moreover, several thermosensitive InhA mutant strains of M. smegmatis constitutively expressed the KasA-containing complex. This study provides the biochemical and genetic evidence. 1) Only inhibition of InhA, but not KasA, induces the KasA-containing complex. 2) INH is not part of the complex. 3) INH does not target KasA, consistent with InhA being the primary target of INH.	Inst Pasteur, Lab Mecanismes Mol Pathogenie Microbienne, INSERM, U447,IBL, F-59019 Lille, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Albert Einstein Coll Med, Howard Hughes Med Inst, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Houston, Dept Biol, Houston, TX 77204 USA; Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Birmingham; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of Houston System; University of Houston; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of New Mexico; Texas A&M University System; Texas A&M University College Station	Kremer, L (corresponding author), Inst Pasteur, Lab Mecanismes Mol Pathogenie Microbienne, INSERM, U447,IBL, F-59019 Lille, France.	laurent.kremer@ibl.fr	Dover, Lynn George/Q-6778-2019; Locht, Camille/L-3516-2018; Dover, Lynn G/F-3021-2010; Kremer, Laurent/M-4935-2017; Baulard, Alain R/E-6830-2017	Dover, Lynn George/0000-0002-4776-2665; Dover, Lynn G/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Baulard, Alain R/0000-0002-0150-5241; Jacobs, William/0000-0003-3321-3080; Besra, Gurdyal/0000-0002-5605-0395; Deretic, Vojo/0000-0002-3624-5208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031139, R21AI043268, R01AI043268] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43268, AI 31139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Basso LA, 1998, J INFECT DIS, V178, P769, DOI 10.1086/515362; Baulard AR, 2000, J BIOL CHEM, V275, P28326; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; Davis MC, 1998, BIOORG MED CHEM LETT, V8, P843, DOI 10.1016/S0960-894X(98)00126-7; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Fan F, 2002, ANTIMICROB AGENTS CH, V46, P3343, DOI 10.1128/AAC.46.11.3343-3347.2002; FOX HH, 1952, SCIENCE, V116, P129, DOI 10.1126/science.116.3006.129; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2002, EXPERT OPIN INV DRUG, V11, P1033; Kremer L, 2002, MICROBIOL-SGM, V148, P3145, DOI 10.1099/00221287-148-10-3145; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Lee ASG, 1999, ANTIMICROB AGENTS CH, V43, P2087, DOI 10.1128/AAC.43.8.2087; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Marrakchi H, 2000, MICROBIOL-UK, V146, P289, DOI 10.1099/00221287-146-2-289; McMurry LM, 1999, ANTIMICROB AGENTS CH, V43, P711, DOI 10.1128/AAC.43.3.711; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MORISAKI N, 1993, EUR J BIOCHEM, V211, P111, DOI 10.1111/j.1432-1033.1993.tb19876.x; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Parrish NM, 1999, J ANTIMICROB CHEMOTH, V43, P219, DOI 10.1093/jac/43.2.219; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; Piatek AS, 2000, ANTIMICROB AGENTS CH, V44, P103, DOI 10.1128/AAC.44.1.103-110.2000; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; SAMBROOK J, 1989, MOL CLOING LAB MANUA; SANDER P, 1995, MOL MICROBIOL, V16, P991, DOI 10.1111/j.1365-2958.1995.tb02324.x; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; Schweizer HP, 2001, FEMS MICROBIOL LETT, V202, P1, DOI 10.1111/j.1574-6968.2001.tb10772.x; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SUITTON B, 1912, CR HEBD ACAD SCI, V155, P860; TAKAYAMA K, 1973, ANTIMICROB AGENTS CH, V4, P62, DOI 10.1128/AAC.4.1.62; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Vannelli TA, 2002, J BIOL CHEM, V277, P12824, DOI 10.1074/jbc.M110751200; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; Zahrt TC, 2001, MOL MICROBIOL, V39, P1174, DOI 10.1046/j.1365-2958.2001.02321.x; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	70	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20547	20554		10.1074/jbc.M302435200	http://dx.doi.org/10.1074/jbc.M302435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654922	hybrid			2022-12-25	WOS:000183230500015
J	Davis, FJ; Gupta, M; Camoretti-Mercado, B; Schwartz, RJ; Gupta, MP				Davis, FJ; Gupta, M; Camoretti-Mercado, B; Schwartz, RJ; Gupta, MP			Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4 - Implications in cardiac muscle gene regulation during hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CAM KINASE; MADS BOX; EXPRESSION; LOCALIZATION; NUCLEAR; ELEMENT; DOMAIN; PHOSPHORYLATION; RECRUITMENT	Serum response factor (SRF) plays a pivotal role in cardiac myocyte development, muscle gene transcription, and hypertrophy. Previously, elevation of intracellular levels of Ca2+ was shown to activate SRF function without involving the Ets family of tertiary complex factors through an unknown regulatory mechanism. Here, we tested the hypothesis that the chromatin remodeling enzymes of class II histone deacetylases (HDAC4) regulate SRF activity in a Ca2+-sensitive manner. Expression of HDAC4 profoundly repressed SRF-mediated transcription in both muscle and nonmuscle cells. Protein interaction studies demonstrated physical association of HDAC4 with SRF in living cells. The SRF/HDAC4 co-association was disrupted by treatment of cells with hypertrophic agonists such as angiotensin-II and a Ca2+ ionophore, ionomycin. Furthermore, activation of Ca2+/calmodulin-dependent protein kinase (CaMK)-IV prevented SRF/HDAC4 interaction and derepressed SRF-dependent transcription activity. The SRF.HDAC4 complex was localized to the cell nucleus, and the activated CaMK-IV disrupted HDAC4/SRF association, leading to export of HDAC4 from the nucleus and stimulation of SRF transcription activity. Thus, these results identify SRF as a functional interacting target of HDAC4 and define a novel tertiary complex factor-independent mechanism for SRF activation by Ca2+/CaMK-mediated signaling.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Hope Childrens Hosp, Oak Lawn, IL 60453 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine	Gupta, MP (corresponding author), Univ Chicago, Dept Surg, MC-5040,5841 S Maryland Ave, Chicago, IL 60637 USA.	mgupta@surgery.bsd.uchicago.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068083] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-68083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Borghi S, 2001, J CELL SCI, V114, P4477; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Bristow MR, 1998, LANCET, V352, P8; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Davis FJ, 2002, AM J PHYSIOL-HEART C, V282, pH1521, DOI 10.1152/ajpheart.00844.2001; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hines WA, 1999, MOL CELL BIOL, V19, P1841; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	54	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20047	20058		10.1074/jbc.M209998200	http://dx.doi.org/10.1074/jbc.M209998200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12663674	hybrid			2022-12-25	WOS:000183078000062
J	Kwon, K; Cao, CY; Stivers, JT				Kwon, K; Cao, CY; Stivers, JT			A novel zinc snap motif conveys structural stability to 3-methyladenine DNA glycosylase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; METALLOREGULATORY PROTEIN; HETERONUCLEAR NMR; BINDING DOMAIN; RECOGNITION; COBALT(II); CARBOXYPEPTIDASE; SUPERFAMILY; RUBREDOXIN; NICKEL(II)	The Escherichia coli 3-methyladenine DNA glycosylase I ( TAG) is a DNA repair enzyme that excises 3-methyladenine in DNA and is the smallest member of the helix-hairpin-helix (HhH) superfamily of DNA glycosylases. Despite many studies over the last 25 years, there has been no suggestion that TAG was a metalloprotein. However, here we establish by heteronuclear NMR and other spectroscopic methods that TAG binds 1 eq of Zn2+ extremely tightly. A family of refined NMR structures shows that 4 conserved residues contributed from the amino- and carboxyl-terminal regions of TAG (Cys(4), His(17), His(175), and Cys(179)) form a Zn2+ binding site. The Zn2+ ion serves to tether the otherwise unstructured amino- and carboxyl-terminal regions of TAG. We propose that this unexpected "zinc snap" motif in the TAG family (CX12-17HXsimilar to150HX3C) serves to stabilize the HhH domain thereby mimicking the functional role of protein-protein interactions in larger HhH superfamily members.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056834] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056834, GM46835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BORDEN KLB, 1995, EMBO J, V14, P5947, DOI 10.1002/j.1460-2075.1995.tb00283.x; BUBACCO L, 1992, BIOCHEMISTRY-US, V31, P9294, DOI 10.1021/bi00153a024; Bujnicki JM, 2002, DNA REPAIR, V1, P391, DOI 10.1016/S1568-7864(02)00017-4; DAIKUN GP, 1986, NATURE, V324, P698; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; Drohat AC, 2002, NAT STRUCT BIOL, V9, P659, DOI 10.1038/nsb829; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; LANE RW, 1977, J AM CHEM SOC, V99, P84, DOI 10.1021/ja00443a017; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAY SW, 1978, BIOCHEMISTRY-US, V17, P3333, DOI 10.1021/bi00609a025; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; Outten CE, 2001, BIOCHEMISTRY-US, V40, P10417, DOI 10.1021/bi0155448; PELTON JG, 1993, PROTEIN SCI, V2, P543; RIAZUDDIN S, 1978, BIOCHEMISTRY-US, V17, P2110, DOI 10.1021/bi00604a014; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P21, DOI 10.1021/ja00834a006; ROSENBERG RC, 1973, P NATL ACAD SCI USA, V70, P161, DOI 10.1073/pnas.70.1.161; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VASAK M, 1981, BIOCHEMISTRY-US, V20, P6659, DOI 10.1021/bi00526a021; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4	28	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19442	19446		10.1074/jbc.M300934200	http://dx.doi.org/10.1074/jbc.M300934200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12654914	hybrid			2022-12-25	WOS:000182932200093
J	Patel, H; Di Pietro, E; MacKenzie, RE				Patel, H; Di Pietro, E; MacKenzie, RE			Mammalian fibroblasts lacking mitochondrial NAD(+)-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase are glycine auxotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; SERINE HYDROXYMETHYLTRANSFERASE ISOZYMES; METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; 5,10-METHYLENETETRAHYDROFOLATE DEHYDROGENASE; C1-TETRAHYDROFOLATE SYNTHASE; CELLS; SYNTHETASE; PURIFICATION; EXPRESSION; FOLATE	Primary fibroblasts established from embryos of NAD-dependent mitochondrial methylenetetrahydrofolate dehydrogenase-cyclohydrolase (NMDMC) knockout mice were spontaneously immortalized or transformed with SV40 Large T antigen. Mitotracker Red CMXRos staining of the cells indicates the presence of intact mitochondria with a membrane potential. The nmdmc((-/-)) cells are auxotrophic for glycine, demonstrating that NMDMC is the only methylenetetrahydrofolate dehydrogenase normally expressed in the mitochondria of these cell lines. Growth of null mutant but not wild type cells on complete medium with dialyzed serum is stimulated about 2-fold by added formate or hypoxanthine. Radiolabeling experiments demonstrated a 3-10x enhanced incorporation of radioactivity into DNA from formate relative to serine by nmdmc((-/-)) cells. The generation of one-carbon units by mitochondria in nmdmc((-/-)) cells is completely blocked, and the cytoplasmic folate pathways alone are insufficient for optimal purine synthesis. The results demonstrate a metabolic role for NMDMC in supporting purine biosynthesis. Despite the recognition of these metabolic defects in the mutant cell lines, the phenotype of nmdmc((-/-)) embryos that begin to die at E13.5 is not improved when pregnant dams are given a glycine-rich diet or daily injections of sodium formate.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	MacKenzie, RE (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	Robert.Mackenzie@mcgill.ca						BARLOWE C K, 1988, Biofactors, V1, P171; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Fu TF, 2001, ARCH BIOCHEM BIOPHYS, V393, P42, DOI 10.1006/abbi.2001.2471; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; HOFFMAN RM, 1982, IN VITRO CELL DEV B, V18, P421; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Li Y, 2000, J BACTERIOL, V182, P2886, DOI 10.1128/JB.182.10.2886-2892.2000; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Minamikawa T, 1999, J CELL SCI, V112, P2419; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Patel H, 2002, ARCH BIOCHEM BIOPHYS, V403, P145, DOI 10.1016/S0003-9861(02)00203-5; Pawelek PD, 1996, BBA-PROTEIN STRUCT M, V1296, P47, DOI 10.1016/0167-4838(96)00052-0; PELLETIER JN, 1995, BIOCHEMISTRY-US, V34, P12673, DOI 10.1021/bi00039a025; PERI KG, 1991, FEBS LETT, V294, P113, DOI 10.1016/0014-5793(91)81354-B; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; SHANNON KW, 1986, J BIOL CHEM, V261, P2266; SMITH GK, 1990, ARCH BIOCHEM BIOPHYS, V283, P367, DOI 10.1016/0003-9861(90)90656-J; Tang BQ, 2000, CANCER RES, V60, P5543; THIGPEN AE, 1990, J BIOL CHEM, V265, P7907; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	35	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19436	19441		10.1074/jbc.M301718200	http://dx.doi.org/10.1074/jbc.M301718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646567	hybrid			2022-12-25	WOS:000182932200092
J	Cohen, R; Elferink, LA; Atlas, D				Cohen, R; Elferink, LA; Atlas, D			The C2A domain of synaptotagmin alters the kinetics of voltagegated Ca2+ channels Ca(v)1.2 (Lc-type) and Ca(v)2.3 (R-type)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; SNARE COMPLEX; TRANSMITTER RELEASE; ANTIBODY INJECTION; C(2)A DOMAIN; C-2 DOMAIN; IN-VIVO; EXOCYTOSIS	Biochemical and genetic studies implicate synaptotagmin (Syt 1) as a Ca2+ sensor for neuronal and neuroendocrine neurosecretion. Calcium binding to Syt 1 occurs through two cytoplasmic repeats termed the C2A and C2B domains. In addition, the C2A domain of Syt I has calcium-independent properties required for neurotransmitter release. For example, mutation of a polylysine motif (residues 189-192) reverses the inhibitory effect of injected recombinant Syt 1 C2A fragment on neurotransmitter release from PC12 cells. Here we examined the requirement of the C2A polylysine motif for Syt 1 interaction with the cardiac Ca(v)1.2 (L-type) and the neuronal Ca(v)2.3 (R-type) voltage-gated Ca2+ channels, two channels required for neurotransmission. We find that the C2A polylysine motif presents a critical interaction surface with Ca(v)1.2 and Ca(v)2.3 since truncated Syt 1 containing a mutated motif (Syt 1*(1-264)) was ineffective at modifying the channel kinetics. Mutating the polylysine motif also abolished C2A binding to Lc(753-893), the cytosolic interacting domain of Syt 1 at Cav1.2 alpha1 subunit. Syt I and Syt 1* harboring the mutation at the KKKK motif modified channel activation, while Syt 1* only partially reversed the syntaxin 1A effects on channel activity. This mutation would interfere with the assembly of Syt 1/channel/syntaxin into an exocytotic unit. The functional interaction of the C2A polylysine domain with Ca(v)1.2 and Ca(v)2.3 is consistent with tethering of the secretory vesicle to the Ca2+ channel. It indicates that calcium-independent properties of Syt 1 regulate voltage-gated Ca2+ channels and contribute to the molecular events underlying transmitter release.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Marine & Biomed Inst, Galveston, TX 77555 USA	Hebrew University of Jerusalem; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Atlas, D (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	datlas@vms.huji.ac.il						Atlas D, 2001, CELL MOL NEUROBIOL, V21, P717, DOI 10.1023/A:1015104105262; Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; Mochida S, 2000, NEUROSCI RES, V36, P175, DOI 10.1016/S0168-0102(99)00128-5; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; Thomas DM, 1999, MOL BIOL CELL, V10, P2285, DOI 10.1091/mbc.10.7.2285; Thomas DM, 1998, J NEUROSCI, V18, P3511; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Wiser O, 1997, FEBS LETT, V404, P203, DOI 10.1016/S0014-5793(97)00130-0; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 2002, P NATL ACAD SCI USA, V99, P3968, DOI 10.1073/pnas.052017299; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	47	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9258	9266		10.1074/jbc.M210270200	http://dx.doi.org/10.1074/jbc.M210270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645522	hybrid			2022-12-25	WOS:000181524000050
J	Ahvazi, B; Boeshans, KM; Idler, W; Baxa, U; Steinert, PM				Ahvazi, B; Boeshans, KM; Idler, W; Baxa, U; Steinert, PM			Roles of calcium ions in the activation and activity of the transglutaminase 3 enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; CROSS-LINKING; GTP; IDENTIFICATION; PARAMETERS; INVOLUCRIN; RECEPTOR; PROGRAM; SITE	The transglutaminase 3 enzyme is widely expressed in many tissues including epithelia. We have shown previously that it can bind three Ca2+ ions, which in site one is constitutively bound, while those in sites two and three are acquired during activation and are required for activity. In particular, binding at site three opens a channel through the enzyme and exposes two tryptophan residues near the active site that are thought to be important for enzyme reaction. In this study, we have solved the structures of three more forms of this enzyme by x-ray crystallography in the presence of Ca2+ and/or Mg2+, which provide new insights on the precise contribution of each Ca2+ ion to activation and activity. First, we found that Ca2+ ion in site one can be exchanged with difficulty, and it has a binding affinity of K-d = 0.3 muM (DeltaH = -6.70 +/- 0.52 kcal/mol), which suggests it is important for the stabilization of the enzyme. Site two can be occupied by some lanthanides but only Ca2+ of the Group 2 family of alkali earth metals, and its occupancy are required for activity. Site three can be occupied by some lanthanides, Ca2+, or Mg2+; however, when Mg2+ is present, the enzyme is inactive, and the channel is closed. Thus Ca2+ binding in both sites two and three cooperate in opening the channel. We speculate that manipulation of the channel opening could be controlled by intracellular cation levels. Together, these data have important implications for reaction mechanism of the enzyme: the opening of a channel perhaps controls access to and manipulation of substrates at the active site.	NIAMS, Lab Xray Crystallog, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Ahvazi, B (corresponding author), NIAMS, Lab Xray Crystallog, Off Sci & Technol, NIH, Bldg 50,Rm 1524,50 South Dr, Bethesda, MD 20892 USA.	Bijan@discus.niams.nih.gov						Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BLANCUZZI Y, 1993, BIOCHEMISTRY-US, V32, P1302, DOI 10.1021/bi00056a015; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Drake SK, 1997, BIOCHEMISTRY-US, V36, P9917, DOI 10.1021/bi9703913; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; Fox BA, 1999, J BIOL CHEM, V274, P4917, DOI 10.1074/jbc.274.8.4917; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hitomi K, 2000, BIOSCI BIOTECH BIOCH, V64, P657, DOI 10.1271/bbb.64.657; IM MJ, 1990, J BIOL CHEM, V265, P18944; Jia J, 2001, ACTA CRYSTALLOGR D, V57, P1843, DOI 10.1107/S0907444901016511; Kim HC, 2001, J STRUCT BIOL, V135, P73, DOI 10.1006/jsbi.2001.4384; KIM HC, 1990, J BIOL CHEM, V265, P21971; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Melino G, 2000, METHOD ENZYMOL, V322, P433; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i	34	46	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23834	23841		10.1074/jbc.M301162200	http://dx.doi.org/10.1074/jbc.M301162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12679341	hybrid			2022-12-25	WOS:000183638600079
J	Langlois, MA; El Fakhry, Y; Mourad, W				Langlois, MA; El Fakhry, Y; Mourad, W			Zinc-binding sites in the N terminus of Mycoplasma arthritidis-derived mitogen permit the dimer formation required for high affinity binding to HLA-DR and for T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; STAPHYLOCOCCAL-ENTEROTOXIN-A; CRYSTAL-STRUCTURE; CROSS-LINKING; PYROGENIC EXOTOXIN; INVARIANT CHAIN; SUPERANTIGEN; MOLECULES; COMPLEX; RECEPTOR	Zinc-dependent superantigens can be divided into two subfamilies based on how they use zinc ions for interactions with major histocompatibility complex (MHC) class II molecules. Members of the first subfamily use zinc ions for interactions with histidine 81 on the beta-chain of MHC class II molecules, whereas members of the second subfamily use zinc ions for dimer formation. The zinc-binding motif is located in the C terminus of the molecule in both subfamilies. While our recent studies with Mycoplasma arthritidis-derived mitogen (MAM) have provided the first direct evidence demonstrating the binding to MHC class II molecules in a zinc-dependent manner, it still not known how zinc coordinates the interaction. Data presented here show that the zinc ion is mainly required to induce MAM/MAM dimer formation. Residues in the N terminus of MAM are involved in dimer formation and MHC class II binding, while histidine 14 and aspartic acid 31 of the MAM sequence are the major residues mediating MAM/MAM dimerization. Zinc-induced dimer formation is necessary for MAM binding, MHC class II-induced cell-cell adhesion, and efficient T cell activation. Together these results depict the unique mode of interaction of MAM in comparison with other superantigens.	Univ Laval, Fac Med, CHU Laval, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada	Laval University	Mourad, W (corresponding author), Univ Laval, Fac Med, CHU Laval, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier,T1-49, Quebec City, PQ G1V 4G2, Canada.	walid.mourad@crchul.ulaval.ca	Langlois, Marc-Andre/J-2103-2012	Langlois, Marc-Andre/0000-0003-4652-3029; Mourad, Walid/0000-0002-1859-9387				Al-Daccak R, 1998, J IMMUNOL, V160, P225; Albert LJ, 1998, CELL IMMUNOL, V183, P42, DOI 10.1006/cimm.1997.1236; Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; BACCALA R, 1992, ARTHRITIS RHEUM-US, V35, P434, DOI 10.1002/art.1780350413; Bernatchez C, 1997, INFECT IMMUN, V65, P2000, DOI 10.1128/IAI.65.6.2000-2005.1997; Bouillon M, 2003, J BIOL CHEM, V278, P7099, DOI 10.1074/jbc.M211566200; Cavallin A, 2000, J BIOL CHEM, V275, P1665, DOI 10.1074/jbc.275.3.1665; Chi YI, 2002, J BIOL CHEM, V277, P22839, DOI 10.1074/jbc.M201932200; Ciurli C, 1998, J EXP MED, V187, P253, DOI 10.1084/jem.187.2.253; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; Cole BC, 1996, J EXP MED, V183, P1105, DOI 10.1084/jem.183.3.1105; Cole BC, 1999, REV RHUM, V66, p45S; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; DOHLSTEN M, 1995, CANCER IMMUNOL IMMUN, V41, P162, DOI 10.1007/s002620050214; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; Etongue-Mayer P, 2002, EUR J IMMUNOL, V32, P50, DOI 10.1002/1521-4141(200201)32:1<50::AID-IMMU50>3.0.CO;2-A; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Green JM, 1996, CELL IMMUNOL, V171, P126, DOI 10.1006/cimm.1996.0182; Hakansson M, 2000, J MOL BIOL, V302, P527, DOI 10.1006/jmbi.2000.4093; Hodtsev AS, 1998, J EXP MED, V187, P319, DOI 10.1084/jem.187.3.319; Houri John M., 1995, Current Opinion in Rheumatology, V7, P201, DOI 10.1097/00002281-199505000-00008; HUDSON KR, 1995, J EXP MED, V182, P711, DOI 10.1084/jem.182.3.711; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; KAWAI K, 1995, NATURE, V374, P68, DOI 10.1038/374068a0; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Langlois MA, 2000, EUR J IMMUNOL, V30, P1748, DOI 10.1002/1521-4141(200006)30:6<1748::AID-IMMU1748>3.0.CO;2-J; Lavoie PM, 1997, P NATL ACAD SCI USA, V94, P6892, DOI 10.1073/pnas.94.13.6892; Lavoie PM, 2001, J IMMUNOL, V166, P7229, DOI 10.4049/jimmunol.166.12.7229; LEE WT, 1992, J EXP MED, V176, P575, DOI 10.1084/jem.176.2.575; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; McDevitt H, 2000, ARTHRITIS RES, V2, P85, DOI 10.1186/ar72; MEHINDATE K, 1995, J EXP MED, V182, P1573, DOI 10.1084/jem.182.5.1573; Morgan MM, 2001, J IMMUNOL, V167, P5708, DOI 10.4049/jimmunol.167.10.5708; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; OCHI A, 1993, J IMMUNOL, V151, P3180; Papageorgiou AC, 1999, EMBO J, V18, P9, DOI 10.1093/emboj/18.1.9; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; ROCKEN M, 1994, J EXP MED, V179, P1885, DOI 10.1084/jem.179.6.1885; Sawitzke A, 2000, J RHEUMATOL, V27, P358; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; Schlievert PM, 2000, INFECT IMMUN, V68, P3630, DOI 10.1128/IAI.68.6.3630-3634.2000; Schodin BA, 1996, IMMUNITY, V5, P137, DOI 10.1016/S1074-7613(00)80490-2; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Shoukry NH, 1997, HUM IMMUNOL, V54, P194, DOI 10.1016/S0198-8859(97)00074-8; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; Swietnicki W, 2003, J BIOL CHEM, V278, P9885, DOI 10.1074/jbc.M206957200; THIBODEAU J, 1994, SCIENCE, V266, P1874, DOI 10.1126/science.7997881; Tiedemann RE, 1996, J IMMUNOL, V157, P3958; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; Wen R, 1996, J EXP MED, V183, P1083, DOI 10.1084/jem.183.3.1083; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G; Zen K, 1996, IMMUNOBIOLOGY, V195, P323, DOI 10.1016/S0171-2985(96)80049-0	62	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22309	22315		10.1074/jbc.M300823200	http://dx.doi.org/10.1074/jbc.M300823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676930	hybrid			2022-12-25	WOS:000183503900020
J	Yin, Z; Haynie, J; Williams, BRG; Yang, YC				Yin, Z; Haynie, J; Williams, BRG; Yang, YC			C114 is a novel IL-11-inducible nuclear double-stranded RNA-binding protein that inhibits protein kinase R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NF-KAPPA-B; 3T3-F442A FIBROBLASTS; MOLECULAR-CLONING; TAT PROTEIN; PKR; ACTIVATION; PHOSPHORYLATION; INTERLEUKIN-11; SUBSTRATE	We have identified a cDNA ( named C114) that encodes novel transcripts induced by IL- 11 in mouse 3T3 L1 cells. Northern analysis of RNAs from multiple mouse tissues detects two C114 transcripts of similar to 1.0 and similar to 2.0 kb with the highest expression in liver, testis, brain, and kidney. The C114 cDNA contains an open reading frame of 187 amino acids with a predicted mass of 21 kDa. Three putative nuclear localization signals are predicted at amino acids 83 - 88, 126 - 131, and 167 - 178. Using green fluorescent protein ( GFP)- C114 fusion plasmids, amino acids 126 - 131 are shown to be essential for the nuclear localization of C114. An arginine- rich region ( amino acids 98 - 143) spanning the nuclear localization signals ( amino acids 126 - 131) exhibits a double- stranded RNA ( dsRNA) binding activity. Competition experiments with different RNA homopolymers demonstrate that C114 preferentially binds to poly( I . C). Similar to other dsRNA- binding proteins, C114 binds to the dsRNA- activated protein kinase, protein kinase R ( PKR), via dsRNA- binding domains of PKR and the N- terminal region of the C114 protein. In vitro kinase assays indicate that C114 inhibits PKR activation via a dsRNA- independent mechanism. Overexpression of C114 protein inhibits the induction of eIF- 2 alpha phosphorylation following poly( I . C) treatment. This is the first demonstration of a novel PKR modulator induced by a gp130 superfamily cytokine that may play a role in cytokine- mediated biological functions.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA078433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA62220, R01 CA78433] Funding Source: Medline; NHLBI NIH HHS [R01 HL48819] Funding Source: Medline; NIAID NIH HHS [R01 AI34039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Calkhoven CF, 2000, GENE DEV, V14, P1920; Coolidge CJ, 2000, NUCLEIC ACIDS RES, V28, P1407, DOI 10.1093/nar/28.6.1407; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; Parker LM, 2001, J BIOL CHEM, V276, P32522, DOI 10.1074/jbc.M104408200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; TOWLE CA, 1984, BIOCHEM BIOPH RES CO, V121, P134, DOI 10.1016/0006-291X(84)90697-1; Trepicchio WL, 1997, J IMMUNOL, V159, P5661; Williams B.R., 2001, SCI STKE, V2001, pre2; Woldehawariat G, 1999, MOL CELL BIOCHEM, V198, P7, DOI 10.1023/A:1006978622240; Yang YC, 1995, ANN NY ACAD SCI, V762, P31; YIN TG, 1992, J BIOL CHEM, V267, P8347	28	14	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22838	22845		10.1074/jbc.M212969200	http://dx.doi.org/10.1074/jbc.M212969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12679338	hybrid			2022-12-25	WOS:000183503900088
J	Zhu, Y; Inouye, M				Zhu, Y; Inouye, M			Analysis of the role of the EnvZ linker region in signal transduction using a chimeric Tar/EnvZ receptor protein, Tez1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE RECEPTOR; HISTIDINE KINASE ENVZ; ESCHERICHIA-COLI; PHOSPHATASE-ACTIVITIES; FUNCTIONAL IMPORTANCE; OSMOSENSOR ENVZ; LIGAND-BINDING; DOMAIN; OSMOREGULATION; MUTAGENESIS	Tez1 is a chimeric protein in which the periplasmic and transmembrane domains of Tar, a chemosensor, are fused to the cytoplasmic catalytic domain of EnvZ, an osmosensing histidine kinase, through the EnvZ linker. Unlike Taz1 ( a similar hybrid with the Tar linker), Tez1 could not respond to Tar ligand, aspartate, whereas single Ala insertion at the transmembrane/ linker junction, as seen in Tez1A1, restored the aspartate- regulatable phenotype. Analysis of the Ala insertion site requirement and the nature of the insertion residue on the phenotype of Tez1 indicated that a junction region between the transmembrane domain and the predicted helix I in the linker is critical to signal transduction. Random mutagenesis revealed that P185Q mutation in the Tez1 linker restored the aspartate- regulatable phenotype. Substitution mutations at Pro- 185 further demonstrated that specific residues are required at this site for an aspartate response. None of the hybrid receptors constructed with different Tar/ EnvZ fusion sites in the linker could respond to aspartate, suggesting that specific interactions between the two predicted helices in the linker are important for the linker function. In addition, a mutation ( F220D) known to cause an OmpC(c) phenotype in EnvZ resulted in similar OmpC(c) phenotypes in both Tez1A1 and Tez1, indicating the importance of the predicted helix II in signal propagation. Together, we propose that the N- terminal junction region modulates the alignment between the two helices in the linker upon signal input. In turn helix II propagates the resultant conformational signal into the downstream catalytic domain of EnvZ to regulate its bifunctional enzymatic activities.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FORST S, 1987, J BIOL CHEM, V262, P16433; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Inouye M., 2003, HISTIDINE KINASES SI, P25; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KORETKE KK, 2003, HISTIDINE KINASES SI, P483; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MIZUNO T, 1986, J BACTERIOL, V168, P86, DOI 10.1128/jb.168.1.86-95.1986; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MURRE C, 1992, TRANSCRIPTIONAL REGU, V1, P961; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; Singh M, 1998, P NATL ACAD SCI USA, V95, P2738, DOI 10.1073/pnas.95.6.2738; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tao W, 2002, MOL MICROBIOL, V43, P459, DOI 10.1046/j.1365-2958.2002.02757.x; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; TOKISHITA S, 1991, J BIOL CHEM, V266, P6780; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Ward SM, 2002, MOL MICROBIOL, V44, P709, DOI 10.1046/j.1365-2958.2002.02902.x; WAUKAU J, 1992, J BACTERIOL, V174, P1522, DOI 10.1128/jb.174.5.1522-1527.1992; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; WOLANIN PM, 2003, HISTIDINE KINASES SI, P73; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808; Zhu Y, 2002, MOL MICROBIOL, V45, P653, DOI 10.1046/j.1365-2958.2002.03061.x	39	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22812	22819		10.1074/jbc.M300916200	http://dx.doi.org/10.1074/jbc.M300916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672798	hybrid			2022-12-25	WOS:000183503900085
J	Heinz, S; Haehnel, V; Karaghiosoff, M; Schwarzfischer, L; Muller, M; Krause, SW; Rehli, M				Heinz, S; Haehnel, V; Karaghiosoff, M; Schwarzfischer, L; Muller, M; Krause, SW; Rehli, M			Species-specific regulation of Toll-like receptor 3 genes in men and mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DENDRITIC CELLS; TARGETED DISRUPTION; INTERFERON-BETA; EXPRESSION; MACROPHAGES; INDUCTION; ACTIVATION; DEFENSE; FAMILY	Toll- like receptor 3 ( TLR3) belongs to a family of evolutionary conserved innate immune recognition molecules and recognizes double- stranded RNA, a molecular pattern associated with viral infections. Earlier studies suggested a differential expression pattern in men and mice; the molecular basis for this observation, however, was unknown. Here we demonstrate that species- specific differences in tissue expression and responses to lipopolysaccaride ( LPS) coincide with the presence of different, evolutionary non- conserved promoter sequences in both species. Despite the overall unrelatedness of TLR3 promoter sequences, mRNA expression of both TLR3 orthologues was induced by interferons, particularly by interferon ( IFN)-beta. The basal and IFN-beta-induced activation of promoters from both species largely depended on similar interferon regulatory factor ( IRF) elements, which constitutively bound IRF- 2 and recruited IRF- 1 after stimulation. In murine macrophages, IFN-beta-induced TLR3 up- regulation required IFNAR1, STAT1, and in part IRF- 1, but not the Janus kinase ( Jak) family member Tyk2. We also show that LPS specifically up- regulates TLR3 expression in murine cells through the induction of autocrine/ paracrine IFN-beta. In humans, however, IFN-beta-induced up- regulation of TLR3 was blocked by pretreatment with LPS, despite the efficient induction of IRF- 1. Our findings reveal a mechanistic basis for the observed differences as well as similarities in TLR3 expression in men and mice. The IFN-beta- TLR3 link further suggests a role of TLR3 in innate and adaptive immune responses to viral infections. It will be interesting and important to clarify whether the observed differences in the transcriptional regulation of TLR3 influence innate immune responses in a species- specific manner.	Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany; Vet Univ Vienna, Inst Genet & Anim Breeding, A-1210 Vienna, Austria	University of Regensburg; University of Veterinary Medicine Vienna	Rehli, M (corresponding author), Univ Hosp, Dept Hematol & Oncol, D-93042 Regensburg, Germany.		Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Heinz, Sven/0000-0002-4665-1007; Krause, Stefan/0000-0002-5259-4651; Muller, Mathias/0000-0002-7879-3552				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Heinz S, 2002, GENOMICS, V79, P608, DOI 10.1006/geno.2002.6743; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kalis C, 2003, EUR J IMMUNOL, V33, P798, DOI 10.1002/eji.200323431; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Means TK, 1999, J IMMUNOL, V163, P3920; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249	29	157	161	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21502	21509		10.1074/jbc.M301476200	http://dx.doi.org/10.1074/jbc.M301476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672806	hybrid			2022-12-25	WOS:000183354200025
J	Meiners, S; Heyken, D; Weller, A; Ludwig, A; Stangl, K; Kloetzel, PM; Kruger, E				Meiners, S; Heyken, D; Weller, A; Ludwig, A; Stangl, K; Kloetzel, PM; Kruger, E			Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; 20S PROTEASOME; PRECURSOR COMPLEXES; PROTEIN-DEGRADATION; ESCHERICHIA-COLI; 26S PROTEASOME; CORE PARTICLE; PATHWAY; UBIQUITIN; MATURATION	The 26 S proteasome is a high molecular mass proteinase complex that is built by at least 32 different protein subunits. Such protease complexes in bacteria and yeast are systems that undergo a highly sophisticated network of gene expression regulation. However, regulation of mammalian proteasome gene expression has been neglected so far as a possible control mechanism for the amount of proteasomes in the cell. Here, we show that treatment of cells with proteasome inhibitors and the concomitant impairment of proteasomal enzyme activity induce a transient and concerted up- regulation of all mammalian 26 S proteasome subunit mRNAs. Proteasome inhibition in combination with inhibition of transcription revealed that the observed up- regulation is mediated by coordinated transcriptional activation of the proteasome genes and not by post- transcriptional events. Our experiments also demonstrate that inhibitor-induced proteasome gene activation results in enhanced de novo protein synthesis of all subunits and in increased de novo formation of proteasomes. This phenomenon is accompanied by enhanced expression of the proteasome maturation factor POMP. Thus, our experiments present the first evidence that the amount of proteasomes in mammalia is regulated at the transcriptional level and that there exists an autoregulatory feedback mechanism that allows the compensation of reduced proteasome activity.	Humboldt Univ, Klinikum Charite, Inst Biochem, D-10117 Berlin, Germany; Humboldt Univ, Klinikum Charite, Med Klin & Poliklin, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kruger, E (corresponding author), Humboldt Univ, Klinikum Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.		Krueger, Elke/B-1462-2012; , Antje Ludwig/ABF-6556-2021; Martinez, Octavio/B-7375-2009; Meiners, S/M-9822-2014	Krueger, Elke/0000-0002-2551-242X; Meiners, S/0000-0003-3678-7995; Ludwig, Antje/0000-0002-8369-7020				Adams J, 1999, CANCER RES, V59, P2615; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Burri L, 2000, P NATL ACAD SCI USA, V97, P10348, DOI 10.1073/pnas.190268597; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; Dou QP, 1999, DRUG RESIST UPDATE, V2, P215, DOI 10.1054/drup.1999.0095; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Fleming JV, 2000, MOL CELL BIOL, V20, P4932, DOI 10.1128/MCB.20.13.4932-4947.2000; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; Goldberg AL, 2002, NAT MED, V8, P338, DOI 10.1038/nm0402-338; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Griffin Thomas A., 2000, Molecular Cell Biology Research Communications, V3, P212, DOI 10.1006/mcbr.2000.0213; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Jagoe RT, 2002, CLIN SCI, V102, P353, DOI 10.1042/CS20010270; Jensen LJ, 2000, BIOINFORMATICS, V16, P326; Kim SS, 1998, FEBS LETT, V433, P47, DOI 10.1016/S0014-5793(98)00883-7; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kruger E, 1996, MOL MICROBIOL, V20, P713, DOI 10.1111/j.1365-2958.1996.tb02511.x; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; Kruger E, 2001, EMBO J, V20, P852, DOI 10.1093/emboj/20.4.852; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Pritts TA, 2002, AM J PHYSIOL-REG I, V282, pR1016, DOI 10.1152/ajpregu.00492.2001; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Salzmann U, 1999, FEBS LETT, V454, P11, DOI 10.1016/S0014-5793(99)00768-1; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Wickner S, 1999, P NATL ACAD SCI USA, V96, P8318, DOI 10.1073/pnas.96.15.8318; Witt E, 2000, J MOL BIOL, V301, P1, DOI 10.1006/jmbi.2000.3959; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; ZIMMERMANN J, 2000, ONCOGENE, V19	49	242	248	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21517	21525		10.1074/jbc.M301032200	http://dx.doi.org/10.1074/jbc.M301032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676932	hybrid			2022-12-25	WOS:000183354200027
J	Harendza, S; Lovett, DH; Panzer, U; Lukacs, Z; Kuhnl, P; Stahl, RAK				Harendza, S; Lovett, DH; Panzer, U; Lukacs, Z; Kuhnl, P; Stahl, RAK			Linked common polymorphisms in the gelatinase A promoter are associated with diminished transcriptional response to estrogen and genetic fitness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-2 GENE; EXPRESSION; CELL; ACTIVATION; ELEMENT; SP1; ANGIOGENESIS; ESTRADIOL; INVASION; YB-1	Gelatinase A ( matrix metalloproteinase- 2) plays a prominent role in multiple biologic processes. Prior studies have established critical roles for gelatinase A transcriptional regulation by defined enhancer elements. To determine possible functional single nucleotide polymorphisms within these elements, we determined the single nucleotide polymorphism distribution within 1,665 bp of the gelatinase A 5'-flanking region, using a healthy homogeneous Caucasian study group of 463 individuals. Among the polymorphisms detected, a G -->A transition at bp - 1575 was located immediately 5' to a half-palindromic potential estrogen receptor binding site. In estrogen receptor-positive MCF-7 cells the - 1575G allele functioned as an enhancer, whereas the - 1575A allele reduced transcription activity significantly. Gel shift assays confirmed that the differences in allelic expression affected binding of the estrogen receptor-alpha to this region. Cotransfection experiments with an estrogen receptor-alpha expression vector in MDA-MB-231 cells, which do not constitutively express an estrogen receptor, revealed that estrogen receptor is absolutely required for enhancing activity. Allelic distribution analysis indicated that a previously reported C-->T transition within an Sp1 binding site at - 1306 was in linkage disequilibrium with the - 1575G 3 A transition. Luciferase reporter studies of the linked variant - 1575A - 1306T allele versus the wild type - 1575G - 1306C allele demonstrated an additive reduction in estrogen-dependent reporter activity. The frequency of the - 1575G 3 A transition deviated significantly from the expected Hardy-Weinberg distribution in two independently assembled study populations consisting of healthy adult blood donors and newborns of Caucasian origin, both with a calculated 21% reduction in genetic fitness. Gelatinase A is a known estrogen-responsive gene and the demonstration of a loss of function polymorphism within an operational estrogen receptor binding site associated with a decrease in genetic fitness underscores the biologic significance of promoter polymorphism analyses.	Univ Hamburg, Dept Med, D-20246 Hamburg, Germany; Univ Hamburg, Div Nephrol, D-20246 Hamburg, Germany; Univ Hamburg, Dept Pediat, D-20246 Hamburg, Germany; Univ Hamburg, Dept Transfus Med & Transplantat Immunol, D-20246 Hamburg, Germany; Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of Hamburg; University of Hamburg; University of Hamburg; University of Hamburg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Harendza, S (corresponding author), Univ Klinikum Hamburg Eppendorf, Zentrum Innere Med, Med Klin 4, Pavillon N26,Martinistr 52, D-20246 Hamburg, Germany.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Crescimanno C, 1996, EXP CELL RES, V227, P240, DOI 10.1006/excr.1996.0273; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; Dubois B, 2000, J CLIN INVEST, V106, P627, DOI 10.1172/JCI10910; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Gao F, 2001, ENDOCRINE, V16, P47, DOI 10.1385/ENDO:16:1:47; Giannelli G, 1999, AM J PATHOL, V154, P1193, DOI 10.1016/S0002-9440(10)65371-0; Guccione M, 2002, AM J PHYSIOL-RENAL, V282, pF164, DOI 10.1152/ajprenal.0318.2000; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harendza S, 2000, J BIOL CHEM, V275, P19552, DOI 10.1074/jbc.M001322200; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; Itoh T, 1998, CANCER RES, V58, P1048; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Noll WW, 2001, AM J PATHOL, V158, P691, DOI 10.1016/S0002-9440(10)64011-4; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200; PUISTOLA U, 1995, FERTIL STERIL, V64, P81, DOI 10.1016/S0015-0282(16)57659-6; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Slaton JW, 2001, AM J PATHOL, V158, P735, DOI 10.1016/S0002-9440(10)64016-3; Tanney DC, 1998, DEV DYNAM, V213, P121, DOI 10.1002/(SICI)1097-0177(199809)213:1<121::AID-AJA12>3.0.CO;2-5; Vyhlidal C, 2000, J MOL ENDOCRINOL, V24, P329, DOI 10.1677/jme.0.0240329; Wingrove CS, 1998, BBA-MOL BASIS DIS, V1406, P169, DOI 10.1016/S0925-4439(97)00097-5; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788; Zhang BP, 1999, HUM GENET, V105, P418, DOI 10.1007/s004390051124; Zhang YL, 2000, HYPERTENSION, V36, P970, DOI 10.1161/01.HYP.36.6.970	41	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20490	20499		10.1074/jbc.M211536200	http://dx.doi.org/10.1074/jbc.M211536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657623	hybrid			2022-12-25	WOS:000183230500008
J	Hazlett, KRO; Rusnak, F; Kehres, DG; Bearden, SW; La Vake, CJ; La Vake, ME; Maguire, ME; Perry, RD; Radolf, JD				Hazlett, KRO; Rusnak, F; Kehres, DG; Bearden, SW; La Vake, CJ; La Vake, ME; Maguire, ME; Perry, RD; Radolf, JD			The Treponema pallidum tro operon encodes a multiple metal transporter, a zinc-dependent transcriptional repressor, and a semi-autonomously expressed phosphoglycerate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; CEREBROSPINAL-FLUID LEVELS; ESCHERICHIA-COLI; YERSINIA-PESTIS; BINDING PROTEIN; UPTAKE SYSTEM; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; MANGANESE HOMEOSTASIS; SUPEROXIDE REDUCTASE	The Treponema pallidum tro operon encodes an ABC transporter (TroABCD), a transcriptional repressor (TroR), and the essential glycolytic enzyme phosphoglycerate mutase (Gpm). The apparently discordant observations that the solute binding protein (TroA) binds Zn2+, whereas DNA binding by TroR in vitro is Mn2+-dependent, have generated uncertainty regarding the identities of the ligand(s) and co-repressor(s) of the permease. Moreover, this operonic structure suggests that Gpm expression, and hence glycolysis, the sole source of ATP for the bacterium, would be suspended during TroR-mediated repression. To resolve these discrepancies, we devised an experimental strategy permitting a more direct assessment of Tro operon function and regulation. We report that (i) apo-TroA has identical affinities for Zn2+ and Mn2+; (ii) the Tro transporter expressed in Escherichia coli imports Zn2+, Mn2+, and possibly iron; (iii) TroR represses transporter expression in E. coli at significantly lower concentrations of Zn2+ than of Mn2+; and (iv) TroR-mediated repression causes a disproportionately greater down-regulation of the transporter genes than of gpm. The much higher concentrations of Zn2+ than of Mn2+ in human body fluids suggests that Zn2+ is both the primary substrate and co-repressor of the permease in vivo. Our data also indicate that Gpm expression and, therefore, glycolysis would not be abrogated when T. pallidum encounters high Zn2+ levels.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA	University of Connecticut; University of Connecticut; University of Connecticut; Mayo Clinic; Case Western Reserve University; University of Kentucky	Hazlett, KRO (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, 263 Farmington Ave, Farmington, CT 06030 USA.				NIAID NIH HHS [AI25098, AI-10573, AI-26756] Funding Source: Medline; NIGMS NIH HHS [GM61748] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026756, F32AI010573, R29AI026756, R01AI025098, R37AI026756, R29AI025098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061748] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSHAKRA FR, 1989, FERTIL STERIL, V52, P307; Akins DR, 1997, J BACTERIOL, V179, P5076, DOI 10.1128/jb.179.16.5076-5086.1997; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Bearden SW, 1999, MOL MICROBIOL, V32, P403, DOI 10.1046/j.1365-2958.1999.01360.x; Benoit S, 2001, J BACTERIOL, V183, P4702, DOI 10.1128/JB.183.16.4702-4708.2001; Bhattacharyya-Pakrasi M, 2002, BIOCHEM SOC T, V30, P768, DOI 10.1042/bst0300768; Bremer H, 1996, ESCHERICHIA COLI SAL; Christianson DW, 1997, PROG BIOPHYS MOL BIO, V67, P217, DOI 10.1016/S0079-6107(97)88477-5; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; Deka RK, 1999, J BACTERIOL, V181, P4420, DOI 10.1128/JB.181.14.4420-4423.1999; Deka RK, 2002, J BIOL CHEM, V277, P41857, DOI 10.1074/jbc.M207402200; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; FENNO JC, 1995, MOL MICROBIOL, V15, P849, DOI 10.1111/j.1365-2958.1995.tb02355.x; Fetherston JD, 1999, MOL MICROBIOL, V32, P289, DOI 10.1046/j.1365-2958.1999.01348.x; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Gong SM, 2001, INFECT IMMUN, V69, P2829, DOI 10.1128/IAI.67.5.2829-2837.2001; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hantke K, 2001, BIOMETALS, V14, P239, DOI 10.1023/A:1012984713391; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; Hazlett KRO, 2002, METHOD ENZYMOL, V353, P140; Hazlett KRO, 2001, J EXP MED, V193, P1015, DOI 10.1084/jem.193.9.1015; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Horsburgh MJ, 2001, INFECT IMMUN, V69, P3744, DOI 10.1128/IAI.69.6.3744-3754.2001; Horsburgh MJ, 2002, MOL MICROBIOL, V44, P1269, DOI 10.1046/j.1365-2958.2002.02944.x; Jakubovics NS, 2001, MICROBIOL-SGM, V147, P1709, DOI 10.1099/00221287-147-7-1709; Jakubovics NS, 2000, MOL MICROBIOL, V38, P140, DOI 10.1046/j.1365-2958.2000.02122.x; Janulczyk R, 1999, MOL MICROBIOL, V34, P596, DOI 10.1046/j.1365-2958.1999.01626.x; Jimenez-Jimenez FJ, 1998, J NEURAL TRANSM, V105, P497, DOI 10.1007/s007020050073; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; Kehres DG, 2000, MOL MICROBIOL, V36, P1085, DOI 10.1046/j.1365-2958.2000.01922.x; Kehres DG, 2002, J BACTERIOL, V184, P3159, DOI 10.1128/JB.184.12.3159-3166.2002; Kitten T, 2000, INFECT IMMUN, V68, P4441, DOI 10.1128/IAI.68.8.4441-4451.2000; KOLENBRANDER PE, 1997, J BACTERIOL, V180, P290; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lombard M, 2000, J BIOL CHEM, V275, P27021; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; Molina JA, 1998, J NEURAL TRANSM, V105, P479, DOI 10.1007/s007020050071; Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x; Oetjen J, 2002, INFECT IMMUN, V70, P5706, DOI 10.1128/IAI.70.10.5706-5714.2002; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Patzer SI, 2000, J BIOL CHEM, V275, P24321, DOI 10.1074/jbc.M001775200; Patzer SI, 2001, J BACTERIOL, V183, P4806, DOI 10.1128/JB.183.16.4806-4813.2001; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Payne Shelley M., 1993, Trends in Microbiology, V1, P66, DOI 10.1016/0966-842X(93)90036-Q; PENDRAK ML, 1991, BIOL MET, V4, P41, DOI 10.1007/BF01135556; PETILLOT Y, 1993, BIOCHEM J, V296, P657, DOI 10.1042/bj2960657; Posey JE, 1999, P NATL ACAD SCI USA, V96, P10887, DOI 10.1073/pnas.96.19.10887; Que Q, 2000, MOL MICROBIOL, V35, P1454, DOI 10.1046/j.1365-2958.2000.01811.x; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Sarker MR, 1997, MOL MICROBIOL, V23, P410, DOI 10.1046/j.1365-2958.1997.t01-1-00190.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TRAMONT EC, 2000, PRINCIPLES PRACTICE, P2474; UMEYAMA T, 1986, FERTIL STERIL, V46, P494; VALLEE BL, 1959, PHYSIOL REV, V39, P443, DOI 10.1152/physrev.1959.39.3.443; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J	63	60	62	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20687	20694		10.1074/jbc.M300781200	http://dx.doi.org/10.1074/jbc.M300781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668673	hybrid			2022-12-25	WOS:000183230500033
J	Koh, DCY; Wong, SM; Liu, DX				Koh, DCY; Wong, SM; Liu, DX			Synergism of the 3 '-untranslated region and an internal ribosome entry site differentially enhances the translation of a plant virus coat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-BRONCHITIS VIRUS; CHLOROTIC RINGSPOT VIRUS; TRACT-BINDING PROTEIN; MESSENGER-RNA; POLIOVIRUS RNA; ENCEPHALOMYOCARDITIS VIRUS; INVITRO TRANSLATION; IN-VITRO; INITIATION; SEQUENCE	The use of internal ribosome entry sites (IRESs) is one of the unorthodox mechanisms exploited by viruses to initiate the translation of internal genes. Herein, we report a plant virus exploiting an IRES and its 3'-untranslated region (UTR) to express its internal genes, notably the 3'-proximal viral coat protein gene. Hibiscus chlorotic ringspot virus (HCRSV), a positive-strand nonpolyadenylated RNA virus, was demonstrated to harbor a unique 100-nucleotide (nt) IRES, located 124 nt upstream of the coat protein gene, that could function in wheat germ extract, rabbit reticulocyte lysate, and mammalian cells. In comparison with other known IRESs of picornaviruses and eukaryotic mRNAs, this 100-nt IRES is distinctively short and simple. The IRES activity was tested in homologous and heterologous bicistronic constructs, and the expression of the 3'-proximal gene was enhanced when the 3'-UTR was present. When the IRES element was bisected, each half still possessed IRES activity and could initiate internal translation on its own. Site-directed mutagenesis and deletion analyses revealed that the primary sequence within the 5' half was crucial for IRES activity, whereas the primary sequence of the second half and a GNRA motif were non-essential. To our knowledge, this is the first report describing a mechanism whereby an IRES, located in the 3' portion of the virus genome, co-operates with the 3'-UTR to enhance gene expression differentially.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Inst Mol Agrobiol, Singapore 117604, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore 637616, Singapore	National University of Singapore; National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wong, SM (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.		Wong, Sek-Man/I-2385-2012; Liu, Ding Xiang/A-2226-2011	Wong, Sek-Man/0000-0002-4620-3706; 				AGRANOVSKY A, 1999, MOL BIOL PLANT VIRUS, P99; Bergamini G, 2000, RNA, V6, P1781, DOI 10.1017/S1355838200001679; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; deQuinto SL, 1997, J VIROL, V71, P4171; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; Dorokhov YL, 2002, P NATL ACAD SCI USA, V99, P5301, DOI 10.1073/pnas.082107599; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLIE DR, 1992, NUCLEIC ACIDS RES, V20, P4631, DOI 10.1093/nar/20.17.4631; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Huang M, 2000, J VIROL, V74, P3149, DOI 10.1128/JVI.74.7.3149-3155.2000; Ito T, 1999, VIROLOGY, V254, P288, DOI 10.1006/viro.1998.9541; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ivanov PA, 1997, VIROLOGY, V232, P32, DOI 10.1006/viro.1997.8525; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Koh DCY, 2002, J VIROL, V76, P1144, DOI 10.1128/JVI.76.3.1144-1153.2002; Kolupaeva VG, 1996, RNA, V2, P1199; Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200; LIU DX, 1991, VIROLOGY, V184, P531, DOI 10.1016/0042-6822(91)90423-9; LIU DX, 1994, J VIROL, V68, P5772, DOI 10.1128/JVI.68.9.5772-5780.1994; Liu DX, 1997, J VIROL, V71, P1814, DOI 10.1128/JVI.71.3.1814-1820.1997; Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559; MATVEEVA OV, 1993, NUCLEIC ACIDS RES, V21, P1007, DOI 10.1093/nar/21.4.1007; Nateri AS, 2000, J VIROL, V74, P6269, DOI 10.1128/JVI.74.14.6269-6277.2000; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pilipenko EV, 2000, GENE DEV, V14, P2028; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Qu F, 2000, J VIROL, V74, P1085, DOI 10.1128/JVI.74.3.1085-1093.2000; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	32	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20565	20573		10.1074/jbc.M210212200	http://dx.doi.org/10.1074/jbc.M210212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663666	hybrid			2022-12-25	WOS:000183230500017
J	Sarkar, B; Lu, JY; Schneider, RJ				Sarkar, B; Lu, JY; Schneider, RJ			Nuclear import and export functions in the different isoforms of the AUF1/heterogeneous nuclear ribonucleoprotein protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP A1; ARGININE METHYLATION; BINDING-PROTEIN; IN-VIVO; TRANSCRIPTION; DOMAIN; SIGNAL; AUF1; IDENTIFICATION	The heterogeneous nuclear ribonucleoprotein D family of proteins also known as AUF1 consists of four isoforms implicated in both nuclear and cytoplasmic functions. The AUF1 proteins are largely nuclear but also are found in the cytoplasm and are thought to undergo nucleocytoplasmic shuttling. The nucleocytoplasmic distribution and potential shuttling activity of the individual AUF1 isoforms have not been previously studied in detail. Therefore, we characterized the nucleocytoplasmic transport of each of the heterogeneous nuclear ribonucleoprotein D/AUF1 isoforms. All four AUF1 proteins were found to undergo rapid nucleocytoplasmic shuttling in a manner that is transcription-independent, carrier-mediated, and energy-requiring. Nucleocytoplasmic shuttling of the AUF1 proteins is shown to utilize a novel arrangement of nuclear import and export signals. Mutagenesis of the AUF1 proteins and fusion of polypeptides to a green fluorescent protein reporter demonstrated that a nuclear import signal is located in the C-terminal domain of the protein and is found only in the two smaller isoforms. Further mapping demonstrated that nuclear export is facilitated by sequences in AUF1 exon 7 found in the C-terminal domain of the two larger AUF1 isoforms. A subset of AUF1 proteins are shown to directly interact in vitro using purified recombinant proteins and in vivo in the absence of RNA. These results suggest that nuclear import of AUF1 is facilitated by sequences found only in the two smaller isoforms and that nuclear export is facilitated by sequences (exon 7 and the C-terminal domain) found only in the two larger isoforms. This novel arrangement of signals might represent a mechanism to assure co-shuttling of a subset of AUF1 proteins that interact in a heterocomplex.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Schneider, RJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	schner01@popmail.med.nyu.edu			NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060428] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09161] Funding Source: Medline; NIGMS NIH HHS [GM60428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fuentes-Panana EM, 2000, J VIROL, V74, P8166, DOI 10.1128/JVI.74.17.8166-8175.2000; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Izaurralde E, 1998, RNA, V4, P351; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Kawamura H, 2002, J BIOL CHEM, V277, P2732, DOI 10.1074/jbc.M108477200; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1998, MOL CELL BIOL, V18, P4141, DOI 10.1128/MCB.18.7.4141; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Vautier D, 2001, J CELL SCI, V114, P1521; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weighardt F, 1999, J CELL SCI, V112, P1465; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	46	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20700	20707		10.1074/jbc.M301176200	http://dx.doi.org/10.1074/jbc.M301176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668672	hybrid			2022-12-25	WOS:000183230500035
J	Furuta, T; Takemura, H; Liao, ZY; Aune, GJ; Redon, C; Sedelnikova, OA; Pilch, DR; Rogakou, EP; Celeste, A; Chen, HT; Nussenzweig, A; Aladjem, MI; Bonner, WM; Pommier, Y				Furuta, T; Takemura, H; Liao, ZY; Aune, GJ; Redon, C; Sedelnikova, OA; Pilch, DR; Rogakou, EP; Celeste, A; Chen, HT; Nussenzweig, A; Aladjem, MI; Bonner, WM; Pommier, Y			Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; S-PHASE; PROTEIN-KINASE; 7-HYDROXYSTAUROSPORINE UCN-01; GENOMIC INSTABILITY; DAMAGE; REPAIR; CYTOTOXICITY; CAMPTOTHECIN; RADIATION	DNA double-strand breaks originating from diverse causes in eukaryotic cells are accompanied by the formation of phosphorylated H2AX (gammaH2AX) foci. Here we show that gammaH2AX formation is also a cellular response to topoisomerase I cleavage complexes known to induce DNA double-strand breaks during replication. In HCT116 human carcinoma cells exposed to the topoisomerase I inhibitor camptothecin, the resulting gammaH2AX formation can be prevented with the phosphatidylinositol 3-OH kinase-related kinase inhibitor wortmannin; however, in contrast to ionizing radiation, only camptothecin-induced gammaH2AX formation can be prevented with the DNA replication inhibitor aphidicolin and enhanced with the checkpoint abrogator 7-hydroxystaurosporine. This gammaH2AX formation is suppressed in ATR ( ataxia telangiectasia and Rad3-related) deficient cells and markedly decreased in DNA-dependent protein kinase-deficient cells but is not abrogated in ataxia telangiectasia cells, indicating that ATR and DNA-dependent protein kinase are the kinases primarily involved in gammaH2AX formation at the sites of replication-mediated DNA double-strand breaks. Mre11- and Nbs1-deficient cells are still able to form gammaH2AX. However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin. These results demonstrate a conserved gammaH2AX response for double-strand breaks induced by replication fork collision. gammaH2AX foci are required for recruiting repair and checkpoint protein complexes to the replication break sites.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Rm 5068A, Bethesda, MD 20892 USA.	pommier@nih.gov	Aune, Gregory/I-5895-2015; Aladjem, Mirit/G-2169-2010	Aune, Gregory/0000-0002-2750-6461; Aladjem, Mirit/0000-0002-1875-3110; Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	NATIONAL CANCER INSTITUTE [ZIABC010411, Z01BC010411, Z01BC006150, ZIABC006150] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Barnett AA, 1996, LANCET, V347, P1613; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Busby EC, 2000, CANCER RES, V60, P2108; Caspari T, 2002, CURR BIOL, V12, pR105, DOI 10.1016/S0960-9822(02)00673-5; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; HOLM C, 1989, CANCER RES, V49, P6365; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; HSIANG YH, 1989, CANCER RES, V49, P5077; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8241, DOI 10.1073/pnas.131009198; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pommier Y, 1994, Adv Pharmacol, V29B, P73; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; POWIS G, 1994, CANCER RES, V54, P2419; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SMERDON MJ, 1983, BIOCHEMISTRY-US, V22, P3516, DOI 10.1021/bi00283a033; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Stucky-Marshall L, 1999, CANCER NURS, V22, P212, DOI 10.1097/00002820-199906000-00004; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Takimoto C H, 1997, Oncology (Williston Park), V11, P1635; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; TSAO YP, 1993, CANCER RES, V53, P5908; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; Yu Q, 2002, CANCER RES, V62, P5743; Zhu Q, 1997, ORAL ONCOL, V33B, P29, DOI 10.1016/S0964-1955(96)00038-3	71	369	387	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20303	20312		10.1074/jbc.M300198200	http://dx.doi.org/10.1074/jbc.M300198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660252	hybrid			2022-12-25	WOS:000183078000093
J	Ghiselli, G; Coffee, N; Munnery, CE; Koratkar, R; Siracusa, LD				Ghiselli, G; Coffee, N; Munnery, CE; Koratkar, R; Siracusa, LD			The cohesin SMC3 is a target the for beta-catenin/TCF4 transactivation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; BASEMENT-MEMBRANE; CDNA CLONING; PROTEIN; COMPLEX; EXPRESSION; TCF; OVEREXPRESSION	The structural maintenance of chromosome protein SMC3 is a component of the cohesin complex that mediates sister chromatid cohesion and segregation in prokaryotes and eukaryotes. It is also present extracellularly in the form of a chondroitin sulfate proteoglycan known as bamacan. We have found previously that SMC3 expression is elevated in a large fraction of human colon carcinomas. The additional finding that the protein is significantly increased in the intestinal polyps of Apc(Min/+) mice has led us to hypothesize that SMC3 expression is linked to activation of the APC/beta-catenin/ TCF4 pathway. The immunohistochemical analysis of colon adenocarcinomas from clinical specimens revealed that beta-catenin and SMC3 antigens co- localize with maximal stain intensity within the transformed areas. Cloning and sequencing of 1578 bp of the human SMC3 promoter unveiled the presence of seven putative consensus sequences for beta-catenin/TCF4 binding, two of which are conserved in the mouse Smc3 promoter. Transient transfection experiments in HCT116 and SW480 human colon carcinoma cells using deletion and mutated promoter constructs in luciferase reporter vectors confirmed that the putative sites, the first located at -48 bp and the second located at -701 bp, are susceptible to beta-catenin/TCF4 transactivation. Co-transfection with a beta-catenin expression vector enhanced the promoter activity whereas E-cadherin had the opposite effect. Binding of beta-catenin/TCF4 complexes from SW480 nuclear extracts to these sequences was confirmed by electrophoretic shift and supershift mobility assays. Altogether these results are consistent with the idea that the beta-catenin/TCF4 transactivation pathway contributes to SMC3 overexpression in intestinal tumorigenesis.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Ghiselli, G (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Rm JAH 371,1020 Locust St, Philadelphia, PA 19107 USA.	giancarlo.ghiselli@mail.tju.edu			NCI NIH HHS [R01 CA82290, R01 CA72027, R01 CA82290-03S1] Funding Source: Medline; PHS HHS [T32-09678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072027, R01CA082290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CONOVER W. J, 1980, PRACTICAL NONPARAMET; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; Erickson AC, 2001, MATRIX BIOL, V19, P769, DOI 10.1016/S0945-053X(00)00126-8; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Ghiselli G, 1999, J BIOL CHEM, V274, P17384, DOI 10.1074/jbc.274.24.17384; Ghiselli G, 2000, J BIOL CHEM, V275, P20235, DOI 10.1074/jbc.C000213200; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Inomata M, 1996, CANCER RES, V56, P2213; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; SAMURA I, 2001, J CELL BIOL, V151, P749; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433; Xu LF, 2000, GENE DEV, V14, P585; Yamada T, 2000, CANCER RES, V60, P4761; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang XB, 2001, CANCER RES, V61, P6050	50	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20259	20267		10.1074/jbc.M209511200	http://dx.doi.org/10.1074/jbc.M209511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651860	hybrid			2022-12-25	WOS:000183078000088
J	Kokura, K; Kim, H; Shinagawa, T; Khan, MM; Nomura, T; Ishii, S				Kokura, K; Kim, H; Shinagawa, T; Khan, MM; Nomura, T; Ishii, S			The Ski-binding protein C184M negatively regulates tumor growth factor-beta signaling by sequestering the Smad proteins in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; SNON; MAD; RETROVIRUSES; ONCOPROTEIN; ANTAGONIST; ONCOGENE; GENE	Ski is a transcriptional co-repressor and is involved in the negative regulation of tumor growth factor-beta (TGF-beta) signaling. To understand more fully the role of Ski in TGF-beta signaling, we searched for novel Ski-interacting proteins. The identified C184M protein consists of 189 amino acids and contains the leucine-rich region. An association between Ski and C184M involving the leucine-rich region of C184M and the C-terminal coiled-coil motif of Ski was confirmed by glutathione S-transferase pull-down and immunoprecipitation assays. The C184M protein is located in the cytosol, and the C184M and Ski signals are co-localized in the cytoplasm when C184M was co-expressed with Ski in CV-1 cells. The cytoplasmic C184M-Ski complex inhibited the nuclear translocation of Smad2. Consistent with this, the activity of promoter containing the Smad-binding sites was repressed by C184M, and the TGF-beta-induced growth inhibition of mink lung Mv1Lu cells was attenuated by the ectopic expression of C184M. Thus, C184M inhibits TGF-beta signaling in concert with Ski. In hepatocytes, which express significant levels of C184M, the Ski signals were found only in the cytoplasm, supporting the notion that C184M forms a complex with Ski in the cytosol.	RIKEN Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Ishii, S (corresponding author), RIKEN Tsukuba Inst, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macias-Silva M, 2002, J BIOL CHEM, V277, P28483, DOI 10.1074/jbc.M202403200; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Reed JA, 2001, CANCER RES, V61, P8074; Sakuma-Takagi M, 1999, BIOCHEM BIOPH RES CO, V263, P737, DOI 10.1006/bbrc.1999.1462; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	37	28	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20133	20139		10.1074/jbc.M210855200	http://dx.doi.org/10.1074/jbc.M210855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646588	hybrid			2022-12-25	WOS:000183078000072
J	Miinalainen, IJ; Chen, ZJ; Torkko, JM; Pirila, PL; Sormunen, RT; Bergmann, U; Qin, YM; Hiltunen, JK				Miinalainen, IJ; Chen, ZJ; Torkko, JM; Pirila, PL; Sormunen, RT; Bergmann, U; Qin, YM; Hiltunen, JK			Characterization of 2-enoyl thioester reductase from mammals - An ortholog of Ybr026p/Mrf1 ' p of the yeast mitochondrial fatty acid synthesis type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; LIPOIC ACID; NEUROSPORA-CRASSA; 2,4-DIENOYL-COA REDUCTASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; RAT-LIVER; GENE; SYNTHASE	A data base search with YBR026c/MRF1', which encodes trans-2-enoyl thioester reductase of the intramitochondrial fatty acid synthesis (FAS) type II in yeast (Torkko, J.M., Koivuranta, K.T., Miinalainen, I.J., Yagi, A.I., Schmitz, W., Kastaniotis, A.J., Airenne, T.T., Gurvitz, A., and Hiltunen, K.J. (2001) Mol. Cell. Biol. 21, 6243-6253), revealed the clone AA393871 (HsNrbf-1, nuclear receptor binding factor 1) in human EST data bank. Expression of HsNrbf-1, tagged C-terminally with green fluorescent protein, in HeLa cells, resulted in a punctated fluorescence signal, superimposable with the MitoTracker Red dye. Wild-type polypeptide was immunoisolated from the extract of bovine heart mitochondria. Recombinant HsNrbf-1p reduces trans-2-enoyl-CoA to acyl-CoA with chain length from C6 to C16 in an NADPH-dependent manner with preference to medium chain length substrate. Furthermore, expression of HsNRBF-1 in the ybr026cDelta yeast strain restored mitochondrial respiratory function allowing growth on glycerol. These findings provide evidence that Nrbf-1ps act as a mitochondrial 2-enoyl thioester reductase, and mammalian cells may possess bacterial type fatty acid synthetase (FAS type II) in mitochondria, in addition to FAS type I in the cytoplasm.	Univ Oulu, Dept Biochem, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Ruhr University Bochum	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, Bioctr Oulu, PO 3000, FIN-90014 Oulu, Finland.	Kalervo.Hiltunen@oulu.fi		Miinalainen, Ilkka/0000-0002-3922-3442				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; CAUGHEY I, 1982, EUR J BIOCHEM, V123, P553; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CVETANOVIC M, 1985, BIOCHEM J, V227, P49, DOI 10.1042/bj2270049; Das AK, 2000, J BIOL CHEM, V275, P24333, DOI 10.1074/jbc.M001168200; De Nys K, 2001, BBA-MOL CELL BIOL L, V1533, P66, DOI 10.1016/S1388-1981(01)00141-X; DOMMES V, 1984, J BIOL CHEM, V259, P1781; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HARINGTON A, 1994, EMBO J, V13, P5531, DOI 10.1002/j.1460-2075.1994.tb06890.x; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Helander HM, 1997, GENOMICS, V46, P112, DOI 10.1006/geno.1997.5004; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Masuda N, 1998, GENE, V221, P225, DOI 10.1016/S0378-1119(98)00461-2; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; NEAT CE, 1981, BIOCHEM J, V196, P149, DOI 10.1042/bj1960149; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Plesofsky N, 2000, BBA-MOL CELL RES, V1495, P223, DOI 10.1016/S0167-4889(99)00170-6; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SANADI DR, 1967, METHODS ENZYMOLOGY 4, V10, P297; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; SCHWEIZER E, 1970, P NATL ACAD SCI USA, V67, P660, DOI 10.1073/pnas.67.2.660; Smith J.A., 2000, CURRENT PROTOCOLS MO; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Triepels R, 1999, J INHERIT METAB DIS, V22, P163, DOI 10.1023/A:1005402020569; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Wanders RJA, 2000, CELL BIOCHEM BIOPHYS, V32, P89, DOI 10.1385/CBB:32:1-3:89; Wharton DC., 1967, METHOD ENZYMOL, P245; YAMAZOE M, 1994, J BIOL CHEM, V269, P15244; Ylitalo K, 2001, BBA-BIOENERGETICS, V1504, P329, DOI 10.1016/S0005-2728(00)00261-9	50	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20154	20161		10.1074/jbc.M302851200	http://dx.doi.org/10.1074/jbc.M302851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654921	hybrid			2022-12-25	WOS:000183078000074
J	Nalaskowski, MM; Bertsch, U; Fanick, W; Stockebrand, MC; Schmale, H; Mayr, GW				Nalaskowski, MM; Bertsch, U; Fanick, W; Stockebrand, MC; Schmale, H; Mayr, GW			Rat inositol 1,4,5-trisphosphate 3-kinase C is enzymatically specialized for basal cellular inositol trisphosphate phosphorylation and shuttles actively between nucleus and cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEPTOMYCIN-B; PHOSPHOLIPASE-C; IN-VIVO; PROTEIN; EXPRESSION; BINDING; CLONING; EXPORT; HEXAKISPHOSPHATE; IDENTIFICATION	The calcium-liberating second messenger inositol 1,4,5-trisphosphate (Ins(1,4,5) P-3) is converted to inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5) P-4) by Ins(1,4,5) P-3 3-kinases (IP3Ks) that add a fourth phosphate group to the 3-position of the inositol ring. Two isoforms of IP3Ks ( named A and B) from different vertebrate species have been well studied. Recently the cloning and examination of a human full-length cDNA encoding a novel isoform, termed human IP3K-C (HsIP3K-C), has been reported. In the present study we report the cloning of a full-length cDNA encoding a rat homologue of HsIP3K-C with a unique mRNA expression pattern, which differs remarkably from the tissue distribution of HsIP3K-C. Of the rat tissues examined, rat IP3K-C ( RnIP3K-C) is mainly present in heart, brain, and testis and shows the strongest expression in an epidermal tissue, namely tongue epithelium. RnIP3K-C has a calculated molecular mass of similar to74.5 kDa and shows an overall identity of similar to75% with HsIP3K-C. A bacterially expressed, enzymatically active and Ca2+-calmodulin-regulated fragment of this isoform displays remarkable enzymatic properties like a very low K-m for Ins(1,4,5) P-3 (similar to0.2 muM), substrate inhibition by high concentrations of Ins( 1,4,5) P-3, allosteric product activation by Ins( 1,3,4,5) P-4 in absence of Ca2+-calmodulin (K-a(app) 0.52 muM), and the ability to efficiently phosphorylate a second InsP(3) substrate, inositol 2,4,5-trisphosphate, to inositol 2,4,5,6-tetrakisphosphate in the presence of Ins( 1,3,4,5) P-4. Furthermore, the RnIP3K-C fused with a fluorescent protein tag is actively transported into and out of the nucleus when transiently expressed in mammalian cells. A leucine-rich nuclear export signal and an uncharacterized nuclear import activity are localized in the N-terminal domain of the protein and determine its nucleocytoplasmic shuttling. These findings point to a particular role of RnIP3K-C in nuclear inositol trisphosphate phosphorylation and cellular growth.	Univ Hamburg, Hosp Eppendorf, Inst Cellular Signal Transduct, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Inst Cell Biochem & Clin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Mayr, GW (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	mayr@uke.uni-hamburg.de						BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bertsch U, 1999, GENE, V228, P61, DOI 10.1016/S0378-1119(99)00018-9; Bertsch U, 2000, J BIOL CHEM, V275, P1557, DOI 10.1074/jbc.275.3.1557; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Cocco L, 2001, BBA-MOL CELL BIOL L, V1530, P1, DOI 10.1016/S1388-1981(00)00169-4; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dewaste V, 2002, BIOCHEM BIOPH RES CO, V291, P400, DOI 10.1006/bbrc.2002.6456; Dewaste V, 2000, BIOCHEM J, V352, P343, DOI 10.1042/0264-6021:3520343; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUSE AH, 1995, J CHROMATOGR B, V672, P189, DOI 10.1016/0378-4347(95)00219-9; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MAYR GW, 1992, CARBOHYD RES, V234, P247, DOI 10.1016/0008-6215(92)85052-2; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MAYR GW, 1990, METHODS INOSITIDE RE, P83; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; ROSS TS, 1992, J BIOL CHEM, V267, P19924; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Segel I.H., 1975, ENZYME KINETICS; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	48	30	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19765	19776		10.1074/jbc.M211059200	http://dx.doi.org/10.1074/jbc.M211059200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649294	hybrid			2022-12-25	WOS:000183078000027
J	Townson, SM; Dobrzycka, KM; Lee, AV; Air, M; Deng, WL; Kang, KY; Jiang, SM; Kioka, N; Michaelis, K; Oesterreich, S				Townson, SM; Dobrzycka, KM; Lee, AV; Air, M; Deng, WL; Kang, KY; Jiang, SM; Kioka, N; Michaelis, K; Oesterreich, S			SAFB2, a new scaffold attachment factor homolog and estrogen receptor corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROFOLATE-REDUCTASE; BINDING-PROTEIN; HET/SAF-B; BIDIRECTIONAL PROMOTER; NUCLEAR-BODIES; G(1) CONTROL; GROWTH; BREAST; FAMILY; GENE	We have characterized previously the nuclear matrix protein/scaffold attachment factor (SAFB) as an estrogen receptor corepressor and as a potential tumor suppressor gene in breast cancer. A search of the human genome for other potential SAFB family members revealed that KIAA00138 (now designated as SAFB2) has high homology to SAFB (now designated as SAFB1). SAFB1 and SAFB2 are mapped adjacent to each other on chromosome 19p13.3 and are arranged in a bidirectional divergent configuration (head to head), being separated by a short(<500 bp) GC-rich intergenic region that can function as a bidirectional promoter. SAFB1 and SAFB2 share common functions but also have unique properties. As shown previously for SAFB1, SAFB2 functions as an estrogen receptor corepressor, and its overexpression results in inhibition of proliferation. SAFB1 and SAFB2 interact directly through a C-terminal domain, resulting in additive repression activity. They are coexpressed in a number of tissues, but unlike SAFB1, which is exclusively nuclear, SAFB2 is found in the cytoplasm as well as the nucleus. Consistent with its cytoplasmic localization, we detected an interaction between SAFB2 and vinexin, a protein involved in linking signaling to the cytoskeleton. Our findings suggest that evolutionary duplication of the SAFB gene has allowed it to retain crucial functions, but also to gain novel functions in the cytoplasm and/or nucleus.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Kyoto Univ, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan	Baylor College of Medicine; Baylor College of Medicine; Kyoto University	Oesterreich, S (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,BCM 600, Houston, TX 77030 USA.	steffio@breastcenter.tmc.edu		Lee, Adrian/0000-0001-9917-514X; Kioka, Noriyuki/0000-0002-2708-537X	NCI NIH HHS [R01 CA-97213, K01 CA-77674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA077674, R01CA097213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achaz G, 2001, MOL BIOL EVOL, V18, P2280, DOI 10.1093/oxfordjournals.molbev.a003774; Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baylin SB, 1998, ADV CANCER RES, V72, P141; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chiodi I, 2000, J CELL SCI, V113, P4043; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; DuPont BR, 1997, CYTOGENET CELL GENET, V79, P284, DOI 10.1159/000134744; Force A, 1999, GENETICS, V151, P1531; FUJII H, 1992, FEBS LETT, V314, P33, DOI 10.1016/0014-5793(92)81455-U; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gunning P, 1998, ANNU REV CELL DEV BI, V14, P339, DOI 10.1146/annurev.cellbio.14.1.339; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jepsen K, 2002, J CELL SCI, V115, P689; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nadeau JH, 1997, GENETICS, V147, P1259; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Oesterreich S, 2000, EUR J CANCER, V36, pS43; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; OESTERREICH S, 1993, CANCER RES, V53, P4443; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; Ohno S., 1970, EVOLUTION GENE DUPLI; Paggi MG, 2001, CANCER RES, V61, P4651; Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Townson SM, 2000, CLIN CANCER RES, V6, P3788; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WALSH JB, 1995, GENETICS, V139, P421; Weighardt F, 1999, J CELL SCI, V112, P1465; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; YEE D, 1989, J BIOL CHEM, V264, P21439; Zamir I, 1996, MOL CELL BIOL, V16, P5458	60	67	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20059	20068		10.1074/jbc.M212988200	http://dx.doi.org/10.1074/jbc.M212988200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660241	hybrid			2022-12-25	WOS:000183078000063
J	Chalmers, S; Nicholls, DG				Chalmers, S; Nicholls, DG			The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; FREE CA-2+ CONCENTRATION; HEART-MITOCHONDRIA; CYCLOSPORINE-A; CYTOCHROME-C; DEHYDROGENASE-ACTIVITY; FOREBRAIN ISCHEMIA; RAT HIPPOCAMPUS; REDOX STATE; CA2+	Three sequential phases of mitochondrial calcium accumulation can be distinguished: matrix dehydrogenase regulation, buffering of extramitochondrial free calcium, and finally activation of the permeability transition. Relationships between these phases, free and total matrix calcium concentration, and phosphate concentration are investigated in rat liver and brain mitochondria. Slow, continuous calcium infusion is employed to avoid transient bioenergetic consequences of bolus additions. Liver and brain mitochondria undergo permeability transitions at precise matrix calcium loads that are independent of infusion rate. Cytochrome c release precedes the permeability transition. Cyclosporin A enhances the loading capacity in the presence or absence of acetoacetate. A remarkably constant free matrix calcium concentration, in the range 1-5 muM as monitored by matrix-loaded fura2-FF, was observed when total matrix calcium was increased from 10 to at least 500 nmol of calcium/mg of protein. Increasing phosphate decreased both the free matrix calcium and the matrix calcium-loading capacity. Thus the permeability transition is not triggered by a critical matrix free calcium concentration. The rate of hydrogen peroxide detection by Amplex Red decreased during calcium infusion arguing against a role for oxidative stress in permeability pore activation in this model. A transition between a variable and buffered matrix free calcium concentration occurred at 10 nmol of total matrix calcium/mg protein. The solubility product of amorphous Ca-3(PO4)(2) is consistent with the observed matrix free calcium concentration, and the matrix pH is proposed to play the major role in maintaining the low matrix free calcium concentration.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Nicholls, DG (corresponding author), Buck Inst Age Res, Novato, CA 94945 USA.		Chalmers, Susan/C-1392-2009; NICHOLLS, DAVID G/K-4300-2012	Chalmers, Susan/0000-0002-8073-7576; 				AL N, 1986, BIOCHEM J, V239, P31; ALLEN SP, 1992, J MOL CELL CARDIOL, V24, P765, DOI 10.1016/0022-2828(92)93390-6; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; COLL KE, 1982, J BIOL CHEM, V257, P8696; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; DAVIS MH, 1987, BIOCHEM BIOPH RES CO, V149, P40, DOI 10.1016/0006-291X(87)91602-0; ERECINSKA M, 1992, CAN J PHYSIOL PHARM, V70, pS190, DOI 10.1139/y92-262; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GRIFFITHS T, 1982, NEUROSCI LETT, V30, P329, DOI 10.1016/0304-3940(82)90421-9; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HANSFORD RG, 1982, J BIOENERG BIOMEMBR, V14, P361, DOI 10.1007/BF00743064; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Kramer R, 1998, EXP PHYSIOL, V83, P259, DOI 10.1113/expphysiol.1998.sp004111; LARSEN MJ, 1986, ARCH ORAL BIOL, V31, P757, DOI 10.1016/0003-9969(86)90008-7; LARSEN MJ, 1985, CALCIFIED TISSUE INT, V37, P189, DOI 10.1007/BF02554840; LEHNINGER AL, 1967, ADV ENZYMOL RAMB, V29, P259; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LUKACS GL, 1988, FEBS LETT, V229, P219, DOI 10.1016/0014-5793(88)80831-7; LUKACS GL, 1987, BIOCHEM J, V248, P609, DOI 10.1042/bj2480609; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; NICHOLLS DG, 1980, BIOCHEM J, V186, P833, DOI 10.1042/bj1860833; NICHOLLS DG, 1978, BIOCHEM J, V176, P463, DOI 10.1042/bj1760463; NICHOLLS DG, 1980, BIOCHEM J, V188, P113, DOI 10.1042/bj1880113; Pitter JG, 2002, CELL CALCIUM, V31, P97, DOI 10.1054/ceca.2001.0264; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; WUTHIER RE, 1985, CALCIFIED TISSUE INT, V37, P401, DOI 10.1007/BF02553710; Zago EB, 2000, FEBS LETT, V478, P29, DOI 10.1016/S0014-5793(00)01815-9; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	46	300	307	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19062	19070		10.1074/jbc.M212661200	http://dx.doi.org/10.1074/jbc.M212661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12660243	hybrid			2022-12-25	WOS:000182932200046
J	Weiss, MM; Kuipers, EJ; Postma, C; Snijders, AM; Siccama, I; Pinkel, D; Westerga, J; Meuwissen, SGM; Albertson, DG; Meijer, GA				Weiss, MM; Kuipers, EJ; Postma, C; Snijders, AM; Siccama, I; Pinkel, D; Westerga, J; Meuwissen, SGM; Albertson, DG; Meijer, GA			Genomic profiling of gastric cancer predicts lymph node status and survival	ONCOGENE			English	Article						gastric cancer; genomic profiling; survival; microarray CGH	DNA COPY NUMBER; HELICOBACTER-PYLORI; GENETIC ALTERATIONS; INTESTINAL-TYPE; CARCINOMA; HYBRIDIZATION; DISSECTION; AMPLICON; SUBTYPES; GAINS	Gastric carcinogenesis is driven by an accumulation of genetic changes that to a large extent occur at the chromosomal level. We analysed the patterns of chromosomal instability in 35 gastric carcinomas and their clinical correlations. With microarray competitive genomic hybridization, genomewide chromosomal copy number changes can be studied with high resolution and sensitivity. A genomewide scanning array with 2275 BAC and PI clones spotted in triplicate was used. This array provided an average resolution of 1.4 Mb across the genome. Patterns of chromosomal aberrations were analysed by hierarchical cluster analysis of the normalized 1092 tumour to normal fluorescence ratios of all clones, and cluster membership was correlated to clinicopathological data including survival. Hierarchical cluster analysis revealed three groups with different genomic profiles that correlated significantly with lymph node status (P = 0.02). Moreover, gastric cancer cases from cluster 3 showed a significantly better prognosis than those from clusters I and 2 (P = 0.02). Genomic profiling of gastric adenocarcinomas based on microarray analysis of chromosomal copy number changes predicted lymph node status and survival. The possibility to discriminate between patients with a high risk of lymph node metastasis could clinically be helpful for selecting patients for extended lymph node resection.	Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Gastroenterol, NL-1007 MB Amsterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; KiQ Ltd, Amsterdam, Netherlands; Slotervaart Hosp, Dept Pathol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; University of California System; University of California San Francisco; Slotervaart Hospital	Meijer, GA (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	ga.meijer@vumc.nl	Kuipers, Ernst J/H-3293-2019	Kuipers, Ernst J/0000-0002-0633-3098; Meijer, Gerrit/0000-0003-0330-3130; Weiss, Marjan M./0000-0002-0936-1406				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Bonenkamp JJ, 1999, NEW ENGL J MED, V340, P908, DOI 10.1056/NEJM199903253401202; Cuschieri A, 1999, BRIT J CANCER, V79, P1522, DOI 10.1038/sj.bjc.6690243; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Guan XY, 2000, CANCER GENET CYTOGEN, V123, P27, DOI 10.1016/S0165-4608(00)00306-X; HAUSEN AZ, 2001, GASTROENTEROLOGY, V121, P612; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen MAJA, 1998, J PATHOL, V186, P356; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Koizumi Y, 1997, CLIN CANCER RES, V3, P1067; Kokkola A, 1998, CANCER GENET CYTOGEN, V107, P32, DOI 10.1016/S0165-4608(98)00092-2; Kokkola A, 1997, GENE CHROMOSOME CANC, V20, P38, DOI 10.1002/(SICI)1098-2264(199709)20:1<38::AID-GCC6>3.0.CO;2-A; Koo SH, 2000, CANCER GENET CYTOGEN, V117, P97, DOI 10.1016/S0165-4608(99)00152-1; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SASAKO M, 1995, BRIT J SURG, V82, P346, DOI 10.1002/bjs.1800820321; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sipponen P, 1998, ALIMENT PHARM THER, V12, P61, DOI 10.1111/j.1365-2036.1998.00005.x; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SUDBERY P, 2002, HUMAN MOL GENETICS; van Dekken H, 2001, AM J PATHOL, V158, P1961, DOI 10.1016/S0002-9440(10)64666-4; van Grieken NCT, 2000, J PATHOL, V192, P301, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH697&gt;3.0.CO;2-F; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varis A, 2002, CANCER RES, V62, P2625; VISSER O, 2001, INCIDENCE CANC NETHE; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243; WEISS MM, 2003, IN PRESS J PATHOL; Wu MS, 2001, GENE CHROMOSOME CANC, V30, P80, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1062>3.0.CO;2-R; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4	34	90	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1872	1879		10.1038/sj.onc.1206350	http://dx.doi.org/10.1038/sj.onc.1206350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660823				2022-12-25	WOS:000181678200014
J	McIlhargey, TL; Yang, YY; Wong, H; Hill, JS				McIlhargey, TL; Yang, YY; Wong, H; Hill, JS			Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHO-IODOSOBENZOIC ACID; SODIUM DODECYL-SULFATE; IN-VIVO EVIDENCE; PANCREATIC LIPASE; GENE FAMILY; SYNTHETIC FRAGMENTS; CHIMERIC LIPASE; PEPTIDE-BONDS; ACTIVATION; DOMAIN	To localize the regions of lipoprotein lipase (LPL) that are responsive to activation by apoC-II, an apoC-II peptide fragment was cross-linked to bovine LPL. Following chemical hydrolysis and peptide separation, a specific fragment of LPL ( residues 65-86) was identified to interact with apoC-II. The fragment contains regions of amino acid sequence dissimilarity compared with hepatic lipase (HL), a member of the same gene family that is not responsive to apoC-II. Using site-directed mutagenesis, two sets of chimeras were created in which the two regions of human LPL ( residues 65-68 and 73-79) were exchanged with the corresponding human HL sequences. The chimeras consisted of an HL backbone with the suspected LPL regions replacing the corresponding HL sequences either individually (HLLPL-(65-68) and HLLPL-(73-79)) or together (HLLPLD). Similarly, LPL chimeras were created in which the candidate regions were replaced with the corresponding HL sequences (LPLHL-(77-80), LPLHL-(85-91), and LPLHLD). Using a synthetic triolein substrate, the lipase activity of the purified enzymes was measured in the presence and absence of apoC-II. Addition of apoC-II to HLLPL-(65-68) and HLLPL-(73-79) did not significantly alter their enzyme activity. However, the activity of HLLPLD increased similar to5-fold in the presence of apoC-II compared with an increase in native LPL activity of similar to11-fold. Addition of apoC-II to LPLHL-(77-80) resulted in similar to10-fold activation, whereas only similar to6- and similar to4-fold activation of enzyme activity was observed in LPLHL-(85-91) and LPLHLD, respectively. In summary, our results have identified 11 amino acid residues in the N-terminal domain of LPL (residues 65-68 and 73-79) that appear to act cooperatively to enable substantial activation of human LPL by apoC-II.	Univ British Columbia, McDonald Res Labs, iCAPTUR4E Ctr,Hlth Heart Program, Dept Pathol & Lab Med,St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V6Z 1Y6, Canada; Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of California System; University of California Los Angeles	Hill, JS (corresponding author), Univ British Columbia, McDonald Res Labs, iCAPTUR4E Ctr,Hlth Heart Program, Dept Pathol & Lab Med,St Pauls Hosp, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jshill@interchange.ubc.ca			NHLBI NIH HHS [HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amar MJA, 1998, J LIPID RES, V39, P2436; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BALASUBRAMANIAM A, 1986, BIOCHEM BIOPH RES CO, V137, P1041, DOI 10.1016/0006-291X(86)90330-X; Bates PA, 1999, PROTEINS, P47; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; CHAILLAN C, 1992, BIOCHEM BIOPH RES CO, V184, P206, DOI 10.1016/0006-291X(92)91179-T; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Q, 1990, BIOCHEM J, V269, P403, DOI 10.1042/bj2690403; CLARKE AR, 1985, BIOCHIM BIOPHYS ACTA, V827, P358, DOI 10.1016/0167-4838(85)90220-1; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DICHEK HL, 1993, J LIPID RES, V34, P1393; Dugi KA, 2000, ARTERIOSCL THROM VAS, V20, P793, DOI 10.1161/01.ATV.20.3.793; EGLOFF MP, 1995, PROTEIN SCI, V4, P44; FONTANA A, 1981, BIOCHEMISTRY-US, V20, P6997, DOI 10.1021/bi00527a034; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAVEL RJ, 1970, CIRC RES, V27, P595, DOI 10.1161/01.RES.27.4.595; HIDE WA, 1992, J LIPID RES, V33, P167; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; KINNUNEN PKJ, 1977, P NATL ACAD SCI USA, V74, P4848, DOI 10.1073/pnas.74.11.4848; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; MacRaild CA, 2001, BIOCHEMISTRY-US, V40, P5414, DOI 10.1021/bi002821m; MAHONEY WC, 1979, BIOCHEMISTRY-US, V18, P3810, DOI 10.1021/bi00584a026; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Olivecrona G, 1997, ARTERIOSCL THROM VAS, V17, P1545, DOI 10.1161/01.ATV.17.8.1545; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; PETERSON J, 1992, J LIPID RES, V33, P1165; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; Shen Y, 2002, J BIOL CHEM, V277, P4334, DOI 10.1074/jbc.M105421200; Smith L C, 1980, Ann N Y Acad Sci, V348, P213; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Storjohann R, 2000, BBA-MOL CELL BIOL L, V1486, P253, DOI 10.1016/S1388-1981(00)00062-7; WANG CS, 1991, PROG LIPID RES, V30, P253, DOI 10.1016/0163-7827(91)90022-W; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1994, J BIOL CHEM, V269, P10319; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; Zambon A, 2000, J LIPID RES, V41, P2094	45	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23027	23035		10.1074/jbc.M300315200	http://dx.doi.org/10.1074/jbc.M300315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682050	hybrid			2022-12-25	WOS:000183503900110
J	Song, ZY; Yao, XB; Wu, M				Song, ZY; Yao, XB; Wu, M			Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CELL-DIVISION; PROMOTES APOPTOSIS; CASPASE ACTIVATION; INHIBITOR; PROTEIN; GENE; XIAP; EXPRESSION; SPINDLE	Survivin is a member of the inhibitor of apoptosis protein (IAP) family that has been implicated in both apoptosis inhibition and cell cycle control. However, its inhibitory mechanism and subcellular localization remain controversial. In this report, we provided evidence for the first time that Survivin physically interacts with Smac/DIABLO both in vitro and in vivo. A point mutation (D71R) in the baculovirus IAP repeat motif and a C-terminal deletion mutant (Surv-BIR) of Survivin fail to bind to Smac/DIABLO and abrogate its ability to inhibit apoptosis. The N-terminal of mature Smac/DIABLO is absolutely required for Survivin.Smac complex formation. Subcellular distributions of Survivin and Smac/DIABLO showed that they co-localized within the cytosol during interphase. In addition, Survivin was found to be incapable of binding to caspase. We also identified that the co-presence of Smac/DIABLO and XIAP was required for Survivin to inhibit caspase cleavage in a cell-free system. In conclusion, our results provide the first evidence that the interaction between Smac/DIABLO and Survivin is an essential step underling the inhibition of apoptosis induced by Taxol.	Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Key Lab Struct Biol, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wu, M (corresponding author), Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Key Lab Struct Biol, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Yao, Xuebiao/P-5771-2014; Wu, Mian/H-2494-2018	Wu, Mian/0000-0002-2714-0500				Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lu CD, 1998, CANCER RES, V58, P1808; Mahotka C, 1999, CANCER RES, V59, P6097; Marone M, 2001, EXP CELL RES, V270, P1, DOI 10.1006/excr.2001.5326; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Panvichian R, 1998, CANCER RES, V58, P4667; Reed JC, 1999, NAT CELL BIOL, V1, pE199, DOI 10.1038/70227; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tamm I, 1998, CANCER RES, V58, P5315; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhao J, 2000, J CELL SCI, V113, P4363	53	309	341	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23130	23140		10.1074/jbc.M300957200	http://dx.doi.org/10.1074/jbc.M300957200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12660240	hybrid			2022-12-25	WOS:000183503900121
J	Martin, GG; Danneberg, H; Kumar, LS; Atshaves, BP; Erol, E; Bader, M; Schroeder, F; Binas, B				Martin, GG; Danneberg, H; Kumar, LS; Atshaves, BP; Erol, E; Bader, M; Schroeder, F; Binas, B			Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; L-CELL-FIBROBLASTS; MEMBRANE-STRUCTURE; KNOCKOUT MICE; L-FABP; EXPRESSION; CHOLESTEROL; CHAIN; METABOLISM; TRANSPORT	Although liver fatty acid- binding protein ( L- FABP) is an important binding site for various hydrophobic ligands in hepatocytes, its in vivo significance is not understood. We have therefore created L- FABP null mice and report here their initial analysis, focusing on the impact of this mutation on hepatic fatty acid binding capacity, lipid composition, and expression of other lipid-binding proteins. Gel- filtered cytosol from L- FABP null liver lacked the main fatty acid binding peak in the fraction that normally comprises both L- FABP and sterol carrier protein- 2 ( SCP- 2). The binding capacity for cis- parinaric acid was decreased > 80% in this region. Molar ratios of cholesterol/ cholesterol ester, cholesteryl ester/ triglyceride, and cholesterol/ phospholipid were 2- to 3- fold greater, reflecting up to 3- fold absolute increases in specific lipid classes in the order cholesterol > cholesterol esters > phospholipids. In contrast, the liver pool sizes of nonesterified fatty acids and triglycerides were not altered. However, hepatic deposition of a bolus of intravenously injected [ (14)C] oleate was markedly reduced, showing altered lipid pool turnover. An increase of similar to 75% of soluble SCP- 2 but little or no change of other soluble ( glutathione S- transferase, albumin) and membrane ( fatty acid transport protein, CD36, aspartate aminotransferase, caveolin) fatty acid transporters was measured. These results ( i) provide for the first time a quantitative assessment of the contribution of L- FABP to cytosolic fatty acid binding capacity, ( ii) establish L- FABP as an important determinant of hepatic lipid composition and turnover, and ( iii) suggest that SCP- 2 contributes to the accumulation of cholesterol in L- FABP null liver.	Texas A&M Univ, Coll Vet Med, Dept Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Coll Vet Med, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Binas, B (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Pathobiol, Raymond Stotzer Pkwy, College Stn, TX 77843 USA.	bbinas@cvm.tamu.edu	Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41402] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 2002, AM J PHYSIOL-CELL PH, V283, pC688, DOI 10.1152/ajpcell.00586.2001; Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Atshaves BP, 2000, J BIOL CHEM, V275, P36852, DOI 10.1074/jbc.M003434200; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Fuchs M, 2001, J BIOL CHEM, V276, P48058, DOI 10.1074/jbc.M106732200; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Hui TY, 1998, J BIOL CHEM, V273, P27420, DOI 10.1074/jbc.273.42.27420; INCERPI S, 1992, ARCH BIOCHEM BIOPHYS, V298, P35, DOI 10.1016/0003-9861(92)90090-J; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; Jolly CA, 1998, BBA-LIPID LIPID MET, V1390, P258, DOI 10.1016/S0005-2760(97)00186-0; Jolly CA, 2000, BBA-MOL CELL BIOL L, V1483, P185, DOI 10.1016/S1388-1981(99)00170-5; Kannenberg F, 1999, J BIOL CHEM, V274, P35455, DOI 10.1074/jbc.274.50.35455; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARZO A, 1971, CLIN CHEM, V17, P145; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Murphy EJ, 2000, LIPIDS, V35, P729, DOI 10.1007/s11745-000-0579-x; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; Owada Y, 2002, J INVEST DERMATOL, V118, P430, DOI 10.1046/j.0022-202x.2001.01616.x; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; Pu LX, 1998, PROTEIN EXPRES PURIF, V13, P337, DOI 10.1006/prep.1998.0908; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; SCHROEDER F, 1989, SER SYMP AD, V1, P29; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Starodub O, 2000, AM J PHYSIOL-CELL PH, V279, pC1259, DOI 10.1152/ajpcell.2000.279.4.C1259; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 1999, J LIPID RES, V40, P708; Zanlungo S, 2000, GASTROENTEROLOGY, V119, P1708, DOI 10.1053/gast.2000.20198; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	57	133	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21429	21438		10.1074/jbc.M300287200	http://dx.doi.org/10.1074/jbc.M300287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670956	hybrid			2022-12-25	WOS:000183354200017
J	Shirakata, Y; Koike, K				Shirakata, Y; Koike, K			Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HBX PROTEIN; CYTOCHROME-C; TRANSGENIC MICE; TUMOR PROMOTER; APOPTOSIS; GENE; TRANSCRIPTION; COMPLEX; DIETHYLNITROSAMINE	The hepatitis B virus X protein (HBx) has been implicated in the carcinogenicity of this virus as a causative factor by means of its transactivation function in development of hepatocellular carcinoma. However, we and others have recently reported that HBx is located in mitochondria and causes subsequent cell death (Takada, S., Shirakata, Y., Kaneniwa, N., and Koike, K. (1999) Oncogene 18, 6965-6973; Rahmani, Z., Huh, K. W., Lasher, R., and Siddiqui, A. ( 2000) J. Virol. 74, 2840-2846). In this study, we, therefore, examined the mechanism of HBx-related cell death. Using enhanced green fluorescent protein (EGFP) fusion constructs of HBx, the region required for its mitochondrial localization was mapped to amino acids (aa) 68-117, which is essential for cell death but inactive for transactivation function. In vitro binding analysis supported the notion that the recombinant HBx associates with isolated mitochondria through the region of aa 68-117 without causing redistribution of cytochrome c and apoptosis-inducing factor (AIF). A cytochemical analysis revealed that mitochondrial membrane potential was decreased by HBx association with mitochondria, suggesting that HBx induces dysfunction of permeability transition pore (PTP) complex. Furthermore, PTP inhibitors, reactive oxygen species (ROS) scavengers and Bcl-xL, which are known to stabilize mitochondrial membrane potential, prevented HBx-induced cell death. Collectively, the present results suggest that location of HBx in mitochondria of hepatitis B virus-infected cells causes loss of mitochondrial membrane potential and subsequently induces mitochondria-dependent cell death.	JFCR, Dept Gene Res, Inst Canc, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research	Koike, K (corresponding author), JFCR, Dept Gene Res, Inst Canc, Toshima Ku, Tokyo 1708455, Japan.							Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; ARII M, 1992, ONCOGENE, V7, P397; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Blum HE, 1998, HEPATITIS B VIRUS, P75; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGHT J, 1994, BIOSCIENCE REP, V14, P67; COLLINS M, 1995, AM J RESP CRIT CARE, V152, pS20, DOI 10.1164/ajrccm/152.4_Pt_2.S20; Dragunow M, 1997, REV NEUROSCIENCE, V8, P223; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Shamay M, 2002, J BIOL CHEM, V277, P9982, DOI 10.1074/jbc.M111354200; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; Wang XD, 2001, GENE DEV, V15, P2922; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	45	127	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22071	22078		10.1074/jbc.M301606200	http://dx.doi.org/10.1074/jbc.M301606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676947	hybrid			2022-12-25	WOS:000183354200095
J	Tsai, YC; Fishman, PS; Thakor, NV; Oyler, GA				Tsai, YC; Fishman, PS; Thakor, NV; Oyler, GA			Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; N-TERMINAL HUNTINGTIN; E3 UBIQUITIN LIGASE; ALPHA-SYNUCLEIN; MOLECULAR CHAPERONES; CELL-DEATH; NEURODEGENERATIVE DISEASES; JUVENILE PARKINSONISM; NUCLEAR INCLUSIONS; ANDROGEN RECEPTOR	Parkin, the most commonly mutated gene in familial Parkinson's disease, encodes an E3 ubiquitin ligase. A number of candidate substrates have been identified for parkin ubiquitin ligase action including CDCrel-1, o-glycosylated alpha-synuclein, Pael-R, and synphilin-1. We now show that parkin promotes the ubiquitination and degradation of an expanded polyglutamine protein. Overexpression of parkin reduces aggregation and cytotoxicity of an expanded polyglutamine ataxin-3 fragment. Using a cellular proteasome indicator system based on a destabilized form of green fluorescent protein, we demonstrate that parkin reduces proteasome impairment and caspase-12 activation induced by an expanded polyglutamine protein. Parkin forms a complex with the expanded polyglutamine protein, heat shock protein 70 (Hsp70) and the proteasome, which may be important for the elimination of the expanded polyglutamine protein. Hsp70 enhances parkin binding and ubiquitination of expanded polyglutamine protein in vitro suggesting that Hsp70 may help to recruit misfolded proteins as substrates for parkin E3 ubiquitin ligase activity. We speculate that parkin may function to relieve endoplasmic reticulum stress by preserving proteasome activity in the presence of misfolded proteins. Loss of parkin function and the resulting proteasomal impairment may contribute to the accumulation of toxic aberrant proteins in neurodegenerative diseases including Parkinson's disease.	Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; Baltimore Vet Affairs Med Ctr, Res Serv, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Oyler, GA (corresponding author), Univ Maryland, Dept Neurol, 10 N Greene St, Baltimore, MD 21201 USA.		Thakor, Nitish V/A-5878-2008; Thakor, Nitish/G-9110-2015	Thakor, Nitish/0000-0002-9981-9395; Tsai, Yien Che/0000-0001-9624-1092	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024282, R21NS043658] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 24282, NS 43658-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; de Cristofaro T, 2000, BIOCHEM BIOPH RES CO, V272, P816, DOI 10.1006/bbrc.2000.2843; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; HARLOW E, 1990, ANTIBODIES LAB MANUA; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kaye FJ, 2000, FEBS LETT, V467, P348, DOI 10.1016/S0014-5793(00)01135-2; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Monoi H, 2000, BIOPHYS J, V78, P2892, DOI 10.1016/S0006-3495(00)76830-5; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Portman AT, 2001, NEUROLOGY, V56, P1759, DOI 10.1212/WNL.56.12.1759; Rankin CA, 2001, J BIOMED SCI, V8, P421; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Ross CA, 1998, PROG BRAIN RES, V117, P397; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Terreni L, 2001, NEUROLOGY, V56, P463, DOI 10.1212/WNL.56.4.463; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	83	215	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22044	22055		10.1074/jbc.M212235200	http://dx.doi.org/10.1074/jbc.M212235200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676955	hybrid			2022-12-25	WOS:000183354200092
J	Martinez-Chantar, ML; Latasa, MU; Varela-Rey, M; Lu, SC; Garcia-Trevijano, ER; Mato, JM; Avila, MA				Martinez-Chantar, ML; Latasa, MU; Varela-Rey, M; Lu, SC; Garcia-Trevijano, ER; Mato, JM; Avila, MA			L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; MESSENGER-RNA STABILITY; S-ADENOSYLMETHIONINE; MOLECULAR-MECHANISMS; LIVER; METABOLISM; GROWTH; METHYLTHIOADENOSINE; PHOSPHORYLASE; INHIBITORS	In mammals, methionine adenosyltransferase (MAT), the enzyme responsible for S-adenosylmethionine (AdoMet) synthesis, is encoded by two genes, MAT1A and MAT2A. In liver, MAT1A expression is associated with high AdoMet levels and a differentiated phenotype, whereas MAT2A expression is associated with lower AdoMet levels and a dedifferentiated phenotype. In the current study, we examined regulation of MAT2A gene expression by L-methionine availability using HepG2 cells. In L-methionine-deficient cells, MAT2A gene expression is rapidly induced, and methionine adenosyltransferase activity is increased. Restoration of L-methionine rapidly down-regulates MAT2A mRNA levels; for this effect, L-methionine needs to be converted into AdoMet. This novel action of AdoMet is not mediated through a methyl transfer reaction. MAT2A gene expression was also regulated by 5'-methylthioadenosine, but this was dependent on 5'-methylthioadenosine conversion to methionine through the salvage pathway. The transcription rate of the MAT2A gene remained unchanged during L-methionine starvation; however, its mRNA half-life was significantly increased (from 100 min to more than 3 h). The effect of L-methionine withdrawal on MAT2A mRNA stabilization requires both gene transcription and protein synthesis. We conclude that MAT2A gene expression is modulated as an adaptive response of the cell to L-methionine availability through its conversion to AdoMet.	Univ Navarra, Fac Med, Div Hepatol & Terapia Genica, Lab Proteom Genom & Bioinformat, Pamplona 31008, Spain; Univ So Calif, Keck Sch Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, USC Res Ctr Liver Dis,Div Gastroenterol & Liver D, Los Angeles, CA 90033 USA	University of Navarra; University of Southern California	Avila, MA (corresponding author), Univ Navarra, Fac Med, Div Hepatol & Terapia Genica, Lab Proteom Genom & Bioinformat, Pamplona 31008, Spain.	maavila@unav.es	MATO, JOSE/A-5187-2011; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021; Lu, Shelly/AAH-5937-2021; Chantar, Maria Luz Martinez/F-5190-2011; Varela-Rey, Marta/C-5460-2019	MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Lu, Shelly/0000-0003-2128-5407; Chantar, Maria Luz Martinez/0000-0002-6446-9911; Latasa, Maria Ujue/0000-0002-0878-1337; Varela-Rey, Marta/0000-0002-2413-8659	NCCIH NIH HHS [R01 AT-1576] Funding Source: Medline; NIAAA NIH HHS [R01 AA-12677, R01 AA013847] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51719] Funding Source: Medline; National Center for Complementary & Integrative Health [R01AT001576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013847, R01AA012677] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ansorena E, 2002, HEPATOLOGY, V35, P274, DOI 10.1053/jhep.2002.30419; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; AVILA MA, 1995, ONCOGENE, V10, P963; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Carretero MV, 2001, BIOCHEM PHARMACOL, V61, P1119, DOI 10.1016/S0006-2952(01)00590-1; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dumontet C, 1996, ONCOL RES, V8, P469; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; Garcia-Trevijano ER, 2000, FASEB J, V14, P2511, DOI 10.1096/fj.00-0121com; Garcia-Trevijano ER, 2002, GASTROENTEROLOGY, V122, P1355, DOI 10.1053/gast.2002.33020; Garrow TA, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P145; HOFFMAN RM, 1985, ANTICANCER RES, V5, P1; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; Latasa MU, 2001, FASEB J, V15, P1248, DOI 10.1096/fj.00-0556fjev1; Lombardini J B, 1970, Adv Enzyme Regul, V9, P349, DOI 10.1016/S0065-2571(71)80054-7; Lu S, 2000, NUTR CANCER, V38, P123, DOI 10.1207/S15327914NC381_17; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P47; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Olteanu H, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P135; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PEGG AE, 1988, CANCER RES, V48, P759; Pegorier J P, 1998, Curr Opin Clin Nutr Metab Care, V1, P329, DOI 10.1097/00075197-199807000-00003; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; TABOR H, 1964, PHARMACOL REV, V16, P245; Tang BQ, 2000, CANCER RES, V60, P5543; VANLEUNGPINEA, 2002, J BIOL CHEM, V277, P16585; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WHITE MW, 1982, BIOCHEM PHARMACOL, V31, P503, DOI 10.1016/0006-2952(82)90151-4; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200	50	65	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19885	19890		10.1074/jbc.M211554200	http://dx.doi.org/10.1074/jbc.M211554200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660248	hybrid			2022-12-25	WOS:000183078000041
J	Waldhoer, M; Casarosa, P; Rosenkilde, MM; Smit, MJ; Leurs, R; Whistler, JL; Schwartz, TW				Waldhoer, M; Casarosa, P; Rosenkilde, MM; Smit, MJ; Leurs, R; Whistler, JL; Schwartz, TW			The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; CHEMOKINE RECEPTOR; NEUROKININ-1 RECEPTOR; SIGNALING PATHWAYS; INVERSE AGONISTS; BETA-ARRESTIN; ACTIVATION; EXPRESSION; DESENSITIZATION	US28 is one of four 7 transmembrane (7TM) chemokine receptors encoded by human cytomegalovirus and has been shown to both signal and endocytose in a ligand-independent, constitutively active manner. Here we show that the constitutive activity and constitutive endocytosis properties of US28 are separable entities in this viral chemokine receptor. We generated chimeric and mutant US28 proteins that were altered in either their constitutive endocytic ( US28 Delta300, US28 Delta317, US28-NK1-ctail, and US28-ORF74-ctail) or signaling properties ( US28R129A). By using this series of mutants, we show that the cytoplasmic tail domain of US28 per se regulates receptor endocytosis, independent of the signaling ability of the core domain of US28. The constitutive endocytic property of the US28 c-tail was transposable to other 7TM receptors, the herpes virus 8-encoded ORF74 and the tachykinin NK1 receptor (ORF74-US28-ctail and NK1-US28-ctail). Deletion of the US28 C terminus resulted in reduced constitutive endocytosis and consequently enhanced signaling capacity of all receptors tested as assessed by inositol phosphate turnover, NF-kappaB, and cAMP-responsive element-binding protein transcription assays. We further show that the constitutive endocytic property of US28 affects the action of its chemokine ligand fractalkine/CX(3)CL1 and show that in the absence of the US28 C terminus, fractalkine/ CX(3)CL1 acts as an agonist on US28. This demonstrates for the first time that the endocytic properties of a 7TM receptor can camouflage the agonist properties of a ligand.	Univ Calif San Francisco, Ernest Gallo Res Ctr, Emeryville, CA 94608 USA; Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Free Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-1081 HV Amsterdam, Netherlands; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of Copenhagen; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Waldhoer, M (corresponding author), Univ Calif San Francisco, Ernest Gallo Res Ctr, 5858 Horton St,Ste 200, Emeryville, CA 94608 USA.		Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021; Waldhoer, Maria/HDO-0619-2022	Leurs, Rob/0000-0003-1354-2848; Waldhoer, Maria/0000-0003-3534-1959; Schwartz, Thue W./0000-0002-0261-6904; Smit, Martine/0000-0003-2713-0238; Rosenkilde, Mette Marie/0000-0001-9600-3254				Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bennett GL, 1997, METHOD ENZYMOL, V288, P134; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Dery O, 2001, AM J PHYSIOL-CELL PH, V280, pC1097, DOI 10.1152/ajpcell.2001.280.5.C1097; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Fraile-Ramos A, 2002, TRAFFIC, V3, P218, DOI 10.1034/j.1600-0854.2002.030307.x; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; SCHWARTZ TW, 1996, TXB RECEPTOR PHARM, P65; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914	37	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19473	19482		10.1074/jbc.M213179200	http://dx.doi.org/10.1074/jbc.M213179200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646575	Green Published, hybrid			2022-12-25	WOS:000182932200097
J	Chauhan, D; Li, GL; Hideshima, T; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Kharbanda, S; Anderson, KC				Chauhan, D; Li, GL; Hideshima, T; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Kharbanda, S; Anderson, KC			JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERCOMES DRUG-RESISTANCE; CYTOCHROME-C; INDEPENDENT ACTIVATION; KINASE; STRESS; DEATH; SMAC/DIABLO; REQUIREMENT; INHIBITOR; INDUCTION	Smac, second mitochondria-derived activator of caspases, promotes apoptosis via activation of caspases. Previous studies have shown that c-Jun NH2-terminal kinase (JNK) is involved in regulating another mitochondrial protein, cytochrome c during apoptosis; however, the role of JNK in the release of mitochondrial Smac is unknown. Here we show that induction of apoptosis in multiple myeloma (MM) cells is associated with activation of JNK, translocation of JNK from cytosol to mitochondria, and release of Smac from mitochondria to cytosol. Blocking JNK either by dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor, SP600125, abrogates both stress-induced release of Smac and induction of apoptosis. These findings demonstrate that activation of JNK is an obligatory event for the release of Smac during stress-induced apoptosis in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NCI NIH HHS [CA 78373] Funding Source: Medline; PHS HHS [50947] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Gibson EM, 2002, J BIOL CHEM, V277, P10573, DOI 10.1074/jbc.M108366200; Hideshima T, 2001, CANCER RES, V61, P3071; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WILLIE AH, 1980, INT REV CYTOL, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	27	177	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17593	17596		10.1074/jbc.C300076200	http://dx.doi.org/10.1074/jbc.C300076200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12665525	hybrid			2022-12-25	WOS:000182838300003
J	Bartunek, P; Kralova, J; Blendinger, G; Dvorak, M; Zenke, M				Bartunek, P; Kralova, J; Blendinger, G; Dvorak, M; Zenke, M			GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter	ONCOGENE			English	Article						c-myb; proto-oncogene; GATA-1; GATA factor; erythropoiesis; red blood cell	TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; ZINC-FINGER PROTEIN; ERYTHROID PROGENITORS; HEMATOPOIETIC-CELLS; IN-VITRO; DNA-BINDING; TERMINAL DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; GLUCOCORTICOID RECEPTOR	GATA-1 and c-Myb transcription factors represent key regulators of red blood cell development. GATA-1 is upregulated and c-myh proto-oncogene expression is downregulated when red cell progenitors differentiate into erythrocytes. Here we have employed a culture system, that faithfully recapitulates red blood cell differentiation in vitro, to follow the kinetics of GATA-1 and c-myb expression. We show that c-myb proto-oncogene expression is high in progenitors and effectively downregulated at the time when nuclear GATA-1 accumulates and cells differentiate into erythrocytes. Additionally, we identified two GATA-1 binding sites within the c-myb promoter and demonstrate that GATA-I protein binds to these sites in vitro. Furthermore, GATA-1 represses c-myb expression through one of the GATA-1 binding sites in transient transfection experiments and this requires FOG-1. Thus, our study provides evidence for a direct molecular link between GATA-1 activity and c-myb proto-oncogene expression during terminal red cell differentiation.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Inst Mol Genet, Prague 16637 6, Czech Republic	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Dvořák, Michal/I-9939-2014; Bartunek, Petr/J-3897-2014; Kralova, Jarmila/G-3834-2014; Dvorak, Michal/G-5861-2014	Bartunek, Petr/0000-0002-6202-7650; Kralova, Jarmila/0000-0002-4735-8857; 				AIRD WC, 1994, J BIOL CHEM, V269, P883; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 2002, ONCOGENE, V21, P400, DOI 10.1038/sj/onc/1205103; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FIBACH E, 1991, INT J CELL CLONING, V9, P57, DOI 10.1002/stem.5530090108; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOZMIK Z, 1990, GENE, V90, P287, DOI 10.1016/0378-1119(90)90192-T; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang DY, 2001, EXP HEMATOL, V29, P1278, DOI 10.1016/S0301-472X(01)00725-1	56	53	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1927	1935		10.1038/sj.onc.1206281	http://dx.doi.org/10.1038/sj.onc.1206281			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673198				2022-12-25	WOS:000181967700003
J	Hedborg, F; Ulleras, E; Grimelius, L; Wassberg, E; Maxwell, PH; Hero, B; Berthold, F; Schilling, F; Harms, D; Sandstedt, B; Franklin, G				Hedborg, F; Ulleras, E; Grimelius, L; Wassberg, E; Maxwell, PH; Hero, B; Berthold, F; Schilling, F; Harms, D; Sandstedt, B; Franklin, G			Evidence for hypoxia-induced neuronal-to-chromaffin metaplasia in neuroblastoma	FASEB JOURNAL			English	Article						angiogenesis; differentiation; sympathetic nervous system; insulin-like growth factor; vascular-endothelial growth factor	GROWTH-FACTOR-II; INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; O-2 HOMEOSTASIS; NERVOUS-SYSTEM; TUMORS; CELLS; CANCER; DIFFERENTIATION; TRANSCRIPTION	We present evidence that in neuroblastoma, a pediatric malignancy of embryonal sympathetic origin, hypoxia, underlies a phenotypic switch from a primitive neuronal to a chromaffin cell type. This conclusion is based on morphological and molecular data on 116 clinical tumors and is supported by data on the phenotypic effects of hypoxia on neuroblastoma cell lines when studied in monolayer culture and as tumor xenografts. In the clinical material, extensive chromaffin features were seen in regions of chronic tumor hypoxia. This was the exclusive form of intratumoral maturation of stroma-poor tumors and was also seen in stroma-rich tumors, either exclusively or in combination with ganglion-like cells. In neuroblastoma cell lines, hypoxia induced changes in gene expression associated with the chromaffin features observed in vivo. We therefore propose tumor hypoxia as a major cue determining phenotype in sympathetic tumors of neuroblastic origin. Because it appears to be reversible upon reoxygenation in monolayer culture, we suggest the term metaplasia for the phenomenon.	Rudbeck Lab, Dept Genet, SE-75185 Uppsala, Sweden; Rudbeck Lab, Dept Pathol, SE-75185 Uppsala, Sweden; Univ Hosp, Dept Women & Child Hlth, SE-75185 Uppsala, Sweden; Univ Uppsala, Evolutionary Biol Ctr, SE-75185 Uppsala, Sweden; Univ Uppsala, Biomed Ctr, SE-75185 Uppsala, Sweden; Univ London Imperial Coll Sci Technol & Med, Renal Sect, London, England; Univ Cologne, Dept Pediat, D-50924 Cologne, Germany; Olga Hosp, Dept Pediat Hematol & Oncol, D-70176 Stuttgart, Germany; Univ Kiel, Dept Pediat Pathol, D-24042 Kiel, Germany; Karolinska Inst, Childhood Canc Res Unit, SE-17176 Stockholm, Sweden; Biacore AB, SE-75450 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University; Imperial College London; University of Cologne; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart; University of Kiel; Karolinska Institutet	Hedborg, F (corresponding author), Rudbeck Lab, Dept Genet, SE-75185 Uppsala, Sweden.	fredrik.hedborg@genpat.uu.se	Maxwell, Patrick H/C-5557-2008	Maxwell, Patrick H/0000-0002-0338-2679				Ambros PF, 2000, NEUROBLASTOMA, P21; Bae SK, 1999, CANCER RES, V59, P5989; BARSON AJ, 1978, ARCH DIS CHILD, V53, P436; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; Brizel DM, 1996, CANCER RES, V56, P941; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brown JM, 1999, CANCER RES, V59, P5863; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Coupland RE., 1965, NATURAL HIST CHROMAF; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Feldser D, 1999, CANCER RES, V59, P3915; Gestblom C, 1997, AM J PATHOL, V150, P107; GRIMELIUS L, 1980, INVEST CELL PATHOL, V3, P3; HARMS D, 1989, EUR J PEDIATR, V148, P720, DOI 10.1007/BF00443094; Hartmann O, 2000, NEUROBLASTOMA, P437; HEDBORG F, 1995, AM J PATHOL, V146, P833; HEDBORG F, 1995, EUR J CANCER, V4, P435; Hockel M, 1996, CANCER RES, V56, P4509; HODGKISS RJ, 1991, BRIT J CANCER, V63, P119, DOI 10.1038/bjc.1991.24; Hodgkiss RJ, 1997, ADV EXP MED BIOL, V428, P61; Hoehner JC, 1998, LAB INVEST, V78, P29; Hoehner JC, 1996, LAB INVEST, V75, P659; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JACKSON A, 1995, J NEUROBIOL, V26, P485, DOI 10.1002/neu.480260403; Kietzmann T, 1997, CELL BIOL TOXICOL, V13, P243, DOI 10.1023/A:1007427206391; Kim KW, 1998, CANCER RES, V58, P348; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Langley K, 1999, CELL TISSUE RES, V298, P185, DOI 10.1007/PL00008810; Matthay KK, 2000, NEUROBLASTOMA, P417; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Mugishima H, 2000, NEUROBLASTOMA, P293; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; Olshan AF, 2000, NEUROBLASTOMA, P33; Pahlman S, 2000, NEUROBLASTOMA, P9; Rijken PFJW, 2000, INT J RADIAT ONCOL, V48, P571, DOI 10.1016/S0360-3016(00)00686-6; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shen YP, 2002, J NEUROSCI, V22, P239, DOI 10.1523/JNEUROSCI.22-01-00239.2002; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Siemann DW, 1998, INT J RADIAT ONCOL, V42, P697, DOI 10.1016/S0360-3016(98)00336-8; Slack JMW, 2001, CURR OPIN GENET DEV, V11, P581, DOI 10.1016/S0959-437X(00)00236-7; Soulier V, 1997, COMP BIOCHEM PHYS A, V118, P1, DOI 10.1016/S0300-9629(96)00369-6; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Tsuchida Y, 2000, NEUROBLASTOMA, P453; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	48	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					598	609		10.1096/fj.02-0390com	http://dx.doi.org/10.1096/fj.02-0390com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665472				2022-12-25	WOS:000182580100004
J	Kosaka, H; Yoneyama, H; Zhang, L; Fujii, S; Yamamoto, A; Igarashi, J				Kosaka, H; Yoneyama, H; Zhang, L; Fujii, S; Yamamoto, A; Igarashi, J			Induction of LOX-1 and iNOS expressions by ischemia-reperfusion of rat kidney and the opposing effect of L-arginine	FASEB JOURNAL			English	Article						NO end product; ox-LDL; renal cortex	NITRIC-OXIDE SYNTHASE; LOW-DENSITY-LIPOPROTEIN; MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; HERITABLE HYPERLIPIDEMIC RABBITS; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; KNOCKOUT MICE; RECEPTOR; ACTIVATION	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) is a newly identified endothelial cell surface major receptor for oxidatively modified low-density lipoprotein. Progression of arthrosclerosis in the donor organ after organ transplantation is a major problem. We hypothesized that ischemia-reperfusion induces LOX-1. After 1 h ischemia of bilateral kidneys plus 3, 6, or 12 h reperfusion, we first revealed that LOX-1 mRNA expression was increased in renal cortex and medulla at 6 h after reperfusion, which was decreased by L-arginine supplement. Plasma nitric oxide (NO) end-product nitrite plus nitrate and inducible nitric oxide synthase (NOS) expression were increased after reperfusion of 6 h. However, NOS substrate L-arginine did not augment but markedly decreased plasma NO end product, because L-arginine supplement suppressed inducible NOS expression in kidney. We hypothesized that available L-arginine is depleted by ischemia-reperfusion, leading to inducible NOS induction. Ischemia decreased L-arginine levels in kidney and L-arginine supplement increased NO end products in renal cortex in the earliest phase of reperfusion. These results disclosed for the first time that a deficiency in L-arginine by ischemia reperfusion causes uncoupling of constitutive NOS, which induces inducible NOS and LOX-1, implying why L-arginine is effective for stroke or transplantation in preventing atherosclerotic progress.	Kagawa Med Univ, Dept Physiol 2, Miki, Kagawa 7610793, Japan	Kagawa University	Kosaka, H (corresponding author), Kagawa Med Univ, Dept Physiol 2, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	hkosaka@kms.ac.jp						BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; CANADA A T, 1986, Journal of Free Radicals in Biology and Medicine, V2, P327, DOI 10.1016/S0748-5514(86)80032-0; Chatterjee PK, 2002, KIDNEY INT, V61, P862, DOI 10.1046/j.1523-1755.2002.00234.x; Chen MY, 2000, ARTERIOSCL THROM VAS, V20, P1107, DOI 10.1161/01.ATV.20.4.1107; Chen MY, 2001, BIOCHEM BIOPH RES CO, V282, P153, DOI 10.1006/bbrc.2001.4516; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hoffmeyer MR, 2000, CIRC RES, V87, P812, DOI 10.1161/01.RES.87.9.812; Kakoki M, 2000, J AM SOC NEPHROL, V11, P301, DOI 10.1681/ASN.V112301; Kakutani M, 2001, BIOCHEM BIOPH RES CO, V282, P180, DOI 10.1006/bbrc.2001.4508; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; Kume N, 1998, CIRC RES, V83, P322, DOI 10.1161/01.RES.83.3.322; Kumura E, 1996, AM J PHYSIOL-CELL PH, V270, pC748, DOI 10.1152/ajpcell.1996.270.3.C748; Li DY, 1999, CIRC RES, V84, P1043, DOI 10.1161/01.RES.84.9.1043; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Luoma JS, 1998, ARTERIOSCL THROM VAS, V18, P157, DOI 10.1161/01.ATV.18.2.157; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Mizoguchi K, 2002, TRANSPLANTATION, V73, P1185, DOI 10.1097/00007890-200204270-00002; Nagase M, 1997, BIOCHEM BIOPH RES CO, V237, P496, DOI 10.1006/bbrc.1997.7176; Nagase M, 2000, J AM SOC NEPHROL, V11, P1826, DOI 10.1681/ASN.V11101826; Node K, 1997, FASEB J, V11, P793, DOI 10.1096/fasebj.11.10.9271364; Okada K, 1998, CIRCULATION, V97, P2346, DOI 10.1161/01.CIR.97.23.2346; POU S, 1992, J BIOL CHEM, V267, P24173; Ravalli S, 1998, CIRCULATION, V97, P2338, DOI 10.1161/01.CIR.97.23.2338; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rueckschloss U, 2001, CIRCULATION, V104, P1767, DOI 10.1161/hc4001.097056; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Tanaka S, 1996, AM J PHYSIOL-GASTR L, V271, pG405, DOI 10.1152/ajpgi.1996.271.3.G405; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Vallon V, 2001, J AM SOC NEPHROL, V12, P1599, DOI 10.1681/ASN.V1281599; Yoneyama H, 2001, BIOCHEM J, V360, P247, DOI 10.1042/0264-6021:3600247; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; Zhou MS, 2001, J HYPERTENS, V19, P421, DOI 10.1097/00004872-200103000-00010; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	38	44	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					636	643		10.1096/fj.02-0585com	http://dx.doi.org/10.1096/fj.02-0585com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665476				2022-12-25	WOS:000182580100008
J	Kim, YC; Yamaguchi, Y; Kondo, N; Masutani, H; Yodoi, J				Kim, YC; Yamaguchi, Y; Kondo, N; Masutani, H; Yodoi, J			Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response	ONCOGENE			English	Article						thioredoxin; Nrf2; antioxidant responsive element (ARE); tert-butylhydroquinone (tBHQ); redox regulation; electrophile	SITE-DIRECTED MUTAGENESIS; MEDIATED EXPRESSION; ACTIVATION; TRANSCRIPTION; NRF2; BINDING; GENE; PROTEINS; DIFFERENTIATION; ASSOCIATION	Thioredoxin is a redox-regulating protein, the expression of which is induced by various forms of oxidative stress. Thioredoxin controls the interactions of various transcription factors through redox regulation. In K562 cells, we have previously reported that hemin induces activation of the thioredoxin gene by regulating NF-E2-related factor (Nrf2) through the antioxidant responsive element (ARE). We showed here that tert-butylhydroquinone (tBHQ), an electrophile stressor, activates the thioredoxin gene through the ARE. In an electrophoretic mobility shift assay, a specific Nrf2/small Maf binding complex was induced by tBHQ and bound to the ARE. Overexpression of Nrf2 increased the tBHQ-induced thioredoxin gene activation through the ARE, whereas that of Jun and Fos suppressed the activation. The tBHQ-induced ARE binding activity was completely abrogated by an oxidizing agent, diamide, whereas 2-mereaptoethanol (2-ME) reversibly recovered the inhibitory effects of diamide, suggesting that ARE binding activity is redox-dependent. Moreover, overexpression of thioredoxin enhanced the ARE-mediated thioredoxin gene activation by tBHQ. Therefore, ARE-mediated induction of thioredoxin expression is a mechanism of enhancing signal transduction through the ARE in electrophile-induced stress responses.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, Biomed Special Res Unit, AIST, Osaka 5638577, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin,Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; PACKER L, 1999, REDOX REGULATION CEL, P251; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; VERHAGEN H, 1989, CARCINOGENESIS, V10, P1947, DOI 10.1093/carcin/10.10.1947	23	103	111	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1860	1865		10.1038/sj.onc.1206369	http://dx.doi.org/10.1038/sj.onc.1206369			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660821				2022-12-25	WOS:000181678200012
J	Yanagisawa, T; Kawakami, M				Yanagisawa, T; Kawakami, M			How does pseudomonas fluorescens avoid suicide from its antibiotic pseudomonic acid? Evidence for two evolutionarily distinct isoleucyl-tRNA synthetases conferring self-defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEVEL MUPIROCIN RESISTANCE; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; GENETIC-CODE; MECHANISM; SEQUENCE; RECOGNITION; EUBACTERIAL; ACTIVATION; EXPRESSION	Two isoleucyl-tRNA synthetases (IleRSs) encoded by two distinct genes (ileS1 and ileS2) were identified in pseudomonic acid (mupirocin)-producing Pseudomonas fluorescens. The most striking difference between the two IleRSs (IleRS-R1 and IleRS-R2) is the difference in their abilities to resist pseudomonic acid. Purified Il-eRSR2 showed no sensitivity to pseudomonic acid even at a concentration of 5 mM, 10(5) times higher than the K-i value of IleRS-R1. The amino acid sequence of IleRS-R2 exhibits eukaryotic features that are originally found in eukaryotic proteins. Escherichia coli cells transformed with the ileS2 gene exerted pseudomonic acid resistance more than did those transformed with ileS1. Cells transformed with both genes became almost as resistant as P. fluorescens. These results suggest that the presence of IleRS-R2 could be the major reason why P. fluorescens is intrinsically resistant to the antibiotic. Here we suggest that the evolutionary scenario of the eukaryotic ileS2 gene can be explained by gene acquisition and that the pseudomonic acid producer may have maintained the ileS2 gene to protect itself from pseudomonic acid.	Nagoya Univ, Grad Sch Sci, Dept Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Yanagisawa, T (corresponding author), RIKEN, Genom Sci Ctr, Suehiro Cho 1-7-22, Yokohama, Kanagawa 2300045, Japan.	yanagi@gsc.riken.go.jp						Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Brown JR, 1998, CURR BIOL, V8, pR365, DOI 10.1016/S0960-9822(98)70238-6; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CAPOBIANCO JO, 1989, ANTIMICROB AGENTS CH, V33, P156, DOI 10.1128/AAC.33.2.156; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CASEWELL MW, 1987, J ANTIMICROB CHEMOTH, V19, P1, DOI 10.1093/jac/19.1.1; CLARK RL, 1990, J BACTERIOL, V172, P3237, DOI 10.1128/jb.172.6.3237-3243.1990; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FELINE TC, 1977, J CHEM SOC P1, V3, P309; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; GILBART J, 1993, ANTIMICROB AGENTS CH, V37, P32, DOI 10.1128/AAC.37.1.32; Glaser P, 1991, DNA Seq, V1, P251, DOI 10.3109/10425179109020780; HIRSHFIELD IN, 1981, J BACTERIOL, V146, P345, DOI 10.1128/JB.146.1.345-351.1981; HODGSON JE, 1994, ANTIMICROB AGENTS CH, V38, P1205, DOI 10.1128/AAC.38.5.1205; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; HUGHES J, 1980, FEBS LETT, V122, P322, DOI 10.1016/0014-5793(80)80465-0; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; Kitabatake M, 2002, J BIOL CHEM, V277, P23882, DOI 10.1074/jbc.M202639200; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; Mantle PG, 2001, J ANTIBIOT, V54, P166, DOI 10.7164/antibiotics.54.166; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; Nakama T, 2001, J BIOL CHEM, V276, P47387, DOI 10.1074/jbc.M109089200; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PARENTI MA, 1987, CLIN PHARMACY, V6, P761; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; Pope AJ, 1998, J BIOL CHEM, V273, P31691, DOI 10.1074/jbc.273.48.31691; PUTZER H, 1990, J BACTERIOL, V172, P4593, DOI 10.1128/jb.172.8.4593-4602.1990; RACHER KI, 1991, J BIOL CHEM, V266, P17158; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassanfar M, 1996, BIOCHEMISTRY-US, V35, P9995, DOI 10.1021/bi9603027; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; Shiba K, 1997, TRENDS BIOCHEM SCI, V22, P453, DOI 10.1016/S0968-0004(97)01135-3; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; SUTHERLAND R, 1985, ANTIMICROB AGENTS CH, V27, P495, DOI 10.1128/AAC.27.4.495; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolf YI, 1999, GENOME RES, V9, P689; YANAGISAWA T, 1994, J BIOL CHEM, V269, P24304	47	31	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25887	25894		10.1074/jbc.M302633200	http://dx.doi.org/10.1074/jbc.M302633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12672810	hybrid			2022-12-25	WOS:000183920200079
J	Cornish, AL; Chong, MM; Davey, GM; Darwiche, R; Nicola, NA; Hilton, DJ; Kay, TW; Starr, R; Alexander, WS				Cornish, AL; Chong, MM; Davey, GM; Darwiche, R; Nicola, NA; Hilton, DJ; Kay, TW; Starr, R; Alexander, WS			Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; IFN-GAMMA; LYMPHOID HOMEOSTASIS; IN-VIVO; MEMORY; DIFFERENTIATION; PROLIFERATION; RECEPTOR; NAIVE; MICE	Suppressor of cytokine signaling- 1 ( SOCS- 1) is an essential regulator of cytokine signaling. SOCS-1(-/-) mice die before weaning with a complex disease characterized by fatty degeneration and necrosis of the liver. This disease is mediated by interferon ( IFN) gamma as neonatal mortality fails to occur in SOCS-1(-/-) IFNgamma(-/-) mice. However, the immune system of healthy SOCS-1(-/-) IFNgamma(-/-) mice is dysregulated with a reduced ratio of CD4: CD8 T cells and increases in some aspects of T cell activation. SOCS-1(-/-) IFNgamma(-/-) mice also die before their wild type and IFNgamma(-/-) counterparts with a range of inflammatory conditions including pneumonia, gut infiltration, and skin ulceration, suggesting that SOCS- 1 controls not only IFNgamma signaling, but also other immunoregulatory factors. This study shows that T cells from SOCS- 1- deficient mice display hypersensitivity to cytokines that act through the gammac receptor. SOCS- 1 expression is induced by interleukin ( IL) 2, IL- 4, IL- 7, and IL- 15, and SOCS- 1-deficient T cells show increased proliferation and prolonged survival in response to IL- 2 and IL- 4. Furthermore, IL- 2 induced increased STAT5 phosphorylation and CD44 expression in SOCS- 1- deficient T cells compared with controls. Hypersensitivity to gammac- dependent cytokines may contribute to abnormal T cell function, as well as the pathology observed in mice lacking SOCS- 1.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Alexander, WS (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	alexandw@wehi.edu.au	Chong, Mark/H-6684-2016; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Chong, Mark/0000-0002-3701-7397; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Davey, Gayle/0000-0002-9514-6023	NCI NIH HHS [CA-22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1998, IMMUNOL REV, V165, P13, DOI 10.1111/j.1600-065X.1998.tb01226.x; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Bullen DVR, 2001, IMMUNOLOGY, V104, P92, DOI 10.1046/j.1365-2567.2001.01294.x; Chong MMW, 2003, IMMUNITY, V18, P475, DOI 10.1016/S1074-7613(03)00078-5; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; Cornish AL, 2003, J IMMUNOL, V170, P878, DOI 10.4049/jimmunol.170.2.878; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Dummer W, 2001, J IMMUNOL, V166, P2460, DOI 10.4049/jimmunol.166.4.2460; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; GATELY MK, 1988, J IMMUNOL, V141, P189; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Geiselhart LA, 2001, J IMMUNOL, V166, P3019, DOI 10.4049/jimmunol.166.5.3019; GODFREY DI, 1994, J IMMUNOL, V152, P2729; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Habib T, 2002, BIOCHEMISTRY-US, V41, P8725, DOI 10.1021/bi0202023; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Leung DTM, 2000, J IMMUNOL, V164, P3527, DOI 10.4049/jimmunol.164.7.3527; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Losman JA, 1999, J IMMUNOL, V162, P3770; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Matsuda T, 2000, FEBS LETT, V472, P235, DOI 10.1016/S0014-5793(00)01444-7; MERTSCHING E, 1995, INT IMMUNOL, V7, P401, DOI 10.1093/intimm/7.3.401; Metcalf D, 2000, P NATL ACAD SCI USA, V97, P9174, DOI 10.1073/pnas.160255197; Metcalf D, 2002, P NATL ACAD SCI USA, V99, P943, DOI 10.1073/pnas.022628499; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Pallard C, 1999, IMMUNITY, V10, P525, DOI 10.1016/S1074-7613(00)80052-7; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Surh CD, 2002, MICROBES INFECT, V4, P51, DOI 10.1016/S1286-4579(01)01509-X; Trop S, 2001, BLOOD, V97, P2269, DOI 10.1182/blood.V97.8.2269; VISSINGA CS, 1992, EXP HEMATOL, V20, P998; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	54	95	99	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22755	22761		10.1074/jbc.M303021200	http://dx.doi.org/10.1074/jbc.M303021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665516	hybrid			2022-12-25	WOS:000183503900078
J	Konno, T; Ebihara, T; Hisaeda, K; Uchiumi, T; Nakamura, T; Shirakusa, T; Kuwano, M; Wada, M				Konno, T; Ebihara, T; Hisaeda, K; Uchiumi, T; Nakamura, T; Shirakusa, T; Kuwano, M; Wada, M			Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION-TRANSPORTER; DUBIN-JOHNSON-SYNDROME; CONJUGATE EXPORT PUMP; HEPATOCYTE CANALICULAR ISOFORM; ATP-DEPENDENT TRANSPORT; LEUKOTRIENE C-4; DRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; APICAL MEMBRANE; PLASMA-MEMBRANE	The human multidrug resistance protein MRP1 and its homolog, MRP2, are both thought to be involved in cancer drug resistance and the transport of a wide variety of organic anions, including the cysteinyl leukotriene C-4 (LTC4) (K-m = 0.1 and 1 muM). To determine which domain of these proteins is associated with substrate specificity and subcellular localization, we constructed various chimeric MRP1/MRP2 molecules and expressed them in polarized mammalian LLC-PK1 cells. We examined the kinetic properties of each chimeric protein by measuring LTC4 and methotrexate transport in inside-out membrane vesicles, sensitivity to an anticancer agent, etoposide, and subcellular localization by indirect immunofluorescence methods. The following results were determined in these studies: (i) when the NH2-proximal 108 amino acids of MRP2, including transmembrane (TM) helices 1-3, were exchanged with the corresponding region of MRP1, K-m( LTC4) values of the chimera decreased similar to4-fold and K-m(methotrexate) values increased similar to5-fold relative to those of wild-type MRP2 and MRP1, respectively, whereas resistance to etoposide increased similar to3-fold; (ii) when the NH2-proximal region up to TM9 of MRP2 was exchanged with the corresponding region of MRP1, a further increase in etoposide resistance was observed, and subcellular localization moved from the apical to the lateral membrane; (iii) when two-thirds of MRP2 at the NH2 terminus were exchanged with the corresponding MRP1 region, the chimeric protein transported LTC4 with an efficiency comparable with that achieved by the wild-type MRP1; and (iv) exchange of the COOH-terminal 51 amino acids between MRP1 and MRP2 did not affect the localization of either of the proteins. These results provide a strong framework for further studies aimed at determining the precise domains of MRP1 and MRP2 with affinity for LTC4 and anticancer agents.	Kyushu Univ, Dept Biochem Med, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Fukuoka Univ, Dept Surg 2, Sch Med, Johnan Ku, Fukuoka 8140180, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Fukuoka 8300011, Japan	Kyushu University; Fukuoka University; Kurume University	Wada, M (corresponding author), Kyushu Univ, Dept Biochem Med, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	wada@biochem1.med.kyushu-u.ac.jp						Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; Buchler M, 1996, J BIOL CHEM, V271, P15091; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez SBM, 2002, J BIOL CHEM, V277, P31048, DOI 10.1074/jbc.M204267200; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; Hashimoto K, 2002, HEPATOLOGY, V36, P1236, DOI 10.1053/jhep.2002.36368; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hooijberg JH, 1999, CANCER RES, V59, P2532; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Jedlitschky G, 1997, BIOCHEM J, V327, P305, DOI 10.1042/bj3270305; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; Keppler D, 1997, BIOL CHEM, V378, P787; Kocher O, 1999, LAB INVEST, V79, P1161; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; Koike K, 1997, CANCER RES, V57, P5475; Kuwano M, 1999, ANTI-CANCER DRUG DES, V14, P123; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Milewski MI, 2001, J CELL SCI, V114, P719; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x; Paulusma CC, 1997, J MOL MED-JMM, V75, P420, DOI 10.1007/s001090050127; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Rappa G, 1997, CANCER RES, V57, P5232; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Scheffer GL, 2000, CANCER RES, V60, P5269; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; Taniguchi K, 1996, CANCER RES, V56, P4124; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhou Y, 1999, MOL PHARMACOL, V56, P997, DOI 10.1124/mol.56.5.997	68	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22908	22917		10.1074/jbc.M302868200	http://dx.doi.org/10.1074/jbc.M302868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682044	hybrid			2022-12-25	WOS:000183503900097
J	Marie, N; Lecoq, I; Jauzac, P; Allouche, S				Marie, N; Lecoq, I; Jauzac, P; Allouche, S			Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SK-N-BE; NEUROBLASTOMA CELL-LINE; PROTEIN-COUPLED RECEPTORS; HAMSTER OVARY CELLS; MOLECULAR MECHANISMS; DOWN-REGULATION; INDUCED DESENSITIZATION; ENDOCYTOSIS; MU; PHOSPHORYLATION	Desensitization and internalization of G protein-coupled receptors observed after agonist activation are considered two important regulatory processes of receptor transduction. Endogenous human delta-opioid receptors (hDOR) are differentially regulated in terms of desensitization by peptide ([D-Pen(2,5)] enkephalin (DPDPE) and Deltorphin I) and alkaloid (etorphine) agonists in the neuroblastoma cell line SK-N-BE (Allouche, S., Roussel, M., Marie, N., and Jauzac, P. (1999) Eur. J. Pharmacol. 371, 235 - 240). In the present study, we examined the role of hDOR internalization and down-regulation in this differential desensitization. Sustained activation by peptides for 30 min caused a marked decrease of both [H-3] diprenorphine binding sites and hDOR immunoreactivity, observed in a Western blot, whereas a moderate reduction by 30% was observed after a 30- and 60-min etorphine exposure in binding experiments without opioid receptor degradation. Using fluorescence microscopy, we visualized hDOR internalization promoted by different agonists in SK-N-BE cells expressing FLAG-tagged hDOR. Agonist withdrawal results in a greater recycling process correlated with a stronger hDOR resensitization after etorphine treatment compared with DPDPE or Deltorphin I, as shown in binding, immunocytochemical, and functional experiments. This suggests a distinct sorting of opioid receptors after their internalization. We demonstrated a lysosomal hDOR targeting upon peptides by using chloroquine in binding, Western blot, and immunocytochemical experiments and by colocalization of this receptor with a late endosome marker. In contrast, when the recycling endosome blocker monensin was used, acceleration of desensitization associated with a strong intracellular immunostaining was observed upon etorphine treatment. The possibility of separate endocytic pathways responsible for the differential sorting of hDOR upon peptide and alkaloid ligand exposure was ruled out by binding and immunocytochemical experiments using sucrose hypertonic solution. First, these results showed complex relationships between hDOR internalization/ down-regulation and desensitization. Second, we demonstrated for the first time that the same receptor could undergo a distinct sorting after internalization by peptide and alkaloid agonists.	Univ Caen, Ctr Hosp & Univ Caen, Lab Pharmacol Mol Tolerance Opiaces, F-14033 Caen, France	CHU de Caen NORMANDIE; Universite de Caen Normandie	Allouche, S (corresponding author), CHU Caen, Biochim Lab A, Ave Cote Nacre, F-14033 Caen, France.	allouche-se@chu-caen.fr	Marie, Nicolas/I-9129-2014	Marie, Nicolas/0000-0002-6491-9898; Allouche, stephane/0000-0003-3134-7501				Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Allouche S, 1996, J NEUROCHEM, V67, P2461; Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Allouche S, 2000, BIOCHEM PHARMACOL, V59, P915, DOI 10.1016/S0006-2952(99)00404-9; Bot G, 1997, MOL PHARMACOL, V52, P272, DOI 10.1124/mol.52.2.272; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Namir N, 1997, J NEUROCHEM, V68, P1764; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; POLASTRON J, 1994, J NEUROCHEM, V62, P898; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28	35	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22795	22804		10.1074/jbc.M300084200	http://dx.doi.org/10.1074/jbc.M300084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672796	hybrid			2022-12-25	WOS:000183503900083
J	Hresko, RC; Murata, H; Mueckler, M				Hresko, RC; Murata, H; Mueckler, M			Phosphoinositide-dependent kinase-2 is a distinct protein kinase enriched in a novel cytoskeletal fraction associated with adipocyte plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; ACTIN CYTOSKELETON; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; SURVIVAL PATHWAY; FOCAL ADHESIONS; LIPID RAFTS; ANNEXIN-II; INSULIN; GLUCOSE	By recombining subcellular components of 3T3-L1 adipocytes in a test tube, early insulin signaling events dependent on phosphatidylinositol 3-kinase ( PI 3-kinase) were successfully reconstituted, up to and including the phosphorylation of glycogen synthase kinase-3 by the serine/threonine kinase, Akt (Murata, H., Hresko, R. C., and Mueckler, M. ( 2003) J. Biol. Chem. 278, 21607 21614). Utilizing the advantages provided by a cell-free methodology, we characterized phosphoinositide-dependent kinase 2 ( PDK2), the putative kinase responsible for phosphorylating Akt on Ser-473. Immunodepleting cytosolic PDK1 from an in vitro reaction containing plasma membrane and cytosol markedly inhibited insulin-stimulated phosphorylation of Akt at the PDK1 site (Thr-308) but had no effect on phosphorylation at the PDK2 site ( Ser-473). In contrast, PDK2 activity was found to be highly enriched in a novel cytoskeletal subcellular fraction associated with plasma membranes. Akt isoforms 1-3 and a kinase-dead Akt1 (K179A) mutant were phosphorylated in a phosphatidylinositol 3,4,5-trisphosphate-dependent manner at Ser-473 in an in vitro reaction containing this novel adipocyte subcellular fraction. Our data indicate that this PDK2 activity is the result of a kinase distinct from PDK1 and is not due to autophosphorylation or transphosphorylation of Akt.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 38495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HELGASEMADROGA M, 1996, NATURE, V379, P560; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Holowka D, 2000, J CELL SCI, V113, P1009; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leitinger B, 2002, J CELL SCI, V115, P963; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Murata H, 2003, J BIOL CHEM, V278, P21607, DOI 10.1074/jbc.M302934200; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; PIPER RC, 1991, AM J PHYSIOL, V260, P570; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	45	45	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21615	21622		10.1074/jbc.M302937200	http://dx.doi.org/10.1074/jbc.M302937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682057	hybrid			2022-12-25	WOS:000183354200039
J	Fourrier, L; Brooks, P; Malinge, JM				Fourrier, L; Brooks, P; Malinge, JM			Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLESION SYNTHESIS; CELLULAR-RESPONSES; REPLICATIVE BYPASS; EXCISION-REPAIR; GPG ADDUCTS; RECOGNITION; OXALIPLATIN; RESISTANCE; MECHANISMS; MISPAIR	The DNA mismatch repair (MMR) system plays a critical role in sensitizing both prokaryotic and eukaryotic cells to the clinically potent anticancer drug cisplatin. It is thought to mediate cytotoxicity through recognition of cisplatin DNA lesions. This drug generates a range of lesions that may also give rise to compound lesions resulting from the misincorporation of a base during translesion synthesis. Using gel mobility shift competition assays and surface plasmon resonance, we have analyzed the interaction of Escherichia coli MutS protein with site-specifically modified DNA oligonucleotides containing each of the four cisplatin cross-links or a set of compound lesions. The major 1,2-d(GpG) cisplatin intrastrand cross-link was recognized with only a 1.5-fold specificity, whereas a 47-fold specificity was found with a natural G/T containing DNA substrate. The rate of association, k(on), for binding to the 1,2-d( GpG) adduct was 3.1 x 10(4) M-1 s(-1) and the specificity of binding was essentially dependent on k(off). DNA duplexes containing a single 1,2-d( ApG), 1,3-d(GpCpG) adduct, and an interstrand cross-link of cisplatin were not preferentially recognized. Among 12 DNA substrates, each containing a different cisplatin compound lesion derived from replicative misincorporation of one base opposite either of the 1,2-intrastrand adducts, 10 were specifically recognized including those that are more likely formed in vivo based on cisplatin mutation spectra. Moreover, among these lesions, two compound lesions formed when an adenine was misincorporated opposite a 1,2-d( GpG) adduct were not substrates for the MutY-dependent mismatch repair pathway. The ability of MutS to sense differentially various platinated DNA substrates suggests that cisplatin compound lesions formed during misincorporation of a base opposite either adducted base of both 1,2-intrastrand cross-links are more plausible critical lesions for MMR-mediated cisplatin cytotoxicity.	CNRS, Ctr Biophys Mol, F-45071 Orleans 02, France; Genoscope Ctr Natl Sequencage, F-91057 Evry, France	Centre National de la Recherche Scientifique (CNRS)	Malinge, JM (corresponding author), CNRS, Ctr Biophys Mol, Rue Charles Sadron, F-45071 Orleans 02, France.	malinge@cnrs-orleans.fr	Malinge, Jean-Marc/O-1131-2017	Malinge, Jean-Marc/0000-0002-6644-868X				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Babic I, 1996, MUTAT RES-FUND MOL M, V372, P87, DOI 10.1016/S0027-5107(96)00170-4; Berardini M, 2000, J BIOL CHEM, V275, P27851; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Brown R, 2000, CANC DRUG DISC DEV, V7, P115; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Cotton F.A., 1972, ADV INORGANIC CHEM, Vthird, P1145; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI [DOI 10.1002/9783906390420.CH4, 10.1002/9783906390420.ch4]; Einhorn LH, 1997, CLIN CANCER RES, V3, P2630; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 2001, CANCER RES, V61, P7369; FRAM RJ, 1985, MOL PHARMACOL, V28, P51; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GIBBONS GR, 1991, CARCINOGENESIS, V12, P2253, DOI 10.1093/carcin/12.12.2253; GiraudPanis MJE, 1996, J BIOL CHEM, V271, P33148, DOI 10.1074/jbc.271.51.33148; Gong JG, 1999, NATURE, V399, P806; Henkels KM, 1997, CANCER RES, V57, P4488; House PG, 2001, PROG NUCLEIC ACID RE, V68, P349; Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Johnson KA, 1999, J BIOL CHEM, V274, P27112, DOI 10.1074/jbc.274.38.27112; JONES M, 1987, GENETICS, V115, P605; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; Malinge JM, 1999, J INORG BIOCHEM, V77, P23, DOI 10.1016/S0162-0134(99)00148-8; Malinge JM, 2000, PRACT APPROACH SER, P25; MAMENTA EL, 1994, CANCER RES, V54, P3500; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Munoz EF, 1996, CARCINOGENESIS, V17, P2741, DOI 10.1093/carcin/17.12.2741; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Patrick SM, 2002, J BIOL CHEM, V277, P16096, DOI 10.1074/jbc.M200816200; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; PILLAIRE MJ, 1994, NUCLEIC ACIDS RES, V22, P2519, DOI 10.1093/nar/22.13.2519; Reedijk J, 1999, CHEM REV, V99, P2499, DOI 10.1021/cr980422f; SCHWARTZ A, 1989, BIOCHEMISTRY-US, V28, P7975, DOI 10.1021/bi00446a001; SU SS, 1988, J BIOL CHEM, V263, P6829; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Vaisman A, 1998, CANCER RES, V58, P3579; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; YAREMA KJ, 1995, NUCLEIC ACIDS RES, V23, P4066, DOI 10.1093/nar/23.20.4066; YAREMA KJ, 1994, J MOL BIOL, V236, P1034, DOI 10.1016/0022-2836(94)90010-8; Zdraveski ZZ, 2002, J BIOL CHEM, V277, P1255, DOI 10.1074/jbc.M105382200; Zdraveski ZZ, 2000, CHEM BIOL, V7, P39, DOI 10.1016/S1074-5521(00)00064-8; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669	62	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21267	21275		10.1074/jbc.M301390200	http://dx.doi.org/10.1074/jbc.M301390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654906	hybrid			2022-12-25	WOS:000183230500105
J	Madge, LA; Li, JH; Choi, JH; Pober, JS				Madge, LA; Li, JH; Choi, JH; Pober, JS			Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MEDIATED HEPATOCYTE APOPTOSIS; CYTOCHROME-C; FACTOR-ALPHA; TNF RECEPTOR; MITOCHONDRIAL RELEASE; SIGNALING PATHWAYS; DEATH; ACTIVATION	In the presence of cycloheximide, tumor necrosis factor or interleukin-1 initiates caspase activation, loss of mitochondrial membrane potential (DeltaPsi), DNA degradation, and nuclear condensation and fragmentation characteristic of apoptotic cell death in human vascular endothelial cells (EC). Inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002, but not inhibition of Akt by dominant-negative mutation, also sensitizes EC to cytokine-initiated apoptosis. Cytokine-initiated caspase activation is slower and comparatively less with LY294002 than with cycloheximide. Cycloheximide but not LY294002 decreases expression of c-FLIP ( cellular FLICE inhibitory protein), an inhibitor of caspase-8 activation. The caspase inhibitor zVADfmk completely blocks caspase activation, DNA degradation, and nuclear fragmentation in both cases but only prevents loss of DeltaPsi and cell death for cytokine plus cycloheximide treatment. In contrast, overexpression of Bcl-2 protects EC treated with cytokine plus LY294002 but not EC treated with cytokine plus cycloheximide. The cathepsin B inhibitor CA-074-Me prevents loss of DeltaPsi, caspase activation, and cell death for EC treated with cytokine plus LY294002 but has no effect on EC treated with cytokine plus cycloheximide. Cathepsin B translocates from lysosomes to cytosol following treatment with LY294002 prior to the activation of caspases. These results suggest that inhibition of PI3K allows cytokines to activate a cathepsin-dependent, mitochondrial death pathway in which caspase activation is secondary, is not inhibited by c-FLIP, and is not essential for cell death.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol, New Haven, CT 06536 USA	Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol, 333 Cedar St, New Haven, CT 06536 USA.		Choi, Jaehyuk/N-6532-2019	Choi, Jaehyuk/0000-0003-2379-2226	NHLBI NIH HHS [HL-36003, HL-62188] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036003, R01HL062188, R01HL036003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amstad PA, 2001, BIOTECHNIQUES, V31, P608, DOI 10.2144/01313pf01; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deas O, 1998, J IMMUNOL, V161, P3375; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JH, 2002, AM J PATHOL, V161, P1485, DOI 10.1016/S0002-9440(10)64424-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Ozes ON, 1999, NATURE, V401, P82; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	45	48	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21295	21306		10.1074/jbc.M212837200	http://dx.doi.org/10.1074/jbc.M212837200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663669	hybrid			2022-12-25	WOS:000183230500108
J	Ogishima, T; Kinoshita, JY; Mitani, F; Suematsu, M; Ito, A				Ogishima, T; Kinoshita, JY; Mitani, F; Suematsu, M; Ito, A			Identification of outer mitochondrial membrane cytochrome b(5) as a modulator for androgen synthesis in Leydig cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; RAT-LIVER MICROSOMES; REDUCTASE-ACTIVITY; 17,20-LYASE ACTIVITY; ELECTRON-TRANSFER; HUMAN P450C17; C REDUCTASE; PURIFICATION; HEMOPROTEIN; ACID	Outer mitochondrial membrane cytochrome b(5) is an isoform of microsomal membrane cytochrome b(5). In rat testes the outer mitochondrial membrane cytochrome b(5) is present in both mitochondria and microsomes, whereas microsomal membrane cytochrome b(5) is undetectable. Outer mitochondrial membrane cytochrome b(5) present in the testis was localized in Leydig cells with cytochrome P-450(17alpha), which catalyzes androgenesis therein. We therefore analyzed the functions of outer mitochondrial membrane cytochrome b(5) in rat testis microsomes by using a proteoliposome system. In a low but physiological concentration of NADPH-cytochrome P-450 reductase and excess amount of progesterone, outer mitochondrial membrane cytochrome b5 stimulated the cytochrome P-450(17alpha)-catalyzed reactions, 17alpha-hydroxylation and C17-C20 bond cleavage. The effects were different from those by microsomal membrane cytochrome b(5) as follows: preferential elevation of the 17alpha-hydroxylase activity by outer mitochondrial membrane cytochrome b(5) in an amount-dependent manner versus that of the lyase activity by microsomal membrane cytochrome b(5) at the low concentration, and the inhibition of both activities at the high concentration. At a low concentration of progesterone reflecting a physiological cholesterol supply, outer mitochondrial membrane cytochrome b(5) elevated primarily the production of 17alpha-hydroxyprogesterone and then facilitated the conversion of the released intermediate to androstenedione. Thus, we demonstrated that outer mitochondrial membrane cytochrome b(5) and not microsomal membrane cytochrome b(5) functions as an activator for androgenesis in rat Leydig cells.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Keio Univ, Dept Biochem & Integrat Med Biol, Tokyo 1608582, Japan	Kyushu University; Keio University	Ogishima, T (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.		Suematsu, Makoto/I-8135-2013; Suematsu, Makoto/O-5762-2018	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336				ABE K, 1979, EUR J BIOCHEM, V101, P423, DOI 10.1111/j.1432-1033.1979.tb19735.x; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FUKUSHIMA K, 1972, J BIOCHEM, V71, P447; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; ITO A, 1981, BIOCHEM BIOPH RES CO, V101, P591, DOI 10.1016/0006-291X(81)91300-0; ITO A, 1980, J BIOCHEM, V87, P73, DOI 10.1093/oxfordjournals.jbchem.a132754; ITO A, 1980, J BIOCHEM, V87, P63, DOI 10.1093/oxfordjournals.jbchem.a132753; KAWATA S, 1985, J BIOL CHEM, V260, P6609; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; KOMINAMI S, 1982, FLAVINS FLAVOPROTEIN, P715; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LEDERER F, 1983, EUR J BIOCHEM, V132, P95, DOI 10.1111/j.1432-1033.1983.tb07330.x; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; NISHINO H, 1986, J BIOCHEM, V100, P1523, DOI 10.1093/oxfordjournals.jbchem.a121859; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; ONODA M, 1982, BIOCHEM BIOPH RES CO, V108, P454, DOI 10.1016/0006-291X(82)90850-6; OZOLS J, 1976, ANN CLIN RES, V8, P182; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHINZAWA K, 1985, BIOCHIM BIOPHYS ACTA, V833, P151; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soucy P, 2002, J STEROID BIOCHEM, V80, P71, DOI 10.1016/S0960-0760(01)00171-6; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; TAGASHIRA H, 1995, BIOCHEMISTRY-US, V34, P10939, DOI 10.1021/bi00034a028; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki T, 1998, BIOCHEMISTRY-US, V37, P2800, DOI 10.1021/bi9715066	35	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21204	21211		10.1074/jbc.M301698200	http://dx.doi.org/10.1074/jbc.M301698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668680	hybrid			2022-12-25	WOS:000183230500098
J	Pedron, T; Girard, R; Chaby, R				Pedron, T; Girard, R; Chaby, R			TLR4-dependent lipopolysaccharide-induced shedding of tumor necrosis factor receptors in mouse bone marrow granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA CONVERTING-ENZYME; ACTIVATED PROTEIN-KINASE; SRC-FAMILY KINASES; INDUCED EXPRESSION; DOWN-REGULATION; TNF RECEPTOR; DIFFERENT MECHANISMS; TISSUE INHIBITOR; CD14 EXPRESSION; RESISTANT MICE	We reported previously that bone marrow granulocytes respond to small amounts of enterobacterial lipopolysaccharide (LPS) via a CD14-independent and TLR4-mediated mechanism by de novo expression of an inducible receptor (CD14) and by down-modulation of a constitutive receptor (L-selectin). In this report we address another effect of LPS: the down-regulation of receptors for tumor necrosis factor-alpha. In mouse bone marrow cells (BMC), this down-regulation is detectable soon ( 20 min) after exposure of the cells to low levels (0.5 ng/ml) of LPS. This temperature-dependent effect is rather selective for LPS and requires the presence of a conventional lipid A structure in the LPS molecule and a functional TLR4 molecule in the cells. The down-modulation, due to a shedding of the receptors, is blocked by p38 MAPK inhibitors, by a furin inhibitor, and by three metalloproteinase inhibitors (BB-3103, TIMP-2, and TIMP-3). In contrast, inhibitors of MEK, protein kinase C, cAMP-dependent protein kinase, and kinases of the Src family do not block the shedding. Analysis of BMC from mice lacking tumor necrosis factor receptor-1 (CD120a(-/-)) or tumor necrosis factor receptor-2 (CD120b(-/-)) indicates that the LPS-induced shedding is specific for CD120b. Thus, exposure of BMC to LPS triggers a rapid shedding of CD120b via a protein kinase C- and Src-independent pathway mediated by p38 MAPK, furin, and metalloproteinase. The additive effects of furin and metalloproteinase inhibitors suggest that these enzymes are involved in parallel shedding pathways.	Univ Paris 11, Endotoxin Grp, UMR 8619, Natl Ctr Sci Res, F-91405 Orsay, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, INSERM, U389, F-75015 Paris, France; Inst Pasteur, URA 1961, Natl Ctr Sci Res, F-75015 Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chaby, R (corresponding author), Univ Paris 11, Endotoxin Grp, UMR 8619, Natl Ctr Sci Res, F-91405 Orsay, France.							AGGARWAL BB, 2000, CYTOKINE REFERENCE, V2, P1619; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; Beer S, 1999, J CELL SCI, V112, P2667; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; CARPENTER A, 1995, J IMMUNOL, V155, P2005; CHABY R, 1993, J IMMUNOL, V151, P4476; CHEN BDM, 1983, J IMMUNOL, V130, P2256; Codony-Servat J, 1999, CANCER RES, V59, P1196; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; DING AH, 1989, J BIOL CHEM, V264, P3924; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GalvedeRochemonteix B, 1996, AM J RESP CELL MOL, V14, P279, DOI 10.1165/ajrcmb.14.3.8845179; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIBBS LS, 1992, FREE RADICAL BIO MED, V12, P107, DOI 10.1016/0891-5849(92)90003-Y; GIRARD R, 1993, J IMMUNOL, V150, P4504; Haziot A, 2001, J IMMUNOL, V166, P1075, DOI 10.4049/jimmunol.166.2.1075; Herman C, 1998, J IMMUNOL, V160, P2478; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HWANG CD, 1993, J IMMUNOL, V151, P5631; JACOBSEN FW, 1994, P NATL ACAD SCI USA, V91, P10695, DOI 10.1073/pnas.91.22.10695; Jin FY, 1999, J IMMUNOL, V162, P3596; Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; OSHEA JJ, 1985, J IMMUNOL, V135, P1325; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pedron T, 1999, CLIN DIAGN LAB IMMUN, V6, P885, DOI 10.1128/CDLI.6.6.885-890.1999; Pedron T, 2000, IMMUNOLOGY, V101, P262, DOI 10.1046/j.1365-2567.2000.00107.x; PEDRON T, 1994, J BIOL CHEM, V269, P2426; Pedron T, 1997, MOL PHARMACOL, V52, P692, DOI 10.1124/mol.52.4.692; Pedron T, 2000, FEMS IMMUNOL MED MIC, V28, P247; Pedron T, 2001, INFECT IMMUN, V69, P4287, DOI 10.1128/IAI.69.7.4287-4294.2001; Pedron T, 2000, BIOCHEM PHARMACOL, V60, P1837, DOI 10.1016/S0006-2952(00)00499-8; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P763, DOI 10.1016/0161-5890(90)90085-E; Takakuwa T, 1996, EUR J IMMUNOL, V26, P2686, DOI 10.1002/eji.1830261121; TEJEDOR F, 1982, ANAL BIOCHEM, V127, P143, DOI 10.1016/0003-2697(82)90156-7; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; WAAGE A, 1987, LANCET, V1, P355; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	64	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20555	20564		10.1074/jbc.M203551200	http://dx.doi.org/10.1074/jbc.M203551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663667	hybrid			2022-12-25	WOS:000183230500016
J	Yan, JS; Cramer, WA				Yan, JS; Cramer, WA			Functional insensitivity of the cytochrome b(6)f complex to structure changes in the hinge region of the Rieske iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS SP PCC-7002; LUMEN-SIDE DOMAIN; BC(1) COMPLEX; ELECTRON-TRANSFER; ANGSTROM RESOLUTION; OXYGENIC PHOTOSYNTHESIS; DIRECTED MUTAGENESIS; SITE CATALYSIS; TETHER REGION; 2FE2S DOMAIN	Structure analysis of the cytochrome bc(1) complex in the presence and absence of Q(p) quinol analog inhibitors implied that a large amplitude motion of the Rieske iron-sulfur protein (ISP) is required to mediate electron transfer from ubiquinol to cytochrome c(1). Studies of the functional consequences of mutagenesis of an 8-residue ISP "hinge" region in the bc(1) complex showed it to be sensitive to structure perturbation, implying that optimum flexibility and length are required for the large amplitude motion. Mutagenesis-function analysis carried out on the ISP hinge region of the cytochrome b(6)f complex using the cyanobacterium Synechococcus sp. PCC 7002 showed the following. (i) Of three petC genes, only that in the petCA operon codes for functional ISP. (ii) The function of the complex was insensitive to changes in the hinge region that increased flexibility, decreased flexibility by substitutions of 4-6 Pro residues, shortened the hinge by a 1-residue deletion, or elongated it by insertion of 4 residues. The latter change increased sensitivity to Q(p) inhibitors, whereas deletion of 2 residues resulted in a loss of inhibitor sensitivity and a decrease in activity, indicating a minimum hinge length of 7 residues required for optimum binding of ISP at the Q(p) site. Thus, in contrast to the bc(1) complex, the function of the b(6)f complex was insensitive to sequence changes in the ISP hinge that altered its length or flexibility. This implies that either the barriers to motion or the amplitude of ISP motion required for function is smaller than in the bc(1) complex.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cramer, WA (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	wac@bilbo.bio.purdue.edu			NIGMS NIH HHS [GM-38323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038323, R01GM038323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baymann F, 2001, BIOCHEMISTRY-US, V40, P10570, DOI 10.1021/bi010194a; BERGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V682, P452, DOI 10.1016/0005-2728(82)90060-3; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Berthold D. A., 1993, Plant Molecular Biology Reporter, V11, P338, DOI 10.1007/BF02905336; Bonisch H, 2002, J MOL BIOL, V319, P791, DOI 10.1016/S0022-2836(02)00323-6; BUZBY JS, 1985, SCIENCE, V230, P805, DOI 10.1126/science.2997920; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; CRAMER WA, 1994, J BIOENERG BIOMEMBR, V26, P31, DOI 10.1007/BF00763218; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; CROWDER MS, 1982, FEBS LETT, V144, P204, DOI 10.1016/0014-5793(82)80638-8; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; de Vitry C, 1999, PLANT CELL, V11, P2031, DOI 10.1105/tpc.11.10.2031; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heimann S, 2000, BIOCHEMISTRY-US, V39, P2692, DOI 10.1021/bi9921992; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee TX, 2001, BBA-BIOENERGETICS, V1504, P235, DOI 10.1016/S0005-2728(00)00253-X; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Obungu VH, 2000, BBA-BIOENERGETICS, V1457, P36, DOI 10.1016/S0005-2728(99)00116-4; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; Ponamarev MV, 2000, BIOCHEMISTRY-US, V39, P5971, DOI 10.1021/bi9928997; Roberts AG, 2002, BIOCHEMISTRY-US, V41, P4070, DOI 10.1021/bi015996k; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200; Schneider D, 2002, J BIOL CHEM, V277, P10949, DOI 10.1074/jbc.M104076200; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; Schoepp B, 2000, J BIOL CHEM, V275, P5275, DOI 10.1074/jbc.275.8.5275; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; Soriano GM, 2001, BIOCHEMISTRY-US, V40, P15109, DOI 10.1021/bi011465k; Soriano GM, 2001, HDB METALLOPROTEINS, P172; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WIDGER WR, 1991, PHOTOSYNTH RES, V30, P71, DOI 10.1007/BF00042005; Zhang HM, 2001, J BIOL CHEM, V276, P38159; Zhang JM, 1996, J BIOL CHEM, V271, P31360, DOI 10.1074/jbc.271.49.31360; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	52	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20925	20933		10.1074/jbc.M212616200	http://dx.doi.org/10.1074/jbc.M212616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12672829	hybrid			2022-12-25	WOS:000183230500063
J	Azmi, S; Sun, H; Ozog, A; Taneja, R				Azmi, S; Sun, H; Ozog, A; Taneja, R			mSharp-1/DEC2, a basic helix-loop-helix protein functions as a transcriptional repressor of E box activity and Stra13 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; DIRECT DNA-BINDING; NEURONAL DIFFERENTIATION; GENE; PROMOTER; HAIRY; MYOD; FAMILY; GROWTH; SPLIT	Transcription factors belonging to the basic helix-loop-helix (bHLH) family play critical roles in the regulation of cellular differentiation of distinct cell types. In this study, we have characterized the DNA-binding and transcriptional properties of the bHLH factor mSharp-1/DEC2. mSharp-1 belongs to the Hairy/Enhancer of Split subfamily of bHLH factors and exhibits the highest structural and sequence identity with Stra13. We show that mSharp-1 specifically binds to the E box motif (CANNTG) as a homodimer and acts as a potent transcriptional repressor of MyoD- and E12-induced E box activity and differentiation. The inhibitory activity of mSharp-1 occurs through several mechanisms including occupancy of E box sites by mSharp-1 homodimers and by direct physical interaction with MyoD and E proteins. Furthermore, by using gel mobility shift assays and chromatin immunoprecipitation experiments, we have identified Stra13 as a target for mSharp-1-mediated repression. We demonstrate that transcriptional repression of Stra13 depends, in part, on binding of mSharp-1 to three conserved E box motifs in the Stra13 proximal promoter. Moreover, mSharp-1 directly interacts with the transcriptional activator Sp1 and impairs Sp1 induction of Stra13 promoter. Our results suggest that mSharp-1 functions as a transcriptional repressor by DNA binding dependent and independent mechanisms.	Mt Sinai Sch Med, Brookdale Dept Med Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Taneja, R (corresponding author), Mt Sinai Sch Med, Brookdale Dept Med Cell & Dev Biol, New York, NY 10029 USA.		Taneja, Reshma/F-9658-2014	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177				Azmi S, 2002, MECH DEVELOP, V114, P181, DOI 10.1016/S0925-4773(02)00049-7; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 1998, MOL CELL BIOL, V18, P3130, DOI 10.1128/MCB.18.6.3130; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2002, DEVELOPMENT, V129, P3077; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	53	58	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20098	20109		10.1074/jbc.M210427200	http://dx.doi.org/10.1074/jbc.M210427200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657651	hybrid			2022-12-25	WOS:000183078000068
J	Houng, A; Polgar, J; Reed, GL				Houng, A; Polgar, J; Reed, GL			Munc18-syntaxin complexes and exocytosis in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GRANULE SECRETION; SYNAPTIC VESICLE FUSION; MOLECULAR MECHANISMS; GLUT4 TRANSLOCATION; NEGATIVE REGULATOR; 3T3-L1 ADIPOCYTES; VACUOLE FUSION; YEAST SEC1; SYNTAXIN; PROTEINS	The Sec1-Munc18 (SM) proteins are required for cellular exocytosis, but their mechanistic function remains poorly understood. We examined SM-syntaxin complexes in human platelets, which are terminally differentiated, anuclear cells that secrete the contents of their intracellular granules through syntaxin 2- and syntaxin 4-dependent mechanisms. Munc18a, Munc18b, and Munc18c were detected in human platelets by immunoblotting and/or PCR. The SM proteins and syntaxin 2 were found in the membrane and cytosolic fractions of cells, whereas syntaxin 4 was detected only in the membrane. Platelet membranes contain Munc18c-syntaxin 4 complexes, but minimal if any Munc18c-syntaxin 2 complexes were found. No significant amounts of Munc18a or Munc18b complexes were seen with either syntaxin. Munc18c-syntaxin 4 complexes were dissociated when cells were activated to secrete. Two potential inhibitors of Munc18c-syntaxin 4 complexes were generated to examine whether complex dissociation may lead to exocytosis. Peptides that mimic the projected intermolecular contact sites of Munc18c with syntaxin enhanced Ca2+-triggered dense granule exocytosis in permeabilized cells. Similarly, an anti-Munc18c monoclonal antibody that inhibited the Munc18c-syntaxin complex potently amplified Ca2+-induced platelet granule secretion. In summary, Munc18 proteins bind to specific syntaxin isoforms in platelets despite the presence of other potential binding partners. Acute inhibition of the SM-syntaxin complex promotes Ca2+-induced exocytosis, suggesting that complex formation per se has a regulatory effect on triggered secretion.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave, Boston, MA 02115 USA.	reed@cvlab.harvard.edu			NHLBI NIH HHS [HL-64057] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKKERMAN JWN, 1982, THROMB RES, V27, P59, DOI 10.1016/0049-3848(82)90278-X; AKKERMAN JWN, 1983, BIOCHEM J, V210, P145, DOI 10.1042/bj2100145; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bracher A, 2000, STRUCTURE, V8, P685, DOI 10.1016/S0969-2126(00)00156-8; Brummer MH, 2001, YEAST, V18, P1525, DOI 10.1002/yea.796; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; COORSSEN JR, 1990, CELL REGUL, V1, P1027, DOI 10.1091/mbc.1.13.1027; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Graham ME, 1997, J NEUROCHEM, V69, P2369; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOLMSEN H, 1989, METHOD ENZYMOL, V169, P205; HOLMSEN H, 1982, BIOCHEM J, V208, P9, DOI 10.1042/bj2080009; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; KAPLAN KL, 1979, BLOOD, V53, P604; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; Kauppi M, 2002, J BIOL CHEM, V277, P43973, DOI 10.1074/jbc.M208315200; KNIGHT DE, 1993, METHOD ENZYMOL, V221, P123, DOI 10.1016/0076-6879(93)21012-W; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; MICHELSON AD, 1996, PRACT APPROACH SER, P111; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Quinones B, 1999, J CELL SCI, V112, P4291; Reed GL, 2000, BLOOD, V96, P3334; REED GL, 1990, P NATL ACAD SCI USA, V87, P1114, DOI 10.1073/pnas.87.3.1114; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Sassa T, 1999, J NEUROSCI, V19, P4772; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; WITTE LD, 1978, CIRC RES, V42, P402, DOI 10.1161/01.RES.42.3.402; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200	54	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19627	19633		10.1074/jbc.M212465200	http://dx.doi.org/10.1074/jbc.M212465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649283	hybrid			2022-12-25	WOS:000183078000010
J	Lin, ZC; Zhang, PW; Zhu, XG; Melgari, JM; Huff, R; Spieldoch, RL; Uhl, GR				Lin, ZC; Zhang, PW; Zhu, XG; Melgari, JM; Huff, R; Spieldoch, RL; Uhl, GR			Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCAINE ANALOG RECOGNITION; FUNCTIONAL REGULATION; PHORBOL ESTERS; STRIATAL SYNAPTOSOMES; RAT STRIATUM; PHOSPHORYLATION; EXPRESSION; RECEPTORS; CLONING; CELLS	The dopamine transporter (DAT) modulates dopamine neurotransmission and is a primary target for psychostimulant influences on locomotion and reward. Selective DAT expression by dopaminergic neurons has led to use of cocaine analog DAT radioligands to assess rates of progression of dopamine neuronal degeneration in Parkinson's disease. We have documented that DAT is a phosphoprotein that is regulated by phosphorylation through pathways that include protein kinase C cascades. We now extend this work using drugs selective for phosphatidylinositol 3-kinase (PI3K), protein kinase C, MEK1/2, p38 kinase, and Ca2+/calmodulin kinase II. We compare the drug effects on wild type DAT to the effects on 20 DAT mutants and a DAT deletion. PI3K and MEK1/2 modulators exert strong effects on DAT expression patterns and dopamine uptake V-max. PKC principally modulates V-max. Neither p38 nor Ca2+/calmodulin kinase II agents exert significant influences on wild type DAT. Several mutants and a DAT with an N-terminal deletion display alterations that interact with the effects of kinase modulators, especially S7A for PKC effects; T62A, S581A, and T612A for PI3K effects; and S12A and T595A mutants for MEK1/2 effects. P-32-Labeling studies confirm several of these effects of kinase pathway modulators on DAT phosphorylation. DAT expression and activities can be regulated by kinase cascades that require phosphoacceptor sites most concentrated in its N terminus. These results have a number of implications for DAT regulation and mandate caution in using DAT radioligand binding to infer changes in dopaminergic neuronal integrity after treatments that alter activities of these kinase pathways.	NIDA, Mol Neurobiol Branch, IRP, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Uhl, GR (corresponding author), NIDA, Mol Neurobiol Branch, IRP, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000159, Z01DA000076, Z01DA000160] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Al-Hasani H, 2002, J CELL SCI, V115, P131; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azam L, 2002, J COMP NEUROL, V444, P260, DOI 10.1002/cne.10138; Bauman AL, 2000, J NEUROSCI, V20, P7571; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; Guttman M, 2001, NEUROLOGY, V56, P1559, DOI 10.1212/WNL.56.11.1559; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; Huff RA, 1997, J NEUROCHEM, V68, P225; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; Kim YJ, 2002, MOVEMENT DISORD, V17, P303, DOI 10.1002/mds.10042; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; Kugaya A, 2000, ANN NUCL MED, V14, P1, DOI 10.1007/BF02990472; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Nocjar C, 2002, NEUROSCIENCE, V111, P163, DOI 10.1016/S0306-4522(01)00593-0; PFENNING MA, 1990, NEUROTRANSMITTER REC, P147; Porras G, 2002, NEUROPSYCHOPHARMACOL, V26, P311, DOI 10.1016/S0893-133X(01)00333-5; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rodriguez-Pallares J, 2001, RECEPTOR CHANNEL, V7, P471; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; UCHIKAWA T, 1995, J NEUROCHEM, V65, P2065; Uhl GR, 2002, MOL PSYCHIATR, V7, P21, DOI 10.1038/sj/mp/4000964; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; Varrone A, 2001, MOVEMENT DISORD, V16, P1023, DOI 10.1002/mds.1256; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; Vrindavanam NS, 1996, NEUROSCI LETT, V216, P133; Yang JM, 2002, BIOCHEM PHARMACOL, V63, P959, DOI 10.1016/S0006-2952(02)00838-9; Zhang L, 1996, EUR J PHARMACOL, V315, P345, DOI 10.1016/S0014-2999(96)00646-2; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2	44	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20162	20170		10.1074/jbc.M209584200	http://dx.doi.org/10.1074/jbc.M209584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660249	hybrid			2022-12-25	WOS:000183078000075
J	Murumagi, A; Vahamurto, P; Peterson, P				Murumagi, A; Vahamurto, P; Peterson, P			Characterization of regulatory elements and methylation pattern of the autoimmune regulator (AIRE) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; BINDING PROTEIN; GENE; EXPRESSION; DNA; TRANSCRIPTION; LOCALIZATION; DEFICIENT; THYMUS; MOUSE	Defects in the AIRE gene cause a monogenic autoimmune syndrome APECED (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy), which is characterized by loss of self-tolerance to multiple organs. In concordance with its role in immune tolerance, AIRE is most strongly expressed in thymic epithelial cells and in cells of monocytic-dendritic lineage. The AIRE protein has been shown to function as a transcriptional regulator, however, the mechanisms regulating AIRE gene expression are not known. Here we have characterized the AIRE promoter region by identifying a minimal promoter region within 350 bp of the translation initiation codon. Electrophoretic mobility shift assays and transient transfections with mutated promoter constructs revealed a functional TATA box (-163 to -153) and binding sites for transcription complexes AP-1 (-307 to -296), NF-Y (-213 to -202), and Sp1 (-202 to -189). The presence of a 390-bp CpG island within the proximal promoter suggested that cytosine methylation has a role in transcriptional regulation of AIRE, which was supported by in vitro methylation experiments of promoter constructs. Sodium bisulfite sequencing showed a less methylated status of AIRE promoter in the thymic epithelial cell line TEC1A3 compared with HeLa and monocytic cells U937 and THP-1. Real-time PCR analysis showed that treatment with 5-aza-2'-deoxycytidine (5-azaCdR), a DNA methyltransferase inhibitor, up-regulated AIRE transcript levels in TEC1A3, U937, and HeLa cells and that even greater activations in TEC1A3 and U937 cells were observed using combined treatments with deacetylase inhibitor trichostatin A. These results suggest that AIRE gene expression is modulated through modifications in chromatin methylation and acetylation.	Univ Tampere, Inst Med Technol, Tampere 33014, Finland; Tampere Univ Hosp, Dept Pathol, Tampere 33014, Finland; Univ Tartu, Dept Biotechnol, EE-51010 Tartu, Estonia	Tampere University; Tampere University; Tampere University Hospital; University of Tartu	Peterson, P (corresponding author), Univ Tampere, Inst Med Technol, Lenkkeilijankatu 6, Tampere 33014, Finland.		Peterson, Pärt/A-5788-2009	Peterson, Pärt/0000-0001-6755-791X				AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mittaz L, 1999, BIOCHEM BIOPH RES CO, V255, P483, DOI 10.1006/bbrc.1999.0223; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Sambrook J., 2002, MOL CLONING LAB MANU	25	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19784	19790		10.1074/jbc.M210437200	http://dx.doi.org/10.1074/jbc.M210437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651856	hybrid			2022-12-25	WOS:000183078000029
J	Hirschler-Laszkiewicz, I; Cavanaugh, AH; Mirza, A; Lun, MY; Hu, QY; Smink, T; Rothblum, LI				Hirschler-Laszkiewicz, I; Cavanaugh, AH; Mirza, A; Lun, MY; Hu, QY; Smink, T; Rothblum, LI			Rrn3 becomes inactivated in the process of ribosomal DNA transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE ENCODES; RDNA TRANSCRIPTION; FACTOR SL1; TIF-IA; PHOSPHORYLATION; INITIATION; GENE; RECRUITMENT; PROMOTER	The human homologue of yeast Rrn3, a 72-kDa protein, is essential for ribosomal DNA (rDNA) transcription. Although the importance of Rrn3 function in rDNA transcription is well established, its mechanism of action has not been determined. It has been suggested that the phosphorylation of either yeast RNA polymerase I or mammalian Rrn3 regulates the formation of RNA polymerase I.Rrn3 complexes that can interact with the committed template. These and other reported differences would have implications with respect to the mechanism by which Rrn3 functions in transcription. For example, in the yeast rDNA transcription system, Rrn3 might function catalytically, but in the mammalian system it might function stoichiometrically. Thus, we examined the question as to whether Rrn3 functions catalytically or stoichiometrically. We report that mammalian Rrn3 becomes the limiting factor as transcription reactions proceed. Moreover, we demonstrate that Rrn3 is inactivated during the transcription reactions. For example, Rrn3 isolated from a reaction that had undergone transcription cannot activate transcription in a subsequent reaction. We also show that this inactivated Rrn3 not only dissociates from RNA polymerase I, but is not capable of forming a stable complex with RNA polymerase I. Our results indicate that Rrn3 functions stoichiometrically in rDNA transcription and that its ability to associate with RNA polymerase I is lost upon transcription.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Danville, PA 17821 USA		Rothblum, LI (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Danville, PA 17821 USA.							Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; Lin CW, 1996, MOL CELL BIOL, V16, P6436; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moorefield B, 2000, P NATL ACAD SCI USA, V97, P4724, DOI 10.1073/pnas.080063997; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Paule MR., 1998, TRANSCRIPTION RIBOSO; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	38	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18953	18959		10.1074/jbc.M301093200	http://dx.doi.org/10.1074/jbc.M301093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646563	hybrid			2022-12-25	WOS:000182932200032
J	Maeda, N; Kawada, N; Seki, S; Arakawa, T; Ikeda, K; Iwao, H; Okuyama, H; Hirabayshi, J; Kasai, K; Yoshizato, K				Maeda, N; Kawada, N; Seki, S; Arakawa, T; Ikeda, K; Iwao, H; Okuyama, H; Hirabayshi, J; Kasai, K; Yoshizato, K			Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; S-TYPE LECTIN; EXTRACELLULAR-MATRIX; ENDOGENOUS LECTIN; MOLECULAR MECHANISMS; SURFACE EXPRESSION; GROWTH-FACTOR; T-CELLS; PROTEIN; ADHESION	We found that the expression of galectin-1 and galectin-3 was significantly up-regulated in hepatic stellate cells (HSCs) both in the course of their transdifferentiation into myofibroblasts, a process of "self-activation," and in the fibrosis of liver tissues. Recombinant galectin-1 and galectin-3 stimulated the proliferation of cultured HSCs via the MEK1/2-ERK1/2 signaling pathway. However, galectin-3 utilized protein kinases C and A to induce this process, whereas galectin-1 did not. We also found that thiodigalactoside, a potent inhibitor of beta-galactoside binding, attenuated the effects of both galectins. In addition, galectin-1, but not galectin-3, promoted the migration of HSCs. Thus, it appears that galectin-1 and galectin-3, generated by activated HSCs, could participate in beta-galactoside binding and induce different intracellular signaling pathways leading to the proliferation of HSCs.	Osaka City Univ, Dept Hepatol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Dept Gastroenterol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Dept Anat, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Dept Pharmacol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Kyoto Univ, Dept Surg Gastroenterol, Grad Sch Med, Sakyo Ku, Kyoto 6068397, Japan; Teikyo Univ, Dept Biol Chem, Fac Pharmaceut Sci, Kanagawa 1990195, Japan; Hiroshia Univ, Dept Sci Biol, Grad Sch Sci, Hiroshima 7398526, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Kyoto University; Teikyo University; Hiroshima University	Kawada, N (corresponding author), Osaka City Univ, Dept Hepatol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan.	kawadanori@med.osaka-cu.ac.jp	kawada, norifumi/AAS-1367-2020					BALLARDINI G, 1983, LIVER, V3, P58; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bianchet MA, 2000, PROTEINS, V40, P378, DOI 10.1002/1097-0134(20000815)40:3<378::AID-PROT40>3.0.CO;2-7; CENACCHI G, 1983, VIRCHOWS ARCH B, V43, P75, DOI 10.1007/BF02932946; Cho MJ, 1997, TRENDS GLYCOSCI GLYC, V9, P47, DOI 10.4052/tigg.9.47; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GRESSNER AM, 1995, DIGESTION, V56, P335, DOI 10.1159/000201257; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; HIRABAYASHI J, 1984, BIOCHEM BIOPH RES CO, V122, P938, DOI 10.1016/0006-291X(84)91181-1; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.3.CO;2-S; Ikeda K, 1999, HEPATOLOGY, V29, P1760, DOI 10.1002/hep.510290640; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; Inohara H, 1996, CANCER RES, V56, P4530; Inohara H, 1998, EXP CELL RES, V245, P294, DOI 10.1006/excr.1998.4253; INOHARA H, 1995, CANCER RES, V55, P3267; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; Mey A, 1996, J IMMUNOL, V156, P1572; MIRLECHAIRE FJ, 1978, NATURE, V272, P256, DOI 10.1038/272256a0; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Moiseeva EP, 2000, CARDIOVASC RES, V45, P493, DOI 10.1016/S0008-6363(99)00276-X; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nakatani K, 2002, VIRCHOWS ARCH, V441, P466, DOI 10.1007/s00428-002-0631-z; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; ODA Y, 1991, GENE, V99, P279; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Okuyama H, 2001, J BIOL CHEM, V276, P28274, DOI 10.1074/jbc.M102995200; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Pinzani M, 1998, LIVER, V18, P2; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 2000, CELL DEATH DIFFER, V7, P747, DOI 10.1038/sj.cdd.4400708; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; Sanjuan X, 1997, GASTROENTEROLOGY, V113, P1906, DOI 10.1016/S0016-5085(97)70010-6; Santucci L, 2000, HEPATOLOGY, V31, P399, DOI 10.1002/hep.510310220; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; Shimonishi T, 2001, HUM PATHOL, V32, P302, DOI 10.1053/hupa.2001.22767; SKRINCOSKY DM, 1993, CANCER RES, V53, P2667; TAKEI Y, 1995, J GASTROEN HEPATOL, V10, pS65, DOI 10.1111/j.1440-1746.1995.tb01802.x; Vespa GNR, 1999, J IMMUNOL, V162, P799; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Walzel H, 2000, GLYCOBIOLOGY, V10, P131, DOI 10.1093/glycob/10.2.131; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	74	121	129	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18938	18944		10.1074/jbc.M209673200	http://dx.doi.org/10.1074/jbc.M209673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646584	hybrid			2022-12-25	WOS:000182932200030
J	Deming, D; Cheng, Q; Jayaraman, V				Deming, D; Cheng, Q; Jayaraman, V			Is the isolated ligand binding domain a good model of the domain in the native receptor?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE GLUTAMATE RECEPTORS; AMPA RECEPTOR; STABLE EXPRESSION; DESENSITIZATION; CORE	Numerous studies have used the atomic level structure of the isolated ligand binding domain of the glutamate receptor to elucidate the agonist-induced activation and desensitization processes in this group of proteins. However, no study has demonstrated the structural equivalence of the isolated ligand binding fragments and the protein in the native receptor. In this report, using visible absorption spectroscopy we show that the electronic environment of the antagonist 6-cyano-7-nitro-2,3-dihydroxyquinoxaline is identical for the isolated protein and the native glutamate receptors expressed in cells. Our results hence establish that the local structure of the ligand binding site is the same in the two proteins and validate the detailed structure-function relationships that have been developed based on a comparison of the structure of the isolated ligand binding domain and electrophysiological consequences in the native receptor.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Jayaraman, V (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, MSB 4-106,6341 Fannin, Houston, TX 77030 USA.							Andersen PH, 1996, EUR J PHARMACOL, V311, P95, DOI 10.1016/0014-2999(96)00399-8; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Hennegriff M, 1997, J NEUROCHEM, V68, P2424; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; MUNSON PJ, 1988, J RECEPTOR RES, V8, P533, DOI 10.3109/10799898809049010; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	16	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17589	17592		10.1074/jbc.C300105200	http://dx.doi.org/10.1074/jbc.C300105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12657650	hybrid			2022-12-25	WOS:000182838300002
J	Rosenblum, G; Meroueh, SO; Kleifeld, O; Brown, S; Singson, SP; Fridman, R; Mobashery, S; Sagi, I				Rosenblum, G; Meroueh, SO; Kleifeld, O; Brown, S; Singson, SP; Fridman, R; Mobashery, S; Sagi, I			Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; TISSUE INHIBITOR; IV COLLAGENASE; ACTIVATION; MECHANISM; SURFACE; LATENT; CANCER; FORMS	The zinc-dependent gelatinases belong to the family of matrix metalloproteinases ( MMPs), enzymes that have been shown to play a key role in angiogenesis and tumor metastasis. These enzymes are capable of hydrolyzing extracellular matrix (ECM) components under physiological conditions. Specific and selective inhibitors aimed at blocking their activity are highly sought for use as potential therapeutic agents. We report herein on a novel mode of inhibition of gelatinase A (MMP-2) by the recently characterized inhibitors 4-(4-phenoxphenylsulfonyl) butane-1,2-dithiol ( inhibitor 1) and 5-(4-phenoxphenylsulfonyl) pentane-1,2-dithiol ( inhibitor 2). These synthetic inhibitors are selective for MMP-2 and MMP-9. We show that the dithiolate moiety of these inhibitors chelates the catalytic zinc ion of MMP-2 via two sulfur atoms. This mode of binding results in alternation of the coordination number of the metal ion and the induction of conformational changes at the microenvironment of the catalytic zinc ion; a set of events that is likely to be at the root of the potent slow binding inhibition behavior exhibited by these inhibitors. This study demonstrates a distinct approach for the understanding of the structural mechanism governing the molecular interactions between potent inhibitors and catalytic sites of MMPs, which may aid in the design of effective inhibitors.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Dept Pharmacol, Detroit, MI 48202 USA; Wayne State Univ, Dept Biochem, Detroit, MI 48202 USA; Wayne State Univ, Dept Biol Mol, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA	Weizmann Institute of Science; Wayne State University; Wayne State University; Wayne State University; Wayne State University; Wayne State University	Sagi, I (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	irit.sagi@weizmann.ac.il	Kleifeld, Oded/G-7304-2012		NATIONAL CANCER INSTITUTE [R01CA100475, R01CA061986, R01CA082298] Funding Source: NIH RePORTER; NCI NIH HHS [CA100475, CA82298, CA61986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Brown PD, 1998, BREAST CANCER RES TR, V52, P125, DOI 10.1023/A:1006119319695; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Case D., 1999, AMBER; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Crabbe T, 1996, FEBS LETT, V380, P53, DOI 10.1016/0014-5793(96)00005-1; Cross JB, 2002, J AM CHEM SOC, V124, P11004, DOI 10.1021/ja0201810; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Frisch M. J., 1998, GAUSSIAN 98; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Kleifeld O, 2003, NAT STRUCT BIOL, V10, P98, DOI 10.1038/nsb889; Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; STERN EA, 1995, PHYSICA B, V208, P117, DOI 10.1016/0921-4526(94)00826-H; STERN EA, 1993, PHYS REV B, V48, P9825, DOI 10.1103/PhysRevB.48.9825; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995	39	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27009	27015		10.1074/jbc.M301139200	http://dx.doi.org/10.1074/jbc.M301139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12679334	hybrid			2022-12-25	WOS:000184155700092
J	Jiang, KC; Pereira, E; Maxfield, M; Russell, B; Goudelock, DM; Sanchez, Y				Jiang, KC; Pereira, E; Maxfield, M; Russell, B; Goudelock, DM; Sanchez, Y			Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; NUCLEAR EXPORT SIGNAL; XENOPUS EGG EXTRACTS; CELL-CYCLE; FISSION YEAST; HUMAN HOMOLOGS; KINASE CHK1; PROTEIN; ATR; COMPLEXES	Checkpoints are biochemical pathways that provide the cell with mechanisms to detect DNA damage and respond by arresting the cell cycle to allow DNA repair. The conserved checkpoint kinase Chk1 regulates mitotic progression in response to DNA damage and replication interference by blocking the activation of Cdk1/cyclin B. Chk1 is phosphorylated on Ser-317 and Ser-345 following a checkpoint signal, a process that is regulated by Atr, and by the sensor complexes containing Rad17 and Hus1. We show that Chk1 is associated with chromatin in cycling cells and that the chromatin-associated Chk1 is phosphorylated in the absence of exogenous DNA damage. The UV-induced Ser-345-phosphorylated forms of Chk1 that appear minutes after treatment are predominantly associated with chromatin. The Ser-345 site is in a 14-3-3 consensus binding motif and is required for nuclear retention of Chk1 following an hydroxyurea-induced checkpoint signal; nonetheless, Ser-345 or Ser-317 are not required for the chromatin association of Chk1. Hus1, a member of the proliferating cell nuclear antigen-like damage recognition complex plays a role in the phosphorylation of Chk1 on Ser-345, however, Hus1 is not required for phosphorylation on Ser-317 or for Chk1 localization to chromatin. These results indicate that there is more than one step in Chk1 activation and that the regulation of this checkpoint signaling is achieved at least in part through phosphorylation of Ser-345, which serves to localize Chk1 in the nucleus presumably by blocking Crm1-dependent nuclear export.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Sanchez, Y (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [R01CA084463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84463] Funding Source: Medline; NIEHS NIH HHS [P30 ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chehab NH, 2000, GENE DEV, V14, P278; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; MEYN MS, 1995, CANCER RES, V55, P5991; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shieh SY, 2000, GENE DEV, V14, P289; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Takai H, 2000, GENE DEV, V14, P1439; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	46	120	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25207	25217		10.1074/jbc.M300070200	http://dx.doi.org/10.1074/jbc.M300070200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12676962	hybrid			2022-12-25	WOS:000183824800115
J	Levin, MK; Gurjar, MM; Patel, SS				Levin, MK; Gurjar, MM; Patel, SS			ATP binding modulates the nucleic acid affinity of hepatitis C virus helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN-3; DOMAIN; COMPLEXES; ADP	The helicase of hepatitis C virus (HCV) unwinds nucleic acid using the energy of ATP hydrolysis. The ATPase cycle is believed to induce protein conformational changes to drive helicase translocation along the length of the nucleic acid. We have investigated the energetics of nucleic acid binding by HCV helicase to understand how the nucleotide ligation state of the helicase dictates the conformation of its nucleic acid binding site. Because most of the nucleotide ligation states of the helicase are transient due to rapid ATP hydrolysis, several compounds were analyzed to find an efficient unhydrolyzable ATP analog. We found that the beta-gamma methylene/amine analogs of ATP, ATPgammaS, or [AlF4] ADP were not effective in inhibiting the ATPase activity of HCV helicase. On the other hand, [BeF3] ADP was found to be a potent inhibitor of the ATPase activity, and it binds tightly to HCV helicase with a 1:1 stoichiometry. Equilibrium binding studies showed that HCV helicase binds single-stranded nucleic acid with a high affinity in the absence of ATP or in the presence of ADP. Upon binding to the ATP analog, a 100-fold reduction in affinity for ssDNA was observed. The reduction in affinity was also observed in duplex DNA with 3' single-stranded tail and in RNA but not in duplex DNA. The results of this study indicate that the nucleic acid binding site of HCV helicase is allosterically modulated by the ATPase reaction. The binding energy of ATP is used to bring HCV helicase out of a tightly bound state to facilitate translocation, whereas ATP hydrolysis and product release steps promote tight rebinding of the helicase to the nucleic acid. On the basis of these results we propose a Brownian motor model for unidirectional translocation of HCV helicase along the nucleic acid length.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Gwack Y, 1999, J VIROL, V73, P2909, DOI 10.1128/JVI.73.4.2909-2915.1999; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; LEVIN MK, 2002, MOL MOTORS, P179; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; PONOMAREV MA, 1995, FEBS LETT, V371, P261, DOI 10.1016/0014-5793(95)00898-J; Porter DJT, 1998, J BIOL CHEM, V273, P7390, DOI 10.1074/jbc.273.13.7390; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Shibuya H, 2002, J BIOCHEM, V132, P573, DOI 10.1093/oxfordjournals.jbchem.a003259; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	19	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23311	23316		10.1074/jbc.M301283200	http://dx.doi.org/10.1074/jbc.M301283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12660239	hybrid			2022-12-25	WOS:000183638600014
J	Bonamore, A; Gentili, P; Ilari, A; Schinina, ME; Boffi, A				Bonamore, A; Gentili, P; Ilari, A; Schinina, ME; Boffi, A			Escherichia coli flavohemoglobin is an efficient alkylhydroperoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL-HYDROPEROXIDE REDUCTASE; NITRIC-OXIDE DIOXYGENASE; HYDROGEN-PEROXIDE; HEMOGLOBINS; RESPONSES; GLOBIN; FAMILY; SOXR	Escherichia coli flavohemoglobin (HMP) is shown to be capable of catalyzing the reduction of several alkylhydroperoxide substrates into their corresponding alcohols using NADH as an electron donor. In particular, HMP possesses a high catalytic activity and a low K-m toward cumyl, linoleic acid, and tert-butyl hydroperoxides, whereas it is a less efficient hydrogen peroxide scavenger. An analysis of UV-visible spectra during the stationary state reveals that at variance with classical peroxidases, HMP turns over in the ferrous state. In particular, an iron oxygen adduct intermediate whose spectrum is similar to that reported for the oxo-ferryl derivative in peroxidases (Compound II), has been identified during the catalysis of hydrogen peroxide reduction. This finding suggests that hydroperoxide cleavage occurs upon direct binding of a peroxide oxygen atom to the ferrous heme iron. Competitive inhibition of the alkylhydroperoxide reductase activity by carbon monoxide has also been observed, thus confirming that heme iron is directly involved in the catalytic mechanism of hydroperoxide reduction. The alkylhydroperoxide reductase activity taken together with the unique lipid binding properties of HMP suggests that this protein is most likely involved in the repair of the lipid membrane oxidative damage generated during oxidative/nitrosative stress.	Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Chem, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; Sapienza University Rome	Boffi, A (corresponding author), Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy.	alberto.boffi@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Ilari, Andrea/T-5501-2017; Patrizia, Gentili/I-4709-2012; Bonamore, Alessandra/AAB-2587-2019	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Bonamore, Alessandra/0000-0002-3940-4657; GENTILI, Patrizia/0000-0001-7410-7538				Anjum MF, 1998, FEMS MICROBIOL LETT, V166, P219, DOI 10.1111/j.1574-6968.1998.tb13893.x; Baier M, 1999, TRENDS PLANT SCI, V4, P166, DOI 10.1016/S1360-1385(99)01398-9; Bollinger CJT, 2001, BIOTECHNOL PROGR, V17, P798, DOI 10.1021/bp010091j; Bonamore A, 2001, BBA-PROTEIN STRUCT M, V1549, P174, DOI 10.1016/S0167-4838(01)00256-4; BONAMORE A, 2003, IN PRESS BIOCHEMISTR; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Gaber A, 2001, FEBS LETT, V499, P32, DOI 10.1016/S0014-5793(01)02517-0; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; Nishiyama Y, 2001, J BACTERIOL, V183, P2431, DOI 10.1128/JB.183.8.2431-2438.2001; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Pathania R, 2002, J BIOL CHEM, V277, P15293, DOI 10.1074/jbc.M111478200; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	31	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22272	22277		10.1074/jbc.M301285200	http://dx.doi.org/10.1074/jbc.M301285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12663656	hybrid, Green Published			2022-12-25	WOS:000183503900014
J	Mendel, J; Heinecke, K; Fyrst, H; Saba, JD				Mendel, J; Heinecke, K; Fyrst, H; Saba, JD			Sphingosine phosphate lyase expression is essential for normal development in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SPHINGOSINE-1-PHOSPHATE LYASE; BACILLUS-THURINGIENSIS; CELL-MIGRATION; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; GENETIC INTERFERENCE; KINASE; 1-PHOSPHATE; RECEPTOR	Sphingolipids are ubiquitous membrane constituents whose metabolites function as signaling molecules in eukaryotic cells. Sphingosine 1-phosphate, a key sphingolipid second messenger, regulates proliferation, motility, invasiveness, and programmed cell death. These effects of sphingosine 1-phosphate and similar phosphorylated sphingoid bases have been observed in organisms as diverse as yeast and humans. Intracellular levels of sphingosine 1-phosphate are tightly regulated by the actions of sphingosine kinase, which is responsible for its synthesis and sphingosine-1-phosphate phosphatase and sphingosine phosphate lyase, the two enzymes responsible for its catabolism. In this study, we describe the cloning of the Caenorhabditis elegans sphingosine phosphate lyase gene along with its functional expression in Saccharomyces cerevisiae. Promoter analysis indicates tissue-specific and developmental regulation of sphingosine phosphate lyase gene expression. Inhibition of C. elegans sphingosine phosphate lyase expression by RNA interference causes accumulation of phosphorylated and unphosphorylated long-chain bases and leads to poor feeding, delayed growth, reproductive abnormalities, and intestinal damage similar to the effects seen with exposure to Bacillus thuringiensis toxin. Our results show that sphingosine phosphate lyase is an essential gene in C. elegans and suggest that the sphingolipid degradative pathway plays a conserved role in regulating animal development.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; California Institute of Technology	Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org			NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA77528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVERY L, 1993, GENETICS, V133, P897; Baumruker T, 2000, INT ARCH ALLERGY IMM, V122, P85, DOI 10.1159/000024363; Brindley DN, 2000, METHOD ENZYMOL, V311, P233; Brownlee C, 2001, CURR BIOL, V11, pR535, DOI 10.1016/S0960-9822(01)00313-X; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CHRISTIANSEN K, 1983, BIOCHIM BIOPHYS ACTA, V735, P225, DOI 10.1016/0005-2736(83)90297-3; Chun J, 1999, CRIT REV NEUROBIOL, V13, P151, DOI 10.1615/CritRevNeurobiol.v13.i2.20; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; EPSTEIN H, 1995, METHOD CELL BIOL, V48, P3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Huang PB, 1998, ANAL BIOCHEM, V259, P89, DOI 10.1006/abio.1998.2633; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kern R, 2001, BIOCHEM BIOPH RES CO, V289, P1268, DOI 10.1006/bbrc.2001.6093; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kim S, 2000, GENETICS, V156, P1519; Kohara Y, 2001, Tanpakushitsu Kakusan Koso, V46, P2425; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Li GC, 2001, DEVELOPMENT, V128, P3473; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Loeb MJ, 2001, J INSECT PHYSIOL, V47, P599, DOI 10.1016/S0022-1910(00)00150-5; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Marroquin LD, 2000, GENETICS, V155, P1693; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; STOFFEL W, 1969, H-S Z PHYSIOL CHEM, V350, P1233, DOI 10.1515/bchm2.1969.350.2.1233; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1994, BIOCHEM J, V299, P597, DOI 10.1042/bj2990597; Vie V, 2001, J MEMBRANE BIOL, V180, P195, DOI 10.1007/s002320010070; White J., 1988, NEMATODE CAENORHABDI, V17, P81; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Young KW, 2000, J BIOL CHEM, V275, P38532, DOI 10.1074/jbc.M006631200; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	55	58	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22341	22349		10.1074/jbc.M302857200	http://dx.doi.org/10.1074/jbc.M302857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682045	Green Accepted, hybrid			2022-12-25	WOS:000183503900024
J	Yamaji-Hasegawa, A; Makino, A; Baba, T; Senoh, Y; Kimura-Suda, H; Sato, SB; Terada, N; Ohno, S; Kiyokawa, E; Umeda, M; Kobayashi, T				Yamaji-Hasegawa, A; Makino, A; Baba, T; Senoh, Y; Kimura-Suda, H; Sato, SB; Terada, N; Ohno, S; Kiyokawa, E; Umeda, M; Kobayashi, T			Oligomerization and pore formation of a sphingomyelin-specific toxin, lysenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EISENIA-FETIDA-ANDREI; VIBRIO-CHOLERAE CYTOLYSIN; CELOMIC FLUID; FORMING PROTEIN; CAUSES CONTRACTION; MEMBRANE FLUIDITY; LIPID-COMPOSITION; BINDING-PROTEIN; STREPTOLYSIN-O; EQUINATOXIN-II	Lysenin is a novel protein derived from coelomic fluid of the earthworm Eisenia foetida, which specifically recognizes sphingomyelin and induces cytolysis. The mechanism underlying lysenin- induced cell lysis has not been clarified. In this report we studied the interaction of lysenin with red blood cells as well as artificial liposomes. Our results showed that lysenin bound membranes and assembled to SDS- resistant oligomers in a sphingomyelin- dependent manner, leading to the formation of pores with a hydrodynamic diameter of similar to 3 nm. Antibody scanning analysis suggested that the C-terminal region of lysenin was exposed, whereas the N- terminal was hidden in the isolated oligomer complex. Differential scanning calorimetry revealed that lysenin interacted with both hydrophilic head group and hydrophobic hydrocarbon tails of sphingomyelin. Oligomerization but not binding was affected by the amide- linked fatty acid composition of sphingomyelin, suggesting the role of membrane fluidity in the oligomerization step.	RIKEN, Suprabiomol Syst Res Grp, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Yamanashi, Dept Anat, Fac Med, Yamanashi 4093898, Japan; Kyoto Univ, Dept Biophys, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; PRESTO, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan; Inst Natl Sci Appl, INSERM, U352, F-69621 Villeurbanne, France	RIKEN; University of Yamanashi; Kyoto University; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon	Kobayashi, T (corresponding author), RIKEN, Suprabiomol Syst Res Grp, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan.		KOBAYASHI, TOSHIHIDE/S-8313-2019; kimura-suda, Hiromi/ABA-9749-2020; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; kimura-suda, Hiromi/0000-0002-4335-9027; Kobayashi, Toshihide/0000-0002-4811-7270				BERNHEIMER AW, 1976, P NATL ACAD SCI USA, V73, P467, DOI 10.1073/pnas.73.2.467; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Fontt EO, 2002, DEV COMP IMMUNOL, V26, P27, DOI 10.1016/S0145-305X(01)00048-9; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; KISHIMOTO Y, 1975, CHEM PHYS LIPIDS, V15, P33, DOI 10.1016/0009-3084(75)90029-8; Kobayashi H, 2000, J EXP ZOOL, V286, P538, DOI 10.1002/(SICI)1097-010X(20000401)286:5<538::AID-JEZ12>3.0.CO;2-W; KOBAYASHI H, 1997, NEUROENDOCRINOLOGY R, P255; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange S, 1997, J BIOL CHEM, V272, P20884, DOI 10.1074/jbc.272.33.20884; Lange S, 1999, EUR J BIOCHEM, V262, P547, DOI 10.1046/j.1432-1327.1999.00407.x; Lassegues M, 1997, EUR J BIOCHEM, V246, P756, DOI 10.1111/j.1432-1033.1997.00756.x; Makino A, 2003, J BIOL CHEM, V278, P3204, DOI 10.1074/jbc.M210347200; Milochau A, 1997, BBA-PROTEIN STRUCT M, V1337, P123, DOI 10.1016/S0167-4838(96)00160-4; Nakai Y, 2000, J NEUROSCI RES, V62, P521, DOI 10.1002/1097-4547(20001115)62:4<521::AID-JNR6>3.0.CO;2-8; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; ROCH P, 1991, DEV COMP IMMUNOL, V15, P27, DOI 10.1016/0145-305X(91)90044-Y; ROCH P, 1989, BIOCHIM BIOPHYS ACTA, V983, P193, DOI 10.1016/0005-2736(89)90233-2; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Sekizawa Y, 1996, BIOMED RES-TOKYO, V17, P197, DOI 10.2220/biomedres.17.197; Sekizawa Y, 1997, GENE, V191, P97, DOI 10.1016/S0378-1119(97)00047-4; Sliwinski-Korell A, 1999, EUR J BIOCHEM, V265, P221, DOI 10.1046/j.1432-1327.1999.00718.x; TOMITA T, 1992, J BIOL CHEM, V267, P13391; VAILLIER J, 1985, DEV COMP IMMUNOL, V9, P11, DOI 10.1016/0145-305X(85)90055-2; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; Zitzer A, 2000, BBA-BIOMEMBRANES, V1509, P264, DOI 10.1016/S0005-2736(00)00303-5	37	106	108	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22762	22770		10.1074/jbc.M213209200	http://dx.doi.org/10.1074/jbc.M213209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676961	hybrid			2022-12-25	WOS:000183503900079
J	Higashi, Y; Itabe, H; Fukase, H; Mori, M; Fujimoto, Y; Takano, T				Higashi, Y; Itabe, H; Fukase, H; Mori, M; Fujimoto, Y; Takano, T			Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; PLASMA-MEMBRANE CHOLESTEROL; APOLIPOPROTEIN-B SECRETION; HEPG2 CELLS; INTRACELLULAR DEGRADATION; APO-B; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; FATTY-ACIDS	Very low density lipoprotein ( VLDL), a large particle containing apolipoprotein B ( apoB) and large amounts of neutral lipids, is formed in the luminal space within the endoplasmic reticulum ( ER) of hepatic cells. The assembly mechanism of VLDL particles is a tightly regulated process where apoB, associated with an insufficient amount of lipids, is selectively degraded intracellularly. In this study we found that treatment of HuH- 7 human hepatoma cells with verapamil inhibited secretion of apoB- containing lipoprotein particles through increasing degradation of apoB. Addition of N- acetyl-leucyl-leucyl- norleucinal, an inhibitor of proteasome and other cysteinyl proteases that are responsible for apoB degradation, restored apoB recovery from verapamil-treated cells. De novo synthesis of lipids from [ C-14] acetate was increased in the presence of verapamil, suggesting that verapamil decreases lipid availability for apoB thus leading to the secretion of apoB- containing lipoprotein. We prepared cytosolic fractions from cells preincubated with [C-14] acetate and used as a donor of radioactive lipids. When this cytosolic fraction was incubated with microsomes isolated separately, radioactive triglyceride ( TG) accumulated in the luminal space of the microsomes. The transfer of radioactive TG from the cytosolic fraction to the microsomal lumen was inhibited in the presence of verapamil, suggesting that there is a verapamil- sensitive mechanism for TG transfer across ER membranes that is involved in formation of apoB- containing lipoprotein particles in ER. Verapamil showed no inhibitory effect on microsomal TG transfer protein, a well known lipid transfer protein in ER. We propose from these results that there is novel machinery for transmembrane movement of neutral lipids, which is involved in providing TG for apoB during VLDL assembly in ER.	Teikyo Univ, Fac Pharmaceut Sci, Dept Mol Pathol, Kanagawa 1990195, Japan	Teikyo University	Takano, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Mol Pathol, 1094-1 Suarashi, Kanagawa 1990195, Japan.		板部板部, 洋之/ABC-7746-2020; Higashi, Yukihito/G-5343-2019					Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; COLEMAN RA, 1983, ENZYMES, V16, P605; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FERRY DR, 1985, BRIT J PHARMACOL, V84, P811, DOI 10.1111/j.1476-5381.1985.tb17375.x; FIELD FJ, 1995, J LIPID RES, V36, P1533; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FORD JM, 1990, PHARMACOL REV, V42, P155; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Graham A, 1996, BBA-LIPID LIPID MET, V1302, P46, DOI 10.1016/0005-2760(96)00030-6; Higashi Y, 2002, BBA-MOL CELL BIOL L, V1581, P127, DOI 10.1016/S1388-1981(02)00157-9; Itabe H, 2000, BBA-MOL CELL BIOL L, V1487, P233, DOI 10.1016/S1388-1981(00)00098-6; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; KWONG TC, 1989, BIOCHEM J, V263, P411, DOI 10.1042/bj2630411; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Liang JS, 2001, J BIOL CHEM, V276, P28606, DOI 10.1074/jbc.M100294200; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; PLUMB JA, 1990, BIOCHEM PHARMACOL, V39, P787, DOI 10.1016/0006-2952(90)90160-M; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SATO R, 1990, J BIOL CHEM, V265, P11880; SATO R, 1990, BIOCHIM BIOPHYS ACTA, V1042, P36, DOI 10.1016/0005-2760(90)90053-Z; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SUCKLING KE, 1985, J LIPID RES, V26, P647; TANAKA M, 1993, J BIOL CHEM, V268, P12713; THRIFT RN, 1986, J LIPID RES, V27, P236; WATTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; Wilcox LJ, 1999, J LIPID RES, V40, P1078; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yang LY, 1996, J LIPID RES, V37, P262; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	41	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21450	21458		10.1074/jbc.M301376200	http://dx.doi.org/10.1074/jbc.M301376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670935	hybrid			2022-12-25	WOS:000183354200019
J	Ly, DP; Zazzali, KM; Corbett, SA				Ly, DP; Zazzali, KM; Corbett, SA			De Novo expression of the Integrin alpha(5)beta(1) regulates alpha(v)beta(3)-mediated adhesion and migration on fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL MIGRATION; FIBRONECTIN RECEPTOR; GLYCOPROTEIN-IIB; LIGAND-BINDING; HIGH-AFFINITY; ACTIVATION; MODULATION; PAXILLIN; ALPHA-V-BETA-3; DOMAIN	Recent evidence demonstrates that interactions between different integrins that are present on the cell surface can strongly influence the adhesive function of individual receptors. In this report, we show that Chinese hamster ovary cells that express the integrin alpha(v)beta(3) in the absence of alpha(5)beta(1) demonstrate increased adhesion and migration on fibrinogen. Furthermore, alpha(v)beta(3)-mediated adhesion to fibrinogen is not augmented by the soluble agonist, MnCl2, suggesting that alpha(v)beta(3) exists in a higher affinity state in these cells. De novo expression of wild-type alpha(5)beta(1) negatively regulates alpha(v)beta(3)-mediated adhesion and migration. This effect is not seen with expression of a chimeric alpha(5)beta(1) integrin in which the cytoplasmic portion of the alpha(5) integrin subunit is replaced by the cytoplasmic portion of the alpha(4) integrin. In addition, it does not require ligation of alpha(5)beta(1) by fibronectin. Cells that express a constitutively active beta(3) integrin that contains a point mutation in the conserved membrane proximal region of the cytoplasmic tail, D723R, are resistant to the effect of alpha(5)beta(1) expression. These data provide additional evidence of "cross-talk" between the integrins alpha(5)beta(1) and alpha(v)beta(3), and support the idea that alpha(5)beta(1) regulates alpha(v)beta(3)-mediated ligand binding. This provides a relevant biological mechanism whereby variations in alpha(5)beta(1) expression in vivo may modulate activation of alpha(v)beta(3) to influence its adhesive function.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Corbett, SA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 061847-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Berman A E, 2000, Membr Cell Biol, V13, P207; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bonnefoy A, 2000, BIOPHYS J, V78, P2834, DOI 10.1016/S0006-3495(00)76826-3; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; CLARK RAF, 1990, J INVEST DERMATOL, V94, P128; Corbett SA, 1999, J SURG RES, V83, P27, DOI 10.1006/jsre.1998.5552; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Gailit J, 1997, EXP CELL RES, V232, P118, DOI 10.1006/excr.1997.3512; Han JW, 2001, J BIOL CHEM, V276, P40903, DOI 10.1074/jbc.M102665200; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; PARISE LV, 1993, BIOCHEM J, V289, P445, DOI 10.1042/bj2890445; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; Stouffer GA, 1998, CIRCULATION, V97, P907, DOI 10.1161/01.CIR.97.9.907; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347	42	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21878	21885		10.1074/jbc.M212538200	http://dx.doi.org/10.1074/jbc.M212538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676956	hybrid			2022-12-25	WOS:000183354200072
J	Wang, YK; Wang, YH; Wang, CZ; Sung, JM; Chiu, WT; Lin, SH; Chang, YH; Tang, MJ				Wang, YK; Wang, YH; Wang, CZ; Sung, JM; Chiu, WT; Lin, SH; Chang, YH; Tang, MJ			Rigidity of collagen fibrils controls collagen gel-induced down-regulation of focal adhesion complex proteins mediated by alpha(2)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; CANINE KIDNEY-CELLS; GROWTH-FACTOR; I COLLAGEN; CYCLIN D1; APOPTOSIS; PHOSPHORYLATION; ACTIVATION; MATRIX; MECHANOTRANSDUCTION	Previous studies have shown that collagen gel overlay induced selective proteolysis of focal adhesion complex proteins in Madin-Darby canine kidney (MDCK) cells. In this study, we examined whether morphological and biochemical changes were present in cells cultured on collagen gel. We found that focal adhesion complex proteins, including focal adhesion kinase (FAK), talin, paxillin, and p130(cas), but not vinculin, were decreased within 1 h when MDCK cells were cultured on collagen gel. Collagen gel-induced selective decrease of focal adhesion proteins was observed in all lines of cells examined, including epithelial, fibroblastic, and cancer cells. Matrigel also induced selective down-regulation of focal adhesion proteins. However, cells cultured on collagen gel- or matrigel-coated dishes did not show any changes of focal adhesion proteins. These data suggest that the physical nature of the gel, i.e. the rigidity, is involved in the expression of focal adhesion proteins. The collagen gel- induced down-regulation of focal adhesion complex proteins was caused by reduction of protein synthesis and activation of proteases such as calpain. Overexpression of a dominant negative mutant of discoidin domain receptor 1 (DDR1) or FAK-related non-kinase ( FRNK) did not prevent collagen gel- induced down-regulation of the focal adhesion complex protein, whereas an anti-alpha(2)beta(1) integrin-neutralizing antibody completely blocked it. Taken together, our results indicate that the rigidity of collagen gel controls the expression of focal adhesion complex proteins, which is mediated by alpha(2)beta(1) integrin but not DDR1.	Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Internal Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Tang, MJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363; Sung, Junne-Ming/0000-0003-1916-7815				Aikawa R, 2002, HYPERTENSION, V39, P233, DOI 10.1161/hy0202.102699; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Davis MJ, 2001, AM J PHYSIOL-HEART C, V280, pH1427, DOI 10.1152/ajpheart.2001.280.4.H1427; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hansen LK, 1999, J CELL SCI, V112, P2971; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jiang ST, 2000, KIDNEY INT, V57, P1539, DOI 10.1046/j.1523-1755.2000.00998.x; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; SHALLER MD, 2001, BIOCHIM BIOPHYS ACTA, V1540, P1; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tang MJ, 1998, AM J PHYSIOL-CELL PH, V275, pC921, DOI 10.1152/ajpcell.1998.275.4.C921; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang YK, 2001, AM J PHYSIOL-CELL PH, V280, pC1440, DOI 10.1152/ajpcell.2001.280.6.C1440; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	45	57	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21886	21892		10.1074/jbc.M300092200	http://dx.doi.org/10.1074/jbc.M300092200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676963	hybrid			2022-12-25	WOS:000183354200073
J	Leimkuhler, S; Hodson, R; George, GN; Rajagopalan, KV				Leimkuhler, S; Hodson, R; George, GN; Rajagopalan, KV			Recombinant Rhodobacter capsulatus xanthine dehydrogenase, a useful model system for the characterization of protein variants leading to xanthinuria I in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURES; NITRATE REDUCTASE; ESCHERICHIA-COLI; OXIDASE; GENE; MECHANISM; FORMS; IDENTIFICATION	Rhodobacter capsulatus xanthine dehydrogenase (XDH) forms an (alphabeta)(2) heterotetramer and is highly homologous to homodimeric eukaryotic XDHs. The crystal structures of bovine XDH and R. capsulatus XDH showed that the two proteins have highly similar folds. We have developed an efficient system for the recombinant expression of R. capsulatus XDH in Escherichia coli. The recombinant protein shows spectral features and a range of substrate specificities similar to bovine milk xanthine oxidase. However, R. capsulatus XDH is at least 5 times more active than bovine XDH and, unlike mammalian XDH, does not undergo the conversion to the oxidase form. EPR spectra were obtained for the FeS centers of the enzyme showing an axial signal for FeSI, which is different from that reported for xanthine oxidase. X-ray absorption spectroscopy at the iron and molybdenum K-edge and the tungsten L-III-edge have been used to probe the different metal coordinations of variant forms of the enzyme. Based on a mutation identified in a patient suffering from xanthinuria I, the corresponding arginine 135 was substituted to a cysteine in R. capsulatus XDH, and the protein variant was purified and characterized. Two different forms of XDH-R135C were purified, an active (alphabeta)(2) heterotetrameric form and an inactive (alphabeta) heterodimeric form. The active form contains a full complement of redox centers, whereas in the inactive form the FeSI center is likely to be missing.	Tech Univ Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Braunschweig University of Technology; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Duke University	Leimkuhler, S (corresponding author), Tech Univ Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	S.Leimkuehler@tu-bs.de	George, Graham N/E-3290-2013	Leimkuhler, Silke/0000-0003-3238-2122; George, Graham/0000-0002-0420-7493	NIGMS NIH HHS [GM 44283] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams B, 2002, BIOCHEM J, V362, P223, DOI 10.1042/0264-6021:3620223; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Amrani L, 2000, MOL MICROBIOL, V38, P114, DOI 10.1046/j.1365-2958.2000.02119.x; Amrani L, 1999, MOL MICROBIOL, V31, P1065, DOI 10.1046/j.1365-2958.1999.01242.x; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; Doyle WA, 1996, BIOCHEM SOC T, V24, pS31, DOI 10.1042/bst024031s; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1985, J BIOL CHEM, V260, P569; Ichida K, 1997, J CLIN INVEST, V99, P2391, DOI 10.1172/JCI119421; Iwasaki T, 2000, J BIOCHEM, V127, P771, DOI 10.1093/oxfordjournals.jbchem.a022669; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Levartovsky D, 2000, KIDNEY INT, V57, P2215, DOI 10.1046/j.1523-1755.2000.00082.x; Nishino T, 2002, J BIOCHEM, V132, P597, DOI 10.1093/oxfordjournals.jbchem.a003262; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Sakamoto N, 2001, HUM GENET, V108, P279, DOI 10.1007/s004390100477; Simmonds H.A., 1995, METABOLIC MOL BASES, P1781; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WAHL RC, 1982, J BIOL CHEM, V257, P1354; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; [No title captured]	33	51	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20802	20811		10.1074/jbc.M303091200	http://dx.doi.org/10.1074/jbc.M303091200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670960	hybrid			2022-12-25	WOS:000183230500048
J	Ferri, N; Garton, KJ; Raines, EW				Ferri, N; Garton, KJ; Raines, EW			An NF-kappa B-dependent transcriptional program is required for collagen remodeling by human smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MATRIX; ACTIVATION; ALPHA; FIBROBLASTS; PROLIFERATION; CONTRACTION; INDUCTION; PATHWAYS; INTEGRIN	Although remodeling of vessels can dramatically alter lumen diameter and clinical sequelae, the molecular mechanisms regulating extracellular matrix turnover and remodeling are still not well understood. To investigate these processes in human smooth muscle, we have compared their culture on monomer and polymerized collagen gels, conditions that mimic some of the features of injured and normal vessels, respectively. We show that culture on polymerized, but not monomer, collagen leads to the activation of the transcription factor NF-kappaB through phosphorylation and degradation of its inhibitor, IkappaBalpha. Coincident with NF-kappaB activation, expression of MMP1, MMP2, and alpha(2) integrin increases on polymerized collagen. Specific inhibition of NF-kappaB by retroviral overexpression of wild-type IkappaBalpha or phosphorylation-resistant, IkappaBalpha-stabilized mutant (IkappaBalpha(Ser32,36/Ala)) reverses the increases in MMP1 and alpha(2)beta(1) on polymerized collagen and decreases collagen gel contraction and degradation. However, forced overexpression of alpha(2)beta(1) integrin or MMP1 in smooth muscle cells expressing IkappaBalpha(Ser32,36/Ala) rescues their ability to contract collagen gels. Thus, polymerized collagen induces NF-kappaB-dependent expression of MMP1 and alpha(2)beta(1) integrin, that are required for smooth muscle extracellular matrix remodeling.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Raines, EW (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, 325 9th Ave,Box 359675, Seattle, WA 98104 USA.	ewraines@u.washington.edu	Ferri, Nicola/F-4879-2013; ferri, nicola/K-7085-2019	Ferri, Nicola/0000-0001-8898-7441; ferri, nicola/0000-0001-8898-7441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Breuss JM, 2002, CIRCULATION, V105, P633, DOI 10.1161/hc0502.102966; Cooke ME, 2000, J CELL SCI, V113, P2375; Deryugina EI, 1998, CANCER RES, V58, P3743; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Faxon DP, 1997, PROG CARDIOVASC DIS, V40, P129, DOI 10.1016/S0033-0620(97)80005-9; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; Rectenwald JE, 2000, CIRCULATION, V102, P1697, DOI 10.1161/01.CIR.102.14.1697; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Scherberich A, 1998, ARTERIOSCL THROM VAS, V18, P1691, DOI 10.1161/01.ATV.18.11.1691; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Viedt C, 2002, ARTERIOSCL THROM VAS, V22, P914, DOI 10.1161/01.ATV.0000019009.73586.7F; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Wilson SH, 2002, ATHEROSCLEROSIS, V160, P147, DOI 10.1016/S0021-9150(01)00546-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709	37	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19757	19764		10.1074/jbc.M212714200	http://dx.doi.org/10.1074/jbc.M212714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649281	hybrid			2022-12-25	WOS:000183078000026
J	Fehr, M; Lalonde, S; Lager, I; Wolff, MW; Frommer, WB				Fehr, M; Lalonde, S; Lager, I; Wolff, MW; Frommer, WB			In vivo imaging of the dynamics of glucose uptake in the cytosol of COS-7 cells by fluorescent nanosensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; SUGAR-TRANSPORT; ESCHERICHIA-COLI; GLUCOKINASE; GLUT1; SPECIFICITY; MEMBRANE; CARRIER; BLOOD	Glucose homeostasis is a function of glucose supply, transport across the plasma membrane, and metabolism. To monitor glucose dynamics in individual cells, a glucose nanosensor was developed by flanking the Escherichia coli periplasmic glucose/galactose-binding protein with two different green fluorescent protein variants. Upon binding of substrate the FLIPglu-170n sensor showed a concentration-dependent decrease in fluorescence resonance energy transfer between the attached chromophores with a binding affinity for glucose of 170 nM. Fluorescence resonance energy transfer measurements with different sugars indicated a broad selectivity for monosaccharides. An affinity mutant with a K-d of similar to600 muM was generated, which showed higher substrate specificity, and thus allowed specific monitoring of reversible glucose dynamics in COS-7 cells in the physiological range. At external glucose concentrations between 0.5 and 10 mM, reflecting typical blood levels, free cytosolic glucose concentrations remained at similar to50% of external levels. The removal of glucose lead to reduced glucose levels in the cell, demonstrating reversibility and visualizing homeostasis. Glucose levels dropped even in the presence of the transport inhibitor cytochalasin B, indicating rapid metabolism. Consistently, the addition of 2-deoxyglucose, which is not recognized by the sensor, affects glucose uptake and metabolism rates. Within the physiological range, glucose utilization, i.e. hexokinase activity, was not limiting. Furthermore, the results show that in COS-7 cells, cytosolic glucose concentrations can vary over at least two orders of magnitude. The glucose nanosensor provides a novel tool with numerous scientific, medical, and environmental applications.	Zentrum Mol Biol Pflanzen Tubingen, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Frommer, WB (corresponding author), Carnegie Inst, 260 Panama St, Stanford, CA 94305 USA.	frommer@andrew2.stanford.edu	Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Wolff, Michael/0000-0001-7443-3122				BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; Borisjuk L, 1998, PLANT J, V15, P583, DOI 10.1046/j.1365-313X.1998.00214.x; Burcelin R, 2000, DIABETES, V49, P1643, DOI 10.2337/diabetes.49.10.1643; Burdakov D, 2002, J PHYSIOL-LONDON, V544, P334, DOI 10.1113/jphysiol.2002.029090; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; Cesar MD, 2002, ARCH BIOCHEM BIOPHYS, V397, P106, DOI 10.1006/abbi.2001.2639; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P13231, DOI 10.1021/bi961208t; Cloherty EK, 2001, BIOCHEMISTRY-US, V40, P15549, DOI 10.1021/bi015586w; De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860; DONOVAN CM, 1994, P NATL ACAD SCI USA, V91, P2863, DOI 10.1073/pnas.91.7.2863; EFRAT S, 1994, TRENDS BIOCHEM SCI, V19, P535, DOI 10.1016/0968-0004(94)90056-6; EHRLICH KC, 1978, IN VITRO CELL DEV B, V14, P443, DOI 10.1007/BF02616106; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Fehr M, 2002, P NATL ACAD SCI USA, V99, P9846, DOI 10.1073/pnas.142089199; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fukami-Kobayashi K, 1999, J MOL BIOL, V286, P279, DOI 10.1006/jmbi.1998.2454; GILARDI G, 1994, ANAL CHEM, V66, P3840, DOI 10.1021/ac00093a047; GRUETTER R, 1992, P NATL ACAD SCI USA, V89, P1109, DOI 10.1073/pnas.89.3.1109; Guillemain G, 2000, J CELL SCI, V113, P841; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Harpur AG, 2001, NAT BIOTECHNOL, V19, P167, DOI 10.1038/84443; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; Heim R, 1999, METHOD ENZYMOL, V302, P408, DOI 10.1016/S0076-6879(99)02036-4; KLETZIEN RF, 1973, J BIOL CHEM, V252, P2226; Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997; LUNDANDERSEN H, 1979, PHYSIOL REV, V59, P305, DOI 10.1152/physrev.1979.59.2.305; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; Mayordomo I, 2001, YEAST, V18, P1309, DOI 10.1002/yea.780; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Oh-hashi K, 2003, J BIOL CHEM, V278, P10531, DOI 10.1074/jbc.M212083200; Pascual JM, 2002, ANN NEUROL, V52, P458, DOI 10.1002/ana.10311; POST RL, 1961, J BIOL CHEM, V236, P269; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; PURICH DL, 1971, J BIOL CHEM, V246, P3456; QUIOCHO FA, 1980, J BIOL CHEM, V255, P6559; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; SCHURMANN A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P245, DOI 10.1016/0167-4781(92)90022-R; Sultzman LA, 1999, BIOCHEMISTRY-US, V38, P6640, DOI 10.1021/bi990130o; Thorens B, 2001, MOL MEMBR BIOL, V18, P265, DOI 10.1080/09687680110100995; Vayro S, 1998, BIOCHEM J, V332, P119, DOI 10.1042/bj3320119; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; ZUKIN RS, 1977, P NATL ACAD SCI USA, V74, P1932, DOI 10.1073/pnas.74.5.1932	45	224	242	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19127	19133		10.1074/jbc.M301333200	http://dx.doi.org/10.1074/jbc.M301333200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649277	hybrid			2022-12-25	WOS:000182932200054
J	Kim, JS; Kang, SO; Lee, JK				Kim, JS; Kang, SO; Lee, JK			The protein complex composed of nickel-binding SrnQ and DNA binding motif-bearing SrnR of Streptomyces griseus represses sodF transcription in the presence of nickel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; COELICOLOR A3(2); GENE; IDENTIFICATION; EXPRESSION; REGULATOR; CLONING; OPERON	Nickel-responsive transcriptional repression of sodF, which codes for iron- and zinc-containing superoxide dismutase of Streptomyces griseus, was mediated through an operator (-2 to +15) spanning over the 5' end (+1) of the transcript. Two open reading frames, SrnR (12,343 Da) and SrnQ (12,486 Da), with overlapping stop-start codons were identified downstream from sodF and found responsible for the repression of sodF. The deduced amino acid sequence of SrnR revealed a DNA binding motif and showed homology to the transcriptional regulators of ArsR family, whereas SrnQ did not show any similarity to any known proteins. When srnRQ DNA was maintained in trans in S. griseus on a multicopy plasmid, sodF transcription was highly repressed by nickel, but neither srnR nor srnQ alone showed the effect. Consistently, the sodF transcription of srnR-interrupted mutant was no longer repressed by nickel, which was complemented only with srnRQ DNA. Nickel-dependent binding of SrnR and SrnQ to the sodF operator DNA was observed only when the two proteins were provided together. The maximum protein-DNA interaction was shown when SrnR and SrnQ were present in one-to-one stoichiometric ratio. The two proteins appear to constitute an octamer composed of four subunits of each protein. SrnR directly interacted with SrnQ, and the protein interaction did not require nickel. The conformation of SrnQ was changed upon nickel binding, which was in the ratio of one Ni2+ ion per protein molecule. A model is proposed in which SrnQ of the protein complex senses nickel and subsequently enhances the DNA binding activity of SrnR through the protein-protein interaction.	Sogang Univ, Dept Life Sci, Seoul 121742, South Korea; Seoul Natl Univ, Sch Biol Sci, Inst Microbiol, Seoul 151742, South Korea	Sogang University; Seoul National University (SNU)	Lee, JK (corresponding author), Sogang Univ, Dept Life Sci, Shinsu 1, Seoul 121742, South Korea.	jgklee@ccs.sogang.ac.kr	LEE, JIN-WON/L-1116-2016	LEE, JIN-WON/0000-0002-1201-8254				Ahmad S., 1995, OXIDATIVE STRESS ANT, P238, DOI DOI 10.1007/978-1-4615-9689-9_7; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Cannio R, 2000, FRONT BIOSCI-LANDMRK, V5, pD768, DOI 10.2741/cannio; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; DEHOFF BS, 1988, J BACTERIOL, V170, P4681, DOI 10.1128/jb.170.10.4681-4692.1988; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; ERASO JM, 1994, MICROBIOLOGY, V141, P1805; GREENER A, 1990, STRATEGIES, V5, P81; Hopwood DA, 1985, GENETIC MANIPULATION, P69; HORINOUCHI S, 1986, J BACTERIOL, V168, P257, DOI 10.1128/jb.168.1.257-269.1986; Imlay KRC, 1996, J BACTERIOL, V178, P2564, DOI 10.1128/jb.178.9.2564-2571.1996; INGRAM C, 1989, J BACTERIOL, V171, P6617, DOI 10.1128/jb.171.12.6617-6624.1989; Kawachi R, 2000, MOL MICROBIOL, V36, P302, DOI 10.1046/j.1365-2958.2000.01819.x; Kim EJ, 1998, MOL MICROBIOL, V27, P187, DOI 10.1046/j.1365-2958.1998.00674.x; Kim EJ, 1998, J BACTERIOL, V180, P2014, DOI 10.1128/JB.180.8.2014-2020.1998; Kim EJ, 1996, EUR J BIOCHEM, V241, P178, DOI 10.1111/j.1432-1033.1996.0178t.x; Kim JS, 2000, BBA-GENE STRUCT EXPR, V1493, P200, DOI 10.1016/S0167-4781(00)00178-0; Kinoshita H, 1997, J BACTERIOL, V179, P6986, DOI 10.1128/jb.179.22.6986-6993.1997; KONDOROSI E, 1991, J MOL BIOL, V222, P885, DOI 10.1016/0022-2836(91)90583-R; Lee CK, 1999, J BACTERIOL, V181, P3293, DOI 10.1128/JB.181.10.3293-3297.1999; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCPHERSON MJ, 1991, DIRECTED MUTAGENESIS; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; Ohnishi Y, 1999, MOL MICROBIOL, V34, P102, DOI 10.1046/j.1365-2958.1999.01579.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RETZLAFF L, 1995, MOL MICROBIOL, V18, P151, DOI 10.1111/j.1365-2958.1995.mmi_18010151.x; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDLMEIER R, 1992, MOL GEN GENET, V236, P76, DOI 10.1007/BF00279645; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; WILLIAMS SG, 1993, MOL MICROBIOL, V9, P751, DOI 10.1111/j.1365-2958.1993.tb01735.x; Youn HD, 1996, ARCH BIOCHEM BIOPHYS, V334, P341, DOI 10.1006/abbi.1996.0463	41	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18455	18463		10.1074/jbc.M211740200	http://dx.doi.org/10.1074/jbc.M211740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644473	hybrid			2022-12-25	WOS:000182838300113
J	Konishi, H; Sugiyama, M; Mizuno, K; Saito, H; Yatabe, Y; Takahashi, T; Osada, H; Takahashi, T				Konishi, H; Sugiyama, M; Mizuno, K; Saito, H; Yatabe, Y; Takahashi, T; Osada, H; Takahashi, T			Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer	ONCOGENE			English	Article						homozygous deletion; 17p13.3; tumor suppressor gene; lung cancer; LOST1	HUMAN-CHROMOSOME 3P21.3; HEPATOCELLULAR-CARCINOMA; EPIGENETIC INACTIVATION; MITOTIC CHECKPOINT; BREAST-CANCER; CELL-LINES; IN-VIVO; GENE; IDENTIFICATION; P53	17p13.3 is one of the chromosomal regions most frequently affected by allelic loss in a variety of human neoplasms including lung cancer. A number of loss of heterozygosity (LOH) analyses have suggested the existence of a tumor suppressor gene at 17p13.3, distal to the p53 locus at 17p13.1. In the present study, we characterized a homozygous deletion at 17p13.3 in a small cell lung cancer cell line by constructing a bacterial artificial chromosome (BAC) contig and a restriction map surrounding the region, as well as by utilizing publicly available draft sequences. We defined the breakpoint, assigned and analysed two known genes, 14-3-3epsilon. and CRK, and a novel gene LOST1 within or at the end of the homozygous deletion of about 170 kb in size. Marked reduction of LOST1 expression was detected in 69% (11/16) of lung cancer specimens by quantitative real-time RT-PCR, while significant DNA hypermethylation was observed at the 5' end of the LOST1 gene in four of six lung cancer cell lines with negligible LOST1 expression. We also show here that a polymorphic marker D17S1174, which resides within the homozygous deletion, was apparently located in the middle of the minimum LOH region, providing further supportive evidence for the presence of a tumor suppressor gene(s) in this region.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				BIEGEL JA, 1992, CANCER RES, V52, P3391; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAIRNS P, 1994, CANCER RES, V54, P1422; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; COGEN PH, 1992, AM J HUM GENET, V50, P584; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUJIMORI M, 1991, CANCER RES, V51, P89; Haataja L, 1997, CANCER RES, V57, P32; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Ji L, 2002, CANCER RES, V62, P2715; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128; Konishi H, 2002, CANCER RES, V62, P271; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lerman MI, 2000, CANCER RES, V60, P6116; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; McHale JC, 2000, CYTOGENET CELL GENET, V88, P225, DOI 10.1159/000015556; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Oh JJ, 2002, CANCER RES, V62, P3207; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Osada H, 2001, CANCER RES, V61, P8331; Phillips NJ, 1996, CANCER RES, V56, P606; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TADOKORO K, 1992, ONCOGENE, V7, P1215; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; Zhao XT, 2001, CANCER RES, V61, P7383	53	29	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2003	22	12					1892	1905		10.1038/sj.onc.1206304	http://dx.doi.org/10.1038/sj.onc.1206304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660825				2022-12-25	WOS:000181678200016
J	Singh, R				Singh, R			Interaction of guanylyl cyclase C with SH3 domain of Src tyrosine kinase - Yet another mechanism for desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; NATRIURETIC PEPTIDE RECEPTOR; DEPENDENT PROTEIN-KINASE; ESCHERICHIA-COLI; CGMP-BINDING; CYCLIC-GMP; PHOSPHODIESTERASE PDE5; FUNCTIONAL EXPRESSION; PARTIAL-PURIFICATION; SIGNALING PROTEINS	Protein-protein interactions mediated by the Src homology 3 (SH3) domain have been implicated in the regulation of receptor functions for subcellular localization of proteins and the reorganization of cytoskeleton. The experiments described in this article begin to identify the interaction of the SH3 domain of Src tyrosine kinase with the guanylyl cyclase C receptor after activation with Escherichia coli heat-stable enterotoxin (ST). Only one of two post-translationally modified forms of guanylyl cyclase C from T84 colonic carcinoma cells bind to GST-SH3 fusion protein of Src and Hck tyrosine kinases. Interestingly, the GST-Src-SH3 fusion protein showed 2-fold more affinity to native guanylyl cyclase C in solution than the GST-Hck-SH3 fusion protein. The affinity of the GST-Src-SH3 fusion protein to guanylyl cyclase C increased on desensitization of receptor in vivo. An in vitro cyclase assay in the presence of GST-Src-SH3 fusion protein indicated inhibition of the catalytic activity of guanylyl cyclase C. The catalytic domain recombinant protein (GST-GCD) of guanylyl cyclase C could pull-down a 60-kDa protein that reacted with Src tyrosine antibody and also showed autophosphorylation. These data suggest that SH3 domain-mediated protein-protein interaction with the catalytic domain of guanylyl cyclase C inhibited the cyclase activity and that such an interaction, possibly mediated by Src tyrosine kinase or additional proteins, might be pivotal for the desensitization phenomenon of the guanylyl cyclase C receptor.	Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India	University of Delhi	Singh, R (corresponding author), Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India.							Bakre MM, 1997, FEBS LETT, V408, P345, DOI 10.1016/S0014-5793(97)00458-4; Bakre MM, 2000, EUR J BIOCHEM, V267, P179, DOI 10.1046/j.1432-1327.2000.00986.x; Bakre MM, 2000, J CELL BIOCHEM, V77, P159; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; Bhandari R, 2000, J BIOSCIENCES, V25, P339, DOI 10.1007/BF02703787; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Crane JK, 1996, MOL CELL BIOCHEM, V165, P111; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DWARAKANATH P, 1989, GENE, V81, P219, DOI 10.1016/0378-1119(89)90182-0; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FIELD M, 1989, NEW ENGL J MED, V321, P800; Forte LR, 1999, REGUL PEPTIDES, V81, P25, DOI 10.1016/S0167-0115(99)00033-6; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; Gouri BSV, 1997, INDIAN J BIOCHEM BIO, V34, P29; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KIM TD, 1994, J BIOL CHEM, V269, P15540; Kuwayama H, 1996, J BIOL CHEM, V271, P23718, DOI 10.1074/jbc.271.39.23718; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Laskey R A, 1980, Methods Enzymol, V65, P363; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Lucas KA, 2000, PHARMACOL REV, V52, P375; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Qian X, 2000, ENDOCRINOLOGY, V141, P3210, DOI 10.1210/en.141.9.3210; RAMARAO CS, 1985, J BIOL CHEM, V260, P8360; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Turko IV, 1998, BIOCHEM J, V329, P505; URBANSKI R, 1995, BIOCHIM BIOPHYS ACTA, V1249, P29; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Vaandrager AB, 2002, MOL CELL BIOCHEM, V230, P73, DOI 10.1023/A:1014231722696; VISWESWARIAH SS, 1994, EUR J BIOCHEM, V219, P727, DOI 10.1111/j.1432-1033.1994.tb18551.x; VISWESWARIAH SS, 1992, MICROB PATHOGENESIS, V12, P209, DOI 10.1016/0882-4010(92)90055-S; WADA A, 1994, MICROBIOL IMMUNOL, V38, P535, DOI 10.1111/j.1348-0421.1994.tb01819.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	49	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24342	24349		10.1074/jbc.M301153200	http://dx.doi.org/10.1074/jbc.M301153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12649275	hybrid			2022-12-25	WOS:000183824800015
J	Inomata, H; Nakamura, Y; Hayakawa, A; Takata, H; Suzuki, T; Miyazawa, K; Kitamura, N				Inomata, H; Nakamura, Y; Hayakawa, A; Takata, H; Suzuki, T; Miyazawa, K; Kitamura, N			A scaffold protein JIP-1b enhances amyloid precursor protein phosphorylation by JNK and its association with kinesin light chain 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL-TRANSPORT; DEPENDENT REGULATION; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; FAMILY; APOPTOSIS; BINDING; FE65; OVEREXPRESSION; ACTIVATION	Amyloid precursor protein (APP) is the precursor molecule of beta-amyloid peptides, the major components of amyloid plaque in patients with Alzheimer's disease. In this study, we isolated JIP-1b, a JNK signaling scaffold protein, as a binding protein of APP, and analyzed the roles of JIP-1b in APP phosphorylation by JNK and the association of kinesin light chain 1 with APP. APP phosphorylation at threonine 668 by JNK was enhanced on the JIP-1b scaffold in vitro and in cultured cells exogenously expressing APP. APP phosphorylation in nerve growth factor-differentiated PC12 cells was mediated by activation of JNK signaling. JIP-1b also enhanced the association of kinesin light chain 1 with APP. Our results suggest that JIP-1b may function as a protein linking the kinesin-I motor protein to the cargo receptor, APP, and that the JNK signaling pathway may regulate the phosphorylation of this cargo protein through the JIP-1b scaffold.	Tokyo Inst Technol, Dept Sci Biol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan	Tokyo Institute of Technology; Hokkaido University	Kitamura, N (corresponding author), Tokyo Inst Technol, Dept Sci Biol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	nkitamur@bio.titech.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; Suzuki, Toshiharu/B-5342-2013					Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Aplin AE, 1996, J NEUROCHEM, V67, P699; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Heber S, 2000, J NEUROSCI, V20, P7951; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Matsuda S, 2001, J NEUROSCI, V21, P6597; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	38	132	139	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22946	22955		10.1074/jbc.M212160200	http://dx.doi.org/10.1074/jbc.M212160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665528	hybrid			2022-12-25	WOS:000183503900101
J	Jung, IL; Kim, IG				Jung, IL; Kim, IG			Polyamines and glutamate decarboxylase-based acid resistance in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN H-NS; SIGMA(S)-DEPENDENT GENES; K-12; SYSTEM; GROWTH; PUTRESCINE; SPERMINE; SIGMA(S); SEQUENCE; MUTANTS	The expression of gadA and gadB, which encode two glutamate decarboxylases ( GADs) of Escherichia coli, is induced by an acidic environment and participate in acid resistance. In this study, we constructed a polyamine-deficient mutant and investigated the role of polyamines in acid resistance. The expression of gadA and gadB was shown to be dependent on polyamines. For that reason, the polyamine- deficient mutant was completely devoid of GAD activity and was very susceptible to low pH if large amounts of polyamines were not provided. We also showed that the polyamine- deficient mutant contained higher cAMP levels than the isogenic polyamine- proficient wild type, and cAMP negatively regulated the expression of gadA and gadB. Therefore, introduction of the cya ( encoding adenylate cyclase) mutation allele into the polyamine- deficient mutant resulted in the increment of GAD activity and thus restored the reduced acid resistance of the mutant. The positive regulators, H- NS ( histone- like protein, encoded by the hns gene) and RpoS ( alternative RNA polymerase sigma subunit, encoded by rpoS gene), also significantly governed the expression of gadA and gadB, respectively. However, polyamines did not regulate either the intracellular H- NS level or rpoS expression under these culture conditions. These results strongly suggest that there are at least two different regulatory systems in acid resistance, one is positive regulation via a H- NS/ RpoS system and the other is negative regulation via a polyamine/ cAMP system.	Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Taejon 305600, South Korea	Korea Atomic Energy Research Institute (KAERI)	Kim, IG (corresponding author), Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, POB 105, Taejon 305600, South Korea.							BARTH M, 1995, J BACTERIOL, V177, P3455, DOI 10.1128/jb.177.12.3455-3464.1995; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; Castanie-Cornet MP, 2001, MICROBIOL-UK, V147, P709, DOI 10.1099/00221287-147-3-709; Cotter PD, 2001, MOL MICROBIOL, V40, P465, DOI 10.1046/j.1365-2958.2001.02398.x; De Biase D, 1999, MOL MICROBIOL, V32, P1198, DOI 10.1046/j.1365-2958.1999.01430.x; DeBiase D, 1996, PROTEIN EXPRES PURIF, V8, P430; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; Foster JW, 2000, BACTERIAL STRESS RESPONSES, P99; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; Hersh BM, 1996, J BACTERIOL, V178, P3978, DOI 10.1128/jb.178.13.3978-3981.1996; Hwang DF, 1997, J CHROMATOGR B, V693, P23, DOI 10.1016/S0378-4347(97)00067-4; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; ILLIANO G, 1982, INT J BIOCHEM, V14, P247, DOI 10.1016/0020-711X(82)90082-9; Kim IG, 2000, TOXICOL LETT, V116, P143, DOI 10.1016/S0378-4274(00)00215-0; Lambert LA, 1997, J BACTERIOL, V179, P7595, DOI 10.1128/jb.179.23.7595-7599.1997; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Miller JH., 1972, EXPT MOL GENETICS; MINTON KW, 1990, P NATL ACAD SCI USA, V87, P2851, DOI 10.1073/pnas.87.7.2851; RICE EW, 1993, APPL ENVIRON MICROB, V59, P4347, DOI 10.1128/AEM.59.12.4347-4349.1993; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; Tkachenko A, 2001, ARCH MICROBIOL, V176, P155, DOI 10.1007/s002030100301; Tramonti A, 2002, J BACTERIOL, V184, P2603, DOI 10.1128/JB.184.10.2603-2613.2002; TSURUOKA T, 1978, J ANTIBIOT, V31, P192, DOI 10.7164/antibiotics.31.192; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; Waterman SR, 1996, MOL MICROBIOL, V21, P925, DOI 10.1046/j.1365-2958.1996.00058.x; YAMASHINO T, 1995, EMBO J, V14, P594, DOI 10.1002/j.1460-2075.1995.tb07035.x; Yatin SM, 2001, J NEUROSCI RES, V63, P395, DOI 10.1002/1097-4547(20010301)63:5<395::AID-JNR1034>3.0.CO;2-Q; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; ZILBERSTEIN D, 1984, J BACTERIOL, V158, P246, DOI 10.1128/JB.158.1.246-252.1984	33	39	40	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22846	22852		10.1074/jbc.M212055200	http://dx.doi.org/10.1074/jbc.M212055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12670930	hybrid			2022-12-25	WOS:000183503900089
J	Kauth, CW; Epp, C; Bujard, H; Lutz, R				Kauth, CW; Epp, C; Bujard, H; Lutz, R			The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum - Interactions and arrangements of subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IDENTIFICATION; MSP-1; GLYCOPROTEIN; FRAGMENTS; ANTIGENS; INVASION; SEQUENCE; PROTEASE; GENE	The major protein component at the surface of merozoites, the infectious form of blood stage malaria parasites, is the merozoite surface protein 1 ( MSP-1) complex. In the human malaria parasite Plasmodium falciparum, this complex is generated by proteolytic cleavage of a 190-kDa glycosylphosphatidylinositol-anchored precursor into four major fragments, which remain non-covalently associated. Here, we describe the in vitro reconstitution of the MSP-1 complex of P. falciparum strain 3D7 from its heterologously produced subunits. We provide evidence for the arrangement of the subunits within the complex and show how they interact with each other. Our data indicate that the conformation assumed by the reassembled complex as well as by the heterologously produced 190-kDa precursor corresponds to the native one. Based on these results we propose a first structural model for the MSP-1 complex. Together with access to faithfully produced material, this information will advance further structure-function studies of MSP-1 that plays an essential role during invasion of erythrocytes by the parasite and that is considered a promising candidate for a malaria vaccine.	Heidelberg Univ, ZMBH, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bujard, H (corresponding author), Heidelberg Univ, ZMBH, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	h.bujard@zmbh.uni-heidelberg.de						Berhe S, 2000, EXP PARASITOL, V94, P194, DOI 10.1006/expr.1999.4481; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P35, DOI 10.1016/0166-6851(91)90128-S; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; Daly TM, 2001, MOL BIOCHEM PARASIT, V117, P27, DOI 10.1016/S0166-6851(01)00329-2; Epp C, 2003, J CHROMATOGR B, V786, P61, DOI 10.1016/S1570-0232(02)00722-5; Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; HOLDER AA, 1984, J EXP MED, V160, P624, DOI 10.1084/jem.160.2.624; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; LYON JA, 1987, J IMMUNOL, V138, P895; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; Mello K, 2002, EUKARYOT CELL, V1, P915, DOI 10.1128/EC.1.6.915-925.2002; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Nikodem DP, 2000, MOL BIOCHEM PARASIT, V108, P79, DOI 10.1016/S0166-6851(00)00206-1; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; SIDDIQUI WA, 1986, INFECT IMMUN, V52, P314, DOI 10.1128/IAI.52.1.314-318.1986; STAFFORD WHL, 1994, MOL BIOCHEM PARASIT, V66, P157, DOI 10.1016/0166-6851(94)90048-5; Stafford WHL, 1996, MOL BIOCHEM PARASIT, V80, P159, DOI 10.1016/0166-6851(96)02696-5; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TOLLE R, 1994, THESIS U HEIDELBERG; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; TUERBACHOVA I, 2000, THESIS U HEIDELBERG	28	41	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22257	22264		10.1074/jbc.M302299200	http://dx.doi.org/10.1074/jbc.M302299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12654909	hybrid			2022-12-25	WOS:000183503900012
J	Lillig, CH; Potamitou, A; Schwenn, JD; Vlamis-Gardikas, A; Holmgren, A				Lillig, CH; Potamitou, A; Schwenn, JD; Vlamis-Gardikas, A; Holmgren, A			Redox regulation of 3 '-phosphoadenylylsulfate reductase from Escherichia coli by glutathione and glutaredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; NF-KAPPA-B; RIBONUCLEOTIDE REDUCTASE; PAPS-REDUCTASE; HYDROGEN DONOR; NULL MUTANTS; THIOREDOXIN; MECHANISM; PURIFICATION	Inorganic sulfate (SO42-, S+VI) is reduced in vivo to sulfite (SO32-, S+IV) via phosphoadenylylsulfate (PAPS) reductase. Escherichia coli lacking glutathione reductase and glutaredoxins (gor(-) grxA(-) grxB(-) grxC(-)) barely grows on sulfate. We found that incubation of PAPS reductase with oxidized glutathione leads to enzyme inactivation with simultaneous formation of a mixed disulfide between glutathione and the active site Cys-239. A newly developed method based on thiol-specific fluorescent alkylation and gel electrophoresis showed that glutathionylated PAPS reductase is reduced by glutaredoxins via a monothiol mechanism. This glutathionylated species was also observed in poorly growing gor(-) grxA(-) grxB(-) grxC(-) cells expressing inactive glutaredoxin 2 (Grx2) C9S/C12S. However, it was absent in better growing cells expressing monothiol Grx2 C12S or wild type Grx2. Reversible glutathionylation may thus regulate the activity of PAPS reductase in vivo.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden; Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany	Karolinska Institutet; Ruhr University Bochum	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, Scheeles Vag 2, S-17177 Stockholm, Sweden.	arne.holmgren@mbb.ki.se	Fernandes, Aristi/D-2507-2015; Lillig, Christopher Horst/AAD-7098-2019; Vlamis, Alexios/AAF-5152-2020	Lillig, Christopher Horst/0000-0003-2509-5117; Vlamis, Alexios/0000-0001-5068-6459				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BERENDT U, 1995, EUR J BIOCHEM, V233, P347, DOI 10.1111/j.1432-1033.1995.347_1.x; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; BORUM PR, 1976, J BACTERIOL, V125, P94, DOI 10.1128/JB.125.1.94-101.1976; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CARTMELHAREL O, 2000, ANNU REV MICROBIOL, V54, P439; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; KRONE FA, 1991, MOL GEN GENET, V225, P314, DOI 10.1007/BF00269864; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Lillig CH, 2001, ARCH BIOCHEM BIOPHYS, V392, P303, DOI 10.1006/abbi.2001.2453; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; Potamitou A, 2002, J BIOL CHEM, V277, P18561, DOI 10.1074/jbc.M201225200; Potamitou A, 2002, J BIOL CHEM, V277, P17775, DOI 10.1074/jbc.M201306200; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; SCHRIEK U, 1986, ARCH MICROBIOL, V145, P32, DOI 10.1007/BF00413024; SCHWENN JD, 1994, Z NATURFORSCH C, V49, P531; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; SCHWENN JD, 1980, J CHROMATOGR, V193, P285, DOI 10.1016/S0021-9673(00)81497-1; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721	46	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22325	22330		10.1074/jbc.M302304200	http://dx.doi.org/10.1074/jbc.M302304200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682041	hybrid			2022-12-25	WOS:000183503900022
J	Suzuki, M; Suzuki, H; Sugimoto, Y; Sugiyama, Y				Suzuki, M; Suzuki, H; Sugimoto, Y; Sugiyama, Y			ABCG2 transports sulfated conjugates of steroids and xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	53rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases	NOV 01-05, 2002	BOSTON, MA	Amer Assoc Study Liver Dis			BREAST-CANCER RESISTANCE; BILE CANALICULAR MEMBRANE; PRIMARY ACTIVE-TRANSPORT; SUBSTRATE-SPECIFICITY; KINETIC-ANALYSIS; STEM-CELLS; PROTEIN; GENE; OVEREXPRESSION; MITOXANTRONE	The mechanism for the cellular extrusion of sulfated conjugates is still unknown. In the present study, we investigated whether human wild type ABCG2 transports estrone 3-sulfate (E1S) using membrane vesicles from cDNA-transfected mouse lymphoma cell line (P388 cells). The uptake of [H-3]E1S into ABCG2-expressing membrane vesicles was stimulated by ATP, and the Km value for [H-3]E1S was determined to be 16.6 muM. The ABCG2-mediated transport of [H-3]E1S was potently inhibited by SN-38 and many sulfate conjugates but not by glucuronide and glutathione conjugates or other anionic compounds. Other sulfate conjugates such as [H-3] dehydroepiandrosterone sulfate (DHEAS) and [S-35]4-methylumbelliferone sulfate (K-m = 12.9 muM) and [S-35]6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate (K-m = 26.9 muM) were also transported by ABCG2. Although [H-3]methotrexate, [H-3]17beta-estradiol-17beta-D-glucuronide, [H-3]2,4-dinitrophenyl-S-glutathione, and [C-14]4-methylumbelliferone glucuronide were transported by ABCG2, this took place to a much lesser extent compared with [H-3]E1S. It was suggested that ABCG2 preferentially transports sulfate conjugates and that E1S and DHEAS are the potential physiological substrates for this transporter.	Univ Tokyo, Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Biotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Suzuki, H (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	suzukihi-tky@umin.ac.jp						Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; Allikmets R, 1998, CANCER RES, V58, P5337; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Cui YH, 2001, MOL PHARMACOL, V60, P934, DOI 10.1124/mol.60.5.934; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Hirohashi T, 2000, J PHARMACOL EXP THER, V292, P265; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Honjo Y, 2001, CANCER RES, V61, P6635; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Nakatomi K, 2001, BIOCHEM BIOPH RES CO, V288, P827, DOI 10.1006/bbrc.2001.5850; Niinuma K, 1999, AM J PHYSIOL-GASTR L, V276, pG1153, DOI 10.1152/ajpgi.1999.276.5.G1153; Niinuma K, 1997, J PHARMACOL EXP THER, V282, P866; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Scheffer GL, 2000, CANCER RES, V60, P2589; Suzuki H, 2002, HEPATOLOGY, V36, p218A; Suzuki H, 2000, EUR J PHARM SCI, V12, P3, DOI 10.1016/S0928-0987(00)00178-0; Suzuki H, 1999, Pharm Biotechnol, V12, P387; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; TAKENAKA O, 1995, PHARMACEUT RES, V12, P1746, DOI 10.1023/A:1016278008658; Volk EL, 2002, CANCER RES, V62, P5035; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	35	279	282	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22644	22649		10.1074/jbc.M212399200	http://dx.doi.org/10.1074/jbc.M212399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	689QF	12682043	hybrid			2022-12-25	WOS:000183503900063
J	Balasenthil, S; Vadlamudi, RK				Balasenthil, S; Vadlamudi, RK			Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSED SEQUENCE TAGS; CELL-CYCLE PROGRESSION; BREAST-CANCER CELLS; D1 EXPRESSION; TRANSCRIPTION; ACTIVATION; KINASE; GROWTH; BINDS; PHOSPHORYLATION	PELP1 (proline-, glutamic acid-, and leucine-rich protein-1 (also referred to as MNAR, or modulator of non-genomic activity of estrogen receptor)), a recently identified novel coactivator of estrogen receptors, is widely expressed in a variety of 17 beta-estradiol (E-2)-responsive reproductive tissues and is developmentally regulated in mammary glands. pRb (retinoblastoma protein), a cell cycle switch protein, plays a fundamental role in the proliferation, development, and differentiation of eukaryotic cells. To study the putative function of PELP1, we established stable MCF-7 breast cancer cell lines overexpressing PELP1. PELP1 overexpression hypersensitized breast cancer cells to E2 signaling, enhanced progression of breast cancer cells to S phase, and led to persistent hyperphosphorylation of pRb in an E-2-dependent manner. Using phosphorylation site-specific pRb antibodies, we identified Ser-807/Ser-811 of pRb as a potential target site of PELP1. Interestingly, PELP1 was discovered to be physiologically associated with pRb and interacted via its C-terminal pocket domain, and PELP1/pRb interaction could be modulated by antiestrogen agents. Using mutant pRb cells, we demonstrated an essential role for PELP1/pRb interactions in the maximal coactivation functions of PELP1 using cyclin D1 as one of the targets. Taken together, these findings suggest that PELP1, a steroid coactivator, plays a permissive role in E-2-mediated cell cycle progression, presumably via its regulatory interaction with the pRb pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Vadlamudi, RK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rvadlamu@mdanderson.org			NCI NIH HHS [CA 84456, R01 CA084456, R01 CA095681, CA 95681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095681, R01CA084456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Altucci L, 1996, ONCOGENE, V12, P2315; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Dyson N, 1989, Princess Takamatsu Symp, V20, P191; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Hirosawa M, 2000, GENOME RES, V10, P1333, DOI 10.1101/gr.129500; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860; Luconi M, 2002, J STEROID BIOCHEM, V80, P369, DOI 10.1016/S0960-0760(02)00041-9; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mendelsohn ME, 2002, AM J CARDIOL, V90, p3F, DOI 10.1016/S0002-9149(02)02418-9; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Osborne CK, 2001, CLIN CANCER RES, V7, p4338S; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Tai H, 2000, BIOCHEM BIOPH RES CO, V267, P311, DOI 10.1006/bbrc.1999.1954; Tamrakar S, 2000, J BIOL CHEM, V275, P27784; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Valverde Miguel A., 2002, Trends in Biochemical Sciences, V27, P172, DOI 10.1016/S0968-0004(02)02075-3; Warner M, 1999, CURR OPIN OBSTET GYN, V11, P249, DOI 10.1097/00001703-199906000-00003; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297	49	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22119	22127		10.1074/jbc.M212822200	http://dx.doi.org/10.1074/jbc.M212822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682072	hybrid, Green Accepted			2022-12-25	WOS:000183354200100
J	Priet, S; Navarro, JM; Querat, G; Sire, J				Priet, S; Navarro, JM; Querat, G; Sire, J			Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; URACIL DNA GLYCOSYLASE; TYPE-1 INTEGRASE; IN-VITRO; PREINTEGRATION COMPLEXES; PRECURSOR PROTEIN; REPAIR ENZYME; ZINC-BINDING; VPR; IDENTIFICATION	The human immunodeficiency virus type 1 (HIV-1) integrase (IN) is essential for integration of viral DNA into host cell chromatin. We have reported previously (Priet, S., Navarro, J.M., Gros, N., Querat, G., and Sire, J. (2003) J. Biol. Chem. 278, 4566-4571) that IN also plays a role in the packaging of the host uracil DNA glycosylase UNG2 into viral particles and that the region of IN encompassing residues 170-180 was responsible for the interaction with UNG2 and for its packaging into virions. In this work, we aimed to investigate the replication of HIV-1 viruses rendered deficient in virion-associated UNG2 by single or double point mutations in the region 170-180 of IN. We show that the L172A/K173A IN mutant virus was deficient for UNG2 packaging and was defective for replication because of a blockage at the stage of proviral DNA integration in host cell DNA. In vitro assays using long term repeat mimics, however, demonstrate that the L172A/K173A IN mutant was catalytically active. Moreover, trans-complementation experiments show that the viral propagation of L172A/K173A viruses could be rescued by the overexpression of Vpr.L172A/K173A IN fusion protein in a dose-dependent manner and that this rescue is independent of UNG2 packaging. Altogether, our data indicate that L172A/K173A mutations of IN induce a subtle defect in the function of IN, which nevertheless dramatically impairs viral replication. Unexpectedly, this blockage of replication could be overcome by forcing the packaging of higher amounts of this same mutated integrase. This is the first study reporting that blockage of the integration process of HIV-1 provirus carrying a mutation of IN could be alleviated by increasing amounts of IN even carrying the same mutations.	INSERM, U372, F-13276 Marseille 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Sire, J (corresponding author), INSERM, U372, 163 Ave Luminy,BP 178, F-13276 Marseille 9, France.		Priet, Stéphane/ABD-4869-2020; Querat, Gilles/E-9577-2014; Priet, Stéphane/N-7952-2017	Priet, Stéphane/0000-0001-7102-3654; Querat, Gilles/0000-0003-1897-8210; Priet, Stéphane/0000-0001-7102-3654				Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BURLESON DG, 1992, P SOC EXP BIOL MED, V199, P305; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; Liu HM, 1997, J VIROL, V71, P7704, DOI 10.1128/JVI.71.10.7704-7710.1997; Liu HM, 1999, J VIROL, V73, P8831, DOI 10.1128/JVI.73.10.8831-8836.1999; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Oz I, 2002, BIOCHEM J, V361, P557, DOI 10.1042/0264-6021:3610557; Priet S, 2003, J BIOL CHEM, V278, P4566, DOI 10.1074/jbc.M209311200; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959; ZHENG R, P NATL ACAD SCI US, V93, P13659	36	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20724	20730		10.1074/jbc.M301768200	http://dx.doi.org/10.1074/jbc.M301768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670953	hybrid			2022-12-25	WOS:000183230500038
J	Tsutsui, S; Tasumi, S; Suetake, H; Suzuki, Y				Tsutsui, S; Tasumi, S; Suetake, H; Suzuki, Y			Lectins homologous to those of monocotyledonous plants in the skin mucus and intestine of pufferfish, Fugu rubripes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING LECTIN; CONGER EEL; PURIFICATION; MYRIASTER; GALECTINS; FAMILY; AGGLUTININS; INFECTION; CELLS; FISH	We have characterized pufflectin, a novel mannose-specific lectin, from the skin mucus of the pufferfish, Fugu rubripes. Molecular mass estimations by gel filtration and matrix-assisted laser desorption ionization time-of-flight mass spectrometry and the SDS-PAGE pattern suggest that pufflectin is a homodimer composed of non-covalently associated subunits of 13 kDa. The full-length pufflectin cDNA consists of 527 bp, with 116 amino acid residues deduced from the open reading frame. The amino acid sequence of pufflectin shows no homology with any known animal lectin. Surprisingly, pufflectin shares sequence homology with mannose-binding lectins of monocotyledonous plants and has conserved two of three carbohydrate recognition domains of these plant lectins. The pufflectin gene is expressed in gills, oral cavity wall, esophagus, and skin. In addition, an isoform occurs exclusively in the intestine. Pufflectin differs from mannose-binding lectins purified from the blood plasma of Fugu. Whereas pufflectin did not agglutinate five bacterial species tested, it was demonstrated to bind to the parasitic trematode, Heterobothrium okamotoi. This finding suggests that pufflectin contributes to the parasite-defense system in Fugu.	Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan	University of Tokyo	Suzuki, Y (corresponding author), Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan.	ayuzuru@mail.ecc.u-tokyo.ac.jp		Tasumi, Satoshi/0000-0003-3047-6942				Alexander John B., 1992, Annual Review of Fish Diseases, V2, P249, DOI 10.1016/0959-8030(92)90066-7; ALHASSAN JM, 1986, COMP BIOCHEM PHYS B, V85, P31, DOI 10.1016/0305-0491(86)90217-8; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; Damme E.J.V., 1991, EUR J BIOCHEM, V202, P23; DAMME EJM, 1993, PLANT MOL BIOL, V23, P365; DAMME EJM, 1994, PLANT MOL BIOL, V24, P825; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; Force A, 1999, GENETICS, V151, P1531; GOTONANCE R, 1995, FISHERIES SCI, V61, P137, DOI 10.2331/fishsci.61.137; INGRAM GA, 1980, J FISH BIOL, V16, P23, DOI 10.1111/j.1095-8649.1980.tb03685.x; KAMIYA H, 1988, DEV COMP IMMUNOL, V12, P309, DOI 10.1016/0145-305X(88)90007-9; KAMIYA H, 1980, BIOCHIM BIOPHYS ACTA, V622, P171, DOI 10.1016/0005-2795(80)90028-8; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kawagishi H, 2001, BIOSCI BIOTECH BIOCH, V65, P2437, DOI 10.1271/bbb.65.2437; KILPATRICK DC, 2000, HDB ANIMAL LECTINS; Kiyono H., 1996, MUCOSAL VACCINES; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laursen SB, 1998, IMMUNOLOGY, V93, P421, DOI 10.1046/j.1365-2567.1998.00446.x; Mistry AC, 2001, BIOCHEM J, V360, P107, DOI 10.1042/0264-6021:3600107; Muramoto K, 1999, COMP BIOCHEM PHYS B, V123, P33, DOI 10.1016/S0305-0491(99)00037-1; MURAMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1116, P129, DOI 10.1016/0304-4165(92)90109-8; Nakamura O, 2001, DEV COMP IMMUNOL, V25, P431, DOI 10.1016/S0145-305X(01)00012-X; Nakao M, 1998, IMMUNOL REV, V166, P27, DOI 10.1111/j.1600-065X.1998.tb01250.x; ODA Y, 1984, J PHARMACOBIO-DYNAM, V7, P614; OGAWA K, 1991, Japanese Journal of Parasitology, V40, P388; Ogawa K, 1997, FISH PATHOL, V32, P15, DOI 10.3147/jsfp.32.15; OGRA PLM, 1999, MUCOSAL IMMUNOLOGY; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; SHIOMI K, 1987, NIPPON SUISAN GAKK, V53, P1275; SHIOMI K, 1990, NIPPON SUISAN GAKK, V56, P119; SHIOMI K, 1989, COMP BIOCHEM PHYS B, V92, P255, DOI 10.1016/0305-0491(89)90275-7; Skin Suzuki Y, 1995, ATLAS FISH HISTOLOGY, P8; Smeets K, 1997, PLANT MOL BIOL, V33, P223, DOI 10.1023/A:1005717020021; Tasumi S, 2002, J BIOL CHEM, V277, P27305, DOI 10.1074/jbc.M202648200; Toda M, 1996, FISHERIES SCI, V62, P138, DOI 10.2331/fishsci.62.138; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vitved L, 2000, IMMUNOGENETICS, V51, P955, DOI 10.1007/s002510000232; YANO T, 1996, FISH IMMUNE SYSTEM O, P129	42	81	84	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20882	20889		10.1074/jbc.M301038200	http://dx.doi.org/10.1074/jbc.M301038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654913	hybrid			2022-12-25	WOS:000183230500058
J	Young, KW; Nash, MS; Challiss, RAJ; Nahorski, SR				Young, KW; Nash, MS; Challiss, RAJ; Nahorski, SR			Role of Ca2+ feedback on single cell inositol 1,4,5-trisphosphate oscillations mediated by G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CALCIUM OSCILLATIONS; KINASE-C; ALPHA(1B)-ADRENERGIC RECEPTOR; CYTOSOLIC CA2+; PHOSPHORYLATION; DESENSITIZATION; IP3; TRISPHOSPHATE; MOBILIZATION	The dynamics of inositol 1,4,5-trisphosphate (Ins (1,4,5)P-3) production during periods of G-protein-coupled receptor-mediated Ca2+ oscillations have been investigated using the pleckstrin homology (PH) domain of phospholipase C (PLC) delta(1) tagged with enhanced green fluorescent protein (eGFP-PHPLCdelta1). Activation of noradrenergic alpha(1B) and muscarinic M-3 receptors recombinantly expressed in the same Chinese hamster ovary cell indicates that Ca(2+)responses to these G-protein-coupled receptors are stimulus strength-dependent. Thus, activation of alpha(1B) receptors produced transient base-line Ca2+ oscillations, sinusoidal Ca2+ oscillations, and then a steady-state plateau level of Ca2+ as the level of agonist stimulation increased. Activation of M-3 receptors, which have a higher coupling efficiency than alpha(1B) receptors, produced a sustained increase in intracellular Ca2+ even at low levels of agonist stimulation. Confocal imaging of eGFP-PHPLCdelta1 visualized periodic increases in Ins(1,4,5)P-3 production underlying the base-line Ca2+ oscillations. Ins(1,4,5)P-3 oscillations were blocked by thapsigargin but not by protein kinase C down-regulation. The net effect of increasing intracellular Ca2+ was stimulatory to Ins(1,4,5)P-3 production, and dual imaging experiments indicated that receptor-mediated Ins(1,4,5)P-3 production was sensitive to changes in intracellular Ca2+ between basal and similar to200 nM. Together, these data suggest that alpha(1B) receptor-mediated Ins(1,4,5)P-3 oscillations result from a positive feedback effect of Ca2+ onto phospholipase C. The mechanisms underlying alpha(1B) receptor-mediated Ca(2+)responses are therefore different from those for the metabotropic glutamate receptor 5a, where Ins(1,4,5)P-3 oscillations are the primary driving force for oscillatory Ca(2+)responses (Nash, M.S., Young, K.W., Challiss, R. A. J., and Nahorski, S. R. (2001) Nature 413, 381-382). For alpha(1B) receptors the Ca2+-dependent Ins(1,4,5)P-3 production may serve to augment the existing regenerative Ca2+-induced Ca2+-release process; however, the sensitivity to Ca2+ feedback is such that only transient base-line Ca2+ spikes may be capable of causing Ins(1,4,5)P-3 oscillations.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Young, KW (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Alcantara-Hernandez R, 2000, BRIT J PHARMACOL, V129, P724, DOI 10.1038/sj.bjp.0703073; Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; Bootman MD, 1999, CURR BIOL, V9, pR876, DOI 10.1016/S0960-9822(00)80072-X; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DELRIO E, 1994, J NEUROCHEM, V63, P535; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; Garcia-Sainz JA, 2000, EUR J PHARMACOL, V389, P1, DOI 10.1016/S0014-2999(99)00896-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KENDALL DA, 1984, J NEUROCHEM, V42, P1388, DOI 10.1111/j.1471-4159.1984.tb02799.x; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THOMPSON NT, 1991, BRIT J PHARMACOL, V103, P1592, DOI 10.1111/j.1476-5381.1991.tb09832.x; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177	39	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20753	20760		10.1074/jbc.M211555200	http://dx.doi.org/10.1074/jbc.M211555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670945	hybrid			2022-12-25	WOS:000183230500042
J	Carter, RS; Pennington, KN; Ungurait, BJ; Ballard, DW				Carter, RS; Pennington, KN; Ungurait, BJ; Ballard, DW			In vivo identification of inducible phosphoacceptors in the IKK gamma/NEMO subunit of human I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAX TRANSFORMING PROTEIN; NECROSIS-FACTOR RECEPTOR; LEUKEMIA-VIRUS TYPE-1; PERSISTENT ACTIVATION; TRANSCRIPTION FACTORS; IMMUNE-RESPONSES; NEMO/IKK-GAMMA; COMPLEX; PHOSPHORYLATION; BETA	Transcription factor NF-kappaB plays a pivotal regulatory role in the genetic programs for cell cycle progression and inflammation. Nuclear translocation of NF-kappaB is controlled by an inducible protein kinase called IKK, which earmarks cytoplasmic inhibitors of NF-kappaB for proteolytic destruction. IKK contains two structurally related catalytic subunits termed IKKalpha and IKKbeta as well as a noncatalytic subunit called IKKgamma/NEMO. Mutations in the X-linked gene encoding IKKgamma can interfere with NF-kappaB signaling and lead to immunodeficiency disease. Although its precise mechanism of action remains unknown, IKKgamma is phosphorylated in concert with the induction of NF-kappaB by the viral oncoprotein Tax and the proinflammatory cytokine tumor necrosis factor alpha (TNF). We now demonstrate that TNF-induced phosphorylation of IKKgamma is blocked in cells deficient for IKKbeta but not IKKalpha. Phosphopeptide-mapping experiments with metabolically radiolabeled cells indicate that IKKbeta phosphorylates human IKKgamma at Ser-31, Ser-43, and Ser-376 following the enforced expression of either the Tax oncoprotein or the type 1 TNF receptor. Inducible phosphorylation of IKKgamma is attenuated following the deletion of its COOH-terminal zinc finger domain ( amino acids 397-419), a frequent target for mutations that occur in IKKgamma-associated immunodeficiencies. As such, IKKbeta-mediated phosphorylation of IKKgamma at these specific serine targets may facilitate proper regulation of NF-kappaB signaling in the immune system.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A4301 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	dean.ballard@vanderbilt.edu			NATIONAL CANCER INSTITUTE [T32CA009385, R01CA082556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052379] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09385, R01 CA082556] Funding Source: Medline; NIAID NIH HHS [AI052379] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hawiger J, 1999, BLOOD, V94, P1711, DOI 10.1182/blood.V94.5.1711.417k20_1711_1716; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	40	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19642	19648		10.1074/jbc.M301705200	http://dx.doi.org/10.1074/jbc.M301705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657630	hybrid			2022-12-25	WOS:000183078000012
J	Planque, S; Taguchi, H; Burr, G; Bhatia, G; Karle, S; Zhou, YX; Nishiyama, Y; Paul, S				Planque, S; Taguchi, H; Burr, G; Bhatia, G; Karle, S; Zhou, YX; Nishiyama, Y; Paul, S			Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; GROWTH-FACTOR RECEPTOR; CATALYTIC ANTIBODY; MONOCLONAL-ANTIBODY; INHIBITORS; CHAIN; AUTOANTIBODIES; HYDROLYSIS; MECHANISM; PROTEINS	Antibody (Ab) nucleophilic reactivity was studied using hapten and polypeptide antigens containing biotinylated phosphonate diester groups ( covalently reactive antigen analogs, CRAs). Polyclonal IgG from healthy donors formed covalent adducts with a positively charged hapten CRA at levels superior to trypsin. Each of the 16 single chain Fv clones studied expressed a similar reactivity, indicating the V domain location of the nucleophiles and their broad distribution in diverse Abs. The formation of hapten CRA-Fv adducts was correlated with Fv proteolytic activity determined by cleavage of a model peptide substrate. Despite excellent nucleophilicity, proteolysis by IgG proceeded at lower rates than trypsin, suggesting that events occurring after nucleophilic attack on the substrate limit the rate of Ab proteolysis. The extracellular domain of the epidermal growth factor receptor with phosphonate diester groups at Lys side chains and a synthetic peptide corresponding to residues 421 - 431 of human immunodeficiency virus glycoprotein (gp) 120 with the phosphonate diester at the C terminus formed covalent adducts with specific polyclonal and monoclonal Abs raised by immunization with epidermal growth factor receptor and synthetic gp120-(421-436) devoid of phosphonate diester groups, respectively. Adduct formation was inhibited by extracellular domain of the epidermal growth factor receptor (exEGFB) and synthetic gp120-( 421 - 436) devoid of phosphonate groups, suggesting that the nucleophiles are located within the antigen binding sites. These results suggest the innate character of the Ab nucleophilic reactivity, its functional coordination with non-covalent adaptive binding interactions developing over the course of B cell maturation, and novel routes toward permanent inhibition of Abs.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA	University of Texas System	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol, 6431 Fannin, Houston, TX 77030 USA.	sudhir.paul@uth.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268, P01AI046029] Funding Source: NIH RePORTER; NCI NIH HHS [CA80312] Funding Source: Medline; NIAID NIH HHS [AI46029, AI31268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; BERMAS BL, 1994, AIDS RES HUM RETROV, V10, P1071, DOI 10.1089/aid.1994.10.1071; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; Fersht A., 1985, ENZYME STRUCTURE MEC; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; Jia Y, 2000, BIOCHEMISTRY-US, V39, P3927, DOI 10.1021/bi9928086; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; KALAGA R, 1995, J IMMUNOL, V155, P2695; Karle S, 2003, VACCINE, V21, P1213, DOI 10.1016/S0264-410X(02)00504-2; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Lefevre S, 2001, FEBS LETT, V489, P25, DOI 10.1016/S0014-5793(01)02075-0; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; Nevinsky GA, 1998, APPL BIOCHEM BIOTECH, V75, P77, DOI 10.1007/BF02787710; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, J MED CHEM, V37, P226, DOI 10.1021/jm00028a004; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; PAUL S, 1990, J BIOL CHEM, V265, P11910; Planque S, 2003, FASEB J, V17, P136, DOI 10.1096/fj.01-0847com; RAO G, 1991, J PROTEIN CHEM, V10, P117, DOI 10.1007/BF01024661; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Taguchi H, 2002, BIOORG MED CHEM LETT, V12, P3167, DOI 10.1016/S0960-894X(02)00640-6; TAKAGI M, 1995, FEBS LETT, V375, P273, DOI 10.1016/0014-5793(95)01224-3; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WUILMART C, 1976, J IMMUNOGENET, V3, P1; ZHAO QJ, 1994, BIOCHEMISTRY-US, V33, P8128, DOI 10.1021/bi00192a018; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	45	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20436	20443		10.1074/jbc.M301468200	http://dx.doi.org/10.1074/jbc.M301468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12668670	hybrid			2022-12-25	WOS:000183078000110
J	Uttamsingh, S; Zong, CS; Wang, LH				Uttamsingh, S; Zong, CS; Wang, LH			Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-ROS; SARCOMA VIRUS UR2; SIGNAL-TRANSDUCTION PATHWAYS; RECEPTOR TYROSINE KINASES; FOCAL ADHESION KINASE; FACTOR-I RECEPTOR; CELL-CYCLE; PROTEIN-KINASE; INSULIN-RECEPTOR; EXTRACELLULAR-MATRIX	The question remains open whether the signaling pathways shown to be important for growth and transformation in adherent cultures proceed similarly and play similar roles for cells grown under anchorage-independent conditions. Chicken embryo fibroblasts (CEF) infected with the avian sarcoma virus UR2, encoding the oncogenic receptor protein-tyrosine kinase ( RPTK) v-Ros, or with two of its transformation-impaired mutants were grown in nonadherent conditions in methylcellulose (MC)-containing medium, and the signaling functions essential for Ros-induced anchorage-independent growth were analyzed. We found that the overall tyrosine phosphorylation of cellular proteins in CEF transformed by v-Ros or by two oncogenic nonreceptor protein-tyrosine kinases ( PTKs), v-Src and v-Yes, was dramatically reduced in nonadherent conditions compared with that in adherent conditions, indicating that cell adhesion to the extracellular matrix plays an important role in efficient substrate phosphorylation by these constitutively activated PTKs. The UR2 transformation-defective mutants were differentially impaired compared with UR2 in the activation of phosphatidylinositol 3-kinase ( PI 3-kinase) and Stat3 in nonadherent conditions. Consistently, the constitutively activated mutants of PI 3-kinase and Stat3 rescued the ability of the UR2 mutants to promote anchorage-independent growth. Conversely, dominant negative mutants of PI 3-kinase and Stat3 inhibited UR2-induced anchorage-independent growth. UR2-infected CEF grown in nonadherent conditions displayed faster cell cycle progression than the control or the UR2 mutant-infected cells, and this appeared to correlate with a PI 3-kinase-dependent increase in cyclin A-associated Cdk2 activity. Treatment of UR2-infected cells with Cdk2 inhibitors led to the loss of the anchorage-independent growth-promoting activity of UR2. In conclusion, we have adopted an experimental system enabling us to study the signaling pathways in cells grown under anchorage-independent conditions and have identified matrix-independent activation of PI 3-kinase and Stat3 signaling functions, as well as the PI 3-kinase-dependent increase of cyclin A-associated Cdk2 kinase activity, to be critical for the Ros-PTK-induced anchorage-independent growth.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, Box 1124, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Wang, Lu-Hai/E-3986-2010		NCI NIH HHS [CA55054, CA29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055054, R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHEN JM, 1994, ONCOGENE, V9, P773; CHEN JM, 1991, ONCOGENE, V6, P257; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Ito T, 1996, MOL CELL BIOL, V16, P943; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; JONG SMJ, 1987, ONCOGENE RES, V1, P7; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin TH, 1997, J BIOL CHEM, V272, P8849; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NECKAMEYER WS, 1984, J VIROL, V50, P914, DOI 10.1128/JVI.50.3.914-921.1984; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Philip A, 2000, J BIOL CHEM, V275, P5911, DOI 10.1074/jbc.275.8.5911; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2001, J CELL SCI, V114, P2553; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SonnenbergRiethmacher E, 1996, GENE DEV, V10, P1184, DOI 10.1101/gad.10.10.1184; Suzuki K, 2000, BIOCHEM BIOPH RES CO, V272, P111, DOI 10.1006/bbrc.2000.2737; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou Q, 2000, BREAST CANCER RES TR, V59, P27, DOI 10.1023/A:1006370603147; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZONG CS, 1994, P NATL ACAD SCI USA, V91, P10982, DOI 10.1073/pnas.91.23.10982; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	88	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18798	18810		10.1074/jbc.M211522200	http://dx.doi.org/10.1074/jbc.M211522200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646574	hybrid			2022-12-25	WOS:000182932200014
J	Vang, T; Abrahamsen, H; Myklebust, S; Horejsi, V; Tasken, K				Vang, T; Abrahamsen, H; Myklebust, S; Horejsi, V; Tasken, K			Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase A inhibits T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SRC KINASE; ENRICHED MICRODOMAINS; TYROSINE KINASES; LIPID RAFTS; ACTIVATION	Raft-associated Csk controls signaling through the T cell receptor (TCR) and was mainly anchored to Cbp/PAG (phosphoprotein associated with glycosphingolipid-enriched membrane domains). Treatment of cells with the cAMP-elevating agent prostaglandin E-2 (PGE(2)) augmented the level of Cbp/PAG phosphorylation with a concomitant increase in amounts of Csk bound to Cbp/PAG. While TCR-triggering resulted in transient dissociation of Csk from Cbp/PAG/rafts allowing TCR-induced tyrosine phosphorylation to occur, pretreatment with PGE(2) reduced Csk dissociation upon TCR triggering. This correlated with lowered TCR-induced phosphorylation of CD3 zeta-chain and linker for activation of T cells. Moreover, competition of endogenous Csk from lipid rafts abolished PGE(2)-mediated inhibition of TCR-induced zeta-chain phosphorylation and activation of the nuclear factor of activated T cells (NFAT) activator protein 1 (AP-1). Finally, raft-associated Csk already activated via Cbp/PAG binding, gained additional increase in phosphotransferase activity upon protein kinase A-mediated phosphorylation of Csk. We propose that cAMP regulates Csk via both spatial and enzymatic mechanisms, thereby inhibiting signaling through the TCR.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Sch Pharm, Dept Pharmacol, N-0317 Oslo, Norway; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic	University of Oslo; University of Oslo; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, POB 1112, N-0317 Oslo, Norway.		Abrahamsen, Hilde/E-5323-2010; Horejsi, Vaclav/G-3113-2014	Horejsi, Vaclav/0000-0003-4925-0142; Tasken, Kjetil/0000-0003-2841-4697				Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Hermiston ML, 2002, J CLIN INVEST, V109, P9; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Werlen G, 2002, CURR OPIN IMMUNOL, V14, P299, DOI 10.1016/S0952-7915(02)00339-4; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813	15	59	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17597	17600		10.1074/jbc.C300077200	http://dx.doi.org/10.1074/jbc.C300077200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12665526	hybrid			2022-12-25	WOS:000182838300004
J	Doherty, TM; Shah, PK; Rajavashisth, TB				Doherty, TM; Shah, PK; Rajavashisth, TB			Cellular origins of atherosclerosis: towards ontogenetic endgame?	FASEB JOURNAL			English	Article							ENDOTHELIAL PROGENITOR CELLS; SMOOTH-MUSCLE-CELLS; BONE-MARROW-CELLS; STEM-CELLS; IN-VIVO; ADULT-RAT; MESENCHYMAL CELLS; GENE-TRANSFER; DIFFERENTIATION; HEPATOCYTES		Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rajavashisth, TB (corresponding author), Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Atherosclerosis Res Ctr, Davis Res Bldg,Room 1062,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	rajavashisth@cshs.org	Rajavashisth, Tripathi/ABB-6379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051980, R01HL058555, R01HL051980] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58555, HL51980] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Andreassi MG, 2000, ENVIRON MOL MUTAGEN, V35, P265, DOI 10.1002/1098-2280(2000)35:4<265::AID-EM1>3.0.CO;2-M; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; BASHIR R, 2002, KIDNEY INT S1, V61, P110; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Botto N, 2001, MUTAT RES-GEN TOX EN, V493, P23, DOI 10.1016/S1383-5718(01)00162-0; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Campbell JH, 2001, ANN NY ACAD SCI, V947, P18; Chung IM, 1998, AM J PATHOL, V152, P913; Dabeva MD, 1997, P NATL ACAD SCI USA, V94, P7356, DOI 10.1073/pnas.94.14.7356; Davies MJ, 2001, AM J CARDIOL, V88, p2F; DeRuiter MC, 1997, CIRC RES, V80, P444, DOI 10.1161/01.RES.80.4.444; DILLEY RJ, 1992, CELL TISSUE RES, V269, P281, DOI 10.1007/BF00319619; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HACKNEY JA, 2002, IN PRESS P NATL ACAD; Hillebrands JL, 2002, NAT MED, V8, P194, DOI 10.1038/nm0302-194; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Houston P, 2001, FEBS LETT, V492, P73, DOI 10.1016/S0014-5793(01)02191-3; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu YH, 2002, CIRCULATION, V106, P1834, DOI 10.1161/01.CIR.0000031333.86845.DD; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Krakowski ML, 1999, AM J PATHOL, V154, P683, DOI 10.1016/S0002-9440(10)65315-1; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Li J, 2001, AM J PATHOL, V158, P1943, DOI 10.1016/S0002-9440(10)64663-9; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Moore MAS, 2002, J CLIN INVEST, V109, P313, DOI 10.1172/JCI200214940; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murry CE, 1997, AM J PATHOL, V151, P697; Nabel EG, 2002, CIRCULATION, V105, P672, DOI 10.1161/circ.105.6.672; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pang WX, 2000, BLOOD, V95, P1106, DOI 10.1182/blood.V95.3.1106; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PENN A, 1990, MUTAT RES, V239, P149, DOI 10.1016/0165-1110(90)90003-T; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Rabbani R, 1999, CARDIOVASC RES, V41, P402, DOI 10.1016/S0008-6363(98)00279-X; RAO MS, 1995, SEMIN CELL BIOL, V6, P151; RAO MS, 1990, CELL DIFFER DEV, V29, P155, DOI 10.1016/0922-3371(90)90118-G; RAO MS, 1989, AM J PATHOL, V134, P1069; RAO MS, 1986, J HISTOCHEM CYTOCHEM, V34, P197, DOI 10.1177/34.2.2418098; RAO MS, 1988, BIOCHEM BIOPH RES CO, V156, P131, DOI 10.1016/S0006-291X(88)80814-3; REDDY JK, 1991, DIGEST DIS SCI, V36, P502, DOI 10.1007/BF01298883; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Seshiah PN, 2002, CIRCULATION, V105, P174, DOI 10.1161/hc0202.102248; Shah PK, 2001, CIRCULATION, V104, P1878, DOI 10.1161/circ.104.16.1878; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Suzuki K, 2001, CIRCULATION, V104, pI207; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Thayer JM, 1995, CELL MOL BIOL RES, V41, P251; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; World Health Organization, 1999, WORLD HLTH REP MAK D	74	18	18	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					592	597		10.1096/fj.02-0913hyp	http://dx.doi.org/10.1096/fj.02-0913hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665471				2022-12-25	WOS:000182580100003
J	Kozlov, S; Gueven, N; Keating, K; Ramsay, J; Lavin, MF				Kozlov, S; Gueven, N; Keating, K; Ramsay, J; Lavin, MF			ATP activates ataxia-telangiectasia mutated (ATM) in vitro - Importance of autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; DNA-DAMAGE; CELL-CYCLE; IONIZING-RADIATION; FUNCTIONAL-LINK; PHOSPHORYLATION; P53; GENE	Ataxia-telangiectasia Mutated (ATM), mutated in the human disorder ataxia-telangiectasia, is rapidly activated by DNA double strand breaks. The mechanism of activation remains unresolved, and it is uncertain whether autophosphorylation contributes to activation. We describe an in vitro immunoprecipitation system demonstrating activation of ATM kinase from unirradiated extracts by preincubation with ATP. Activation is both time- and ATP concentration-dependent, other nucleotides fail to activate ATM, and DNA is not required. ATP activation is specific for ATM since it is not observed with kinase-dead ATM, it requires Mn2+, and it is inhibited by wortmannin. Exposure of activated ATM to phosphatase abrogates activity, and repeat cycles of ATP and phosphatase treatment reveal a requirement for autophosphorylation in the activation process. Phosphopeptide mapping revealed similarities between the patterns of autophosphorylation for irradiated and ATP-treated ATM. Caffeine inhibited ATM kinase activity for substrates but did not interfere with ATM autophosphorylation. ATP failed to activate either A-T and rad3-related protein (ATR) or DNA-dependent protein kinase under these conditions, supporting the specificity for ATM. These data demonstrate that ATP can specifically induce activation of ATM by a mechanism involving autophosphorylation. The relationship of this activation to DNA damage activation remains unclear but represents a useful model for understanding in vivo activation.	Queensland Inst Med Res, Canc Fund Res Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Surg, Herston, Qld 4029, Australia; Mater Hosp, Queensland Radium Inst, Brisbane, Qld 4101, Australia; ERIX Therapeut Ltd, Cork, Ireland	QIMR Berghofer Medical Research Institute; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, Canc Fund Res Unit, POB Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	martinL@qimr.edu.au	Ramsay, Jonathan/F-7009-2013; Lavin, Martin F/F-5961-2014; Kozlov, Sergei/M-2067-2014; Kozlov, Sergei/T-9779-2019	Lavin, Martin F/0000-0002-5940-4769; Kozlov, Sergei/0000-0001-6183-7339; Guven, Nuri/0000-0003-3782-767X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATOH T, 1991, J BIOL CHEM, V266, P3039; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Roseman AM, 2001, J STRUCT BIOL, V135, P115, DOI 10.1006/jsbi.2001.4374; Sarkaria JN, 1999, CANCER RES, V59, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sowadski JM, 1999, PHARMACOL THERAPEUT, V82, P157, DOI 10.1016/S0163-7258(98)00054-0; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; ZIV Y, 2000, METHODS MOL BIOL STR, P99	62	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9309	9317		10.1074/jbc.M300003200	http://dx.doi.org/10.1074/jbc.M300003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645530	hybrid			2022-12-25	WOS:000181524000056
J	Porter, JD; Merriam, AP; Khanna, S; Andrade, FH; Richmonds, CR; Leahy, P; Cheng, G; Karathanasis, P; Zhou, XH; Kusner, LL; Adams, ME; Willem, M; Mayer, U; Kaminski, HJ				Porter, JD; Merriam, AP; Khanna, S; Andrade, FH; Richmonds, CR; Leahy, P; Cheng, G; Karathanasis, P; Zhou, XH; Kusner, LL; Adams, ME; Willem, M; Mayer, U; Kaminski, HJ			Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice	FASEB JOURNAL			English	Article						muscular dystrophy; dystrophin-glycoprotein complex; DNA microarray; gene profiling	DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT SKELETAL-MUSCLE; GENE-EXPRESSION; NITRIC-OXIDE; ACETYLCHOLINE-RECEPTOR; ALPHA-7-BETA-1 INTEGRIN; CALCIUM HOMEOSTASIS; MOUSE DYSTROPHY; CARDIAC-MUSCLE; ANIMAL-MODELS	Extraocular muscle (EOM) is spared in Duchenne muscular dystrophy. Here, we tested putative EOM sparing mechanisms predicted from existing dystrophinopathy models. Data show that mdx mouse EOM contains dystrophin-glycoprotein complex (DGC)-competent and DGC-deficient myofibers distributed in a fiber type-specific pattern. Up-regulation of a dystrophin homologue, utrophin, mediates selective DGC retention. Counter to the DGC mechanical hypothesis, an intact DGC is not a precondition for EOM sarcolemmal integrity, and active adaptation at the level of calcium homeostasis is not mechanistic in protection. A partial, fiber type-specific retention of antiischemic nitric oxide to vascular smooth muscle signaling is not a factor in EOM sparing, because mice deficient in dystrophin and alpha-syntrophin, which localizes neuronal nitric oxide synthase to the sarcolemma, have normal EOMs. Moreover, an alternative transmembrane protein, alpha7beta1 integrin, does not appear to substitute for the DGC in EOM. Finally, genomewide expression profiling showed that EOM does not actively adapt to dystrophinopathy but identified candidate genes for the constitutive protection of mdx EOM. Taken together, data emphasize the conditional nature of dystrophinopathy and the potential importance of nonmechanical DGC roles and support the hypothesis that broad, constitutive structural cell signaling, and/or biochemical differences between EOM and other skeletal muscles are determinants of differential disease responsiveness.	Univ Hosp Cleveland, Dept Ophthalmol, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Kentucky, Dept Toxicol, Lexington, KY 40536 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester, Lancs, England	University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Kentucky; University of Washington; University of Washington Seattle; Max Planck Society; University of Manchester	Porter, JD (corresponding author), Univ Hosp Cleveland, Dept Ophthalmol, Res Inst, 11100 Euclid Ave, Cleveland, OH 44106 USA.	jdp7@po.cwru.edu	Andrade, Francisco H/F-1258-2011	Andrade, Francisco H/0000-0002-2460-5798; Kaminski, Henry/0000-0002-8195-0141; Kusner, Linda/0000-0002-5530-2140; Mayer, Ulrike/0000-0003-2328-0052				Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Andrade FH, 2000, MICROSC RES TECHNIQ, V48, P192, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J; Apostolova MD, 2000, BIOCHEM CELL BIOL, V78, P27, DOI 10.1139/bcb-78-1-27; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BRIGGS MM, 1988, J MUSCLE RES CELL M, V9, P241, DOI 10.1007/BF01773894; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cheng G, 2002, INVEST OPHTH VIS SCI, V43, P1048; Cohn RD, 1999, J NEUROL SCI, V163, P140, DOI 10.1016/S0022-510X(99)00012-X; Dowling P, 2002, NATURWISSENSCHAFTEN, V89, P75, DOI 10.1007/s00114-001-0289-4; DUNN JF, 1991, J NEUROL SCI, V103, P226, DOI 10.1016/0022-510X(91)90168-7; Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Hodges BL, 1997, J CELL SCI, V110, P2873; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Infante JP, 1999, MOL CELL BIOCHEM, V195, P155, DOI 10.1023/A:1006972315739; JACOBY J, 1990, J MUSCLE RES CELL M, V11, P25, DOI 10.1007/BF01833323; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; Kaminski HJ, 1996, INVEST OPHTH VIS SCI, V37, P345; KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; KARPATI G, 1990, J NEUROPATH EXP NEUR, V49, P96, DOI 10.1097/00005072-199003000-00002; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; KHURANA TS, 1995, J EXP MED, V182, P467, DOI 10.1084/jem.182.2.467; Lin S, 1998, J NEUROPATH EXP NEUR, V57, P780, DOI 10.1097/00005072-199808000-00007; Lin S, 2000, DEV BRAIN RES, V119, P289, DOI 10.1016/S0165-3806(99)00165-0; MAIER A, 1994, INVEST OPHTH VIS SCI, V35, P3103; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; McLoon LK, 2002, MUSCLE NERVE, V25, P348, DOI 10.1002/mus.10056; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; ODA K, 1986, J NEUROL SCI, V74, P125, DOI 10.1016/0022-510X(86)90099-7; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Porter JD, 1998, CELL TISSUE RES, V292, P495, DOI 10.1007/s004410051078; Porter JD, 1999, BIOCHEM BIOPH RES CO, V257, P678, DOI 10.1006/bbrc.1999.0536; Porter JD, 2001, NEUROMUSCULAR DISORD, V11, P197, DOI 10.1016/S0960-8966(00)00171-1; Porter JD, 2001, P NATL ACAD SCI USA, V98, P12062, DOI 10.1073/pnas.211257298; Porter JD, 1998, NEUROMUSCULAR DISORD, V8, P198, DOI 10.1016/S0960-8966(98)00015-7; Porter JD, 1998, J CELL SCI, V111, P1801; PORTER JD, 1988, INVEST OPHTH VIS SCI, V29, P163; PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30; Rafael JA, 2000, HUM MOL GENET, V9, P1357, DOI 10.1093/hmg/9.9.1357; Rafael JA, 2000, MICROSC RES TECHNIQ, V48, P155, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<155::AID-JEMT4>3.0.CO;2-0; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Ragusa RJ, 1996, J NEUROL SCI, V139, P180; Ragusa RJ, 1997, NEUROMUSCULAR DISORD, V7, P379, DOI 10.1016/S0960-8966(97)00096-5; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Rando TA, 2001, MICROSC RES TECHNIQ, V55, P223, DOI 10.1002/jemt.1172; Reeve JL, 1997, MUSCLE NERVE, V20, P357, DOI 10.1002/(SICI)1097-4598(199703)20:3<357::AID-MUS14>3.0.CO;2-Y; Rubinstein NA, 2000, INVEST OPHTH VIS SCI, V41, P3391; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716	70	58	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					893	+		10.1096/fj.02-0810fje	http://dx.doi.org/10.1096/fj.02-0810fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670877				2022-12-25	WOS:000181892600015
J	Chen, Z; Raman, M; Chen, L; Lee, SF; Gilman, AG; Cobb, MH				Chen, Z; Raman, M; Chen, L; Lee, SF; Gilman, AG; Cobb, MH			TAO (thousand-and-one amino acid) protein kinases mediate signaling from carbachol to p38 mitogen-activated protein kinase and ternary complex factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; JUN NH2-TERMINAL KINASE; REGULATED KINASE; BETA-GAMMA; PATHWAYS; PHOSPHORYLATION; JNK; EXPRESSION; ERK2; IDENTIFICATION	The TAO ( for thousand-and-one amino acids) protein kinases activate p38 mitogen-activated protein ( MAP) kinase cascades in vitro and in cells by phosphorylating the MAP/ERK kinases ( MEKs) 3 and 6. We found that TAO2 activity was increased by carbachol and that carbachol and the heterotrimeric G protein Galpha(o) could activate p38 in 293 cells. Using dominant interfering kinase mutants, we found that MEKs 3 and 6 and TAOs were required for p38 activation by carbachol or the constitutively active mutant Galpha(o) Q205L. To explore events downstream of TAOs, the effects of TAO2 on ternary complex factors ( TCFs) were investigated. Transfection studies demonstrated that TAO2 stimulates phosphorylation of the TCF Elk1 on the major activating site, Ser(383), and that TAO2 stimulates transactivation of Elk1 and the related TCF, Sap1. Reporter activity was reduced by the p38-selective inhibitor SB203580. Taken together, these studies suggest that TAO protein kinases relay signals from carbachol through heterotrimeric G proteins to the p38 MAP kinase, which then activates TCFs in the nucleus.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473; raman, malavika/0000-0002-4773-8673	NIGMS NIH HHS [GM34497, GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Hirai S, 1996, ONCOGENE, V12, P641; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771	42	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22278	22283		10.1074/jbc.M301173200	http://dx.doi.org/10.1074/jbc.M301173200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665513	hybrid			2022-12-25	WOS:000183503900015
J	Kysela, B; Doherty, AJ; Chovanec, M; Stiff, T; Ameer-Beg, SM; Vojnovic, B; Girard, PM; Jeggo, PA				Kysela, B; Doherty, AJ; Chovanec, M; Stiff, T; Ameer-Beg, SM; Vojnovic, B; Girard, PM; Jeggo, PA			Ku stimulation of DNA ligase IV-dependent ligation requires inward movement along the DNA molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; ATOMIC-FORCE MICROSCOPY; PROTEIN-KINASE; V(D)J RECOMBINATION; XRCC4 PROTEIN; COMPLEX; END; TRANSLOCATION; BINDING	The DNA ligase IV.XRCC4 complex ( LX) functions in DNA non- homologous- end joining, the main pathway for double- strand break repair in mammalian cells. We show that, in contrast to ligation by T4 ligase, the efficiency of LX ligation of double- stranded ( ds) ends is critically dependent upon the length of the DNA substrate. The effect is specific for ds ligation, and LX/ DNA binding is not influenced by the substrate length. Ku stimulates LX ligation at concentrations resulting in 1 - 2 Ku molecules bound per substrate, whereas multiply Ku- bound DNA molecules inhibit ds ligation. The combined footprint of DNA with Ku and LX bound is the sum of each individual footprint suggesting that the two complexes are located in tandem at the DNA end. Inhibition of Ku translocation by the presence of cis- platinum adducts on the DNA substrate severely inhibits ligation by LX. Fluorescence resonance energy transfer analysis using fluorophore- labeled Ku and DNA molecules showed that, as expected, Ku makes close contact with the DNA end and that addition of LX can disrupt this close contact. Finally, we show that recruitment of LX by Ku is impaired in an adenylation- defective mutant providing further evidence that LX interacts directly with the DNA end, possibly via the 5 '- phosphate as shown for prokaryotic ligases. Taken together, our results suggest that, when LX binds to a Ku- bound DNA molecule, it causes inward translocation of Ku and that freedom to move inward on the DNA is essential to Ku stimulation of LX activity.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England	University of Sussex; University of Cambridge; University of Cambridge; University of Oxford	Kysela, B (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	b.kysela@sussex.ac.uk; p.a.jeggo@sussex.ac.uk	Chovanec, Miroslav/H-6818-2018; Vojnovic, Borivoj/AAV-4756-2021	Chovanec, Miroslav/0000-0001-9120-5084; Vojnovic, Borivoj/0000-0001-9013-3816; Ameer-Beg, Simon/0000-0001-5227-575X; Doherty, Aidan/0000-0002-6370-1109				Arosio D, 2002, J BIOL CHEM, V277, P9741, DOI 10.1074/jbc.M111916200; Becker W, 2001, PROC SPIE, V4262, P414, DOI 10.1117/12.424584; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P95; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Pang DL, 1997, CANCER RES, V57, P1412; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Turchi JJ, 2000, NUCLEIC ACIDS RES, V28, P4634, DOI 10.1093/nar/28.23.4634; Turchi JJ, 1996, BIOCHEMISTRY-US, V35, P2992, DOI 10.1021/bi951843j; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679	29	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22466	22474		10.1074/jbc.M303273200	http://dx.doi.org/10.1074/jbc.M303273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682039	hybrid			2022-12-25	WOS:000183503900041
J	Beha, D; Deitermann, S; Muller, M; Koch, HG				Beha, D; Deitermann, S; Muller, M; Koch, HG			Export of beta-lactamase is independent of the signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYTOPIC MEMBRANE-PROTEIN; ESCHERICHIA-COLI REQUIRES; PLASMA-MEMBRANE; TARGETING PATHWAY; TRIGGER FACTOR; CYTOPLASMIC MEMBRANE; SECRETORY PROTEINS; IN-VITRO; TRANSLOCATION; SECA	In Escherichia coli, three different types of proteins engage the SecY translocon of the inner bacterial membrane for translocation or insertion: 1) polytopic membrane proteins that prior to their insertion into the membrane are targeted to the translocon using the bacterial signal recognition particle (SRP) and its receptor; 2) secretory proteins that are targeted to and translocated across the SecY translocon in a SecA- and SecB-dependent reaction; and 3) membrane proteins with large periplasmic domains, requiring SRP for targeting and SecA for the translocation of the periplasmic moiety. In addition to its role as a targeting device for membrane proteins, a function of the bacterial SRP in the export of SecB-independent secretory proteins has also been postulated. In particular, beta-lactamase, a hydrolytic enzyme responsible for cleavage of the beta-lactam ring containing antibiotics, is considered to be recognized and targeted by SRP. To examine the role of the SRP pathway in beta-lactamase targeting and export, we performed a detailed in vitro analysis. Chemical cross-linking and membrane binding assays did not reveal any significant interaction between SRP and beta-lactamase nascent chains. More importantly, membrane vesicles prepared from mutants lacking a functional SRP pathway did block the integration of SRP-dependent membrane proteins but supported the export of beta-lactamase in the same way as that of the SRP-independent protein OmpA. These data demonstrate that in contrast to previous results, the bacterial SRP is not involved in the export of beta-lactamase and further suggest that secretory proteins of Gram-negative bacteria in general are not substrates of SRP.	Univ Freiburg, Inst Biochem & Mol Biol, Fac Biol, D-79104 Freiburg, Germany	University of Freiburg	Koch, HG (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Fac Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.							Adams H, 2002, EUR J BIOCHEM, V269, P5564, DOI 10.1046/j.1432-1033.2002.03262.x; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Helde R, 1997, J BACTERIOL, V179, P4003, DOI 10.1128/jb.179.12.4003-4012.1997; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kim J, 2001, FEBS LETT, V505, P245, DOI 10.1016/S0014-5793(01)02784-3; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1987, EMBO J, V6, P3855, DOI 10.1002/j.1460-2075.1987.tb02723.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7737, DOI 10.1073/pnas.81.24.7737; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Park SK, 2002, J BACTERIOL, V184, P2642, DOI 10.1128/JB.184.10.2642-2653.2002; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Rothe C, 1998, EUR J BIOCHEM, V252, P16, DOI 10.1046/j.1432-1327.1998.2520016.x; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 2001, ANTON LEEUW INT J G, V79, P17, DOI 10.1023/A:1010256109582; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22161	22167		10.1074/jbc.M300929200	http://dx.doi.org/10.1074/jbc.M300929200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682042	hybrid			2022-12-25	WOS:000183354200105
J	McMahon, M; Itoh, K; Yamamoto, M; Hayes, JD				McMahon, M; Itoh, K; Yamamoto, M; Hayes, JD			Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE EXPRESSION; 26S PROTEASOME; IN-VIVO; UBIQUITIN; PROTEIN; GLUTATHIONE; INDUCTION; BINDING; ACTIVATION; ENZYMES	Keap1 is a negative regulator of Nrf2, a bZIP transcription factor that mediates adaptation to oxidative stress. Previous studies suggested this negative regulation is a consequence of Keap1 controlling the subcellular distribution of Nrf2. We now report that Keap1 also controls the total cellular level of Nrf2 protein. In the RL34 non-transformed rat liver cell line, Nrf2 was found to accumulate rapidly in response to oxidative stress caused by treatment with sulforaphane, and the accumulation resulted from inhibition of proteasomal-mediated degradation of the bZIP protein. By heterologously expressing in COS1 cells epitope-tagged Nrf2 and an Nrf2(DeltaETGE) mutant lacking the Keap1-binding site, in both the presence and absence of Keap1 we demonstrate that Nrf2 is subject to ubiquitination and proteasomal degradation independently of both Keap1 and the redox environment of the cell. In oxidatively stressed cells, this is the sole mechanism responsible for Nrf2 degradation. However, under homeostatic conditions Nrf2 is subject to a substantially more rapid mode of proteasomal degradation than it is in oxidatively stressed cells, and this rapid turnover of Nrf2 requires it to interact with Keap1. Within Nrf2, the N-terminal Neh2 domain is identified as the redox-sensitive degron. These data suggest that Keap1 negatively regulates Nrf2 by both enhancing its rate of proteasomal degradation and altering its subcellular distribution.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	University of Dundee; University of Tsukuba; University of Tsukuba	McMahon, M (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	m.j.m.mcmahon@dundee.ac.uk	McMahon, Michael J/F-7070-2010; Yamamoto, Masayuki/A-4873-2010; McMahon, Michael J/A-1702-2008; Itoh, Ken/B-9506-2013	McMahon, Michael J/0000-0001-8615-9351; Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Hayes, John/0000-0002-2927-5548				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Bonnesen C, 2001, CANCER RES, V61, P6120; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Cadenas E., 1995, OXIDATIVE STRESS ANT, P1, DOI 10.1007/978-1- 4615-9689-9_1; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; De Conto F, 2000, J CELL SCI, V113, P2399; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; FARBER E, 1984, CAN J BIOCHEM CELL B, V62, P486, DOI 10.1139/o84-066; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jager S, 2001, EMBO J, V20, P4423, DOI 10.1093/emboj/20.16.4423; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kelly VP, 2000, CANCER RES, V60, P957; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; McMahon M, 2001, CANCER RES, V61, P3299; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Morimitsu Y, 2002, J BIOL CHEM, V277, P3456, DOI 10.1074/jbc.M110244200; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Thimmulappa RK, 2002, CANCER RES, V62, P5196; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	53	839	862	4	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21592	21600		10.1074/jbc.M300931200	http://dx.doi.org/10.1074/jbc.M300931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682069	hybrid			2022-12-25	WOS:000183354200036
J	Muhia, DK; Swales, CA; Eckstein-Ludwig, U; Saran, S; Polley, SD; Kelly, JM; Schaap, P; Krishna, S; Baker, DA				Muhia, DK; Swales, CA; Eckstein-Ludwig, U; Saran, S; Polley, SD; Kelly, JM; Schaap, P; Krishna, S; Baker, DA			Multiple splice variants encode a novel adenylyl cyclase of possible plastid origin expressed in the sexual stage of the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; GUANYLYL CYCLASE; DICTYOSTELIUM DEVELOPMENT; CYCLIC-NUCLEOTIDES; CATALYTIC DOMAINS; GAMETOCYTES; PARAMECIUM; CULTURE; GENE; SYNCHRONIZATION	We report the characterization of an unusual adenylyl cyclase gene from Plasmodium falciparum, here designated PfACalpha. The level of mRNA expression is maximum during development of gametocytes (the sexual blood stage of the parasite life cycle). The gene is highly interrupted by 22 introns, and reverse transcriptase-PCR analysis revealed that there are multiple mRNA splice variants. One intron has three alternative 3'-splice sites that confer the potential to encode distinct forms of the enzyme using alternative start codons. Deduced amino acid sequences predict membrane-spanning regions, the number of which can vary between two and six depending on the splice variant. Expression of a synthetic form of two of these variants in Xenopus oocytes and in Dictyostelium adenylyl cyclase-deficient mutants, confirms that PfACalpha is a functional adenylyl cyclase. These results identify a novel mechanism in P. falciparum for the generation of multiple isoforms of a key, membrane-bound signaling molecule from a single genomic copy. Comparisons of the catalytic domains of PfACalpha and a second putative P. falciparum adenylyl cyclase (PfACbeta) with those from other species reveal an unexpected similarity with adenylyl cyclases from certain prokaryotes including the cyanobacteria (blue green algae). In addition, the presence of an unusual active site substitution in a position that determines substrate specificity, also characteristic of these prokaryotic forms of the enzyme, further suggests a plastid origin for the Plasmodium cyclases.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England; Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of London; London School of Hygiene & Tropical Medicine; St Georges University London; University of Dundee	Baker, DA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		Polley, Spencer/F-7766-2013; Schaap, Pauline/A-3682-2009; Schaap, Pauline/M-5355-2019	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555; Baker, David/0000-0002-5490-8933; Krishna, Sanjeev/0000-0003-0066-0634				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER DA, 1994, PARASITOLOGY, V108, P129, DOI 10.1017/S0031182000068219; Bieger B, 2001, EMBO J, V20, P433, DOI 10.1093/emboj/20.3.433; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Carter R, 1993, Methods Mol Biol, V21, P67; Carucci DJ, 2000, J BIOL CHEM, V275, P22147, DOI 10.1074/jbc.M001021200; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GILMAN AG, 1972, ADV CYCL NUCL RES<D>, V2, P9; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; HAWKING F, 1971, T ROY SOC TROP MED H, V65, P549, DOI 10.1016/0035-9203(71)90036-8; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Katayama M, 1997, J BACTERIOL, V179, P3588, DOI 10.1128/jb.179.11.3588-3593.1997; KAUSHAL DC, 1980, NATURE, V286, P490, DOI 10.1038/286490a0; KAWAMOTO F, 1990, MOL BIOCHEM PARASIT, V42, P101, DOI 10.1016/0166-6851(90)90117-5; Kim HJ, 1998, J BIOL CHEM, V273, P30859, DOI 10.1074/jbc.273.47.30859; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Linder JU, 2000, J BIOL CHEM, V275, P11235, DOI 10.1074/jbc.275.15.11235; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; Meima ME, 1999, DEV BIOL, V212, P182, DOI 10.1006/dbio.1999.9352; Muhia DK, 2001, MOL MICROBIOL, V42, P553, DOI 10.1046/j.1365-2958.2001.02665.x; OGWANG RA, 1993, AM J TROP MED HYG, V49, P25, DOI 10.4269/ajtmh.1993.49.25; Pace T, 1998, MOL BIOCHEM PARASIT, V97, P45, DOI 10.1016/S0166-6851(98)00130-3; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PONNUDURAI T, 1986, PARASITOLOGY, V93, P263, DOI 10.1017/S003118200005143X; READ LK, 1991, J PARASITOL, V77, P346, DOI 10.2307/3283117; READ LK, 1991, MOL BIOCHEM PARASIT, V45, P109, DOI 10.1016/0166-6851(91)90032-2; Roelofs J, 2002, MOL BIOL EVOL, V19, P2239, DOI 10.1093/oxfordjournals.molbev.a004047; Roelofs J, 2001, EMBO J, V20, P4341, DOI 10.1093/emboj/20.16.4341; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZ JE, 1993, ADV SEC MESS PHOSPH, V27, P25; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; Soderbom F, 1999, DEVELOPMENT, V126, P5463; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sutherland E W, 1971, Lakartidningen, V68, P4991; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Taylor MC, 1999, MOL BIOCHEM PARASIT, V104, P205, DOI 10.1016/S0166-6851(99)00154-1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; vanEs S, 1996, J BIOL CHEM, V271, P23623, DOI 10.1074/jbc.271.39.23623; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	59	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22014	22022		10.1074/jbc.M301639200	http://dx.doi.org/10.1074/jbc.M301639200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668669	hybrid			2022-12-25	WOS:000183354200088
J	Ahn, JW; Urist, M; Prives, C				Ahn, JW; Urist, M; Prives, C			Questioning the role of checkpoint kinase 2 in the p53 DNA damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; P53-MEDIATED G(1) ARREST; CELL-CYCLE REGULATION; LI-FRAUMENI-SYNDROME; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; PROTEIN-KINASE; INDUCED PHOSPHORYLATION; IONIZING-RADIATION; HUMAN CHK1	Cdc25C and p53 have been reported to be physiological targets of checkpoint kinase 2 (Chk2). Surprisingly, although Chk2 purified from DNA damage sustaining cells has dramatically increased ability to phosphorylate Cdc25C when compared with untreated cells, its ability to phosphorylate p53 is weak before treatment, and there is no increase in its activity toward p53 after DNA damage by gamma irradiation or the radiomimetic agent neocarzinostatin. Furthermore, introduction of Chk2 short interfering RNA into three different human tumor cell lines leads to marked reduction of Chk2 protein, but p53 is still stabilized and active after DNA damage. The results with Chk1 short interfering RNA indicate as well that Chk1 does not play a role in human p53 stabilization after DNA damage. Thus, Chk1 and Chk2 are unlikely to be regulators of p53 in at least some human tumor cells. We discuss our results in the context of previous findings demonstrating a requirement for Chk2 in p53 stabilization and activity.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2000, CANCER RES, V60, P5934; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vahteristo P, 2001, CANCER RES, V61, P5718; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	61	93	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20480	20489		10.1074/jbc.M213185200	http://dx.doi.org/10.1074/jbc.M213185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654916	hybrid			2022-12-25	WOS:000183230500007
J	Peinado, H; Quintanilla, M; Cano, A				Peinado, H; Quintanilla, M; Cano, A			Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines - Mechanisms for epithelial mesenchymal transitions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; E-CADHERIN EXPRESSION; TGF-BETA; SMAD PROTEINS; HA-RAS; CARCINOMA; KINASE; TRANSDIFFERENTIATION; TGF-BETA-1; INDUCTION	The Snail transcription factor has been described recently as a strong repressor of E-cadherin in epithelial cell lines, where its stable expression leads to the loss of E-cadherin expression and induces epithelial-mesenchymal transitions and an invasive phenotype. The mechanisms regulating Snail expression in development and tumor progression are not yet known. We show here that transforming growth factor beta-1 (TGFbeta1) induces Snail expression in Madin-Darby canine kidney cells and triggers epithelial-mesenchymal transitions by a mechanism dependent on the MAPK signaling pathway. Furthermore, TGFbeta1 induces the activity of Snail promoter, whereas fibroblast growth factor-2 has a milder effect but cooperates with TGFbeta1 in the induction of Snail promoter. Interestingly, TGFbeta1-mediated induction of Snail promoter is blocked by a dominant negative form of H-Ras (N17Ras), whereas oncogenic H-Ras ( V12Ras) induces Snail promoter activity and synergistically cooperates with TGFbeta1. The effects of TGFbeta1 on Snail promoter are dependent of MEK1/2 activity but are apparently independent of Smad4 activity. In addition, H-Ras-mediated induction of Snail promoter, alone or in the presence of TGFbeta1, depends on both MAPK and phosphatidylinositol 3-kinase activities. These data support that MAPK and phosphatidylinositol 3-kinase signaling pathways are implicated in TGFbeta1-mediated induction of Snail promoter, probably through Ras activation and its downstream effectors.	CSIC UAM, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; UAM, Dept Bioquim, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Cano, A (corresponding author), CSIC UAM, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Peinado, Hector/A-6417-2013; Quintanilla, Miguel/K-9293-2017	Peinado, Hector/0000-0002-4256-3413; Quintanilla, Miguel/0000-0002-2124-7657				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1987, CANCER RES, V47, P707; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay ED, 1995, ACTA ANAT, V154, P8; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MIGDAL M, 1995, J CELL PHYSIOL, V162, P266, DOI 10.1002/jcp.1041620212; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Piek E, 1999, J CELL SCI, V112, P4557; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Spagnoli FM, 2000, J CELL SCI, V113, P3639; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Sun DZ, 2000, DEV BIOL, V228, P337, DOI 10.1006/dbio.2000.9946; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Valdes F, 2002, MOL CANCER RES, V1, P68; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809	59	508	541	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21113	21123		10.1074/jbc.M211304200	http://dx.doi.org/10.1074/jbc.M211304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665527	hybrid			2022-12-25	WOS:000183230500087
J	Jakopitsch, C; Auer, M; Ivancich, A; Ruker, F; Furtmuller, PG; Obinger, C				Jakopitsch, C; Auer, M; Ivancich, A; Ruker, F; Furtmuller, PG; Obinger, C			Total conversion of bifunctional catalase-peroxidase (KatG) to monofunctional peroxidase by exchange of a conserved distal side tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COMPOUND-I; HORSERADISH-PEROXIDASE; ASCORBATE PEROXIDASE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; KINETIC CHARACTERIZATION; ANACYSTIS-NIDULANS; HEME CAVITY; IDENTIFICATION	Catalase-peroxidases (KatGs) are unique peroxidases exhibiting a high catalase activity and a peroxidase activity with a wide range of artificial electron donors. Exchange of tyrosine 249 in Synechocystis KatG, a distal side residue found in all as yet sequenced KatGs, had dramatic consequences on the bifunctional activity and the spectral features of the redox intermediate compound II. The Y249F variant lost catalase activity but retained a peroxidase activity (substrates o-dianisidine, pyrogallol, guaiacol, tyrosine, and ascorbate) similar to the wild-type protein. In contrast to wild-type KatG and similar to monofunctional peroxidases, the formation of the redox intermediate compound I could be followed spectroscopically even by addition of equimolar hydrogen peroxide to ferric Y249F. The corresponding bimolecular rate constant was determined to be (1.1+/-0.1) x 10(7) M-1 s(-1) (pH 7 and 15degreesC), which is typical for most peroxidases. Additionally, for the first time a clear transition of compound I to an oxoferryl-like compound II with peaks at 418, 530, and 558 nm was monitored when one-electron donors were added to compound I. Rate constants of reaction of compound I and compound II with tyrosine ((5.0+/-0.3) x 10(4) M-1 s(-1) and (1.7+/-0.4) x 10(2) M-1 s(-1)) and ascorbate ((1.3+/-0.2) x 10(4) M-1 s(-1) and (8.8+/-0.1) x 10(1) M-1 s(-1) at pH 7 and 15degreesC) were determined by using the sequential stopped-flow technique. The relevance of these findings is discussed with respect to the bifunctional activity of KatGs and the recently published first crystal structure.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; CEA Saclay, Dept Biol Joliot Curie, CNRS,URA 2096, Serv Bioenerget, F-91191 Gif Sur Yvette, France; Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Natural Resources & Life Sciences, Vienna	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.		Obinger, Christian/AAV-3173-2021; Furtmüller, Paul G./Y-5819-2018	Furtmüller, Paul G./0000-0002-1199-2469; Obinger, Christian/0000-0002-7133-3430; Rueker, Florian/0000-0001-7639-2686; Jakopitsch, Christa/0000-0002-5855-2057; Ivancich, Anabella/0000-0002-4275-0980				BALNY C, 1987, FEBS LETT, V221, P349, DOI 10.1016/0014-5793(87)80954-7; BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Dunford H. B., 1999, HEME PEROXIDASES; Engleder M, 2000, BIOCHIMIE, V82, P211, DOI 10.1016/S0300-9084(00)00204-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heering HA, 2002, BIOCHEMISTRY-US, V41, P9237, DOI 10.1021/bi025740u; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HINER ANP, 1995, EUR J BIOCHEM, V234, P506, DOI 10.1111/j.1432-1033.1995.506_b.x; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Jakopitsch C, 2002, J INORG BIOCHEM, V91, P78, DOI 10.1016/S0162-0134(02)00374-4; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; LOO S, 1975, BIOCHEMISTRY-US, V14, P3467, DOI 10.1021/bi00686a027; Mandelman D, 1998, BIOCHEMISTRY-US, V37, P17610, DOI 10.1021/bi981958y; Marquez LA, 1996, FEBS LETT, V389, P153, DOI 10.1016/0014-5793(96)00562-5; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Obinger C, 1997, BIOCHEM BIOPH RES CO, V235, P545, DOI 10.1006/bbrc.1997.6847; OHLSSON PI, 1986, BIOCHIM BIOPHYS ACTA, V874, P160, DOI 10.1016/0167-4838(86)90113-5; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RALSTON I, 1978, CAN J BIOCHEM CELL B, V56, P1115, DOI 10.1139/o78-175; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 2001, BIOCHEM SOC T, V29, P99; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834	29	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20185	20191		10.1074/jbc.M211625200	http://dx.doi.org/10.1074/jbc.M211625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649295	hybrid			2022-12-25	WOS:000183078000078
J	Mosley, AL; Ozcan, S				Mosley, AL; Ozcan, S			Glucose regulates insulin gene transcription by hyperacetylation of histone H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; DNA-BINDING ACTIVITY; FACTOR 1-ALPHA; FACTOR PDX-1; GLUT2 GENE; C-MYC; EXPRESSION; PROTEIN; CHROMATIN; HOMEODOMAIN	Induction of insulin gene expression in response to high blood glucose levels is essential for maintaining glucose homeostasis. Although several transcription factors including Beta-2, Ribe3b1, and Pdx-1 have been shown to play a role in glucose stimulation of insulin gene expression, the exact molecular mechanism(s) by which this regulation occurs is unknown. Previous data demonstrate that the transcription factors Beta-2/NeuroD1 and Pdx-1, which are involved in glucose-stimulated insulin gene expression, interact with the histone acetylase p300, suggesting a role for histone acetylation in glucose regulation of the insulin gene expression. We report that exposure of mouse insulinoma 6 cells to high concentrations of glucose results in hyperacetylation of histone H4 at the insulin gene promoter, which correlates with the increased level of insulin gene transcription. In addition, we demonstrate that hyperacetylation of histone H4 in response to high concentrations of glucose also occurs at the glucose transporter-2 gene promoter. Using histone deacetylase inhibitors, we show that increases in histone H4 acetylation cause stimulation of insulin gene transcription even in the absence of high concentrations of glucose. Furthermore, we show that fibroblasts, which lack insulin gene expression, also lack histone acetylation at the insulin gene promoter. In summary, our data support the idea that high concentrations of glucose stimulate insulin gene expression by causing hyperacetylation of histone H4 at the insulin gene promoter.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Albert B Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Albert B Chandler Med Ctr, 800 Rose St,MN 608, Lexington, KY 40536 USA.	sozcan@uky.edu						Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bonny C, 1997, MOL CELL ENDOCRINOL, V135, P59, DOI 10.1016/S0303-7207(97)00190-1; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LeRoith D., 2000, DIABETES MELLITUS FU; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Macfarlane WM, 2000, DIABETES, V49, P418, DOI 10.2337/diabetes.49.3.418; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roderigo-Milne H, 2002, BIOCHEM BIOPH RES CO, V296, P589, DOI 10.1016/S0006-291X(02)00913-0; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rout UK, 2002, REPROD TOXICOL, V16, P253, DOI 10.1016/S0890-6238(02)00022-9; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; Semenza GL, 2002, P NATL ACAD SCI USA, V99, P11570, DOI 10.1073/pnas.192442299; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; Sharma A, 1999, MOL CELL BIOL, V19, P704; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Shinozuka Y, 2001, BIOCHEM BIOPH RES CO, V287, P229, DOI 10.1006/bbrc.2001.5573; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 2001, SCIENCE, V293, P1054, DOI 10.1126/science.1064050; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WAEBER G, 1994, J BIOL CHEM, V269, P26912; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	66	82	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19660	19666		10.1074/jbc.M212375200	http://dx.doi.org/10.1074/jbc.M212375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665509	hybrid			2022-12-25	WOS:000183078000014
J	Ravindranath, RMH; Basilrose, RM; Ravindranath, NH; Vaitheesvaran, B				Ravindranath, RMH; Basilrose, RM; Ravindranath, NH; Vaitheesvaran, B			Amelogenin interacts with cytokeratin-5 in ameloblasts during enamel growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; ACETYL-D-GLUCOSAMINE; HUMAN KERATIN-14; TETRATRICOPEPTIDE REPEATS; GLCNAC TRANSFERASE; MATRIX PROTEINS; IN-VITRO; EXPRESSION; TOOTH; ORGAN	The enamel protein amelogenin binds to GlcNAc (Ravindranath, R. M. H., Moradian-Oldak, R., and Fincham, A. G. ( 1999) J. Biol. Chem. 274, 2464 - 2471) and to the GlcNAc-mimicking peptide (GMp) ( Ravindranath, R. M. H., Tam, W., Nguyen, P., and Fincham, A. G. ( 2000) J. Biol. Chem. 275, 39654 - 39661). The GMp motif in the N-terminal region of the cytokeratin 14 of ameloblasts binds to trityrosyl motif peptide ( ATMP) of amelogenin ( Ravindranath, R. M. H., Tam, W., Bringas, P., Santos, V., and Fincham, A. G. ( 2001) J. Biol. Chem. 276, 36586 36597). K14 ( Type I) pairs with K5 ( Type II) in basal epithelial cells; GlcNAc-acylated K5 is identified in ameloblasts. Dosimetric analysis showed the binding affinity of amelogenin to K5 and to GlcNAc-acylated-positive control, ovalbumin. The specific binding of [H-3] ATMP with K5 or ovalbumin was confirmed by Scatchard analysis. [H-3] ATMP failed to bind to K5 after removal of GlcNAc. Blocking K5 with ATMP abrogates the K5-amelogenin interaction. K5 failed to bind to ATMP when the third proline was substituted with threonine, as in some cases of human X-linked amelogenesis imperfecta or when tyrosyl residues were substituted with phenylalanine. Confocal laser scan microscopic observations on ameloblasts during postnatal (PN) growth of the teeth showed that the K5-amelogenin complex migrated from the cytoplasm to the periphery ( on PN day 1) and accumulated at the apical region on day 3. Secretion of amelogenin commences from day 1. K5, similar to K14, may play a role of chaperone during secretion of amelogenin. Upon secretion of amelogenin, K5 pairs with K14. Pairing of K5 and K14 commences on day 3 and ends on day 9. The pairing of K5 and K14 marks the end of secretion of amelogenin.	Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA	University of Southern California	Ravindranath, RMH (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, 2250 Alcazar St, Los Angeles, CA 90033 USA.				NIDCR NIH HHS [DE-03660] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHRISTNER PJ, 1983, ARCH ORAL BIOL, V28, P773, DOI 10.1016/0003-9969(83)90114-0; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Domingues MG, 2000, EUR J ORAL SCI, V108, P43, DOI 10.1034/j.1600-0722.2000.00717.x; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEORGOPOULOS G, 1993, ANN REV CELL BIOL, V3, P75; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; KASPER M, 1989, DIFFERENTIATION, V40, P207, DOI 10.1111/j.1432-0436.1989.tb00600.x; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MERRIFIELD B, 1996, SCIENCE, V232, P341; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NANCI A, 1985, J HISTOCHEM CYTOCHEM, V33, P1153, DOI 10.1177/33.11.4056379; Nanci A, 1998, J HISTOCHEM CYTOCHEM, V46, P911, DOI 10.1177/002215549804600806; Omary M B, 1998, Subcell Biochem, V31, P105; RAVINDRANATH MH, 1997, TECHNIQUES GLYCOBIOL, P137; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; Ravindranath RMH, 2000, J BIOL CHEM, V275, P39654, DOI 10.1074/jbc.M006471200; Ravindranath RMH, 2001, J BIOL CHEM, V276, P36586, DOI 10.1074/jbc.M104656200; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; SILVA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P465; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SLAVKIN HC, 1982, DIFFERENTIATION, V23, P73, DOI 10.1111/j.1432-0436.1982.tb01268.x; SLAVKIN HC, 1984, INSERM, V125, P341; STEPHENS K, 1993, J INVEST DERMATOL, V101, P240, DOI 10.1111/1523-1747.ep12365079; Sun T T, 1983, Curr Probl Dermatol, V11, P277; SUN TT, 1984, TRANSFORMED PHENOTYP, V1, P169; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; VIDRICH A, 1985, ANN NY ACAD SCI, V455, P354, DOI 10.1111/j.1749-6632.1985.tb50422.x; WILSON AK, 1992, J CELL BIOL, V119, P401, DOI 10.1083/jcb.119.2.401	37	21	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20293	20302		10.1074/jbc.M211184200	http://dx.doi.org/10.1074/jbc.M211184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657653	hybrid			2022-12-25	WOS:000183078000092
J	Budd, DC; McDonald, J; Emsley, N; Cain, K; Tobin, AB				Budd, DC; McDonald, J; Emsley, N; Cain, K; Tobin, AB			The C-terminal tail of the M-3-muscarinic receptor possesses anti-apoptotic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; ACTIVATED PROTEIN-KINASE; COUPLED RECEPTORS; PHOSPHORYLATION; CELLS; JUN; EXPRESSION; PATHWAY; CALCIUM; SYSTEM	This study investigates the mechanisms by which the muscarinic receptor gene family can protect against apoptosis. Chinese hamster ovary cells transfected with human muscarinic receptor subtypes underwent apoptotic cell death following treatment with the DNA-damaging agent etoposide. Apoptosis was significantly reduced following muscarinic receptor stimulation of cells that were transfected with receptor subtypes that couple to the G(q/11)/phospholipase C pathway, namely M-1, M-3, and M-5. No protection was detected in cells transfected with the G(i)-coupled M-2 and M-4 receptors. Further analysis of the G(q/11)-coupled M-3 receptor revealed that truncation of the carboxyl-tail (Delta565-M-3 mutant) removed the ability of the receptor to protect against etoposide-induced cell death. This mutation did not affect the ability of the receptor to signal through the phospholipase C pathway. Furthermore, activation of the Delta565-M-3 receptor resulted in robust activation of the extracellular-regulated kinase (ERK) and c-Jun kinase (JNK). The Delta565-M-3 receptor mutant also underwent agonist-driven phosphorylation in a similar manner to the wild-type receptor indicating that the anti-apoptotic effect of the M3 receptor is independent of receptor phosphorylation. Consistent with this was the fact that two M-3-muscarinic receptor mutants deficient in agonist-induced receptor phosphorylation were capable of producing a full anti-apoptotic response. We conclude that the anti-apoptotic response of the muscarinic receptor family was confined to the G(q/11)-coupled members of this family. The direct involvement of G(q/11)/phospholipase C signaling and the ERK-1/2 and JNK pathways together with receptor phosphorylation in the anti-apoptotic response were eliminated. Mutation of a poly-basic region within the short C-terminal tail of the M-3-muscarinic receptor inhibited the ability of the receptor to induce an anti-apoptotic response. We conclude that the conserved poly-basic region in the C-terminal tail of the M-1, M-3, and M-5 receptors contributes to the ability of these receptors to mediate protection against apoptotic cell death.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Budd, DC (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Budd DC, 1999, MOL PHARMACOL, V56, P813; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fujii T, 2000, N-S ARCH PHARMACOL, V362, P14, DOI 10.1007/s002100000251; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kawashima K, 2000, PHARMACOL THERAPEUT, V86, P29, DOI 10.1016/S0163-7258(99)00071-6; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Leloup C, 2000, CELL DEATH DIFFER, V7, P825, DOI 10.1038/sj.cdd.4400713; LINDENBOIM L, 1995, J NEUROCHEM, V64, P2491; MILLER WE, 2001, SCI STKE; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tanaka K, 1999, BIOSCI BIOTECH BIOCH, V63, P368, DOI 10.1271/bbb.63.368; Tang XW, 2002, J BIOL CHEM, V277, P338, DOI 10.1074/jbc.M108927200; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; TREJO J, 1991, J BIOL CHEM, V266, P7876; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; Wu-Wong JR, 2000, J PHARMACOL EXP THER, V293, P514; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; YAN GM, 1995, MOL PHARMACOL, V47, P248	33	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19565	19573		10.1074/jbc.M211670200	http://dx.doi.org/10.1074/jbc.M211670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649280	hybrid			2022-12-25	WOS:000182932200108
J	Paine, ML; Wang, HJ; Luo, W; Krebsbach, PH; Snead, ML				Paine, ML; Wang, HJ; Luo, W; Krebsbach, PH; Snead, ML			A transgenic animal model resembling amelogenesis imperfecta related to ameloblastin overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTAL ENAMEL; RAT INCISORS; DNA-SEQUENCE; GENE; LOCALIZATION; EXPRESSION; PROTEIN; ANTIBODIES; MUTATION; CLONING	Genetic diseases that affect tooth enamel are grouped under the classification amelogenesis imperfecta. Human pedigrees and experiments on transgenic and null mice have all demonstrated that mutations to the secreted proteins amelogenin, enamelin, and enamelysin result in visibly, structurally, or mechanically defective enamel. In an attempt to better define a physiologic function for ameloblastin during enamel formation, we have produced transgenic mice that misexpress the ameloblastin gene. These transgenic animals exhibit imperfections in their enamel that is evident at the nanoscale level. Specifically, ameloblastin overexpression influences enamel crystallite habit and enamel rod morphology. These findings suggest enamel crystallite habit and rod morphology are influenced by the temporal and spatial expression of ameloblastin and may implicate the role of the ameloblastin gene locus in the etiology of a number of undiagnosed autosomally dominant cases of amelogenesis imperfecta.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA	University of Southern California; University of Michigan System; University of Michigan	Paine, ML (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA.	paine@usc.edu	Krebsbach, Paul H./AAC-4765-2021		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013045, R01DE006988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE012502, R01DE013404, R37DE013045] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE06988, DE13045, DE13404, DE12502] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; Caterina JJ, 2002, J BIOL CHEM, V277, P49598, DOI 10.1074/jbc.M209100200; Cerny R, 1996, J BONE MINER RES, V11, P883; Dhamija S, 2001, J BIOL CHEM, V276, P35159, DOI 10.1074/jbc.M010719200; Dong J, 2000, EUR J ORAL SCI, V108, P353, DOI 10.1034/j.1600-0722.2000.108005353.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FORSMAN K, 1994, HUM MOL GENET, V3, P1621, DOI 10.1093/hmg/3.9.1621; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Hart PS, 2002, ARCH ORAL BIOL, V47, P261, DOI 10.1016/S0003-9969(02)00003-1; HAYASHI Y, 1986, BASIC APPL HISTOCHEM, V30, P291; Hu CC, 1997, J DENT RES, V76, P1720, DOI 10.1177/00220345970760110201; Hu CC, 1997, J DENT RES, V76, P648, DOI 10.1177/00220345970760020501; Hu CC, 2000, J DENT RES, V79, P912, DOI 10.1177/00220345000790040501; Iijima M, 2002, J DENT RES, V81, P69, DOI 10.1177/154405910208100115; Kida M, 2002, J DENT RES, V81, P738, DOI 10.1177/0810738; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lee SK, 1996, INT J DEV BIOL, V40, P1141; Li W, 2001, MATRIX BIOL, V19, P755, DOI 10.1016/S0945-053X(00)00121-9; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Mardh CK, 2001, EUR J ORAL SCI, V109, P8; Mardh CK, 2002, HUM MOL GENET, V11, P1069, DOI 10.1093/hmg/11.9.1069; Nanci A, 1998, J HISTOCHEM CYTOCHEM, V46, P911, DOI 10.1177/002215549804600806; Paine CT, 2000, J BIOL CHEM, V275, P22284, DOI 10.1074/jbc.M000118200; Paine ML, 2001, MATRIX BIOL, V20, P273, DOI 10.1016/S0945-053X(01)00153-6; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; RISNES S, 1985, SCAND J DENT RES, V93, P135; ROBINSON C, 1986, J DENT RES, V65, P500; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; Snead ML, 1998, CONNECT TISSUE RES, V38, P279, DOI 10.3109/03008209809017048; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; WARSHAWSKY H, 1987, SCANNING MICROSCOPY, V1, P1913; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L	39	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19447	19452		10.1074/jbc.M300445200	http://dx.doi.org/10.1074/jbc.M300445200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12657627	hybrid			2022-12-25	WOS:000182932200094
J	Skabkina, OV; Skabkin, MA; Popova, NV; Lyabin, DN; Penalva, LO; Ovchinnikov, LP				Skabkina, OV; Skabkin, MA; Popova, NV; Lyabin, DN; Penalva, LO; Ovchinnikov, LP			Poly(A)-binding protein positively affects YB-1 mRNA translation through specific interaction with YB-1 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-SHOCK DOMAIN; Y-BOX PROTEINS; IMMUNODEFICIENCY-VIRUS TYPE-1; 3 UNTRANSLATED REGION; MAJOR CORE PROTEIN; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN PARTICLES; DEPENDENT TRANSLATION; TRANSCRIPTION FACTOR; CYTOPLASMIC MRNP	The major protein of cytoplasmic mRNPs from rabbit reticulocytes, YB-1, is a member of an ancient family of proteins containing a common structural feature, cold-shock domain. In eukaryotes, this family is represented by multifunctional mRNA/Y-box DNA-binding proteins that control gene expression at different stages. To address possible post-transcriptional regulation of YB-1 gene expression, we examined effects of exogenous 5'- and 3'-untranslatable region-containing fragments of YB-1 mRNA on its translation and stability in a cell-free system. The addition of the 3' mRNA fragment as well as its subfragment I shut off protein synthesis at the initiation stage without affecting mRNA stability. UV cross-linking revealed four proteins (69, 50, 46, and 44 kDa) that specifically interacted with the 3' mRNA fragment; the inhibitory subfragment I bound two of them, 69- and 50-kDa proteins. We have identified these proteins as PABP (poly(A)-binding protein) (69 kDa) and YB-1 (50 kDa) and demonstrated that titrating out of PABP by poly(A) strongly and specifically inhibits YB-1 mRNA cap(+)poly(A)(-) translation in a cell-free system. Thus, PABP is capable of positively affecting YB-1 mRNA translation in a poly(A) tail-independent manner.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Duke Univ, Med Ctr, Ctr RNA Biol, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Russian Academy of Sciences; Duke University	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	ovchinn@vega.protres.ru	Lyabin, Dmitry/K-3178-2013; Popova, Nadezhda/ABD-7185-2021; Popova, Nadezhda/AAJ-8312-2020; Ovchinnikov, Lev/L-2397-2015	Popova, Nadezhda/0000-0002-6761-589X; Popova, Nadezhda/0000-0002-6761-589X; Penalva, Luiz/0000-0003-4491-6769				BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Braun RE, 2000, INT J ANDROL, V23, P92, DOI 10.1046/j.1365-2605.2000.00027.x; Chung DJ, 1998, BIOCHEMISTRY-US, V37, P16298, DOI 10.1021/bi980935g; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Di Liegro CM, 2000, BIOCHEM J, V352, P109, DOI 10.1042/0264-6021:3520109; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; Fang L, 1997, MOL MICROBIOL, V23, P355, DOI 10.1046/j.1365-2958.1997.2351592.x; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hornstein E, 1999, FEBS LETT, V457, P209, DOI 10.1016/S0014-5793(99)01039-X; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Knirsch L, 2000, BIOCHEM BIOPH RES CO, V272, P164, DOI 10.1006/bbrc.2000.2754; Knirsch L, 2001, BIOCHEMISTRY-US, V40, P7890, DOI 10.1021/bi010197n; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE SJ, 1994, MOL MICROBIOL, V11, P833, DOI 10.1111/j.1365-2958.1994.tb00361.x; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Ohga T, 1996, CANCER RES, V56, P4224; Ovchinnikov L. P., 2001, Molekulyarnaya Biologiya (Moscow), V35, P548; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pisarev AV, 2002, J BIOL CHEM, V277, P15445, DOI 10.1074/jbc.M111954200; POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; Wakiyama M, 1997, BIOCHIMIE, V79, P781, DOI 10.1016/S0300-9084(97)86937-4; Wallstrom EL, 2001, BIOCHEM J, V356, P627, DOI 10.1042/bj3560627; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WOLFFE AP, 1992, NEW BIOL, V4, P290; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; Xia B, 2002, J BIOL CHEM, V277, P6005, DOI 10.1074/jbc.M109700200; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862	60	42	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18191	18198		10.1074/jbc.M209073200	http://dx.doi.org/10.1074/jbc.M209073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646583	hybrid			2022-12-25	WOS:000182838300079
J	Flinterman, M; Gaken, J; Farzaneh, F; Tavassoli, M				Flinterman, M; Gaken, J; Farzaneh, F; Tavassoli, M			E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines	ONCOGENE			English	Article						E1A; EGFR; PML; apoptosis; head and neck cancer; gene therapy	GROWTH-FACTOR RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; TUMOR SUPPRESSION; ADENOVIRUS-5 E1A; NUCLEAR-BODIES; CANCER CELLS; IN-VIVO; P53; PML; TRANSCRIPTION	Previous studies have shown early region 1A (E1A) gene to inhibit the proliferation of tumour cells with wild-type, but not mutant, p53. E1A has also been shown to downregulate c-erb-B-2/neu expression, resulting in inhibition of growth in c-erb-B-2/neu overexpressing tumour cells. In this study, we have investigated the effect of E1A expression on four head and neck squamous cell carcinoma (HNSCC) cell lines that do not overexpress c-erb-B-2/neu. Cell cycle and Western blot analysis show E1A-mediated induction of apoptosis in all cell lines examined. This induction of apoptosis was independent of the p53 status as it occurred in the cell lines with wildtype, mutated or deleted p53. However, there was no evidence of E1A-induced apoptosis in a p53(+ve) normal human fibroblast cell line, 1BR3. Analysis of apoptosis in the SCC cell lines demonstrated E1A-mediated downregulation of EGFR, which was overexpressed in each of these cell lines. Overexpression of an exogenously introduced EGFR, under the control of an E1A-insensitive heterologous promoter, blocked E1A induction of apoptosis in these cells. Therefore, E1A-mediated downregulation of EGFR expression appears to be the cause, rather than a consequence of E1A-induced apoptosis in these SCC cell lines. Previous studies have shown downregulation of EGFR expression by PML. Interestingly, E1A expression in the HNSCC cells altered the pattern of PML distribution and induced the level of PML protein, thus suggesting that E1A-mediated downregulation of EGFR may occur via direct or indirect interactions with PML. These findings demonstrate a novel pathway by which E1A can induce apoptosis and identify EGFR as a potential target for the development of therapeutic strategies against epithelial malignancies, the majority of which have abnormal EGFR expression.	Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, Rayne Inst, London SE5 9NU, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Rayne Inst, Dept Mol Med, London SE5 9NU, England	University of London; King's College London; University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				AKUSJARVI G, 1979, J MOL BIOL, V134, P143, DOI 10.1016/0022-2836(79)90417-0; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Averbuch SD, 2002, CLIN CANCER RES, V8, P1; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Davies DE, 1996, BIOCHEM PHARMACOL, V51, P1101, DOI 10.1016/0006-2952(95)02232-5; de Melker AA, 2001, J CELL SCI, V114, P2167; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; Duque PM, 1999, CANCER GENE THER, V6, P554, DOI 10.1038/sj.cgt.7700077; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; IRISH JC, 1993, LARYNGOSCOPE, V103, P42; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Prudenziati M, 2000, INT J CANCER, V88, P943, DOI 10.1002/1097-0215(20001215)88:6<943::AID-IJC17>3.0.CO;2-F; RUSCH V, 1993, CANCER RES, V53, P2379; Saha V, 1998, J CELL BIOCHEM, P264, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<264::AID-JCB32>3.0.CO;2-U; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Tavassoli M, 2002, CARCINOGENESIS, V23, P1569, DOI 10.1093/carcin/23.10.1569; TEODORO JG, 1995, ONCOGENE, V11, P467; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tian XX, 1999, BRIT J CANCER, V81, P994, DOI 10.1038/sj.bjc.6690798; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; YAN DH, 1991, ONCOGENE, V6, P343; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L; YU DH, 1995, ONCOGENE, V11, P1383	58	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1965	1977		10.1038/sj.onc.1206190	http://dx.doi.org/10.1038/sj.onc.1206190			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673202	Bronze			2022-12-25	WOS:000181967700007
J	Rodriguez, S; Jafer, O; Goker, H; Summersgill, BM; Zafarana, G; Gillis, AJM; van Gurp, RJHLM; Oosterhuis, JW; Lu, YJ; Huddart, R; Cooper, CS; Clark, J; Looijenga, LHJ; Shipley, JM				Rodriguez, S; Jafer, O; Goker, H; Summersgill, BM; Zafarana, G; Gillis, AJM; van Gurp, RJHLM; Oosterhuis, JW; Lu, YJ; Huddart, R; Cooper, CS; Clark, J; Looijenga, LHJ; Shipley, JM			Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1	ONCOGENE			English	Article						testicular germ cell tumors of adolescents and adults; isochromosome 12p; amplification; microarray expression profiling; comparative expressed sequence hybridization; candidate genes	COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; IN-SITU; C-MYC; IDENTIFICATION; TESTIS; OVERREPRESENTATION; CHROMOSOME-12; TUMORIGENESIS; MICROARRAYS	Gain of 12p material is invariably associated with testicular germ cell tumors (TGCTs) of adolescents and adults, most usually as an isochromosome 12p. We analyzed TGCTs with i(12p) using a global approach to expression profiling targeting chromosomes (comparative expressed sequence hybridization, CESH). This indicated overexpression of genes from 12p11.2-p12.1 relative to testis tissue and fibroblasts. The nonseminoma subtype showed higher levels of expression than seminomas. Notably, 12p11.2-p12.1 is amplified in about 10% of TGCTs and CESH analysis of such amplicon cases showed high levels of overexpression from this region. Microarray analysis, including cDNA clones representing most UniGene clusters from 12p11.2-p12.1, was applied to DNA and RNA from 5 TGCTs with amplification of 12p11.2-p12.1 and seven TGCTs with gain of the entire short arm of chromosome 12. Expression profiles were consistent with the CESH data and overexpression of EST595078, MRPS35 and LDHB at 12p11.2-p12.1 was detected in most TGCTs. High-level overexpression of BCAT1 was specific to nonseminomas and overexpression of genes such as CMAS, EKI1, KRAS2, SURB7 and various ESTs correlated with their amplification. Genes such as CCND2, GLU3, LRP6 and HPH1 at 12p13 were also overexpressed. The overexpressed sequences identified, particularly those in the region amplified, represent candidate genes for involvement in TGCT development.	Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England; Erasmus MC Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Josephine Nefkens Inst,Pathol Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands; Inst Canc Res, Sect Paediat Oncol, Sutton SM2 5NG, Surrey, England; Royal Marsden Natl Hlth Serv Trust, Acad Dept Urol, Surrey, England; Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Shipley, JM (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	shipley@icr.ac.uk	Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Looijenga, Leendert/0000-0002-8146-1911; huddart, robert/0000-0003-3604-1990; Lu, Yong-Jie/0000-0001-6174-6621; Shipley, Janet/0000-0001-6748-8678; Zafarana, Gaetano/0000-0003-1391-4488				ATKIN NB, 1982, LANCET, V2, P1349; BALDINI A, 1990, AM J HUM GENET, V46, P784; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Bourdon V, 2002, CANCER RES, V62, P6218; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006-291X(02)00578-8; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Lu YJ, 2001, P NATL ACAD SCI USA, V98, P9197, DOI 10.1073/pnas.161272798; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Olie RA, 1996, BRIT J CANCER, V74, P133, DOI 10.1038/bjc.1996.328; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao PH, 1998, CANCER RES, V58, P4260; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rorth M, 2000, SCAND J UROL NEPHROL, V34, P166, DOI 10.1080/00365590050509896; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; Sambrook J, 2001, MOL CLONING LAB MANU; Skotheim RI, 2002, CANCER RES, V62, P2359; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; von Eyben FE, 2000, ACTA ONCOL, V39, P509, DOI 10.1080/028418600750013438; Windstetter D, 1997, Eur J Med Res, V2, P431; Zafarana G, 2002, CANCER RES, V62, P1822	34	125	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1880	1891		10.1038/sj.onc.1206302	http://dx.doi.org/10.1038/sj.onc.1206302			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660824				2022-12-25	WOS:000181678200015
J	Bobkova, EV; Yan, YP; Jordan, DB; Kurilla, MG; Pompliano, DL				Bobkova, EV; Yan, YP; Jordan, DB; Kurilla, MG; Pompliano, DL			Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; PROTEIN-SYNTHESIS; BOND FORMATION; DOMAIN-V; A-SITES; P-SITES; RNA; MUTATIONS; BACTERIA; SUBUNIT	Kinetic analysis of ribosomal peptidyltransferase activity in a methanolic puromycin reaction with wild type and drug-resistant 23 S RNA mutants was used to probe the structural basis of catalysis and mechanism of resistance to antibiotics. 23 S RNA mutants G2032A and G2447A are resistant to oxazolidinones both in vitro and in vivo with the latter displaying a 5-fold increase in the value of K-m for initiator tRNA and a 100-fold decrease in V-max in puromycin reaction. Comparison of the K-i values for oxazolidinones, chloramphenicol, and sparsomycin revealed partial cross-resistance between oxazolidinones and chloramphenicol; no cross-resistance was observed with sparsomycin, a known inhibitor of the peptidyltransferase A-site. Inhibition of the mutants using a truncated CCA-Phe-X-Biotin fragment as a P-site substrate is similar to that observed with the intact initiator tRNA, indicating that the inhibition is substrate-independent and that the peptidyltransferase itself is the oxazolidinone target. Mapping of all known mutations that confer resistance to these drugs onto the spatial structure of the 50 S ribosomal subunit allows for docking of an oxazolidinone into a proposed binding pocket. The model suggests that oxazolidinones bind between the P- and A-loops, partially overlapping with the peptidyltransferase P-site. Thus, kinetic, mutagenesis, and structural data suggest that oxazolidinones interfere with initiator fMet-tRNA binding to the P-site of the ribosomal peptidyltransferase center.	Bristol Myers Squibb Co, Wilmington, DE 19880 USA	Bristol-Myers Squibb	Bobkova, EV (corresponding author), Johnson & Johnson PRD, San Diego, CA 92121 USA.							Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Baranov PV, 1998, NUCLEIC ACIDS RES, V26, P187, DOI 10.1093/nar/26.1.187; BOBKOVA EV, 1999, RIBOSOME STRUCTURE F, P30; Burghardt H, 1998, FEBS LETT, V425, P40, DOI 10.1016/S0014-5793(98)00194-X; CELMA ML, 1971, FEBS LETT, V13, P247, DOI 10.1016/0014-5793(71)80546-X; EUSTICE DC, 1988, ANTIMICROB AGENTS CH, V32, P1218, DOI 10.1128/AAC.32.8.1218; FERNANDEZMUNOZ R, 1973, MOL BIOL REP, V1, P75, DOI 10.1007/BF00357584; GARRET RA, 2000, RIBOSOMES STRUCTURE, P217; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; HARRIS R, 1973, J BIOL CHEM, V248, P1168; HERNER AE, 1969, BIOCHEMISTRY-US, V8, P1335, DOI 10.1021/bi00832a006; HILL WH, 1990, RIBOSOME STRUCTURE F, P217; Kloss P, 1999, J MOL BIOL, V294, P93, DOI 10.1006/jmbi.1999.3247; Lin AH, 1997, ANTIMICROB AGENTS CH, V41, P2127, DOI 10.1128/AAC.41.10.2127; Matassova NB, 1999, RNA, V5, P939, DOI 10.1017/S1355838299990210; MILLS JA, 1999, RIBOSOME STRUCTURE F; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MONRO RE, 1967, J MOL BIOL, V28, P161, DOI 10.1016/S0022-2836(67)80085-8; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Patel U, 2001, J BIOL CHEM, V276, P37199, DOI 10.1074/jbc.M102966200; PESTKA S, 1970, ARCH BIOCHEM BIOPHYS, V136, P80, DOI 10.1016/0003-9861(70)90329-2; PESTKA S, 1969, P NATL ACAD SCI USA, V64, P709, DOI 10.1073/pnas.64.2.709; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; Shinabarger DL, 1997, ANTIMICROB AGENTS CH, V41, P2132, DOI 10.1128/AAC.41.10.2132; SLEE AM, 1987, ANTIMICROB AGENTS CH, V31, P1791, DOI 10.1128/AAC.31.11.1791; SPIRIN AS, 1999, RIBOSOMES, P133; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; Swaney SM, 1998, ANTIMICROB AGENTS CH, V42, P3251, DOI 10.1128/AAC.42.12.3251; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Thompson J, 2002, J MOL BIOL, V322, P273, DOI 10.1016/S0022-2836(02)00784-2; Xiong LQ, 2000, J BACTERIOL, V182, P5325, DOI 10.1128/JB.182.19.5325-5331.2000	34	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9802	9807		10.1074/jbc.M209249200	http://dx.doi.org/10.1074/jbc.M209249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645571	hybrid			2022-12-25	WOS:000181524000123
J	Boffa, MB; Hamill, JD; Maret, D; Brown, D; Scott, ML; Nesheim, ME; Koschinsky, ML				Boffa, MB; Hamill, JD; Maret, D; Brown, D; Scott, ML; Nesheim, ME; Koschinsky, ML			Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-1-ACID GLYCOPROTEIN; PLASMA PROCARBOXYPEPTIDASE-B; MESSENGER-RNA STABILITY; PRO-CARBOXYPEPTIDASE-R; GLUCOCORTICOID RECEPTOR; BINDING PROTEIN; MAMMALIAN-CELLS; ANTIGEN LEVELS; CROSS-TALK; ACTIVATION	Thrombin-activable fibrinolysis inhibitor (TAFI) has recently been identified as a positive acute phase protein in mice, an observation that may have important implications for the interaction of the coagulation, fibrinolytic, and inflammatory systems. Activated TAFI (TAFIa) inhibits fibrinolysis by removing the carboxyl-terminal lysines from partially degraded fibrin that are important for maximally efficient plasminogen activation. In addition, TAFIa has been shown to be capable of removing the carboxyl-terminal arginine residues from the anaphylatoxins and bradykinin, thus implying a role for the TAFI pathway in the vascular responses to inflammation. In the current study, we investigated the ability of acute phase mediators to modulate human TAFI gene expression in cultured human hepatoma (HepG2) cells. Surprisingly, we found that treatment of HepG2 cells with a combination of interleukin (IL)-1beta and IL-6 suppressed endogenous TAFI mRNA abundance in HepG2 cells (similar to60% decrease), while treatment with IL-1beta or IL-6 alone had no effect. Treatment with IL-1beta and/or IL-6 had no effect on TAFI promoter activity as measured using a luciferase reporter plasmid containing the human TAFI 5'-flanking region, whereas treatment with IL-1beta and IL-6 in combination, but not alone, decreased the stability of the endogenous TAFI mRNA. Treatment with the synthetic glucocorticoid dexamethasone resulted in a 2-fold increase of both TAFI mRNA levels and promoter activity. We identified a functional glucocorticoid response element (GRE) in the human TAFI promoter between nucleotides -92 and -78. The GRE was capable of binding the glucocorticoid receptor, as assessed by gel mobility shift assays, and mutation of this element markedly decreased the ability of the TAFI promoter to be activated by dexamethasone.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Room A208 Botterell Hall, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; Boffa MB, 1999, BIOCHEMISTRY-US, V38, P6547, DOI 10.1021/bi990229v; Boffa MB, 2002, J BIOL CHEM, V277, P25329, DOI 10.1074/jbc.M203688200; BOLYARD MG, 1988, GENE, V66, P183, DOI 10.1016/0378-1119(88)90355-1; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; EATON DL, 1991, J BIOL CHEM, V266, P21833; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guo XY, 1999, MICROBIOL IMMUNOL, V43, P691, DOI 10.1111/j.1348-0421.1999.tb02457.x; Hendriks D, 1992, Agents Actions Suppl, V38 ( Pt 1), P407; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489; Juhan-Vague I, 2000, ARTERIOSCL THROM VAS, V20, P2156, DOI 10.1161/01.ATV.20.9.2156; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MARI SS, 1999, J BIOL CHEM, V274, P35046; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sato T, 2000, J IMMUNOL, V165, P1053, DOI 10.4049/jimmunol.165.2.1053; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; Silveira A, 2000, THROMB HAEMOSTASIS, V84, P364; Stromqvist M, 2001, THROMB HAEMOSTASIS, V85, P12, DOI 10.1055/s-0037-1612656; Takeda T, 1998, J ENDOCRINOL, V159, P323, DOI 10.1677/joe.0.1590323; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WILSON GM, 1995, PLASMID, V33, P198, DOI 10.1006/plas.1995.1021; WRIGHT APH, 1993, J STEROID BIOCHEM, V47, P11, DOI 10.1016/0960-0760(93)90052-X; Zhang ZX, 2000, BLOOD, V96, P3466, DOI 10.1182/blood.V96.10.3466.h8003466_3466_3472; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	46	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9250	9257		10.1074/jbc.M209588200	http://dx.doi.org/10.1074/jbc.M209588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645517	hybrid			2022-12-25	WOS:000181524000049
J	Apetri, AC; Surewicz, WK				Apetri, AC; Surewicz, WK			Atypical effect of salts on the thermodynamic stability of human prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CONVERSION; RESISTANT; DOMAIN; INTERMEDIATE; MECHANISM; SUP35; HELIX; WATER; MICE	Prion diseases are associated with the conversion of cellular prion protein, PrPC, into a misfolded oligomeric form, PrPSc. Previous studies indicate that salts promote conformational conversion of the recombinant prion protein into a PrPSc-like form. To gain insight into the mechanism of this effect, here we have studied the influence of a number of salts ( sodium sulfate, sodium fluoride, sodium acetate, and sodium chloride) on the thermodynamic stability of the recombinant human prion protein. Chemical unfolding studies in urea show that at low concentrations ( below similar to50 mM), all salts tested significantly reduced the thermodynamic stability of the protein. This highly unusual response to salts was observed for both the full-length prion protein as well as the N-truncated fragments huPrP90-231 and huPrP122-231. At higher salt concentrations, the destabilizing effect was gradually reversed, and salts behaved according to their ranking in the Hofmeister series. The present data indicate that electrostatic interactions play an unusually important role in the stability of the prion protein. The abnormal effect of salts is likely because of the ion-induced destabilization of salt bridges (Asp(144)-Arg(148) and/or Asp(147)-Arg(151)) in the extremely hydrophilic helix 1. Contrary to previous suggestions, this effect is not due to the interaction of ions with the glycine-rich flexible N-terminal region of the prion protein. The results of this study suggest that ionic species present in the cellular environment may control the PrPC to PrPSc conversion by modulating the thermodynamic stability of the native PrPC isoform.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wks3@po.cwru.edu			NINDS NIH HHS [NS38604] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ebel C, 1999, BIOCHEMISTRY-US, V38, P9039, DOI 10.1021/bi9900774; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Morrissey MP, 1999, P NATL ACAD SCI USA, V96, P11293, DOI 10.1073/pnas.96.20.11293; Nandi PK, 2002, BIOCHEMISTRY-US, V41, P11017, DOI 10.1021/bi025886t; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Speare JO, 2003, J BIOL CHEM, V278, P12522, DOI 10.1074/jbc.M211599200; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1991, FASEB J, V5, P2799, DOI 10.1096/fasebj.5.13.1916104; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Wright DB, 2002, J MOL BIOL, V323, P327, DOI 10.1016/S0022-2836(02)00916-6; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	41	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22187	22192		10.1074/jbc.M302130200	http://dx.doi.org/10.1074/jbc.M302130200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676939	hybrid			2022-12-25	WOS:000183503900002
J	Rubtsova, MP; Sizova, DV; Dmitriev, SE; Ivanov, DS; Prassolov, VS; Shatsky, IN				Rubtsova, MP; Sizova, DV; Dmitriev, SE; Ivanov, DS; Prassolov, VS; Shatsky, IN			Distinctive properties of the 5 '-untranslated region of human Hsp70 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; ENCEPHALOMYOCARDITIS VIRUS-RNA; INTERNAL TRANSLATION INITIATION; HEPATITIS-C; PROTEIN-SYNTHESIS; HELA-CELLS; FACTOR 4E; BINDING; ELEMENT; INHIBITION	A relaxed cap-dependence of translation of the mRNA-encoding mammalian heat shock protein Hsp70 may suggest that its 5'-untranslated region (UTR) possesses an internal ribosome entry site (IRES). In this study, this possibility has been tested in transfected cells using plasmids that express dicistronic mRNAs. Using a reporter gene construct, Renilla luciferase/Photinus pyralis luciferase, we show that the 216-nt long 5'-UTR of Hsp70 mRNA acts as an IRES that directs ribosomes to the downstream start codon by a cap-independent mechanism. The relative activity of this IRES (100-fold over the empty vector) is similar to that of the classical picornaviral IRESs. Additional controls indicate that this high expression of the downstream reporter is not due to readthrough from the upstream cistron, nor is it due to translation of cryptic monocistronic transcripts. The effect of small deletions within the 5'-UTR of Hsp70 mRNA on the IRES activity varies in dependence on their position within the 5'-UTR sequence. With the exception of deletion of nt 33-50, it is small for the 5'-terminal half of the 5'-UTR and rather strong for the 3'-terminal section. However, neither of these small deletions abolishes the IRES activity completely. Excision of larger sections (> 50 nt) by truncation of the 5'-UTR from the 5'-end or by internal deleting results in a dramatic impairment of the IRES function. Taken together, these data suggest that the IRES activity of the 5'-UTR of Hsp70 mRNA requires integrity of almost the entire sequence of the 5'-UTR. The data are discussed in terms of a model that allows a three-dimensional rather than linear mode of selection of the initiation region surrounding the start codon of Hsp70 mRNA.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	Lomonosov Moscow State University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Shatsky, IN (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Bldg A, Moscow 119899, Russia.		Shatsky, Ivan N/A-5331-2012; Rubtsova, Maria P/E-2644-2012; Ivanov, Dmitry/AAE-6026-2020; Dmitriev, Sergey/D-9694-2011	Dmitriev, Sergey/0000-0002-1774-8475; Sizova, Daria/0000-0001-5471-6010				AUSUBEL RM, 1987, CURRENT PROTOCOLS MO; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Jubin R, 2000, J VIROL, V74, P10430, DOI 10.1128/JVI.74.22.10430-10437.2000; KAMINSKI A, 1994, EMBO J, V13, P1673, DOI 10.1002/j.1460-2075.1994.tb06431.x; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; MASEJAK DG, 1991, NATURE, V359, P90; MEYER K, 1995, J VIROL, V69, P2819, DOI 10.1128/JVI.69.5.2819-2824.1995; PANIERS R, 1984, EUR J BIOCHEM, V140, P209; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516; Robertson MEM, 1999, RNA, V5, P1167, DOI 10.1017/S1355838299990301; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Tang SX, 1999, J VIROL, V73, P2359, DOI 10.1128/JVI.73.3.2359-2364.1999; UINTO SLD, 2000, RNA, V6, P1380; UINTO SLD, 1997, J VIROL, V71, P4171; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vivinus S, 2001, EUR J BIOCHEM, V268, P1908, DOI 10.1046/j.1432-1327.2001.02064.x; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	35	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22350	22356		10.1074/jbc.M303213200	http://dx.doi.org/10.1074/jbc.M303213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682055	hybrid			2022-12-25	WOS:000183503900025
J	Schreiter, C; Hovius, R; Costioli, M; Pick, H; Kellenberger, S; Schild, L; Vogel, H				Schreiter, C; Hovius, R; Costioli, M; Pick, H; Kellenberger, S; Schild, L; Vogel, H			Characterization of the ligand-binding site of the serotonin 5-HT3 receptor - The role of glutamate residues 97, 224, and 235	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; 5HT(3) RECEPTOR; DOMAIN; IDENTIFICATION; RECOGNITION; SUBUNIT; MODEL	Ligand- gated ion channels of the Cys loop family are receptors for small amine- containing neurotransmitters. Charged amino acids are strongly conserved in the ligand- binding domain of these receptor proteins. To investigate the role of particular residues in ligand binding of the serotonin 5-HT3AS receptor (5-HT3R), glutamate amino acid residues at three different positions, Glu(97), Glu(224), and Glu(235), in the extracellular N- terminal domain were substituted with aspartate and glutamine using site- directed mutagenesis. Wild type and mutant receptor proteins were expressed in HEK293 cells and analyzed by electrophysiology, radioligand binding, fluorescence measurements, and immunochemistry. A structural model of the ligand- binding domain of the 5- HT3R based on the acetylcholine binding protein revealed the position of the mutated amino acids. Our results demonstrate that mutations of Glu(97), distant from the ligand- binding site, had little effect on the receptor, whereas mutations Glu(224) and Glu(235), close to the predicted binding site, are indeed important for ligand binding. Mutations E224Q, E224D, and E235Q decreased EC50 and K-d values 5 - 20- fold, whereas E235D was functionally expressed at a low level and had a more than 100- fold increased EC50 value. Comparison of the fluorescence properties of a fluorescein- labeled antagonist upon binding to wild type 5- HT3R and E235Q, allowed us to localize Glu(235) within a distance of 1 nm around the ligand- binding site, as proposed by our model.	Swiss Fed Inst Technol, Inst Biomol Sci, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne	Vogel, H (corresponding author), Swiss Fed Inst Technol, Inst Biomol Sci, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland.	Horst.Vogel@epfl.ch	Hovius, Ruud/B-5647-2009	Hovius, Ruud/0000-0001-9258-6587; Kellenberger, Stephan/0000-0003-1755-6198				Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DUBIN AE, 2001, Patent No. 0116297; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hope AG, 1999, MOL PHARMACOL, V55, P1037, DOI 10.1124/mol.55.6.1037; Hovius R, 1998, J NEUROCHEM, V70, P824; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIQUEL MC, 1991, BIOCHEM PHARMACOL, V42, P1453, DOI 10.1016/0006-2952(91)90459-I; Mochizuki S, 1999, EUR J PHARMACOL, V369, P125, DOI 10.1016/S0014-2999(99)00058-8; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; Pick H, 2003, BIOCHEMISTRY-US, V42, P877, DOI 10.1021/bi026576d; Pitera JW, 2001, BIOPHYS J, V80, P2546, DOI 10.1016/S0006-3495(01)76226-1; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Spier AD, 1999, MOL BRAIN RES, V67, P221; Steward LJ, 2000, MOL PHARMACOL, V57, P1249; SZABO A, 1984, J CHEM PHYS, V81, P150, DOI 10.1063/1.447378; Tairi AP, 1998, BIOCHEMISTRY-US, V37, P15850, DOI 10.1021/bi981812z; Vallotton P, 2001, BIOCHEMISTRY-US, V40, P12237, DOI 10.1021/bi0106989; Vallotton P, 2001, CHEMBIOCHEM, V2, P205, DOI 10.1002/1439-7633(20010302)2:3<205::AID-CBIC205>3.3.CO;2-A; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537	30	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22709	22716		10.1074/jbc.M301801200	http://dx.doi.org/10.1074/jbc.M301801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12660235	hybrid			2022-12-25	WOS:000183503900072
J	Forouhar, F; Huang, WN; Liu, JH; Chien, KY; Wu, WG; Hsiao, CD				Forouhar, F; Huang, WN; Liu, JH; Chien, KY; Wu, WG; Hsiao, CD			Structural basis of membrane-induced cardiotoxin A3 oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE CARDIOTOXIN; NAJA-NAJA-ATRA; COBRA CARDIOTOXIN; BINDING MOTIF; VENOM; GAMMA; CRYSTALLOGRAPHY; PHOSPHOLIPIDS; FLUORESCENCE; NIGRICOLLIS	Cobra cardiotoxins (CTXs) have previously been shown to induce membrane fusion of vesicles formed by phospholipids such as cardiolipin or sphingomyelin. CTX can also form a pore in membrane bilayers containing a anionic lipid such as phosphatidylserine or phosphatidylglycerol. Herein, we show that the interaction of CTX with negatively charged lipids causes CTX dimerization, an important intermediate for the eventual oligomerization of CTX during the CTX-induced fusion and pore formation process. The structural basis of the lipid-induced oligomerization of CTX A3, a major CTX from Naja atra, is then illustrated by the crystal structure of CTX A3 in complex with SDS; SDS likely mimics anionic lipids of the membrane under micelle conditions at 1.9-Angstrom resolution. The crystal packing reveals distinct SDS-free and SDS-rich regions; in the latter two types of interconnecting CTX A3 dimers, D1 and D2, and several SDS molecules can be identified to stabilize D1 and D2 by simultaneously interacting with residues at each dimer interface. When the three CTX-SDS complexes in the asymmetric unit are overlaid, the orientation of CTX A3 monomers relative to the SDS molecules in the crystal is strikingly similar to that of the toxin with respect to model membranes as determined by NMR and Fourier transform infrared methods. These results not only illustrate how lipid-induced CTX dimer formation may be transformed into oligomers either as inverted micelles of fusion intermediates or as membrane pore of anionic lipid bilayers but also underscore a potential role for SDS in x-ray diffraction study of protein-membrane interactions in the future.	Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan	National Tsing Hua University; Academia Sinica - Taiwan; National Defense Medical Center	Wu, WG (corresponding author), Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan.		Hsiao, Chwan-Deng/D-7327-2013; Hsiao, Chwan-Deng/AAZ-8869-2021; Liu, Jyung-Hurng/C-1340-2010	Hsiao, Chwan-Deng/0000-0002-7012-1532; Liu, Jyung-Hurng/0000-0002-7173-0372				ARIPOV TF, 1989, GEN PHYSIOL BIOPHYS, V8, P459; BATENBURG AM, 1985, BIOCHEMISTRY-US, V24, P7101, DOI 10.1021/bi00346a013; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BOHRER MP, 1979, J GEN PHYSIOL, V74, P583, DOI 10.1085/jgp.74.5.583; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARLSSON FHH, 1987, INT J BIOCHEM, V19, P915, DOI 10.1016/0020-711X(87)90172-8; Chiang CM, 1996, BIOCHEMISTRY-US, V35, P9177, DOI 10.1021/bi960077t; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; DAUPLAIS M, 1995, EUR J BIOCHEM, V230, P213, DOI 10.1111/j.1432-1033.1995.0213i.x; Dubovskii PV, 2001, J MOL BIOL, V305, P137, DOI 10.1006/jmbi.2000.4283; DUFOURCQ J, 1978, BIOCHEMISTRY-US, V17, P1170, DOI 10.1021/bi00600a006; DUFTON MJ, 1987, PHARMACOL THERAPEUT, V36, P1; Efremov RG, 2002, BIOPHYS J, V83, P144, DOI 10.1016/S0006-3495(02)75156-4; Fyfe PK, 2001, TRENDS BIOCHEM SCI, V26, P106, DOI 10.1016/S0968-0004(00)01746-1; HOUSSET D, 1996, PROTEIN TOXIN STRUCT, P271; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KLOWDEN MJ, 1992, TOXICON, V30, P295, DOI 10.1016/0041-0101(92)90870-B; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Lin YH, 2000, INT J BIOL MACROMOL, V27, P171, DOI 10.1016/S0141-8130(00)00117-3; Lo CC, 1998, BIOPHYS J, V75, P2382, DOI 10.1016/S0006-3495(98)77682-9; Lo Conte L, 1999, J MOL BIOL, V285, P2177; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REES B, 1993, CHEM RES TOXICOL, V6, P285; RUNNELS LW, 1995, BIOPHYS J, V69, P1569, DOI 10.1016/S0006-3495(95)80030-5; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SARMA VR, 1971, J BIOL CHEM, V246, P3753; Sharpe JC, 1999, J MEMBRANE BIOL, V171, P209, DOI 10.1007/s002329900572; Sue SC, 1997, BIOCHEMISTRY-US, V36, P9826, DOI 10.1021/bi970413l; Sue SC, 2002, J BIOL CHEM, V277, P2666, DOI 10.1074/jbc.M104887200; Sue SC, 2001, BIOCHEMISTRY-US, V40, P12782, DOI 10.1021/bi010848f; Sun YJ, 1997, BIOCHEMISTRY-US, V36, P2403, DOI 10.1021/bi962594h; SUREWICZ WK, 1988, J BIOL CHEM, V263, P786; Wu WG, 1997, J TOXICOL-TOXIN REV, V16, P115, DOI 10.3109/15569549709016451	40	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21980	21988		10.1074/jbc.M208650200	http://dx.doi.org/10.1074/jbc.M208650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660250	hybrid			2022-12-25	WOS:000183354200084
J	Takayama, Y; Takahashi, H; Mizumachi, K; Takezawa, T				Takayama, Y; Takahashi, H; Mizumachi, K; Takezawa, T			Low density lipoprotein receptor-related protein (LRP) is required for lactoferrin-enhanced collagen gel contractile activity of human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; MUSCLE CELL CONTRACTION; GROWTH-FACTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MATRIX CONTRACTION; UROKINASE RECEPTOR; CYTOSOLIC ADAPTER; LIGAND-BINDING	Fibroblasts plated on a type I collagen gel can reduce the size of the gel in a way that mimics the reorganization of the collagen matrix that accompanies the wound healing process. We demonstrated previously that lactoferrin (Lf) specifically binds to WI-38 human fibroblasts and enhances their collagen gel contractile activity. The effect of Lf correlated with the phosphorylation of myosin light chain (MLC), suggesting that Lf promotes fibroblast contractile activity by regulating MLC phosphorylation. We found here that the binding of Lf to WI-38 cells was inhibited by recombinant receptor-associated protein (RAP), a universal competitor for ligand binding to LRP (LDL receptor-related protein), and RAP can also promote the collagen gel contractile activity. These observations suggest that LRP is a receptor that mediates the Lf-induced enhancement of collagen gel contractile activity in WI-38 fibroblasts. To confirm the hypothesis, we utilized LRP antisense oligonucleotide, which was modified by morpholino linkage. Suppression of LRP expression abrogated the Lf-induced enhancement the contractile activity in fibroblasts. Treatment of fibroblasts with Lf enhanced the phosphorylation of ERK1/2 and the activation of MLC kinase (MLCK). These effects were attenuated by suppression of LRP expression. These findings suggest that LRP is involved in the Lf-enhanced collagen gel contractile activity of WI-38 fibroblasts by converting the Lf binding signal into the activation of ERK1/2 and MLCK.	Natl Inst Livestock & Grassland Sci, Funct Biomol Lab, Tsukuba, Ibaraki 3050901, Japan; Natl Inst Livestock & Grassland Sci, Maternal & Fetal Physiol Lab, Tsukuba, Ibaraki 3050901, Japan; Natl Inst Agrobiol Sci, Anim Cell Biol Lab, Tsukuba, Ibaraki 3050901, Japan	National Agriculture & Food Research Organization - Japan; National Agriculture & Food Research Organization - Japan; National Institute of Agrobiological Sciences - Japan	Takayama, Y (corresponding author), Natl Inst Livestock & Grassland Sci, Funct Biomol Lab, 2 Ikenodai, Tsukuba, Ibaraki 3050901, Japan.		Takayama, Yoshiharu/M-8826-2019; Takayama, Yoshiharu/E-3662-2010	Takayama, Yoshiharu/0000-0003-4532-7114; Takayama, Yoshiharu/0000-0003-4532-7114; Takezawa, Toshiaki/0000-0002-1825-838X				Baveye S, 2000, INFECT IMMUN, V68, P6519, DOI 10.1128/IAI.68.12.6519-6525.2000; BAYNES RD, 1986, SCAND J HAEMATOL, V36, P79; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; Chazaud B, 2000, EXP CELL RES, V258, P237, DOI 10.1006/excr.2000.4934; Dieckgraefe BK, 1997, BIOCHEM BIOPH RES CO, V233, P389, DOI 10.1006/bbrc.1997.6469; Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HAGIWARA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1875, DOI 10.1271/bbb.59.1875; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; JAY PY, 1995, J CELL SCI, V108, P387; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Lee DJ, 2000, EXP CELL RES, V257, P190, DOI 10.1006/excr.2000.4866; LEVEUGLE B, 1993, EUR J BIOCHEM, V213, P1205, DOI 10.1111/j.1432-1033.1993.tb17871.x; Lorget F, 2002, BIOCHEM BIOPH RES CO, V296, P261, DOI 10.1016/S0006-291X(02)00849-5; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; MANN DM, 1994, J BIOL CHEM, V269, P23661; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; Nassar T, 2002, J BIOL CHEM, V277, P40499, DOI 10.1074/jbc.M207172200; Nassar T, 2002, BLOOD, V100, P4026, DOI 10.1182/blood-2002-04-1080; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; Nuijens JH, 1996, J MAMMARY GLAND BIOL, V1, P285, DOI 10.1007/BF02018081; Oh SM, 2001, J BIOL CHEM, V276, P42575, DOI 10.1074/jbc.M107724200; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; REJMAN JJ, 1994, INT J BIOCHEM, V26, P201, DOI 10.1016/0020-711X(94)90146-5; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Suzuki YA, 2001, BIOCHEMISTRY-US, V40, P15771, DOI 10.1021/bi0155899; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Takayama Y, 2001, FEBS LETT, V508, P111, DOI 10.1016/S0014-5793(01)03041-1; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; Webb DJ, 2000, J CELL SCI, V113, P123; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Ziere GJ, 1996, BIOCHEM J, V313, P289, DOI 10.1042/bj3130289; ZIMECKI M, 1991, IMMUNOL LETT, V30, P119, DOI 10.1016/0165-2478(91)90099-V; ZIMECKI M, 1995, IMMUNOLOGY, V86, P122	46	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22112	22118		10.1074/jbc.M300894200	http://dx.doi.org/10.1074/jbc.M300894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672816	hybrid			2022-12-25	WOS:000183354200099
J	Takeyama, K; Aguiar, RCT; Gu, LQ; He, CY; Freeman, GJ; Kutok, JL; Aster, JC; Shipp, MA				Takeyama, K; Aguiar, RCT; Gu, LQ; He, CY; Freeman, GJ; Kutok, JL; Aster, JC; Shipp, MA			The BAL-binding protein BBAP and related deltex family members exhibit ubiquitin-protein isopeptide ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER; REGULATOR; GENE; MDM2; BRCA1-BARD1; DOMAIN	Members of the DTX (Deltex) family act as Notch signaling modifiers and may also regulate transcription through interactions with specific transcription factors. DTX proteins have a basic N terminus; a central proline-rich region; and a C-terminal RING finger domain, a motif often found in ubiquitin-protein isopeptide ligases (E3). Recently, we identified and characterized a unique diffuse large B-cell lymphoma risk-related gene named BAL (B aggressive lymphoma). Using a yeast two-hybrid screen for BAL-binding partners, we have now identified a novel protein termed BBAP (B-lymphoma- and BAL-associated protein). Although BBAP has a unique N terminus, the C-terminal region is highly homologous to that of DTX family members. Herein, we report that BBAP and the human family of DTX proteins (DTX1, DTX2, and DTX3) function as E3 ligases based on their capacity for self-ubiquitination. DTX family members homodimerize and heterodimerize in vivo, suggesting that physical interactions between various DTX family members modify E3 activity and/or substrate availability. Consistent with this idea, BBAP and DTX1 associate via their unique N termini, resulting in enhanced self-ubiquitination.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Shipp, MA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	margaret_shipp@dfci.harvard.edu	Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616				Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuno K, 2002, DEVELOPMENT, V129, P1049; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shipp Margaret A., 1997, P2165; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	33	93	99	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21930	21937		10.1074/jbc.M301157200	http://dx.doi.org/10.1074/jbc.M301157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670957	hybrid			2022-12-25	WOS:000183354200078
J	Wentworth, M; Ruban, AV; Horton, P				Wentworth, M; Ruban, AV; Horton, P			Thermodynamic investigation into the mechanism of the chlorophyll fluorescence quenching in isolated photosystem II light-harvesting complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-DISSIPATION; IN-VITRO; XANTHOPHYLL CYCLE; KINETIC-ANALYSIS; AGGREGATION; STATE; PH; ZEAXANTHIN; BINDING; PLANTS	Chlorophyll fluorescence quenching can be stimulated in vitro in purified photosystem II antenna complexes. It has been shown to resemble nonphotochemical quenching observed in isolated chloroplasts and leaves in several important respects, providing a model system for study of the mechanism of photoprotective energy dissipation. The effect of temperature on the rate of quenching in trimeric and monomeric antenna complexes revealed the presence of two temperature-dependent processes with different activation energies, one between similar to15 and 35degreesC and another between similar to40 and 60degreesC. The temperature of the transition between the two phases was higher for trimers than for monomers. Throughout this temperature range, the quenching was almost completely reversible, the protein CD was unchanged, and pigment binding was maintained. The activation energy for the low temperature phase was consistent with local rearrangements of pigments within some of the protein domains, whereas the higher temperature phase seemed to arise from large scale conformational transitions. For both phases, there was a strong linear correlation between the quenching rate and the appearance of an absorption band at 685 nm. In addition, quenching was correlated with a loss of CD at similar to495 nm from Lutein 1 and at 680 nm from chlorophylls a1 and a2, the terminal emitters. The results obtained indicate that quenching of chlorophyll fluorescence in antenna complexes is brought about by perturbation of the lutein 1/chlorophyll a1/chlorophyll a2 locus, forming a poorly fluorescing chlorophyll associate, either a dimer or an excimer.	Univ Sheffield, Robert Hill Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Horton, P (corresponding author), Univ Sheffield, Robert Hill Inst, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	p.horton@sheffield.ac.uk	Horton, Peter/A-3958-2012	Horton, Peter/0000-0002-6095-1460				AGOSTIANO A, 1991, J PHOTOCH PHOTOBIO A, V58, P201, DOI 10.1016/1010-6030(91)85047-K; Aspinall-O'Dea M, 2002, P NATL ACAD SCI USA, V99, P16331, DOI 10.1073/pnas.252500999; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1991, J PHOTOCH PHOTOBIO B, V9, P335, DOI 10.1016/1011-1344(91)80170-M; BEDDARD GS, 1976, NATURE, V260, P366, DOI 10.1038/260366a0; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Dominici P, 2002, J BIOL CHEM, V277, P22750, DOI 10.1074/jbc.M200604200; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Gilmore AM, 1998, BIOCHEMISTRY-US, V37, P13582, DOI 10.1021/bi981384x; Horton P, 1999, ADV PHOTOSYNTH, V8, P271; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; HORTON P, 2000, PHILOS T R SOC LON B, V355, P1; Horton P., 1994, PHOTOINHIBITION PHOT, P111; KRAUSE GH, 1992, PHOTOSYNTHETICA, V27, P249; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2002, FUNCT PLANT BIOL, V29, P1131, DOI 10.1071/FP02065; Li XP, 2002, J BIOL CHEM, V277, P33590, DOI 10.1074/jbc.M204797200; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Naqvi KR, 1997, SPECTROCHIM ACTA A, V53, P2659, DOI 10.1016/S1386-1425(97)00160-1; Naqvi KR, 1999, SPECTROCHIM ACTA A, V55, P193; Owens T. G., 1994, PHOTOINHIBITION PHOT, P95; Pieper J, 1999, J PHYS CHEM A, V103, P2422, DOI 10.1021/jp983958d; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Rogl H, 1999, BIOCHEMISTRY-US, V38, P16214, DOI 10.1021/bi990739p; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1998, BIOCHEMISTRY-US, V37, P11586, DOI 10.1021/bi9809369; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P39, DOI 10.1016/0167-4838(92)90496-Z; Ruban AV, 2001, BIOCHEMISTRY-US, V40, P9896, DOI 10.1021/bi010370f; Ruban AV, 1997, BBA-BIOENERGETICS, V1321, P61, DOI 10.1016/S0005-2728(97)00047-9; UEHARA K, 1991, PHOTOCHEM PHOTOBIOL, V53, P371, DOI 10.1111/j.1751-1097.1991.tb03643.x; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; Wentworth M, 2000, FEBS LETT, V471, P71, DOI 10.1016/S0014-5793(00)01369-7; Wentworth M, 2001, BIOCHEMISTRY-US, V40, P9902, DOI 10.1021/bi0103718	43	59	60	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21845	21850		10.1074/jbc.M302586200	http://dx.doi.org/10.1074/jbc.M302586200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670939	hybrid			2022-12-25	WOS:000183354200068
J	Ghiran, I; Klickstein, LB; Nicholson-Weller, A				Ghiran, I; Klickstein, LB; Nicholson-Weller, A			Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CELL-SURFACE; ACTIVATED NEUTROPHILS; SUPEROXIDE PRODUCTION; COLLECTIN RECEPTOR; HUMAN-ERYTHROCYTES; MEMBRANE-PROTEIN; APOPTOTIC CELLS; BINDING LECTIN; CROSS-LINKING	Calreticulin, which has been proposed to be a C1q receptor on neutrophils, has neither a transmembrane domain nor a GPI-anchor attachment site and must utilize an adaptor molecule to attach to the plasma membrane. The expression of ecto-calreticulin on purified human neutrophils did not result from contamination by soluble or intracellular calreticulin released during cell fractionation because it was expressed on circulating neutrophils, and the expression did not increase significantly with neutrophil isolation. All neutrophils expressed calreticulin with a unimodal distribution. Treatment of neutrophils with either a cholesterol-binding agent or phosphatidylinositol-specific phospholipase C dramatically decreased ecto-calreticulin expression indicating that the adaptor molecule(s) are located in lipid rafts and have a GPI-anchor. Analysis for the co-expression of specific GPI-anchored proteins and ecto-calreticulin in cells that were deficient in specific GPI-anchored proteins, indicated that ecto-calreticulin was best associated with CD59. Calreticulin reciprocally immunoprecipited with CD59, which provided direct evidence that CD59 is an adaptor for ecto-calreticulin. Immunofluorescence and confocal microscopy demonstrated that ecto-calreticulin co-localized with a fraction of CD59 at the cell surface. Cross-linking ecto-calreticulin with antibodies induced a Ca2+ flux, which suggests that ecto-calreticulin is capable of signaling following ligand binding. Ecto-calreticulin has been associated with diverse cellular functions. An appreciation that the adaptors for ecto-calreticulin are GPI-anchored will provide a framework for understanding any common features underlying ecto-calreticulin ligation.	Beth Israel Deaconess Med Ctr, Div Allergy Inflammat, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol & Immunol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ghiran, I (corresponding author), Beth Israel Deaconess Med Ctr, Div Allergy Inflammat, Dna Bldg,Rm 617,330 Brookline Ave, Boston, MA 02215 USA.				NIAID NIH HHS [R01 AI 42987] Funding Source: Medline; NIDDK NIH HHS [P30 DK 34845] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Berwin B, 2001, TRAFFIC, V2, P690, DOI 10.1034/j.1600-0854.2001.21003.x; Bordin S, 2003, J IMMUNOL, V170, P667, DOI 10.4049/jimmunol.170.2.667; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; Dunn DE, 2000, PAROXYSMAL NOCTURNAL, P113; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; EGGLETON P, 1994, BLOOD, V84, P1640; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; ERDEI A, 1988, BIOCHEM J, V255, P493; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GHEBREHIWET B, 1988, J IMMUNOL METHODS, V110, P251, DOI 10.1016/0022-1759(88)90111-1; Ghiran I, 2002, IMMUNOBIOLOGY, V205, P407, DOI 10.1078/0171-2985-00142; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GOODMAN EB, 1992, J IMMUNOL, V148, P3920; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; KLICKSTEIN LB, 1995, LEUCOCYTE TYPING 5, V2, P1476; KLICKSTEIN LB, 1993, LEUKOCYTE TYPING 5, V2, P1478; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; MERI S, 1990, J EXP MED, V172, P367, DOI 10.1084/jem.172.1.367; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; Murray EW, 1998, J BIOL CHEM, V273, P25279, DOI 10.1074/jbc.273.39.25279; NICHOLSONWELLER A, 1985, BLOOD, V65, P1237; NICULESCU F, 1993, J IMMUNOL, V150, P214; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Persson S, 2002, GENE, V297, P151, DOI 10.1016/S0378-1119(02)00880-6; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; Seddiki N, 2001, J IMMUNOL, V166, P6423, DOI 10.4049/jimmunol.166.10.6423; SHAW S, 1995, LEUCOCYTE TYPING 5, V1, P87; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; Tas SW, 1999, J IMMUNOL, V163, P5056; Tyagi S, 2000, ARTHRITIS RHEUM, V43, P2248, DOI 10.1002/1529-0131(200010)43:10<2248::AID-ANR12>3.0.CO;2-S; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	49	84	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21024	21031		10.1074/jbc.M302306200	http://dx.doi.org/10.1074/jbc.M302306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12646570	hybrid			2022-12-25	WOS:000183230500076
J	Hayakawa, J; Depatie, C; Ohmichi, M; Mercola, D				Hayakawa, J; Depatie, C; Ohmichi, M; Mercola, D			The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; REGULATED PROTEIN-KINASE; NUCLEAR ANTIGEN GENE; OVARIAN-CANCER; CELL-LINES; TOPOISOMERASE GENE; RESPONSE ELEMENT; BINDING PROTEIN; MELANOMA-CELLS	The activating transcription factor 2 (ATF2) is a member of the ATF/cAMP-response element-binding protein family of basic-leucine zipper proteins involved in cellular stress response. The transcription potential of ATF2 is enhanced markedly by NH2-terminal phosphorylation by c-Jun NH2-terminal kinase (JNK) and mediates stress responses including DNA-damaging events. We have observed that four DNA-damaging agents ( cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity. Selective inhibition studies with PD98059, SB202190, SP600125, and the dominant negative JNK indicate that activation of JNK but not p38 kinase or ERK kinase is required for the phosphorylation and transcriptional activation of ATF2. Stable expression of ATF2 in human breast carcinoma BT474 cells increases transcriptional activity and confers resistance to the four DNA-damaging agents, but not to transplatin. Conversely, stable expression of a dominant negative ATF2 ( dnATF2) quantitatively blocks phosphorylation of endogenous ATF2 leading to a marked decrease in transcriptional activity by endogenous ATF2 and a markedly increased sensitivity to the four agents as judged by decreased cell viability. Similarly, application of SB202190 at 50 muM or SP600125 inhibited JNK activity, blocked transactivation, and sensitized parental cells to the four DNA-damaging drugs. Moreover, the wild type ATF2-expressing clones exhibited rapid DNA repair after treatment with the four DNA-damaging agents but not transplatin. Conversely, expression of dnATF2 quantitatively blocks DNA repair. These results indicate that JNK-dependent phosphorylation of ATF2 plays an important role in the drug resistance phenotype likely by mediating enhanced DNA repair by a p53-independent mechanism. JNK may be a rational target for sensitizing tumor cells to DNA-damaging chemotherapy agents.	Sidney Kimmel Canc Ctr, Dept Canc Gene Therapy, San Diego, CA 92121 USA; Osaka Univ, Dept Obstet & Gynecol, Sch Med, Osaka 5650871, Japan; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Osaka University; University of California System; University of California San Diego	Mercola, D (corresponding author), Sidney Kimmel Canc Ctr, Dept Canc Gene Therapy, 10835 Altman Row, San Diego, CA 92121 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [R01 CA084107, CA84107, R01 CA063783, CA63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783, R01CA084107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Baselga J, 2001, ANN ONCOL, V12, P49, DOI 10.1023/A:1011167909059; BAUMGARTNER B, 1994, BBA-GENE STRUCT EXPR, V1218, P123, DOI 10.1016/0167-4781(94)90114-7; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Crenesse D, 2000, HEPATOLOGY, V32, P1029, DOI 10.1053/jhep.2000.19065; Cripe LD, 2002, LEUKEMIA, V16, P799, DOI 10.1038/sj.leu.2402457; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis PL, 1998, ANTICANCER RES, V18, P2919; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELSTNER E, 1995, CANCER RES, V55, P2822; ENGLANDER EW, 1991, NUCLEIC ACIDS RES, V19, P3369, DOI 10.1093/nar/19.12.3369; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; Gjerset RA, 1999, CELL GROWTH DIFFER, V10, P545; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haghighi A, 1999, BIOCHEMISTRY-US, V38, P12432, DOI 10.1021/bi991079r; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayakawa J, 2000, CANCER RES, V60, P5988; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HEILAND S, 1993, EUR J BIOCHEM, V217, P813, DOI 10.1111/j.1432-1033.1993.tb18309.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; JENNERWEIN MM, 1991, NUCLEIC ACIDS RES, V19, P6209, DOI 10.1093/nar/19.22.6209; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; Kim R, 2002, ONCOL REP, V9, P3; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANS DRA, 1991, BIOCHEM PHARMACOL, V42, P2131, DOI 10.1016/0006-2952(91)90348-9; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; PIGRAM WJ, 1972, NATURE-NEW BIOL, V235, P17, DOI 10.1038/newbio235017a0; Potapova O, 1996, CANCER RES, V56, P280; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang SC, 2001, SEMIN ONCOL, V28, P21, DOI 10.1053/sonc.2001.29724; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHANG X, 1989, ONCOGENE, V4, P985	64	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20582	20592		10.1074/jbc.M210992200	http://dx.doi.org/10.1074/jbc.M210992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663670	hybrid, Green Published			2022-12-25	WOS:000183230500019
J	Janvilisri, T; Venter, H; Shahi, S; Reuter, G; Balakrishnan, L; van Veen, HW				Janvilisri, T; Venter, H; Shahi, S; Reuter, G; Balakrishnan, L; van Veen, HW			Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; HALF-TRANSPORTER; PLASMA-MEMBRANE; ATPASE ACTIVITY; GENE; OVEREXPRESSION; MITOXANTRONE; CELLS; CHOLESTEROL	The human breast cancer resistance protein (BCRP, also know as ABCG2, MXR, or ABCP) is one of the more recently discovered ATP-binding cassette (ABC) transporters that confer resistance on cancer cells by mediating multidrug efflux. In the present study, we have obtained functional expression of human BCRP in the Gram-positive bacterium Lactococcus lactis. BCRP expression conferred multidrug resistance on the lactococcal cells, which was based on ATP-dependent drug extrusion. BCRP-mediated ATPase and drug transport activities were inhibited by the BCRP-specific modulator fumitremorgin C. To our knowledge these data represent the first example of the functional expression of a mammalian ABC half-transporter in bacteria. Although members of the ABCG subfamily (such as ABCG1 and ABCG5/8) have been implicated in the transport of sterols, such a role has not yet been established for BCRP. Interestingly, the BCRP-associated ATPase activity in L. lactis was significantly stimulated by (i) sterols including cholesterol and estradiol, (ii) natural steroids such as progesterone and testosterone, and (iii) the antiestrogen anticancer drug tamoxifen. In addition, BCRP mediated the efflux of [H-3] estradiol from lactococcal cells. Our findings suggest that BCRP may play a role in the transport of sterols in human, in addition to its ability to transport multiple drugs and toxins.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	Venter, Rietie/E-4795-2013; van Veen, Hendrik W./A-4162-2008; Janvilisri, Tavan/O-6679-2019; Janvilisri, Tavan/C-8391-2015	Venter, Rietie/0000-0001-5569-7755; van Veen, Hendrik W./0000-0002-9658-8077; Janvilisri, Tavan/0000-0002-6376-5575; Janvilisri, Tavan/0000-0002-6376-5575				Albrecht C, 2002, BBA-BIOMEMBRANES, V1567, P133, DOI 10.1016/S0005-2736(02)00608-9; Allen JD, 1999, CANCER RES, V59, P4237; Brangi M, 1999, CANCER RES, V59, P5938; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kim M, 2002, CLIN CANCER RES, V8, P22; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CANCER RES, V61, P3458; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Nielsen D, 2000, BIOCHEM PHARMACOL, V60, P363, DOI 10.1016/S0006-2952(00)00337-3; Oram JF, 2001, J LIPID RES, V42, P1173; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Rabindran SK, 2000, CANCER RES, V60, P47; Rebbeor JF, 1998, BBA-BIOMEMBRANES, V1369, P85, DOI 10.1016/S0005-2736(97)00185-5; Robey RW, 2001, CLIN CANCER RES, V7, P145; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SALTON MRJ, 1976, ANNU REV MICROBIOL, V30, P451, DOI 10.1146/annurev.mi.30.100176.002315; Scheffer GL, 2000, CANCER RES, V60, P2589; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; van der Kolk DM, 2002, BLOOD, V99, P3763, DOI 10.1182/blood.V99.10.3763; van Helvoort A, 1997, J CELL SCI, V110, P75; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	39	140	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20645	20651		10.1074/jbc.M301358200	http://dx.doi.org/10.1074/jbc.M301358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668685	hybrid			2022-12-25	WOS:000183230500027
J	Steinle, JJ; Booz, GW; Meininger, CJ; Day, JNE; Granger, HJ				Steinle, JJ; Booz, GW; Meininger, CJ; Day, JNE; Granger, HJ			beta(3)-Adrenergic receptors regulate retinal endothelial cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-3-ADRENERGIC RECEPTOR; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; ADRENERGIC-RECEPTORS; GROWTH-FACTOR; IN-VITRO; PATHWAY; RAT; AGONISTS; BINDING	Sympathetic nerves may play a role in vascular disorders of the eye. In the present study, we hypothesized that activation of beta(3)-adrenergic receptors on retinal endothelial cells would promote migration and proliferation of these cells, two markers of an angiogenic phenotype. We show, for the first time, expression of beta(3)-adrenergic receptors on cultured retinal endothelial cells. Activation of these receptors with BRL37344, a specific beta(3)-adrenergic receptor agonist, promoted migration that was blocked by inhibitors of phosphatidylinositol 3-kinase (PI3K), the mitogen activated protein kinase component MEK, and matrix metalloproteinases (MMPs) 2 and 9. BRL37344 stimulated proliferation, which could be blocked by inhibitors of Src, PI3K, and MEK. These cells also express the beta(1)-adrenergic receptor with no beta(2)-adrenergic receptor expression observed. Stimulation of the beta(1)-adrenergic receptor with xamoterol, a specific partial agonist, did not promote proliferation or migration. These results support the hypothesis that beta(3)-adrenergic receptors play a role in proliferation and migration of cultured human retinal endothelial cells.	Texas A&M Univ Syst, Dept Med Physiol, Inst Cardiovasc Res, Ctr Hlth Sci,Coll Med, Temple, TX 76504 USA; Texas A&M Univ Syst, Dept Internal Med, Inst Cardiovasc Res, Ctr Hlth Sci,Coll Med, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University System	Steinle, JJ (corresponding author), Texas A&M Univ Syst, Dept Med Physiol, Inst Cardiovasc Res, Ctr Hlth Sci,Coll Med, 702 SWHK Loop,Rm 202A, Temple, TX 76504 USA.		; Meininger, Cynthia/D-2846-2014	Steinle, Jena/0000-0002-7539-2892; Meininger, Cynthia/0000-0002-1314-5044				AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BRAUTBOUCHER F, 1995, J IMMUNOL METHODS, V178, P41, DOI 10.1016/0022-1759(94)00239-S; de Souza CJ, 2001, CURR PHARM DESIGN, V7, P1433, DOI 10.2174/1381612013397339; Ferro A, 1999, BRIT J PHARMACOL, V126, P1872, DOI 10.1038/sj.bjp.0702512; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; FULK GW, 1991, OPTOMETRY VISION SCI, V68, P954, DOI 10.1097/00006324-199112000-00008; Harris A, 1999, PROG RETIN EYE RES, V18, P669; ISHIKAWA S, 1985, OPHTHALMOLOGICA, V191, P172, DOI 10.1159/000309582; Kim Lincoln R., 1998, Wound Repair and Regeneration, V6, P194, DOI 10.1046/j.1524-475X.1998.60305.x; Klein R, 1996, ANNU REV PUBL HEALTH, V17, P137; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; MUZZIN P, 1992, FEBS LETT, V298, P162, DOI 10.1016/0014-5793(92)80046-J; Naga Prasad SV, 2001, TRENDS GENET, V17, pS44; OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x; Schmidt RE, 1997, BRAIN RES, V769, P375, DOI 10.1016/S0006-8993(97)00806-8; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182; Steinle JJ, 2002, BRIT J PHARMACOL, V136, P730, DOI 10.1038/sj.bjp.0704771; TOEWS ML, 1983, P NATL ACAD SCI-BIOL, V80, P3553, DOI 10.1073/pnas.80.12.3553; Yang A, 2002, CELL BIOL TOXICOL, V18, P97, DOI 10.1023/A:1015328100876	21	71	75	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20681	20686		10.1074/jbc.M300368200	http://dx.doi.org/10.1074/jbc.M300368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670949	hybrid			2022-12-25	WOS:000183230500032
J	Spiller, OB; Blackbourn, DJ; Mark, L; Proctor, DG; Blom, AM				Spiller, OB; Blackbourn, DJ; Mark, L; Proctor, DG; Blom, AM			Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROL PROTEIN; C4B-BINDING PROTEIN; FACTOR-I; VIRUS; INHIBITION; C3B; PURIFICATION; DEGRADATION; SEQUENCES; HOMOLOG	Kaposi's sarcoma-associated herpesvirus (KSHV) is closely associated with Kaposi's sarcoma and certain B-cell lymphomas. The fourth open reading frame of the KSHV genome encodes a protein (KSHV complement control protein (KCP, previously termed ORF4)) predicted to have complement-regulating activity. Here, we show that soluble KCP strongly enhanced the decay of classical C3-convertase but not the alternative pathway C3-convertase, when compared with the host complement regulators: factor H, C4b-binding protein, and decay-accelerating factor. The equilibrium affinity constant (K-D) of KCP for C3b and C4b was determined by surface plasmon resonance analysis to range between 0.47-10 muM and 0.025-6.1 muM, respectively, depending on NaCl concentration and cation presence. Soluble and cell-associated KCP acted as a cofactor for factor I (FI)-mediated cleavage of both C4b and C3b and induced the cleavage products C4d and iC3b, respectively. In the presence of KCP, FI further cleaved iC3b to C3d, which has never been described before as complement receptor 1 only mediates the production of C3dg by FI. KCP would enhance virus pathogenesis through evading complement attack, opsonization, and anaphylaxis but may also aid in targeting KSHV to one of its host reservoirs since C3d is a ligand for complement receptor 2 on B-cells.	Lund Univ, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland; Cardiff Univ, Coll Med, Virus Receptor & Immune Evas Grp, Dept Med Biochem, Cardiff CF14 4XX, S Glam, Wales	Lund University; Skane University Hospital; University of Glasgow; Cardiff University	Blom, AM (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.	Anna.Blom@klkemi.mas.lu.se	Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022; Spiller, Owen Brad/AAC-2474-2020	Blom, Anna/0000-0002-1348-1734; Spiller, Owen Brad/0000-0002-9117-6911; Blackbourn, David/0000-0002-6703-4497				ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DODDS AW, 1997, PRACTICAL APPROACH S, P182; EKDAHL KN, 1990, J IMMUNOL, V144, P4269; FODOR WL, 1995, J VIROL, V69, P3889, DOI 10.1128/JVI.69.6.3889-3892.1995; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Kapadia SB, 2002, IMMUNITY, V17, P143, DOI 10.1016/S1074-7613(02)00369-2; Kapadia SB, 1999, J VIROL, V73, P7658, DOI 10.1128/JVI.73.9.7658-7670.1999; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Kotwal GJ, 1998, MOL CELL BIOCHEM, V185, P39, DOI 10.1023/A:1006844624825; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Miller CG, 1997, VIROLOGY, V229, P126, DOI 10.1006/viro.1996.8396; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Rosengard AM, 1999, MOL IMMUNOL, V36, P685, DOI 10.1016/S0161-5890(99)00081-4; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sahu A, 1998, J IMMUNOL, V160, P5596; Schulz TF, 2001, EUR J CANCER, V37, P1217, DOI 10.1016/S0959-8049(01)00115-0; Spiller OB, 2003, J VIROL, V77, P592, DOI 10.1128/JVI.77.1.592-599.2003; Uvarova EA, 2001, VIRUS RES, V81, P39, DOI 10.1016/S0168-1702(01)00332-X; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; ZABERN I, 1982, J IMMUNOL, V128, P1433	39	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9283	9289		10.1074/jbc.M211579200	http://dx.doi.org/10.1074/jbc.M211579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645526	hybrid			2022-12-25	WOS:000181524000053
J	Levites, Y; Amit, T; Mandel, S; Youdim, MBH				Levites, Y; Amit, T; Mandel, S; Youdim, MBH			Neuroprotection and neurorescue against A beta toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate	FASEB JOURNAL			English	Article						neurodegeneration; Alzheimer's disease; protein kinase C; antioxidant	ALPHA-SECRETASE CLEAVAGE; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; CONVERTING-ENZYME; NERVE-CELLS; ACTIVATION; DISINTEGRIN; ANTIOXIDANT; MELATONIN	Green tea extract and its main polyphenol constituent (-)-epigallocatechin-3-gallate (EGCG) possess potent neuroprotective activity in cell culture and mice model of Parkinson's disease. The central hypothesis guiding this study is that EGCG may play an important role in amyloid precursor protein (APP) secretion and protection against toxicity induced by beta-amyloid (Abeta). The present study shows that EGCG enhances (similar to6-fold) the release of the non-amyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) into the conditioned media of human SH-SY5Y neuroblastoma and rat pheochromocytoma PC12 cells. sAPP release was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790, which indicated mediation via secretase activity. Inhibition of protein kinase C (PKC) with the inhibitor GF109203X, or by down-regulation of PKC, blocked the EGCG-induced sAPPalpha secretion, suggesting the involvement of PKC. Indeed, EGCG induced the phosphorylation of PKC, thus identifying a novel PKC-dependent mechanism of EGCG action by activation of the non-amyloidogenic pathway. EGCG is not only able to protect, but it can rescue PC12 cells against the beta-amyloid (Abeta) toxicity in a dose-dependent manner. In addition, administration of EGCG (2 mg/kg) to mice for 7 or 14 days significantly decreased membrane-bound holoprotein APP levels, with a concomitant increase in sAPPalpha levels in the hippocampus. Consistently, EGCG markedly increased PKCalpha and PKCepsilon in the membrane and the cytosolic fractions of mice hippocampus. Thus, EGCG has protective effects against Abeta-induced neurotoxicity and regulates secretory processing of non-amyloidogenic APP via PKC pathway.	Technion Israel Inst Technol, Fac Med,Dept Pharmacol, Ctr Excellence Neurodegenerat Dis Res, Eve Topf & USA Natl Parkinson Fdn, IL-31096 Haifa, Israel; Intradept Unit Biotechnol, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med,Dept Pharmacol, Ctr Excellence Neurodegenerat Dis Res, Eve Topf & USA Natl Parkinson Fdn, POB 9697, IL-31096 Haifa, Israel.	Youdim@Tx.Technion.ac.il						ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Bachurin S, 1999, ANN NY ACAD SCI, V890, P155, DOI 10.1111/j.1749-6632.1999.tb07990.x; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Bastianetto S, 2000, BRIT J PHARMACOL, V131, P711, DOI 10.1038/sj.bjp.0703626; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Benussi L, 1998, NEUROSCI LETT, V240, P97, DOI 10.1016/S0304-3940(97)00894-X; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2; Chyan YJ, 1999, J BIOL CHEM, V274, P21937, DOI 10.1074/jbc.274.31.21937; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Daniels WMU, 1998, J PINEAL RES, V24, P78, DOI 10.1111/j.1600-079X.1998.tb00370.x; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gassen M, 1998, MOVEMENT DISORD, V13, P242, DOI 10.1002/mds.870130208; Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1; Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Katiyar SK, 1999, PHOTOCHEM PHOTOBIOL, V69, P148, DOI 10.1111/j.1751-1097.1999.tb03267.x; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KINOUCHI T, 1995, FEBS LETT, V364, P203, DOI 10.1016/0014-5793(95)00392-M; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; Levites Y, 2002, BIOCHEM PHARMACOL, V63, P21, DOI 10.1016/S0006-2952(01)00813-9; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Lin AMY, 1998, CHINESE J PHYSIOL, V41, P189; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; Longo VD, 2000, J NEUROCHEM, V75, P1977, DOI 10.1046/j.1471-4159.2000.0751977.x; Matsushima H, 1996, J NEUROCHEM, V67, P317; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; MOREL I, 1993, BIOCHEM PHARMACOL, V45, P13, DOI 10.1016/0006-2952(93)90371-3; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nanjo F, 1996, FREE RADICAL BIO MED, V21, P895, DOI 10.1016/0891-5849(96)00237-7; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Pike CJ, 1997, J NEUROCHEM, V69, P1601; Racchi M, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P679; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Rottkamp CA, 2001, FREE RADICAL BIO MED, V30, P447, DOI 10.1016/S0891-5849(00)00494-9; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter H, 2001, BIOCHEM J, V358, P547, DOI 10.1042/0264-6021:3580547; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SMALL DH, 1994, J NEUROSCI, V14, P2117; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yeon SW, 2001, BIOCHEM BIOPH RES CO, V280, P782, DOI 10.1006/bbrc.2000.4181	67	294	318	0	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					952	+		10.1096/fj.02-0881fje	http://dx.doi.org/10.1096/fj.02-0881fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670874	Bronze			2022-12-25	WOS:000181892600013
J	Zahalka, MA; Barak, V; Traub, L; Moroz, C				Zahalka, MA; Barak, V; Traub, L; Moroz, C			PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway	FASEB JOURNAL			English	Article						immunomodulator; cytokines; fetal-maternal interface	HEAVY-CHAIN FERRITIN; HUMAN MACROPHAGES; HUMAN PLACENTA; CYTOTROPHOBLASTS; INTERLEUKIN-10; EXPRESSION	Recently, we reported the cloning and preliminary characterization of a novel human immunomodulator named PLIF (placenta immunomodulatory ferritin). PLIF has a unique molecular structure, which is composed of a ferritin heavy chain-like domain and a novel cytokine-like domain called C48. Both intact molecule and C48 inhibit T cell proliferation following allogeneic or anti-CD3 stimuli. PLIF is localized at the fetal-maternal interface of human placenta and might play a role in down-modulating the maternal immune reaction toward the embryo. The inhibitory effect of PLIF on T cell activation can be direct, indirect through cytokine mediators, or both. In the present study we investigated the possible indirect effects of PLIF by using its bioactive domain C48. Measurement of various cytokines revealed that C48, predominantly, induce pronounced and rapid IL-10 production in monocytes, which is immune activation-independent. Further, we discovered that C48-induced IL-10 production is mediated through a calcium/calmodulin-p38 mitogen-activated protein (MAP) kinase signaling pathway. However, extracellular signal-related kinases1,2 (ERK1,2), also activated by C48 stimulation, exhibited a limiting effect on IL-10 production.	Tel Aviv Univ, Lab Mol Immunol, Felsenstein Med Res Ctr, Sackler Sch Med,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel; Hadassah Med Ctr, Immunol Oncol Lab, IL-91120 Jerusalem, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center	Moroz, C (corresponding author), Tel Aviv Univ, Lab Mol Immunol, Felsenstein Med Res Ctr, Sackler Sch Med,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel.	hmoroz@post.tau.ac.il						Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; CHAOUAT G, 1995, J IMMUNOL, V154, P4261; DEWAALMALEFYT R, 1991, J EXP MED, V174, P1209; DEWAALMALEFYT R, 1991, J EXP MED, V174, P915; Gray CP, 2002, BLOOD, V99, P3326, DOI 10.1182/blood.V99.9.3326; Gray CP, 2001, INT J CANCER, V92, P843, DOI 10.1002/ijc.1269; Hanna N, 2000, J IMMUNOL, V164, P5721, DOI 10.4049/jimmunol.164.11.5721; Hennessy A, 1999, J IMMUNOL, V163, P3491; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Lee GW, 2001, EUR J IMMUNOL, V31, P687, DOI 10.1002/1521-4141(200103)31:3<687::AID-IMMU687>3.0.CO;2-I; LIN TM, 1974, J CLIN INVEST, V54, P576, DOI 10.1172/JCI107794; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MANDAL M, 1995, AM J REPROD IMMUNOL, V33, P60, DOI 10.1111/j.1600-0897.1995.tb01139.x; Matsuoka T, 2001, J IMMUNOL, V166, P2202, DOI 10.4049/jimmunol.166.4.2202; MATZNER Y, 1979, BRIT J HAEMATOL, V42, P345, DOI 10.1111/j.1365-2141.1979.tb01142.x; Moroz C, 2002, J BIOL CHEM, V277, P12901, DOI 10.1074/jbc.M200956200; Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339; Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539; Wessells J, 2000, EUR J IMMUNOL, V30, P1830, DOI 10.1002/1521-4141(200007)30:7&lt;1830::AID-IMMU1830&gt;3.0.CO;2-M; YASSEL H, 1992, J IMMUNOL, V149, P2378	21	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					955	+		10.1096/fj.02-0960fje	http://dx.doi.org/10.1096/fj.02-0960fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670872				2022-12-25	WOS:000181892600001
J	Park, KM; Byun, JY; Kramers, C; Kim, JI; Huang, PL; Bonventre, JV				Park, KM; Byun, JY; Kramers, C; Kim, JI; Huang, PL; Bonventre, JV			Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-RENAL-FAILURE; INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; HEAT-SHOCK PROTEINS; L-ARGININE; CELL INJURY; URETERAL OBSTRUCTION; REPERFUSION INJURY; CONSCIOUS RABBITS; CARDIAC MYOCYTES	Ischemic preconditioning renders the mouse kidney resistant to subsequent ischemia. Understanding the mechanisms responsible for ischemic preconditioning is important for formulating therapeutic strategies aimed at mimicking protective mechanisms. We report that the resistance afforded by 30 min of bilateral kidney ischemia persists for 12 weeks after preconditioning. The protection is reflected by improved postischemic renal function, reduced leukocyte infiltration, reduced postischemic disruption of the actin cytoskeleton, and reduced postischemic expression of kidney injury molecule-1 (Kim-1). The protection is observed in both BALB/c and C57BL/6J strains of mice. Thirty minutes of prior ischemia increases the expression of inducible nitric-oxide synthase ( iNOS) and endothelial NOS ( eNOS) and the expression of heat shock protein (HSP)-25 and is associated with increased interstitial expression of alpha-smooth muscle actin (alpha-SMA), an indication of long term postischemic sequelae. Treatment with Nomega-nitro-L-arginine (L-NNA), an inhibitor of NO synthesis, increases kidney susceptibility to ischemia. Gene deletion of iNOS increases kidney susceptibility to ischemia, whereas gene deletion of eNOS has no effect. Pharmacological inhibition of NOS by L-NNA or L-N6-(1-iminoethyl) lysine (L-NIL, a specific inhibitor of iNOS) mitigates the kidney protection afforded by 30 min of ischemic preconditioning. Fifteen minutes of prior ischemic preconditioning, which does not result in the disruption of the actin cytoskeleton, impairment of renal function, increased interstitial alpha-SMA, or increased iNOS or eNOS expression, but does increase HSP-25 expression, partially protects the kidney from ischemia on day 8 via a mechanism that is not abolished by L-NIL treatment. Thus, iNOS is responsible for a significant component of the long term protection afforded the kidney by ischemic preconditioning, which results in persistent renal interstitial disease, but does not explain the preconditioning seen with shorter periods of ischemia.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Massachusetts Gen Hosp, Med Serv, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Harvard MIT Div Hlth Sci & Technol, Boston, MA USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT)	Bonventre, JV (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, MRB4,75 Francis St, Boston, MA 02115 USA.	joseph_bonventre@hms.harvard.edu	Kramers, C./L-4458-2015	Huang, Paul/0000-0002-5436-8658	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R01DK039773, R37DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39773, DK 38452] Funding Source: Medline; NINDS NIH HHS [NS 10828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basile DP, 2003, AM J PHYSIOL-RENAL, V284, pF338, DOI 10.1152/ajprenal.00169.2002; Basile DP, 2001, AM J PHYSIOL-RENAL, V281, pF887, DOI 10.1152/ajprenal.0050.2001; Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; Bolli R, 1998, BASIC RES CARDIOL, V93, P325, DOI 10.1007/s003950050101; Bolli R, 2001, J MOL CELL CARDIOL, V33, P1897, DOI 10.1006/jmcc.2001.1462; Bolli R, 1997, CIRC RES, V81, P42, DOI 10.1161/01.RES.81.1.42; BORKAN SC, 1997, AM J PHYSIOL, pF347; Centeno JM, 1999, BRAIN RES, V836, P62, DOI 10.1016/S0006-8993(99)01610-8; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; Fukumoto Y, 1997, CIRCULATION, V96, P3104, DOI 10.1161/01.CIR.96.9.3104; Goligorsky MS, 2002, KIDNEY INT, V61, P855, DOI 10.1046/j.1523-1755.2002.00233.x; HAYES JM, 1970, NEPHRON, V7, P155, DOI 10.1159/000179817; Heinzelmann M, 1999, AM J KIDNEY DIS, V34, P384, DOI 10.1016/S0272-6386(99)70375-6; Hickey MJ, 2001, ACTA PHYSIOL SCAND, V173, P119, DOI 10.1046/j.1365-201X.2001.00892.x; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Jefayri MK, 2000, BJU INT, V85, P1007, DOI 10.1046/j.1464-410x.2000.00678.x; Jerkic M, 1999, NEPHROL DIAL TRANSPL, V14, P1398, DOI 10.1093/ndt/14.6.1398; JOANNIDIS M, 1995, KIDNEY INT, V47, P1752, DOI 10.1038/ki.1995.242; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; KELLERMAN PS, 1992, KIDNEY INT, V42, P896, DOI 10.1038/ki.1992.366; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Kelly KJ, 2001, KIDNEY INT, V59, P1798, DOI 10.1046/j.1523-1755.2001.0590051798.x; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Kuehn EW, 2002, AM J PHYSIOL-RENAL, V283, pF1326, DOI 10.1152/ajprenal.00166.2002; Laroux FS, 2001, ACTA PHYSIOL SCAND, V173, P113, DOI 10.1046/j.1365-201X.2001.00891.x; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lefer AM, 1999, AM J PHYSIOL-GASTR L, V276, pG572, DOI 10.1152/ajpgi.1999.276.3.G572; LIEBERTHAL W, 1998, AM J PHYSIOL, pF623; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; MacNider WD, 1929, J EXP MED, V49, P411, DOI 10.1084/jem.49.3.411; Martin JL, 1997, CIRCULATION, V96, P4343; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474; Noiri E, 1996, J CLIN INVEST, V97, P2377, DOI 10.1172/JCI118681; Ozturk H, 2001, BJU INT, V88, P93, DOI 10.1046/j.1464-410x.2001.02247.x; Park KM, 2002, J BIOL CHEM, V277, P2040, DOI 10.1074/jbc.M107525200; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; POMBO CM, 1994, J BIOL CHEM, V269, P26546; SCHOTT RJ, 1990, CIRC RES, V66, P1133, DOI 10.1161/01.RES.66.4.1133; Schramm L, 2002, KIDNEY INT, V61, P1423, DOI 10.1046/j.1523-1755.2002.00268.x; Schwartz N, 1999, AM J PHYSIOL-RENAL, V276, pF544, DOI 10.1152/ajprenal.1999.276.4.F544; Sheridan AM, 2001, CONTRIB NEPHROL, V132, P7; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shoskes DA, 1997, TRANSPLANTATION, V63, P495, DOI 10.1097/00007890-199702270-00002; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; Takano H, 1998, CIRCULATION, V98, P441, DOI 10.1161/01.CIR.98.5.441; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Tokuno S, 2002, LIFE SCI, V71, P679, DOI 10.1016/S0024-3205(02)01711-3; Vos IHC, 2001, J AM SOC NEPHROL, V12, P361, DOI 10.1681/ASN.V122361; Wang Y, 2002, J MOL CELL CARDIOL, V34, P5, DOI 10.1006/jmcc.2001.1482; Yang JW, 2003, AM J PHYSIOL-RENAL, V284, pF349, DOI 10.1152/ajprenal.00154.2002; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; ZAGER RA, 1994, KIDNEY INT, V45, P1760, DOI 10.1038/ki.1994.229; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	55	162	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27256	27266		10.1074/jbc.M301778200	http://dx.doi.org/10.1074/jbc.M301778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12682064	hybrid, Green Published			2022-12-25	WOS:000184155700122
J	Chen, Y; Wu, J; Ghosh, G				Chen, Y; Wu, J; Ghosh, G			kappa B-Ras binds to the unique insert within the ankyrin repeat domain of I kappa B beta and regulates cytoplasmic retention of I kappa B beta center dot NF-kappa B complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; PERSISTENT ACTIVATION; IMMUNE-RESPONSES; REL PROTEINS; DNA-BINDING; PEST DOMAIN; GLIAL-CELLS; ALPHA; EXPRESSION; LOCALIZATION	The IkappaBalpha and IkappaBbeta proteins inhibit the transcriptional potential of active NF-kappaB dimers through stable complex formation. It has been shown that inactive IkappaBalpha.NF-kappaB complexes shuttle in and out of the nucleus, whereas IkappaBbeta.NF-kappaB complexes are retained exclusively in the cytoplasm of resting cells. The biochemical mechanism underlying this functional difference and its consequences are unknown. Although the two IkappaB proteins are significantly homologous, IkappaBbeta contains a unique 47-amino acid insertion of unknown function within its ankyrin repeat domain. In this study, we assess the role of the IkappaBalpha insert in regulating cytoplasmic retention of IkappaBbeta.NF-kappaB complexes. Deletion of the IkappaBalpha insert renders IkappaBalpha.NF-kappaB complexes capable of shuttling between the nucleus and cytoplasm, similar to IkappaBalpha.NF-kappaB complexes. A small Ras-like G-protein, kappaB-Ras, participates with the IkappaBbeta insert to effectively mask the NF-kappaB nuclear localization potential. Similarly, a complex between NF-kappaB and a mutant IkappaBbeta protein containing four serine to alanine mutations within its C-terminal proline, glutamic acid, serine, and threonine-rich sequence exhibits nucleocytoplasmic shuttling. This suggests a phosphorylation state-dependent role for the C-terminal proline, glutamic acid, serine, and threonine-rich sequence of IkappaBbeta in proper localization of IkappaBbeta.NF-kappaB complexes. These results are consistent with structural studies, which predicted that binary IkappaBbeta.NF-kappaB complexes should be capable of nuclear translocation, and with previous observations that hypophosphorylated IkappaBbeta.NF-kappaB complexes can reside in the nucleus.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,MS 0359, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA078749] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bitko V, 1998, J VIROL, V72, P5610, DOI 10.1128/JVI.72.7.5610-5618.1998; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Malek S, 2003, J BIOL CHEM, V278, P23094, DOI 10.1074/jbc.M301022200; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Palmer GH, 1997, P NATL ACAD SCI USA, V94, P12527, DOI 10.1073/pnas.94.23.12527; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Stasiolek M, 2000, J BIOL CHEM, V275, P24847, DOI 10.1074/jbc.M910284199; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Venkatakrishnan A, 2000, AM J RESP CELL MOL, V23, P396, DOI 10.1165/ajrcmb.23.3.3949; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weil R, 1997, IMMUNOBIOLOGY, V198, P14, DOI 10.1016/S0171-2985(97)80023-X; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	43	23	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23101	23106		10.1074/jbc.M301021200	http://dx.doi.org/10.1074/jbc.M301021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672800	hybrid			2022-12-25	WOS:000183503900118
J	Anderluh, G; Hong, Q; Boetzel, R; MacDonald, C; Moore, GR; Virden, R; Lakey, JH				Anderluh, G; Hong, Q; Boetzel, R; MacDonald, C; Moore, GR; Virden, R; Lakey, JH			Concerted folding and binding of a flexible colicin domain to its periplasmic receptor TolA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; TRANSFER DISTANCE MEASUREMENTS; C-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MEMBRANE INSERTION; CROSS-RESISTANCE; PROTEIN; DIFFUSION; RECOGNITION	Compared with folded structures, natively unfolded protein domains are over- represented in protein-protein and protein-DNA interactions. Such domains are common features of all colicins and are required for their translocation across the outer membrane of the target Escherichia coli cell. All of these domains bind to at least one periplasmic protein of the Tol or Ton family. Similar domains are found in Ton-dependent outer membrane transporters, indicating they may interact in a related manner. In this article we have studied binding of the colicin N translocation domain to its periplasmic receptor TolA, by fluorescence resonance energy transfer ( FRET) using fluorescent probes attached to engineered cysteine residues and NMR techniques. The domain exhibits a random coil circular dichroism spectrum. However, FRET revealed that guanidinium hydrochloride denaturation caused increases in all measured intramolecular distances showing that, although natively unfolded, the domain is not extended. Furthermore NMR reported a compact hydrodynamic radius of 18 Angstrom. Nevertheless the FRET-derived distances changed upon binding to TolA indicating a significant structural rearrangement. Using H-1-N-15 NMR we show that, when bound, the peptide switches from a disordered state to an ordered state. The kinetics of binding and the associated structural change were measured by stopped-flow methods, and both events appear to occur simultaneously. The data therefore suggest that this molecular recognition involves the concerted binding and folding of a flexible but collapsed state.	Newcastle Univ, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana 1000, Slovenia; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	Newcastle University - UK; University of Ljubljana; University of East Anglia	Lakey, JH (corresponding author), Newcastle Univ, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.h.l@ncl.ac.uk	Anderluh, Gregor/C-6905-2014	Anderluh, Gregor/0000-0002-9916-8465				Anderluh G, 2003, PROTEIN EXPRES PURIF, V28, P173, DOI 10.1016/S1046-5928(02)00681-2; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; Click EM, 1998, J BACTERIOL, V180, P1723, DOI 10.1128/JB.180.7.1723-1728.1998; COLLINS ES, 2002, J MOL BIOL, V122, P145; Cooper A, 2001, BIOPHYS CHEM, V93, P215, DOI 10.1016/S0301-4622(01)00222-8; DAVIES JK, 1975, J BACTERIOL, V123, P102, DOI 10.1128/JB.123.1.102-117.1975; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deprez C, 2002, BIOCHEMISTRY-US, V41, P2589, DOI 10.1021/bi0157262; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Eisenhawer M, 2001, BIOCHEMISTRY-US, V40, P12321, DOI 10.1021/bi0107694; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; Gokce I, 2000, J MOL BIOL, V304, P621, DOI 10.1006/jmbi.2000.4232; Guilbault G. G., 1990, PRACTICAL FLUORESCEN; Holliger P, 1999, J MOL BIOL, V288, P649, DOI 10.1006/jmbi.1999.2720; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LEVENGOODFREYERMUTH SK, 1993, J BACTERIOL, V175, P222, DOI 10.1128/JB.175.1.222-228.1993; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Lundback T, 2000, BIOCHEMISTRY-US, V39, P7570, DOI 10.1021/bi000377h; MARRIOTT G, 1990, BIOCHEMISTRY-US, V29, P7004, DOI 10.1021/bi00482a008; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; Navon A, 2001, BIOCHEMISTRY-US, V40, P105, DOI 10.1021/bi001946o; PUGSLEY AP, 1987, MOL MICROBIOL, V1, P317, DOI 10.1111/j.1365-2958.1987.tb01938.x; Raggett EM, 1998, MOL MICROBIOL, V28, P1335, DOI 10.1046/j.1365-2958.1998.00899.x; RAGGETT EM, 1997, PROTEIN SCI, V6, P63; Schendel SL, 1997, J BACTERIOL, V179, P3683, DOI 10.1128/jb.179.11.3683-3690.1997; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vakharia HL, 2002, J BACTERIOL, V184, P5508, DOI 10.1128/JB.184.19.5508-5512.2002; VANDERMEER BW, 1991, RESONANCE ENERGY TRA; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; WAHL P, 1975, BIOCHEMICAL FLUORESC, V1, P1; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417	48	27	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21860	21868		10.1074/jbc.M300411200	http://dx.doi.org/10.1074/jbc.M300411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12679333	hybrid			2022-12-25	WOS:000183354200070
J	Vos, MD; Martinez, A; Ellis, CA; Vallecorsa, T; Clark, GJ				Vos, MD; Martinez, A; Ellis, CA; Vallecorsa, T; Clark, GJ			The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT BINDING DOMAINS; EPIGENETIC INACTIVATION; CELL-GROWTH; K-RAS; PROTEIN; EXPRESSION; RASSF1A; DIFFERENTIATION; TRANSFORMATION; METHYLATION	Ras oncoproteins mediate multiple biological effects by activating multiple effectors. Classically, Ras activation has been associated with enhanced cellular growth and transformation. However, activated forms of Ras may also inhibit growth by inducing senescence, apoptosis, and differentiation. Induction of apoptosis by Ras may be mediated by its effector RASSF1, which appears to function as a tumor suppressor. We now show that the Ras effector Nore1, which is structurally related to RASSF1, can also mediate a Ras-dependent apoptosis. Moreover, an analysis of Nore1 protein expression showed that it is frequently down-regulated in lung tumor cell lines and primary lung tumors. Like RASSF1, this correlates with methylation of the Nore1 promoter rather than gene deletion. Finally, re- introduction of Nore1, driven by its own promoter, impairs the growth in soft agar of a human lung tumor cell line. Consequently, we propose that the Ras effector Nore1 is a member of a family of Ras effector/tumor suppressors that includes RASSF1.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr, Rockville, MD 20850 USA.		Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010359, Z01SC010279] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1992, CANCER BIOL, V3, P199; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHEN CY, 1995, ONCOGENE, V11, P1487; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; FANTON CP, 2001, J BIOL CHEM; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HUBER BE, 1988, ONCOGENE, V3, P245; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MORGENSTERN J, 1990, NUCLEIC ACIDS RES, V25, P3587; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Steiner G, 1996, CANCER RES, V56, P5044; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VANROY FM, 1986, CANCER RES, V46, P4787; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	45	96	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21938	21943		10.1074/jbc.M211019200	http://dx.doi.org/10.1074/jbc.M211019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676952	hybrid			2022-12-25	WOS:000183354200079
J	Mikule, K; Sunpaweravong, S; Gatlin, JC; Pfenninger, KH				Mikule, K; Sunpaweravong, S; Gatlin, JC; Pfenninger, KH			Eicosanoid activation of protein kinase C epsilon - Involvement in growth cone repellent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT-BRAIN; HUMAN NEUROBLASTOMA-CELLS; ARACHIDONIC-ACID; NERVE GROWTH; PHOSPHOLIPASE A(2); NEURITE OUTGROWTH; MARCKS FAMILY; PKC-EPSILON; FATTY-ACIDS; PC12 CELLS	Exposure of growing neurons to thrombin or semaphorin 3A stimulates a receptor-mediated signaling cascade that results in collapse of their growth cones. This collapse response necessitates eicosanoid production, as we have shown earlier. The present report investigates whether and which protein kinase C (PKC) isoforms may be activated by such eicosanoids. To examine these questions, we isolated growth cones from fetal rat brain and tested whether thrombin or the eicosanoid, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), could activate endogenous growth cone PKC. We show that both thrombin and 12(S)-HETE stimulate the phosphorylation of the myristoylated alanine-rich protein kinase C substrate, an 87-kDa adhesion site protein. Furthermore, we show both with immunoprecipitated and with recombinant PKC that 12(S)-HETE activation is selective for the epsilon isoform and does not require accessory proteins. Last, we demonstrate that PKC activation is necessary for thrombin-induced growth cone collapse. These data indicate that eicosanoid-mediated repellent effects result from the direct and selective activation of PKCepsilon and suggest the involvement of myristoylated alanine-rich protein kinase C substrate phosphorylation in growth cone collapse.	Univ Colorado, Sch Med, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Pfenninger, KH (corresponding author), Univ Colorado, Sch Med, Dept Cellular & Struct Biol, 4200 E 9th Ave, Denver, CO 80262 USA.				NINDS NIH HHS [5F31 NS44705, 1R01 NS41029] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS044705, R01NS041029] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; Bell R M, 1986, Methods Enzymol, V124, P353; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bonsall J, 1999, BRAIN RES, V839, P120, DOI 10.1016/S0006-8993(99)01725-4; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37; CAMPENOT RB, 1994, J NEUROCHEM, V63, P868; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chen W, 1999, AM J PHYSIOL-HEART C, V276, pH2094, DOI 10.1152/ajpheart.1999.276.6.H2094; Cheng S, 2000, CELL MOTIL CYTOSKEL, V47, P337, DOI 10.1002/1097-0169(200012)47:4<337::AID-CM7>3.3.CO;2-2; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; Clark GD, 2000, NEUROCHEM RES, V25, P603, DOI 10.1023/A:1007598617374; de la Houssaye BA, 1999, J NEUROSCI, V19, P10843, DOI 10.1523/JNEUROSCI.19-24-10843.1999; Disatnik MH, 2002, J CELL SCI, V115, P2151; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; FIELDS RD, 1993, J NEUROBIOL, V24, P1080, DOI 10.1002/neu.480240807; Fu WM, 1997, NEUROREPORT, V8, P2005, DOI 10.1097/00001756-199705260-00041; Gomez TM, 2000, J NEUROBIOL, V44, P174, DOI 10.1002/1097-4695(200008)44:2<174::AID-NEU7>3.3.CO;2-I; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Helmke S, 1998, J CELL SCI, V111, P2465; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Isbister CM, 2000, J NEUROBIOL, V44, P271, DOI 10.1002/1097-4695(200008)44:2<271::AID-NEU15>3.3.CO;2-1; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; IVINS JK, 1991, J NEUROSCI, V11, P1597; Kabir N, 2001, J CELL BIOL, V152, P1033, DOI 10.1083/jcb.152.5.1033; KATZ F, 1985, J NEUROSCI, V5, P1402; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Kitano T, 1986, Methods Enzymol, V124, P349; LI HN, 1992, J NEUROSCI, V12, P2393; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lohse K, 1996, DEV BRAIN RES, V96, P83, DOI 10.1016/0165-3806(96)00076-4; LOPEZRUIZ MP, 1992, ENDOCRINOLOGY, V130, P1122, DOI 10.1210/en.130.3.1122; Loschinger J, 1997, J NEUROBIOL, V33, P825, DOI 10.1002/(SICI)1097-4695(19971120)33:6<825::AID-NEU9>3.0.CO;2-B; Mackay K, 2001, CARDIOVASC RES, V50, P65, DOI 10.1016/S0008-6363(00)00322-9; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; MOORMAN SJ, 1993, J NEUROSCI, V13, P4727; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; Nakayama T, 1999, J NEUROBIOL, V41, P326, DOI 10.1002/(SICI)1097-4695(19991115)41:3<326::AID-NEU2>3.0.CO;2-W; NATARAJAN R, 1994, MOL CELL ENDOCRINOL, V101, P59, DOI 10.1016/0303-7207(94)90219-4; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1992, J BIOL CHEM, V267, P15263; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; PFENNINGER KH, 1981, J CELL BIOL, V89, P536, DOI 10.1083/jcb.89.3.536; PFENNINGER KH, 1991, MOL NEUROBIOL, V5, P143, DOI 10.1007/BF02935543; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Renaudin A, 1999, J NEUROSCI RES, V55, P458, DOI 10.1002/(SICI)1097-4547(19990215)55:4<458::AID-JNR6>3.0.CO;2-D; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Rosner H, 1999, EUR J CELL BIOL, V78, P698; Ross S, 2000, CELL GROWTH DIFFER, V11, P19; SCHAECHTER JD, 1993, J NEUROSCI, V13, P4361; Schwartz Z, 1999, ENDOCRINOLOGY, V140, P2991, DOI 10.1210/en.140.7.2991; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Shibata K, 2000, PROSTAG OTH LIPID M, V62, P385, DOI 10.1016/S0090-6980(00)00090-3; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Suter DM, 2000, J NEUROBIOL, V42, P370, DOI 10.1002/(SICI)1097-4695(20000215)42:3<370::AID-NEU8>3.3.CO;2-M; Suter DM, 1998, J CELL BIOL, V141, P227, DOI 10.1083/jcb.141.1.227; Szekeres CK, 2000, J BIOL CHEM, V275, P38831, DOI 10.1074/jbc.M002673200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THEODORE L, 1995, J NEUROSCI, V15, P7158; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Ueki S, 1999, J CELL PHYSIOL, V178, P63, DOI 10.1002/(SICI)1097-4652(199901)178:1<63::AID-JCP8>3.0.CO;2-J; Wen Y, 2000, BIOCHEM J, V349, P481, DOI 10.1042/0264-6021:3490481; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501	78	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21168	21177		10.1074/jbc.M211828200	http://dx.doi.org/10.1074/jbc.M211828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665507	hybrid			2022-12-25	WOS:000183230500094
J	Paterson, AD; Parton, RG; Ferguson, C; Stow, JL; Yap, AS				Paterson, AD; Parton, RG; Ferguson, C; Stow, JL; Yap, AS			Characterization of E-cadherin endocytosis in isolated MCF-7 and Chinese hamster ovary cells - The initial fate of unbound E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; ADHERENS JUNCTIONS; ADHESION MOLECULES; MEMBRANE DOMAINS; ENDOSOMES; INHIBITION; RAC1; ARF6; RAB5; LOCALIZATION	The endocytosis of E-cadherin has recently emerged as an important determinant of cadherin function with the potential to participate in remodeling adhesive contacts. In this study we focused on the initial fate of E-cadherin when it predominantly exists free on the cell surface prior to adhesive binding or incorporation into junctions. Surface-labeling techniques were used to define the endocytic itinerary of E-cadherin in MCF-7 cells and in Chinese hamster ovary cells stably expressing human E-cadherin. We found that in this experimental system E-cadherin entered a transferrin-negative compartment before transport to the early endosomal compartment, where it merged with classical clathrin-mediated uptake pathways. E-cadherin endocytosis was inhibited by mutant dynamin, but not by an Eps15 mutant that effectively blocked transferrin internalization. Furthermore, sustained signaling by the ARF6 GTPase appeared to trap endocytosed E-cadherin in large peripheral structures. We conclude that in isolated cells unbound E-cadherin on the cell surface is predominantly endocytosed by a clathrin-independent pathway resembling macropinocytotic internalization, which then fuses with the early endosomal system. Taken with earlier reports, this suggests the possibility that multiple pathways exist for E-cadherin entry into cells that are likely to reflect cell context and regulation.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Mircoanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	a.yap@mailbox.uq.edu.au	Stow, Jennifer L/I-4723-2013; Yap, Alpha S./J-1554-2014; Parton, Robert G/C-5673-2009	Stow, Jennifer L/0000-0002-5409-9101; Yap, Alpha S./0000-0002-1038-8956; Parton, Robert G/0000-0002-7494-5248				Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Benmerah A, 1999, J CELL SCI, V112, P1303; BRIEHER WM, 1994, J CELL BIOL, V126, P519, DOI 10.1083/jcb.126.2.519; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Jarrett O, 2002, INT J DEV BIOL, V46, P467; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774	51	153	156	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21050	21057		10.1074/jbc.M300082200	http://dx.doi.org/10.1074/jbc.M300082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657640	hybrid			2022-12-25	WOS:000183230500079
J	Sah, NK; Munshi, A; Kurland, JF; McDonnell, TJ; Su, B; Meyn, RE				Sah, NK; Munshi, A; Kurland, JF; McDonnell, TJ; Su, B; Meyn, RE			Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; JNK; INDUCTION; RECEPTOR; DEATH; PATHWAY; SURVIVAL; MEMBER	Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) induces apoptosis in several human tumors both in vitro and in vivo, however, some tumors remain resistant for poorly understood reasons. Using a quantitative DNA fragmentation assay for apoptosis, we have shown that human prostate cancer cells are resistant to a wide range of TRAIL doses up to 500 ng/ml. However, translation inhibitors, such as anisomycin, cycloheximide, emetine, harringtonine, and puromycin, unlike several transcription inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis. These effects were inhibited in PC3 cells engineered to express bcl2 (PC3-bcl2). Translation inhibitors led to activation of c-JunN-terminal kinase (JNK), which plays a role in this sensitization process because inhibition of JNK activation resulted in protection against TRAIL plus translation inhibitor-induced apoptosis. JNK activation may be required for this process, but it is not sufficient because activation of JNK using an MEKK2 expression vector did not mimic the sensitizing effect of translation inhibitors. Other stress-activated protein kinases, such as ERK and p38, play an insignificant role in determining the apoptotic sensitivity. We conclude that activation of JNK is required for sensitization of PC3 cells to TRAIL-induced apoptosis by translation inhibitors in cells that are otherwise TRAIL-resistant. However, in addition to JNK activation, other aspects of translation inhibition such as the suppressed activity of apoptosis-inhibitory proteins or activation of other signal transduction pathways must also be involved.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rmeyn@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA069003] Funding Source: NIH RePORTER; NCI NIH HHS [CA69003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Eggert A, 2001, CANCER RES, V61, P1314; Eid MA, 2002, INT J ONCOL, V21, P111; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jobin C, 1999, J IMMUNOL, V163, P3474; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V234, P681, DOI 10.1006/bbrc.1997.6699; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shifrin VI, 1999, J BIOL CHEM, V274, P13985, DOI 10.1074/jbc.274.20.13985; Sidhu JS, 1998, J BIOL CHEM, V273, P4769, DOI 10.1074/jbc.273.8.4769; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; SUSIN CA, 1999, NAT STRUCT BIOL, V9, P442; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thomas RP, 2002, SURGERY, V132, P127, DOI 10.1067/msy.2002.124930; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Watanabe N, 2002, ARCH BIOCHEM BIOPHYS, V405, P231, DOI 10.1016/S0003-9861(02)00399-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang XD, 1999, CANCER RES, V59, P2747	60	57	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20593	20602		10.1074/jbc.M211010200	http://dx.doi.org/10.1074/jbc.M211010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663665	hybrid			2022-12-25	WOS:000183230500020
J	Sowa, H; Kaji, H; Canaff, L; Hendy, GN; Tsukamoto, T; Yamaguchi, T; Miyazono, K; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Canaff, L; Hendy, GN; Tsukamoto, T; Yamaguchi, T; Miyazono, K; Sugimoto, T; Chihara, K			Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; DIFFERENTIATION; EXPRESSION; CBFA1; TRANSCRIPTION; C3H10T1/2; INTERACTS; GROWTH; BMP-2; OVEREXPRESSION	The physiological roles of menin, the product of the multiple endocrine neoplasia type 1 gene, are not known. Homozygous menin knockout mice exhibit cranial and facial hypoplasia. We, therefore, investigated the role of menin in the regulation of osteoblastic differentiation. Menin antisense oligonucleotides (AS-oligo) reduced endogenous menin expression in the C3H10T1/2 (10T1/2) mouse mesenchymal stem cells and antagonized alkaline phosphatase ( ALP) activity and the expression of type I collagen, Runx2/cbfa1 (Runx2), and osteocalcin (OCN) induced by bone morphogenetic protein 2 (BMP-2). AS-oligo did not affect adipogenic markers ( Oil red staining and PPARgamma expression) and chondrogenic markers ( Alcian blue staining and type IX collagen) induced by BMP-2 in 10T1/2 cells. Menin co-immunoprecipitated with Smad1 and Smad5, and inactivation of menin antagonized BMP-2-induced transcriptional activity of Smad1/5. In osteoblastic MC3T3-E1 cells, AS-oligo affected neither BMP-2-stimulated ALP activity nor the expression of Runx2 and OCN. Stable inactivation of menin in MC3T3-E1 cells increased ALP activity, mineralization, and the expression of type I collagen and OCN. In 21-day cultures of MC3T3-E1 cells and BMP-2-treated 10T1/2 cells, endogenous menin expression increased up to day 14 and declined thereafter. These data indicate that menin inactivation specifically inhibits the commitment of pluripotent mesenchymal stem cells to the osteoblast lineage, mediated by menin and Smad1/5 interactions. Menin is important for both early differentiation of osteoblasts and inhibition of their later differentiation, and it might be crucial for intramembranous ossification.	Kobe Univ, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Japanese Fdn Canc Res, Dept Biochem, Inst Canc, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	Kobe University; McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital; Japanese Foundation for Cancer Research; University of Tokyo	Sugimoto, T (corresponding author), Kobe Univ, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med, Grad Sch Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	sugimot@med.kobe-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200; Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Fang JM, 1997, ANAT EMBRYOL, V196, P349, DOI 10.1007/s004290050104; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HARRIS SE, 1994, J BONE MINER RES, V9, P389; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; LOWRY OH, 1954, ANAL BIOCHEM, V17, P19; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186	58	76	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21058	21069		10.1074/jbc.M302044200	http://dx.doi.org/10.1074/jbc.M302044200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649288	hybrid			2022-12-25	WOS:000183230500080
J	Chiang, PW; Oiso, N; Gautam, R; Suzuki, T; Swank, RT; Spritz, RA				Chiang, PW; Oiso, N; Gautam, R; Suzuki, T; Swank, RT; Spritz, RA			The Hermansky-Pudlak Syndrome 1 (HPS1) and HPS4 proteins are components of two complexes, BLOC-3 and BLOC-4, involved in the biogenesis of lysosome-related organelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALE EAR EP; MUTATION; MELANOSOMES; HOMOLOG; CELLS; GENE; MELANOCYTES; DISORDERS; TRANSPORT; MELANOMA	Hermansky-Pudlak syndrome (HPS) is a genetic disease of lysosome, melanosome, and granule biogenesis. Mutations of six different loci have been associated with HPS in humans, the most frequent of which are mutations of the HPS1 and HPS4 genes. Here, we show that the HPS1 and HPS4 proteins are components of two novel protein complexes involved in biogenesis of melanosome and lysosome-related organelles: biogenesis of lysosome-related organelles complex-(BLOC) 3 and BLOC-4. The phenotypes of Hps1-mutant (pale-ear; ep) and Hps4-mutant (light-ear; le) mice and humans are very similar, and cells from ep and le mice exhibit similar abnormalities of melanosome morphology. HPS1 protein is absent from ep-mutant cells, and HPS4 from le-mutant cells, but le-mutant cells also lack HPS1 protein. HPS4 protein seems to be necessary for stabilization of HPS1, and the HPS1 and HPS4 proteins co-immunoprecipitate, indicating that they are in a complex. HPS1 and HPS4 do not interact directly in a yeast two-hybrid system, although HPS4 interacts with itself. In a partially purified vesicular/organellar fraction, HPS1 and HPS4 are both components of a complex with a molecular mass of similar to500 kDa, termed BLOC-3. Within BLOC-3, HPS1 and HPS4 are components of a discrete similar to200-kDa module termed BLOC-4. In the cytosol, HPS1 ( but not HPS4) is part of yet another complex, termed BLOC-5. We propose that the BLOC-3 and BLOC-4 HPS1 . HPS4 complexes play a central role in trafficking cargo proteins to newly formed cytoplasmic organelles.	Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roswell Park Cancer Institute	Spritz, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, 4200 E 9th Ave,Box B161, Denver, CO 80262 USA.		Oiso, Naoki/H-6540-2019	Oiso, Naoki/0000-0001-5593-6496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031698, R01HL051480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER; NCI NIH HHS [CA16506] Funding Source: Medline; NEI NIH HHS [EY12104] Funding Source: Medline; NHLBI NIH HHS [HL31698, HL51480] Funding Source: Medline; NIAMS NIH HHS [AR39892] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CICIOTTE SL, 2003, IN PRESS BLOOD; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; LANE PW, 1967, J HERED, V58, P17, DOI 10.1093/oxfordjournals.jhered.a107529; LANE PW, 1967, J HERED, V58, P21, DOI 10.1093/oxfordjournals.jhered.a107531; MEISLER M, 1980, AM J PATHOL, V101, P581; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; PIANTELLI M, 1995, J INVEST DERMATOL, V105, P248, DOI 10.1111/1523-1747.ep12317599; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Starcevic M, 2002, SEMIN CELL DEV BIOL, V13, P271, DOI 10.1016/S1084952102000563; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087	30	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20332	20337		10.1074/jbc.M300090200	http://dx.doi.org/10.1074/jbc.M300090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12663659	hybrid			2022-12-25	WOS:000183078000097
J	Gonzalez-Sapienza, G; Cachau, RE				Gonzalez-Sapienza, G; Cachau, RE			Identification of critical residues of an immunodominant region of Echinococcus granulosus antigen B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES; PHAGE	Immune evasion strategies often shape the immunogenicity of parasite components. We recently found that the N-terminal extension of the major subunit of Echinococcus granulosus antigen B (AgB), the causative agent of hydatid disease, concentrates the immunoreactive B cell epitopes of the native molecule. The nature of this immunodominance was analyzed using four monoclonal antibodies (mAbs) defining overlapping epitopes in this region of the AgB molecule. The minimal epitope requirements of these mAbs were determined using phage display peptide libraries. The consensus sequences isolated with the mAbs, and alanine replacement analysis with synthetic peptides mapped the relevant molecular contacts within a short stretch corresponding to residues 17-24 of the AgB major subunit. Substitution of two critical residues within this stretch produced a dramatic loss of antigenicity, as determined by using patient sera. The circular dichroism spectra of the antigen, together with the distribution of the contact residues, suggest that this region adopts an amphipathic alpha-helix structure that clusters the contact residues on its polar side. To provide further insight in the interpretation of the structure activity relationships for this immunoreactive region of E. granulosus AgB, we developed a model for the N-terminal extension of the AgB major subunit, which helps to rationalize our data.	Univ Republica, Fac Quim, Catedra Inmunol, Inst Higiene, Montevideo 11600, Uruguay; NCI, Adv Biomed Comp Ctr, NIH, Sci Applicat Int Corp, Frederick, MD 21702 USA	Universidad de la Republica, Uruguay; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Gonzalez-Sapienza, G (corresponding author), Univ Republica, Fac Quim, Catedra Inmunol, Inst Higiene, Av A Navarro 3051, Montevideo 11600, Uruguay.	ggonzal@fg.edu.uy		Gonzalez-Sapienza, Gualberto/0000-0003-1824-0611	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbieri M, 1998, PARASITE IMMUNOL, V20, P51, DOI 10.1046/j.1365-3024.1998.00117.x; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BRUNGER A, 1993, X PLOR VERSION 3 1 M; CACHAU RE, 1996, ADV COMPUTATIONAL BI, V2, P66; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; Chemale G, 2001, MOL BIOCHEM PARASIT, V116, P233, DOI 10.1016/S0166-6851(01)00316-4; Cwirla SE, 1999, METH MOL B, V128, P131; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Gonzalez G, 1996, PARASITE IMMUNOL, V18, P587, DOI 10.1046/j.1365-3024.1996.d01-38.x; Gonzalez-Sapienza G, 2000, J CLIN MICROBIOL, V38, P3979; JANIN J, 1990, J BIOL CHEM, V265, P16027; Lazaridis T, 1996, J CHEM PHYS, V105, P4294, DOI 10.1063/1.472247; LEGGATT GR, 1994, PARASITE IMMUNOL, V16, P87, DOI 10.1111/j.1365-3024.1994.tb00327.x; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; ORIOL C, 1975, AM J TROP MED HYG, V24, P96, DOI 10.4269/ajtmh.1975.24.96; Rigano R, 2001, INFECT IMMUN, V69, P288, DOI 10.1128/IAI.69.1.288-296.2001; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SHEPHERD JC, 1991, MOL BIOCHEM PARASIT, V44, P81, DOI 10.1016/0166-6851(91)90223-S; Starovasnik MA, 1996, BIOCHEMISTRY-US, V35, P15558, DOI 10.1021/bi961409x	22	33	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20179	20184		10.1074/jbc.M212724200	http://dx.doi.org/10.1074/jbc.M212724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660242	hybrid			2022-12-25	WOS:000183078000077
J	Valdes, VJ; Sampieri, A; Sepulveda, J; Vaca, L				Valdes, VJ; Sampieri, A; Sepulveda, J; Vaca, L			Using double-stranded RNA to prevent in vitro and in vivo viral infections by recombinant baculovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ENVELOPE FUSION PROTEIN; GENE-FUNCTION; INTERFERENCE; GP64; CELLS; MICE	Introduction of double-stranded RNA (dsRNA) into a wide variety of cells and organisms results in post-transcriptional depletion of the homologue endogenous mRNA. This well-preserved phenomenon known as RNA interference (RNAi) is present in evolutionarily diverse organisms such as plants, fungi, insects, metazoans, and mammals. Because the identification of the targeted mRNA by the RNAi machinery depends upon Watson-Crick base-pairing interactions, RNAi can be exquisitely specific. We took advantage of this powerful and flexible technique to demonstrate that selective silencing of genes essential for viral propagation prevents in vitro and in vivo viral infection. Using the baculovirus Autographa californica, a rapidly replicating and highly cytolytic double-stranded DNA virus that infects many different insect species, we show for the first time that introduction of dsRNA from gp64 and ie1, two genes essential for baculovirus propagation, results in prevention of viral infection in vitro and in vivo. This is the first report demonstrating the use of RNAi to inhibit a viral infection in animals. This inhibition was specific, because dsRNA from the polyhedrin promoter (used as control) or unrelated dsRNAs did not affect the time course of viral infection. The most relevant consequences from the present study are: 1) RNAi offers a rapid and efficient way to interfere with viral genes to assess the role of specific proteins in viral function and 2) using RNAi to interfere with viral genes essential for cell infection may provide a powerful therapeutic tool for the treatment of viral infections.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Vaca, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico.		Sampieri, Alicia/L-3896-2019; Valdes, Julian/C-1840-2017	Valdes, Julian/0000-0001-6157-1358; Vaca, Luis/0000-0003-2266-4847				Dernburg AF, 2002, CELL, V111, P159, DOI 10.1016/S0092-8674(02)01039-5; Finnegan EJ, 2001, CURR BIOL, V11, pR99, DOI 10.1016/S0960-9822(01)00039-2; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; HUH NE, 1990, J GEN VIROL, V71, P195, DOI 10.1099/0022-1317-71-1-195; Jackson J A, 1991, Bioprocess Technol, V13, P402; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; KOVACS GR, 1991, J VIROL, V65, P5281, DOI 10.1128/JVI.65.10.5281-5288.1991; Kuwabara PE, 2000, PARASITOL TODAY, V16, P347, DOI 10.1016/S0169-4758(00)01677-X; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Molinari JL, 1998, PARASITOL RES, V84, P173, DOI 10.1007/s004360050379; Monsma SA, 1996, J VIROL, V70, P4607, DOI 10.1128/JVI.70.7.4607-4616.1996; Oomens AGP, 1999, VIROLOGY, V254, P297, DOI 10.1006/viro.1998.9523; OOMENS AGP, 1995, VIROLOGY, V209, P592, DOI 10.1006/viro.1995.1291; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; Reyes-Cruz G, 2000, J CELL BIOCHEM, V76, P658, DOI 10.1002/(SICI)1097-4644(20000315)76:4<658::AID-JCB14>3.3.CO;2-Z; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Ueda R, 2001, J NEUROGENET, V15, P193, DOI 10.3109/01677060109167376; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168	21	44	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19317	19324		10.1074/jbc.M212039200	http://dx.doi.org/10.1074/jbc.M212039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646552	hybrid			2022-12-25	WOS:000182932200078
J	Wu, SC; Castellino, FJ; Wong, SL				Wu, SC; Castellino, FJ; Wong, SL			A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; LIGAND-BINDING; BACILLUS-SUBTILIS; SECRETION SYSTEM; PLASMA CLOTS; AMINO-ACIDS; ACTIVATOR; EXPRESSION; VARIANTS; FRAGMENT	To develop a fast-acting clot dissolving agent, a clot-targeting domain derived from the Kringle-1 domain in human plasminogen was fused to the C-terminal end of staphylokinase with a linker sequence in between. Production of this fusion protein in Bacillus subtilis and Pichia pastoris was examined. The Kringle domain in the fusion protein produced from B. subtilis was improperly folded because of its complicated disulfide-bond profile, whereas the staphylokinase domain produced from P. pastoris was only partially active because of an N-linked glycosylation. A change of the glycosylation residue, Thr-30, to alanine resulted in a non-glycosylated biologically active fusion. The resulting mutein, designated SAKM3-L-K1, was overproduced in P. pastoris. Each domain in SAKM3-L-K1 was functional, and this fusion showed fibrin binding ability by binding directly to plasmin-digested clots. In vitro fibrin clot lysis in a static environment and plasma clot lysis in a flow-cell system demonstrated that the engineered fusion outperformed the non-fused staphylokinase. The time required for 50% clot lysis was reduced by 20 to 500% under different conditions. Faster clot lysis can potentially reduce the degree of damage to occluded heart tissues.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA	University of Calgary; University of Notre Dame; University of Notre Dame	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	slwong@ucalgary.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013423, R01HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Braunwald E, 2000, EUR HEART J, V21, P2005; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P2739, DOI 10.1021/bi00009a002; Castellino FJ, 1997, CIBA F SYMP, V212, P46; Chang Y, 1998, BIOCHEMISTRY-US, V37, P3258, DOI 10.1021/bi972284e; Collen D, 2000, CIRCULATION, V102, P1766; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; DEWERCHIN M, 1989, EUR J BIOCHEM, V185, P141, DOI 10.1111/j.1432-1033.1989.tb15095.x; Douglas JT, 2002, BIOCHEMISTRY-US, V41, P3302, DOI 10.1021/bi016018j; Gase A, 1996, THROMB HAEMOSTASIS, V76, P755; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guzman, 1997, J Thromb Thrombolysis, V4, P337, DOI 10.1023/A:1008889030954; HABER E, 1989, SCIENCE, V243, P51, DOI 10.1126/science.2492113; Hantgan RR, 1998, BLOOD, V92, P2064, DOI 10.1182/blood.V92.6.2064.418k07_2064_2074; HAUPTMANN J, 1995, BLOOD COAGUL FIBRIN, V6, P579, DOI 10.1097/00001721-199509000-00013; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENNING WP, 1995, S AFR J ANIM SCI, V25, P7; HOOVER GJ, 1993, BIOCHEMISTRY-US, V32, P10936, DOI 10.1021/bi00092a002; Icke C, 2002, MOL PHARMACOL, V62, P203, DOI 10.1124/mol.62.2.203; Laroche Y, 2000, BLOOD, V96, P1425, DOI 10.1182/blood.V96.4.1425; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; Miele RG, 1999, J BIOL CHEM, V274, P7769, DOI 10.1074/jbc.274.12.7769; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Rosenfeld SA, 1999, METHOD ENZYMOL, V306, P154; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUNGE MS, 1988, BIOCHEMISTRY-US, V27, P1153, DOI 10.1021/bi00404a012; Sakharov DV, 1996, J BIOL CHEM, V271, P27912, DOI 10.1074/jbc.271.44.27912; Sakharov DV, 2000, THROMB HAEMOSTASIS, V83, P469; SCHLOTT B, 1994, BBA-PROTEIN STRUCT M, V1204, P235, DOI 10.1016/0167-4838(94)90013-2; Schlott B, 1998, J BIOL CHEM, V273, P22346, DOI 10.1074/jbc.273.35.22346; SEHL LC, 1990, J BIOL CHEM, V265, P5482; SERIZAWA K, 1993, THROMB RES, V71, P289, DOI 10.1016/0049-3848(93)90198-W; SILENCE K, 1993, J BIOL CHEM, V268, P9811; Sinnaeve P, 2001, THROMB RES, V103, pS71, DOI 10.1016/S0049-3848(01)00301-2; SUEHIRO A, 1995, THROMB RES, V80, P135, DOI 10.1016/0049-3848(95)00159-O; Szarka SJ, 1999, APPL ENVIRON MICROB, V65, P506; SZEMRAJ J, 2001, THROMB HAEMOSTASI SP, V86, P438; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; Tsikouris JP, 2001, PHARMACOTHERAPY, V21, P207, DOI 10.1592/phco.21.2.207.34103; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; WONG SL, 1989, GENE, V83, P215, DOI 10.1016/0378-1119(89)90107-8; WONG SL, 1994, APPL ENVIRON MICROB, V60, P517, DOI 10.1128/AEM.60.2.517-523.1994; Wu SC, 2002, APPL ENVIRON MICROB, V68, P3261, DOI 10.1128/AEM.68.7.3261-3269.2002; WU TP, 1994, BLOOD COAGUL FIBRIN, V5, P157, DOI 10.1097/00001721-199404000-00001; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991; Ye RQ, 1999, BIOTECHNOL BIOENG, V62, P87; Zajicek J, 2000, J MOL BIOL, V301, P333, DOI 10.1006/jmbi.2000.3972; Zhu YH, 1999, CIRCULATION, V99, P3050, DOI 10.1161/01.CIR.99.23.3050	51	28	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18199	18206		10.1074/jbc.M210919200	http://dx.doi.org/10.1074/jbc.M210919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646571	hybrid			2022-12-25	WOS:000182838300080
J	Demoulin, JB; Louahed, J; Dumoutier, L; Stevens, M; Renauld, JC				Demoulin, JB; Louahed, J; Dumoutier, L; Stevens, M; Renauld, JC			MAP kinase activation by interleukin-9 in lymphoid and mast cell lines	ONCOGENE			English	Article						cytokines; ERK; proliferation	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; IL-9 RECEPTOR; PROLIFERATION; PROTEIN; RAS	Interleukin-9 (IL-9) stimulates the proliferation of mast cells and lymphocytes. In the present study, we showed that IL-9 induced a transient phosphorylation of MEK, ERK2 and p90/RSK in murine lymphoid and mast cell lines. ERK2 in vitro kinase activity was also increased upon IL-9 stimulation. Similar results were obtained with IL-4, which had not been previously reported to activate these kinases in hematopoietic cells. Analysis of IL-9 receptor mutants showed that activation of the pathway was correlated with proliferation and with phosphorylation of the adaptor protein SHC, but not IRS2 or GAB2. The MEK inhibitor PD98059 reduced the mitogenic response to IL-4 and IL-9. In addition, expression of a dominant-negative RAS variant blocked ERK phosphorylation and significantly decreased Ba/F3 cell growth in the presence of IL-9, but did not affect expression of pim-1, a STAT target gene. In summary, these results indicate that IL-9 can transiently activate the mitogen-activated protein kinase pathway, which contributes to growth stimulation of hematopoietic cell tines.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Univ, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Renauld, JC (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, Ave Hippocrate 74, B-1200 Brussels, Belgium.	Jean-Christophe.Renauld@bru.licr.org	Demoulin, Jean-Baptiste/E-5847-2010; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Demoulin, Jean-Baptiste/0000-0002-8016-6689; Dumoutier, Laure/0000-0002-6645-684X				Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Demoulin JB, 2000, FEBS LETT, V482, P200, DOI 10.1016/S0014-5793(00)02059-7; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gingras S, 2000, MOL ENDOCRINOL, V14, P229, DOI 10.1210/me.14.2.229; Gomez J, 1996, J IMMUNOL, V157, P2272; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Lemoli RM, 1996, BLOOD, V87, P3852, DOI 10.1182/blood.V87.9.3852.bloodjournal8793852; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MIYAZAWA K, 1992, BLOOD, V80, P1685; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Renauld Jean-Christophe, 1998, P313; Richard M, 2000, P NATL ACAD SCI USA, V97, P767, DOI 10.1073/pnas.97.2.767; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Vink A, 1999, J EXP MED, V189, P1413, DOI 10.1084/jem.189.9.1413; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zamorano J, 1998, J IMMUNOL, V161, P859; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	43	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1763	1770		10.1038/sj.onc.1206253	http://dx.doi.org/10.1038/sj.onc.1206253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660812	Bronze			2022-12-25	WOS:000181678200003
J	Zhang, B; Potyagaylo, V; Fenton, RG				Zhang, B; Potyagaylo, V; Fenton, RG			IL-6-independent expression of Mcl-1 in human multiple myeloma	ONCOGENE			English	Article						Mcl-1; apoptosis; multiple myeloma; gene expression; IL-6	CHRONIC LYMPHOCYTIC-LEUKEMIA; ACTIVATED PROTEIN-KINASES; IN-VIVO; PLASMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DRUG-RESISTANCE; BCL2 FAMILY; APOPTOSIS; SURVIVAL; GENE	Mcl-1 is a critical antiapoptotic survival factor for human multiple myeloma (MM). We examined the importance of IL-6 for Mcl-1 expression in five MM cell lines and in primary MM cells from 14 patients. While culture of MM.1S cells in IL-6 did induce Mcl-1 expression, four other MM cell lines exhibited high levels of Mcl-1 expression that were unaffected by IL-6. Similarly, Mcl-1 expression in 10 of 14 primary MM isolates was found to be IL-6-independent. An analysis of the mechanisms responsible for IL-6-independent Mcl-1 expression was undertaken. ERK1/2 activity did not influence Mcl-1 expression, distinct from Mcl-1 regulation that occurs during myeloid differentiation from hematopoietic progenitor cells. Inhibition of the PI3K pathway led to growth inhibition of 8226 and ANBL-6 cells without reduction of Mcl-1 levels, and high level Mcl-1 expression was maintained in the absence of activated STAT3. Analysis of the transcriptional activity of 5-regulatory sequences from the human Mcl-1 gene in MM cells demonstrated high levels of IL-6-independent indicator gene activation as predicted. These data demonstrate that the mechanisms regulating Mcl-1 levels in MM cells are heterogeneous, and are often independent from IL-6 signaling pathways.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Fenton, RG (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Bressler Res Bldg,Rm 7-023,655 W Baltimore St, Baltimore, MD 21201 USA.	rfent001@umaryland.edu						Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bright JJ, 1999, J IMMUNOL, V162, P6255; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fonseca R, 1999, HEMATOL ONCOL CLIN N, V13, P1169, DOI 10.1016/S0889-8588(05)70119-2; Gauthier ER, 1996, CANCER RES, V56, P1451; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Halloran PJ, 1998, CANCER RES, V58, P3855; HANADA M, 1993, BLOOD, V82, P1820; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jelinek DF, 1997, J IMMUNOL, V159, P487; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 2000, BLOOD, V96, P393; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McConkey DJ, 1996, J IMMUNOL, V156, P2624; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Metcalf D, 1998, STEM CELLS, V16, P314, DOI 10.1002/stem.160314; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miguel-Garcia A, 1998, HAEMATOLOGICA, V83, P298; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; ONG F, 1995, LEUKEMIA, V9, P1282; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Puthier D, 1999, LEUKEMIA, V13, P289, DOI 10.1038/sj.leu.2401302; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAGHOEBIER S, 1991, BLOOD, V77, P1560; Rajkumar SV, 1999, HEMATOL ONCOL CLIN N, V13, P1295, DOI 10.1016/S0889-8588(05)70128-3; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROWLEY JD, 1988, J CLIN ONCOL, V6, P919, DOI 10.1200/JCO.1988.6.5.919; Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Thomas A, 1996, ONCOGENE, V12, P1055; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tricot G, 1997, J CLIN ONCOL, V15, P2659, DOI 10.1200/JCO.1997.15.7.2659; Tu YP, 1998, CANCER RES, V58, P256; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; Zhang B, 2002, J CELL PHYSIOL, V193, P42, DOI 10.1002/jcp.10148; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	68	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1848	1859		10.1038/sj.onc.1206358	http://dx.doi.org/10.1038/sj.onc.1206358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660820				2022-12-25	WOS:000181678200011
J	McLuskey, K; Harrison, JA; Schuttelkopf, AW; Boxer, DH; Hunter, WN				McLuskey, K; Harrison, JA; Schuttelkopf, AW; Boxer, DH; Hunter, WN			Insight into the role of Escherichia coli MobB in molybdenum cofactor biosynthesis based on the high resolution crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCTS; PROTEIN; MOLYBDOPTERIN; MOEA; RECOGNITION; SEQUENCES; PROGRAM; ENZYMES; MOTIFS; LOCUS	Two proteins, which are co-transcribed in Escherichia coli (MobA and MobB), are involved in the attachment of a nucleotide moiety to the molybdenum cofactor to form active molybdopterin guanine dinucleotide. Although not essential for this process, the dimeric MobB increases the activation of molybdoenzymes, incorporating this cofactor by a mechanism that is not understood. The structure of MobB has been elucidated in two crystal forms, one of which has provided a model at 1.9-Angstrom resolution with R-work and R-free values of 21.5 and 28.7%, respectively. The MobB subunit displays an alpha/beta-fold arranged into a major and minor domain, the latter of which is inserted between the major and minor domains of the partner subunit, creating an elongated dimer constructed around a 16-stranded beta-sheet. Structural homologues have been identified, and they include a number of nucleotide-binding proteins. Comparisons indicate that although the phosphate-binding regions are highly conserved, MobB lacks the elements of structure required to interact with and efficiently bind a nucleotide base. In the present structure, a sulfate is bound to the Walker A phosphate-binding motif of MobB. The possibility that MobB forms a complex with the nucleotide-binding MobA, the protein with which it is co-transcribed, is explored, and modeling suggests that such a MobA: MobB complex is feasible. This hypothesis is supported by recent biochemical evidence indicating that MobB interacts with several proteins involved in various stages of molybdenum cofactor biosynthesis including MobA. We propose therefore that MobB is an adapter protein that acts in concert with MobA to achieve the efficient biosynthesis and utilization of molybdopterin guanine dinucleotide.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	w.n.hunter@dundee.ac.uk	Hunter, William/AAE-3947-2019	McLuskey, Karen/0000-0002-9841-4943				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bond CS, 2003, BIOINFORMATICS, V19, P311, DOI 10.1093/bioinformatics/19.2.311; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hayashi I, 2001, EMBO J, V20, P1819, DOI 10.1093/emboj/20.8.1819; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; IOBBINIVOL C, 1995, MICROBIOL-SGM, V141, P1663; Jang SB, 2000, BIOCHEMISTRY-US, V39, P14745, DOI 10.1021/bi001705g; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leimkuhler S, 1999, J BACTERIOL, V181, P5930; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Schrag JD, 2001, J MOL BIOL, V310, P419, DOI 10.1006/jmbi.2001.4771; Stevenson CEM, 2000, STRUCTURE, V8, P1115, DOI 10.1016/S0969-2126(00)00518-9; STIEFEL EI, 1993, ACS SYM SER, V535, P1; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wuebbens MM, 2000, STRUCTURE, V8, P709, DOI 10.1016/S0969-2126(00)00157-X; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	48	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23706	23713		10.1074/jbc.M301485200	http://dx.doi.org/10.1074/jbc.M301485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12682065	hybrid			2022-12-25	WOS:000183638600064
J	Agasoster, AV; Halskau, O; Fuglebakk, E; Froystein, NA; Muga, A; Holmsen, H; Martinez, A				Agasoster, AV; Halskau, O; Fuglebakk, E; Froystein, NA; Muga, A; Holmsen, H; Martinez, A			The interaction of peripheral proteins and membranes studied with alpha-lactalbumin and phospholipid bilayers of various compositions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PARTIALLY FOLDED CONFORMATIONS; FATTY-ACID COMPOSITION; MOLTEN GLOBULE; HYDROGEN-EXCHANGE; LIPID-COMPOSITION; MODEL MEMBRANES; APOLIPOPHORIN-III; BREAST-CANCER; MILK-PROTEINS	To characterize the interaction of peripheral proteins and membranes at the molecular level, we studied the reversible association of bovine alpha-lactalbumin (BLA) with lipid bilayers composed of different molecular forms of phosphatidylserine or equimolar mixtures of these phosphatidylserine forms and egg yolk phosphatidylcholine. At pH 4.5, almost all BLA (>90%) associates to negatively charged small unilamellar vesicles. The conformational changes that binding to these bilayers induced on the protein were characterized by circular dichroism and fluorescence spectroscopy. Because binding of BLA to negatively charged vesicles is reverted by adjusting the pH back to >6.0, we also investigated the conformation of the membrane-bound protein by NMR-monitored H-D exchange of the backbone amide protons. The conformation adopted by BLA bound to these bilayers resembles a molten globule-like state but the negative ellipticity at 222 nm and the apparent alpha-helix content of the bound protein senses the changes in the physical properties of the membrane. Binding to bilayers in the gel state appears to correlate with an increased amount of alpha-helical structure and with a lower extent of integration into the membrane, corresponding to the adsorbed protein, while the opposite is found for BLA bound to vesicles in the liquid-crystalline phase, corresponding to the embedded conformation. A common feature for the membrane-bound conformations of BLA is that the amphipathic helix C (residues 86 to 99) is an important determinant for the adsorption and further integration of the protein into the membrane.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Univ Basque Country, Dept Biochem & Mol Biol, E-48080 Bilbao, Spain	University of Bergen; University of Bergen; University of Basque Country	Martinez, A (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, Jonas Liesvei 91, N-5009 Bergen, Norway.		Fuglebakk, Edvin/P-4596-2019; Martinez, Aurora/M-3088-2019; Fuglebakk, Edvin/K-8396-2012; Muga, Arturo/N-1174-2014	Fuglebakk, Edvin/0000-0002-3192-6768; Martinez, Aurora/0000-0003-1643-6506; Fuglebakk, Edvin/0000-0002-3192-6768; Muga, Arturo/0000-0003-0345-6882; Halskau, Oyvind/0000-0003-2517-1060				Agasosler AV, 2001, BIOCHEM PHARMACOL, V61, P817, DOI 10.1016/S0006-2952(01)00542-1; ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Banuelos S, 1996, BIOCHEMISTRY-US, V35, P3892, DOI 10.1021/bi951468v; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; Banuelos S, 1996, FEBS LETT, V386, P21, DOI 10.1016/0014-5793(96)00406-1; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Braschi S, 1999, J LIPID RES, V40, P522; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; CAFFREY M, 1992, CHEM PHYS LIPIDS, V61, P1, DOI 10.1016/0009-3084(92)90002-7; CHAJES V, 1995, INT J CANCER, V63, P169, DOI 10.1002/ijc.2910630204; Chajes V, 1999, INT J CANCER, V83, P585, DOI 10.1002/(SICI)1097-0215(19991126)83:5&lt;585::AID-IJC2&gt;3.0.CO;2-Z; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CULLIS PR, 1991, BIOCH LIPIDS LIPOPRO, V20, P1; Dahim M, 1998, BIOCHEMISTRY-US, V37, P8369, DOI 10.1021/bi973015r; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; Farrell HM, 2002, J DAIRY SCI, V85, P459, DOI 10.3168/jds.S0022-0302(02)74096-4; Fisher CA, 1999, J LIPID RES, V40, P93; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; Gadd ME, 2000, BIOCHEMISTRY-US, V39, P9623, DOI 10.1021/bi000322f; Goddard T. D., 1999, SPARKY 3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hakansson A, 1999, EXP CELL RES, V246, P451, DOI 10.1006/excr.1998.4265; Halskau O, 2002, J MOL BIOL, V321, P99, DOI 10.1016/S0022-2836(02)00565-X; HIETANEN E, 1986, CARCINOGENESIS, V7, P1965, DOI 10.1093/carcin/7.12.1965; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Imafidon GI, 1997, CRIT REV FOOD SCI, V37, P663, DOI 10.1080/10408399709527794; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; Kohler C, 2001, EUR J BIOCHEM, V268, P186, DOI 10.1046/j.1432-1327.2001.01870.x; Krishnamurthy VV, 1997, MAGN RESON CHEM, V35, P9, DOI 10.1002/(SICI)1097-458X(199701)35:1<9::AID-OMR930>3.0.CO;2-R; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAKEY JH, 1994, EUR J BIOCHEM, V220, P155, DOI 10.1111/j.1432-1033.1994.tb18610.x; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Monteggia E, 2000, CANCER DETECT PREV, V24, P207; Nerdal W, 2000, BBA-BIOMEMBRANES, V1464, P165, DOI 10.1016/S0005-2736(00)00125-5; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; PHILLIPS MC, 1970, BIOCHIM BIOPHYS ACTA, V196, P35, DOI 10.1016/0005-2736(70)90163-X; Pike ACW, 1996, STRUCTURE, V4, P691, DOI 10.1016/S0969-2126(96)00075-5; Sahoo D, 1998, J BIOL CHEM, V273, P1403, DOI 10.1074/jbc.273.3.1403; SCHANBACHER FL, 1971, BIOCHIM BIOPHYS ACTA, V229, P226, DOI 10.1016/0005-2795(71)90337-0; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; Soulages JL, 2000, J BIOL CHEM, V275, P17501, DOI 10.1074/jbc.M909661199; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; VANBLITTERSWIJK WJ, 1982, BIOCHIM BIOPHYS ACTA, V688, P495, DOI 10.1016/0005-2736(82)90361-3; VANDIJCK PWM, 1978, BIOCHIM BIOPHYS ACTA, V512, P84, DOI 10.1016/0005-2736(78)90219-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang SX, 2000, BIOCHEM J, V348, P103, DOI 10.1042/0264-6021:3480103; Wang W, 1998, J BIOL CHEM, V273, P27438, DOI 10.1074/jbc.273.42.27438; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951	58	60	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21790	21797		10.1074/jbc.M211466200	http://dx.doi.org/10.1074/jbc.M211466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660251	hybrid			2022-12-25	WOS:000183354200061
J	Moran, ST; Haider, K; Ow, Y; Milton, P; Chen, LJ; Pillai, S				Moran, ST; Haider, K; Ow, Y; Milton, P; Chen, LJ; Pillai, S			Protein kinase C-associated kinase can activate NF kappa B in both a kinase-dependent and a kinase-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN; RIP-LIKE KINASE; DEATH DOMAIN; SRC FAMILY; CELL-DEATH; PHOSPHORYLATION; APOPTOSIS; IDENTIFICATION; PATHWAYS; CLONING	Protein kinase C-associated kinase (PKK, also known as RIP4/DIK) activates NFkappaB when overexpressed in cell lines and is required for keratinocyte differentiation in vivo. However, very little is understood about the factors upstream of PKK or how PKK activates NFkappaB. Here we show that certain catalytically inactive mutants of PKK can activate NFkappaB, although to a lesser degree than wild type PKK. The deletion of specific domains of wild type PKK diminishes the ability of this enzyme to activate NFkappaB; the same deletions made on a catalytically inactive PKK background completely ablate NFkappaB activation. PKK may be phosphorylated by two specific mitogen-activated protein kinase kinase kinases, MEKK2 and MEKK3, and this interaction may in part be mediated through a critical activation loop residue, Thr(184). Catalytically inactive PKK mutants that block phorbol ester-induced NFkappaB activation do not interfere with, but unexpectedly enhance, the activation of NFkappaB by these two mitogen-activated protein kinase kinase kinases. Taken together, these data indicate that PKK may function in both a kinase-dependent as well as a kinase-independent manner to activate NFkappaB.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Pillai, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33507] Funding Source: Medline; NIDDK NIH HHS [DK 43351] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bahr C, 2000, J BIOL CHEM, V275, P36350, DOI 10.1074/jbc.M004771200; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Chen LJ, 2001, J BIOL CHEM, V276, P21737, DOI 10.1074/jbc.M008069200; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Holland PM, 2002, CURR BIOL, V12, P1424, DOI 10.1016/S0960-9822(02)01075-8; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Inohara N, 2000, J BIOL CHEM, V275, P27823; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meylan E, 2002, EMBO REP, V3, P1201, DOI 10.1093/embo-reports/kvf236; Muto A, 2002, J BIOL CHEM, V277, P31871, DOI 10.1074/jbc.M202222200; Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	36	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21526	21533		10.1074/jbc.M301575200	http://dx.doi.org/10.1074/jbc.M301575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676934	hybrid			2022-12-25	WOS:000183354200028
J	Tsuboi, Y; Inoue, H; Nakamura, N; Kanazawa, H				Tsuboi, Y; Inoue, H; Nakamura, N; Kanazawa, H			Identification of membrane domains of the Na(+)/H(+) antiporter (NhaA) protein from Helicobacter pylori required for ion transport and pH sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE; CLONING; OVERPRODUCTION; EXPRESSION; RESIDUES; ANT; H+	The Na(+)/H(+) antiporter from Helicobacter pylori ( HP NhaA) is normally active within the pH range 6.0 - 8.5. In contrast, the NhaA from Escherichia coli ( EC NhaA) is active only within the alkaline pH range 7.5 - 8.5. We studied structures of HP NhaA involved in ion transport and pH sensing by analyzing mutants with defects in NhaA activity. The 36 mutants were classified into three types. The first type exhibited very low or null activity at all pH levels and had amino acid substitutions in the transmembrane segments ( TM) 4, 5, 10, and 11, implicating these TMs in ion transport. The second type, which had amino acid substitutions at Met- 138, Phe- 144, and Lys- 347 in TM 4 and 10, exhibited very low antiporter activity at acidic pH but had significantly higher activity at alkaline pH. These results imply that TM 4 ( Met-138 and Phe- 144) and 10 ( Lys- 347) are involved in supporting transport activity at acidic pH, in addition to their essential role in the overall transport mechanism. The third type of mutant exhibited very low antiporter activity at alkaline pH but relatively normal activity at acidic pH and had amino acid substitutions in loop 7 ( a hydrophilic region between TM 7 and 8) as well as in TM 8, suggesting that these regions are involved in antiporter activation at alkaline pH. Three revertants that suppress a Lys- 347 mutation were identified. Two of three suppressor mutations were located in loops 2 and 4, suggesting a functional interaction between these regions ( loops 2 and 4 and TM 10). Thus, HP NhaA activity may be modulated by two independent factors that are dependent on pH: an activation mechanism at acidic pH, which is regulated by residues within TM 4 and 10 and another mechanism functioning at alkaline pH regulated by residues within loop 7 and TM 8.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5600043, Japan	Osaka University	Kanazawa, H (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Machikaneyama Cho 1-16, Osaka 5600043, Japan.	kanazawa@bio.sci.osaka-u.ac.jp						Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Inoue H, 1998, BIOL PHARM BULL, V21, P1128; Inoue H, 1999, FEBS LETT, V443, P11, DOI 10.1016/S0014-5793(98)01652-4; Inoue S, 2001, J BIOCHEM, V129, P569, DOI 10.1093/oxfordjournals.jbchem.a002892; IVEY DM, 1993, J BIOL CHEM, V268, P11296; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KARPEL R, 1988, J BIOL CHEM, V263, P10408; Maniatis T., 1982, MOL CLONING LAB MANU; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIKI J, 1994, J BIOL CHEM, V269, P4227; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Nozaki K, 1996, BIOCHEM BIOPH RES CO, V222, P774, DOI 10.1006/bbrc.1996.0820; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 1998, MICR EXTREM UNUSUAL, P163; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1994, J BIOL CHEM, V269, P26274; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534	24	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21467	21473		10.1074/jbc.M301932200	http://dx.doi.org/10.1074/jbc.M301932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670937	hybrid			2022-12-25	WOS:000183354200021
J	Chinault, SL; Blumer, KJ				Chinault, SL; Blumer, KJ			The C-terminal tail preceding the CAAX box of a yeast G protein gamma subunit is dispensable for receptor-mediated G protein activation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE-RESPONSE PATHWAY; ALPHA-FACTOR RECEPTOR; RHODOPSIN TRANSDUCIN INTERACTIONS; HETEROTRIMERIC G-PROTEIN; DUAL LIPID MODIFICATION; G-BETA-GAMMA; SACCHAROMYCES-CEREVISIAE; MUSCARINIC RECEPTOR; SIGNAL-TRANSDUCTION; ADENOSINE RECEPTORS	The gamma subunits of heterotrimeric G proteins are required for receptor-G protein coupling. The C-terminal domains of Ggamma subunits can contact receptors and influence the efficiency of receptor-G protein coupling in vitro. However, it is unknown whether receptor interaction with the C terminus of Ggamma is required for signaling in vivo. To address this question, we cloned Ggamma homologs with diverged C-terminal sequences from five species of budding yeast. Each Ggamma homolog functionally replaced the Ggamma subunit of the yeast Saccharomyces cerevisiae (STE18 gene product). Mutagenesis of S. cerevisiae Ste18 likewise indicated that specific C-terminal sequence motifs are not required for signaling. Strikingly, an internal in-frame deletion removing sequences preceding the C-terminal CAAX box of Ste18 did not impair signaling by either of its cognate G protein-coupled pheromone receptors. Therefore, receptor interaction with the C-terminal domain of yeast Ggamma is not required for receptor-mediated G protein activation in vivo. Because the mechanism of G protein activation by receptors is conserved from yeast to humans, mammalian receptors may not require interaction with the tail of Ggamma for G protein activation in vivo. However, receptor-Ggamma interaction may modulate the efficiency of receptor-G protein coupling or promote activation of Gbetagamma effectors that co-cluster with receptors.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Blumer, Kendall J/C-5268-2012		NIGMS NIH HHS [GM44592] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; Kallal L, 1997, MOL CELL BIOL, V17, P2897, DOI 10.1128/MCB.17.5.2897; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lim WK, 2001, BIOCHEMISTRY-US, V40, P10532, DOI 10.1021/bi010950c; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; Mentesana PE, 2002, METHOD ENZYMOL, V344, P92; Murphree LJ, 2002, MOL PHARMACOL, V61, P455, DOI 10.1124/mol.61.2.455; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Ongay-Larios L, 2000, FEBS LETT, V467, P22, DOI 10.1016/S0014-5793(00)01106-6; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WHITEWAY MS, 1994, GENETICS, V137, P967; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	46	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20638	20644		10.1074/jbc.M212701200	http://dx.doi.org/10.1074/jbc.M212701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665529	hybrid			2022-12-25	WOS:000183230500026
J	Gralnick, JA; Downs, DM				Gralnick, JA; Downs, DM			The YggX protein of Salmonella enterica is involved in Fe(II) trafficking and minimizes the DNA damage caused by hydroxyl radicals - Residue Cys-7 is essential for YggX function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SEROVAR TYPHIMURIUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; STRAND SCISSION; OXYGEN RADICALS; REGULATED GENES; FUR MUTANTS; FREE-IRON; SUPEROXIDE	Previous work from our laboratory identified YggX as a protein whose accumulation increased the resistance of Salmonella enterica to superoxide stress, reversed defects attributed to oxidized [Fe-S] clusters, and decreased the spontaneous mutation frequency of the cells. Here we present work aimed at determining why the accumulation of YggX correlates with reduced mutation frequency. Genetic and biochemical data showed that accumulation of YggX reduced the damage to DNA by hydroxyl radicals. The ability of purified YggX to protect DNA from Fenton chemistry mediated damage in vitro and to decrease the concentration of Fe(II) ions in solution available for chelation provided a framework for the interpretation of data obtained from in vivo experiments. The interpretation of in vitro assay results, within the context of the in vivo phenotypes, was validated by a mutant variant of YggX (C7S) that was unable to function in vivo or in vitro. We propose a model, based on data presented here and reported earlier, that suggests YggX is a player in Fe( II) trafficking in bacteria.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, DM (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.			Gralnick, Jeffrey/0000-0001-9250-7770	NIGMS NIH HHS [GM 47296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Tehrani H, 1999, J BACTERIOL, V181, P1415, DOI 10.1128/JB.181.5.1415-1428.1999; Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; Boudsocq F, 1997, J MOL BIOL, V270, P201, DOI 10.1006/jmbi.1997.1098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun V, 1997, BIOL CHEM, V378, P779; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; Davis R., 1980, ADV BACTERIAL GENETI; Demple B, 1999, BIOCHEM SOC SYMP, P119; DOWNS DM, 1992, J BACTERIOL, V174, P1515, DOI 10.1128/jb.174.5.1515-1521.1992; Expert D, 1999, ANNU REV PHYTOPATHOL, V37, P307, DOI 10.1146/annurev.phyto.37.1.307; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; Gifford CM, 1999, J BACTERIOL, V181, P4223, DOI 10.1128/JB.181.14.4223-4236.1999; Gralnick J, 2000, J BACTERIOL, V182, P5180, DOI 10.1128/JB.182.18.5180-5187.2000; Gralnick J, 2001, P NATL ACAD SCI USA, V98, P8030, DOI 10.1073/pnas.151243198; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hantke K, 2003, P NATL ACAD SCI USA, V100, P3677, DOI 10.1073/pnas.0737682100; Harlow E., 1988, ANTIBODIES LAB MANUA; Hudson RE, 2002, MOL BIOL EVOL, V19, P85, DOI 10.1093/oxfordjournals.molbev.a003986; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LESKO SA, 1980, BIOCHEMISTRY-US, V19, P3023, DOI 10.1021/bi00554a029; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141; LUCKEY M, 1972, Journal of Bacteriology, V111, P731; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Miller J.H., 1972, EXPT MOL GENETICS; Nakamura J, 1998, CANCER RES, V58, P222; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Nunoshiba T, 1999, J BIOL CHEM, V274, P34832, DOI 10.1074/jbc.274.49.34832; Petrat F, 2002, BIOL CHEM, V383, P489, DOI 10.1515/BC.2002.051; Pomposiello PJ, 2000, J BACTERIOL, V182, P23, DOI 10.1128/JB.182.1.23-29.2000; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; Skovran E, 2003, J BACTERIOL, V185, P98, DOI 10.1128/JB.185.1.98-106.2003; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Van Houten B, 2000, MUTAT RES-DNA REPAIR, V460, P81, DOI 10.1016/S0921-8777(00)00018-5; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	51	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20708	20715		10.1074/jbc.M301577200	http://dx.doi.org/10.1074/jbc.M301577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670952	hybrid			2022-12-25	WOS:000183230500036
J	Chen, FS; Tandon, A; Sanjo, N; Gu, YJ; Hasegawa, H; Arawaka, S; Lee, FJS; Ruan, XY; Mastrangelo, P; Erdebil, S; Wang, L; Westaway, D; Mount, HTJ; Yankner, B; Fraser, PE; St George-Hyslop, P				Chen, FS; Tandon, A; Sanjo, N; Gu, YJ; Hasegawa, H; Arawaka, S; Lee, FJS; Ruan, XY; Mastrangelo, P; Erdebil, S; Wang, L; Westaway, D; Mount, HTJ; Yankner, B; Fraser, PE; St George-Hyslop, P			Presenilin 1 and presenilin 2 have differential effects on the stability and maturation of nicastrin in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE CLEAVAGE; BETA-PEPTIDE PRODUCTION; MISSENSE MUTATIONS; NOTCH; DROSOPHILA; CELLS; RELEASE; MICE	The presenilins and nicastrin form high molecular mass, multimeric protein complexes involved in the intramembranous proteolysis of several proteins. Post-translational glycosylation and trafficking of nicastrin is necessary for the activity of these complexes. We report here that although there are differences in the post-translational processing of nicastrin in neurons and glia, both of the presenilins are required for the physiological post-translational modification and for the correct subcellular distribution of nicastrin. Absence of presenilin 1 (PS1) is associated with dramatic reductions in the level of mature glycosylated nicastrin and with redistribution of nicastrin away from the cell surface. In contrast, absence of presenilin 2 (PS2) is associated with only modest reductions in the levels of immature nicastrin. It is notable that these differential effects parallel the differential effects of null mutations in PS1 and PS2 on APP and Notch processing. Our data therefore suggest that the differential interactions of PS1 and PS2 with nicastrin reflect different functions for the PS1 and PS2 complexes.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02049 USA; Toronto Western Hosp, Univ Hlth Network, Dept Med, Div Neurol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys & Med, Toronto, ON M5S 1A8, Canada	University of Toronto; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W,Tanz Neurosci Bldg, Toronto, ON M5S 3H2, Canada.		Lee, Frank J.S./D-5899-2017; Mount, Howard/B-4097-2013	Lee, Frank J.S./0000-0002-5768-3776; Arawaka, Shigeki/0000-0002-1505-3012; St George-Hyslop, Peter/0000-0003-0796-7209; Sanjo, Nobuo/0000-0002-1226-2425				Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rozmahel R, 2002, P NATL ACAD SCI USA, V99, P14452, DOI 10.1073/pnas.222413999; Rozmahel R, 2002, NEUROBIOL AGING, V23, P187, DOI 10.1016/S0197-4580(01)00267-6; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	26	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19974	19979		10.1074/jbc.M210049200	http://dx.doi.org/10.1074/jbc.M210049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646573	hybrid			2022-12-25	WOS:000183078000053
J	Clausen, JD; McIntosh, DB; Vilsen, B; Woolley, DG; Andersen, JP				Clausen, JD; McIntosh, DB; Vilsen, B; Woolley, DG; Andersen, JP			Importance of conserved N-domain residues Thr(441), Glu(442), Lys(515), Arg(560), and Leu(562) of sarcoplasmic reticulum Ca2+-ATPase for MgATP binding and subsequent catalytic steps - Plasticity of the nucleotide-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; ATP-BINDING; AMINO-ACIDS; ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; PHOSPHOENZYME INTERMEDIATE; CONFORMATIONAL-CHANGES; PHOSPHORYLATION LOOP; STRUCTURAL-CHANGES	Nine single mutations were introduced to amino acid residues Thr(441), Glu(442), Lys(515), Arg(560), Cys(561), and Leu(562) located in the nucleotide-binding domain of sarcoplasmic reticulum Ca2+-ATPase, and the functional consequences were studied in a direct nucleotide binding assay, as well as by steady-state and transient kinetic measurements of the overall and partial reactions of the transport cycle. Some partial reaction steps were also examined in mutants with alterations to Phe(487), Arg(489), and Lys(492). The results implicate all these residues, except Cys(561), in high affinity nucleotide binding at the substrate site. Mutations Thr(441)-->Ala, Glu(442)-->Ala, and Leu(562) --> Phe were more detrimental to MgATP binding than to ATP binding, thus pointing to a role for these residues in the binding of Mg2+ or to a difference between the interactions with MgATP and ATP. Subsequent catalytic steps were also selectively affected by the mutations, showing the involvement of the nucleotide-binding domain in these reactions. Mutation of Arg560 inhibited phosphoryl transfer but enhanced the E1PCa2 --> E2P conformational transition, whereas mutations Thr(441) --> Ala, Glu(442) --> Ala, Lys(492) --> Leu, and Lys(515) --> Ala inhibited the E1PCa2 --> E2P transition. Hydrolysis of the E2P phosphoenzyme intermediate was enhanced in Glu(442) --> Ala, Lys(492) --> Leu, Lys(515) --> Ala, and Arg(560)-->Glu. None of the mutations affected the low affinity activation by nucleotide of the phosphoenzyme-processing steps, indicating that modulatory nucleotide interacts differently from substrate nucleotide. Mutation Glu(442) --> Ala greatly enhanced reaction of Lys(515) with fluorescein isothiocyanate, indicating that the two residues form a salt link in the native protein.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark; Univ Cape Town, Div Chem Pathol, Dept Clin Lab Sci, Fac Hlth Sci, ZA-7925 Cape Town, South Africa	Aarhus University; University of Cape Town	McIntosh, DB (corresponding author), Univ Cape Town, Div Chem Pathol, Dept Clin Lab Sci, Fac Hlth Sci, ZA-7925 Cape Town, South Africa.	davidmci@chempath.uct.ac.za; jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; COAN C, 1993, J BIOL CHEM, V268, P6917; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; Hua SM, 2002, BIOCHEMISTRY-US, V41, P2264, DOI 10.1021/bi015684h; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1978, J BIOL CHEM, V253, P385; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; PATCHORNIK G, BIOCHEMISTRY, V41, P11740; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STEFANOVA HI, 1992, BIOCHEMISTRY-US, V31, P6023, DOI 10.1021/bi00141a010; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VERJOVSKIALMEIDA S, 1979, J BIOL CHEM, V254, P18; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; Ward DG, 1998, J BIOL CHEM, V273, P33759, DOI 10.1074/jbc.273.50.33759; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	64	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20245	20258		10.1074/jbc.M301122200	http://dx.doi.org/10.1074/jbc.M301122200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649284	hybrid			2022-12-25	WOS:000183078000087
J	Mahapatra, NR; Mahata, M; O'Connor, DT; Mahata, SK				Mahapatra, NR; Mahata, M; O'Connor, DT; Mahata, SK			Secretin activation of chromogranin A gene transcription - Identification of the signaling pathways in cis and in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE ACTIVITY; CYCLIC ADENOSINE-MONOPHOSPHATE; VASOACTIVE-INTESTINAL-PEPTIDE; SECRETOGRANIN-II GENE; NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; PROTEIN-KINASE; ADENYLATE-CYCLASE; CATECHOLAMINE RELEASE; CRUCIAL ROLE	Secretin evokes catecholamine secretion from PC12 pheochromocytoma cells. We tested whether secretin activates transcription of the major vesicular core protein chromogranin A (CgA). Secretin stimulated both endogenous CgA gene transcription (similar to4-6-fold) as well as transfected CgA promoter activity (similar to8-10-fold; EC50, similar to7 nM) in PC12 cells. Studies on CgA promoter 5'-deletion mutant/luciferase reporter constructs, point mutations of the CgA cAMP response element (CRE), and their transfer to a heterologous promoter implicated CRE in cis as both necessary and sufficient for secretin-stimulated CgA gene transcription. Secretin-induced CgA gene transcription was inhibited/abolished by cytosolic Ca2+ chelation, chemical blockade of phospholipase C, protein kinase A (PKA), or mitogen-activated protein ( MAP) kinase extracellular signal regulated kinase (ERK) 1/2 and the expression of dominant negative mutants of ERK1/2, CRE binding protein (CREB) kinase RSK2, or CREB. Secretin also augmented (similar to4-fold) phosphorylation of ERK1/2. Trans-activation (similar to21-fold) of GAL4-CREB fusion protein by secretin indicates involvement of CREB in secretin signaling to gene transcription. Electrophoretic mobility shift assays also identified CREB as the mediator of secretin-induced CgA gene transcription, and pCREB supershifts indicated Ser-133 as the active CREB moiety in vitro. This conclusion was reinforced in vivo by results of chromatin pCREB immunoprecipitation assays. We conclude that secretin signals to CgA gene transcription through the CRE domain in cis and through cAMP, Ca2+, PKA, MAP kinase, and the transcription factor CREB in trans. Thus, multiple signal transduction pathways seem to subserve the function of stimulus-transcription coupling after this peptidergic stimulus to chromaffin cells.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Mahata, SK (corresponding author), Univ Calif San Diego, Dept Med 0838, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Mahapatra, Nitish R/D-4123-2014; Mahata, Sushil/AAF-8781-2021	Mahapatra, Nitish R/0000-0002-0695-3510; 	NHLBI NIH HHS [HL58120, HL55583, HL69758] Funding Source: Medline; NIDA NIH HHS [DA11311] Funding Source: Medline; NIDDK NIH HHS [DK60702] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055583, U01HL069758, P01HL058120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011311, R29DA011311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEIJER HJM, 1979, ARCH INT PHARMACOD T, V240, P269; BOLONDI L, 1990, GUT, V31, P1306, DOI 10.1136/gut.31.11.1306; CHATELAIN P, 1980, PFLUG ARCH EUR J PHY, V389, P29, DOI 10.1007/BF00587925; DAY RN, 1989, J BIOL CHEM, V264, P431; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Fowkes RC, 2001, J ENDOCRINOL, V171, pR5, DOI 10.1677/joe.0.171R005; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; GUNNES P, 1986, EUR HEART J, V7, P146, DOI 10.1093/oxfordjournals.eurheartj.a062037; GUNNES P, 1983, SCAND J CLIN LAB INV, V43, P637; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; IP NY, 1984, PEPTIDES, V5, P309, DOI 10.1016/0196-9781(84)90225-0; Ip NY, 2000, J NEUROBIOL, V42, P14, DOI 10.1002/(SICI)1097-4695(200001)42:1<14::AID-NEU2>3.0.CO;2-Y; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KOPIN AS, 1990, P NATL ACAD SCI USA, V87, P2299, DOI 10.1073/pnas.87.6.2299; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Mahapatra NR, 2000, ENDOCRINOLOGY, V141, P3668, DOI 10.1210/en.141.10.3668; Mahata M, 2001, HYPERTENSION, V38, P508; Mahata SK, 2000, MOL ENDOCRINOL, V14, P1525, DOI 10.1210/me.14.10.1525; Mahata SK, 1999, NEUROSCIENCE, V88, P405, DOI 10.1016/S0306-4522(98)00225-5; Mahata SK, 1999, ENDOCRINOLOGY, V140, P739, DOI 10.1210/en.140.2.739; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Nozaki S, 2002, BIOCHEM BIOPH RES CO, V292, P133, DOI 10.1006/bbrc.2002.6640; OLSEN O, 1993, SCAND J GASTROENTERO, V28, P622, DOI 10.3109/00365529309096100; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1989, HYPERTENSION, V14, P435, DOI 10.1161/01.HYP.14.4.435; ROSKOSKI R, 1989, MOL PHARMACOL, V36, P925; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAKIYYUDDIN MA, 1995, HYPERTENSION, V26, P213, DOI 10.1161/01.HYP.26.1.213; TAKIYYUDDIN MA, 1990, CIRCULATION, V81, P185, DOI 10.1161/01.CIR.81.1.185; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Tang KC, 1997, J CLIN INVEST, V100, P1180, DOI 10.1172/JCI119630; Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; Turquier V, 2001, MOL PHARMACOL, V60, P42, DOI 10.1124/mol.60.1.42; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yung WH, 2001, J NEUROSCI, V21, P7063, DOI 10.1523/JNEUROSCI.21-18-07063.2001	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19986	19994		10.1074/jbc.M207983200	http://dx.doi.org/10.1074/jbc.M207983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646581	hybrid			2022-12-25	WOS:000183078000055
J	Kalogeraki, VS; Tornaletti, S; Hanawalt, PC				Kalogeraki, VS; Tornaletti, S; Hanawalt, PC			Transcription arrest at a lesion in the transcribed DNA strand in vitro is not affected by a nearby lesion in the opposite strand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLOBUTANE PYRIMIDINE DIMER; ELONGATION-FACTOR-SII; THYMINE DIMER; REPAIR; SITE; COMPLEXES; TEMPLATE; DAMAGE; ADDUCTS	Cis-syn cyclobutane pyrimidine dimers (CPDs) are the most frequently formed lesions in UV-irradiated DNA. CPDs are repaired by the nucleotide excision repair pathway. Additionally, they are subject to transcription-coupled DNA repair. In the general model for transcription-coupled DNA repair, an RNA polymerase arrested at a lesion on the transcribed DNA strand facilitates repair by recruiting the repair machinery to the site of the lesion. Consistent with this model, transcription experiments in vitro have shown that CPDs in the transcribed DNA strand interfere with the translocation of prokaryotic and eukaryotic RNA polymerases. Here, we study the behavior of RNA polymerase when transcribing a template that contains two closely spaced lesions, one on each DNA strand. Similar DNA templates containing no CPD, or a single CPD on either the transcribed or the nontranscribed strand were used as controls. Using an in vitro transcription system with purified T7 RNA polymerase ( T7 RNAP) or rat liver RNAP II, we characterized transcript length and efficiency of transcription in vitro. We also tested the sensitivity of the arrested RNAP II-DNA-RNA ternary complex, at a CPD in the transcribed strand, to transcription factor TFIIS. The presence of a nearby CPD in the nontranscribed strand did not affect the behavior of either RNA polymerase nor did it affect the reverse translocation ability of the RNAP II-arrested complex. Our results additionally indicate that the sequence context of a CPD affects the efficiency of T7 RNAP arrest more significantly than that of RNAP II.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Stanford University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R56CA077712, R01CA063503, R01CA077712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63503, CA-77712, R01 CA077712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONURA T, 1975, PHOTOCHEM PHOTOBIOL, V22, P243, DOI 10.1111/j.1751-1097.1975.tb06743.x; BRADLEY MO, 1981, P NATL ACAD SCI-BIOL, V78, P3619, DOI 10.1073/pnas.78.6.3619; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHOI DJ, 1994, BIOCHEMISTRY-US, V33, P780, DOI 10.1021/bi00169a020; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; CORDA Y, 1991, BIOCHEMISTRY-US, V30, P222, DOI 10.1021/bi00215a032; CORDA Y, 1993, BIOCHEMISTRY-US, V32, P8582, DOI 10.1021/bi00084a027; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; LAM LH, 1986, MUTAT RES, V166, P199, DOI 10.1016/0167-8817(86)90018-0; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MIKITA T, 1994, BIOCHEMISTRY-US, V33, P9195, DOI 10.1021/bi00197a023; MINTON K, 1974, INT J RADIAT BIOL, V26, P81, DOI 10.1080/09553007414550981; NATH ST, 1991, CARCINOGENESIS, V12, P973, DOI 10.1093/carcin/12.6.973; Ordoukhanian P, 1997, NUCLEIC ACIDS RES, V25, P3783, DOI 10.1093/nar/25.19.3783; Perlow RA, 2002, J MOL BIOL, V321, P29, DOI 10.1016/S0022-2836(02)00593-4; REINES D, 1991, J BIOL CHEM, V266, P10510; REYNOLDS JR, 1987, MUTAT RES, V184, P197; Roth RB, 2001, BIOCHEMISTRY-US, V40, P5200, DOI 10.1021/bi0024355; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHI YB, 1988, J BIOL CHEM, V263, P527; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; TAYLOR JS, 1988, NUCLEIC ACIDS RES, V16, P5123, DOI 10.1093/nar/16.11.5123; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6	48	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19558	19564		10.1074/jbc.M301060200	http://dx.doi.org/10.1074/jbc.M301060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646562	hybrid			2022-12-25	WOS:000182932200107
J	Sparrow, JR; Vollmer-Snarr, HR; Zhou, JL; Jang, YP; Jockusch, S; Itagaki, Y; Nakanishi, K				Sparrow, JR; Vollmer-Snarr, HR; Zhou, JL; Jang, YP; Jockusch, S; Itagaki, Y; Nakanishi, K			A2E-epoxides damage DNA in retinal pigment epithelial cells - Vitamin E and other antioxidants inhibit A2E-epoxide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED DAMAGE; MACULAR DEGENERATION; LIPOFUSCIN FLUOROPHORE; PHOTOPHYSICAL PROPERTIES; GEOGRAPHIC ATROPHY; COMET ASSAY; FUNDUS AUTOFLUORESCENCE; LIPOPROTEIN OXIDATION; AGING RETINA; IN-VITRO	The autofluorescent pigments that accumulate in retinal pigment epithelial cells with aging and in some retinal disorders have been implicated in the etiology of macular degeneration. The major constituent is the fluorophore A2E, a pyridinium bisretinoid. Light-exposed A2E-laden retinal pigment epithelium exhibits a propensity for apoptosis with light in the blue region of the spectrum being most damaging. Efforts to understand the events precipitating the death of the cells have revealed that during irradiation (430 nm), A2E self-generates singlet oxygen with the singlet oxygen in turn reacting with A2E to generate epoxides at carbon-carbon double bonds. Here we demonstrate that A2E-epoxides, independent of singlet oxygen, exhibit reactivity toward DNA with oxidative base changes being at least one of these lesions. Mass spectrometry revealed that the antioxidants vitamins E and C, butylated hydroxytoluene, resveratrol, a trolox analogue (PNU-83836-E), and bilberry extract reduce A2E-epoxidation, whereas single cell gel electrophoresis and cell viability studies revealed a corresponding reduction in the incidence of DNA damage and cell death. Vitamin E, a lipophilic antioxidant, produced a more pronounced decrease in A2E-epoxidation than vitamin C, and treatment with both vitamins simultaneously did not confer additional benefit. Studies in which singlet oxygen was generated by endoperoxide in the presence of A2E revealed that vitamin E, butylated hydroxytoluene, resveratrol, the trolox analogue, and bilberry reduced A2E-epoxidation by quenching singlet oxygen. Conversely, vitamin C and ginkgolide B were not efficient quenchers of singlet oxygen under these conditions.	Columbia Univ, Dept Ophthalmol, New York, NY 10028 USA; Columbia Univ, Dept Chem, New York, NY 10028 USA	Columbia University; Columbia University	Nakanishi, K (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	kn5@columbia.edu	Jang, Young Pyo/AAJ-8782-2020	Jang, Young Pyo/0000-0001-5865-9228; Jockusch, Steffen/0000-0002-4592-5280; Vollmer-Snarr, Heidi/0000-0002-7312-4907	NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034509, R37GM034509] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12951] Funding Source: Medline; NIGMS NIH HHS [GM 34509] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVELINE BM, 1995, J PHOTOCH PHOTOBIO B, V30, P161, DOI 10.1016/1011-1344(95)07174-Z; Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; Bohr VA, 2001, ADV CELL AGING GERON, V4, P191; BUNTING JR, 1992, PHOTOCHEM PHOTOBIOL, V55, P81, DOI 10.1111/j.1751-1097.1992.tb04212.x; Burkle A, 2001, EYE, V15, P371, DOI 10.1038/eye.2001.139; Busch EM, 1999, VISION RES, V39, P1233, DOI 10.1016/S0042-6989(98)00233-8; Cabelof DC, 2002, MUTAT RES-FUND MOL M, V500, P135, DOI 10.1016/S0027-5107(02)00003-9; Campo GM, 1997, FREE RADICAL RES, V27, P577, DOI 10.3109/10715769709097861; Carnelley TJ, 2001, CHEM RES TOXICOL, V14, P1513, DOI 10.1021/tx0100946; CASOLI U, 1967, IND ITAL CONSERVE, V42, P11; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; Egner PA, 2001, P NATL ACAD SCI USA, V98, P14601, DOI 10.1073/pnas.251536898; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; Giri I, 2002, CHEM RES TOXICOL, V15, P638, DOI 10.1021/tx010187n; Green MHL, 1996, METHOD ENZYMOL, V269, P243; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198; HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029; Henderson RF, 2001, CHEM-BIOL INTERACT, V135, P53, DOI 10.1016/S0009-2797(01)00170-3; Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051; Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; Huang HY, 2002, AM J CLIN NUTR, V76, P549, DOI 10.1093/ajcn/76.3.549; JEFFREY AM, 1979, SCIENCE, V206, P1309, DOI 10.1126/science.316186; JEFFREY AM, 1977, NATURE, V269, P348, DOI 10.1038/269348a0; JEFFREY AM, 1976, P NATL ACAD SCI USA, V73, P2311, DOI 10.1073/pnas.73.7.2311; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; KOHDA K, 1986, BIOCHEM BIOPH RES CO, V139, P626, DOI 10.1016/S0006-291X(86)80036-5; Koivisto P, 1999, CARCINOGENESIS, V20, P1253, DOI 10.1093/carcin/20.7.1253; Kontush A, 2001, FREE RADICAL BIO MED, V31, P345, DOI 10.1016/S0891-5849(01)00595-0; Koskinen M, 2000, CHEM-BIOL INTERACT, V129, P209, DOI 10.1016/S0009-2797(00)00206-4; KRIEG M, 1993, BIOCHIM BIOPHYS ACTA, V1151, P168, DOI 10.1016/0005-2736(93)90101-5; Krieg M, 1996, BIOCHEM PHARMACOL, V51, P1461, DOI 10.1016/0006-2952(96)00087-1; Lamb LE, 2001, J PHYS CHEM B, V105, P11507, DOI 10.1021/jp0123177; LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; McCarthy PJ, 1997, MUTAGENESIS, V12, P209, DOI 10.1093/mutage/12.4.209; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Muth E R, 2000, Altern Med Rev, V5, P164; Nyman NA, 2001, J AGR FOOD CHEM, V49, P4183, DOI 10.1021/jf010572i; Olshansky SJ, 2002, SCI AM, V286, P92, DOI 10.1038/scientificamerican0602-92; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286; Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8; Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414; Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2; Rojas E, 1999, J CHROMATOGR B, V722, P225, DOI 10.1016/S0378-4347(98)00313-2; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; Selzer RR, 1999, CARCINOGENESIS, V20, P285, DOI 10.1093/carcin/20.2.285; SHEN HM, 1995, CARCINOGENESIS, V16, P419, DOI 10.1093/carcin/16.2.419; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222; Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; SPARROW JR, 2003, IN PRESS INVEST OPHT; Stocker Roland, 1994, Current Opinion in Lipidology, V5, P422, DOI 10.1097/00041433-199412000-00005; SUN DY, 1993, BIOCHEMISTRY-US, V32, P8068, DOI 10.1021/bi00083a003; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Szeto YT, 2002, MUTAT RES-FUND MOL M, V500, P31, DOI 10.1016/S0027-5107(01)00298-6; TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035; VANBEEK TA, 2000, GINKGO BILOBA MED AR; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; Yarborough A, 1996, CANCER RES, V56, P683; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9; Zadok D, 1999, EYE, V13, P734, DOI 10.1038/eye.1999.218	85	210	229	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18207	18213		10.1074/jbc.M300457200	http://dx.doi.org/10.1074/jbc.M300457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646558	hybrid			2022-12-25	WOS:000182838300081
J	Bangale, Y; Karle, S; Planque, S; Zhou, YX; Taguchi, H; Nishiyama, Y; Li, L; Kalaga, R; Paul, S				Bangale, Y; Karle, S; Planque, S; Zhou, YX; Taguchi, H; Nishiyama, Y; Li, L; Kalaga, R; Paul, S			VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease	FASEB JOURNAL			English	Article						SLE; neuroimmune regulation; catalytic antibodies	VASOACTIVE-INTESTINAL-PEPTIDE; CATALYTIC ANTIBODIES; FACTOR-VIII; CLEAVAGE; EXPRESSION; INHIBITORS; RECEPTOR; AMIDASE	The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purified IgG from Fas-defective C3H/gld mice, lupus patients, and autoimmune thyroiditis patients. No VIPase activity was detected in IgG from control mice and humans. Kinetic analyses of VIPase IgG preparations suggested low-affinity recognition of VIP. Yet the VIPase activity was VIP selective, judged by lack of correlation with other protease activities expressed by the IgG and by noninterference of unrelated peptides in the activity. Recombinant Fv constructs selected from a human lupus phage show library displayed VIPase activity, confirming that the active site is located in the V domains. Inhibition of the VIPase activity by di-isopropylfluorophosphate suggested a serine protease-like mechanism of catalysis. Irreversible binding of a biotinyated phosphonate diester by the IgG and Fv preparations was observed, consistent with the presence of activated nucleophiles similar to those in enzymes capable of covalent catalysis. These observations show that VIP is a target for specific catalytic autoantibodies in autoimmune disease.	Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Med, Chem Immunol Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas System	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, 6431 Fannin, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu			NIAID NIH HHS [AI 31268, AI 46029] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R01AI031268, R21AI031268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; Bracci-Laudiero L, 1998, NEUROSCI LETT, V248, P97, DOI 10.1016/S0304-3940(98)00342-5; CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Dorsam G, 2000, ANN NY ACAD SCI, V921, P79; Feher E, 1997, NEUROIMMUNOMODULAT, V4, P250, DOI 10.1159/000097344; Fersht A., 1985, ENZYME STRUCTURE MEC; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; GAO QS, 1994, J BIOL CHEM, V269, P32389; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Jackson DS, 1998, J MED CHEM, V41, P2289, DOI 10.1021/jm970543s; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 2002, NEW ENGL J MED, V346, P662, DOI 10.1056/NEJMoa011979; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; MATSUURA K, 1994, BIOCHEM BIOPH RES CO, V204, P57, DOI 10.1006/bbrc.1994.2425; Matsuura K, 2000, APPL BIOCHEM BIOTECH, V83, P107, DOI 10.1385/ABAB:83:1-3:107; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; Paul S, 1997, J IMMUNOL, V159, P1530; PAUL S, 1991, J BIOL CHEM, V266, P16128; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; SAID SI, 1986, J ENDOCRINOL INVEST, V9, P191, DOI 10.1007/BF03348097; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Sun JL, 2001, J IMMUNOL, V167, P5775, DOI 10.4049/jimmunol.167.10.5775; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; SUN M, 1991, J BIOL CHEM, V266, P15571; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; Vassiliou E, 2001, Arch Physiol Biochem, V109, P365, DOI 10.1076/apab.109.4.365.4245; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	36	33	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					628	635		10.1096/fj.02-0475com	http://dx.doi.org/10.1096/fj.02-0475com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665475				2022-12-25	WOS:000182580100007
J	Lacour, S; Micheau, O; Hammann, A; Drouineaud, V; Tschopp, J; Solary, E; Dimanche-Boitrel, MT				Lacour, S; Micheau, O; Hammann, A; Drouineaud, V; Tschopp, J; Solary, E; Dimanche-Boitrel, MT			Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; UP-REGULATION; APO-2 LIGAND; FAS LIGAND; DEATH; RECEPTOR; EXPRESSION; CASPASE-8	Cytokines such as Fas-ligand (Fas-L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) can induce human colon cancer cell apoptosis through engagement of their death domain receptors. All the cancer cells are not sensitive to these cytokines. We have shown recently that low doses of cytotoxic drugs could restore TRAIL-induced cell death in resistant colon cancer cell lines. The present work further explores the death pathway triggered by the cytotoxic drug/TRAIL combination in HT-29 colon cancer cells (www.alexiscorp.com). Clinically relevant concentrations of cisplatin, doxorubicin and 5-fluorouracil synergize with TRAIL to trigger HT-29 cell death. Activation of this pathway leads to apoptosis that involves both caspases and the mitochondria. An increased recruitment of Fas-associated death domain (FADD) and procaspase-8 to the TRAIL-induced death-inducing signaling complex (DISC) was shown in cells exposed to anticancer drugs. Following caspase-8 activation at the DISC level, the mitochondria-dependent death pathway is activated, as demonstrated by the cleavage of Bid, the dissipation of DeltaPsi(m), the release of mitochondrial proteins in the cytosol and the inhibitory effect of Bcl-2 expression. Importantly, besides mitochondrial potentiation, we show here that cytotoxic drugs sensitize HT-29 colon cancer cells to TRAIL-induced cell death by enhancing FADD and procaspase-8 recruitment to the DISC, a novel mechanism whose efficacy could depend partly on Bcl-2 expression level.	Fac Med & Pharm Dijon, INSERM, IFR 100, U517, F-21033 Dijon, France; Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Lausanne	Dimanche-Boitrel, MT (corresponding author), Fac Med & Pharm Dijon, INSERM, IFR 100, U517, 7 Blvd Jeanne Arc, F-21033 Dijon, France.	marie-therese.boitrel@rennes.inserm.fr	micheau, olivier/C-3574-2011; Dimanche-Boitrel, Marie-Therese M/I-4642-2015	micheau, olivier/0000-0001-8499-7984; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Solary, Eric/0000-0002-8629-1341				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BISIAU H, 1995, NOUV REV FR HEMATOL, V37, P241; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Burns TF, 2001, J BIOL CHEM, V276, P37879; CHAPMAN PB, 1987, J CLIN ONCOL, V5, P1942, DOI 10.1200/JCO.1987.5.12.1942; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gorlick R, 1999, SEMIN ONCOL, V26, P606; Gottlieb RA, 2001, BIOL SIGNAL RECEPT, V10, P147; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Keane MM, 1999, CANCER RES, V59, P734; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacour S, 2001, CANCER RES, V61, P1645; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Seol DW, 2001, CANCER RES, V61, P1138; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tanaka M, 1997, J IMMUNOL, V158, P2303; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang XD, 1999, CANCER RES, V59, P2747	46	111	118	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1807	1816		10.1038/sj.onc.1206127	http://dx.doi.org/10.1038/sj.onc.1206127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660816				2022-12-25	WOS:000181678200007
J	Wang, B; Wei, DY; Crum, VE; Richardson, EL; Xiong, HH; Luo, Y; Huang, S; Abbruzzese, JL; Xie, KP				Wang, B; Wei, DY; Crum, VE; Richardson, EL; Xiong, HH; Luo, Y; Huang, S; Abbruzzese, JL; Xie, KP			A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis	ONCOGENE			English	Article						nitric oxide; angiogenesis; metastasis; tumor; pancreas	SYNTHASE-II GENE; EXPRESSION; CELLS; ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; DISRUPTION; BIOLOGY; ABILITY; MICE	In the present study, a model system for studying the role of nitric oxide (NO) in tumor growth and metastasis was reported. Incubation of Panc02 murine pancreatic adenocarcinoma cells in vitro with cytokines and interferon led to heterogeneous expression of NO synthase 11 (NOS 11) protein. Clonal sublines expressing different levels of NOS 11 were then established using a limited dilution technique. After orthotopical implantation into the pancreas of syngeneic C57BL/6 mice, clones with a low level of NOS 11 expression produced tumors in pancreas, metastasized to the liver, and formed ascites, whereas those having a high level of NOS 11 expression did not. Liver-metastasis variants having low to high metastatic ability were also established using in vivo/in vitro passage. Compared with parental Panc02 cells exhibiting a high level of NOS 11 expression, these variants had a decreased level of NOS 11 expression. Furthermore, the heterogeneous Panc02 cells were injected intravenously into a large number of syngeneic mice. Variants that metastasized to the liver, lung, skin, peritoneum, ovary, and lymph nodes were established. All of the metastatic variants exhibited a lower level of NOS 11 expression than the parental Panc02 cell line did. However, the phenotypes of NOS 11 induction and metastatic ability were unstable. Multiple in vitrolin vivo selection led to stable low NOS 11 expression and high metastatic potential. Finally, to further confirm the role of NOS 11 expression derived from tumor cells in metastasis, poorly metastatic Panc02-H0 and highly metastatic Panc02-H7 cells were injected into the pancreas of syngeneic NOS II-/- mice, and groups of mice received i.p. injections of either phosphate-buffered saline or L-N-6-(I-iminoethyl) lysine. Inhibition of NOS 11 activity in vivo significantly promoted distant liver metastasis. Collectively, these data show that NOS 11 expression is highly heterogeneous and dynamically regulated, which can directly influence tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Box 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	kepxie@mail.mdanderson.org			NCI NIH HHS [1R01-CA093829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Ambs S, 1998, CANCER RES, V58, P334; COBBS CS, 1995, CANCER RES, V55, P727; CORBETT TH, 1984, CANCER RES, V44, P717; DiNapoli MR, 1996, J EXP MED, V183, P1323, DOI 10.1084/jem.183.4.1323; DONG ZY, 1994, CANCER RES, V54, P789; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; Fukumura D, 1998, CANCER METAST REV, V17, P77, DOI 10.1023/A:1005908805527; Gansauge S, 1998, CELL GROWTH DIFFER, V9, P611; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; JUANG SH, 1998, CANCER BIOTHERAPY, V12, P167; Jurasz P, 2001, CANCER RES, V61, P376; Kong G, 2001, INT J PANCREATOL, V29, P133, DOI 10.1385/IJGC:29:3:133; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lala PK, 1998, CANCER METAST REV, V17, P91, DOI 10.1023/A:1005960822365; Martinez A, 2001, Med Sci Monit, V7, P646; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Moochhala S, 1996, CARCINOGENESIS, V17, P1171, DOI 10.1093/carcin/17.5.1171; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nussler AK, 1998, LANGENBECK ARCH SURG, V383, P474, DOI 10.1007/s004230050163; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1991, CANCER RES, V51, P6073; Shi Q, 2000, CANCER RES, V60, P2579; Shi Q, 1999, CANCER RES, V59, P2072; THOMSEN LL, 1994, BRIT J CANCER, V72, P41; Wang BL, 2001, INT J PANCREATOL, V29, P37, DOI 10.1385/IJGC:29:1:37; Wang BL, 2001, ONCOGENE, V20, P6930, DOI 10.1038/sj.onc.1204871; Wang BL, 2001, INT J CANCER, V91, P607, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1109>3.0.CO;2-D; Wang BL, 2001, CANCER RES, V61, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; XIE K, 2003, IN PRESS FREE RAD BI; XIE K, 1997, CLIN CANCER RES, V3, P2189; Xie KP, 1997, J NATL CANCER I, V89, P421, DOI 10.1093/jnci/89.6.421; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1997, ONCOGENE, V15, P771, DOI 10.1038/sj.onc.1201239; Xie KP, 2001, INT J PANCREATOL, V29, P25, DOI 10.1385/IJGC:29:1:25; XIE KP, 1993, INT J ONCOL, V3, P1043; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333	43	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1771	1782		10.1038/sj.onc.1206386	http://dx.doi.org/10.1038/sj.onc.1206386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660813				2022-12-25	WOS:000181678200004
J	Mileykovskaya, E; Fishov, I; Fu, XY; Corbin, BD; Margolin, W; Dowhan, W				Mileykovskaya, E; Fishov, I; Fu, XY; Corbin, BD; Margolin, W; Dowhan, W			Effects of phospholipid composition on MinD-membrane interactions in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL DIVISION; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ESCHERICHIA-COLI; LIPID DOMAINS; SITE PLACEMENT; Z-RING; PROTEIN; LOCALIZATION; FTSZ; ATP	The peripheral membrane ATPase MinD is a component of the Min system responsible for correct placement of the division site in Escherichia coli cells. By rapidly migrating from one cell pole to the other, MinD helps to block unwanted septation events at the poles. MinD is an amphitropic protein that is localized to the membrane in its ATP-bound form. A C-terminal domain essential for membrane localization is predicted to be an amphipathic alpha-helix with hydrophobic residues interacting with lipid acyl chains and cationic residues on the opposite face of the helix interacting with the head groups of anionic phospholipids (Szeto, T. H., Rowland, S. L., Rothfield, L. I., and King, G. F. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 15693 - 15698). To investigate whether E. coli MinD displays a preference for anionic phospholipids, we first examined the localization dynamics of a green fluorescent protein-tagged derivative of MinD expressed in a mutant of E. coli that lacks phosphatidylethanolamine. In these cells, which contain only anionic phospholipids ( phosphatidylglycerol and cardiolipin), green fluorescent protein-MinD assembled into dynamic focal clusters instead of the broad zones typical of cells with normal phospholipid content. In experiments with liposomes composed of only zwitterionic, only anionic, or a mixture of anionic and zwitterionic phospholipids, purified MinD bound to these liposomes in the presence of ATP with positive cooperativity with respect to the protein concentration and exhibited Hill coefficients of about 2. Oligomerization of MinD on the liposome surface also was detected by fluorescence resonance energy transfer between MinD molecules labeled with different fluorescent probes. The affinity of MinD-ATP for anionic liposomes as well as liposomes composed of both anionic and zwitterionic phospholipids increased 9- and 2-fold, respectively, relative to zwitterionic liposomes. The degree of acyl chain unsaturation contributed positively to binding strength. These results suggest that MinD has a preference for anionic phospholipids and that MinD oscillation behavior, and therefore cell division site selection, may be regulated by membrane phospholipid composition.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77225 USA; Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	University of Texas System; University of Texas System; Ben Gurion University	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	William.Dowhan@uth.tmc.edu	FISHOV, ITZHAK/F-2264-2012	Mileykovskaya, Eugenia/0000-0002-8775-4467; Fishov, Itzhak/0000-0002-2125-0012	NIGMS NIH HHS [GM61074, GM20487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061074] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addinall SG, 2002, J MOL BIOL, V318, P219, DOI 10.1016/S0022-2836(02)00024-4; AKERLUND T, 1992, MOL MICROBIOL, V6, P2073, DOI 10.1111/j.1365-2958.1992.tb01380.x; Christensen H, 1999, MOL MICROBIOL, V31, P1561, DOI 10.1046/j.1365-2958.1999.01304.x; Corbin BD, 2002, EMBO J, V21, P1998, DOI 10.1093/emboj/21.8.1998; Cordell SC, 2001, FEBS LETT, V492, P160, DOI 10.1016/S0014-5793(01)02216-5; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Drobnies AE, 2002, BBA-BIOMEMBRANES, V1564, P82, DOI 10.1016/S0005-2736(02)00404-2; EISENBERG D, 1989, PREDICTION PROTEIN S, P635; Fishov I, 1999, MOL MICROBIOL, V32, P1166, DOI 10.1046/j.1365-2958.1999.01425.x; Haiens TH, 2002, FEBS LETT, V528, P35, DOI 10.1016/S0014-5793(02)03292-1; Hu ZL, 1999, P NATL ACAD SCI USA, V96, P14819, DOI 10.1073/pnas.96.26.14819; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Hu ZL, 2003, J BACTERIOL, V185, P196, DOI 10.1128/JB.185.1.196-203.2003; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 2000, J BACTERIOL, V182, P3965, DOI 10.1128/JB.182.14.3965-3971.2000; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; KARNOVSKY MJ, 1982, J CELL BIOL, V94, P1, DOI 10.1083/jcb.94.1.1; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; Lackner LL, 2003, J BACTERIOL, V185, P735, DOI 10.1128/JB.185.3.735-749.2003; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Margolin W, 2001, CURR OPIN MICROBIOL, V4, P647, DOI 10.1016/S1369-5274(01)00264-8; Margolin W, 2001, CURR BIOL, V11, pR395, DOI 10.1016/S0960-9822(01)00217-2; Meinhardt H, 2001, P NATL ACAD SCI USA, V98, P14202, DOI 10.1073/pnas.251216598; METCALF TN, 1986, P NATL ACAD SCI USA, V83, P95, DOI 10.1073/pnas.83.1.95; Mileykovskaya E, 1998, J BACTERIOL, V180, P4252, DOI 10.1128/JB.180.16.4252-4257.1998; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Phoenix DA, 2002, MOL MEMBR BIOL, V19, P1, DOI 10.1080/09687680110103631; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423; Rothfield LI, 2001, CELL, V106, P13, DOI 10.1016/S0092-8674(01)00432-9; Rye HS, 2001, METHODS, V24, P278, DOI 10.1006/meth.2001.1188; Sakai N, 2001, STRUCTURE, V9, P817, DOI 10.1016/S0969-2126(01)00638-4; Shih YL, 2002, EMBO J, V21, P3347, DOI 10.1093/emboj/cdf323; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suefuji K, 2002, P NATL ACAD SCI USA, V99, P16776, DOI 10.1073/pnas.262671699; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	42	133	136	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22193	22198		10.1074/jbc.M302603200	http://dx.doi.org/10.1074/jbc.M302603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676941	hybrid			2022-12-25	WOS:000183503900003
J	Ghosh-Choudhury, NG; Abboud, SL; Mahimainathan, L; Chandrasekar, B; Choudhury, GG				Ghosh-Choudhury, NG; Abboud, SL; Mahimainathan, L; Chandrasekar, B; Choudhury, GG			Phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2 (BMP-2)-induced myocyte enhancer factor 2A-dependent transcription of BMP-2 gene in cardiomyocyte precursor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; C-FOS; PHOSPHOINOSITIDE 3-KINASE; RETINOBLASTOMA PROTEIN; MUSCLE DIFFERENTIATION; MEF2 PROTEINS; DNA-SYNTHESIS; KINASE; GROWTH; ACTIVATION	The growth and differentiation factor bone morphogenetic protein-2 (BMP-2) regulates cardiac development during vertebrate embryogenesis. In cardiac precursor cells, BMP-2 has recently been shown to induce expression of cardiac transcription factors, including myocyte enhancer factor 2A (MEF-2A). The specific signal transduction mechanism by which BMP-2 regulates these actions is not known. We investigated the role of phosphatidylinositol (PI) 3-kinase in regulating these processes in cardiomyocyte precursor CL6 cells. BMP-2 increased PI 3-kinase activity in these cells in a time-dependent manner, resulting in increased expression of sarcomeric myosin heavy chain (MHC) and MEF-2A. Inhibition of PI 3-kinase abolished these actions of BMP-2, indicating the involvement of PI 3-kinase in these processes. Furthermore, BMP-2 stimulated specific protein.DNA complex formation when an MEF-2 DNA recognition element was used as probe. Antibody supershift assay confirmed the presence of MEF-2A in this protein.DNA complex. Inhibition of PI 3-kinase activity completely prevented the MEF-2A.DNA complex formation. BMP-2 also increased transcription of a reporter gene driven by an MEF-2-specific DNA element in a PI 3-kinase-dependent manner. Ectopic expression of MEF-2A increased BMP-2 transcription to the same extent induced by BMP-2, indicating that MEF-2A may participate in BMP-2 autoregulation in CL6 cells. Expression of dominant negative PI 3-kinase completely abolished BMP-2-induced as well as MEF-2A-mediated BMP-2 transcription. Furthermore expression of MEF-2A increased MHC expression in a PI 3-kinase-dependent manner. Together these data provide the first evidence that BMP-2-induced PI 3-kinase signaling regulates MEF-2A expression and define a mechanism of MEF-2A-dependent BMP-2 transcription.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Geriatric Research Education & Clinical Center	Ghosh-Choudhury, NG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			/0000-0001-5077-3552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68020] Funding Source: Medline; NIAMS NIH HHS [AR 42306] Funding Source: Medline; NIDDK NIH HHS [R01 DK 55815] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelwahid E, 2001, CELL TISSUE RES, V305, P67, DOI 10.1007/s004410100399; Bardgette J, 1999, J RECEPT SIGNAL TR R, V19, P865, DOI 10.3109/10799899909042878; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Chanut F, 1997, DEVELOPMENT, V124, P559; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Choudhury GG, 2000, BIOCHEM BIOPH RES CO, V273, P1069, DOI 10.1006/bbrc.2000.3081; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Izumi M, 2001, J BIOL CHEM, V276, P31133, DOI 10.1074/jbc.M101463200; Jamali M, 2001, FEBS LETT, V509, P126, DOI 10.1016/S0014-5793(01)03151-9; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Knochel S, 2001, MECH DEVELOP, V109, P79, DOI 10.1016/S0925-4773(01)00506-8; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Monzen K, 1999, MOL CELL BIOL, V19, P7096; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21998	22005		10.1074/jbc.M302277200	http://dx.doi.org/10.1074/jbc.M302277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663654	hybrid			2022-12-25	WOS:000183354200086
J	Senoo-Matsuda, N; Hartman, PS; Akatsuka, A; Yoshimura, S; Ishii, N				Senoo-Matsuda, N; Hartman, PS; Akatsuka, A; Yoshimura, S; Ishii, N			A complex II defect affects mitochondrial structure, leading to ced-3- and ced-4-dependent apoptosis and aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; SENSITIVE MUTANT; CELL-DEATH; OXYGEN; LIFE; MEV-1	The mev-1(kn1) mutation of Caenorhabditis elegans is in Cyt-1, which encodes a subunit of succinate-coenzyme Q oxidoreductase in the mitochondrial electron transport chain. Mutants are hypersensitive to oxidative stress and age precociously in part because of increased superoxide anion production. Here, we show that mev-1 mutants are defective in succinate-coenzyme Q oxidoreductase, possess ultrastructural mitochondrial abnormalities ( especially in muscle cells), show a loss of membrane potential, have altered CED-9 and Cyt-1 protein levels under hyperoxia, and contain ced-3- and ced-4-dependent supernumerary apoptotic cells. These defects likely explain the failure of mev-1 to complete embryonic development under hyperoxia as well as its reduced life span.	Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan; Tokai Univ, Sch Med, Lab Struct & Funct Res, Kanagawa 2591193, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Texas Christian Univ, Dept Biol, Ft Worth, TX 76129 USA	Tokai University; Tokai University; Kyowa Kirin Ltd; Texas Christian University	Ishii, N (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan.	nishii@is.icc.u-tokai.ac.jp						Adachi H, 1998, J GERONTOL A-BIOL, V53, pB240, DOI 10.1093/gerona/53A.4.B240; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BRENNER S, 1974, GENETICS, V77, P71; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Liu QA, 1999, ANN NY ACAD SCI, V887, P92, DOI 10.1111/j.1749-6632.1999.tb07925.x; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MITCHELL DH, 1979, J GERONTOL, V34, P28, DOI 10.1093/geronj/34.1.28; Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	18	78	89	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22031	22036		10.1074/jbc.M211377200	http://dx.doi.org/10.1074/jbc.M211377200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672828	hybrid			2022-12-25	WOS:000183354200090
J	Duval, M; Bedard-Goulet, S; Delisle, C; Gratton, JP				Duval, M; Bedard-Goulet, S; Delisle, C; Gratton, JP			Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination - Consequences on nitric oxide production from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; FACTOR RECEPTOR; C-CBL; ACTIN REORGANIZATION; SIGNALING PATHWAYS; EGF RECEPTOR; P85 SUBUNIT; IN-VIVO; ACTIVATION; PHOSPHORYLATION	Ligand-stimulated degradation of receptor tyrosine kinase (RTK) is an important regulatory step of signal transduction. The vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is responsible for the VEGF-stimulated nitric oxide (NO) production from endothelial cells. Cellular mechanisms mediating the negative regulation of Flk-1 signaling in endothelial cells have not been investigated. Here we show that Flk-1 is rapidly down-regulated following VEGF stimulation of bovine aortic endothelial cells (BAECs). Consequently, VEGF pretreatment of endothelial cells prevents any further stimulation of Flk-1, resulting in decreased NO production from subsequent VEGF challenges. Ubiquitination of RTKs targets them for degradation; we demonstrate that activation of Flk-1 by VEGF leads to its polyubiquitination in BAECs. Furthermore, VEGF stimulation of BAECs or COS-7 cells transiently transfected with Flk-1 results in the phosphorylation of the ubiquitin ligase Cbl, the enhanced association of Cbl with Flk-1, and the relocalization of Cbl to vesicular structures in BAECs. Overexpression of Cbl in COS-7 cells enhances VEGF-induced ubiquitination of Flk-1, whereas a Cbl mutant lacking the ubiquitin ligase RING finger domain, 70Z/3-Cbl, does not. Moreover, expression of Cbl in contrast to 70Z/3-Cbl inhibits the Flk-1-dependent activation of eNOS and, thus, NO release. In BAEC overexpressing Cbl, the degradation of Flk-1 upon VEGF stimulation is accelerated compared with cells transfected with a control vector (green fluorescent protein). Our findings demonstrate that Flk-1 is rapidly down-regulated following sustained VEGF stimulation and identify Cbl as a negative regulator of Flk-1 signaling to eNOS. Cbl thus plays a role in the regulation of VEGF signaling by mediating the stimulated ubiquitination and, consequently, degradation of Flk-1 in endothelial cells.	Inst Rech Clin Montreal, Lan Endothelial Cell Biol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Gratton, JP (corresponding author), Inst Rech Clin Montreal, Lan Endothelial Cell Biol, 110 Pins Ave W, Montreal, PQ H2W 1R7, Canada.	jean-philippe.gratton@ircm.qc.ca		Gratton, Jean-Philippe/0000-0001-9877-8520; Bedard-Goulet, Sara/0000-0002-7966-8569				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; de Melker AA, 2001, J CELL SCI, V114, P2167; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GALLAND F, 1993, ONCOGENE, V8, P1233; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kallies A, 2002, BLOOD, V99, P3213, DOI 10.1182/blood.V99.9.3213; Kovala AT, 2000, FASEB J, V14, P2486, DOI 10.1096/fj.00-0147com; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Marengere LEM, 1997, J IMMUNOL, V159, P70; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Miao H, 2002, BIOCHEM BIOPH RES CO, V292, P892, DOI 10.1006/bbrc.2002.6750; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	44	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20091	20097		10.1074/jbc.M301410200	http://dx.doi.org/10.1074/jbc.M301410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649282	hybrid			2022-12-25	WOS:000183078000067
J	Marszal, E; Danino, D; Shrake, A				Marszal, E; Danino, D; Shrake, A			A novel mode of polymerization of alpha(1)-proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ALPHA-1-PROTEINASE INHIBITOR; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; CONFORMATIONAL DISEASE; ALPHA-1-ANTITRYPSIN; ALPHA(1)-ANTITRYPSIN; SERPINS; LIVER; DEFICIENCY	Patients homozygous for the Z mutant form of alpha(1)-proteinase inhibitor (alpha(1)-PI) have an increased risk for the development of liver disease because of the accumulation in hepatocytes of inclusion bodies containing linear polymers of mutant alpha(1)-PI. The most widely accepted model of polymerization proposes that a linear, head-to-tail polymer forms by sequential insertion of the reactive center loop (RCL) of one alpha(1)-PI monomer between the central strands of the A beta-sheet of an adjacent monomer. This model derives primarily from two observations: peptides that are homologous with the RCL insert into the A beta-sheet of alpha(1)-PI monomer and this insertion prevents alpha(1)-PI polymerization. Normal alpha(1)-PI monomer does not spontaneously polymerize; however, here we show that the disulfide-linked dimer of normal alpha(1)-PI spontaneously forms linear polymers in buffer. The monomers within this dimer are joined head-to-head. Thus, the arrangement of monomers in these polymers must be different from that predicted by the loop-A sheet model. Therefore, we propose a new model for alpha(1)-PI polymer. In addition, polymerization of disulfide-linked dimer is not inhibited by the presence of the peptide even though dimer appears to interact with the peptide. Thus, RCL insertion into A beta-sheets may not occur during polymerization of this dimer.	US FDA, Ctr Biol Evaluat & Res, Div Hematol, Off Blood Res & Review, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shrake, A (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Hematol, Off Blood Res & Review, Bethesda, MD 20892 USA.		Danino, Dganit/D-6832-2016	Danino, Dganit/0000-0002-9782-4940				BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; Beleski-Carneiro EB, 1999, INT J BIOL MACROMOL, V26, P219, DOI 10.1016/S0141-8130(99)00086-0; BRANTLY M, 1988, AM J MED, V84, P13; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Carrell RW, 1996, CHEST, V110, pS243, DOI 10.1378/chest.110.6_Supplement.243S; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; DOTY P, 1953, PROTEINS           A, V1, P393; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FRAIZER GC, 1989, AM J HUM GENET, V44, P894; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; Heyer AG, 1998, CARBOHYD RES, V313, P165, DOI 10.1016/S0008-6215(98)00281-X; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kang HA, 1997, J BIOL CHEM, V272, P510; Laurell CB, 1979, CHEM PHYSL HUMAN PLA, P329; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MCELVANEY NG, 1997, LUNG SCI FDN, P2537; MEMORANDA, 1997, B WHO, V75, P397; Morrison ED, 2000, POSTGRAD MED, V107, P147, DOI 10.3810/pgm.2000.02.872; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Pace C N, 1986, Methods Enzymol, V131, P266; Perlmutter D H, 2000, Clin Liver Dis, V4, P387, DOI 10.1016/S1089-3261(05)70115-X; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RINEHART AR, 1993, AM J RESP CELL MOL, V9, P666, DOI 10.1165/ajrcmb/9.6.666; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sreerama N, 1999, PROTEIN SCI, V8, P370; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Tran ST, 2001, ARCH BIOCHEM BIOPHYS, V385, P322, DOI 10.1006/abbi.2000.2186; Villain-Simonnet A, 2000, INT J BIOL MACROMOL, V27, P65, DOI 10.1016/S0141-8130(99)00120-8; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; 2002, CDPRO SOFTWARE PACKA	58	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19611	19618		10.1074/jbc.M210720200	http://dx.doi.org/10.1074/jbc.M210720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649292	hybrid			2022-12-25	WOS:000183078000008
J	Sharma, P; Fatma, N; Kubo, E; Shinohara, T; Chylack, LT; Singh, DP				Sharma, P; Fatma, N; Kubo, E; Shinohara, T; Chylack, LT; Singh, DP			Lens epithelium-derived growth factor relieves transforming growth factor-beta 1-induced transcription repression of heat shock proteins in human lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN AQUEOUS-HUMOR; FACTOR-BETA; OXIDATIVE-STRESS; GENE-EXPRESSION; DOWN-REGULATION; MATRIX METALLOPROTEINASE-1; FIBER DIFFERENTIATION; APAF-1 APOPTOSOME; AKR-2B CELLS; FACTOR LEDGF	Lens epithelium-cell derived growth factor ( LEDGF) is a transcriptional activator. It protects the cells by binding to cis-stress response ((A/T) GGGG(T/A)), and heat shock (HSE; nGAAn) elements in the stress genes and activating their transcription. Transforming growth factor-beta(TGF-beta) has been implicated in the control of tissue homeostasis, terminal differentiation, and apoptosis. Here we provide evidence that TGF-beta1 down-regulates LEDGF expression and diminishes its affinity for DNA during TGF-beta1-induced phenotypic changes and apoptosis in human lens epithelial cells. Surprisingly, TGF-beta1 treatment for 48 h markedly decreased the LEDGF, Hsp27, and alphaB-crystallin promoter activities with the decrease of abundance of LEDGF mRNA and protein. Deletion mutants of the LEDGF promoter showed that one TGF-beta1 inhibitory element (TIE) like sequence nnnTTGGnnn (-444 to -433) contributed to this negative regulation. Mutation of TIE ( TTGG to TATT) abolished the down-regulation of the LEDGF promoter. Gel mobility and supershift assays showed that LEDGF in the nuclear extracts of TGF-beta1-treated human lens epithelial cells did not bind to stress-response elements and HSE. The TGF-beta1-induced down-regulation of LEDGF, Hsp27, and alphaB-crystallin promoters activity was reversed by cotransfection with a plasmid expressing LEDGF. Because overexpression of LEDGF was able to relieve TGF-beta1 and/or stress-induced changes, it would be a candidate molecule to postpone age-related degenerating disorders.	Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Ophthalm Res, Boston, MA 02115 USA; Fukui Med Univ, Dept Ophthalmol, Fukui 9101193, Japan	University of Nebraska System; University of Nebraska Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Fukui	Singh, DP (corresponding author), Univ Nebraska, Med Ctr, Dept Ophthalmol, Wittsin Hall,Rm 2008-9, Omaha, NE 68198 USA.	dpsingh@unmc.edu		Shinohara, Toshimichi/0000-0002-7197-9039	NEI NIH HHS [EY13394-01A1] Funding Source: Medline; PHS HHS [GA01051] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013394] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARLTROP JA, 1991, BIOORG MED CHEM LETT, V1, P611, DOI 10.1016/S0960-894X(01)81162-8; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; BONIFACINO JS, 1999, CURRENT PROTOCOLS CE, V1; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CONNOR AM, 1989, BIOCHIM BIOPHYS ACTA, V1009, P75, DOI 10.1016/0167-4781(89)90081-X; COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Dahm R, 1997, BIOCHEM SOC T, V25, pS584, DOI 10.1042/bst025s584; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; De Iongh RU, 2001, EXP EYE RES, V72, P649, DOI 10.1006/exer.2001.1001; de Longh RU, 2001, DEVELOPMENT, V128, P3995; EINSTEIN R, 1991, CURR EYE RES, V10, P157; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GRANSTEIN RD, 1990, J IMMUNOL, V144, P3021; HALES AM, 1994, CURR EYE RES, V13, P885, DOI 10.3109/02713689409015091; HALES AM, 1995, INVEST OPHTH VIS SCI, V36, P1709; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JAMPEL HD, 1990, CURR EYE RES, V9, P963, DOI 10.3109/02713689009069932; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; JONES CM, 1991, DEVELOPMENT, V111, P531; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kubo E, 2002, J MOL BIOL, V320, P1053, DOI 10.1016/S0022-2836(02)00551-X; KUROSAKA D, 1994, INVEST OPHTH VIS SCI, V35, P3408; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Lim JM, 2001, BIOCHEM BIOPH RES CO, V284, P33; LIN JK, 1992, CANCER RES, V52, P385; LIU J, 1994, INVEST OPHTH VIS SCI, V35, P388; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Matsui H, 2001, INVEST OPHTH VIS SCI, V42, P2935; MCAVOY JW, 1998, INVEST OPHTH VIS SCI, V39, P7; Mostert V, 1999, FEBS LETT, V460, P23, DOI 10.1016/S0014-5793(99)01298-3; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P1168; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; Oberhammer F, 1996, MICROSC RES TECHNIQ, V34, P247, DOI 10.1002/(SICI)1097-0029(19960615)34:3<247::AID-JEMT7>3.0.CO;2-M; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Sharma P, 2000, BIOCHEM BIOPH RES CO, V276, P1320, DOI 10.1006/bbrc.2000.3606; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; SINGH DP, 2002, INVESTIG OPHTHALMO S, V2345, P342; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TRIPATHI BJ, 1991, AM J ANAT, V192, P442, DOI 10.1002/aja.1001920411; White LA, 2000, BBA-GENE STRUCT EXPR, V1490, P259, DOI 10.1016/S0167-4781(00)00002-6; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Wu X, 2002, CELL DEATH DIFFER, V9, P915, DOI 10.1038/sj.cdd.4401063; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	81	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20037	20046		10.1074/jbc.M212016200	http://dx.doi.org/10.1074/jbc.M212016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649267	hybrid			2022-12-25	WOS:000183078000061
J	Vella, F; Thielens, NM; Bersch, B; Arlaud, GJ; Frachet, P				Vella, F; Thielens, NM; Bersch, B; Arlaud, GJ; Frachet, P			A recombinant chimeric epidermal growth factor-like module with high binding affinity for integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; POLYMERASE CHAIN-REACTION; GLYCOPROTEIN IIB-IIIA; ALPHA-V INTEGRINS; CELL-ADHESION; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; CHEMICAL SYNTHESIS; BACKBONE DYNAMICS; OVERLAP EXTENSION	Integrins are cell surface receptors involved in numerous pathological processes such as metastasis invasion and abnormal angiogenesis. To target these receptors, the epidermal growth factor (EGF)-like domain of human complement protease C1r was used as a natural scaffold to design chimeric modules containing the RGD motif. Here we report a high yield bacterial expression system and its application to the production of two such modules, EGF-RGD and V2, the latter variant mimicking the RGD-containing domain of disintegrins. These modules were characterized chemically, and their biological activity was investigated by cellular assays using various Chinese hamster ovary cell lines expressing beta(1) and beta(3) integrins and by surface plasmon resonance spectroscopy. Remarkably, the modifications leading to the V2 variant had differential effects on the interaction with beta(3) and beta(1) integrins. The disintegrin-like V2 module exhibited enhanced binding affinities compared with EGF-RGD, with K-D values of 7.2 nM for alpha(5)beta(1) ( a 4-fold decrease) and 3.5 nM for alpha(v)beta(3) (a 1.5-fold decrease), comparable with the values determined for natural integrin ligands. Analysis by NMR spectroscopy also revealed a differential dynamic behavior of the RGD motif in the EGF-RGD and V2 variants, providing insights into the structural basis of their relative binding efficiency. These novel RGD-containing EGF modules open the way to the design of improved variants with selective affinity for particular integrins and their use as carriers for other biologically active modules.	Univ Grenoble 1, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, CNRS,CEA, F-38027 Grenoble 1, France; Univ Grenoble 1, Inst Biol Struct Jean Pierre Ebel, Lab Resonance Magnet Nucl, CNRS,CEA, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Frachet, P (corresponding author), Univ Grenoble 1, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, CNRS,CEA, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Thielens, Nicole M/F-2512-2013; frachet, philippe/Q-2869-2019; Bersch, Beate/A-7011-2013; Frachet, philippe/C-3797-2018	Thielens, Nicole M/0000-0002-7354-0302; frachet, philippe/0000-0002-1658-3859; Bersch, Beate/0000-0003-1138-4911; Frachet, philippe/0000-0002-1658-3859				AOTA S, 1994, J BIOL CHEM, V269, P24756; ARLAUD GJ, 1977, BIOCHIM BIOPHYS ACTA, V485, P215, DOI 10.1016/0005-2744(77)90208-X; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Carr PA, 1997, STRUCTURE, V5, P949, DOI 10.1016/S0969-2126(97)00248-7; Colin M, 2000, GENE THER, V7, P139, DOI 10.1038/sj.gt.3301056; Copie V, 1998, J MOL BIOL, V277, P663; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Eliceiri BP, 1998, MOL MED, V4, P741, DOI 10.1007/BF03401768; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HANTGAN RR, 1992, THROMB HAEMOSTASIS, V68, P694; Hernandez JF, 1997, J PEPT RES, V49, P221; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hu B, 2000, BIOCHEMISTRY-US, V39, P12284, DOI 10.1021/bi000144q; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, J CLIN INVEST, V98, P2193, DOI 10.1172/JCI119027; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jenkins RG, 2000, GENE THER, V7, P393, DOI 10.1038/sj.gt.3301095; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; O'Neal VK, 2000, MOL MED, V6, P179, DOI 10.1007/BF03402113; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Parkes RJ, 2000, ADV DRUG DELIVER REV, V44, P135, DOI 10.1016/S0169-409X(00)00091-0; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Vella F, 1999, J PEPT RES, V54, P415, DOI 10.1034/j.1399-3011.1999.00137.x; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	57	6	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19834	19843		10.1074/jbc.M301470200	http://dx.doi.org/10.1074/jbc.M301470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654911	hybrid			2022-12-25	WOS:000183078000035
J	Ma, DD; Zhou, P; Harbour, JW				Ma, DD; Zhou, P; Harbour, JW			Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; CELL-CYCLE; UVEAL MELANOMA; G(1) CONTROL; G1 ARREST; PHOSPHORYLATION; E2F; INHIBITION; PRB	The retinoblastoma protein, Rb, suppresses tumorigenesis by inhibiting cell proliferation and promoting senescence and differentiation. Paradoxically, Rb also inhibits apoptosis, which would seem to oppose its tumor suppressor function. Further, most human cancer cells inactivate Rb by hyperphosphorylation and demonstrate increased proliferative capacity but not high levels of apoptosis. As a potential explanation for these findings, we show here that the tumor suppressor and antiapoptotic functions of Rb are regulated by distinct phosphorylation events. Phosphorylation of sites in the C terminus occurs efficiently every cell cycle and regulates proliferation. Phosphorylation of Ser(567) is inefficient and does not occur during the normal cell cycle. However, high cyclin-dependent kinase activity promotes phosphorylation of Ser(567) by inducing an intramolecular interaction that leads to release of E2F, degradation of Rb, and susceptibility to apoptosis. Thus, phosphorylation of Ser(567) may limit excessive proliferation by triggering cell death under hyperproliferative conditions. These findings suggest that the antiproliferative and antiapoptotic activities of Rb may represent complementary functions that work in concert to maintain the proliferation rate of cells within certain limits. As a survival strategy, some cancer cells may exploit this dual role of Rb by phosphorylating sites that regulate tumor suppression but avoiding phosphorylation of Ser(567) and consequent apoptotic stimulus.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Harbour, JW (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.	harbour@vision.wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809	NEI NIH HHS [R01 EY13169, K08 EY00382] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013169, K08EY000382] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Berry DE, 1996, ONCOGENE, V12, P1809; Brantey MA, 2000, CANCER RES, V60, P4320; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Pan WJ, 2001, CANCER RES, V61, P2885; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rigberg DA, 1999, J SURG RES, V84, P101, DOI 10.1006/jsre.1999.5617; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang J, 1997, CANCER RES, V57, P351; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xin SJ, 2002, DEVELOPMENT, V129, P1345; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yilmaz S, 1998, Hum Mutat, V12, P434, DOI 10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU16>3.3.CO;2-Z; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19358	19366		10.1074/jbc.M301761200	http://dx.doi.org/10.1074/jbc.M301761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646568	hybrid			2022-12-25	WOS:000182932200084
J	Nourani, A; Howe, L; Pray-Grant, MG; Workman, JL; Grant, PA; Cote, J				Nourani, A; Howe, L; Pray-Grant, MG; Workman, JL; Grant, PA; Cote, J			Opposite role of yeast ING family members in p53-dependent transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P33(ING1); HISTONE DEACETYLASE; ACETYLTRANSFERASE COMPLEXES; SACCHAROMYCES-CEREVISIAE; ACETYLATION; P53; COMPONENT; PROTEIN; NUA4	The inhibitor-of-growth (ING) family of proteins was founded by human ING1, a tumor suppressor interacting with p53 in vivo and required for its function in transcription/apoptosis. There are five different ING genes in humans, three of which have been linked to p53 function. In this study, we analyzed the three ING family members present in yeast. We demonstrate that each one is purified as a key component of a specific histone-modifying complex. Pho23 is part of Rpd3/Sin3 histone deacetylase complex, while Yng1 and Yng2 are subunits of the NuA3 and NuA4 histone acetyltransferase complexes, respectively. We also show that the three different ING proteins have opposite roles in transcriptional activation by p53 in vivo. These effects are linked to the presence of each ING in its respective chromatin modifying complex, since mutation of the corresponding catalytic subunit gave similar results. Depletion of Pho23/Rpd3 leads to increased p53-dependent transcription in vivo while depletion of Yng2 abrogates it. Surprisingly, deletion of YNG1 or SAS3 leads to increased transcriptional activation by p53. These data suggest that the NuA3 complex can function in gene-specific repression, an unusual role for a histone acetyltransferase complex. They also demonstrate the key specific role of ING proteins in different chromatin modifying complexes and their opposite functions in p53-dependent transcription.	Univ Laval, Ctr Canc Res, Hotel Dieu Quebec CHUQ, Quebec City, PQ G1R 2J6, Canada; Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Laval University; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Virginia	Cote, J (corresponding author), Univ Laval, Ctr Canc Res, Hotel Dieu Quebec CHUQ, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.		Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Howe L, 2002, MOL CELL BIOL, V22, P5047, DOI 10.1128/MCB.22.14.5047-5053.2002; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; John S, 2000, GENE DEV, V14, P1196; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lau WTW, 1998, GENETICS, V150, P1349; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	22	36	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19171	19175		10.1074/jbc.C300036200	http://dx.doi.org/10.1074/jbc.C300036200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12672825	hybrid			2022-12-25	WOS:000182932200060
J	Escartin, Q; Lallam-Laroye, C; Baroukh, B; Morvan, FO; Caruelle, JP; Godeau, G; Barritault, D; Saffar, JL				Escartin, Q; Lallam-Laroye, C; Baroukh, B; Morvan, FO; Caruelle, JP; Godeau, G; Barritault, D; Saffar, JL			A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers	FASEB JOURNAL			English	Article						RGTA; periodontal destruction; gingival inflammation; bone loss; tissue restructuring; osteoprogenitor cells; osteoclasts	SMOOTH-MUSCLE CELLS; MATRIX METALLOPROTEINASES; CRANIOTOMY DEFECTS; GELATINASE-A; EXPRESSION; COLLAGEN; HEPARIN; DISEASE; REGENERATION; GINGIVAL	Periodontitis are diseases of the supportive tissues of the teeth provoked by bacteria and characterized by gingival inflammation and bone destruction. We have developed a new strategy to repair tissues by administrating agents (RGTA) that mimic heparan sulfates by protecting selectively some of the growth factors naturally present within the injured tissue and interfering with inflammation. After periodontitis induction in hamsters, the animals were left untreated or received weekly i.m. injections of RGTA1507 at a dose of 100 mug/kg, 400 mug/kg, 1.5 mg/kg, or 15 mg/kg for 4 wk. RGTA treatment significantly reduced gingival tissue inflammation, thickened the pocket epithelium by increasing cell proliferation, and enhanced collagen accumulation in the gingiva. A marked reduction in bone loss was observed, resulting from depression of osteoclasia and robust stimulation of bone formation at the dose of 1.5 mg/kg. RGTA treatment for 8 wk at this dose reversed macroscopic bone loss, sharply contrasting with the extensive bone destruction in the untreated animals. RGTA treatment decreased gelatinase A (MMP-2) and B (MMP-9) proforms in gingival tissues. Our data indicate that a 4 wk treatment dose-dependently attenuated gingival and bone manifestations of the disease, whereas a longer treatment restored alveolar bone close to controls. By modulating and coordinating host responses, RGTA has unique therapeutic properties and is a promising candidate for the treatment of human periodontitis.	Univ Paris 05, Fac Chirurg Dent, Lab Biol & Physiopathol Craniofaciales, F-92120 Montrouge, France; Univ Paris 12, Fac Sci, CNRS, Lab CRRET, F-94010 Creteil, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Saffar, JL (corresponding author), Univ Paris 12, CNRS, FRE 2412,Av Gen Gaulle, F-94000 Creteil, France.	saffar@odontologie.univ-paris5.fr		Saffar, Jean-Louis/0000-0001-6288-9325				Albandar JM, 2002, PERIODONTOL 2000, V29, P7, DOI 10.1034/j.1600-0757.2002.290101.x; Albo D, 1996, J CRANIOFAC SURG, V7, P19, DOI 10.1097/00001665-199601000-00007; Alexakis C, 2001, FASEB J, V15, P1546, DOI 10.1096/fj.00-0756com; BARON R, 1978, J PERIODONTAL RES, V13, P309, DOI 10.1111/j.1600-0765.1978.tb00185.x; BERANGER JY, 1994, CELL BIOL INT, V18, P715, DOI 10.1006/cbir.1994.1100; Berton A, 2000, MATRIX BIOL, V19, P139, DOI 10.1016/S0945-053X(00)00057-3; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; CHANG KM, 1994, J PERIODONTAL RES, V29, P242, DOI 10.1111/j.1600-0765.1994.tb01218.x; Colombier ML, 1999, CELLS TISSUES ORGANS, V164, P131, DOI 10.1159/000016651; Dahan M, 2001, J CLIN PERIODONTOL, V28, P128, DOI 10.1034/j.1600-051x.2001.028002128.x; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; Golub LM, 1997, INFLAMM RES, V46, P310, DOI 10.1007/s000110050193; Ivanovski S, 2001, J PERIODONTAL RES, V36, P131, DOI 10.1034/j.1600-0765.2001.360301.x; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Lafont J, 1998, GROWTH FACTORS, V16, P23, DOI 10.3109/08977199809017489; LAFONT J, 1994, CELL MATER, V4, P219; LASFARGUES JJ, 1983, J PERIODONTAL RES, V18, P110, DOI 10.1111/j.1600-0765.1983.tb00342.x; Ledoux D, 2000, J BIOL CHEM, V275, P29383, DOI 10.1074/jbc.M000837200; Makela M, 1999, EXP CELL RES, V251, P67, DOI 10.1006/excr.1999.4564; MATSUKI Y, 1992, IMMUNOLOGY, V76, P42; Medalion B, 1997, CIRCULATION, V95, P1853; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 1996, INT J BIOL MACROMOL, V18, P141, DOI 10.1016/0141-8130(95)01074-2; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; Meddahi A, 2002, J BIOMED MATER RES, V62, P525, DOI 10.1002/jbm.10283; Mestries P, 2001, MATRIX BIOL, V20, P171, DOI 10.1016/S0945-053X(01)00131-7; Mestries P, 1998, J BIOMED MATER RES, V42, P286, DOI 10.1002/(SICI)1097-4636(199811)42:2<286::AID-JBM14>3.3.CO;2-F; Okada H, 1998, CRIT REV ORAL BIOL M, V9, P248, DOI 10.1177/10454411980090030101; Paquette DW, 1997, J CLIN PERIODONTOL, V24, P521, DOI 10.1111/j.1600-051X.1997.tb00223.x; REDDY MS, 1993, J CLIN PERIODONTOL, V20, P635, DOI 10.1111/j.1600-051X.1993.tb00708.x; Scannapleco FA, 1999, J PERIODONTAL RES, V34, P340, DOI 10.1111/j.1600-0765.1999.tb02263.x; Seguier S, 2000, J PERIODONTOL, V71, P1079, DOI 10.1902/jop.2000.71.7.1079; TARDIEU M, 1992, J CELL PHYSIOL, V150, P194, DOI 10.1002/jcp.1041500126; TARDIEU M, 1989, Journal of Biomaterials Science Polymer Edition, V1, P63, DOI 10.1163/156856289X00064; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Yamauchi H, 2000, FASEB J, V14, P2133	39	45	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					644	651		10.1096/fj.02-0708com	http://dx.doi.org/10.1096/fj.02-0708com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665477				2022-12-25	WOS:000182580100009
J	Soelaiman, S; Wei, BQQ; Bergson, P; Lee, YS; Shen, YQ; Mrksich, M; Shoichet, BK; Tang, WJ				Soelaiman, S; Wei, BQQ; Bergson, P; Lee, YS; Shen, YQ; Mrksich, M; Shoichet, BK; Tang, WJ			Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DOCKING; LETHAL FACTOR; BACILLUS-ANTHRACIS; BORDETELLA-PERTUSSIS; PROTECTIVE ANTIGEN; CRYSTAL-STRUCTURE; YERSINIA-PESTIS; BETA-LACTAMASE; CALMODULIN; BINDING	Edema factor (EF) and CyaA are adenylyl cyclase toxins secreted by pathogenic bacteria that cause anthrax and whooping cough, respectively. Using the structure of the catalytic site of EF, we screened a data base of commercially available, small molecular weight chemicals for those that could specifically inhibit adenylyl cyclase activity of EF. From 24 compounds tested, we have identified one quinazoline compound, ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate, that specifically inhibits adenylyl cyclase activity of EF and CyaA with similar to20 muM K-i. This compound neither affects the activity of host resident adenylyl cyclases type I, II, and V nor exhibits promiscuous inhibition. The compound is a competitive inhibitor, consistent with the prediction that it binds to the adenine portion of the ATP binding site on EF. EF is activated by the host calcium sensor, calmodulin. Surface plasmon resonance spectroscopic analysis shows that this compound does not affect the binding of calmodulin to EF. This compound is dissimilar from a previously described, non-nucleoside inhibitor of host adenylyl cyclase. It may serve as a lead to design antitoxins to address the role of adenylyl cyclase toxins in bacterial pathogenesis and to fight against anthrax and whooping cough.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA	University of California System; University of California San Francisco; University of Chicago; Northwestern University; University of Chicago	Tang, WJ (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Genentech Hall,600 16th St, San Francisco, CA 94143 USA.		Mrksich, Milan/G-2469-2011; Lee, Young-Sam/A-2499-2013; Wei, Bingqing/A-4525-2008	Wei, Bingqing/0000-0002-9416-1731; Mrksich, Milan/0000-0002-4964-796X; Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM62548, GM53459] Funding Source: Medline; PHS HHS [59957] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459, R01GM062548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abagyan R, 2001, CURR OPIN CHEM BIOL, V5, P375, DOI 10.1016/S1367-5931(00)00217-9; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Bertelli L, 2000, EUR J MED CHEM, V35, P333, DOI 10.1016/S0223-5234(00)90154-5; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brossier F, 2000, INFECT IMMUN, V68, P1781, DOI 10.1128/IAI.68.4.1781-1786.2000; Chambers CC, 1996, J PHYS CHEM-US, V100, P16385, DOI 10.1021/jp9610776; Cummings RT, 2002, P NATL ACAD SCI USA, V99, P6603, DOI 10.1073/pnas.062171599; Doman TN, 2002, J MED CHEM, V45, P2213, DOI 10.1021/jm010548w; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Drum CL, 2000, J BIOL CHEM, V275, P36334, DOI 10.1074/jbc.M004778200; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; Guidi-Rontani C, 2001, MOL MICROBIOL, V42, P931, DOI 10.1046/j.1365-2958.2001.02695.x; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; Hodneland CD, 2002, P NATL ACAD SCI USA, V99, P5048, DOI 10.1073/pnas.072685299; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Kumar P, 2001, INFECT IMMUN, V69, P6532, DOI 10.1128/IAI.69.10.6532-6536.2001; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; Li JB, 1998, J PHYS CHEM A, V102, P1820, DOI 10.1021/jp972682r; Lorber DM, 2002, PROTEIN SCI, V11, P1393, DOI 10.1110/ps.2830102; Lorber DM, 1998, PROTEIN SCI, V7, P938; McGovern SL, 2003, J MED CHEM, V46, P1478, DOI 10.1021/jm020427b; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; MENG EC, 1993, PROTEINS, V17, P266, DOI 10.1002/prot.340170305; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MICHANKIN BN, 1992, B SOC PATHOL EXOT, V85, P17; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Mourez M, 2001, NAT BIOTECHNOL, V19, P958, DOI 10.1038/nbt1001-958; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Onda T, 2001, J BIOL CHEM, V276, P47785, DOI 10.1074/jbc.M107233200; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Powers RA, 2002, STRUCTURE, V10, P1013, DOI 10.1016/S0969-2126(02)00799-2; Sellman BR, 2001, SCIENCE, V292, P695, DOI 10.1126/science.109563; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; SHEVCHENKO LA, 1987, ZH MIKROBIOL EPIDEMI, V7, P59; SHOICHET BK, 1993, PROTEIN ENG, V6, P723, DOI 10.1093/protein/6.7.723; Shoichet BK, 1999, PROTEINS, V34, P4, DOI 10.1002/(SICI)1097-0134(19990101)34:1<4::AID-PROT2>3.0.CO;2-6; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Wang XJ, 2002, PROTEINS, V47, P86, DOI 10.1002/prot.10058; Wei BQQ, 2002, J MOL BIOL, V322, P339, DOI 10.1016/S0022-2836(02)00777-5; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899	54	78	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25990	25997		10.1074/jbc.M301232200	http://dx.doi.org/10.1074/jbc.M301232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12676933	hybrid			2022-12-25	WOS:000183920200094
J	Doughman, RL; Firestone, AJ; Wojtasiak, ML; Bunce, MW; Anderson, RA				Doughman, RL; Firestone, AJ; Wojtasiak, ML; Bunce, MW; Anderson, RA			Membrane ruffling requires coordination between type I alpha phosphatidylinositol phosphate kinase and Rac signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; 4-PHOSPHATE 5-KINASE; PLASMA-MEMBRANE; BINDING PROTEIN; ACTIN CYTOSKELETON; EXCHANGE FACTOR; LIVING CELLS; ACTIVATION; RHO	Membrane ruffle formation requires remodeling of cortical actin filaments, a process dependent upon the small G-protein Rac. Growth factors stimulate actin remodeling and membrane ruffling by integration of signaling pathways that regulate actin-binding proteins. Phosphatidylinositol 4,5-bisphosphate (PIP2) regulates the activity of many actin-binding proteins and is produced by the type I phosphatidylinositol phosphate kinases (PIPKIs). Here we show in MG-63 cells that only the PIPKIalpha isoform is localized to platelet-derived growth factor (PDGF)-induced membrane ruffles. Further, expression of kinase dead PIPKIalpha, which acts as a dominant negative mutant, blocked membrane ruffling, suggesting that PIPKIalpha and PIP2 participate in ruffling. To explore this, PIPKIalpha was overexpressed in serum-starved cells and stimulated with PDGF. In serum-starved cells, PIPKIalpha expression did not stimulate actin remodeling, but when these cells were stimulated with PDGF, actin rapidly reorganized into foci but not membrane ruffles. PIPKIalpha-mediated formation of actin foci was independent of both Rac1 and phosphatidylinositol 3-kinase activities. Significantly, coexpression of dominant active Rac1 with PIPKIalpha in PDGF-stimulated cells resulted in membrane ruffling. The PDGF- and Rac1-stimulated ruffling was inhibited by expression of kinase-dead PIPKIalpha. Combined, these data support a model where the localized production of PIP2 by PIPKIalpha is necessary for actin remodeling, whereas formation of membrane ruffles required Rac signaling.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave, Madison, WI 53706 USA.			Firestone, Ari/0000-0001-9902-443X; Anderson, Richard/0000-0001-6265-8359	NIGMS NIH HHS [GM-144-KW76] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Coppolino MG, 2002, J BIOL CHEM, V277, P43849, DOI 10.1074/jbc.M209046200; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Diakonova M, 2002, J BIOL CHEM, V277, P10669, DOI 10.1074/jbc.M111138200; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kunz J, 2002, J BIOL CHEM, V277, P5611, DOI 10.1074/jbc.M110775200; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Ruusala A, 1998, J CELL SCI, V111, P111; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; Thomas JE, 1997, J CELL BIOCHEM, V64, P182, DOI 10.1002/(SICI)1097-4644(199702)64:2<182::AID-JCB2>3.0.CO;2-T; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; van Rheenen J, 2002, MOL BIOL CELL, V13, P3257, DOI 10.1091/mbc.E02-04-0231; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	58	94	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23036	23045		10.1074/jbc.M211397200	http://dx.doi.org/10.1074/jbc.M211397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682053	hybrid			2022-12-25	WOS:000183503900111
J	Broquet, AH; Thomas, G; Masliah, J; Trugnan, G; Bachelet, M				Broquet, AH; Thomas, G; Masliah, J; Trugnan, G; Bachelet, M			Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HEAT-SHOCK PROTEINS; STRESS PROTEINS; CELL-SURFACE; ANTIGEN PRESENTATION; BINDING-PROTEINS; MAMMALIAN-CELLS; CACO-2 CELLS; LIPID RAFTS; CALRETICULIN	Accumulating evidence suggests that some heat shock proteins ( Hsps), in particular the 72-kDa inducible Hsp70, associate to the cell membrane and might be secreted through an unknown mechanism to exert important functions in the immune response and signal transduction. We speculated that specialized structures named lipid rafts, known as important platforms for the delivery of proteins to the cell membrane, might be involved in the unknown mechanism ensuring membrane association and secretion of Hsp70. Lipid rafts are sphingolipid-cholesterol-rich structures that have been mainly characterized in polarized epithelial cells and can be isolated as detergent-resistant microdomains (DRMs). Analysis of soluble and DRM fractions prepared from unstressed Caco-2 epithelial cells revealed that Hsp70, and to a lesser extent calnexin, were present in DRM fractions. Increased expression of Hsps, through heat shock or by using drugs acting on protein trafficking or intracellular calcium level, induced an efficient translocation to DRM. We also found that Hsp70 was released by epithelial Caco-2 cells, and this release dramatically increased after heat shock. Drugs known to block the classical secretory pathway were unable to reduce Hsp70 release. By contrast, release of the protein was affected by the raft-disrupting drug methyl-beta-cyclodextrin. Our data suggest that lipid rafts are part of a mechanism ensuring the correct functions of Hsps and provide a rational explanation for the observed membrane association and release of Hsp70.	Ctr Hosp Univ St Antoine, INSERM, U538, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bachelet, M (corresponding author), Ctr Hosp Univ St Antoine, INSERM, U538, 27 Rue Chaligny, F-75571 Paris 12, France.			Broquet, Alexis/0000-0002-6635-9601				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bush KT, 1999, AM J PHYSIOL-RENAL, V277, pF211, DOI 10.1152/ajprenal.1999.277.2.F211; CHOUCHANE L, 1994, J INFECT DIS, V169, P253, DOI 10.1093/infdis/169.2.253; Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617; GARCIA M, 1993, J CELL SCI, V104, P1281; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; Sapin C, 2002, J VIROL, V76, P4591, DOI 10.1128/JVI.76.9.4591-4602.2002; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Wells AD, 2000, IMMUNOL TODAY, V21, P129, DOI 10.1016/S0167-5699(99)01558-3; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	26	246	255	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21601	21606		10.1074/jbc.M302326200	http://dx.doi.org/10.1074/jbc.M302326200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682040	hybrid			2022-12-25	WOS:000183354200037
J	O'Reilly, D; Quinn, CM; El-Shanawany, T; Gordon, S; Greaves, DR				O'Reilly, D; Quinn, CM; El-Shanawany, T; Gordon, S; Greaves, DR			Multiple Ets factors and interferon regulatory factor-4 modulate CD68 expression in a cell type-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; TRANSCRIPTION FACTOR PU.1; STIMULATING FACTOR-RECEPTOR; TARGET GENE SPECIFICITY; LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; MULTIPROTEIN COMPLEX; MOLECULAR-CLONING; POTENTIAL ROLE; HOST-DEFENSE	CD68 is a transmembrane glycoprotein expressed in all cells of the mononuclear phagocyte lineage including monocytes and tissue resident macrophages. Deletion analysis of the 5'-flanking sequences of the gene demonstrated that the proximal -150-bp sequence of the CD68 promoter exhibits high level promoter activity in macrophages. Mutations that abolish Ets factor binding at positions -106 and -89 reduce promoter activity in macrophages to 12 and 30%, respectively. Band shift experiments show that PU.1 associates with the -89 site whereas, Elf-1 preferentially binds the -106 Ets binding site and enhances CD68 activity in vitro. Furthermore, chromatin immunoprecipitation experiments confirm that Elf-1 and PU.1 associate with the CD68 proximal promoter in vivo in THP-1 cells. PU.1 does not bind to the CD68 promoter alone but instead forms heterocomplexes with members of the interferon regulatory factor family (IRF) including IRF-4 and IRF-8. IRF-4 and IRF-8 typically mediate transcriptional activation when associated with PU.1 on composite elements. However, our data show that PU.1/IRF-4 and IRF-8 heterocomplexes down-regulate CD68 promoter activity in macrophages and repression is dependent on the integrity of both the IRF and PU.1 half-sites of this composite element. Chromatin immunoprecipitation data reveal that neither IRF-4 nor IRF-8 associate with the CD68 proximal promoter in macrophages in vivo but IRF-4 is associated with the promoter in B lymphocytes. We propose that expression of CD68 in myeloid cells requires the Ets transcription factors Elf-1 and PU.1 and CD68 expression is down-regulated in lymphoid cells by combinatorial interactions between PU.1 and IRF-4.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Greaves, DR (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.			Greaves, David/0000-0003-2856-9410				Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; Greaves DR, 1998, GENOMICS, V54, P165, DOI 10.1006/geno.1998.5546; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOLNESS CL, 1993, BLOOD, V81, P1607; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Jiang ZM, 1998, GENOMICS, V50, P199, DOI 10.1006/geno.1998.5327; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jones E, 1998, GENOMICS, V53, P248, DOI 10.1006/geno.1998.5515; Juang YT, 2002, J IMMUNOL, V168, P2865, DOI 10.4049/jimmunol.168.6.2865; Kautz B, 2001, J BIOL CHEM, V276, P37868; KISTLER B, 1995, ONCOGENE, V11, P1095; Levi BZ, 2002, J INTERF CYTOK RES, V22, P153, DOI 10.1089/107999002753452764; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Liu XD, 1999, J BIOL CHEM, V274, P3285, DOI 10.1074/jbc.274.6.3285; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2002, J INTERF CYTOK RES, V22, P121, DOI 10.1089/107999002753452737; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Newlands S, 1998, GENE DEV, V12, P2748, DOI 10.1101/gad.12.17.2748; PARWARESCH MR, 1986, AM J PATHOL, V125, P141; Perkel JM, 1998, J IMMUNOL, V160, P241; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PULFORD KAF, 1990, INT IMMUNOL, V2, P973, DOI 10.1093/intimm/2.10.973; Quinn CM, 1999, GENOMICS, V62, P468, DOI 10.1006/geno.1999.6031; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; ROSS IL, 1994, ONCOGENE, V9, P121; Sambrook J., 2002, MOL CLONING LAB MANU; Sarafova S, 1999, J BIOL CHEM, V274, P16126, DOI 10.1074/jbc.274.23.16126; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Searles RP, 1999, J VIROL, V73, P3040, DOI 10.1128/JVI.73.4.3040-3053.1999; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shi MJ, 2001, INT IMMUNOL, V13, P733, DOI 10.1093/intimm/13.6.733; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Tsujimura H, 2002, J IMMUNOL, V169, P1261, DOI 10.4049/jimmunol.169.3.1261; VanVelzen AG, 1997, BIOCHEM J, V322, P411; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yabu T, 1998, MOL MAR BIOL BIOTECH, V7, P138; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	65	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21909	21919		10.1074/jbc.M212150200	http://dx.doi.org/10.1074/jbc.M212150200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676954	hybrid			2022-12-25	WOS:000183354200076
J	Yang, SW; Kim, DH; Lee, JJ; Chun, YJ; Lee, JH; Kim, YJ; Chung, IK; Kim, WT				Yang, SW; Kim, DH; Lee, JJ; Chun, YJ; Lee, JH; Kim, YJ; Chung, IK; Kim, WT			Expression of the telomeric repeat binding factor gene NgTRF1 is closely coordinated with the cell division program in tobacco BY-2 suspension culture cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC BINDING; MYB-LIKE DOMAIN; REVERSE-TRANSCRIPTASE; DNA RECOGNITION; PROTEIN; LENGTH; YEAST; TRF1; TELOBOX; RAP1	Telomeres are vital for preserving chromosome integrity during cell division. Several genes encoding potential telomere- binding proteins have recently been identified in higher plants, but nothing is known about their function or regulation during cell division. In this study, we have isolated and characterized a cDNA clone, pNgTRF1, encoding a putative double- stranded telomeric repeat binding factor of Nicotiana glutinosa, a diploid tobacco plant. The predicted protein sequence of NgTRF1 ( M-r = 75,000) contains a single Myb- like domain with significant homology to a corresponding motif in human TRF1/ Pin2 and TRF2. Gel retardation assays revealed that bacterially expressed full- length NgTRF1 was able to form a specific complex only with probes containing three or more contiguous telomeric TTTAGGG repeats. The Myb- like domain of NgTRF1 is essential, but not sufficient, to bind the telomeric repeat sequence. The glutamine- rich extreme C- terminal region, which does not exist in animal proteins, was additionally required to form a specific telomere- protein complex. The dissociation constant ( K-d) of the Myb motif plus the glutamine- rich domain of NgTRF1 to the two-telomeric repeat sequence was evaluated to be 4.5 +/- 0.2 x 10(-9) M, which is comparable to that of the Myb domain of human TRF1. Expression analysis showed that NgTRF1 gene activity was inversely correlated with the cell division capacity of tobacco root cells and during the 9- day culture period of BY- 2 suspension cells, while telomerase activity was positively correlated with cell division. In synchronized BY- 2 cells, NgTRF1 was selectively expressed in G(1) phase, whereas telomerase activity peaked in S phase. These findings suggest that telomerase activity and NgTRF1 expression are differentially regulated in an opposing fashion during growth and cell division in tobacco plants. The possible physiological functions of NgTRF1 in tobacco cells are also discussed.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea	Yonsei University	Kim, WT (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea.	wtkim@yonsei.ac.kr						ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; Chen CM, 2001, J BIOL CHEM, V276, P16511, DOI 10.1074/jbc.M009659200; Choi D, 2000, BBA-GENE STRUCT EXPR, V1492, P211, DOI 10.1016/S0167-4781(00)00073-7; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Fitzgerald MS, 1996, P NATL ACAD SCI USA, V93, P14422, DOI 10.1073/pnas.93.25.14422; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Fulneckova J, 2000, FEBS LETT, V467, P305, DOI 10.1016/S0014-5793(00)01178-9; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Heller K, 1996, MOL GEN GENET, V252, P342, DOI 10.1007/BF02173780; Hwang MG, 2001, FEBS LETT, V503, P35, DOI 10.1016/S0014-5793(01)02685-0; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; Kim JH, 1998, PLANT MOL BIOL, V36, P661, DOI 10.1023/A:1005994719175; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Lee JH, 2000, PLANT MOL BIOL, V42, P547, DOI 10.1023/A:1006373917321; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lundblad V, 1998, P NATL ACAD SCI USA, V95, P8415, DOI 10.1073/pnas.95.15.8415; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McKnight TD, 2002, PLANT MOL BIOL, V48, P331, DOI 10.1023/A:1014091032750; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; Planchais S, 2000, FEBS LETT, V476, P78, DOI 10.1016/S0014-5793(00)01675-6; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X; REGAD F, 1994, J MOL BIOL, V239, P163, DOI 10.1006/jmbi.1994.1360; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Riha K, 1998, PLANT CELL, V10, P1691, DOI 10.1105/tpc.10.10.1691; Riha K, 2000, PLANT J, V23, P633, DOI 10.1046/j.1365-313x.2000.00831.x; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shippen DE, 1998, TRENDS PLANT SCI, V3, P126, DOI 10.1016/S1360-1385(98)01214-X; Shore D, 2001, CURR OPIN GENET DEV, V11, P189, DOI 10.1016/S0959-437X(00)00178-7; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Spink KG, 2000, NUCLEIC ACIDS RES, V28, P527, DOI 10.1093/nar/28.2.527; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TAKEUCHI Y, 1992, PLANT MOL BIOL, V18, P835, DOI 10.1007/BF00020031; Tamura K, 1999, J BIOL CHEM, V274, P20997, DOI 10.1074/jbc.274.30.20997; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vassetzky NS, 1999, NUCLEIC ACIDS RES, V27, P4687, DOI 10.1093/nar/27.24.4687; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yang Seong Wook, 2001, Journal of Plant Biology, V44, P168; Yang SW, 2002, PLANT J, V29, P617, DOI 10.1046/j.0960-7412.2001.01244.x; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	67	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21395	21407		10.1074/jbc.M209973200	http://dx.doi.org/10.1074/jbc.M209973200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12646586	hybrid			2022-12-25	WOS:000183354200013
J	Elam, JS; Malek, K; Rodriguez, JA; Doucette, PA; Taylor, AB; Hayward, LJ; Cabelli, DE; Valentine, JS; Hart, PJ				Elam, JS; Malek, K; Rodriguez, JA; Doucette, PA; Taylor, AB; Hayward, LJ; Cabelli, DE; Valentine, JS; Hart, PJ			An alternative mechanism of bicarbonate-mediated peroxidation by copper-zinc superoxide dismutase - Rates enhanced via proposed enzyme-associated peroxycarbonate intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ELECTRON-DENSITY MAPS; HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; MUTANT SUPEROXIDE-DISMUTASE-1; RADICAL PRODUCTION; AXONAL-TRANSPORT; MOUSE MODEL; K-M; INACTIVATION	Hydrogen peroxide can interact with the active site of copper-zinc superoxide dismutase (SOD1) to generate a powerful oxidant. This oxidant can either damage amino acid residues at the active site, inactivating the enzyme (the self-oxidative pathway), or oxidize substrates exogenous to the active site, preventing inactivation (the external oxidative pathway). It is well established that the presence of bicarbonate anion dramatically enhances the rate of oxidation of exogenous substrates. Here, we show that bicarbonate also substantially enhances the rate of self-inactivation of human wild type SOD1. Together, these observations suggest that the strong oxidant formed by hydrogen peroxide and SOD1 in the presence of bicarbonate arises from a pathway mechanistically distinct from that producing the oxidant in its absence. Self-inactivation rates are further enhanced in a mutant SOD1 protein (L38V) linked to the fatal neurodegenerative disorder, familial amyotrophic lateral sclerosis. The 1.4 Angstrom resolution crystal structure of pathogenic SOD1 mutant D125H reveals the mode of oxyanion binding in the active site channel and implies that phosphate anion attenuates the bicarbonate effect by competing for binding to this site. The orientation of the enzyme-associated oxyanion suggests that both the self-oxidative and external oxidative pathways can proceed through an enzyme-associated peroxycarbonate intermediate.	Univ Texas, Hlth Sci Ctr, Dept Biochem, X Ray Crystallog Core Lab, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; United States Department of Energy (DOE); Brookhaven National Laboratory	Valentine, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, X Ray Crystallog Core Lab, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jsv@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Taylor, Alexander/0000-0003-3517-6033; Hayward, Lawrence/0000-0003-0579-0358	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112, R01NS044170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [NS39112, R01 NS044170, NS44170, R01 NS039112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; DEFREITAS DM, 1987, INORG CHEM, V26, P2788; ELAM JS, 2003, IN PRESS NAT STRUCT; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; Gurney ME, 1998, J INHERIT METAB DIS, V21, P587, DOI 10.1023/A:1005475206997; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalyanaraman R, 2001, NUCL INSTRUM METH B, V175, P182, DOI 10.1016/S0168-583X(00)00662-5; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurahashi T, 2001, J AM CHEM SOC, V123, P9268, DOI 10.1021/ja015953r; LEVINSKI AM, 1983, HARRISONS PRINCIPLES; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; *POV TEAM, PERS VIS RAY TRAC VE; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; RIGO A, 1975, BIOCHEM BIOPH RES CO, V63, P1013, DOI 10.1016/0006-291X(75)90670-1; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Sankarapandi S, 1999, J BIOL CHEM, V274, P34576, DOI 10.1074/jbc.274.49.34576; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 1999, ADV EXP MED BIOL, V448, P193; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200	53	71	72	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21032	21039		10.1074/jbc.M300484200	http://dx.doi.org/10.1074/jbc.M300484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649272	hybrid			2022-12-25	WOS:000183230500077
J	Harrison, CA; Gray, PC; Koerber, SC; Fischer, W; Vale, W				Harrison, CA; Gray, PC; Koerber, SC; Fischer, W; Vale, W			Identification of a functional binding site for activin on the type I receptor ALK4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE; BETA; INHIBIN; DEFICIENT; ROLES; FOLLISTATIN; ECTODOMAIN; COMPLEXES; RESPONSES; LIGAND	Activins, like other members of the transforming growth factor-beta (TGF-beta) superfamily, initiate signaling by assembling a complex of two types of transmembrane serine/threonine receptor kinases classified as type II (ActRII or ActRIIB) and type I (ALK4). A kinase-deleted version of ALK4 can form an inactive complex with activin and ActRII/IIB and thereby acts in a dominant negative manner to block activin signaling. Using the complex structure of bone morphogenetic protein-2 bound to its type I receptor (ALK3) as a guide, we introduced extracellular domain mutations in the context of the truncated ALK4 (ALK4-trunc) construct and assessed the ability of the mutants to inhibit activin function. We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu(40), Ile(70), Val(73), Leu(75), and Pro(77)) that, when mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity. In addition, eleven mutants partially affected activin binding to ALK4. Together, these residues likely constitute the binding surface for activin on ALK4. Cross-linking studies measuring binding of I-125-activin-A to the ALK4-trunc mutants in the presence of ActRII implicated the same residues. Our results indicate that there is only a partial overlap of the binding sites on ALK4 and ALK3 for activin-A and bone morphogenetic protein-2, respectively. In addition three of the residues required for activin binding to ALK4 are conserved on the type I TGF-beta receptor ALK5, suggesting the corresponding region on ALK5 may be important for TGF-beta binding.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	Salk Institute	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu		Harrison, Craig/0000-0003-1059-3682				Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BILEZIKJIAN LM, 1992, TRENDS ENDOCRIN MET, V3, P218, DOI 10.1016/1043-2760(92)90031-U; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fischer WH, 2003, J ENDOCRINOL, V176, P61, DOI 10.1677/joe.0.1760061; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Guimond A, 2002, FEBS LETT, V513, P147, DOI 10.1016/S0014-5793(01)03231-8; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Phillips DJ, 2001, MOL CELL ENDOCRINOL, V180, P155, DOI 10.1016/S0303-7207(01)00516-0; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; Su GH, 2001, P NATL ACAD SCI USA, V98, P3254, DOI 10.1073/pnas.051484398; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; VALE W, 1988, RECENT PROG HORM RES, V44, P1; Vale W., 1990, HDB EXPT PHARM, P211; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066	43	44	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21129	21135		10.1074/jbc.M302015200	http://dx.doi.org/10.1074/jbc.M302015200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665502	hybrid			2022-12-25	WOS:000183230500089
J	Feng, ZP; Doering, CJ; Winkfein, RJ; Beedle, AM; Spafford, JD; Zamponi, GW				Feng, ZP; Doering, CJ; Winkfein, RJ; Beedle, AM; Spafford, JD; Zamponi, GW			Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; NEUROPATHIC PAIN; CA2+ CHANNELS; BLOCKADE; ZICONOTIDE; CONOPEPTIDES; CATIONS; PEPTIDE; RAT	The Conus magus peptide toxin omega-conotoxin MVIIA is considered an irreversible, specific blocker of N-type calcium channels, and is now in clinical trials as an intrathecal analgesic. Here, we have examined the action of MVIIA on mutant and wild type calcium channels transiently expressed in tsA-201 cells. Although we have shown previously that mutations in a putative external EF-hand motif in the domain IIIS5-H5 region alters block by both omega-conotoxin GVIA and MVIIA (Feng, Z.P., Hamid, J., Doering, C., Bosey, G.M., Snutch, T.P., and Zamponi, G.W. (2001) J. Biol. Chem. 276, 15728-15735), the introduction of five point mutations known to affect GVIA blocking ( and located downstream of the EF-hand) affected MVIIA block to a smaller degree compared with GVIA. These data suggest that despite some overlap, MVIIA and GVIA block does not share identical channel structural determinants. At higher concentrations (similar to3 muM), MVIIA reversibly blocked L-, P/Q-, and R-type, but not T-type channels, indicating that the overall architecture of the MVIIA site is conserved in all types of high voltage-activated calcium channels. A kinetic analysis of the MVIIA effects on the N-type channel showed that MVIIA blocked resting, open, and inactivated channels. Although the development of MVIIA block did not appear to be voltage-, nor frequency-dependent, the degree of recovery from block strongly depended on the potential applied during washout. Interestingly, the degree of washout was highly variable and appeared to weakly depend on the holding potential applied during toxin application. We propose a model in which N-type calcium channels can form both reversible and irreversible complexes with MVIIA.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Tuluc, Petronel/C-2527-2011; Beedle, Aaron/AAI-7014-2020; Beedle, Aaron M/K-1902-2015	Beedle, Aaron M/0000-0002-1019-3235; Zamponi, Gerald W./0000-0002-0644-9066				Adams DJ, 2003, J BIOL CHEM, V278, P4057, DOI 10.1074/jbc.M209969200; Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P3908, DOI 10.1021/bi992651h; Beedle AM, 2002, J MEMBRANE BIOL, V187, P225, DOI 10.1007/s00232-001-0166-2; Bourinet E, 2001, BIOPHYS J, V81, P79, DOI 10.1016/S0006-3495(01)75681-0; CARBONE E, 1988, PFLUG ARCH EUR J PHY, V413, P14, DOI 10.1007/BF00581223; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Feng ZP, 2001, J BIOL CHEM, V276, P15728, DOI 10.1074/jbc.M100406200; Feng ZP, 2001, J BIOL CHEM, V276, P5726, DOI 10.1074/jbc.C000791200; FOX JA, 1995, PFLUG ARCH EUR J PHY, V429, P873, DOI 10.1007/BF00374813; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P2403, DOI 10.1517/13543784.9.10.2403; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; Levin T, 2002, PSYCHOSOMATICS, V43, P63, DOI 10.1176/appi.psy.43.1.63; Liang HY, 2002, J NEUROSCI, V22, P8884; MCDONOUGH SI, 1995, SOC NEUR ABSTR, V21, P1409; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; Roullet JB, 1999, J BIOL CHEM, V274, P25439, DOI 10.1074/jbc.274.36.25439; Saegusa H, 2002, NEUROSCI RES, V43, P1, DOI 10.1016/S0168-0102(02)00017-2; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; Scott DA, 2002, EUR J PHARMACOL, V451, P279, DOI 10.1016/S0014-2999(02)02247-1; Sidach SS, 2000, J NEUROSCI, V20, P7174; Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200; Stocker JW, 1997, J NEUROSCI, V17, P3002; Stotz SC, 2000, J MEMBRANE BIOL, V174, P157, DOI 10.1007/s002320001040; WOPPMANN A, 1994, MOL CELL NEUROSCI, V5, P350, DOI 10.1006/mcne.1994.1042	27	77	86	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20171	20178		10.1074/jbc.M300581200	http://dx.doi.org/10.1074/jbc.M300581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654924	hybrid			2022-12-25	WOS:000183078000076
J	Marienfeld, R; May, MJ; Berberich, I; Serfling, E; Ghosh, S; Neumann, M				Marienfeld, R; May, MJ; Berberich, I; Serfling, E; Ghosh, S; Neumann, M			RelB forms transcriptionally inactive complexes with RelA/p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MULTIORGAN INFLAMMATION; IMMUNE-RESPONSES; DEFICIENT MICE; IKK-ALPHA; T-CELLS; I-REL; ACTIVATION; FAMILY; PHOSPHORYLATION	RelB is an unusual member of the NF-kappaB transcription factor family that acts as both a transcriptional activator as well as a repressor of NF-kappaB-dependent gene expression. Although RelB promotes gene expression when it associates with p50/NF-kappaB1 or p52/NF-kappaB2, the precise molecular mechanisms through which it represses NF-kappaB remain unclear. To examine this inhibitory function in more detail, we employed reporter gene assays and found that RelB represses at the level of RelA. Furthermore, electrophoretic mobility shift analysis revealed that in vitro translated RelB impaired the DNA binding activity of RelA and that overexpressed RelB significantly reduced tumor necrosis factor-alpha-induced RelA activity in murine embryonic fibroblasts. Intriguingly, this inhibitory effect was due to the formation of RelA.RelB heterodimers that were unable to bind to kappaB sites in vitro strongly suggesting that these newly described NF-kappaB dimers cannot bind DNA. Expression pattern analysis revealed that RelA.RelB heterodimers appeared at relatively low levels in both lymphoid and non-lymphoid cells. However, the presence of these complexes increased following stimulation with phorbolesters or lipopolysaccharide or by overexpression of constitutively active IKKbeta. Functional characterization of RelA.RelB heterodimers in NIH3T3 murine embryonic fibroblasts revealed that they are not regulated by IkappaB proteins and are located in both the cytoplasm and the nucleus. Taken together, our findings demonstrate that sequestration of RelA in transcriptionally inactive RelA.RelB complexes provides a molecular mechanism that may explain the repressive role of RelB on NF-kappaB-dependent gene expression.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Wurzburg, Inst Virol & Immunobiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany; Univ Magdeburg, Inst Expt Internal Med, D-39120 Magdeburg, Germany	Yale University; Yale University; University of Wurzburg; University of Wurzburg; Otto von Guericke University	Marienfeld, R (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 300 Cedar St, New Haven, CT 06520 USA.		Serfling, Edgar/X-7212-2019	May, Michael/0000-0002-2485-3716				BOURS V, 1994, ONCOGENE, V9, P1699; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Chapman NR, 2002, BIOCHEM J, V366, P459, DOI 10.1042/BJ20020444; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Francis DA, 1998, INT IMMUNOL, V10, P285, DOI 10.1093/intimm/10.3.285; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Jiang HY, 2002, J VIROL, V76, P5737, DOI 10.1128/JVI.76.11.5737-5747.2002; Kistler B, 1998, J IMMUNOL, V160, P2308; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Neumann M, 1996, J IMMUNOL, V157, P4862; Neumann M, 2000, BLOOD, V95, P277; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Weih F, 1997, J IMMUNOL, V158, P5211; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xia YY, 1999, MOL CELL BIOL, V19, P7688; Xia YY, 1997, AM J PATHOL, V151, P375; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	35	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19852	19860		10.1074/jbc.M301945200	http://dx.doi.org/10.1074/jbc.M301945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657634	hybrid			2022-12-25	WOS:000183078000037
J	Stevens, LA; Bourgeois, C; Bortell, R; Moss, J				Stevens, LA; Bourgeois, C; Bortell, R; Moss, J			Regulatory role of arginine 204 in the catalytic activity of rat alloantigens ART2a and ART2b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; AUTO-ADP-RIBOSYLATION; NAD GLYCOHYDROLASE; RT6; RIBOSYLTRANSFERASES; EXPRESSION; MONO(ADP-RIBOSYL)TRANSFERASES; AUTOMODIFICATION; ACTIVATION; IDENTIFY	ART2a (RT6.1) and ART2b (RT6.2) are NAD glycohydrolases (NADases) that are linked to T lymphocytes by glycosylphosphatidylinositol anchors. Although both mature proteins possess three conserved regions ( I, II, III) that form the NAD-binding site and differ by only ten amino acids, only ART2b is auto-ADP-ribosylated and only ART2a is glycosylated. To investigate the structural basis for these differences, wild-type and mutant ART2a and ART2b were expressed in rat mammary adenocarcinoma (NMU) cells and released with phosphatidylinositol-specific phospholipase C. All mutants were immunoreactive NADases. Arginine 204 (Arg(204)), NH2-terminal to essential glutamate 209 in Region III, is found in ART2b, but not ART2a. Replacement of Arg(204) in ART2b with lysine, tyrosine, or glutamate abolished auto-ADP-ribosylation. Unlike wild-type ART2a, ART2a( Y204R) was auto-ADP-ribosylated. The tryptophan mutant ART2b( R204W) was auto-ADP-ribosylated and exhibited enhanced NADase activity. Incubation with NAD and auto-ADP-ribosylation decreased the NADase activities of wild-type ART2b and ART2b ( R204W), whereas activity of ART2b( R204K), which is not auto-modified, was unchanged by NAD. Facilitation of auto-ADP-ribosylation by tryptophan 204 suggests that the hydrophobic amino acid mimics an ADP-ribosylated arginine. Thus, Arg(204) in ART2b serves as a regulatory switch whose presence is required for additional auto-ADP-ribosylation and regulation of catalytic activity.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Med Ctr, Diabet Div, Worcester, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Massachusetts System; University of Massachusetts Worcester	Stevens, LA (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bortell R, 2001, AUTOIMMUNITY, V33, P199, DOI 10.3109/08916930109008047; Bortell R, 2001, J IMMUNOL, V167, P2049, DOI 10.4049/jimmunol.167.4.2049; Bredehorst K, 1997, ADV EXP MED BIOL, V419, P185; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; GREINER DL, 1986, J IMMUNOL, V136, P148; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1994, J MOL BIOL, V243, P537, DOI 10.1006/jmbi.1994.1680; Han S, 2002, INT J MED MICROBIOL, V291, P523; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; Karsten S, 1997, ADV EXP MED BIOL, V419, P175; KOCH F, 1988, IMMUNOLOGY, V65, P259; Maehama T, 1996, FEBS LETT, V388, P189, DOI 10.1016/0014-5793(96)00568-6; Mojcik C F, 1991, Dev Immunol, V1, P191, DOI 10.1155/1991/87067; Moss J, 1999, MOL CELL BIOCHEM, V193, P109, DOI 10.1023/A:1006924514074; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; Rigby MR, 1996, J IMMUNOL, V156, P4259; Rigby MR, 1996, DIABETES, V45, P1419, DOI 10.2337/diabetes.45.10.1419; TAKADA T, 1994, J BIOL CHEM, V269, P9420; Thiele HG, 2001, IMMUNOL REV, V184, P96, DOI 10.1034/j.1600-065x.2001.1840109.x; Thiele HG, 1997, ADV EXP MED BIOL, V419, P109; THIELE HG, 1986, IMMUNOLOGY, V59, P195; Weng BY, 1999, J BIOL CHEM, V274, P31797, DOI 10.1074/jbc.274.45.31797; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19591	19596		10.1074/jbc.M210364200	http://dx.doi.org/10.1074/jbc.M210364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649291	hybrid			2022-12-25	WOS:000183078000005
J	Robin, MA; Prabu, SK; Raza, H; Anandatheerthavarada, HK; Avadhani, NG				Robin, MA; Prabu, SK; Raza, H; Anandatheerthavarada, HK; Avadhani, NG			Phosphorylation enhances mitochondrial targeting of GSTA4-4 through increased affinity for binding to cytoplasmic Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTEIN-KINASE-C; OXIDATIVE STRESS; LIPID-PEROXIDATION; ALPHA-CLASS; MEDIATED PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; LIVER-MITOCHONDRIA; IMPORT; INDUCTION	Recently we showed that three different isoforms of cytosolic glutathione S-transferases (GST), including GSTA4-4, are also localized in the mitochondrial compartment. In this study, we have investigated the mechanism of mouse GSTA4-4 targeting to mitochondria, using a combination of in vitro mitochondrial import assay and in vivo targeting in COS cells transfected with cDNA. Our results show that the mitochondrial GSTA4-4 is more heavily phosphorylated compared with its cytosolic counterpart. Protein kinase activators (cAMP, forskolin, or phorbol-12-myristate-13-acetate) markedly increased GSTA4-4 targeting to mitochondria, whereas kinase inhibitors caused its retention in the cytosol. Immunoinhibition and immunodepletion studies showed that the Hsp70 chaperone is required for the efficient translation of GSTA4-4 as well as its translocation to mitochondria. Co-immunoprecipitation studies showed that kinase inhibitors attenuate the affinity of GSTA4-4 for cytoplasmic Hsp70 suggesting the importance of phosphorylation for binding to the chaperone. Mutational analysis show that the putative mitochondrial targeting signal resides within the C-terminal 20 amino acid residues of the protein and that the targeting signal requires activation by phosphorylation at the C-terminal-most protein kinase A (PKA) site at Ser-189 or protein kinase C (PKC) site at Thr-193. We demonstrate for the first time that PKA and PKC modulate the cytoplasmic and mitochondrial pools of GSTA4-4.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Marie Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu		Raza, Haider/0000-0001-9680-5388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34883-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Ceccarelli EA, 1996, EUR J BIOCHEM, V238, P192, DOI 10.1111/j.1432-1033.1996.0192q.x; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Desmots F, 2002, FREE RADICAL BIO MED, V32, P93, DOI 10.1016/S0891-5849(01)00767-5; ECKL PM, 1993, MUTAT RES, V290, P183, DOI 10.1016/0027-5107(93)90158-C; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; JARVIS WD, 1994, CANCER RES, V54, P1707; KOCH JA, 1991, METHOD ENZYMOL, V206, P305; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; Mottaran E, 2002, FREE RADICAL BIO MED, V32, P38, DOI 10.1016/S0891-5849(01)00757-2; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Prabhu KS, 2001, BIOCHEM J, V360, P345, DOI 10.1042/0264-6021:3600345; Raza H, 2002, BIOCHEM J, V366, P45, DOI 10.1042/BJ20020533; Rimon G, 1998, BBA-GEN SUBJECTS, V1380, P289, DOI 10.1016/S0304-4165(97)00153-0; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Robin MA, 2001, J BIOL CHEM, V276, P24680, DOI 10.1074/jbc.M100363200; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Sayre LM, 1999, METHOD ENZYMOL, V309, P133; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; SUNDBERG AGM, 1993, PHARMACOL TOXICOL, V72, P321, DOI 10.1111/j.1600-0773.1993.tb01658.x; TERADA K, 1995, MOL CELL BIOL, V15, P3708; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Woodgett JR, 1996, CANCER SURV, V27, P127	49	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18960	18970		10.1074/jbc.M301807200	http://dx.doi.org/10.1074/jbc.M301807200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646569	hybrid			2022-12-25	WOS:000182932200033
J	Merry, AH; Gilbert, RJC; Shore, DA; Royle, L; Miroshnychenko, O; Vuong, M; Wormald, MR; Harvey, DJ; Dwek, RA; Classon, BJ; Rudd, PM; Davis, SJ				Merry, AH; Gilbert, RJC; Shore, DA; Royle, L; Miroshnychenko, O; Vuong, M; Wormald, MR; Harvey, DJ; Dwek, RA; Classon, BJ; Rudd, PM; Davis, SJ			O-glycan sialylation and the structure of the stalk-like region of the T cell co-receptor CD8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE SUBMAXILLARY MUCIN; HAMSTER OVARY CELLS; PERFORMANCE LIQUID-CHROMATOGRAPHY; CLASS-I MOLECULES; MHC CLASS; LINKED OLIGOSACCHARIDES; SEQUENCING TECHNOLOGY; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; N-GLYCOSYLATION	Studies of mucins suggest that the structural effects of O-glycans are restricted to steric interactions between peptide-linked GalNAc residues and adjacent polypeptide residues. It has been proposed, however, that differential O-glycan sialylation alters the structure of the stalk-like region of the T cell co-receptor, CD8, and that this, in turn, modulates ligand binding (Daniels, M. A., Devine, L., Miller, J. D., Moser, J. M., Lukacher, A. E., Altman, J. D., Kavathas, P., Hogquist, K. A., and Jameson, S. C. ( 2001) Immunity 15, 1051 - 1061; Moody, A. M., Chui, D., Reche, P. A., Priatel, J. J., Marth, J. D., and Reinherz, E. L. ( 2001) Cell 107, 501 - 512). We characterize the glycosylation of soluble, chimeric forms of the alphaalpha- and alphabeta-isoforms of murine CD8 containing the O-glycosylated stalk of rat CD8alphaalpha, and we show that the stalk O-glycans are differentially sialylated in CHO K1 versus Lec3.2.8.1 cells (82 versus similar to6%, respectively). Sedimentation analysis indicates that the Perrin functions, P-exp, which reflect overall molecular shape, are very similar (1.61 versus 1.54), whereas the sedimentation coefficients (s) of the CHO K1- and Lec3.2.8.1-derived proteins differ considerably (3.73 versus 3.13 S). The hydrodynamic properties of molecular models also strongly imply that the sialylated and non-sialylated forms of the chimera have parallel, equally highly extended stalks (similar to2.6 Angstrom/residue). Our analysis indicates that, as in the case of mucins, the overall structure of O-glycosylated stalk-like peptides is sialylation-independent and that the functional effects of differential CD8 O-glycan sialylation need careful interpretation.	Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England; Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Cent Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Monash Univ, Monash Med Sch, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	University of Oxford; University of Oxford; University of Oxford; University of Oxford; Monash University	Rudd, PM (corresponding author), Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Harvey, David/A-5579-2013; Wormald, Mark R/G-2785-2011	Wormald, Mark R/0000-0002-4853-2773; Harvey, David/0000-0003-0544-771X; Gilbert, Robert/0000-0001-9336-5604				Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Baum LG, 2002, IMMUNITY, V16, P5, DOI 10.1016/S1074-7613(02)00265-0; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bietlot HP, 1997, J CHROMATOGR A, V759, P177, DOI 10.1016/S0021-9673(96)00767-4; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; Butters TD, 1999, PROTEIN SCI, V8, P1696, DOI 10.1110/ps.8.8.1696; Byron O, 1997, BIOPHYS J, V72, P408, DOI 10.1016/S0006-3495(97)78681-8; Carrasco B, 1999, BIOPHYS J, V77, P2902, DOI 10.1016/S0006-3495(99)77123-7; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; CLASSON BJ, 1992, INT IMMUNOL, V4, P215, DOI 10.1093/intimm/4.2.215; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; Davis SJ, 2003, NAT IMMUNOL, V4, P217, DOI 10.1038/ni0303-217; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Gao GF, 1998, PROTEIN SCI, V7, P1245, DOI 10.1002/pro.5560070520; Gao GF, 2002, TRENDS IMMUNOL, V23, P408, DOI 10.1016/S1471-4906(02)02282-2; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; HARVEY DJ, 1994, ORG MASS SPECTROM, V29, P753, DOI 10.1002/oms.1210291208; Iwase H, 1993, Methods Mol Biol, V14, P151; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kern P, 1999, J BIOL CHEM, V274, P27237, DOI 10.1074/jbc.274.38.27237; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lu XY, 1997, P NATL ACAD SCI USA, V94, P2380, DOI 10.1073/pnas.94.6.2380; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; MERRY AH, 1992, BIOCHEM SOC T, V20, P91; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PARNES JR, 1989, COLD SPRING HARB SYM, V54, P649; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; Pellicci DG, 2000, J IMMUNOL METHODS, V246, P149, DOI 10.1016/S0022-1759(00)00280-5; PILLER F, 1988, J BIOL CHEM, V263, P15146; REMALEY AT, 1991, J BIOL CHEM, V266, P24176; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; ROSE MC, 1984, J BIOL CHEM, V259, P3167; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; Rudd PM, 2001, PROTEOMICS, V1, P285, DOI 10.1002/1615-9861(200102)1:2<285::AID-PROT285>3.0.CO;2-G; Rudd PM, 1997, NATURE, V388, P205, DOI 10.1038/40677; Rudd PM, 1999, BIOTECHNOL GENET ENG, V16, P1; Schuck P, 1999, ANAL BIOCHEM, V272, P199, DOI 10.1006/abio.1999.4172; Schuck P, 1998, BIOPHYS J, V74, P466, DOI 10.1016/S0006-3495(98)77804-X; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SQUIRE PG, 1979, ARCH BIOCHEM BIOPHYS, V196, P165, DOI 10.1016/0003-9861(79)90563-0; SUKHATME VP, 1985, J EXP MED, V161, P429, DOI 10.1084/jem.161.2.429; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2	66	45	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27119	27128		10.1074/jbc.M213056200	http://dx.doi.org/10.1074/jbc.M213056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12676960	hybrid			2022-12-25	WOS:000184155700106
J	Hessel, E; Heck, M; Muller, P; Herrmann, A; Hofmann, KP				Hessel, E; Heck, M; Muller, P; Herrmann, A; Hofmann, KP			Signal transduction in the visual cascade involves specific lipid-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD CGMP-PHOSPHODIESTERASE; RESISTANT MEMBRANE RAFTS; SEGMENT DISK MEMBRANES; OUTER SEGMENTS; PHOTORECEPTOR-MEMBRANES; HUMAN-ERYTHROCYTES; RETINAL RODS; PHOSPHOLIPIDS; ACTIVATION; SUBUNITS	In retinal rod photoreceptor cells, transducin ( G(t)) and cyclic GMP phosphodiesterase ( PDE) are peripherally anchored to the cytoplasmic surface of the disk saccules. We have examined the role of specific phospholipids in the interaction of these proteins with native osmotically intact disk vesicles, employing spin- labeled phospholipid analogues ( 2% of total phospholipids) and bovine serum albumin back- exchange assay. Inactive GDP-bound transducin exclusively reduced the extraction of negatively charged phosphatidylserine. The effect disappeared upon activation of the G- protein with guanosine 5 '- O-( 3- thiotriphosphate) ( GTPgammaS). PDE affected the extraction of the zwitterionic phosphatidylcholine and, to a smaller extent, of phosphatidylethanolamine. When active G(t)GTP gamma S interacted with the PDE to form the active effector, the interaction with phosphatidylcholine was specifically enhanced. Each copy of the G- protein bound 3 +/- 1 molecules of phosphatidylserine, whereas the PDE bound a much larger amount ( 70 +/- 10) of a mixture of phosphatidylcholine and ethanolamine. The results are interpreted as a head group- specific and state- dependent interaction of the signaling proteins with the phospholipids of the photoreceptor membrane.	Humboldt Univ, Inst Med Phys & Biophys, Univ Klinikum Charite, D-10098 Berlin, Germany; Humboldt Univ, Inst Biol Biophys, Math Nat Wissensch Fak 1, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Hessel, E (corresponding author), Humboldt Univ, Inst Med Phys & Biophys, Univ Klinikum Charite, Ziegelstr 5-9, D-10098 Berlin, Germany.							ANANT JS, 1992, J BIOL CHEM, V267, P687; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BOESZEBATTAGLIA K, 1992, EXP EYE RES, V54, P821, DOI 10.1016/0014-4835(92)90040-Y; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CRAIN RC, 1978, BIOCHEMISTRY-US, V17, P4186, DOI 10.1021/bi00613a012; DAEMEN FJM, 1969, NATURE, V222, P879, DOI 10.1038/222879a0; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Escriba PV, 1997, P NATL ACAD SCI USA, V94, P11375, DOI 10.1073/pnas.94.21.11375; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HAEST CWM, 1981, BIOCHIM BIOPHYS ACTA, V649, P701, DOI 10.1016/0005-2736(81)90174-7; Heck M, 2000, METHOD ENZYMOL, V315, P329; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hessel E, 2000, EUR J BIOCHEM, V267, P1473, DOI 10.1046/j.1432-1327.2000.01147.x; Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200; HOFMANN KP, 1996, BIOMEMBRANE, V2, P142; KUHN H, 1982, METHOD ENZYMOL, V81, P556; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Marx U, 1997, BIOPHYS J, V73, P1645, DOI 10.1016/S0006-3495(97)78196-7; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; Murray D, 2001, J BIOL CHEM, V276, P45153, DOI 10.1074/jbc.M101784200; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; SKLAR LA, 1980, FEBS LETT, V118, P308, DOI 10.1016/0014-5793(80)80245-6; WU G, 1993, BIOCHEMISTRY-US, V32, P879, DOI 10.1021/bi00054a020; Young JE, 2000, EXP EYE RES, V70, P809, DOI 10.1006/exer.2000.0821	44	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22853	22860		10.1074/jbc.M302747200	http://dx.doi.org/10.1074/jbc.M302747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676942	hybrid			2022-12-25	WOS:000183503900090
J	Suh, JM; Song, JH; Kim, DW; Kim, H; Chung, HK; Hwang, JH; Kim, JM; Hwang, ES; Chung, JK; Han, JH; Cho, BY; Ro, HK; Shong, MH				Suh, JM; Song, JH; Kim, DW; Kim, H; Chung, HK; Hwang, JH; Kim, JM; Hwang, ES; Chung, JK; Han, JH; Cho, BY; Ro, HK; Shong, MH			Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYCLIC-AMP; CELL PROLIFERATION; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; PHOSPHORYLATION SITES; ACTIVATION; GROWTH; THYROTROPIN; INSULIN; RAP1	Thyroid-stimulating hormone (TSH) regulates the growth and differentiation of thyrocytes by activating the TSH receptor (TSHR). This study investigated the roles of the phosphatidylinositol 3-kinase (PI3K), PDK1, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 (S6K1) signaling mechanism by which TSH and the stimulating type TSHR antibodies regulate thyrocyte proliferation and the follicle activities in vitro and in vivo. The TSHR immunoprecipitates exhibited PI3K activity, which was higher in the cells treated with either TSH or 8-bromo-cAMP. TSH and cAMP increased the tyrosine phosphorylation of TSHR and the association between TSHR and the p85alpha regulatory subunit of PI3K. TSH induced a redistribution of PDK1 from the cytoplasm to the plasma membrane in the cells in a PI3K- and protein kinase A-dependent manner. TSH induced the PDK1-dependent phosphorylation of S6K1 but did not induce Akt/protein kinase B phosphorylation. The TSH-induced S6K1 phosphorylation was inhibited by a dominant negative p85alpha regulatory subunit or by the PI3K inhibitors wortmannin and LY294002. Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP. The stimulating type TSHR antibodies from patients with Graves disease also induced S6K1 activation, whereas the blocking type TSHR antibodies from patients with primary myxedema inhibited TSH- but not the insulin-induced phosphorylation of S6K1. In addition, rapamycin treatment in vivo inhibited the TSH- stimulated thyroid follicle hyperplasia and follicle activity. These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B. This pathway may play a role in the TSH/stimulating type TSH receptor antibody-mediated thyrocyte proliferation in vitro and in the response to TSH in vivo.	Chungnam Natl Univ, Dept Internal Med, Lab Endocrine Cell Biol, Taejon 301721, South Korea; Chungnam Natl Univ, Dept Pathol, Taejon 301721, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Sungkyunkwan Univ, Coll Pharm, Dept Biochem, Suwon 440756, South Korea; Seoul Natl Univ, Dept Internal Med, Seoul 110744, South Korea	Chungnam National University; Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST); Sungkyunkwan University (SKKU); Seoul National University (SNU)	Shong, MH (corresponding author), Chungnam Natl Univ, Sch Med, Dept Internal Med, Lab Endocrine Cell Biol, 640 Daesadong Chungku, Taejon 301040, South Korea.	minhos@cnu.ac.kr	/H-7803-2012	KIM, JIN MAN/0000-0003-0905-9730; shong, minho/0000-0002-0247-7115				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BANDI HR, 1993, J BIOL CHEM, V268, P4530; Bell A, 2002, AM J PHYSIOL-CELL PH, V283, pC1056, DOI 10.1152/ajpcell.00058.2002; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Coulonval K, 2000, BIOCHEM J, V348, P351, DOI 10.1042/0264-6021:3480351; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; De Vita G, 2000, CANCER RES, V60, P3916; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kim WB, 1997, J CLIN ENDOCR METAB, V82, P1953, DOI 10.1210/jc.82.6.1953; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; LUCIA ER, 1999, J BIOL CHEM, V274, P8347; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; Nedachi T, 2000, ENDOCRINOLOGY, V141, P2429, DOI 10.1210/en.141.7.2429; OKKENHAUG K, 2001, SCI STKE; Park ES, 2000, MOL ENDOCRINOL, V14, P662, DOI 10.1210/mend.14.5.0458; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Saito J, 2001, THYROID, V11, P339, DOI 10.1089/10507250152039073; SAMAYOR A, 1999, BIOCHEM J, V342, P287; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1995, J IMMUNOL, V155, P3418; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tonacchera M, 1996, CLIN ENDOCRINOL, V44, P621, DOI 10.1046/j.1365-2265.1996.746567.x; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	58	61	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21960	21971		10.1074/jbc.M300805200	http://dx.doi.org/10.1074/jbc.M300805200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668683	hybrid			2022-12-25	WOS:000183354200082
J	Vara, D; Bicknell, KA; Coxon, CH; Brooks, G				Vara, D; Bicknell, KA; Coxon, CH; Brooks, G			Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE REGULATORY MOLECULES; IN-VIVO; TRANSCRIPTION FACTOR; DEPENDENT KINASES; GENE-THERAPY; PROTEINS; FAMILY; DIFFERENTIATION; CARDIOMYOCYTES; EXPRESSION	Growth of the post- natal mammalian heart occurs primarily by cardiac myocyte hypertrophy. Previously, we and others have shown that a partial re- activation of the cell cycle machinery occurs in myocytes undergoing hypertrophy such that cells progress through the G(1)/ S transition. In this study, we have examined the regulation of the E2F family of transcription factors that are crucial for the G(1)/ S phase transition during normal cardiac development and the development of myocyte hypertrophy in the rat. Thus, mRNA and protein levels of E2F- 1, 3, and 4 and DP- 1 and DP- 2 were down- regulated during development to undetectable levels in adult myocytes. Interestingly, E2F- 5 protein levels were substantially up- regulated during development. In contrast, an induction of E2F- 1, 3, and 4 and the DP- 1 protein was observed during the development of myocyte hypertrophy in neonatal myocytes treated with serum or phenylephrine, whereas the protein levels of E2F- 5 were decreased with serum stimulation. E2F activity, as measured by a cyclin E promoter luciferase assay and E2F- DNA binding activity, increased significantly during the development of hypertrophy with serum and phenylephrine compared with non- stimulated cells. Inhibiting E2F activity with a specific peptide that blocks E2F- DP heterodimerization prevented the induction of hypertrophic markers ( atrial natriuretic factor and brain natriuretic peptide) in response to serum and phenylephrine, reduced the increase in myocyte size, and inhibited protein synthesis in stimulated cells. Thus, we have shown that the inhibition of E2F function prevents the development of hypertrophy. Targeting E2F function might be a useful approach for treating diseases that cause pathophysiological hypertrophic growth.	Univ Reading, Cardiovasc Res Grp, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Brooks, G (corresponding author), Univ Reading, Cardiovasc Res Grp, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.		Bicknell, Katrina/B-8263-2009	Bicknell, Katrina/0000-0002-5888-1424				Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2261, DOI 10.1006/jmcc.1997.0471; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Kusek JC, 2000, INT J DEV BIOL, V44, P267; Kusek JC, 2001, BRAIN RES BULL, V54, P187, DOI 10.1016/S0361-9230(00)00447-0; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; Li FQ, 1996, J MOL CELL CARDIOL, V28, P1737, DOI 10.1006/jmcc.1996.0163; Li JM, 1998, AM J PHYSIOL-HEART C, V275, pH814, DOI 10.1152/ajpheart.1998.275.3.H814; Li JM, 1999, EUR HEART J, V20, P406, DOI 10.1053/euhj.1998.1308; Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Piano MR, 1998, HEART LUNG, V27, P3, DOI 10.1016/S0147-9563(98)90063-2; Poolman RA, 1998, J MOL CELL CARDIOL, V30, P2121, DOI 10.1006/jmcc.1998.0808; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; von Harsdorf R, 1999, CIRC RES, V85, P128, DOI 10.1161/01.RES.85.2.128	22	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21388	21394		10.1074/jbc.M212612200	http://dx.doi.org/10.1074/jbc.M212612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682052	hybrid			2022-12-25	WOS:000183354200012
J	Zhu, K; Amin, MA; Kim, MJ; Katschke, KJ; Park, CC; Koch, AE				Zhu, K; Amin, MA; Kim, MJ; Katschke, KJ; Park, CC; Koch, AE			A novel function for a glucose analog of blood group H antigen as a mediator of leukocyte-endothelial adhesion via intracellular adhesion molecule 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; RHEUMATOID-ARTHRITIS; INTERFERON-GAMMA; SYNOVIAL TISSUE; STAT PATHWAY; EXPRESSION; CELLS; ICAM-1; ACTIVATION; INHIBITION	The 4A11 antigen is a unique cytokine-inducible antigen up-regulated on rheumatoid arthritis synovial endothelium compared with normal endothelium. In soluble form, this antigen, Lewis(y)-6/H-5-2 (Le(y)/H), or its glucose analog, 2-fucosyllactose (H-2g), mediates angiogenesis. The Le(y)/H antigen is structurally related to the soluble E-selectin ligand, sialyl Lewis(x), and is selectively expressed in skin, lymphoid organs, thymus, and synovium, suggesting that it may be important in leukocyte homing or adhesion. In the present study, we used H-2g as a functional substitute to demonstrate a novel property for Le(y)/H antigen in inducing leukocyte-endothelial adhesion. H-2g significantly enhanced the expression of human dermal microvascular endothelial cells (HM-VECs) intercellular adhesion molecule-1 (ICAM-1), but not vascular cell adhesion molecule-1, E-selectin, and P-selectin. Immunoprecipitation and Western blotting showed glycolipids Le(y)-6, H-5-2, or the glucose analog H-2g quickly activated human microvascular endothelial cell line-1 (HMEC-1) Janus kinase 2 (JAK2) and that the JAK2 inhibitor, AG-490, completely inhibited HMVEC ICAM-1 expression and HL-60 adhesion to HMEC-1s. Use of a JAK/signal transducer and activator of transcription ( STAT) profiling system confirmed that H-2g selectively activated STAT3 but not STAT1 and STAT2. AG-490 inhibited H-2g-induced Erk1/2 and PI3K-Akt activation, suggesting that JAK2 is upstream of the Erk1/2 and PI3K-Akt pathways. Furthermore, the JAK2 inhibitor AG-490, the Erk1/2 inhibitor PD98059, or the phosphatidylinositol 3-kinase inhibitor LY294002 or antisense oligodeoxynucleotides directed against JAK2, Erk1/2, or phosphatidylinositol 3-kinase blocked H-2g-induced HMVEC ICAM-1 expression and HL-60 adhesion to HMEC-1s. Hence, H-2g signals through JAK2 and its downstream signal transducers STAT3, Erk1/2, and phosphatidylinositol 3-kinase result in ICAM-1 expression and cell adhesion. Potential treatment strategies through the inhibition of JAK-dependent pathways to target H-2g signals may provide a useful approach in inflammation-driven diseases like rheumatoid arthritis.	Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Koch, AE (corresponding author), 303 E Chicago Ave,Ward Bldg 3-315, Chicago, IL 60611 USA.		Koch, Alisa E/B-6894-2011; Park, Christy/AAH-1543-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040987, K08AI049287, R21AI040987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58695] Funding Source: Medline; NIAID NIH HHS [AI 49287, AI 40987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Duperray A, 1997, J BIOL CHEM, V272, P435; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Feizi T, 2000, GLYCOCONJUGATE J, V17, P553, DOI 10.1023/A:1011022509500; Furuzawa-Carballeda J, 1999, SCAND J IMMUNOL, V50, P215; Halloran MM, 2000, J IMMUNOL, V164, P4868, DOI 10.4049/jimmunol.164.9.4868; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Innocenti M, 2002, INFECT IMMUN, V70, P4581, DOI 10.1128/IAI.70.8.4581-4590.2002; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; KOCH AE, 1994, CLIN IMMUNOL IMMUNOP, V71, P208, DOI 10.1006/clin.1994.1074; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1994, AM J PATHOL, V144, P244; Lacha J, 2002, J LEUKOCYTE BIOL, V71, P311; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; LINDSLEY HB, 1992, SEMIN ARTHRITIS RHEU, V21, P330, DOI 10.1016/0049-0172(92)90026-A; LINDSLEY HB, 1993, CLIN IMMUNOL IMMUNOP, V68, P311, DOI 10.1006/clin.1993.1132; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Matsumiya T, 2002, LIFE SCI, V70, P3179, DOI 10.1016/S0024-3205(02)01560-6; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Morel JCM, 2001, J BIOL CHEM, V276, P37069, DOI 10.1074/jbc.M103574200; POBER JS, 1986, J IMMUNOL, V136, P1680; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Striz I, 1999, AM J PHYSIOL-LUNG C, V277, pL58, DOI 10.1152/ajplung.1999.277.1.L58; SZEKANECZ Z, 1994, ARTHRITIS RHEUM, V37, P221, DOI 10.1002/art.1780370211; TAK PP, 1995, CLIN IMMUNOL IMMUNOP, V77, P236, DOI 10.1006/clin.1995.1149; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Wilson JL, 1998, J RHEUMATOL, V25, P499; Wu AJ, 1997, J CELL PHYSIOL, V173, P110, DOI 10.1002/(SICI)1097-4652(199710)173:1<110::AID-JCP13>3.0.CO;2-M; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001	32	29	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21869	21877		10.1074/jbc.M213052200	http://dx.doi.org/10.1074/jbc.M213052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672794	hybrid			2022-12-25	WOS:000183354200071
J	Bjornberg, O; Neuhard, J; Nyman, PO				Bjornberg, O; Neuhard, J; Nyman, PO			A bifunctional dCTP deaminase-dUTP nucleotidohydrolase from the hyperthermophilic archaeon Methanocaldococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DNA-POLYMERASES; BINDING MOTIF; PYROPHOSPHATASE; EXPRESSION; PROTEIN; RNA	By the sequential action of dCTP deaminase and dUTPase, dCTP is converted to dUMP, the precursor of thymidine nucleotides. In addition, dUTPase has an essential role as a safeguard against uracil incorporation in DNA. The putative dCTP deaminase (MJ0430) and dUTPase (MJ1102) from the hyperthermophilic archaeon Methanocaldococcus jannaschii were overproduced in Escherichia coli. Unexpectedly, we found the MJ0430 protein capable of both reactions, i.e. hydrolytic deamination of the cytosine ring and hydrolytic cleavage of the phosphoanhydride bond between the alpha- and beta-phosphates. When the reaction was followed by thin layer chromatography using [H-3] dCTP as substrate, dUMP and not dUTP was identified as a reaction product. In the presence of unlabeled dUTP, which acted as an inhibitor, no label was transferred from [H-3] dCTP to the pool of dUTP. This finding strongly suggests that the two consecutive steps of the reaction are tightly coupled within the enzyme. The hitherto unknown bifunctionality of the MJ0430 protein appears beneficial for the cells because the toxic intermediate dUTP is never released. The MJ0430 protein also catalyzed the hydrolysis of dUTP to dUMP but with a low affinity for the substrate (K-m>100 muM). According to limited proteolysis, the C-terminal residues constitute a flexible region. The other protein investigated, MJ1102, is a specific dUTPase with a K-m for dUTP (0.4 muM) comparable in magnitude with that found for previously characterized dUTPases. Its physiological function is probably to degrade dUTP derived from other reactions in nucleotide metabolism.	Univ Copenhagen, Dept Biol Chem, Inst Mol Biol, DK-1307 Copenhagen K, Denmark; Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen O, Denmark; Lund Univ, Dept Biochem, S-22100 Lund, Sweden	University of Copenhagen; University of Copenhagen; Lund University	Neuhard, J (corresponding author), Univ Copenhagen, Dept Biol Chem, Inst Mol Biol, Solvgade 83 H, DK-1307 Copenhagen K, Denmark.	neuhard@mermaid.molbio.ku.dk						BECK CF, 1975, J BIOL CHEM, V250, P609; BERGMAN AC, 1995, PROTEIN EXPRES PURIF, V6, P379, DOI 10.1006/prep.1995.1050; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Hogrefe HH, 2002, P NATL ACAD SCI USA, V99, P596, DOI 10.1073/pnas.012372799; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Lasken RS, 1996, J BIOL CHEM, V271, P17692, DOI 10.1074/jbc.271.30.17692; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Neuhard J., 1996, ESCHERICHIA COLI SAL, V2nd, P580; Nord J, 1997, FEBS LETT, V414, P271, DOI 10.1016/S0014-5793(97)00935-6; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; NORD J, 2000, NUCLEOTIDE BINDING T; Prangishvili D, 1998, J BIOL CHEM, V273, P6024, DOI 10.1074/jbc.273.11.6024; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; REIZER J, 1994, PROTEIN SCI, V3, P853; Shao H, 1997, BBA-PROTEIN STRUCT M, V1339, P181, DOI 10.1016/S0167-4838(96)00229-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; WANG LH, 1992, J BACTERIOL, V174, P5647, DOI 10.1128/JB.174.17.5647-5653.1992	31	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20667	20672		10.1074/jbc.M213010200	http://dx.doi.org/10.1074/jbc.M213010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670946	hybrid			2022-12-25	WOS:000183230500030
J	Guerin, M; Parodi, AJ				Guerin, M; Parodi, AJ			The UDP-glucose : glycoprotein glucosyltransferase is organized in at least two tightly bound domains from yeast to mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; ENZYME; OLIGOSACCHARIDES; PURIFICATION; HOMOGENEITY; VIABILITY; PROTEIN; STRESS	The endoplasmic reticulum UDP-Glc:glycoprotein glucosyltransferase (GT) exclusively glucosylates nonnative glycoprotein conformers. GT sequence analysis suggests that it is composed of at least two domains: the N-terminal domain, which composes 80% of the molecule, has no significant similarity to other known proteins and was proposed to be involved in the recognition of non-native conformers and the C-terminal or catalytic domain, which displays a similar size and significant similarity to members of glycosyltransferase family 8. Here, we show that N- and C-terminal domains from Rattus norvegicus and Schizosaccharomyces pombe GTs remained tightly but not covalently bound upon a mild proteolytic treatment and could not be separated without loss of enzymatic activity. The notion of a two-domain protein was reinforced by the synthesis of an active enzyme upon transfection of S. pombe GT null mutants with two expression vectors, each of them encoding one of both domains. Transfection with the C-terminal domain-encoding vector alone yielded an inactive, rapidly degraded protein, thus indicating that the N- terminal domain is required for proper folding of the C-terminal catalytic portion. If, indeed, the N- terminal domain is, as proposed, also involved in glycoprotein conformation recognition, the tight association between N- and C-terminal domains may explain why only N-glycans in close proximity to protein structural perturbations are glucosylated by the enzyme. Although S. pombe and Drosophila melanogaster GT N- terminal domains display an extremely poor similarity (16.3%), chimeras containing either yeast N- terminal and fly C-terminal domains or the inverse construction were enzymatically and functionally active in vivo, thus indicating that the N- terminal domains of both GTs shared three-dimensional features.	Univ San Martin, Biotechnol Res Inst, RA-1650 San Martin, Argentina		Parodi, AJ (corresponding author), Univ San Martin, Biotechnol Res Inst, CC30, RA-1650 San Martin, Argentina.		Guerin, Marcelo M/N-7245-2016	Guerin, Marcelo M/0000-0001-9524-3184	NIGMS NIH HHS [GM 44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; QUIRIN K, 2002, THESIS SWISS FEDERAL; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; Trombetta ES, 2002, ADV PROTEIN CHEM, V59, P303; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WRIGHT A, 1965, BIOCHIM BIOPHYS ACTA, V104, P594, DOI 10.1016/0304-4165(65)90366-1	19	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20540	20546		10.1074/jbc.M300891200	http://dx.doi.org/10.1074/jbc.M300891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649273	hybrid			2022-12-25	WOS:000183230500014
J	Heinz, U; Bauer, R; Wommer, S; Meyer-Klaucke, W; Papamichaels, C; Bateson, J; Adolph, HW				Heinz, U; Bauer, R; Wommer, S; Meyer-Klaucke, W; Papamichaels, C; Bateson, J; Adolph, HW			Coordination geometries of metal ions in D- or L-captopril-inhibited metallo-beta-lactamases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING ENZYME-INHIBITORS; PERTURBED-ANGULAR-CORRELATION; BINDING; DYNAMICS; POTENT; SITES; EXAFS	D- and L-captopril are competitive inhibitors of metallo-beta-lactamases. For the enzymes from Bacillus cereus (BcII) and Aeromonas hydrophila (CphA), we found that the mononuclear enzymes are the favored targets for inhibition. By combining results from extended x-ray absorption fine structure, perturbed angular correlation of gamma-rays spectroscopy, and a study of metal ion binding, we derived that for Cd(II)(1)-BcII, the thiolate sulfur of D-captopril binds to the metal ion located at the site defined by three histidine ligand residues. This is also the case for the inhibited Co(II)(1) and Co(II)(2) enzymes as observed by UV-visible spectroscopy. Although the single metal ion in Cd(II)(1)-BcII is distributed between both available binding sites in both the uninhibited and the inhibited enzyme, Cd(II)(1)-CphA shows only one defined ligand geometry with the thiolate sulfur coordinating to the metal ion in the site composed of 1 Cys, 1 His, and 1 Asp. CphA shows a strong preference for D- captopril, which is also reflected in a very rigid structure of the complex as determined by perturbed angular correlation spectroscopy. For BcII and CphA, which are representatives of the metallo-beta-lactamase subclasses B1 and B2, we find two different inhibitor binding modes.	Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany; Univ Saarland, Dept Biochem, D-66041 Saarbrucken, Germany; Royal Vet & Agr Univ, Dept Math & Phys, DK-1871 Frederiksberg, Denmark; DESY, European Mol Biol Lab Outstn Hamburg, D-22603 Hamburg, Germany; Univ Oxford, Dyson Perrins Lab, Dept Chem, Oxford OX1 3QY, England; GlaxoSmithKline, Dept Med Chem, MMPD, CEDD, Harlow CM19 5AW, Essex, England	Saarland University; Saarland University; University of Copenhagen; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Oxford; GlaxoSmithKline	Adolph, HW (corresponding author), Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany.	hwadolph@mx.uni-saarland.de	Adolph, Hans W/A-2104-2008; Meyer-Klaucke, Wolfram/G-1148-2010					Bauer R, 1997, BIOCHEMISTRY-US, V36, P11514, DOI 10.1021/bi970936t; BAUER R, 1985, Q REV BIOPHYS, V18, P1, DOI 10.1017/S0033583500004972; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; Hemmingsen L, 1996, EUR J BIOCHEM, V241, P546, DOI 10.1111/j.1432-1033.1996.00546.x; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; JOYNER RW, 1987, J PHYS C SOLID STATE, V20, P4005, DOI 10.1088/0022-3719/20/25/028; LEE PA, 1975, PHYS REV B, V11, P2795, DOI 10.1103/PhysRevB.11.2795; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; Mollard C, 2001, J BIOL CHEM, V276, P45015, DOI 10.1074/jbc.M107054200; Paul-Soto R, 1999, BIOCHEMISTRY-US, V38, P16500, DOI 10.1021/bi9911381; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Payne DJ, 2000, EXPERT OPIN INV DRUG, V9, P247, DOI 10.1517/13543784.9.2.247; SKILES JW, 1986, J MED CHEM, V29, P784, DOI 10.1021/jm00155a032; SMITH EM, 1988, J MED CHEM, V31, P875, DOI 10.1021/jm00399a033; SUH JT, 1985, J MED CHEM, V28, P57, DOI 10.1021/jm00379a013; Teo, 1986, EXAFS BASIC PRINCIPL; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; Villadares MH, 1996, MICROB DRUG RESIST, V2, P253, DOI 10.1089/mdr.1996.2.253; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Zervosen A, 2001, EUR J BIOCHEM, V268, P3840, DOI 10.1046/j.1432-1327.2001.02298.x	29	72	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20659	20666		10.1074/jbc.M212581200	http://dx.doi.org/10.1074/jbc.M212581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668674	hybrid			2022-12-25	WOS:000183230500029
J	Murata, T; Arechaga, I; Fearnley, IM; Kakinuma, Y; Yamato, I; Walker, JE				Murata, T; Arechaga, I; Fearnley, IM; Kakinuma, Y; Yamato, I; Walker, JE			The membrane domain of the Na+-motive V-ATPase from Enterococcus hirae contains a heptameric rotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; 16-KDA PROTEOLIPID SUBUNIT; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; MOLECULAR ARCHITECTURE; TRANSLOCATING ATPASE; CHROMAFFIN GRANULES; UNDECAMERIC ROTOR; ROTARY CATALYSIS; COUPLING RATIO	In F-ATPases, ATP hydrolysis is coupled to translocation of ions through membranes by rotation of a ring of c subunits in the membrane. The ring is attached to a central shaft that penetrates the catalytic domain, which has pseudo-3-fold symmetry. The ion translocation pathway lies between the external circumference of the ring and another hydrophobic protein. The H+ or Na+: ATP ratio depends upon the number of ring protomers, each of which has an essential carboxylate involved directly in ion translocation. This number and the ratio differ according to the source, and 10, 11, and 14 protomers have been found in various enzymes, with corresponding calculated H+ or Na+: ATP ratios of 3.3, 3.7, and 4.7. V-ATPases are related in structure and function to F-ATPases. Oligomers of subunit K from the Na+-motive V-ATPase of Enterococcus hirae also form membrane rings but, as reported here, with 7-fold symmetry. Each protomer has one essential carboxylate. Thus, hydrolysis of one ATP provides energy to extrude 2.3 sodium ions. Symmetry mismatch between the catalytic and membrane domains appears to be an intrinsic feature of both V- and F-ATPases.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Muroran Inst Technol, Dept Appl Chem, Muroran, Hokkaido 0508585, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Chiba 2788510, Japan	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Muroran Institute of Technology; Tokyo University of Science	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Murata, Takeshi/F-6114-2011; Murata, Takeshi/J-6181-2017; Arechaga, Ignacio/K-2198-2014	Murata, Takeshi/0000-0002-5748-4670; Arechaga, Ignacio/0000-0002-1342-9370; Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arechaga I, 2002, FEBS LETT, V515, P189, DOI 10.1016/S0014-5793(02)02447-X; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Ferguson SJ, 2000, CURR BIOL, V10, pR804, DOI 10.1016/S0960-9822(00)00765-X; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Gibson LCD, 2002, BIOCHEM J, V366, P911, DOI 10.1042/BJ20020171; HARRISON MA, 1994, EUR J BIOCHEM, V221, P111, DOI 10.1111/j.1432-1033.1994.tb18719.x; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; JOHNSON RG, 1982, J BIOL CHEM, V257, P701; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; Kakinuma Y, 1999, J BIOENERG BIOMEMBR, V31, P7, DOI 10.1023/A:1005499126939; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Muller DJ, 2001, FEBS LETT, V504, P219, DOI 10.1016/S0014-5793(01)02708-9; Muller ML, 1996, J BIOL CHEM, V271, P1916; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Murata T, 1999, J BIOCHEM, V125, P414, DOI 10.1093/oxfordjournals.jbchem.a022302; Nelson N, 2002, NAT REV MOL CELL BIO, V3, P876, DOI 10.1038/nrm955; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Neumann S, 1998, J BACTERIOL, V180, P3312, DOI 10.1128/JB.180.13.3312-3316.1998; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 1997, BBA-BIOENERGETICS, V1322, P183, DOI 10.1016/S0005-2728(97)00079-0; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VanWalraven HS, 1996, FEBS LETT, V379, P309, DOI 10.1016/0014-5793(95)01536-1; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Yabe I, 1999, J BIOL CHEM, V274, P34903, DOI 10.1074/jbc.274.49.34903; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	59	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21162	21167		10.1074/jbc.M301620200	http://dx.doi.org/10.1074/jbc.M301620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651848	hybrid			2022-12-25	WOS:000183230500093
J	Papo, N; Shahar, M; Eisenbach, L; Shai, Y				Papo, N; Shahar, M; Eisenbach, L; Shai, Y			A novel lytic peptide composed of DL-Amino acids selectively kills cancer cells in culture and in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDES; ALPHA-HELIX; MEMBRANE; SPECTROSCOPY; RESONANCE; PHASE	The high toxicity of most chemotherapeutic drugs and their inactivation by multidrug resistance phenotypes motivated extensive search for drugs with new modes of action. We designed a short cationic diastereomeric peptide composed of D- and L-leucines, lysines, and arginines that has selective toxicity toward cancer cells and significantly inhibits lung metastasis formation in mice (86%) with no detectable side effects. Its ability to depolarize the transmembrane potential of cancer cells at the same rate (within minutes) and concentration (3 muM), at which it shows biological activity, suggests a killing mechanism that involves plasma membrane perturbation. Confocal microscopy experiments verified that the cells died as a result of acute injury, swelling, and bursting, suggesting necrosis. Biosensor binding experiments and attenuated total reflectance-Fourier transform infrared spectroscopy using model membranes have substantiated its high selectivity toward cancer cells. Although this is an initial study that looked at tumor formation rather than the ability of the peptides to reduce established tumors, the simple sequence of the peptide, its high solubility, substantial resistance to degradation, and inactivation by serum components might make it a good candidate for future anticancer treatment.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Papo, Niv/R-3946-2017	Eisenbach, Lea R/0000-0002-4816-1968				Abu-Raya S, 1998, J PHARMACOL EXP THER, V287, P889; BAKER MA, 1993, CANCER RES, V53, P3052; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CAMERON DG, 1980, BIOCHIM BIOPHYS ACTA, V596, P463, DOI 10.1016/0005-2736(80)90135-2; Chan SC, 1998, J PEPT SCI, V4, P413, DOI 10.1002/(SICI)1099-1387(1998110)4:7<413::AID-PSC160>3.3.CO;2-X; Chen YX, 2001, CANCER RES, V61, P2434; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P923, DOI 10.1002/bip.360230509; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; KRAUSE E, 1995, ANAL CHEM, V67, P252, DOI 10.1021/ac00098a003; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Oren Z, 2000, BIOCHEMISTRY-US, V39, P6103, DOI 10.1021/bi992408i; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; PORGADOR A, 1993, J IMMUNOL, V150, P1458; ROTHEMUND S, 1995, BIOCHEMISTRY-US, V34, P12954, DOI 10.1021/bi00040a005; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; Smith LL, 2000, CRIT REV TOXICOL, V30, P571, DOI 10.1080/10408440008951120; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	24	134	144	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21018	21023		10.1074/jbc.M211204200	http://dx.doi.org/10.1074/jbc.M211204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12646578	hybrid			2022-12-25	WOS:000183230500075
J	Davies, BA; Topp, JD; Sfeir, AJ; Katzmann, DJ; Carney, DS; Tall, GG; Friedberg, AS; Deng, L; Chen, ZJ; Horazdovsky, BF				Davies, BA; Topp, JD; Sfeir, AJ; Katzmann, DJ; Carney, DS; Tall, GG; Friedberg, AS; Deng, L; Chen, ZJ; Horazdovsky, BF			Vps9p CUE domain ubiquitin binding is required for efficient endocytic protein traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; NUCLEOTIDE EXCHANGE; GENE; RAS; LOCALIZATION; INTERACTS; IDENTIFICATION; DEGRADATION; EXPRESSION; REGULATOR	Rab5 GTPases are key regulators of protein trafficking through the early stages of the endocytic pathway. The yeast Rab5 ortholog Vps21p is activated by its guanine nucleotide exchange factor Vps9p. Here we show that Vps9p binds ubiquitin and that the CUE domain is necessary and sufficient for this interaction. Vps9p ubiquitin binding is required for efficient endocytosis of Ste3p but not for the delivery of the biosynthetic cargo carboxypeptidase Y to the vacuole. In addition, Vps9p is itself monoubiquitylated. Ubiquitylation is dependent on a functional CUE domain and Rsp5p, an E3 ligase that participates in cell surface receptor endocytosis. These findings define a new ubiquitin binding domain and implicate ubiquitin as a modulator of Vps9p function in the endocytic pathway.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Mayo Clinic; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horazdovsky, BF (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	Horazdovsky.Bruce@mayo.edu	Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251	NIGMS NIH HHS [GM-055301] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1996, MOL CELL BIOL, V16, P2369; Chen YJ, 1996, EUR J CELL BIOL, V70, P289; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kaminska J, 2002, MOL CELL BIOL, V22, P6946, DOI 10.1128/MCB.22.20.6946-6958.2002; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nagase T, 2000, DNA RES, V7, P273; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Sherman F, 1979, METHODS YEAST GENETI; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	49	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19826	19833		10.1074/jbc.M301059200	http://dx.doi.org/10.1074/jbc.M301059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654912	hybrid			2022-12-25	WOS:000183078000034
J	Liu, XH; Tesfai, J; Evrard, YA; Dent, SYR; Martinez, E				Liu, XH; Tesfai, J; Evrard, YA; Dent, SYR; Martinez, E			C-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; IN-VIVO; ESSENTIAL COFACTOR; ONCOGENIC TRANSFORMATION; MYC/MAX/MAD NETWORK; HISTONE ACETYLATION; GENE ACTIVATION; CAD PROMOTER; SAGA; COACTIVATOR	Deregulation of the c-Myc oncoprotein (Myc) is implicated in many types of cancer. Myc is a sequence-specific transcription factor that regulates transcription of genes involved in the control of cell proliferation and apoptosis via mechanisms that are still poorly understood. Cell transformation by Myc involves its association with the transformation-transactivation domain-associated protein ( TRRAP) and the human histone acetyltransferase ( HAT) GCN5. TRRAP and GCN5 are components of a variety of shared and distinct multiprotein HAT complexes with diverse functions. Myc induces TRRAP recruitment and histone hyperacetylation at specific Myc-activated genes in vivo. However, the identity of the HAT complexes recruited by Myc and the roles of TRRAP and GCN5 in Myc function are still unclear. Here we show that Myc co-recruits TRRAP and GCN5 via direct physical interactions of its N-terminal activation/transformation domain with the human STAGA (SPT3-TAF-GCN5 acetylase) coactivator complex. We demonstrate that GCN5 and TRRAP cooperate to enhance transcription activation by the N-terminal activation domain of Myc in vivo and that this synergy requires both the SPT3/GCN5 interaction domain of TRRAP and the HAT activity of GCN5. Thus, TRRAP might function as an adaptor within the STAGA complex, which helps recruit GCN5 HAT activity to Myc during transcription activation.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of California System; University of California Riverside; University of Texas System; UTMD Anderson Cancer Center	Martinez, E (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269	NIGMS NIH HHS [T34 GM062756] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM062756] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hardy S, 2002, J BIOL CHEM, V277, P32875, DOI 10.1074/jbc.M205860200; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	43	90	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20405	20412		10.1074/jbc.M211795200	http://dx.doi.org/10.1074/jbc.M211795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660246	hybrid, Green Accepted			2022-12-25	WOS:000183078000106
J	Lopez-Monteon, A; Ramos-Ligonio, A; Perez-Castillo, L; Talamas-Rohana, P; Rosales-Encina, JL				Lopez-Monteon, A; Ramos-Ligonio, A; Perez-Castillo, L; Talamas-Rohana, P; Rosales-Encina, JL			Specific antibody immune response against the parasitic portion of a glutathione-S-transferase fusion protein	FASEB JOURNAL			English	Article						immunization; antibodies; isotype; induction; humoral response	ALBUMIN-BINDING REGION; CELL-MEDIATED-IMMUNITY; ENTAMOEBA-HISTOLYTICA; RECOMBINANT PROTEIN; ESCHERICHIA-COLI; CYTOKINE PROFILE; IN-VIVO; ANTIGEN; IMMUNIZATION; MICE	The humoral immune response against an Entamoeba histolytica recombinant protein has been investigated. The 628 by Bam HI-Eco RI DNA fragment (L1b) from the M11 cDNA clone, partially coding for a 220 kDa (L220) protein, was ligated in-frame into the pGEX-3X plasmid vector to produce the fusion protein GST-L1b. BALB/c mice were immunized with different doses of the GST-L1b fusion protein (10-500 mug). GST-L1b doses of 100/50/50, 300, or 500 jig induced an antibody response (IgG1 >IgG3, IgG2a>IgG2b) specific for the amoebic part of the fusion protein (L1b). These antibodies were able to recognize the native protein in amoebic total extract. Anti-GST antibodies were not detected. On the other hand, doses of 10/ 10/10 or 200/100/100 mug induced antibodies able to recognize both GST (IgG2a>IgG1>IgG2b) and L1b (IgG1, IgG2a>IgG3>IgG2b). When mice were immunized with GST alone (100/50/50, 300 or 500 jig), antibodies against GST-L1b or GST were not detected. However, GST doses of 10/10/10 or 200/100/100 jig induced an antibody response able to recognize both GST-L1b and GST. We propose that an immunization protocol similar to the one used in this work may allow induction of high antibody titers specific against the parasite segment of a GST-fusion protein.	IPN, CINVESTAV, Dept Expt Pathol, Mexico City 07360, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Rosales-Encina, JL (corresponding author), IPN, CINVESTAV, Dept Expt Pathol, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico.	rosales@mail.cinvestav.mx	Talamás-Rohana, Patricia/AAF-3925-2021	Talamás-Rohana, Patricia/0000-0002-5085-814X; Ramos-Ligonio, Angel/0000-0003-3896-7447				Andersson C, 1999, J IMMUNOL METHODS, V222, P171, DOI 10.1016/S0022-1759(98)00195-1; Andre C I, 1975, Dev Biol Stand, V28, P237; Avramidis N, 2002, VET MICROBIOL, V88, P325, DOI 10.1016/S0378-1135(02)00128-1; BANCROFT AJ, 1994, EUR J IMMUNOL, V24, P3113, DOI 10.1002/eji.1830241230; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Chaturvedi P, 1996, INT IMMUNOL, V8, P745, DOI 10.1093/intimm/8.5.745; Chowdhury PS, 2001, J IMMUNOL METHODS, V249, P147, DOI 10.1016/S0022-1759(00)00353-7; CONSTANT S, 1995, J IMMUNOL, V154, P4915; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Daly TM, 1996, INFECT IMMUN, V64, P2602, DOI 10.1128/IAI.64.7.2602-2608.1996; GOLD D, 1990, METHODS ENZYMOLOGY G, V185; HAJISHENGALLIS G, 1995, J IMMUNOL, V154, P4322; HANSSON M, 1994, BIO-TECHNOL, V12, P285, DOI 10.1038/nbt0394-285; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Jimenez-Delgadillo B, 1997, Arch Med Res, V28 Spec No, P173; KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Libon C, 1999, VACCINE, V17, P406, DOI 10.1016/S0264-410X(98)00198-4; Lovgren-Bengtsson K, 1998, METHOD MICROBIOL, V25, P471; MEZA I, 1987, J INFECT DIS, V156, P798, DOI 10.1093/infdis/156.5.798; MURBY M, 1995, EUR J BIOCHEM, V230, P38, DOI 10.1111/j.1432-1033.1995.tb20531.x; MURBY M, 1994, SEPARATIONS BIOTECHN, V3; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Power CA, 1998, INFECT IMMUN, V66, P5743, DOI 10.1128/IAI.66.12.5743-5750.1998; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; RIGGS P, 1997, CURRENT PROTOCOLS MO, V2; ROSALESENCINA JL, 1987, J INFECT DIS, V156, P790, DOI 10.1093/infdis/156.5.790; Rudolph Rainer, 1996, P283; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; Sjolander A, 1997, J IMMUNOL METHODS, V201, P115, DOI 10.1016/S0022-1759(96)00217-7; SJOLANDER A, 1993, IMMUNOMETHODS, V2, P79; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHERS SR, 1989, PARASITE IMMUNOL, V11, P301, DOI 10.1111/j.1365-3024.1989.tb00669.x; TALAMASROHANA P, 1995, INFECT IMMUN, V63, P3953; TEW JG, 1980, IMMUNOL REV, V53, P175; Towbin H, 1992, Biotechnology, V24, P145; TOYE B, 1990, INFECT IMMUN, V58, P3909, DOI 10.1128/IAI.58.12.3909-3913.1990; VARLEY CA, 1992, PARASITE IMMUNOL, V14, P557, DOI 10.1111/j.1365-3024.1992.tb00028.x; Von Seggern DJ, 1999, GENE EXPRESSION SYSTEMS, P111, DOI 10.1016/B978-012253840-7/50006-7; WHITE RG, 1976, ANNU REV MICROBIOL, V30, P579, DOI 10.1146/annurev.mi.30.100176.003051	43	7	8	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					621	627		10.1096/fj.02-0471com	http://dx.doi.org/10.1096/fj.02-0471com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665474				2022-12-25	WOS:000182580100006
J	Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S				Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S			P14(ARF) induces G(2) arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice	ONCOGENE			English	Article						apoptosis; G(2) arrest; tumour regression; ARF; p53	DNA-DAMAGE CHECKPOINT; CELL-CYCLE ARREST; INHIBITORY PHOSPHORYLATION; P53-DEPENDENT APOPTOSIS; PROTEIN-KINASE; CDC25 PROTEIN; FEEDBACK LOOP; LUNG-CANCER; SUPPRESSOR; P19(ARF)	Until recently, the ability of ARF (human p14(ARF), murine p19(ARF)) tumour-suppressor protein, encoded by the INK4A/ARF locus, to inhibit cell growth in response to various stimuli was related to its ability to stabilize p53 through the so-called ARF/MDM2/p53 pathway. However, recent data have demonstrated that ARF is not implicated in this unique p53-dependent pathway. By use of transient and stable expression, we show here that human p14(ARF) inhibits the growth of human tumoral cells lacking functional p53 by inducing a transient G(2) arrest and subsequently apoptosis. This p14(ARF)-induced G2 arrest was correlated with inhibition of CDC2 activity, inactivation of CDC25C phosphatase and induction of the CDK inhibitor p21(WAF1). Apoptosis was demonstrated using Hoechst 33352 staining, proteolytic activation of caspase-3 and PARP cleavage. Similar results were obtained in experiments with cells synchronized by hydroxyurea block. Importantly, we were able to reproduce these effects 'in vivo' by showing that p14(ARF) inhibits the growth of p53 nullizygous human tumours in nude mice and induces the regression of p53 -/- established tumours. In these experiments, tumoral regression was associated with inhibition of cell proliferation as well as induction of apoptosis confirming the data obtained in cell lines.	Inst Albert Bonniot, INSERM, Equipe 9924, Grp Rech Canc Poumon,EA 2021, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Equipe 9924, Grp Rech Canc Poumon,EA 2021, F-38706 La Tronche, France.	Sylvie.Gazzeri@ujf-grenoble.fr	Coll, Jean-Luc/G-2520-2013; eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013	Coll, Jean-Luc/0000-0002-2453-3552; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Athar M, 2000, BIOCHEM BIOPH RES CO, V277, P107, DOI 10.1006/bbrc.2000.3436; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Draetta G.F., 1997, CURR BIOL, V7, P50; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esteller M, 2000, CANCER RES, V60, P129; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FAN SJ, 1995, CANCER RES, V55, P1649; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gazzeri S, 1998, CANCER RES, V58, P3926; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, ONCOGENE, V9, P2261; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1997, CANCER RES, V57, P5168; POWELL SN, 1995, CANCER RES, V55, P1643; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yarbrough WG, 2002, CANCER RES, V62, P1171; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	69	103	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1822	1835		10.1038/sj.onc.1206303	http://dx.doi.org/10.1038/sj.onc.1206303			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660818	Green Submitted			2022-12-25	WOS:000181678200009
J	Nimonkar, AV; Boehmer, PE				Nimonkar, AV; Boehmer, PE			The herpes simplex virus type-1 single-strand DNA-binding protein (ICP8) promotes strand invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION; ORIGIN; RECA; RECOMBINATION; EXCHANGE; HELIX	ICP8, the herpes simplex virus type-1 single-strand DNA-binding protein, was recently shown to promote strand exchange in conjunction with the viral replicative helicase (Nimonkar, A. V., and Boehmer, P. E. (2002) J. Biol. Chem. 277,15182-15189). Here we show that ICP8 also catalyzes strand invasion in an ATP-independent manner. Thus, ICP8 promotes the assimilation of a single-stranded donor molecule into a homologous plasmid, resulting in the formation of a displacement loop. Invasion of a homologous duplex by single-stranded DNA requires homology at either 3' or 5' end of the invading strand. The reaction is dependent on the free energy of supercoiling and alters the topology of the acceptor plasmid. Hence, strand invasion products formed by ICP8 are resistant to the action of restriction endonucleases that cleave outside of the area of pairing. The ability to catalyze strand invasion is a novel activity of ICP8 and the first demonstration of a eukaryotic viral single-strand DNA-binding protein to promote this reaction. In this regard ICP8 is functionally similar to the prototypical prokaryotic recombinase RecA and its eukaryotic homologs. This strand invasion activity of ICP8 coupled with DNA synthesis may explain the high prevalence of branched DNA structures during viral replication.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-629,POB 016129, Miami, FL 33101 USA.			Boehmer, Paul/0000-0003-4479-0529	NIGMS NIH HHS [GM62643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER WR, 1980, SCI AM, V243, P118; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DUTCH RE, 1992, J VIROL, V66, P277, DOI 10.1128/JVI.66.1.277-285.1992; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; Huang KJ, 2002, J BIOL CHEM, V277, P21071, DOI 10.1074/jbc.M201785200; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Nimonkar AV, 2002, J BIOL CHEM, V277, P15182, DOI 10.1074/jbc.M109988200; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Severini A, 1996, J VIROL, V70, P3169, DOI 10.1128/JVI.70.5.3169-3175.1996; Xu LW, 2002, J BIOL CHEM, V277, P14321, DOI 10.1074/jbc.M112418200	19	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9678	9682		10.1074/jbc.M212555200	http://dx.doi.org/10.1074/jbc.M212555200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645567	hybrid			2022-12-25	WOS:000181524000106
J	Linn, T; Schneider, K; Hammes, HP; Preissner, KT; Brandhorst, H; Morgenstern, E; Kiefer, F; Bretzel, RG				Linn, T; Schneider, K; Hammes, HP; Preissner, KT; Brandhorst, H; Morgenstern, E; Kiefer, F; Bretzel, RG			Angiogenic capacity of endothelial cells in islets of Langerhans	FASEB JOURNAL			English	Article						islet transplantation; vascularization; Tie-2 LacZ	PANCREATIC-ISLETS; GROWTH; RAT; HYPOXIA; EXPRESSION; OXYGEN; MODEL; VEGF	Transplantation of pancreatic islets reconstitutes glucose homeostasis in diabetes mellitus. Before transplantation, islets are disrupted from the surrounding blood vessels by the isolation procedure, with the grafted tissue being subject to ischemic damage. The survival of transplanted islets is assumed to depend on effective revascularization. Perfusion studies suggest that newly formed microvessels supplying the graft with nutrients are exclusively rebuilt by the host. It is generally not known whether isolated islets contain endothelial cells (EC), which potentially participate in the revascularization process. Therefore, we tried to detect immature EC in isolated islets by transformation with polyoma middle T antigen. Endothelioma cells were generated, implicating the presence of de-differentiated EC within isolated islets. When embedded in a fibrin gel, the islets developed cellular cords consisting of EC, whereas FGF-2 and VEGF stimulated the formation of cord-like structures. Furthermore, we studied the presence of donor EC in islet grafts by using transgenic mice with an EC lineage-specific promotor-LacZ reporter construct (Tie-2LacZ). Following islet transplantation, Tie-2LacZ-positive EC of both donor and recipient were identified in the vicinity of or within the graft up to 3 wk after transplantation. In conclusion, EC and/or their progenitors with angiogenic capacity reside within isolated islets of different species, and their proliferative potential can be stimulated by various inducers. These graft-related endothelia persist after islet transplantation and are integrated within newly formed microvessels.	Univ Giessen, Clin Res Unit, Med Clin & Policlin 3, D-35392 Giessen, Germany; Heidelberg Univ, Med Clin 5, Fac Med, Mannheim, Germany; Univ Giessen, Inst Biochem, Fac Med, D-35392 Giessen, Germany; Univ Saarland, Dept Med Biol, Fac Med, D-66421 Homburg, Germany; Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Saarland University; Max Planck Society	Linn, T (corresponding author), Univ Giessen, Clin Res Unit, Med Clin & Policlin 3, Rodthohl 6, D-35392 Giessen, Germany.	thomas.linn@innere.med.uni-giessen.de	Hammes, Hans-Peter/S-3719-2019	Kiefer, Friedemann/0000-0002-3002-8237				Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Brandhorst H, 1998, CELL TRANSPLANT, V7, P489, DOI 10.1016/S0963-6897(98)00028-1; Brandhorst H, 1999, TRANSPLANTATION, V68, P355, DOI 10.1097/00007890-199908150-00006; Brunicardi FC, 1996, DIABETES, V45, P385, DOI 10.2337/diab.45.4.385; Carlsson PO, 2000, TRANSPLANTATION, V69, P761; Christiani, 1995, Int J Occup Environ Health, V1, P9; Compagni A, 2000, CANCER RES, V60, P7163; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; DIONNE KE, 1993, DIABETES, V42, P12, DOI 10.2337/diabetes.42.1.12; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401; Hart AW, 2000, NATURE, V408, P864, DOI 10.1038/35048589; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kawakami Y, 2000, CELL TRANSPLANT, V9, P729, DOI 10.1177/096368970000900523; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Kroon ME, 2001, J CELL SCI, V114, P825; LINN T, 1989, TRANSPLANT P, V21, P2685; Lou JN, 1999, DIABETES, V48, P1773, DOI 10.2337/diabetes.48.9.1773; Lupia E, 1996, EUR J IMMUNOL, V26, P1690, DOI 10.1002/eji.1830260804; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; Mattsson G, 2002, DIABETES, V51, P1362, DOI 10.2337/diabetes.51.5.1362; MENGER MD, 1992, J CLIN INVEST, V90, P1361, DOI 10.1172/JCI116002; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; PAPACCIO G, 1993, J ANAT, V182, P45; Papas KK, 1996, BBA-GEN SUBJECTS, V1291, P163, DOI 10.1016/0304-4165(96)00062-1; VAJKOCZY P, 1995, AM J PATHOL, V146, P1397; Vasir B, 2001, TRANSPLANTATION, V71, P924, DOI 10.1097/00007890-200104150-00018	27	81	83	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					881	+		10.1096/fj.02-0615fje	http://dx.doi.org/10.1096/fj.02-0615fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670881				2022-12-25	WOS:000181892600008
J	Salgado, FJ; Lojo, J; Alonso-Lebrero, JL; Lluis, C; Franco, R; Cordero, OJ; Nogueira, M				Salgado, FJ; Lojo, J; Alonso-Lebrero, JL; Lluis, C; Franco, R; Cordero, OJ; Nogueira, M			A role for interleukin-12 in the regulation of T cell plasma membrane compartmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-IV; CD45 TYROSINE PHOSPHATASE; RECEPTOR SIGNAL-TRANSDUCTION; HUMAN ACTIVATED LYMPHOCYTES; ANTIGEN-RECEPTOR; LIPID RAFTS; DEPENDENT REGULATION; CD26 EXPRESSION; ASSOCIATION; SURFACE	The immunological synapse initiates the clustering and stabilization of the T cell receptor by the formation of a large lipid microdomain that accumulates (e.g. CD4/CD8) and segregates (e.g. CD45 and LFA-1) some proteins of the T cell plasma membrane. This work shows that a fraction of transmembrane glycoproteins CD26 and CD45 (the R0 isoform in particular) is present in the rafts of fresh and activated human T lymphocytes. CD26 is proposed as the costimulator of TCR-dependent activation, and CD45 is essential to the T cell activation process because it dephosphorylates at least the inhibitory site of Src kinases. These findings support a more complex model of compartmentation, depending on the stage of T cell maturation and post-transcriptional and post-translational regulation. In addition, interleukin 12 (IL-12; inducer of T(H)1 responses) drives CD26 and CD45R0 to particular microdomains, thereby involving interleukins in the rules governing raft inclusion or exclusion. The physical association of CD26 and CD45R0 has long been reported. The results presented in this work fit a model in which IL-12 up-regulates a certain type of CD26 expression that interacts on the cell surface with CD45R0, near but outside of the raft core. The use of antisense oligonucleotides for the CD26 mRNAs demonstrated that both events (enhanced by IL-12), CD26-CD45R0 association and membrane compartment redistribution, are related. Thus, CD26 could be part of a shuttling mechanism for CD45 that regulates membrane tyrosine-phosphatase activities, e. g. to control IL-12 receptor-dependent signal transduction.	Univ Santiago de Compostela, Dept Bioquim & Biol Mol, Fac Biol, Santiago De Compostela 15782, Galicia, Spain; Univ Autonoma Madrid, Serv Inmunol, Hosp Princesa, Madrid 28006, Spain; Univ Barcelona, Dept Biochem & Mol Biol, Barcelona 08108, Spain	Universidade de Santiago de Compostela; Autonomous University of Madrid; Hospital de La Princesa; University of Barcelona	Nogueira, M (corresponding author), Univ Santiago de Compostela, Dept Bioquim & Biol Mol, Fac Biol, Campus Sur, Santiago De Compostela 15782, Galicia, Spain.		Cordero, Oscar J/K-5415-2015; Castro, Francisco Javier Salgado/AAA-9464-2019; Franco, Rafael/C-3694-2015	Cordero, Oscar J/0000-0003-1026-124X; Castro, Francisco Javier Salgado/0000-0003-4738-215X; Franco, Rafael/0000-0003-2549-4919				ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; Baldwin TA, 2000, J BIOL CHEM, V275, P32071, DOI 10.1074/jbc.M003088200; Blank N, 2001, J IMMUNOL, V166, P6034, DOI 10.4049/jimmunol.166.10.6034; BLAZQUEZ MV, 1992, J IMMUNOL, V149, P3073; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Cayota A, 1996, CLIN EXP IMMUNOL, V104, P11, DOI 10.1046/j.1365-2249.1996.d01-652.x; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cordero OJ, 1997, IMMUNOBIOLOGY, V197, P522, DOI 10.1016/S0171-2985(97)80084-8; Cordero OJ, 1998, IMMUNOL LETT, V61, P7, DOI 10.1016/S0165-2478(97)00154-5; Cordero OJ, 2001, J LEUKOCYTE BIOL, V70, P920; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; Herrera C, 2001, J BIOL CHEM, V276, P19532, DOI 10.1074/jbc.M004586200; Holst JJ, 1998, DIABETES, V47, P1663, DOI 10.2337/diabetes.47.11.1663; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ilangumaran S, 1997, BBA-BIOMEMBRANES, V1328, P227, DOI 10.1016/S0005-2736(97)00099-0; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ishii T, 2001, P NATL ACAD SCI USA, V98, P12138, DOI 10.1073/pnas.211439098; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; JOHNSON P, 1996, WEIRS HDB EXPT IMMUN, V2; Klaus SJ, 1996, J IMMUNOL, V156, P2743; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; LOSTER K, 1995, BIOCHEM BIOPH RES CO, V217, P341, DOI 10.1006/bbrc.1995.2782; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Martinez-Pomares L, 1999, J BIOL CHEM, V274, P35211, DOI 10.1074/jbc.274.49.35211; Mattern T, 1998, IMMUNOBIOLOGY, V198, P465, DOI 10.1016/S0171-2985(98)80053-3; Mirabet M, 1999, J CELL SCI, V112, P491; MITTRUCKER HW, 1995, EUR J IMMUNOL, V25, P295, DOI 10.1002/eji.1830250149; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Parkin ET, 1996, BIOCHEM J, V319, P887, DOI 10.1042/bj3190887; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROTH AD, 1995, CLIN EXP IMMUNOL, V101, P362; ROTH MD, 1994, J EXP MED, V179, P857, DOI 10.1084/jem.179.3.857; Salgado FJ, 2000, CYTOKINE, V12, P1136, DOI 10.1006/cyto.1999.0643; Salgado FJ, 2002, IMMUNOL CELL BIOL, V80, P138, DOI 10.1046/j.1440-1711.2002.01055.x; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Struyf S, 1999, J IMMUNOL, V162, P4903; TANAKA T, 1992, J IMMUNOL, V149, P481; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; von Bonin A, 1998, IMMUNOL REV, V161, P43; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822	65	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24849	24857		10.1074/jbc.M212978200	http://dx.doi.org/10.1074/jbc.M212978200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12676959	hybrid			2022-12-25	WOS:000183824800073
J	Lostao, A; Daoudi, F; Irun, MP; Ramon, A; Fernandez-Cabrera, C; Romero, A; Sancho, J				Lostao, A; Daoudi, F; Irun, MP; Ramon, A; Fernandez-Cabrera, C; Romero, A; Sancho, J			How FMN binds to Anabaena apoflavodoxin - A hydrophobic encounter at an open binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN ASSOCIATION; OXIDIZED FLAVODOXIN; PEPTOSTREPTOCOCCUS-ELSDENII; TRANSITION-STATE; LIGAND-BINDING; KINETICS; ENZYME; THERMODYNAMICS; PATHWAY; STABILIZATION	Molecular recognition begins when two molecules approach and establish interactions of certain strength. The mechanisms of molecular recognition reactions between biological molecules are not well known, and few systems have been analyzed in detail. We investigate here the reaction between an apoprotein and its physiological cofactor (apoflavodoxin and flavin mononucleotide) that binds reversibly to form a non-covalent complex (flavodoxin) involved in electron transfer reactions. We have analyzed the fast binding reactions between the FMN cofactor (and shorter analogs) and wild type (and nine mutant apoflavodoxins where residues interacting with FMN in the final complex have been replaced). The x-ray structures of two such mutants are reported that show the mutations are well tolerated by the protein. From the calculated microscopic binding rate constants we have performed a Phi analysis of the transition state of complex formation that indicates that the binding starts by interaction of the isoalloxazine-fused rings in FMN with residues of its hydrophobic binding site. In contrast, the phosphate in FMN, known to contribute most to the affinity of the final holoflavodoxin complex, is not bound in the transition state complex. Both the effects of ionic strength and of phosphate concentration on the wild type complex rate constant agree with this scenario. As suggested previously by nmr data, it seems that the isoalloxazine-binding site may be substantially open in solution. Interestingly, although FMN is a charged molecule, electrostatic interactions seem not to play a role in directing the binding, unlike what has been reported for other biological complexes. The binding can thus be best described as a hydrophobic encounter at an open binding site.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Zaragoza, Biocomputat & Complex Syst Phys Inst, E-50009 Zaragoza, Spain; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	University of Zaragoza; University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Sancho, J (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	jsancho@posta.unizar.es	Sancho, javier/AAA-1225-2019; Romero, Antonio/K-5754-2014; Lostao, Anabel/P-8693-2015	Sancho, javier/0000-0002-2879-9200; Romero, Antonio/0000-0002-6990-6973; Lostao, Anabel/0000-0001-7460-5916; Irun Irun, Maria Pilar/0000-0003-3392-7200				Baerga-Ortiz A, 2000, J MOL BIOL, V296, P651, DOI 10.1006/jmbi.1999.3447; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; Biertumpfel C, 2002, ACTA CRYSTALLOGR D, V58, P1657, DOI 10.1107/S0907444902012738; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casaus JL, 2002, J BIOL CHEM, V277, P22338, DOI 10.1074/jbc.M112258200; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Diaz JF, 2000, J BIOL CHEM, V275, P26265, DOI 10.1074/jbc.M003120200; Druhan LJ, 1998, BIOCHEMISTRY-US, V37, P9668, DOI 10.1021/bi980770b; Dumortier C, 1996, BIOCHEMISTRY-US, V35, P4387, DOI 10.1021/bi952451f; EDMONDSON DE, 1971, BIOCHEMISTRY-US, V10, P124; Fernandez-Recio J, 2001, BIOCHEMISTRY-US, V40, P15234, DOI 10.1021/bi010216t; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; FILLAT MF, 1991, BIOCHEM J, V280, P187, DOI 10.1042/bj2800187; Freigang J, 2002, PROTEIN SCI, V11, P253, DOI 10.1110/ps.28602; Frisch C, 2001, J MOL BIOL, V308, P69, DOI 10.1006/jmbi.2001.4577; FUKUYAMA K, 1990, J BIOL CHEM, V265, P15804; Gabdoulline RR, 2002, CURR OPIN STRUC BIOL, V12, P204, DOI 10.1016/S0959-440X(02)00311-1; Gabdoulline RR, 2001, J MOL BIOL, V306, P1139, DOI 10.1006/jmbi.2000.4404; GAST R, 1976, BIOCHIM BIOPHYS ACTA, V446, P463, DOI 10.1016/0005-2795(76)90012-X; GAST R, 1978, HELV CHIM ACTA, V61, P1353, DOI 10.1002/hlca.19780610418; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Irun MP, 2001, J MOL BIOL, V306, P877, DOI 10.1006/jmbi.2001.4436; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Langdon GM, 2001, PROTEINS, V43, P476, DOI 10.1002/prot.1059; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; Lostao A, 2000, J BIOL CHEM, V275, P9518, DOI 10.1074/jbc.275.13.9518; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; Maldonado S, 2002, PROTEIN SCI, V11, P1260, DOI 10.1110/ps.2980102; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; Muller F., 2017, CHEM BIOCH FLAVOENZY, V3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; Pueyo JJ, 1996, BIOCHEM J, V313, P855, DOI 10.1042/bj3130855; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; SANCHO J, 1991, J MOL BIOL, V221, P1007, DOI 10.1016/0022-2836(91)80188-Z; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; Smoluchowski M., 1917, Z PHYS CHEM, V92, P129, DOI [10.1515/zpch-1918-9209, DOI 10.1515/ZPCH-1918-9209]; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; Wade RC, 1998, P NATL ACAD SCI USA, V95, P5942, DOI 10.1073/pnas.95.11.5942; WADE RC, 1994, NAT STRUCT BIOL, V1, P65, DOI 10.1038/nsb0194-65; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9	55	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24053	24061		10.1074/jbc.M301049200	http://dx.doi.org/10.1074/jbc.M301049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12682068	hybrid, Green Submitted			2022-12-25	WOS:000183638600108
J	Hernandez-Guzman, FG; Higashiyama, T; Pangborn, W; Osawa, Y; Ghosh, D				Hernandez-Guzman, FG; Higashiyama, T; Pangborn, W; Osawa, Y; Ghosh, D			Structure of human estrone sulfatase suggests functional roles of membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ICHTHYOSIS; STEROID-SULFATASE; BREAST-CANCER; CRYSTAL-STRUCTURE; ARYLSULFATASE-C; PURIFICATION; INHIBITION; EXPRESSION; ENZYME; PROLIFERATION	Estrone sulfatase (ES; 562 amino acids), one of the key enzymes responsible for maintaining high levels of estrogens in breast tumor cells, is associated with the membrane of the endoplasmic reticulum ( ER). The structure of ES, purified from the microsomal fraction of human placentas, has been determined at 2.60-Angstrom resolution by x-ray crystallography. This structure shows a domain consisting of two antiparallel alpha-helices that protrude from the roughly spherical molecule, thereby giving the molecule a "mushroom-like" shape. These highly hydrophobic helices, each about 40 Angstrom long, are capable of traversing the membrane, thus presumably anchoring the functional domain on the membrane surface facing the ER lumen. The location of the transmembrane domain is such that the opening to the active site, buried deep in a cavity of the "gill" of the "mushroom," rests near the membrane surface, thereby suggesting a role of the lipid bilayer in catalysis. This simple architecture could be a prototype utilized by the ER membrane in dictating the form and the function of ER-resident enzymes.	Hauptman Woodward Med Res Inst, Dept Biol Struct, Buffalo, NY 14203 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA	Hauptman Woodward Medical Research Institute; Roswell Park Cancer Institute	Ghosh, D (corresponding author), Hauptman Woodward Med Res Inst, Dept Biol Struct, 73 High St, Buffalo, NY 14203 USA.	ghosh@hwi.buffalo.edu			NCRR NIH HHS [RR-01646] Funding Source: Medline; NIGMS NIH HHS [GM62794] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062794] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alperin ES, 1997, J BIOL CHEM, V272, P20756, DOI 10.1074/jbc.272.33.20756; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Billich A, 2000, J STEROID BIOCHEM, V73, P225, DOI 10.1016/S0960-0760(00)00077-7; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNS GRJ, 1983, BIOCHIM BIOPHYS ACTA, V759, P199, DOI 10.1016/0304-4165(83)90313-6; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; DIBBELT L, 1986, BIOL CHEM H-S, V367, P1223, DOI 10.1515/bchm3.1986.367.2.1223; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Ghosh D, 2001, CHEM-BIOL INTERACT, V130, P637, DOI 10.1016/S0009-2797(00)00255-6; Hernandez-Guzman FG, 2001, J STEROID BIOCHEM, V78, P441, DOI 10.1016/S0960-0760(01)00119-4; Hernandez-Martin A, 1999, BRIT J DERMATOL, V141, P617; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL H, 1983, J STEROID BIOCHEM, V19, P1591, DOI 10.1016/0022-4731(83)90375-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasqualini JR, 2002, BREAST CANCER: PROGNOSIS, TREATMENT, AND PREVENTION, P187; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Purohit A, 1998, CHEM-BIOL INTERACT, V109, P183, DOI 10.1016/S0009-2797(97)00132-4; Purohit A, 1999, J STEROID BIOCHEM, V69, P227, DOI 10.1016/S0960-0760(99)00039-4; Reed MJ, 1997, ENDOCR REV, V18, P701, DOI 10.1210/er.18.5.701; Reed MJ, 1996, ENDOCR-RELAT CANCER, V3, P9, DOI 10.1677/erc.0.0030009; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selcer KW, 1997, CANCER RES, V57, P702; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STEIN C, 1989, J BIOL CHEM, V264, P13865; SUZUKI T, 1992, ENDOCRINOL JAPON, V39, P93; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VACCARO AM, 1987, ENZYME, V37, P115, DOI 10.1159/000469248; VANDERLOOS CM, 1984, J INHERIT METAB DIS, V7, P97, DOI 10.1007/BF01801762; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; Yanaihara A, 2001, STEROIDS, V66, P87, DOI 10.1016/S0039-128X(00)00204-X	41	141	142	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22989	22997		10.1074/jbc.M211497200	http://dx.doi.org/10.1074/jbc.M211497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12657638	hybrid			2022-12-25	WOS:000183503900106
J	Martinez-Morales, JR; Dolez, V; Rodrigo, I; Zaccarini, R; Leconte, L; Bovolenta, P; Saule, S				Martinez-Morales, JR; Dolez, V; Rodrigo, I; Zaccarini, R; Leconte, L; Bovolenta, P; Saule, S			OTX2 activates the molecular network underlying retina pigment epithelium differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER TRANSCRIPTION FACTOR; DNA-BINDING DOMAINS; NEURAL RETINA; GENE-EXPRESSION; IN-VITRO; MICROPHTHALMIA; PROTEIN; HOMEODOMAIN; PROMOTER; MOUSE	The retina pigment epithelium ( RPE) is fundamental for the development and function of the vertebrate eye. Molecularly, the presumptive RPE can be identified by the early expression of two transcription factors, Mitf and Otx. In mice deficient for either gene, RPE development is impaired with loss of melanogenic gene expression, raising the possibility that in the eye OTX proteins operate either in a feedback loop or in cooperation with MITF for the control of RPE- specific gene expression. Here we show that Otx2 induces a pigmented phenotype when overexpressed in avian neural retina cells. In addition, OTX2 binds specifically to a bicoid motif present in the promoter regions of three Mitf target genes, QNR71, TRP- 1, and tyrosinase, leading to their transactivation. OTX2 and MITF co- localize in the nuclei of RPE cells and physically interact, and their co- expression results in a cooperative activation of QNR71 and tyrosinase promoters. Collectively, these data suggest that both transcription factors operate at the same hierarchical level to establish the identity of the RPE.	CSIC, Inst Cajal, E-28002 Madrid, Spain; Ctr Univ, Inst Curie, Sect Rech, Unitee Mixte Res 146, F-91405 Orsay, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Bovolenta, P (corresponding author), CSIC, Inst Cajal, Dr Arce 37, E-28002 Madrid, Spain.		Martinez-Morales, Juan R/K-7622-2014	Martinez-Morales, Juan R/0000-0002-4650-4293				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; Arnheiter H, 1998, NATURE, V391, P632, DOI 10.1038/35487; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; Boncinelli E, 2001, TRENDS GENET, V17, P633, DOI 10.1016/S0168-9525(01)02418-0; Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141; Bovolenta P, 1997, J NEUROSCI, V17, P4243; Briata P, 1999, FEBS LETT, V445, P160, DOI 10.1016/S0014-5793(99)00113-1; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Courtois V, 2003, J NEUROCHEM, V84, P840, DOI 10.1046/j.1471-4159.2003.01583.x; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Gammill LS, 1997, DEVELOPMENT, V124, P471; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Goding CR, 2000, GENE DEV, V14, P1712; Guazzi S, 1998, J BIOL CHEM, V273, P11092, DOI 10.1074/jbc.273.18.11092; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Mahalingam H, 1997, EXP CELL RES, V237, P83, DOI 10.1006/excr.1997.3773; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Martinez-Morales JR, 2001, DEVELOPMENT, V128, P2019; Morgan R, 1999, MECH DEVELOP, V85, P97, DOI 10.1016/S0925-4773(99)00091-X; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; PANNESE M, 1995, DEVELOPMENT, V121, P707; Pittack C, 1997, DEVELOPMENT, V124, P805; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; Planque N, 2001, J BIOL CHEM, V276, P35751, DOI 10.1074/jbc.M104523200; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; Sato S, 2001, PIGM CELL RES, V14, P428, DOI 10.1034/j.1600-0749.2001.140602.x; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Simeone A, 2002, CURR OPIN GENET DEV, V12, P409, DOI 10.1016/S0959-437X(02)00318-0; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Takeda K, 2002, BBA-GENE STRUCT EXPR, V1574, P15, DOI 10.1016/S0167-4781(01)00339-6; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Wada S, 2002, DEV DYNAM, V225, P46, DOI 10.1002/dvdy.10135; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Yasumoto K, 1997, J BIOL CHEM, V272, P503	48	135	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21721	21731		10.1074/jbc.M301708200	http://dx.doi.org/10.1074/jbc.M301708200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663655	hybrid			2022-12-25	WOS:000183354200053
J	Santra, MK; Panda, D				Santra, MK; Panda, D			Detection of an intermediate during unfolding of bacterial cell division protein FtsZ - Loss of functional properties precedes the global unfolding of FtsZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; TUBULIN POLYMERIZATION; GTP HYDROLYSIS; MECHANISM; CONFORMATION; FLUORESCENCE; BINDING	Using environment- sensitive fluorescence of 1- anilinonaphthalene-8- sulfonic acid, polarization of fluorescein 5 '- isothiocyanate- labeled FtsZ, and far- UV circular dichroism spectroscopy, the chemical unfolding of FtsZ was found to proceed through two steps. The first step of the urea- induced unfolding produced an intermediate, which then unfolded at higher concentrations of urea. The intermediate state contains native- like secondary structure and much less tertiary structure compared with the native state. It is distinct from the native state as well as from the unfolded state. Similar to urea- induced unfolding of FtsZ, thermal unfolding of FtsZ also occurs in two steps. The midpoints for the first and second thermal unfolding transitions were found to be 38 +/- 4 and 77 +/- 5 degreesC, respectively. Further, the functional properties of FtsZ are extremely sensitive to urea, guanidium chloride, and sodium dodecyl sulfate. For example, 50% inhibition of the FtsZ assembly and GTP hydrolysis occurred at 0.1 and 0.2 M of urea, respectively. FtsZ lost its functional properties before any significant perturbation in the secondary or tertiary structure was detected by using several fluorescence techniques and far UV- CD indicating preferential local unfolding of the functional region( s). In addition, the unfolded FtsZ regains its ability to polymerize fully upon removal of urea. The data taken together suggest that FtsZ unfolds reversibly through a multistep process, and local responses that inhibit functional properties precede the global transition of FtsZ to the unfolded state.	Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Panda, D (corresponding author), Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India.	panda@btc.iitb.ac.in						Andreu JM, 2002, J BIOL CHEM, V277, P43262, DOI 10.1074/jbc.M206723200; Baldwin RL, 2002, SCIENCE, V295, P1657, DOI 10.1126/science.1069893; Beuria TK, 2003, J BIOL CHEM, V278, P3735, DOI 10.1074/jbc.M205760200; BI E, 1990, J BACTERIOL, V172, P2765, DOI 10.1128/jb.172.5.2765-2768.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clarke AR, 1997, CURR OPIN BIOTECH, V8, P400, DOI 10.1016/S0958-1669(97)80060-2; Daggett V, 2003, TRENDS BIOCHEM SCI, V28, P18, DOI 10.1016/S0968-0004(02)00012-9; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Diaz JF, 2001, J BIOL CHEM, V276, P17307, DOI 10.1074/jbc.M010920200; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GUHA S, 1995, BIOCHEMISTRY-US, V34, P6925, DOI 10.1021/bi00021a003; Guha S, 1997, BIOCHEMISTRY-US, V36, P13208, DOI 10.1021/bi970993m; Gupta K, 2002, BIOCHEMISTRY-US, V41, P13029, DOI 10.1021/bi025952r; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; LALA AK, 1992, J BIOL CHEM, V267, P19914; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1998, J STRUCT BIOL, V124, P235, DOI 10.1006/jsbi.1998.4041; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; NOLTING B, 1995, P NATL ACAD SCI USA, V92, P10668, DOI 10.1073/pnas.92.23.10668; PANDA D, 1992, BIOCHEMISTRY-US, V31, P9709, DOI 10.1021/bi00155a026; Panda M, 2000, J BIOL CHEM, V275, P63, DOI 10.1074/jbc.275.1.63; Plaxco KW, 1996, CURR OPIN STRUC BIOL, V6, P630, DOI 10.1016/S0959-440X(96)80029-7; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P739, DOI 10.1021/bi00351a035; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SACKETT DL, 1994, BIOCHEMISTRY-US, V33, P12868, DOI 10.1021/bi00209a019; Sau AK, 2002, BIOPHYS CHEM, V98, P267, DOI 10.1016/S0301-4622(02)00076-5; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; van den Ent F, 2001, CURR OPIN MICROBIOL, V4, P634, DOI 10.1016/S1369-5274(01)00262-4; WARD JL, 1971, METHOD ENZYMOL, V117, P509; Wolff J, 1996, BIOCHEMISTRY-US, V35, P5910, DOI 10.1021/bi9527395; YI QM, 1985, GENE, V36, P241; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; Yu XC, 1999, J CELL SCI, V112, P2301; Yu XC, 1998, J BIOL CHEM, V273, P10216, DOI 10.1074/jbc.273.17.10216	48	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21336	21343		10.1074/jbc.M301303200	http://dx.doi.org/10.1074/jbc.M301303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12649276	hybrid			2022-12-25	WOS:000183354200006
J	Hortala, M; Ferjoux, G; Estival, A; Bertrand, C; Schulz, S; Pradayrol, L; Susini, C; Clemente, F				Hortala, M; Ferjoux, G; Estival, A; Bertrand, C; Schulz, S; Pradayrol, L; Susini, C; Clemente, F			Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform - Implication of JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; FACTOR-II; NUCLEAR-LOCALIZATION; FGF-2 ISOFORMS; MESSENGER-RNA; G-PROTEINS; EXPRESSION; MODULATION; TRANSLATION; AR4-2J	The fibroblast growth factor (FGF)-2 isoform of 210 amino acids ( HMW FGF-2) contains a nuclear localization sequence (NLS) and is targeted to the nucleus. This FGF-2 isoform allows cells to grow in low serum concentrations through still unknown mechanisms called intracrine regulations. Different peptide hormones and cytokines have been found to be nuclearized through NLS and to induce cell proliferation. The existence of molecules acting as negative regulators of the intracrine-induced cell growth has not been explored. Pancreatic cells AR4-2J were stably transfected to express selectively the HMW FGF-2. We demonstrated that activation of the somatostatin receptor subtype SST2 by the somatostatin analogue RC-160 in serum-deprived medium inhibits the mitogenic effect of the HMW FGF-2, without affecting growth of control cells. The signaling pathway implicates Galpha(i)/ JAK2/SHP-1. The Galpha(i) inhibitor pertussis toxin and the JAK2 inhibitor AG490 abrogate the inhibitory effect of RC-160 on HMW FGF-2-induced cell growth. Co-immunoprecipitation studies demonstrate the constitutive association of JAK2 and SHP-1, and RC-160 induces a rapid activation of both proteins followed by the dissociation of the complex. AG490 prevents the RC-160 induced SHP-1 activation indicating the implication of JAK2 in this process. JAK2 and SHP-1 are immunoprecipitated with SST2 in basal conditions indicating the existence of a functional signaling complex at the receptor level. In summary, these data provide the following evidence: 1) the intracrine-induced proliferation can be reversed by extracellular acting polypeptides; 2) SST2 inhibitory signaling may involve the JAK2/SHP-1 pathway.	CHU Rangueil, INSERM, U531, Inst Louis Bugnard, F-31403 Toulouse 4, France; Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Otto von Guericke University	Clemente, F (corresponding author), CHU Rangueil, INSERM, U531, Inst Louis Bugnard, Bat L3,Av Jean Poulhes, F-31403 Toulouse 4, France.		Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				Amiri F, 1999, J BIOL CHEM, V274, P32382, DOI 10.1074/jbc.274.45.32382; Arnaud E, 1999, MOL CELL BIOL, V19, P505; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Clarke WE, 2001, MOL CELL NEUROSCI, V17, P17, DOI 10.1006/mcne.2000.0920; Dahl JP, 2000, BIOCHEMISTRY-US, V39, P14877, DOI 10.1021/bi001073y; Delrieu I, 1999, BIOCHEM J, V340, P201, DOI 10.1042/0264-6021:3400201; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; ESTIVAL A, 1993, CANCER RES, V53, P1182; Estival A, 1996, BIOCHEM J, V315, P619, DOI 10.1042/bj3150619; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Gu YZ, 1997, MOL ENDOCRINOL, V11, P527, DOI 10.1210/me.11.5.527; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Keresztes M, 1999, J CELL BIOL, V145, P421, DOI 10.1083/jcb.145.3.421; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Monzat V, 1996, EUR J CELL BIOL, V69, P316; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; Re RN, 2002, REGUL PEPTIDES, V106, P1, DOI 10.1016/S0167-0115(02)00031-9; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Schulz S, 1998, CLIN CANCER RES, V4, P2047; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; THEVENIAU MA, 1994, J NEUROCHEM, V63, P447; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VIDAL C, 1994, MOL PHARMACOL, V46, P97; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Wu DW, 2000, BLOOD CELL MOL DIS, V26, P15, DOI 10.1006/bcmd.2000.0273; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yu CL, 1997, J IMMUNOL, V159, P5206; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	50	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20574	20581		10.1074/jbc.M210767200	http://dx.doi.org/10.1074/jbc.M210767200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665520	hybrid			2022-12-25	WOS:000183230500018
J	Jallepalli, PV; Lengauer, C; Vogelstein, B; Bunz, F				Jallepalli, PV; Lengauer, C; Vogelstein, B; Bunz, F			The Chk2 tumor suppressor is not required for p53 responses in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MEDIATED G(1) ARREST; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; CHECKPOINT PATHWAY; COLORECTAL-CANCER; BREAST-CANCER; PHOSPHORYLATION; ACTIVATION; KINASE	Ionizing radiation damages chromosomal DNA and activates p53-dependent transcription in mammalian cells. The Chk2 protein kinase has been hypothesized to be the primary mediator of this response. We have rigorously tested this hypothesis in human cells by disrupting the CHK2 gene through homologous recombination. We found that the p53 response was unexpectedly robust in such cells. Phosphorylation of p53 at serine 20, accumulation of p53 protein, transcriptional activation of p53 target genes, and cell cycle arrest and apoptotic death phenotypes were completely intact regardless of CHK2 status. Our results indicate that Chk2 kinase is not required for p53 activation in human cells and explain why CHK2 and TP53 mutations can jointly occur in human tumors.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Bunz, F (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2000, CANCER RES, V60, P5934; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BROWN KD, 2002, NAT GENET, V225, P25; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1994, CANCER RES, V54, P5054; Chan TA, 2000, GENE DEV, V14, P1584; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Lee SB, 2001, CANCER RES, V61, P8062; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shieh SY, 2000, GENE DEV, V14, P289; Sodha N, 2000, Science, V289, P359; Sparks AB, 1998, CANCER RES, V58, P1130; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yu Q, 2002, CANCER RES, V62, P5743; Zhao RB, 2000, GENE DEV, V14, P981	44	134	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20475	20479		10.1074/jbc.M213159200	http://dx.doi.org/10.1074/jbc.M213159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654917	hybrid			2022-12-25	WOS:000183230500006
J	Li, ZY; Wang, CC				Li, ZY; Wang, CC			A PHO80-like cyclin and a B-type cyclin control the cell cycle of the procyclic form of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; DNA-REPLICATION; KINETOPLAST; COMPLEX; GENES; TRANSCRIPTION; CYTOKINESIS; SEGREGATION; EXPRESSION; GAMBIENSE	Cyclins bind and activate cyclin-dependent kinases that regulate cell cycle progression in eukaryotes. Cell cycle control in Trypanosoma brucei was analyzed in the present study. Genes encoding four PHO80 cyclin homologues and three B-type cyclin homologues but no G(1) cyclin homologues were identified in this organism. Through knocking down expression of the seven cyclin genes with the RNA interference technique in the procyclic form of T. brucei, we demonstrated that one PHO80 homologue (CycE1/CYC2) and a B-type cyclin homologue (CycB2) are the essential cyclins regulating G(1)/S and G(2)/M transitions, respectively. This lack of overlapping cyclin function differs significantly from that observed in the other eukaryotes. Also, PHO80 cyclin is known for its involvement only in phosphate signaling in yeast with no known function in cell cycle control. Both observations thus suggest the presence of simple and novel cell cycle regulators in trypanosomes. T. brucei cells deficient in CycE1/CYC2 displayed a long slender morphology, whereas those lacking CycB2 assumed a fat stumpy form. These cells apparently still can undergo cytokinesis generating small numbers of anucleated daughter cells, each containing a single kinetoplast known as a zoid. Two different types of zoids were identified, the slender zoid derived from reduced CycE1/CYC2 expression and the stumpy zoid from CycB2 deficiency. This observation indicates an uncoupling between the kinetoplast and the nuclear cycle, resulting in cell division driven by kinetoplast segregation with neither a priori S phase nor mitosis in the trypanosome.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu		Li, Ziyin/0000-0002-3960-9716	NIAID NIH HHS [R01 AI021786, R01 AI-21786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aerne BL, 1998, MOL BIOL CELL, V9, P945, DOI 10.1091/mbc.9.4.945; Bastin P, 2000, J CELL SCI, V113, P3321; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; HEMERLY A, 1992, P NATL ACAD SCI USA, V89, P3295, DOI 10.1073/pnas.89.8.3295; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KOUCHI H, 1995, PLANT CELL, V7, P1143, DOI 10.1105/tpc.7.8.1143; Kuntzel H, 1996, BIOL CHEM, V377, P481; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Lee M, 2000, MOL MICROBIOL, V38, P411, DOI 10.1046/j.1365-2958.2000.02140.x; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F; ONO T, 1976, BIKEN J, V19, P63; ONO T, 1975, BIKEN J, V18, P257; Ploubidou A, 1999, J CELL SCI, V112, P4641; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Timms MW, 2002, MOL BIOL CELL, V13, P3747, DOI 10.1091/mbc.E02-05-0266; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; Van Hellemond JJ, 2000, MOL BIOCHEM PARASIT, V111, P275, DOI 10.1016/S0166-6851(00)00318-2; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	34	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20652	20658		10.1074/jbc.M301635200	http://dx.doi.org/10.1074/jbc.M301635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665514	hybrid			2022-12-25	WOS:000183230500028
J	Goubaeva, F; Ghosh, M; Malik, S; Yang, J; Hinkle, PM; Griendling, KK; Neubig, RR; Smrcka, AV				Goubaeva, F; Ghosh, M; Malik, S; Yang, J; Hinkle, PM; Griendling, KK; Neubig, RR; Smrcka, AV			Stimulation of cellular signaling and G protein subunit dissociation by G protein beta gamma subunit-binding peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; CRYSTAL-STRUCTURE; RECEPTOR; SITE; ACTIVATION; PHOSDUCIN; CELLS; DETERMINANTS; RESOLUTION; CYCLASE	We previously developed peptides that bind to G protein betagamma subunits and selectively block interactions between betagamma subunits and a subset of effectors in vitro (Scott, J. K., Huang, S. F., Gangadhar, B. P., Samoriski, G. M., Clapp, P., Gross, R. A., Taussig, R., and Smrcka, A. V. (2001) EMBO J. 20, 767-776). Here, we created cell-permeating versions of some of these peptides by N-terminal modification with either myristate or the cell permeation sequence from human immunodeficiency virus TAT protein. The myristoylated betagamma-binding peptide (mSIRK) applied to primary rat arterial smooth muscle cells caused rapid activation of extracellular signal-regulated kinase 1/2 in the absence of an agonist. This activation did not occur if the peptide lacked a myristate at the N terminus, if the peptide had a single point mutation to eliminate betagamma subunit binding, or if the cells stably expressed the C terminus of betaARK1. A human immunodeficiency virus TAT-modified peptide (TAT-SIRK) and a myristoylated version of a second peptide (mSCAR) that binds to the same site on betagamma subunits as mSIRK, also caused extracellular signal-regulated kinase activation. mSIRK also stimulated Jun N-terminal kinase phosphorylation, p38 mitogen-activated protein kinase phosphorylation, and phospholipase C activity and caused Ca2+ release from internal stores. When tested with purified G protein subunits in vitro, SIRK promoted alpha subunit dissociation from betagamma subunits without stimulating nucleotide exchange. These data suggest a novel mechanism by which selective betagamma-binding peptides can release G protein betagamma subunits from heterotrimers to stimulate G protein pathways in cells.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Emory Univ, Dept Med, Atlanta, GA 30322 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Rochester; Emory University; University of Michigan System; University of Michigan	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.		Ghosh, Mousumi/D-3180-2011	Griendling, Kathy/0000-0002-9456-8582; Neubig, Richard/0000-0003-0501-0008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46417] Funding Source: Medline; NIDDK NIH HHS [DK19974] Funding Source: Medline; NIGMS NIH HHS [GM60286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Duffy S, 1998, ANAL BIOCHEM, V262, P122, DOI 10.1006/abio.1998.2770; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GUTKIND JS, 2001, SCI STKE; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Romoser VA, 2001, MOL ENDOCRINOL, V15, P125, DOI 10.1210/me.15.1.125; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Sarvazyan NA, 2002, BIOCHEMISTRY-US, V41, P12858, DOI 10.1021/bi026212l; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Ushio-Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Yoshikawa DM, 2001, J BIOL CHEM, V276, P11246, DOI 10.1074/jbc.M006073200	31	58	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19634	19641		10.1074/jbc.M300052200	http://dx.doi.org/10.1074/jbc.M300052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649269	hybrid			2022-12-25	WOS:000183078000011
J	Mayo, MW; Denlinger, CE; Broad, RM; Yeung, F; Reilly, ET; Shi, Y; Jones, DR				Mayo, MW; Denlinger, CE; Broad, RM; Yeung, F; Reilly, ET; Shi, Y; Jones, DR			Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CELL LUNG-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; DNA METHYLTRANSFERASE; RELA/P65 SUBUNIT; GENE-EXPRESSION; RETINOIC ACID; P65 SUBUNIT; PHOSPHORYLATION; KINASE	Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer agents for the treatment of solid and hematological malignancies. Although HDAC inhibitors induce cell death through an apoptotic process, little is known about the molecular events that control their effectiveness. In this study, we demonstrate that HDAC inhibitors are limited in their ability to induce apoptosis in non-small cell lung cancer (NSCLC) cell lines despite their ability to effectively inhibit deacetylase activity. Because the anti-apoptotic transcription factor NF-kappaB has been shown to be under the control of HDAC-mediated repression, we analyzed whether HDAC inhibitors activated NF-kappaB in NSCLC cells. HDAC inhibitors effectively stimulated endogenous NF-kappaB-dependent gene expression by up-regulating IL-8, Bcl-XL, and MMP-9 transcripts. The ability of HDAC inhibitors to increase NF-kappaB transcriptional activity was not associated with signaling events that stimulated nuclear translocation, but rather modulated the transactivation potential of the RelA/p65 subunit of NF-kappaB. The inhibition of HDAC activity was associated with the recruitment of the p300 transcriptional co-activator to chromatin in an Akt-dependent manner. Moreover, Akt directly phosphorylated p300 in vitro and was required for stimulating the transactivation potential of the co-activator following the addition of HDAC inhibitors. Selective inhibition of either the phosphoinositide 3-kinase/Akt pathway, or NF-kappaB itself blocked the ability of HDAC inhibitors to activate NF-kappaB and dramatically sensitized NSCLC cells to apoptosis following of the addition of HDAC inhibitors. Our study indicates that the ineffectiveness of HDAC inhibitors to induce apoptosis in NSCLC cancer cells is associated with the ability of these molecules to stimulate NF-kappaB-dependent transcription and cell survival.	Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Virginia; University of Virginia; Harvard University; Harvard Medical School	Jones, DR (corresponding author), Univ Virginia, Dept Surg, Box 800679, Charlottesville, VA 22908 USA.	djones@virginia.edu		Broad, R Michael/0000-0002-0383-3847; Jones, David/0000-0002-3318-0146	NATIONAL CANCER INSTITUTE [K01CA078595, K08CA083920, R01CA095644] Funding Source: NIH RePORTER; NCI NIH HHS [CA83920, CA095644, CA78595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)02125-0; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH S, 2002, GENE DEV, V109, pS81; Goodman RH, 2000, GENE DEV, V14, P1553; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Jones DR, 2002, J THORAC CARDIOV SUR, V123, P310, DOI 10.1067/mtc.2002.118684; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; LEDINKO N, 1990, ANTICANCER RES, V10, P1335; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Novick S, 1999, BLOOD, V94, p61A; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sandor V, 2002, CLIN CANCER RES, V8, P718; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhu WG, 2001, CANCER RES, V61, P1327	64	162	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18980	18989		10.1074/jbc.M211695200	http://dx.doi.org/10.1074/jbc.M211695200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649266	hybrid			2022-12-25	WOS:000182932200035
J	Kominsky, SL; Argani, P; Korz, D; Evron, E; Raman, V; Garrett, E; Rein, A; Sauter, G; Kallioniemi, OP; Sukumar, S				Kominsky, SL; Argani, P; Korz, D; Evron, E; Raman, V; Garrett, E; Rein, A; Sauter, G; Kallioniemi, OP; Sukumar, S			Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast	ONCOGENE			English	Article						breast cancer; tight junction; claudin-7; methylation	GENE-EXPRESSION; CANCER; CELLS; HYPERMETHYLATION; METHYLATION; OCCLUDIN; CADHERIN; STRANDS; TUMORS; ZO-1	Claudius are transmembrane proteins that seal tight junctions, and are critical for maintaining cell-to-cell adhesion in epithelial cell sheets. However, their role in cancer progression remains largely unexplored. Here, we report that Claudin-7 (CLDN-7) expression is lower in invasive ductal carcinomas (IDC) of the breast than in normal breast epithelium, as determined by both RT-PCR (9/10) and Western analysis (6/8). Immunohistochemical (IHC) analysis of ductal carcinoma in situ (IDS) and IDC showed that the loss of CLDN-7 expression correlated with histological grade in both MIS (P<0.001, n=38) and IDC (P=0.014, n=31), occurring predominantly in high-grade (Nuclear and Elston grade 3) lesions. Tissue array analysis of 355 IDC cases further confirmed the inverse correlation between CLDN-7 expression and histological grade (P = 0.03). This pattern of expression is consistent with the biological function of CLDN-7, as greater discohesion is typically observed in high-grade lesions. In line with this observation, by IHC analysis, CLDN-7 expression was lost in the vast majority (13/17) of cases of lobular carcinoma in situ, which is defined by cellular discohesion. In fact, inducing disassociation of MCF-7 and T47D cells in culture by treating with HGF/scatter factor resulted in a loss of CLDN-7 expression within 24h. Silencing of CLDN-7 expression correlated with promoter hypermethylation as determined by methylation-specific PCR (MSP) and nucleotide sequencing in breast cancer cell lines (3/3), but not in IDCs (0/5). In summary, these studies provide insight into the potential role of CLDN-7 in the progression and ability of breast cancer cells to disseminate.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Oncol Biostat, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21231 USA; NCI, HIV Drug Resistance Program, Frederick, MD 21072 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel	Sukumar, S (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, BBCRB Room 410,1650 Orleans St, Baltimore, MD 21231 USA.		Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Evron, Ella/0000-0002-1003-5042	NATIONAL CANCER INSTITUTE [P50CA088843, ZIABC010511, Z01BC010511] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA88843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BERGSTRAESSER LM, 1993, CANCER RES, V53, P2644; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Evron E, 2001, CANCER RES, V61, P2782; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fujii T, 2002, CANCER RES, V62, P3340; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Loeb DM, 2001, CANCER RES, V61, P921; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nacht M, 1999, CANCER RES, V59, P5464; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Sirotkin H, 1997, GENOMICS, V42, P245, DOI 10.1006/geno.1997.4734; SOLER AP, 1995, HUM PATHOL, V26, P1363, DOI 10.1016/0046-8177(95)90302-X; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Wilcox ER, 2001, CELL, V104, P165, DOI 10.1016/S0092-8674(01)00200-8	25	364	384	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2021	2033		10.1038/sj.onc.1206199	http://dx.doi.org/10.1038/sj.onc.1206199			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673207				2022-12-25	WOS:000181967700012
J	Minamisawa, S; Wang, YB; Chen, J; Ishikawa, Y; Chien, KR; Matsuoka, R				Minamisawa, S; Wang, YB; Chen, J; Ishikawa, Y; Chien, KR; Matsuoka, R			Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; PHOSPHOLAMBAN GENE-EXPRESSION; MYOCARDIAL-CONTRACTILITY; CARDIOMYOPATHY; ABLATION; INVITRO; SERCA1; CHAIN; HEART; MICE	Intracellular Ca2+ regulation is critical in the normal cardiac function and development of pathologic hearts. Phospholamban, an endogenous inhibitor of sarcoplasmic reticulum Ca2+ ATPase in the sarcoplasmic reticulum, plays an important role in Ca2+ cycling in heart. Recently, sarcolipin has been identified as having a similar function as phospholamban in skeletal muscle. Because phospholamban is differentially expressed in atrial and ventricular myocardia and its expression is often altered in diseased hearts, we investigated the cardiac chamber specificity of sarcolipin expression and its regulation during development and hypertrophic remodeling. Northern blot analysis revealed that the expression of mouse sarcolipin mRNA was most abundant in the atria and was undetectable in the ventricles, indicating an atrial chamber-specific expression pattern. Atrial chamber-specific expression of sarcolipin mRNA was increased during development. These findings were confirmed by in situ hybridization studies. In addition, sarcolipin expression was down-regulated in the atria of hypertrophic heart when induced by ventricular specific overexpression of the activated H-ras gene. In humans, sarcolipin mRNA was also expressed in the atria but not detected in the ventricles, although sarcolipin expression was most abundant in skeletal muscle. Taken together, sarcolipin is likely to be an atrial chamber-specific regulator of Ca2+ cycling in heart.	Tokyo Womens Med Univ, Grad Sch Med, Dept Pediat Cardiol, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Grad Sch Med, Div Genom Med, Inst Adv Biomed Engn & Sci, Tokyo 1628666, Japan; Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Med & Dent New Jersey, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA	Tokyo Women's Medical University; Tokyo Women's Medical University; Yokohama City University; University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center	Minamisawa, S (corresponding author), Tokyo Womens Med Univ, Heart Inst Japan, Dept Pediat, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.		Chen, Ju/E-5579-2011	Minamisawa, Susumu/0000-0003-4728-2116; Wang, Yibin/0000-0003-0852-0767				Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Dash R, 2001, CIRCULATION, V103, P889, DOI 10.1161/01.CIR.103.6.889; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; KOSS KL, 1995, CIRC RES, V77, P342, DOI 10.1161/01.RES.77.2.342; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Machida S, 2000, DEV DYNAM, V217, P37, DOI 10.1002/(SICI)1097-0177(200001)217:1<37::AID-DVDY4>3.0.CO;2-3; Mascioni A, 2002, BIOCHEMISTRY-US, V41, P475, DOI 10.1021/bi011243m; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; NAKANISHI T, 1984, AM J PHYSIOL, V246, pH61; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Tada M, 1998, ANN NY ACAD SCI, V853, P116, DOI 10.1111/j.1749-6632.1998.tb08261.x; Tada M, 1996, J Card Fail, V2, pS77, DOI 10.1016/S1071-9164(96)80062-5; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8	25	90	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9570	9575		10.1074/jbc.M213132200	http://dx.doi.org/10.1074/jbc.M213132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645548	hybrid			2022-12-25	WOS:000181524000092
J	Venkatesh, J; Kumar, P; Krishna, PSM; Manjunath, R; Varshney, U				Venkatesh, J; Kumar, P; Krishna, PSM; Manjunath, R; Varshney, U			Importance of uracil DNA glycosylase in Pseudomonas aeruginosa and Mycobacterium smegmatis, G+C-rich bacteria, in mutation prevention, tolerance to acidified nitrite, and endurance in mouse macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INHIBITOR PROTEIN; CRYSTAL-STRUCTURE; N-GLYCOSIDASE; COMPLEX; SURVIVAL; MIMICRY; ENZYME; REPAIR; SUSCEPTIBILITY	Uracil DNA glycosylase (Ung (or UDG)) initiates the excision repair of an unusual base, uracil, in DNA. Ung is a highly conserved protein found in all organisms. Paradoxically, loss of this evolutionarily conserved enzyme has not been seen to result in severe growth phenotypes in the cellular life forms. In this study, we chose G + C-rich genome containing bacteria (Pseudomonas aeruginosa and Mycobacterium smegmatis) as model organisms to investigate the biological significance of ung. Ung deficiency was created either by expression of a highly specific inhibitor protein, Ugi, and/or by targeted disruption of the ung gene. We show that abrogation of Ung activity in P. aeruginosa and M. smegmatis confers upon them an increased mutator phenotype and sensitivity to reactive nitrogen intermediates generated by acidified nitrite. Also, in a mouse macrophage infection model, P. aeruginosa (Ung(-)) shows a significant decrease in its survival. Infections of the macrophages with M. smegmatis show an initial increase in the bacterial counts that remain for up to 48 h before a decline. Interestingly, abrogation of Ung activity in M. smegmatis results in nearly a total abolition of their multiplication and a much-decreased residency in macrophages stimulated with interferon gamma. These observations suggest Ung as a useful target to control growth of G + C-rich bacteria.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Varshney, U (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	varshney@mcbl.iisc.ernet.in	Varshney, Umesh/A-8062-2009; Kumar, Pradeep/I-7989-2014; Varshney, Umesh/Q-6914-2019	Kumar, Pradeep/0000-0003-0042-7525; 				Acharya N, 2002, J MOL BIOL, V321, P579, DOI 10.1016/S0022-2836(02)00654-X; Acharya N, 2002, J MOL BIOL, V318, P1251, DOI 10.1016/S0022-2836(02)00053-0; CHEN JD, 1991, J BACTERIOL, V173, P283, DOI 10.1128/jb.173.1.283-290.1991; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CONE R, 1980, J BIOL CHEM, V255, P354; DasGupta SK, 1998, BIOCHEM BIOPH RES CO, V246, P797, DOI 10.1006/bbrc.1998.8724; Dastur A, 2002, ARCH MICROBIOL, V178, P288, DOI 10.1007/s00203-002-0460-0; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; DIVER JM, 1990, ANAL BIOCHEM, V189, P75, DOI 10.1016/0003-2697(90)90046-C; Duncan B. K., 1978, DNA REPAIR MECHANISM, V1978, P183; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; HATFULL GF, 2002, MOL GENETICS MYCOBAC, P313; HEMAVATHY KC, 1995, FEMS IMMUNOL MED MIC, V11, P291, DOI 10.1016/0928-8244(95)00037-8; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Krokan HE, 1997, BIOCHEM J, V325, P1; Lagier B, 1998, MOL MICROBIOL, V29, P465, DOI 10.1046/j.1365-2958.1998.00933.x; Lancaster JR, 1996, METHOD ENZYMOL, V268, P31; Liew FY, 1991, IMMUNOL TODAY, V12, P17; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Mokkapati SK, 2001, MOL MICROBIOL, V41, P1101, DOI 10.1046/j.1365-2958.2001.02559.x; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Morissette C, 1996, INFECT IMMUN, V64, P4984, DOI 10.1128/IAI.64.12.4984-4992.1996; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MULLANEY J, 1989, J GEN VIROL, V70, P449, DOI 10.1099/0022-1317-70-2-449; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; OBRIEN L, 1994, INFECT IMMUN, V62, P5187, DOI 10.1128/IAI.62.11.5187-5190.1994; OLSEN LC, 1991, NUCLEIC ACIDS RES, V19, P4473, DOI 10.1093/nar/19.16.4473; Opperman T, 1999, P NATL ACAD SCI USA, V96, P9218, DOI 10.1073/pnas.96.16.9218; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; Purnapatre K, 1998, EUR J BIOCHEM, V256, P580, DOI 10.1046/j.1432-1327.1998.2560580.x; Putnam CD, 1999, J MOL BIOL, V287, P331, DOI 10.1006/jmbi.1999.2605; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; RASTOGI N, 1992, CURR MICROBIOL, V25, P203, DOI 10.1007/BF01570720; Ravishankar R, 1998, NUCLEIC ACIDS RES, V26, P4880, DOI 10.1093/nar/26.21.4880; Reddy GB, 1999, EUR J BIOCHEM, V261, P610, DOI 10.1046/j.1432-1327.1999.00271.x; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Roy S, 1998, PROTEIN EXPRES PURIF, V13, P155, DOI 10.1006/prep.1998.0878; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sander P, 2001, INFECT IMMUN, V69, P3562, DOI 10.1128/IAI.69.6.3562-3568.2001; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Spek EJ, 2001, J BACTERIOL, V183, P131, DOI 10.1128/JB.183.1.131-138.2001; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Vasanthakrishna M, 1997, MICROBIOL-SGM, V143, P3591, DOI 10.1099/00221287-143-11-3591; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	57	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24350	24358		10.1074/jbc.M302121200	http://dx.doi.org/10.1074/jbc.M302121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12679366	hybrid			2022-12-25	WOS:000183824800016
J	Liang, JS; Kim, T; Fang, SY; Yamaguchi, J; Weissman, AM; Fisher, EA; Ginsberg, HN				Liang, JS; Kim, T; Fang, SY; Yamaguchi, J; Weissman, AM; Fisher, EA; Ginsberg, HN			Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; PROTEASOME PATHWAY; APOPROTEIN B100; TRANSLOCATION; COMPLEX; HEAT-SHOCK-PROTEIN-70; MECHANISMS	Apolipoprotein B100 (apoB) is a large (520-kDa) complex secretory protein; its secretion is regulated post-transcriptionally by several degradation pathways. The best described of these degradative processes is co-translational ubiquitinylation and proteasomal degradation of nascent apoB, involving the 70- and 90-kDa heat shock proteins and the multiple components of the proteasomal pathway. Ubiquitinylation involves several proteins, including ligases called E3s, that coordinate the covalent binding of ubiquitin to target proteins. The recent discovery that tumor autocrine motility factor receptor, also known as gp78, is an endoplasmic reticulum (ER)-associated E3, raised the possibility that this E3 might be involved in the ER-associated degradation of nascent apoB. In a series of experiments in HepG2 cells, we demonstrated that overexpression of gp78 was sufficient for increased ubiquitinylation and proteasomal degradation of apoB, with reduced secretion of apoB-lipoproteins. This action of gp78 was specific: overexpression of the protein did not affect secretion of either albumin or apolipoprotein AI. Furthermore, overexpression of a cytosolic E3, Itch, had no effect on apoB secretion. Finally, using an in vitro translation system, we demonstrated that gp78 led to increased ubiquitinylation and proteasomal degradation of apoB48. Together, these results indicate that an ER-associated protein, gp78, is a bona fide E3 ligase in the apoB ER-associated degradation pathway.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10025 USA; Mt Sinai Sch Med, Dept Biochem, New York, NY 10025 USA; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.		Fisher, Edward/ABE-7469-2020; Fang, Shengyun/H-3802-2011	Fisher, Edward/0000-0001-9802-143X; Fang, Shengyun/0000-0001-7280-5463	NHLBI NIH HHS [HL58541, HL55368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009392] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; NABI IR, 1987, INT J CANCER, V40, P396, DOI 10.1002/ijc.2910400319; NABI IR, 1991, CELL MOTILITY FACTOR, V59, P163; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WU XJ, 1994, J LIPID RES, V35, P1200; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	34	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23984	23988		10.1074/jbc.M302683200	http://dx.doi.org/10.1074/jbc.M302683200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12670940	hybrid			2022-12-25	WOS:000183638600098
J	Wang, YQ; Ge, Q; Houston, D; Thorner, J; Errede, B; Dohlman, HG				Wang, YQ; Ge, Q; Houston, D; Thorner, J; Errede, B; Dohlman, HG			Regulation of Ste7 ubiquitination by Ste11 phosphorylation and the Skp1-cullin-F-box complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; PROTEIN-PROTEIN INTERACTIONS; MAP KINASE CASCADE; END RULE PATHWAY; SACCHAROMYCES-CEREVISIAE; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; FACTOR RECEPTOR; IN-VITRO	Ste7 is a mitogen-activated protein kinase kinase that mediates pheromone signaling in Saccharomyces cerevisiae. We showed previously that Ste7 is ubiquitinated upon prolonged stimulation by pheromone and that accumulation of ubiquitinated Ste7 results in enhanced transcription and cell division arrest responses (Wang, Y., and Dohlman, H. G. ( 2002) J. Biol. Chem. 277, 15766 15772). We now report that ubiquitination of Ste7 requires Ste11 kinase and Skp1/Cullin/F-box (SCF) ubiquitin-conjugating activities. Ste7 is not ubiquitinated in Ste11-deficient cells or when the Ste11 phosphorylation sites have been mutated. Ste7 ubiquitination and degradation ( but not phosphorylation) is specifically blocked in mutants defective for the E2 ubiquitin-conjugating enzyme Cdc34 or the cullin homologue Cdc53. Both are components of the SCF complex that ubiquitinates proteins during the G(1)-S transition of the cell cycle. Our findings suggest that SCF promotes the ubiquitination and degradation of Ste7, thereby favoring the resumption of cell division cycling after pheromone-induced growth arrest.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.		THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R29GM055316, R01GM039582, R01GM021841, R01GM055316, R01GM059167] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055316, GM39582, GM55316, R01 GM059167, GM021841, GM59167] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; CHOI KY, 1994, CELL, V78, P499; Chung CY, 1998, GENE DEV, V12, P3564, DOI 10.1101/gad.12.22.3564; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Esch RK, 2002, P NATL ACAD SCI USA, V99, P9160, DOI 10.1073/pnas.142034399; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Inouye C, 1997, GENETICS, V147, P479; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MARCHESE A, 2001, J BIOL CHEM, V18, P18; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; Mathias N, 1996, MOL CELL BIOL, V16, P6634; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PRINTEN JA, 1994, GENETICS, V138, P609; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sobko A, 2002, DEV CELL, V2, P745, DOI 10.1016/S1534-5807(02)00186-7; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	47	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22284	22289		10.1074/jbc.M301272200	http://dx.doi.org/10.1074/jbc.M301272200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668671	hybrid			2022-12-25	WOS:000183503900016
J	Woelfle, J; Billiard, J; Rotwein, P				Woelfle, J; Billiard, J; Rotwein, P			Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; C-FOS; SIGNAL TRANSDUCER; SEXUAL-DIMORPHISM; SOMATOMEDIN-C; RAPID CHANGES; DNA-BINDING; ACTIVATION; EXPRESSION; INDUCTION	Many of the effects of growth hormone (GH) are mediated by insulin-like growth factor-I (IGF-I), a secreted peptide whose gene transcription is induced by GH by unknown mechanisms. Recent studies in mice have implicated Stat5b as part of a GH-regulated somatic growth pathway, because mice lacking this transcription factor show diminished growth rates and a decline in serum IGF-I levels. To test the role of Stat5b in GH-stimulated IGF-I gene expression, we have delivered modified versions of the protein to pituitary-deficient male rats by quantitative adenovirus-mediated gene transfer. In pilot studies in cell culture, both constitutively active and dominant-negative Stat5b appropriately regulated transcription from a GH-responsive Stat5-dependent reporter gene. After in vivo expression, neither protein impaired GH-induced activation of cytoplasmic signaling pathways or blocked nuclear accumulation of Stats 1 and 3 in the liver, the major site of IGF-I production. Dominant-negative Stat5b completely prevented GH-stimulated IGF-I gene transcription, whereas constitutively active Stat5b led to robust IGF-I gene expression in the absence of hormone. An adenovirus encoding enhanced green fluorescent protein was without effect. Similar results were seen with the GH-responsive Stat5b-dependent Spi 2.1 gene, whereas GH-stimulated c-fos transcription was minimally altered. These results establish Stat5b as a key component of GH-stimulated IGF-I gene transcription, and they demonstrate the feasibility of using in vivo gene transfer to target distinct components of hormone-activated signaling pathways.	Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, Portland, OR 97239 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, 3181 SW Sam Jackson Pk Rd,Mail Code HRC3, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Woellfe, joachim F/E-9406-2014; Rotwein, Peter/R-5783-2019	, Joachim/0000-0002-9132-6174; Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [5R01DK37449, R01 DK063073, 5F32DK09802] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063073, F32DK009802, R01DK037449] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamo ML., 1995, DIABETES REV, V3, P2; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Benbassat C, 1999, ENDOCRINOLOGY, V140, P3073, DOI 10.1210/en.140.7.3073; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P4741, DOI 10.1210/en.136.11.4741; Gronowski AM, 1996, ENDOCRINOLOGY, V137, P55, DOI 10.1210/en.137.1.55; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HYNES MA, 1987, MOL ENDOCRINOL, V1, P233, DOI 10.1210/mend-1-3-233; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JONES WK, 1985, J BIOL CHEM, V260, P7042; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Rotwein P, 1999, CONT ENDOCRINOL, V17, P19; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Ye P, 1997, ENDOCRINOLOGY, V138, P5466, DOI 10.1210/en.138.12.5466; YOON JB, 1990, J BIOL CHEM, V265, P19947	40	152	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22696	22702		10.1074/jbc.M301362200	http://dx.doi.org/10.1074/jbc.M301362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682066	hybrid			2022-12-25	WOS:000183503900070
J	Fernandez-Tornero, C; Lozano, RM; Redondo-Horcajo, M; Gomez, AM; Lopez, JC; Quesada, E; Valverde, S; Cuevas, P; Romero, A; Gimenez-Gallego, G				Fernandez-Tornero, C; Lozano, RM; Redondo-Horcajo, M; Gomez, AM; Lopez, JC; Quesada, E; Valverde, S; Cuevas, P; Romero, A; Gimenez-Gallego, G			Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity - Crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalenesulfonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAMYCIN-A DERIVATIVES; PLASMINOGEN-ACTIVATOR; HEPARAN-SULFATE; FACTOR FAMILY; TUMOR-GROWTH; SURAMIN; ANGIOGENESIS; 1,3,6-NAPHTHALENETRISULFONATE; BINDING; IDENTIFICATION	Inhibition of angiogenesis-promoting factors such as fibroblast growth factors is considered to be a potential procedure for inhibiting solid tumor growth. Although several peptide-based inhibitors are currently under study, the development of antiangiogenic compounds of small molecular size is a pharmacological goal of considerable interest. We have already shown that certain naphthalene sulfonates constitute minimal functional substitutes of the antiangiogenic compounds of the suramin and suradista family. Using those data as a lead, we have carried out a rational search for new angiogenesis inhibitors that could provide new pharmacological insights for the development of antiangiogenic treatments. The results of the study strongly underline the relevance of the stereochemistry for an efficient inhibition of acidic fibroblast growth factor mitogenic activity by the naphthalene sulfonate family and allow us to formulate rules to aid in searching for new inhibitors and pharmaceutical developments. To provide further leads for such developments and acquire a detailed insight into the basis of the inhibitory activity of the naphthalene sulfonate derivatives, we solved the three-dimensional structure of acidic fibroblast growth factor complexed to 5-amino-2-naphthalenesulfonate, the most pharmacologically promising of the identified inhibitors. The structure shows that binding of this compound would hamper the interaction of acidic fibroblast growth factor with the different components of the cell membrane mitogenesis-triggering complex.	CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, E-28006 Madrid, Spain; CSIC, Inst Quim Organ Gen, Dept Nat Prod, E-28006 Madrid, Spain; Hosp Ramon & Cajal, Dept Invest, Serv Histol, E-28034 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG); Hospital Universitario Ramon y Cajal	Gimenez-Gallego, G (corresponding author), CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, C Velazquez 144, E-28006 Madrid, Spain.	gimenez_gallego@cib.csic.es	Gomez, Ana/I-3342-2015; Lopez, J Cristobal/K-2260-2014; Gomez, Ana Maria/M-8512-2019; Gomez, Ana M/GVU-4726-2022; Romero, Antonio/K-5754-2014; Fernandez-Tornero, Carlos/AAV-8028-2021; Gómez, Ana María/Q-3324-2017; Fernandez-Tornero, Carlos/I-6888-2015; del Sol, Ernesto Quesada/B-7823-2008; Uriel, Clara/I-3306-2015	Gomez, Ana/0000-0002-8703-3360; Lopez, J Cristobal/0000-0003-0370-4727; Gomez, Ana M/0000-0002-8703-3360; Romero, Antonio/0000-0002-6990-6973; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Gómez, Ana María/0000-0002-8703-3360; Fernandez-Tornero, Carlos/0000-0001-5097-731X; del Sol, Ernesto Quesada/0000-0001-6886-0523; Lozano, Rosa Maria/0000-0003-2762-6938; Uriel, Clara/0000-0003-4598-7438				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAIRD A, 1990, HDB EXPT PHARM, V95, P369; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CIOMEI M, 1994, BIOCHEM PHARMACOL, V47, P295, DOI 10.1016/0006-2952(94)90020-5; Cuevas P, 1999, NEUROL RES, V21, P191, DOI 10.1080/01616412.1999.11740917; Cuevas P, 1999, NEUROSCI LETT, V275, P149, DOI 10.1016/S0304-3940(99)00752-1; Cuevas P, 1999, NEUROL RES, V21, P481, DOI 10.1080/01616412.1999.11740962; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gagliardi ART, 1998, CANCER CHEMOTH PHARM, V41, P117; GIMENEZGALLEGO G, 1986, BIOCHEM BIOPH RES CO, V135, P541, DOI 10.1016/0006-291X(86)90028-8; GIMENEZGALLEGO G, 1994, NEUROL RES, V16, P313; Hagedorn M, 2000, CRIT REV ONCOL HEMAT, V34, P89, DOI 10.1016/S1040-8428(00)00056-1; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HORI A, 1991, CANCER RES, V51, P6180; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim J, 2002, PROTEIN SCI, V11, P459, DOI 10.1110/ps.43802; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kruger EA, 2001, SEMIN ONCOL, V28, P570, DOI 10.1053/sonc.2001.28600; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Lozano RM, 1998, J MOL BIOL, V281, P899, DOI 10.1006/jmbi.1998.1977; Lozano RM, 2001, J BIOL CHEM, V276, P35723, DOI 10.1074/jbc.M101565200; Lozano RM, 2000, BIOCHEMISTRY-US, V39, P4982, DOI 10.1021/bi992544n; Mandriota SJ, 1997, J CELL SCI, V110, P2293; Manetti F, 2000, CURR PHARM DESIGN, V6, P1897, DOI 10.2174/1381612003398528; Mariani M, 1992, EXS, V61, P455; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; PESENTI E, 1992, BRIT J CANCER, V66, P367, DOI 10.1038/bjc.1992.272; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; Rak J, 2002, CANCER RES, V62, P1931; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Romero A, 1996, EUR J BIOCHEM, V241, P453, DOI 10.1111/j.1432-1033.1996.00453.x; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; STEIN CA, 1993, CANCER RES, V53, P2239; TAKANO S, 1994, CANCER RES, V54, P2654; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Zamai M, 1997, MED CHEM RES, V7, P36; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	54	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21774	21781		10.1074/jbc.M212833200	http://dx.doi.org/10.1074/jbc.M212833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676958	hybrid			2022-12-25	WOS:000183354200059
J	Ma, B; Wang, G; Palcic, MM; Hazes, B; Taylor, DE				Ma, B; Wang, G; Palcic, MM; Hazes, B; Taylor, DE			C-terminal amino acids of Helicobacter pylori alpha 1,3/4 fucosyltransferases determine type I and type II transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SITE-DIRECTED MUTAGENESIS; FUCOSYL-TRANSFERASES; HUMAN ALPHA-1,3-FUCOSYL-TRANSFERASE-V; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PHASE VARIATION; LEWIS-X; HUMAN ALPHA-1,3/4-FUCOSYL-TRANSFERASES; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE	The alpha1,3/4 fucosyltransferase (FucT) enzyme from Helicobacter pylori catalyzes fucose transfer from donor GDP-beta-L-fucose to the GlcNAc group of two series of acceptor substrates in H. pylori lipopolysaccharide: betaGal1,3betaGlcNAc (Type I) or betaGal1,4betaGlcNAc (Type II). Fucose is added either in alpha1,3 linkage of Type II acceptor to produce Lewis X or in alpha1,4 linkage of Type I acceptor to produce Lewis A, respectively. H. pylori FucTs from different strains have distinct Type I or Type II substrate specificities. FucT in H. pylori strain NCTC11639 has an exclusive alpha1,3 activity because it recognizes only Type II substrates, whereas FucT in H. pylori strain UA948 can utilize both Type II and Type I acceptors; thus it has both alpha1,3 and alpha1,4 activity, respectively. To identify elements conferring substrate specificity, 12 chimeric FucTs were constructed by domain swapping between 11639FucT and UA948FucT and characterized for their ability to transfer fucose to Type I and Type II acceptors. Our results indicate that the C-terminal region of H. pylori FucTs controls Type I and Type II acceptor specificity. In particular, the highly divergent C-terminal portion, seven amino acids DNP-FIFC at positions 347-353 in 11639FucT, and the corresponding 10 amino acids CNDAHYSALH at positions 345-354 in UA948FucT, controls the Type I and Type II acceptor recognition. This is the opposite of mammalian FucTs where acceptor preference is determined primarily by the N-terminal residues in the hypervariable stem domain.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Alberta; University of Alberta	Taylor, DE (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 1-28 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	diane.taylor@ualberta.ca						Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Appelmelk BJ, 2000, INFECT IMMUN, V68, P5928, DOI 10.1128/IAI.68.10.5928-5932.2000; Appelmelk BJ, 1999, INFECT IMMUN, V67, P5361, DOI 10.1128/IAI.67.10.5361-5366.1999; Bakker H, 2001, FEBS LETT, V507, P307, DOI 10.1016/S0014-5793(01)02999-4; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen L, 2002, BIOCHEMISTRY-US, V41, P6824, DOI 10.1021/bi0256678; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; de Vries T, 2001, GLYCOBIOLOGY, V11, p119R, DOI 10.1093/glycob/11.10.119R; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Dupuy F, 2002, MOL BIOL EVOL, V19, P815, DOI 10.1093/oxfordjournals.molbev.a004138; Ernst B, 1999, GLYCOCONJUGATE J, V16, P161, DOI 10.1023/A:1026496714403; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gosselin S, 1996, BIOORGAN MED CHEM, V4, P2023, DOI 10.1016/S0968-0896(97)81455-1; Johnson KF, 1999, GLYCOCONJUGATE J, V16, P141, DOI 10.1023/A:1026440509859; Legaigneur P, 2001, J BIOL CHEM, V276, P21608, DOI 10.1074/jbc.M100860200; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Leonard R, 2002, GLYCOBIOLOGY, V12, P299, DOI 10.1093/glycob/12.5.299; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Meldal M, 1997, CURR OPIN CHEM BIOL, V1, P552, DOI 10.1016/S1367-5931(97)80052-X; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Ogata H, 2000, SCIENCE, V290, P347, DOI 10.1126/science.290.5490.347; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Pykari M, 2000, J BIOL CHEM, V275, P40057, DOI 10.1074/jbc.M007922200; Qiao L, 1996, J AM CHEM SOC, V118, P7653, DOI 10.1021/ja960274f; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; Rasko DA, 2000, EUR J BIOCHEM, V267, P6059, DOI 10.1046/j.1432-1327.2000.01683.x; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; RASKO DA, 2000, THESIS U ALBERTA EDM, P220; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sherwood AL, 2002, GLYCOBIOLOGY, V12, P599, DOI 10.1093/glycob/cwf075; Stroeher UH, 1997, J BACTERIOL, V179, P2740, DOI 10.1128/jb.179.8.2740-2747.1997; Sullivan JT, 2002, J BACTERIOL, V184, P3086, DOI 10.1128/JB.184.11.3086-3095.2002; TAYLOR DE, 1987, AM J CLIN PATHOL, V87, P49, DOI 10.1093/ajcp/87.1.49; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Wang G, 1997, BIOCHEMISTRY-US, V36, P9486, DOI 10.1021/bi970650o; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wang G, 2000, MOL MICROBIOL, V36, P1187, DOI 10.1046/j.1365-2958.2000.01934.x; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	57	31	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21893	21900		10.1074/jbc.M301704200	http://dx.doi.org/10.1074/jbc.M301704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676935	hybrid			2022-12-25	WOS:000183354200074
J	Maun, HR; Eigenbrot, C; Lazarus, RA				Maun, HR; Eigenbrot, C; Lazarus, RA			Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR; COAGULATION-FACTOR; BINDING; SPECIFICITY; SITE; SELECTION; AFFINITY; IDENTIFICATION; ANTICOAGULANT; RECOGNITION	Limitations of current anticoagulant therapies have led us to develop two distinct classes of exosite peptide inhibitors for the initiator of the clotting process, the tissue factor-factor VIIa (TF.FVIIa) complex (Roberge, M., Santell, L., Dennis, M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R. A. ( 2001) Biochemistry 40, 9522-9531). Although both peptide classes are potent and selective inhibitors of TF.FVIIa, neither showed 100% inhibition at saturating concentrations. Crystal structures of these peptides in complex with the FVII/FVIIa protease domain revealed their distinct binding sites and close proximity to the active site. The favorable orientation of the 15-mer A-site peptide A-183 (EEWEVLCWTWETCER) suggested that a C-terminal extension into the FVIIa active site could yield a chimeric inhibitor that was not only potent and selective but complete as well. A novel two-step "protease switch" approach using substrate phage display was developed by first binding all phage containing A-183 and C-terminal extension libraries to immobilized and inactive FVIIa. Upon altering pH and adding TF to switch on FVIIa enzymatic activity, only those phage released by proteolytic cleavage within the extension were propagated. This process selected for both preferred sequence and length in the extension, leading to a 27-mer peptide A-183X (EEWEVLCWTWET-CERGEGVEEELWEWR) with a C-terminal 12-mer extension containing an Arg in the P-1 position. A-183X was a more potent and complete inhibitor of FX activation, having a maximal extent of inhibition of similar to99% with an IC50 of 230 pM versus A-183 which maximally inhibited to 74% with an IC50 of 1.5 nM. A-183X also had a maximal prolongation of the prothrombin time of 7.6-versus 1.9-fold for A-183, making it a more effective anticoagulant.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Roche Holding; Genentech; University of Freiburg	Lazarus, RA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	lazarus.bob@gene.com						Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; Dennis MS, 2001, BIOCHEMISTRY-US, V40, P9513, DOI 10.1021/bi010591l; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Hervio LS, 2000, CHEM BIOL, V7, P443, DOI 10.1016/S1074-5521(00)00125-3; Hirsh J, 2001, AM HEART J, V142, pS3, DOI 10.1067/mhj.2001.117031; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZARUS RA, 2002, PROTEINASE PEPTIDASE, P202; Leblond L, 1999, HANDB EXP PHARM, V132, P1; Lee GF, 1997, BIOCHEMISTRY-US, V36, P5607, DOI 10.1021/bi970388j; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; Mcree D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Moll S, 2002, SEMIN HEMATOL, V39, P145, DOI 10.1053/shem.2002.34087; Morrissey JH, 2001, THROMB HAEMOSTASIS, V86, P66; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; PARRY MAA, 1994, BIOCHEMISTRY-US, V33, P14807, DOI 10.1021/bi00253a020; Roberge M, 2002, BIOCHEM J, V363, P387, DOI 10.1042/0264-6021:3630387; Roberge M, 2001, BIOCHEMISTRY-US, V40, P9522, DOI 10.1021/bi010592d; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SIDHU SS, 1994, J BIOL CHEM, V269, P20167; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Starovasnik MA, 1999, PROTEIN SCI, V8, P1423, DOI 10.1110/ps.8.7.1423; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6	44	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21823	21830		10.1074/jbc.M300951200	http://dx.doi.org/10.1074/jbc.M300951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12657647	hybrid			2022-12-25	WOS:000183354200065
J	Xia, ZQ; Gray, JA; Compton-Toth, BA; Roth, BL				Xia, ZQ; Gray, JA; Compton-Toth, BA; Roth, BL			A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAINS; PREFRONTAL CORTEX; SUBCELLULAR-DISTRIBUTION; ANTIPSYCHOTIC-DRUGS; SALVINORIN-A; PROTEIN; BINDING; ASSOCIATION; INTERNALIZATION; ADULT	The serotonin (5-hydroxytryptamine) 2A receptor (5-HT2A) is an important G protein-coupled receptor ( GPCR) that mediates the effects of hallucinogens and is the target of a number of commonly prescribed medications including atypical antipsychotics, antidepressants, and anxiolytics. The 5-HT2A receptor possesses a canonical Type I PDZ-binding domain (X-Ser/Thr-X-Phi) at the carboxyl terminus and has been predicted, but never demonstrated, to interact with PDZ domain-containing proteins. We discovered that PSD-95, a prototypic PDZ domain-containing protein, directly associates with the 5-HT2A receptor and regulates 5-HT2A receptor-mediated signaling and trafficking in HEK-293 cells. Co-immunoprecipitation studies revealed that the native 5-HT2A receptor, but not a mutant lacking the PDZ-binding domain, interacted directly with PSD-95. The association with PSD-95 enhanced 5-HT2A receptor-mediated signal transduction, a novel action of PSD-95 on GPCRs. The augmentation of 5-HT2A receptor signaling by PSD-95 was not accompanied by alteration in the kinetics of 5-HT2A receptor desensitization but was associated with the inhibition of agonist-induced 5-HT2A receptor internalization. Additional studies demonstrated that 5-HT2A receptor and PSD-95 were co-localized in clusters on the cell surface of HEK-293 cells. Taken together, the present work elucidates novel roles for PSD-95 in regulating the functional activity and intracellular trafficking of 5-HT2A receptors and possibly other GPCRs.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Roth, BL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Rm W438,10900 Euclid Ave, Cleveland, OH 44106 USA.	roth@biocserver.cwru.edu	Xia, Zongqi/AAX-3091-2020; Xia, Zongqi/AAB-1565-2022; Roth, Bryan/ABE-7032-2020; Gray, John Alan/Y-5730-2019; Roth, Bryan L/F-3928-2010	Xia, Zongqi/0000-0003-1500-2589; Xia, Zongqi/0000-0003-1500-2589; Roth, Bryan/0000-0002-0561-6520; Gray, John/0000-0002-7287-0748	NIA NIH HHS [AG 00271] Funding Source: Medline; NIGMS NIH HHS [GM 07250] Funding Source: Medline; NIMH NIH HHS [K02 MH 01366, R01 MH 61887] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061887, K02MH001366] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aoki C, 2001, SYNAPSE, V40, P239, DOI 10.1002/syn.1047; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Berry SA, 1996, MOL PHARMACOL, V50, P306; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cornea-Hebert V, 2002, NEUROSCIENCE, V113, P23, DOI 10.1016/S0306-4522(02)00146-X; Cornea-Hebert V, 1999, J COMP NEUROL, V409, P187, DOI 10.1002/(SICI)1096-9861(19990628)409:2<187::AID-CNE2>3.0.CO;2-P; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Gray JA, 2003, MOL PHARMACOL, V63, P961, DOI 10.1124/mol.63.5.961; Gray JA, 2002, SCIENCE, V297, P529, DOI 10.1126/science.1075453; Gray JA, 2001, BRAIN RES BULL, V56, P441, DOI 10.1016/S0361-9230(01)00623-2; Gray JA, 2001, MOL PHARMACOL, V60, P1020, DOI 10.1124/mol.60.5.1020; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Harris BZ, 2001, J CELL SCI, V114, P3219; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jakab RL, 1998, P NATL ACAD SCI USA, V95, P735, DOI 10.1073/pnas.95.2.735; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kroeze Wesley K., 2002, Current Topics in Medicinal Chemistry, V2, P507, DOI 10.2174/1568026023393796; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Martin-Ruiz R, 2001, J NEUROSCI, V21, P9856, DOI 10.1523/JNEUROSCI.21-24-09856.2001; Meltzer HY, 1999, NEUROPSYCHOPHARMACOL, V21, pS106, DOI 10.1038/sj.npp.1395370; MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238; Miner LAH, 2003, NEUROSCIENCE, V116, P107, DOI 10.1016/S0306-4522(02)00580-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Ohnuma T, 2000, NEUROREPORT, V11, P3133, DOI 10.1097/00001756-200009280-00019; Prange O, 2001, J NEUROSCI, V21, P9325, DOI 10.1523/JNEUROSCI.21-23-09325.2001; ROTH BL, 1986, J PHARMACOL EXP THER, V238, P480; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Toyooka K, 2002, J NEUROCHEM, V83, P797, DOI 10.1046/j.1471-4159.2002.01181.x; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Willins DL, 1999, NEUROSCIENCE, V91, P599, DOI 10.1016/S0306-4522(98)00653-8; Willins DL, 1997, SYNAPSE, V27, P79, DOI 10.1002/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Zhang DF, 1999, SPECTROSC SPECT ANAL, V19, P108	52	125	126	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21901	21908		10.1074/jbc.M301905200	http://dx.doi.org/10.1074/jbc.M301905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682061	Green Published, hybrid			2022-12-25	WOS:000183354200075
J	Xiao, Z; Chen, ZH; Gunasekera, AH; Sowin, TJ; Rosenberg, SH; Fesik, S; Zhang, HY				Xiao, Z; Chen, ZH; Gunasekera, AH; Sowin, TJ; Rosenberg, SH; Fesik, S; Zhang, HY			Chk1 mediates S and G(2) arrests through Cdc25A degradation in response to DNA-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN PHOSPHATASE; CHECKPOINT PATHWAY; G(1)/S TRANSITION; PHASE CHECKPOINT; ACTIVATION; PHOSPHORYLATION; EXPRESSION; TRIGGERS; KINASES	UV and ionizing radiation (IR) activate DNA damage checkpoints and induce Cdc25A degradation (Mailand, N., Falck, J., Lukas, C., Syljuasen, R. G., Welcker, M., Bartek, J., and Lukas, J. (2000) Science 288, 1425-1429; Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J., and Lukas J. (2001) Nature 410, 842-847). The degradation of Cdc25A is abrogated by caffeine, which implicates Chk1 as the potential mediator (Mailand, N., Falck, J., Lukas, C., Syljuasen, R. G., Welcker, M., Bartek, J., and Lukas, J. (2000) Science 288, 1425-1429). However, the involvement of Chk1 is far from clear, because caffeine is a rather nonspecific inhibitor of the ATR/Chk1 signaling pathway. Additionally, it is not known whether DNA-damaging drugs commonly used in chemotherapy, which may activate different signal transduction pathways than UV or IR, also confer Cdc25A degradation. Herein, we show that camptothecin and doxorubicin, two widely used topoisomerase inhibitors conferring S and G(2) arrest, respectively, cause the degradation of Cdc25A. Using a small interfering RNA that enables the specific elimination of Chk1 expression, we show that the observed proteolysis of Cdc25A is mediated through Chk1. Moreover, Cdc25A overexpression abrogates the Chk1-mediated degradation and overcomes the doxorubicin-induced G(2) arrest through dephosphorylation and activation of Cdc2/Cdk1 in a dose-dependent manner. These results suggest that: (a) Cdc25A is involved in the G(2)/M transition in addition to its commonly accepted effect on G1/S progression, and (b) Chk1 mediates both S and G(2) checkpoint and is thus a more ubiquitous cell cycle checkpoint mediator than previously thought.	Abbott Labs, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Zhang, HY (corresponding author), Abbott Labs, Canc Res, Abbott Pk, IL 60064 USA.							Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Lammer C, 1998, J CELL SCI, V111, P2445; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; NAGATA A, 1991, NEW BIOL, V3, P959; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWELL SN, 1995, CANCER RES, V55, P1643; Pu LX, 2002, J BIOL CHEM, V277, P46877, DOI 10.1074/jbc.M207902200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wu WG, 1998, CANCER RES, V58, P4082; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598	32	298	321	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21767	21773		10.1074/jbc.M300229200	http://dx.doi.org/10.1074/jbc.M300229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676925	hybrid			2022-12-25	WOS:000183354200058
J	Goodwin, M; Kovacs, EM; Thoreson, MA; Reynolds, AB; Yap, AS				Goodwin, M; Kovacs, EM; Thoreson, MA; Reynolds, AB; Yap, AS			Minimal mutation of the cytoplasmic tail inhibits the ability of E-cadherin to activate Rac but not phosphatidylinositol 3-kinase - Direct evidence of a role for cadherin-activated Rac signaling in adhesion and contact formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; CELL-CELL JUNCTIONS; PROTEIN-KINASE; BETA-CATENIN; ASSOCIATION; LOCALIZATION; MODULATION; P120(CTN); DYNAMICS; COMPLEX	Classic cadherins are adhesion-activated cell signaling receptors. In particular, homophilic cadherin ligation can directly activate Rho family GTPases and phosphatidylinositol 3-kinase (PI3-kinase), signaling molecules with the capacity to support the morphogenetic effects of these adhesion molecules during development and disease. However, the molecular basis for cadherin signaling has not been elucidated, nor is its precise contribution to cadherin function yet understood. One attractive hypothesis is that cadherin-activated signaling participates in stabilizing adhesive contacts ( Yap, A. S., and Kovacs, E. M. ( 2003) J. Cell Biol. 160, 11-16). We now report that minimal mutation of the cadherin cytoplasmic tail to uncouple binding of p120-ctn ablated the ability of E-cadherin to activate Rac. This was accompanied by profound defects in the capacity of cells to establish stable adhesive contacts, defects that were rescued by sustained Rac signaling. These data provide direct evidence for a role of cadherin-activated Rac signaling in contact formation and adhesive stabilization. In contrast, cadherin-activated PI3-kinase signaling was not affected by loss of p120-ctn binding. The molecular requirements for E-cadherin to activate Rac signaling thus appear distinct from those that stimulate PI3-kinase, and we postulate that p120-ctn may play a central role in the E-cadherin-Rac signaling pathway.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	University of Queensland; University of Queensland; Vanderbilt University	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	a.yap@mailbox.uq.edu.au	Kovacs, Eva/U-3526-2019; Yap, Alpha S./J-1554-2014	Kovacs, Eva/0000-0002-7228-4028; Yap, Alpha S./0000-0002-1038-8956				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Cantrell DA, 2001, J CELL SCI, V114, P1439; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grosheva I, 2001, J CELL SCI, V114, P695; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lambert M, 2000, J CELL SCI, V113, P2207; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Nakagawa M, 2001, J CELL SCI, V114, P1829; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Niessen CM, 2002, J CELL BIOL, V156, P389, DOI 10.1083/jcb.200108040; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	36	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20533	20539		10.1074/jbc.M213171200	http://dx.doi.org/10.1074/jbc.M213171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12672818	hybrid			2022-12-25	WOS:000183230500013
J	Stevens, JM; Daltrop, O; Higham, CW; Ferguson, SJ				Stevens, JM; Daltrop, O; Higham, CW; Ferguson, SJ			Interaction of heme with variants of the heme chaperone CcmE carrying active site mutations and a cleavable N-terminal His tag	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C MATURATION; ESCHERICHIA-COLI; APOCYTOCHROME-C; PROTEIN; BINDING; OXIDASE; SYSTEM	Cytochrome c maturation in the periplasms of many bacteria requires the heme chaperone CcmE, which binds heme covalently both in vivo and in vitro via a histidine residue before transferring the heme to apocytochromes c. To investigate the mechanism and specificity of heme attachment to CcmE, we have mutated the conserved histidine 130 of a soluble C-terminally His-tagged version of CcmE ( CcmE(sol)-C-His(6)) from Escherichia coli to alanine or cysteine. Remarkably, covalent bond formation with heme occurs with the protein carrying the cysteine mutation, and the process occurs both in vivo and in vitro. The yield of holo-H130C CcmE(sol)-C-His(6) produced in vivo is low compared with the wild type. In vitro heme attachment occurs only under reducing conditions. We demonstrate the involvement of one of the heme vinyl groups and a side chain at residue 130 in the bond formation by showing that in vitro attachment does not occur either with the heme analogue mesoheme or when alanine is present at residue 130. These results have implications for the mechanism of heme attachment to the histidine of CcmE. In vitro, CcmE(sol) lacking a His tag binds 8-anilino-1-naphthalenesulphonate and heme, the latter both noncovalently and via a covalent bond from the histidine side chain, similarly to the tagged proteins, thus countering a recent proposal that the His tag causes the heme binding. However, the His tag does appear to enhance the rate of in vitro covalent heme binding and to affect the heme ligation in the ferric b-type cytochrome form.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.							Allen JWA, 2002, J BIOL CHEM, V277, P33559, DOI 10.1074/jbc.M204963200; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; BODUSZEK B, 1980, MONATSH CHEM, V111, P1111, DOI 10.1007/BF00909667; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; Enggist E, 2003, J BACTERIOL, V185, P175, DOI 10.1128/JB.185.1.175-183.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; KOJO S, 1981, J CHEM SOC PERK T 1, P2864, DOI 10.1039/p19810002864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; TOHJO M, 1963, ARCH BIOCHEM BIOPHYS, V103, P401, DOI 10.1016/0003-9861(63)90429-6; Tomlinson EJ, 2000, J BIOL CHEM, V275, P32530, DOI 10.1074/jbc.M004022200; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c	27	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20500	20506		10.1074/jbc.M212925200	http://dx.doi.org/10.1074/jbc.M212925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657624	hybrid			2022-12-25	WOS:000183230500009
J	Zeng, HY; Zhao, DZ; Yang, SP; Datta, K; Mukhopadhyay, D				Zeng, HY; Zhao, DZ; Yang, SP; Datta, K; Mukhopadhyay, D			Heterotrimeric G alpha(q)/G alpha(11) proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CELL PROLIFERATION; DEPENDENT ACTIVATION; TYROSINE KINASE; DNA-SYNTHESIS; TUMOR-CELLS; PLC-GAMMA; MIGRATION; ANGIOGENESIS; FLT-1	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) functions by activating two receptor-tyrosine kinases, Flt-1 (VEGF receptor (VEGFR)-1) and KDR (VEGFR-2), both of which are selectively expressed on primary vascular endothelium. KDR is responsible for VPF/VEGF-stimulated endothelial cell proliferation and migration, whereas Flt-1 down-modulates KDR-mediated endothelial cell proliferation. Our most recent works show that pertussis toxin-sensitive G proteins and Gbetagamma subunits are required for Flt-1-mediated down-regulation of human umbilical vein endothelial cell (HUVEC) proliferation and that G(q/11) proteins are required for KDR-mediated RhoA activation and HUVEC migration. In this study, we demonstrate that G(q/11) proteins are also required for VPF/VEGF-stimulated HUVEC proliferation. Our results further indicate that G(q/11) proteins specifically mediate KDR signaling such as intracellular Ca2+ mobilization rather than Flt-1-induced CDC42 activation and that a G(q/11) antisense oligonucleotide completely inhibits MAPK phosphorylation induced by KDR but has no effect on Flt-1-induced MAPK activation. More importantly, we demonstrate that G(q/11) proteins interact with KDR in vivo, and the interaction of G(q/11) proteins with KDR does not require KDR tyrosine phosphorylation. Surprisingly, the G(q/11) antisense oligonucleotide completely inhibits VPF/VEGF-stimulated KDR phosphorylation. Expression of a constitutively active mutant of G(11) but not G(q) can cause phosphorylation of KDR and MAPK. In addition, a Gbetagamma minigene, hbetaARK1(495), inhibits VPF/VEGF-stimulated HUVEC proliferation, MAPK phosphorylation, and intracellular Ca2+ mobilization but has no effect on KDR phosphorylation. Taken together, this study demonstrates that G(q/11) proteins mediate KDR tyrosine phosphorylation and KDR-mediated HUVEC proliferation through interaction with KDR.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN270H, Boston, MA 02215 USA.	dmukhopa@caregroup.harvard.edu			NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567, HL072178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072178, R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; BROCK TA, 1991, AM J PATHOL, V138, P213; Clague MJ, 2001, J CELL SCI, V114, P3075; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; Dvorak H.F., 1984, DEV ONCOL, V22, P96; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Folkman J, 1997, EXS, V79, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sanchez-Blazquez P, 1998, J PHARMACOL EXP THER, V285, P820; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200	49	59	65	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20738	20745		10.1074/jbc.M209712200	http://dx.doi.org/10.1074/jbc.M209712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670961	hybrid			2022-12-25	WOS:000183230500040
J	Fechter, P; Mingay, L; Sharps, J; Chambers, A; Fodor, E; Brownlee, GG				Fechter, P; Mingay, L; Sharps, J; Chambers, A; Fodor, E; Brownlee, GG			Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL COMPLEMENTARY RNA; AMINO-ACID MUTATION; MESSENGER-RNA; VIRUS POLYMERASE; STRUCTURAL BASIS; VIRION RNA; PA SUBUNIT; RECOGNITION; PROTEIN; ENDONUCLEASE	mRNAs are capped at their 5'-end by a unique cap structure containing N-7-methyl guanine. Recognition of the cap structure is of paramount importance in some of the most central processes of gene expression as well as in some viral processes, such as priming of influenza virus transcription. The recent resolution of the structure of three evolutionary unrelated cap binding proteins, the vaccinia viral protein VP39, the eukaryotic translation factor eIF4E, and the nuclear cap-binding protein CBP20 showed that the recognition of the cap structure is achieved by the same general mechanism, i.e. by "sandwiching" of the N-7-methyl guanine of the cap structure between two aromatic amino acid residues. The purpose of the present study was to test whether a similar cap recognition mechanism had independently evolved for the RNA polymerase of influenza virus. Combining in vivo and in vitro methods, we characterized two crucial aromatic amino acids, Phe(363) and Phe(404), in the PB2 subunit of the viral RNA polymerase that are essential for cap binding. The aromaticity of these two residues is conserved in influenza A, B, and C and even in the divergent Thogoto virus PB2 subunits. Thus, our results favor a similar mechanism of cap binding by the influenza RNA polymerase as in the evolutionary unrelated VP39, eIF4E, and CBP20.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Brownlee, GG (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	George.Brownlee@path.ox.ac.uk		Fodor, Ervin/0000-0003-3249-196X; Chambers, Anna/0000-0001-8133-6240				BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BLAAS D, 1982, NUCLEIC ACIDS RES, V10, P4803; BOULOY M, 1980, P NATL ACAD SCI-BIOL, V77, P3952, DOI 10.1073/pnas.77.7.3952; BOULOY M, 1979, J VIROL, V32, P895, DOI 10.1128/JVI.32.3.895-904.1979; BROWNLEE GG, 1995, NUCLEIC ACIDS RES, V23, P2641, DOI 10.1093/nar/23.14.2641; Brownlee GG, 2002, J VIROL, V76, P7103, DOI 10.1128/JVI.76.14.7103-7113.2002; Calero G, 2002, NAT STRUCT BIOL, V9, P912, DOI 10.1038/nsb874; CIANCI C, 1995, J VIROL, V69, P3995, DOI 10.1128/JVI.69.7.3995-3999.1995; DIGARD P, 1989, VIROLOGY, V171, P162, DOI 10.1016/0042-6822(89)90523-0; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fodor E, 2003, J VIROL, V77, P5017, DOI 10.1128/JVI.77.8.5017-5020.2003; FODOR E, 1993, J GEN VIROL, V74, P1327, DOI 10.1099/0022-1317-74-7-1327; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Fodor E, 2002, J VIROL, V76, P8989, DOI 10.1128/JVI.76.18.8989-9001.2002; Fodor E, 2002, PERSP MED V, V7, P1; Fodor E, 1998, J VIROL, V72, P6283, DOI 10.1128/JVI.72.8.6283-6290.1998; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; Honda A, 1999, GENES CELLS, V4, P475, DOI 10.1046/j.1365-2443.1999.00275.x; HOOKER L, 2002, 12 C VIR PAR FRANC J; Hsu PC, 2000, BIOCHEMISTRY-US, V39, P13730, DOI 10.1021/bi000623p; Hu GH, 2002, BIOCHEMISTRY-US, V41, P7677, DOI 10.1021/bi0201926; ISHIDA T, 1988, NUCLEIC ACIDS RES, V16, P6175, DOI 10.1093/nar/16.13.6175; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; Lamb RA, 2001, FIELDS VIROL, V1, P1487; Leahy MB, 1998, J VIROL, V72, P2305, DOI 10.1128/JVI.72.3.2305-2309.1998; Li ML, 1998, EMBO J, V17, P5844, DOI 10.1093/emboj/17.19.5844; Li ML, 2001, EMBO J, V20, P2078, DOI 10.1093/emboj/20.8.2078; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MAHY BWJ, 1981, REPLICATION NEGATIVE, P379; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mazza C, 2002, EMBO J, V21, P5548, DOI 10.1093/emboj/cdf538; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; Pleschka S, 1996, J VIROL, V70, P4188, DOI 10.1128/JVI.70.6.4188-4192.1996; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; PLOTCH SJ, 1979, P NATL ACAD SCI USA, V76, P1618, DOI 10.1073/pnas.76.4.1618; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Portela A, 1999, ADV VIRUS RES, V54, P319, DOI 10.1016/S0065-3527(08)60370-X; Quiocho FA, 2000, CURR OPIN STRUC BIOL, V10, P78, DOI 10.1016/S0959-440X(99)00053-6; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; ULMANEN I, 1981, P NATL ACAD SCI-BIOL, V78, P7355, DOI 10.1073/pnas.78.12.7355; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166	47	125	139	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20381	20388		10.1074/jbc.M300130200	http://dx.doi.org/10.1074/jbc.M300130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646557	hybrid			2022-12-25	WOS:000183078000103
J	Fitzpatrick, TB; Amrhein, N; Macheroux, P				Fitzpatrick, TB; Amrhein, N; Macheroux, P			Characterization of YqjM, an old yellow enzyme homolog from Bacillus subtilis involved in the oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAERYTHRITOL TETRANITRATE REDUCTASE; ENTEROBACTER-CLOACAE PB2; SPECTRAL PROPERTIES; 2,4,6-TRINITROTOLUENE; SEQUENCE; DEGRADATION; SPECIFICITY; EXPLOSIVES; TRINITRATE; COMPLEXES	In this paper, we demonstrate that a protein from Bacillus subtilis (YqjM) shares many characteristic biochemical properties with the homologous yeast Old Yellow Enzyme (OYE); the enzyme binds FMN tightly but noncovalently, preferentially uses NADPH as a source of reducing equivalents, and forms charge transfer complexes with phenolic compounds such as p-hydroxybenzaldehyde. Like yeast OYE and other members of the family, YqjM catalyzes the reduction of the double bond of an array of alpha,beta-unsaturated aldehydes and ketones including nitroester and nitroaromatic compounds. Although yeast OYE was the first member of this family to be discovered in 1933 and was the first flavoenzyme ever to be isolated, the physiological role of the family still remains obscure. The finding that alpha, beta-unsaturated compounds are substrates provoked speculation that the OYE family might be involved in reductive degradation of xenobiotics or lipid peroxidation products. Here, for the first time, we demonstrate on the protein level that whereas YqjM shows a basal level of expression in B. subtilis, the addition of the toxic xenobiotic, trinitrotoluene, leads to a rapid induction of the protein in vivo denoting a role in detoxification. Moreover, we show that YqjM is rapidly induced in response to oxidative stress as exerted by hydrogen peroxide, demonstrating a potential physiological role for this enigmatic class of proteins.	ETH, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Fitzpatrick, TB (corresponding author), ETH, Inst Pflanzenwissensch, Univ Str 2, CH-8092 Zurich, Switzerland.		Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X				ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; Aliverti A, 1999, METH MOL B, V131, P9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Blehert DS, 1997, J BACTERIOL, V179, P6912, DOI 10.1128/jb.179.22.6912-6920.1997; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Breithaupt C, 2001, STRUCTURE, V9, P419, DOI 10.1016/S0969-2126(01)00602-5; Cenas N, 2001, BBA-GEN SUBJECTS, V1528, P31, DOI 10.1016/S0304-4165(01)00169-6; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Fitzpatrick TB, 2001, J BIOL CHEM, V276, P18052, DOI 10.1074/jbc.M100867200; French CE, 1999, NAT BIOTECHNOL, V17, P491, DOI 10.1038/8673; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Hannink N, 2001, NAT BIOTECHNOL, V19, P1168, DOI 10.1038/nbt1201-1168; Harlow E., 1988, ANTIBODIES LAB MANUA; HARWOOD CR, 1992, TRENDS BIOTECHNOL, V10, P247, DOI 10.1016/0167-7799(92)90233-L; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Homma-Takeda S, 2002, FREE RADICAL RES, V36, P555, DOI 10.1080/10715760290025933; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; Kong L Y, 1989, Biomed Environ Sci, V2, P72; Kumagai Y, 2000, FEBS LETT, V478, P295, DOI 10.1016/S0014-5793(00)01841-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; Pak JW, 2000, APPL ENVIRON MICROB, V66, P4742, DOI 10.1128/AEM.66.11.4742-4750.2000; Sambrook J., 2002, MOL CLONING LAB MANU; Schaller F, 2000, PLANTA, V210, P979, DOI 10.1007/s004250050706; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; Strassner J, 1999, J BIOL CHEM, V274, P35067, DOI 10.1074/jbc.274.49.35067; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Warburg O, 1933, BIOCHEM Z, V266, P377; WARBURG O, 1932, NATURWISSENSCHAFTEN, V20, P688	39	128	134	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19891	19897		10.1074/jbc.M211778200	http://dx.doi.org/10.1074/jbc.M211778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660247	Green Published, hybrid			2022-12-25	WOS:000183078000042
J	Geiszt, M; Lekstrom, K; Witta, J; Leto, TL				Geiszt, M; Lekstrom, K; Witta, J; Leto, TL			Proteins homologous to p47(phox) and p67(phox) support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; FLAVOCYTOCHROME B(558); ACTIVATION DOMAIN; PHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION; COMPONENTS; CLONING	Superoxide production by phagocytes involves activation of a multi-component NADPH oxidase. Recently, several homologues of the catalytic component of the phagocyte oxidase, gp91(phox), were identified in various tissues. Here we describe two proteins, p41 and p51, with significant homology to two cytosolic components of the phagocytic oxidase, p47(phox) and p67(phox). Like p47(phox), p41 contains an amino-terminal Phox homology domain, two SH3 domains, and a conserved carboxyl-terminal, proline-rich motif. Similarly, p51 is homologous to p67(phox), containing four amino-terminal tetratricopeptide repeats, a conserved "activation domain" motif, a PB1 domain, and a carboxyl-terminal SH3 domain. The highest levels of p41 transcript are detected in the colon and in other gastrointestinal tissues that express Nox1, the predominant gp91(phox) homologue in these tissues. In contrast, the p51 transcript showed a more widespread expression pattern, suggesting that it may support other tissue-specific oxidases. Mouse colon in situ hybridization detected both transcripts in the epithelial cells of colon crypts. Heterologous co-expression of p41 and p51 significantly enhances the superoxide-generating activity of Nox1-expressing cells; thus, p41 and p51 appear to be novel regulators of Nox1. These proteins also support the activity of gp91(phox), albeit at much lower levels than the cytosolic phox counterparts. Our results suggest colon epithelial cells contain a multi-component NAD(P) H oxidase with a molecular architecture similar to the phagocytic oxidase.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Semmelweis University; Uniformed Services University of the Health Sciences - USA	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, Z01AI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; ElBenna J, 1996, J BIOL CHEM, V271, P6374; FINAN P, 1994, J BIOL CHEM, V269, P13752; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leto TL., 1999, INFLAMMATION BASIC P, P769; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LI F, 1994, BLOOD, V84, P53, DOI 10.1182/blood.V84.1.53.bloodjournal84153; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169	28	241	253	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20006	20012		10.1074/jbc.M301289200	http://dx.doi.org/10.1074/jbc.M301289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657628	hybrid			2022-12-25	WOS:000183078000057
J	McLellan, CA; Raynes, DA; Guerriero, V				McLellan, CA; Raynes, DA; Guerriero, V			HspBP1, an Hsp70 cochaperone, has two structural domains and is capable of altering the conformation of the Hsp70 ATPase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; PROTEIN	We present here the first structural information for HspBP1, an Hsp70 cochaperone. Using circular dichroism, HspBP1 was determined to be 35% helical. Although HspBP1 is encoded by seven exons, limited proteolysis shows that it has only two structural domains. Domain I, amino acids 1-83, is largely unstructured. Domain II, amino acids 84-359, is predicted to be 43% helical using circular dichroism. Using limited proteolysis we have also shown that HspBP1 association changes the conformation of the ATPase domain of Hsp70. Only domain II of HspBP1 is required to bring about this conformational change. Truncation mutants of HspBP1 were tested for their ability to inhibit the renaturation of luciferase and bind to Hsp70 in reticulocyte lysate. A carboxyl terminal truncation mutant that was slightly longer than domain I was inactive in these assays, but domain II was sufficient to perform both functions. Domain II was less active than full-length HspBP1 in these assays, and addition of amino acids from domain I improved both functions. These studies show that HspBP1 domain II can bind Hsp70, change the conformation of the ATPase domain, and inhibit Hsp70-associated protein folding.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Anim Sci, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Guerriero, V (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	Guerrier@email.arizona.edu			ORS NIH HHS [SIORR13838] Funding Source: Medline	ORS NIH HHS		CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GUERRIERO V, 1989, J CELL PHYSIOL, V140, P471, DOI 10.1002/jcp.1041400310; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; KABANI M, 2002, FEBS LETT; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Nollen EAA, 2002, J CELL SCI, V115, P2809; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440	18	24	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19017	19022		10.1074/jbc.M301109200	http://dx.doi.org/10.1074/jbc.M301109200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12651857	hybrid			2022-12-25	WOS:000182932200039
J	Kunduzova, OR; Escourrou, G; Seguelas, MH; Delagrange, P; De La Farge, F; Cambon, C; Parini, A				Kunduzova, OR; Escourrou, G; Seguelas, MH; Delagrange, P; De La Farge, F; Cambon, C; Parini, A			Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion	FASEB JOURNAL			English	Article						oxidative stress; kidney; rat; acute renal failure; hormone	ISCHEMIA-REPERFUSION; LIPID-PEROXIDATION; ANTIOXIDANT ACTIVITY; OXIDATIVE STRESS; INJURY; INHIBITION; PITUITARY; PROTEINS; NECROSIS; MECHANISM	The pineal hormone melatonin has been reported to protect tissue from oxidative damage. This study was designed to determine whether melatonin could prevent cell events leading to tissue injury and renal dysfunction after ischemia/reperfusion (I/R). Using an in vivo rat model of I/R, we show a significant increase in kidney malondialdehyde concentrations, reflecting lipid peroxidation, and cell apoptosis measured by TUNEL staining. This apoptotic cell death was associated with an increase in the activity of the proapoptotic factor caspase-3, determined by fluorometric protease activity assay. Histomorphological analysis of ischemic kidneys revealed that the most extensive tubular necrosis occurred at 24 and 48 h after reperfusion, which correlated with peak elevations in blood urea nitrogen and creatinine. Rat pretreatment with melatonin prevented lipid peroxidation, cell apoptosis, and necrosis and blocked caspase-3 activity. The prevention of tissue injury was associated with the improvement of renal function as shown by the decrease in blood urea nitrogen and creatinine concentrations. The demonstration that melatonin prevents postreperfusion apoptotic and necrotic cell death and improves renal function suggests that melatonin may represent a novel therapeutic approach for prevention of I/R injury.	CHU Rangueil, INSERM, U388,IFR31, Inst Louis Bugnard, F-31403 Toulouse 4, France; CHU Rangueil, Dept Pathol, F-31403 Toulouse 4, France; Inst Rech Int Servier, F-92415 Courbevoie, France; CHU Rangueil, Biochem Lab, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Servier; Institut de Recherches Internationales Servier; CHU de Toulouse	Parini, A (corresponding author), CHU Rangueil, INSERM, U388,IFR31, Inst Louis Bugnard, Bat L3, F-31403 Toulouse 4, France.	parini@toulouse.inserm.fr		Kunduzova, Oksana/0000-0003-2503-6555; Parini, Angelo/0000-0002-9848-8838				ARUOMA OI, 1989, BIOCHEM J, V258, P617, DOI 10.1042/bj2580617; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P9; Celebi S, 2002, EUR J OPHTHALMOL, V12, P77, DOI 10.1177/112067210201200201; Chan ASL, 2002, CELL SIGNAL, V14, P249, DOI 10.1016/S0898-6568(01)00240-6; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Dhalla NS, 2000, CARDIOVASC RES, V47, P446, DOI 10.1016/S0008-6363(00)00078-X; Donnahoo KK, 1999, J UROLOGY, V162, P196, DOI 10.1097/00005392-199907000-00068; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; Elliott RM, 2000, FREE RADICAL BIO MED, V28, P1438, DOI 10.1016/S0891-5849(00)00271-9; Garcia-Criado FJ, 1998, TRANSPLANTATION, V66, P982, DOI 10.1097/00007890-199810270-00003; Hazlerigg DG, 1996, ENDOCRINOLOGY, V137, P210, DOI 10.1210/en.137.1.210; HORTON JW, 1993, BIOCHEM PHARMACOL, V45, P1721; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Kazmers A, 1997, J SURG RES, V67, P62, DOI 10.1006/jsre.1996.4946; KORNBLIHTT LI, 1993, J PINEAL RES, V14, P184, DOI 10.1111/j.1600-079X.1993.tb00501.x; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kunduzova OR, 2002, FASEB J, V16, P1129, DOI 10.1096/fj.01-1008fje; Lagneux C, 2000, LIFE SCI, V66, P503, DOI 10.1016/S0024-3205(99)00620-7; Lankoff A, 2002, ARCH TOXICOL, V76, P158, DOI 10.1007/s00204-001-0310-x; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; Mangano CM, 1998, ANN INTERN MED, V128, P194, DOI 10.7326/0003-4819-128-3-199802010-00005; Martinez-Cruz F, 2002, NEUROSCI LETT, V326, P147, DOI 10.1016/S0304-3940(02)00020-4; Melnikov VY, 2001, J CLIN INVEST, V107, P1145, DOI 10.1172/JCI12089; MORGAN PJ, 1990, J NEUROENDOCRINOL, V2, P773, DOI 10.1111/j.1365-2826.1990.tb00639.x; Naskalski JW, 2001, ADV CLIN CHEM, V35, P161, DOI 10.1016/S0065-2423(01)35017-5; Nava M, 2000, AM J PHYSIOL-RENAL, V279, pF910, DOI 10.1152/ajprenal.2000.279.5.F910; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Ortega-Gutierrez S, 2002, NEUROSCI LETT, V323, P55, DOI 10.1016/S0304-3940(01)02530-7; Peng XX, 2002, PHARMACOL RES, V45, P491, DOI 10.1006/phrs.2002.0991; Pevet P, 2000, BIOL SIGNAL RECEPT, V9, P203; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V80, P211; Portilla D, 2000, AM J PHYSIOL-RENAL, V278, pF667, DOI 10.1152/ajprenal.2000.278.4.F667; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Ricardo SD, 1998, SEMIN NEPHROL, V18, P612; Salahudeen AK, 2001, TRANSPLANTATION, V72, P798, DOI 10.1097/00007890-200109150-00010; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; SCHUMER M, 1992, AM J PATHOL, V140, P831; Skwarlo-Sonta K, 2002, NEUROENDOCRINOL LETT, V23, P61; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; TANAKA J, 1993, BIOL PHARM BULL, V16, P29, DOI 10.1248/bpb.16.29; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Todor A, 2002, AM J PHYSIOL-HEART C, V283, pH990, DOI 10.1152/ajpheart.01003.2001; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9; VANECEK J, 1990, NEUROSCI LETT, V110, P199, DOI 10.1016/0304-3940(90)90811-M; VANECEK J, 1992, ENDOCRINOLOGY, V130, P701, DOI 10.1210/en.130.2.701; Weisberg LS, 1997, ARCH INTERN MED, V157, P1833, DOI 10.1001/archinte.157.16.1833; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x	55	71	74	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					872	+		10.1096/fj.02-0504fje	http://dx.doi.org/10.1096/fj.02-0504fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670883				2022-12-25	WOS:000181892600003
J	Gaiddon, C; Lokshin, M; Gross, I; Levasseur, D; Taya, Y; Loeffler, JP; Prives, C				Gaiddon, C; Lokshin, M; Gross, I; Levasseur, D; Taya, Y; Loeffler, JP; Prives, C			Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; C-ABL; P53-RELATED PROTEIN; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; P53-HOMOLOG P73; P53 MUTANTS; DEATH; NEUROBLASTOMA	p73 transcription factors are members of the p53 family and participate in developmental processes and DNA damage response. p73 expression was shown to be regulated during the cell cycle, suggesting that p73 might play a role in cell growth and might be a target for cyclin-dependent kinases. Consistent with this hypothesis, we discovered that p73 interacts physically with various cyclins (A, B, D, and E). Furthermore, cyclin A/CDK1/2, cyclin B/CDK1/2, and cyclin E/CDK2 complexes can phosphorylate multiple p73 isoforms in vitro at threonine 86. A specific antibody directed against phosphorylated Thr(86) showed that this site is phosphorylated in vivo and that such phosphorylation is regulated in a cell cycle-dependent manner. Thr(86) phosphorylation is induced during S phase and is maximal in the G(2)/M phase. Accordingly inhibitors of cell growth, such as p16 and serum starvation, reduce Thr(86) phosphorylation. Finally, we found that cyclin-dependent kinase (CDK)-dependent Thr(86) phosphorylation represses the ability of p73 to induce endogenous p21 expression. Our results demonstrate that p73 proteins are targets of CDK complexes and that phosphorylation on Thr(86) by CDKs regulates p73 functions.	Univ Strasbourg 1, Equipe Accecil Signalisat Mol & Neurodegenetescen, F-67000 Strasbourg, France; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; INSERM, U381, F-67000 Strasbourg, France; Natl Canc Ctr, Tokyo 10040045, Japan	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Cancer Center - Japan	Gaiddon, C (corresponding author), Univ Strasbourg 1, Equipe Accecil Signalisat Mol & Neurodegenetescen, F-67000 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020; Gross, Isabelle/P-9859-2019; Gaiddon, Christian/F-7321-2012; Gross, Isabelle/I-4972-2016	Gross, Isabelle/0000-0002-2783-8773; Gaiddon, Christian/0000-0003-4315-3851; Gross, Isabelle/0000-0002-2783-8773	NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER; NCI NIH HHS [CA77742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Endicott JA, 1998, STRUCT FOLD DES, V6, P535, DOI 10.1016/S0969-2126(98)00055-0; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gong JG, 1999, NATURE, V399, P806; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lamm GM, 1997, NUCLEIC ACIDS RES, V25, P4855, DOI 10.1093/nar/25.23.4855; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Reed SI, 1997, CANCER SURV, V29, P7; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Silhavy T.J., 1984, EXPT GENE FUSIONS; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tsuji K, 2002, J BIOL CHEM, V277, P2951, DOI 10.1074/jbc.M108535200; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zheng HW, 2002, NATURE, V420, P445, DOI 10.1038/nature01220; Zhu JH, 1998, CANCER RES, V58, P5061	43	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27421	27431		10.1074/jbc.M300251200	http://dx.doi.org/10.1074/jbc.M300251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12676926	hybrid			2022-12-25	WOS:000184242700013
J	Liepinsh, E; Banyai, L; Pintacuda, G; Trexler, M; Patthy, L; Otting, G				Liepinsh, E; Banyai, L; Pintacuda, G; Trexler, M; Patthy, L; Otting, G			NMR structure of the netrin-like domain (NTR) of human type I procollagen C-proteinase enhancer defines structural consensus of NTR domains and assesses potential proteinase inhibitory activity and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING-CONSTANTS; BIOLOGICAL MACROMOLECULES; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; TISSUE INHIBITOR; MULTIPLE TYPES; ALIGNMENT; METALLOPROTEINASE; GLYCOPROTEIN; EXPRESSION	Procollagen C-proteinase enhancer (PCOLCE) proteins are extracellular matrix proteins that enhance the activities of procollagen C-proteinases by binding to the C-propeptide of procollagen I. PCOLCE proteins are built of three structural modules, consisting of two CUB domains followed by a C-terminal netrin-like (NTR) domain. While the enhancement of proteinase activity can be ascribed solely to the CUB domains, sequence homology of the NTR domain with tissue inhibitors of metalloproteinases suggest proteinase inhibitory activity for the NTR domain. Here we present the three-dimensional structure of the NTR domain of human PCOLCE1 as the first example of a structural domain with the canonical features of an NTR module. The structure rules out a binding mode to metalloproteinases similar to that of tissue inhibitors of metalloproteinases but suggests possible inhibitory function toward specific serine proteinases. Sequence conservation between 13 PCOLCE proteins from different organisms suggests a conserved binding surface for other protein partners.	Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	Australian National University; Karolinska Institutet; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Otting, G (corresponding author), Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia.		Otting, Gottfried/H-8413-2014; Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013	Otting, Gottfried/0000-0002-0563-0146; 				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Andersson P, 1998, J BIOMOL NMR, V12, P435, DOI 10.1023/A:1008239027287; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; Billeter M, 1995, J BIOMOL NMR, V5, P1; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Chong JM, 2002, J BIOL CHEM, V277, P5134, DOI 10.1074/jbc.M108533200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Luginbuhl P, 1996, J BIOMOL NMR, V8, P136; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Ponstingl H, 1998, J BIOMOL NMR, V12, P319, DOI 10.1023/A:1008293016073; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SEVILLASIERRA P, 1994, J MOL BIOL, V235, P1003, DOI 10.1006/jmbi.1994.1053; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Stetefeld J, 2001, NAT STRUCT BIOL, V8, P705, DOI 10.1038/90422; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Trexler M, 2002, BIOL CHEM, V383, P223, DOI 10.1515/BC.2002.023; Trexler M, 2001, P NATL ACAD SCI USA, V98, P3705, DOI 10.1073/pnas.061028398; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Xu H, 2000, GENOMICS, V66, P264, DOI 10.1006/geno.2000.6229; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	40	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25982	25989		10.1074/jbc.M302734200	http://dx.doi.org/10.1074/jbc.M302734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12670942	hybrid			2022-12-25	WOS:000183920200093
J	Jambal, P; Masterson, S; Nesterova, A; Bouchard, R; Bergman, B; Hutton, JC; Boxer, LM; Reusch, JEB; Pugazhenthi, S				Jambal, P; Masterson, S; Nesterova, A; Bouchard, R; Bergman, B; Hutton, JC; Boxer, LM; Reusch, JEB; Pugazhenthi, S			Cytokine-mediated down-regulation of the transcription factor cAMP-response element-binding protein in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; INSULIN-RESISTANCE; DIABETES-MELLITUS; CYCLIC-AMP; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; BCL-2 EXPRESSION; GENE-EXPRESSION	Cytokines are known to induce apoptosis of pancreatic beta-cells. Impaired expression of the anti-apoptotic gene bcl-2 is one of the mechanisms involved. In this study, we identified a defect involving transcription factor cAMP-response element-binding protein ( CREB) in the expression of bcl-2. Exposure of mouse pancreatic beta-cell line, MIN6 cells, to cytokines (interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma) led to a significant (p < 0.01) decrease in Bcl-2 protein and mRNA levels. Cytokines decreased (56%) the activity of the bcl-2 promoter that contains a cAMP-response element (CRE) site. Similar decreases were seen with a luciferase reporter gene driven by tandem repeats of CRE and a CREB-specific Gal4-luciferase reporter, suggesting a defect at the level of CREB. The active phospho form (serine 133) of CREB diminished significantly (p < 0.01) in cells exposed to cytokines. Examination of signaling pathways upstream of CREB revealed a reduction in the active form of Akt. Cytokine-induced decrease of bcl-2 promoter activity was partially restored when cells were cotransfected with a constitutively active form of Akt. Several end points of cytokine action including decreases in phospho-CREB, phospho-Akt, and BCl-2 levels and activation of caspase-9 were observed in isolated mouse islets. Overexpression of wild-type CREB in MIN6 cells by plasmid transfection and adenoviral infection led to protection against cytokine-induced apoptosis. Adenoviral transfer of dominant-negative forms of CREB, on the other hand, resulted in activation of caspase-9 and exaggeration of cytokine-induced beta-cell apoptosis. Together, these results point to CREB as a novel target for strategies aimed at improving the survival of beta-cells.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80262 USA; Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO 80220 USA; Barbara Davis Ctr Childhood Diabet, Denver, CO 80220 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University	Pugazhenthi, S (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, 4200 E 9th Ave, Denver, CO 80262 USA.			Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [DK 57516-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Aikin R, 2000, BIOCHEM BIOPH RES CO, V277, P455, DOI 10.1006/bbrc.2000.3664; Ban N, 2000, DIABETES, V49, P1142, DOI 10.2337/diabetes.49.7.1142; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; Castrillo A, 2000, DIABETES, V49, P209, DOI 10.2337/diabetes.49.2.209; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Contreras JL, 2001, TRANSPLANTATION, V71, P1015, DOI 10.1097/00007890-200104270-00001; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Eckert B, 1996, ENDOCRINOLOGY, V137, P225, DOI 10.1210/en.137.1.225; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Eizirik DL, 2001, DIABETES, V50, pS64, DOI 10.2337/diabetes.50.2007.S64; EIZIRIK DL, 1999, ADV MOL CEL, V29, P47; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Freeland K, 2001, MOL BRAIN RES, V92, P98, DOI 10.1016/S0169-328X(01)00158-9; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenberg AS, 2002, EUR J CLIN INVEST, V32, P24, DOI 10.1046/j.1365-2362.32.s3.4.x; Inada A, 1998, BIOCHEM BIOPH RES CO, V253, P712, DOI 10.1006/bbrc.1998.9833; Iwahashi H, 1996, DIABETOLOGIA, V39, P530, DOI 10.1007/s001250050475; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; Karlsen AE, 2000, J CLIN ENDOCR METAB, V85, P830, DOI 10.1210/jc.85.2.830; Kurrer MO, 1997, P NATL ACAD SCI USA, V94, P213, DOI 10.1073/pnas.94.1.213; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Mandrup-Poulsen T, 2001, DIABETES, V50, pS58, DOI 10.2337/diabetes.50.2007.S58; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Piro S, 2001, TRANSPLANTATION, V71, P21, DOI 10.1097/00007890-200101150-00004; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Rabinovitch A, 1999, DIABETES, V48, P1223, DOI 10.2337/diabetes.48.6.1223; Rayat GR, 2000, TRANSPLANTATION, V70, P976, DOI 10.1097/00007890-200009270-00016; Saldeen J, 2000, ENDOCRINOLOGY, V141, P2003, DOI 10.1210/en.141.6.2003; Segal M, 1998, NEURAL PLAST, V6, P1, DOI 10.1155/NP.1998.1; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Trincavelli ML, 2002, J CELL BIOCHEM, V84, P636, DOI 10.1002/jcb.10035.abs; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Van de Casteele M, 2002, ENDOCRINOLOGY, V143, P320, DOI 10.1210/en.143.1.320; Walker WH, 1998, MOL CELL ENDOCRINOL, V143, P167, DOI 10.1016/S0303-7207(98)00082-3; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YAMADA K, 1993, DIABETES, V42, P1026, DOI 10.2337/diabetes.42.7.1026; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	61	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23055	23065		10.1074/jbc.M212450200	http://dx.doi.org/10.1074/jbc.M212450200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12679364	hybrid			2022-12-25	WOS:000183503900113
J	Lesso, H; Li, RA				Lesso, H; Li, RA			Helical secondary structure of the external S3-S4 linker of pacemaker (HCN) channels revealed by site-dependent perturbations of activation phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF PURKINJE-FIBERS; PACE-MAKER CURRENT; GATING KINETICS; ION CHANNELS; PREDICTION; IDENTIFICATION; CURRENTS; RESIDUES; FAMILY; ROLES	I-f, encoded by the hyperpolarization-activated cyclic nucleotide- modulated channel family (HCN1-4), contributes significantly to neuronal and cardiac pacing. Recently, we reported that the S3-S4 residue Glu-235 of HCN1 influences activation by acting as a surface charge. However, it is uncertain whether other residues of the external S3-S4 linker are also involved in gating. Furthermore, the secondary conformation of the linker is not known. Here we probed the structural and functional role of the HCN1 S3-S4 linker by introducing systematic mutations into the entire linker ( defined as 229 237) and studying their effects. We found that the mutations K230A (-62.2 +/- 3.4 mV versus -72.2 +/- 1.7 mV of wild type (WT)), G231A (-64.4 +/- 1.3 mV), M232A (V-1/2 = -63.1 +/- 1.1 mV), and E235G (-65.4 +/- 1.5 mV) produced depolarizing activation shifts. Although E229A and M232A decelerated gating kinetics (<13- and 3-fold, respectively), K230A and G231A accelerated both activation and deactivation (< similar to2-3-fold). D233A, S234A, V236A, and Y237A channels exhibited WT properties (p > 0.05). Shortening the linker (EVY235 - 237DeltaDeltaDelta) caused depolarizing activation shift and slowed kinetics that could not be explained by removing the charge at position 235 alone. Secondary structural predictions by the modeling algorithms SSpro2 and PROF, along with refinements by our experimental data, suggest that part of the S3-S4 linker conforms a helical structure with the functionally important residues Met-232, Glu-235, and Gly-231 (\DeltaDeltaG\ > 1 kcal/mol) clustered on one side.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.	ronaldli@jhmi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-52768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; BROWN HF, 1977, J PHYSIOL-LONDON, V271, P783, DOI 10.1113/jphysiol.1977.sp012026; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Henrikson CA, 2002, CIRCULATION, V106, P226; Henrikson CA, 2003, J BIOL CHEM, V278, P13647, DOI 10.1074/jbc.M211025200; Ishii TM, 2001, J PHYSIOL-LONDON, V537, P93, DOI 10.1111/j.1469-7793.2001.0093k.x; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Ludwig A, 1999, CELL PHYSIOL BIOCHEM, V9, P179, DOI 10.1159/000016315; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; Mathur R, 1997, J GEN PHYSIOL, V109, P191, DOI 10.1085/jgp.109.2.191; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Schulze-Bahr E, 2001, CIRCULATION, V104, P192; Shi WM, 1999, CIRC RES, V85, pE1; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Xue T, 2002, J BIOL CHEM, V277, P46233, DOI 10.1074/jbc.M204915200; Yamagishi T, 2001, J GEN PHYSIOL, V118, P171, DOI 10.1085/jgp.118.2.171; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V388, P255, DOI 10.1007/BF00658491	40	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22290	22297		10.1074/jbc.M302466200	http://dx.doi.org/10.1074/jbc.M302466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668666	hybrid			2022-12-25	WOS:000183503900017
J	Sarkar, M; Hamilton, CJ; Fairlamb, AH				Sarkar, M; Hamilton, CJ; Fairlamb, AH			Properties of phosphoenolpyruvate mutase, the first enzyme in the aminoethylphosphonate biosynthetic pathway in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-PHOSPHORUS BOND; TETRAHYMENA-PYRIFORMIS; PHOSPHATE DIKINASE; PHOSPHONOLIPIDS; TRYPANOTHIONE; PYRUVATE; PROTEINS; CLONING	Phosphoenolpyruvate ( PEP) mutase catalyzes the conversion of phosphoenolpyruvate to phosphonopyruvate, the initial step in the formation of many naturally occurring phosphonate compounds. The phosphonate compound 2- aminoethylphosphonate is present as a component of complex carbohydrates on the surface membrane of many trypanosomatids including glycosylinositolphospholipids of Trypanosoma cruzi. Using partial sequence information from the T. cruzi genome project we have isolated a full- length gene with significant homology to PEP mutase from the free- living protozoan Tetrahymena pyriformis and the edible mussel Mytilus edulis. Recombinant expression in Escherichia coli confirms that it encodes a functional PEP mutase with a K-m apparent of 8 muM for phosphonopyruvate and a k(cat) of 12 s(-1). The native enzyme is a homotetramer with an absolute requirement for divalent metal ions and displays negative cooperativity for Mg2+ (S-0.5 0.4 muM; n = 0.46). Immunofluorescence and sub- cellular fractionation indicates that PEP mutase has a dual localization in the cell. Further evidence to support this was obtained by Western analysis of a partial sub- cellular fractionation of T. cruzi cells. Southern and Western analysis suggests that PEP mutase is unique to T. cruzi and is not present in the other medically important parasites, Trypanosoma brucei and Leishmania spp.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.		Fairlamb, Alan/A-5272-2009; hamilton, chris/C-5651-2009	Fairlamb, Alan/0000-0001-5134-0329; Sarkar-Tyson, Mitali/0000-0002-6764-8499				Acosta-Serrano A, 2001, MOL BIOCHEM PARASIT, V114, P143, DOI 10.1016/S0166-6851(01)00245-6; Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; BOWMAN ED, 1990, BIOCHEMISTRY-US, V29, P7059, DOI 10.1021/bi00482a016; Branquinha MH, 1999, MOL BIOCHEM PARASIT, V102, P179, DOI 10.1016/S0166-6851(99)00107-3; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Carreira JC, 1996, GLYCOCONJUGATE J, V13, P955, DOI 10.1007/BF01053191; COUTROT P, 1978, SYNTHESIS-STUTTGART, P36; FERGUSON MAJ, 1982, BIOCHEM J, V207, P171, DOI 10.1042/bj2070171; FLORINCHRISTENSEN J, 1986, TRENDS BIOCHEM SCI, V11, P354, DOI 10.1016/0968-0004(86)90198-2; FREEMAN S, 1991, J CHEM SOC PERK T 2, P263, DOI 10.1039/p29910000263; HILDERBRAND RL, 1983, ROLE PHOSPHONATES LI; Huang K, 1999, STRUCT FOLD DES, V7, P539, DOI 10.1016/S0969-2126(99)80070-7; Kim A, 1998, J BIOL CHEM, V273, P4443, DOI 10.1074/jbc.273.8.4443; Kononova SV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P184, DOI 10.1023/A:1014409929875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maldonado RA, 2001, MOL BIOCHEM PARASIT, V112, P183, DOI 10.1016/S0166-6851(00)00362-5; Mukhamedova KS, 2000, CHEM NAT COMPD+, V36, P329, DOI 10.1023/A:1002804409503; Oza SL, 2002, J BIOL CHEM, V277, P35853, DOI 10.1074/jbc.M204403200; Parsons M, 2001, MOL BIOCHEM PARASIT, V115, P19, DOI 10.1016/S0166-6851(01)00261-4; PREVIATO JO, 1992, J BIOL CHEM, V267, P24279; RIFKIN MR, 1995, J BIOL CHEM, V270, P16160, DOI 10.1074/jbc.270.27.16160; ROUTIER FH, 1995, MOL BIOCHEM PARASIT, V69, P81, DOI 10.1016/0166-6851(94)00202-X; SALTO ML, 2002, MOL PAR M 12 SEPT 22; SEIDEL HM, 1992, BIOCHEMISTRY-US, V31, P2598, DOI 10.1021/bi00124a021; SEIDEL HM, 1994, BIOCHEMISTRY-US, V33, P5641, DOI 10.1021/bi00184a037; SEIDEL HM, 1988, NATURE, V335, P457, DOI 10.1038/335457a0; TONER JJ, 1972, BIOCHEM BIOPH RES CO, V46, P652, DOI 10.1016/S0006-291X(72)80190-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5	30	21	22	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22703	22708		10.1074/jbc.M302419200	http://dx.doi.org/10.1074/jbc.M302419200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672809	hybrid			2022-12-25	WOS:000183503900071
J	Urbatsch, IL; Tyndall, GA; Tombline, G; Senior, AE				Urbatsch, IL; Tyndall, GA; Tombline, G; Senior, AE			P-glycoprotein catalytic mechanism - Studies of the ADP-vanadate inhibited state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; DISULFIDE CROSS-LINKING; PICHIA-PASTORIS CELLS; MULTIDRUG-RESISTANCE; NUCLEOTIDE-BINDING; TRANSITION-STATE; ABC TRANSPORTER; DRUG-BINDING; CYTOPLASMIC MEMBRANE; ELECTRON-MICROSCOPY	Kinetics of inhibition of ATPase activity of pure mouse Mdr3 P-glycoprotein upon incubation with MgADP and vanadate were studied along with the trapping of [C-14] ADP in presence of vanadate. The presence of verapamil strongly magnified both effects. Inhibition of ATPase was also increased by several other drugs known to bind to drug-binding sites. Inhibition by ADP-vanadate was slow and depended cooperatively on nucleotide binding. Stoichiometry of [C-14] ADP trapping by vanadate was 1 mol/mol P-glycoprotein at full inhibition. Catalytic site mutants prevented [C-14] ADP trapping, whereas interdomain signal communication mutants reduced it in approximate correlation with their effects upon drug stimulation of ATPase. In explanation of the results, we propose that a "closed conformation" involving dimerization and interdigitation of the two nucleotide-binding domains is necessary to allow inhibition by ADP-vanadate. The results suggest that such a conformation occurs naturally during ATP hydrolysis. It is proposed that in order for the catalytic transition state to form, the two nucleotide-binding domains dimerize to form an integrated single entity containing two bound ATP with just one of the two ATP being hydrolyzed per dimerization event.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Qu Q, 2002, BIOCHEMISTRY-US, V41, P4744, DOI 10.1021/bi0120897; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2000, BIOCHEM BIOPH RES CO, V276, P1314, DOI 10.1006/bbrc.2000.3576; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2001, ARCH BIOCHEM BIOPHYS, V388, P171, DOI 10.1006/abbi.2001.2299; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	56	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23171	23179		10.1074/jbc.M301957200	http://dx.doi.org/10.1074/jbc.M301957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12670938	hybrid			2022-12-25	WOS:000183503900125
J	Hasler, U; Mordasini, D; Bianchi, M; Vandewalle, A; Feraille, E; Pierre-Yves, M				Hasler, U; Mordasini, D; Bianchi, M; Vandewalle, A; Feraille, E; Pierre-Yves, M			Dual influence of aldosterone on AQP2 expression in cultured renal collecting duct principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL EXPRESSION; DEPENDENT SODIUM-TRANSPORT; INDUCED DOWN-REGULATION; MESSENGER-RNA; UP-REGULATION; MOUSE KIDNEY; VASOPRESSIN ANTAGONIST; HUMAN AQUAPORIN; RAT; MEMBRANE	In the renal collecting duct ( CD) the major physiological role of aldosterone is to promote Na+ reabsorption. In addition, aldosterone may also influence CD water permeability elicited by vasopressin (AVP). We have previously shown that endogenous expression of the aquaporin-2 (AQP2) water channel in immortalized mouse cortical CD principal cells (mpkCCD(C14)) grown on filters is dramatically increased by administration of physiological concentrations of AVP. In the present study, we investigated the influence of aldosterone on AQP2 expression in mpkCCDC14 cells by RNase protection assay and Western blot analysis. Aldosterone reduced AQP2 mRNA and protein expression when administered together with AVP for short periods of time (less than or equal to 24 h). For longer periods of time, however, aldosterone increased AQP2 protein expression despite sustained low expression levels of AQP2 mRNA. Both events were dependent on mineralocorticoid receptor occupancy because they were both induced by a low concentration of aldosterone ( 10(-9) M) and were abolished by the mineralocorticoid receptor antagonist canrenoate. Inhibition of lysosomal AQP2 protein degradation increased AQP2 protein expression in AVP-treated cells, an effect that was potentiated by aldosterone. Finally, both aldosterone and actinomycin D delayed AQP2 protein decay following AVP washout, but in a non-cumulative manner. Taken together, our data suggest that aldosterone tightly modulates AQP2 protein expression in cultured mpkCCDC14 cells by increasing AQP2 protein turnover while maintaining low levels of AQP2 mRNA expression.	Fdn Rech Med, Div Nephrol, CH-1211 Geneva 4, Switzerland; Univ Paris 07, INSERM, U478, IFR 02, F-75870 Paris 18, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Hasler, U (corresponding author), Fdn Rech Med, Div Nephrol, 64 Ave Roseraie, CH-1211 Geneva 4, Switzerland.	Udo.Hasler@medecine.unige.ch		Feraille, Eric/0000-0003-1656-8365				Apostol E, 1997, J AM SOC NEPHROL, V8, P15; Bens M, 1999, J AM SOC NEPHROL, V10, P923; BOYKIN J, 1979, MINER ELECTROL METAB, V2, P310; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; Earm JH, 1998, J AM SOC NEPHROL, V9, P2181; Ecelbarger CA, 1997, J CLIN INVEST, V99, P1852, DOI 10.1172/JCI119352; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Funder JW, 1998, CLIN EXP PHARMACOL P, V25, pS47, DOI 10.1111/j.1440-1681.1998.tb02300.x; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Hasler U, 2002, J BIOL CHEM, V277, P10379, DOI 10.1074/jbc.M111880200; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; ISHIKAWA S, 1982, KIDNEY INT, V22, P587, DOI 10.1038/ki.1982.216; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jonassen TEN, 1998, AM J PHYSIOL-RENAL, V275, pF216, DOI 10.1152/ajprenal.1998.275.2.F216; Jonassen TEN, 2000, AM J PHYSIOL-RENAL, V278, pF246, DOI 10.1152/ajprenal.2000.278.2.F246; Kwon TH, 2002, AM J PHYSIOL-RENAL, V283, pF1403, DOI 10.1152/ajprenal.00059.2002; Kwon TH, 1998, AM J PHYSIOL-RENAL, V275, pF724, DOI 10.1152/ajprenal.1998.275.5.F724; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; MacDonald P, 2000, J ENDOCRINOL, V165, P25, DOI 10.1677/joe.0.1650025; Marples D, 1998, AM J PHYSIOL-RENAL, V275, pF400, DOI 10.1152/ajprenal.1998.275.3.F400; Marples D, 1996, J CLIN INVEST, V97, P1960, DOI 10.1172/JCI118628; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P358; Nejsum LN, 2000, BIOCHEM BIOPH RES CO, V277, P164, DOI 10.1006/bbrc.2000.3638; Nelson RD, 1998, AM J PHYSIOL-CELL PH, V275, pC216, DOI 10.1152/ajpcell.1998.275.1.C216; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Ohara M, 1998, J CLIN INVEST, V101, P1076, DOI 10.1172/JCI649; Ohara M, 2002, BIOCHEM BIOPH RES CO, V299, P285, DOI 10.1016/S0006-291X(02)02634-7; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruiz-Echevarria MJ, 2001, J BIOL CHEM, V276, P30995, DOI 10.1074/jbc.M010833200; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SCHWARTZ MJ, 1980, J CLIN INVEST, V66, P234, DOI 10.1172/JCI109849; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; UCHIDA S, 1994, J BIOL CHEM, V269, P23451; UFFERMAN RC, 1972, J CLIN INVEST, V51, P1639, DOI 10.1172/JCI106965; Vandewalle A, 1999, CURR OPIN NEPHROL HY, V8, P581, DOI 10.1097/00041552-199909000-00009; VANVLIET AA, 1993, AM J CARDIOL, V71, pA21, DOI 10.1016/0002-9149(93)90241-4; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Willson DM, 1939, J CLIN INVEST, V18, P35, DOI 10.1172/JCI101023; Xu DL, 1997, J CLIN INVEST, V99, P1500, DOI 10.1172/JCI119312; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808	54	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21639	21648		10.1074/jbc.M212388200	http://dx.doi.org/10.1074/jbc.M212388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660245	hybrid			2022-12-25	WOS:000183354200042
J	Baird, TR; Walsh, PN				Baird, TR; Walsh, PN			Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET-AGGREGATION; COAGULATION FACTOR-XI; IX-V COMPLEX; BLOOD-COAGULATION; PLASMA PREKALLIKREIN; HEAVY-CHAIN; LIGHT-CHAIN; ACTIVATED PLATELETS; CONSOLIDATION PHASE; EXPRESSION CLONING	Previous studies on the interaction of high molecular weight kininogen (HK) with endothelial cells have reported a large number of binding sites (10(6)-10(7) sites/cell) with differing relative affinities (K-D = 7-130 nM) and have implicated various receptors or receptor complexes. In this study, we examined the binding of HK to human umbilical vein endothelial cells ( HUVEC) with a novel assay system utilizing HUVEC immobilized on microcarrier beads, which eliminates the detection of the high affinity binding sites found nonspecifically in conventional microtiter well assays. We report that HK binds to 8.5 x 10(4) high affinity (K-D = 21 nM) sites per HUVEC, i.e. 10-100-fold fewer than previously reported. Although HK binding is unaffected by the presence of a physiological concentration of prekallikrein, factor XI abrogates HK binding to HUVEC in a concentration-dependent manner. Disruption of the naturally occurring complex between factor XI and HK by the addition of a 31-amino acid peptide mimicking the factor XI-binding site on HK restored HK binding to HUVEC. Furthermore, HK inhibited thrombin-stimulated von Willebrand factor release by HUVEC but not thrombin receptor activation peptide (SFLLRN-amide)-stimulated von Willebrand factor release. Factor XI restored the ability of thrombin to stimulate von Willebrand factor release in the presence of low HK concentrations. These results suggest that free HK, or HK in complex with prekallikrein but not in complex with factor XI, interacts with the endothelium and can maintain endothelial cell quiescence by preventing endothelial stimulation by thrombin.	Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Med, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL046213, P01HL056914, R01HL070683] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46213, HL56914, HL64943, HL70683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, BLOOD, V85, P2078, DOI 10.1182/blood.V85.8.2078.bloodjournal8582078; Baglia FA, 1996, J BIOL CHEM, V271, P3652; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAGLIA FA, 1989, BLOOD, V74, P244; Baird TR, 2002, J BIOL CHEM, V277, P28498, DOI 10.1074/jbc.M203427200; Baird TR, 2002, J BIOL CHEM, V277, P38462, DOI 10.1074/jbc.M205902200; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; Colman R. W., 2001, HEMOSTASIS THROMBOSI, P103; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; Dedio J, 1998, J IMMUNOL, V160, P3534; FISHER CA, 1982, BLOOD, V59, P963; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Guo YL, 2001, ARTERIOSCL THROM VAS, V21, P1427, DOI 10.1161/hq0901.095277; Hasan AAK, 1996, CIRCULATION, V94, P517, DOI 10.1161/01.CIR.94.3.517; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JACOBSEN S, 1967, BRIT J PHARM CHEMOTH, V29, P25, DOI 10.1111/j.1476-5381.1967.tb01935.x; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2001, BIOL CHEM, V382, P71, DOI 10.1515/BC.2001.012; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; PURI RN, 1991, BLOOD, V77, P500; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; Schmaier AH, 1999, THROMB HAEMOSTASIS, V82, P226; SCOTT CF, 1985, J BIOL CHEM, V260, P856; Scott CF, 1997, THROMB HAEMOSTASIS, V77, P109; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; WIGGINS RC, 1983, J BIOL CHEM, V258, P8963; Zhao YQ, 2001, AM J PHYSIOL-HEART C, V280, pH1821, DOI 10.1152/ajpheart.2001.280.4.H1821	57	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20618	20623		10.1074/jbc.M300224200	http://dx.doi.org/10.1074/jbc.M300224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663668	hybrid			2022-12-25	WOS:000183230500023
J	Detich, N; Hamm, S; Just, G; Knox, JD; Szyf, M				Detich, N; Hamm, S; Just, G; Knox, JD; Szyf, M			The methyl donor S-adenosylmethionine inhibits active demethylation of DNA - A candidate novel mechanism for the pharmacological effects of S-adenosylmethionine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; METHYLENETETRAHYDROFOLATE REDUCTASE; GENE; HYPOMETHYLATION; EXPRESSION; PROMOTER; LIVER; RAT; DIFFERENTIATION; NEOPLASIA	S-Adenosylmethionine (AdoMet) is the methyl donor of numerous methylation reactions. The current model is that an increased concentration of AdoMet stimulates DNA methyltransferase reactions, triggering hypermethylation and protecting the genome against global hypomethylation, a hallmark of cancer. Using an assay of active demethylation in HEK 293 cells, we show that AdoMet inhibits active demethylation and expression of an ectopically methylated CMV-GFP (green fluorescent protein) plasmid in a dose-dependent manner. The inhibition of GFP expression is specific to methylated GFP; AdoMet does not inhibit an identical but unmethylated CMV-GFP plasmid. S-Adenosylhomocysteine (AdoHcy), the product of methyltransferase reactions utilizing AdoMet does not inhibit demethylation or expression of CMV-GFP. In vitro, AdoMet but not AdoHcy inhibits methylated DNA-binding protein 2/DNA demethylase as well as endogenous demethylase activity extracted from HEK 293, suggesting that AdoMet directly inhibits demethylase activity, and that the methyl residue on AdoMet is required for its interaction with demethylase. Taken together, our data support an alternative mechanism of action for AdoMet as an inhibitor of intracellular demethylase activity, which results in hypermethylation of DNA.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YG, Canada; McGill Univ, Dept Chem, Montreal, PQ H3G 1YG, Canada	McGill University; McGill University	Szyf, M (corresponding author), 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Cai JX, 1998, CANCER RES, V58, P1444; Caudill MA, 2001, J NUTR, V131, P2811, DOI 10.1093/jn/131.11.2811; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1988, CANCER RES, V48, P1159; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; Fuso A, 2001, FEBS LETT, V508, P337, DOI 10.1016/S0014-5793(01)03030-7; GARCEA R, 1989, CARCINOGENESIS, V10, P1183, DOI 10.1093/carcin/10.7.1183; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; PASCALE R, 1991, CANCER LETT, V56, P259, DOI 10.1016/0304-3835(91)90011-6; Pascale RM, 2002, ALCOHOL, V27, P193, DOI 10.1016/S0741-8329(02)00227-6; POGRIBNY IP, 1995, CARCINOGENESIS, V16, P2863, DOI 10.1093/carcin/16.11.2863; Poirier LA, 2002, J NUTR, V132, p2336S, DOI 10.1093/jn/132.8.2336S; Potter JD, 2002, J NUTR, V132, p2410S, DOI 10.1093/jn/132.8.2410S; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Sibani S, 2002, CARCINOGENESIS, V23, P61, DOI 10.1093/carcin/23.1.61; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; Steinmetz KL, 1998, CARCINOGENESIS, V19, P1487, DOI 10.1093/carcin/19.8.1487; Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849; Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; Szyf Moshe, 2002, Methods Mol Biol, V200, P155; Watson WH, 1999, BIOCHEM J, V342, P21, DOI 10.1042/0264-6021:3420021; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	42	153	159	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20812	20820		10.1074/jbc.M211813200	http://dx.doi.org/10.1074/jbc.M211813200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12676953	hybrid			2022-12-25	WOS:000183230500049
J	Okada, Y; Montero, A; Zhang, XX; Sobue, T; Lorenzo, J; Doetschman, T; Coffin, JD; Hurley, MM				Okada, Y; Montero, A; Zhang, XX; Sobue, T; Lorenzo, J; Doetschman, T; Coffin, JD; Hurley, MM			Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; CELL-FORMATION; MULTINUCLEATED CELLS; INHIBITORY FACTOR; DIFFERENTIATION FACTOR; OSTEOTROPIC HORMONES; OSTEOBLASTIC CELLS; RIBONUCLEIC-ACID; MESSENGER-RNA	Fibroblast growth factor (FGF)-2 and parathyroid hormone (PTH) are potent inducers of osteoclast (OCL) formation, and PTH increases FGF-2 mRNA and protein expression in osteoblasts. To elucidate the role of endogenous FGF-2 in PTH responses, we examined PTH-induced OCL formation in bone marrow cultures from wild type and mice with a disruption of the Fgf2 gene. FGF-2-induced OCL formation was similar in marrow culture from both genotypes. In contrast, PTH-stimulated OCL formation in bone marrow cultures or cocultures of osteoblast-spleen cells from Fgf2 -/- mice was significantly impaired. PTH increased RANKL mRNA expression in osteoblasts cultures from both genotypes. After 6 days of treatment, osteoprotegerin protein in cell supernatants was 40-fold higher in vehicle-treated and 30-fold higher in PTH-treated co-cultures of osteoblast and spleen cells from Fgf2 -/- mice compared with Fgf2 -/- mice. However, a neutralizing antibody to osteoprotegerin did not rescue reduced OCL formation in response to PTH. Injection of PTH caused hypercalcemia in Fgf2 -/- but not Fgf2 -/- mice. We conclude that PTH stimulates OCL formation and bone resorption in mice in part by endogenous FGF-2 synthesis by osteoblasts. Because RANKL- and interleukin-11-induced OCL formation was also reduced in bone marrow cultures from Fgf2 -/- mice, we further conclude that endogenous FGF-2 is necessary for maximal OCL formation by multiple bone resorbing factors.	Univ Connecticut, Ctr Hlth, Div Endocrinol & Metab, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Dept Mol Genet, Farmington, CT 06030 USA; Univ Montana, Dept Pharmaceut Sci, Sch Pharm & Allied Hlth Sci, Missoula, MT 59812 USA	University of Connecticut; University of Connecticut; University of Montana System; University of Montana	Hurley, MM (corresponding author), Univ Connecticut, Ctr Hlth, Div Endocrinol & Metab, Dept Med, Farmington, CT 06030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046025] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-46025] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; BRUNERBRUNNER G, 1993, BLOOD, V3, P631; CHAPOTEAU E, 1993, CLIN CHEM, V39, P1820; Chikazu D, 2000, J BIOL CHEM, V275, P31444, DOI 10.1074/jbc.M910132199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Fitzpatrick Lorraine A., 1996, P339; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1994, BLOOD, V83, P907; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HATTERSLEY G, 1990, J CELL PHYSIOL, V142, P201, DOI 10.1002/jcp.1041420125; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Hock J. M., 2001, PARATHYROIDS BASIC C, P183; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756-3282(97)00292-5; Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776; HURLEY MM, 1994, J BIOL CHEM, V269, P9392; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Kodama Y, 1998, J BONE MINER RES, V13, P1370, DOI 10.1359/jbmr.1998.13.9.1370; KURIHARA N, 1990, J IMMUNOL, V144, P4226; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo-120-6-2326; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; Miyamoto A, 1998, BIOCHEM BIOPH RES CO, V242, P703, DOI 10.1006/bbrc.1997.8046; Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756-3282(00)00355-0; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; MURRILLS RJ, 1989, J BONE MINER RES, V4, P259; Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601; Oliver LJ, 1990, GROWTH FACTORS, V3, P231, DOI 10.3109/08977199009043907; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; Rifas L, 1999, CALCIFIED TISSUE INT, V64, P1, DOI 10.1007/s002239900570; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; ROODMAN GD, 1985, P NATL ACAD SCI USA, V82, P8213, DOI 10.1073/pnas.82.23.8213; ROODMAN GD, 1995, CALCIFIED TISSUE INT, V56, pS22, DOI 10.1007/BF03354645; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAKAHASHI S, 1995, ENDOCRINOLOGY, V136, P1441, DOI 10.1210/en.136.4.1441; WILSON EL, 1991, BLOOD, V77, P954; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Yang XH, 2002, BIOCHEM BIOPH RES CO, V290, P42, DOI 10.1006/bbrc.2001.6176; Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	55	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21258	21266		10.1074/jbc.M302113200	http://dx.doi.org/10.1074/jbc.M302113200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665515	hybrid			2022-12-25	WOS:000183230500104
J	Peisajovich, SG; Gallo, SA; Blumenthal, R; Shai, Y				Peisajovich, SG; Gallo, SA; Blumenthal, R; Shai, Y			C-terminal octylation rescues an inactive T20 mutant - Implications for the mechanism of HIV/simian immunodeficiency virus-induced membrane fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; HIV-1 ENTRY; INFLUENZA HEMAGGLUTININ; 3(10)-HELICAL PEPTIDES; TRANSMEMBRANE PROTEIN; ACTIVE CONFORMATION; VIRAL FUSION; SIV GP41; ECTODOMAIN; INHIBITION	T20, a synthetic peptide corresponding to a C-terminal segment of the envelope glycoprotein (gp41) of human and simian immunodeficiency viruses, is a potent inhibitor of viral infection. We report here that C-terminal octylation of simian immunodeficiency virus gp41-derived T20 induces a significant increase in its inhibitory potency. Furthermore, when C-terminally octylated, an otherwise inactive mutant in which the C-terminal residues GNWF were replaced by ANAA has potency similar to that of the wild type T20. This effect cannot be explained by a trivial inhibitory effect of the octyl group added to the peptides, because the N-terminally octylated peptides have the same activity as the non-octylated parent peptides. The effects caused by octylation on the oligomerization, secondary structure, and membrane-interaction properties of the peptides were investigated. Our results shed light on the mechanism of inhibition by T20 and provide experimental support for the existence of a pre-hairpin intermediate.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Lab Expt & Computat Biol, NIH, Ft Detrick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Peisajovich, Sergio/C-6641-2011	Gallo, Stephen/0000-0001-6043-2153	NATIONAL CANCER INSTITUTE [ZIABC008303, Z01BC008303] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Crisma M, 2002, BIOPOLYMERS, V64, P236, DOI 10.1002/bip.10178; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dehner A, 2001, J AM CHEM SOC, V123, P6678, DOI 10.1021/ja010635d; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Formaggio F, 2000, CHEM-EUR J, V6, P4498, DOI 10.1002/1521-3765(20001215)6:24<4498::AID-CHEM4498>3.3.CO;2-W; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; George C, 1996, PEPTIDE RES, V9, P315; Hackeng TM, 1999, P NATL ACAD SCI USA, V96, P10068, DOI 10.1073/pnas.96.18.10068; HARTER C, 1989, J BIOL CHEM, V264, P6459; Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001; Jin BS, 2000, AIDS RES HUM RETROV, V16, P1797, DOI 10.1089/08892220050195757; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Otaka A, 2002, ANGEW CHEM INT EDIT, V41, P2938, DOI 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J; Pereira FB, 1999, CHEM PHYS LIPIDS, V103, P11, DOI 10.1016/S0009-3084(99)00087-0; Pispisa B, 2002, BIOPOLYMERS, V67, P247, DOI 10.1002/bip.10118; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	41	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21012	21017		10.1074/jbc.M212773200	http://dx.doi.org/10.1074/jbc.M212773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12646555	hybrid			2022-12-25	WOS:000183230500074
J	Quinlivan, EP; Roje, S; Basset, G; Shachar-Hill, Y; Gregory, JF; Hanson, AD				Quinlivan, EP; Roje, S; Basset, G; Shachar-Hill, Y; Gregory, JF; Hanson, AD			The folate precursor p-aminobenzoate is reversibly converted to its glucose ester in the plant cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; GTP-CYCLOHYDROLASE-I; SACCHAROMYCES-CEREVISIAE; LIQUID-CHROMATOGRAPHY; CARBON METABOLISM; FOLIC-ACID; BIOSYNTHESIS; SYNTHASE; BIOTRANSFORMATION; 4-AMINOBENZOATE	Plants synthesize p-aminobenzoate (pABA) in chloroplasts and use it for folate synthesis in mitochondria. It has generally been supposed that pABA exists as the free acid in plant cells and that it moves between organelles in this form. Here we show that fruits and leaves of tomato and leaves of a diverse range of other plants have a high capacity to convert exogenously supplied pABA to its beta-D-glucopyranosyl ester (pABA-Glc), whereas yeast and Escherichia coli do not. High performance liquid chromatography analysis indicated that much of the endogenous pABA in fruit and leaf tissues is esterified and that the total pool of pABA ( free plus esterified) varies greatly between tissues (from 0.2 to 11 nmol g(-1) of fresh weight). UDP-glucose: pABA glucosyltransferase activity was readily detected in fruit and leaf extracts, and the reaction was found to be freely reversible. p-Aminobenzoic acid beta-D-glucopyranosyl ester esterase activity was also detected in extracts. Subcellular fractionation indicated that the glucosyltransferase and esterase activities are predominantly if not solely cytosolic. Taken together, these results show that reversible formation of pABA-Glc in the cytosol is interposed between pABA production in chloroplasts and pABA consumption in mitochondria. As pABA is a hydrophobic weak acid, its uncharged form is membrane-permeant, and its anion is consequently prone to distribute itself spontaneously among subcellular compartments according to their pH. Esterification of pABA may eliminate such errant behavior and provide a readily reclaimable storage form of pABA as well as a substrate for membrane transporters.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Michigan State University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu	Quinlivan, Eoin P/B-8454-2008; Shachar-Hill, Yair/B-6165-2013; Quinlivan, Eoin/AAJ-1979-2021	Quinlivan, Eoin P/0000-0002-0908-1762; Shachar-Hill, Yair/0000-0001-8793-5084; Quinlivan, Eoin/0000-0002-0908-1762; Roje, Sanja/0000-0002-6302-5382; Gregory, Jesse/0000-0002-9976-2085				Appendino G, 2000, FITOTERAPIA, V71, P258, DOI 10.1016/S0367-326X(99)00168-9; BACHER A, 1973, Z NATURFORSCH C, VC 28, P614; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Bouis HE, 2002, J NUTR, V132, p491S, DOI 10.1093/jn/132.3.491S; Cherest H, 2000, J BIOL CHEM, V275, P14056, DOI 10.1074/jbc.275.19.14056; Ciucani G, 2002, PEST MANAG SCI, V58, P467, DOI 10.1002/ps.484; CLINE K, 1986, J BIOL CHEM, V261, P4804; COHEN FS, 1977, J MEMBRANE BIOL, V37, P361, DOI 10.1007/BF01940940; Cossins E, 2000, CAN J BOT, V78, P691, DOI 10.1139/cjb-78-6-691; COSSINS EA, 1987, BIOCH PLANTS, V11, P317, DOI DOI 10.1016/B978-0-12-675411-7.50015-X; COWAN IR, 1982, AUST J PLANT PHYSIOL, V9, P489, DOI 10.1071/PP9820489; DAWSON RMC, 1986, DATA BIOCH RES, P116; DONLON BA, 1995, APPL ENVIRON MICROB, V61, P3889, DOI 10.1128/AEM.61.11.3889-3893.1995; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; ELLIS GP, 1966, CHEM ING, V22, P902; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; Furuya T, 1998, PHYTOCHEMISTRY, V49, P109, DOI 10.1016/S0031-9422(97)01016-9; Gambonnet B, 2001, J SCI FOOD AGR, V81, P835, DOI 10.1002/jsfa.870; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; GREGORY JF, 1984, J NUTR, V114, P341, DOI 10.1093/jn/114.2.341; GUANGHUA L, 2001, CHEM J INTERNET, V3, P74; Hampele IC, 1997, J MOL BIOL, V268, P21, DOI 10.1006/jmbi.1997.0944; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; KITAMURA M, 1960, J BIOCHEM-TOKYO, V47, P60, DOI 10.1093/oxfordjournals.jbchem.a127040; LEZNICKI AJ, 1988, PLANT PHYSIOL, V88, P1481, DOI 10.1104/pp.88.4.1481; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Nardese V, 1996, BIOCHEM BIOPH RES CO, V218, P273, DOI 10.1006/bbrc.1996.0048; Panjaitan TS, 2000, JPC-J PLANAR CHROMAT, V13, P114; Pfeiffer CM, 1997, J AGR FOOD CHEM, V45, P407, DOI 10.1021/jf960633q; RAPPOLD H, 1976, Z NATURFORSCH C, V31, P285; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Rebeille F, 1999, PR PHYT SOC, V42, P53; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; Siebert M, 1996, PLANT PHYSIOL, V112, P811, DOI 10.1104/pp.112.2.811; Syahrani A, 1999, PHYTOCHEMISTRY, V51, P615, DOI 10.1016/S0031-9422(99)00112-0; Tissot G, 1997, BIOCHEM J, V323, P179, DOI 10.1042/bj3230179; Trossat C, 1996, PLANT PHYSIOL, V111, P965, DOI 10.1104/pp.111.4.965; VISWANATHAN VK, 1995, J BACTERIOL, V177, P5918, DOI 10.1128/jb.177.20.5918-5923.1995; WILSON SD, 1984, ANAL BIOCHEM, V142, P529, DOI 10.1016/0003-2697(84)90502-5; Wink M, 1997, ADV BOT RES, V25, P141, DOI 10.1016/S0065-2296(08)60151-2	43	51	54	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20731	20737		10.1074/jbc.M302894200	http://dx.doi.org/10.1074/jbc.M302894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668665	hybrid			2022-12-25	WOS:000183230500039
J	Shen, YL; Tang, XF; Matsui, I				Shen, YL; Tang, XF; Matsui, I			Subunit interaction and regulation of activity through terminal domains of the family D DNA polymerase from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SACCHAROMYCES-CEREVISIAE; HYPERTHERMOPHILIC ARCHAEON; POL-EPSILON; REPLICATION; FURIOSUS; HOMOLOG; DELTA	Functions of the terminal domains of the family D DNA polymerase from Pyrococcus horikoshii (PolDPho) were analyzed by making and characterizing various truncated proteins. Based on a co-expression vector developed previously ( Shen, Y., Musti, K., Hiramoto, M., Kikuchi, H., Kawabayashi, Y., and Matsui, I. ( 2001) J. Biol. Chem. 276, 27376 - 27383), 25 vectors for terminal truncated proteins were constructed. The expressed proteins were characterized in terms of thermostability, subunit interaction, and polymerization and 3'-5' exonuclease activities. The carboxyl-terminal ( 1255 - 1332) of the large subunit (DP2Pho) and two regions, the 201 - 260 and 599 - 622, of the small subunit (DP1Pho) were found to be critical for the complex formation, and probable subunit interaction of PolDPho. The amino-terminal ( 1 300) of DP2Pho is essential for the folding of PolDPho and is likely the oligomerization domain of PolDPho. A short region at the extreme C-terminal of DP2Pho ( from 1385 to 1434) and the N-terminal of DP1Pho( 1 - 200), which forms a stable protein, are not absolutely necessary for either polymerization or the 3'-5' exonuclease activity. We identified a possible regulatory role of DP1Pho( 1 - 200) for the 3'-5' exonuclease. Deletion of DP1Pho( 1 - 200) increased the exonuclease and DNA binding activities of PolDPho. Adding DP1Pho( 1 - 200) to the truncated protein suppressed the elevated exonuclease activity. We also constructed and analyzed three internal deletion mutants and two site-directed mutants in the region of the putative zinc finger motif ( cysteine cluster II) of DP2Pho at the COOH-terminal. We found that the internal region of the zinc finger motif is critical for the 3'-5' exonuclease, but is dispensable for the DNA polymerization.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan.	ik-matsui@aist.go.jp						Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Connelly JC, 2002, TRENDS BIOCHEM SCI, V27, P410, DOI 10.1016/S0968-0004(02)02144-8; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; FAOUD TI, 2003, J BIOL CHEM, V278, P3145; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; Gueguen Y, 2001, EUR J BIOCHEM, V268, P5961, DOI 10.1046/j.0014-2956.2001.02550.x; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Ishino Y, 1998, J BACTERIOL, V180, P2232, DOI 10.1128/JB.180.8.2232-2236.1998; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; Kawashima T, 1999, P JPN ACAD B-PHYS, V75, P213, DOI 10.2183/pjab.75.213; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; Motz M, 2002, J BIOL CHEM, V277, P16179, DOI 10.1074/jbc.M107793200; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Robb FT, 2001, METHOD ENZYMOL, V330, P134; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Shen YL, 2001, J BIOL CHEM, V276, P27376, DOI 10.1074/jbc.M011762200; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	38	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21247	21257		10.1074/jbc.M212286200	http://dx.doi.org/10.1074/jbc.M212286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654919	hybrid			2022-12-25	WOS:000183230500103
J	Wu, TY; Yankovskaya, V; McIntire, WS				Wu, TY; Yankovskaya, V; McIntire, WS			Cloning, sequencing, and heterologous expression of the murine peroxisomal flavoprotein, N-1-acetylated polyamine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-CRESOL METHYLHYDROXYLASE; MONOAMINE-OXIDASE; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; CEREBRAL-ISCHEMIA; ESCHERICHIA-COLI; CELL-DEATH; RAT-LIVER; ANALOG; IDENTIFICATION; OXIDATION	The aminoacyl sequences of three regions of pure bovine N-1-acetylated polyamine oxidase (PAO) were obtained and used to search GenBank(TM). This led to the cloning and sequencing of a complete coding cDNA for murine PAO (mPAO) and the 5'-truncated coding region of the bovine pao (bpao) gene. A search of GenBank(TM) indicated that mpao maps to murine chromosome 7 as seven exons. The translated amino acid sequences of mpao and bpao have a - Pro-Arg-Leu peroxisomal targeting signal at the extreme C termini. A beta-alpha-beta FAD-binding motif is present in the N-terminal portion of mPAO. This and several other regions of mPAO and bPAO are highly similar to corresponding sections of other flavoprotein amine oxidases, although the overall identity of aligned sequences indicates that PAO represents a new subfamily of flavoproteins. A fragment of mpao was used as a probe to establish the relative transcription levels of this gene in various mature murine tissues and murine embryonic and breast tissues at different developmental stages. An Escherichia coli expression system has been developed for manufacturing mPAO at a reasonable level. The mPAO so produced was purified to homogeneity and characterized. It was demonstrated definitively that PAO oxidizes N-1-acetylspermine to spermidine and 3-acetamidopropanal and that it also oxidizes N-1-acetylspermidine to putrescine and 3-acetamidopropanal. Thus, this is the classical polyamine oxidase (EC 1.5.3.11) that is defined as the enzyme that oxidizes these N-1-acetylated polyamines on the exo-side of their N-4-amino groups. This enzyme is distinguishable from the plant polyamine oxidase that oxidizes spermine on the endo-side of the N-4-nitrogen. It differs also from mammalian spermine oxidase that oxidizes spermine ( but not N-1-acetylspermine or N-1-acetylspermidine) at the exo-carbon of its N-4-amino group. This report provides details of the biochemical, spectral, oxidation-reduction, and steady-state kinetic properties of pure mPAO.	Dept Vet Affairs Med Ctr, Div Mol Biol, No Calif Inst Res & Educ, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Northern California Institute for Research & Education; University of California System; University of California San Francisco	McIntire, WS (corresponding author), Dept Vet Affairs Med Ctr, Div Mol Biol, No Calif Inst Res & Educ, San Francisco, CA 94121 USA.							BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bergeron RJ, 2000, CANCER RES, V60, P4433; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Bergeron RJ, 2000, J MED CHEM, V43, P224, DOI 10.1021/jm990375z; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; BITONTI AJ, 1990, J BIOL CHEM, V265, P382; BOLKENIUS FN, 1989, BIOL CHEM H-S, V370, P525, DOI 10.1515/bchm3.1989.370.1.525; Chopra S, 1998, BIOCHEM PHARMACOL, V55, P1119, DOI 10.1016/S0006-2952(97)00601-1; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; EDMONDSON DE, 1995, XENOBIOTICA, V25, P735, DOI 10.3109/00498259509061889; Efimov I, 2001, BIOCHEMISTRY-US, V40, P2155, DOI 10.1021/bi001644m; Engst S, 1999, BIOCHEMISTRY-US, V38, P16620, DOI 10.1021/bi991273d; Ferioli ME, 1999, BIOCHEM PHARMACOL, V58, P1907, DOI 10.1016/S0006-2952(99)00280-4; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; Gasparian V K, 1995, Biokhimiia, V60, P1632; GASPARYAN VK, 1991, BIOKHIMIYA, V55, P1223; Goudar CT, 1999, BBA-PROTEIN STRUCT M, V1429, P377, DOI 10.1016/S0167-4838(98)00247-7; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HATCHER J, 2000, SOC NEUR ABSTR, V26; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Holt A, 1997, ANAL BIOCHEM, V244, P384, DOI 10.1006/abio.1996.9911; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HOLTTA E, 1983, METHOD ENZYMOL, V94, P306; HOUEN G, 1994, ACTA CHEM SCAND, V48, P52, DOI 10.3891/acta.chem.scand.48-0052; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Hunter K J, 1998, Methods Mol Biol, V79, P119; ISHIZUKA H, 1993, J GEN MICROBIOL, V139, P425, DOI 10.1099/00221287-139-3-425; Ivanova S, 2002, P NATL ACAD SCI USA, V99, P5579, DOI 10.1073/pnas.082609299; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Kramer DL, 1999, CANCER RES, V59, P1278; Lindsay GS, 1999, BIOCHEM J, V337, P83, DOI 10.1042/0264-6021:3370083; Mank-Seymour AR, 1998, CLIN CANCER RES, V4, P2003; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MCINTIRE W, 1985, BIOCHEM J, V228, P325, DOI 10.1042/bj2280325; McIntire W. S., 1993, COPPER CONTAINING AM, P97; Morgan DML, 1998, BIOCHEM SOC T, V26, P586, DOI 10.1042/bst0260586; Mullis K B, 1991, PCR Methods Appl, V1, P1; Murray-Stewart T, 2002, BIOCHEM J, V368, P673, DOI 10.1042/BJ20021587; Nishikawa M, 2000, FEBS LETT, V476, P150, DOI 10.1016/S0014-5793(00)01708-7; NISHIOKA K, 1993, CANCER RES, V53, P2689; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; Rao AM, 2000, J NEUROCHEM, V74, P1106; Roh JH, 2000, BIOCHEM BIOPH RES CO, V268, P293, DOI 10.1006/bbrc.2000.2113; Sablin SO, 1998, J BIOL CHEM, V273, P14074, DOI 10.1074/jbc.273.23.14074; Sablin SO, 1998, EUR J BIOCHEM, V253, P270, DOI 10.1046/j.1432-1327.1998.2530270.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILLING B, 1995, BBA-GEN SUBJECTS, V1243, P529, DOI 10.1016/0304-4165(94)00183-X; Seiler N, 1995, PROG BRAIN RES, V106, P333; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tavladoraki P, 1998, FEBS LETT, V426, P62, DOI 10.1016/S0014-5793(98)00311-1; TSUKADA T, 1988, INT J BIOCHEM, V20, P695, DOI 10.1016/0020-711X(88)90164-4; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wallace HM, 2000, CLIN CANCER RES, V6, P3657; Wallace HM, 1998, BIOCHEM SOC T, V26, P569, DOI 10.1042/bst0260569; Wang YL, 2001, CANCER RES, V61, P5370; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P319; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Zoli M, 1996, MOL BRAIN RES, V38, P122, DOI 10.1016/0169-328X(95)00339-T; [No title captured]	69	97	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20514	20525		10.1074/jbc.M302149200	http://dx.doi.org/10.1074/jbc.M302149200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12660232	hybrid			2022-12-25	WOS:000183230500011
J	Li, GM; Alexander, EA; Schwartz, JH				Li, GM; Alexander, EA; Schwartz, JH			Syntaxin isoform specificity in the regulation of renal H+-ATPase exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; IDENTIFICATION; SECRETION; DOMAIN	Intercalated and inner medullary collecting duct (IMCD) cells of the kidney mediate the transport of H+ by a plasma membrane H+-ATPase. The rate of H+ transport in these cells is regulated by exocytic insertion of H+-ATPase-laden vesicles into the apical membrane. We have shown that the exocytic insertion of proton pumps (H+-ATPase) into the apical membrane of rat IMCD cells, in culture, involves SNARE proteins (syntaxin (synt), SNAP-23, and VAMP). The membrane fusion complex observed in IMCD cells with the induction of proton pump exocytosis not only included these SNAREs but also the H+-ATPase. Based on these observations, we suggested that the targeting of these vesicles to the apical membrane is mediated by an interaction between the H+-ATPase and a specific t-SNARE. To evaluate this hypothesis, we utilized a "pull-down" assay in which we identified, by Western analysis, the proteins in a rat kidney medullary homogenate that complexed with glutathione S-transferase (GST) fusion syntaxin isoforms attached to Sepharose 4B-glutathione beads. The syntaxin isoforms employed were 1A, 1B, 2, 4, 5, and also 1A that was truncated to exclude the H3 SNARE binding domain (synt-1ADeltaH3). All full-length syntaxin isoforms formed complexes with SNAP-23 and VAMP. Neither GST nor synt-1ADeltaH3 formed complexes with these SNAREs. H+-ATPase (subunits E, a, and c) bound to syntaxin-1A and to a lesser extent to synt-1B but not to synt-1ADeltaH3 or synt-2, -4, and -5. In cultured IMCD cells transfected to express syntaxin truncated for the membrane binding domain (synt-DeltaC), expression of synt-1ADeltaC, but not synt-4DeltaC, inhibited H+-ATPase exocytosis. In conclusion, because all full-length syntaxins examined bound VAMP-2 and SNAP-23, but only non-H3-truncated syntaxin-1 bound H+-ATPase, and synt-1ADeltaC expression by intact IMCD cells inhibited H+-ATPase exocytosis, it is likely that the H+-ATPase binds directly to the H3 domain of syntaxin-1 and not through VAMP-2 or SNAP-23. Interaction between the syntaxin-1A and H+-ATPase is important in the targeted exocytosis of the proton pump to the apical membrane of intercalated cells.	Boston Univ, Med Ctr, Renal Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Schwartz, JH (corresponding author), Evans Biomed Res Ctr, 650 Albany St, Boston, MA 02118 USA.	jhsch@bu.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Alexander, Edward/0000-0002-6659-8186; Li, Guangmu/0000-0001-7115-0928	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059529] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-59529] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Awqati Q, 1985, Soc Gen Physiol Ser, V39, P149; Alexander EA, 1999, AM J PHYSIOL-CELL PH, V276, pC758, DOI 10.1152/ajpcell.1999.276.3.C758; Alexander EA, 1997, AM J PHYSIOL-RENAL, V273, pF1054, DOI 10.1152/ajprenal.1997.273.6.F1054; Banerjee A, 2001, AM J PHYSIOL-CELL PH, V280, pC775; Banerjee A, 1999, J BIOL CHEM, V274, P26518, DOI 10.1074/jbc.274.37.26518; Banfield DK, 2001, TRENDS BIOCHEM SCI, V26, P67, DOI 10.1016/S0968-0004(00)01744-8; Breton S, 2002, AM J PHYSIOL-RENAL, V282, pF523, DOI 10.1152/ajprenal.00128.2001; Breton S, 2000, AM J PHYSIOL-RENAL, V278, pF717, DOI 10.1152/ajprenal.2000.278.5.F717; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; FOTGAC M, 1999, J BIOL CHEM, V274, P12951; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408	21	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19791	19797		10.1074/jbc.M212250200	http://dx.doi.org/10.1074/jbc.M212250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651853	hybrid			2022-12-25	WOS:000183078000030
J	Lusa, S; Heino, S; Ikonen, E				Lusa, S; Heino, S; Ikonen, E			Differential mobilization of newly synthesized cholesterol and biosynthetic sterol precursors from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; SERUM-CHOLESTEROL; CHAPERONE COMPLEX; HUMAN FIBROBLASTS; CORONARY PATIENTS; TRANSPORT; REDUCTASE; PROTEIN	Previous work demonstrates that the biosynthetic precursor of cholesterol, desmosterol, is released from cells and that its efflux to high density lipoprotein or phosphatidylcholine vesicles is greater than that of newly synthesized cholesterol (Johnson, W. J., Fischer, R. T., Phillips, M. C., and Rothblat, G. H. (1995) J. Biol. Chem. 270, 25037-25046). Here we report that the release of individual precursor sterols varies with the efflux of newly synthesized zymosterol being greater than that of lathosterol and both exceeding that of newly synthesized cholesterol when using either methyl-beta-cyclodextrin or complete serum as acceptors. The transfer of newly synthesized lathosterol to methyl-beta-cyclodextrin was inhibited by actin polymerization but not by Golgi disassembly whereas that of newly synthesized cholesterol was inhibited by both conditions. Newly synthesized lathosterol associated with cellular detergent-resistant membranes more rapidly than newly synthesized cholesterol. Upon efflux to serum, newly synthesized cholesterol precursors associated with both high and low density lipoproteins. Stimulation of the formation of direct endoplasmic reticulum-plasma membrane contacts was accompanied by enhanced efflux of newly synthesized lathosterol but not of newly synthesized cholesterol to serum acceptors. The data indicate that the efflux of cholesterol precursors differs not only from that of cholesterol but also from each other, with the more polar zymosterol being more avidly effluxed. Moreover, the results suggest that the intracellular routing of cholesterol precursors differs from that of newly synthesized cholesterol and implicates a potential role for the actin cytoskeleton and endoplasmic reticulum-plasma membrane contacts in the efflux of lathosterol.	Natl Publ Hlth Inst, Biomedicum Helsinki, Dept Mol Med, Helsinki 00251, Finland	Finland National Institute for Health & Welfare; University of Helsinki	Ikonen, E (corresponding author), Natl Publ Hlth Inst, Biomedicum Helsinki, Dept Mol Med, POB 104,Haartmaninkatu 8, Helsinki 00251, Finland.							Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Berge KE, 2002, J LIPID RES, V43, P486; BJORKHEM I, 1987, J LIPID RES, V28, P1137; Brunetti-Pierri N, 2002, AM J HUM GENET, V71, P952, DOI 10.1086/342668; BURKI E, 1987, J LIPID RES, V28, P1199; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gylling H, 2002, J LIPID RES, V43, P1472, DOI 10.1194/jlr.M200155-JLR200; Gylling H, 2002, ATHEROSCLEROSIS, V160, P477, DOI 10.1016/S0021-9150(01)00608-6; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hogenboom S, 2002, J LIPID RES, V43, P90; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Kim JH, 2001, J BIOL CHEM, V276, P18153, DOI 10.1074/jbc.M101661200; KOIVISTO PVI, 1988, SCAND J GASTROENTERO, V23, P422, DOI 10.3109/00365528809093889; Krisans SK, 1996, ANN NY ACAD SCI, V804, P142, DOI 10.1111/j.1749-6632.1996.tb18614.x; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusa S, 2001, J CELL SCI, V114, P1893; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Miettinen TA, 2002, ATHEROSCLEROSIS, V164, P147, DOI 10.1016/S0021-9150(02)00054-0; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Phillips JE, 1998, J LIPID RES, V39, P2459; REINHART MP, 1987, J BIOL CHEM, V262, P9649; Rothblat GH, 2002, ATHEROSCLEROSIS, V163, P1, DOI 10.1016/S0021-9150(01)00713-4; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANHANEN HT, 1993, J LIPID RES, V34, P1535; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19844	19851		10.1074/jbc.M212503200	http://dx.doi.org/10.1074/jbc.M212503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657643	hybrid			2022-12-25	WOS:000183078000036
J	Ellerbroek, SM; Wennerberg, K; Burridge, K				Ellerbroek, SM; Wennerberg, K; Burridge, K			Serine phosphorylation negatively regulates RhoA in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; BINDING PROTEIN; CELL-ADHESION; ACTIVATION; INTEGRIN; GTPASES; RAC; MIGRATION; MYOSIN	Previous work indicates that RhoA phosphorylation on Ser(188) by cAMP or cGMP-dependent kinases inhibits its activity. However, these studies lacked the possibility to directly study phosphorylated RhoA activity in vivo. Therefore, we created RhoA proteins containing phosphomimetic residues in place of the cAMP/cGMP-dependent kinase phosphorylation site. RhoA phosphorylation or phosphomimetic substitution did not affect Rho guanine nucleotide exchange factor, GTPase activating protein, or geranylgeranyl transferase activity in vitro but promoted binding to the Rho guanine-dissociation inhibitor as measured by exchange factor competition assays. The in vitro similarities between RhoA phosphomimetic proteins and phosphorylated RhoA allowed us to study function of phosphorylated RhoA in vivo. RhoA phosphomimetic proteins display depressed GTP loading when transiently expressed in NIH 3T3 cells. Stable-expressing RhoA and RhoA(S188A) clones spread significantly slower than mock-transfected or RhoA(S188E) clones. RhoA(S188A) clones were protected from the morphological effects of a cAMP agonist, whereas phosphomimetic clones exhibit stress fiber disassembly similar to control cells. Together, these data provide in vivo evidence that addition of a charged group to Ser(188) upon phosphorylation negatively regulates RhoA activity and indicates that this occurs through enhanced Rho guanine-dissociation inhibitor interaction rather than direct perturbation of guanine nucleotide exchange factor, GTPase activating protein, or geranylgeranyl transferase activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ellerbroek, SM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, CB 7295, Chapel Hill, NC 27599 USA.	hawkeye@med.unc.edu	Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Faucheux N, 2002, BIOMATERIALS, V23, P2295, DOI 10.1016/S0142-9612(01)00363-5; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; HORI Y, 1991, ONCOGENE, V6, P515; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; KHOSRAVIFAR R, 1995, METHOD ENZYMOL, V255, P46; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kwak JY, 2000, BIOCHEM BIOPH RES CO, V267, P305, DOI 10.1006/bbrc.1999.1941; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; Manganello JM, 2003, J BIOL CHEM, V278, P124, DOI 10.1074/jbc.M209219200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056	40	245	253	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19023	19031		10.1074/jbc.M213066200	http://dx.doi.org/10.1074/jbc.M213066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12654918	Green Published, hybrid			2022-12-25	WOS:000182932200040
J	Han, WJ; Christen, P				Han, WJ; Christen, P			Mechanism of the targeting action of DnaJ in the DnaK molecular chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SUBSTRATE-SPECIFICITY; ATP HYDROLYSIS; J-DOMAIN; BINDING; HOMOLOG; HSP70; CYCLE	In the DnaK (Hsp70) molecular chaperone system of Escherichia coli, the substrate polypeptide is fed into the chaperone cycle by association with the fast-binding, ATP-liganded form of the DnaK. The substrate binding properties of DnaK are controlled by its two co-chaperones DnaJ (Hsp40) and GrpE. DnaJ stimulates the hydrolysis of DnaK-bound ATP, and GrpE accelerates ADP/ATP exchange. DnaJ has been described as targeting the substrate to DnaK, a concept that has remained rather obscure. Based on binding experiments with peptides and polypeptides we propose here a novel mechanism for the targeting action of DnaJ: ATP.DnaK and DnaJ with its substrate-binding domain bind to different segments of one and the same polypeptide chain forming (ATP.DnaK)(m).substrate.DnaJ(n) complexes; in these ternary complexes efficient cis-interaction of the J-domain of DnaJ with DnaK is favored by their propinquity and triggers the hydrolysis of DnaK-bound ATP, converting DnaK to its ADP-liganded high affinity state and thus locking it onto the substrate polypeptide.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						Bischofberger P, 2003, J BIOL CHEM, V278, P19044, DOI 10.1074/jbc.M300922200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FERSHT A, 1999, STRUCTURE MECH PROTE, P65; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P7; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Merlin A, 1999, J CELL BIOL, V145, P961, DOI 10.1083/jcb.145.5.961; Minami Y, 1999, GENES CELLS, V4, P721, DOI 10.1046/j.1365-2443.1999.00299.x; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; PIERRE G, 2001, J BIOL CHEM, V276, P7906; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; Westermann B, 1997, J MOL BIOL, V272, P477, DOI 10.1006/jmbi.1997.1267; Westermann B, 1996, MOL CELL BIOL, V16, P7063; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809	49	94	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19038	19043		10.1074/jbc.M300756200	http://dx.doi.org/10.1074/jbc.M300756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12654915	hybrid			2022-12-25	WOS:000182932200042
J	Dang, TP; Eichenberger, S; Gonzalez, A; Olson, S; Carbone, DP				Dang, TP; Eichenberger, S; Gonzalez, A; Olson, S; Carbone, DP			Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice	ONCOGENE			English	Article						Notch3; differentiation; pneumocytes; transgenics	RESPIRATORY EPITHELIUM; INTRACELLULAR DOMAIN; KAPPA-B; IN-VIVO; EXPRESSION; GENE; MORPHOGENESIS; CELLS; TRANSLOCATION; NEOPLASMS	Notch3 is a transmembrane receptor and a member of the Notch signaling pathway essential for cellular differentiation in a variety of developing tissues in both invertebrates and vertebrates. Emerging data support the role of the Notch signaling pathway in tumorigenesis. We have previously demonstrated the expression of Notch3 in a subset of lung adenocarcinomas. To further elucidate the role of Notch3 in development of lung cancer, we established a transgenic mouse model in which the intracellular domain of Notch3 is expressed using the surfactant protein C promoter/enhancer. Constitutive expression of Notch3 in the peripheral epithelium in the developing lung resulted in altered lung morphology and delayed development, leading to perinatal lethality in these transgenic mice. Cell-specific markers and electron microscopy examination showed that the majority of the epithelial cells are undifferentiated, with some maturation of type 11 pneumocytes. No type I alveolar cells were evident. Metaplasia of undifferentiated cells in the terminal airways was also observed. Although the mice did not live long enough to assess tumor development, these findings demonstrate that ectopic expression of Notch3 in airway epithelium potentially contributes to the multistep evolution of lung cancer through the inhibition of terminal differentiation.	Vanderbilt Univ, Med Ctr, Div Hematol & Med Oncol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Dang, TP (corresponding author), Vanderbilt Ingram Canc Ctr, 642 PRB, Nashville, TN 37232 USA.				NCI NIH HHS [1 P50 CA090949, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, P50CA090949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 1999, DEVELOPMENT, V126, P3925; Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Ito T, 2000, DEVELOPMENT, V127, P3913; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Linnoila RI, 2000, CANCER RES, V60, P4005; Llimargas M, 1999, DEVELOPMENT, V126, P2355; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Post LC, 2000, MECH DEVELOP, V98, P95, DOI 10.1016/S0925-4773(00)00432-9; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Taichman DB, 2002, DEV DYNAM, V225, P166, DOI 10.1002/dvdy.10146; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zhou L, 1997, DEV DYNAM, V210, P305, DOI 10.1002/(SICI)1097-0177(199711)210:3<305::AID-AJA10>3.0.CO;2-9	31	87	97	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1988	1997		10.1038/sj.onc.1206230	http://dx.doi.org/10.1038/sj.onc.1206230			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673204				2022-12-25	WOS:000181967700009
J	Mashima, H; Ueda, N; Ohno, H; Suzuki, J; Ohnishi, H; Yasuda, H; Tsuchida, T; Kanamaru, C; Makita, N; Iiri, T; Omata, M; Kojima, I				Mashima, H; Ueda, N; Ohno, H; Suzuki, J; Ohnishi, H; Yasuda, H; Tsuchida, T; Kanamaru, C; Makita, N; Iiri, T; Omata, M; Kojima, I			A novel mitochondrial Ca2+-dependent solute carrier in the liver identified by mRNA differential display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC AR42J CELLS; STRUCTURAL RELATIONSHIP; PROTEINS; BETACELLULIN; EXOCRINE; GLUCAGON; SEQUENCE; MEMBER	Pancreatic AR42J cells have the feature of pluripotency of the precursor cells of the gut endoderm. Dexamethasone converts them to exocrine cells or liver cells. Using mRNA differential display techniques, we have identified a novel Ca2+-dependent member of the mitochondrial solute carrier superfamily, which is expressed during the course of differentiation, and have designated it MCSC. The corresponding cDNA comprises an open reading frame of 1407 base pairs encoding a polypeptide of 469 amino acids. The carboxyl-terminal-half of MCSC has high similarity with other mitochondrial carriers, and the amino-terminal-half has three canonical elongation factor-hand motifs and has calcium binding capacity. The deduced amino acid sequence revealed 79.1% homology to the rabbit peroxisomal Ca2+-dependent member of the mitochondrial superfamily, but the subcellular localization of the protein was exclusively mitochondrial, not peroxisomal. Northern blot and Western blot analyses revealed its predominant expression in the liver and the skeletal muscle. In the liver, the expression level of MCSC was higher in the adult stage than in the fetal stage, and MCSC was highly up-regulated in dexamethasone-treated AR42J cells before the expression of albumin. Taken together, MCSC may play an important role in regulating the function of hepatocytes rather than in differentiation in vivo.	Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan; Univ Tokyo, Sch Med, Dept Endocrinol & Nephrol, Tokyo 1138655, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan	University of Tokyo; University of Tokyo; Gunma University	Mashima, H (corresponding author), Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan.	hmashima1-tky@umin.ac.jp	Mashima, Hirosato/ABE-6412-2020					Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Deutsch G, 2001, DEVELOPMENT, V128, P871; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kikuno R, 2002, NUCLEIC ACIDS RES, V30, P166, DOI 10.1093/nar/30.1.166; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Mashima H, 1999, DIABETES, V48, P304, DOI 10.2337/diabetes.48.2.304; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OHNISHI H, 1995, J CLIN INVEST, V95, P2304, DOI 10.1172/JCI117922; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; ROSEWICZ S, 1992, EUR J CELL BIOL, V59, P80; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Seno M, 1996, GROWTH FACTORS, V13, P181, DOI 10.3109/08977199609003220; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TEITELMAN G, 1987, DEV BIOL, V121, P454, DOI 10.1016/0012-1606(87)90182-5; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3	31	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9520	9527		10.1074/jbc.M208398200	http://dx.doi.org/10.1074/jbc.M208398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645546	hybrid			2022-12-25	WOS:000181524000086
J	Escames, G; Leon, J; Macias, M; Khaldy, H; Acuna-Castroviejo, D				Escames, G; Leon, J; Macias, M; Khaldy, H; Acuna-Castroviejo, D			Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats	FASEB JOURNAL			English	Article						melatonin; mtNOS; NO; sepsis; mitochondria; electron transport chain	OXIDATIVE DAMAGE; BRAIN; DYSFUNCTION; RESPIRATION; GLUTATHIONE; DECLINE; KIDNEY; LIVER	Mitochondrial nitric oxide synthase (mtNOS) is expressed constitutively, although it might be induced. Nitric oxide (NO) is a physiological regulator of mitochondrial respiration. Melatonin prevents mitochondrial oxidative damage and inhibits iNOS expression induced by bacterial lipopolysaccharide (LPS). The loss of melatonin with age may be related to the age-dependent mitochondrial damage. Thus, we examined the protective role of melatonin against the effects of LPS on mtNOS and on respiratory complexes activity in liver and lung mitochondria from young and old rats. The activity of mtNOS in control lung was low and did not change with age. LPS administration (10 mg/kg, i.v.) significantly increased mtNOS expression and activity and NO production in lung mitochondria, and the effect was greater in old rats. LPS administration also reduced the age-dependent decrease of the respiratory complexes I and IV. Melatonin administration (60 mg/kg, i.p.) prevented the LPS toxicity, decreasing mitochondrial NOS activity and NO production. Melatonin also counteracted LPS-induced inhibition of complexes I and IV. In general, the actions of melatonin were stronger in older animals than in younger ones. The results suggest that an inducible component of mtNOS, together with mitochondrial damage, occurs during sepsis, and melatonin prevents the mitochondrial failure that occurs during endotoxemia.	Univ Granada, Dept Fisiol, Inst Biotecnol, Granada, Spain	University of Granada	Acuna-Castroviejo, D (corresponding author), Fac Med, Dept Fisiol, Avda Madrid 11, E-18012 Granada, Spain.	dacuna@ugr.es	Leon, Pepi/K-8972-2014; Acuna-Castroviejo, Dario/N-7456-2016; Escames, Germaine/N-7501-2016; Khaldy, Hoda/I-4161-2015	Leon, Pepi/0000-0002-0543-4823; Acuna-Castroviejo, Dario/0000-0002-9680-1560; Escames, Germaine/0000-0003-1256-7656; Khaldy, Hoda/0000-0002-5906-7598				Acuna Castroviejo Dario, 2002, Curr Top Med Chem, V2, P133; Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; Aguilera-Aguirre L, 2002, MITOCHONDRION, V1, P413, DOI 10.1016/S1567-7249(02)00002-8; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; Blanchard B, 2000, J PINEAL RES, V29, P184, DOI 10.1034/j.1600-079X.2000.290308.x; Boczkowski J, 1999, FASEB J, V13, P1637, DOI 10.1096/fasebj.13.12.1637; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Bustamante J, 2002, NITRIC OXIDE-BIOL CH, V6, P333, DOI 10.1006/niox.2001.0420; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; Comtois AS, 1999, AM J RESP CRIT CARE, V159, P1975, DOI 10.1164/ajrccm.159.6.9809020; Crespo E, 1999, FASEB J, V13, P1537, DOI 10.1096/fasebj.13.12.1537; DEGREY ADN, 1999, MOL BIOL INTELLIGENC; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Jun T, 1996, J HUM HYPERTENS, V10, P305; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kantrow SP, 1997, ARCH BIOCHEM BIOPHYS, V345, P278, DOI 10.1006/abbi.1997.0264; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; LAEMMLI UK, 1970, NATURE, V259, P860; Leach M, 1998, BRIT J PHARMACOL, V125, P817, DOI 10.1038/sj.bjp.0702123; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macias M, 1999, J PINEAL RES, V27, P86, DOI 10.1111/j.1600-079X.1999.tb00601.x; Martin M, 2000, FASEB J, V14, P1677; Martin M, 2000, J PINEAL RES, V28, P242, DOI 10.1034/j.1600-079X.2000.280407.x; McCann SM, 1998, EXP GERONTOL, V33, P813, DOI 10.1016/S0531-5565(98)00050-3; Okatani Y, 2002, J PINEAL RES, V32, P143, DOI 10.1034/j.1600-079x.2002.1o106.x; Okatani Y, 2002, NEUROBIOL AGING, V23, P639, DOI 10.1016/S0197-4580(02)00005-2; PAVETO C, 1995, J BIOL CHEM, V270, P16576, DOI 10.1074/jbc.270.28.16576; Poeggeler B, 2002, J PINEAL RES, V33, P20, DOI 10.1034/j.1600-079X.2002.01873.x; Prunet-Marcassus B, 2001, J PINEAL RES, V30, P108, DOI 10.1034/j.1600-079X.2001.300206.x; SCHAPIRA AHV, 1992, MUTAT RES, V275, P133, DOI 10.1016/0921-8734(92)90018-K; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Tian LQ, 1998, FREE RADICAL BIO MED, V24, P1477, DOI 10.1016/S0891-5849(98)00025-2; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; Wu CC, 2001, J PINEAL RES, V30, P147, DOI 10.1034/j.1600-079X.2001.300303.x	51	162	171	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					932	+		10.1096/fj.02-0692fje	http://dx.doi.org/10.1096/fj.02-0692fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670878				2022-12-25	WOS:000181892600004
J	Haller, D; Holt, L; Kim, SC; Schwabe, RF; Sartor, RB; Jobin, C				Haller, D; Holt, L; Kim, SC; Schwabe, RF; Sartor, RB; Jobin, C			Transforming growth factor-beta 1 inhibits non-pathogenic gram-negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; BETA SIGNAL-TRANSDUCTION; TGF-BETA; MUCOSAL INFLAMMATION; TRANSGENIC RATS; SMAD PROTEINS; COLITIS; CBP/P300; PHOSPHORYLATION; INDUCTION	We have shown that non-pathogenic enteric Gram-negative Bacteroides vulgatus induces RelA phosphorylation, NF-kappaB activation, and proinflammatory gene expression in primary and intestinal epithelial cell (IEC) lines. We now demonstrate the transient induction of nuclear phospho-RelA (day 3) followed by persistent activation of phospho-Smad2 (days 3 and 7) in IEC from mucosal tissue sections of B. vulgatus-monoassociated rats, indicating that both NF-kappaB and transforming growth factor-beta1 (TGF-beta1) signaling are induced in vivo following bacterial colonization. Interestingly, TGF-beta1 inhibited B. vulgatus- and lipopolysaccharide (LPS)-induced NF-kappaB transcriptional activity as well as interleukin-6 (IL-6) mRNA accumulation and protein secretion in IEC. The inhibitory effect of TGF-beta1 is mediated independently of B. vulgatus/LPS-induced IkappaBalpha, Akt, and RelA phosphorylation as well as NF-kappaB DNA binding activity. Moreover, the specific histone deacetylase inhibitor trichostatin A blocked B. vulgatus/LPS-induced histone acetylation/phosphorylation (Lys-9/Ser-10) and reversed TGF-beta1-mediated inhibition of IL-6 gene expression. Chromatin immunoprecipitation analysis revealed that B. vulgatus/LPS-induced RelA recruitment to the IL-6 promoter is inhibited by TGF-beta1 treatment. Adenoviral delivery of Smad7 and dominant negative Smad3 (SmadDelta3) reversed the TGF-beta1-mediated inhibition of NF-kappaB transcriptional activity and NF-kappaB recruitment to the IL-6 promoter. In addition, TGF-beta1 and Ad5Smad3/4 prevent B. vulgatus/LPS-induced CBP/p300 and p65 nuclear co-association. We concluded that the TGF-beta1/Smad signaling pathway helps maintain normal intestinal homeostasis to commensal luminal enteric bacteria by regulating NF-kappaB signaling in IEC through altered histone acetylation.	Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jobin, C (corresponding author), Univ N Carolina, Dept Med, Div Digest Dis & Nutr, CB 7038,Glaxo Bldg, Chapel Hill, NC 27599 USA.		Schwabe, Robert/AAY-6506-2021	Haller, Dirk/0000-0002-6977-4085	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R01DK047700, R56DK047700, R01DK040249] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987, DK47700, DK40249] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bhan AK, 1999, IMMUNOL REV, V169, P195, DOI 10.1111/j.1600-065X.1999.tb01316.x; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Bouzahzah B, 2000, CANCER RES, V60, P4531; Chen WJ, 1998, J IMMUNOL, V161, P6297; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; Jobin C, 1997, J IMMUNOL, V158, P226; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kitani A, 2000, J EXP MED, V192, P41, DOI 10.1084/jem.192.1.41; KULKARNI AB, 1995, AM J PATHOL, V146, P264; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Massague J, 2000, GENE DEV, V14, P627; Melhuish TA, 2001, J BIOL CHEM, V276, P32109, DOI 10.1074/jbc.M103377200; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 2001, J CELL SCI, V114, P4359; Muegge K, 2002, NAT IMMUNOL, V3, P16, DOI 10.1038/ni0102-16; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; ONDERDONK AB, 1981, INFECT IMMUN, V32, P225, DOI 10.1128/IAI.32.1.225-231.1981; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; SARTOR RB, 1997, AM J GASTROENTEROL, V92, P5; Song XY, 1999, J IMMUNOL, V163, P4020; Strober W, 1998, ANN NY ACAD SCI, V859, P37, DOI 10.1111/j.1749-6632.1998.tb11109.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	45	112	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23851	23860		10.1074/jbc.M300075200	http://dx.doi.org/10.1074/jbc.M300075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12672795	hybrid, Green Published			2022-12-25	WOS:000183638600081
J	Rey, O; Yuan, JZ; Young, SH; Rozengurt, E				Rey, O; Yuan, JZ; Young, SH; Rozengurt, E			Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-CANCER CELLS; PHORBOL ESTERS; MOLECULAR-CLONING; RAPID ACTIVATION; PHOSPHOLIPASE-C; GROWTH-FACTORS; LOOP SER(744); DNA-SYNTHESIS; LEPTOMYCIN-B; D INTERACTS	The protein kinase D (PKD) family consists of three serine/threonine kinases: PKCmu/PKD, PKD2, and PKCnu/PKD3. Whereas PKD has been the focus of most studies, virtually nothing is known about the effect of G protein-coupled receptor agonists ( GPCR) on the regulatory properties and intracellular distribution of PKD3. Consequently, we examined the mechanism that mediates its activation and intracellular distribution. GPCR agonists induced a rapid activation of PKD3 by a protein kinase C (PKC)-dependent pathway that leads to the phosphorylation of the activation loop of PKD3. Comparison of the steady-state distribution of endogenous or tagged PKD3 versus PKD and PKD2 in unstimulated cells indicated that whereas PKD and PKD2 are predominantly cytoplasmic, PKD3 is present both in the nucleus and cytoplasm. This distribution of PKD3 results from its continuous shuttling between both compartments by a mechanism that requires a nuclear import receptor and a competent CRM1-nuclear export pathway. Cell stimulation with the GPCR agonist neurotensin induced a rapid and reversible plasma membrane translocation of PKD3 that is PKC-dependent. Interestingly, the nuclear accumulation of PKD3 can be dramatically enhanced in response to its activation. Thus, this study demonstrates that the intracellular distribution of PKD isoenzymes are distinct, and suggests that their signaling properties are regulated by differential localization.	Univ Calif Los Angeles, Sch Med,CURE Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med,CURE Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu		Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [P50 CA090388, K01CA097956-01] Funding Source: Medline; NIDDK NIH HHS [DK55003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA097956, P50CA090388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; D'Santos CS, 1999, CURR BIOL, V9, P437, DOI 10.1016/S0960-9822(99)80193-6; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Edidin M., 1994, MOBILITY PROXIMITY B, P109; Elek J, 2000, ANTICANCER RES, V20, P53; Ellenrieder V, 2001, CANCER RES, V61, P4222; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guha S, 2002, CANCER RES, V62, P1632; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; IRVINE R, 2000, SCI STKE, V48, P1; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kornmann M, 1999, CANCER RES, V59, P3505; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kusama T, 2001, CANCER RES, V61, P4885; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Lippincott-Schwartz J, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P243; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Neri LM, 2002, MOL BIOL CELL, V13, P947, DOI 10.1091/mbc.01-02-0086; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paolucci L, 1999, CANCER RES, V59, P572; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Reubi JC, 1998, GUT, V42, P546, DOI 10.1136/gut.42.4.546; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; Rozen S, 2000, Methods Mol Biol, V132, P365; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; Ryder NM, 2001, J CELL PHYSIOL, V186, P53, DOI 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Tamiya-Koizumi K, 2002, J BIOCHEM, V132, P13, DOI 10.1093/oxfordjournals.jbchem.a003190; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Wang L, 2000, CLIN CANCER RES, V6, P566; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YAMAKASI L, 1992, NUCL TRAFFICKING, P137; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	89	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23773	23785		10.1074/jbc.M300226200	http://dx.doi.org/10.1074/jbc.M300226200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12676944	hybrid			2022-12-25	WOS:000183638600072
J	He, QM; Wei, YQ; Tian, L; Zhao, X; Su, JM; Yang, L; Lu, Y; Kan, B; Lou, YY; Huang, MJ; Xiao, F; Liu, JY; Hu, B; Luo, F; Jiang, Y; Wen, YJ; Deng, HX; Li, J; Niu, T; Yang, JL				He, QM; Wei, YQ; Tian, L; Zhao, X; Su, JM; Yang, L; Lu, Y; Kan, B; Lou, YY; Huang, MJ; Xiao, F; Liu, JY; Hu, B; Luo, F; Jiang, Y; Wen, YJ; Deng, HX; Li, J; Niu, T; Yang, JL			Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; IN-VIVO; ANGIOGENESIS; CANCER; IMMUNITY; TOLERANCE; GENE; DNA; AUTOIMMUNITY; EXPRESSION	Angiogenesis is important for the growth of solid tumors. The breaking of the immune tolerance against the molecule associated with angiogenesis should be a useful approach for cancer therapy. However, the immunity to self-molecules is difficult to elicit by a vaccine based on autologous or syngeneic molecules due to immune tolerance. Basic fibroblast growth factor ( bFGF) is a specific and potent angiogenic factor implicated in tumor growth. The biological activity of bFGF is mediated through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR-1). In this study, we selected Xenopus FGFR-1 as a model antigen by the breaking of immune tolerance to explore the feasibility of cancer therapy in murine tumor models. We show here that vaccination with Xenopus FGFR-1 (pxFR1) is effective at antitumor immunity in three murine models. FGFR-1-specific autoantibodies in sera of pxFR1-immunized mice could be found in Western blotting analysis. The purified immunoglobulins were effective at the inhibition of endothelial cell proliferation in vitro and at the antitumor activity in vivo. The antitumor activity and production of FGFR-1-specific autoantibodies could be abrogated by depletion of CD4(+) T lymphocytes. Histological examination revealed that the autoantibody was deposited on the endothelial cells within tumor tissues from pxFR1-immunized mice, and intratumoral angiogenesis was significantly suppressed. Furthermore, the inhibition of angiogenesis could also be found in alginate-encapsulate tumor cell assay. These observations may provide a new vaccine strategy for cancer therapy through the induction of autoimmunity against FGFR-1 associated with angiogenesis in a cross-reaction.	Minist Educ, Key Lab Biotherapy Human Dis, Beijing, Peoples R China; W China Hosp, Ctr Canc, Chengdu 610041, Sichuan, Peoples R China; Sichuan Univ, W China Med Sch, W China Hosp 2, Dept Gynecol & Obstet, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Sichuan University	Wei, YQ (corresponding author), Minist Educ, Key Lab Biotherapy Human Dis, Beijing, Peoples R China.		Niu, Tao/B-7983-2008; Hu, Bing/G-9745-2011	Wei, Yu-quan/0000-0002-6211-3217; Hu, Bing/0000-0003-0810-6670				Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Auguste P, 2001, CANCER RES, V61, P1717; Barinaga M, 2000, SCIENCE, V288, P245; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheng WF, 2001, J CLIN INVEST, V108, P669, DOI 10.1172/JCI200112346; Cleaver O, 1997, DEV DYNAM, V210, P66, DOI 10.1002/(SICI)1097-0177(199709)210:1<66::AID-AJA7>3.3.CO;2-S; De Silva HD, 1998, IMMUNOLOGY, V93, P405; Ding L, 2002, J BIOL CHEM, V277, P31056, DOI 10.1074/jbc.M203658200; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; Gouttefangeas C, 2000, NAT BIOTECHNOL, V18, P491, DOI 10.1038/75343; Grossman Z, 2000, SEMIN IMMUNOL, V12, P197, DOI 10.1006/smim.2000.0232; Guddo F, 1999, HUM PATHOL, V30, P788, DOI 10.1016/S0046-8177(99)90139-9; Hedges SB, 2002, SCIENCE, V297, P1283; Hoffmann J, 1997, CANCER RES, V57, P3847; Horton HM, 1999, P NATL ACAD SCI USA, V96, P1553, DOI 10.1073/pnas.96.4.1553; Houghton AN, 2001, CURR OPIN IMMUNOL, V13, P134, DOI 10.1016/S0952-7915(00)00195-3; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kang L, 2002, J EXP MED, V196, P1091; Kornberg TB, 2000, SCIENCE, V287, P2218, DOI 10.1126/science.287.5461.2218; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; Kumar V, 1996, J EXP MED, V184, P1609, DOI 10.1084/jem.184.5.1609; Marx J, 2000, SCIENCE, V289, P1121; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murray JS, 1998, IMMUNOL TODAY, V19, P157, DOI 10.1016/S0167-5699(97)01237-1; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Pardoll DM, 1999, P NATL ACAD SCI USA, V96, P5340, DOI 10.1073/pnas.96.10.5340; Plum SM, 2000, VACCINE, V19, P1294, DOI 10.1016/S0264-410X(00)00210-3; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROBBIE EP, 1995, DEVELOPMENT, V121, P1775; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Shortman K, 2001, NAT IMMUNOL, V2, P988, DOI 10.1038/ni1101-988; Sigmund K, 2001, NATURE, V414, P403, DOI 10.1038/35106672; St Croix B, 2000, SCIENCE, V289, P1197; Takanami I, 1997, NEOPLASMA, V44, P295; Valesky M, 2002, MOL MED, V8, P103, DOI 10.1007/BF03402080; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	49	65	83	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21831	21836		10.1074/jbc.M300880200	http://dx.doi.org/10.1074/jbc.M300880200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12651849	hybrid			2022-12-25	WOS:000183354200066
J	Jonsson, M; Eklund, E; Fransson, LA; Oldberg, A				Jonsson, M; Eklund, E; Fransson, LA; Oldberg, A			Initiation of the decorin glycosaminoglycan chain in the endoplasmic reticulum-Golgi intermediate compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; LEUCINE-RICH PROTEOGLYCANS; BETA-D-XYLOSYLTRANSFERASE; LUMINAL ER PROTEINS; HEPARAN-SULFATE; CHONDROITIN SULFATE; MOLECULAR-CLONING; BREFELDIN-A; KEY ENZYME; IN-VIVO	We have transiently expressed decorin with a C- terminal KDEL endoplasmic reticulum retention signal peptide in COS- 7 cells to study initiation of galactosaminoglycan synthesis in the endoplasmic reticulum- Golgi intermediate compartment. All decorin- KDEL molecules were substituted with N- linked oligosaccharides sensitive to endoglycosidase H, indicating that the core protein was located proximal to the medial- Golgi. O-Linked glycosylation was only initiated in a minor fraction of the molecules. The O- linked saccharides were characterized by gel filtration after stepwise degradations using chondroitin ABC/ AC-I lyases, beta1 - 3- glycuronidase, beta-galactosidase, and alkaline phosphatase. The major O- linked saccharide was the linkage region pentasaccharide GalNAcbeta1-4GlcUAbeta1-3Galbeta1-3Galbeta1-4-Xyl- 2- phosphate, demonstrating initiation of chondroitin synthesis in the endoplasmic reticulum- Golgi intermediate compartment. In the presence of brefeldin A, partial elongation of a chondroitin chain took place, indicating retrieval of polymerases but not of sulfotransferases.	Lund Univ, Dept Cell & Mol Biol, SE-22184 Lund, Sweden	Lund University	Oldberg, A (corresponding author), Lund Univ, Dept Cell & Mol Biol, BMC C13, SE-22184 Lund, Sweden.	Ake.Oldberg@medkem.lu.se						Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRESSE H, 1971, EUR J BIOCHEM, V22, P557, DOI 10.1111/j.1432-1033.1971.tb01577.x; Moriarity JL, 2002, J BIOL CHEM, V277, P16968, DOI 10.1074/jbc.M109316200; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Prydz K, 2000, J CELL SCI, V113, P193; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; UhlinHansen L, 1997, J BIOL CHEM, V272, P3200, DOI 10.1074/jbc.272.6.3200; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	40	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21415	21420		10.1074/jbc.M210977200	http://dx.doi.org/10.1074/jbc.M210977200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668676	hybrid			2022-12-25	WOS:000183354200015
J	Liang, Y; Fotiadis, D; Filipek, S; Saperstein, DA; Palczewski, K; Engel, A				Liang, Y; Fotiadis, D; Filipek, S; Saperstein, DA; Palczewski, K; Engel, A			Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENT; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; LATERAL DIFFUSION; DISK MEMBRANES; VISUAL PIGMENT; TRANSDUCIN; ARRESTIN; ACTIVATION	G protein- coupled receptors ( GPCRs), which constitute the largest and structurally best conserved family of signaling molecules, are involved in virtually all physiological processes. Crystal structures are available only for the detergent-solubilized light receptor rhodopsin. In addition, this receptor is the only GPCR for which the presumed higher order oligomeric state in native membranes has been demonstrated ( Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D. A., Engel, A., and Palczewski, K. ( 2003) Nature 421, 127 - 128). Here, we have determined by atomic force microscopy the organization of rhodopsin in native membranes obtained from wild- type mouse photoreceptors and opsin isolated from photoreceptors of Rpe65 -/- mutant mice, which do not produce the chromophore 11- cis-retinal. The higher order organization of rhodopsin was present irrespective of the support on which the membranes were adsorbed for imaging. Rhodopsin and opsin form structural dimers that are organized in paracrystalline arrays. The intradimeric contact is likely to involve helices IV and V, whereas contacts mainly between helices I and II and the cytoplasmic loop connecting helices V and VI facilitate the formation of rhodopsin dimer rows. Contacts between rows are on the extracellular side and involve helix I. This is the first semi- empirical model of a higher order structure of a GPCR in native membranes, and it has profound implications for the understanding of how this receptor interacts with partner proteins.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Basel, ME Muller Inst Microscopy, Biozentrum, CH-4056 Basel, Switzerland; Warsaw Univ, Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Warsaw Univ, Fac Chem, PL-02109 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Basel; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061, P30EY001730, R03EY013726] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008061, P30 EY001730, EY 017301, EY08061, EY 13726, R03 EY013726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Arimoto R, 2001, BIOPHYS J, V81, P3285, DOI 10.1016/S0006-3495(01)75962-0; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BLASIE JK, 1965, J MOL BIOL, V14, P143, DOI 10.1016/S0022-2836(65)80236-4; BLASIE JK, 1969, J MOL BIOL, V39, P417, DOI 10.1016/0022-2836(69)90136-3; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUCKERT F, 1992, BIOPHYS J, V63, P616, DOI 10.1016/S0006-3495(92)81650-8; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; CORLESS JM, 1982, P NATL ACAD SCI-BIOL, V79, P1116, DOI 10.1073/pnas.79.4.1116; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; DRATZ EA, 1985, BIOCHIM BIOPHYS ACTA, V832, P337, DOI 10.1016/0167-4838(85)90268-7; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HENDERSON R, 1990, PHILOS T ROY SOC B, V326, P379, DOI 10.1098/rstb.1990.0019; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P660; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Marshall GR, 2001, BIOPOLYMERS, V60, P246, DOI 10.1002/1097-0282(2001)60:3<246::AID-BIP10044>3.0.CO;2-V; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Muller DJ, 1997, BIOPHYS J, V73, P1633, DOI 10.1016/S0006-3495(97)78195-5; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/pnas.90.8.3241; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; SAIBIL H, 1976, NATURE, V262, P266, DOI 10.1038/262266a0; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Scheuring S, 1999, EMBO J, V18, P4981, DOI 10.1093/emboj/18.18.4981; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; STRYER L, 1985, BIOPOLYMERS, V24, P29, DOI 10.1002/bip.360240105; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Wagner HJ, 1998, PROG RETIN EYE RES, V17, P637, DOI 10.1016/S1350-9462(98)00003-2; Walz T, 1996, J MOL BIOL, V264, P907, DOI 10.1006/jmbi.1996.0686; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YEAGER MJ, 1976, BROOKHAVEN SYM BIOL, pR3	60	522	536	1	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21655	21662		10.1074/jbc.M302536200	http://dx.doi.org/10.1074/jbc.M302536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663652	hybrid, Green Accepted			2022-12-25	WOS:000183354200044
J	Lucero, H; Gae, D; Taccioli, GE				Lucero, H; Gae, D; Taccioli, GE			Novel localization of the DNA-PK complex in lipid rafts - A putative role in the signal transduction pathway of the ionizing radiation response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; CALCIUM-BINDING PROTEIN; STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; CARCINOMA-CELLS; IN-VITRO; KAPPA-B; KU	Increased sensitivity to ionizing radiation (IR) has been shown to be due to defects in DNA double-strand break repair machinery. The major pathway in mammalian cells dedicated to the repair of DNA double-strand breaks is by the nonhomologous end-joining machinery. Six components function in this pathway, of which three (Ku70, Ku86, and DNA-PKcs) constitute a protein complex known as DNA-dependent protein kinase (DNAPK). However, it is now recognized that the cellular radiation response is complex, and radiosensitivity may be also regulated at different levels in the radiation signal transduction pathway. In addition to DNA damage, exposure to IR triggers intracellular signaling cascades that overlap with pathways initiated by ligand engagement to a receptor. In this study, we provide evidence for the novel localization of the DNA-PK complex in lipid rafts. We also show this property is not a generalized characteristic of all DNA repair proteins. Furthermore, we have detected Ku86 in yeast lipid rafts. Our results suggest that the components of this complex might be recruited separately to the plasma membrane by tethering with raft-resident proteins. In addition, we found an irradiation-induced differential protein phosphorylation pattern dependent upon DNA-PKcs in lipid rafts. Thus, we speculate that another role for the DNA-PKcs subunit and perhaps for the holoenzyme is in the signal transduction of IR response.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Mol & Cellular Biol, Goldman Sch Dent Med, Boston, MA 02118 USA	Boston University; Boston University	Taccioli, GE (corresponding author), Boston Univ, Sch Med, Dept Microbiol, 706 Albany St, Boston, MA 02118 USA.	taccioli@bu.edu			NCI NIH HHS [CA 76409] Funding Source: Medline; NIGMS NIH HHS [GM31318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031318, R37GM031318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; AVILA MA, 1993, CANCER RES, V53, P4474; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bonner JA, 1998, INT J RADIAT ONCOL, V42, P921, DOI 10.1016/S0360-3016(98)00325-3; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; DALZIEL RG, 1992, AUTOIMMUNITY, V13, P265, DOI 10.3109/08916939209112334; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Featherstone C, 1999, BRIT J CANCER, V80, P14; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Ginis I, 2000, CANCER LETT, V154, P163, DOI 10.1016/S0304-3835(00)00388-8; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Grandvaux N, 1999, J CELL SCI, V112, P503; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grazide S, 2002, FASEB J, V16, P1685, DOI 10.1096/fj.01-0794fje; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Herrlich P, 1999, CR ACAD SCI III-VIE, V322, P121, DOI 10.1016/S0764-4469(99)80033-X; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Knebel A, 1996, ADV EXP MED BIOL, V387, P57; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Knebel A, 2000, METHOD ENZYMOL, V319, P255; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; Kumaravel TS, 1998, INT J RADIAT BIOL, V74, P481, DOI 10.1080/095530098141357; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li NX, 2000, METHOD ENZYMOL, V319, P273; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIU Y, 1998, POSTTRANSLATIONAL ME, V2; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mizuta R, 1996, INT IMMUNOL, V8, P1467, DOI 10.1093/intimm/8.9.1467; Mondello C, 2001, CANCER RES, V61, P4520; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nagasawa H, 2002, CANCER RES, V62, P2531; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Ruiz MT, 2002, ELECTROPHORESIS, V23, P2485, DOI 10.1002/1522-2683(200208)23:15<2485::AID-ELPS2485>3.0.CO;2-C; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Shakibai N, 1996, P NATL ACAD SCI USA, V93, P11569, DOI 10.1073/pnas.93.21.11569; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Teoh G, 1998, J CLIN INVEST, V101, P1379; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yan J, 2000, INT J RADIAT BIOL, V76, P1025, DOI 10.1080/09553000050111497; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188	79	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22136	22143		10.1074/jbc.M301579200	http://dx.doi.org/10.1074/jbc.M301579200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672807	hybrid			2022-12-25	WOS:000183354200102
J	Tonetti, M; Zanardi, D; Gurnon, JR; Fruscione, F; Armirotti, A; Damonte, G; Sturla, L; De Flora, A; Van Etten, JL				Tonetti, M; Zanardi, D; Gurnon, JR; Fruscione, F; Armirotti, A; Damonte, G; Sturla, L; De Flora, A; Van Etten, JL			Paramecium bursaria Chlorella virus 1 encodes two enzymes involved in the biosynthesis of GDP-L-fucose and GDP-D-rhamnose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 4,6-DEHYDRATASE; PROTEIN GLYCOSYLATION; MASS-SPECTROMETRY; NOVO SYNTHESIS; MUR1 GENE; PBCV-1; ALGAE; GDP-D-MANNOSE-4,6-DEHYDRATASE; ARABIDOPSIS; INFECTION	At least three structural proteins in Paramecium bursaria Chlorella virus (PBCV-1) are glycosylated, including the major capsid protein Vp54. However, unlike other glycoprotein-containing viruses that use host-encoded enzymes in the endoplasmic reticulum-Golgi to glycosylate their proteins, PBCV-1 encodes at least many, if not all, of the glycosyltransferases used to glycosylate its structural proteins. As described here, PBCV-1 also encodes two open reading frames that resemble bacterial and mammalian enzymes involved in de novo GDP-L-fucose biosynthesis. This pathway, starting from GDP-D-mannose, consists of two sequential steps catalyzed by GDP-D-mannose 4,6 dehydratase (GMD) and GDP-4-keto-6-deoxy-D-mannose epimerase/ reductase, respectively. The two PBCV-1-encoded genes were expressed in Escherichia coli, and the recombinant proteins had the predicted enzyme activity. However, in addition to the dehydratase activity, PBCV-1 GMD also had a reductase activity, producing GDP-D-rhamnose. In vivo studies established that PBCV-1 GMD and GDP-4-keto- 6-deoxy-D-mannose epimerase/ reductase are expressed after virus infection and that both GDP-L-fucose and GDP-D-rhamnose are produced in virus-infected cells. Thus, PBCV-1 is the first virus known to encode enzymes involved in nucleotide sugar metabolism. Because fucose and rhamnose are components of the glycans attached to Vp54, the pathway could circumvent a limited supply of GDP sugars by the algal host.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Ist Giannina Gaslini, I-16147 Genoa, Italy; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA	University of Genoa; University of Genoa; University of Nebraska System; University of Nebraska Lincoln; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Nebraska System; University of Nebraska Lincoln	Tonetti, M (corresponding author), Univ Genoa, DIMES, Viale Benedetto XV 1, I-16132 Genoa, Italy.		Armirotti, Andrea/AAB-3284-2019; Tonetti, Michela/F-3039-2018; fruscione, floriana/AAA-8747-2020; TONETTI, MICHELA/AAF-3404-2021	TONETTI, MICHELA/0000-0002-8829-7173; Armirotti, Andrea/0000-0002-3766-8755; fruscione, floriana/0000-0002-4054-645X	NIGMS NIH HHS [GM 32441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisso A, 1999, FEBS LETT, V456, P370, DOI 10.1016/S0014-5793(99)00982-5; Bonin CP, 2000, PLANT J, V21, P445, DOI 10.1046/j.1365-313x.2000.00698.x; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; Graves MV, 1999, VIROLOGY, V257, P15, DOI 10.1006/viro.1999.9628; Graves MV, 2001, VIROLOGY, V285, P332, DOI 10.1006/viro.2001.0937; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; Kneidinger B, 2001, J BIOL CHEM, V276, P5577, DOI 10.1074/jbc.M010027200; Landstein D, 1998, VIROLOGY, V250, P388, DOI 10.1006/viro.1998.9388; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; MEINTS RH, 1988, VIROLOGY, V164, P15, DOI 10.1016/0042-6822(88)90614-9; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; Miketova P, 1997, MOL BIOTECHNOL, V8, P249, DOI 10.1007/BF02760778; Nandhagopal N, 2002, P NATL ACAD SCI USA, V99, P14758, DOI 10.1073/pnas.232580699; QUE QD, 1994, VIROLOGY, V203, P320, DOI 10.1006/viro.1994.1490; SCHUSTER AM, 1986, VIROLOGY, V148, P181, DOI 10.1016/0042-6822(86)90413-7; Sturla L, 1997, FEBS LETT, V412, P126, DOI 10.1016/S0014-5793(97)00762-X; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Sun LW, 1999, VIROLOGY, V263, P376, DOI 10.1006/viro.1999.9958; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; Van Etten JL, 2002, ARCH VIROL, V147, P1479, DOI 10.1007/s00705-002-0822-6; VANETTEN JL, 1984, VIROLOGY, V134, P443, DOI 10.1016/0042-6822(84)90311-8; VANETTEN JL, 1981, VIROLOGY, V113, P704, DOI 10.1016/0042-6822(81)90199-9; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; VANETTEN JL, 1983, VIROLOGY, V126, P117, DOI 10.1016/0042-6822(83)90466-X; WANG IN, 1993, P NATL ACAD SCI USA, V90, P3840, DOI 10.1073/pnas.90.9.3840	27	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21559	21565		10.1074/jbc.M301543200	http://dx.doi.org/10.1074/jbc.M301543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12679342	hybrid			2022-12-25	WOS:000183354200032
J	Chastain, PD; Makhov, AM; Nossal, NG; Griffith, J				Chastain, PD; Makhov, AM; Nossal, NG; Griffith, J			Architecture of the replication complex and DNA loops at the fork generated by the bacteriophage T4 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; POLYMERASE-III HOLOENZYME; HELICASE ASSEMBLY PROTEIN; LEADING-STRAND; ESCHERICHIA-COLI; PURIFICATION; BINDING; VISUALIZATION; PROCESSIVITY; TEMPLATE	Rolling circle replication has previously been reconstituted in vitro using M13 duplex circles containing preformed forks and the 10 purified T4 bacteriophage replication proteins. Leading and lagging strand synthesis in these reactions is coupled and the size of the Okazaki fragments produced is typical of those generated in T4 infections. In this study the structure of the DNAs and DNA-protein complexes engaged in these in vitro reactions has been examined by electron microscopy. Following deproteinization, circular duplex templates with linear tails as great as 100 kb are observed. The tails are fully duplex except for one to three single-stranded DNA segments close to the fork. This pattern reflects Okazaki fragments stopped at different stages in their synthesis. Examination of the DNA-protein complexes in these reactions reveals M13 duplex circles in which 64% contain a single large protein mass ( replication complex) and a linear duplex tail. In 56% of the replicating molecules with a tail there is at least one fully duplex loop at the replication complex resulting from the portion of the lagging strand engaged in Okazaki fragment synthesis folding back to the replisome. The single-stranded DNA segments at the fork bound by gene 32 and 59 proteins are not extended but rather appear organized into highly compact structures ("bobbins"). These bobbins constitute a major portion of the mass of the full replication complex.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Griffith, J (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; Alley SC, 2000, BIOCHEMISTRY-US, V39, P3076, DOI 10.1021/bi992377r; BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DELIUS H, 1972, J MOL BIOL, V67, P341, DOI 10.1016/0022-2836(72)90454-8; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GRIFFITH JD, 1995, J MOL BIOL, V246, P576, DOI 10.1016/S0022-2836(05)80107-X; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KIM YT, 1992, J BIOL CHEM, V267, P15022; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAKI H, 1988, J BIOL CHEM, V263, P6570; MORRICAL SW, 1991, J BIOL CHEM, V266, P14031; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; WU CA, 1992, J BIOL CHEM, V267, P4064; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	40	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21276	21285		10.1074/jbc.M301573200	http://dx.doi.org/10.1074/jbc.M301573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649286	hybrid			2022-12-25	WOS:000183230500106
J	Reddy, RK; Mao, CH; Baumeister, P; Austin, RC; Kaufman, RJ; Lee, AS				Reddy, RK; Mao, CH; Baumeister, P; Austin, RC; Kaufman, RJ; Lee, AS			Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors - Role of ATP binding site in suppression of caspase-7 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; STRESS-PROTEIN; OXIDATIVE STRESS; DEATH PROGRAM; CANCER-CELLS; RESISTANCE; EXPRESSION; INDUCTION; BIP; MECHANISM	A large number of correlative studies have established that the activation of the unfolded protein response (UPR) alters the cell's sensitivity to chemotherapeutic agents. Although the induction of the glucose-regulated proteins (GRPs) is commonly used as an indicator for the UPR, the direct role of the GRPs in conferring resistance to DNA damaging agents has not been proven. We report here that without the use of endoplasmic reticulum (ER) stress inducers, specific overexpression of GRP78 results in reduced apoptosis and higher colony survival when challenged with topoisomerase II inhibitors, etoposide and doxorubicin, and topoisomerase I inhibitor, camptothecin. While investigating the mechanism for the GRP78 protective effect against etoposide-induced cell death, we discovered that in contrast to the UPR, GRP78 overexpression does not result in G(1) arrest or depletion of topoisomerase II. Caspase-7, an executor caspase that is associated with the ER, is activated by etoposide. We show here that specific expression of GRP78 blocks caspase-7 activation by etoposide both in vivo and in vitro, and this effect can be reversed by addition of dATP in a cell-free system. Recently, it was reported that ectopically expressed GRP78 and caspases-7 and -12 form a complex, thus coupling ER stress to the cell death program. However, the mechanism of how GRP78, a presumably ER lumen protein, can regulate cytosolic effectors of apoptosis is not known. Here we provide evidence that a subpopulation of GRP78 can exist as an ER transmembrane protein, as well as co-localize with caspase-7, as confirmed by fluorescence microscopy. Co-immunoprecipitation studies further reveal endogenous GRP78 constitutively associates with procaspase-7 but not with procaspase-3. Lastly, a GRP78 mutant deleted of its ATP binding domain fails to bind procaspase-7 and loses its protective effect against etoposide-induced apoptosis.	Univ So Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA; McMaster Univ, Dept Pathol & Mol Biol, Hamilton, ON L8V 1C3, Canada; Henerson Res Ctr, Hamilton, ON L8V 1C3, Canada; Univ Michigan, Howard Hughes Med Inst, Dept Biol Chem, Med Ctr, Ann Arbor, MI 48109 USA	University of Southern California; University of Southern California; McMaster University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Lee, AS (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Keck Sch Med, 1441 Eastlake Ave,Rm 5308,MC-9176, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607, 2P30 CA14089] Funding Source: Medline; NEI NIH HHS [EY03040] Funding Source: Medline; NIAID NIH HHS [AI42394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014089, R01CA027607, R37CA027607] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brown JM, 1998, CANCER RES, V58, P1408; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; CHATTERJEE S, 1994, CANCER RES, V54, P4405; CHATTERJEE S, 1990, CANCER RES, V50, P2713; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Gazit G, 1999, CANCER RES, V59, P3100; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; KANG HS, 1991, J BIOL CHEM, V266, P5643; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Koomagi R, 1999, ANTICANCER RES, V19, P4333; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Lin ZP, 1998, CANCER RES, V58, P3059; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Miyake H, 2000, J CELL BIOCHEM, V77, P396, DOI 10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; PATIERNO SR, 1987, CANCER RES, V47, P6220; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Sacchi CM, 1996, ANTICANCER RES, V16, P3659; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Triantafilou M, 2001, HUM IMMUNOL, V62, P764, DOI 10.1016/S0198-8859(01)00269-5; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wooden S.K., 1992, DNA Sequence, V3, P41, DOI 10.3109/10425179209039694; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Yun J, 1995, ONCOL RES, V7, P583; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	48	582	611	1	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20915	20924		10.1074/jbc.M212328200	http://dx.doi.org/10.1074/jbc.M212328200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665508	hybrid			2022-12-25	WOS:000183230500062
J	Strausak, D; Howie, MK; Firth, SD; Schlicksupp, A; Pipkorn, R; Multhaup, G; Mercer, JFB				Strausak, D; Howie, MK; Firth, SD; Schlicksupp, A; Pipkorn, R; Multhaup, G; Mercer, JFB			Kinetic analysis of the interaction of the copper chaperone Atox1 with the metal binding sites of the Menkes protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; WILSON DISEASE GENE; TRANSPORTING ATPASE; CANDIDATE GENE; FUNCTIONAL EXPRESSION; ATX1 METALLOCHAPERONE; DOMAIN; TRAFFICKING; ENCODES; IDENTIFICATION	Excess copper is effluxed from mammalian cells by the Menkes or Wilson P-type ATPases (MNK and WND, respectively). MNK and WND have six metal binding sites (MBSs) containing a CXXC motif within their N-terminal cytoplasmic region. Evidence suggests that copper is delivered to the ATPases by Atox1, one of three cytoplasmic copper chaperones. Attempts to monitor a direct Atox1-MNK interaction and to determine kinetic parameters have not been successful. Here we investigated interactions of Atox1 with wild-type and mutated pairs of the MBSs of MNK using two different methods: yeast two-hybrid analysis and real-time surface plasmon resonance (SPR). A copper-dependent interaction of Atox1 with the MBSs of MNK was observed by both approaches. Cys to Ser mutations of conserved CXXC motifs affected the binding of Atox1 underlining the essentiality of Cys residues for the copper-induced interaction. Although the yeast two-hybrid assay failed to show an interaction of Atox1 with MBS5/6, SPR analysis clearly demonstrated a copper-dependent binding with all six MBSs highlighting the power and sensitivity of SPR as compared with other, more indirect methods like the yeast two-hybrid system. Binding constants for copper- dependent chaperone-MBS interactions were determined to be 10(-5)-10(-6) M for all the MBSs representing relatively low affinity binding events. The interaction of Atox1 with pairs of the MBSs was non-cooperative. Therefore, a functional difference of the MBSs in the MNK N terminus cannot be attributed to cooperativity effects or varying affinities of the copper chaperone Atox1 with the MBSs.	Deakin Univ, Ctr Cellular & Mol Biol, Sch Biol & Chem Sci, Burwood, Vic 3125, Australia; Heidelberg Univ, ZMBH, Ctr Biol Mol, D-69120 Heidelberg, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Deakin University; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Mercer, JFB (corresponding author), Deakin Univ, Ctr Cellular & Mol Biol, Sch Biol & Chem Sci, 221 Burwood Highway, Burwood, Vic 3125, Australia.	jmercer@deakin.edu.au	Mercer, Julian/R-8583-2019					Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Bal W, 1998, J INORG BIOCHEM, V70, P33, DOI 10.1016/S0162-0134(98)00010-5; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Cobine P, 1999, FEBS LETT, V445, P27, DOI 10.1016/S0014-5793(99)00091-5; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; Himelblau E, 1998, PLANT PHYSIOL, V117, P1227, DOI 10.1104/pp.117.4.1227; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; La Fontaine S, 1998, PLASMID, V39, P245, DOI 10.1006/plas.1997.1334; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Mann DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/ja9818506; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Multhaup G, 2001, BIOCHEM BIOPH RES CO, V288, P172, DOI 10.1006/bbrc.2001.5757; Nagano K, 1998, HEPATOLOGY, V27, P799, DOI 10.1002/hep.510270323; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Schalow F, 1999, BRIT J AESTHET, V39, P314, DOI 10.1093/bjaesthetics/39.3.314; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wakabayashi T, 1998, FEBS LETT, V440, P141, DOI 10.1016/S0014-5793(98)01431-8; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597	49	56	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20821	20827		10.1074/jbc.M212437200	http://dx.doi.org/10.1074/jbc.M212437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12679332	hybrid			2022-12-25	WOS:000183230500050
J	Yin, F; Li, P; Zheng, M; Chen, L; Xu, Q; Chen, K; Wang, YY; Zhang, YY; Han, C				Yin, F; Li, P; Zheng, M; Chen, L; Xu, Q; Chen, K; Wang, YY; Zhang, YY; Han, C			Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTE HYPERTROPHY; BETA-ADRENERGIC STIMULATION; ANGIOTENSIN-II; TRANSCRIPTIONAL ACTIVATION; PROINFLAMMATORY CYTOKINES; RECEPTOR STIMULATION; NITRIC-OXIDE; RAT-HEART; EXPRESSION; FAILURE	This study was aimed to determine whether beta-adrenergic receptor ( beta-AR) stimulated by isoproterenol (ISO) activates signal transducers and activators of transcription ( STAT) in mouse heart and, if so, to examine the underlying mechanism. We found that treatment of adult male mice by ISO ( 15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation ( at 60 120 min), which was fully abolished by beta-AR antagonist, propranolol. ISO-induced phosphorylation of STAT3 was markedly enhanced by phosphodiesterase inhibitor amrinone, indicating that cAMP is critically involved in beta-AR-mediated STAT3 activation. In addition, beta-AR stimulation significantly increased gene expression of interleukin-6 (IL-6) family of cytokines (IL-6, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin-1). IL-6 protein levels in serum and mouse myocardium were also significantly increased in response to ISO treatment. In cultured cardiac fibroblasts, IL-6 level was enhanced significantly after ISO (10(-6) mol/liter) stimulation for 2 h and then peaked at 12 h, whereas the response of IL-6 in cultured cardiomyocytes to ISO stimulation was not significant, suggesting that ISO-induced increase in IL-6 is primarily from cardiac fibroblasts rather than cardiomyocytes. Most importantly, IL-6 could activate STAT3 in a time-dependent manner in cultured cardiomyocytes, and inhibition of IL-6 level by anti-IL-6-neutralizing antibody clearly attenuated ISO-induced phosphorylation of STAT3 in myocardium. Taken together, these results indicate that beta-AR stimulation leads to a delayed STAT3 activation via an IL-6 family of cytokine-mediated pathway and that cardiac fibroblasts, but not cardiomyocytes, is probably the predominant source of IL-6 in response to ISO stimulation in mouse myocardium.	Peking Univ, Inst Vasc Med, Hosp 3, Hlth Sci Ctr, Beijing 100083, Peoples R China; Peking Univ, Reference Lab Educ, Minist Mol Cardiol, Hlth Sci Ctr, Beijing 100083, Peoples R China; Peking Univ, Inst Cardiovasc Sci, Hlth Sci Ctr, Beijing 100083, Peoples R China	Peking University; Peking University; Peking University	Zhang, YY (corresponding author), Peking Univ, Inst Vasc Med, Hosp 3, Hlth Sci Ctr, Beijing 100083, Peoples R China.		Yin, Feng/F-6052-2010; Wang, Yongyu/F-9039-2011; YIN, FENG/AAM-3823-2020	Wang, Yongyu/0000-0002-8804-3472; YIN, FENG/0000-0002-8444-1123; Wang, Yongyu/0000-0002-6088-8887				Baumgarten G, 2000, TRENDS CARDIOVAS MED, V10, P216, DOI 10.1016/S1050-1738(00)00063-3; BRODDE OE, 1991, PHARMACOL REV, V43, P203; Burger A, 2001, AM J PHYSIOL-HEART C, V281, pH14, DOI 10.1152/ajpheart.2001.281.1.H14; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dzimiri N, 1999, PHARMACOL REV, V51, P465; Funamoto M, 2000, J MOL CELL CARDIOL, V32, P1275, DOI 10.1006/jmcc.2000.1161; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; Gray MO, 1998, CARDIOVASC RES, V40, P352, DOI 10.1016/S0008-6363(98)00121-7; Gustafsson AB, 2000, MOL PHARMACOL, V58, P1470, DOI 10.1124/mol.58.6.1470; HAVELL EA, 1991, J IMMUNOL, V146, P756; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ito Y, 1998, BRAIN RES, V793, P321, DOI 10.1016/S0006-8993(98)00242-X; Kubota T, 2000, J HEART LUNG TRANSPL, V19, P819, DOI 10.1016/S1053-2498(00)00173-X; Kucharz, 2000, Eur J Intern Med, V11, P253, DOI 10.1016/S0953-6205(00)00098-4; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MAY LT, 1993, J IMMUNOL, V151, P3225; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Murray DR, 2000, CIRCULATION, V101, P2338, DOI 10.1161/01.CIR.101.20.2338; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Orus J, 2000, J HEART LUNG TRANSPL, V19, P419, DOI 10.1016/S1053-2498(00)00083-8; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Prabhu SD, 2000, CIRCULATION, V101, P2103, DOI 10.1161/01.CIR.101.17.2103; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sano M, 2000, J BIOL CHEM, V275, P29717, DOI 10.1074/jbc.M003128200; SANO M, 2001, EUR J HEART FAIL, V3, P415; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka T, 2001, J MOL CELL CARDIOL, V33, P1627, DOI 10.1006/jmcc.2001.1428; Van Andel RA, 2000, J MED MICROBIOL, V49, P171, DOI 10.1099/0022-1317-49-2-171; Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4	33	58	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21070	21075		10.1074/jbc.M211028200	http://dx.doi.org/10.1074/jbc.M211028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665506	hybrid			2022-12-25	WOS:000183230500081
J	Henry, PC; Kanelis, V; O'Brien, MC; Kim, B; Gautschi, I; Forman-Kay, J; Schild, L; Rotin, D				Henry, PC; Kanelis, V; O'Brien, MC; Kim, B; Gautschi, I; Forman-Kay, J; Schild, L; Rotin, D			Affinity and specificity of interactions between Nedd4 isoforms and the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN LIGASE NEDD4; SODIUM-CHANNEL; LIDDLES-SYNDROME; WW DOMAIN; BETA-SUBUNIT; C2 DOMAIN; HUMAN HYPERTENSION; MISSENSE MUTATION; APICAL MEMBRANE	The epithelial Na+ channel (alphabetagammaENaC) regulates salt and fluid homeostasis and blood pressure. Each ENaC subunit contains a PY motif (PPXY) that binds to the WW domains of Nedd4, a Hect family ubiquitin ligase containing 3-4 WW domains and usually a C2 domain. It has been proposed that Nedd4-2, but not Nedd4-1, isoforms can bind to and suppress ENaC activity. Here we challenge this notion and show that, instead, the presence of a unique WW domain (WW3*) in either Nedd4-2 or Nedd4-1 determines high affinity interactions and the ability to suppress ENaC. WW3* from either Nedd4-2 or Nedd4-1 binds ENaC-PY motifs equally well (e.g. K(d)similar to10 muM for alpha- or betaENaC, 3-6-fold higher affinity than WW4), as determined by intrinsic tryptophan fluorescence. Moreover, dNedd4-1, which naturally contains a WW3* instead of WW2, is able to suppress ENaC function equally well as Nedd4-2. Homology models of the WW3*.beta ENaC-PY complex revealed that a Pro and Ala conserved in all WW3*, but not other Nedd4-WW domains, help form the binding pocket for PY motif prolines. Extensive contacts are formed between the betaENaC-PY motif and the Pro in WW3*, and the small Ala creates a large pocket to accommodate the peptide. Indeed, mutating the conserved Pro and Ala in WW3* reduces binding affinity 2-3-fold. Additionally, we demonstrate that mutations in PY motif residues that form contacts with the WW domain based on our previously solved structure either abolish or severely reduce binding affinity to the WW domain and that the extent of binding correlates with the level of ENaC suppression. Independently, we show that a peptide encompassing the PY motif of sgk1, previously proposed to bind to Nedd4-2 and alter its ability to regulate ENaC, does not bind (or binds poorly) the WW domains of Nedd4-2. Collectively, domain-PY-motif interactions rather than affiliation with Nedd4-1/Nedd-2 is critical for ENaC suppression by Nedd4 proteins.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Struct Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Lausanne	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.ca		Forman-Kay, Julie/0000-0001-8265-972X				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Asher C, 2001, BIOCHEM BIOPH RES CO, V286, P1228, DOI 10.1006/bbrc.2001.5508; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; CUTHBERT AW, 1977, NATURE, V266, P468, DOI 10.1038/266468a0; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; Inoue T, 1998, EUR J ENDOCRINOL, V138, P691, DOI 10.1530/eje.0.1380691; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lott JS, 2002, BIOCHEM J, V361, P481, DOI 10.1042/0264-6021:3610481; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SELVIN S, 2001, EPIDEMIOLOGIC ANAL; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; Yamashita Y, 2001, AM J KIDNEY DIS, V37, P499	62	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20019	20028		10.1074/jbc.M211153200	http://dx.doi.org/10.1074/jbc.M211153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654927	hybrid			2022-12-25	WOS:000183078000059
J	Hobbs, RM; Watt, FM				Hobbs, RM; Watt, FM			Regulation of interleukin-1 alpha expression by integrins and epidermal growth factor receptor in keratinocytes from a mouse model of inflammatory skin disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; CULTURED HUMAN KERATINOCYTES; HEPARIN-BINDING; FACTOR-ALPHA; EGF RECEPTOR; COLLAGENASE-1 EXPRESSION; MURINE KERATINOCYTES; PSORIATIC EPIDERMIS	Transgenic mice expressing beta(1) integrins in the suprabasal epidermal layers have sporadic skin hyperproliferation and inflammation correlated with activation of extracellular signal-regulated kinase (Erk) mitogen-activated protein kinase and increased interleukin (IL)-1alpha production. We investigated the link between aberrant integrin expression, Erk activation, and expression of IL-1alpha. Transgenic keratinocytes had higher basal Erk activity and IL-1alpha levels than nontransgenic controls and were more sensitive to stimulation of Erk activity and IL-1alpha production by IL-1alpha, 12-O-tetradecanoylphorbol-13-acetate (TPA), epidermal growth factor (EGF), and serum. Inhibition of Erk in transgenic keratinocytes reduced basal IL-1alpha levels and the stimulation of IL-1alpha production by serum or phorbol ester, demonstrating that Erk could regulate IL-1alpha expression. TPA or IL-1alpha treatment resulted in rapid down-regulation of the EGF receptor in transgenic cells, indicative of transactivation. Inhibition of transactivation blocked basal and TPA or IL-1alpha induced Erk activation, but not IkappaBalpha degradation, and abolished increased IL-1alpha production in transgenic cells. In transgene-negative cells, constitutive activation of IL-1-dependent signaling by wild type or kinase-dead IRAK1 stimulated IL-1alpha production independent of Erk. We conclude that suprabasal integrin expression leads to Erk activation and increased IL-1alpha expression by potentiating activation of the EGF receptor. These results provide a mechanism by which aberrant integrin expression triggers epidermal hyperproliferation and inflammation.	Canc Res UK London Res Inst, Keratinocyte Lab, London WC2A 3PX, England	Cancer Research UK	Watt, FM (corresponding author), Canc Res UK London Res Inst, Keratinocyte Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Watt, Fiona/AHB-0226-2022; Hobbs, Robin/I-2577-2014	Watt, Fiona/0000-0001-9151-5154; Hobbs, Robin/0000-0002-3853-2614				ANSEL JC, 1988, J IMMUNOL, V140, P2274; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Carter KB, 2000, J BIOL CHEM, V275, P27858; CHEN JD, 1995, J INVEST DERMATOL, V104, P729, DOI 10.1111/1523-1747.ep12606970; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; COOK PW, 1995, J CELL PHYSIOL, V163, P407, DOI 10.1002/jcp.1041630221; COOK PW, 1992, IN VITRO CELL DEV-AN, V28A, P218; Cooke EL, 2001, BIOCHEM J, V359, P403, DOI 10.1042/0264-6021:3590403; CORRADI A, 1995, EXP CELL RES, V217, P355, DOI 10.1006/excr.1995.1097; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Debets R, 1997, J IMMUNOL, V158, P2955; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; GROVES RW, 1995, J IMMUNOL, V154, P4065; GRUAZCHATELLARD D, 1991, FEBS LETT, V294, P137, DOI 10.1016/0014-5793(91)81360-K; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Haase I, 2002, J INVEST DERMATOL, V118, P891, DOI 10.1046/j.1523-1747.2002.17631.x; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; Komine M, 2001, J INVEST DERMATOL, V116, P330, DOI 10.1046/j.1523-1747.2001.01249.x; Kondo S, 1999, J INVEST DERM SYMP P, V4, P177, DOI 10.1038/sj.jidsp.5640205; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; La E, 1999, MOL CARCINOGEN, V24, P276, DOI 10.1002/(SICI)1098-2744(199904)24:4<276::AID-MC5>3.0.CO;2-#; Lee RT, 1997, J IMMUNOL, V159, P5084; LEE WY, 1994, J BIOL CHEM, V269, P17971; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Murphy JE, 2000, J INVEST DERMATOL, V114, P602, DOI 10.1046/j.1523-1747.2000.00917.x; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Owens DM, 2001, CANCER RES, V61, P5248; PHILLIPS WG, 1995, CLIN EXP IMMUNOL, V101, P177; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Pilcher BK, 1999, J BIOL CHEM, V274, P10372, DOI 10.1074/jbc.274.15.10372; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; Rikimaru K, 1997, EXP DERMATOL, V6, P214, DOI 10.1111/j.1600-0625.1997.tb00165.x; ROGERS HW, 1992, P NATL ACAD SCI USA, V89, P1011, DOI 10.1073/pnas.89.3.1011; Romero MR, 1999, EXP DERMATOL, V8, P53, DOI 10.1111/j.1600-0625.1999.tb00348.x; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; ROSS K, 2002, J BIOL CHEM, V23, P23; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Thomas JA, 1999, J IMMUNOL, V163, P978; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wan YS, 2001, INT J MOL MED, V7, P329; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Werner E, 2001, J CELL SCI, V114, P3333; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	85	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19798	19807		10.1074/jbc.M300513200	http://dx.doi.org/10.1074/jbc.M300513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654926	hybrid			2022-12-25	WOS:000183078000031
J	Price, GB; Allarakhia, M; Cossons, N; Nielsen, T; Diaz-Perez, M; Friedlander, P; Tao, L; Zannis-Hadjopoulos, M				Price, GB; Allarakhia, M; Cossons, N; Nielsen, T; Diaz-Perez, M; Friedlander, P; Tao, L; Zannis-Hadjopoulos, M			Identification of a cis-element that determines autonomous DNA replication in eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; MAMMALIAN ORIGIN; CPG ISLANDS; HELA-CELLS; IN-VIVO; INITIATION ZONE; DELETION ANALYSIS; DEPENDENT ATPASE; HUMAN GENOME; MONKEY DNA	A 36-bp human consensus sequence (CCTMDAWKSG-BYTSMAAWTWBCMYTTRSCAAATTCC) is capable of supporting autonomous replication of a plasmid after transfection into eukaryotic cells. After transfection and in vitro DNA replication, replicated plasmid DNA containing a mixture of oligonucleotides of this consensus was found to reiterate the consensus. Initiation of DNA replication in vitro occurs within the consensus. One version, A3/4, in pYACneo, could be maintained under selection in HeLa cells, unrearranged and replicating continuously for > 170 cell doublings. Stability of plasmid without selection was high (greater than or equal to0.9/ cell/generation). Homologs of the consensus are found consistently at mammalian chromosomal sites of initiation and within CpG islands. Versions of the consensus function as origins of DNA replication in normal and malignant human cells, immortalized monkey and mouse cells, and normal cow, chicken, and fruit fly cells. Random mutagenesis studies suggest an internal 20-bp consensus sequence of the 36 bp may be sufficient to act as a core origin element. This cis-element consensus sequence is an opportunity for focused analyses of core origin elements and the regulation of initiation of DNA replication.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Ottawa Hosp, Dept Internal Med, Ottawa, ON K1H 8L6, Canada; Univ British Columbia, Fac Med, Vancouver, BC V6T 1Z3, Canada	McGill University; University of Ottawa; Ottawa Hospital Research Institute; University of British Columbia	Price, GB (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.							Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; ARIIZUMI K, 1993, P NATL ACAD SCI USA, V90, P3695, DOI 10.1073/pnas.90.8.3695; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DiazPerez MJ, 1996, J CELL BIOCHEM, V61, P444, DOI 10.1002/(SICI)1097-4644(19960601)61:3<444::AID-JCB11>3.0.CO;2-J; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; Fox JL, 2000, NAT BIOTECHNOL, V18, P377, DOI 10.1038/74422; Fox JL, 1999, NAT BIOTECHNOL, V17, P1153, DOI 10.1038/70689; FRAPPIER L, 1987, P NATL ACAD SCI USA, V84, P6668, DOI 10.1073/pnas.84.19.6668; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HELD PG, 1992, BIOCHIM BIOPHYS ACTA, V1130, P235, DOI 10.1016/0167-4781(92)90435-3; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LANDRY S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P234, DOI 10.1016/0167-4781(91)90059-U; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; NIELSEN T, 1994, MOL GEN GENET, V242, P280, DOI 10.1007/BF00280417; Nielsen TO, 2000, J CELL BIOCHEM, V76, P674, DOI 10.1002/(SICI)1097-4644(20000315)76:4<674::AID-JCB15>3.0.CO;2-2; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; PEARSON CE, 1994, SOMAT CELL MOLEC GEN, V20, P147, DOI 10.1007/BF02254755; PEARSON CE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P156, DOI 10.1016/0167-4781(91)90096-5; Pelletier R, 1997, J CELL BIOCHEM, V66, P87; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; Ruiz MT, 1999, MOL BIOL CELL, V10, P567, DOI 10.1091/mbc.10.3.567; RUIZ MT, 1995, J CELL BIOCHEM, V58, P221, DOI 10.1002/jcb.240580211; Schild-Poulter C, 2003, DNA CELL BIOL, V22, P65, DOI 10.1089/104454903321515887; Sinnett D, 1996, GENE, V173, P171, DOI 10.1016/0378-1119(96)00106-0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; Strehl S, 1997, MOL CELL BIOL, V17, P6157, DOI 10.1128/MCB.17.10.6157; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; TOTH EC, 1993, NUCLEIC ACIDS RES, V21, P3257, DOI 10.1093/nar/21.14.3257; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VISHWANATHA JK, 1990, BIOCHEMISTRY-US, V29, P8753, DOI 10.1021/bi00489a036; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P241, DOI 10.1016/0167-4781(93)90193-H; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P258, DOI 10.1016/0167-4781(93)90194-I; Zannis-Hadjopoulos M, 1998, CRIT REV EUKAR GENE, V8, P81, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.40; Zannis-Hadjopoulos M, 1999, J CELL BIOCHEM, P1; ZANNISHADJOPOULOS M, 1994, GENE, V151, P273, DOI 10.1016/0378-1119(94)90670-X; ZHAO YP, 1994, NUCLEIC ACIDS RES, V22, P5385, DOI 10.1093/nar/22.24.5385	51	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19649	19659		10.1074/jbc.M207002200	http://dx.doi.org/10.1074/jbc.M207002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665518	hybrid			2022-12-25	WOS:000183078000013
J	Soto, P; Price-Schiavi, SA; Carraway, KL				Soto, P; Price-Schiavi, SA; Carraway, KL			SMAD2 and SMAD7 involvement in the post-translational regulation of Muc4 via the transforming growth factor-beta and interferon-gamma pathways in rat mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE SIALOMUCIN COMPLEX; INTRAMEMBRANE MODULATOR; ADENOCARCINOMA CELLS; SIGNAL-TRANSDUCTION; OVEREXPRESSION; KINASE	Muc4/sialomucin complex (SMC) is a heterodimeric glycoprotein complex derived from a single gene that is post-translationally processed into mucin (ASGP-1) and transmembrane (ASGP-2) subunits. Muc4/SMC is tightly regulated in the rat mammary gland, low in the virgin, increased during pregnancy and lactation, and overexpressed in some aggressive mammary tumors. Investigations of primary rat mammary epithelial cells (MEC) have shown that Muc4/SMC expression is post-translationally regulated through inhibition of Muc4/SMC precursor processing by transforming growth factor-beta (TGF-beta). Localization studies suggest that TGF-beta inhibition of Muc4/SMC expression is mediated through SMAD2, a TGF-beta effector that, when activated, functions as a transcription factor. SMAD2 antisense oligonucleotide blocks the inhibition of Muc4/SMC expression by TGF-beta. The TGF-beta effect on Muc4/SMC expression is repressed by interferon-gamma (IFN-gamma). IFN-gamma treatment of MEC activates and relocalizes signal transducer and activator of transcription-1 (STAT-1) to induce an inhibitor SMAD, SMAD7. SMAD7 antisense oligonucleotide prevents IFN-gamma from blocking the TGF-beta inhibition of Muc4/SMC expression. These results suggest that TGF-beta regulates Muc4/SMC expression via the SMAD pathway by a transcriptional effect on a protein in the Muc4/SMC processing step, possibly the protease that cleaves the precursor.	Univ Miami, Sch Med, Dept Cell Biol & Anat R124, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, POB 016960, Miami, FL 33101 USA.	kcarrawa@med.miami.edu			NCI NIH HHS [CA 52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 2001, PROG NUCL ACIDS RES, V171, P149; Chen TP, 1998, CANCER RES, V58, P4805; He W, 2002, EMBO J, V21, P2580, DOI 10.1093/emboj/21.11.2580; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Ito Y, 2001, J BIOL CHEM, V276, P44163, DOI 10.1074/jbc.M011424200; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 2001, J CELL SCI, V114, P4359; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	28	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20338	20344		10.1074/jbc.M301886200	http://dx.doi.org/10.1074/jbc.M301886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12668667	hybrid			2022-12-25	WOS:000183078000098
J	Taylor, SW; Fahy, E; Murray, J; Capaldi, RA; Ghosh, SS				Taylor, SW; Fahy, E; Murray, J; Capaldi, RA; Ghosh, SS			Oxidative post-translational modification of tryptophan residues in cardiac mitochondrial proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; CELL-DEATH; IDENTIFICATION; PEROXYNITRITE; INACTIVATION; COMPLEXES; NITRATION; TISSUE; MICE	We examined the distribution of N-formylkynurenine, a product of the dioxidation of tryptophan residues in proteins, throughout the human heart mitochondrial proteome. This oxidized amino acid is associated with a distinct subset of proteins, including an over-representation of complex I subunits as well as complex V subunits and enzymes involved in redox metabolism. No relationship was observed between the tryptophan modification and methionine oxidation, a known artifact of sample handling. As the mitochondria were isolated from normal human heart tissue and not subject to any artificially induced oxidative stress, we suggest that the susceptible tryptophan residues in this group of proteins are "hot spots" for oxidation in close proximity to a source of reactive oxygen species in respiring mitochondria.	MitoKor, San Diego, CA 92121 USA; Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA	University of Oregon	Taylor, SW (corresponding author), MitoKor, 11494 Sorrento Valley Rd, San Diego, CA 92121 USA.							Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Anderson LB, 2002, P NATL ACAD SCI USA, V99, P14676, DOI 10.1073/pnas.232591599; Bienvenut WV, 2002, PROTEOMICS, V2, P868, DOI 10.1002/1615-9861(200207)2:7<868::AID-PROT868>3.0.CO;2-D; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Karty JA, 2002, J CHROMATOGR B, V782, P363, DOI 10.1016/S1570-0232(02)00550-0; KURODA M, 1975, J BIOCHEM-TOKYO, V78, P641, DOI 10.1093/oxfordjournals.jbchem.a130951; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Potgieter HC, 1997, ANAL BIOCHEM, V248, P86, DOI 10.1006/abio.1997.2075; PREVIERO A, 1967, J MOL BIOL, V24, P261, DOI 10.1016/0022-2836(67)90331-2; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Sweetlove LJ, 2002, PLANT J, V32, P891, DOI 10.1046/j.1365-313X.2002.01474.x; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; Thiede B, 2000, RAPID COMMUN MASS SP, V14, P496, DOI 10.1002/(SICI)1097-0231(20000331)14:6<496::AID-RCM899>3.0.CO;2-1; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	26	150	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19587	19590		10.1074/jbc.C300135200	http://dx.doi.org/10.1074/jbc.C300135200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12679331	hybrid			2022-12-25	WOS:000183078000004
J	Tietz, PS; Marinelli, RA; Chen, XM; Huang, B; Cohn, J; Kole, J; McNiven, MA; Alper, S; LaRusso, NF				Tietz, PS; Marinelli, RA; Chen, XM; Huang, B; Cohn, J; Kole, J; McNiven, MA; Alper, S; LaRusso, NF			Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCT EPITHELIAL-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; RAT-LIVER; SUBCELLULAR FRACTIONATION; MEDIATED MECHANISM; SJOGRENS-SYNDROME; AQUAPORIN CHIP; BILE FORMATION; CYCLIC-AMP	We previously proposed that ductal bile formation is regulated by secretin-responsive relocation of aquaporin 1 (AQP1), a water-selective channel protein, from an intracellular vesicular compartment to the apical membrane of cholangiocytes. In this study, we immunoisolated AQP1-containing vesicles from cholangiocytes prepared from rat liver; quantitative immunoblotting revealed enrichment in these vesicles of not only AQP1 but also cystic fibrosis transmembrane regulator (CFTR) and AE2, a Cl- channel and a Cl-/ HCO3- exchanger, respectively. Dual labeled immunogold electron microscopy of cultured polarized mouse cholangiocytes showed significant colocalization of AQP1, CFTR, and AE2 in an intracellular vesicular compartment; exposure of cholangiocytes to dibutyryl-cAMP ( 100 muM) resulted in co-redistribution of all three proteins to the apical cholangiocyte plasma membrane. After administration of secretin to rats in vivo, bile flow increased, and AQP1, CFTR, and AE2 co-redistributed to the apical cholangiocyte membrane; both events were blocked by pharmacologic disassembly of microtubules. Based on these in vitro and in vivo observations utilizing independent and complementary approaches, we propose that cholangiocytes contain an organelle that sequesters functionally related proteins that can account for ion-driven water transport, that this organelle moves to the apical cholangiocyte membrane in response to secretory agonists, and that these events account for ductal bile secretion at a molecular level.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Biochem & Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Fac Ciencias Bioquim, Dept Fisiol, RA-2000 Rosario, Santa Fe, Argentina; Duke Univ, Med Ctr, Durham, NC USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Mayo Clinic; Mayo Clinic; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	LaRusso, NF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.	larusso.nicholas@mayo.edu			NIDDK NIH HHS [DK24031, DK44650] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK024031, R01DK024031, R37DK044650, R01DK044650, R29DK044650] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acher R, 2002, ANN ENDOCRINOL-PARIS, V63, P197; ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; ALVARO D, 1993, J CLIN INVEST, V92, P1314, DOI 10.1172/JCI116705; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BENEDETTI A, 1994, P NATL ACAD SCI USA, V91, P792, DOI 10.1073/pnas.91.2.792; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Biner HL, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134836; BISHOP YMM, 1975, DISCRETE MULTIVARIAT, P344; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; Boyer JL, 1996, AM J PHYSIOL-GASTR L, V270, pG1, DOI 10.1152/ajpgi.1996.270.1.G1; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F; Colombo C, 1998, SEMIN LIVER DIS, V18, P227, DOI 10.1055/s-2007-1007159; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DUPOURQUE D, 1969, METHOD ENZYMOL, V13, P116; ELKJAER ML, 1995, EUR J CELL BIOL, V67, P57; FARQUHAR MG, 1974, J CELL BIOL, V60, P8, DOI 10.1083/jcb.60.1.8; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; HOWELL KE, 1989, METHOD CELL BIOL, V31, P265; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; KATO A, 1992, J BIOL CHEM, V267, P15523; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; Marinelli RA, 1997, HEPATOLOGY, V26, P1081, DOI 10.1002/hep.510260539; Marinelli RA, 1996, SEMIN LIVER DIS, V16, P221, DOI 10.1055/s-2007-1007234; Marinelli RA, 1999, AM J PHYSIOL-GASTR L, V276, pG280, DOI 10.1152/ajpgi.1999.276.1.G280; MCCAFFERY JM, 1995, METHOD ENZYMOL, V257, P259; Mennone A, 2002, AM J PHYSIOL-GASTR L, V283, pG739, DOI 10.1152/ajpgi.00540.2001; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; O'Reilly CM, 2000, GASTROENTEROLOGY, V118, P1187, DOI 10.1016/S0016-5085(00)70372-6; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PRIETO J, 1993, GASTROENTEROLOGY, V105, P572, DOI 10.1016/0016-5085(93)90735-U; RAEDER MG, 1995, CURR OPIN GASTROEN, V11, P439; REEVES WJ, 1966, METHOD ENZYMOL, V9, P288; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; Shukla A, 2001, AM J PHYSIOL-RENAL, V281, pF546, DOI 10.1152/ajprenal.2001.281.3.F546; Steinfeld S, 2001, LAB INVEST, V81, P143, DOI 10.1038/labinvest.3780221; TIETZ PS, 1995, BIOCHEMISTRY-US, V34, P15436, DOI 10.1021/bi00047a007; Tsubota K, 2001, LANCET, V357, P688, DOI 10.1016/S0140-6736(00)04140-4; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Yahagi K, 1998, IN VITRO CELL DEV-AN, V34, P512; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546	45	93	95	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20413	20419		10.1074/jbc.M302108200	http://dx.doi.org/10.1074/jbc.M302108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660234	hybrid			2022-12-25	WOS:000183078000107
J	Wu, RY; Zhang, RG; Zagnitko, O; Dementieva, I; Maltzev, N; Watson, JD; Laskowski, R; Gornicki, P; Joachimiak, A				Wu, RY; Zhang, RG; Zagnitko, O; Dementieva, I; Maltzev, N; Watson, JD; Laskowski, R; Gornicki, P; Joachimiak, A			Crystal structure of Enterococcus faecalis SlyA-like transcriptional factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEINS; EXPRESSION; YERSINIA; ACTIVATION; REGULATORS; FAMILY; CLYA	The crystal structure of a SlyA transcriptional regulator at 1.6 Angstrom resolution is presented, and structural relationships between members of the MarR/SlyA family are discussed. The SlyA family, which includes SlyA, Rap, Hor, and RovA proteins, is widely distributed in bacterial and archaeal genomes. Current evidence suggests that SlyA-like factors act as repressors, activators, and modulators of gene transcription. These proteins have been shown to up-regulate the expression of molecular chaperones, acid-resistance proteins, and cytolysin, and down-regulate several biosynthetic enzymes. The structure of SlyA from Enterococcus faecalis, determined as a part of an ongoing structural genomics initiative (www.mcsg.anl.gov), revealed the same winged helix DNA-binding motif that was recently found in the MarR repressor from Escherichia coli and the MexR repressor from Pseudomonas aeruginosa, a sequence homologue of MarR. Phylogenetic analysis of the MarR/ SlyA family suggests that Sly is placed between the SlyA and MarR subfamilies and shows significant sequence similarity to members of both subfamilies.	Argonne Natl Lab, Biosci Div, Struct Biol Ctr, Argonne, IL 60439 USA; Argonne Natl Lab, Div Math & Comp Sci, Argonne, IL 60439 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Wellcome Trust Genome Campus, European Bioinformat Inst, Cambridge CB10 1SD, England	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute	Joachimiak, A (corresponding author), Argonne Natl Lab, Biosci Div, Struct Biol Ctr, 9700 S Cass Ave,Bldg 202, Argonne, IL 60439 USA.	andrzejj@anl.gov		Laskowski, Roman/0000-0001-5528-0087	NIGMS NIH HHS [P50 GM062414, GM62414, P50 GM062414-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC, 2000, QUANTA; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DEHOUX P, 1995, MOL MICROBIOL, V15, P591, DOI 10.1111/j.1365-2958.1995.tb02272.x; Finnin MS, 1997, EMBO J, V16, P1992, DOI 10.1093/emboj/16.8.1992; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Kenney LJ, 2002, CURR OPIN MICROBIOL, V5, P135, DOI 10.1016/S1369-5274(02)00310-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; Oscarsson J, 2002, INFECT IMMUN, V70, P5759, DOI 10.1128/IAI.70.10.5759-5769.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Rueda E, 2001, J MOL EVOL, V53, P172, DOI 10.1007/s002390010207; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Revell PA, 2001, FEMS MICROBIOL LETT, V205, P159, DOI [10.1111/j.1574-6968.2001.tb10941.x, 10.1016/S0378-1097(01)00476-1]; Spory A, 2002, J BACTERIOL, V184, P3549, DOI 10.1128/JB.184.13.3549-3559.2002; Thomson NR, 1997, MOL MICROBIOL, V26, P531, DOI 10.1046/j.1365-2958.1997.5981976.x; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	23	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20240	20244		10.1074/jbc.M300292200	http://dx.doi.org/10.1074/jbc.M300292200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649270	hybrid, Green Accepted			2022-12-25	WOS:000183078000086
J	Barletta, GM; Kovari, IA; Verma, RK; Kerjaschki, D; Holzman, LB				Barletta, GM; Kovari, IA; Verma, RK; Kerjaschki, D; Holzman, LB			Nephrin and Neph1 co-localize at the podocyte foot process intercellular junction and form cis hetero-oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR SLIT DIAPHRAGM; CONGENITAL NEPHROTIC SYNDROME; EPITHELIAL-CELL; PROTEIN; GENE; COMPONENT; ADHESION; MICE; IDENTIFICATION; DIMERIZATION	Glomerular visceral epithelial cells (podocytes) appear to play a central role in maintaining the selective filtration barrier of the renal glomerulus. While the immunoglobulin superfamily member Nephrin was proposed to act as a cell adhesion molecule at the podocyte intercellular junction necessary for maintaining glomerular perm selectivity, the Nephrin ligand has not been identified. The existence of a new subfamily of Nephrin-like molecules including Neph1 was recently described. Genetic deletion of Nephrin or Neph1 resulted in similar phenotypes of podocyte foot process effacement and proteinuria. The subcellular localization of Neph1 and the possibility that Nephrin and Neph1 interact was investigated. Polyclonal antiserum for Neph1 was raised and characterized. Neph1 migrated as a 90-kDa protein on SDS-PAGE under reducing conditions. Neph1 was identified in a glomerular and podocyte-specific distribution in adult rat kidney. Like Nephrin and Podocin, Neph1 was enriched in Triton X-100 detergent-resistant membrane fractions. Consistent with this observation, immunogold electron microscopy demonstrated that Neph1 localized exclusively to lateral margins of podocyte foot processes at the insertion of the slit diaphragm. Neph1 and Nephrin participate in a direct cis-interaction involving their cytoplasmic domains. In addition, interactions between the extracellular domain of Nephrin and itself and between the extracellular domain of Nephrin and that of Neph1 were detected. Neph1 did not interact via a homophilic interaction. These observations suggest that Nephrin and Neph1 form a hetero-oligomeric receptor complex in the plane of the membrane that might interact across the foot process intercellular junction through interactions between Nephrin with itself and Neph1.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Vienna, Allgemeines Krankenhaus, Inst Clin Pathol, A-1090 Vienna, Austria; Dept Vet Affairs, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Vienna	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1560 MSRB II, Ann Arbor, MI 48109 USA.	lholzman@umich.edu		Holzman, Lawrence/0000-0002-8961-234X				Ahrens T, 2002, J BIOL CHEM, V277, P19455, DOI 10.1074/jbc.M200606200; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Dworak HA, 2001, DEVELOPMENT, V128, P4265; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; Gil OD, 1998, J NEUROSCI, V18, P9312; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; Jalanko H, 2001, ANN MED, V33, P526, DOI 10.3109/07853890108995962; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; Karle SM, 2002, J AM SOC NEPHROL, V13, P388, DOI 10.1681/ASN.V132388; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Moeller MJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015614.68893.0B; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Regele HM, 2000, J AM SOC NEPHROL, V11, P403, DOI 10.1681/ASN.V113403; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SALANT DJ, 1980, J CLIN INVEST, V66, P71, DOI 10.1172/JCI109837; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Yuan HP, 2002, AM J PHYSIOL-RENAL, V282, pF585, DOI 10.1152/ajprenal.00290.2001	34	140	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19266	19271		10.1074/jbc.M301279200	http://dx.doi.org/10.1074/jbc.M301279200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646566	hybrid			2022-12-25	WOS:000182932200071
J	Devchand, PR; Arita, M; Hong, S; Bannenberg, G; Moussignac, RL; Gronert, K; Serhan, CN				Devchand, PR; Arita, M; Hong, S; Bannenberg, G; Moussignac, RL; Gronert, K; Serhan, CN			Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense	FASEB JOURNAL			English	Article						eicosanoids; lipoxin A(4); resolution of inflammation; inhibition of NF kappa B; G-protein-coupled receptor	ASPIRIN-TRIGGERED LIPOXINS	Signaling pathways instrumental in the temporal and spatial progression of acute inflammation toward resolution are of wide interest. Here a transgenic mouse with myeloid-selective expression of human lipoxin A(4) receptor (hALX) was prepared and used to evaluate in vivo the effect of hALX expression. hALX-transfected HEK293 cells transmitted LXA(4) signals that inhibit TNFalpha-induced NFkappaB activation. Transgenic FvB mice were generated by DNA injections of a 3.8 kb transgene consisting of the full-length hALX cDNA driven by a fragment of the hCD11b promoter. When topically challenged via dermal ear skin, hALX transgenic mice gave attenuated neutrophil infiltration (similar to80% reduction) in response to leukotriene B-4 (LTB4) plus prostaglandin E-2 (PGE(2)) as well as similar to50% reduction in PMN infiltrates (P<0.02) to receptor-bypass inflammation evoked by phorbol ester. The hALX transgenic mice gave markedly decreased PMN infiltrates to the peritoneum with zymosan and altered the dynamics of this response. Transgenic hALX mice displayed increased sensitivity with >50% reduction in PMN infiltrates to suboptimal doses (10 ng/mouse) of the ligand lipoxin A(4) stable analog compared with < 10% reduction of PMN in nontransgenic littermates. Soluble mediators generated within the local inflammatory milieu of hALX mice showed diminished ability to activate the proinflammatory transcription factor NF kappa B. Analyses of the lipid-derived mediators from exudates using LC-MS tandem mass spectroscopy indicated an altered profile in hALX transgenic mice that included lower levels of LTB4 and increased amounts of lipoxin A(4) compared with nontransgenic littermates. Together these results demonstrate a gain-of-function with hALX transgenic mouse and indicate that ALX is a key receptor and sensor in formation of acute exudates and their resolution.	Harvard Univ, Sch Med,Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Serhan, CN (corresponding author), Harvard Univ, Sch Med,Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Thorn Bldg Med Res,7th Floor,75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Bannenberg, Gerard/AAF-6216-2020	Arita, Makoto/0000-0001-9902-0463; Bannenberg, Gerard/0000-0001-7763-6224	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305, K01DK060583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R37GM038765, R29GM038765] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01-AR02219] Funding Source: Medline; NIDDK NIH HHS [DK50305, K01 DK060583-03] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030; Cotran R., 1999, ROBBINS PATHOLOGIC B, P1; Cotran R. S., 1999, ROBBINS PATHOLOGIC B, V6th; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DZIENNIS S, 1995, BLOOD, V85, P319; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gallin J.I., 1999, INFLAMMATION BASIC P; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Kang Y, 2000, BIOCHEMISTRY-US, V39, P13551, DOI 10.1021/bi001196i; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Perez H D, 1994, Curr Opin Hematol, V1, P40; QIU FH, 2001, FASEB J, DOI DOI 10.1096/FJ.1001-0576FJE; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Serhan Charles N, 2002, ScientificWorldJournal, V2, P169; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693	27	152	162	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					652	659		10.1096/fj.02-0770com	http://dx.doi.org/10.1096/fj.02-0770com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665478				2022-12-25	WOS:000182580100010
J	Matsushima-Hibiya, Y; Watanabe, M; Hidari, KIPJ; Miyamoto, D; Suzuki, Y; Kasama, T; Kanazawa, T; Koyama, K; Sugimura, T; Wakabayashi, K				Matsushima-Hibiya, Y; Watanabe, M; Hidari, KIPJ; Miyamoto, D; Suzuki, Y; Kasama, T; Kanazawa, T; Koyama, K; Sugimura, T; Wakabayashi, K			Identification of glycosphingolipid receptors for pierisin-1, a guanine-specific ADP-ribosylating toxin from the cabbage butterfly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING PROTEIN; BOTULINUM TYPE-C; RICIN B-CHAIN; CYTOTOXIC ACTIVITY; MOLECULAR-CLONING; CARCINOMA-CELLS; BINDING; RAPAE; PURIFICATION; GLYCOLIPIDS	Pierisin-1, a cytotoxic protein found naturally in the cabbage butterfly, induces apoptosis of mammalian cells. Our recent studies suggest that pierisin-1 consists of an N-terminal ADP-ribosyltransferase domain, and a C-terminal region that binds to receptors on the surfaces of target cells and incorporates the protein into cells. The present study was undertaken to identify receptors for pierisin-1. The cross-linking and cloning experiments suggested that the proteins on cell membrane had no binding ability to pierisin-1. Inhibitory assays of fractionated lipids from human cervical carcinoma HeLa cells, which are highly sensitive to pierisin-1, indicated neutral glycosphingolipids on the cell surface to show receptor activity. Inhibitory assays and TLC immunostaining using anti-pierisin-1 antibodies demonstrated two neutral glycosphingolipids as active components. Analysis of their structures with glycosphingolipid-specific antibodies and negative secondary ion mass spectrometry identified them as globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4). The receptor activities of Gb3 and Gb4 for pierisin-1 were also confirmed with these authentic compounds. Pierisin-l-insensitive mouse melanoma MEB4 cells were found to lack pierisin-1 receptors, including Gb3 and Gb4, but pretreatment of the cells with glycosphingolipid Gb3 or Gh4 enhanced their sensitivity to pierisin-1. Thus, Gb3 and Gb4 were proven to serve as pierisin-1 receptors. The C-terminal region of pierisin-1 consists of possible lectin domains of a ricin B-chain, containing QXW sequences, which are essential for its structural organization. Alteration of QXW by site-directed mutagenesis caused marked reduction of pierisin-1 cytotoxicity. Thus, our results suggest that pierisin-1 binds to Gb3 and Gb4 receptors at the C-terminal region, in a manner similar to ricin, and then exhibits cytotoxicity after incorporation into the cell.	Natl Canc Ctr, Res Inst, Canc Prevent Div, Chuo Ku, Tokyo 1040045, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; Tokyo Med & Dent Univ, Instrumental Anal Res Ctr Life Sci, Bunkyo Ku, Tokyo 1138510, Japan	National Cancer Center - Japan; University of Shizuoka; Tokyo Medical & Dental University (TMDU)	Matsushima-Hibiya, Y (corresponding author), Natl Canc Ctr, Res Inst, Canc Prevent Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	yhibiya@gan2.ncc.go.jp		Yasuo, Suzuki/0000-0003-3518-5642				ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Fujinaga Y, 2000, FEBS LETT, V467, P179, DOI 10.1016/S0014-5793(00)01147-9; HAZES B, 1995, NAT STRUCT BIOL, V2, P358, DOI 10.1038/nsb0595-358; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; HIRAI R, 1992, EXP CELL RES, V201, P119, DOI 10.1016/0014-4827(92)90355-C; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Inoue K, 1996, INFECT IMMUN, V64, P1589, DOI 10.1128/IAI.64.5.1589-1594.1996; Inoue K, 1999, MICROBIOL-UK, V145, P2533, DOI 10.1099/00221287-145-9-2533; ITASAKA O, 1983, BIOCHIM BIOPHYS ACTA, V751, P8, DOI 10.1016/0005-2760(83)90250-3; Kanazawa T, 2001, P NATL ACAD SCI USA, V98, P2226, DOI 10.1073/pnas.051628898; Kasama T, 1996, GLYCOCONJUGATE J, V13, P461, DOI 10.1007/BF00731479; Kono T, 1999, CANCER LETT, V137, P75, DOI 10.1016/S0304-3835(98)00346-2; Koyama K, 1996, JPN J CANCER RES, V87, P1259, DOI 10.1111/j.1349-7006.1996.tb03141.x; Matsushima-Hibiya Y, 2000, EUR J BIOCHEM, V267, P5742, DOI 10.1046/j.1432-1327.2000.01640.x; Miyamoto D, 1997, GLYCOCONJUGATE J, V14, P379, DOI 10.1023/A:1018578829997; MURAYAMA K, 1986, CANCER RES, V46, P1395; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; SPHYRIS N, 1995, J BIOL CHEM, V270, P20292, DOI 10.1074/jbc.270.35.20292; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; Takamura-Enya T, 2001, P NATL ACAD SCI USA, V98, P12414, DOI 10.1073/pnas.221444598; Tao Bernard Y., 1994, P69; TSUZUKI K, 1990, INFECT IMMUN, V58, P3173, DOI 10.1128/IAI.58.10.3173-3177.1990; VONDEMBORNE AEGK, 1986, BRIT J HAEMATOL, V63, P35; Watanabe M, 1999, P NATL ACAD SCI USA, V96, P10608, DOI 10.1073/pnas.96.19.10608; Watanabe M, 1998, JPN J CANCER RES, V89, P556, DOI 10.1111/j.1349-7006.1998.tb03297.x; WIEGANDT H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P117, DOI 10.1016/0005-2760(92)90101-Z	31	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9972	9978		10.1074/jbc.M212114200	http://dx.doi.org/10.1074/jbc.M212114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645583	hybrid			2022-12-25	WOS:000181524000145
J	Agarwal, S; Long, P; Seyedain, A; Piesco, N; Shree, A; Gassner, R				Agarwal, S; Long, P; Seyedain, A; Piesco, N; Shree, A; Gassner, R			A central role for nuclear factor-kappa B pathway in the antiinflammatory and proinflammatory actions of mechanical strain	FASEB JOURNAL			English	Article						NF-kappa B; signal transduction; osteoblastic cells; mechanical strain	HUMAN PERIODONTAL-LIGAMENT; SIGNAL-TRANSDUCTION; TENSILE STRAIN; EXPRESSION; CELLS; INDUCTION; STRESS; ALPHA; GENE; OSTEOGENESIS	Mechanical signals play an integral role in bone homeostasis. These signals are observed at the interface of bone and teeth, where osteoblast-like periodontal ligament (PDL) cells constantly take part in bone formation and resorption in response to applied mechanical forces. Earlier, we reported that signals generated by tensile strain of low magnitude (TENS-L) are antiinflammatory, whereas tensile strain of high magnitude (TENS-H) is proinflammatory and catabolic. In this study, we examined the mechanisms of intracellular actions of the antiinflammatory and proinflammatory signals generated by TENS of various magnitudes. We show that both low and high magnitudes of mechanical strain exploit nuclear factor (NF)-kappaB as a common pathway for transcriptional inhibition/activation of proinflammatory genes and catabolic processes. TENS-L is a potent inhibitor of interleukin (IL)-1beta-induced I-kappaBbeta degradation and prevents dissociation of NF-kappaB from cytoplasmic complexes and thus its nuclear translocation. This leads to sustained suppression of IL-1beta-induced NF-kappaB transcriptional regulation of proinflammatory genes. In contrast, TENS-H is a proinflammatory signal that induces I-kappaBbeta degradation, nuclear translocation of NF-kappaB, and transcriptional activation of proinflammatory genes. These findings are the first to describe the largely unknown intracellular mechanism of action of applied tensile forces in osteoblast-like cells and have critical implications in bone remodeling.	Univ Pittsburgh, McGowen Inst Regenerat Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Agarwal, S (corresponding author), Univ Pittsburgh, McGowen Inst Regenerat Med, 589 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.	sagar@pitt.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015399] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT000646] Funding Source: Medline; NIDCR NIH HHS [R01 DE015399] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agarwal S, 1998, INFECT IMMUN, V66, P932, DOI 10.1128/IAI.66.3.932-937.1998; Bolcato-Bellemin AL, 2000, J DENT RES, V79, P1712, DOI 10.1177/00220345000790091201; BURGER EH, 1992, J BONE MINER RES, V7, pS397, DOI 10.1002/jbmr.5650071406; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHIBA M, 1993, J BIOMECH, V26, P561, DOI 10.1016/0021-9290(93)90017-9; Chien HH, 1999, CALCIFIED TISSUE INT, V64, P402, DOI 10.1007/PL00005822; DAVIDOVITCH Z, 1996, BIOL MECH TOOTH MOVE, P255; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Du W, 1995, J BIOMECH, V28, P1485, DOI 10.1016/0021-9290(95)00096-8; Fermor B, 1998, BONE, V22, P637, DOI 10.1016/S8756-3282(98)00047-7; Gassner R, 1999, J IMMUNOL, V163, P2187; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Howard PS, 1998, J PERIODONTAL RES, V33, P500; Ikegame M, 2001, J BONE MINER RES, V16, P24, DOI 10.1359/jbmr.2001.16.1.24; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Klein-Nulend J, 2002, OSTEOPOROSIS INT, V13, P137, DOI 10.1007/s001980200005; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Ko KS, 2001, BIOCHEM BIOPH RES CO, V285, P1077, DOI 10.1006/bbrc.2001.5177; Long P, 2002, BONE, V30, P547, DOI 10.1016/S8756-3282(02)00673-7; Long P, 2001, J DENT RES, V80, P1416, DOI 10.1177/00220345010800050601; Long P, 2001, ARTHRITIS RHEUM, V44, P2311, DOI 10.1002/1529-0131(200110)44:10<2311::AID-ART393>3.0.CO;2-Q; McCulloch CAG, 2000, PERIODONTOL 2000, V24, P56, DOI 10.1034/j.1600-0757.2000.2240104.x; Rubin J, 2000, AM J PHYSIOL-CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126; Salter DM, 2001, CLIN ORTHOP RELAT R, pS49; Shimizu N, 1998, J PERIODONTOL, V69, P670, DOI 10.1902/jop.1998.69.6.670; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; Yamaguchi M, 1997, J PERIODONTAL RES, V32, P308, DOI 10.1111/j.1600-0765.1997.tb00539.x; Yang JH, 1998, J BIOL CHEM, V273, P6550, DOI 10.1074/jbc.273.11.6550	30	57	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					899	+		10.1096/fj.02-0901fje	http://dx.doi.org/10.1096/fj.02-0901fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670873	Green Accepted			2022-12-25	WOS:000181892600005
J	Smit, JJ; van Loveren, H; Hoekstra, MO; Nijkamp, FP; Bloksma, N				Smit, JJ; van Loveren, H; Hoekstra, MO; Nijkamp, FP; Bloksma, N			Influence of the macrophage bacterial resistance gene Nramp1 (Slc11a1) on the induction of allergic asthma in the mouse	FASEB JOURNAL			English	Article						Th1/Th2 cells; allergy; natural-resistance-associated macrophage protein 1	MAST-CELLS; NATURAL-RESISTANCE; AIRWAY HYPERRESPONSIVENESS; EOSINOPHILIC INFLAMMATION; INTRACELLULAR PARASITES; EPITHELIAL-CELLS; BCG VACCINATION; MURINE MODEL; IN-VITRO; MICE	Based on the hygiene hypothesis that lack of early childhood bacterial infections would favor development of allergic disease, we hypothesize that genes controlling antibacterial resistance may be important as well. We, therefore, studied whether Nramp1 alleles that determine resistance (Nramp1(r)) or susceptibility (Nramp1(s)) to intracellular bacteria at the macrophage level affect sensitivity to induction of allergic asthma. Nramp1(s) and congenic Nramp1(r) mice were sensitized with ovalbumin/alum on days 0 and 14 and challenged with ovalbumin or saline aerosols on days 42, 45, and 48. On day 49, airway responsiveness was assessed, blood was withdrawn, and lung lavage was performed. We demonstrated that ovalbumin sensitization and challenge of Nramp1(s) and Nramp1(r) mice caused comparable airway hyperreactivity and airway eosinophilia and a similar increase in serum levels of ovalbumin-specific IgG1 and IgG2a. Ovalbumin challenge, however, induced significantly lower serum levels of total and ovalbumin-specific IgE and significantly lower mast cell degranulation in Nramp1(r) mice as compared with Nramp1(s) mice. In addition, ovalbumin challenge of Nramp1(r) mice led to significantly less release of Th2 cytokines into the airways. Results show that Nramp1 can affect the development of allergy but not the development of airway hyperresponsiveness in the mouse.	Univ Utrecht, Dept Pharmacol & Pathophysiol, Utrecht Inst Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands; Univ Utrecht, Fac Biol, NL-3508 TB Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, Lab Pathol & Immunobiol, Bilthoven, Netherlands; Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Maastricht, Netherlands; UMC, Dept Gen Pediat, Wilhelmina Childrens Hosp, Utrecht, Netherlands	Utrecht University; Utrecht University; Netherlands National Institute for Public Health & the Environment; Maastricht University; Wilhelmina Kinderziekenhuis	Bloksma, N (corresponding author), Univ Utrecht, Dept Pharmacol & Pathophysiol, Utrecht Inst Pharmaceut Sci, POB 80082, NL-3508 TB Utrecht, Netherlands.	M.A.Bloksma@pharm.uu.nl		Smit, Joost/0000-0003-4612-4036				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Araujo LMM, 1998, EUR J IMMUNOL, V28, P2913, DOI 10.1002/(SICI)1521-4141(199809)28:09&lt;2913::AID-IMMU2913&gt;3.0.CO;2-3; Bellamy R, 1999, MICROBES INFECT, V1, P23, DOI 10.1016/S1286-4579(99)80010-0; Bingisser RM, 2001, SWISS MED WKLY, V131, P171; BIOZZI G, 1984, ADV IMMUNOL, V36, P189, DOI 10.1016/S0065-2776(08)60902-5; Blackwell JM, 1999, IMMUNOL LETT, V65, P73, DOI 10.1016/S0165-2478(98)00127-8; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; Blackwell JM, 1996, PARASITOLOGY, V112, pS67, DOI 10.1017/S0031182000076678; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chu SJ, 2000, J IMMUNOL, V165, P4640, DOI 10.4049/jimmunol.165.8.4640; COLEMAN JW, 2000, MAST CELLS BASOPHILS, P221; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Corry DB, 1999, NATURE, V402, pB18; de Bie JJ, 2000, EXP LUNG RES, V26, P491; Eastmond NC, 1997, J IMMUNOL, V159, P1444; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; Govoni G, 1997, J LEUKOCYTE BIOL, V62, P277, DOI 10.1002/jlb.62.2.277; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; HESSEL EM, 1995, EUR J PHARM-ENVIRON, V293, P401, DOI 10.1016/0926-6917(95)90061-6; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, J IMMUNOL, V161, P1501; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Houtman R, 2001, J IMMUNOL, V166, P861, DOI 10.4049/jimmunol.166.2.861; Karupiah G, 2000, Rev Immunogenet, V2, P387; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lalmanach AC, 1999, MICROBES INFECT, V1, P719, DOI 10.1016/S1286-4579(99)80073-2; Lang T, 1997, INFECT IMMUN, V65, P380, DOI 10.1128/IAI.65.2.380-386.1997; Lin TJ, 1997, J IMMUNOL, V159, P4015; MOCK BA, 1994, INFECT IMMUN, V62, P325, DOI 10.1128/IAI.62.1.325-328.1994; Olivier M, 1998, EUR J BIOCHEM, V251, P734, DOI 10.1046/j.1432-1327.1998.2510734.x; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Rojas M, 1999, J IMMUNOL, V162, P6122; Rook GAW, 2000, IMMUNOL TODAY, V21, P249, DOI 10.1016/S0167-5699(00)01630-3; Sears MR, 1997, LANCET, V350, P1; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Skamene E, 1998, ANNU REV MED, V49, P275, DOI 10.1146/annurev.med.49.1.275; Soo SS, 1998, INFECT IMMUN, V66, P1910, DOI 10.1128/IAI.66.5.1910-1917.1998; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Strannegard O, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.056002091.x; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; von Hertzen LC, 2000, ANN MED, V32, P397, DOI 10.3109/07853890008995946; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	54	16	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					958	+		10.1096/fj.02-0985fje	http://dx.doi.org/10.1096/fj.02-0985fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670871				2022-12-25	WOS:000181892600002
J	Duda, KM; Brooks, CL				Duda, KM; Brooks, CL			Identification of residues outside the two binding sites that are critical for activation of the lactogenic activity of human growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; ANGSTROM RESOLUTION; RECEPTOR; COMPLEX; PROTEINS; AFFINITY; DESIGN; DIMERIZATION	Human growth hormone ( hGH) binds lactogenic or somatotrophic receptors, creating active heterotrimeric complexes. Comparison of hGH structures, either free or bound to a single lactogenic or somatotrophic receptor, shows binding is associated with structural changes. Changes in hGH structure are unique when binding either lactogenic or somatotrophic receptors and they influence the spatial arrangement of residues constituting the second receptor- binding site. Using site- directed mutagenesis, we identified a contiguous set of largely hydrophobic residues that forms a motif communicating between the two receptor- binding sites of hGH. The residues are external to the receptor- binding epitopes and were identified when their mutation reduced site 2 function without changing site 1 function. The motif includes Phe(44), Leu(93), Tyr(160), Leu(163), and Tyr(164), located in two hydrophobic clusters between the receptor- binding sites. Their mutation to Glu disrupts hydrophobic interactions and reduces lactogenic activity between 4.7- and 85- fold with little effect on somatotrophic activity or spectroscopic properties. These differential effects indicate that loss of lactogenic activity is not a result of global mis- folding. We propose the loss of lactogenic activity results from disruption of specific hydrophobic clusters that disables the site 1 binding- induced structuring of the second receptor- binding site.	Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Brooks, CL (corresponding author), Ohio State Univ, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.	brooks.8@osu.edu						BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHANTALAT L, 1995, PROTEIN PEPTIDE LETT, V2, P333; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Duda KM, 1999, FEBS LETT, V449, P120, DOI 10.1016/S0014-5793(99)00416-0; FUH G, 1993, J BIOL CHEM, V268, P5376; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, V2, P1688; HUGHES JP, 1985, ANNU REV PHYSIOL, V47, P469, DOI 10.1146/annurev.ph.47.030185.002345; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; Kossiakoff AA, 1999, ADV PROTEIN CHEM, V52, P67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Peterson FC, 1999, PROTEIN EXPRES PURIF, V15, P16, DOI 10.1006/prep.1998.0984; Peterson FC, 1997, J BIOL CHEM, V272, P21444, DOI 10.1074/jbc.272.34.21444; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	27	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22734	22739		10.1074/jbc.M212550200	http://dx.doi.org/10.1074/jbc.M212550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682073	hybrid			2022-12-25	WOS:000183503900075
J	Evans, PC; Smith, TS; Lai, MJ; Williams, MG; Burke, DF; Heyninck, K; Kreike, MM; Beyaert, R; Blundell, TL; Kilshaw, PJ				Evans, PC; Smith, TS; Lai, MJ; Williams, MG; Burke, DF; Heyninck, K; Kreike, MM; Beyaert, R; Blundell, TL; Kilshaw, PJ			A novel type of deubiquitinating enzyme*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT FACETS; COMPLEX; DEGRADATION; ACTIVATION; PROTEASOME; SUBSTRATE; METALLOPROTEASE; ISOPEPTIDASE; SPECIFICITY; CLEAVAGE	A previous report from this laboratory described two novel proteins that have sequence similarity to A20, a negative regulator of NF-kappaB (Evans, P. C., Taylor, E. R., Coadwell, J., Heyninck, K., Beyaert, R., and Kilshaw, P. J. (2001) Biochem. J. 357, 617-623). One of these molecules, cellular zinc finger anti-NF-kappaB (Cezanne), a 100-kDa cytoplasmic protein, also suppressed NF-kappaB. Here we demonstrate that Cezanne is a novel deubiquitinating enzyme, distinct from the two known families of deubiquitinases, Types I and II. We show that Cezanne contains an N-terminal catalytic domain that belongs to the recently discovered ovarian tumor protein (OTU) superfamily, a group of proteins displaying structural similarity to cysteine proteases but having no previously described function. Recombinant Cezanne cleaved ubiquitin monomers from linear or branched synthetic ubiquitin chains and from ubiquitinated proteins. Mutation of a conserved cysteine residue in the catalytic site of the proteolytic domain caused Cezanne to co-precipitate polyubiquitinated cellular proteins. We also provide evidence for an additional ubiquitin binding site in the C-terminal part of the molecule. Our data provide the first demonstration of functional activity among OTU proteins.	Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9000 Ghent, Belgium	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University	Evans, PC (corresponding author), Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England.	paul.evans@bbsrc.ac.uk	Burke, David F/C-2091-2013; Beyaert, Rudi/B-2589-2009	Burke, David F/0000-0001-8830-3951; Beyaert, Rudi/0000-0002-5704-582X; Evans, Paul/0000-0001-7975-681X				Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Chen X, 2002, GENE DEV, V16, P289, DOI 10.1101/gad.961502; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DeValck D, 1996, FEBS LETT, V384, P61, DOI 10.1016/0014-5793(96)00283-9; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Fischer JA, 1997, DEV GENET, V21, P167, DOI 10.1002/(SICI)1520-6408(1997)21:2<167::AID-DVG6>3.3.CO;2-T; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	29	132	142	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23180	23186		10.1074/jbc.M301863200	http://dx.doi.org/10.1074/jbc.M301863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12682062	hybrid			2022-12-25	WOS:000183503900126
J	Plambeck, CA; Kwan, AHY; Adams, DJ; Westman, BJ; van der Weyden, L; Medcalf, RL; Morris, BJ; Mackay, JP				Plambeck, CA; Kwan, AHY; Adams, DJ; Westman, BJ; van der Weyden, L; Medcalf, RL; Morris, BJ; Mackay, JP			The structure of the zinc finger domain from human splicing factor ZNF265 fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-RNA-BINDING; HIV REV PEPTIDE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; SR PROTEINS; RECOGNITION; GENE; DROSOPHILA; QUALITY; SITE	Identification of the protein domains that are responsible for RNA recognition has lagged behind the characterization of protein- DNA interactions. However, it is now becoming clear that a range of structural motifs bind to RNA and their structures and molecular mechanisms of action are beginning to be elucidated. In this report, we have expressed and purified one of the two putative RNA- binding domains from ZNF265, a protein that has been shown to bind to the spliceosomal components U1- 70K and U2AF(35) and to direct alternative splicing. We show that this domain, which contains four highly conserved cysteine residues, forms a stable, monomeric structure upon the addition of 1 molar eq of Zn( II). Determination of the solution structure of this domain reveals a conformation comprising two stacked beta- hairpins oriented at similar to80degrees to each other and sandwiching the zinc ion; the fold resembles the zinc ribbon class of zinc- binding domains, although with one less beta- strand than most members of the class. Analysis of the structure reveals a striking resemblance to known RNA-binding motifs in terms of the distribution of key surface residues responsible for making RNA contacts, despite a complete lack of structural homology. Furthermore, we have used an RNA gel shift assay to demonstrate that a single crossed finger domain from ZNF265 is capable of binding to an RNA message. Taken together, these results define a new RNA- binding motif and should provide insight into the functions of the > 100 uncharacterized proteins in the sequence data bases that contain this domain.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ Sydney, Basic & Clin Genom Lab, Sch Med Sci, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Monash Univ, Dept Med, Box Hill Hosp, Box Hill, Vic 3128, Australia	University of Sydney; University of Sydney; University of Sydney; Box Hill Hospital; Monash University	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.	j.mackay@mmb.usyd.edu.au	Medcalf, Robert L/E-9632-2011; van der Weyden, Louise/AAV-5711-2021; Mackay, Joel/D-6834-2011	van der Weyden, Louise/0000-0002-0645-1879; Adams, David/0000-0001-9490-0306; Kwan, Ann/0000-0002-1506-2226; Mackay, Joel/0000-0001-7508-8033				Adams DJ, 2001, J CELL BIOL, V154, P25, DOI 10.1083/jcb.200010059; Adams DJ, 2000, CYTOGENET CELL GENET, V88, P68, DOI 10.1159/000015487; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CLARKE PA, 1995, RNA, V1, P7; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; FASANO L, 1991, CELL, V64, P63, DOI 10.1016/0092-8674(91)90209-H; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; FU XD, 1995, RNA, V1, P663; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hall KB, 2002, CURR OPIN STRUC BIOL, V12, P283, DOI 10.1016/S0959-440X(02)00323-8; Hayes DB, 1994, SEDNTERP INTERPRETAT; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karginova EA, 1997, AM J PHYSIOL-RENAL, V273, pF731, DOI 10.1152/ajprenal.1997.273.5.F731; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Ladomery M, 2000, GENE, V256, P293, DOI 10.1016/S0378-1119(00)00375-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Markus MA, 1997, NAT STRUCT BIOL, V4, P70, DOI 10.1038/nsb0197-70; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakano M, 1998, GENE, V225, P59, DOI 10.1016/S0378-1119(98)00536-8; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Searles MA, 2000, J MOL BIOL, V301, P47, DOI 10.1006/jmbi.2000.3946; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	68	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22805	22811		10.1074/jbc.M301896200	http://dx.doi.org/10.1074/jbc.M301896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12657633	hybrid			2022-12-25	WOS:000183503900084
J	Schaffer, A; Kim, EC; Wu, XP; Zan, H; Testoni, L; Salamon, S; Cerutti, A; Casali, P				Schaffer, A; Kim, EC; Wu, XP; Zan, H; Testoni, L; Salamon, S; Cerutti, A; Casali, P			Selective inhibition of class switching to IgG and IgE by recruitment of the HoxC4 and Oct-1 homeodomain proteins and Ku70/Ku86 to newly identified ATTT cis-elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; BCL-6 SOMATIC HYPERMUTATION; DNA-BINDING PROTEIN; CD30(+) T-CELLS; GERMLINE PROMOTER; TRANSCRIPTIONAL REPRESSION; RESPONSIVE ELEMENT; CD40 LIGAND; RECOMBINATION; IL-4	Immunoglobulin (Ig) class switching is central to the maturation of the antibody response as IgG, IgA, and IgE are endowed with more diverse biological effector functions than IgM. It is induced upon engagement of CD40 on B lymphocytes by CD40L expressed by activated CD4(+) T cells and exposure of B cells to T cell-secreted cytokines including interleukin-4 and transforming growth factor-beta. It begins with germ line I-H-C-H transcription and unfolds through class switch DNA recombination (CSR). We show here that the HoxC4 and Oct-1 homeodomain proteins together with the Ku70/Ku86 heterodimer bind as a complex to newly identified switch ( S) regulatory ATTT elements (SREs) in the Igamma and Iepsilon promoters and downstream regions to dampen basal germ line Igamma-Cgamma and Igamma-Cepsilon transcriptions and repress CSR to Cgamma and Cepsilon. This mechanism is inactive in the Calpha1/Calpha2 loci because of the lack of SREs in the Ialpha1/Ialpha2 promoters. Accordingly, in resting human IgM(+)IgD(+) B cells, HoxC4, Oct-1, and Ku70/Ku86 can be readily identified as bound to the Igamma and Iepsilon promoters but not the Ialpha1/Ialpha2 promoters. CD40 signaling dissociates the HoxC4.Oct-1.Ku complex from the Igamma and Iepsilon promoter SREs, thereby relieving the I-H-C-H transcriptional repression and allowing CSR to unfold. Dissociation of HoxC4.Oct-1.Ku from DNA is hampered by CD153 engagement, a CD40-signaling inhibitor. Thus, these findings outline a HoxC4.Oct-1.Ku-dependent mechanism of selective regulation of class switching to IgG and IgE and further suggest distinct co-evolution and shared CSR activation pathways in the Cgamma and Cepsilon as opposed to the Calpha1/Calpha2 loci.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, Div Mol Immunol, New York, NY 10021 USA; Univ Calif Irvine, Sch Biol Sci, Ctr Immunol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Irvine, CA 92697 USA	Cornell University; University of California System; University of California Irvine; University of California System; University of California Irvine	Casali, P (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, Div Mol Immunol, New York, NY 10021 USA.		Casali, Paolo/F-6579-2010	Cerutti, Andrea/0000-0003-3026-4704	NIAID NIH HHS [R56 AI045011, AI 45011, T32 AI007621, AI 07621, R01 AI045011] Funding Source: Medline; NIAMS NIH HHS [R01 AR040908, AR 47872, AR 40908] Funding Source: Medline; NIA NIH HHS [AG 13910] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045011, T32AI007621, R01AI045011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040908, R01AR047872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agresti A, 2002, MOL IMMUNOL, V38, P849, DOI 10.1016/S0161-5890(01)00121-3; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Berry M, 2000, EMBO J, V19, P2946, DOI 10.1093/emboj/19.12.2946; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Cerutti A, 1998, IMMUNITY, V9, P247, DOI 10.1016/S1074-7613(00)80607-X; Cerutti A, 1998, J IMMUNOL, V160, P2145; Cerutti A, 2001, NAT IMMUNOL, V2, P150, DOI 10.1038/84254; Cerutti A, 2000, J IMMUNOL, V165, P786, DOI 10.4049/jimmunol.165.2.786; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Drouin EE, 2002, J IMMUNOL, V168, P2847, DOI 10.4049/jimmunol.168.6.2847; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; ICHIKI T, 1993, J IMMUNOL, V150, P5408; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; Linehan LA, 1998, J IMMUNOL, V161, P302; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; MILLS FC, 1995, J IMMUNOL, V155, P3021; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; NILSSON L, 1991, INT IMMUNOL, V3, P1107, DOI 10.1093/intimm/3.11.1107; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P51, DOI 10.1093/nar/10.1.51; Qiu G, 1998, J IMMUNOL, V161, P2906; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Schaffer A, 1999, J IMMUNOL, V162, P5327; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Shen CH, 2001, J IMMUNOL, V166, P411, DOI 10.4049/jimmunol.166.1.411; Sideras P, 1989, Int Immunol, V1, P631, DOI 10.1093/intimm/1.6.631; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; Thienes CP, 1997, J IMMUNOL, V158, P5874; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; WANG JS, 1994, J CELL SCI, V107, P3223; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zan H, 2000, J IMMUNOL, V165, P830, DOI 10.4049/jimmunol.165.2.830; Zan H, 1999, J IMMUNOL, V162, P3437; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zan H, 1998, J IMMUNOL, V161, P5217; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	51	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23141	23150		10.1074/jbc.M212952200	http://dx.doi.org/10.1074/jbc.M212952200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672812	hybrid			2022-12-25	WOS:000183503900122
J	Harreman, MT; Cohen, PE; Hodel, MR; Truscott, GJ; Corbett, AH; Hodel, AE				Harreman, MT; Cohen, PE; Hodel, MR; Truscott, GJ; Corbett, AH; Hodel, AE			Characterization of the auto-inhibitory sequence within the N-terminal domain of importin alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; YEAST NUCLEOPORIN; NUCLEOCYTOPLASMIC TRANSPORT; LOCALIZATION SIGNAL; KARYOPHERIN-ALPHA; PROTEIN; EXPORT; RAN; SUBSTRATE; NUP2P	Protein cargoes that contain a classic nuclear localization signal ( NLS) are transported into the nucleus through binding to a heterodimeric receptor comprised of importin/ karyopherin alpha and beta. An evolutionarily conserved auto- inhibitory sequence within the N- terminal importin beta binding ( IBB) domain of importin alpha regulates NLS- cargo binding to the NLS binding pocket on importin alpha. In this study, we have used site- directed mutagenesis coupled with in vitro binding assays and in vivo analyses to investigate the intramolecular interaction of the N- terminal IBB domain and the NLS binding pocket of Saccharomyces cerevisiae importin alpha, Srp1p. We find that mutations within the IBB domain that decrease the binding affinity of the auto- inhibitory sequence for the NLS binding pocket impact importin alpha function in vivo. In addition, the severity of the in vivo phenotype is directly correlated to the reduction of auto- inhibition measured in vitro, suggesting that the in vivo phenotypes are directly related to the loss of auto- inhibitory function. We exploit a conditional auto- inhibitory mutant, srp1 - 55, to study the in vivo functional overlap between the N- terminal IBB domain of importin alpha and other factors implicated in NLS- cargo release, Cse1p and Nup2p. We propose that the N- terminal IBB domain of importin alpha and Cse1p function together in NLS- cargo release, whereas Nup2p contributes to cargo release/ importin alpha recycling through a distinct mechanism.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NIGMS NIH HHS [GM 58728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Sambrook J, 2001, MOL CLONING LAB MANU; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SIKORSKI RS, 1989, GENETICS, V122, P19; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Straight AF, 1997, METHOD ENZYMOL, V283, P425; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880	44	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21361	21369		10.1074/jbc.M301114200	http://dx.doi.org/10.1074/jbc.M301114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672802	hybrid			2022-12-25	WOS:000183354200009
J	Komaba, S; Inoue, A; Maruta, S; Hosoya, H; Ikebe, M				Komaba, S; Inoue, A; Maruta, S; Hosoya, H; Ikebe, M			Determination of human myosin III as a motor protein having a protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; DROSOPHILA-NINAC KINASE; LIGHT-CHAIN KINASE; ACTIN-BASED MOTOR; UNCONVENTIONAL MYOSINS; DOMAIN DETERMINES; PROCESSIVE MOTOR; BRUSH-BORDER; LARGE STEP; VI	The class III myosin is the most divergent member of the myosin superfamily, having a domain with homology to a protein kinase. However, the function of class III myosin at a molecular level is not known at all, and it has been questioned whether it is actually an actin-based motor molecule. Here, we showed that human myosin III has an ATPase activity that is significantly activated by actin ( 20- fold) with K-actin of 112 muM and V-max of 0.34 s(-1), indicating the mechanoenzymatic activity of myosin III. Furthermore, we found that human myosin III has actin translocating activity ( 0.11 +/- 0.05 mum/ s) using an in vitro actin gliding assay, and it moves toward the plus end of actin filaments. Myosin III containing calmodulin as the light chain subunit showed a protein kinase activity and underwent autophosphorylation. The autophosphorylation was the intramolecular process, and the sites were at the C- terminal end of the motor domain. Autophosphorylation significantly activated the kinase activity, although it did not affect the ATPase activity. The present study is the first report that clearly demonstrates that the class III myosin is an actin- based motor protein having a protein kinase activity.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Hiroshima Univ, Dept Biol Sci, Higashihiroshima 7398526, Japan; Soka Univ, Dept Bioengn, Fac Engn, Hachioji, Tokyo 1928577, Japan	University of Massachusetts System; University of Massachusetts Worcester; Hiroshima University; Soka University	Komaba, S (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NIAMS NIH HHS [AR 41653] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ando T, 2001, P NATL ACAD SCI USA, V98, P12468, DOI 10.1073/pnas.211400898; ARIKAWA K, 1990, J CELL BIOL, V110, P1993, DOI 10.1083/jcb.110.6.1993; Battelle BA, 1998, J NEUROSCI, V18, P4548; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Dose AC, 2002, GENOMICS, V79, P621, DOI 10.1006/geno.2002.6749; Dose AC, 2000, GENOMICS, V67, P333, DOI 10.1006/geno.2000.6256; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; HICKS JL, 1992, J CELL SCI, V101, P247; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, J BIOL CHEM, V260, P27; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Kashiyama T, 2000, J BIOCHEM-TOKYO, V127, P1065, DOI 10.1093/oxfordjournals.jbchem.a022699; Kron S. J., 1991, METH ENZYMOL, V196, P399, DOI [10.1016/0076-6879(91)96035-P, DOI 10.1016/0076-6879(91)96035-P]; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Morimatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P147, DOI 10.1006/bbrc.2000.2391; Ng KP, 1996, BIOCHEMISTRY-US, V35, P9392, DOI 10.1021/bi960181a; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Pak W.L., 1979, P67; PAK WL, 1976, ANNU REV BIOPHYS BIO, V5, P397, DOI 10.1146/annurev.bb.05.060176.002145; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEPHENSON RS, 1983, SYM SOC EXP BIOL, P477; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Wes PD, 1999, NAT NEUROSCI, V2, P447, DOI 10.1038/8116; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	56	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21352	21360		10.1074/jbc.M300757200	http://dx.doi.org/10.1074/jbc.M300757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672820	hybrid			2022-12-25	WOS:000183354200008
J	Lin, YW; Chuang, SM; Yang, JL				Lin, YW; Chuang, SM; Yang, JL			ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-KINASE; CATALYTIC ACTIVATION; DOCKING SITES; IN-VIVO; SPECIFICITY; CELLS; INHIBITION; DOMAINS; GROWTH	Sustained extracellular signal-regulated kinase 1/2 (ERK1/2) activation does not always correlate with its upstream Ras-Raf-mitogen-activated protein kinase kinase 1/2 ( MKK1/ 2) signal cascade in cancer cells, and the mechanism remains elusive. Here we report a novel mechanism by which sustained ERK1/2 activation is established. We demonstrate that Pb(II), a carcinogenic metal, persistently induces ERK1/2 activity in CL3 human lung cancer cells and that Ras-Raf-MKK1/2 signaling cannot fully account for such activation. It is intriguing that Pb( II) treatment reduces mitogen-activated protein kinase phosphatase 1 (MKP-1) protein levels in time- and dose-dependent manners, which correlates with sustained ERK1/2 activation, and that Pb( II) also induces mRNA and de novo protein synthesis of MKP-1. In Pb( II)-treated cells, MKP-1 is polyubiquitinated, and proteasome inhibitors markedly alleviate the ubiquitination and degradation of MKP-1. Inhibiting the Pb( II)-induced ERK1/2 activation by PD98059 greatly suppresses MKP-1 ubiquitination and degradation. It is remarkable that constitutive activation of MKK1/ 2 triggers endogenous MKP-1 ubiquitination and degradation in various mammalian cell lines. Furthermore, expression of functional MKP-1 decreases ERK1/2 activation and the c-Fos protein level and enhances cytotoxicity under Pb( II) exposure. Taken together, these results demonstrate that activated ERK1/2 can trigger MKP-1 degradation via the ubiquitin-proteasome pathway, thus facilitating long-term activation of ERK1/2 against cytotoxicity.	Natl Tsing Hua Univ, Mol Carcinogenesis Lab, Inst Biotechnol, Dept Life Sci, Hsinchu 300, Taiwan	National Tsing Hua University	Yang, JL (corresponding author), Natl Tsing Hua Univ, Mol Carcinogenesis Lab, Inst Biotechnol, Dept Life Sci, Hsinchu 300, Taiwan.			Chuang, Show-Mei/0000-0003-2986-0736				ALESSI DR, 1993, ONCOGENE, V8, P2015; Barry OP, 2001, J BIOL CHEM, V276, P15537, DOI 10.1074/jbc.M010847200; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Gioeli D, 1999, CANCER RES, V59, P279; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hutter D, 2002, MOL CELL BIOCHEM, V233, P107, DOI 10.1023/A:1015502226940; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin YW, 2003, CARCINOGENESIS, V24, P53, DOI 10.1093/carcin/24.1.53; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; Manzano RG, 2002, ONCOGENE, V21, P4435, DOI 10.1038/sj.onc.1205542; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tong ZM, 2002, CANCER RES, V62, P5528; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wu M, 2000, GENE DEV, V14, P301	49	104	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21534	21541		10.1074/jbc.M301854200	http://dx.doi.org/10.1074/jbc.M301854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12676937	hybrid			2022-12-25	WOS:000183354200029
J	Lynch, DK; Winata, SC; Lyons, RJ; Hughes, WE; Lehrbach, GM; Wasinger, V; Corthals, G; Cordwell, S; Daly, RJ				Lynch, DK; Winata, SC; Lyons, RJ; Hughes, WE; Lehrbach, GM; Wasinger, V; Corthals, G; Cordwell, S; Daly, RJ			A cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ALDRICH-SYNDROME PROTEIN; TYROSINE PHOSPHORYLATION; BINDING PROTEIN; DOWN-REGULATION; ARP2/3 COMPLEX; C-CBL; MEMBRANE DYNAMICS; PLASMA-MEMBRANE; ADAPTER PROTEIN	Growth factor regulation of the cortical actin cytoskeleton is fundamental to a wide variety of cellular processes. The cortical actin-associated protein, cortactin, regulates the formation of dynamic actin networks via the actin-related protein (Arp)2/3 complex and hence is a key mediator of such responses. In order to reveal novel roles for this versatile protein, we used a proteomics-based approach to isolate cortactin-interacting proteins. This identified several proteins, including CD2-associated protein (CD2AP), as targets for the cortactin Src homology 3 domain. Co-immunoprecipitation of CD2AP with cortactin occurred at endogenous expression levels, was transiently induced by epidermal growth factor (EGF) treatment, and required the cortactin Src homology 3 domain. The CD2AP-binding site for cortactin mapped to the second of three proline-rich regions. Because CD2AP is closely related to Cbl-interacting protein of 85 kDa (CIN85), which regulates growth factor receptor down-regulation via complex formation with Cbl and endophilin, we investigated whether the CD2AP-cortactin complex performs a similar function. EGF treatment of cells led to transient association of Cbl and the epidermal growth factor receptor ( EGFR) with a constitutive CD2AP-endophilin complex. Cortactin was recruited into this complex with slightly delayed kinetics compared with Cbl and the EGFR. Immunofluorescence analysis revealed that the EGFR, CD2AP, and cortactin co-localized in regions of EGF-induced membrane ruffles. Therefore, by binding both CD2AP and the Arp2/3 complex, cortactin links receptor endocytosis to actin polymerization, which may facilitate the trafficking of internalized growth factor receptors.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Diabet & Obes Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Prot Anal Facil, Sydney, NSW 2010, Australia; Macquarie Univ, Australian Proteome Anal Facil, Sydney, NSW 2109, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Macquarie University	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Wasinger, Valerie/AAC-5004-2021; Corthals, Garry/G-9417-2016; Daly, Roger J/C-8179-2009	Wasinger, Valerie/0000-0001-5338-0869; Corthals, Garry/0000-0001-9423-5596; Daly, Roger/0000-0002-5739-8027; Cordwell, Stuart/0000-0002-0995-0171; Hughes, William/0000-0002-7149-3987				BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1999, CANCER RES, V59, P5376; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; CORTHALS GL, 1999, PROTEOME RES 2D GEL, P197; de Melker AA, 2001, J CELL SCI, V114, P2167; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; JANES PW, 1994, ONCOGENE, V9, P3601; Kaksonen M, 2000, J CELL SCI, V113, P4421; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Li YS, 2001, CANCER RES, V61, P6906; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; MAA MC, 1992, ONCOGENE, V7, P2429; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mizutani K, 2002, CANCER RES, V62, P669; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; Sambrook J., 2002, MOL CLONING LAB MANU; Schafer DA, 2000, TRAFFIC, V1, P892; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769	50	171	178	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21805	21813		10.1074/jbc.M211407200	http://dx.doi.org/10.1074/jbc.M211407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672817	hybrid			2022-12-25	WOS:000183354200063
J	Maton, G; Thibier, C; Castro, A; Lorca, T; Prigent, C; Jessus, C				Maton, G; Thibier, C; Castro, A; Lorca, T; Prigent, C; Jessus, C			Cdc2-cyclin B triggers H3 kinase activation of Aurora-A in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-DIVISION; CHROMOSOME SEGREGATION; MEIOTIC MATURATION; CAENORHABDITIS-ELEGANS; SIGNALING PATHWAY; LAEVIS OOCYTES; MESSENGER-RNA; METAPHASE-I; HISTONE H3	Xenopus oocytes are arrested in meiotic prophase I and resume meiotic divisions in response to progesterone. Progesterone triggers activation of M- phase promoting factor ( MPF) or Cdc2- cyclin B complex and neosynthesis of Mos kinase, responsible for MAPK activation. Both Cdc2 and MAPK activities are required for the success of meiotic maturation. However, the signaling pathway induced by progesterone and leading to MPF activation is poorly understood, and most of the targets of both Cdc2 and MAPK in the oocyte remain to be determined. Aurora- A is a Ser/ Thr kinase involved in separation of centrosomes and in spindle assembly during mitosis. It has been proposed that in Xenopus oocytes Aurora- A could be an early component of the progesterone-transduction pathway, acting through the regulation of Mos synthesis upstream Cdc2 activation. We addressed here the question of Aurora- A regulation during meiotic maturation by using new in vitro and in vivo experimental approaches. We demonstrate that Cdc2 kinase activity is necessary and sufficient to trigger both Aurora- A phosphorylation and kinase activation in Xenopus oocyte. In contrast, these events are independent of the Mos/ MAPK pathway. Aurora- A is phosphorylated in vivo at least on three residues that regulate differentially its kinase activity. Therefore, Aurora-A is under the control of Cdc2 in the Xenopus oocyte and could be involved in meiotic spindle establishment.	Univ Paris 06, Dev Biol Lab, UMR 7622, CNRS, F-75252 Paris 05, France; Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; Univ Rennes 1, Grp Cycle Cellulaire, UMR 6061, CNRS,IFR 97, F-34317 Rennes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Jessus, C (corresponding author), Univ Paris 06, Dev Biol Lab, UMR 7622, CNRS, Boite 24,4 Pl Jussieu, F-75252 Paris 05, France.	jessus@ccr.jussieu.fr	CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; CHAN CSM, 1993, GENETICS, V135, P677; De Smedt V, 2002, J BIOL CHEM, V277, P28592, DOI 10.1074/jbc.M202742200; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fisher DL, 1999, DEVELOPMENT, V126, P4537; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; Frank-Vaillant M, 2000, J CELL SCI, V113, P1127; Frank-Vaillant M, 2001, DEV BIOL, V231, P279, DOI 10.1006/dbio.2000.0142; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; HACCARD O, 1993, MOL REPROD DEV, V36, P96, DOI 10.1002/mrd.1080360114; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; HUCHON D, 1981, REPROD NUTR DEV, V21, P135, DOI 10.1051/rnd:19810112; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; JESSUS C, 1993, COMP BIOCHEM PHYS A, V106, P431, DOI 10.1016/0300-9629(93)90236-W; JESSUS C, 1986, BIOL CELL, V56, P113, DOI 10.1111/j.1768-322X.1986.tb00448.x; JESSUS C, 1987, J CELL SCI, V87, P705; Karaiskou A, 1999, J CELL SCI, V112, P3747; Karaiskou A, 1998, EXP CELL RES, V244, P491, DOI 10.1006/excr.1998.4220; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; LORCA T, 1992, FEBS LETT, V306, P90, DOI 10.1016/0014-5793(92)80844-7; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MALLER JL, 1993, MOL CELL BIOCHEM, V128, P267, DOI 10.1007/BF01076777; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Roghi C, 1998, J CELL SCI, V111, P557; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	61	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21439	21449		10.1074/jbc.M300811200	http://dx.doi.org/10.1074/jbc.M300811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670933	Green Published, hybrid			2022-12-25	WOS:000183354200018
J	Whittaker, MM; Whittaker, JW				Whittaker, MM; Whittaker, JW			Cu(I)-dependent biogenesis of the galactose oxidase redox cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; ZINC SUPEROXIDE-DISMUTASE; CYTOCHROME-C-OXIDASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; METHYLAMINE DEHYDROGENASE; PHANEROCHAETE-CHRYSOSPORIUM; PARACOCCUS-DENITRIFICANS; APOGALACTOSE OXIDASE; ANGSTROM RESOLUTION	Galactose oxidase is a copper metalloenzyme containing a novel protein-derived redox cofactor in its active site, formed by cross-linking two residues, Cys(228) and Tyr(272). Previous studies have shown that formation of the tyrosyl-cysteine (Tyr-Cys) cofactor is a self-processing step requiring only copper and dioxygen. We have investigated the biogenesis of cofactor-containing galactose oxidase from pregalactose oxidase lacking the Tyr-Cys cross-link but having a fully processed N-terminal sequence, using both Cu(I) and Cu(II). Mature galactose oxidase forms rapidly following exposure of a pregalactose oxidase-Cu(I) complex to dioxygen (t(1/2) = 3.9 s at pH7). In contrast, when Cu(II) is used in place of Cu( I) the maturation process requires several hours (t(1/2) = 5.1 h). EDTA prevents reaction of pregalactose oxidase with Cu(II) but does not interfere with the Cu(I)-dependent biogenesis reaction. The yield of cross-link corresponds to the amount of copper added, although a fraction of the pregalactose oxidase protein is unable to undergo this cross-linking reaction. The latter component, which may have an altered conformation, does not interfere with analysis of cofactor biogenesis at low copper loading. The biogenesis product has been quantitatively characterized, and mechanistic studies have been developed for the Cu(I)-dependent reaction, which forms oxidized, mature galactose oxidase and requires two molecules of O-2. Transient kinetics studies of the biogenesis reaction have revealed a pH sensitivity that appears to reflect ionization of a protein group (pK(a) = 7.3) at intermediate pH resulting in a rate acceleration and protonation of an early oxygenated intermediate at lower pH competing with commitment to cofactor formation. These spectroscopic, kinetic, and biochemical results lead to new insights into the biogenesis mechanism.	Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, Beaverton, OR 97006 USA	Oregon Health & Science University	Whittaker, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, 20000 NW Walker Rd, Beaverton, OR 97006 USA.				NIGMS NIH HHS [GM 46749] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046749] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboelella NW, 2002, J AM CHEM SOC, V124, P10660, DOI 10.1021/ja027164v; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; ARMSTRONG DA, 1999, S CTR RADICALS, P38; AVIGAD G, 1962, J BIOL CHEM, V237, P2736; BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BARON AJ, 1994, J BIOL CHEM, V269, P25095; Borman CD, 1997, J BIOL INORG CHEM, V2, P480, DOI 10.1007/s007750050159; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P14985, DOI 10.1021/bi970071j; CLAIBORNE A, 1999, BIOCHEMISTRY-US, V38, P15047; CLARK K, 1994, BIOCHEMISTRY-US, V33, P12553, DOI 10.1021/bi00208a004; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Davidson VL, 2001, ADV PROTEIN CHEM, V58, P95; DELRIO LA, 1992, FREE RADICAL BIO MED, V13, P557, DOI 10.1016/0891-5849(92)90150-F; Firbank SJ, 2001, P NATL ACAD SCI USA, V98, P12932, DOI 10.1073/pnas.231463798; Frey PA, 1997, CURR OPIN CHEM BIOL, V1, P347, DOI 10.1016/S1367-5931(97)80072-5; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; Gerfen GJ, 1996, J PHYS CHEM-US, V100, P16739, DOI 10.1021/jp960709l; Gielens C, 1997, EUR J BIOCHEM, V248, P879, DOI 10.1111/j.1432-1033.1997.00879.x; Graichen ME, 1999, J BACTERIOL, V181, P4216, DOI 10.1128/JB.181.14.4216-4222.1999; HAMILTON GA, 1981, COPPER PROTEINS META, V3, P193; Higgins DR, 1998, METH MOL B, V103, P1; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Itoh S, 1997, INORG CHEM, V36, P1407, DOI 10.1021/ic961144a; KERSTEN PJ, 1990, P NATL ACAD SCI USA, V87, P2936, DOI 10.1073/pnas.87.8.2936; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Kosman D. J., 1984, COPPER PROTEINS COPP, V2, P1; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Lu Y, 1996, INORG CHEM, V35, P1692, DOI 10.1021/ic9513189; MARCH J, 1977, ADV ORG CHEM, P619; MCGLASHEN ML, 1995, J PHYS CHEM-US, V99, P4918, DOI 10.1021/j100014a008; NELSON TJ, 2000, TNIMAGE SCI IMAGE ME; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Patil PV, 2000, ANAL BIOCHEM, V286, P187, DOI 10.1006/abio.2000.4802; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rogers MS, 2000, J AM CHEM SOC, V122, P990, DOI 10.1021/ja993385y; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Stratton J, 1998, METH MOL B, V103, P107; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; TRESSEL PS, 1982, METHOD ENZYMOL, V89, P163; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; van Amsterdam IMC, 2002, J BIOL CHEM, V277, P44121, DOI 10.1074/jbc.M202977200; vanPouderoyen G, 1996, BIOCHEMISTRY-US, V35, P1397, DOI 10.1021/bi951604w; WHITTAKER JW, 1994, MET IONS BIOL SYST, V30, P315; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4466; Whittaker JW, 2002, ADV PROTEIN CHEM, V60, P1; Whittaker MM, 2000, PROTEIN EXPRES PURIF, V20, P105, DOI 10.1006/prep.2000.1287; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1993, J AM CHEM SOC, V115, P10029, DOI 10.1021/ja00075a019; Whittaker MM, 1996, J BIOL CHEM, V271, P681, DOI 10.1074/jbc.271.2.681; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; Whittaker MM, 1998, BIOCHEMISTRY-US, V37, P8426, DOI 10.1021/bi980328t; Wright C, 2001, J INORG BIOCHEM, V85, P237, DOI 10.1016/S0162-0134(01)00214-8; YOU KS, 1975, BIOCHIM BIOPHYS ACTA, V384, P317, DOI 10.1016/0005-2744(75)90033-9	59	75	77	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22090	22101		10.1074/jbc.M300112200	http://dx.doi.org/10.1074/jbc.M300112200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672814	hybrid			2022-12-25	WOS:000183354200097
J	Higuchi, Y; Otsu, K; Nishida, K; Hirotani, S; Nakayama, H; Yamaguchi, O; Hikoso, S; Kashiwase, K; Takeda, T; Watanabe, T; Mano, T; Matsumura, Y; Ueno, H; Hori, M				Higuchi, Y; Otsu, K; Nishida, K; Hirotani, S; Nakayama, H; Yamaguchi, O; Hikoso, S; Kashiwase, K; Takeda, T; Watanabe, T; Mano, T; Matsumura, Y; Ueno, H; Hori, M			The small GTP-binding protein rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear Factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CARDIOMYOCYTE HYPERTROPHY; RHO-FAMILY GTPASES; SARCOPLASMIC-RETICULUM; PATHWAY; GENE; TRANSDUCTION; INVOLVEMENT; REQUIREMENT; EXPRESSION; RECEPTOR	The small guanine nucleotide-binding protein Rac1 has emerged as an important molecule involved in cardiac myocyte hypertrophy. Recently, we reported on apoptosis signal-regulating kinase (ASK) 1 and a transcriptional factor, nuclear factor-kappaB (NF-kappaB), as novel signaling intermediates in cardiac myocyte hypertrophy. The aim of the study presented here was to clarify the role of Rac1 in the ASK1-NF-kappaB signaling pathway. Infection of isolated neonatal cardiac myocytes with an adenovirus expressing a constitutively active form of Rac1 (RacV12) enhanced the expression of a kappaB-dependent reporter gene construct and induced the degradation of IkappaBalpha. Expression of a degradation-resistant mutant of IkappaBalpha inhibited the RacV12-induced hypertrophic responses, including increases in protein synthesis and atrial natriuretic factor production and the enhancement of sarcomeric organization. An immune complex kinase assay indicated that the expression of RacV12 activated ASK1. Expression of a dominant negative mutant of ASK1 eliminated the RacV12-induced NF-kappaB activation and the biochemical and morphological hypertrophic responses, whereas expression of a dominant negative form of Rac1 attenuated phenylephrine-induced activation of ASK1 and NF-kappaB and cardiac myocyte hypertrophy. These findings suggest that Rac1 induces cardiac myocyte hypertrophy mediated through ASK1 and NF-kappaB.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Med Informat Sci, Suita, Osaka 5650871, Japan; Univ Occupat & Environm Hlth, Dept Biochem & Mol Pathophysiol, Sch Med, Fukuoka 8078555, Japan	Osaka University; Osaka University; University of Occupational & Environmental Health - Japan	Otsu, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Box A8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hikoso, Shungo/R-4281-2018	Hikoso, Shungo/0000-0003-2284-1970; Yamaguchi, Osamu/0000-0002-7461-369X				CHIEN KR, 1999, MOL BASIS CARDIOVASC, P211; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Higuchi Y, 2002, J MOL CELL CARDIOL, V34, P233, DOI 10.1006/jmcc.2001.1505; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KIMURA Y, 1994, J MOL CELL CARDIOL, V26, P1145, DOI 10.1006/jmcc.1994.1133; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Nishida K, 1996, EUR J BIOCHEM, V240, P408; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	53	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20770	20777		10.1074/jbc.M213203200	http://dx.doi.org/10.1074/jbc.M213203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12672819	hybrid			2022-12-25	WOS:000183230500044
J	Breukink, E; van Heusden, HE; Vollmerhaus, PJ; Swiezewska, E; Brunner, L; Walker, S; Heck, AJR; de Kruijff, B				Breukink, E; van Heusden, HE; Vollmerhaus, PJ; Swiezewska, E; Brunner, L; Walker, S; Heck, AJR; de Kruijff, B			Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL BIOSYNTHESIS; ESCHERICHIA-COLI; PEPTIDOGLYCAN; PRECURSOR; BINDING; SPECIFICITY; PROXIMITY; VESICLES	The peptidoglycan layers surrounding bacterial membranes are essential for bacterial cell survival and provide an important target for antibiotics. Many antibiotics have mechanisms of action that involve binding to Lipid II, the prenyl chain-linked donor of the peptidoglycan building blocks. One of these antibiotics, the pore-forming peptide nisin uses Lipid II as a receptor molecule to increase its antimicrobial efficacy dramatically. Nisin is the first example of a targeted membrane-permeabilizing peptide antibiotic. However, it was not known whether Lipid II functions only as a receptor to recruit nisin to bacterial membranes, thus increasing its specificity for bacterial cells, or whether it also plays a role in pore formation. We have developed a new method to produce large amounts of Lipid II and variants thereof so that we can address the role of the lipid-linked disaccharide in the activity of nisin. We show here that Lipid II is not only the receptor for nisin but an intrinsic component of the pore formed by nisin, and we present a new model for the pore complex that includes Lipid II.	Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Utrecht University; Utrecht University; Utrecht University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Princeton University	Breukink, E (corresponding author), Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Heck, Albert/D-7098-2011; Breukink, Eefjan/I-3039-2016	Heck, Albert/0000-0002-2405-4404; Breukink, Eefjan/0000-0002-7311-0660; Swiezewska, Ewa/0000-0002-3439-8948				BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; Breukink E, 2000, BIOCHEMISTRY-US, V39, P10247, DOI 10.1021/bi000915q; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253; KONINGS WN, 1973, J BACTERIOL, V116, P1456, DOI 10.1128/JB.116.3.1456-1465.1973; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; PALAMARCZYK G, 1980, EUR J BIOCHEM, V105, P517, DOI 10.1111/j.1432-1033.1980.tb04527.x; PLESS DD, 1978, BIOCHIM BIOPHYS ACTA, V529, P21, DOI 10.1016/0005-2760(78)90099-1; Rush JS, 1997, GLYCOBIOLOGY, V7, P315, DOI 10.1093/glycob/7.2.315; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; Schwartz B, 2001, J AM CHEM SOC, V123, P11638, DOI 10.1021/ja0166848; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; Somerharju P, 2002, CHEM PHYS LIPIDS, V116, P57, DOI 10.1016/S0009-3084(02)00020-8; Swiezewska Ewa, 1994, Acta Biochimica Polonica, V41, P221; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; van Heusden HE, 2002, BIOCHEMISTRY-US, V41, P12171, DOI 10.1021/bi026090x; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; VanNieuwenhze MS, 2002, J AM CHEM SOC, V124, P3656, DOI 10.1021/ja017386d; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Ye XY, 2001, J AM CHEM SOC, V123, P3155, DOI 10.1021/ja010028q; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	28	249	253	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19898	19903		10.1074/jbc.M301463200	http://dx.doi.org/10.1074/jbc.M301463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12663672	Green Published, hybrid			2022-12-25	WOS:000183078000043
J	Choi, KM; McMahon, LP; Lawrence, JC				Choi, KM; McMahon, LP; Lawrence, JC			Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; SIGNALING PATHWAY; (S/T)P SITES; PROTEIN; INSULIN; IDENTIFICATION; REGULATOR; TOR; ASSOCIATION; ACTIVATION	Mammalian target of rapamycin ( mTOR) is the central element of a signaling pathway involved in the control of mRNA translation and cell growth. The actions of mTOR are mediated in part through the phosphorylation of the eukaryotic initiation factor 4E-binding protein, PHAS-I. In vitro mTOR phosphorylates PHAS-I in sites that control PHAS-I binding to eukaryotic initiation factor 4E; however, whether mTOR directly phosphorylates PHAS-I in cells has been a point of debate. The Arg-Ala-Ile-Pro (RAIP motif) and Phe-Glu-Met-Asp-Ile ( tor signaling motif) sequences found in the NH2- and COOH-terminal regions of PHAS-I, respectively, are required for the efficient phosphorylation of PHAS-I in cells. Here we show that mutations in either motif markedly decreased the phosphorylation of recombinant PHAS-I by mTOR in vitro. Wild-type PHAS-I, but none of the mutant proteins, was coimmunoprecipitated with hemagglutinin-tagged raptor, an mTOR-associated protein, after extracts of cells overexpressing raptor had been supplemented with recombinant PHAS-I proteins. Moreover, raptor overexpression enhanced the phosphorylation of wild-type PHAS-I by mTOR but not the phosphorylation of the mutant proteins. The results not only provide direct evidence that both the RAIP and tor signaling motifs are important for the phosphorylation by mTOR, possibly by allowing PHAS-I binding to raptor, but also support the view that mTOR phosphorylates PHAS-I in cells.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lawrence, JC (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu			NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence J C Jr, 2001, Prog Mol Subcell Biol, V26, P1; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Sekulic A, 2000, CANCER RES, V60, P3504; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	37	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19667	19673		10.1074/jbc.M301142200	http://dx.doi.org/10.1074/jbc.M301142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665511	hybrid			2022-12-25	WOS:000183078000015
J	Fenster, SD; Kessels, MM; Qualmann, B; Chung, WJ; Nash, J; Gundelfinger, ED; Garner, CC				Fenster, SD; Kessels, MM; Qualmann, B; Chung, WJ; Nash, J; Gundelfinger, ED; Garner, CC			Interactions between Piccolo and the actin/dynamin-binding protein Abp1 link vesicle endocytosis to presynaptic active zones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; DENDRITIC SPINES; SH3 DOMAINS; SYNAPSES; CYTOSKELETON; CYTOMATRIX; BASSOON; LOCALIZATION	Piccolo is a high molecular weight multi-domain protein shown to be a structural component of the presynaptic CAZ ( cytoskeletal matrix assembled at active zones). These features indicate that Piccolo may act to scaffold proteins involved in synaptic vesicle endo- and exocytosis near their site of action. To test this hypothesis, we have utilized a functional cell-based endocytosis assay and identified the N-terminal proline-rich Q domain in Piccolo as a region that interferes with clathrin-mediated endocytosis. Utilizing the Piccolo Q domain as bait in a yeast two-hybrid screen, we have identified the F-actin-binding protein Abp1 ( also called SH3P7 or HIP55) as a potential binding partner for this domain. The physiological relevance of this interaction is supported by in vitro binding studies, colocalization in nerve terminals, in vivo recruitment studies, and immunoprecipitation experiments. Intriguingly, Abp1 binds to both F-actin and the GTPase dynamin and has been implicated in linking the actin cytoskeleton to clathrin-mediated endocytosis. Our results suggest that Piccolo, as a structural protein of the CAZ, may serve to localize Abp1 at active zones where it can actively participate in creating a functional connection between the dynamic actin cytoskeleton and synaptic vesicle recycling.	Stanford Univ, Dept Psychiat & Behav Sci, Nancy Friend Pritzker Lab, Palo Alto, CA 94304 USA; Univ Alabama Birmingham, Dept Neurobiol, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany	Stanford University; University of Alabama System; University of Alabama Birmingham; Leibniz Institut fur Neurobiologie (LIN)	Garner, CC (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Nancy Friend Pritzker Lab, 1200 Welch Rd, Palo Alto, CA 94304 USA.	cgarner@stanford.edu		Garner, Craig/0000-0003-1970-5417; Fenster, Steven/0000-0002-4470-8145	NIA NIH HHS [AG 12978-02, AG 06569-09] Funding Source: Medline; NICHD NIH HHS [P50 HD32901, P30 HD38985-03] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012978, P01AG006569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; ENGQVISTGOLDSTE.AE, 1999, J CELL BIOL, V154, P1209; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Garner CC, 2002, TRENDS NEUROSCI, V25, P243, DOI 10.1016/S0166-2236(02)02152-5; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Goslin K., 1998, CULTURING NERVE CELL, P339; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; HONORE B, 1993, FEBS LETT, V330, P151, DOI 10.1016/0014-5793(93)80262-S; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Matus A, 2000, HIPPOCAMPUS, V10, P555, DOI 10.1002/1098-1063(2000)10:5<555::AID-HIPO5>3.0.CO;2-Z; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Righter K, 1999, J COMP NEUROL, V408, P437, DOI 10.1002/(SICI)1096-9861(19990607)408:3<437::AID-CNE9>3.0.CO;2-5; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Spilker C, 2002, J NEUROSCI, V22, P7331; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Yamazaki H, 2001, EUR J NEUROSCI, V14, P998, DOI 10.1046/j.0953-816x.2001.01727.x; Zamorano PL, 2001, NEURON, V32, P3, DOI 10.1016/S0896-6273(01)00458-5; Zhai R, 2000, MOL CELL NEUROSCI, V15, P417, DOI 10.1006/mcne.2000.0839; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	65	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20268	20277		10.1074/jbc.M210792200	http://dx.doi.org/10.1074/jbc.M210792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654920	hybrid			2022-12-25	WOS:000183078000089
J	Fiorentini, C; Gardoni, F; Spano, PF; Di Luca, M; Missale, C				Fiorentini, C; Gardoni, F; Spano, PF; Di Luca, M; Missale, C			Regulation of dopamine D-1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTOR; BASAL GANGLIA; STRIATAL NEURONS; EXPRESSION; SUBUNIT; RAT; NR2A; PHOSPHORYLATION; INTERNALIZATION	Activation of dopamine D-1 receptors is critical for the generation of glutamate-induced long-term potentiation at corticostriatal synapses. In this study, we report that, in striatal neurons, D-1 receptors are co-localized with N-methyl-D-aspartate ( NMDA) receptors in the postsynaptic density and that they co-immunoprecipitate with NMDA receptor subunits from postsynaptic density preparations. Using modified bioluminescence resonance energy transfer, we demonstrate that D-1 and NMDA receptor clustering reflects the existence of direct interactions. The tagged D-1 receptor and NR1 subunit cotransfected in COS-7 cells generated a significant bioluminescence resonance energy transfer signal that was insensitive to agonist stimulation and that did not change in the presence of the NR2B subunit, suggesting that the D-1 receptor constitutively and selectively interacts with the NR1 subunit of the NMDA channel. Oligomerization with the NR1 subunit substantially modified D-1 receptor trafficking. In individually transfected HEK293 cells, NR1 was localized in the endoplasmic reticulum, whereas the D-1 receptor was targeted to the plasma membrane. In cotransfected cells, both the D-1 receptor and NR1 subunit were retained in cytoplasmic compartments. In the presence of the NR2B subunit, the NR1-D-1 receptor complex was translocated to the plasma membrane. These data suggest that D-1 and NMDA receptors are assembled within intracellular compartments as constitutive heteromeric complexes that are delivered to functional sites. Coexpression with NR1 and NR2B subunits also abolished agonist-induced D-1 receptor cytoplasmic sequestration, indicating that oligomerization with the NMDA receptor could represent a novel regulatory mechanism modulating D-1 receptor desensitization and cellular trafficking.	Univ Brescia, Div Pharmacol, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ Brescia, Ctr Excellence Diagnost & Therapeut Innovat, I-25123 Brescia, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy	University of Brescia; University of Brescia; University of Milan	Missale, C (corresponding author), Univ Brescia, Div Pharmacol, Dept Biomed Sci & Biotechnol, Viale Europa 11, I-25123 Brescia, Italy.	cmissale@med.unibs.it	Missale, Mariacristina/E-6600-2010; Gardoni, Fabrizio/A-3135-2009; Spano, Pier Franco F/J-9944-2016; DiLuca, Monica/A-7632-2012; Spano, Pier Franco A/E-7621-2010	Gardoni, Fabrizio/0000-0003-4598-5563; Spano, Pier Franco F/0000-0002-9906-0964; DiLuca, Monica/0000-0003-2298-615X; 				Aizman O, 2000, NAT NEUROSCI, V3, P226, DOI 10.1038/72929; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bergson C, 1995, J NEUROSCI, V15, P7821; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bernard V, 1998, EUR J NEUROSCI, V10, P3721, DOI 10.1046/j.1460-9568.1998.00380.x; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; Calabresi P, 2000, J NEUROSCI, V20, P8443, DOI 10.1523/JNEUROSCI.20-22-08443.2000; Calabresi P, 1996, TRENDS NEUROSCI, V19, P19, DOI 10.1016/0166-2236(96)81862-5; Caputi A, 1999, EUR J NEUROSCI, V11, P141, DOI 10.1046/j.1460-9568.1999.00414.x; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; Dumartin B, 1998, J NEUROSCI, V18, P1650; Flores-Hernandez J, 2002, J NEUROPHYSIOL, V88, P3010, DOI 10.1152/jn.00361.2002; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kerr JND, 2001, J NEUROPHYSIOL, V85, P117, DOI 10.1152/jn.2001.85.1.117; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; LANDWEHRMEYER GB, 1995, J NEUROSCI, V15, P5297; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Levine MS, 1996, J NEUROSCI, V16, P5870; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MISSALE C, 1991, J BIOL CHEM, V266, P23392; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Obeso JA, 2000, TRENDS NEUROSCI, V23, pS1, DOI 10.1016/S1471-1931(00)00060-4; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Scott L, 2002, P NATL ACAD SCI USA, V99, P1661, DOI 10.1073/pnas.032654599; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SMITH AD, 1990, TRENDS NEUROSCI, V13, P259; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Tiberi M, 1996, J BIOL CHEM, V271, P3771; YUNG KKL, 1995, NEUROSCIENCE, V65, P709, DOI 10.1016/0306-4522(94)00536-E; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	43	174	180	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20196	20202		10.1074/jbc.M213140200	http://dx.doi.org/10.1074/jbc.M213140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646556	hybrid			2022-12-25	WOS:000183078000080
J	Pause, A; Kukolj, G; Bailey, M; Brault, M; Do, F; Halmos, T; Lagace, L; Maurice, R; Marquis, M; McKercher, G; Pellerin, C; Pilote, L; Thibeault, D; Lamarre, D				Pause, A; Kukolj, G; Bailey, M; Brault, M; Do, F; Halmos, T; Lagace, L; Maurice, R; Marquis, M; McKercher, G; Pellerin, C; Pilote, L; Thibeault, D; Lamarre, D			An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PROTEINASE DOMAIN; PEPTIDE-BASED INHIBITORS; CRYSTAL-STRUCTURE; PEPTIDOMIMETIC INHIBITORS; NON-A; IDENTIFICATION; INTERFERON; ASSAY; TRANSLATION; ACTIVATION	The hepatitis C virus (HCV) NS3 protease is essential for polyprotein maturation and viral propagation, and it has been proposed as a suitable target for antiviral drug discovery. An N-terminal hexapeptide cleavage product of a dodecapeptide substrate identified as a weak competitive inhibitor of the NS3 protease activity was optimized to a potent and highly specific inhibitor of the enzyme. The effect of this potent NS3 protease inhibitor was evaluated on replication of subgenomic HCV RNA and compared with interferon-alpha (IFN-alpha), which is currently used in the treatment of HCV-infected patients. Treatment of replicon-containing cells with the NS3 protease inhibitor or IFN-alpha showed a dose-dependent decrease in subgenomic HCV RNA that reached undetectable levels following a 14-day treatment. Kinetic studies in the presence of either NS3 protease inhibitor or IFN-alpha also revealed similar profiles in HCV RNA decay with half-lives of 11 and 14 h, respectively. The finding that an antiviral specifically targeting the NS3 protease activity inhibits HCV RNA replication further validates the NS3 enzyme as a prime target for drug discovery and supports the development of NS3 protease inhibitors as a novel therapeutic approach for HCV infection.	Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Res & Dev, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Dept Chem, Res & Dev, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim; Boehringer Ingelheim	Lamarre, D (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Res & Dev, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	dlamarre@lav.boehringer-ingelheim.com						Andrews DM, 2002, ORG LETT, V4, P4475, DOI 10.1021/ol027013x; Barbato G, 1999, J MOL BIOL, V289, P371, DOI 10.1006/jmbi.1999.2745; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cicero DO, 1999, J MOL BIOL, V289, P385, DOI 10.1006/jmbi.1999.2746; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; Diamond MS, 2001, VIROLOGY, V289, P297, DOI 10.1006/viro.2001.1114; Dymock BW, 2000, ANTIVIR CHEM CHEMOTH, V11, P79, DOI 10.1177/095632020001100201; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; Fukuda K, 2000, EUR J BIOCHEM, V267, P3685, DOI 10.1046/j.1432-1327.2000.01400.x; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Han JQ, 2002, RNA, V8, P512, DOI 10.1017/S1355838202020617; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Ingallinella P, 2002, BIOCHEMISTRY-US, V41, P5483, DOI 10.1021/bi025603x; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Kumar PKR, 1997, VIROLOGY, V237, P270, DOI 10.1006/viro.1997.8773; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LaPlante SR, 1999, J BIOL CHEM, V274, P18618, DOI 10.1074/jbc.274.26.18618; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Llinas-Brunet M, 2000, BIOORG MED CHEM LETT, V10, P2267, DOI 10.1016/S0960-894X(00)00465-0; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; LLINASBRUNET M, 1998, Patent No. 6143715; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Martell M, 1999, J CLIN MICROBIOL, V37, P327, DOI 10.1128/JCM.37.2.327-332.1999; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray EM, 2003, J VIROL, V77, P2928, DOI 10.1128/JVI.77.5.2928-2935.2003; Ogilvie W, 1997, J MED CHEM, V40, P4113, DOI 10.1021/jm970104t; Poupart MA, 2001, J ORG CHEM, V66, P4743, DOI 10.1021/jo010164d; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; Thibeault D, 2001, J BIOL CHEM, V276, P46678, DOI 10.1074/jbc.M108266200; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Yan YW, 1998, PROTEIN SCI, V7, P837; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Zhang RM, 2002, BIOORG MED CHEM LETT, V12, P1005, DOI 10.1016/S0960-894X(02)00102-6	50	81	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20374	20380		10.1074/jbc.M210785200	http://dx.doi.org/10.1074/jbc.M210785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646587	hybrid			2022-12-25	WOS:000183078000102
J	Schafer, T; Scheuer, C; Roemer, K; Menger, MD; Vollmar, B				Schafer, T; Scheuer, C; Roemer, K; Menger, MD; Vollmar, B			Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death	FASEB JOURNAL			English	Article						apoptosis; necrosis; pifithrin-alpha; LPS; microcirculation; caspase 3; NF-kappa B; ICAM-1; intravital fluorescence microscopy; bisbenzimide	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; MULTIPLE ORGAN FAILURE; NF-KAPPA-B; IN-VIVO; HEPATOCELLULAR APOPTOSIS; HEPATOCYTE APOPTOSIS; PERFUSION FAILURE; MURINE MODEL; SHOCK MODEL	There is increasing evidence that apoptotic and necrotic hepatocyte death following endotoxin-induced liver injury act as signals for leukocyte sequestration in the liver vasculature. p53 has been implicated to promote apoptosis through traps-activation and down-regulation of specific pro- and antiapoptotic genes. Here, we report that inhibition of p53 decreases apoptotic and necrotic tissue injury as well as inflammatory cell response. Sprague-Dawley rats were injected intraperitoneally with 2.2 mg/kg pifithrin-a (PFT), a p53-inactivating agent, or the vehicle DMSO 30 min before intravenous exposure to lipopolysaccharide (LPS). In vehicle-pretreated animals, LPS induced significant apoptosis and necrosis of hepatocytes, which was associated with intrahepatic leukocyte recruitment, microvascular dysfunction, and enzyme release. Inhibition of p53 effectively attenuated (P<0.05) hepatocellular apoptosis and necrosis, but also reduced leukocyte recruitment and microvascular dysfunction. Western blot analysis revealed that PFT lowered the nuclear-to-cytoplasmic p53 ratio and reduced both activation of NF-kappa B and cleavage of procaspase 3 (P<0.05). In parallel, immunohistochemistry of PFT-pretreated, but not vehicle-pretreated, endotoxic animals exhibited nuclear p53 exclusion and reduced NF-kappaB p65 staining. This indicates that p53 mediates, at least in part, LPS-associated apoptosis and contributes to inflammatory endotoxic tissue injury through leukocyte activation and intraorgan sequestration.	Univ Rostock, Dept Expt Surg, D-18055 Rostock, Germany; Univ Saarland, Inst Clin & Expt Surg, D-66421 Homburg, Germany; Univ Saarland, Dept Virol, D-66421 Homburg, Germany	University of Rostock; Saarland University; Saarland University	Vollmar, B (corresponding author), Univ Rostock, Dept Expt Surg, D-18055 Rostock, Germany.	brigitte.vollmar@med.uni-rostock.de						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BAUE AE, 1994, SHOCK, V2, P385, DOI 10.1097/00024382-199412000-00001; Burns M, 1999, WESTERN HUM REV, V53, P239; CLEMENS MG, 1985, AM J PHYSIOL, V248, pH804, DOI 10.1152/ajpheart.1985.248.6.H804; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Essani NA, 1996, J IMMUNOL, V156, P2956; Gantner F, 1995, EUR J PHARMACOL, V294, P353, DOI 10.1016/0014-2999(95)00724-5; Haendeler J, 1996, SHOCK, V6, P405, DOI 10.1097/00024382-199612000-00004; HARRIS NR, 1994, CIRC SHOCK, V43, P155; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jaeschke H, 1997, J LEUKOCYTE BIOL, V61, P647, DOI 10.1002/jlb.61.6.647; Jaeschke H, 1997, AM J PHYSIOL-GASTR L, V273, pG602, DOI 10.1152/ajpgi.1997.273.3.G602; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lawson JA, 1998, HEPATOLOGY, V28, P761, DOI 10.1002/hep.510280324; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1995, AM J PATHOL, V146, P1220; LIVINGSTON DH, 1995, ANN MED, V27, P13, DOI 10.3109/07853899509031931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Menger MD, 2000, MICROCIRCULATION, V7, P291, DOI 10.1038/sj.mn.7300117; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; Rogers HW, 1996, J IMMUNOL, V156, P679; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Tsuji H, 1997, INFECT IMMUN, V65, P1892, DOI 10.1128/IAI.65.5.1892-1898.1997; VOLLMAR B, 1994, AM J PHYSIOL-GASTR L, V267, pG786, DOI 10.1152/ajpgi.1994.267.5.G786; VOLLMAR B, 1995, J HEPATOL, V23, P613, DOI 10.1016/0168-8278(95)80070-0; VOLLMAR B, 1994, AM J PATHOL, V145, P1421; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	33	90	94	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					660	667		10.1096/fj.02-0774com	http://dx.doi.org/10.1096/fj.02-0774com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665479				2022-12-25	WOS:000182580100011
J	Umeda, J; Sano, S; Kogawa, K; Motoyama, N; Yoshikawa, K; Itami, S; Kondoh, G; Watanabe, T; Takeda, J				Umeda, J; Sano, S; Kogawa, K; Motoyama, N; Yoshikawa, K; Itami, S; Kondoh, G; Watanabe, T; Takeda, J			In vivo cooperation between Bcl-x(L) and the phosphoinositide 3-kinase-Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis	FASEB JOURNAL			English	Article						Cre-LoxP; UVB irradiation; sunburn cells	GROWTH-FACTOR RECEPTOR; BCL-X EXPRESSION; CELL-DEATH; IN-VIVO; PROTEIN FAMILY; CYTOCHROME-C; SURVIVAL; STAT3; MICE; MITOCHONDRIA	To investigate the function of Bcl-x(L) in the skin, we established keratinocyte-specific Bcl-x gene-targeted mice under the keratin 5 promoter (K5). K5.Bcl-x(L)-/- mice were viable, devoid of alteration in the development of skin or appendages. However, they harbored spontaneous apoptotic keratinocytes in the epidermis. Bcl-x(L)-deficient keratinocytes cultured in vitro readily underwent apoptosis in the absence of growth factors, but the addition of HGF or EGF resulted in restoration of cell survival, which was reversed by treatment with wortmannin, an inhibitor of phosphoinositide-3 kinase (PI3K). Topical treatment of K5.Bcl-x(L)-/- mice with wortmannin sensitized the skin for apoptosis induced by UV (UV) B, although wild-type epidermis was only marginally affected by this treatment, suggesting that the resistance to UVB largely depended on PI3KAkt signaling in Bcl-xL deficient mice but not in wild-type mice. Furthermore, UVB irradiation resulted in redistribution of phosphorylated Akt from the basal layer to the suprabasal layer, indicating that Akt could spatially cooperate with Bcl-xL upon UVB exposure in the upper epidermis where Bcl-xL is normally localized. These results suggest that Bcl-xL and the PI3KAkt pathway form a cooperative, intercompensatory axis for the protection of epidermal keratinocytes from apoptosis in vivo.	Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Osaka 5650871, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Fukuoka 8128582, Japan	Osaka University; Osaka University; Kyushu University	Sano, S (corresponding author), Osaka Univ, Grad Sch Med, Dept Dermatol, 2-2 Yamadaoka, Osaka 5650871, Japan.	sano@derma.med.osaka-u.ac						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Pena JC, 1999, EMBO J, V18, P3596, DOI 10.1093/emboj/18.13.3596; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodeck U, 1997, J CELL SCI, V110, P113; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Sano S, 2000, P NATL ACAD SCI USA, V97, P13824, DOI 10.1073/pnas.240303097; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	42	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					610	620		10.1096/fj.02-0597com	http://dx.doi.org/10.1096/fj.02-0597com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665473				2022-12-25	WOS:000182580100005
J	Giannattasio, M; Sabbioneda, S; Minuzzo, M; Plevani, P; Muzi-Falconi, M				Giannattasio, M; Sabbioneda, S; Minuzzo, M; Plevani, P; Muzi-Falconi, M			Correlation between checkpoint activation and in vivo assembly of the yeast checkpoint complex Rad17-Mec3-Ddc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; STALLED REPLICATION FORKS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CELL-CYCLE; SLIDING CLAMP; PROTEIN DDC1P; FACTOR-C; PHOSPHORYLATION; RAD53	Rad17-Mec3-Ddc1 forms a proliferating cell nuclear antigen-like complex that is required for the DNA damage response in Saccharomyces cerevisiae and acts at an early step of the signal transduction cascade activated by DNA lesions. We used the mec3-dn allele, which causes a dominant negative checkpoint defect in G(1) but not in G(2), to test the stability of the complex in vivo and to correlate its assembly and disassembly with the mechanisms controlling checkpoint activation. Under physiological conditions, the mutant complex is formed both in G(1) and G(2), although the mutant phenotype is detectable only in G(1), suggesting that is not the presence of the mutant complex per se to cause a checkpoint defect. Our data indicate that the Rad17-Mec3-Ddc1 complex is very stable, and it takes several hours to replace Mec3 with Mec3-dn within a wild type complex. On the other hand, the mutant complex is rapidly assembled when starting from a condition where the complex is not pre-assembled, indicating that the critical factor for the substitution is the disassembly step rather than complex formation. Moreover, the kinetics of mutant complex assembly, starting from conditions in which the wild type form is present, parallels the kinetics of checkpoint inactivation, suggesting that the complex acts in a stoichiometric way, rather than catalytically.	Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20133 Milan, Italy	University of Milan	Muzi-Falconi, M (corresponding author), Univ Milan, Dipartimento Genet & Biol Microorganismi, Via Celoria 26, I-20133 Milan, Italy.		Sabbioneda, Simone/N-7017-2015; Giannattasio, Michele/M-8318-2019; Muzi-Falconi, Marco/A-6035-2012	Sabbioneda, Simone/0000-0001-8551-5465; Giannattasio, Michele/0000-0001-7099-5718; Muzi-Falconi, Marco/0000-0001-7046-6090; PLEVANI, PAOLO/0000-0003-1869-2626				Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Giannattasio M, 2002, P NATL ACAD SCI USA, V99, P12997, DOI 10.1073/pnas.202463999; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Longhese MP, 1996, MOL CELL BIOL, V16, P3235; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	3	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22303	22308		10.1074/jbc.M301260200	http://dx.doi.org/10.1074/jbc.M301260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672803	hybrid			2022-12-25	WOS:000183503900019
J	Rose, T; Moreau, JL; Eckenberg, R; Theze, J				Rose, T; Moreau, JL; Eckenberg, R; Theze, J			Structural analysis and modeling of a synthetic interleukin-2 mimetic and its interleukin-2R beta(2) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-2 RECEPTOR; ALPHA-CHAIN; BETA-CHAIN; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTORS; PROTEIN STRUCTURES; HIGH-AFFINITY; GAMMA-CHAIN; BINDING; EXPRESSION	Peptide p1-30, which is composed of the 30 amino-terminal residues (alpha-helix A) of human interleukin-2 (IL-2), binds as a tetramer to the dimeric IL-2Rbeta(2) receptor, whereas the entire IL-2 recognizes the tricomponent receptor IL-2Ralphabetagamma. p1-30 is an IL-2 mimetic that activates CD8 low lymphocytes and natural killer cells, because these cells produce IL-2Rbeta constitutively. It also induces a strong lymphokine-activated killer cell response. A series of truncated peptides were analyzed by circular dichroism and analytical centrifugation to elucidate the role of p1-30 residues. We propose a model where residues 10-30 of the p1-30 peptide form an alpha-helix with eight hydrophobic side chains on the same surface buried in a hydrophobic core when four anti-parallel helices combine to form a bundle. IL-2Rbeta dimerization was further studied, and three-dimensional models of the free IL-2Rbeta(2) receptor and the p1-30(4).IL-2Rbeta(2) complex were built by comparative modeling based on the crystal structure of the erythropoietin receptor complex, because this belongs to the same hematopoietin family as IL-2. These models suggest that binding of the p1-30 tetramer rotates the COOH-terminal domains and brings both transmembrane regions 50 Angstrom closer together, driving the association of the two intracytoplasmic domains that would transduce the signal into the cytoplasm.	Inst Pasteur, Dept Biol Struct & Chim, F-75724 Paris 15, France; Inst Pasteur, Unite Immunogenet Cellulaire, Dept Mol Med, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Theze, J (corresponding author), Inst Pasteur, Dept Mol Med, Unite Immunogenet, 28 Rue Dr Roux, F-75724 Paris 15, France.			ROSE, Thierry/0000-0001-8863-0207				Baker BM, 1998, METHOD ENZYMOL, V295, P294; Baluna R, 1999, P NATL ACAD SCI USA, V96, P3957, DOI 10.1073/pnas.96.7.3957; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BUCHLI P, 1993, ARCH BIOCHEM BIOPHYS, V307, P411, DOI 10.1006/abbi.1993.1608; Cheetham JC, 1998, NAT STRUCT BIOL, V5, P861, DOI 10.1038/2302; DAquino JA, 1996, PROTEINS, V25, P143, DOI 10.1002/prot.1; David D, 1998, BLOOD, V91, P165, DOI 10.1182/blood.V91.1.165.165_165_172; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Eckenberg R, 1997, CYTOKINE, V9, P488, DOI 10.1006/cyto.1996.0192; Eckenberg R, 2000, J EXP MED, V191, P529, DOI 10.1084/jem.191.3.529; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MACKAY D, 1992, SCIENCE, V257, P410; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; ROBB RJ, 1984, P NATL ACAD SCI-BIOL, V81, P6486, DOI 10.1073/pnas.81.20.6486; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; THEZE J, 1994, EUR CYTOKINE NETW, V5, P353; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; UCHIYAMA T, 1981, J IMMUNOL, V126, P1293; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WANG ZY, 1995, EUR J IMMUNOL, V25, P1212, DOI 10.1002/eji.1830250512; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	43	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22868	22876		10.1074/jbc.M301757200	http://dx.doi.org/10.1074/jbc.M301757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676936	hybrid			2022-12-25	WOS:000183503900092
J	Godecke, A; Molojavyi, A; Heger, J; Flogel, U; Ding, ZP; Jacoby, C; Schrader, JR				Godecke, A; Molojavyi, A; Heger, J; Flogel, U; Ding, ZP; Jacoby, C; Schrader, JR			Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; TUMOR-NECROSIS-FACTOR; DILATED CARDIOMYOPATHY; MITOCHONDRIAL RESPIRATION; CYTOCHROME-OXIDASE; FAILURE; OXYGEN; MICE; EXPRESSION; FLAVOHEMOGLOBIN	The role of inducible nitric-oxide synthase ( iNOS) in the pathogenesis of heart failure is still a matter of controversy. In contrast to early reports favoring a contribution of iNOS because of the negative inotropic and apoptotic potential of NO, more recent clinical and experimental data question a causative role. Here we report that transgenic mice with cardiac specific iNOS-overexpression and concomitant myoglobin-deficiency (tg-iNOS(+)/myo(-/-)) develop signs of heart failure with cardiac hypertrophy, ventricular dilatation, and interstitial fibrosis. In addition, reactivation of the fetal gene expression program typical for heart failure occurs. The structural and molecular changes are accompanied by functional depression such as reduced contractility, ejection fraction, and cardiac energetics. Our findings indicate that excessive cardiac NO formation can cause heart failure; however, under normal circumstances myoglobin constitutes the important barrier that efficiently protects the heart from nitrosative stress.	Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Godecke, A (corresponding author), Univ Dusseldorf, Inst Herz & Kreislaufphysiol, Postfach 101007, D-40001 Dusseldorf, Germany.							Azzawi M, 1999, CARDIOVASC RES, V43, P850, DOI 10.1016/S0008-6363(99)00138-8; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bernstein RD, 1996, CIRC RES, V79, P840, DOI 10.1161/01.RES.79.4.840; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brunner F, 2001, CIRCULATION, V104, P3097, DOI 10.1161/hc5001.101966; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cotton JM, 2001, CIRCULATION, V104, P2318, DOI 10.1161/hc4401.098515; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DEBELDER AJ, 1995, BRIT HEART J, V74, P426; DECKING UKM, 1995, AM J PHYSIOL-HEART C, V268, pH2460, DOI 10.1152/ajpheart.1995.268.6.H2460; Drexler H, 1998, J AM COLL CARDIOL, V32, P955, DOI 10.1016/S0735-1097(98)00336-2; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Funakoshi H, 2002, CIRC RES, V90, P959, DOI 10.1161/01.RES.0000017632.83720.68; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Heymes C, 1999, CIRCULATION, V99, P3009, DOI 10.1161/01.CIR.99.23.3009; Jurgens KD, 2000, NEWS PHYSIOL SCI, V15, P269; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; Kelm M, 1997, CARDIOVASC RES, V36, P185, DOI 10.1016/S0008-6363(97)00149-1; Kojda G, 1996, CIRC RES, V78, P91, DOI 10.1161/01.RES.78.1.91; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Loke KE, 1999, CIRCULATION, V100, P1291, DOI 10.1161/01.CIR.100.12.1291; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; OBRIEN PJ, 1992, J MOL CELL CARDIOL, V24, P721, DOI 10.1016/0022-2828(92)93386-X; Paulus WJ, 1997, CIRCULATION, V96, P3436; Paulus WJ, 2001, CIRCULATION, V104, P2260, DOI 10.1161/circ.104.19.2260; PAULUS WJ, 1994, CIRCULATION, V89, P2070, DOI 10.1161/01.CIR.89.5.2070; Pearce LL, 2002, J BIOL CHEM, V277, P13556, DOI 10.1074/jbc.M109838200; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Taimor G, 2001, FASEB J, V15, P2518, DOI 10.1096/fj.01-0353fje; Weekes J, 1999, ELECTROPHORESIS, V20, P898, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<898::AID-ELPS898>3.0.CO;2-B; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Xie YW, 1996, CIRC RES, V79, P381, DOI 10.1161/01.RES.79.3.381; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhao G, 1999, CORONARY ARTERY DIS, V10, P315, DOI 10.1097/00019501-199907000-00007	43	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21761	21766		10.1074/jbc.M302573200	http://dx.doi.org/10.1074/jbc.M302573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12665503	hybrid			2022-12-25	WOS:000183354200057
J	Inaba, T; Matsuda, M; Shimamura, M; Takei, N; Terasaka, N; Ando, Y; Yasumo, H; Koishi, R; Makishima, M; Shimomura, I				Inaba, T; Matsuda, M; Shimamura, M; Takei, N; Terasaka, N; Ando, Y; Yasumo, H; Koishi, R; Makishima, M; Shimomura, I			Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; NUCLEAR RECEPTOR; LXR-ALPHA; LIPOPROTEIN-LIPASE; INTERNAL PROMOTER; GENE-EXPRESSION; TRANSGENIC MICE; IN-VIVO; ACID; CHOLESTEROL	The KK/ San obese and diabetic mouse, a mutant strain from KK obese mice, exhibits significantly low plasma triglyceride levels. In KK/ San mice, genetic analysis identified a mutation in the gene encoding angiopoietin-like protein 3 ( Angpt13), a liver- specific secretory protein, which had suppressive effect on lipoprotein lipase activity. In the current study, LXR ligands augmented Angpt13 mRNA expression and protein production in hepatoma cells. LXR ligands and LXR . retinoid X receptor ( RXR) complex increased the promoter activity of Angpt13 gene. Serial deletion and point mutation of Angpt13 promoter identified an LXR response element ( LXRE). Gel mobility shift assay showed the direct binding of LXR . RXR complex to the LXRE of the Angpt13 promoter. Furthermore, treatment of mice with synthetic LXR ligand caused triglyceride accumulation in the liver and plasma, which was accompanied by induction of hepatic mRNAs of several LXR target genes, including sterol regulatory element binding protein- 1c ( SREBP- 1c), fatty acid synthase ( FAS), and Angpt13. In Angpt13- deficient C57BL/ 6J mice, LXR ligand did not cause hypertriglyceridemia but accumulation of triglyceride in the liver. Our results demonstrate that Angpt13 is a direct target of LXR and that induction of hepatic Angpt13 accounts for hypertriglyceridemia associated with the treatment of LXR ligand.	Osaka Univ, Dept Med & Pathophysiol, Grad Sch Frontier Biosci, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Osaka 5650871, Japan; Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan; Japan Sco Promot Sci, 21st Century COE Program, Tokyo 1028471, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	Osaka University; Osaka University; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Japan Science & Technology Agency (JST)	Makishima, M (corresponding author), Osaka Univ, Dept Pathol & Med, Grad Sch Frontier Biosci, 2-2 Yamadaoka, Osaka 5650871, Japan.			Ando, Yukio/0000-0001-7115-9105				Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Goldberg IJ, 2001, J CLIN ENDOCR METAB, V86, P965, DOI 10.1210/jc.86.3.965; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Rossetti L, 2002, NAT MED, V8, P112, DOI 10.1038/nm0202-112; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	34	115	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21344	21351		10.1074/jbc.M213202200	http://dx.doi.org/10.1074/jbc.M213202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672813	hybrid			2022-12-25	WOS:000183354200007
J	Kopp, DA; Berg, EA; Costello, CE; Lippard, SJ				Kopp, DA; Berg, EA; Costello, CE; Lippard, SJ			Structural features of covalently cross-linked hydroxylase and reductase proteins of soluble methane monooxygenase as revealed by mass spectrometric analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; LIGHT-ACTIVATED RHODOPSIN; ELECTRON-TRANSFER; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; COMPONENT-B; BIOLOGICAL OXIDATION; CONTACT SITES; LINKING	Soluble methane monooxygenase requires complexes between its three component proteins for efficient catalysis. The hydroxylase (MMOH) must bind both to the reductase (MMOR) and to the regulatory protein (MMOB) to facilitate oxidation of methane to methanol. Although structures of MMOH, MMOB, and one domain of MMOR have been determined, less geometric information is available for the complexes. To address this deficiency, MMOH and MMOR were cross-linked by a carbodiimide reagent and analyzed by specific proteolysis, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and capillary high performance liquid chromatography mass spectrometry. Tandem mass spectra conclusively identified two amine-to-carboxylate cross-linked sites involving the alpha subunit of MMOH and the [2Fe-2S] domain of MMOR (MMOR-Fd). In particular, the N terminus of the MMOH alpha subunit forms cross-links to the side chains of MMOR-Fd residues Glu-56 and Glu-91. These Glu residues are close to one another on the surface of MMOR-Fd and >25 Angstrom from the [2Fe-2S] cluster. Because the N terminus of the alpha subunit of MMOH was not located in the crystal structure of MMOH, a detailed structural model of the complex based on the cross-link was precluded; however, a previously proposed binding site for MMOR on MMOH could be ruled out. Based on the cross-linking results, a MMOR E56Q/E91Q double mutant was generated. The mutant retains >80% of MMOR NADH oxidase activity but reduces sMMO activity to similar to65% of the level supported by the wild type reductase. Cross-linking to MMOH was diminished but not abolished in the double mutant, indicating that other residues of MMOR also form cross-links to MMOH.	MIT, Dept Chem, Cambridge, MA 02139 USA; Boston Univ, Sch Med, Mass Spectrometry Resource, Boston, MA 02118 USA	Massachusetts Institute of Technology (MIT); Boston University	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.			Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032134, R37GM032134] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR15942, P41-RR10888] Funding Source: Medline; NIGMS NIH HHS [GM32134] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; Balendra S, 2002, BIOCHEMISTRY-US, V41, P2571, DOI 10.1021/bi015714g; Blazyk JL, 2002, BIOCHEMISTRY-US, V41, P15780, DOI 10.1021/bi026757f; Buzy A, 1998, EUR J BIOCHEM, V254, P602, DOI 10.1046/j.1432-1327.1998.2540602.x; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Chang SL, 1999, BIOCHEMISTRY-US, V38, P5799, DOI 10.1021/bi982992f; Chang SL, 2001, BIOCHEMISTRY-US, V40, P9539, DOI 10.1021/bi0103462; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Elango N, 1997, PROTEIN SCI, V6, P556; FOX BG, 1991, J BIOL CHEM, V266, P540; Furukawa Y, 2002, J AM CHEM SOC, V124, P4008, DOI 10.1021/ja0171916; Gallagher SC, 1999, BIOCHEMISTRY-US, V38, P6752, DOI 10.1021/bi982991n; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Kopp DA, 2001, BIOCHEMISTRY-US, V40, P14932, DOI 10.1021/bi015556t; MacArthur R, 2002, J AM CHEM SOC, V124, P13392, DOI 10.1021/ja0279904; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Merkx M, 2002, J BIOL CHEM, V277, P5858, DOI 10.1074/jbc.M107712200; Muller EC, 2001, EUR J BIOCHEM, V268, P1837, DOI 10.1046/j.1432-1327.2001.02058.x; Muller J, 2002, BIOCHEMISTRY-US, V41, P42, DOI 10.1021/bi015668k; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Peri S, 2001, TRENDS BIOCHEM SCI, V26, P687, DOI 10.1016/S0968-0004(01)01954-5; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1994, ACCOUNTS CHEM RES, V27, P229, DOI 10.1021/ar00044a003; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Walters KJ, 1999, P NATL ACAD SCI USA, V96, P7877, DOI 10.1073/pnas.96.14.7877; Whittington DA, 2001, J AM CHEM SOC, V123, P827, DOI 10.1021/ja003240n; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487; Whittington DA, 2001, J AM CHEM SOC, V123, P1794, DOI 10.1021/ja0031725; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314	36	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20939	20945		10.1074/jbc.M301581200	http://dx.doi.org/10.1074/jbc.M301581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12660237	hybrid			2022-12-25	WOS:000183230500065
J	Lipschutz, JH; Lingappa, VR; Mostov, KE				Lipschutz, JH; Lingappa, VR; Mostov, KE			The exocyst affects protein synthesis by acting on the translocation machinery of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; SEC6/8 COMPLEX; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN COMPLEX; SECRETORY PROTEINS; MOLECULAR-CLONING; PLASMA-MEMBRANE; SEC61-BETA; EXOCYTOSIS; TRANSPORT	We previously showed that the exocyst complex specifically affected the synthesis and delivery of secretory and basolateral plasma membrane proteins. Significantly, the entire spectrum of secreted proteins was increased when the hSec10 (human Sec10) component of the exocyst complex was overexpressed, suggestive of post-transcriptional regulation (Lipschutz, J. H., Guo, W., O'Brien, L. E., Nguyen, Y. H., Novick, P., and Mostov, K. E. (2000) Mol. Biol. Cell 11, 4259-4275). Here, using an exogenously transfected basolateral protein, the polymeric immunoglobulin receptor (pIgR), and a secretory protein, gp80, we show that pIgR and gp80 protein synthesis and delivery are increased in cells overexpressing Sec10 despite the fact that mRNA levels are unchanged, which is highly indicative of post-transcriptional regulation. To test specificity, we also examined the synthesis and delivery of an exogenous apical protein, CNT1 (concentrative nucleoside transporter 1), and found no increase in CNT1 protein synthesis, delivery, or mRNA levels in cells overexpressing Sec10. Sec10-GFP-overexpressing cell lines were created, and staining was seen in the endoplasmic reticulum. It was demonstrated previously in yeast that high levels of expression of SEB1, the Sec61beta homologue, suppressed sec15-1, an exocyst mutant (Toikkanen, J., Gatti, E., Takei, K., Saloheimo, M., Olkkonen, V. M., Soderlund, H., De Camilli, P., and Keranen, S. (1996) Yeast 12, 425-438). Sec61beta is a member of the Sec61 heterotrimer, which is the main component of the endoplasmic reticulum translocon. By coimmunoprecipitation we show that Sec10, which forms an exocyst subcomplex with Sec15, specifically associates with the Sec61beta component of the translocon and that Sec10 overexpression increases the association of other exocyst complex members with Sec61beta. Proteosome inhibition does not appear to be the mechanism by which increased protein synthesis occurs in the face of equivalent amounts of mRNA. Although the exact mechanism remains to be elucidated, the exocyst/Sec61beta interaction represents an important link between the cellular membrane trafficking and protein synthetic machinery.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lipschutz, JH (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; mostov, keith/0000-0002-8123-6247				Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BREITFELD PP, 1989, AM J RESP CELL MOL, V1, P257, DOI 10.1165/ajrcmb/1.4.257; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DEITCHER DL, 1986, J CELL BIOL, V102, P911, DOI 10.1083/jcb.102.3.911; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Gruss OJ, 1999, EUR J BIOCHEM, V260, P785, DOI 10.1046/j.1432-1327.1999.00215.x; GUMBINER B, 1987, AM J PHYSIOL, V253, P749; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Haddad A, 1997, P NATL ACAD SCI USA, V94, P10675, DOI 10.1073/pnas.94.20.10675; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kinch LN, 2002, TRENDS BIOCHEM SCI, V27, P170, DOI 10.1016/S0968-0004(01)02055-2; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; LIPSCHUTZ JH, 2001, CURRENT PROTOCOLS CE; Mangravite LM, 2001, AM J PHYSIOL-RENAL, V280, pF879, DOI 10.1152/ajprenal.2001.280.5.F879; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Ruohonen L, 1997, YEAST, V13, P337, DOI 10.1002/(SICI)1097-0061(19970330)13:4<337::AID-YEA98>3.3.CO;2-B; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; SIMONS K, 1985, ANN REV CELL BIOL, V1, P295; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; Toikkanen JH, 2003, J BIOL CHEM, V278, P20946, DOI 10.1074/jbc.M213111200; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735	46	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20954	20960		10.1074/jbc.M213210200	http://dx.doi.org/10.1074/jbc.M213210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665531	hybrid			2022-12-25	WOS:000183230500067
J	Pons, V; Hullin-Matsuda, F; Nauze, M; Barbaras, R; Peres, C; Collet, X; Perret, B; Chap, H; Gassama-Diagne, A				Pons, V; Hullin-Matsuda, F; Nauze, M; Barbaras, R; Peres, C; Collet, X; Perret, B; Chap, H; Gassama-Diagne, A			Enterophilin-1, a new partner of sorting nexin 1, decreases cell surface epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; FAMILY; DOMAIN; ENTEROCYTE; DIFFERENTIATION; LOCALIZATION; DEGRADATION; INTERACTS; COMPLEX; BINDING	We previously described enterophilin-1 (Ent-1), a new intestinal protein bearing an extended leucine zipper and a B30.2 domain. Ent-1 expression is associated with growth arrest and enterocyte differentiation. To investigate the importance of Ent-1 in the differentiation, we performed a yeast two-hybrid screening. We identified sorting nexin 1 ( SNX1) as a novel partner of Ent-1 and confirmed the specificity of interaction by co-immunoprecipitation experiments in mammalian cells. SNX1 is associated with endosomal membranes and triggers the endosome-to-lysosome pathway of epidermal growth factor receptor ( EGFR). We observe by immunofluorescence microscopy that Ent-1 and SNX1 are co-localized on vesicular and tubulovesicular structures, which are different from early endosome antigen 1-containing endosomes. By gel filtration chromatography, we show that Ent-1 and SNX1 co-eluted in macromolecular complexes containing part of EGFR. Furthermore, overexpressed Ent-1 decreases cell surface EGFR. Ent-1 and SNX1 co-overexpression strongly extends EGFR diminution, indicating a synergetic effect of both proteins on cell surface EGFR removal. Interestingly, the increase of endogenous Ent-1 expression correlates with the decrease of EGFR during spontaneous differentiation of Caco-2 cells. We thus propose a role of Ent-1 in the trafficking of EGFR to down-regulate intestinal mitogenic signals, highlighting the mechanisms of cell growth arrest associated with enterocytic differentiation.	Ctr Hosp Univ Toulouse, INSERM,Hop Purpan, Unite 563, Lab Lipoprot & Lipid Mediators, F-31059 Toulouse, France; Univ Toulouse 3, Inst Federatif Rech Claude Preval, IFR 30, F-31062 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Gassama-Diagne, A (corresponding author), Ctr Hosp Univ Toulouse, INSERM,Hop Purpan, Unite 563, Lab Lipoprot & Lipid Mediators, Bat C, F-31059 Toulouse, France.	Ama.Gassama@toulouse.inserm.fr	Peres, Carlos A./ABE-8361-2020; Peres, Carlos A./B-1276-2013; Hullin-Matsuda, Françoise/N-3880-2017; Peres, Carlos Augusto/N-8275-2019; Collet, Xavier/M-6938-2017	Peres, Carlos A./0000-0002-1588-8765; Peres, Carlos A./0000-0002-1588-8765; Hullin-Matsuda, Françoise/0000-0002-6042-2841; PONS, Veronique/0000-0001-5821-8481; Bertrand, PERRET/0000-0001-7568-445X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; Gassama-Diagne A, 2001, J BIOL CHEM, V276, P18352, DOI 10.1074/jbc.M009784200; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Kuwada SK, 1999, GROWTH FACTORS, V17, P139, DOI 10.3109/08977199909103522; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Loeffler M, 1997, J THEOR BIOL, V186, P41, DOI 10.1006/jtbi.1996.0340; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; PINTO M, 1983, BIOL CELL, V47, P323; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; Schwarz DG, 2002, MOL BIOL CELL, V13, P3588, DOI 10.1091/mbc.E02-03-0145; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	28	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21155	21161		10.1074/jbc.M211008200	http://dx.doi.org/10.1074/jbc.M211008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657642	hybrid			2022-12-25	WOS:000183230500092
J	Tan, K; Shaw, AL; Madsen, B; Jensen, K; Taylor-Papadimitriou, J; Freemont, PS				Tan, K; Shaw, AL; Madsen, B; Jensen, K; Taylor-Papadimitriou, J; Freemont, PS			Human PLU-1 has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RETINOBLASTOMA BINDING-PROTEIN-2; DNA-BINDING PROTEINS; ONCOGENIC TRANSFORMATION; BREAST-CANCER; QIN PROTEIN; GROUCHO; EXPRESSION; DOMAINS; FAMILY; GENES	PLU-1 is a large ( 1544 amino acids) nuclear protein that is highly expressed in breast cancers and is proposed to function as a regulator of gene expression. A yeast two-hybrid screen using PLU-1 as bait has identified two unrelated PLU-1 interacting proteins, namely brain factor-1 (BF-1) and paired box 9 (PAX9), both of which are developmental transcription factors. BF-1 and PAX9 interact with PLU-1 via a novel conserved sequence motif ( Ala-X-Ala-Ala-X-Val-Pro-X-4-Val-Pro-X(8)Pro, termed the VP motif), because deletion or site-directed mutagenesis of this motif in either protein abolishes PLU-1 interaction in vivo. In a reporter assay system, PLU-1 has potent transcriptional repression activity. BF-1 and PAX9 also represses transcription in the same assay, but co-expression of PLU-1 with BF-1 or PAX9 significantly enhances this repression. Mutation of the PLU-1 binding motifs in BF-1 and PAX9 abolishes the observed PLU-1 co-repression activity. These data support a role for PLU-1 acting as a transcriptional corepressor of two unrelated developmental transcription factors. Because both BF-1 and PAX proteins interact with members of the groucho co-repressor family, it is plausible that PLU-1 has a role in groucho-mediated transcriptional repression.	Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Dept Sci Biol, London SW7 2AZ, England; Lincolns Inn Fields, Mol Struct & Funct Lab, Canc Res UK, London WC2A 3PX, England; Guys Hosp, Breast Canc Biol Grp, Canc Res UK, London SE1 9RT, England	Imperial College London; University of London; Institute of Cancer Research - UK; Cancer Research UK; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Freemont, PS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Dept Sci Biol, Armstrong Rd, London SW7 2AZ, England.			Freemont, Paul/0000-0002-5658-8486				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200; Chang HW, 1996, ONCOGENE, V13, P441; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Gildea JJ, 2000, GENETICS, V156, P645; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Hebert JM, 2000, DEV BIOL, V222, P296, DOI 10.1006/dbio.2000.9732; Huh SO, 1999, DEV BIOL, V211, P53, DOI 10.1006/dbio.1999.9303; James P, 1996, GENETICS, V144, P1425; Kashuba V, 2000, EUR J HUM GENET, V8, P407, DOI 10.1038/sj.ejhg.5200474; Keranen SVE, 1999, DEV GENES EVOL, V209, P495, DOI 10.1007/s004270050282; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; MADSEN B, 2002, MECH DEV GENE EXPT P, V2, P275; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; Peters H, 1998, EUR J ORAL SCI, V106, P38, DOI 10.1111/j.1600-0722.1998.tb02151.x; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; Quadbeck-Seeger C, 2000, MOL MICROBIOL, V38, P154, DOI 10.1046/j.1365-2958.2000.02128.x; Rodriguez C, 2001, J BIOL CHEM, V276, P30224, DOI 10.1074/jbc.M102759200; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Vogt T, 1999, LAB INVEST, V79, P1615; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001	42	74	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20507	20513		10.1074/jbc.M301994200	http://dx.doi.org/10.1074/jbc.M301994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657635	hybrid			2022-12-25	WOS:000183230500010
J	Wright, G; Higgin, JJ; Raines, RT; Steenbergen, C; Murphy, E				Wright, G; Higgin, JJ; Raines, RT; Steenbergen, C; Murphy, E			Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, heme oxygenase-1, and nitric-oxide synthase proteins and confers protection from metabolic inhibition to cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; NECROSIS-FACTOR-ALPHA; CARDIAC MYOCYTES; HIF-ALPHA; FACTOR-I; EXPRESSION; GENE; 4-HYDROXYLASE; MECHANISM; COLLAGEN	Recently an oxygen-sensing/transducing mechanism has been identified as a family of O-2-dependent prolyl hydroxylase domain-containing enzymes (PHD). In normoxia, PHD hydroxylates a specific proline residue that directs the degradation of constitutively synthesized hypoxia-inducible factor-1alpha. During hypoxia, the cessation of hydroxylation of this proline results in less degradation and thus increases hypoxia-inducible factor-1alpha protein levels. In this study we have examined the consequences of activating the PHD oxygen-sensing pathway in cultured neonatal myocytes using ethyl-3,4 dihydroxybenzoate and dimethyloxalylglycine, inhibitors that, similar to hypoxia, inhibit this family of O-2-dependent PHD enzymes. Increased glucose uptake and enhanced glycolytic metabolism are classical cellular responses to hypoxia. Ethyl-3,4 dihydroxybenzoate treatment of cardiomyocyte cultures for 24 h increased [H-3] deoxy-4-glucose uptake concurrent with an induction of GLUT1 protein. In addition, ethyl-3,4 dihydroxybenzoate, dimethyloxalylglycine, and hypoxia treatments were found to induce protein levels of nitricoxide synthase-2 and heme oxygenase-1, two important cardioregulatory proteins whose expression in response to hypoxic conditions is poorly understood. In conjunction with these changes in gene expression, activation of the PHD oxygen-sensing mechanism was found to preserve myocyte viability in the face of metabolic inhibition with cyanide and 2-deoxyglucose. These results point to a key role for the PHD pathway in the phenotypic changes that are observed in a hypoxic myocyte and may suggest a strategy to pharmacologically induce protection in heart.	NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Murphy, E (corresponding author), NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, NIH, 111 Alexander Dr,Bldg 101,F207, Res Triangle Pk, NC 27709 USA.	murphy1@niehs.nih.gov	Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NHLBI NIH HHS [HL39752, R01 HL039752] Funding Source: Medline; NIAMS NIH HHS [AR44276] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039752, R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; Behrooz A, 1999, NEWS PHYSIOL SCI, V14, P105; Bolli R, 1997, CIRC RES, V81, P1094; Borger DR, 1998, AM J PHYSIOL-HEART C, V274, pH965, DOI 10.1152/ajpheart.1998.274.3.H965; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; EyssenHernandez R, 1996, FEBS LETT, V382, P229, DOI 10.1016/0014-5793(96)00127-5; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Hangaishi M, 2000, BIOCHEM BIOPH RES CO, V279, P582, DOI 10.1006/bbrc.2000.3973; Heusch G, 2000, CIRC RES, V87, P146, DOI 10.1161/01.RES.87.2.146; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kacimi R, 1997, CIRCULATION, V96, P1937, DOI 10.1161/01.CIR.96.6.1937; Kalra DK, 2002, CIRCULATION, V105, P1537, DOI 10.1161/01.CIR.0000013846.72805.7E; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Rouet-Benzineb P, 1999, J MOL CELL CARDIOL, V31, P1697, DOI 10.1006/jmcc.1999.1005; SASAKI T, 1987, J BIOL CHEM, V262, P9397; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; TSCHANK G, 1991, BIOCHEM J, V275, P469, DOI 10.1042/bj2750469; Wang Y, 2002, J MOL CELL CARDIOL, V34, P5, DOI 10.1006/jmcc.2001.1482; Wright G, 2002, AM J PHYSIOL-HEART C, V282, pH872, DOI 10.1152/ajpheart.00256.2001; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	34	54	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20235	20239		10.1074/jbc.M301391200	http://dx.doi.org/10.1074/jbc.M301391200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649278	hybrid			2022-12-25	WOS:000183078000085
J	Lah, N; Lah, J; Zegers, I; Wyns, L; Messens, J				Lah, N; Lah, J; Zegers, I; Wyns, L; Messens, J			Specific potassium binding stabilizes pI258 arsenate reductase from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION BINDING; MONOVALENT CATIONS; CRYSTAL-STRUCTURE; PROTEIN; SITES; PHOSPHATASE; THERMODYNAMICS; DESIGN; DOMAIN; CALORIMETRY	Arsenate reductase ( ArsC) from Staphylococcus aureus plasmid pI258 catalyzes the reduction of arsenate to arsenite and plays a role in bacterial heavy metal resistance. The high resolution x-ray structure of ArsC reveals the atomic details of the K+ binding site situated next to the catalytic P-loop structural motif of this redox enzyme. A full thermodynamic study of the binding characteristics of a series of monovalent cations (Li+, Na+, K+, Rb+, and Cs+) and their influence on the thermal stability of ArsC was performed with isothermal titration calorimetry, circular dichroism spectroscopy, and differential scanning calorimetry. Potassium has the largest affinity with a K-a of 3.8 x 10(3) M-1, and the effectiveness of stabilization of ArsC by monovalent cations follows the binding affinity order: K+ > Rb+ > Cs+ > Na+ > Li+. A mutagenesis study on the K+ binding side chains showed that Asn-13 and Asp-65 are essential for potassium binding, but the impact on the stability of ArsC was the most extreme when mutating Ser-36. Additionally, the thermal stabilization by K+ is significantly reduced in the case of the ArsC E21A mutant, showing the importance of a Glu-21-coordinated water molecule in its contact with K+. Although potassium is not essential for catalysis, in its presence the k(cat)/K-M increases with a factor of 5. Altogether, the interaction of K+ with specific residues in ArsC is an enthalpy-driven process that stabilizes ArsC and increases the specific activity of this redox enzyme.	Free Univ Brussels VIB, Dept Ultrastruct, B-1050 Brussels, Belgium; Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; University of Ljubljana	Lah, N (corresponding author), Free Univ Brussels VIB, Dept Ultrastruct, Pleinlaan 2, B-1050 Brussels, Belgium.	nina.lah@uni-lj.si	Messens, Joris/AAH-3008-2020	Messens, Joris/0000-0002-2128-8264				Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Alexander PA, 2001, BIOCHEMISTRY-US, V40, P10634, DOI 10.1021/bi010797m; Andersson CE, 2002, J MOL BIOL, V315, P409, DOI 10.1006/jmbi.2001.5248; Bennett MS, 2001, P NATL ACAD SCI USA, V98, P13577, DOI 10.1073/pnas.241397198; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLACK CB, 1994, COORDIN CHEM REV, V135, P165, DOI 10.1016/0010-8545(94)80068-5; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P15400, DOI 10.1021/bi9814991; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; Deswarte J, 2001, EUR J BIOCHEM, V268, P3993, DOI 10.1046/j.1432-1327.2001.02310.x; DiTusa CA, 2001, BIOCHEMISTRY-US, V40, P5338, DOI 10.1021/bi001731e; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; FITZGERALD MM, 1995, PROTEIN SCI, V4, P1844, DOI 10.1002/pro.5560040919; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Henzl MT, 2000, BIOCHEMISTRY-US, V39, P5859, DOI 10.1021/bi992762g; Hofmeister F., 1888, N-S ARCH EXP PATH PH, V24, P247; HOHENESTER E, 1994, BIOCHEMISTRY-US, V33, P13561, DOI 10.1021/bi00250a008; JERNIGAN R, 1994, CURR OPIN STRUC BIOL, V4, P256, DOI 10.1016/S0959-440X(94)90317-4; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; Lah J, 2001, J PHYS CHEM B, V105, P1670, DOI 10.1021/jp002304d; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; Lopez Maria M, 2002, Methods Mol Biol, V173, P113; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; Lu Y, 2001, CHEM REV, V101, P3047, DOI 10.1021/cr0000574; Martin P, 2001, STRUCTURE, V9, P1071, DOI 10.1016/S0969-2126(01)00672-4; Messens J, 2002, P NATL ACAD SCI USA, V99, P8506, DOI 10.1073/pnas.132142799; Messens J, 2002, J BIOL INORG CHEM, V7, P146, DOI 10.1007/s007750100282; MESSENS J, 2003, IN PRESS J CHROMAT B; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Press W., 1992, NUMERICAL RECIPES FO; Ramirez-Silva L, 2001, EUR J BIOCHEM, V268, P3267, DOI 10.1046/j.1432-1327.2001.02222.x; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yang W, 2002, PROTEINS, V47, P344, DOI 10.1002/prot.10093; Zegers I, 2001, NAT STRUCT BIOL, V8, P843, DOI 10.1038/nsb1001-843; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714	44	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24673	24679		10.1074/jbc.M303194200	http://dx.doi.org/10.1074/jbc.M303194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12682056	hybrid			2022-12-25	WOS:000183824800053
J	Athenstaedt, K; Daum, G				Athenstaedt, K; Daum, G			YMR313c/TGL3 encodes a novel triacylglycerol lipase located in lipid particles of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; YEAST; PROTEINS; CELLS; METABOLISM; GENE; ACID; STEROIDOGENESIS; IDENTIFICATION; LOCALIZATION	Previous work from our laboratory (Athenstaedt, K., Zweytick, D., Jandrositz, A., Kohlwein, S. D., and Daum, G. (1999) J. Bacteriol. 181, 6441-6448) showed that the gene product of YMR313c (named Tgl3p) is a component of yeast lipid particles, and deletion of this gene led to an increase in the cellular level of triacylglycerols (TAG). These observations suggested that TGL3 may encode a TAG lipase of Saccharomyces cerevisiae. Here we demonstrate by cell fractionation and by microscopic inspection of a strain bearing a Tgl3p-GFP hybrid that this polypeptide is highly enriched in the lipid particle fraction but virtually absent from other organelles. The entire TAG lipase activity of lipid particles is attributed to Tgl3p, because the activity in this organelle is completely absent in a Deltatgl3 deletion mutant, whereas it is significantly enhanced in a strain overexpressing Tgl3p. A His(6)-tagged Tgl3p hybrid purified close to homogeneity from a yeast strain overexpressing this fusion protein exhibited high TAG lipase activity. Most importantly, experiments in vivo using the fatty acid synthesis inhibitor cerulenin demonstrated that deletion of TGL3 resulted in a decreased mobilization of TAG from lipid particles. The amino acid sequence deduced from the open reading frame YMR313c contains the consensus sequence motif GXSXG typical for lipolytic enzymes. Otherwise, Tgl3p has no significant sequence homology to other lipases identified so far. In summary, our data identified Tgl3p as a novel yeast TAG lipase at the molecular level and by function in vivo and in vitro.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at		Athenstaedt, Karin/0000-0001-7198-3989				ABRAHAM PR, 1992, YEAST, V8, P227, DOI 10.1002/yea.320080309; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Belguith H, 2000, BIOCHEM SOC T, V28, P974, DOI 10.1042/BST0280974; BISGAIER CL, 1985, J STEROID BIOCHEM, V23, P967, DOI 10.1016/0022-4731(85)90054-8; Daum G, 1999, YEAST, V15, P601, DOI 10.1002/(SICI)1097-0061(199905)15:7<601::AID-YEA390>3.0.CO;2-N; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HAID A, 1983, METHOD ENZYMOL, V96, P192; HILAIRE N, 1995, J BIOL CHEM, V270, P27027, DOI 10.1074/jbc.270.45.27027; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; INOKOSHI J, 1994, MOL GEN GENET, V244, P90, DOI 10.1007/BF00280191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MORRISON WR, 1964, J LIPID RES, V5, P600; MURPHY DJ, 1990, PROG LIPID RES, V29, P299; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Neugnot V, 2002, EUR J BIOCHEM, V269, P1734, DOI 10.1046/j.1432-1327.2002.02828.x; Osterlund T, 2001, EUR J BIOCHEM, V268, P1899, DOI 10.1046/j.1432-1327.2001.02097.x; RADOM J, 1987, BIOCHIM BIOPHYS ACTA, V920, P131, DOI 10.1016/0005-2760(87)90252-9; SCHOUSBOE I, 1976, BIOCHIM BIOPHYS ACTA, V450, P165, DOI 10.1016/0005-2760(76)90088-6; SCHOUSBOE I, 1976, BIOCHIM BIOPHYS ACTA, V424, P366, DOI 10.1016/0005-2760(76)90026-6; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spalinger JH, 1998, BBA-LIPID LIPID MET, V1393, P119, DOI 10.1016/S0005-2760(98)00068-X; Svendsen A, 2000, BBA-PROTEIN STRUCT M, V1543, P223, DOI 10.1016/S0167-4838(00)00239-9; Teter SA, 2001, J BIOL CHEM, V276, P2083, DOI 10.1074/jbc.C000739200; Van Heusden GPH, 1998, YEAST, V14, P225, DOI 10.1002/(SICI)1097-0061(199802)14:3<225::AID-YEA215>3.0.CO;2-#; WELLER PF, 1994, J ALLERGY CLIN IMMUN, V94, P1151, DOI 10.1016/0091-6749(94)90325-5; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1995, J LIPID RES, V36, P125; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	42	147	153	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23317	23323		10.1074/jbc.M302577200	http://dx.doi.org/10.1074/jbc.M302577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12682047	hybrid			2022-12-25	WOS:000183638600015
J	Engelsberg, A; Hermosilla, R; Karsten, U; Schulein, R; Dorken, B; Rehm, A				Engelsberg, A; Hermosilla, R; Karsten, U; Schulein, R; Dorken, B; Rehm, A			The Golgi protein RCAS1 controls cell surface expression of tumor-associated O-linked glycan antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE TOPOLOGY; CLEAVAGE SITES; CANCER-CELLS; GLYCOSYLATION; PROGRESSION; CARCINOMA; UTERINE; PROTEOGLYCANS; BIOSYNTHESIS; INHIBITION	Tumor immunology has received a large impetus from the identification of tumor-associated antigens. Among them, a monoclonal antibody, 22.1.1, was instrumental in defining a novel tumor-associated antigen that was termed "receptor binding cancer antigen expressed on SiSo cells" (RCAS1). RCAS1 was proposed to induce growth arrest and apoptosis on activated immune cells, mediated by a putative death receptor. Structurally, RCAS1 was predicted to exist as a type II transmembrane protein and in a soluble form. Here, we analyzed occurrence, membrane topology, and subcellular localization of the RCAS1-encoded gene product. RCAS1 was shown to be a ubiquitously expressed type III transmembrane protein with a Golgi-predominant localization. Monoclonal antibody 22.1.1 failed to recognize RCAS1, as demonstrated by confocal microscopy. Instead, we showed that the cognate 22.1.1 epitope is identical with the tumor-associated O-linked glycan Tn (N-acetyl-D-galactosamine, GalNAc). Overexpression of RCAS1 in cell lines that are negative for 22.1.1 surface staining led to the generation of Tn and the closely related TF (Thomsen-Friedenreich, Galbeta1-3GalNAc) antigen, thus providing a functional link to the generation of the 22.1.1 epitope. We suggest that RCAS1 modulates surface expression of tumor-associated, normally cryptic O-linked glycan structures and contributes indirectly to the antigenicity of tumor cells.	Max Delbruck Ctr Mol Med, Dept Hematol Oncol & Tumoimmunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Glycoconjugates, D-13125 Berlin, Germany; Humboldt Univ, Robert Rossle Klin, Dept Hematol Oncol & Tumorimmunol, Univ Klinikum Charite, D-13125 Berlin, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rehm, A (corresponding author), Max Delbruck Ctr Mol Med, Dept Hematol Oncol & Tumoimmunol, D-13125 Berlin, Germany.							Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CAO Y, 1995, CANCER-AM CANCER SOC, V76, P1700, DOI 10.1002/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HUET G, 1995, J CELL SCI, V108, P1275; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Ikeda K, 2000, BIOCHEM BIOPH RES CO, V273, P654, DOI 10.1006/bbrc.2000.2920; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Izumi M, 2001, CANCER, V92, P446, DOI 10.1002/1097-0142(20010715)92:2<446::AID-CNCR1341>3.0.CO;2-3; KARSTEN U, 1995, HYBRIDOMA, V14, P37, DOI 10.1089/hyb.1995.14.37; Kochl R, 2002, J BIOL CHEM, V277, P16131, DOI 10.1074/jbc.M111674200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Kubokawa M, 2001, INT J ONCOL, V19, P695; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lenk U, 2002, J CELL SCI, V115, P3007; Matsushima T, 2001, BLOOD, V98, P313, DOI 10.1182/blood.V98.2.313; Nakakubo Y, 2002, CANCER LETT, V177, P101, DOI 10.1016/S0304-3835(01)00773-X; Nakashima M, 1999, NAT MED, V5, P938, DOI 10.1038/11383; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohshima K, 2001, CLIN EXP IMMUNOL, V123, P481, DOI 10.1046/j.1365-2249.2001.01461.x; Oshikiri T, 2001, BRIT J CANCER, V85, P1922, DOI 10.1054/bjoc.2001.2192; Pasquier C, 1999, PROTEIN ENG, V12, P631, DOI 10.1093/protein/12.8.631; Rousseau J, 2002, BIOCHEM BIOPH RES CO, V293, P1544, DOI 10.1016/S0006-291X(02)00401-1; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; Sonoda K, 1996, CANCER, V77, P1501, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3; Sonoda K, 2000, GYNECOL ONCOL, V79, P424, DOI 10.1006/gyno.2000.5981; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Toma L, 1996, J BIOL CHEM, V271, P3897; Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0; Zhang SL, 1997, INT J CANCER, V73, P50, DOI 10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.3.CO;2-O	36	54	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22998	23007		10.1074/jbc.M301361200	http://dx.doi.org/10.1074/jbc.M301361200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672804	hybrid			2022-12-25	WOS:000183503900107
J	Harrigan, JA; Opresko, PL; von Kobbe, C; Kedar, PS; Prasad, R; Wilson, SH; Bohr, VA				Harrigan, JA; Opresko, PL; von Kobbe, C; Kedar, PS; Prasad, R; Wilson, SH; Bohr, VA			The Werner syndrome protein stimulates DNA polymerase beta strand displacement synthesis via its helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; FUNCTIONAL INTERACTION; REPEAT SEQUENCE; WRN PROTEIN; HUMAN-CELLS; INTERACTS; BINDING; COMPLEX; DELTA; 3'->5'-EXONUCLEASE	Werner syndrome is a hereditary premature aging disorder characterized by genomic instability. Genetic analysis and protein interaction studies indicate that the defective gene product (WRN) may play an important role in DNA replication, recombination, and repair. DNA polymerase beta (polbeta) is a central participant in both short and long-patch base excision repair (BER) pathways, which function to process most spontaneous, alkylated, and oxidative DNA damage. We report here a physical interaction between WRN and pol beta, and using purified proteins reconstitute of a portion of the long-patch BER pathway to examine a potential role for WRN in this repair response. We demonstrate that WRN stimulates pol beta strand displacement DNA synthesis and that this stimulation is dependent on the helicase activity of WRN. In addition, a truncated WRN protein, containing primarily the helicase domain, retains helicase activity and is sufficient to mediate the stimulation of pol beta. The WRN helicase also unwinds a BER substrate, providing evidence that WRN plays a role in unwinding DNA repair intermediates. Based on these findings, we propose a novel mechanism by which WRN may mediate pol beta-directed long-patch BER.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293; Opresko, Patricia/0000-0002-6470-2189; von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, ZIAES050159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hartenstine MJ, 2002, J BIOL CHEM, V277, P41379, DOI 10.1074/jbc.M207013200; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	57	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22686	22695		10.1074/jbc.M213103200	http://dx.doi.org/10.1074/jbc.M213103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665521	hybrid			2022-12-25	WOS:000183503900069
J	Hemmi, H; Ishibashi, J; Tomie, T; Yamakawa, M				Hemmi, H; Ishibashi, J; Tomie, T; Yamakawa, M			Structural basis for new pattern of conserved amino acid residues related to chitin-binding in the antifungal peptide from the coconut rhinoceros beetle Oryctes rhinoceros	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; VECTOR ANOPHELES-GAMBIAE; PRAWN PENAEUS-JAPONICUS; SPIN COUPLING-CONSTANTS; WHEAT-GERM-AGGLUTININ; ANTIMICROBIAL PEPTIDES; AMARANTHUS-CAUDATUS; DISTANCE GEOMETRY; MOLECULAR-CLONING; NMR-SPECTROSCOPY	Scarabaecin isolated from hemolymph of the coconut rhinoceros beetle Oryctes rhinoceros is a 36- residue polypeptide that has antifungal activity. The solution structure of scarabaecin has been determined from two-dimensional H-1 NMR spectroscopic data and hybrid distance geometry- simulated annealing protocol calculation. Based on 492 interproton and 10 hydrogen- bonding distance restraints and 36 dihedral angle restraints, we obtained 20 structures. The average backbone root-mean-square deviation for residues 4 - 35 is 0.728 +/- 0.217 Angstrom from the mean structure. The solution structure consists of a two- stranded antiparallel beta- sheet connected by a type- I beta- turn after a short helical turn. All secondary structures and a conserved disulfide bond are located in the C- terminal half of the peptide, residues 18 - 36. Overall folding is stabilized by a combination of a disulfide bond, seven hydrogen bonds, and numerous hydrophobic interactions. The structural motif of the C- terminal half shares a significant tertiary structural similarity with chitin- binding domains of plant and invertebrate chitin- binding proteins, even though scarabaecin has no overall sequence similarity to other peptide/ polypeptides including chitin- binding proteins. The length of its primary structure, the number of disulfide bonds, and the pattern of conserved functional residues binding to chitin in scarabaecin differ from those of chitin- binding proteins in other invertebrates and plants, suggesting that scarabaecin does not share a common ancestor with them. These results are thought to provide further strong experimental evidence to the hypothesis that chitin- binding proteins of invertebrates and plants are correlated by a convergent evolution process.	Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058634, Japan; Nissan Chem Ind Co Ltd, Biol Res Labs, Shiraoka, Saitama 3490294, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; National Institute of Agrobiological Sciences - Japan; Nissan Chemical Corporation	Hemmi, H (corresponding author), Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.							ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; ASESIO JL, 1998, GLYCOBIOLOGY, V8, P569; ASESIO JL, 1995, EUR J BIOCHEM, V230, P621; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; BRUNGER A, 1993, X PLOR VERSION 3 1 M; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; Ciopraga J, 1999, BBA-GEN SUBJECTS, V1428, P424, DOI 10.1016/S0304-4165(99)00085-9; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; Ha SC, 2001, ACTA CRYSTALLOGR D, V57, P263, DOI 10.1107/S090744490001516X; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; KAWANO K, 1990, J BIOL CHEM, V265, P15365; Koo JC, 1998, BBA-PROTEIN STRUCT M, V1382, P80, DOI 10.1016/S0167-4838(97)00148-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRISHNAN A, 1994, J BIOL CHEM, V269, P20971; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lamberty M, 2001, BIOCHEMISTRY-US, V40, P11995, DOI 10.1021/bi0103563; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Martins JC, 1996, J MOL BIOL, V258, P322, DOI 10.1006/jmbi.1996.0253; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P9799, DOI 10.1021/bi970588v; Muhle SA, 2001, BIOCHEMISTRY-US, V40, P5777, DOI 10.1021/bi0100384; PARIJS JV, 1991, PLANTA, V183, P258; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Saul FA, 2000, STRUCTURE, V8, P593, DOI 10.1016/S0969-2126(00)00142-8; Shen ZC, 1999, J MOL EVOL, V48, P341, DOI 10.1007/PL00006478; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Shen ZC, 1998, J BIOL CHEM, V273, P17665, DOI 10.1074/jbc.273.28.17665; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; TAMURA H, 1993, BIOCHIM BIOPHYS ACTA, V1163, P209; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; Watanabe T, 1998, BBA-PROTEIN STRUCT M, V1382, P181, DOI 10.1016/S0167-4838(97)00184-2; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299; Weaver JL, 1998, BIOCHEMISTRY-US, V37, P116, DOI 10.1021/bi971619p; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC	50	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22820	22827		10.1074/jbc.M301025200	http://dx.doi.org/10.1074/jbc.M301025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676931	hybrid			2022-12-25	WOS:000183503900086
J	Bar, EE; Ellicott, AT; Stone, DE				Bar, EE; Ellicott, AT; Stone, DE			G beta gamma recruits Rho1 to the site of polarized growth during mating in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; HETEROTRIMERIC G-PROTEIN; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; 1,3-BETA-GLUCAN SYNTHASE; GENE; LOCALIZATION	In mating mixtures of Saccharomyces cerevisiae, cells polarize their growth toward their conjugation partners along a pheromone gradient. This chemotropic phenomenon is mediated by structural proteins such as Far1 and Bem1 and by signaling proteins such as Cdc24, Cdc42, and Gbetagamma. The Gbetagamma subunit is thought to provide a positional cue that recruits the polarity establishment proteins, and thereby induces polarization of the actin cytoskeleton. We identified RHO1 in a screen for allele-specific high-copy suppressors of Gbetagamma overexpression, suggesting that Rho1 binds Gbetagamma in vivo. Inactivation of Rho1 GTPase activity augmented the rescue phenotype, suggesting that it is the activated form of Rho1 that binds Gbetagamma. We also found, in a pull-down assay, that Rho1 associates with GST-Ste4 and that Rho1 is localized to the neck and tip of mating projections. Moreover, a mutation in STE4 that disrupts Gbetagamma-Rho1 interaction reduces the projection tip localization of Rho1 and compromises the integrity of pheromone-treated cells deficient in Rho1 activity. In addition to its roles as a positive regulator of 1,3-beta-glucan synthase and of the cell integrity MAP kinase cascade, it was recently shown that Rho1 is necessary for the formation of mating projections. Together, these results suggest that Gbetagamma recruits Rho1 to the site of polarized growth during mating.	Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Stone, DE (corresponding author), Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA.		Bar, Eli/A-4592-2008					ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Andrews PD, 2000, J CELL SCI, V113, P2685; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Ayscough KR, 1998, CURR BIOL, V8, P927, DOI 10.1016/S0960-9822(07)00374-0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Guthrie C, 1991, GUIDE YEAST GENETICS; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kim JA, 2000, MOL CELL BIOL, V20, P8826, DOI 10.1128/MCB.20.23.8826-8835.2000; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1994, CELL MOL BIOL RES, V40, P229; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Li E, 1998, GENETICS, V148, P947; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; Metodiev MV, 2002, SCIENCE, V296, P1483, DOI 10.1126/science.1070540; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Saka A, 2001, J BIOL CHEM, V276, P46165, DOI 10.1074/jbc.M103805200; Schrick K, 1997, GENETICS, V147, P19; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; Sekiya-Kawasaki M, 2002, GENETICS, V162, P663; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	51	27	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21798	21804		10.1074/jbc.M212636200	http://dx.doi.org/10.1074/jbc.M212636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660244	hybrid, Green Published			2022-12-25	WOS:000183354200062
J	Noga, AA; Vance, DE				Noga, AA; Vance, DE			A gender-specific role for phosphatidylethanolamine n-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; TRANSFER PROTEIN; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HEPATIC OVEREXPRESSION; CHOLINE DEFICIENCY; APOLIPOPROTEIN-B; APO-B; SECRETION; BIOSYNTHESIS; METHYLATION	Phosphatidylethanolamine N-methyltransferase (PEMT) is involved in a secondary pathway for production of phosphatidylcholine (PC) in liver. We fed Pemt(-/-) mice a high fat/high cholesterol diet for 3 weeks to determine whether or not PC derived from PEMT is required for very low density lipoprotein secretion. Lipid analyses of plasma and liver indicated that male Pemt(-/-) mice accumulated triacylglycerols in their livers and were unable to secrete the same amount of triacylglycerols from the liver as did Pemt-/- mice. Plasma levels of triacylglycerol and both apolipoproteins B100 and B48 were significantly decreased only in male Pemt(-/-) mice. Experiments in which mice were injected with Triton WR1339 showed that, whereas hepatic apoB100 secretion was decreased in male Pemt(-/-) mice, the decrease in plasma apoB48 in male Pemt(-/-) mice was not due to reduced secretion. Moreover, female and, to a lesser extent, male Pemt(-/-) mice showed a striking 40% decrease in plasma PC and cholesterol in high density lipoproteins. These results suggest that, even though the content of hepatic PC was normal in PEMT-deficient mice, plasma lipoprotein levels were profoundly altered in a gender-specific manner.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.							AMADOR E, 1962, CLIN CHEM, V8, P343; BELINA H, 1975, BIOCHEM PHARMACOL, V24, P303; BJORNSTAD P, 1966, J LIPID RES, V7, P38; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHEEMA SK, 1997, J LIPID RES, V38, P157; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Cohen DE, 1999, CURR OPIN LIPIDOL, V10, P295, DOI 10.1097/00041433-199908000-00002; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kuipers F, 1997, Subcell Biochem, V28, P295; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; NISHIMAKIMOGAMI T, 1996, BIOCHIM BIOPHYS ACTA, V1304, P12; Noga AA, 2003, J BIOL CHEM, V278, P5952, DOI 10.1074/jbc.M212194200; PANI P, 1978, EXP MOL PATHOL, V28, P154, DOI 10.1016/0014-4800(78)90048-5; PORTAL I, 1993, AM J PHYSIOL, V264, pG1052, DOI 10.1152/ajpgi.1993.264.6.G1052; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; Tietge UJF, 1999, J LIPID RES, V40, P2134; TONHAZY NE, 1950, ARCH BIOCHEM, V28, P36; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1986, J BIOL CHEM, V261, P4486; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1986, FEBS LETT, V204, P243, DOI 10.1016/0014-5793(86)80820-1; VANCE JE, 1986, BIOCHIM BIOPHYS ACTA, V875, P501, DOI 10.1016/0005-2760(86)90070-6; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; Vermeulen PS, 1997, J LIPID RES, V38, P447; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Wu XJ, 1996, J LIPID RES, V37, P1198; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9; ZHOU X, 1992, J LIPID RES, V33, P1233	47	150	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21851	21859		10.1074/jbc.M301982200	http://dx.doi.org/10.1074/jbc.M301982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668679	hybrid			2022-12-25	WOS:000183354200069
J	Tani, K; Sato, S; Sukezane, T; Kojima, H; Hirose, H; Hanafusa, H; Shishido, T				Tani, K; Sato, S; Sukezane, T; Kojima, H; Hirose, H; Hanafusa, H; Shishido, T			Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING ACTIVITY; PROTEIN; BINDING; ACTIN; FAMILY; DOMAIN; VASP; PROTOONCOGENE; SUPPRESSOR; MUTATIONS	Mammalian Enabled ( Mena) is a mammalian homologue of Drosophila Enabled ( Ena), which genetically interacts with Drosophila Abl tyrosine kinase. The signaling pathway involving c- Abl and Mena ( Ena) is not fully understood. To find molecules that participate in the c- Abl/ Mena pathway, we searched for Mena- binding proteins using a yeast two- hybrid system. We identified Abl interactor 1 ( Abi- 1), which is known to interact with c- Abl, as a binding protein for Mena. Binding analysis revealed that the Ena/ Vasp homology 1 domain of Mena and the polyproline structure of Abi- 1 are necessary for the interaction. The interaction between Mena and Abi- 1 was also observed in a mammalian expression system. Importantly, Abi- 1 dramatically promoted c- Abl-mediated tyrosine phosphorylation of Mena but not other substrates such as c- Cbl. Mutational analysis demonstrated that the phosphorylation site of Mena is Tyr-296. Our results suggest that Abi- 1 regulates c- Abl- mediated phosphorylation of Mena by interacting with both proteins.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan; Osaka Biosci Inst, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Saitama 3320012, Japan; Japan Soc Promot Sci, Tokyo 1028471, Japan	Tokyo University of Pharmacy & Life Sciences; Osaka University; Japan Science & Technology Agency (JST); Japan Society for the Promotion of Science	Tani, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan.		Sato, Seiichi/D-6445-2012	Shishido, Tomoyuki/0000-0002-8944-2088				Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFF SP, 1982, SCIENCE, V218, P1317, DOI 10.1126/science.6293057; Ikeguchi A, 2001, ONCOGENE, V20, P4926, DOI 10.1038/sj.onc.1204502; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Nakajima K, 2002, J BIOL CHEM, V277, P11329, DOI 10.1074/jbc.M111092200; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JM, 2002, FRONT BIOSCI, V7, pD31; Stradal T, 2001, CURR BIOL, V11, P891, DOI 10.1016/S0960-9822(01)00239-1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1984, CELL, V36, P349; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878	34	77	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21685	21692		10.1074/jbc.M301447200	http://dx.doi.org/10.1074/jbc.M301447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672821	hybrid			2022-12-25	WOS:000183354200048
J	Wakabayashi, M; Ito, T; Mitsushima, M; Aizawa, S; Ueda, K; Amachi, T; Kioka, N				Wakabayashi, M; Ito, T; Mitsushima, M; Aizawa, S; Ueda, K; Amachi, T; Kioka, N			Interaction of lp-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING PROTEIN; ALPHA-CATENIN; JUNCTIONAL COMPLEX; SIGNALING COMPLEX; STRESS FIBERS; ADHESION; DOMAINS; SRC; ARCHITECTURE; AFADIN	Vinexin is a recently identified cytoskeletal protein and plays a key role in the regulation of cytoskeletal organization and signal transduction. Vinexin localizes at sites of cell- extracellular matrix adhesion in NIH3T3 fibroblasts and at sites of cell- cell contact in epithelial LLC- PK1 cells. Expression of vinexin promotes the formation of actin stress fiber, but the role of vinexin at sites of cell- cell contact is unclear. Here we identified lp- dlg/ KIAA0583 as a novel binding partner for vinexin by using yeast two- hybrid screening. lp- dlg/ KIAA0583 has a NH2- terminal coiled- coil- like domain, in addition to four PDZ domains, an Src homology ( SH) 3 domain, and a guanylate kinase domain, which are conserved structures in membrane- associated guanylate kinase family proteins. The third SH3 domain of vinexin bound to the region between the second and third PDZ domain of lp- dlg, which contains a proline- rich sequence. lp- dlg colocalized with vinexin at sites of cell- cell contact in LLC- PK1 cells. Furthermore, lp- dlg colocalized with beta- catenin, a major adherens junction protein, in LLCPK1 cells. Co- immunoprecipitation experiments revealed that both endogenous and epitope- tagged deletion mutants of lp- dlg/ KIAA0583 associated with beta- catenin. We also showed that these three proteins could form a ternary complex. Together these findings suggest that lp- dlg/ KIAA0583 is a novel scaffolding protein that can link the vinexin- vinculin complex and beta- catenin at sites of cell- cell contact.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fukada T, 1998, FEBS LETT, V436, P228, DOI 10.1016/S0014-5793(98)01136-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harris BZ, 2001, J CELL SCI, V114, P3219; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakamura H, 1998, FEBS LETT, V433, P63, DOI 10.1016/S0014-5793(98)00882-5; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Rudiger M, 1998, BIOESSAYS, V20, P733; Shah G, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-14; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	28	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21709	21714		10.1074/jbc.M211004200	http://dx.doi.org/10.1074/jbc.M211004200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12657639	hybrid			2022-12-25	WOS:000183354200051
J	Ho, MS; Carniol, K; Losick, R				Ho, MS; Carniol, K; Losick, R			Evidence in support of a docking model for the release of the transcription factor sigma(F) from the antisigma factor SpoIIAB in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; ASYMMETRIC DIVISION; SPORULATION; ACTIVATION; SITES; PHOSPHORYLATION; ESTABLISHMENT; GOVERNS; CONTACT; KINASE	Cell-specific activation of the transcription factor sigma(F) during the process of sporulation in Bacillus subtilis is governed by an antisigma factor SpoIIAB and an anti-antisigma factor SpoIIAA. SpoIIAB, which exists as a dimer, binds to sigma(F) in a complex of stoichiometry sigma(F).SpoIIAB(2). Escape from the complex is mediated by SpoIIAA, which reacts with the complex to cause the release of free sigma(F). Previous evidence indicated that Arg-20 in SpoIIAB is a contact site for both sigma(F) and SpoIIAA and that contact with sigma(F) is mediated by Arg-20 on only one of the two subunits in the sigma(F).SpoIIAB(2) complex. Here we report the construction of heterodimers of SpoIIAB in which one subunit is wild type and the other subunit is a mutant for Arg-20. We show that the dissociation constant for the binding of sigma(F) to the heterodimer was similar to that for the wild type, a finding consistent with the idea that sigma(F) contacts Arg-20 on only one of the two subunits. Although SpoIIAA was highly effective in causing the release of sigma(F) from the wild type homodimer, the anti-antisigma factor had little effect on the release of sigma(F) from the heterodimer. This finding is consistent with a model in which SpoIIAA docks on the sigma(F).SpoIIAB(2) complex, making contact with the subunit in which Arg-20 is not in contact with sigma(F). SpoIIAB is both an anti-sigma(F) factor and a protein kinase that phosphorylates and thereby inactivates SpoIIAA. We show that SpoIIAA effectively displaces sigma(F) from a complex of sigma(F) with a mutant ( SpoIIAB(R105A)) that is impaired in the kinase function of SpoIIAB. This result shows that SpoIIAA-mediated displacement of sigma(F) from SpoIIAB does not require concomitant phosphorylation of SpoIIAA.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Losick, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.		Ho, Margaret/K-6310-2017	Ho, Margaret/0000-0002-2387-7564	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; Arigoni F, 1996, P NATL ACAD SCI USA, V93, P3238, DOI 10.1073/pnas.93.8.3238; Campbell EA, 2000, J MOL BIOL, V300, P17, DOI 10.1006/jmbi.2000.3838; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Decatur AL, 1996, GENE DEV, V10, P2348, DOI 10.1101/gad.10.18.2348; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; Feucht A, 1996, GENE DEV, V10, P794, DOI 10.1101/gad.10.7.794; Garsin DA, 1998, J MOL BIOL, V284, P569, DOI 10.1006/jmbi.1998.2202; Garsin DA, 1998, J MOL BIOL, V284, P557, DOI 10.1006/jmbi.1998.2201; HARWOOD CR, 1990, MOL BIOL METHODS BAC, P442; Lee CS, 2000, J BACTERIOL, V182, P6250, DOI 10.1128/JB.182.21.6250-6253.2000; Lee J, 2001, BIOORGAN MED CHEM, V9, P19, DOI 10.1016/S0968-0896(00)00216-9; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; PIGGOT PJ, 2002, BACILLUS SUBTILIS IT, P1; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; Schuck P, 1996, ANAL BIOCHEM, V240, P262, DOI 10.1006/abio.1996.0356; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297	25	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20898	20905		10.1074/jbc.M302305200	http://dx.doi.org/10.1074/jbc.M302305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12676949	hybrid			2022-12-25	WOS:000183230500060
J	Oltean, S; Banerjee, R				Oltean, S; Banerjee, R			Nutritional modulation of gene expression and homocysteine utilization by vitamin B-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE BIOSYNTHESIS; MESSENGER-RNA; HEPATITIS-C; BINDING; SYNTHASE; PROTEIN; FOLATE; IDENTIFICATION; TRANSLATION; ENZYMES	Vitamins B-12, B-6, and folic acid converge at the homocysteine metabolic junction where they support the activities of two key enzymes involved in intracellular homocysteine management, methionine synthase (MS) and cystathionine beta-synthase. The molecular mechanism for the regulation of homocysteine metabolism by B-12 supplementation has been investigated in this study. B-12 supplementation does not alter mRNA or protein turnover rates but induces translational up-regulation of MS by shifting the mRNA from the ribonucleoprotein to the polysome pool. The B-12-responsive element has been localized by deletion analysis using a reporter gene assay to a 70-bp region located at the 3' end of the 5'-untranslated region of the MS mRNA. The cellular consequence of the B-12 response is a 2- and 3.5-fold increase in the flux of homocysteine through the MS-dependent transmethylation pathway in HepG2 and 293 cells, respectively. It is speculated that B-12-induced up-regulation of MS may have evolved as an adaptive strategy for rapidly sequestering an essential and rare nutrient whose availability may have been limited in the evolutionary history of mammals, a problem that is exacerbated by the absence of this vitamin from the plant kingdom.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu		Oltean, Sebastian/0000-0001-7890-8439				Chen HP, 1997, BIOCHEMISTRY-US, V36, P7884, DOI 10.1021/bi970169y; Chen LH, 1997, J BIOL CHEM, V272, P3628, DOI 10.1074/jbc.272.6.3628; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; FAZZONE H, 1993, J CLIN INVEST, V92, P1278, DOI 10.1172/JCI116700; Gelfand MS, 1999, TRENDS GENET, V15, P439, DOI 10.1016/S0168-9525(99)01856-9; Gulati S, 1999, BIOCHEM BIOPH RES CO, V259, P436, DOI 10.1006/bbrc.1999.0696; KAMELY D, 1973, P NATL ACAD SCI USA, V70, P2585, DOI 10.1073/pnas.70.9.2585; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; Lott WB, 2001, P NATL ACAD SCI USA, V98, P4916, DOI 10.1073/pnas.081072798; MANGUM JH, 1968, BIOCHEM BIOPH RES CO, V32, P105, DOI 10.1016/0006-291X(68)90433-6; MANGUM JH, 1969, BIOCHEMISTRY-US, V8, P3496, DOI 10.1021/bi00837a002; MARCHAJ A, 1995, J AM CHEM SOC, V117, P11640, DOI 10.1021/ja00152a003; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; Nou XW, 2000, P NATL ACAD SCI USA, V97, P7190, DOI 10.1073/pnas.130013897; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; Ravnum S, 2001, MOL MICROBIOL, V39, P1585, DOI 10.1046/j.1365-2958.2001.02346.x; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; Takyar SS, 2002, J MOL BIOL, V319, P1, DOI 10.1016/S0022-2836(02)00300-5; Yamada K, 2000, J NUTR, V130, P1894, DOI 10.1093/jn/130.8.1894	34	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20778	20784		10.1074/jbc.M300845200	http://dx.doi.org/10.1074/jbc.M300845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670934	hybrid			2022-12-25	WOS:000183230500045
J	Puri, V; Jefferson, JR; Singh, RD; Wheatley, CL; Marks, DL; Pagano, RE				Puri, V; Jefferson, JR; Singh, RD; Wheatley, CL; Marks, DL; Pagano, RE			Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; PICK C1 PROTEIN; NIEMANN-PICK; GOLGI-APPARATUS; GLUCOSYLCERAMIDE; TRANSCRIPTION; INTERNALIZATION; SPHINGOMYELIN; PROTEOLYSIS; METABOLISM	We showed previously that the intracellular transport of sphingolipids (SLs) is altered in SL storage disease fibroblasts, due in part to the secondary accumulation of free cholesterol. In the present study we examined the mechanism of cholesterol elevation in normal human skin fibroblasts induced by treatment with SLs. When cells were incubated with various natural SLs for 44 h, cholesterol levels increased 25-35%, and cholesterol esterification was reduced. Catabolism of the exogenous SLs was not required for elevation of cholesterol because (i) a non-hydrolyzable and a degradable SL analog elevated cellular cholesterol to similar extents, and (ii) incubation of cells with various SL catabolites, including ceramide, had no effect on cholesterol levels. Elevated cholesterol was derived primarily from low density lipoproteins (LDL) and resulted from up-regulation of LDL receptors induced by cleavage of the sterol regulatory element-binding protein-1. Upon SL treatment, cholesterol accumulated with exogenous SLs in late endosomes and lysosomes. These results suggest a model in which excess SLs present in endocytic compartments serve as a "molecular trap" for cholesterol, leading to a reduction in cholesterol at the endoplasmic reticulum, induction of sterol regulatory element-binding protein-1 cleavage, and up-regulation of LDL receptors.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Stabile 8,200 1st St SW, Rochester, MN 55905 USA.	Pagano.richard@mayo.edu	Takhter, Ramandeep/AAG-8977-2019	Takhter, Ramandeep/0000-0002-1441-2722	NIGMS NIH HHS [GM60934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRECHT B, 1995, CARBOHYD RES, V276, P289, DOI 10.1016/0008-6215(95)00189-Z; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Diomede L, 2001, EUR CYTOKINE NETW, V12, P625; Fielding CJ, 1997, J LIPID RES, V38, P1503; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Pagano RE, 2000, METHOD ENZYMOL, V312, P523; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Radin N S, 1981, Methods Enzymol, V72, P673; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Schuchman EH, 2001, METABOLIC MOL BASES, V3, P3589; SCHWARZMANN G, 1995, J BIOL CHEM, V270, P21271, DOI 10.1074/jbc.270.36.21271; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SCRIVER CR, 2001, METABOLIC MOL BASES, V3, P3371; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Skipski V P, 1975, Methods Enzymol, V35, P396, DOI 10.1016/0076-6879(75)35178-1; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; THOMAS PD, 1988, BIOCHEM J, V251, P55, DOI 10.1042/bj2510055; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	38	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20961	20970		10.1074/jbc.M300304200	http://dx.doi.org/10.1074/jbc.M300304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657626	hybrid			2022-12-25	WOS:000183230500068
J	Toikkanen, JH; Miller, KJ; Soderlund, H; Jantti, J; Keranen, S				Toikkanen, JH; Miller, KJ; Soderlund, H; Jantti, J; Keranen, S			The beta subunit of the Sec61p endoplasmic reticulum translocon interacts with the exocyst complex in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; PROTEIN TRANSLOCATION; SECRETORY PROTEIN; RIBOSOME RECEPTOR; PLASMA-MEMBRANE; YEAST; COMPONENTS; TRANSPORT; EXOCYTOSIS; BINDING	The exocyst is a conserved protein complex proposed to mediate vesicle tethering at the plasma membrane. Previously, we identified SEB1/SBH1, encoding the beta subunit of the Sec61p ER translocation complex, as a multicopy suppressor of the sec15-1 mutant, defective for one subunit of the exocyst complex. Here we show the functional and physical interaction between components of endoplasmic reticulum translocon and the exocytosis machinery. We show that overexpression of SEB1 suppresses the growth defect in all exocyst sec mutants. In addition, overexpression of SEC61 or SSS1 encoding the other two components of the Sec61p complex suppressed the growth defects of several exocyst mutants. Seb1p was coimmunoprecipitated from yeast cell lysates with Sec15p and Sec8p, components of the exocyst complex, and with Sec4p, a secretory vesicle associated Rab GTPase that binds to Sec15p and is essential for exocytosis. The interaction between Seb1p and Sec15p was abolished in sec15-1 mutant and was restored upon SEB1 overexpression. Furthermore, in wild type cells overexpression of SEB1 as well as SEC4 resulted in increased production of secreted proteins. These findings propose a novel functional and physical link between the endoplasmic reticulum translocation complex and the exocyst.	VTT Biotechnol, FIN-02044 Espoo, Finland	VTT Technical Research Center Finland	Keranen, S (corresponding author), VTT Biotechnol, POB 1500, FIN-02044 Espoo, Finland.	sirkka.keranen@vtt.fi						AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Adamo JE, 2001, J CELL BIOL, V155, P581, DOI 10.1083/jcb.200106065; Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; Brachmann CB, 1998, YEAST, V14, P115; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Haarer BK, 1996, GENETICS, V144, P495; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Hazuka CD, 1999, J NEUROSCI, V19, P1324; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hyde M, 2002, J CELL BIOL, V156, P993, DOI 10.1083/jcb.200112008; Jantti J, 2002, J CELL SCI, V115, P409; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; Prinz A, 2000, BIOL CHEM, V381, P1025, DOI 10.1515/BC.2000.126; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; RUOHONEN L, 1995, J BIOTECHNOL, V39, P193, DOI 10.1016/0168-1656(95)00024-K; Ruohonen L, 1997, YEAST, V13, P337, DOI 10.1002/(SICI)1097-0061(19970330)13:4<337::AID-YEA98>3.3.CO;2-B; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHERMAN F, 1983, METHODS YEAST GENETI, P61; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Short B, 2002, CURR BIOL, V12, pR18, DOI 10.1016/S0960-9822(01)00641-8; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; Terbush DR, 2001, METHOD ENZYMOL, V329, P100; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wilkinson BM, 2001, DEV CELL, V1, P401, DOI 10.1016/S1534-5807(01)00043-0; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	65	65	67	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20946	20953		10.1074/jbc.M213111200	http://dx.doi.org/10.1074/jbc.M213111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665530	hybrid			2022-12-25	WOS:000183230500066
J	Barrowman, J; Wang, W; Zhang, YY; Ferro-Novick, S				Barrowman, J; Wang, W; Zhang, YY; Ferro-Novick, S			The Yip1p center dot Yif1p complex is required for the fusion competence of endoplasmic reticulum-derived vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MEMBRANE-PROTEIN; GDP-DISSOCIATION INHIBITOR; PRENYLATED RAB ACCEPTOR; TRANSPORT VESICLES; SNARE COMPLEXES; YEAST GENES; GTPASE; BINDING; DOCKING; YPT1P	Here we report that Yip1p and Yif1p, two members of an integral membrane protein complex that bind to the Rab Ypt1p, are required for membrane fusion with the Golgi in vitro. To block fusion, anti-Yip1p or anti-Yif1p antibodies must be added before vesicles bud from the endoplasmic reticulum (ER). These antibodies do not block the packaging of Yip1p, Yif1p, or the soluble NSF attachment protein receptor (SNAREs) into vesicles. We propose that Yip1p and Yif1p perform a critical role in establishing the fusion competence of ER to Golgi vesicles at the time of budding. Consistent with this proposal, we observe that the Yip1p.Yif1p complex binds to the ER to Golgi SNAREs Bos1p and Sec22p, two components of the membrane fusion machinery.	Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Cell Biol, New Haven, CT 06519 USA	Howard Hughes Medical Institute; Yale University	Ferro-Novick, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Cell Biol, 295 Congress Ave,Rm 254B, New Haven, CT 06519 USA.	susan.ferronovick@yale.edu						Abdul-Ghani M, 2001, J BIOL CHEM, V276, P6225, DOI 10.1074/jbc.M009073200; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; Barrowman J, 2000, EMBO J, V19, P862, DOI 10.1093/emboj/19.5.862; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Calero M, 2002, FEBS LETT, V515, P89, DOI 10.1016/S0014-5793(02)02442-0; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Liang ZM, 2000, BIOCHEM BIOPH RES CO, V275, P509, DOI 10.1006/bbrc.2000.3316; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; Tang BL, 2001, J BIOL CHEM, V276, P40008, DOI 10.1074/jbc.M106189200; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Wang W, 2002, MOL BIOL CELL, V13, P3336, DOI 10.1091/mbc.01-12-0577; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whyte JRC, 2002, J CELL SCI, V115, P2627; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	50	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19878	19884		10.1074/jbc.M302406200	http://dx.doi.org/10.1074/jbc.M302406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657649	hybrid			2022-12-25	WOS:000183078000040
J	Cannon, W; Bordes, P; Wigneshweraraj, SR; Buck, M				Cannon, W; Bordes, P; Wigneshweraraj, SR; Buck, M			Nucleotide-dependent triggering of RNA polymerase-DNA interactions by an AAA regulator of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; TERMINAL SEQUENCES; ESCHERICHIA-COLI; BINDING PROTEIN; SIGMA(54); SIGMA-54; ATPASE; ROLES; NTRC	Enhancer-dependent activator proteins, which act upon the bacterial RNA polymerase containing the sigma(54) promoter specificity factor, belong to the AAA superfamily of ATPases. Activator-sigma(54) contact is required for the sigma(54)-RNAP to isomerize and engage the DNA template for transcription. How ATP hydrolysis is used to trigger changes in sigma(54)-RNA polymerase and promoter DNA that lead to DNA opening is poorly understood. Here, band shift and footprinting assays were used to investigate the DNA binding activities of sigma(54) and sigma(54)-RNA polymerase in the presence of the activator protein PspF bound to poorly hydrolysable analogues of ATP and the ATP hydrolysis transition-state analogue ADP.AlFx. Results show that different nucleotide-bound forms of PspF can change the interactions between sigma(54), sigma(54)-RNA polymerase, and a DNA fork junction structure present within closed promoter complexes. This provides evidence that in the activation transduction pathway, several functional states of the activator, prior to ATP hydrolysis, can serve to alter the fork junction binding activity of sigma(54) and sigma(54)-RNA polymerase that precede full DNA opening. A sequential set of nucleotide-dependent transitions in sigma(54)-RNA polymerase promoter complexes needed for productive open complex formation may therefore depend upon different nucleotide-bound forms of the activator.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	Imperial College London	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	m.buck@imperial.ac.uk		Wigneshweraraj, Sivaramesh/0000-0002-1418-4029; Bordes, Patricia/0000-0002-5746-0556				Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Darst RP, 2003, J BIOL CHEM, V278, P13216, DOI 10.1074/jbc.M211445200; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wigneshweraraj SR, 2003, J BIOL CHEM, V278, P3455, DOI 10.1074/jbc.M209442200; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	26	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19815	19825		10.1074/jbc.M301296200	http://dx.doi.org/10.1074/jbc.M301296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649285	hybrid			2022-12-25	WOS:000183078000033
J	Gamel-Didelon, K; Kunz, L; Fohr, KJ; Gratzl, M; Mayerhofer, A				Gamel-Didelon, K; Kunz, L; Fohr, KJ; Gratzl, M; Mayerhofer, A			Molecular and physiological evidence for functional gamma-aminobutyric acid (GABA)-C receptors in growth hormone-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL BIPOLAR CELLS; GABA(C) RECEPTOR; RHO-SUBUNITS; PHARMACOLOGICAL PROPERTIES; ANTERIOR-PITUITARY; CHLORIDE CHANNELS; XENOPUS OOCYTES; IN-VITRO; SYSTEMS; EXPRESSION	The neurotransmitter gamma-aminobutyric acid (GABA), released by hypothalamic neurons as well as by growth hormone-(GH) and adrenocorticotropin-producing cells, is a regulator of pituitary endocrine functions. Different classes of GABA receptors may be involved. In this study, we report that GH cells, isolated by laser microdissection from rat pituitary slices, possess the GABA-C receptor subunit rho(2). We also demonstrate that in the GH adenoma cell line, GH3, GABA-C receptor subunits are not only expressed but also form functional channels. GABA-induced Cl- currents were recorded using the whole cell patch clamp technique; these currents were insensitive to bicuculline (a GABA-A antagonist) but could be induced by the GABA-C agonist cis-4-aminocrotonic acid. In contrast to typical GABA-C mediated currents in neurons, they quickly desensitized. Ca-i(2+) recordings were also performed on GH3 cells. The application of either GABA or cis-4-aminocrotonic acid led to Ca2+ transients of similar amplitude, indicating that the activation of GABA-C receptors in GH3 cells may cause membrane depolarization, opening of voltage-gated Ca2+ channels, and a subsequent Ca2+ influx. Our results point at a role for GABA in pituitary GH cells and disclose an additional pathway to the one known via GABA-B receptors.	Univ Munich, Inst Anat, D-80802 Munich, Germany; Univ Ulm, Anasthesiol Klin, D-89070 Ulm, Germany	University of Munich; Ulm University	Mayerhofer, A (corresponding author), Univ Munich, Inst Anat, Biedersteiner Str 29, D-80802 Munich, Germany.			Mayerhofer, Artur/0000-0002-9388-4639				Akinci MK, 1999, NEUROSCI RES, V35, P145, DOI 10.1016/S0168-0102(99)00078-4; ANDERSON RA, 1986, J ENDOCRINOL, V108, P1, DOI 10.1677/joe.0.1080001; Barnard EA, 1998, PHARMACOL REV, V50, P291; Boue-Grabot E, 2000, ENDOCRINOLOGY, V141, P1627, DOI 10.1210/en.141.5.1627; BoueGrabot E, 1995, BRAIN RES, V704, P125, DOI 10.1016/0006-8993(95)01192-7; Cherubini E, 1998, PERSPECT DEV NEUROBI, V5, P289; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Enz R, 2001, BIOL CHEM, V382, P1111, DOI 10.1515/BC.2001.141; Enz R, 1999, EUR J NEUROSCI, V11, P41, DOI 10.1046/j.1460-9568.1999.00423.x; Enz R, 1996, J NEUROSCI, V16, P4479; FOHR KJ, 1993, J CLIN ENDOCR METAB, V76, P367, DOI 10.1210/jc.76.2.367; Fritz S, 2002, J CLIN ENDOCR METAB, V87, P1362, DOI 10.1210/jc.87.3.1362; Frungieri MB, 2002, FERTIL STERIL, V78, P298, DOI 10.1016/S0015-0282(02)03206-5; Gamel-Didelon K, 2002, NEUROENDOCRINOLOGY, V76, P170, DOI 10.1159/000064523; Hackam AS, 1998, J NEUROCHEM, V70, P40; Han MH, 1997, NEUROREPORT, V8, P1331, DOI 10.1097/00001756-199704140-00003; Hayashi M, 2003, J BIOL CHEM, V278, P1966, DOI 10.1074/jbc.M206758200; Jansen A, 2000, PFLUG ARCH EUR J PHY, V441, P294, DOI 10.1007/s004240000412; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kullmann PHM, 2002, EUR J NEUROSCI, V15, P1093, DOI 10.1046/j.1460-9568.2002.01946.x; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; Lux-Lantos V, 2001, NEUROENDOCRINOLOGY, V73, P334, DOI 10.1159/000054650; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mayerhofer A, 1996, BIOL REPROD, V55, P509, DOI 10.1095/biolreprod55.3.509; Mayerhofer Artur, 2001, FASEB Journal, V15, P1089; Pan ZH, 2000, EUR J NEUROSCI, V12, P3137, DOI 10.1046/j.1460-9568.2000.00198.x; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; Qian HH, 1998, J NEUROBIOL, V37, P305, DOI 10.1002/(SICI)1097-4695(19981105)37:2<305::AID-NEU9>3.0.CO;2-6; Safa P, 2001, J BIOL CHEM, V276, P38727, DOI 10.1074/jbc.M103724200; SCHIMCHOWITSCH S, 1991, EXP BRAIN RES, V83, P575; Schutze K, 1998, CELL MOL BIOL, V44, P735; Shields CR, 2000, J NEUROSCI, V20, P2673; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; VINCENT SR, 1982, NEUROENDOCRINOLOGY, V34, P117, DOI 10.1159/000123288	35	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20192	20195		10.1074/jbc.M301729200	http://dx.doi.org/10.1074/jbc.M301729200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660236	hybrid			2022-12-25	WOS:000183078000079
J	Louis, JM; Nesheiwat, I; Chang, LC; Clore, GM; Bewley, CA				Louis, JM; Nesheiwat, I; Chang, LC; Clore, GM; Bewley, CA			Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PEPTIDE INHIBITOR; NEUTRALIZING ANTIBODIES; ANTIVIRAL ACTIVITY; ATOMIC-STRUCTURE; ENTRY; DESIGN; GLYCOPROTEIN; 2G12; ECTODOMAIN	We have engineered two soluble, covalently linked, trimeric polypeptides, N35(CCG)-N13 and N34(CCG) comprising only the internal trimeric coiled-coil of the ectodomain of HIV-1 gp41. Both trimers inhibit human immunodeficiency virus, type 1 ( HIV-1) envelope (Env)mediated cell fusion at nanomolar concentrations by targeting the exposed C-terminal region of the gp41 ectodomain in the prehairpin intermediate state. The IC50 values for N35(CCG)-N13 and N34(CCG) are similar to15 and similar to95 nM, respectively, in a quantitative vaccinia virus-based reporter gene assay for HIV-1 Env-mediated cell fusion using Env from the T cell tropic strain LAV. Polyclonal antibodies were raised against N35(CCG)-N13 and a tightly binding fraction of anti-N35(CCG)-N13 inhibits T cell and macrophage tropic HIV-1 Env- mediated cell fusion with respective IC50 values of similar to0.5 and similar to1.5 mug/ml at 37 degreesC. The tightly binding anti-N35(CCG)-N13 antibody fraction targets the exposed internal trimeric coiled-coil in the prehairpin intermediate state of gp41 in a manner analogous to peptides derived from the C region of the gp41 ectodomain. The potency of the tightly binding anti-N35(CCG)-N13 antibody fraction in the fusion assay is comparable with that of the broadly neutralizing monoclonal antibody 2G12. These results indicate that N35(CCG)-N13 is a potential anti-HIV therapeutic agent and represents a suitable immunogen for the generation of neutralizing monoclonal antibodies targeted to the internal trimeric coiled-coil of gp41. The data on the tightly binding anti-N35(CCG)-N13 antibody fraction demonstrate that the internal trimeric coiled-coil of gp41 in the prehairpin intermediate state is accessible to antibodies and that access is not restricted by either antibody size or the presence of a kinetic barrier.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bewley, CA (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8,Rm 1A-02, Bethesda, MD 20892 USA.	cb194k@nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899; Bewley, Carole/0000-0003-2203-0852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023, Z01DK032103, ZIADK032103] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; De Rosny E, 2001, J VIROL, V75, P8859, DOI 10.1128/JVI.75.18.8859-8863.2001; Dimitrov DS, 1999, VIROLOGY, V259, P1, DOI 10.1006/viro.1999.9747; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002; Harlow E., 1988, ANTIBODIES LAB MANUA; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; NASHI LO, 1997, ANAL BIOCHEM, V253, P246; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	37	96	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20278	20285		10.1074/jbc.M301627200	http://dx.doi.org/10.1074/jbc.M301627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654905	hybrid			2022-12-25	WOS:000183078000090
J	Pummill, PE; DeAngelis, PL				Pummill, PE; DeAngelis, PL			Alteration of polysaccharide size distribution of a vertebrate hyaluronan synthase by mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; CONSERVED CYSTEINE RESIDUES; HUMAN CHONDROSARCOMA CELLS; CHEMOKINE GENE-EXPRESSION; NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; ANGIOGENIC OLIGOSACCHARIDES; MURINE MACROPHAGES; ENDOTHELIAL-CELLS; MOUSE MACROPHAGES	Hyaluronan (HA) is a nonsulfated glycosaminoglycan that has long been known to play structural roles in vertebrates. Recently, it has become increasingly obvious that this linear polysaccharide has many more uses than simply scaffolding or space filler. HA has been found to be involved in development, cell signaling, cell motility, and metastasis. These roles are often dictated by the length of the HA polymer, which can vary from a few to about 10,000 sugar residues in length. Three distinct isoforms of HA synthase exist in mammals. It has been shown previously by others that each isoform produces HA that differs in size distribution, but the regulatory mechanism is not yet known. Mutations have been described that alter the size distribution of the HA produced by the streptococcal HA synthases. We show that by mutating one particular amino acid residue of a vertebrate HA synthase, depending on the introduced side chain, the size of HA produced can be either reduced or increased. We postulate that several cysteine residues and a serine residue may be involved in binding directly or indirectly to the nascent HA chain. These data support the theory that the relative strength of the interaction between the catalyst and the polymer may be a major factor in HA size control.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DeAngelis PL, 2000, ANAL BIOCHEM, V284, P167, DOI 10.1006/abio.2000.4699; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fujita Y, 2002, FEBS LETT, V528, P101, DOI 10.1016/S0014-5793(02)03262-3; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; HELDERMON C, 1999, NEW FRONTIERS MED SC, P41; Heldermon CD, 2001, GLYCOBIOLOGY, V11, P1017, DOI 10.1093/glycob/11.12.1017; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 1999, J IMMUNOL, V162, P4171; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Horton MR, 1998, J IMMUNOL, V160, P3023; Horton MR, 2002, J BIOL CHEM, V277, P43757, DOI 10.1074/jbc.M206007200; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Kobayashi H, 2002, INT J CANCER, V102, P379, DOI 10.1002/ijc.10710; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Kosaki R, 1999, CANCER RES, V59, P1141; Kumari K, 2002, J BIOL CHEM, V277, P13943, DOI 10.1074/jbc.M110638200; Laurent T. C., 1996, IMMUNOL CELL BIOL, V74, pA1, DOI [10.1038/icb.1996.32, DOI 10.1038/ICB.1996.32]; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; LEES VC, 1995, LAB INVEST, V73, P259; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Liu NF, 2001, CANCER RES, V61, P1022; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Meyer K, 1934, J BIOL CHEM, V107, P629; Nasreen N, 2001, ONCOL RES, V13, P71; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; Oertli B, 1998, J IMMUNOL, V161, P3431; Ohkawara Y, 2000, AM J RESP CELL MOL, V23, P444, DOI 10.1165/ajrcmb.23.4.3875; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Pummill PE, 2002, J BIOL CHEM, V277, P21610, DOI 10.1074/jbc.M202456200; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Slevin M, 1998, LAB INVEST, V78, P987; SLEVIN M, 2002, J BIOL CHEM; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Suzuki M, 2002, BBA-MOL CELL RES, V1591, P37, DOI 10.1016/S0167-4889(02)00246-X; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TANFORD C, 1980, HYDROPHOBIC EFFECT F, P11; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	70	31	38	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19808	19814		10.1074/jbc.M301097200	http://dx.doi.org/10.1074/jbc.M301097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654925	hybrid			2022-12-25	WOS:000183078000032
J	Stary, A; Kannouche, P; Lehmann, AR; Sarasin, A				Stary, A; Kannouche, P; Lehmann, AR; Sarasin, A			Role of DNA polymerase eta in the UV mutation spectrum in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; THYMINE-THYMINE DIMER; CYCLOBUTANE PYRIMIDINE DIMERS; XERODERMA-PIGMENTOSUM; TRANSLESION SYNTHESIS; MAMMALIAN-CELLS; SHUTTLE VECTOR; TRICHOTHIODYSTROPHY CELLS; 6-4 PHOTOPRODUCT; ESCHERICHIA-COLI	In humans, inactivation of the DNA polymerase eta gene (pol eta) results in sunlight sensitivity and causes the cancer-prone xeroderma pigmentosum variant syndrome (XP-V). Cells from XP-V individuals have a reduced capacity to replicate UV-damaged DNA and show hypermutability after UV exposure. Biochemical assays have demonstrated the ability of pol eta to bypass cis-syn-cyclobutane thymine dimers, the most common lesion generated in DNA by UV. In most cases, this bypass is error-free. To determine the actual requirement of pol eta in vivo, XP-V cells (XP30RO) were complemented by the wild type pol eta gene. We have used two pol eta-corrected clones to study the in vivo characteristics of mutations produced by DNA polymerases during DNA synthesis of UV-irradiated shuttle vectors transfected into human host cells, which had or had not been exposed previously to UV radiation. The functional complementation of XP-V cells by pol eta reduced the mutation frequencies both at CG and TA base pairs and restored UV mutagenesis to a normal level. UV irradiation of host cells prior to transfection strongly increased the mutation frequency in undamaged vectors and, in addition, especially in the pol eta-deficient XP30RO cells at 5'-TT sites in UV-irradiated plasmids. These results clearly show the protective role of pol eta against UV-induced lesions and the activation by UV of pol eta-independent mutagenic processes.	Inst Gustave Roussy, Lab Genet Instabil & Canc, CNRS, UPR 2169, F-94805 Villejuif, France; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Sussex	Stary, A (corresponding author), Inst Gustave Roussy, Lab Genet Instabil & Canc, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	stary@igr.fr	stary, anne/GRY-3781-2022					ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; ARLETT CF, 1975, MUTAT RES, V33, P341, DOI 10.1016/0027-5107(75)90209-2; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; CARIELLO NF, 1994, CANCER RES, V54, P4454; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Douki T, 2001, BIOCHEMISTRY-US, V40, P2495, DOI 10.1021/bi0022543; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kamiya H, 1998, NUCLEIC ACIDS RES, V26, P2611, DOI 10.1093/nar/26.11.2611; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Lehmann AR, 2000, GENE, V253, P1, DOI 10.1016/S0378-1119(00)00250-X; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Marionnet C, 1998, CANCER RES, V58, P102; MARIONNET C, 1995, J MOL BIOL, V252, P550, DOI 10.1006/jmbi.1995.0519; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; STARY A, 1992, J GEN VIROL, V73, P1679, DOI 10.1099/0022-1317-73-7-1679; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Svoboda DL, 1998, CANCER RES, V58, P2445; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Tissier A, 2001, BIOCHEM SOC T, V29, P183, DOI 10.1042/0300-5127:0290183; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; VOLPE JPG, 1995, MUTAT RES-DNA REPAIR, V337, P111, DOI 10.1016/0921-8777(95)00015-C; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; Yao JQ, 2001, ENVIRON MOL MUTAGEN, V38, P19, DOI 10.1002/em.1046; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001	63	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18767	18775		10.1074/jbc.M211838200	http://dx.doi.org/10.1074/jbc.M211838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644471	hybrid			2022-12-25	WOS:000182932200010
J	Ohtsuka, T; Buchsbaum, D; Oliver, P; Makhija, S; Kimberly, R; Zhou, T				Ohtsuka, T; Buchsbaum, D; Oliver, P; Makhija, S; Kimberly, R; Zhou, T			Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway	ONCOGENE			English	Article						apoptosis; TRAIL receptor; chemotherapy; JNK; mitochondria	TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; BLADDER-CANCER CELLS; N-TERMINAL KINASE; MEDIATED APOPTOSIS; DR5-MEDIATED APOPTOSIS; TUMORICIDAL ACTIVITY; ANTITUMOR-ACTIVITY; ANTICANCER AGENTS	Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.	Sankyo Co Ltd, Biomed Res Labs, Tokyo 1408710, Japan; Univ Alabama, Dept Med Radiobiol, Birmingham, AL 35294 USA; Univ Alabama, Div Gynecol Oncol, Birmingham, AL 35294 USA; Univ Alabama, Dept Math, Birmingham, AL 35294 USA	Daiichi Sankyo Company Limited; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhou, T (corresponding author), Univ Alabama, Dept Med, 465 LHRB,701 19th St S, Birmingham, AL 35249 USA.			Kimberly, Robert/0000-0002-5330-3086; Makhija, Sharmila/0000-0002-4078-9822; Buchsbaum, Donald/0000-0003-2797-5847	NCI NIH HHS [CA83591, CA89019] Funding Source: Medline; NIAMS NIH HHS [AR44982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083591, P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Decaudin D, 1997, CANCER RES, V57, P62; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lacour S, 2001, CANCER RES, V61, P1645; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Mizutani Y, 2001, J UROLOGY, V165, P263, DOI 10.1097/00005392-200101000-00076; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	48	140	165	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2034	2044		10.1038/sj.onc.1206290	http://dx.doi.org/10.1038/sj.onc.1206290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673208				2022-12-25	WOS:000181967700013
J	Bebien, M; Salinas, S; Becamel, C; Richard, W; Linares, L; Hipskind, RA				Bebien, M; Salinas, S; Becamel, C; Richard, W; Linares, L; Hipskind, RA			Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF	ONCOGENE			English	Article						c-fos; egr-1; mkp-1; ERK; SAPK; p38	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; TERNARY COMPLEX FACTORS; C-FOS EXPRESSION; HISTONE H3 PHOSPHORYLATION; N-TERMINAL KINASE; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; TRANSDUCTION PATHWAYS; SODIUM ARSENITE	Cellular stress activates multiple mitogen-activated protein kinase (MAPK) cascades and immediate-early gene (IEG) transcription. To address how these events are linked, we investigated the endogenous signaling/transcription factor network driving IEG activation by arsenite and anisomycin in the human osteosarcoma cell line HOS/TE-85. Induction of IEG transcription by both stresses corresponded temporally with the phosphorylation of the regulatory factors Elk-1 and cAMP response element-binding protein (CREB), along with activation of the extracellular signal-regulated kinase (ERK), stress-activated protein kinase (SAPK) and p38 MAPK cascades. To assess the role of the different cascades, they were selectively inhibited with PD98059, SP600125 and SB203580, respectively. This implicated all three cascades in Elk-1 phosphorylation after arsenite treatment, whereas ERK and SAPK inhibition diminished this, and IEG mRNA levels, downstream of anisomycin. SB blocked phosphorylation of both serum response factor (SRF) and CREB, and strongly reduced IEG activation by both stresses. Combining PD with SB further reduced arsenite induction of IEG transcription. Thus, all three MAPK cascades mediate anisomycin- and arsenite-induced signaling to IEG promoters in HOS cells through the differential targeting of Elk-1, SRF and CREB.	CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Hipskind, RA (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 24, 1919 Route Mende, F-34293 Montpellier, France.	hipskind@soleil.igm.cnrs-mop.fr	Linares, Laetitia LKL/F-9901-2018; Salinas, Sara/O-1150-2019; Salinas, Sara/O-1856-2013	Linares, Laetitia LKL/0000-0003-1661-2119; Salinas, Sara/0000-0003-4492-2093; Salinas, Sara/0000-0003-4492-2093				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHIOU HY, 1995, CANCER RES, V55, P1296; Chiou HY, 2001, AM J EPIDEMIOL, V153, P411, DOI 10.1093/aje/153.5.411; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GUBITS RM, 1988, ONCOGENE, V3, P163; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RANI AS, 1993, CARCINOGENESIS, V14, P947, DOI 10.1093/carcin/14.5.947; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUTHER U, 1989, ONCOGENE, V4, P861; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TINWELL H, 1991, ENVIRON HEALTH PERSP, V95, P205, DOI 10.2307/3431125; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	72	50	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1836	1847		10.1038/sj.onc.1206334	http://dx.doi.org/10.1038/sj.onc.1206334			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660819				2022-12-25	WOS:000181678200010
